02016000000000397000450099100020000070000020000270600020000470100020000609100090
00081300036000174210017000531510019000700350010000894800042000990300020001419300
00400161117000800165085000300173935001000176032000600186036000700192042000200199
20000020020106500090020312200030021204800140021504800140022904800240024304300530
0267043005300320043005300373540038800426540040200814540039601216541000601612#1#0
#i#1#20110411#Arquivos Brasileiros de Cardiologia#Arq Bras Cardiol#Arq. bras. ca
rdiol#0066-782X#Sociedade Brasileira de Cardiologia - SBC#Arq. Bras. Cardiol.#AB
C#vancouv#nd#0066-782X#ahead#201150#1#0#20110000#49#^les^hSumario#^lpt^hSumário#
^len^hTable of Contents#^les^tArq. Bras. Cardiol.^nno.ahead^cSão Paulo^a2011#^lp
t^tArq. Bras. Cardiol.^nno.ahead^cSão Paulo^a2011#^len^tArq. Bras. Cardiol.^nno.
ahead^cSão Paulo^a2011#^t<a rel="license" href="http://creativecommons.org/licen
ses/by-nc/3.0/"><img alt="Creative Commons License" style="border-width:0" src="
http://i.creativecommons.org/l/by-nc/3.0/80x15.png" /></a> Todo el contenido de 
esta revista, excepto dónde está identificado, est&#225; bajo una <a rel="licens
e" href="http://creativecommons.org/licenses/by-nc/3.0/">Licencia Creative Commo
ns</a>^les#^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/3.
0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.cre
ativecommons.org/l/by-nc/3.0/80x15.png" /></a> Todo o conteúdo deste periódico, 
exceto onde est&#225 identificado, est&#225; licenciado sob uma <a rel="license"
 href="http://creativecommons.org/licenses/by-nc/3.0/">Licen&#231;a Creative Com
mons</a>^lpt#^t<a rel="license" href="http://creativecommons.org/licenses/by-nc/
3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.c
reativecommons.org/l/by-nc/3.0/80x15.png" /></a> All the contents of this journa
l, except where otherwise noted, is licensed under a <a rel="license" href="http
://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution License
</a>^len#BY-NC##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#o#1#1#
article#1#20110331#080902#aop00711.htm#307##
04887000000000637000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200950
01780120086002730100031003590100031003900100034004210100030004550700106004850700
09900591083165500690085000802345085005202353085002402405085003702429083159002466
08500080405608500460406408500250411008500360413511700080417107200030417911200090
4182111000904191116000904200115000904209114000904218113000904227002001304236#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#h#2#1#article#1#oa
#pt#br1.1#1#4.0#ILUS#TAB#17#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066
-782X#20110225#Avanços recentes do impacto da apneia obstrutiva do sono na hiper
tensão arterial sistêmica^lpt#Recent advances of the impact of obstructive sleep
 apnea on systemic hypertension^len#^rND^1A01^nRodrigo P.^sPedrosa#^rND^1A02^nEd
uardo M.^sKrieger#^rND^1A02^nGeraldo^sLorenzi-Filho#^rND^1A02^nLuciano F.^sDrage
r#Universidade de Pernambuco^iA01^1Pronto Socorro Cardiológico de Pernambuco^2La
boratório do Sono e Coração#Universidade de São Paulo^iA02^1Faculdade de Medicin
a^2Hospital das Clínicas^3Instituto do Coração#^lpt^aA apneia obstrutiva do sono
 (AOS) é uma condição clínica comum na população em geral, principalmente entre 
os pacientes portadores de doenças cardiovasculares. Mais do que um fenômeno loc
al de obstrução das vias aéreas superiores, a AOS traz repercussões sistêmicas q
ue podem incluir a hipóxia intermitente, a redução abrupta da pressão intratorác
ica e a ocorrência de microdespertares com fragmentação do sono. Nas últimas déc
adas, inúmeras evidências apontam de forma consistente a AOS como um importante 
fator envolvido na ocorrência de doenças cardiovasculares. Particularmente, a re
lação entre a AOS e a hipertensão arterial sistêmica (HAS) é a que encontra um m
aior conjunto de evidências. Atualmente, encontram-se dados que consideram a AOS
 uma importante causa secundária de HAS. Mais do que isso, a AOS está independen
temente associada a um pior controle pressórico, alteração do descenso noturno d
a pressão arterial e à presença de lesões de órgãos-alvo, tais como a hipertrofi
a do ventrículo esquerdo e a microalbuminúria. Estudos randomizados sugerem que 
o tratamento da AOS, especialmente com a pressão positiva contínua de vias aérea
s superiores (CPAP), considerado o tratamento padrão para a AOS, promove redução
 significante da pressão arterial nas 24 horas, efeito esse mais significante no
 subgrupo de pacientes com HAS não controlada e nos pacientes com HAS resistente
. A despeito de todas essas evidências, a AOS ainda continua sendo subdiagnostic
ada. O objetivo desta revisão é discutir os recentes avanços nos mecanismos fisi
opatológicos, na apresentação clínica e no tratamento da AOS, e o benefício sobr
e a pressão arterial.#^dnd^i1#^tm^lpt^kApneia do sono tipo obstrutiva^i1^sterapi
a#^tm^lpt^khipertensão^i1#^tm^lpt^kdoenças cardiovasculares^i1#^len^aObstructive
 sleep apnea (OSA) is a common clinical condition in the general population, esp
ecially among patients with cardiovascular diseases. More than just a local phen
omenon of upper respiratory tract obstruction, OSA leads to systemic consequence
s that may include intermittent hypoxia, sudden reduction of the intrathoracic p
ressure, and the occurrence of micro-awakenings with sleep fragmentation. In the
 past decades, innumerous evidences have consistently pointed to OSA as an impor
tant factor related to the presence of cardiovascular diseases. In particular, t
he relationship between OSA and systemic hypertension (SH) is the one supported 
by the largest body of evidence. Currently, there are data suggesting that OSA i
s an important secondary cause of SH. More importantly, OSA is independently ass
ociated with poorer blood pressure control, changes in sleep dip, and presence o
f target-organ damage such as left ventricular hypertrophy and microalbuminuria.
 Randomized studies suggest that the management of OSA, especially with continuo
us positive airway pressure (CPAP) - which is considered the standard treatment 
for OSA - promotes a significant 24-hour blood pressure reduction, and this effe
ct is more significant in the subgroup of patients with uncontrolled SH and drug
-resistant SH. Despite all those evidences, OSA has still been underdiagnosed. T
he objective of this review is to discuss the recent advances in the pathophysio
logical mechanisms, clinical presentation, and treatment of OSA, as well as the 
benefits this treatment can bring on blood pressure.#^dnd^i2#^tm^len^kSleep apne
a, obstructive^i2^stherapy#^tm^len^khypertension^i2#^tm^len^kcardiovascular dise
ases^i2#vancouv#75#20100505#05/05/10#20100507#07/05/10#20100920#20/09/10#aop0071
1.htm##
04901000000000637000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201020
01780120093002800100031003730100031004040100034004350100030004690700106004990700
09900605083165500704085000802359085005202367085002402419085003702443083159002480
08500080407008500460407808500250412408500360414911700080418507200030419311200090
4196111000904205116000904214115000904223114000904232113000904241002001304250#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#f#3#1#article#1#oa
#pt#br1.1#1#4.0#ILUS#TAB#17#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066
-782X#20110225#<b>Avanços recentes do impacto da apneia obstrutiva do sono na hi
pertensão arterial sistêmica</b>^lpt#<b>Recent advances of the impact of obstruc
tive sleep apnea on systemic hypertension</b>^len#^rND^1A01^nRodrigo P.^sPedrosa
#^rND^1A02^nEduardo M.^sKrieger#^rND^1A02^nGeraldo^sLorenzi-Filho#^rND^1A02^nLuc
iano F.^sDrager#Universidade de Pernambuco^iA01^1Pronto Socorro Cardiológico de 
Pernambuco^2Laboratório do Sono e Coração#Universidade de São Paulo^iA02^1Faculd
ade de Medicina^2Hospital das Clínicas^3Instituto do Coração#^lpt^aA apneia obst
rutiva do sono (AOS) é uma condição clínica comum na população em geral, princip
almente entre os pacientes portadores de doenças cardiovasculares. Mais do que u
m fenômeno local de obstrução das vias aéreas superiores, a AOS traz repercussõe
s sistêmicas que podem incluir a hipóxia intermitente, a redução abrupta da pres
são intratorácica e a ocorrência de microdespertares com fragmentação do sono. N
as últimas décadas, inúmeras evidências apontam de forma consistente a AOS como 
um importante fator envolvido na ocorrência de doenças cardiovasculares. Particu
larmente, a relação entre a AOS e a hipertensão arterial sistêmica (HAS) é a que
 encontra um maior conjunto de evidências. Atualmente, encontram-se dados que co
nsideram a AOS uma importante causa secundária de HAS. Mais do que isso, a AOS e
stá independentemente associada a um pior controle pressórico, alteração do desc
enso noturno da pressão arterial e à presença de lesões de órgãos-alvo, tais com
o a hipertrofia do ventrículo esquerdo e a microalbuminúria. Estudos randomizado
s sugerem que o tratamento da AOS, especialmente com a pressão positiva contínua
 de vias aéreas superiores (CPAP), considerado o tratamento padrão para a AOS, p
romove redução significante da pressão arterial nas 24 horas, efeito esse mais s
ignificante no subgrupo de pacientes com HAS não controlada e nos pacientes com 
HAS resistente. A despeito de todas essas evidências, a AOS ainda continua sendo
 subdiagnosticada. O objetivo desta revisão é discutir os recentes avanços nos m
ecanismos fisiopatológicos, na apresentação clínica e no tratamento da AOS, e o 
benefício sobre a pressão arterial.#^dnd^i1#^tm^lpt^kApneia do sono tipo obstrut
iva^i1^sterapia#^tm^lpt^khipertensão^i1#^tm^lpt^kdoenças cardiovasculares^i1#^le
n^aObstructive sleep apnea (OSA) is a common clinical condition in the general p
opulation, especially among patients with cardiovascular diseases. More than jus
t a local phenomenon of upper respiratory tract obstruction, OSA leads to system
ic consequences that may include intermittent hypoxia, sudden reduction of the i
ntrathoracic pressure, and the occurrence of micro-awakenings with sleep fragmen
tation. In the past decades, innumerous evidences have consistently pointed to O
SA as an important factor related to the presence of cardiovascular diseases. In
 particular, the relationship between OSA and systemic hypertension (SH) is the 
one supported by the largest body of evidence. Currently, there are data suggest
ing that OSA is an important secondary cause of SH. More importantly, OSA is ind
ependently associated with poorer blood pressure control, changes in sleep dip, 
and presence of target-organ damage such as left ventricular hypertrophy and mic
roalbuminuria. Randomized studies suggest that the management of OSA, especially
 with continuous positive airway pressure (CPAP) - which is considered the stand
ard treatment for OSA - promotes a significant 24-hour blood pressure reduction,
 and this effect is more significant in the subgroup of patients with uncontroll
ed SH and drug-resistant SH. Despite all those evidences, OSA has still been und
erdiagnosed. The objective of this review is to discuss the recent advances in t
he pathophysiological mechanisms, clinical presentation, and treatment of OSA, a
s well as the benefits this treatment can bring on blood pressure.#^dnd^i2#^tm^l
en^kSleep apnea, obstructive^i2^stherapy#^tm^len^khypertension^i2#^tm^len^kcardi
ovascular diseases^i2#vancouv#75#20100505#05/05/10#20100507#07/05/10#20100920#20
/09/10#aop00711.htm##
05007000000000661000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120095001840120086002790100030003650100030003950100034004250100029004590700
10800488070010100596083165500697085000802352085005202360085002402412085003702436
08315900247308500080406308500460407108500250411708500360414211700080417807200030
41861120009041891110009041981160009042071150009042161140009042251130009042340020
01304243008008904256#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.
htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#tab#17#nd#nd#Arq. bras. card
iol#ahead#20110000#^f0^l0#0066-782X#20110225#Avanços recentes do impacto da apne
ia obstrutiva do sono na hipertensão arterial sistêmica^lpt#Recent advances of t
he impact of obstructive sleep apnea on systemic hypertension^len#^rND^1A01^nRod
rigo P^sPedrosa#^rND^1A02^nEduardo M^sKrieger#^rND^1A02^nGeraldo^sLorenzi-Filho#
^rND^1A02^nLuciano F^sDrager#^iA01^1Universidade de Pernambuco^2Pronto Socorro C
ardiológico de Pernambuco^3Laboratório do Sono e Coração#^iA02^1Universidade de 
São Paulo^2Faculdade de Medicina^3Hospital das Clínicas. Instituto do Coração#^l
pt^aA apneia obstrutiva do sono (AOS) é uma condição clínica comum na população 
em geral, principalmente entre os pacientes portadores de doenças cardiovascular
es. Mais do que um fenômeno local de obstrução das vias aéreas superiores, a AOS
 traz repercussões sistêmicas que podem incluir a hipóxia intermitente, a reduçã
o abrupta da pressão intratorácica e a ocorrência de microdespertares com fragme
ntação do sono. Nas últimas décadas, inúmeras evidências apontam de forma consis
tente a AOS como um importante fator envolvido na ocorrência de doenças cardiova
sculares. Particularmente, a relação entre a AOS e a hipertensão arterial sistêm
ica (HAS) é a que encontra um maior conjunto de evidências. Atualmente, encontra
m-se dados que consideram a AOS uma importante causa secundária de HAS. Mais do 
que isso, a AOS está independentemente associada a um pior controle pressórico, 
alteração do descenso noturno da pressão arterial e à presença de lesões de órgã
os-alvo, tais como a hipertrofia do ventrículo esquerdo e a microalbuminúria. Es
tudos randomizados sugerem que o tratamento da AOS, especialmente com a pressão 
positiva contínua de vias aéreas superiores (CPAP), considerado o tratamento pad
rão para a AOS, promove redução significante da pressão arterial nas 24 horas, e
feito esse mais significante no subgrupo de pacientes com HAS não controlada e n
os pacientes com HAS resistente. A despeito de todas essas evidências, a AOS ain
da continua sendo subdiagnosticada. O objetivo desta revisão é discutir os recen
tes avanços nos mecanismos fisiopatológicos, na apresentação clínica e no tratam
ento da AOS, e o benefício sobre a pressão arterial.#^dnd^i1#^tm^lpt^kApneia do 
sono tipo obstrutiva^i1^sterapia#^tm^lpt^khipertensão^i1#^tm^lpt^kdoenças cardio
vasculares^i1#^len^aObstructive sleep apnea (OSA) is a common clinical condition
 in the general population, especially among patients with cardiovascular diseas
es. More than just a local phenomenon of upper respiratory tract obstruction, OS
A leads to systemic consequences that may include intermittent hypoxia, sudden r
eduction of the intrathoracic pressure, and the occurrence of micro-awakenings w
ith sleep fragmentation. In the past decades, innumerous evidences have consiste
ntly pointed to OSA as an important factor related to the presence of cardiovasc
ular diseases. In particular, the relationship between OSA and systemic hyperten
sion (SH) is the one supported by the largest body of evidence. Currently, there
 are data suggesting that OSA is an important secondary cause of SH. More import
antly, OSA is independently associated with poorer blood pressure control, chang
es in sleep dip, and presence of target-organ damage such as left ventricular hy
pertrophy and microalbuminuria. Randomized studies suggest that the management o
f OSA, especially with continuous positive airway pressure (CPAP) - which is con
sidered the standard treatment for OSA - promotes a significant 24-hour blood pr
essure reduction, and this effect is more significant in the subgroup of patient
s with uncontrolled SH and drug-resistant SH. Despite all those evidences, OSA h
as still been underdiagnosed. The objective of this review is to discuss the rec
ent advances in the pathophysiological mechanisms, clinical presentation, and tr
eatment of OSA, as well as the benefits this treatment can bring on blood pressu
re.#^dnd^i2#^tm^len^kSleep apnea, obstructive^i2^stherapy#^tm^len^khypertension^
i2#^tm^len^kcardiovascular diseases^i2#vancouv#75#20100505#05/05/10#20100507#07/
05/10#20100920#20/09/10#aop00711.htm#Internet^ihttp://www.scielo.br/scielo.php?s
cript=sci_arttext&pid=S0066-782X2011005000017##
00467000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022500083002001300308#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#5#1#article#228#<p><a name="
top"></a><font face="verdana, arial, helvetica, sans-serif" size="4"><b>Avan&cce
dil;os    recentes do impacto da apneia obstrutiva do sono na hipertens&atilde;o
 arterial    sist&ecirc;mica</b> </font></p>     ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#6#2#article#228#<p>&nbsp;</p
>     ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#7#3#article#228#<p>&nbsp;</p
>     ^cY#aop00711.htm##
00470000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022800083002001300311#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#8#4#article#228#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Rodrigo P. Pedrosa<sup>I</
sup>;    Eduardo M. Krieger<sup>II</sup>; Geraldo Lorenzi-Filho<sup>III</sup>; L
uciano    F. Drager<sup>II</sup></b></font></p>     ^cY#aop00711.htm##
00487000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704024500083002001300328#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#9#5#article#228#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Laborat&oacute;ri
o    do Sono e Cora&ccedil;&atilde;o, Pronto Socorro Cardiol&oacute;gico de Pern
ambuco    (PROCAPE), Universidade de Pernambuco - UPE, Recife, PE    ^cY#aop0071
1.htm##
00444000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704020100084002001300285#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#10#6#article#228#<br>   <sup
>II</sup>Unidade de Hipertens&atilde;o - Instituto do Cora&ccedil;&atilde;o    (
InCor) do Hospital das Cl&iacute;nicas da Faculdade de Medicina da Universidade 
   de S&atilde;o Paulo    ^cY#aop00711.htm##
00515000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704027200084002001300356#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#11#7#article#228#<br>   <sup
>III</sup>Laborat&oacute;rio do Sono da Disciplina de Pneumologia do Instituto  
  do Cora&ccedil;&atilde;o (InCor) do Hospital das Cl&iacute;nicas da Faculdade 
   de Medicina da Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP - Brasi
l</font></p>     ^cY#aop00711.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#12#8#article#228#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop00711.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#13#9#article#228#<p>&nbsp;</
p>     ^cY#aop00711.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#14#10#article#228#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop00711.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#15#11#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>   
  ^cY#aop00711.htm##
02490000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704224600085002001302331#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#16#12#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A apneia obstrutiva    do s
ono (AOS) &eacute; uma condi&ccedil;&atilde;o cl&iacute;nica comum na popula&cce
dil;&atilde;o    em geral, principalmente entre os pacientes portadores de doen&
ccedil;as cardiovasculares.    Mais do que um fen&ocirc;meno local de obstru&cce
dil;&atilde;o das vias a&eacute;reas    superiores, a AOS traz repercuss&otilde;
es sist&ecirc;micas que podem incluir    a hip&oacute;xia intermitente, a redu&c
cedil;&atilde;o abrupta da press&atilde;o    intrator&aacute;cica e a ocorr&ecir
c;ncia de microdespertares com fragmenta&ccedil;&atilde;o    do sono. Nas &uacut
e;ltimas d&eacute;cadas, in&uacute;meras evid&ecirc;ncias    apontam de forma co
nsistente a AOS como um importante fator envolvido na ocorr&ecirc;ncia    de doe
n&ccedil;as cardiovasculares. Particularmente, a rela&ccedil;&atilde;o    entre 
a AOS e a hipertens&atilde;o arterial sist&ecirc;mica (HAS) &eacute; a    que en
contra um maior conjunto de evid&ecirc;ncias. Atualmente, encontram-se    dados 
que consideram a AOS uma importante causa secund&aacute;ria de HAS. Mais    do q
ue isso, a AOS est&aacute; independentemente associada a um pior controle    pre
ss&oacute;rico, altera&ccedil;&atilde;o do descenso noturno da press&atilde;o   
 arterial e &agrave; presen&ccedil;a de les&otilde;es de &oacute;rg&atilde;os-al
vo,    tais como a hipertrofia do ventr&iacute;culo esquerdo e a microalbumin&ua
cute;ria.    Estudos randomizados sugerem que o tratamento da AOS, especialmente
 com a press&atilde;o    positiva cont&iacute;nua de vias a&eacute;reas superior
es (CPAP), considerado    o tratamento padr&atilde;o para a AOS, promove redu&cc
edil;&atilde;o significante    da press&atilde;o arterial nas 24 horas, efeito e
sse mais significante no subgrupo    de pacientes com HAS n&atilde;o controlada 
e nos pacientes com HAS resistente.    A despeito de todas essas evid&ecirc;ncia
s, a AOS ainda continua sendo subdiagnosticada.    O objetivo desta revis&atilde
;o &eacute; discutir os recentes avan&ccedil;os    nos mecanismos fisiopatol&oac
ute;gicos, na apresenta&ccedil;&atilde;o cl&iacute;nica    e no tratamento da AO
S, e o benef&iacute;cio sobre a press&atilde;o arterial.</font></p>     ^cY#aop0
0711.htm##
00467000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022300085002001300308#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#17#13#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:</b>    A
pneia do sono tipo obstrutiva/terapia, hipertens&atilde;o; doen&ccedil;as cardio
vasculares.</font></p> <hr size="1" noshade>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#18#14#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#19#15#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#20#16#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop00711.htm##
02933000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704268900085002001302774#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#21#17#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A apneia obstrutiva    do s
ono (AOS) &eacute; um importante dist&uacute;rbio respirat&oacute;rio do    sono
 caracterizado pela obstru&ccedil;&atilde;o recorrente das vias a&eacute;reas   
 superiores, levando a repetidas pausas respirat&oacute;rias completas (denomina
das    apneias) ou parciais (denominadas hipopneias). As pausas respirat&oacute;
rias    s&atilde;o associadas &agrave; hip&oacute;xia intermitente, redu&ccedil;
&atilde;o    da press&atilde;o intrator&aacute;cica durante os esfor&ccedil;os r
espirat&oacute;rios    e despertares frequentes com consequente fragmenta&ccedil
;&atilde;o do sono<sup>1</sup>.    O crescente interesse por essa condi&ccedil;&
atilde;o cl&iacute;nica aumentou    de forma consider&aacute;vel nas &uacute;lti
mas tr&ecirc;s d&eacute;cadas, n&atilde;o    somente pela epidemia de obesidade 
verificada em diferentes popula&ccedil;&otilde;es    (que, em paralelo, conduz a
 um aumento na ocorr&ecirc;ncia da AOS), mas tamb&eacute;m    pelas consistentes
 evid&ecirc;ncias de que a AOS est&aacute; estritamente relacionada    &agrave; 
ocorr&ecirc;ncia de in&uacute;meras doen&ccedil;as cardiovasculares.    Entre el
as, a rela&ccedil;&atilde;o entre a AOS e hipertens&atilde;o arterial    sist&ec
irc;mica (HAS) &eacute; a que tem mais respaldo na literatura. Em 2002,    publi
camos a primeira revis&atilde;o sobre AOS e HAS nos Arquivos Brasileiros    de C
ardiologia<sup>2</sup>. Desde ent&atilde;o, um conjunto enorme de evid&ecirc;nci
as    refor&ccedil;ou a import&acirc;ncia da AOS na fisiopatologia, apresenta&cc
edil;&atilde;o    cl&iacute;nica e evolutiva do paciente hipertenso. Como conseq
u&ecirc;ncia,    um ano ap&oacute;s esta primeira revis&atilde;o, o <i>VII Joint
 National Comittee    on Prevention, Detection, Evaluation and Treatment of High
 Blood Pressure<sup>3</sup></i>    incluiu a AOS como uma nova causa de HAS secu
nd&aacute;ria. Esse mesmo procedimento    foi adotado pela <i>V Diretriz Brasile
ira de Hipertens&atilde;o</i>, publicada    mais recentemente<sup>4</sup>. Na pr
esente revis&atilde;o, discutiremos os recentes    avan&ccedil;os das evid&ecirc
;ncias epidemiol&oacute;gicas, os mecanismos fisiopatol&oacute;gicos,    a apres
enta&ccedil;&atilde;o cl&iacute;nica (o que inclui as caracter&iacute;sticas    
que ajudam na suspeita cl&iacute;nica da AOS em pacientes hipertensos) e o trata
mento    da AOS com enfoque no benef&iacute;cio sobre a press&atilde;o arterial.
 Finalmente,    delinearemos algumas perspectivas futuras de investiga&ccedil;&a
tilde;o que    podem contribuir para aumentar nossa compreens&atilde;o do impact
o da AOS na    HAS.</font></p>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#22#18#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010300085002001300188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#23#19#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Epidemiologia</b></font>
</p>     ^cY#aop00711.htm##
01404000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704116000085002001301245#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#24#20#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Estudos epidemiol&oacute;gi
cos    realizados nos Estados Unidos mostram que a AOS acomete um em cada quatro
 homens    e uma em cada dez mulheres na popula&ccedil;&atilde;o geral<sup>5</su
p>. Uma    recente publica&ccedil;&atilde;o brasileira avaliou a preval&ecirc;nc
ia da AOS    em 1.042 participantes representativos da popula&ccedil;&atilde;o d
e S&atilde;o    Paulo. Os autores encontraram dados alarmantes: 32,8% apresentar
am o diagn&oacute;stico    compat&iacute;vel com AOS, sugerindo que o dist&uacut
e;rbio &eacute; bem mais    comum do que se pensava<sup>6</sup>. Mais do que ser
 uma condi&ccedil;&atilde;o    cl&iacute;nica comum, a AOS pode apresentar reper
cuss&otilde;es s&eacute;rias    &agrave; qualidade de vida dos pacientes, devido
 &agrave; possibilidade de promover    sonol&ecirc;ncia diurna excessiva, mau de
sempenho nas atividades di&aacute;rias,    irritabilidade, labilidade do humor e
tc<sup>7</sup>. Mais recentemente, a AOS    tem sido tamb&eacute;m implicada de 
forma independente para o aumento da mortalidade    geral e cardiovascular<sup>8
-11</sup>.</font></p>     ^cY#aop00711.htm##
01240000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099600085002001301081#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#25#21#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Particularmente    nos paci
entes com HAS, a preval&ecirc;ncia da AOS &eacute; ainda maior do que    a verif
icada na popula&ccedil;&atilde;o geral. Nos hipertensos, a preval&ecirc;ncia    
varia entre 38 e 56%<sup>12,13</sup> e pode chegar a 82% em indiv&iacute;duos   
 com HAS refrat&aacute;ria<sup>14</sup>. Em um desses estudos, Gon&ccedil;alves 
   e cols.<sup>15</sup> encontraram uma preval&ecirc;ncia de AOS de 71% <i>versu
s</i>    38% em indiv&iacute;duos com e sem HAS refrat&aacute;ria, respectivamen
te. Esse    artigo n&atilde;o afirma que a AOS causa, obrigatoriamente, a HAS ne
ssa magnitude,    mas que a presen&ccedil;a dela &eacute; comum entre os indiv&i
acute;duos hipertensos.    Conforme discutiremos adiante, a AOS, al&eacute;m de 
ser um dist&uacute;rbio    comum, participa ativamente na modula&ccedil;&atilde;
o da press&atilde;o arterial    e na evolu&ccedil;&atilde;o dos pacientes hipert
ensos.</font></p>     ^cY#aop00711.htm##
01356000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704111200085002001301197#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#26#22#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O estudo epidemiol&oacute;g
ico    que explorou a rela&ccedil;&atilde;o entre a AOS e a HAS e foi mais citad
o na    literatura &eacute; a coorte de Wisconsin, que avaliou 709 indiv&iacute;
duos    normotensos com estudo polissonogr&aacute;fico<sup>16</sup>. Ap&oacute;s
 seguimento    de quatro anos, houve um aumento na ocorr&ecirc;ncia da HAS em in
div&iacute;duos    que tinham AOS. Al&eacute;m disso, os autores observaram uma 
rela&ccedil;&atilde;o    dose-resposta entre a gravidade da AOS &#91;medida pelo
 &iacute;ndice de apneia    e hipopneia (IAH) - ver adiante&#93; e o risco de ap
arecimento da HAS. Pacientes    com AOS moderada e grave (IAH <u>&gt;</u> 15 eve
ntos/hora de sono pela polissonografia)    apresentam um aumento de cerca de tr&
ecirc;s vezes no risco de desenvolvimento    de HAS durante o seguimento de quat
ro anos em rela&ccedil;&atilde;o aos indiv&iacute;duos    que n&atilde;o tiveram
 eventos durante o sono. Outras coortes que se seguiram    mostraram resultados 
semelhantes aos descritos<sup>17,18</sup>.</font></p>     ^cY#aop00711.htm##
01285000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704104100085002001301126#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#27#23#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na popula&ccedil;&atilde;o 
   geral, os fatores de risco para a AOS incluem a idade entre 40 e 70 anos, o  
  sexo masculino, obesidade, presen&ccedil;a de sonol&ecirc;ncia excessiva, ronc
os,    anormalidades estruturais de vias a&eacute;reas superiores, abuso no uso 
do    &aacute;lcool e hist&oacute;ria familiar de AOS<sup>19</sup>. No entanto, 
esses    mesmos fatores podem n&atilde;o ser verdadeiros em popula&ccedil;&otild
e;es    espec&iacute;ficas, tais como em popula&ccedil;&otilde;es com doen&ccedi
l;as    cardiovasculares. De fato, evid&ecirc;ncias recentes sugerem que o sexo 
masculino,    a sonol&ecirc;ncia diurna excessiva e o ronco n&atilde;o parecem s
er bons preditores    da presen&ccedil;a da AOS na popula&ccedil;&atilde;o de pa
cientes hipertensos<sup>13,20</sup>.    Por outro lado, a presen&ccedil;a da s&i
acute;ndrome metab&oacute;lica mostrou-se    um excelente preditor da presen&cce
dil;a da AOS em pacientes hipertensos<sup>13</sup>.</font></p>     ^cY#aop00711.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#28#24#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#29#25#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Fisiopatologia</b></font
></p>     ^cY#aop00711.htm##
00892000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064800085002001300733#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#30#26#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Embora n&atilde;o    sejam 
totalmente conhecidos os mecanismos pelos quais a AOS promova o aumento    da pr
ess&atilde;o arterial, diversos trabalhos apontam o poss&iacute;vel envolvimento
    de fatores como a ativa&ccedil;&atilde;o neuro-humoral, as altera&ccedil;&ot
ilde;es    do quimiorreflexo, a diminui&ccedil;&atilde;o da sensibilidade dos ba
rorreceptores,    a disfun&ccedil;&atilde;o endotelial, a altera&ccedil;&atilde;
o no metabolismo    do sal e &aacute;gua, entre outros<sup>21</sup> (<a href="/i
mg/revistas/abc/2011nahead/00711f01.jpg">Figura    1</a>).</font></p>     ^cY#ao
p00711.htm##
01299000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704105500085002001301140#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#31#27#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A ativa&ccedil;&atilde;o   
 neuro-humoral na AOS compreende o aumento da atividade simp&aacute;tica durante
    o sono e tamb&eacute;m na vig&iacute;lia, bem como aumento nos n&iacute;veis
    de angiotensina II e aldosterona. Esse &eacute; provavelmente o principal me
canismo    envolvido na g&ecirc;nese da HAS em portadores de AOS. O tratamento d
a AOS utilizando-se    um dispositivo de press&atilde;o positiva cont&iacute;nua
 em vias a&eacute;reas    (do ingl&ecirc;s, "CPAP") durante a noite produz redu&
ccedil;&atilde;o significativa    da atividade simp&aacute;tica determinada por 
dosagem plasm&aacute;tica e urin&aacute;ria    de norepinefrina, bem como ativid
ade do nervo fibular<sup>22</sup>, o que permite    confirmar a import&acirc;nci
a desse mecanismo fisiopatol&oacute;gico. Da mesma    forma, alguns trabalhos su
gerem que o tratamento da AOS tamb&eacute;m contribui    para a redu&ccedil;&ati
lde;o dos n&iacute;veis de renina e angiotensina II<sup>23</sup>.</font></p>    
 ^cY#aop00711.htm##
01952000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704170800085002001301793#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#32#28#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os mecanismos envolvidos   
 no aumento do t&ocirc;nus simp&aacute;tico na AOS est&atilde;o aparentemente   
 ligados &agrave; ativa&ccedil;&atilde;o do quimiorreflexo, que &eacute; o mecan
ismo    dominante na regula&ccedil;&atilde;o da resposta ventilat&oacute;ria e c
irculat&oacute;ria    &agrave;s mudan&ccedil;as do conte&uacute;do arterial de o
xig&ecirc;nio (O<sub>2</sub>)    e g&aacute;s carb&ocirc;nico (CO<sub>2</sub>)<s
up>24</sup>. A ativa&ccedil;&atilde;o    quimiorreflexa leva ao aumento da ativi
dade simp&aacute;tica, frequ&ecirc;ncia    card&iacute;aca, press&atilde;o arter
ial e volume minuto<sup>25</sup>. O corpo    carot&iacute;deo, que &eacute; o pr
imeiro quimiorreceptor a detectar altera&ccedil;&otilde;es    na press&atilde;o 
parcial arterial de O<sub>2</sub>, medeia o aumento reflexo    da atividade simp
&aacute;tica e da press&atilde;o arterial durante a hip&oacute;xia    cr&ocirc;n
ica intermitente. H&aacute; evid&ecirc;ncias que demonstram que a    hip&oacute;
xia cr&ocirc;nica intermitente exerce dois efeitos no corpo carot&iacute;deo<sup
>26</sup>:    1) sensibiliza&ccedil;&atilde;o da resposta &agrave; hip&oacute;xi
a (pela gera&ccedil;&atilde;o    de esp&eacute;cies reativas de oxig&ecirc;nio) 
e 2) indu&ccedil;&atilde;o da    chamada facilita&ccedil;&atilde;o a longo prazo
 (<i>long term facilitation</i>),    que &eacute; o mecanismo de manuten&ccedil;
&atilde;o da hiperativa&ccedil;&atilde;o    simp&aacute;tica ap&oacute;s longos 
per&iacute;odos que sucedem o fim da hip&oacute;xia,    podendo contribuir para 
explicar a eleva&ccedil;&atilde;o da press&atilde;o    arterial durante o dia.</
font></p>     ^cY#aop00711.htm##
01737000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704149300085002001301578#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#33#29#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os barorreceptores    arter
iais s&atilde;o termina&ccedil;&otilde;es nervosas sensoriais sens&iacute;veis  
  ao estiramento e est&atilde;o localizados em regi&otilde;es estrat&eacute;gica
s    como o seio carot&iacute;deo e o arco a&oacute;rtico<sup>27</sup>. O barorr
eflexo    arterial &eacute; o mecanismo prim&aacute;rio de resposta compensat&oa
cute;ria    &agrave;s altera&ccedil;&otilde;es agudas e cont&iacute;nuas flutua&
ccedil;&otilde;es    da press&atilde;o arterial que ocorrem em diversas situa&cc
edil;&otilde;es.    A diminui&ccedil;&atilde;o do controle barorreflexo da frequ
&ecirc;ncia card&iacute;aca    &eacute; descrita na AOS<sup>28</sup>. No entanto
, n&atilde;o est&aacute; claro    se a diminui&ccedil;&atilde;o do controle baro
rreflexo na AOS representa uma    adapta&ccedil;&atilde;o neural ou se &eacute; 
secund&aacute;ria &agrave; diminui&ccedil;&atilde;o    da complac&ecirc;ncia art
erial carot&iacute;dea e a&oacute;rtica<sup>29</sup>    que, como sabemos, promo
ve a adapta&ccedil;&atilde;o dos barorreceptores arteriais    na hipertens&atild
e;o arterial<sup>30,31</sup>. Essa disfun&ccedil;&atilde;o    do barorreflexo pa
rece ser respons&aacute;vel pelo descontrole da press&atilde;o    arterial duran
te as apneias, enquanto a disfun&ccedil;&atilde;o do quimiorreflexo    seria res
pons&aacute;vel pelas altera&ccedil;&otilde;es da press&atilde;o arterial    nas
 24 horas<sup>26</sup>.</font></p>     ^cY#aop00711.htm##
01413000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704116900085002001301254#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#34#30#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A disfun&ccedil;&atilde;o  
  endotelial tem sido consistentemente relatada em pacientes com AOS, mas essa  
  rela&ccedil;&atilde;o n&atilde;o depende de outros fatores de confus&atilde;o 
   como a obesidade<sup>32-34</sup>. Tal como &eacute; sugerido na g&ecirc;nese 
   da HAS essencial, acredita-se que a disfun&ccedil;&atilde;o endotelial tamb&e
acute;m    participe na g&ecirc;nese da HAS induzida pela AOS. Entre os mecanism
os propostos,    est&atilde;o a redu&ccedil;&atilde;o da biodisponibilidade do &
oacute;xido n&iacute;trico,    aumento da apoptose endotelial e diminui&ccedil;&
atilde;o da capacidade de regenera&ccedil;&atilde;o    celular induzida pela hip
&oacute;xia, caracterizada pela diminui&ccedil;&atilde;o    da produ&ccedil;&ati
lde;o de c&eacute;lulas progenitoras endoteliais<sup>35</sup>.    Mesmo com o su
porte de uma rela&ccedil;&atilde;o de causalidade, diversos estudos    mostram q
ue o tratamento com o CPAP reduz a disfun&ccedil;&atilde;o endotelial    em para
lelo com um aumento na capacidade de regenera&ccedil;&atilde;o do endot&eacute;l
io<sup>34,35</sup>.</font></p>     ^cY#aop00711.htm##
00910000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066600085002001300751#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#35#31#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Outro fator relacionado    
&agrave; disfun&ccedil;&atilde;o endotelial e ao aumento da vasomotricidade    n
a AOS &eacute; o aumento da endotelina. A endotelina est&aacute; aumentada    na
 AOS<sup>36</sup>, correlaciona-se positivamente &agrave; gravidade da AOS<sup>3
7</sup>    e teve sua concentra&ccedil;&atilde;o reduzida com o tratamento da AO
S<sup>38</sup>.    A despeito dessas evid&ecirc;ncias, o papel relativo da endot
elina na g&ecirc;nese    da HAS induzida pela AOS n&atilde;o est&aacute; ainda d
efinido, visto que n&atilde;o    existe consenso da literatura<sup>39</sup>.</fo
nt></p>     ^cY#aop00711.htm##
01842000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704159800085002001301683#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#36#32#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A ativa&ccedil;&atilde;o   
 do sistema renina-angiotensina-aldosterona por vias independentes da produ&cced
il;&atilde;o    de renina &eacute; encontrada na AOS, demonstrada por meio de n&
iacute;veis    aumentados de angiotensina II e aldosterona comparados em indiv&i
acute;duos    de mesmo &iacute;ndice de massa corp&oacute;rea<sup>23</sup>. Esse
s pacientes    podem apresentar baixa atividade plasm&aacute;tica de renina e re
la&ccedil;&atilde;o    aldosterona/renina elevada, o que pode conduzir a falso d
iagn&oacute;stico de    hiperaldosteronismo prim&aacute;rio<sup>40</sup>. A elev
a&ccedil;&atilde;o da    aldosterona tem import&acirc;ncia terap&ecirc;utica, po
is sugere um efeito aditivo    dos inibidores da aldosterona no controle press&o
acute;rico desses pacientes    associado ao tratamento da AOS<sup>41</sup>. Por 
outro lado, indiv&iacute;duos    com AOS e n&iacute;veis aumentados de aldostero
na podem apresentar maior reten&ccedil;&atilde;o    de l&iacute;quido. Essa rete
n&ccedil;&atilde;o pode contribuir para maior edema    de tecidos das vias a&eac
ute;reas e gerar mais apneias obstrutivas<sup>42</sup>,    o que permite a cria&
ccedil;&atilde;o de um ciclo perpetuador da HAS. No entanto,    o papel do siste
ma renina-angiotensina-aldosterona na AOS tamb&eacute;m n&atilde;o    est&aacute
; completamente definido, uma vez que n&atilde;o existe ainda consenso    na lit
eratura da participa&ccedil;&atilde;o desse eixo na g&ecirc;nese da hipertens&at
ilde;o    relacionada &agrave; AOS<sup>43</sup>.</font></p>     ^cY#aop00711.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#37#33#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00378000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013400085002001300219#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#38#34#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Apresenta&ccedil;&atilde
;o    cl&iacute;nica</b></font></p>     ^cY#aop00711.htm##
00913000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066900085002001300754#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#39#35#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A despeito das    evid&ecir
c;ncias cient&iacute;ficas, a AOS &eacute; ainda subdiagnosticada na    popula&c
cedil;&atilde;o geral, o que tamb&eacute;m &eacute; verdade para os    pacientes
 hipertensos. As causas para esse tipo de problema s&atilde;o m&uacute;ltiplas: 
   falta de conhecimento do m&eacute;dico que atende o paciente hipertenso, difi
culdade    de acesso ao diagn&oacute;stico e ao tratamento da AOS e a aus&ecirc;
ncia de    sintomas como a sonol&ecirc;ncia diurna em porcentagem significante d
os pacientes    hipertensos (ver aspectos epidemiol&oacute;gicos)<sup>13</sup>.<
/font></p>     ^cY#aop00711.htm##
00941000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704069700085002001300782#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#40#36#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Para a suspeita    diagn&oa
cute;stica da AOS no paciente hipertenso, devemos buscar ativamente    por sinai
s/sintomas e n&atilde;o esperar que o paciente aborde o problema, porque    &eac
ute; comum o paciente n&atilde;o se queixar para o cl&iacute;nico/cardiologista 
   sobre a qualidade do sono. Conforme descrito anteriormente, a presen&ccedil;a
    da s&iacute;ndrome metab&oacute;lica &eacute; uma boa dica para a presen&cce
dil;a    da AOS no paciente hipertenso<sup>13</sup>. Outros preditores s&atilde;
o a idade    entre 40 e 70 anos e o alto risco para AOS pelo question&aacute;rio
 de Berlin<sup>13,44</sup>.</font></p>     ^cY#aop00711.htm##
01979000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704173500085002001301820#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#41#37#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O exame de escolha    para 
o diagn&oacute;stico da AOS &eacute; a polissonografia noturna, que apresenta   
 sensibilidade e especificidade pr&oacute;ximas de 95%<sup>1</sup>. A polissonog
rafia    consiste na monitoriza&ccedil;&atilde;o simult&acirc;nea do eletroencef
alograma,    eletro-oculograma, eletromiograma, satura&ccedil;&atilde;o de oxig&
ecirc;nio,    fluxo de ar, movimentos tor&aacute;cicos e abdominais e frequ&ecir
c;ncia card&iacute;aca.    Dessa forma, a polissonografia noturna permite n&atil
de;o somente a avalia&ccedil;&atilde;o    da arquitetura e a efici&ecirc;ncia do
 sono, mas tamb&eacute;m o diagn&oacute;stico    e a diferencia&ccedil;&atilde;o
 dos dist&uacute;rbios do sono. Na AOS, observamos    que, durante os eventos re
spirat&oacute;rios, h&aacute; movimenta&ccedil;&atilde;o    tor&aacute;cica e ab
dominal ativa traduzidas em tentativas f&uacute;teis de    libera&ccedil;&atilde
;o da via a&eacute;rea em decorr&ecirc;ncia da obstru&ccedil;&atilde;o.    Os ev
entos respirat&oacute;rios s&atilde;o seguidos por dessatura&ccedil;&otilde;es  
  de oxig&ecirc;nio e frequentemente terminam com o surgimento de microdespertar
es,    momento em que ocorre a desobstru&ccedil;&atilde;o da via a&eacute;rea. A
 AOS    &eacute; classificada em leve, moderada e grave de acordo com a soma dos
 eventos    respirat&oacute;rios (apneia e hipopneias) por hora de sono. Conside
ra-se um    valor normal quando a soma dos eventos for &lt; 5 eventos por hora d
e sono.    Definimos AOS leve, moderada e grave quando o &iacute;ndice de apneia
 e hipopneia    for entre 5 e 14,9; 15 e 29,9 e <u>&gt;</u> 30 eventos por hora 
de sono, respectivamente.</font></p>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#42#38#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015000085002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#43#39#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Padr&atilde;o    de comp
ortamento da press&atilde;o arterial</b></font></p>     ^cY#aop00711.htm##
01079000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083500085002001300920#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#44#40#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Tipicamente, pacientes    c
om AOS podem apresentar HAS diast&oacute;lica isolada como primeira manifesta&cc
edil;&atilde;o    de HAS<sup>45,46</sup>. As causas para isto ainda n&atilde;o s
&atilde;o totalmente    conhecidas, mas especula-se que seja em parte explicado 
pelo aumento da resist&ecirc;ncia    vascular perif&eacute;rica devido &agrave; 
hiperatividade simp&aacute;tica comumente    observada nesses pacientes. Um estu
do mostrou uma associa&ccedil;&atilde;o significante    entre a AOS e a ocorr&ec
irc;ncia de HAS sist&oacute;lica e diast&oacute;lica    combinada somente em pac
ientes &lt; 60 anos de idade, mas nenhuma associa&ccedil;&atilde;o    entre HAS 
arterial sist&oacute;lica isolada e a AOS em faixa et&aacute;ria alguma<sup>47</
sup>.</font></p>     ^cY#aop00711.htm##
01538000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704129400085002001301379#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#45#41#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Uma das caracter&iacute;sti
cas    marcantes da AOS &eacute; a ocorr&ecirc;ncia de altera&ccedil;&atilde;o d
o descenso    noturno pela monitoriza&ccedil;&atilde;o ambulatorial da press&ati
lde;o arterial    (MAPA). De fato, a altera&ccedil;&atilde;o no descenso noturno
 da press&atilde;o    arterial &eacute; um dos achados que mais levam cl&iacute;
nicos e cardiologistas    a pensar na possibilidade de AOS, embora esse achado n
&atilde;o seja patognom&ocirc;nico    da AOS. Atribui-se que a altera&ccedil;&at
ilde;o da press&atilde;o arterial    seja decorrente da ativa&ccedil;&atilde;o s
imp&aacute;tica pelos eventos respirat&oacute;rios    e pelos despertares freque
ntes que ocorrem durante o sono nesses pacientes.    Essa altera&ccedil;&atilde;
o parece ser mais comum em pacientes da ra&ccedil;a    negra e nos portadores de
 HAS<sup>48</sup>. No entanto, a altera&ccedil;&atilde;o    no descenso noturno 
tamb&eacute;m &eacute; frequente nos pacientes normotensos    com AOS, o que sug
ere a poss&iacute;vel contribui&ccedil;&atilde;o desse fator    para a explica&c
cedil;&atilde;o do aumento do risco cardiovascular na AOS, mesmo    na aus&ecirc
;ncia de outras condi&ccedil;&otilde;es associadas<sup>49</sup>.</font></p>     
^cY#aop00711.htm##
01050000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080600085002001300891#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#46#42#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Outro achado que    parece 
ser comum em pacientes com AOS e que pode tamb&eacute;m contribuir para    o aum
ento do risco cardiovascular &eacute; a ocorr&ecirc;ncia da HAS mascarada<sup>50
</sup>.    Evid&ecirc;ncia recente sugere que indiv&iacute;duos com AOS e HAS ma
scarada    apresentaram uma rigidez arterial maior do que indiv&iacute;duos com 
AOS isoladamente    e controles<sup>50</sup>. No entanto, a rigidez arterial nos
 pacientes com AOS    sem HAS mascarada foi tamb&eacute;m maior do que no grupo 
controle, e, portanto,    isso pode sugerir que o dano vascular promovido pela A
OS n&atilde;o &eacute;    somente mediado pelas varia&ccedil;&otilde;es e aument
o sustentado da press&atilde;o    arterial<sup>50</sup>.</font></p>     ^cY#aop0
0711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#47#43#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00385000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014100085002001300226#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#48#44#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>AOS e les&otilde;es    d
e &oacute;rg&atilde;os-alvo</b></font></p>     ^cY#aop00711.htm##
01849000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704160500085002001301690#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#49#45#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Evid&ecirc;ncias    recente
s prop&otilde;em que a presen&ccedil;a da AOS est&aacute; associada &agrave;    
maior ocorr&ecirc;ncia de les&otilde;es de &oacute;rg&atilde;os-alvo independent
emente    de outros fatores de confus&atilde;o, tais como a HAS e a obesidade<su
p>51,52</sup>.    No entanto, a presen&ccedil;a da AOS e HAS no mesmo individuo 
parece ter um    efeito aditivo na ocorr&ecirc;ncia de les&atilde;o vascular e r
emodelamento    card&iacute;aco do que cada fator individualmente<sup>52,53</sup
> (<a href="#f2">Figura    2</a>). Embora n&atilde;o estejam claros os mecanismo
s de remodelamento card&iacute;aco    na AOS, acredita-se que o aumento da rigid
ez arterial de grandes art&eacute;rias    contribua para aumentar a p&oacute;s-c
arga do ventr&iacute;culo esquerdo<sup>52</sup>.    Al&eacute;m disso, a press&a
tilde;o intrator&aacute;cica negativa durante as    apneias pode contribuir para
 aumentar a press&atilde;o transmural do ventr&iacute;culo    esquerdo. Outros a
chados diretamente relacionados ao remodelamento vascular    e aumento da p&oacu
te;s-carga do ventr&iacute;culo esquerdo dizem respeito ao    aumento atrial esq
uerdo<sup>54</sup> e da aorta ascendente<sup>55</sup>. Esses    dados sugerem qu
e a AOS pode piorar a evolu&ccedil;&atilde;o do paciente hipertenso    e predisp
or a ocorr&ecirc;ncia de complica&ccedil;&otilde;es como a insufici&ecirc;ncia  
  card&iacute;aca. No entanto, mais evid&ecirc;ncias s&atilde;o necess&aacute;ri
as    para conclus&otilde;es definitivas nesse sentido.</font></p>     ^cY#aop00
711.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#50#46#article#228#<p><a name
="f2"></a></p>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#51#47#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#52#48#article#228#<p align="
center"><img src="/img/revistas/abc/2011nahead/00711f02.jpg"></p>     ^cY#aop007
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#53#49#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#54#50#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Tratamento</b></font></p
>     ^cY#aop00711.htm##
02601000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704235700085002001302442#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#55#51#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">At&eacute; o momento,    ce
rca de 30 estudos n&atilde;o controlados e 22 estudos controlados demonstram    
uma redu&ccedil;&atilde;o m&eacute;dia da press&atilde;o arterial de cerca de   
 2,5 mmHg por meio do tratamento com CPAP. No entanto, poucos ensaios cl&iacute;
nicos    randomizados avaliaram uma popula&ccedil;&atilde;o com predom&iacute;ni
o de    pacientes hipertensos descontrolados. Um desses estudos envolveu o trata
mento    com o CPAP ou "Sham" CPAP (isto &eacute;, CPAP com press&otilde;es m&ia
cute;nimas    sem efeito terap&ecirc;utico) por dois meses de dura&ccedil;&atild
e;o em pacientes    com sonol&ecirc;ncia diurna e AOS. Os autores encontraram um
a redu&ccedil;&atilde;o    de 10 mmHg na press&atilde;o arterial sist&oacute;lic
a e diast&oacute;lica de    24 horas no grupo CPAP<sup>56</sup>. J&aacute; em ou
tro estudo mais curto e    com um n&uacute;mero menor de participantes, em que o
s pacientes sem sonol&ecirc;ncia    diurna fizeram um <i>cross-over</i> para o u
so do CPAP, n&atilde;o houve redu&ccedil;&atilde;o    da press&atilde;o arterial
 com o uso do CPAP<sup>57</sup>. Dessa forma, a presen&ccedil;a    da sonol&ecir
c;ncia diurna parece ser um preditor de resposta press&oacute;rica    ao tratame
nto com o CPAP, embora os mecanismos sejam desconhecidos. O maior    estudo at&e
acute; o presente momento que avaliou o impacto do CPAP na redu&ccedil;&atilde;o
    da press&atilde;o arterial incluiu 359 pacientes hipertensos sem sonol&ecirc
;ncia    diurna. Os pacientes foram randomizados para tratamento com CPAP ou tra
tamento    conservador<sup>58</sup>. Esse estudo encontrou redu&ccedil;&atilde;o
 modesta    apenas da press&atilde;o diast&oacute;lica (2,2 mmHg) ao final de 12
 meses de    seguimento no grupo tratado com CPAP. Esse benef&iacute;cio foi enc
ontrado principalmente    nos pacientes que usaram o CPAP por mais de 5,6 horas 
por noite. Vale ressaltar    que apenas metade dos participantes usavam anti-hip
ertensivos e que a avalia&ccedil;&atilde;o    da press&atilde;o arterial era fei
ta em consulta ambulatorial, sem o uso da    MAPA<sup>58</sup>. A <a href="/img/
revistas/abc/2011nahead/00711t01.jpg">Tabela 1</a> mostra os principais    estud
os randomizados em que ao menos 50% dos participantes eram hipertensos<sup>56-60
</sup>.</font></p>     ^cY#aop00711.htm##
02662000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704241800085002001302503#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#56#52#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Sumarizando esses    achado
s, uma revis&atilde;o sistem&aacute;tica<sup>61</sup> e quatro meta-an&aacute;li
ses<sup>62-65</sup>    que avaliam o impacto do CPAP na press&atilde;o arterial 
foram publicadas nos    &uacute;ltimos anos. Todas apontam para uma redu&ccedil;
&atilde;o da press&atilde;o    arterial com o uso do CPAP. Apenas uma delas<sup>
62</sup> n&atilde;o encontrou    benef&iacute;cio do tratamento com CPAP no cont
role da press&atilde;o arterial,    mas, quando analisados apenas os seis estudo
s com pacientes mais graves (IAH    &gt; 30 eventos/hora), houve redu&ccedil;&at
ilde;o de press&atilde;o arterial    sist&oacute;lica de 3,03 e diast&oacute;lic
a de 2,03 mmHg. No estudo de Haentjens    e cols.<sup>63</sup>, o qual analisou 
12 ensaios placebo-controlados, em que    a MAPA foi utilizada para avalia&ccedi
l;&atilde;o da press&atilde;o arterial,    houve redu&ccedil;&atilde;o de 1,77 e
 1,79 mmHg nas press&otilde;es sist&oacute;licas    e diast&oacute;licas m&eacut
e;dias de 24 horas, respectivamente. A mais recente    meta-an&aacute;lise avali
ou 818 pacientes e demonstrou redu&ccedil;&atilde;o    da press&atilde;o arteria
l de 2,46 mmHg na press&atilde;o arterial sist&oacute;lica    e 1,83 mmHg na pre
ss&atilde;o arterial diast&oacute;lica ap&oacute;s o uso do    CPAP<sup>65</sup>
. Deve-se destacar que esses n&iacute;veis de redu&ccedil;&atilde;o    de press&
atilde;o arterial j&aacute; s&atilde;o respons&aacute;veis por redu&ccedil;&atil
de;o    de eventos cardiovasculares em longo prazo. Entretanto, a escolha dos tr
abalhos    inclu&iacute;dos nessas meta-an&aacute;lises &eacute; sujeita a cr&ia
cute;ticas    - envolveram estudos com indiv&iacute;duos normotensos, o que pode
 contribuir    para o resultado modesto da queda da press&atilde;o arterial<sup>
66</sup>. Por    outro lado, um achado importante que uma das meta-an&aacute;lis
es encontrou    foi que a magnitude da queda da press&atilde;o arterial estava d
iretamente associada    ao n&uacute;mero de horas de uso de CPAP durante o sono<
sup>65</sup>. As evid&ecirc;ncias    atuais do benef&iacute;cio do tratamento da
 AOS em pacientes com HAS refrat&aacute;ria<sup>67-69</sup>    s&atilde;o ainda 
mais fracas, embora os estudos atuais apontem para uma redu&ccedil;&atilde;o    
ainda maior da press&atilde;o arterial (<a href="#t2">Tabela 2</a>).</font></p> 
    ^cY#aop00711.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#57#53#article#228#<p><a name
="t2"></a></p>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#58#54#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#59#55#article#228#<p align="
center"><img src="/img/revistas/abc/2011nahead/00711t02.jpg"></p>     ^cY#aop007
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#60#56#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00758000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051400085002001300599#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#61#57#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No que se refere    aos tra
tamentos alternativos da AOS, o uso de dispositivos de avan&ccedil;o    mandibul
ar, que tracionam a mand&iacute;bula para frente e, consequentemente,    a base 
da l&iacute;ngua, mostrou-se eficaz na redu&ccedil;&atilde;o da press&atilde;o  
  arterial e deve ser considerado como um tratamento alternativo em pacientes   
 n&atilde;o aderentes ao CPAP ou em pacientes com AOS leve/moderada<sup>70,71</s
up>.</font></p>     ^cY#aop00711.htm##
01834000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704159000085002001301675#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#62#58#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o h&aacute;    est
udos definitivos quanto ao uso de medica&ccedil;&otilde;es anti-hipertensivas   
 espec&iacute;ficas para os pacientes hipertensos portadores de AOS. Clonidina  
  pode reduzir o sono REM e, ent&atilde;o, reduzir os epis&oacute;dios de apneia
    durante essa fase do sono e melhorar a hipoxemia noturna<sup>72</sup>. Uma c
ompara&ccedil;&atilde;o    entre cinco classes de drogas comumente utilizadas (a
tenolol, amlodipino, enalapril,    losartan e hidroclorotiazida) n&atilde;o most
rou diferen&ccedil;a na gravidade    da AOS. Todas as drogas apresentaram efeito
s similares na press&atilde;o arterial    diurna, mas o atenolol propiciou discr
eta melhora na press&atilde;o arterial    noturna em compara&ccedil;&atilde;o ao
s demais<sup>73</sup>. Por fim, conforme    j&aacute; comentado nesse texto, o a
ntagonismo do sistema renina-angiotensina-aldosterona,    por meio da espironola
ctona, pode ter benef&iacute;cios no tratamento da press&atilde;o    arterial em
 pacientes com AOS e HAS resistente<sup>41</sup>. Esse benef&iacute;cio    pode 
ser mediado pela redu&ccedil;&atilde;o do edema em vias a&eacute;reas superiores
,    pois evid&ecirc;ncias recentes sugerem que, durante a noite, h&aacute; aume
nto    do retorno venoso dos membros inferiores e consequente ac&uacute;mulo de 
l&iacute;quido    dos tecidos da via a&eacute;rea, o que poderia ser um dos fato
res respons&aacute;veis    pelo aumento da colapsabilidade da via a&eacute;rea e
specialmente nos homens<sup>74,75</sup>.</font></p>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#63#59#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#64#60#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Perspectivas    futuras<
/b></font></p>     ^cY#aop00711.htm##
02161000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704191700085002001302002#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#65#61#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O conjunto das    evid&ecir
c;ncias aponta a AOS como uma importante causa secund&aacute;ria de    HAS. Mesm
o nos indiv&iacute;duos que j&aacute; apresentam HAS, a presen&ccedil;a    da AO
S pode contribuir para piorar o controle press&oacute;rico e aumentar a    ocorr
&ecirc;ncia de les&otilde;es de &oacute;rg&atilde;os-alvo. A despeito da    mode
sta redu&ccedil;&atilde;o m&eacute;dia da press&atilde;o arterial obtida    com 
o tratamento considerado padr&atilde;o para a AOS (levando-se em conta todos    
os estudos, com a inclus&atilde;o de indiv&iacute;duos com press&atilde;o arteri
al    controlada e indiv&iacute;duos normotensos), o benef&iacute;cio maior do C
PAP    em termos de redu&ccedil;&atilde;o da press&atilde;o arterial parece ser 
nos    casos de HAS resistente. Embora haja evid&ecirc;ncias de um estudo observ
acional    que mostra a poss&iacute;vel redu&ccedil;&atilde;o da ocorr&ecirc;nci
a de eventos    cardiovasculares fatais e n&atilde;o fatais por meio do tratamen
to da AOS<sup>8</sup>,    nenhum estudo randomizado at&eacute; o momento mostrou
 tal efeito. Al&eacute;m    disso, ainda est&aacute; para ser esclarecido se a r
edu&ccedil;&atilde;o da    press&atilde;o arterial est&aacute; envolvida na dimi
nui&ccedil;&atilde;o do    risco cardiovascular mediada pela AOS. Estudos futuro
s s&atilde;o necess&aacute;rios    para definir formas alternativas e eficazes d
e tratar a AOS e, ao mesmo tempo,    diminuir o risco cardiovascular. Outra &aac
ute;rea de crescente interesse consiste    em explorar o impacto dos anti-hipert
ensivos j&aacute; dispon&iacute;veis e    novas gera&ccedil;&otilde;es de drogas
 no tratamento da HAS em indiv&iacute;duos    com AOS. Apesar de algumas promess
as de benef&iacute;cio m&uacute;tuo no tratamento    da HAS e da AOS<sup>41</sup
>, novos estudos s&atilde;o necess&aacute;rios.</font></p>     ^cY#aop00711.htm#
#
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#66#62#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    de
 Interesses</b></font></p>     ^cY#aop00711.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#67#63#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    haver
 conflito de interesses pertinentes.</font></p>     ^cY#aop00711.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#68#64#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop00711.htm##
00375000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013100085002001300216#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#69#65#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    foi fi
nanciado pela FAPESP.</font></p>     ^cY#aop00711.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#70#66#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;o
    Acad&ecirc;mica</b></font></p>     ^cY#aop00711.htm##
00439000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019500085002001300280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#71#67#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o h&aacute;    vin
cula&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atil
de;o.</font></p>     ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#72#68#article#228#<p>&nbsp;<
/p>     ^cY#aop00711.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#73#69#article#228#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop00711.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704030800087002001300395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#74#70#article#22
8#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Sleep-rela
ted    breathing disorders in adults: recommendations for syndrome definition an
d measurement    techniques in clinical research. The Report of an American Acad
emy of Sleep    Medicine Task Force. Sleep.1999; 22 (5): 667-89.    ^cY#aop00711
.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#75#71#article#228#</font></p
>     ^cY#aop00711.htm##
00550000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704029200087002001300379#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#76#72#article#22
8#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Drager LF,
 Ladeira    RT, Brand&atilde;o-Neto RA, Lorenzi-Filho G, Bense&ntilde;or IM. Obs
tructive    sleep apnea syndrome and its relation with systemic arterial hyperte
nsion. Arq    Bras Cardiol. 2002; 78 (5): 531-6.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#77#73#article#228#</font></p
>     ^cY#aop00711.htm##
00800000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704054200087002001300629#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#78#74#article#22
8#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Chobanian 
AV,    Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint Natio
nal    Committee on Prevention, Detection, Evaluation, and Treatment of High Blo
od    Pressure. National Heart, Lung, and Blood Institute; National High Blood P
ressure    Education Program Coordinating Committee. Seventh report of the Joint
 National    Committee on Prevention, Detection, Evaluation, and Treatment of Hi
gh Blood    Pressure. Hypertension. 2003; 42 (6): 1206-52.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#79#75#article#228#</font></p
>     ^cY#aop00711.htm##
00650000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704039200087002001300479#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#80#76#article#22
8#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Mion Jr D,
 Kohlmann    Jr O, Machado CA, Amodeo C, Gomes MAM, Praxedes JN, et al. / Socied
ade Brasileira    de Cardiologia-SBC, Sociedade Brasileira de Hipertens&atilde;o
-SBH, Sociedade    Brasileira de Nefrologia-SBN. V Diretrizes brasileiras de hip
ertens&atilde;o    arterial. Arq Bras Cardiol. 2007; 89 (3): e24-79.    ^cY#aop0
0711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#81#77#article#228#</font></p
>     ^cY#aop00711.htm##
00496000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023800087002001300325#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#82#78#article#22
8#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Young T, P
eppard    PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population
 health    perspective. Am J Respir Crit Care Med. 2002; 165 (9): 1217-39.    ^c
Y#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#83#79#article#228#</font></p
>     ^cY#aop00711.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704024000087002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#84#80#article#22
8#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Tufik S, S
antos-Silva    R, Taddei JA, Bittencourt LR. Obstructive sleep apnea syndrome in
 the Sao Paulo    Epidemiologic Sleep Study. Sleep Med. 2010; 11 (5): 441-6.    
^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#85#81#article#228#</font></p
>     ^cY#aop00711.htm##
00502000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704024400087002001300331#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#86#82#article#22
8#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Engleman H
M,    Douglas NJ. Sleep. 4: sleepiness, cognitive function, and quality of life 
in    obstructive sleep apnoea/hypopnoea syndrome. Thorax. 2004; 59 (7): 618-22.
    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#87#83#article#228#</font></p
>     ^cY#aop00711.htm##
00592000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704033400087002001300421#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#88#84#article#22
8#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Marin JM, 
Carrizo    SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men wi
th obstructive    sleep apnoea-hypopnoea with or without treatment with continuo
us positive airway    pressure: an observational study. Lancet. 2005; 365 (9464)
: 1046-53.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#89#85#article#228#</font></p
>     ^cY#aop00711.htm##
00536000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027800087002001300365#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#90#86#article#22
8#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Young T, F
inn    L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ, et al. Sleep disordered 
breathing    and mortality: eighteen-year follow-up of the Wisconsin sleep cohor
t. Sleep.    2008; 31 (8): 1071-8.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#91#87#article#228#</font></p
>     ^cY#aop00711.htm##
00534000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704027500088002001300363#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#92#88#article#22
8#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Marshall
 NS,    Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an 
independent    risk factor for all-cause mortality: the Busselton Health Study. 
Sleep. 2008;    31 (8): 1079-85.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#93#89#article#228#</font></p
>     ^cY#aop00711.htm##
00523000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704026400088002001300352#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#94#90#article#22
8#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Punjabi 
NM,    Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O'Connor GT, et al. Sleep-d
isordered    breathing and mortality: a prospective cohort study. PLoS Med. 2009
; 6 (8):    e1000132.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#95#91#article#228#</font></p
>     ^cY#aop00711.htm##
00543000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704028400088002001300372#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#96#92#article#22
8#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Sj&ouml;
str&ouml;m    C, Lindberg E, Elmasry A, H&auml;gg A, Sv&auml;rdsudd K, Janson C.
 Prevalence    of sleep apnoea and snoring in hypertensive men: a population bas
ed study. Thorax.    2002; 57 (7): 602-7.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#97#93#article#228#</font></p
>     ^cY#aop00711.htm##
00552000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704029300088002001300381#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#98#94#article#22
8#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Drager L
F,    Genta PR, Pedrosa RP, Nerbass FB, Gonzaga CC, Krieger EM, et al. Character
istics    and predictors of obstructive sleep apnea in patients with systemic hy
pertension.    Am J Cardiol. 2010;105 (8): 1135-9.    ^cY#aop00711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#99#95#article#228#</font></p
>     ^cY#aop00711.htm##
00529000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704026900089002001300358#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#100#96#article#2
28#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Logan A
G, Perlikowski    SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High pre
valence of unrecognized    sleep apnoea in drug-resistant hypertension. J Hypert
ens. 2001; 19 (12): 2271-7.    ^cY#aop00711.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#101#97#article#228#</font></
p>     ^cY#aop00711.htm##
00536000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704027600089002001300365#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#102#98#article#2
28#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Gon&cce
dil;alves    SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I, et 
al. Obstructive    sleep apnea and resistant hypertension: a case-control study.
 Chest. 2007; 132    (6): 1858-62.    ^cY#aop00711.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#103#99#article#228#</font></
p>     ^cY#aop00711.htm##
00511000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025000090002001300340#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#104#100#article#
228#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Peppar
d PE,    Young T, Palta M, Skatrud J. Prospective study of the association betwe
en sleep-disordered    breathing and hypertension. N Engl J Med. 2000; 342 (19):
 1378-84.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#105#101#article#228#</font><
/p>     ^cY#aop00711.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022900090002001300319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#106#102#article#
228#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Lavie 
P, Herer    P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor f
or hypertension:    population study. BMJ. 2000; 320 (7233): 479-82.    ^cY#aop0
0711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#107#103#article#228#</font><
/p>     ^cY#aop00711.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#108#104#article#
228#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Nieto 
FJ, Young    TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of s
leep-disordered    breathing, sleep apnea, and hypertension in a large community
-based study. Sleep    Heart Health Study. JAMA. 2000; 283 (14): 1829-36.    ^cY
#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#109#105#article#228#</font><
/p>     ^cY#aop00711.htm##
00455000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019400090002001300284#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#110#106#article#
228#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Young 
T, Skatrud    J, Peppard PE. Risk factors for obstructive sleep apnea in adults.
 JAMA. 2004;    291 (16): 2013-6.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#111#107#article#228#</font><
/p>     ^cY#aop00711.htm##
00623000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036200090002001300452#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#112#108#article#
228#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Gus M,
 Gon&ccedil;alves    SC, Martinez D, de Abreu Silva EO, Moreira LB, Fuchs SC, et
 al. Risk for obstructive    sleep apnea by Berlin Questionnaire, but not daytim
e sleepiness, is associated    with resistant hypertension: a case-control study
. Am J Hypertens. 2008; 21    (7): 832-5.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#113#109#article#228#</font><
/p>     ^cY#aop00711.htm##
00456000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019500090002001300285#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#114#110#article#
228#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Dempse
y JA,    Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. Phy
siol    Rev. 2010; 90 (1): 47-112.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#115#111#article#228#</font><
/p>     ^cY#aop00711.htm##
00475000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021400090002001300304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#116#112#article#
228#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Somers
 V, Dyken    M, Clary M, Abboud F. Sympathetic neural mechanisms in obstructive 
sleep apnea.    J Clin Invest. 1995; 96 (4):1897-904.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#117#113#article#228#</font><
/p>     ^cY#aop00711.htm##
00506000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024500090002001300335#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#118#114#article#
228#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Moller
 DS,    Lind P, Strunge B, Pedersen EB. Abnormal vasoactive hormones and 24 hour
 blood    pressure in obstructive sleep apnea. Am J Hypertens. 2003; 16 (4): 274
-80.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#119#115#article#228#</font><
/p>     ^cY#aop00711.htm##
00581000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032000090002001300410#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#120#116#article#
228#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Narkie
wicz    K, van de Borne P, Montano N, Dyken M, Phillips B, Somers V. Contributio
n of    tonic chemoreflex activation to sympathetic activity and blood pressure 
in patients    with obstructive sleep apnea. Circulation. 1998; 97 (10): 943-5. 
   ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#121#117#article#228#</font><
/p>     ^cY#aop00711.htm##
00465000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020400090002001300294#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#122#118#article#
228#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Bradle
y TD,    Floras JS. Sleep apnea and heart failure: Part I: obstructive sleep apn
ea. Circulation.    2003; 107 (12): 1671-8.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#123#119#article#228#</font><
/p>     ^cY#aop00711.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#124#120#article#
228#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Prabha
kar NR,    Dick TE, Nanduri J, Kumar GK. Systemic, cellular and molecular analys
is of chemoreflex-mediated    sympathoexcitation by chronic intermittent hypoxia
. Exp Physiol. 2007; 92 (1):    39-44.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#125#121#article#228#</font><
/p>     ^cY#aop00711.htm##
00512000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025100090002001300341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#126#122#article#
228#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Kriege
r EM,    Michelini LC. Dados b&aacute;sicos sobre a manuten&ccedil;&atilde;o da 
press&atilde;o    arterial. Rev Soc Cardiol Estado de S&atilde;o Paulo. 1992; 2 
(4): 9-17.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#127#123#article#228#</font><
/p>     ^cY#aop00711.htm##
00628000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036700090002001300457#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#128#124#article#
228#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Noda A
, Nakata    S, Koike Y, Miyata S, Kitaichi K, Nishizawa T, e cols. Continuous po
sitive airway    pressure improves daytime baroreflex sensitivity and nitric oxi
de production    in patients with moderate to severe obstructive sleep apnea syn
drome. Hypertens    Res. 2007; 30 (8): 669-76.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#129#125#article#228#</font><
/p>     ^cY#aop00711.htm##
00493000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023200090002001300322#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#130#126#article#
228#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Macefi
eld VG,    Elam M. Prolonged surges of baroreflex-resistant muscle sympathetic d
rive during    periodic breathing. Clin Auton Res. 2002; 12 (3): 165-9.    ^cY#a
op00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#131#127#article#228#</font><
/p>     ^cY#aop00711.htm##
00475000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021400090002001300304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#132#128#article#
228#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Kriege
r EM.    Aortic diastolic caliber changes as determinant for complete aortic bar
oreceptor    resetting. Fed Proc. 1987; 46 (1): 41-5.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#133#129#article#228#</font><
/p>     ^cY#aop00711.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029000090002001300380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#134#130#article#
228#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Xavier
 Neto    J, Moreira ED, Krieger EM. Viscoelastic mechanisms of aortic baroreceto
r resetting    to hemorrhagic hypotension and to hypertension. Am J Phsyiol (Hea
rt and Circ    Physiol). 1996; 271 (40): 1407-15.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#135#131#article#228#</font><
/p>     ^cY#aop00711.htm##
00577000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031600090002001300406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#136#132#article#
228#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Kato M
, Roberts-Thomson    P, Phillips BG, Haynes WG, Winnicki M, Accurso V, e cols. I
mpairment of endothelium-dependent    vasodilation of resistance vessels in pati
ents with obstructive sleep apnea.    Circulation. 2000. 102 (21): 2607-10.    ^
cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#137#133#article#228#</font><
/p>     ^cY#aop00711.htm##
00506000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024500090002001300335#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#138#134#article#
228#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Ip MS,
 Tse    HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep a
pnea    and response to treatment. Am J Respir Crit Care Med. 2004; 169 (3): 348
-53.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#139#135#article#228#</font><
/p>     ^cY#aop00711.htm##
00501000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024000090002001300330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#140#136#article#
228#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Jelic 
S, Lederer    DJ, Adams T, Padeletti M, Colombo PC, Factor PH, et al. Vascular i
nflammation    in obesity and sleep apnea. Circulation. 2010; 121 (8): 1014-21. 
   ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#141#137#article#228#</font><
/p>     ^cY#aop00711.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029900090002001300389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#142#138#article#
228#35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Jelic 
S, Padeletti    M, Kawut SM, Higgins C, Canfield SM, Onat D, et al. Inflammation
, oxidative    stress, and repair capacity of the vascular endothelium in obstru
ctive sleep    apnea. Circulation. 2008; 117 (17): 2270-8.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#143#139#article#228#</font><
/p>     ^cY#aop00711.htm##
00514000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025300090002001300343#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#144#140#article#
228#36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Philli
ps BG,    Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK. Effects of obs
tructive    sleep apnea on endothelin-1 and blood pressure. J Hypertens. 1999; 1
7 (1): 61-6.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#145#141#article#228#</font><
/p>     ^cY#aop00711.htm##
00599000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033800090002001300428#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#146#142#article#
228#37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Gj&osl
ash;rup    PH, Sadauskiene L, Wessels J, Nyvad O, Strunge B, Pedersen EB. Abnorm
ally increased    endothelin-1 in plasma during the night in obstructive sleep a
pnea: relation    to blood pressure and severity of disease. Am J Hypertens. 200
7; 20 (1): 44-52.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#147#143#article#228#</font><
/p>     ^cY#aop00711.htm##
00603000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034200090002001300432#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#148#144#article#
228#38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Zhang 
XL, Yin    KS, Mao H, Wang H, Yang Y. Effect of continuous positive airway press
ure treatment    on vascular endothelial function in patients with obstructive s
leep apnea hypopnea    syndrome and coronary artery disease. Chin Med J (Engl). 
2004; 117 (6): 844-7.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#149#145#article#228#</font><
/p>     ^cY#aop00711.htm##
00531000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027000090002001300360#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#150#146#article#
228#39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Grimpe
n F,    Kanne P, Schulz E, Hagenah G, Hasenfuss G, Andreas S. Endothelin-1 plasm
a levels    are not elevated in patients with obstructive sleep apnoea. Eur Resp
ir J. 2000;    15 (2): 320-5.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#151#147#article#228#</font><
/p>     ^cY#aop00711.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022500090002001300315#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#152#148#article#
228#40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Goodfr
iend    TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldost
erone    theory and therapy. Hypertension. 2004; 43 (3): 518-24.    ^cY#aop00711
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#153#149#article#228#</font><
/p>     ^cY#aop00711.htm##
00578000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031700090002001300407#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#154#150#article#
228#41#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Gaddam
 K, Pimenta    E, Thomas SJ, Cofield SS, Oparil S, Harding SM, et al. Spironolac
tone reduces    severity of obstructive sleep apnoea in patients with resistant 
hypertension:    a preliminary report. J Hum Hypertens. 2010; 24 (8): 532-7.    
^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#155#151#article#228#</font><
/p>     ^cY#aop00711.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029900090002001300389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#156#152#article#
228#42#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Shiota
 S, Ryan    CM, Chiu KL, Ruttanaumpawan P, Haight J, Arzt M, et al. Alterations 
in upper    airway cross-sectional area in response to lower body positive press
ure in healthy    subjects. Thorax. 2007; 62 (10): 868-72.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#157#153#article#228#</font><
/p>     ^cY#aop00711.htm##
00487000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022600090002001300316#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#158#154#article#
228#43#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Svatik
ova A,    Olson LJ, Wolk R, Phillips BG, Adachi T, Schwartz GL, et al. Obstructi
ve sleep    apnea and aldosterone. Sleep. 2009; 32 (12): 1589-92.    ^cY#aop0071
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#159#155#article#228#</font><
/p>     ^cY#aop00711.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026500090002001300355#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#160#156#article#
228#44#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Netzer
 NC,    Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire
 to    identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1
999;    131 (7): 485-91.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#161#157#article#228#</font><
/p>     ^cY#aop00711.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030000090002001300390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#162#158#article#
228#45#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Baguet
 JP,    Hammer L, Levy P, Pierre H, Rossini E, Mouret S, et al. Night-time and d
iastolic    hypertension are common and underestimated conditions in newly diagn
osed apnoeic    patients. J Hypertens. 2005; 23 (3): 521-7.    ^cY#aop00711.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#163#159#article#228#</font><
/p>     ^cY#aop00711.htm##
00585000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032400090002001300414#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#164#160#article#
228#46#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">46. Sharab
i Y,    Scope A, Chorney N, Grotto I, Dagan Y. Diastolic blood pressure is the f
irst    to rise in association with early subclinical obstructive sleep apnea: l
essons    from periodic examination screening. Am J Hypertens. 2003; 16 (3): 236
-9.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#165#161#article#228#</font><
/p>     ^cY#aop00711.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027100090002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#166#162#article#
228#47#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">47. Haas D
C, Foster    GL, Nieto FJ, Redline S, Resnick HE, Robbins JA, et al. Age-depende
nt associations    between sleep-disordered breathing and hypertension. Circulat
ion. 2005; 111    (5): 614-21.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#167#163#article#228#</font><
/p>     ^cY#aop00711.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030200090002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#168#164#article#
228#48#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">48. Ancoli
-Israel    S, Stepnowsky C, Dimsdale J, Marler M, Cohen-Zion M, Johnson S. The e
ffect of    race and sleep-disordered breathing on nocturnal BP "dipping": analy
sis in an    older population. Chest. 2002; 122 (4): 1148-55.    ^cY#aop00711.ht
m##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#169#165#article#228#</font><
/p>     ^cY#aop00711.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022900090002001300319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#170#166#article#
228#49#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">49. Kapa S
, Sert    Kuniyoshi FH, Somers VK. Sleep apnea and hypertension: interactions an
d implications    for management. Hypertension. 2008; 51 (3): 605-8.    ^cY#aop0
0711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#171#167#article#228#</font><
/p>     ^cY#aop00711.htm##
00541000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028000090002001300370#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#172#168#article#
228#50#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">50. Drager
 LF,    Diegues-Silva L, Diniz PM, Bortolotto LA, Pedrosa RP, Couto RB, et al. O
bstructive    sleep apnea, masked hypertension, and arterial stiffness in men. A
m J Hypertens.    2010; 23 (3): 249-54.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#173#169#article#228#</font><
/p>     ^cY#aop00711.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025900090002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#174#170#article#
228#51#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">51. Faulx 
MD, Storfer-Isser    A, Kirchner HL, Jenny NS, Tracy RP, Redline S. Obstructive 
sleep apnea is associated    with increased urinary albumin excretion. Sleep. 20
07; 30 (7): 923-9.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#175#171#article#228#</font><
/p>     ^cY#aop00711.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029900090002001300389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#176#172#article#
228#52#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">52. Drager
 LF,    Bortolotto LA, Figueiredo AC, Silva BC, Krieger EM, Lorenzi-Filho G. Obs
tructive    sleep apnea, hypertension, and their interaction on arterial stiffne
ss and heart    remodeling. Chest. 2007; 131 (5): 1379-86.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#177#173#article#228#</font><
/p>     ^cY#aop00711.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027800090002001300368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#178#174#article#
228#53#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">53. Drager
 LF,    Bortolotto LA, Krieger EM, Lorenzi-Filho G. Additive effects of obstruct
ive    sleep apnea and hypertension on early markers of carotid atherosclerosis.
 Hypertension.    2009; 53 (1): 64-9.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#179#175#article#228#</font><
/p>     ^cY#aop00711.htm##
00614000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704035300090002001300443#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#180#176#article#
228#54#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">54. Drager
 LF,    Bortolotto LA, Pedrosa RP, Krieger EM, Lorenzi-Filho G. Left atrial diam
eter    is independently associated with arterial stiffness in patients with obs
tructive    sleep apnea: potential implications for atrial fibrillation. Int J C
ardiol.    2010; 144 (2): 257-9.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#181#177#article#228#</font><
/p>     ^cY#aop00711.htm##
00585000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032400090002001300414#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#182#178#article#
228#55#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">55. Pedros
a RP,    Drager LF, Genta PR, Amaro AC, Antunes MO, Matsumoto AY, et al. Obstruc
tive    sleep apnea is common and independently associated with atrial fibrillat
ion    in patients with hypertrophic cardiomyopathy. Chest. 2010; 137 (5): 1078-
84.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#183#179#article#228#</font><
/p>     ^cY#aop00711.htm##
00574000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031300090002001300403#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#184#180#article#
228#56#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">56. Becker
 HF,    Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, et al. Effect of 
nasal    continuous positive airway pressure treatment on blood pressure in pati
ents    with obstructive sleep apnea. Circulation. 2003; 107 (1): 68-73.    ^cY#
aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#185#181#article#228#</font><
/p>     ^cY#aop00711.htm##
00549000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028800090002001300378#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#186#182#article#
228#57#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">57. Robins
on GV,    Smith DM, Langford BA, Davies RJ, Stradling JR. Continuous positive ai
rway pressure    does not reduce blood pressure in nonsleepy hypertensive OSA pa
tients. Eur Respir    J. 2006; 27 (6): 1229-35.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#187#183#article#228#</font><
/p>     ^cY#aop00711.htm##
00577000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031600090002001300406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#188#184#article#
228#58#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">58. Barbe 
F, Duran-Cantolla    J, Capote F, de la Pe&ntilde;a M, Chiner E, Masa JF, et al.
 Long-term effect    of continuous positive airway pressure in hypertensive pati
ents with sleep apnea.    Am J Respir Crit Care Med. 2010; 181 (7): 718-26.    ^
cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#189#185#article#228#</font><
/p>     ^cY#aop00711.htm##
00583000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032200090002001300412#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#190#186#article#
228#59#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">59. Kaneko
 Y, Floras    JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD. Cardi
ovascular    effects of continuous positive airway pressure in patients with hea
rt failure    and obstructive sleep apnea. N Engl J Med. 2003; 348 (13): 1233-41
.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#191#187#article#228#</font><
/p>     ^cY#aop00711.htm##
00604000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034300090002001300433#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#192#188#article#
228#60#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">60. Mills 
PJ, Kennedy    BP, Loredo JS, Dimsdale JE, Ziegler MG. Effects of nasal continuo
us positive    airway pressure and oxygen supplementation on norepinephrine kine
tics and cardiovascular    responses in obstructive sleep apnea. J Appl Physiol.
 2006; 100 (1): 343-8.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#193#189#article#228#</font><
/p>     ^cY#aop00711.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027800090002001300368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#194#190#article#
228#61#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">61. Giles 
TL, Lasserson    TJ, Smith BJ, White J, Wright J, Cates CJ. Continuous positive 
airways pressure    for obstructive sleep apnea in adults. Cochrane Database Sys
t Rev. 2006 Jan    25; (1): CD001106.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#195#191#article#228#</font><
/p>     ^cY#aop00711.htm##
00614000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704035300090002001300443#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#196#192#article#
228#62#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">62. Alajmi
 M, Mulgrew    AT, Fox J, Davidson W, Schulzer M, Mak E, et al. Impact of contin
uous positive    airway pressure therapy on blood pressure in patients with obst
ructive sleep    apnea hypopnea: a meta-analysis of randomized controlled trials
. Lung. 2007;    185 (2): 67-72.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#197#193#article#228#</font><
/p>     ^cY#aop00711.htm##
00662000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704040100090002001300491#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#198#194#article#
228#63#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">63. Haentj
ens P,    Van Meerhaeghe A, Moscariello A, De Weerdt S, Poppe K, Dupont A, et al
. The    impact of continuous positive airway pressure on blood pressure in pati
ents    with obstructive sleep apnea syndrome: evidence from a meta-analysis of 
placebo-controlled    randomized trials. Arch Intern Med. 2007; 167 (8): 757-64.
    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#199#195#article#228#</font><
/p>     ^cY#aop00711.htm##
00586000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032500090002001300415#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#200#196#article#
228#64#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">64. Mo L, 
He Q.    Effect of long-term continuous positive airway pressure ventilation on 
blood    pressure in patients with obstructive sleep apnea hypopnea syndrome: a 
meta-analysis    of clinical trials. Zhonghua Yi Xue Za Zhi. 2007; 87 (17): 1177
-80.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#201#197#article#228#</font><
/p>     ^cY#aop00711.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026500090002001300355#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#202#198#article#
228#65#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">65. Bazzan
o LA,    Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive
 airway    pressure on blood pressure in obstructive sleep apnea. Hypertension. 
2007; 50    (2): 417-23.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#203#199#article#228#</font><
/p>     ^cY#aop00711.htm##
00492000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023100090002001300321#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#204#200#article#
228#66#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">66. Floras
 JS,    Bradley TD. Treating obstructive sleep apnea: is there more to the story
 than    2 millimeters of mercury? Hypertension. 2007; 50 (2): 289-91.    ^cY#ao
p00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#205#201#article#228#</font><
/p>     ^cY#aop00711.htm##
00693000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704043200090002001300522#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#206#202#article#
228#67#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">67. Dernai
ka TA,    Kinasewitz GT, Tawk MM. Effects of nocturnal continuous positive airwa
y pressure    therapy in patients with resistant hypertension and obstructive sl
eep apnea:    effects of nocturnal continuous positive airway pressure therapy i
n patients    with resistant hypertension and obstructive sleep apnea. J Clin Sl
eep Med. 2009;    5 (2): 103-7.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#207#203#article#228#</font><
/p>     ^cY#aop00711.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028400090002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#208#204#article#
228#68#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">68. Logan 
AG, Tkacova    R, Perlikowski SM, Leung RS, Tisler A, Floras JS, et al. Refracto
ry hypertension    and sleep apnoea: effect of CPAP on blood pressure and barore
flex. Eur Respir    J. 2003; 21 (2): 241-7.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#209#205#article#228#</font><
/p>     ^cY#aop00711.htm##
00636000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037500090002001300465#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#210#206#article#
228#69#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">69. Mart&i
acute;nez-Garc&iacute;a    MA, G&oacute;mez-Aldarav&iacute; R, Soler-Catalu&ntil
de;a JJ, Mart&iacute;nez    TG, Bern&aacute;cer-Alpera B, Rom&aacute;n-S&aacute;
nchez P. Positive effect    of CPAP treatment on the control of difficult-to-tre
at hypertension. Eur Respir    J. 2007; 29 (5): 951-7.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#211#207#article#228#</font><
/p>     ^cY#aop00711.htm##
00514000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025300090002001300343#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#212#208#article#
228#70#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">70. Gotsop
oulos    H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure
 in obstructive    sleep apnea: a randomized, controlled trial. Sleep. 2004; 27 
(5): 934-41.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#213#209#article#228#</font><
/p>     ^cY#aop00711.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027400090002001300364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#214#210#article#
228#71#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">71. Otsuka
 R, Ribeiro    de Almeida F, Lowe AA, Linden W, Ryan F. The effect of oral appli
ance therapy    on blood pressure in patients with obstructive sleep apnea. Slee
p Breath. 2006;    10 (1): 29-36.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#215#211#article#228#</font><
/p>     ^cY#aop00711.htm##
00444000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018300090002001300273#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#216#212#article#
228#72#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">72. Issa F
G. Effect    of clonidine in obstructive sleep apnea. Am Rev Respir Dis. 1992; 1
45 (2 Pt    1): 435-9.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#217#213#article#228#</font><
/p>     ^cY#aop00711.htm##
00587000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032600090002001300416#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#218#214#article#
228#73#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">73. Kraicz
i H,    Hedner J, Peker Y, Grote L. Comparison of atenolol, amlodipine, enalapri
l, hydrochlorothiazide,    and losartan for antihypertensive treatment in patien
ts with obstructive sleep    apnea. Am J Respir Crit Care Med. 2000; 161 (5): 14
23-8.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#219#215#article#228#</font><
/p>     ^cY#aop00711.htm##
00556000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029500090002001300385#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#220#216#article#
228#74#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">74. Redolf
i S,    Yumino D, Ruttanaumpawan P, Yau B, Su MC, Lam J, et al. Relationship bet
ween    overnight rostral fluid shift and obstructive sleep apnea in nonobese me
n. Am    J Respir Crit Care Med. 2009; 179 (3): 241-6.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#221#217#article#228#</font><
/p>     ^cY#aop00711.htm##
00593000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033200090002001300422#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#222#218#article#
228#75#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">75. Yumino
 D, Redolfi    S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, et al. Nocturnal 
rostral fluid    shift: a unifying concept for the pathogenesis of obstructive a
nd central sleep    apnea in men with heart failure. Circulation. 2010; 121 (14)
: 1598-605.    ^cY#aop00711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#223#219#article#228#</font><
/p>     ^cY#aop00711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#224#220#article#228#<p>&nbsp
;</p>     ^cY#aop00711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#225#221#article#228#<p>&nbsp
;</p>     ^cY#aop00711.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#226#222#article#228#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop00711.htm##
00283000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003700087002001300124#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#227#223#article#228#<br>   <
/b> Luciano F. Drager    ^cY#aop00711.htm##
00300000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005400087002001300141#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#228#224#article#228#<br>   A
v. En&eacute;as Carvalho de Aguiar, 44    ^cY#aop00711.htm##
00313000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006700087002001300154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#229#225#article#228#<br>   B
loco 2 / 2º andar / sala 8 - Cerqueira C&eacute;sar    ^cY#aop00711.htm##
00302000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005600087002001300143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#230#226#article#228#<br>   0
5403-904 - S&atilde;o Paulo, SP - Brasil    ^cY#aop00711.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704011100087002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#231#227#article#228#<br>   E
-mail: <a href="mailto:luciano.drager@incor.usp.br">luciano.drager@incor.usp.br<
/a></font></p>     ^cY#aop00711.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop00711.htm#S#p#232#228#article#228#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 05/
05/10; revisado recebido em 07/05/10; aceito em 20/09/10.</font></p>     ^cY#aop
00711.htm##
00623000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840120201000860300006002870650
00900293064000500302031000300307032000200310014000700312865000900319002001300328
035001000341801000600351#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00
711.htm#S#c#233#1#article#75#1#Sleep-related breathing disorders in adults: reco
mmendations for syndrome definition and measurement techniques in clinical resea
rch. The Report of an American Academy of Sleep Medicine Task Force^len#Sleep#19
990000#1999#22#5#667-89#20110000#aop00711.htm#0161-8105#Sleep##
00693000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030100
02300121010002300144010001900167012009000186030001700276065000900293064000500302
03100030030703200020031001400060031286500090031800200130032703500100034080100170
0350#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#234#2#ar
ticle#75#2#^rND^sDrager^nLF#^rND^sLadeira^nRT#^rND^sBrandão-Neto^nRA#^rND^sLoren
zi-Filho^nG#^rND^sBenseñor^nIM#Obstructive sleep apnea syndrome and its relation
 with systemic arterial hypertension^len#Arq Bras Cardiol#20020000#2002#78#5#531
-6#20110000#aop00711.htm#0066-782X#Arq Bras Cardiol##
00973000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100017001060100
01600123010001800139010001600157010001800173810000600191012034100197030001300538
06500090055106400050056003100030056503200020056801400080057086500090057800200130
0587035001000600801001300610#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#235#3#article#75#3#^rND^sChobanian^nAV#^rND^sBakris^nGL#^rND^sBl
ack^nHR#^rND^sCushman^nWC#^rND^sGreen^nLA#^rND^sIzzo^nJL Jr#et al#Joint National
 Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pre
ssure: National Heart, Lung, and Blood Institute; National High Blood Pressure E
ducation Program Coordinating Committee. Seventh report of the Joint National Co
mmittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressu
re^len#Hypertension#20030000#2003#42#6#1206-52#20110000#aop00711.htm#0194-911X#H
ypertension##
00819000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100021001030100
01800124010001600142010001700158010001900175810000600194012017700200030001700377
06500090039406400050040303100030040803200020041101400070041386500090042000200130
0429035001000442801001700452#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#236#4#article#75#4#^rND^sMion Jr^nD#^rND^sKohlmann Jr^nO#^rND^sM
achado^nCA#^rND^sAmodeo^nC#^rND^sGomes^nMAM#^rND^sPraxedes^nJN#et al#/ Sociedade
 Brasileira de Cardiologia-SBC, Sociedade Brasileira de Hipertensão-SBH, Socieda
de Brasileira de Nefrologia-SBN: V Diretrizes brasileiras de hipertensão arteria
l^lpt#Arq Bras Cardiol#20070000#2007#89#3#e24-79#20110000#aop00711.htm#0066-782X
#Arq Bras Cardiol##
00629000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100018001010100
01900119012007700138030002600215065000900241064000500250031000400255032000200259
014000800261865000900269002001300278035001000291801002600301#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop00711.htm#S#c#237#5#article#75#5#^rND^sYoung^n
T#^rND^sPeppard^nPE#^rND^sGottlieb^nDJ#Epidemiology of obstructive sleep apnea: 
a population health perspective^len#Am J Respir Crit Care Med#20020000#2002#165#
9#1217-39#20110000#aop00711.htm#1073-449X#Am J Respir Crit Care Med##
00603000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100022001010100
01700123010002200140012008000162030001000242710000200252065000900254064000500263
031000300268032000200271014000600273865000900279002001300288#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop00711.htm#S#c#238#6#article#75#6#^rND^sTufik^n
S#^rND^sSantos-Silva^nR#^rND^sTaddei^nJA#^rND^sBittencourt^nLR#Obstructive sleep
 apnea syndrome in the Sao Paulo Epidemiologic Sleep Study^len#Sleep Med#2#20100
000#2010#11#5#441-6#20110000#aop00711.htm##
00598000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100018001050120
11300123030000700236065000900243064000500252031000300257032000200260014000700262
865000900269002001300278035001000291801000700301#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#239#7#article#75#7#^rND^sEngleman^nHM#^rND^s
Douglas^nNJ#Sleep: 4: sleepiness, cognitive function, and quality of life in obs
tructive sleep apnoea/hypopnoea syndrome^len#Thorax#20040000#2004#59#7#618-22#20
110000#aop00711.htm#0040-6376#Thorax##
00721000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01700120010001700137012017600154030000700330065000900337064000500346031000400351
032000500355014000800360865000900368002001300377035001000390801000700400#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#240#8#article#75#8#^
rND^sMarin^nJM#^rND^sCarrizo^nSJ#^rND^sVicente^nE#^rND^sAgusti^nAG#Long-term car
diovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or with
out treatment with continuous positive airway pressure: an observational study^l
en#Lancet#20050000#2005#365#9464#1046-53#20110000#aop00711.htm#0099-5355#Lancet#
#
00711000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100014001010100
01800115010002000133010001600153010001600169810000600185012010000191030000600291
06500090029706400050030603100030031103200020031401400070031686500090032300200130
0332035001000345801000600355#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#241#9#article#75#9#^rND^sYoung^nT#^rND^sFinn^nL#^rND^sPeppard^nP
E#^rND^sSzklo-Coxe^nM#^rND^sAustin^nD#^rND^sNieto^nFJ#et al#Sleep disordered bre
athing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort^len#
Sleep#20080000#2008#31#8#1071-8#20110000#aop00711.htm#0161-8105#Sleep##
00698000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01400122010001700136010001800153010002000171012009800191030000600289065000900295
06400050030403100030030903200020031201400080031486500090032200200130033103500100
0344801000600354#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#242#10#article#75#10#^rND^sMarshall^nNS#^rND^sWong^nKK#^rND^sLiu^nPY#^rND^sC
ullen^nSR#^rND^sKnuiman^nMW#^rND^sGrunstein^nRR#Sleep apnea as an independent ri
sk factor for all-cause mortality: the Busselton Health Study^len#Sleep#20080000
#2008#31#8#1079-85#20110000#aop00711.htm#0161-8105#Sleep##
00672000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01800122010001900140010001700159010001900176810000600195012007300201030000900274
71000020028306500090028506400050029403100020029903200020030101400090030386500090
0312002001300321#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#243#11#article#75#11#^rND^sPunjabi^nNM#^rND^sCaffo^nBS#^rND^sGoodwin^nJL#^rN
D^sGottlieb^nDJ#^rND^sNewman^nAB#^rND^sO'Connor^nGT#et al#Sleep-disordered breat
hing and mortality: a prospective cohort study^len#PLoS Med#2#20090000#2009#6#8#
e1000132#20110000#aop00711.htm##
00688000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01700124010001400141010001900155010001600174012008900190030000700279065000900286
06400050029503100030030003200020030301400060030586500090031100200130032003500100
0333801000700343#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#244#12#article#75#12#^rND^sSjöström^nC#^rND^sLindberg^nE#^rND^sElmasry^nA#^r
ND^sHägg^nA#^rND^sSvärdsudd^nK#^rND^sJanson^nC#Prevalence of sleep apnoea and sn
oring in hypertensive men: a population based study^len#Thorax#20020000#2002#57#
7#602-7#20110000#aop00711.htm#0040-6376#Thorax##
00735000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01800121010001800139010001800157010001800175810000600193012010100199030001300300
06500090031306400050032203100040032703200020033101400070033386500090034000200130
0349035001000362801001300372#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#245#13#article#75#13#^rND^sDrager^nLF#^rND^sGenta^nPR#^rND^sPedr
osa^nRP#^rND^sNerbass^nFB#^rND^sGonzaga^nCC#^rND^sKrieger^nEM#et al#Characterist
ics and predictors of obstructive sleep apnea in patients with systemic hyperten
sion^len#Am J Cardiol#20100000#2010#105#8#1135-9#20110000#aop00711.htm#0002-9149
#Am J Cardiol##
00712000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100022001040100
01500126010001600141010001700157010001900174810000600193012008000199030001200279
06500090029106400050030003100030030503200030030801400070031186500090031800200130
0327035001000340801001200350#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#246#14#article#75#14#^rND^sLogan^nAG#^rND^sPerlikowski^nSM#^rND^
sMente^nA#^rND^sTisler^nA#^rND^sTkacova^nR#^rND^sNiroumand^nM#et al#High prevale
nce of unrecognized sleep apnoea in drug-resistant hypertension^len#J Hypertens#
20010000#2001#19#12#2271-7#20110000#aop00711.htm#0263-6352#J Hypertens##
00703000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100018001080100
01300126010002500139010001900164010001500183810000600198012007700204030000600281
06500090028706400050029603100040030103200020030501400080030786500090031500200130
0324035001000337801000600347#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#247#15#article#75#15#^rND^sGonçalves^nSC#^rND^sMartinez^nD#^rND^
sGus^nM#^rND^sde Abreu-Silva^nEO#^rND^sBertoluci^nC#^rND^sDutra^nI#et al#Obstruc
tive sleep apnea and resistant hypertension: a case-control study^len#Chest#2007
0000#2007#132#6#1858-62#20110000#aop00711.htm#0012-3692#Chest##
00647000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01500121010001700136012009300153030001300246065000900259064000500268031000400273
032000300277014000800280865000900288002001300297035001000310801001300320#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#248#16#article#75#16
#^rND^sPeppard^nPE#^rND^sYoung^nT#^rND^sPalta^nM#^rND^sSkatrud^nJ#Prospective st
udy of the association between sleep-disordered breathing and hypertension^len#N
 Engl J Med#20000000#2000#342#19#1378-84#20110000#aop00711.htm#0028-4793#N Engl 
J Med##
00599000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030100
01900118012009000137030000400227065000900231064000500240031000400245032000500249
014000700254865000900261002001300270035001000283801000400293#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop00711.htm#S#c#249#17#article#75#17#^rND^sLavie
^nP#^rND^sHerer^nP#^rND^sHoffstein^nV#Obstructive sleep apnoea syndrome as a ris
k factor for hypertension: population study^len#BMJ#20000000#2000#320#7233#479-8
2#20110000#aop00711.htm#0959-8138#BMJ##
00747000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01500120010001600135010001600151010001700167810000600184012013600190030000500326
06500090033106400050034003100040034503200030034901400080035286500090036000200130
0369035001000382801000500392#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#250#18#article#75#18#^rND^sNieto^nFJ#^rND^sYoung^nTB#^rND^sLind^
nBK#^rND^sShahar^nE#^rND^sSamet^nJM#^rND^sRedline^nS#et al#Association of sleep-
disordered breathing, sleep apnea, and hypertension in a large community-based s
tudy: Sleep Heart Health Study^len#JAMA#20000000#2000#283#14#1829-36#20110000#ao
p00711.htm#0098-7484#JAMA##
00565000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01800120012005500138030000500193065000900198064000500207031000400212032000300216
014000700219865000900226002001300235035001000248801000500258#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop00711.htm#S#c#251#19#article#75#19#^rND^sYoung
^nT#^rND^sSkatrud^nJ#^rND^sPeppard^nPE#Risk factors for obstructive sleep apnea 
in adults^len#JAMA#20040000#2004#291#16#2013-6#20110000#aop00711.htm#0098-7484#J
AMA##
00795000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100020001010100
01800121010002500139010001800164010001600182810000600198012015400204030001500358
06500090037306400050038203100030038703200020039001400060039286500090039800200130
0407035001000420801001500430#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#252#20#article#75#20#^rND^sGus^nM#^rND^sGonçalves^nSC#^rND^sMart
inez^nD#^rND^sde Abreu Silva^nEO#^rND^sMoreira^nLB#^rND^sFuchs^nSC#et al#Risk fo
r obstructive sleep apnea by Berlin Questionnaire, but not daytime sleepiness, i
s associated with resistant hypertension: a case-control study^len#Am J Hyperten
s#20080000#2008#21#7#832-5#20110000#aop00711.htm#0895-7061#Am J Hypertens##
00591000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01700123010002000140012003500160030001200195065000900207064000500216031000300221
032000200224014000700226865000900233002001300242035001000255801001200265#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#253#21#article#75#21
#^rND^sDempsey^nJA#^rND^sVeasey^nSC#^rND^sMorgan^nBJ#^rND^sO'Donnell^nCP#Pathoph
ysiology of sleep apnea^len#Physiol Rev#20100000#2010#90#1#47-112#20110000#aop00
711.htm#0031-9333#Physiol Rev##
00613000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01500119010001600134012006100150030001400211065000900225064000500234031000300239
032000200242014000900244865000900253002001300262035001000275801001400285#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#254#22#article#75#22
#^rND^sSomers^nV#^rND^sDyken^nM#^rND^sClary^nM#^rND^sAbboud^nF#Sympathetic neura
l mechanisms in obstructive sleep apnea^len#J Clin Invest#19950000#1995#96#4#189
7-904#20110000#aop00711.htm#0021-9738#J Clin Invest##
00644000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100014001050100
01700119010001900136012008700155030001500242065000900257064000500266031000300271
032000200274014000700276865000900283002001300292035001000305801001500315#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#255#23#article#75#23
#^rND^sMoller^nDS#^rND^sLind^nP#^rND^sStrunge^nB#^rND^sPedersen^nEB#Abnormal vas
oactive hormones and 24 hour blood pressure in obstructive sleep apnea^len#Am J 
Hypertens#20030000#2003#16#4#274-80#20110000#aop00711.htm#0895-7061#Am J Hyperte
ns##
00749000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100022001080100
01700130010001500147010001800162010001600180012013300196030001200329065000900341
06400050035003100030035503200030035801400060036186500090036700200130037603500100
0389801001200399#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#256#24#article#75#24#^rND^sNarkiewicz^nK#^rND^svan de Borne^nP#^rND^sMontano
^nN#^rND^sDyken^nM#^rND^sPhillips^nB#^rND^sSomers^nV#Contribution of tonic chemo
reflex activation to sympathetic activity and blood pressure in patients with ob
structive sleep apnea^len#Circulation#19980000#1998#97#10#943-5#20110000#aop0071
1.htm#0009-7322#Circulation##
00564000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060120
06700123030001200190065000900202064000500211031000400216032000300220014000700223
865000900230002001300239035001000252801001200262#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#257#25#article#75#25#^rND^sBradley^nTD#^rND^
sFloras^nJS#Sleep apnea and heart failure: Part I: obstructive sleep apnea^len#C
irculation#20030000#2003#107#12#1671-8#20110000#aop00711.htm#0009-7322#Circulati
on##
00672000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100015001080100
01700123010001600140012012100156030001200277065000900289064000500298031000300303
032000200306014000600308865000900314002001300323035001000336801001200346#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#258#26#article#75#26
#^rND^sPrabhakar^nNR#^rND^sDick^nTE#^rND^sNanduri^nJ#^rND^sKumar^nGK#Systemic, c
ellular and molecular analysis of chemoreflex-mediated sympathoexcitation by chr
onic intermittent hypoxia^len#Exp Physiol#20070000#2007#92#1#39-44#20110000#aop0
0711.htm#0958-0670#Exp Physiol##
00544000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100020001060120
05700126030003600183710000200219065000900221064000500230031000200235032000200237
014000500239865000900244002001300253#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop00711.htm#S#c#259#27#article#75#27#^rND^sKrieger^nEM#^rND^sMichelini^n
LC#Dados básicos sobre a manutenção da pressão arterial^lpt#Rev Soc Cardiol Esta
do de São Paulo#2#19920000#1992#2#4#9-17#20110000#aop00711.htm##
00787000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100016001020100
01500118010001600133010001800149010001900167012017700186030001400363065000900377
06400050038603100030039103200020039401400070039686500090040300200130041203500100
0425801001400435#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#260#28#article#75#28#^rND^sNoda^nA#^rND^sNakata^nS#^rND^sKoike^nY#^rND^sMiya
ta^nS#^rND^sKitaichi^nK#^rND^sNishizawa^nT#Continuous positive airway pressure i
mproves daytime baroreflex sensitivity and nitric oxide production in patients w
ith moderate to severe obstructive sleep apnea syndrome^len#Hypertens Res#200700
00#2007#30#8#669-76#20110000#aop00711.htm#0916-9636#Hypertens Res##
00595000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100014001080120
09600122030001500218065000900233064000500242031000300247032000200250014000600252
865000900258002001300267035001000280801001500290#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#261#29#article#75#29#^rND^sMacefield^nVG#^rN
D^sElam^nM#Prolonged surges of baroreflex-resistant muscle sympathetic drive dur
ing periodic breathing^len#Clin Auton Res#20020000#2002#12#3#165-9#20110000#aop0
0711.htm#0959-9851#Clin Auton Res##
00553000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880120095001060300
00900201065000900210064000500219031000300224032000200227014000500229865000900234
002001300243035001000256801000900266#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop00711.htm#S#c#262#30#article#75#30#^rND^sKrieger^nEM#Aortic diastolic 
caliber changes as determinant for complete aortic baroreceptor resetting^len#Fe
d Proc#19870000#1987#46#1#41-5#20110000#aop00711.htm#0014-9446#Fed Proc##
00633000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100018001090100
01800127012010700145030003800252710000200290065000900292064000500301031000400306
032000300310014000800313865000900321002001300330#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#263#31#article#75#31#^rND^sXavier Neto^nJ#^r
ND^sMoreira^nED#^rND^sKrieger^nEM#Viscoelastic mechanisms of aortic barorecetor 
resetting to hemorrhagic hypotension and to hypertension^len#Am J Phsyiol (Heart
 and Circ Physiol)#2#19960000#1996#271#40#1407-15#20110000#aop00711.htm##
00737000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100025001020100
01900127010001700146010001800163010001700181012011600198030001200314065000900326
06400050033503100040034003200030034401400080034786500090035500200130036403500100
0377801001200387#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#264#32#article#75#32#^rND^sKato^nM#^rND^sRoberts-Thomson^nP#^rND^sPhillips^n
BG#^rND^sHaynes^nWG#^rND^sWinnicki^nM#^rND^sAccurso^nV#Impairment of endothelium
-dependent vasodilation of resistance vessels in patients with obstructive sleep
 apnea^len#Circulation#20000000#2000#102#21#2607-10#20110000#aop00711.htm#0009-7
322#Circulation##
00673000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100014001010100
01300115010001600128010001400144012007800158030002600236065000900262064000500271
03100040027603200020028001400070028286500090028900200130029803500100031180100260
0321#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#265#33#a
rticle#75#33#^rND^sIp^nMS#^rND^sTse^nHF#^rND^sLam^nB#^rND^sTsang^nKW#^rND^sLam^n
WK#Endothelial function in obstructive sleep apnea and response to treatment^len
#Am J Respir Crit Care Med#20040000#2004#169#3#348-53#20110000#aop00711.htm#1073
-449X#Am J Respir Crit Care Med##
00683000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100018001030100
01500121010001900136010001800155010001700173810000600190012005300196030001200249
06500090026106400050027003100040027503200020027901400080028186500090028900200130
0298035001000311801001200321#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#266#34#article#75#34#^rND^sJelic^nS#^rND^sLederer^nDJ#^rND^sAdam
s^nT#^rND^sPadeletti^nM#^rND^sColombo^nPC#^rND^sFactor^nPH#et al#Vascular inflam
mation in obesity and sleep apnea^len#Circulation#20100000#2010#121#8#1014-21#20
110000#aop00711.htm#0009-7322#Circulation##
00739000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01600122010001700138010001900155010001400174810000600188012011100194030001200305
06500090031706400050032603100040033103200030033501400070033886500090034500200130
0354035001000367801001200377#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#267#35#article#75#35#^rND^sJelic^nS#^rND^sPadeletti^nM#^rND^sKaw
ut^nSM#^rND^sHiggins^nC#^rND^sCanfield^nSM#^rND^sOnat^nD#et al#Inflammation, oxi
dative stress, and repair capacity of the vascular endothelium in obstructive sl
eep apnea^len#Circulation#20080000#2008#117#17#2270-8#20110000#aop00711.htm#0009
-7322#Circulation##
00685000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100020001070100
01600127010001700143010001600160010001700176012007400193030001200267065000900279
06400050028803100030029303200020029601400050029886500090030300200130031203500100
0325801001200335#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#268#36#article#75#36#^rND^sPhillips^nBG#^rND^sNarkiewicz^nK#^rND^sPesek^nCA#
^rND^sHaynes^nWG#^rND^sDyken^nME#^rND^sSomers^nVK#Effects of obstructive sleep a
pnea on endothelin-1 and blood pressure^len#J Hypertens#19990000#1999#17#1#61-6#
20110000#aop00711.htm#0263-6352#J Hypertens##
00763000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01700126010001500143010001700158010001900175012014400194030001500338065000900353
06400050036203100030036703200020037001400060037286500090037800200130038703500100
0400801001500410#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#269#37#article#75#37#^rND^sGjørup^nPH#^rND^sSadauskiene^nL#^rND^sWessels^nJ#
^rND^sNyvad^nO#^rND^sStrunge^nB#^rND^sPedersen^nEB#Abnormally increased endothel
in-1 in plasma during the night in obstructive sleep apnea: relation to blood pr
essure and severity of disease^len#Am J Hypertens#20070000#2007#20#1#44-52#20110
000#aop00711.htm#0895-7061#Am J Hypertens##
00759000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100014001040100
01300118010001400131010001400145012018000159030001800339065000900357064000500366
03100040037103200020037501400060037786500090038300200130039203500100040580100180
0415#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#270#38#a
rticle#75#38#^rND^sZhang^nXL#^rND^sYin^nKS#^rND^sMao^nH#^rND^sWang^nH#^rND^sYang
^nY#Effect of continuous positive airway pressure treatment on vascular endothel
ial function in patients with obstructive sleep apnea hypopnea syndrome and coro
nary artery disease^len#Chin Med J (Engl)#20040000#2004#117#6#844-7#20110000#aop
00711.htm#0366-6999#Chin Med J (Engl)##
00700000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01600120010001700136010001900153010001700172012009000189030001300279065000900292
06400050030103100030030603200020030901400060031186500090031700200130032603500100
0339801001300349#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#271#39#article#75#39#^rND^sGrimpen^nF#^rND^sKanne^nP#^rND^sSchulz^nE#^rND^sH
agenah^nG#^rND^sHasenfuss^nG#^rND^sAndreas^nS#Endothelin-1 plasma levels are not
 elevated in patients with obstructive sleep apnoea^len#Eur Respir J#20000000#20
00#15#2#320-5#20110000#aop00711.htm#0903-1936#Eur Respir J##
00586000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100018001090120
08500127030001300212065000900225064000500234031000300239032000200242014000700244
865000900251002001300260035001000273801001300283#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#272#40#article#75#40#^rND^sGoodfriend^nTL#^r
ND^sCalhoun^nDA#Resistant hypertension, obesity, sleep apnea, and aldosterone th
eory and therapy^len#Hypertension#20040000#2004#43#3#518-24#20110000#aop00711.ht
m#0194-911X#Hypertension##
00761000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01700121010001800138010001600156010001800172810000600190012012600196030001600322
06500090033806400050034703100030035203200020035501400060035786500090036300200130
0372035001000385801001600395#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#273#41#article#75#41#^rND^sGaddam^nK#^rND^sPimenta^nE#^rND^sThom
as^nSJ#^rND^sCofield^nSS#^rND^sOparil^nS#^rND^sHarding^nSM#et al#Spironolactone 
reduces severity of obstructive sleep apnoea in patients with resistant hyperten
sion: a preliminary report^len#J Hum Hypertens#20100000#2010#24#8#532-7#20110000
#aop00711.htm#0950-9240#J Hum Hypertens##
00734000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01500119010002400134010001600158010001400174810000600188012011700194030000700311
06500090031806400050032703100030033203200030033501400070033886500090034500200130
0354035001000367801000700377#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#274#42#article#75#42#^rND^sShiota^nS#^rND^sRyan^nCM#^rND^sChiu^n
KL#^rND^sRuttanaumpawan^nP#^rND^sHaight^nJ#^rND^sArzt^nM#et al#Alterations in up
per airway cross-sectional area in response to lower body positive pressure in h
ealthy subjects^len#Thorax#20070000#2007#62#10#868-72#20110000#aop00711.htm#0040
-6376#Thorax##
00663000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01400123010001900137010001600156010001900172810000600191012004400197030000600241
06500090024706400050025603100030026103200030026401400080026786500090027500200130
0284035001000297801000600307#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#275#43#article#75#43#^rND^sSvatikova^nA#^rND^sOlson^nLJ#^rND^sWo
lk^nR#^rND^sPhillips^nBG#^rND^sAdachi^nT#^rND^sSchwartz^nGL#et al#Obstructive sl
eep apnea and aldosterone^len#Sleep#20090000#2009#32#12#1589-92#20110000#aop0071
1.htm#0161-8105#Sleep##
00679000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01700122010001500139010001700154012009300171030001500264065000900279064000500288
03100040029303200020029701400070029986500090030600200130031503500100032880100150
0338#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#276#44#a
rticle#75#44#^rND^sNetzer^nNC#^rND^sStoohs^nRA#^rND^sNetzer^nCM#^rND^sClark^nK#^
rND^sStrohl^nKP#Using the Berlin Questionnaire to identify patients at risk for 
the sleep apnea syndrome^len#Ann Intern Med#19990000#1999#131#7#485-91#20110000#
aop00711.htm#0003-4819#Ann Intern Med##
00740000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01400121010001600135010001700151010001600168810000600184012011900190030001200309
06500090032106400050033003100030033503200020033801400060034086500090034600200130
0355035001000368801001200378#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#277#45#article#75#45#^rND^sBaguet^nJP#^rND^sHammer^nL#^rND^sLevy
^nP#^rND^sPierre^nH#^rND^sRossini^nE#^rND^sMouret^nS#et al#Night-time and diasto
lic hypertension are common and underestimated conditions in newly diagnosed apn
oeic patients^len#J Hypertens#20050000#2005#23#3#521-7#20110000#aop00711.htm#026
3-6352#J Hypertens##
00738000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01700120010001600137010001500153012015700168030001500325065000900340064000500349
03100030035403200020035701400060035986500090036500200130037403500100038780100150
0397#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#278#46#a
rticle#75#46#^rND^sSharabi^nY#^rND^sScope^nA#^rND^sChorney^nN#^rND^sGrotto^nI#^r
ND^sDagan^nY#Diastolic blood pressure is the first to rise in association with e
arly subclinical obstructive sleep apnea: lessons from periodic examination scre
ening^len#Am J Hypertens#20030000#2003#16#3#236-9#20110000#aop00711.htm#0895-706
1#Am J Hypertens##
00711000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01600120010001700136010001800153010001800171810000600189012008300195030001200278
06500090029006400050029903100040030403200020030801400070031086500090031700200130
0326035001000339801001200349#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#279#47#article#75#47#^rND^sHaas^nDC#^rND^sFoster^nGL#^rND^sNieto
^nFJ#^rND^sRedline^nS#^rND^sResnick^nHE#^rND^sRobbins^nJA#et al#Age-dependent as
sociations between sleep-disordered breathing and hypertension^len#Circulation#2
0050000#2005#111#5#614-21#20110000#aop00711.htm#0009-7322#Circulation##
00725000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100020001110100
01800131010001600149010002000165010001700185012011300202030000600315065000900321
06400050033003100040033503200020033901400080034186500090034900200130035803500100
0371801000600381#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#280#48#article#75#48#^rND^sAncoli-Israel^nS#^rND^sStepnowsky^nC#^rND^sDimsda
le^nJ#^rND^sMarler^nM#^rND^sCohen-Zion^nM#^rND^sJohnson^nS#The effect of race an
d sleep-disordered breathing on nocturnal BP "dipping": analysis in an older pop
ulation^len#Chest#20020000#2002#122#4#1148-55#20110000#aop00711.htm#0012-3692#Ch
est##
00608000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100025001020100
01700127012007900144030001300223065000900236064000500245031000300250032000200253
014000600255865000900261002001300270035001000283801001300293#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop00711.htm#S#c#281#49#article#75#49#^rND^sKapa^
nS#^rND^sSert Kuniyoshi^nFH#^rND^sSomers^nVK#Sleep apnea and hypertension: inter
actions and implications for management^len#Hypertension#20080000#2008#51#3#605-
8#20110000#aop00711.htm#0194-911X#Hypertension##
00723000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100023001050100
01600128010002100144010001800165010001600183810000600199012008000205030001500285
06500090030006400050030903100030031403200020031701400070031986500090032600200130
0335035001000348801001500358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#282#50#article#75#50#^rND^sDrager^nLF#^rND^sDiegues-Silva^nL#^rN
D^sDiniz^nPM#^rND^sBortolotto^nLA#^rND^sPedrosa^nRP#^rND^sCouto^nRB#et al#Obstru
ctive sleep apnea, masked hypertension, and arterial stiffness in men^len#Am J H
ypertens#20100000#2010#23#3#249-54#20110000#aop00711.htm#0895-7061#Am J Hyperten
s##
00685000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100023001040100
01900127010001600146010001600162010001700178012008300195030000600278065000900284
06400050029303100030029803200020030101400060030386500090030900200130031803500100
0331801000600341#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#283#51#article#75#51#^rND^sFaulx^nMD#^rND^sStorfer-Isser^nA#^rND^sKirchner^n
HL#^rND^sJenny^nNS#^rND^sTracy^nRP#^rND^sRedline^nS#Obstructive sleep apnea is a
ssociated with increased urinary albumin excretion^len#Sleep#20070000#2007#30#7#
923-9#20110000#aop00711.htm#0161-8105#Sleep##
00722000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
02100126010001600147010001800163010002300181012010800204030000600312065000900318
06400050032703100040033203200020033601400080033886500090034600200130035503500100
0368801000600378#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#284#52#article#75#52#^rND^sDrager^nLF#^rND^sBortolotto^nLA#^rND^sFigueiredo^
nAC#^rND^sSilva^nBC#^rND^sKrieger^nEM#^rND^sLorenzi-Filho^nG#Obstructive sleep a
pnea, hypertension, and their interaction on arterial stiffness and heart remode
ling^len#Chest#20070000#2007#131#5#1379-86#20110000#aop00711.htm#0012-3692#Chest
##
00672000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01800126010002300144012010900167030001300276065000900289064000500298031000300303
032000200306014000500308865000900313002001300322035001000335801001300345#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#285#53#article#75#53
#^rND^sDrager^nLF#^rND^sBortolotto^nLA#^rND^sKrieger^nEM#^rND^sLorenzi-Filho^nG#
Additive effects of obstructive sleep apnea and hypertension on early markers of
 carotid atherosclerosis^len#Hypertension#20090000#2009#53#1#64-9#20110000#aop00
711.htm#0194-911X#Hypertension##
00763000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01800126010001800144010002300162012016600185030001400351065000900365064000500374
03100040037903200020038301400060038586500090039100200130040003500100041380100140
0423#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#286#54#a
rticle#75#54#^rND^sDrager^nLF#^rND^sBortolotto^nLA#^rND^sPedrosa^nRP#^rND^sKrieg
er^nEM#^rND^sLorenzi-Filho^nG#Left atrial diameter is independently associated w
ith arterial stiffness in patients with obstructive sleep apnea: potential impli
cations for atrial fibrillation^len#Int J Cardiol#20100000#2010#144#2#257-9#2011
0000#aop00711.htm#0167-5273#Int J Cardiol##
00758000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01600123010001600139010001800155010002000173810000600193012013700199030000600336
06500090034206400050035103100040035603200020036001400080036286500090037000200130
0379035001000392801000600402#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#287#55#article#75#55#^rND^sPedrosa^nRP#^rND^sDrager^nLF#^rND^sGe
nta^nPR#^rND^sAmaro^nAC#^rND^sAntunes^nMO#^rND^sMatsumoto^nAY#et al#Obstructive 
sleep apnea is common and independently associated with atrial fibrillation in p
atients with hypertrophic cardiomyopathy^len#Chest#20100000#2010#137#5#1078-84#2
0110000#aop00711.htm#0012-3692#Chest##
00753000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01500125010001500140010001600155010001900171810000600190012012500196030001200321
06500090033306400050034203100040034703200020035101400060035386500090035900200130
0368035001000381801001200391#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#288#56#article#75#56#^rND^sBecker^nHF#^rND^sJerrentrup^nA#^rND^s
Ploch^nT#^rND^sGrote^nL#^rND^sPenzel^nT#^rND^sSullivan^nCE#et al#Effect of nasal
 continuous positive airway pressure treatment on blood pressure in patients wit
h obstructive sleep apnea^len#Circulation#20030000#2003#107#1#68-73#20110000#aop
00711.htm#0009-7322#Circulation##
00700000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01900123010001700142010002000159012011000179030001300289065000900302064000500311
03100030031603200020031901400080032186500090032900200130033803500100035180100130
0361#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#289#57#a
rticle#75#57#^rND^sRobinson^nGV#^rND^sSmith^nDM#^rND^sLangford^nBA#^rND^sDavies^
nRJ#^rND^sStradling^nJR#Continuous positive airway pressure does not reduce bloo
d pressure in nonsleepy hypertensive OSA patients^len#Eur Respir J#20060000#2006
#27#6#1229-35#20110000#aop00711.htm#0903-1936#Eur Respir J##
00763000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100024001030100
01600127010002000143010001600163010001500179810000600194012010200200030002600302
06500090032806400050033703100040034203200020034601400070034886500090035500200130
0364035001000377801002600387#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#290#58#article#75#58#^rND^sBarbe^nF#^rND^sDuran-Cantolla^nJ#^rND
^sCapote^nF#^rND^sde la Peña^nM#^rND^sChiner^nE#^rND^sMasa^nJF#et al#Long-term e
ffect of continuous positive airway pressure in hypertensive patients with sleep
 apnea^len#Am J Respir Crit Care Med#20100000#2010#181#7#718-26#20110000#aop0071
1.htm#1073-449X#Am J Respir Crit Care Med##
00788000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01400121010001600135010001700151010001400168010001400182010001800196012012500214
03000130033906500090035206400050036103100040036603200030037001400080037386500090
0381002001300390035001000403801001300413#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop00711.htm#S#c#291#59#article#75#59#^rND^sKaneko^nY#^rND^sFloras^nJ
S#^rND^sUsui^nK#^rND^sPlante^nJ#^rND^sTkacova^nR#^rND^sKubo^nT#^rND^sAndo^nS#^rN
D^sBradley^nTD#Cardiovascular effects of continuous positive airway pressure in 
patients with heart failure and obstructive sleep apnea^len#N Engl J Med#2003000
0#2003#348#13#1233-41#20110000#aop00711.htm#0028-4793#N Engl J Med##
00757000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01700122010001900139010001800158012016700176030001500343065000900358064000500367
03100040037203200020037601400060037886500090038400200130039303500100040680100150
0416#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#292#60#a
rticle#75#60#^rND^sMills^nPJ#^rND^sKennedy^nBP#^rND^sLoredo^nJS#^rND^sDimsdale^n
JE#^rND^sZiegler^nMG#Effects of nasal continuous positive airway pressure and ox
ygen supplementation on norepinephrine kinetics and cardiovascular responses in 
obstructive sleep apnea^len#J Appl Physiol#20060000#2006#100#1#343-8#20110000#ao
p00711.htm#0021-8987#J Appl Physiol##
00675000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100020001040100
01600124010001500140010001600155010001600171012007900187030002700266710000200293
06500090029506400090030403100030031303200020031601400090031886500090032700200130
0336#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#293#61#a
rticle#75#61#^rND^sGiles^nTL#^rND^sLasserson^nTJ#^rND^sSmith^nBJ#^rND^sWhite^nJ#
^rND^sWright^nJ#^rND^sCates^nCJ#Continuous positive airways pressure for obstruc
tive sleep apnea in adults^len#Cochrane Database Syst Rev#2#20060100#2006 Jan#25
#1#CD001106#20110000#aop00711.htm##
00783000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01300122010001800135010001800153010001300171810000600184012017500190030000500365
06500090037006400050037903100040038403200020038801400060039086500090039600200130
0405035001000418801000500428#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#294#62#article#75#62#^rND^sAlajmi^nM#^rND^sMulgrew^nAT#^rND^sFox
^nJ#^rND^sDavidson^nW#^rND^sSchulzer^nM#^rND^sMak^nE#et al#Impact of continuous 
positive airway pressure therapy on blood pressure in patients with obstructive 
sleep apnea hypopnea: a meta-analysis of randomized controlled trials^len#Lung#2
0070000#2007#185#2#67-72#20110000#aop00711.htm#0341-2040#Lung##
00842000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100024001070100
02100131010001900152010001500171010001600186810000600202012019300208030001600401
06500090041706400050042603100040043103200020043501400070043786500090044400200130
0453035001000466801001600476#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#295#63#article#75#63#^rND^sHaentjens^nP#^rND^sVan Meerhaeghe^nA#
^rND^sMoscariello^nA#^rND^sDe Weerdt^nS#^rND^sPoppe^nK#^rND^sDupont^nA#et al#The
 impact of continuous positive airway pressure on blood pressure in patients wit
h obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-con
trolled randomized trials^len#Arch Intern Med#20070000#2007#167#8#757-64#2011000
0#aop00711.htm#0003-9926#Arch Intern Med##
00650000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100012000880100012001000120
18500112030002300297710000200320065000900322064000500331031000300336032000300339
014000800342865000900350002001300359#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop00711.htm#S#c#296#64#article#75#64#^rND^sMo^nL#^rND^sHe^nQ#Effect of l
ong-term continuous positive airway pressure ventilation on blood pressure in pa
tients with obstructive sleep apnea hypopnea syndrome: a meta-analysis of clinic
al trials^len#Zhonghua Yi Xue Za Zhi#2#20070000#2007#87#17#1177-80#20110000#aop0
0711.htm##
00659000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100014001060100
01800120010001200138012011100150030001300261065000900274064000500283031000300288
032000200291014000700293865000900300002001300309035001000322801001300332#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#297#65#article#75#65
#^rND^sBazzano^nLA#^rND^sKhan^nZ#^rND^sReynolds^nK#^rND^sHe^nJ#Effect of nocturn
al nasal continuous positive airway pressure on blood pressure in obstructive sl
eep apnea^len#Hypertension#20070000#2007#50#2#417-23#20110000#aop00711.htm#0194-
911X#Hypertension##
00593000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050120
09600123030001300219065000900232064000500241031000300246032000200249014000700251
865000900258002001300267035001000280801001300290#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#298#66#article#75#66#^rND^sFloras^nJS#^rND^s
Bradley^nTD#Treating obstructive sleep apnea: is there more to the story than 2 
millimeters of mercury?^len#Hypertension#20070000#2007#50#2#289-91#20110000#aop0
0711.htm#0194-911X#Hypertension##
00769000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100021001070100
01500128012027100143030001700414710000200431065000900433064000500442031000200447
032000200449014000600451865000900457002001300466#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#299#67#article#75#67#^rND^sDernaika^nTA#^rND
^sKinasewitz^nGT#^rND^sTawk^nMM#Effects of nocturnal continuous positive airway 
pressure therapy in patients with resistant hypertension and obstructive sleep a
pnea: effects of nocturnal continuous positive airway pressure therapy in patien
ts with resistant hypertension and obstructive sleep apnea^len#J Clin Sleep Med#
2#20090000#2009#5#2#103-7#20110000#aop00711.htm##
00725000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
02200121010001600143010001600159010001700175810000600192012009400198030001300292
06500090030506400050031403100030031903200020032201400060032486500090033000200130
0339035001000352801001300362#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#300#68#article#75#68#^rND^sLogan^nAG#^rND^sTkacova^nR#^rND^sPerl
ikowski^nSM#^rND^sLeung^nRS#^rND^sTisler^nA#^rND^sFloras^nJS#et al#Refractory hy
pertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex^len
#Eur Respir J#20030000#2003#21#2#241-7#20110000#aop00711.htm#0903-1936#Eur Respi
r J##
00739000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100026000880100024001140100
02500138010001900163010002500182010002300207012008800230030001300318065000900331
06400050034003100030034503200020034801400060035086500090035600200130036503500100
0378801001300388#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#
S#c#301#69#article#75#69#^rND^sMartínez-García^nMA#^rND^sGómez-Aldaraví^nR#^rND^
sSoler-Cataluña^nJJ#^rND^sMartínez^nTG#^rND^sBernácer-Alpera^nB#^rND^sRomán-Sánc
hez^nP#Positive effect of CPAP treatment on the control of difficult-to-treat hy
pertension^len#Eur Respir J#20070000#2007#29#5#951-7#20110000#aop00711.htm#0903-
1936#Eur Respir J##
00625000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100016001090100
01900125012010900144030000600253065000900259064000500268031000300273032000200276
014000700278865000900285002001300294035001000307801000600317#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop00711.htm#S#c#302#70#article#75#70#^rND^sGotso
poulos^nH#^rND^sKelly^nJJ#^rND^sCistulli^nPA#Oral appliance therapy reduces bloo
d pressure in obstructive sleep apnea: a randomized, controlled trial^len#Sleep#
20040000#2004#27#5#934-41#20110000#aop00711.htm#0161-8105#Sleep##
00653000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100028001040100
01500132010001600147010001400163012010000177030001300277710000200290065000900292
064000500301031000300306032000200309014000600311865000900317002001300326#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#303#71#article#75#71
#^rND^sOtsuka^nR#^rND^sRibeiro de Almeida^nF#^rND^sLowe^nAA#^rND^sLinden^nW#^rND
^sRyan^nF#The effect of oral appliance therapy on blood pressure in patients wit
h obstructive sleep apnea^len#Sleep Breath#2#20060000#2006#10#1#29-36#20110000#a
op00711.htm##
00540000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880120051001030300
01800154065000900172064000500181031000400186032000200190034000200192014000600194
865000900200002001300209035001000222801001800232#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop00711.htm#S#c#304#72#article#75#72#^rND^sIssa^nFG#Effect o
f clonidine in obstructive sleep apnea^len#Am Rev Respir Dis#19920000#1992#145#2
#1#435-9#20110000#aop00711.htm#0003-0805#Am Rev Respir Dis##
00733000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01500121010001500136012015700151030002600308065000900334064000500343031000400348
032000200352014000700354865000900361002001300370035001000383801002600393#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop00711.htm#S#c#305#73#article#75#73
#^rND^sKraiczi^nH#^rND^sHedner^nJ#^rND^sPeker^nY#^rND^sGrote^nL#Comparison of at
enolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihyperte
nsive treatment in patients with obstructive sleep apnea^len#Am J Respir Crit Ca
re Med#20000000#2000#161#5#1423-8#20110000#aop00711.htm#1073-449X#Am J Respir Cr
it Care Med##
00749000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
02400121010001300145010001300158010001300171810000600184012009900190030002600289
06500090031506400050032403100040032903200020033301400060033586500090034100200130
0350035001000363801002600373#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#306#74#article#75#74#^rND^sRedolfi^nS#^rND^sYumino^nD#^rND^sRutt
anaumpawan^nP#^rND^sYau^nB#^rND^sSu^nMC#^rND^sLam^nJ#et al#Relationship between 
overnight rostral fluid shift and obstructive sleep apnea in nonobese men^len#Am
 J Respir Crit Care Med#20090000#2009#179#3#241-6#20110000#aop00711.htm#1073-449
X#Am J Respir Crit Care Med##
00772000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
02400121010001300145010001500158010001700173810000600190012014000196030001200336
06500090034806400050035703100040036203200030036601400090036986500090037800200130
0387035001000400801001200410#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op00711.htm#S#c#307#75#article#75#75#^rND^sYumino^nD#^rND^sRedolfi^nS#^rND^sRutt
anaumpawan^nP#^rND^sSu^nMC#^rND^sSmith^nS#^rND^sNewton^nGE#et al#Nocturnal rostr
al fluid shift: a unifying concept for the pathogenesis of obstructive and centr
al sleep apnea in men with heart failure^len#Circulation#20100000#2010#121#14#15
98-605#20110000#aop00711.htm#0009-7322#Circulation##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#o#1#1#
article#1#20110331#080906#aop01011.htm#183##
05482000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200700017301200680
02430100035003110100033003460100038003790100029004170100024004460100027004700100
03000497070008100527070005900608083197200667085000802639085002702647085003202674
08500400270608500260274608318120277208500080458408500270459208500310461908500400
46500850028046901170008047180720003047261120009047291110009047381160009047471150
00904756114000904765113000904774002001304783#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop01011.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#21#nd#nd#Arq
. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110225#Autoanticorpos anti-&#
946;2-glicoproteína I e síndrome metabólica^lpt#Anti-beta2-glycoprotein I autoan
tibodies and metabolic syndrome^len#^rND^1A01^nRodrigo B. Krás^sBorges#^rND^1A01
^nLuis Carlos^sBodanese#^rND^1A01^nCarlos Alberto von^sMühlen#^rND^1A01^nGiusepp
e^sRepetto#^rND^1A01^nMario^sViehe#^rND^1A02^nGary L.^sNorman#^rND^1A01^nHenriqu
e L.^sStaub#Pontifícia Universidade Católica do Rio Grande do Sul^iA01^cPorto Al
egre^pBrasil#INOVA Laboratory^iA02^sSan Diego^pUnited States of America#^lpt^aFU
NDAMENTO: A síndrome metabólica (SM) é uma entidade pró-aterogênica. Autoanticor
pos tais como &#946;2-glicoproteína I (&#946;2-gpI) podem influenciar o aparecim
ento de ateromas. Estudos anteriores confirmaram uma associação entre anticorpos
 IgA anti-&#946;2-gpI e isquemia cerebral, infarto do miocárdio, doença arterial
 periférica e doença da carótida. OBJETIVO: O objetivo desse estudo de caso-cont
role foi avaliar uma possível associação entre anticorpos anti-&#946;2-gpI e ant
icardiolipina (aCL) com SM não-complicada. MÉTODOS: Pacientes com SM sem históri
co de eventos vasculares e indivíduos-controle, consistindo em pacientes da Enfe
rmaria de Ortopedia admitidos devido a doenças musculoesqueléticas foram incluíd
os no estudo. Idade, sexo, etnia, histórico de hipertensão, tabagismo, hipercole
sterolemia e diabetes mellitus foram avaliados como fatores de risco em ambos os
 grupos. Anticorpos IgG, IgM, e IgA anti-&#946;2-gpI e aCL foram detectados atra
vés de imunoensaios enzimáticos. RESULTADOS: Um total de 68 pacientes com SM e 8
2 controles foram estudados. Os pacientes com SM tinham média de idade superior 
à dos controles (P = 0,001), enquanto homens (P = 0,003; OR 0,31; IC95%: 0,15-0,
16) e etnia caucasiana (P = 0,004; OR 0,25; IC95%:0,10-0,60) eram predominantes 
nos controles. Histórico de hipertensão, hipercolesterolemia e diabetes mellitus
 foi mais prevalente nos pacientes com SM do que nos controles (P < 0.05). A fre
quência de anticorpos aCL (todos os isotipos) e do IgG e IgM anti-&#946;2 gpI nã
o diferiu de forma significante nos pacientes com SM e controles. Anticorpos IgA
 anti-&#946;2-gpI foram significantemente mais frequentes nos pacientes com SM (
42,2%) do que nos controles (10,9%) (P < 0,001). O OR ajustado para anticorpos I
gA anti-&#946;2-gpI foi 3,60 (IC95%: 1,55-8,37; P = 0,003). CONCLUSÃO: O present
e estudo mostra que níveis elevados de autoanticorpos IgA para &#946;2-gpI podem
 estar independentemente associados com SM.#^dnd^i1#^tm^lpt^kAutoanticorpos^i1#^
tm^lpt^ksíndrome metabólica^i1#^tm^lpt^kanticorpos anticardialipina^i1#^tm^lpt^k
aterosclerose^i1#^len^aBACKGROUND: The metabolic syndrome (MetS) is a proatherog
enic entity. Autoantibodies to phospholipid cofactors such as beta2-glycoprotein
 I (beta2-gpI) can influence atheroma appearance. Previous studies confirmed an 
association of IgA anti-beta2-gpI antibodies with cerebral ischemia, myocardial 
infarction, peripheral artery disease and carotid disease. OBJECTIVE: This case-
control study evaluates a possible association of anti-beta2-gpI and anticardiol
ipin (aCL) antibodies with non-complicated MetS. METHODS: Cases comprised patien
ts with MetS without history of vascular events; controls included individuals f
rom the Orthopedic Infirmary admitted due to musculoskeletal disorders. Age, sex
, race, history of hypertension, smoking, hypercholesterolemia and diabetes mell
itus were evaluated as risk factors in both groups. IgG, IgM, and IgA anti-beta2
-gpI and aCL antibodies were detected by enzymatic immunoassay. RESULTS: Sixty-e
ight patients with MetS and 82 controls were studied. Patients with MetS showed 
mean age higher than controls (P = 0.001), while males (P = 0.003; OR 0.31; 95%C
I 0.15-0.16) and Caucasian ethnicity (P = 0.004; OR 0.25; 95%CI 0.10-0.60) predo
minated in controls. History of hypertension, hypercholesterolemia and diabetes 
mellitus were more prevalent in cases than in controls (P < 0.05). The frequency
 of aCL antibodies (all isotypes) and of IgG and IgM anti-beta2 gpI did not sign
ificantly differ in cases and controls. IgA anti-beta2-gpI antibodies were signi
ficantly more frequent in MetS patients (42.2%) than controls (10.9%) (P < 0.001
). The adjusted OR for IgA anti-beta2-gpI antibodies was 3.60 (95%CI 1.55-8.37; 
P = 0.003). CONCLUSION: The current study shows that elevated levels of IgA auto
antibodies to &#946;2-gpI might be independently associated to MetS.#^dnd^i2#^tm
^len^kAutoantibodies^i2#^tm^len^kmetabolic syndrome^i2#^tm^len^kantibodies, anti
cardiolipin^i2#^tm^len^katherosclerosis^i2#vancouv#34#20100326#26/03/10#20100714
#14/07/10#20100917#17/09/10#aop01011.htm##
05578000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200770017301200750
02500100035003250100033003600100038003930100029004310100024004600100027004840100
03000511070008100541070005900622083201300681085000802694085002702702085003202729
08500400276108500260280108318530282708500080468008500270468808500310471508500400
47460850028047861170008048140720003048221120009048251110009048341160009048431150
00904852114000904861113000904870002001304879#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop01011.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#21#nd#nd#Arq
. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110225#<b>Autoanticorpos anti
-&#946;2-glicoproteína I e síndrome metabólica</b>^lpt#<b>Anti-beta2-glycoprotei
n I autoantibodies and metabolic syndrome</b>^len#^rND^1A01^nRodrigo B. Krás^sBo
rges#^rND^1A01^nLuis Carlos^sBodanese#^rND^1A01^nCarlos Alberto von^sMühlen#^rND
^1A01^nGiuseppe^sRepetto#^rND^1A01^nMario^sViehe#^rND^1A02^nGary L.^sNorman#^rND
^1A01^nHenrique L.^sStaub#Pontifícia Universidade Católica do Rio Grande do Sul^
iA01^cPorto Alegre^pBrasil#INOVA Laboratory^iA02^sSan Diego^pUnited States of Am
erica#^lpt^a<b>FUNDAMENTO:</b> A síndrome metabólica (SM) é uma entidade pró-ate
rogênica. Autoanticorpos tais como &#946;2-glicoproteína I (&#946;2-gpI) podem i
nfluenciar o aparecimento de ateromas. Estudos anteriores confirmaram uma associ
ação entre anticorpos IgA anti-&#946;2-gpI e isquemia cerebral, infarto do miocá
rdio, doença arterial periférica e doença da carótida. <b>OBJETIVO: </b>O objeti
vo desse estudo de caso-controle foi avaliar uma possível associação entre antic
orpos anti-&#946;2-gpI e anticardiolipina (aCL) com SM não-complicada. <b>MÉTODO
S: </b>Pacientes com SM sem histórico de eventos vasculares e indivíduos-control
e, consistindo em pacientes da Enfermaria de Ortopedia admitidos devido a doença
s musculoesqueléticas foram incluídos no estudo. Idade, sexo, etnia, histórico d
e hipertensão, tabagismo, hipercolesterolemia e diabetes mellitus foram avaliado
s como fatores de risco em ambos os grupos. Anticorpos IgG, IgM, e IgA anti-&#94
6;2-gpI e aCL foram detectados através de imunoensaios enzimáticos. <b>RESULTADO
S:</b> Um total de 68 pacientes com SM e 82 controles foram estudados. Os pacien
tes com SM tinham média de idade superior à dos controles (P = 0,001), enquanto 
homens (P = 0,003; OR 0,31; IC95%: 0,15-0,16) e etnia caucasiana (P = 0,004; OR 
0,25; IC95%:0,10-0,60) eram predominantes nos controles. Histórico de hipertensã
o, hipercolesterolemia e diabetes mellitus foi mais prevalente nos pacientes com
 SM do que nos controles (P &lt; 0.05). A frequência de anticorpos aCL (todos os
 isotipos) e do IgG e IgM anti-&#946;2 gpI não diferiu de forma significante nos
 pacientes com SM e controles. Anticorpos IgA anti-&#946;2-gpI foram significant
emente mais frequentes nos pacientes com SM (42,2%) do que nos controles (10,9%)
 (P &lt; 0,001). O OR ajustado para anticorpos IgA anti-&#946;2-gpI foi 3,60 (IC
95%: 1,55-8,37; P = 0,003). <b>CONCLUSÃO: </b>O presente estudo mostra que nívei
s elevados de autoanticorpos IgA para &#946;2-gpI podem estar independentemente 
associados com SM.#^dnd^i1#^tm^lpt^kAutoanticorpos^i1#^tm^lpt^ksíndrome metabóli
ca^i1#^tm^lpt^kanticorpos anticardialipina^i1#^tm^lpt^katerosclerose^i1#^len^a<b
>BACKGROUND:</b> The metabolic syndrome (MetS) is a proatherogenic entity. Autoa
ntibodies to phospholipid cofactors such as beta2-glycoprotein I (beta2-gpI) can
 influence atheroma appearance. Previous studies confirmed an association of IgA
 anti-beta2-gpI antibodies with cerebral ischemia, myocardial infarction, periph
eral artery disease and carotid disease. <b>OBJECTIVE:</b> This case-control stu
dy evaluates a possible association of anti-beta2-gpI and anticardiolipin (aCL) 
antibodies with non-complicated MetS. <b>METHODS:</b> Cases comprised patients w
ith MetS without history of vascular events; controls included individuals from 
the Orthopedic Infirmary admitted due to musculoskeletal disorders. Age, sex, ra
ce, history of hypertension, smoking, hypercholesterolemia and diabetes mellitus
 were evaluated as risk factors in both groups. IgG, IgM, and IgA anti-beta2-gpI
 and aCL antibodies were detected by enzymatic immunoassay. <b>RESULTS:</b> Sixt
y-eight patients with MetS and 82 controls were studied. Patients with MetS show
ed mean age higher than controls (P = 0.001), while males (P = 0.003; OR 0.31; 9
5%CI 0.15-0.16) and Caucasian ethnicity (P = 0.004; OR 0.25; 95%CI 0.10-0.60) pr
edominated in controls. History of hypertension, hypercholesterolemia and diabet
es mellitus were more prevalent in cases than in controls (P &lt; 0.05). The fre
quency of aCL antibodies (all isotypes) and of IgG and IgM anti-beta2 gpI did no
t significantly differ in cases and controls. IgA anti-beta2-gpI antibodies were
 significantly more frequent in MetS patients (42.2%) than controls (10.9%) (P &
lt; 0.001). The adjusted OR for IgA anti-beta2-gpI antibodies was 3.60 (95%CI 1.
55-8.37; P = 0.003). <b>CONCLUSION:</b> The current study shows that elevated le
vels of IgA autoantibodies to &#946;2-gpI might be independently associated to M
etS.#^dnd^i2#^tm^len^kAutoantibodies^i2#^tm^len^kmetabolic syndrome^i2#^tm^len^k
antibodies, anticardiolipin^i2#^tm^len^katherosclerosis^i2#vancouv#34#20100326#2
6/03/10#20100714#14/07/10#20100917#17/09/10#aop01011.htm##
05683000000000709000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001200700
01790120068002490100035003170100033003520100038003850100029004230100024004520100
02600476010002900502070008300531070006100614083201700675085000802692085002702700
08500320272708500400275908500260279908318470282508500080467208500270468008500310
47070850040047380850028047781170008048060720003048141120009048171110009048261160
00904835115000904844114000904853113000904862002001304871008008904884#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#l#4#1#article#1#^a2011#oa#
pt#br1.1#1#4.0#tab#21#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#2
0110225#Autoanticorpos anti-&#946;2-glicoproteína I e síndrome metabólica^lpt#An
ti-beta2-glycoprotein I autoantibodies and metabolic syndrome^len#^rND^1A01^nRod
rigo B. Krás^sBorges#^rND^1A01^nLuis Carlos^sBodanese#^rND^1A01^nCarlos Alberto 
von^sMühlen#^rND^1A01^nGiuseppe^sRepetto#^rND^1A01^nMario^sViehe#^rND^1A02^nGary
 L^sNorman#^rND^1A01^nHenrique L^sStaub#^iA01^1Pontifícia Universidade Católica 
do Rio Grande do Sul^cPorto Alegre^pBrasil#^iA02^1INOVA Laboratory^sSan Diego^pU
nited States of America#^lpt^aFUNDAMENTO: A síndrome metabólica (SM) é uma entid
ade pró-aterogênica. Autoanticorpos tais como &#946;2-glicoproteína I (&#946;2-g
pI) podem influenciar o aparecimento de ateromas. Estudos anteriores confirmaram
 uma associação entre anticorpos IgA anti-&#946;2-gpI e isquemia cerebral, infar
to do miocárdio, doença arterial periférica e doença da carótida. OBJETIVO: O ob
jetivo desse estudo de caso-controle foi avaliar uma possível associação entre a
nticorpos anti-&#946;2-gpI e anticardiolipina (aCL) com SM não-complicada. MÉTOD
OS: Pacientes com SM sem histórico de eventos vasculares e indivíduos-controle, 
consistindo em pacientes da Enfermaria de Ortopedia admitidos devido a doenças m
usculoesqueléticas foram incluídos no estudo. Idade, sexo, etnia, histórico de h
ipertensão, tabagismo, hipercolesterolemia e diabetes mellitus foram avaliados c
omo fatores de risco em ambos os grupos. Anticorpos IgG, IgM, e IgA anti-&#946;2
-gpI e aCL foram detectados através de imunoensaios enzimáticos. RESULTADOS: Um 
total de 68 pacientes com SM e 82 controles foram estudados. Os pacientes com SM
 tinham média de idade superior à dos controles (P = 0,001), enquanto homens (P 
= 0,003; OR 0,31; IC95 por cento: 0,15-0,16) e etnia caucasiana (P = 0,004; OR 0
,25; IC95 por cento:0,10-0,60) eram predominantes nos controles. Histórico de hi
pertensão, hipercolesterolemia e diabetes mellitus foi mais prevalente nos pacie
ntes com SM do que nos controles (P < 0.05). A frequência de anticorpos aCL (tod
os os isotipos) e do IgG e IgM anti-&#946;2 gpI não diferiu de forma significant
e nos pacientes com SM e controles. Anticorpos IgA anti-&#946;2-gpI foram signif
icantemente mais frequentes nos pacientes com SM (42,2 por cento) do que nos con
troles (10,9 por cento) (P < 0,001). O OR ajustado para anticorpos IgA anti-&#94
6;2-gpI foi 3,60 (IC95 por cento: 1,55-8,37; P = 0,003). CONCLUSÃO: O presente e
studo mostra que níveis elevados de autoanticorpos IgA para &#946;2-gpI podem es
tar independentemente associados com SM.#^dnd^i1#^tm^lpt^kAutoanticorpos^i1#^tm^
lpt^ksíndrome metabólica^i1#^tm^lpt^kanticorpos anticardialipina^i1#^tm^lpt^kate
rosclerose^i1#^len^aBACKGROUND: The metabolic syndrome (MetS) is a proatherogeni
c entity. Autoantibodies to phospholipid cofactors such as beta2-glycoprotein I 
(beta2-gpI) can influence atheroma appearance. Previous studies confirmed an ass
ociation of IgA anti-beta2-gpI antibodies with cerebral ischemia, myocardial inf
arction, peripheral artery disease and carotid disease. OBJECTIVE: This case-con
trol study evaluates a possible association of anti-beta2-gpI and anticardiolipi
n (aCL) antibodies with non-complicated MetS. METHODS: Cases comprised patients 
with MetS without history of vascular events; controls included individuals from
 the Orthopedic Infirmary admitted due to musculoskeletal disorders. Age, sex, r
ace, history of hypertension, smoking, hypercholesterolemia and diabetes mellitu
s were evaluated as risk factors in both groups. IgG, IgM, and IgA anti-beta2-gp
I and aCL antibodies were detected by enzymatic immunoassay. RESULTS: Sixty-eigh
t patients with MetS and 82 controls were studied. Patients with MetS showed mea
n age higher than controls (P = 0.001), while males (P = 0.003; OR 0.31; 95 perc
entCI 0.15-0.16) and Caucasian ethnicity (P = 0.004; OR 0.25; 95 percentCI 0.10-
0.60) predominated in controls. History of hypertension, hypercholesterolemia an
d diabetes mellitus were more prevalent in cases than in controls (P < 0.05). Th
e frequency of aCL antibodies (all isotypes) and of IgG and IgM anti-beta2 gpI d
id not significantly differ in cases and controls. IgA anti-beta2-gpI antibodies
 were significantly more frequent in MetS patients (42.2 percent) than controls 
(10.9 percent) (P < 0.001). The adjusted OR for IgA anti-beta2-gpI antibodies wa
s 3.60 (95 percentCI 1.55-8.37; P = 0.003). CONCLUSION: The current study shows 
that elevated levels of IgA autoantibodies to &#946;2-gpI might be independently
 associated to MetS.#^dnd^i2#^tm^len^kAutoantibodies^i2#^tm^len^kmetabolic syndr
ome^i2#^tm^len^kantibodies, anticardiolipin^i2#^tm^len^katherosclerosis^i2#vanco
uv#34#20100326#26/03/10#20100714#14/07/10#20100917#17/09/10#aop01011.htm#Interne
t^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X201100500002
1##
00538000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704029600083002001300379#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#5#1#article#145#<p><a name="
top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Autoanti
corpos    anti-</b></font><b><font size="4">&#946;</font><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="4">2-glicoprote&iacute;na    I e s&iacute;ndro
me metab&oacute;lica</font></b></p>     ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#6#2#article#145#<p>&nbsp;</p
>     ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#7#3#article#145#<p>&nbsp;</p
>     ^cY#aop01011.htm##
00575000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704033300083002001300416#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#8#4#article#145#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Rodrigo B. Kr&aacute;s    
Borges<sup>I</sup>; Luis Carlos Bodanese<sup>I</sup>; Carlos Alberto von M&uuml;
hlen<sup>I</sup>;    Giuseppe Repetto<sup>I</sup>; Mario Viehe<sup>I</sup>; Gary
 L. Norman<sup>II</sup>;    Henrique L. Staub<sup>I</sup></b></font></p>     ^cY
#aop01011.htm##
00490000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704024800083002001300331#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#9#5#article#145#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Reumatologia,    
Cardiologia e Endocrinologia - Departamento da Pontif&iacute;cia Universidade   
 Cat&oacute;lica do Rio Grande do Sul (PUCRS), Porto Alegre - Brasil    ^cY#aop0
1011.htm##
00337000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009400084002001300178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#10#6#article#145#<br>   <sup
>II</sup>INOVA Laboratory, San Diego - United States of America</font></p>     ^
cY#aop01011.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#11#7#article#145#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#12#8#article#145#<p>&nbsp;</
p>     ^cY#aop01011.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#13#9#article#145#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01011.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#14#10#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>   
  ^cY#aop01011.htm##
01055000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704081100085002001300896#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#15#11#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>FUNDAMENTO:</b>    A s&i
acute;ndrome metab&oacute;lica (SM) &eacute; uma entidade pr&oacute;-aterog&ecir
c;nica.    Autoanticorpos tais como </font><font size="2">&#946;</font><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2-glicoprote&iacute;na    I (
</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-s
erif" size="2">2-gpI)    podem influenciar o aparecimento de ateromas. Estudos a
nteriores confirmaram    uma associa&ccedil;&atilde;o entre anticorpos IgA anti-
</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-s
erif" size="2">2-gpI    e isquemia cerebral, infarto do mioc&aacute;rdio, doen&c
cedil;a arterial perif&eacute;rica    e doen&ccedil;a da car&oacute;tida.    ^cY
#aop01011.htm##
00558000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031400085002001300399#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#16#12#article#145#<br>   <b>
OBJETIVO: </b> O objetivo desse estudo de caso-controle foi avaliar uma poss&iac
ute;vel    associa&ccedil;&atilde;o entre anticorpos anti-</font><font size="2">
&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI  
  e anticardiolipina (aCL) com SM n&atilde;o-complicada.    ^cY#aop01011.htm##
00913000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066900085002001300754#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#17#13#article#145#<br>   <b>
M&Eacute;TODOS: </b> Pacientes com SM sem hist&oacute;rico de eventos vasculares
    e indiv&iacute;duos-controle, consistindo em pacientes da Enfermaria de Orto
pedia    admitidos devido a doen&ccedil;as musculoesquel&eacute;ticas foram incl
u&iacute;dos    no estudo. Idade, sexo, etnia, hist&oacute;rico de hipertens&ati
lde;o, tabagismo,    hipercolesterolemia e diabetes mellitus foram avaliados com
o fatores de risco    em ambos os grupos. Anticorpos IgG, IgM, e IgA anti-</font
><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" 
size="2">2-gpI    e aCL foram detectados atrav&eacute;s de imunoensaios enzim&aa
cute;ticos.    ^cY#aop01011.htm##
01439000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704119500085002001301280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#18#14#article#145#<br>   <b>
RESULTADOS:</b> Um total de 68 pacientes com SM e 82 controles foram estudados. 
   Os pacientes com SM tinham m&eacute;dia de idade superior &agrave; dos contro
les    (P = 0,001), enquanto homens (P = 0,003; OR 0,31; IC95%: 0,15-0,16) e etn
ia    caucasiana (P = 0,004; OR 0,25; IC95%:0,10-0,60) eram predominantes nos co
ntroles.    Hist&oacute;rico de hipertens&atilde;o, hipercolesterolemia e diabet
es mellitus    foi mais prevalente nos pacientes com SM do que nos controles (P 
&lt; 0.05).    A frequ&ecirc;ncia de anticorpos aCL (todos os isotipos) e do IgG
 e IgM anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helve
tica, sans-serif" size="2">2    gpI n&atilde;o diferiu de forma significante nos
 pacientes com SM e controles.    Anticorpos IgA anti-</font><font size="2">&#94
6;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    fo
ram significantemente mais frequentes nos pacientes com SM (42,2%) do que    nos
 controles (10,9%) (P &lt; 0,001). O OR ajustado para anticorpos IgA anti-</font
><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" 
size="2">2-gpI    foi 3,60 (IC95%: 1,55-8,37; P = 0,003).    ^cY#aop01011.htm##
00532000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028800085002001300373#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#19#15#article#145#<br>   <b>
CONCLUS&Atilde;O: </b> O presente estudo mostra que n&iacute;veis elevados    de
 autoanticorpos IgA para </font><font size="2">&#946;</font><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2">2-gpI    podem estar independentemente a
ssociados com SM. </font></p>     ^cY#aop01011.htm##
00473000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022900085002001300314#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#20#16#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Autoanticorpos, s&iacute;ndrome metab&oacute;lica, anticorpos anticardialipina, 
   aterosclerose.</font></p> <hr size="1" noshade>     ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#21#17#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#22#18#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#23#19#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01011.htm##
00856000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704061200085002001300697#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#24#20#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A s&iacute;ndrome    metab&
oacute;lica (SM) &eacute; um grupo de anormalidades metab&oacute;licas,    inclu
indo resist&ecirc;ncia &agrave; insulina, dislipidemia e hipertens&atilde;o    s
ist&ecirc;mica, na qual a obesidade visceral &eacute; acentuada<sup>1</sup>.    
Inicialmente identificada h&aacute; sessenta anos, a SM &eacute; atualmente    u
m quest&atilde;o de grande interesse<sup>2</sup>. &Eacute; bem aceito o fato    
de que a SM prediz diabetes mellitus (DM)<sup>3</sup> e doen&ccedil;as cardiovas
culares<sup>3-4</sup>.</font></p>     ^cY#aop01011.htm##
00894000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704065000085002001300735#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#25#21#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na SM, part&iacute;culas   
 de lipoprote&iacute;nas de baixa densidade (LDL) apresentam tend&ecirc;ncia    
&agrave; oxida&ccedil;&atilde;o<sup>5</sup>. Hiperglicemia persistente acelera  
  a gera&ccedil;&atilde;o de produtos da glica&ccedil;&atilde;o avan&ccedil;ada,
    outro fator desencadeante de inflama&ccedil;&atilde;o arterial<sup>6</sup>. 
   O ac&uacute;mulo de adip&oacute;citos, por sua vez, favorece a secre&ccedil;&
atilde;o    do fator de necrose tumoral (TNF) e reduz os n&iacute;veis de adipon
ectina,    uma adipocina anti-aterog&ecirc;nica<sup>7</sup>.</font></p>     ^cY#
aop01011.htm##
00825000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058100085002001300666#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#26#22#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A aterosclerose    &eacute;
 atualmente considerada uma condi&ccedil;&atilde;o imunoinflamat&oacute;ria.    
A ativa&ccedil;&atilde;o endotelial, um evento prim&aacute;rio na aterog&ecirc;n
ese,    pode ser uma consequ&ecirc;ncia de manifesta&ccedil;&otilde;es t&iacute;
picas    da SM ou efeito do TNF. A c&eacute;lula endotelial ativada &eacute; car
acterizada    por baixa produ&ccedil;&atilde;o de trombomodulina e um fen&oacute
;tipo com    tend&ecirc;ncia &agrave; hipercoagulabilidade<sup>8</sup>.</font></
p>     ^cY#aop01011.htm##
01046000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080200085002001300887#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#27#23#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A auto-imunidade,    partic
ularmente anticorpos anticardiolipina ou cofatores fosfol&iacute;pides    tais c
omo </font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sa
ns-serif" size="2">2-glicoprote&iacute;na    I (</font><font size="2">&#946;</fo
nt><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI),    podem 
influenciar o desenvolvimento de ateroma<sup>9</sup>. Anticorpos anticardiolipin
a    (aCL) s&atilde;o classicamente detectados na assim chamada s&iacute;ndrome 
antifosfol&iacute;pide    (SAF), uma di&aacute;tese tromb&oacute;tica caracter&i
acute;stica de jovens    adultos<sup>10</sup>. O papel etiopatog&ecirc;nico dos 
anticorpos aCL na SM    ainda &eacute; desconhecido.</font></p>     ^cY#aop01011
.htm##
01820000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704157600085002001301661#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#28#24#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A </font><font size="2">&#9
46;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    &
eacute; um cofator fosfol&iacute;pide com 50 kilodaltons e 5 dom&iacute;nios,   
 o qual &eacute; um anticoagulante natural. Em pacientes com SAF, os efeitos    
inibit&oacute;rios da </font><font size="2">&#946;</font><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">2-gpI    nas vias de coagula&ccedil;&atilde
;o s&atilde;o aparentemente desreguladas por    anticorpos antifosfol&iacute;pid
es<sup>11</sup>. A </font><font size="2">&#946;</font><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">2-gpI    &eacute; encontrada na placa ateroscl
er&oacute;tica e pode ser imunog&ecirc;nica.    A indu&ccedil;&atilde;o de atero
sclerose em camundongos deficientes para receptor    de LDL imunizados com </fon
t><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif"
 size="2">2-gpI    tem sido relatada<sup>12</sup>. A administra&ccedil;&atilde;o
 oral de </font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetic
a, sans-serif" size="2">2-gpI    humana em camundongos previne a forma&ccedil;&a
tilde;o de ateroma<sup>13</sup>.    Sabe-se que a </font><font size="2">&#946;</
font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    liga-s
e a part&iacute;culas de LDL oxidadas; o complexo pode ser internalizado    some
nte por anticorpos que ocupam os receptores Fc na superf&iacute;cie dos    macr&
oacute;fagos<sup>14</sup>.</font></p>     ^cY#aop01011.htm##
00927000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068300085002001300768#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#29#25#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Uma poss&iacute;vel    asso
cia&ccedil;&atilde;o de autoanticorpos anti-</font><font size="2">&#946;</font><
font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    com SM n&ati
lde;o-complicada ainda n&atilde;o foi avaliada. O objetivo do presente    estudo
 &eacute; verificar a frequ&ecirc;ncia de autoanticorpos aCL e anti-</font><font
 size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="
2">2-gpI    em pacientes com SM e tamb&eacute;m avaliar a possibilidade de que e
sses autoanticorpos    estejam associados com a ocorr&ecirc;ncia de SM n&atilde;
o-complicada.</font></p>     ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#30#26#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#31#27#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&eacute;todos</b></font
></p>     ^cY#aop01011.htm##
00343000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009900085002001300184#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#32#28#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Pacientes</b></font></p>
     ^cY#aop01011.htm##
01783000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704153900085002001301624#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#33#29#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Esse estudo de    caso-cont
role de casos incidentes incluiu pacientes com SM de nosso Ambulat&oacute;rio   
 de Risco Cardiometab&oacute;lico, n&atilde;o selecionados por sexo ou etnia.   
 Os pacientes com SM inclu&iacute;dos nesse estudo n&atilde;o apresentavam hist&
oacute;rico    de eventos vasculares isqu&ecirc;micos. O diagn&oacute;stico de S
M foi baseado    nos crit&eacute;rios cl&aacute;ssicos do Programa Nacional de E
duca&ccedil;&atilde;o    em Colesterol (NCEP): circunfer&ecirc;ncia abdominal &g
t; 102 para homens ou    &gt; 88 para mulheres; n&iacute;veis s&eacute;ricos de 
triglic&eacute;rides    &gt; 150 mg/dl; press&atilde;o arterial <u>&gt;</u> 130/
85 mmHg; glicemia de    jejum &gt; 110 mg/dl; pelo menos tr&ecirc;s dos crit&eac
ute;rios deveriam estar    presentes para definir o diagn&oacute;stico<sup>15</s
up>. Os crit&eacute;rios    de exclus&atilde;o foram os seguintes: 1) hist&oacut
e;rico de infarto agudo    do mioc&aacute;rdio (IAM), derrame isqu&ecirc;mico ou
 oclus&atilde;o arterial    aguda dos membros inferiores; 2) endocardite infecci
osa; 3) neoplasmas (atuais    ou pr&eacute;vios); 4) infec&ccedil;&atilde;o pelo
 v&iacute;rus da imunodefici&ecirc;ncia    humana v&iacute;rus ou <i>treponema p
allidum;</i> 5) presen&ccedil;a de causa    heredit&aacute;ria conhecida de trom
bose, tal como homocistin&uacute;ria ou    muta&ccedil;&atilde;o do fator V de L
eiden; 5) SAF ou outro dist&uacute;rbio    de tecido conjuntivo (DTC)</font></p>
     ^cY#aop01011.htm##
00823000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057900085002001300664#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#34#30#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O grupo controle    consist
iu em pacientes da Enfermaria de Ortopedia, admitidos devido a fraturas    ou di
st&uacute;rbios musculares-ligamentosos, que n&atilde;o apresentavam diagn&oacut
e;stico    pr&eacute;vio de SM. Os crit&eacute;rios de exclus&atilde;o foram: 1)
 osteonecrose;    2) infec&ccedil;&otilde;es e neoplasias atuais, doen&ccedil;as
 heredit&aacute;rias,    SAF, ou DTC; 3) hist&oacute;rico de IAM, derrame isqu&e
circ;mico ou oclus&atilde;o    arterial aguda dos membros inferiores.</font></p>
     ^cY#aop01011.htm##
00963000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071900085002001300804#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#35#31#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os dados cl&iacute;nicos   
 e demogr&aacute;ficos foram obtidos atrav&eacute;s de revis&atilde;o de prontu&
aacute;rios    e entrevistas com os pacientes e suas fam&iacute;lias ap&oacute;s
 obten&ccedil;&atilde;o    do consentimento livre e informado, considerando-se a
s seguintes caracter&iacute;sticas:    1) idade, sexo, etnia; 2) hist&oacute;ric
o de press&atilde;o arterial elevada<sup>16</sup>;    3) tabagismo atual<sup>17<
/sup>; 4) DM, de acordo com hist&oacute;rico cl&iacute;nico    ou tratamento atu
al com insulina e/ou medicamentos antidiab&eacute;ticos<sup>18</sup>;    5) hist
&oacute;rico de hipercolesterolemia<sup>19</sup>.</font></p>     ^cY#aop01011.ht
m##
00342000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009800085002001300183#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#36#32#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Amostras</b></font></p> 
    ^cY#aop01011.htm##
01692000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704144800085002001301533#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#37#33#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As amostras de    soro fora
m centrifugadas e congeladas em at&eacute; 2 horas ap&oacute;s a coleta    e, su
bsequentemente, armazenadas a -70&deg; C at&eacute; os testes laboratoriais    d
e ensaio imunoenzim&aacute;tico (ELISA) serem realizados. Anticorpos aCL IgG,   
 IgM e IgA (INOVA Quantalite Cardiolipin kits, INOVA Diagnostics, Inc., San Dieg
o,    EUA)<sup>20</sup> e anticorpos anti-</font><font size="2">&#946;</font><fo
nt face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    (INOVA Quantal
ite </font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sa
ns-serif" size="2">2-gpI    kits, INOVA Diagnostics, Inc., San Diego, EUA)<sup>2
1</sup> foram testados.    Os ensaios foram avaliados por espectrofotometria, me
dindo e comparando a intensidade    da cor nas amostras dos pacientes com a cor 
das amostras dos controles. T&iacute;tulos    moderados a altos de anticorpos aC
L e anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetic
a, sans-serif" size="2">2-gpI    (&gt; 20 unidades para todos os isotipos) foram
 considerados positivos<sup>20,21</sup>.    Baixos t&iacute;tulos de aCL ou anti
-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-
serif" size="2">2-gpI    (10-20 unidades) n&atilde;o foram considerados. O estud
o foi aprovado pelo comit&ecirc;    de &Eacute;tica local.</font></p>     ^cY#ao
p01011.htm##
00360000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011600085002001300201#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#38#34#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    de dad
os</b></font></p>     ^cY#aop01011.htm##
01220000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097600085002001301061#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#39#35#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Odds ratios</i>    (OR) 
com intervalos de confian&ccedil;a de 95% (IC95%) foram utilizados na an&aacute;
lise    univariada. Regress&atilde;o log&iacute;stica com IC95% foi realizada pa
ra ajuste    dos efeitos da idade, sexo, etnia e tabagismo atual. A escala de Ho
pkins para    OR foi utilizada, onde um OR de 1-1,5 foi considerado trivial; ent
re 1,5-3,5,    baixo; entre 3,5-9, moderado; entre 9-32, alto; e acima de 32, mu
ito alto<sup>22</sup>.    Os testes exato de Fisher e Qui-quadrado foram usados 
para comparar vari&aacute;veis    categ&oacute;ricas e o teste <i>t</i> de Stude
nt foi usado para a compara&ccedil;&atilde;o    de vari&aacute;veis cont&iacute;
nuas. O n&iacute;vel de signific&acirc;ncia    de 5% foi estabelecido (P &lt; 0,
05). Todas as an&aacute;lises estat&iacute;sticas    foram realizadas com o <i>s
oftware</i> SPSS para Windows, vers&atilde;o 11.5,    Chicago, IL.</font></p>   
  ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#40#36#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#41#37#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Resultados</b></font></p
>     ^cY#aop01011.htm##
00908000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066400085002001300749#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#42#38#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Um total de 68    pacientes
 no grupo SM e 82 controles foram inclu&iacute;dos no estudo. Os pacientes    co
m SM tinham maior probabilidade de serem mais velhos, enquanto indiv&iacute;duos
    do sexo masculino e caucasianos predominaram no grupo controle. Hipertens&at
ilde;o,    hipercolesterolemia e DM foram significantemente mais prevalentes no 
grupo com    SM do que no grupo controle. Tabagismo foi mais prevalente no grupo
 controle.    As caracter&iacute;sticas cl&iacute;nicas e demogr&aacute;ficas do
s casos e    controles s&atilde;o mostradas na <a href="#t1">Tabela 1</a>.</font
></p>     ^cY#aop01011.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#43#39#article#145#<p><a name
="t1"></a></p>     ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#44#40#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#45#41#article#145#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01011t01.jpg"></p>     ^cY#aop
01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#46#42#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
01039000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079500085002001300880#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#47#43#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A <a href="/img/revistas/ab
c/2011nahead/aop01011t02.jpg">Tabela    2</a> categoriza casos e controles de ac
ordo com os perfis aCL e anti-</font><font size="2">&#946;</font><font face="Ver
dana, Arial, Helvetica, sans-serif" size="2">2-gpI.    A frequ&ecirc;ncia de ant
icorpos aCL (todos os isotipos) e anticorpos IgG e    IgM anti-</font><font size
="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2 
   gpI n&atilde;o foram significantemente diferentes nos casos e controles. Anti
corpos    IgA anti-</font><font size="2">&#946;</font><font face="Verdana, Arial
, Helvetica, sans-serif" size="2">2-gpI    foram significantemente mais frequent
es nos pacientes com SM do que nos controles.</font></p>     ^cY#aop01011.htm##
00784000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054000085002001300625#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#48#44#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O OR para anticorpos    aCL
 e anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica
, sans-serif" size="2">2-gpI    ajustados fatores de risco (idade, sexo, etnia e
 tabagismo atual) s&atilde;o    mostrados na <a href="#t3">Tabela 3</a>. Anticor
pos IgA anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helv
etica, sans-serif" size="2">2-gpI,    mas n&atilde;o outros, mostraram-se indepe
ndentemente associados com SM.</font></p>     ^cY#aop01011.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#49#45#article#145#<p><a name
="t3"></a></p>     ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#50#46#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00405000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016100085002001300246#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#51#47#article#145#<p align="
center"><font face="Verdana, Arial, Helvetica, sans-serif" size="3"><b><img src=
"/img/revistas/abc/2011nahead/aop01011t03.jpg"></b></font></p>     ^cY#aop01011.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#52#48#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#53#49#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop01011.htm##
01275000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704103100085002001301116#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#54#50#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    avalia
, pela primeira vez, a frequ&ecirc;ncia de anticorpos aCL e anti-</font><font si
ze="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">
2-gpI    em pacientes com SM. Os casos foram selecionados de uma clinica terci&a
acute;ria    especializada em risco cardiometab&oacute;lico. Os pacientes com SM
 apresentavam    uma m&eacute;dia de idade mais alta, quando comparados aos cont
roles, enquanto    os indiv&iacute;duos do sexo masculino e a etnia Caucasiana p
redominaram no    grupo controle. Essas diferen&ccedil;as foram corrigidas atrav
&eacute;s da regress&atilde;o    log&iacute;stica, de qualquer maneira. Os fator
es de risco cl&aacute;ssicos    para aterosclerose foram avaliados em ambas as p
opula&ccedil;&otilde;es. Algumas    vari&aacute;veis (hipertens&atilde;o, DM) s&
atilde;o crit&eacute;rios para SM    e previsivelmente, foram mais frequentes no
s casos, quando comparados aos controles.</font></p>     ^cY#aop01011.htm##
01580000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704133600085002001301421#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#55#51#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os dados n&atilde;o-ajustad
os    mostraram que apenas anticorpos IgA anti-</font><font size="2">&#946;</fon
t><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    diferiram
 nos dois grupos, sendo significantemente mais altos nos pacientes    com SM. &E
acute; interessante notar que o ponto de corte utilizado para os ensaios    aCL 
e anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica,
 sans-serif" size="2">2-gpI    seguiram as recomenda&ccedil;&otilde;es internaci
onais, com t&iacute;tulos somente    moderados a altos (&gt; 20 unidades) sendo 
considerados relevantes<sup>20,21</sup>.    Os n&iacute;veis de anticorpos aCL e
 anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, 
sans-serif" size="2">2-gpI    n&atilde;o foram estratificados, j&aacute; que as 
implica&ccedil;&otilde;es    cl&iacute;nicas para n&iacute;veis moderados a alto
s n&atilde;o diferem entre    si<sup>10</sup>. De qualquer maneira, o ponto de c
orte dos anticorpos IgM e    IgA anti-</font><font size="2">&#946;</font><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    mostrou resultado 
positivo em aproximadamente 10% dos controles, o que provavelmente    ir&aacute;
 exigir ajustes no futuro.</font></p>     ^cY#aop01011.htm##
00659000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041500085002001300500#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#56#52#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Ap&oacute;s o ajuste    par
a sexo, idade, etnia e tabagismo, o OR (3,60) indicou uma associa&ccedil;&atilde
;o    independente entre os anticorpos IgA anti-</font><font size="2">&#946;</fo
nt><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    e SM, co
m signific&acirc;ncia estat&iacute;stica convincente (P = 0,003).</font></p>    
 ^cY#aop01011.htm##
00909000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066500085002001300750#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#57#53#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Uma poss&iacute;vel    asso
cia&ccedil;&atilde;o entre anticorpos IgG aCL com a SM (OR ajustado de 3,79)    
n&atilde;o pode ser confirmada (P = 0,273). Um eventual efeito protetor do antic
orpo    IgG anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2">2-gpI    para SM (OR ajustado de 0,62) tamb&eacu
te;m n&atilde;o foi confirmado (P = 0,618).    Enfatizamos que as vari&aacute;ve
is hipertens&atilde;o, hipercolesterolemia    e DM n&atilde;o foram utilizadas p
ara ajustes, pois s&atilde;o crit&eacute;rios    diagn&oacute;sticos da SM.</fon
t></p>     ^cY#aop01011.htm##
01013000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076900085002001300854#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#58#54#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O significado da    associa
&ccedil;&atilde;o entre anticorpos IgA anti-</font><font size="2">&#946;</font><
font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    e SM ainda &
eacute; desconhecida para n&oacute;s. Autoanticorpos IgA para </font><font size=
"2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-g
pI,    de acordo com estudos anteriores realizados por nosso grupo, associaram-s
e de    forma independente com doen&ccedil;a cerebral isqu&ecirc;mica<sup>23</su
p>,    infarto agudo do mioc&aacute;rdio<sup>24</sup>, doen&ccedil;a arterial pe
rif&eacute;rica    sintom&aacute;tica<sup>25</sup> e doen&ccedil;a da car&oacute
;tida<sup>26</sup>.</font></p>     ^cY#aop01011.htm##
01269000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704102500085002001301110#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#59#55#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Recentemente, uma    associ
a&ccedil;&atilde;o relevante entre anticorpos IgA anti-</font><font size="2">&#9
46;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    e
 IgG anti-fosfatidilserina e derrame isqu&ecirc;mico foi relatada<sup>27</sup>. 
   &Eacute; interessante mencionar que anticorpos IgM anti-</font><font size="2"
>&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI 
   estavam ligados &agrave; dist&uacute;rbios tromb&oacute;ticos em mulheres jov
ens    sem doen&ccedil;a autoimune, particularmente quando os fatores de risco c
l&aacute;ssicos    ou SM estavam ausentes; o isotipo IgA n&atilde;o foi testado 
nesse estudo<sup>28</sup>.    Esses dados sugerem que autoanticorpos IgM anti-</
font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-ser
if" size="2">2-gpI    podem comportar-se de forma diferente do isotipo IgA em re
la&ccedil;&atilde;o    &agrave; SM.</font></p>     ^cY#aop01011.htm##
00634000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039000085002001300475#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#60#56#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O teste para anticorpos    
aCL apresentou resultados negativos na maioria desses estudos<sup>23-28</sup>   
 e tamb&eacute;m em nossos pacientes com SM. Conjuntamente, esses achados n&atil
de;o    demonstram um papel relevante dos anticorpos aCL em pacientes com doen&c
cedil;a    ateroscler&oacute;tica ou SM.</font></p>     ^cY#aop01011.htm##
01239000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099500085002001301080#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#61#57#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A boa especificidade    dos
 anticorpos anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2">2-gpI    em pacientes com aterosclerose e SAF pa
rece ser diferente<sup>29</sup>. Anticorpos    anti-</font><font size="2">&#946;
</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    de p
acientes com SAF tem como alvo o dom&iacute;nio 1 da mol&eacute;cula<sup>30</sup
>.    Recentemente, tem sido demonstrado que anticorpos IgA de pacientes com ate
rosclerose    reconhecem especificamente o dom&iacute;nio 4 de </font><font size
="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-
gpI<sup>31</sup>.    Assim, um subgrupo distinto de anticorpos anti-</font><font
 size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="
2">2-gpI    em pacientes com doen&ccedil;a ateroscler&oacute;tica pode ser postu
lado.</font></p>     ^cY#aop01011.htm##
01092000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704084800085002001300933#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#62#58#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Sabe-se que o complexo    <
/font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-se
rif" size="2">2-gpI/LDL    oxidado &eacute; internalizado para o macr&oacute;fag
o via ocupa&ccedil;&atilde;o    de receptores Fc para IgG<sup>14,32</sup>. Alter
nativamente, poder&iacute;amos    considerar a hip&oacute;tese de que anticorpos
 IgA anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helveti
ca, sans-serif" size="2">2-gpI    (que podem ligar-se ao complexo como um todo) 
tamb&eacute;m tem esse papel na    superf&iacute;cie do macr&oacute;fago. De fat
o, os receptores Fc para IgA s&atilde;o    encontrados nas membranas dos macr&oa
cute;fagos<sup>33</sup>. Esse complexo    assim internalizado pode gerar c&eacut
e;lulas espumosas.</font></p>     ^cY#aop01011.htm##
00906000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066200085002001300747#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#63#59#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nossos dados em    paciente
s com doen&ccedil;a ateroscler&oacute;tica estabelecida<sup>23-26</sup>    e SM 
parecem ser reprodut&iacute;veis em rela&ccedil;&atilde;o &agrave; frequ&ecirc;n
cia    de autoanticorpos IgA anti-</font><font size="2">&#946;</font><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI.    Dados sobre a SM, n&a
tilde;o relatados anteriormente, sugerem que os autoanticorpos    IgA anti-</fon
t><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif"
 size="2">2-gpI    circulantes podem preceder um evento isqu&ecirc;mico.</font><
/p>     ^cY#aop01011.htm##
00774000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053000085002001300615#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#64#60#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A raz&atilde;o    pela qual
 o is&oacute;topo IgA est&aacute; envolvido nessa resposta imunol&oacute;gica   
 ainda n&atilde;o est&aacute; bem definida, mas infec&ccedil;&atilde;o cr&ocirc;
nica    pode ser postulada. &Eacute; digno de nota o fato de que mimetismo molec
ular    de produtos virais e bacterianos com </font><font size="2">&#946;</font>
<font face="Verdana, Arial, Helvetica, sans-serif" size="2">2-gpI    tem sido re
latado<sup>34</sup>.</font></p>     ^cY#aop01011.htm##
00690000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044600085002001300531#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#65#61#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nosso estudo mostra    limi
ta&ccedil;&otilde;es que devem ser mencionadas. O desenho de caso-controle    co
m pequeno tamanho amostral e uma an&aacute;lise multivariada limitada n&atilde;o
    &eacute; capaz de definir a quest&atilde;o ou controlar todos os fatores de 
   risco: &eacute; bastante explorat&oacute;rio e estudos maiores s&atilde;o nec
ess&aacute;rios.</font></p>     ^cY#aop01011.htm##
00767000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052300085002001300608#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#66#62#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em resumo, anticorpos    Ig
A anti-</font><font size="2">&#946;</font><font face="Verdana, Arial, Helvetica,
 sans-serif" size="2">2-gpI    foram mais frequentes em pacientes com SM do que 
nos controles. Essa associa&ccedil;&atilde;o    ocorreu independentemente de out
ros fatores de risco para doen&ccedil;a ateroscler&oacute;tica.    As implica&cc
edil;&otilde;es cl&iacute;nicas resultantes desses achados devem    ser detalhad
as no futuro.</font></p>     ^cY#aop01011.htm##
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#67#63#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    de
 Interesses</b></font></p>     ^cY#aop01011.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#68#64#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    haver
 conflito de interesses pertinentes.</font></p>     ^cY#aop01011.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#69#65#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01011.htm##
00397000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015300085002001300238#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#70#66#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    n&atil
de;o teve fontes de financiamento externas.</font></p>     ^cY#aop01011.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#71#67#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;o
    Acad&ecirc;mica</b></font></p>     ^cY#aop01011.htm##
00515000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027100085002001300356#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#72#68#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Este artigo &eacute;    par
te de disserta&ccedil;&atilde;o de Mestrado de Rodrigo B. Kr&aacute;s Borges    
pela Pontif&iacute;cia Universidade Cat&oacute;lica do Rio Grande do Sul (PUCRS)
.</font></p>     ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#73#69#article#145#<p>&nbsp;<
/p>     ^cY#aop01011.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#74#70#article#145#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01011.htm##
00436000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704017800087002001300265#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#75#71#article#14
5#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Despr&eacu
te;s    JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;44
4(7121):881-7.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#76#72#article#145#</font></p
>     ^cY#aop01011.htm##
00663000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704040500087002001300492#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#77#73#article#14
5#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Kahn R, Bu
se    J, Ferrannini E, Stern M. American Diabetes Association, European Associat
ion    for the Study of Diabetes. The metabolic syndrome: time for a critical ap
praisal:    joint statement from the American Diabetes Association and the Europ
ean Association    for the Study of Diabetes. Diabetes Care. 2005;28(9):2289-304
.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#78#74#article#145#</font></p
>     ^cY#aop01011.htm##
00553000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704029500087002001300382#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#79#75#article#14
5#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Juutilaine
n    A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria and metabolic synd
rome    as predictors of cardiovascular death in non-diabetic and type 2 diabeti
c men    and women. Diabetologia. 2006;49(1):56-65.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#80#76#article#145#</font></p
>     ^cY#aop01011.htm##
00536000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027800087002001300365#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#81#77#article#14
5#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Lakka HM, 
Laaksonen    DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The me
tabolic syndrome    and total and cardiovascular disease mortality in middle-age
d men. JAMA. 2002;288(21):2709-16.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#82#78#article#145#</font></p
>     ^cY#aop01011.htm##
00447000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704018900087002001300276#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#83#79#article#14
5#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Holvoet P,
 De    Keyzer D, Jacobs DR. Oxidized LDL and the metabolic syndrome. Future Lipi
dol.    2008;3(6):637-49.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#84#80#article#145#</font></p
>     ^cY#aop01011.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704030300087002001300390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#85#81#article#14
5#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Schmidt AM
,    Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation 
end    products: a mechanism for chronic vascular dysfunction in diabetic vascul
opathy    and atherosclerosis. Circ Res. 1999;84(5):489-97.    ^cY#aop01011.htm#
#
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#86#82#article#145#</font></p
>     ^cY#aop01011.htm##
00423000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704016500087002001300252#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#87#83#article#14
5#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Matsuzawa 
Y.    The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580(12):2917-21
.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#88#84#article#145#</font></p
>     ^cY#aop01011.htm##
00616000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704035800087002001300445#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#89#85#article#14
5#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. B&eacute;c
hard    D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al
. Human    endothelial-cell specific molecule-1 binds directly to the integrin C
D11a/CD18    (LFA-1) and blocks binding to intercellular adhesion molecule-1. J 
Immunol.    2001;167 (6):3099-106.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#90#86#article#145#</font></p
>     ^cY#aop01011.htm##
00421000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704016300087002001300250#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#91#87#article#14
5#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Wick G, Xu
 Q.    Atherosclerosis: an autoimmune disease. Exp Gerontol. 1999;34(4):559-66. 
   ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#92#88#article#145#</font></p
>     ^cY#aop01011.htm##
00547000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704028800088002001300376#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#93#89#article#14
5#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Miyakis 
S,    Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International
 consensus    statement on an update of the classification criteria for definite
 APS. J Thromb    Haemost. 2006;4(2):295-306.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#94#90#article#145#</font></p
>     ^cY#aop01011.htm##
00407000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704014800088002001300236#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#95#91#article#14
5#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Kandiah 
DA,    Krilis SA. Beta 2-glycoprotein I. Lupus. 1994;3(4):207-12.    ^cY#aop0101
1.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#96#92#article#145#</font></p
>     ^cY#aop01011.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704028600088002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#97#93#article#14
5#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. George J
, Afek    A, Gilburd B, Blank M, Levy Y, Aron-Maor A, et al. Induction of early 
atherosclerosis    in LDL-receptor-deficient mice immunized with beta2-glycoprot
ein I. Circulation.    1998;98(11):1108-15.    ^cY#aop01011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#98#94#article#145#</font></p
>     ^cY#aop01011.htm##
00435000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704017600088002001300264#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#99#95#article#14
5#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Harats D
, George    J. Beta2-glycoprotein I and atherosclerosis. Curr Opin Lipidol. 2001
;12(5):543-6.    ^cY#aop01011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#100#96#article#145#</font></
p>     ^cY#aop01011.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704030000089002001300389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#101#97#article#1
45#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Kobayas
hi K,    Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, et al. Circula
ting    oxidized LDL forms complexes with beta2-glycoprotein I: implication as a
therogenic    autoantigen. J Lipid Res. 2003;44(4):716-26.    ^cY#aop01011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#102#98#article#145#</font></
p>     ^cY#aop01011.htm##
00673000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704041300089002001300502#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#103#99#article#1
45#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Expert 
Panel    on Detection, Evaluation, and Treatment of High Blood Cholesterol in Ad
ults.    Executive Summary of the Third Report of the National Cholesterol Educa
tion    Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of H
igh    Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(1
9):2486-97.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#104#100#article#145#</font><
/p>     ^cY#aop01011.htm##
00593000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033200090002001300422#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#105#101#article#
145#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Choban
ian AV,    Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Sev
enth Report    of the Joint National committee on Prevention, Detection, Evaluat
ion, and Treatment    of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(1
9):2560-72.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#106#102#article#145#</font><
/p>     ^cY#aop01011.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020100090002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#107#103#article#
145#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Filozo
f C,    Fernandez Pinilla MC, Fern&aacute;ndez-Cruz A. Smoking cessation and wei
ght    gain. Obes Rev. 2004;5(2):95-103.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#108#104#article#145#</font><
/p>     ^cY#aop01011.htm##
00691000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704043000090002001300520#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#109#105#article#
145#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Grundy
 SM,    Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. / Ameri
can    Heart Association; Natural Heart, Lung, and Blood Institute. Diagnosis an
d management    of the metabolic syndrome. An American Heart Association/Nationa
l Heart, Lung,    and Blood Institute Scientific Statement. Executive summary. C
ardiol Rev. 2005;13(6):322-7.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#110#106#article#145#</font><
/p>     ^cY#aop01011.htm##
00523000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026200090002001300352#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#111#107#article#
145#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Donahu
e RP,    Abott RD, Reed DM, Yano K. Physical activity and coronary heart disease
 in middle-aged    and elderly men: the Honolulu Heart Program. Am J Public Heal
th. 1988;78(6):683-5.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#112#108#article#145#</font><
/p>     ^cY#aop01011.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023700090002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#113#109#article#
145#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Gharav
i AE,    Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype 
distribution    and phospholipid specificity. Ann Rheum Dis. 1987;46(1):1-6.    
^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#114#110#article#145#</font><
/p>     ^cY#aop01011.htm##
00569000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030800090002001300398#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#115#111#article#
145#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Lewis 
S, Keil    LB, Binder WL, DeBari VA. Standardized measurement of major immunoglo
bulin class    (IgG, IgA, IgM) antibodies to beta2-glicoprotein I in patients wi
th antiphospholipid    syndrome. J Clin Lab Anal. 1998;12(5):293-7.    ^cY#aop01
011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#116#112#article#145#</font><
/p>     ^cY#aop01011.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030200090002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#117#113#article#
145#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Hopkin
s WG.    A new view of statistics. &#91;Acessed on 2004 Apr 11&#93;. Available f
rom:    <a href="http://sportsci.org/resource/stats/index.html" target="_blank">
http://sportsci.org/resource/stats/index.html</a></font></p>     ^cY#aop01011.ht
m##
00601000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034000090002001300430#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#118#114#article#
145#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Staub 
HL, Norman    GL, Crowther T, da Cunha VR, Polanczyk A, Bohn JM, et al. Antibodi
es to the    atherosclerotic plaque components beta2-glycoprotein I and heat sho
ck proteins    as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr. 
2003;61(3B):757-63.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#119#115#article#145#</font><
/p>     ^cY#aop01011.htm##
00544000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028300090002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#120#116#article#
145#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Ranzol
in A,    Bohn JM, Norman GL, Manenti E, Bodanese LC, von Muhlen CA, et al. Anti-
beta2-glycoprotein    I antibodies as risk factors for acute myocardial infarcti
on. Arq Bras Cardiol.    2004;83(2):141-4.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#121#117#article#145#</font><
/p>     ^cY#aop01011.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030000090002001300390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#122#118#article#
145#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Franck
 M, Staub    HL, Petracco JB, Norman GL, Lassen AJ, Schiavo N, et al. Autoantibo
dies to the    atheroma component beta2-glycoprotein I and risk of symptomatic p
eripheral artery    disease. Angiology. 2007;58(3):295-302.    ^cY#aop01011.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#123#119#article#145#</font><
/p>     ^cY#aop01011.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023700090002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#124#120#article#
145#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Recuer
o ML,    Silva JB, Norman GL, von M&uuml;hlen CA, Staub HL. IgA antibodies to be
ta2-glycoprotein    I and carotid disease. Isr Med Assoc J. 2007;9(6):495-6.    
^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#125#121#article#145#</font><
/p>     ^cY#aop01011.htm##
00554000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029300090002001300383#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#126#122#article#
145#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Kahles
 T, Humpich    M, Steinmetz H, Sitzer M, Lindhoff-Last E. Phosphatidylserine IgG
 and beta-2-glycoprotein    I IgA antibodies may be a risk factor for ischaemic 
stroke. Rheumatology (Oxford).    2005;44(9):1161-5.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#127#123#article#145#</font><
/p>     ^cY#aop01011.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029800090002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#128#124#article#
145#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Salobi
r B,    Sabovic M, Hojnik M, Cucnik S, Kveder T. Anti-beta 2-glycoprotein I anti
bodies    of IgM class are linked to thrombotic disorders in young women without
 autoimmune    disease. Immunobiology. 2007;212(3):193-9.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#129#125#article#145#</font><
/p>     ^cY#aop01011.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025900090002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#130#126#article#
145#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Arvieu
x J,    Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity an
d immunochemical    properties of anti-beta2-gpI autoantibodies. Thromb Haemost.
 1998;80(3):393-8.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#131#127#article#145#</font><
/p>     ^cY#aop01011.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027100090002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#132#128#article#
145#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Iverso
n GM,    Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantib
odies    recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sc
i USA.    1998;95(26):15542-6.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#133#129#article#145#</font><
/p>     ^cY#aop01011.htm##
00603000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034200090002001300432#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#134#130#article#
145#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Iverso
n GM,    von M&uuml;hlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients 
with    atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA 
autoantibodies    that preferentially target domain 4 of beta(2)-GPI. J Autoimmu
n. 2006;27(4):266-71.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#135#131#article#145#</font><
/p>     ^cY#aop01011.htm##
00460000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019900090002001300289#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#136#132#article#
145#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Matsuu
ra E,    Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosi
s. Autoimmun    Rev. 2002;1(6):348-53.    ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#137#133#article#145#</font><
/p>     ^cY#aop01011.htm##
00419000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704015800090002001300248#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#138#134#article#
145#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Shen L
. Receptors    for IgA in phagocytic cells. Immunol Res. 1992;11(3-4):273-82.   
 ^cY#aop01011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#139#135#article#145#</font><
/p>     ^cY#aop01011.htm##
00488000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022700090002001300317#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#140#136#article#
145#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Blank 
M, Shoenfeld    Y. Beta2-glycoprotein I, infections, antiphospholipid syndrome a
nd therapeutic    considerations. Clin Immunol. 2004;112(2):190-9.    ^cY#aop010
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#141#137#article#145#</font><
/p>     ^cY#aop01011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#142#138#article#145#<p>&nbsp
;</p>     ^cY#aop01011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#143#139#article#145#<p>&nbsp
;</p>     ^cY#aop01011.htm##
00444000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019800087002001300285#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#144#140#article#145#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a 
href="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    
Correspond&ecirc;ncia:    ^cY#aop01011.htm##
00283000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003700087002001300124#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#145#141#article#145#<br>   <
/b> Henrique L. Staub    ^cY#aop01011.htm##
00293000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004700087002001300134#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#146#142#article#145#<br>   A
v. Ipiranga 6690/220 - Ipiranga    ^cY#aop01011.htm##
00298000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005200087002001300139#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#147#143#article#145#<br>   9
0610-000 - Porto Alegre, RS - Brasil    ^cY#aop01011.htm##
00426000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704018000087002001300267#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#148#144#article#145#<br>   E
-mail: <a href="mailto:reumatopucrs@gmail.com">reumatopucrs@gmail.com</a>,    <a
 href="mailto:henriquestaub@terra.com.br">henriquestaub@terra.com.br</a></font><
/p>     ^cY#aop01011.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01011.htm#S#p#149#145#article#145#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 26/
03/10; revisado recebido em 14/07/10; aceito em 17/09/10.</font></p>     ^cY#aop
01011.htm##
00531000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100017001040120
04500121030000700166065000900173064000500182031000400187032000500191014000600196
865000900202002001300211035001000224801000700234#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01011.htm#S#c#150#1#article#34#1#^rND^sDesprés^nJP#^rND^sL
emieux^nI#Abdominal obesity and metabolic syndrome^len#Nature#20060000#2006#444#
7121#881-7#20110000#aop01011.htm#0028-0836#Nature##
00799000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100014001000100
02000114010001500134012024800149030001400397065000900411064000500420031000300425
032000200428014000900430865000900439002001300448035001000461801001400471#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#151#2#article#34#2#^
rND^sKahn^nR#^rND^sBuse^nJ#^rND^sFerrannini^nE#^rND^sStern^nM#American Diabetes 
Association, European Association for the Study of Diabetes: The metabolic syndr
ome: time for a critical appraisal: joint statement from the American Diabetes A
ssociation and the European Association for the Study of Diabetes^len#Diabetes C
are#20050000#2005#28#9#2289-304#20110000#aop01011.htm#0149-5992#Diabetes Care##
00709000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100015001070100
01800122010001700140010001600157012012700173030001300300065000900313064000500322
03100030032703200020033001400060033286500090033800200130034703500100036080100130
0370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#152#3#ar
ticle#34#3#^rND^sJuutilainen^nA#^rND^sLehto^nS#^rND^sRonnemaa^nT#^rND^sPyorala^n
K#^rND^sLaakso^nM#Proteinuria and metabolic syndrome as predictors of cardiovasc
ular death in non-diabetic and type 2 diabetic men and women^len#Diabetologia#20
060000#2006#49#1#56-65#20110000#aop01011.htm#0012-186X#Diabetologia##
00716000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100020001020100
01600122010001900138010001900157010002000176810000600196012009300202030000500295
06500090030006400050030903100040031403200030031801400080032186500090032900200130
0338035001000351801000500361#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#153#4#article#34#4#^rND^sLakka^nHM#^rND^sLaaksonen^nDE#^rND^sLak
ka^nTA#^rND^sNiskanen^nLK#^rND^sKumpusalo^nE#^rND^sTuomilehto^nJ#et al#The metab
olic syndrome and total and cardiovascular disease mortality in middle-aged men^
len#JAMA#20020000#2002#288#21#2709-16#20110000#aop01011.htm#0098-7484#JAMA##
00537000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100019001030100
01700122012004400139030001500183710000200198065000900200064000500209031000200214
032000200216014000700218865000900225002001300234#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01011.htm#S#c#154#5#article#34#5#^rND^sHolvoet^nP#^rND^sDe
 Keyzer^nD#^rND^sJacobs^nDR#Oxidized LDL and the metabolic syndrome^len#Future L
ipidol#2#20080000#2008#3#6#637-49#20110000#aop01011.htm##
00695000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100014001040100
01800118010001500136012015400151030000900305065000900314064000500323031000300328
032000200331014000700333865000900340002001300349035001000362801000900372#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#155#6#article#34#6#^
rND^sSchmidt^nAM#^rND^sYan^nSD#^rND^sWautier^nJL#^rND^sStern^nD#Activation of re
ceptor for advanced glycation end products: a mechanism for chronic vascular dys
function in diabetic vasculopathy and atherosclerosis^len#Circ Res#19990000#1999
#84#5#489-97#20110000#aop01011.htm#0009-7330#Circ Res##
00510000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860120046001050300
01000151065000900161064000500170031000400175032000300179014000800182865000900190
002001300199035001000212801001000222#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01011.htm#S#c#156#7#article#34#7#^rND^sMatsuzawa^nY#The metabolic synd
rome and adipocytokines^len#FEBS Lett#20060000#2006#580#12#2917-21#20110000#aop0
1011.htm#0014-5793#FEBS lett##
00787000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100021001030100
01600124010001700140010002100157010001900178810000600197012015300203030001000356
06500090036606400050037503100040038003200020038401400090038686500090039500200130
0404035001000417801001000427#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#157#8#article#34#8#^rND^sBéchard^nD#^rND^sScherpereel^nA#^rND^sH
ammad^nH#^rND^sGentina^nT#^rND^sTsicopoulos^nA#^rND^sAumercier^nM#et al#Human en
dothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LF
A-1) and blocks binding to intercellular adhesion molecule-1^len#J Immunol#20010
000#2001#167#6#3099-106#20110000#aop01011.htm#0022-1767#J Immunol##
00529000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100012001000120
04300112030001300155065000900168064000500177031000300182032000200185014000700187
865000900194002001300203035001000216801001300226#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01011.htm#S#c#158#9#article#34#9#^rND^sWick^nG#^rND^sXu^nQ
#Atherosclerosis: an autoimmune disease^len#Exp Gerontol#19990000#1999#34#4#559-
66#20110000#aop01011.htm#0531-5565#Exp Gerontol##
00699000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01600124010001700140010001500157010001700172810000600189012009900195030001700294
71000020031106500090031306400050032203100020032703200020032901400080033186500090
0339002001300348#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#
S#c#159#10#article#34#10#^rND^sMiyakis^nS#^rND^sLockshin^nMD#^rND^sAtsumi^nT#^rN
D^sBranch^nDW#^rND^sBrey^nRL#^rND^sCervera^nR#et al#International consensus stat
ement on an update of the classification criteria for definite APS^len#J Thromb 
Haemost#2#20060000#2006#4#2#295-306#20110000#aop01011.htm##
00508000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060120
02600123030000600149065000900155064000500164031000200169032000200171014000700173
865000900180002001300189035001000202801000600212#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01011.htm#S#c#160#11#article#34#11#^rND^sKandiah^nDA#^rND^
sKrilis^nSA#Beta 2-glycoprotein I^lpt#Lupus#19940000#1994#3#4#207-12#20110000#ao
p01011.htm#0961-2033#Lupus##
00729000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100014001040100
01700118010001500135010001400150010001900164810000600183012010600189030001200295
06500090030706400050031603100030032103200030032401400080032786500090033500200130
0344035001000357801001200367#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#161#12#article#34#12#^rND^sGeorge^nJ#^rND^sAfek^nA#^rND^sGilburd
^nB#^rND^sBlank^nM#^rND^sLevy^nY#^rND^sAron-Maor^nA#et al#Induction of early ath
erosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I^
len#Circulation#19980000#1998#98#11#1108-15#20110000#aop01011.htm#0009-7322#Circ
ulation##
00548000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040120
04500120030001800165065000900183064000500192031000300197032000200200014000600202
865000900208002001300217035001000230801001800240#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01011.htm#S#c#162#13#article#34#13#^rND^sHarats^nD#^rND^sG
eorge^nJ#Beta2-glycoprotein I and atherosclerosis^len#Curr Opin Lipidol#20010000
#2001#12#5#543-6#20110000#aop01011.htm#0957-9672#Curr Opin Lipidol##
00743000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01600122010002300138010001600161010001700177810000600194012011100200030001200311
06500090032306400050033203100030033703200020034001400070034286500090034900200130
0358035001000371801001200381#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#163#14#article#34#14#^rND^sKobayashi^nK#^rND^sKishi^nM#^rND^sAts
umi^nT#^rND^sBertolaccini^nML#^rND^sMakino^nH#^rND^sSakairi^nN#et al#Circulating
 oxidized LDL forms complexes with beta2-glycoprotein I: implication as atheroge
nic autoantigen^len#J Lipid Res#20030000#2003#44#4#716-26#20110000#aop01011.htm#
0022-2275#J Lipid Res##
00738000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110089000880120212001770300
00500389065000900394064000500403031000400408032000300412014000800415865000900423
002001300432035001000445801000500455#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01011.htm#S#c#164#15#article#34#15#Expert Panel on Detection, Evaluati
on, and Treatment of High Blood Cholesterol in Adults#Executive Summary of the T
hird Report of the National Cholesterol Education Program (NCEP) Expert Panel on
 Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult
 Treatment Panel III)^len#JAMA#20010000#2001#285#19#2486-97#20110000#aop01011.ht
m#0098-7484#JAMA##
00768000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
01600125010001800141010001600159010001800175810000600193012014800199030000500347
06500090035206400050036103100040036603200030037001400080037386500090038100200130
0390035001000403801000500413#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#165#16#article#34#16#^rND^sChobanian^nAV#^rND^sBakris^nGL#^rND^s
Black^nHR#^rND^sCushman^nWC#^rND^sGreen^nLA#^rND^sIzzo^nJL Jr#et al#The Seventh 
Report of the Joint National committee on Prevention, Detection, Evaluation, and
 Treatment of High Blood Pressure: the JNC 7 report^len#JAMA#20030000#2003#289#1
9#2560-72#20110000#aop01011.htm#0098-7484#JAMA##
00543000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100028001050100
02400133012003800157030000900195710000200204065000900206064000500215031000200220
032000200222014000700224865000900231002001300240#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01011.htm#S#c#166#17#article#34#17#^rND^sFilozof^nC#^rND^s
Fernandez Pinilla^nMC#^rND^sFernández-Cruz^nA#Smoking cessation and weight gain^
len#Obes Rev#2#20040000#2004#5#2#95-103#20110000#aop01011.htm##
00870000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01800123010001700141010001600158010001900174810000600193012024000199030001200439
06500090045106400050046003100030046503200020046801400060047086500090047600200130
0485035001000498801001200508#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#167#18#article#34#18#^rND^sGrundy^nSM#^rND^sCleeman^nJI#^rND^sDa
niels^nSR#^rND^sDonato^nKA#^rND^sEckel^nRH#^rND^sFranklin^nBA#et al#/ American H
eart Association; Natural Heart, Lung, and Blood Institute: Diagnosis and manage
ment of the metabolic syndrome. An American Heart Association/National Heart, Lu
ng, and Blood Institute Scientific Statement. Executive summary^len#Cardiol Rev#
20050000#2005#13#6#322-7#20110000#aop01011.htm#1061-5377#Cardiol Rev##
00668000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01500122010001400137012010800151030001900259065000900278064000500287031000300292
032000200295014000600297865000900303002001300312035001000325801001900335#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#168#19#article#34#19
#^rND^sDonahue^nRP#^rND^sAbott^nRD#^rND^sReed^nDM#^rND^sYano^nK#Physical activit
y and coronary heart disease in middle-aged and elderly men: the Honolulu Heart 
Program^len#Am J Public Health#19880000#1988#78#6#683-5#20110000#aop01011.htm#00
90-0036#Am J Public Health##
00638000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01900123010001700142012008200159030001400241065000900255064000500264031000300269
032000200272014000400274865000900278002001300287035001000300801001400310#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#169#20#article#34#20
#^rND^sGharavi^nAE#^rND^sHarris^nEN#^rND^sAsherson^nRA#^rND^sHughes^nGR#Anticard
iolipin antibodies: isotype distribution and phospholipid specificity^len#Ann Rh
eum Dis#19870000#1987#46#1#1-6#20110000#aop01011.htm#0003-4967#Ann Rheum Dis##
00708000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030100
01700118010001700135012015300152030001600305065000900321064000500330031000300335
032000200338014000600340865000900346002001300355035001000368801001600378#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#170#21#article#34#21
#^rND^sLewis^nS#^rND^sKeil^nLB#^rND^sBinder^nWL#^rND^sDeBari^nVA#Standardized me
asurement of major immunoglobulin class (IgG, IgA, IgM) antibodies to beta2-glic
oprotein I in patients with antiphospholipid syndrome^len#J Clin Lab Anal#199800
00#1998#12#5#293-7#20110000#aop01011.htm#0887-8013#J Clin Lab Anal##
00442000000000217000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160018000880180029001061100
00900135109001200144037004600156865000900202002001300211#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop01011.htm#S#c#171#22#article#34#22#^rND^sHopkins^n
WG#A new view of statistics^len#20040411#2004 Apr 11#http://sportsci.org/resourc
e/stats/index.html#20110000#aop01011.htm##
00790000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01800121010001900139010001900158010001500177810000600192012014500198030001900343
06500090036206400050037103100030037603200030037901400070038286500090038900200130
0398035001000411801001900421#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#172#23#article#34#23#^rND^sStaub^nHL#^rND^sNorman^nGL#^rND^sCrow
ther^nT#^rND^sda Cunha^nVR#^rND^sPolanczyk^nA#^rND^sBohn^nJM#et al#Antibodies to
 the atherosclerotic plaque components beta2-glycoprotein I and heat shock prote
ins as risk factors for acute cerebral ischemia^len#Arq Neuropsiquiatr#20030000#
2003#61#3B#757-63#20110000#aop01011.htm#0004-282X#Arq Neuropsiquiatr##
00731000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01700121010001700138010001900155010002100174810000600195012008900201030001700290
06500090030706400050031603100030032103200020032401400060032686500090033200200130
0341035001000354801001700364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#173#24#article#34#24#^rND^sRanzolin^nA#^rND^sBohn^nJM#^rND^sNorm
an^nGL#^rND^sManenti^nE#^rND^sBodanese^nLC#^rND^svon Muhlen^nCA#et al#Anti-beta2
-glycoprotein I antibodies as risk factors for acute myocardial infarction^len#A
rq Bras Cardiol#20040000#2004#83#2#141-4#20110000#aop01011.htm#0066-782X#Arq Bra
s Cardiol##
00741000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01900120010001700139010001700156010001700173810000600190012011600196030001000312
06500090032206400050033103100030033603200020033901400080034186500090034900200130
0358035001000371801001000381#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01011.htm#S#c#174#25#article#34#25#^rND^sFranck^nM#^rND^sStaub^nHL#^rND^sPetra
cco^nJB#^rND^sNorman^nGL#^rND^sLassen^nAJ#^rND^sSchiavo^nN#et al#Autoantibodies 
to the atheroma component beta2-glycoprotein I and risk of symptomatic periphera
l artery disease^len#Angiology#20070000#2007#58#3#295-302#20110000#aop01011.htm#
0003-3197#Angiology##
00617000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01700122010002100139010001600160012006300176030001600239710000200255065000900257
064000500266031000200271032000200273014000600275865000900281002001300290#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#175#26#article#34#26
#^rND^sRecuero^nML#^rND^sSilva^nJB#^rND^sNorman^nGL#^rND^svon Mühlen^nCA#^rND^sS
taub^nHL#IgA antibodies to beta2-glycoprotein I and carotid disease^len#Isr Med 
Assoc J#2#20070000#2007#9#6#495-6#20110000#aop01011.htm##
00675000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01900121010001600140010002300156012011000179030002200289710000200311065000900313
064000500322031000300327032000200330014000700332865000900339002001300348#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#176#27#article#34#27
#^rND^sKahles^nT#^rND^sHumpich^nM#^rND^sSteinmetz^nH#^rND^sSitzer^nM#^rND^sLindh
off-Last^nE#Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may 
be a risk factor for ischaemic stroke^len#Rheumatology (Oxford)#2#20050000#2005#
44#9#1161-5#20110000#aop01011.htm##
00714000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01600122010001600138010001600154012013200170030001400302065000900316064000500325
03100040033003200020033401400060033686500090034200200130035103500100036480100140
0374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#S#c#177#28#a
rticle#34#28#^rND^sSalobir^nB#^rND^sSabovic^nM#^rND^sHojnik^nM#^rND^sCucnik^nS#^
rND^sKveder^nT#Anti-beta 2-glycoprotein I antibodies of IgM class are linked to 
thrombotic disorders in young women without autoimmune disease^len#Immunobiology
#20070000#2007#212#3#193-9#20110000#aop01011.htm#0171-2985#IMMUNOBIOLOGY##
00697000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01800123010001700141010001700158010001600175012008100191030001500272065000900287
06400050029603100030030103200020030401400060030686500090031200200130032103500100
0334801001500344#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#
S#c#178#29#article#34#29#^rND^sArvieux^nJ#^rND^sRegnault^nV#^rND^sHachulla^nE#^r
ND^sDarnige^nL#^rND^sRoussel^nB#^rND^sBensa^nJC#Heterogeneity and immunochemical
 properties of anti-beta2-gpI autoantibodies^len#Thromb Haemost#19980000#1998#80
#3#393-8#20110000#aop01011.htm#0340-6245#Thromb Haemost##
00660000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01800125012010900143030002300252065000900275064000500284031000300289032000300292
014000800295865000900303002001300312035001000325801002300335#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01011.htm#S#c#179#30#article#34#30#^rND^sIvers
on^nGM#^rND^sVictoria^nEJ#^rND^sMarquis^nDM#Anti-beta2 glycoprotein I (beta2GPI)
 autoantibodies recognize an epitope on the first domain of beta2GPI^len#Proc Na
tl Acad Sci USA#19980000#1998#95#26#15542-6#20110000#aop01011.htm#0027-8424#Proc
 Natl Acad Sci USA##
00769000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100021001060100
01600127010001700143010001600160010001700176012015600193030001200349065000900361
06400050037003100030037503200020037801400070038086500090038700200130039603500100
0409801001200419#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01011.htm#
S#c#180#31#article#34#31#^rND^sIverson^nGM#^rND^svon Mühlen^nCA#^rND^sStaub^nHL#
^rND^sLassen^nAJ#^rND^sBinder^nW#^rND^sNorman^nGL#Patients with atherosclerotic 
syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that pref
erentially target domain 4 of beta(2)-GPI^len#J Autoimmun#20060000#2006#27#4#266
-71#20110000#aop01011.htm#0896-8411#J Autoimmun##
00566000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01500125010001900140012004200159030001400201710000200215065000900217064000500226
031000200231032000200233014000700235865000900242002001300251#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01011.htm#S#c#181#32#article#34#32#^rND^sMatsu
ura^nE#^rND^sKobayashi^nK#^rND^sKoike^nT#^rND^sShoenfeld^nY#Autoantibody-mediate
d atherosclerosis^len#Autoimmun Rev#2#20020000#2002#1#6#348-53#20110000#aop01011
.htm##
00506000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880120042001020300
01200144065000900156064000500165031000300170032000400173014000700177865000900184
002001300193035001000206801001200216#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01011.htm#S#c#182#33#article#34#33#^rND^sShen^nL#Receptors for IgA in 
phagocytic cells^len#Immunol Res#19920000#1992#11#3-4#273-82#20110000#aop01011.h
tm#0257-277X#Immunol Res##
00558000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030120
09500122030001300217710000200230065000900232064000500241031000400246032000200250
014000600252865000900258002001300267#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01011.htm#S#c#183#34#article#34#34#^rND^sBlank^nM#^rND^sShoenfeld^nY#B
eta2-glycoprotein I, infections, antiphospholipid syndrome and therapeutic consi
derations^len#Clin Immunol#2#20040000#2004#112#2#190-9#20110000#aop01011.htm##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#o#1#1#
article#1#20110331#080909#aop01111.htm#221##
05322000000000673000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801201190
01770120121002960100039004170100024004560100033004800700116005130831778006290850
00802407085003002415085002202445085004602467085002702513085003502540083179802575
08500080437308500220438108500210440308500490442408500280447308500340450105800350
45351170008045700720003045781120009045811110009045901160009045991150009046081140
00904617113000904626002001304635#2011nahead#V:\SciELO\serial\abc\2011nahead\mark
up\aop01111.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#20#nd#nd#Arq. Bras. 
Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110225#Efeito do vinho tinto associad
o ao exercício físico no sistema cardiovascular de ratos espontaneamente hiperte
nsos^lpt#Effect of red wine associated with physical exercise in the cardiovascu
lar system of spontaneously hipertensive rats^len#^rND^1A01^nPaulo Roberto^sSoar
es Filho#^rND^1A01^nIran^sCastro#^rND^1A01^nAdriene^sStahlschmidt#Fundação Unive
rsitária de Cardiologia^iA01^1Instituto de Cardiologia do Rio Grande do Sul^cPor
to Alegre^sRS^pBrasil#^lpt^aFUNDAMENTO: Prática de exercício físico (EF) é efici
ente no tratamento e na prevenção da hipertensão, associada à melhora do perfil 
lipídico e da função contrátil cardíaca. Consumo moderado e regular de bebidas a
lcoólicas, como vinho tinto, desempenha efeito cardiovascular protetor. Polifenó
is da bebida apresentam propriedades antioxidantes, beneficiando vasos sanguíneo
s. Há poucas evidências sobre o consumo de vinho tinto associado ao EF e as infl
uências no sistema cardiovascular. OBJETIVO: Investigar o efeito da interação en
tre o EF e o consumo moderado de vinho tinto na pressão arterial sistólica (PAS)
, lipoproteína de alta densidade (HDL), desempenho físico e fração de ejeção do 
ventrículo esquerdo (FEVE) de ratos espontaneamente hipertensos (SHR). MÉTODOS: 
Amostra de 32 SHR distribuídos em quatro grupos: grupo vinho e exercício (GVE), 
grupo vinho (GV), grupo exercício (GE) e grupo controle (GC). Doses de vinho tin
to, equivalentes ao consumo moderado em humanos, foram administradas por gavagem
, durante dez semanas, simultâneas ao período de EF, realizado em esteira. Os SH
R receberam 3,715 ml/kg/dia de vinho. O desempenho físico foi analisado por test
e de esforço (TE), e a FEVE foi obtida por medidas ecocardiográficas. A aferição
 da PAS ocorreu antes e após o protocolo do EF. RESULTADOS: Demonstrou-se reduçã
o significativa da PAS nos grupos de intervenção, comparados ao GC. Ao final do 
protocolo, o GVE apresentou a maior redução. Assim como na PAS, o GVE apresentou
 melhor resultado nos níveis de HDL. Não houve diferença significativa no desemp
enho físico e na FEVE entre os grupos. CONCLUSÃO: O EF associado à ingesta moder
ada de vinho tinto exerce efeito cardioprotetor na PAS e na HDL de SHR. O desemp
enho físico e a FEVE não são alterados.#^dnd^i1#^tm^lpt^kVinho^i1^sutilização#^t
m^lpt^kexercício^i1#^tm^lpt^khipertensão^i1^sprevenção e controle#^tm^lpt^kcoles
terol HDL^i1#^tm^lpt^ksistema cardiovascular^i1#^len^aBACKGROUND: Physical exerc
ise (PE) is effective in the treatment and prevention of hypertension associated
 with improved lipid profile and cardiac contractile function. Regular and moder
ate consumption of alcoholic beverages such as red wine brings a cardiovascular 
protective effect. Beverage-derived polyphenols have antioxidant properties bene
fiting blood vessels. There is little evidence on the consumption of red wine as
sociated with PE and the influences on the cardiovascular system. OBJECTIVE: To 
investigate the effect of physical exercise (PE) and moderate red wine intake in
teraction on systolic blood pressure (SBP), high density lipoprotein (HDL) level
s, physical performance (PP) and left ventricular ejection fraction (LVEF) in sp
ontaneously hypertensive rats (SHR). METHODS: Sample of 32 SHRs divided into fou
r groups: wine and exercise group (WEG), wine group (WG), exercise group (EG) an
d control group (CG). Red wine doses were given by intra-gastric gavage, during 
ten weeks, coincident with PE period, performed on treadmills. The SHRs received
 red wine doses of 3.715 ml/kg/day. Physical performance was analyzed by maximal
 exercise test (MET) and LVEF by echocardiographic measures. SBP measurement was
 made before and after the PE protocol. RESULTS: Demonstrated that the three gro
ups which suffered intervention presented significant SBP reduction compared to 
CG. At the end of the protocol, WEG showed the largest reduction. Like in SBP re
sults, WEG showed the best outcome on HDL levels at the experiment end. There wa
s no significant difference of physical performance and LVEF between groups. CON
CLUSION: PE associated with moderate red wine intake has cardioprotective effect
s on SBP and HDL levels in SHR. Their physical performance and LVEF are not modi
fied.#^dnd^i2#^tm^len^kWine^i2^suse#^tm^len^kexercise^i2#^tm^len^khypertension^i
2^sprevention and control#^tm^len^kHDL cholesterol^i2#^tm^len^kcardiovascular sy
stem^i2#Associação Brasileira dos Enólogos#vancouv#40#20100325#25/03/10#20100809
#09/08/10#20100818#18/08/10#aop01111.htm##
05406000000000673000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801201260
01770120128003030100039004310100024004700100033004940700116005270831813006430850
00802456085003002464085002202494085004602516085002702562085003502589083183302624
08500080445708500220446508500210448708500490450808500280455708500340458505800350
46191170008046540720003046621120009046651110009046741160009046831150009046921140
00904701113000904710002001304719#2011nahead#V:\SciELO\serial\abc\2011nahead\mark
up\aop01111.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#20#nd#nd#Arq. Bras. 
Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110225#<b>Efeito do vinho tinto assoc
iado ao exercício físico no sistema cardiovascular de ratos espontaneamente hipe
rtensos</b>^lpt#<b>Effect of red wine associated with physical exercise in the c
ardiovascular system of spontaneously hipertensive rats</b>^len#^rND^1A01^nPaulo
 Roberto^sSoares Filho#^rND^1A01^nIran^sCastro#^rND^1A01^nAdriene^sStahlschmidt#
Fundação Universitária de Cardiologia^iA01^1Instituto de Cardiologia do Rio Gran
de do Sul^cPorto Alegre^sRS^pBrasil#^lpt^a<b>FUNDAMENTO: </b>Prática de exercíci
o físico (EF) é eficiente no tratamento e na prevenção da hipertensão, associada
 à melhora do perfil lipídico e da função contrátil cardíaca. Consumo moderado e
 regular de bebidas alcoólicas, como vinho tinto, desempenha efeito cardiovascul
ar protetor. Polifenóis da bebida apresentam propriedades antioxidantes, benefic
iando vasos sanguíneos. Há poucas evidências sobre o consumo de vinho tinto asso
ciado ao EF e as influências no sistema cardiovascular. <b>OBJETIVO: </b>Investi
gar o efeito da interação entre o EF e o consumo moderado de vinho tinto na pres
são arterial sistólica (PAS), lipoproteína de alta densidade (HDL), desempenho f
ísico e fração de ejeção do ventrículo esquerdo (FEVE) de ratos espontaneamente 
hipertensos (SHR). <b>MÉTODOS:</b> Amostra de 32 SHR distribuídos em quatro grup
os: grupo vinho e exercício (GVE), grupo vinho (GV), grupo exercício (GE) e grup
o controle (GC). Doses de vinho tinto, equivalentes ao consumo moderado em human
os, foram administradas por gavagem, durante dez semanas, simultâneas ao período
 de EF, realizado em esteira. Os SHR receberam 3,715 ml/kg/dia de vinho. O desem
penho físico foi analisado por teste de esforço (TE), e a FEVE foi obtida por me
didas ecocardiográficas. A aferição da PAS ocorreu antes e após o protocolo do E
F. <b>RESULTADOS: </b>Demonstrou-se redução significativa da PAS nos grupos de i
ntervenção, comparados ao GC. Ao final do protocolo, o GVE apresentou a maior re
dução. Assim como na PAS, o GVE apresentou melhor resultado nos níveis de HDL. N
ão houve diferença significativa no desempenho físico e na FEVE entre os grupos.
 <b>CONCLUSÃO: </b>O EF associado à ingesta moderada de vinho tinto exerce efeit
o cardioprotetor na PAS e na HDL de SHR. O desempenho físico e a FEVE não são al
terados.#^dnd^i1#^tm^lpt^kVinho^i1^sutilização#^tm^lpt^kexercício^i1#^tm^lpt^khi
pertensão^i1^sprevenção e controle#^tm^lpt^kcolesterol HDL^i1#^tm^lpt^ksistema c
ardiovascular^i1#^len^a<b>BACKGROUND:</b> Physical exercise (PE) is effective in
 the treatment and prevention of hypertension associated with improved lipid pro
file and cardiac contractile function. Regular and moderate consumption of alcoh
olic beverages such as red wine brings a cardiovascular protective effect. Bever
age-derived polyphenols have antioxidant properties benefiting blood vessels. Th
ere is little evidence on the consumption of red wine associated with PE and the
 influences on the cardiovascular system. <b>OBJECTIVE:</b> To investigate the e
ffect of physical exercise (PE) and moderate red wine intake interaction on syst
olic blood pressure (SBP), high density lipoprotein (HDL) levels, physical perfo
rmance (PP) and left ventricular ejection fraction (LVEF) in spontaneously hyper
tensive rats (SHR). <b>METHODS:</b> Sample of 32 SHRs divided into four groups: 
wine and exercise group (WEG), wine group (WG), exercise group (EG) and control 
group (CG). Red wine doses were given by intra-gastric gavage, during ten weeks,
 coincident with PE period, performed on treadmills. The SHRs received red wine 
doses of 3.715 ml/kg/day. Physical performance was analyzed by maximal exercise 
test (MET) and LVEF by echocardiographic measures. SBP measurement was made befo
re and after the PE protocol. <b>RESULTS:</b> Demonstrated that the three groups
 which suffered intervention presented significant SBP reduction compared to CG.
 At the end of the protocol, WEG showed the largest reduction. Like in SBP resul
ts, WEG showed the best outcome on HDL levels at the experiment end. There was n
o significant difference of physical performance and LVEF between groups. <b>CON
CLUSION:</b> PE associated with moderate red wine intake has cardioprotective ef
fects on SBP and HDL levels in SHR. Their physical performance and LVEF are not 
modified.#^dnd^i2#^tm^len^kWine^i2^suse#^tm^len^kexercise^i2#^tm^len^khypertensi
on^i2^sprevention and control#^tm^len^kHDL cholesterol^i2#^tm^len^kcardiovascula
r system^i2#Associação Brasileira dos Enólogos#vancouv#40#20100325#25/03/10#2010
0809#09/08/10#20100818#18/08/10#aop01111.htm##
05443000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106038000400110121000300114049000300117
15800030012003000190012303200060014206500090014801400070015703500100016422300090
01740120119001830120121003020100039004230100024004620100033004860700118005190831
77800637085000802415085003002423085002202453085004602475085002702521085003502548
08317980258308500080438108500220438908500210441108500490443208500280448108500340
45090580035045431170008045780720003045861120009045891110009045981160009046071150
00904616114000904625113000904634002001304643008008904656#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop01111.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4
.0#gra#tab#20#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110225#
Efeito do vinho tinto associado ao exercício físico no sistema cardiovascular de
 ratos espontaneamente hipertensos^lpt#Effect of red wine associated with physic
al exercise in the cardiovascular system of spontaneously hipertensive rats^len#
^rND^1A01^nPaulo Roberto^sSoares Filho#^rND^1A01^nIran^sCastro#^rND^1A01^nAdrien
e^sStahlschmidt#^iA01^1Fundação Universitária de Cardiologia^2Instituto de Cardi
ologia do Rio Grande do Sul^cPorto Alegre^sRS^pBrasil#^lpt^aFUNDAMENTO: Prática 
de exercício físico (EF) é eficiente no tratamento e na prevenção da hipertensão
, associada à melhora do perfil lipídico e da função contrátil cardíaca. Consumo
 moderado e regular de bebidas alcoólicas, como vinho tinto, desempenha efeito c
ardiovascular protetor. Polifenóis da bebida apresentam propriedades antioxidant
es, beneficiando vasos sanguíneos. Há poucas evidências sobre o consumo de vinho
 tinto associado ao EF e as influências no sistema cardiovascular. OBJETIVO: Inv
estigar o efeito da interação entre o EF e o consumo moderado de vinho tinto na 
pressão arterial sistólica (PAS), lipoproteína de alta densidade (HDL), desempen
ho físico e fração de ejeção do ventrículo esquerdo (FEVE) de ratos espontaneame
nte hipertensos (SHR). MÉTODOS: Amostra de 32 SHR distribuídos em quatro grupos:
 grupo vinho e exercício (GVE), grupo vinho (GV), grupo exercício (GE) e grupo c
ontrole (GC). Doses de vinho tinto, equivalentes ao consumo moderado em humanos,
 foram administradas por gavagem, durante dez semanas, simultâneas ao período de
 EF, realizado em esteira. Os SHR receberam 3,715 ml/kg/dia de vinho. O desempen
ho físico foi analisado por teste de esforço (TE), e a FEVE foi obtida por medid
as ecocardiográficas. A aferição da PAS ocorreu antes e após o protocolo do EF. 
RESULTADOS: Demonstrou-se redução significativa da PAS nos grupos de intervenção
, comparados ao GC. Ao final do protocolo, o GVE apresentou a maior redução. Ass
im como na PAS, o GVE apresentou melhor resultado nos níveis de HDL. Não houve d
iferença significativa no desempenho físico e na FEVE entre os grupos. CONCLUSÃO
: O EF associado à ingesta moderada de vinho tinto exerce efeito cardioprotetor 
na PAS e na HDL de SHR. O desempenho físico e a FEVE não são alterados.#^dnd^i1#
^tm^lpt^kVinho^i1^sutilização#^tm^lpt^kexercício^i1#^tm^lpt^khipertensão^i1^spre
venção e controle#^tm^lpt^kcolesterol HDL^i1#^tm^lpt^ksistema cardiovascular^i1#
^len^aBACKGROUND: Physical exercise (PE) is effective in the treatment and preve
ntion of hypertension associated with improved lipid profile and cardiac contrac
tile function. Regular and moderate consumption of alcoholic beverages such as r
ed wine brings a cardiovascular protective effect. Beverage-derived polyphenols 
have antioxidant properties benefiting blood vessels. There is little evidence o
n the consumption of red wine associated with PE and the influences on the cardi
ovascular system. OBJECTIVE: To investigate the effect of physical exercise (PE)
 and moderate red wine intake interaction on systolic blood pressure (SBP), high
 density lipoprotein (HDL) levels, physical performance (PP) and left ventricula
r ejection fraction (LVEF) in spontaneously hypertensive rats (SHR). METHODS: Sa
mple of 32 SHRs divided into four groups: wine and exercise group (WEG), wine gr
oup (WG), exercise group (EG) and control group (CG). Red wine doses were given 
by intra-gastric gavage, during ten weeks, coincident with PE period, performed 
on treadmills. The SHRs received red wine doses of 3.715 ml/kg/day. Physical per
formance was analyzed by maximal exercise test (MET) and LVEF by echocardiograph
ic measures. SBP measurement was made before and after the PE protocol. RESULTS:
 Demonstrated that the three groups which suffered intervention presented signif
icant SBP reduction compared to CG. At the end of the protocol, WEG showed the l
argest reduction. Like in SBP results, WEG showed the best outcome on HDL levels
 at the experiment end. There was no significant difference of physical performa
nce and LVEF between groups. CONCLUSION: PE associated with moderate red wine in
take has cardioprotective effects on SBP and HDL levels in SHR. Their physical p
erformance and LVEF are not modified.#^dnd^i2#^tm^len^kWine^i2^suse#^tm^len^kexe
rcise^i2#^tm^len^khypertension^i2^sprevention and control#^tm^len^kHDL cholester
ol^i2#^tm^len^kcardiovascular system^i2#Associação Brasileira dos Enólogos#vanco
uv#40#20100325#25/03/10#20100809#09/08/10#20100818#18/08/10#aop01111.htm#Interne
t^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X201100500002
0##
00484000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704024200083002001300325#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#5#1#article#177#<p><a name="
top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Efeito  
  do vinho tinto associado ao exerc&iacute;cio f&iacute;sico no sistema cardiova
scular    de ratos espontaneamente hipertensos</b></font></p>     ^cY#aop01111.h
tm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#6#2#article#177#<p>&nbsp;</p
>     ^cY#aop01111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#7#3#article#177#<p>&nbsp;</p
>     ^cY#aop01111.htm##
00396000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704015400083002001300237#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#8#4#article#177#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Paulo Roberto    Soares Fi
lho; Iran Castro; Adriene Stahlschmidt</b></font></p>     ^cY#aop01111.htm##
00464000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022200083002001300305#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#9#5#article#177#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Instituto de Cardiologia    d
o Rio Grande do Sul - Funda&ccedil;&atilde;o Universit&aacute;ria de Cardiologia
,    Porto Alegre, RS - Brasil</font></p>     ^cY#aop01111.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#10#6#article#177#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#11#7#article#177#<p>&nbsp;</
p>     ^cY#aop01111.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#12#8#article#177#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01111.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#13#9#article#177#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop01111.htm##
00964000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704072000085002001300805#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#14#10#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>FUNDAMENTO:    </b> Pr&a
acute;tica de exerc&iacute;cio f&iacute;sico (EF) &eacute; eficiente    no trata
mento e na preven&ccedil;&atilde;o da hipertens&atilde;o, associada    &agrave; 
melhora do perfil lip&iacute;dico e da fun&ccedil;&atilde;o contr&aacute;til    
card&iacute;aca. Consumo moderado e regular de bebidas alco&oacute;licas, como  
  vinho tinto, desempenha efeito cardiovascular protetor. Polifen&oacute;is da  
  bebida apresentam propriedades antioxidantes, beneficiando vasos sangu&iacute;
neos.    H&aacute; poucas evid&ecirc;ncias sobre o consumo de vinho tinto associ
ado ao    EF e as influ&ecirc;ncias no sistema cardiovascular.    ^cY#aop01111.h
tm##
00631000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038700085002001300472#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#15#11#article#177#<br>   <b>
OBJETIVO: </b> Investigar o efeito da intera&ccedil;&atilde;o entre o EF    e o 
consumo moderado de vinho tinto na press&atilde;o arterial sist&oacute;lica    (
PAS), lipoprote&iacute;na de alta densidade (HDL), desempenho f&iacute;sico    e
 fra&ccedil;&atilde;o de eje&ccedil;&atilde;o do ventr&iacute;culo esquerdo    (
FEVE) de ratos espontaneamente hipertensos (SHR).    ^cY#aop01111.htm##
00906000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066200085002001300747#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#16#12#article#177#<br>   <b>
M&Eacute;TODOS:</b> Amostra de 32 SHR distribu&iacute;dos em quatro grupos:    g
rupo vinho e exerc&iacute;cio (GVE), grupo vinho (GV), grupo exerc&iacute;cio   
 (GE) e grupo controle (GC). Doses de vinho tinto, equivalentes ao consumo moder
ado    em humanos, foram administradas por gavagem, durante dez semanas, simult&
acirc;neas    ao per&iacute;odo de EF, realizado em esteira. Os SHR receberam 3,
715 ml/kg/dia    de vinho. O desempenho f&iacute;sico foi analisado por teste de
 esfor&ccedil;o    (TE), e a FEVE foi obtida por medidas ecocardiogr&aacute;fica
s. A aferi&ccedil;&atilde;o    da PAS ocorreu antes e ap&oacute;s o protocolo do
 EF.    ^cY#aop01111.htm##
00659000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041500085002001300500#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#17#13#article#177#<br>   <b>
RESULTADOS: </b> Demonstrou-se redu&ccedil;&atilde;o significativa da PAS    nos
 grupos de interven&ccedil;&atilde;o, comparados ao GC. Ao final do protocolo,  
  o GVE apresentou a maior redu&ccedil;&atilde;o. Assim como na PAS, o GVE apres
entou    melhor resultado nos n&iacute;veis de HDL. N&atilde;o houve diferen&cce
dil;a    significativa no desempenho f&iacute;sico e na FEVE entre os grupos.   
 ^cY#aop01111.htm##
00481000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023700085002001300322#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#18#14#article#177#<br>   <b>
CONCLUS&Atilde;O: </b> O EF associado &agrave; ingesta moderada de vinho    tint
o exerce efeito cardioprotetor na PAS e na HDL de SHR. O desempenho f&iacute;sic
o    e a FEVE n&atilde;o s&atilde;o alterados. </font></p>     ^cY#aop01111.htm#
#
00523000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027900085002001300364#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#19#15#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Vinho/utiliza&ccedil;&atilde;o, exerc&iacute;cio, hipertens&atilde;o/preven&cced
il;&atilde;o    e controle, colesterol HDL, sistema cardiovascular.</font></p> <
hr size="1" noshade>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#20#16#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#21#17#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#22#18#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01111.htm##
00809000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056500085002001300650#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#23#19#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Eleva&ccedil;&atilde;o    d
a press&atilde;o arterial (PA) representa fator de risco independente, linear   
 e cont&iacute;nuo para a doen&ccedil;a cardiovascular<sup>1</sup>. Uma das prin
cipais    limita&ccedil;&otilde;es no controle da hipertens&atilde;o est&aacute;
 alicer&ccedil;ada    no conceito de que essa doen&ccedil;a &eacute; complexa e 
polig&ecirc;nica e    sofre influ&ecirc;ncia de fatores ambientais como dieta, i
ngesta de sal e obesidade,    entre outros<sup>2</sup>.</font></p>     ^cY#aop01
111.htm##
00941000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704069700085002001300782#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#24#20#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Pela facilidade    na obten
&ccedil;&atilde;o dos n&iacute;veis press&oacute;ricos elevados, o rato    espon
taneamente hipertenso (SHR - <i>spontaneously hypertensive rats</i>) &eacute;   
 o modelo animal de hipertens&atilde;o mais utilizado<sup>3</sup>. Os SHR s&atil
de;o    pr&eacute;-hipertensos nas primeiras seis a oito semanas de vida. A hipe
rtens&atilde;o    estabelece-se entre 12 e 14 semanas. O desenvolvimento da hipe
rtens&atilde;o    caracteriza-se por aumento da resist&ecirc;ncia vascular perif
&eacute;rica,    hiperatividade simp&aacute;tica e aumento da frequ&ecirc;ncia c
ard&iacute;aca<sup>3</sup>.</font></p>     ^cY#aop01111.htm##
01080000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083600085002001300921#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#25#21#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O exerc&iacute;cio    f&iac
ute;sico (EF) proporciona benef&iacute;cios ao sistema cardiovascular,    utiliz
ado e comprovado por alguns experimentos<sup>4-7</sup> como medida n&atilde;o   
 farmacol&oacute;gica eficiente no tratamento e na preven&ccedil;&atilde;o da   
 hipertens&atilde;o. Esse efeito hipotensor &eacute; causado principalmente pela
    redu&ccedil;&atilde;o do d&eacute;bito card&iacute;aco associada &agrave; qu
eda    da frequ&ecirc;ncia card&iacute;aca<sup>7</sup> e &agrave; redu&ccedil;&a
tilde;o    da resist&ecirc;ncia vascular perif&eacute;rica<sup>6</sup>. A pr&aac
ute;tica    de EF tamb&eacute;m confere melhora ao perfil lip&iacute;dico<sup>8<
/sup> e    &agrave; fun&ccedil;&atilde;o contr&aacute;til card&iacute;aca<sup>9<
/sup>.</font></p>     ^cY#aop01111.htm##
01028000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078400085002001300869#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#26#22#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O consumo moderado    de al
guns tipos de bebidas alco&oacute;licas, entre as quais o vinho tinto (uma    a 
duas doses di&aacute;rias), apresenta associa&ccedil;&atilde;o inversa com    o 
desenvolvimento de doen&ccedil;a arterial coronariana (DAC)<sup>10,11</sup>.    
Em meta-an&aacute;lise<sup>12</sup> que envolveu 13 estudos, os benef&iacute;cio
s    do vinho tinto incorporaram mais sustenta&ccedil;&atilde;o, pois demonstrou
-se    redu&ccedil;&atilde;o de 32% no desenvolvimento de doen&ccedil;a arterosc
ler&oacute;tica    nos consumidores da bebida. Os polifen&oacute;is presentes no
 vinho tinto podem    ajudar na manuten&ccedil;&atilde;o da sa&uacute;de dos vas
os sangu&iacute;neos<sup>11</sup>.</font></p>     ^cY#aop01111.htm##
01249000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704100500085002001301090#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#27#23#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Poucas evid&ecirc;ncias    
existem sobre o consumo de vinho tinto associado ao EF e sobre suas influ&ecirc;
ncias    no sistema cardiovascular<sup>13</sup>. Est&aacute; estabelecido que o 
&aacute;lcool,    em doses moderadas, desempenha efeito protetor no sistema card
iovascular. Os    polifen&oacute;is presentes no vinho tinto s&atilde;o dotados 
de propriedades    antioxidantes que atuam beneficamente nos vasos sangu&iacute;
neos<sup>14-16</sup>.    O EF regular est&aacute; demonstrado como um agente con
trolador e regulador    da press&atilde;o arterial (PA)<sup>17,18</sup>. Dessa f
orma, o experimento    buscou investigar o efeito da intera&ccedil;&atilde;o ent
re o EF e o consumo    moderado de vinho tinto na press&atilde;o arterial sist&o
acute;lica (PAS), HDL-colesterol,    desempenho f&iacute;sico (DF) e fra&ccedil;
&atilde;o de eje&ccedil;&atilde;o    do ventr&iacute;culo esquerdo (FEVE) de rat
os hipertensos.</font></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#28#24#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#29#25#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&eacute;todos</b></font
></p>     ^cY#aop01111.htm##
00341000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009700085002001300182#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#30#26#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Amostra</b></font></p>  
   ^cY#aop01111.htm##
01264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704102000085002001301105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#31#27#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Foram utilizados    32 rato
s SHR machos, com idade de tr&ecirc;s meses (338,84 &plusmn; 21,25 g),    obtido
s no biot&eacute;rio da Universidade Federal de S&atilde;o Paulo (UNIFESP).    O
s animais permaneceram em ambiente com temperatura controlada (20º C a 25º    C)
, com ciclo claro/escuro (12/12 horas), alimentados com ra&ccedil;&atilde;o    b
alanceada para roedores e &aacute;gua (<i>Ad libitum</i>). Os ratos foram distri
bu&iacute;dos    em quatro grupos experimentais: grupo vinho e exerc&iacute;cio 
(GVE), grupo    vinho (GV), grupo exerc&iacute;cio (GE) e grupo controle (GC). D
oses de vinho    de 3,715 ml/kg/dia (mantidas as propor&ccedil;&otilde;es entre 
o consumo di&aacute;rio    considerado moderado para um humano de 70 kg e escalo
nadas para um rato de aproximadamente    0,333 kg)<sup>19,20</sup>. Foram admini
stradas por meio de gavagem, durante    dez semanas, cinco vezes por semana, no 
in&iacute;cio da manh&atilde;.</font></p>     ^cY#aop01111.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#32#28#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Protocolos experimentais
</b></font></p>     ^cY#aop01111.htm##
01649000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704140500085002001301490#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#33#29#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Doses de vinho    de 3,715 
ml/kg/dia foram administradas por meio de gavagem, durante dez semanas    (cinco
 vezes por semana, no in&iacute;cio da manh&atilde;). O vinho utilizado    foi o
 Dal Pizzol Cabernet Sauvignon (Rio Grande do Sul, Brasil), com 12% de    &aacut
e;lcool na composi&ccedil;&atilde;o. O protocolo de treinamento f&iacute;sico,  
  que teve mesma dura&ccedil;&atilde;o, foi realizado cinco vezes por semana no 
   in&iacute;cio da noite e baseou-se no m&eacute;todo de varia&ccedil;&atilde;o
    de intensidade, sempre respeitando os limites entre 40 e 70% da capacidade m
&aacute;xima.    Os ratos que se exercitaram foram adaptados &agrave; esteira (e
spec&iacute;fica    para ratos, marca Inbramed, Brasil) antes do primeiro teste 
de esfor&ccedil;o    e do come&ccedil;o do protocolo de treinamento, que iniciou
 com dura&ccedil;&atilde;o    di&aacute;ria de 20 minutos e teve um aumento grad
ativo at&eacute; chegar a    60 minutos. O estudo segue as normas estabelecidas 
no <i>Guide for the Care    and Use of Laboratory Animals</i> (<i>Institute of L
aboratory Animal Resources,    National Academy of Sciences</i>, Washington, D.C
., 1996) e nos <i>Princ&iacute;pios    &Eacute;ticos na Experimenta&ccedil;&atil
de;o Animal do Col&eacute;gio Brasileiro    de Experimenta&ccedil;&atilde;o Anim
al</i> (COBEA).</font></p>     ^cY#aop01111.htm##
00365000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012100085002001300206#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#34#30#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Teste de esfor&ccedil;o 
   (TE)</b></font></p>     ^cY#aop01111.htm##
00711000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046700085002001300552#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#35#31#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Foi realizado em    tr&ecir
c;s momentos do estudo (in&iacute;cio, meio e final do protocolo de treinamento)
    e consistia em iniciar com a velocidade de 0,3 km/h e aument&aacute;-la (0,3
    km/h) a cada tr&ecirc;s minutos at&eacute; a intensidade para cada rato fadi
gar<sup>21</sup>.    Os TE foram aplicados somente aos grupos que realizaram tre
inamento f&iacute;sico    (GVE e GE).</font></p>     ^cY#aop01111.htm##
00393000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014900085002001300234#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#36#32#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Aferi&ccedil;&atilde;o  
  da PAS e an&aacute;lise do plasma</b></font></p>     ^cY#aop01111.htm##
01130000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704088600085002001300971#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#37#33#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A aferi&ccedil;&atilde;o   
 da PAS foi realizada pela cauda dos ratos, em dois momentos: entre o d&eacute;c
imo    e o quinto dia antes do in&iacute;cio do protocolo e entre o quinto e o d
&eacute;cimo    dia ap&oacute;s o final do protocolo (in&iacute;cio e final do p
rotocolo de    treinamento f&iacute;sico). O equipamento utilizado foi o MP100 W
SW, Biopac    Systems (Santa Barbara, CA, USA). Ao final do experimento, os rato
s foram sedados    com quetamina (50 mg/kg) e xilazina (20 mg/kg) e sacrificados
 pelo m&eacute;todo    de deslocamento cervical, sendo realizado, neste momento,
 a coleta do sangue    por meio de pun&ccedil;&atilde;o card&iacute;aca. Os n&ia
cute;veis s&eacute;ricos    de HDL foram mensurados por meio do m&eacute;todo co
lorim&eacute;trico enzim&aacute;tico    homog&ecirc;neo.</font></p>     ^cY#aop0
1111.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010500085002001300190#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#38#34#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Ecocardiografia</b></fon
t></p>     ^cY#aop01111.htm##
00989000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704074500085002001300830#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#39#35#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os animais foram    sedados
 com quetamina (1 mcl/g) e xilazina (0,5 mcl/g), e, logo ap&oacute;s,    como pr
epara&ccedil;&atilde;o para o exame, o pelo da regi&atilde;o peitoral    foi rem
ovido. A ecocardiografia foi realizada por meio do equipamento Philips,    com t
ransdutor de 7,5 MHz. As imagens foram salvas, e as aferi&ccedil;&otilde;es    f
oram realizadas separadamente por dois observadores independentes. A fra&ccedil;
&atilde;o    de eje&ccedil;&atilde;o do ventr&iacute;culo esquerdo foi a medida 
escolhida    para an&aacute;lise subsequente. N&atilde;o houve varia&ccedil;&ati
lde;o entre    as an&aacute;lises realizadas pelos diferentes observadores.</fon
t></p>     ^cY#aop01111.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012600085002001300211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#40#36#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    estat&
iacute;stica</b></font></p>     ^cY#aop01111.htm##
00921000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067700085002001300762#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#41#37#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os dados est&atilde;o    ap
resentados em m&eacute;dia e desvio padr&atilde;o. Os resultados foram verificad
os    estatisticamente por meio de teste <i>t</i> de <i>Student</i>, pareado par
a    a compara&ccedil;&atilde;o da medida inicial com a final. Para comparar os 
resultados    entre os grupos, foi utilizado o teste de an&aacute;lise de vari&a
circ;ncia    (ANOVA). As compara&ccedil;&otilde;es m&uacute;ltiplas, entre os gr
upos, do    resultado da diferen&ccedil;a da PAS inicial para a PAS final foram 
feitas pelo    teste Tukey. O <i>software</i> utilizado foi o SPSS, vers&atilde;
o 13.0.</font></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#42#38#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#43#39#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Resultados</b></font></p
>     ^cY#aop01111.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#44#40#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Press&atilde;o    arteri
al sist&oacute;lica</b></font></p>     ^cY#aop01111.htm##
01989000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704174500085002001301830#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#45#41#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A <a href="#t1">Tabela    1
</a> demonstra os resultados relativos &agrave; PAS, sendo o <i>valor p</i>    a
presentado em rela&ccedil;&atilde;o ao n&iacute;vel de signific&acirc;ncia    en
tre a diferen&ccedil;a da PAS inicial e a da PAS final dentro do pr&oacute;prio 
   grupo. Quando essa diferen&ccedil;a foi comparada entre os grupos, todos apre
sentaram    signific&acirc;ncia (p&lt;0,001) em rela&ccedil;&atilde;o ao GC. O G
VE mostrou    uma redu&ccedil;&atilde;o significativa entre a primeira e a segun
da aferi&ccedil;&atilde;o,    sendo esse grupo o que demonstrou maior redu&ccedi
l;&atilde;o na PAS. Quando    comparado aos outros grupos, essa diferen&ccedil;a
 entre o in&iacute;cio e o    final do protocolo foi significativa em rela&ccedi
l;&atilde;o ao GV e ao GC    (p&lt;0,001). Por outro lado, comparado ao grupo qu
e praticou somente atividade    f&iacute;sica (GE), a diferen&ccedil;a da PAS in
icial para a PAS final, apesar    de maior, n&atilde;o apresentou signific&acirc
;ncia (p=0,83). O exerc&iacute;cio    f&iacute;sico de forma isolada demonstrou 
ser eficiente no controle da hipertens&atilde;o    em SHR, pois, em nosso experi
mento, o GE obteve uma redu&ccedil;&atilde;o significativa    entre a primeira e
 segunda aferi&ccedil;&atilde;o. Quando comparado aos outros    grupos, essa dif
eren&ccedil;a da PAS inicial para a PAS final foi significativa    em rela&ccedi
l;&atilde;o ao GV e ao GC (p&lt;0,001). Entre nossos grupos experimentais,    o 
GV apresentou uma pequena redu&ccedil;&atilde;o na m&eacute;dia da PAS. Por&eacu
te;m,    quando comparado ao GC, a diferen&ccedil;a entre a PAS inicial e a fina
l foi    significante (p&lt;0,001).</font></p>     ^cY#aop01111.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#46#42#article#177#<p><a name
="t1"></a></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#47#43#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#48#44#article#177#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01111t01.jpg"></p>     ^cY#aop
01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#49#45#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#50#46#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Desempenho f&iacute;sico
    (DF)</b></font></p>     ^cY#aop01111.htm##
01054000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704081000085002001300895#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#51#47#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O DF dos ratos    foi mensu
rado por meio de teste de esfor&ccedil;o (TE) no in&iacute;cio, meio    e final 
das dez semanas de protocolo de treinamento f&iacute;sico. O TE foi    aplicado 
somente nos dois grupos que realizaram exerc&iacute;cio (GE e GVE).    A m&eacut
e;dia da dist&acirc;ncia percorrida no &uacute;ltimo TE pelo GVE mostrou    uma 
diferen&ccedil;a n&atilde;o significativa (p=0,385) com rela&ccedil;&atilde;o   
 ao GE. Na compara&ccedil;&atilde;o entre o primeiro e o &uacute;ltimo TE, o    
GVE mostrou um aumento em 62,6% na dist&acirc;ncia percorrida, enquanto o GE    
aumentou 60,5% a dist&acirc;ncia percorrida no primeiro TE (<a href="/img/revist
as/abc/2011nahead/aop01111g01.jpg">Gr&aacute;fico    1</a>).</font></p>     ^cY#
aop01111.htm##
00374000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013000085002001300215#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#52#48#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Lipoprote&iacute;na    d
e alta densidade</b></font></p>     ^cY#aop01111.htm##
00964000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704072000085002001300805#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#53#49#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os n&iacute;veis    s&eacut
e;ricos da lipoprote&iacute;na de alta densidade (HDL) foram analisados    ao fi
nal do protocolo de treinamento e consumo de vinho (<a href="#g2">Gr&aacute;fico
    2</a>), demonstrando-se n&iacute;veis mais elevados de HDL no GVE, com signi
fic&acirc;ncia    estat&iacute;stica, quando comparado ao GC (p=0,019) e ao GE (
p=0,042). Na compara&ccedil;&atilde;o    com o GV, o GVE apresentou maiores n&ia
cute;veis HDL, por&eacute;m, n&atilde;o    significativos (p&gt;0,05). No GE, o 
n&iacute;vel de HDL sangu&iacute;neo n&atilde;o    se diferenciou significativam
ente do GC (p=0,946) - <a href="#t2">Tabela 2</a>.</font></p>     ^cY#aop01111.h
tm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#54#50#article#177#<p><a name
="g2"></a></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#55#51#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#56#52#article#177#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01111g02.jpg"></p>     ^cY#aop
01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#57#53#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#58#54#article#177#<p><a name
="t2"></a></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#59#55#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#60#56#article#177#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01111t02.jpg"></p>     ^cY#aop
01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#61#57#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016700085002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#62#58#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fra&ccedil;&atilde;o    
de eje&ccedil;&atilde;o do ventr&iacute;culo esquerdo</b></font></p>     ^cY#aop
01111.htm##
01041000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079700085002001300882#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#63#59#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O exame ecocardiogr&aacute;
fico    foi realizado antes e ap&oacute;s o protocolo das interven&ccedil;&otild
e;es    do estudo. Apesar de n&atilde;o haver diferen&ccedil;a significativa ent
re os    grupos (p = 0,579), os resultados mostram, no GVE, um aumento n&atilde;
o significativo    (p = 0,077) entre a primeira e a segunda aferi&ccedil;&atilde
;o da FEVE, sendo    esse grupo o que mais aumentou a FEVE. Assim como o GVE, os
 outros grupos do    experimento apresentaram, em menor propor&ccedil;&atilde;o,
 um aumento na FEVE,    estando os resultados dispostos na <a href="#t3">Tabela 
3</a>. Apesar do crescimento    da FEVE em todos os grupos, nenhum apresentou si
gnific&acirc;ncia para um valor    p &lt; 0,05.</font></p>     ^cY#aop01111.htm#
#
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#64#60#article#177#<p><a name
="t3"></a></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#65#61#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#66#62#article#177#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01111t03.jpg"></p>     ^cY#aop
01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#67#63#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#68#64#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop01111.htm##
01830000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704158600085002001301671#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#69#65#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O exerc&iacute;cio    f&iac
ute;sico regular parece ser uma das principais terapias utilizadas na preven&cce
dil;&atilde;o    do desenvolvimento da doen&ccedil;a cardiovascular, pois provoc
a uma s&eacute;rie    de respostas fisiol&oacute;gicas, resultantes de adapta&cc
edil;&otilde;es auton&ocirc;micas    e hemodin&acirc;micas que v&atilde;o influe
nciar o sistema cardiovascular<sup>6,22</sup>    e, quando associadas &agrave;s 
altera&ccedil;&otilde;es na dieta, influenciam    positivamente quase todos os f
atores de risco<sup>6</sup>. com rela&ccedil;&atilde;o    &agrave; dieta, o cons
umo moderado de vinho tinto est&aacute; associado com    uma significante redu&c
cedil;&atilde;o de risco cardiovascular<sup>12</sup>,    mesmo para indiv&iacute
;duos que utilizam uma dieta rica em gordura saturada,    situa&ccedil;&atilde;o
 paradoxal encontrada em alguns pa&iacute;ses, como a    Fran&ccedil;a. Nossos r
esultados confirmam e seguem esses conceitos, pois encontramos,    em nossos dad
os, uma significante redu&ccedil;&atilde;o em marcadores de risco    card&iacute
;aco. Ambos os grupos de ratos hipertensos que receberam as interven&ccedil;&oti
lde;es    de forma isolada, exerc&iacute;cio ou vinho, demonstraram redu&ccedil;
&atilde;o    da PAS. Por&eacute;m, o principal resultado desse experimento foi t
er encontrado,    no grupo que associou o programa de treinamento f&iacute;sico 
e o consumo em    doses moderadas de vinho tinto, a maior redu&ccedil;&atilde;o 
na PAS entre os    grupos do estudo.</font></p>     ^cY#aop01111.htm##
01464000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122000085002001301305#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#70#66#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Sendo o exerc&iacute;cio   
 f&iacute;sico um reconhecido agente hipotensor tanto em humanos como em animais
<sup>4,5,17</sup>,    entender os mecanismos desse efeito, que podem diferir de 
acordo com o tipo    de exerc&iacute;cio empregado e a popula&ccedil;&atilde;o e
studada, &eacute;    importante para sua utiliza&ccedil;&atilde;o terap&ecirc;ut
ica. O efeito de    um programa de exerc&iacute;cio f&iacute;sico com intensidad
e de 60% do VO<sub>2</sub>    m&aacute;ximo e dura&ccedil;&atilde;o de quatro me
ses em indiv&iacute;duos hipertensos    controlados foi analisado por Monteiro e
 cols.<sup>23</sup>, mostrando, nos    resultados, uma queda de 6% na PAS, assoc
iada a uma melhora no condicionamento    cardiorrespirat&oacute;rio e aumento no
s n&iacute;veis de HDL. O principal mecanismo    atribu&iacute;do a esse resulta
do &eacute; a redu&ccedil;&atilde;o do d&eacute;bito    card&iacute;aco associad
o &agrave; queda da frequ&ecirc;ncia card&iacute;aca<sup>7</sup>.    A redu&cced
il;&atilde;o da resist&ecirc;ncia vascular perif&eacute;rica contribui    para o
 efeito hipotensor causado pelo treinamento f&iacute;sico<sup>6</sup>.</font></p
>     ^cY#aop01111.htm##
01162000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704091800085002001301003#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#71#67#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Melo e cols.<sup>21</sup>  
  investigaram e compararam, em ratos SHR e Wistar-Kyoto, os efeitos de um progr
ama    de exerc&iacute;cio f&iacute;sico com dura&ccedil;&atilde;o de 13 semanas
 e    intensidade entre 50% e 60% da capacidade m&aacute;xima. Os resultados mos
traram    que somente os ratos SHR treinados reduziram a PA significantemente (e
m m&eacute;dia,    15 mmHg) em rela&ccedil;&atilde;o aos ratos do grupo controle
, confirmando o    efeito hipotensor mais pronunciado do condicionamento f&iacut
e;sico em hipertensos.    O crescimento e a prolifera&ccedil;&atilde;o de pequen
as v&ecirc;nulas assim    como a regress&atilde;o da hipertrofia das paredes das
 arter&iacute;olas s&atilde;o    ajustes compensat&oacute;rios causados pelo tre
inamento f&iacute;sico e foram    indicados como contribuintes para o efeito hip
otensor.</font></p>     ^cY#aop01111.htm##
01548000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704130400085002001301389#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#72#68#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Outro mecanismo    causado 
pelo exerc&iacute;cio f&iacute;sico &eacute; a diminui&ccedil;&atilde;o    da at
ividade do sistema nervoso simp&aacute;tico, que est&aacute; associada    &agrav
e; redu&ccedil;&atilde;o da PA. Bertagnolli e cols.<sup>24</sup> mensuraram    a
 PA e a concentra&ccedil;&atilde;o de norepinefrina no tecido card&iacute;aco   
 de ratos SHR que participaram de um programa de exerc&iacute;cio f&iacute;sico,
    com dura&ccedil;&atilde;o de dez semanas. Os resultados mostraram, no grupo 
   treinado, uma redu&ccedil;&atilde;o da concentra&ccedil;&atilde;o de norepine
frina    no tecido card&iacute;aco, justificando a queda da PA dos animais, send
o esse    fato associado &agrave; diminui&ccedil;&atilde;o da atividade do siste
ma simp&aacute;tico.    Anteriores a esses achados, mecanismos hemodin&acirc;mic
os, como a redu&ccedil;&atilde;o    do d&eacute;bito card&iacute;aco associada &
agrave; bradicardia de repouso,    foram descritos como respons&aacute;veis pela
 atenua&ccedil;&atilde;o da hipertens&atilde;o    arterial em ratos SHR que part
iciparam de um programa de exerc&iacute;cios com    intensidade leve &agrave; mo
derada, correspondendo a 55% do VO<sub>2</sub> m&aacute;ximo<sup>25</sup>.</font
></p>     ^cY#aop01111.htm##
01534000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704129000085002001301375#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#73#69#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O consumo de &aacute;lcool 
   tamb&eacute;m pode influenciar a PA. Estudos experimentais, com a linhagem SH
R,    demonstraram que a administra&ccedil;&atilde;o cr&ocirc;nica de doses mode
radas    de etanol previne a eleva&ccedil;&atilde;o da PA decorrente da idade<su
p>26</sup>.    Quando o efeito do consumo dessa subst&acirc;ncia &eacute; analis
ado de maneira    aguda, doses moderadas proporcionam queda da PA em SHR<sup>27<
/sup>. Quando    a bebida consumida &eacute; o vinho tinto, os polifen&oacute;is
, independentemente    da presen&ccedil;a ou n&atilde;o do &aacute;lcool, desemp
enham papel cardioprotetor,    por meio da a&ccedil;&atilde;o antioxidante do LD
L-colesterol<sup>11,14,15</sup>    e inibidora da express&atilde;o de prote&iacu
te;nas pr&oacute;-inflamat&oacute;rias<sup>16</sup>.    Estudos que utilizaram s
uplementa&ccedil;&atilde;o de composto com os mesmos    componentes do vinho tin
to, por&eacute;m livre de &aacute;lcool, demonstraram    que, tanto em coelhos<s
up>28</sup> como em ratos<sup>29</sup> hipercolester&ecirc;micos,    o composto 
fen&oacute;lico teve um papel antitromb&oacute;tico devido &agrave;    inibi&cce
dil;&atilde;o da agrega&ccedil;&atilde;o plaquet&aacute;ria.</font></p>     ^cY#
aop01111.htm##
01440000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704119600085002001301281#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#74#70#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os polifen&oacute;is    s&a
tilde;o normalmente divididos em dois grupos, os flavonoides e os n&atilde;o    
flavonoides. Os flavonoides mais presentes no vinho tinto s&atilde;o: quercetina
,    flavon&oacute;is, tanino e catequinas. Entre os n&atilde;o flavonoides, des
taca-se    o resveratrol (3,4,5-trihidro-stilbeno)<sup>30</sup>. Subst&acirc;nci
a capaz    de melhorar a express&atilde;o endotelial da NO sintase, liberando ma
is &oacute;xido    n&iacute;trico (NO) para as c&eacute;lulas endoteliais<sup>31
</sup>, bem como    inibir a s&iacute;ntese da endotelina-1, o mais potente vaso
constritor derivado    do endot&eacute;lio<sup>32</sup>. O resveratrol e outros 
polifen&oacute;is est&atilde;o    ausentes na maioria das frutas e dos vegetais 
normalmente utilizados. Assim,    o consumo de vinho tinto poderia constituir-se
 a &uacute;nica fonte na dieta,    ainda mais que a fermenta&ccedil;&atilde;o da
 bebida leva ao enriquecimento    do conte&uacute;do total de polifen&oacute;is,
 e, melhor ainda, a solubiliza&ccedil;&atilde;o    dos polifen&oacute;is resulta
 em sua maior biodisponibilidade<sup>33</sup>.</font></p>     ^cY#aop01111.htm##
00982000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073800085002001300823#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#75#71#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A lipoprote&iacute;na    de
 alta densidade foi outro marcador de risco analisado em nosso experimento.    O
 consumo moderado de &aacute;lcool causa um aumento nos n&iacute;veis de HDL-col
esterol,    podendo chegar a 12% em humanos<sup>34</sup>, sendo esse aumento res
ultado da    eleva&ccedil;&atilde;o nas subfra&ccedil;&otilde;es HDL2 e HDL3, e 
apoA-1 e    apoA-2, o que proporciona um eficiente transporte reverso das mol&ea
cute;culas    de LDL. O condicionamento f&iacute;sico tamb&eacute;m impulsiona o
s n&iacute;veis    de HDL, sendo esse um tratamento n&atilde;o medicamentoso que
 comprovadamente    melhora o perfil lip&iacute;dico<sup>8,35</sup>.</font></p> 
    ^cY#aop01111.htm##
01226000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098200085002001301067#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#76#72#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Assim como nos    resultado
s da PA, o grupo que associou treinamento f&iacute;sico com doses moderadas    d
e vinho tinto mostrou o melhor resultado nos n&iacute;veis s&eacute;ricos de    
HDL. Outro dado interessante foi o GV ter apresentado &iacute;ndice de HDL mais 
   alto do que o GE, que, por sua vez, ainda demonstrou melhor resultado que o  
  GC. O fato de n&atilde;o ser poss&iacute;vel verificar o n&iacute;vel de HDL  
  inicial dos ratos participantes do estudo enfraqueceu o poder dos resultados  
  relativos aos n&iacute;veis dessa lipoprote&iacute;na, mesmo sabendo que os   
 SHR possuem caracter&iacute;stica isog&ecirc;nica. Em ratos hipertensos que    
praticaram atividade f&iacute;sica durante seis semanas, com intensidades entre 
   30 e 60%, houve um aumento significativo (p &lt; 0,001) nos n&iacute;veis de 
   HDL em rela&ccedil;&atilde;o aos SHR sedent&aacute;rios<sup>28</sup>.</font><
/p>     ^cY#aop01111.htm##
00865000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704062100085002001300706#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#77#73#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Um indicador de    adapta&c
cedil;&atilde;o ao treinamento f&iacute;sico encontrado em nosso estudo    foi a
 evolu&ccedil;&atilde;o do desempenho dos ratos nos TE realizados. O programa   
 de condicionamento realizado nesse experimento proporcionou um aumento de cerca
    de 60% na dist&acirc;ncia percorrida pelos ratos no &uacute;ltimo TE. &Eacut
e;    importante ressaltar que o desempenho do grupo que recebeu vinho durante o
 protocolo    de exerc&iacute;cios n&atilde;o se diferenciou do grupo que realiz
ou somente    exerc&iacute;cio.</font></p>     ^cY#aop01111.htm##
01330000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704108600085002001301171#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#78#74#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A sobrecarga press&oacute;r
ica    na hipertens&atilde;o resulta em hipertrofia card&iacute;aca patol&oacute
;gica,    tendo como consequ&ecirc;ncia a redu&ccedil;&atilde;o da fun&ccedil;&a
tilde;o    card&iacute;aca e podendo levar ao quadro de insufici&ecirc;ncia card
&iacute;aca<sup>36</sup>.    O exerc&iacute;cio tamb&eacute;m est&aacute; relaci
onado com altera&ccedil;&otilde;es    estruturais card&iacute;acas em SHR, por&e
acute;m, a hipertrofia desencadeada    pelo treinamento f&iacute;sico &eacute; b
en&eacute;fica ao sistema cardiovascular    e definida como fisiol&oacute;gica<s
up>9</sup>. A reprodutibilidade da fra&ccedil;&atilde;o    de eje&ccedil;&atilde
;o do ventr&iacute;culo esquerdo (FEVE) tem sido demonstrada    universalmente, 
sendo a medida preferida para expressar a integralidade da contra&ccedil;&atilde
;o    card&iacute;aca. Dessa forma, a FEVE &eacute; utilizada como uma &oacute;t
ima    express&atilde;o do desempenho mec&acirc;nico do ventr&iacute;culo esquer
do<sup>37</sup>.</font></p>     ^cY#aop01111.htm##
01581000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704133700085002001301422#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#79#75#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O modelo SHR &eacute;    um
 considerado muito similar ao modelo de hipertens&atilde;o humana e conduz    a 
insufici&ecirc;ncia card&iacute;aca<sup>3</sup>. Exame ecocardiogr&aacute;fico  
  foi utilizado para demonstrar aumento do volume diast&oacute;lico e sist&oacut
e;lico,    assim como redu&ccedil;&atilde;o da FEVE em SHR ap&oacute;s os 18 mes
es de vida<sup>38</sup>.    Dentro de nossa amostra, as interven&ccedil;&otilde;
es n&atilde;o causaram diferen&ccedil;a    significativa da FEVE, apesar de o gr
upo GVE ter apresentado o melhor resultado    na compara&ccedil;&atilde;o da FEV
E entre o primeiro e o segundo exame ecocardiogr&aacute;fico.    O efeito do EF 
no tratamento de ratos hipertensos com insufici&ecirc;ncia card&iacute;aca    (S
HHF) parece diferir de acordo com a intensidade do treinamento f&iacute;sico.   
 Emter e cols.<sup>39</sup> aplicaram um protocolo de EF de baixa intensidade   
 em SHHF e obtiveram como resultado um retardamento na chegada da insufici&ecirc
;ncia    card&iacute;aca. Por outro lado, Schultz e cols.<sup>40</sup> demonstra
ram que    o EF em excesso desencadeia efeitos delet&eacute;rios no remodelament
o card&iacute;aco    e pode acelerar a progress&atilde;o da insufici&ecirc;ncia 
card&iacute;aca de    SHHF.</font></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#80#76#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#81#77#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop01111.htm##
01407000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704116300085002001301248#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#82#78#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em modelo animal    SHR, a 
associa&ccedil;&atilde;o do vinho tinto ao exerc&iacute;cio f&iacute;sico    mos
trou efeitos ben&eacute;ficos, diminuindo significativamente a press&atilde;o   
 arterial sist&oacute;lica. Por&eacute;m, n&atilde;o houve diferen&ccedil;a em  
  rela&ccedil;&atilde;o ao grupo com interven&ccedil;&atilde;o de somente exerc&
iacute;cio,    mas significativamente maior do que no grupo com somente ingesta 
de vinho. Este,    por sua vez, apresentou redu&ccedil;&atilde;o da press&atilde
;o arterial em    compara&ccedil;&atilde;o com o grupo controle. Essa associa&cc
edil;&atilde;o    mostrou tamb&eacute;m eleva&ccedil;&atilde;o significativa dos
 n&iacute;veis    de HDL em compara&ccedil;&atilde;o com os ratos que sofreram i
nterven&ccedil;&otilde;es    isoladas. Ressaltemos, ainda, que, nesse modelo, a 
fra&ccedil;&atilde;o de eje&ccedil;&atilde;o    do ventr&iacute;culo esquerdo n&
atilde;o sofreu influ&ecirc;ncia pelas interven&ccedil;&otilde;es    aplicadas e
 que o desempenho f&iacute;sico n&atilde;o foi prejudicado pelo consumo    moder
ado de vinho.</font></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#83#79#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#84#80#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Agradecimentos</b></font
></p>     ^cY#aop01111.htm##
00550000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030600085002001300391#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#85#81#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Este estudo foi    apoiado 
pela ABE (Associa&ccedil;&atilde;o Brasileira dos En&oacute;logos).    Os autore
s agradecem &agrave; equipe do laborat&oacute;rio de pesquisa experimental    do
 IC/FUC (Porto Alegre, RS - Brasil).</font></p>     ^cY#aop01111.htm##
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#86#82#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    de
 Interesses</b></font></p>     ^cY#aop01111.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#87#83#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    haver
 conflito de interesses pertinentes.</font></p>     ^cY#aop01111.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#88#84#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01111.htm##
00437000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019300085002001300278#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#89#85#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    foi pa
rcialmente financiado pela Associa&ccedil;&atilde;o Brasileira dos En&oacute;log
os.</font></p>     ^cY#aop01111.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#90#86#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;o
    Acad&ecirc;mica</b></font></p>     ^cY#aop01111.htm##
00456000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704021200085002001300297#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#91#87#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Este artigo &eacute;    par
te da tese de mestrado de Paulo Roberto Soares Filho pelo Instituto de Cardiolog
ia    de Porto Alegre.</font></p>     ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#92#88#article#177#<p>&nbsp;<
/p>     ^cY#aop01111.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#93#89#article#177#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01111.htm##
00582000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032400087002001300411#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#94#90#article#17
7#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Lewington 
S,    Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual 
blood    pressure to vascular mortality: a meta-analysis of individual data for 
one million    adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13.
    ^cY#aop01111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#95#91#article#177#</font></p
>     ^cY#aop01111.htm##
00495000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023700087002001300324#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#96#92#article#17
7#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Krieger JE
,    Drager LF, Pereira AC, Krieger EM. Gen&eacute;tica e hipertens&atilde;o art
erial.    Rev Soc Cardiol Estado de S&atilde;o Paulo. 2004;14(3):499-507.    ^cY
#aop01111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#97#93#article#177#</font></p
>     ^cY#aop01111.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704021200087002001300299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#98#94#article#17
7#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Rhoden EL,
 Rhoden    CR. Princ&iacute;pios e t&eacute;cnicas em experimenta&ccedil;&atilde
;o animal.    Porto Alegre: Editora UFRGS; 2006.    ^cY#aop01111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#99#95#article#177#</font></p
>     ^cY#aop01111.htm##
00530000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704027100088002001300359#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#100#96#article#1
77#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Brum PC, 
Da    Silva GJ, Moreira ED, Ida F, Negrao CE, Krieger EM. Exercise training incr
eases    baroreceptor gain sensitivity in normal and hypertensive rats. Hyperten
sion.    2000;36(6):1018-22.    ^cY#aop01111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#101#97#article#177#</font></
p>     ^cY#aop01111.htm##
00446000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704018700088002001300275#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#102#98#article#1
77#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Kokkinos 
PF,    Narayan P, Papademetriou V. Exercise as hypertension therapy. Cardiol Cli
n.    2001;19(3):507-16.    ^cY#aop01111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#103#99#article#177#</font></
p>     ^cY#aop01111.htm##
00481000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704022100089002001300310#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#104#100#article#
177#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Monteiro
 MF,    Sobral Filho DC. Exerc&iacute;cio f&iacute;sico e controle da press&atil
de;o    arterial. Rev Brasil Med Esporte. 2004;10(6):513-6.    ^cY#aop01111.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#105#101#article#177#</font><
/p>     ^cY#aop01111.htm##
00537000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704027700089002001300366#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#106#102#article#
177#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Nami R, 
Mondillo    S, Agricola E, Lenti S, Ferro G, Nami N, et al. Aerobic exercise tra
ining fails    to reduce blood pressure in nondipper-type hypertension. Am J Hyp
ertens. 2000;13(6    Pt 1):593-600.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#107#103#article#177#</font><
/p>     ^cY#aop01111.htm##
00501000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704024100089002001300330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#108#104#article#
177#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Carroll 
S, Dudfield    M. What is the relationship between exercise and metabolic abnorm
alities? A    review of the metabolic syndrome. Sports Med. 2004;34(6):371-418. 
   ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#109#105#article#177#</font><
/p>     ^cY#aop01111.htm##
00459000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704019900089002001300288#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#110#106#article#
177#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Fagard R
H. Impact    of different sports and training on cardiac structure and function.
 Cardiol    Clin. 1997;15(3):397-412.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#111#107#article#177#</font><
/p>     ^cY#aop01111.htm##
00609000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034800090002001300438#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#112#108#article#
177#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Goldbe
rg IJ,    Mosca L, Piano MR, Fisher EA. AHA Science Advisory: wine and your hear
t: a science    advisory for healthcare professionals from the nutrition committ
ee, council    on cardiovascular nursing of the American Heart Association. Circ
ulation. 2001;103(3):472-5.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#113#109#article#177#</font><
/p>     ^cY#aop01111.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020900090002001300299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#114#110#article#
177#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Szmitk
o PE,    Verma S. Antiatherogenic potential of red wine: clinician update. J Phy
siol    Heart Circ Physiol. 2005;288(5):2023-30.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#115#111#article#177#</font><
/p>     ^cY#aop01111.htm##
00514000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025300090002001300343#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#116#112#article#
177#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Di Cas
telnuovo    A, Rotondo S, Iacoviello L, Donati MB, Gaetano G. Meta-analysis of w
ine and    beer consumption in relation to vascular risk. Circulation. 2002;105(
24):2836-44.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#117#113#article#177#</font><
/p>     ^cY#aop01111.htm##
00406000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704014500090002001300235#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#118#114#article#
177#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Kaplan
 NM.    Alcohol and hypertension. Lancet. 1995;345(8955):1588-9.    ^cY#aop01111
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#119#115#article#177#</font><
/p>     ^cY#aop01111.htm##
00508000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024700090002001300337#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#120#116#article#
177#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Kondo 
K, Matsumoto    A, Kurata H, Tanahashi H, Koda H, Amachi T, et al. Inhibition of
 oxidation of    low-density lipoprotein with red wine. Lancet. 1994;344(8930):1
152-9.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#121#117#article#177#</font><
/p>     ^cY#aop01111.htm##
00517000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025600090002001300346#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#122#118#article#
177#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Kerry 
NL, Abbey    M. Red wine and fractionated phenolic compounds prepared from red w
ine inhibit    low density lipoprotein oxidation in vitro. Atherosclerosis. 1997
;135(1):93-102.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#123#119#article#177#</font><
/p>     ^cY#aop01111.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#124#120#article#
177#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Rosenk
ranz    S, Knirel D, Dietrich H, Flesch M, Erdmann E, B&ouml;hm M. Inhibition of
 the    PDGF receptor by red wine flavonoids provides a molecular explanation fo
r the    "French paradox" FASEB J. 2002;16(14):1952-60.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#125#121#article#177#</font><
/p>     ^cY#aop01111.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#126#122#article#
177#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Mion J
r D,    Kohlmann Jr O, Machado CA, Amodeo C, Gomes MAM, Praxedes JN, et al. / So
ciedade    Brasileira de Cardiologia. V Diretrizes brasileiras de hipertens&atil
de;o arterial.    Arq Bras Cardiol. 2007;89(3):e24-e79.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#127#123#article#177#</font><
/p>     ^cY#aop01111.htm##
00550000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028900090002001300379#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#128#124#article#
177#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Brum P
C, Forjaz    CLM, Tinucci T, Negr&atilde;o CE. Adapta&ccedil;&otilde;es agudas e
 cr&ocirc;nicas    do exerc&iacute;cio f&iacute;sico no sistema cardiovascular. 
Rev paul Educ Fis.    2004;18(nº especial):21-3.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#129#125#article#177#</font><
/p>     ^cY#aop01111.htm##
00518000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025700090002001300347#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#130#126#article#
177#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Celott
i E,    Ferrarini R, Zironi R, Conte LS. Resveratrol content of some wines obtai
ned    from dried Valpolicella grapes: Recioto and Amarone. J Chromatogr A. 1996
;730(1-2):47-52.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#131#127#article#177#</font><
/p>     ^cY#aop01111.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024300090002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#132#128#article#
177#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Bertel
li A,    Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol con
centrations    and pharmacological activity. Drugs Exp Clin Res. 1998;24(3):133-
8.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#133#129#article#177#</font><
/p>     ^cY#aop01111.htm##
00541000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028000090002001300370#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#134#130#article#
177#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Melo R
M, Martinho    Jr. E, Michelini LC. Training-induced, pressure-lowering effect i
n SHR: wide    effects on circulatory profile of exercised and nonexercised musc
les. Hypertension.    2003;42(4):851-7.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#135#131#article#177#</font><
/p>     ^cY#aop01111.htm##
00453000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019200090002001300282#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#136#132#article#
177#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. O'Keef
e JH,    Nelson J, Harris WB. Lifestyle change for coronary artery disease. Post
grad    Med. 1996;99(2):89-106.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#137#133#article#177#</font><
/p>     ^cY#aop01111.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031100090002001300401#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#138#134#article#
177#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Montei
ro HL,    Rolim LMC, Squinca DA, Silva FC, Ticianeli CCC, Amaral SL. Exercise pr
ogram    effectiveness on physical fitness, metabolic profile and blood pressure
 of hypertensive    patients. Rev Bras Med Esporte. 2007;13(2):107-12.    ^cY#ao
p01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#139#135#article#177#</font><
/p>     ^cY#aop01111.htm##
00616000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704035500090002001300445#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#140#136#article#
177#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Bertag
nolli    M, Schenkel PC, Campos C, Mostarda CT, Casarini DE, Bell&oacute;-Klein 
A, et    al. Exercise training reduces sympathetic modulation on cardiovascular 
system    and cardiac oxidative stress in spontaneously hypertensive rats. Am J 
Hypertens.    2008;21(11):1188-93.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#141#137#article#177#</font><
/p>     ^cY#aop01111.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#142#138#article#
177#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. V&eacu
te;ras-Silva    AS, Mattos KC, Gava NS, Brum PC, Negr&atilde;o CE, Krieger EM. L
ow-intesity    exercise training decreases cardiac output and hypertension in sp
ontaneously    hypertensive rats. Am J Physiol. 1997;273(6 Pt 2):2627-31.    ^cY
#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#143#139#article#177#</font><
/p>     ^cY#aop01111.htm##
00547000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028600090002001300376#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#144#140#article#
177#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Guilla
ume P,    Jankowski M, Gianoulakis C, Gutkowska J. Effect of chronic ethanol con
sumption    on the atrial natriuretic system of spontaneously hypertensive rats.
 Alcohol    Clin Exp Res. 1996;20(9):1653-61.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#145#141#article#177#</font><
/p>     ^cY#aop01111.htm##
00510000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024900090002001300339#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#146#142#article#
177#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. El-Mas
 MM,    Abdel-Rahman AA. Acute hemodynamic effects of ethanol in conscious spont
aneously    hypertensive and normotensive rats. Alcohol Clin Exp Res. 1999;23(2)
:285-92.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#147#143#article#177#</font><
/p>     ^cY#aop01111.htm##
00543000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028200090002001300372#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#148#144#article#
177#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Da Luz
 PL,    Serrano Jr CV, Chacra AP, Monteiro HP, Yoshida VM, Furtado M, et al The 
effect    of red wine on experimental atherosclerosis: lipid-independent protect
ion. Exp    Mol Pathol. 1999;65(3):150-9.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#149#145#article#177#</font><
/p>     ^cY#aop01111.htm##
00610000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034900090002001300439#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#150#146#article#
177#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. De Cur
tis A,    Murzilli S, Di Castelnuovo A, Rotilio D, Donati MB, De Gaetano G, et a
l. Alcohol-free    red wine prevents arterial thrombosis in dietary-induced hype
rcholesterolemic    rats: experimental support for the 'French paradox'. J Throm
b Haemost. 2005;3(2):346-50.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#151#147#article#177#</font><
/p>     ^cY#aop01111.htm##
00437000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704017600090002001300266#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#152#148#article#
177#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Van de
 Wiel    A, Van Golde PHM, Hart HC. Blessings of the grape. Eur J Intern Med. 20
01;12(6):484-9.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#153#149#article#177#</font><
/p>     ^cY#aop01111.htm##
00499000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023800090002001300328#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#154#150#article#
177#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Waller
ath T,    Poleo D, Li H, Forstermann U. Red wine increases the expression of hum
an endothelial    nitric oxide synthase. J Am Coll Cardiol. 2003;41(3):471-8.   
 ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#155#151#article#177#</font><
/p>     ^cY#aop01111.htm##
00495000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023400090002001300324#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#156#152#article#
177#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Corder
 R, Douthwaite    JA, Lees DM, Khan NQ, Viseu Dos Santos AC, Wood EG, et al. End
othelin-1 synthesis    reduced by red wine. Nature. 2001;414(6866):863-4.    ^cY
#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#157#153#article#177#</font><
/p>     ^cY#aop01111.htm##
00467000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020600090002001300296#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#158#154#article#
177#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Soleas
 GJ,    Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? 
And    gone? Clin Biochem. 1997;30(2):91-113.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#159#155#article#177#</font><
/p>     ^cY#aop01111.htm##
00558000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029700090002001300387#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#160#156#article#
177#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Linn S
, Carroll    M, Johnson C, Fulwood R, Kalsbeek W, Briefel R. High-density lipopr
otein cholesterol    and alcohol consumption in US white and black adults: data 
from NHANES II. Am    J Public Health. 1993;83(6):811-6.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#161#157#article#177#</font><
/p>     ^cY#aop01111.htm##
00457000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019600090002001300286#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#162#158#article#
177#35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Toth P
P. Cardiology    patient page: the "good cholesterol": high-density lipoprotein.
 Circulation.    2005;111(5):89-91.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#163#159#article#177#</font><
/p>     ^cY#aop01111.htm##
00469000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020800090002001300298#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#164#160#article#
177#36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Richey
 PA,    Brown SP. Pathological versus physiological left ventricular hypertrophy
: a    review. J Sports Sci. 1998;16(2):129-41.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#165#161#article#177#</font><
/p>     ^cY#aop01111.htm##
00458000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019700090002001300287#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#166#162#article#
177#37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Gottsc
hall    CAM. Din&acirc;mica cardiovascular: do mi&oacute;cito &agrave; maratona.
 S&atilde;o    Paulo: Atheneu; 2005.    ^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#167#163#article#177#</font><
/p>     ^cY#aop01111.htm##
00578000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031700090002001300407#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#168#164#article#
177#38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Bing O
H, Brooks    WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, et al. The sponta
neously hypertensive    rat as a model of the transition from compensated left v
entricular hypertrophy    to failure. J Mol Cell Cardiol. 1995;27(1):383-96.    
^cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#169#165#article#177#</font><
/p>     ^cY#aop01111.htm##
00577000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031600090002001300406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#170#166#article#
177#39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Emter 
CA, McCune    SA, Sparagna GC, Radin MJ, Moore RL. Low-intensity exercise traini
ng delays    onset of decompensated heart failure in spontaneously hypertensive 
heart failure    rats. Am J Physiol Heart Circ Physiol. 2005;289(5):2030-8.    ^
cY#aop01111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#171#167#article#177#</font><
/p>     ^cY#aop01111.htm##
00570000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030900090002001300399#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#172#168#article#
177#40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Schult
z RL,    Swallow, JG, Waters RP, Kuzman JA, Redetzke RA, Said S, et al. Effects 
of excessive    long-term exercise on cardiac function and myocyte remodeling in
 hypertensive    heart failure rats. Hypertension. 2007;50(2):410-6.    ^cY#aop0
1111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#173#169#article#177#</font><
/p>     ^cY#aop01111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#174#170#article#177#<p>&nbsp
;</p>     ^cY#aop01111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#175#171#article#177#<p>&nbsp
;</p>     ^cY#aop01111.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#176#172#article#177#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop01111.htm##
00292000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004600087002001300133#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#177#173#article#177#<br>   <
/b> Paulo Roberto Soares Filho    ^cY#aop01111.htm##
00311000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006500087002001300152#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#178#174#article#177#<br>   A
v. Cinco de Novembro, 31/302 - Teres&oacute;polis    ^cY#aop01111.htm##
00298000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005200087002001300139#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#179#175#article#177#<br>   9
0870-160 - Porto Alegre, RS - Brasil    ^cY#aop01111.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010500087002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#180#176#article#177#<br>   E
-mail: <a href="mailto:paulosoares75@pop.com.br">paulosoares75@pop.com.br</a></f
ont></p>     ^cY#aop01111.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01111.htm#S#p#181#177#article#177#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 25/
03/10; revisado recebido em 09/08/10; aceito em 18/08/10.</font></p>     ^cY#aop
01111.htm##
00732000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100016001050100
01900121010001400140010001700154012015800171030000700329065000900336064000500345
03100040035003200050035401400080035986500090036700200130037603500100038980100070
0399#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#182#1#ar
ticle#40#1#^rND^sLewington^nS#^rND^sClarke^nR#^rND^sQizilbash^nN#^rND^sPeto^nR#^
rND^sCollins^nR#Age-specific relevance of usual blood pressure to vascular morta
lity: a meta-analysis of individual data for one million adults in 61 prospectiv
e studies^len#Lancet#20020000#2002#360#9349#1903-13#20110000#aop01111.htm#0099-5
355#Lancet##
00582000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100017001040100
01800121010001800139012003600157030003600193710000200229065000900231064000500240
031000300245032000200248014000800250865000900258002001300267#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01111.htm#S#c#183#2#article#40#2#^rND^sKrieger
^nJE#^rND^sDrager^nLF#^rND^sPereira^nAC#^rND^sKrieger^nEM#Genética e hipertensão
 arterial^lpt#Rev Soc Cardiol Estado de São Paulo#2#20040000#2004#14#3#499-507#2
0110000#aop01111.htm##
00476000000000241000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840160017000860160017001030180
05100120066001300171062001400184065000900198064000500207865000900212002001300221
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#184#3#articl
e#40#3#^rND^sRhoden^nEL#^rND^sRhoden^nCR#Princípios e técnicas em experimentação
 animal^lpt#Porto Alegre#Editora UFRGS#20060000#2006#20110000#aop01111.htm##
00703000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100019001010100
01800120010001300138010001700151010001800168012009400186030001300280065000900293
06400050030203100030030703200020031001400080031286500090032000200130032903500100
0342801001300352#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#
S#c#185#4#article#40#4#^rND^sBrum^nPC#^rND^sDa Silva^nGJ#^rND^sMoreira^nED#^rND^
sIda^nF#^rND^sNegrao^nCE#^rND^sKrieger^nEM#Exercise training increases barorecep
tor gain sensitivity in normal and hypertensive rats^len#Hypertension#20000000#2
000#36#6#1018-22#20110000#aop01111.htm#0194-911X#Hypertension##
00568000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100017001050100
02300122012003700145030001300182065000900195064000500204031000300209032000200212
014000700214865000900221002001300230035001000243801001300253#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01111.htm#S#c#186#5#article#40#5#^rND^sKokkino
s^nPF#^rND^sNarayan^nP#^rND^sPapademetriou^nV#Exercise as hypertension therapy^l
en#Cardiol Clin#20010000#2001#19#3#507-16#20110000#aop01111.htm#0733-8651#Cardio
l Clin##
00530000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100023001050120
05200128030002300180710000200203065000900205064000500214031000300219032000200222
014000600224865000900230002001300239#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01111.htm#S#c#187#6#article#40#6#^rND^sMonteiro^nMF#^rND^sSobral Filho
^nDC#Exercício físico e controle da pressão arterial^lpt#Rev Brasil Med Esporte#
2#20040000#2004#10#6#513-6#20110000#aop01111.htm##
00731000000000361000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100018001000100
01800118010001500136010001500151010001400166810000600180012009200186030001500278
06500090029306400050030203100030030703200020031003400020031201400080031486500090
0322002001300331035001000344801001500354#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop01111.htm#S#c#188#7#article#40#7#^rND^sNami^nR#^rND^sMondillo^nS#^
rND^sAgricola^nE#^rND^sLenti^nS#^rND^sFerro^nG#^rND^sNami^nN#et al#Aerobic exerc
ise training fails to reduce blood pressure in nondipper-type hypertension^len#A
m J Hypertens#20000000#2000#13#6#1#593-600#20110000#aop01111.htm#0895-7061#Am J 
Hypertens##
00603000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030120
11100121030001100232065000900243064000500252031000300257032000200260014000800262
865000900270002001300279035001000292801001100302#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01111.htm#S#c#189#8#article#40#8#^rND^sCarroll^nS#^rND^sDu
dfield^nM#What is the relationship between exercise and metabolic abnormalities?
: A review of the metabolic syndrome^len#Sports Med#20040000#2004#34#6#371-418#2
0110000#aop01111.htm#0112-1642#Sports Med##
00544000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860120078001030300
01300181065000900194064000500203031000300208032000200211014000800213865000900221
002001300230035001000243801001300253#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01111.htm#S#c#190#9#article#40#9#^rND^sFagard^nRH#Impact of different 
sports and training on cardiac structure and function^len#Cardiol Clin#19970000#
1997#15#3#397-412#20110000#aop01111.htm#0733-8651#Cardiol Clin##
00744000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01600122010001700138012019300155030001200348065000900360064000500369031000400374
032000200378014000600380865000900386002001300395035001000408801001200418#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#191#10#article#40#10
#^rND^sGoldberg^nIJ#^rND^sMosca^nL#^rND^sPiano^nMR#^rND^sFisher^nEA#AHA Science 
Advisory: wine and your heart: a science advisory for healthcare professionals f
rom the nutrition committee, council on cardiovascular nursing of the American H
eart Association^len#Circulation#20010000#2001#103#3#472-5#20110000#aop01111.htm
#0009-7322#Circulation##
00540000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060120
06000121030002900181710000200210065000900212064000500221031000400226032000200230
014000800232865000900240002001300249#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01111.htm#S#c#192#11#article#40#11#^rND^sSzmitko^nPE#^rND^sVerma^nS#An
tiatherogenic potential of red wine: clinician update^len#J Physiol Heart Circ P
hysiol#2#20050000#2005#288#5#2023-30#20110000#aop01111.htm##
00670000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100024000880100017001120100
02000129010001700149010001700166012007600183030001200259065000900271064000500280
03100040028503200030028901400080029286500090030000200130030903500100032280100120
0332#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#193#12#a
rticle#40#12#^rND^sDi Castelnuovo^nA#^rND^sRotondo^nS#^rND^sIacoviello^nL#^rND^s
Donati^nMB#^rND^sGaetano^nG#Meta-analysis of wine and beer consumption in relati
on to vascular risk^len#Circulation#20020000#2002#105#24#2836-44#20110000#aop011
11.htm#0009-7322#Circulation##
00488000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120029001050300
00700134065000900141064000500150031000400155032000500159014000700164865000900171
002001300180035001000193801000700203#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01111.htm#S#c#194#13#article#40#13#^rND^sKaplan^nNM#Alcohol and hypert
ension^len#Lancet#19950000#1995#345#8955#1588-9#20110000#aop01111.htm#0099-5355#
Lancet##
00688000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01600122010001900138010001400157010001600171810000600187012006900193030000700262
06500090026906400050027803100040028303200050028701400070029286500090029900200130
0308035001000321801000700331#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#195#14#article#40#14#^rND^sKondo^nK#^rND^sMatsumoto^nA#^rND^sKur
ata^nH#^rND^sTanahashi^nH#^rND^sKoda^nH#^rND^sAmachi^nT#et al#Inhibition of oxid
ation of low-density lipoprotein with red wine^len#Lancet#19940000#1994#344#8930
#1152-9#20110000#aop01111.htm#0099-5355#Lancet##
00623000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040120
12300119030001600242065000900258064000500267031000400272032000200276014000700278
865000900285002001300294035001000307801001600317#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01111.htm#S#c#196#15#article#40#15#^rND^sKerry^nNL#^rND^sA
bbey^nM#Red wine and fractionated phenolic compounds prepared from red wine inhi
bit low density lipoprotein oxidation in vitro^len#Atherosclerosis#19970000#1997
#135#1#93-102#20110000#aop01111.htm#0021-9150#Atherosclerosis##
00720000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100016001080100
01800124010001600142010001700158010001400175012011700189030000800306065000900314
06400050032303100030032803200030033101400080033486500090034200200130035103500100
0364801000800374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#
S#c#197#16#article#40#16#^rND^sRosenkranz^nS#^rND^sKnirel^nD#^rND^sDietrich^nH#^
rND^sFlesch^nM#^rND^sErdmann^nE#^rND^sBöhm^nM#Inhibition of the PDGF receptor by
 red wine flavonoids provides a molecular explanation for the "French paradox"^l
en#FASEB J#20020000#2002#16#14#1952-60#20110000#aop01111.htm#0892-6638#FASEB j##
00737000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01800126010001600144010001700160010001900177810000600196012009200202030001700294
06500090031106400050032003100030032503200020032801400080033086500090033800200130
0347035001000360801001700370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#198#17#article#40#17#^rND^sMion Jr^nD#^rND^sKohlmann Jr^nO#^rND^
sMachado^nCA#^rND^sAmodeo^nC#^rND^sGomes^nMAM#^rND^sPraxedes^nJN#et al#/ Socieda
de Brasileira de Cardiologia: V Diretrizes brasileiras de hipertensão arterial^l
pt#Arq Bras Cardiol#20070000#2007#89#3#e24-e79#20110000#aop01111.htm#0066-782X#A
rq Bras Cardiol##
00609000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100018001030100
01700121010001700138012007900155030001800234710000200252065000900254064000500263
031000300268032000900271014000500280865000900285002001300294#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01111.htm#S#c#199#18#article#40#18#^rND^sBrum^
nPC#^rND^sForjaz^nCLM#^rND^sTinucci^nT#^rND^sNegrão^nCE#Adaptações agudas e crôn
icas do exercício físico no sistema cardiovascular^lpt#Rev paul Educ Fis#2#20040
000#2004#18#especial#21-3#20110000#aop01111.htm##
00659000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01600124010001600140012009900156030001500255065000900270064000500279031000400284
032000400288014000600292865000900298002001300307035001000320801001500330#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#200#19#article#40#19
#^rND^sCelotti^nE#^rND^sFerrarini^nR#^rND^sZironi^nR#^rND^sConte^nLS#Resveratrol
 content of some wines obtained from dried Valpolicella grapes: Recioto and Amar
one^len#J Chromatogr A#19960000#1996#730#1-2#47-52#20110000#aop01111.htm#0021-96
73#J Chromatogr A##
00649000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01700125010002000142012007800162030001900240065000900259064000500268031000300273
032000200276014000600278865000900284002001300293035001000306801001900316#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#201#20#article#40#20
#^rND^sBertelli^nA#^rND^sBertelli^nAA#^rND^sGozzini^nA#^rND^sGiovannini^nL#Plasm
a and tissue resveratrol concentrations and pharmacological activity^len#Drugs E
xp Clin Res#19980000#1998#24#3#133-8#20110000#aop01111.htm#0378-6501#Drugs Exp C
lin Res##
00659000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100022001030100
02000125012012900145030001300274065000900287064000500296031000300301032000200304
014000600306865000900312002001300321035001000334801001300344#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01111.htm#S#c#202#21#article#40#21#^rND^sMelo^
nRM#^rND^sMartinho Jr.^nE#^rND^sMichelini^nLC#Training-induced, pressure-lowerin
g effect in SHR: wide effects on circulatory profile of exercised and nonexercis
ed muscles^len#Hypertension#20030000#2003#42#4#851-7#20110000#aop01111.htm#0194-
911X#Hypertension##
00574000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01700122012004900139030001300188065000900201064000500210031000300215032000200218
014000700220865000900227002001300236035001000249801001300259#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01111.htm#S#c#203#22#article#40#22#^rND^sO'Kee
fe^nJH#^rND^sNelson^nJ#^rND^sHarris^nWB#Lifestyle change for coronary artery dis
ease^len#Postgrad Med#19960000#1996#99#2#89-106#20110000#aop01111.htm#0032-5481#
Postgrad Med##
00773000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070100
01800124010001600142010002100158010001700179012011800196030002100314065000900335
06400050034403100030034903200020035201400070035486500090036100200130037003500100
0383801004200393#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#
S#c#204#23#article#40#23#^rND^sMonteiro^nHL#^rND^sRolim^nLMC#^rND^sSquinca^nDA#^
rND^sSilva^nFC#^rND^sTicianeli^nCCC#^rND^sAmaral^nSL#Exercise program effectiven
ess on physical fitness, metabolic profile and blood pressure of hypertensive pa
tients^len#Rev Bras Med Esporte#20070000#2007#13#2#107-12#20110000#aop01111.htm#
1517-8692#Revista Brasileira de Medicina do Esporte##
00791000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100019001090100
01600128010001900144010001900163010002100182810000600203012014200209030001500351
06500090036606400050037503100030038003200030038301400080038686500090039400200130
0403035001000416801001500426#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#205#24#article#40#24#^rND^sBertagnolli^nM#^rND^sSchenkel^nPC#^rN
D^sCampos^nC#^rND^sMostarda^nCT#^rND^sCasarini^nDE#^rND^sBelló-Klein^nA#et al#Ex
ercise training reduces sympathetic modulation on cardiovascular system and card
iac oxidative stress in spontaneously hypertensive rats^len#Am J Hypertens#20080
000#2008#21#11#1188-93#20110000#aop01111.htm#0895-7061#Am J Hypertens##
00742000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880100017001100100
01500127010001500142010001700157010001800174012011200192030001300304065000900317
06400050032603100040033103200020033503400020033701400080033986500090034700200130
0356035001000369801001300379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#206#25#article#40#25#^rND^sVéras-Silva^nAS#^rND^sMattos^nKC#^rND
^sGava^nNS#^rND^sBrum^nPC#^rND^sNegrão^nCE#^rND^sKrieger^nEM#Low-intesity exerci
se training decreases cardiac output and hypertension in spontaneously hypertens
ive rats^len#Am J Physiol#19970000#1997#273#6#2#2627-31#20110000#aop01111.htm#00
02-9513#Am J Physiol##
00691000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
02100126010001900147012011000166030002100276065000900297064000500306031000300311
032000200314014000800316865000900324002001300333035001000346801002100356#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#207#26#article#40#26
#^rND^sGuillaume^nP#^rND^sJankowski^nM#^rND^sGianoulakis^nC#^rND^sGutkowska^nJ#E
ffect of chronic ethanol consumption on the atrial natriuretic system of spontan
eously hypertensive rats^len#Alcohol Clin Exp Res#19960000#1996#20#9#1653-61#201
10000#aop01111.htm#0145-6008#Alcohol Clin Exp Res##
00621000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100023001050120
10300128030002100231065000900252064000500261031000300266032000200269014000700271
865000900278002001300287035001000300801002100310#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01111.htm#S#c#208#27#article#40#27#^rND^sEl-Mas^nMM#^rND^s
Abdel-Rahman^nAA#Acute hemodynamic effects of ethanol in conscious spontaneously
 hypertensive and normotensive rats^len#Alcohol Clin Exp Res#19990000#1999#23#2#
285-92#20110000#aop01111.htm#0145-6008#Alcohol Clin Exp Res##
00729000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01700126010001900143010001800162010001700180810000600197012008900203030001500292
06500090030706400050031603100030032103200020032401400060032686500090033200200130
0341035001000354801001500364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#209#28#article#40#28#^rND^sDa Luz^nPL#^rND^sSerrano Jr^nCV#^rND^
sChacra^nAP#^rND^sMonteiro^nHP#^rND^sYoshida^nVM#^rND^sFurtado^nM#et al#The effe
ct of red wine on experimental atherosclerosis: lipid-independent protection^len
#Exp Mol Pathol#19990000#1999#65#3#150-9#20110000#aop01111.htm#0014-4800#Exp Mol
 Pathol##
00760000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
02400125010001700149010001700166010002000183810000600203012014700209030001700356
71000020037306500090037506400050038403100020038903200020039101400070039386500090
0400002001300409#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#
S#c#210#29#article#40#29#^rND^sDe Curtis^nA#^rND^sMurzilli^nS#^rND^sDi Castelnuo
vo^nA#^rND^sRotilio^nD#^rND^sDonati^nMB#^rND^sDe Gaetano^nG#et al#Alcohol-free r
ed wine prevents arterial thrombosis in dietary-induced hypercholesterolemic rat
s: experimental support for the 'French paradox'^len#J Thromb Haemost#2#20050000
#2005#3#2#346-50#20110000#aop01111.htm##
00528000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100021001090100
01500130012002700145030001700172710000200189065000900191064000500200031000300205
032000200208014000600210865000900216002001300225#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01111.htm#S#c#211#30#article#40#30#^rND^sVan de Wiel^nA#^r
ND^sVan Golde^nPHM#^rND^sHart^nHC#Blessings of the grape^len#Eur J Intern Med#2#
20010000#2001#12#6#484-9#20110000#aop01111.htm##
00643000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01200122010002100134012008100155030001800236065000900254064000500263031000300268
032000200271014000600273865000900279002001300288035001000301801001800311#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#212#31#article#40#31
#^rND^sWallerath^nT#^rND^sPoleo^nD#^rND^sLi^nH#^rND^sForstermann^nU#Red wine inc
reases the expression of human endothelial nitric oxide synthase^len#J Am Coll C
ardiol#20030000#2003#41#3#471-8#20110000#aop01111.htm#0735-1097#J Am Coll Cardio
l##
00675000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100021001040100
01500125010001500140010002700155010001500182810000600197012004700203030000700250
06500090025706400050026603100040027103200050027501400060028086500090028600200130
0295035001000308801000700318#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#213#32#article#40#32#^rND^sCorder^nR#^rND^sDouthwaite^nJA#^rND^s
Lees^nDM#^rND^sKhan^nNQ#^rND^sViseu Dos Santos^nAC#^rND^sWood^nEG#et al#Endothel
in-1 synthesis reduced by red wine^len#Nature#20010000#2001#414#6866#863-4#20110
000#aop01111.htm#0028-0836#Nature##
00589000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01900125012005900144030001300203065000900216064000500225031000300230032000200233
014000700235865000900242002001300251035001000264801001300274#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01111.htm#S#c#214#33#article#40#33#^rND^sSolea
s^nGJ#^rND^sDiamandis^nEP#^rND^sGoldberg^nDM#Resveratrol: a molecule whose time 
has come? And gone?^len#Clin Biochem#19970000#1997#30#2#91-113#20110000#aop01111
.htm#0009-9120#Clin Biochem##
00736000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100017001020100
01700119010001700136010001800153010001700171012011500188030001900303065000900322
06400050033103100030033603200020033901400060034186500090034700200130035603500100
0369801001900379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#
S#c#215#34#article#40#34#^rND^sLinn^nS#^rND^sCarroll^nM#^rND^sJohnson^nC#^rND^sF
ulwood^nR#^rND^sKalsbeek^nW#^rND^sBriefel^nR#High-density lipoprotein cholestero
l and alcohol consumption in US white and black adults: data from NHANES II^len#
Am J Public Health#19930000#1993#83#6#811-6#20110000#aop01111.htm#0090-0036#Am J
 Public Health##
00541000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880120078001030300
01200181065000900193064000500202031000400207032000200211014000600213865000900219
002001300228035001000241801001200251#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01111.htm#S#c#216#35#article#40#35#^rND^sToth^nPP#Cardiology patient p
age: the "good cholesterol": high-density lipoprotein^len#Circulation#20050000#2
005#111#5#89-91#20110000#aop01111.htm#0009-7322#Circulation##
00572000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050120
07700121030001300198065000900211064000500220031000300225032000200228014000700230
865000900237002001300246035001000259801001300269#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01111.htm#S#c#217#36#article#40#36#^rND^sRichey^nPA#^rND^s
Brown^nSP#Pathological versus physiological left ventricular hypertrophy: a revi
ew^len#J Sports Sci#19980000#1998#16#2#129-41#20110000#aop01111.htm#0264-0414#J 
Sports Sci##
00445000000000229000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160022000880180051001100660
01000161062000800171065000900179064000500188865000900193002001300202#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#218#37#article#40#37#^rN
D^sGottschall^nCAM#Dinâmica cardiovascular: do miócito à maratona^lpt#São Paulo#
Atheneu#20050000#2005#20110000#aop01111.htm##
00767000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01900120010001800139010001600157010001700173810000600190012012500196030001900321
06500090034006400050034903100030035403200020035701400070035986500090036600200130
0375035001000388801001900398#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#219#38#article#40#38#^rND^sBing^nOH#^rND^sBrooks^nWW#^rND^sRobin
son^nKG#^rND^sSlawsky^nMT#^rND^sHayes^nJA#^rND^sLitwin^nSE#et al#The spontaneous
ly hypertensive rat as a model of the transition from compensated left ventricul
ar hypertrophy to failure^len#J Mol Cell Cardiol#19950000#1995#27#1#383-96#20110
000#aop01111.htm#0022-2828#J Mol Cell Cardiol##
00698000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01900121010001600140010001600156012012900172030003200301710000200333065000900335
064000500344031000400349032000200353014000700355865000900362002001300371#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01111.htm#S#c#220#39#article#40#39
#^rND^sEmter^nCA#^rND^sMcCune^nSA#^rND^sSparagna^nGC#^rND^sRadin^nMJ#^rND^sMoore
^nRL#Low-intensity exercise training delays onset of decompensated heart failure
 in spontaneously hypertensive heart failure rats^len#Am J Physiol Heart Circ Ph
ysiol#2#20050000#2005#289#5#2030-8#20110000#aop01111.htm##
00752000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01700124010001700141010001900158010001400177810000600191012012200197030001300319
06500090033206400050034103100030034603200020034901400060035186500090035700200130
0366035001000379801001300389#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01111.htm#S#c#221#40#article#40#40#^rND^sSchultz^nRL#^rND^sSwallow^nJG#^rND^sW
aters^nRP#^rND^sKuzman^nJA#^rND^sRedetzke^nRA#^rND^sSaid^nS#et al#Effects of exc
essive long-term exercise on cardiac function and myocyte remodeling in hyperten
sive heart failure rats^len#Hypertension#20070000#2007#50#2#410-6#20110000#aop01
111.htm#0194-911X#Hypertension##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#o#1#1#
article#1#20110331#080915#aop01211.htm#309##
02778000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200510017301200530
02240100032002770100022003090100034003310700095003650830617004600850008010770850
02601085085007101111085002801182085003701210083064401247085000801891085002601899
08500830192508500360200808500300204411700080207407200030208211200090208511100090
2094116000902103115000902112114000902121113000902130002001302139#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#h#2#1#article#1#oa#pt#br1.1#1#
4.0#TAB#22#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110225#Co
ntracepção hormonal e sistema cardiovascular^lpt#Hormonal contraception and card
iovascular system^len#^rND^1A01^nMilena Bastos^sBrito#^rND^nFernando^sNobre#^rND
^1A01^nCarolina Sales^sVieira#Universidade de São Paulo^iA01^1Faculdade de Medic
ina de Ribeirão Preto^cSão Paulo^sSP^pBrasil#^lpt^aA contracepção hormonal é o m
étodo mais utilizado para prevenção de gestações não planejadas. A literatura te
m demonstrado associação entre risco cardiovascular e uso de hormonioterapia. A 
fim de melhorar a orientação contraceptiva para mulheres com fatores de risco pa
ra doença cardiovascular, realizamos uma revisão da literatura em relação ao ass
unto. Esta revisão descreve os dados mais recentes da literatura científica acer
ca da influência dos contraceptivos hormonais em relação a trombose venosa, arte
rial e hipertensão arterial sistêmica, doenças cada dia mais prevalentes na popu
lação feminina jovem.#^dnd^i1#^tm^lpt^kAnticoncepção^i1#^tm^lpt^kanticoncepciona
is^i1^scontraindicações, planejamento familiar#^tm^lpt^ktrombose venosa^i1#^tm^l
pt^kdoenças cardiovasculares^i1#^len^aHormonal contraception is the most widely 
used method to prevent unplanned pregnancies. The literature has shown an associ
ation between cardiovascular risk and use of hormone therapy. With the purpose o
f providing better guidelines on contraception methods for women with risk facto
rs for cardiovascular disease, we have reviewed the literature on the subject. T
his review describes the latest data from the scientific literature concerning t
he influence of hormonal contraceptives on arterial thrombosis, venous thrombosi
s and systemic high blood pressure, which are diseases that have become increasi
ngly prevalent among young females.#^dnd^i2#^tm^len^kContraception^i2#^tm^len^kc
ontraceptive agents^i2^scontraindications familyplanning (public health)#^tm^len
^kcardiovascular diseases^i2#^tm^len^kvenous thrombosis^i2#vancouv#75#20091030#3
0/10/09#20100127#27/01/10#20100323#23/03/10#aop01211.htm##
02792000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200580017301200600
02310100032002910100022003230100034003450700095003790830617004740850008010910850
02601099085007101125085002801196085003701224083064401261085000801905085002601913
08500830193908500360202208500300205811700080208807200030209611200090209911100090
2108116000902117115000902126114000902135113000902144002001302153#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#f#3#1#article#1#oa#pt#br1.1#1#
4.0#TAB#22#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110225#<b
>Contracepção hormonal e sistema cardiovascular</b>^lpt#<b>Hormonal contraceptio
n and cardiovascular system</b>^len#^rND^1A01^nMilena Bastos^sBrito#^rND^nFernan
do^sNobre#^rND^1A01^nCarolina Sales^sVieira#Universidade de São Paulo^iA01^1Facu
ldade de Medicina de Ribeirão Preto^cSão Paulo^sSP^pBrasil#^lpt^aA contracepção 
hormonal é o método mais utilizado para prevenção de gestações não planejadas. A
 literatura tem demonstrado associação entre risco cardiovascular e uso de hormo
nioterapia. A fim de melhorar a orientação contraceptiva para mulheres com fator
es de risco para doença cardiovascular, realizamos uma revisão da literatura em 
relação ao assunto. Esta revisão descreve os dados mais recentes da literatura c
ientífica acerca da influência dos contraceptivos hormonais em relação a trombos
e venosa, arterial e hipertensão arterial sistêmica, doenças cada dia mais preva
lentes na população feminina jovem.#^dnd^i1#^tm^lpt^kAnticoncepção^i1#^tm^lpt^ka
nticoncepcionais^i1^scontraindicações, planejamento familiar#^tm^lpt^ktrombose v
enosa^i1#^tm^lpt^kdoenças cardiovasculares^i1#^len^aHormonal contraception is th
e most widely used method to prevent unplanned pregnancies. The literature has s
hown an association between cardiovascular risk and use of hormone therapy. With
 the purpose of providing better guidelines on contraception methods for women w
ith risk factors for cardiovascular disease, we have reviewed the literature on 
the subject. This review describes the latest data from the scientific literatur
e concerning the influence of hormonal contraceptives on arterial thrombosis, ve
nous thrombosis and systemic high blood pressure, which are diseases that have b
ecome increasingly prevalent among young females.#^dnd^i2#^tm^len^kContraception
^i2#^tm^len^kcontraceptive agents^i2^scontraindications familyplanning (public h
ealth)#^tm^len^kcardiovascular diseases^i2#^tm^len^kvenous thrombosis^i2#vancouv
#75#20091030#30/10/09#20100127#27/01/10#20100323#23/03/10#aop01211.htm##
02899000000000649000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001200510
01790120053002300100032002830100022003150100034003370700097003710830617004680850
00801085085002601093085007101119085002801190085003701218083064401255085000801899
08500260190708500830193308500360201608500300205211700080208207200030209011200090
20931110009021021160009021111150009021201140009021291130009021380020013021470080
08902160#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#l#4#1#
article#1#^a2011#oa#pt#br1.1#1#4.0#tab#22#nd#nd#Arq. bras. cardiol#ahead#2011000
0#^f0^l0#0066-782X#20110225#Contracepção hormonal e sistema cardiovascular^lpt#H
ormonal contraception and cardiovascular system^len#^rND^1A01^nMilena Bastos^sBr
ito#^rND^nFernando^sNobre#^rND^1A01^nCarolina Sales^sVieira#^iA01^1Universidade 
de São Paulo^2Faculdade de Medicina de Ribeirão Preto^cSão Paulo^sSP^pBrasil#^lp
t^aA contracepção hormonal é o método mais utilizado para prevenção de gestações
 não planejadas. A literatura tem demonstrado associação entre risco cardiovascu
lar e uso de hormonioterapia. A fim de melhorar a orientação contraceptiva para 
mulheres com fatores de risco para doença cardiovascular, realizamos uma revisão
 da literatura em relação ao assunto. Esta revisão descreve os dados mais recent
es da literatura científica acerca da influência dos contraceptivos hormonais em
 relação a trombose venosa, arterial e hipertensão arterial sistêmica, doenças c
ada dia mais prevalentes na população feminina jovem.#^dnd^i1#^tm^lpt^kAnticonce
pção^i1#^tm^lpt^kanticoncepcionais^i1^scontraindicações, planejamento familiar#^
tm^lpt^ktrombose venosa^i1#^tm^lpt^kdoenças cardiovasculares^i1#^len^aHormonal c
ontraception is the most widely used method to prevent unplanned pregnancies. Th
e literature has shown an association between cardiovascular risk and use of hor
mone therapy. With the purpose of providing better guidelines on contraception m
ethods for women with risk factors for cardiovascular disease, we have reviewed 
the literature on the subject. This review describes the latest data from the sc
ientific literature concerning the influence of hormonal contraceptives on arter
ial thrombosis, venous thrombosis and systemic high blood pressure, which are di
seases that have become increasingly prevalent among young females.#^dnd^i2#^tm^
len^kContraception^i2#^tm^len^kcontraceptive agents^i2^scontraindications family
planning (public health)#^tm^len^kcardiovascular diseases^i2#^tm^len^kvenous thr
ombosis^i2#vancouv#75#20091030#30/10/09#20100127#27/01/10#20100323#23/03/10#aop0
1211.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-
782X2011005000022##
00413000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704017100083002001300254#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#5#1#article#230#<p><a name="
top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Contrace
p&ccedil;&atilde;o    hormonal e sistema cardiovascular</b></font></p>     ^cY#a
op01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#6#2#article#230#<p>&nbsp;</p
>     ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#7#3#article#230#<p>&nbsp;</p
>     ^cY#aop01211.htm##
00393000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704015100083002001300234#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#8#4#article#230#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Milena Bastos    Brito; Fe
rnando Nobre; Carolina Sales Vieira</b></font></p>     ^cY#aop01211.htm##
00443000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704020100083002001300284#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#9#5#article#230#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Faculdade de Medicina    de R
ibeir&atilde;o Preto - Universidade de S&atilde;o Paulo, S&atilde;o Paulo,    SP
 - Brasil</font></p>     ^cY#aop01211.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#10#6#article#230#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#11#7#article#230#<p>&nbsp;</
p>     ^cY#aop01211.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#12#8#article#230#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01211.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#13#9#article#230#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop01211.htm##
01154000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704091000085002001300995#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#14#10#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A contracep&ccedil;&atilde;
o    hormonal &eacute; o m&eacute;todo mais utilizado para preven&ccedil;&atilde
;o    de gesta&ccedil;&otilde;es n&atilde;o planejadas. A literatura tem demonst
rado    associa&ccedil;&atilde;o entre risco cardiovascular e uso de hormonioter
apia.    A fim de melhorar a orienta&ccedil;&atilde;o contraceptiva para mulhere
s com    fatores de risco para doen&ccedil;a cardiovascular, realizamos uma revi
s&atilde;o    da literatura em rela&ccedil;&atilde;o ao assunto. Esta revis&atil
de;o descreve    os dados mais recentes da literatura cient&iacute;fica acerca d
a influ&ecirc;ncia    dos contraceptivos hormonais em rela&ccedil;&atilde;o a tr
ombose venosa, arterial    e hipertens&atilde;o arterial sist&ecirc;mica, doen&c
cedil;as cada dia mais    prevalentes na popula&ccedil;&atilde;o feminina jovem.
</font></p>     ^cY#aop01211.htm##
00532000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028800085002001300373#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#15#11#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Anticoncep&ccedil;&atilde;o, anticoncepcionais / contraindica&ccedil;&otilde;es,
    planejamento familiar, trombose venosa, doen&ccedil;as cardiovasculares.</fo
nt></p> <hr size="1" noshade>     ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#16#12#article#230#<p>&nbsp;<
/p>     ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#17#13#article#230#<p>&nbsp;<
/p>     ^cY#aop01211.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#18#14#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01211.htm##
01410000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704116600085002001301251#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#19#15#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os contraceptivos    hormon
ais s&atilde;o o m&eacute;todo revers&iacute;vel mais utilizado pela popula&cced
il;&atilde;o    feminina brasileira (&plusmn; 25%) para planejamento familiar<su
p>1</sup> e    consiste da associa&ccedil;&atilde;o entre um estrog&ecirc;nio (e
m geral, etinilestradiol)    e um progestag&ecirc;nio; ou em apresenta&ccedil;&o
tilde;es de progestag&ecirc;nio    isolado sem o componente estrog&ecirc;nico. E
st&atilde;o dispon&iacute;veis    em diversas formula&ccedil;&otilde;es e vias d
e administra&ccedil;&atilde;o    (oral, intramuscular, implantes subd&eacute;rmi
cos, transd&eacute;rmica, vaginal    e associado a sistema intrauterino). Agem c
om a finalidade de bloquear a ovula&ccedil;&atilde;o,    ao inibir a secre&ccedi
l;&atilde;o dos horm&ocirc;nios fol&iacute;culo-estimulante    e luteinizante; e
spessam o muco cervical dificultando a passagem dos espermatoz&oacute;ides;    t
ornam o endom&eacute;trio n&atilde;o receptivo &agrave; implanta&ccedil;&atilde;
o    e; alteram a secre&ccedil;&atilde;o e peristalse das trompas de fal&oacute;
pio<sup>2.</sup></font></p>     ^cY#aop01211.htm##
00697000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045300085002001300538#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#20#16#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os efeitos dos    horm&ocir
c;nios sexuais femininos sobre o sistema cardiovascular t&ecirc;m sido    tema d
e bastante interesse cient&iacute;fico, porque os vasos sangu&iacute;neos    s&a
tilde;o alvo dos efeitos desses horm&ocirc;nios, uma vez que existem receptores 
   de estrog&ecirc;nio e progesterona em todas as camadas constituintes dos vaso
s    sangu&iacute;neos.</font></p>     ^cY#aop01211.htm##
01118000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087400085002001300959#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#21#17#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">V&aacute;rios estudos    ep
idemiol&oacute;gicos t&ecirc;m demonstrado uma associa&ccedil;&atilde;o clara   
 entre o uso de contraceptivos orais combinados (COC) e o aumento de risco para 
   trombose venosa e arterial<sup>3-5</sup>. Apesar de as tromboses venosas e ar
teriais    possu&iacute;rem alguns fatores de riscos em comum para sua ocorr&eci
rc;ncia,    sabe-se que a estase sangu&iacute;nea e a hipercoagulabilidade repre
sentam os    principais fatores etiopatog&ecirc;nicos para o desencadeamento do 
tromboembolismo    venoso (TEV), enquanto a les&atilde;o do endot&eacute;lio rep
resenta a principal    determinante da trombose arterial (TA). Vale ressaltar qu
e a TA &eacute; menos    frequente na idade reprodutiva que o TEV (1 caso de TA 
para cada 5-10 casos    de TEV)<sup>6</sup>.</font></p>     ^cY#aop01211.htm##
01615000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704137100085002001301456#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#22#18#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O objetivo desta    revis&a
tilde;o &eacute; a discuss&atilde;o dos principais efeitos dos esteroides    sex
uais sobre os fatores de risco para doen&ccedil;a cardiovascular e expor    as e
vid&ecirc;ncias cient&iacute;ficas dispon&iacute;veis para prescri&ccedil;&atild
e;o    dos m&eacute;todos contraceptivos hormonais em portadoras de trombose ven
osa    e arterial e hipertens&atilde;o arterial sist&ecirc;mica. A maioria dos a
rtigos    publicados sobre contracep&ccedil;&atilde;o e doen&ccedil;as cardiovas
culares    &eacute; de estudos observacionais ou ensaios cl&iacute;nicos de desf
echos intermedi&aacute;rios,    o que diminui a for&ccedil;a de evid&ecirc;ncia 
das recomenda&ccedil;&otilde;es;    por&eacute;m, atualmente, s&atilde;o as melh
ores evid&ecirc;ncias dispon&iacute;veis    para guiar a pr&aacute;tica cl&iacut
e;nica. O conhecimento dessas informa&ccedil;&otilde;es    pelos cardiologistas 
&eacute; imperativo, j&aacute; que muitas vezes s&atilde;o    eles que indicam o
u contraindicam os m&eacute;todos hormonais para pacientes    com risco cardiova
scular a pedido dos ginecologistas. A abordagem ser&aacute;    feita de acordo c
om os crit&eacute;rios de elegibilidade da Organiza&ccedil;&atilde;o    Mundial 
de Sa&uacute;de (OMS)<sup>7</sup> (<a href="#t1">tab. 1</a>).</font></p>     ^cY
#aop01211.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#23#19#article#230#<p><a name
="t1"></a></p>     ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#24#20#article#230#<p>&nbsp;<
/p>     ^cY#aop01211.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#25#21#article#230#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01211t01.jpg"></p>     ^cY#aop
01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#26#22#article#230#<p>&nbsp;<
/p>     ^cY#aop01211.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#27#23#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Contracep&ccedil;&atilde
;o    hormonal e trombose venosa</b></font></p>     ^cY#aop01211.htm##
01043000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079900085002001300884#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#28#24#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O etinilestradiol    (EE) i
nduz altera&ccedil;&otilde;es significativas no sistema de coagula&ccedil;&atild
e;o,    culminando com aumento da gera&ccedil;&atilde;o de trombina. Ocorre tamb
&eacute;m    aumento dos fatores de coagula&ccedil;&atilde;o (fibrinog&ecirc;nio
, VII, VIII,    IX, X, XII e XIII) e redu&ccedil;&atilde;o dos inibidores natura
is da coagula&ccedil;&atilde;o    (prote&iacute;na S e antitrombina), produzindo
 um efeito pr&oacute;-coagulante    leve<sup>8,9</sup>. Esses efeitos s&atilde;o
 mais claramente observados em testes    que avaliam globalmente a hemostasia, q
ue mostram resist&ecirc;ncia adquirida    &agrave; prote&iacute;na C e aumento d
e gera&ccedil;&atilde;o de trombina<sup>10</sup>.</font></p>     ^cY#aop01211.ht
m##
00887000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064300085002001300728#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#29#25#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O risco de TEV    &eacute; 
dependente da dosagem de EE. A alta dosagem de EE (<u>&gt;</u>50 mcg)    est&aac
ute; associada a um aumento de duas vezes no risco de TEV quando comparada    &a
grave; baixa dosagem desse horm&ocirc;nio (&lt;50 mcg)<sup>9,11,12</sup>.    Rec
entemente, publicou-se que as formula&ccedil;&otilde;es contendo 20 mcg de    EE
 foram associadas menor risco tromb&oacute;tico (OR: 0,8; IC95%: 0,5-1,2)    qua
ndo comparadas &agrave;s prepara&ccedil;&otilde;es com 30 mcg de EE, por&eacute;
m    sem diferen&ccedil;a significativa<sup>11</sup>.</font></p>     ^cY#aop0121
1.htm##
01104000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086000085002001300945#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#30#26#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Inicialmente, achava-se    
que a trombose era resultado apenas da dose de estrog&ecirc;nio utilizado, o    
que culminou na redu&ccedil;&atilde;o da dose de EE dos contraceptivos (de 150  
  mcg para 15-20 mcg). Por&eacute;m, em 1995, demonstrou-se que COC contendo pro
gestag&ecirc;nios    de terceira gera&ccedil;&atilde;o (gestodeno, desogestrel) 
associavam-se a um    risco duas vezes maior de trombose do que os que continham
 progestag&ecirc;nios    de segunda gera&ccedil;&atilde;o (levonorgestrel)<sup>4
,13</sup>. Dessa forma,    o tipo de progestag&ecirc;nio associado ao estrog&eci
rc;nio, e n&atilde;o s&oacute;    a dose deste &uacute;ltimo, tornou-se motivo d
e estudos sobre o papel dos progestag&ecirc;nios    na hemostasia e na determina
&ccedil;&atilde;o da trombose.</font></p>     ^cY#aop01211.htm##
01112000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086800085002001300953#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#31#27#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os progestag&ecirc;nios    
formam um grupo de esteroides que, apesar de possu&iacute;rem a caracter&iacute;
stica    comum de se ligarem aos receptores de progesterona, t&ecirc;m efeitos s
ist&ecirc;micos    diferentes e que s&atilde;o mediados n&atilde;o s&oacute; pel
a afinidade aos    pr&oacute;prios receptores de progesterona, mas principalment
e pela capacidade    de liga&ccedil;&atilde;o com os receptores de outros estero
ides, como os estrog&ecirc;nios,    androg&ecirc;nios, glicocorticoides e minera
locorticoides<sup>14</sup>. Essa    capacidade de ligar-se a outros receptores d
e esteroides, bem como o perfil    de afinidade por cada um desses receptores po
dem resultar em riscos diferentes    para a trombose, a depender do progestag&ec
irc;nio associado ao estrog&ecirc;nio.</font></p>     ^cY#aop01211.htm##
03340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704309600085002001303181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#32#28#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Contraceptivos    orais com
binados com progestag&ecirc;nios de terceira gera&ccedil;&atilde;o    est&atilde
;o associados ao desenvolvimento de resist&ecirc;ncia adquirida &agrave;    prot
e&iacute;na C ativada mais pronunciada<sup>15</sup> e a uma tend&ecirc;ncia    d
e produzir n&iacute;veis mais altos de fatores de coagula&ccedil;&atilde;o    e 
n&iacute;veis mais baixos de anticoagulantes naturais, quando comparados a    CO
C contendo progestag&ecirc;nio de segunda gera&ccedil;&atilde;o<sup>10,16,17</su
p>.    Esses achados poderiam explicar as observa&ccedil;&otilde;es epidemiol&oa
cute;gicas    de risco aumentado para TEV em usu&aacute;rias de COC que cont&eci
rc;m progestag&ecirc;nios    de terceira gera&ccedil;&atilde;o, j&aacute; que a 
resist&ecirc;ncia &agrave;    a&ccedil;&atilde;o da prote&iacute;na C (adquirida
 ou herdada) &eacute; um marcador    importante para risco aumentado de TEV<sup>
18</sup>. Outro achado &eacute; que    a hiperfibrin&oacute;lise &eacute; menos 
acentuada em usu&aacute;rias de COC    com progestag&ecirc;nios de terceira gera
&ccedil;&atilde;o do que aqueles com    os de segunda gera&ccedil;&atilde;o<sup>
16</sup>. Outros progestag&ecirc;nios    tamb&eacute;m foram estudados em rela&c
cedil;&atilde;o ao risco de trombose    quando associados ao EE. O estudo mais r
ecente, coordenado pela Universidade    de Leiden, Holanda, conduzido para avali
ar os diferentes progestag&ecirc;nios    e risco para trombose venosa &#91;<i>Mu
ltiple Environmental and Genetics Assessment    of Risk Factors for Venous Throm
bosis</i> (MEGA)&#93;<sup>11</sup> confirmou    associa&ccedil;&atilde;o entre o
 tipo de progestag&ecirc;nio e risco para trombose,    por&eacute;m evidenciou u
ma diferen&ccedil;a menos pronunciada que previamente    descrita entre os difer
entes progestag&ecirc;nios. Algumas formula&ccedil;&otilde;es,    contudo, apres
entaram uma amostra pequena para uma conclus&atilde;o definitiva.    comparado a
 n&atilde;o usu&aacute;rias de contraceptivos hormonais, o COC contendo    levon
orgestrel foi associado a um risco para trombose venosa quatro vezes maior    (O
R:3,6; 95%IC: 2,9-4,6). O levonorgestrel foi o progestag&ecirc;nio associado    
ao menor risco para trombose, seguido do gestodeno (OR:5,6; 95%IC:3,7-8,4);    d
rospirenona (OR: 6,3; 95%IC: 2,9-13,7); acetato de ciproterona (OR: 6,8; 95%IC: 
   4,7-10); desogestrel (OR: 7,3; 95%IC: 5,3-10). Assim, considerando o risco de
    TEV, o levonorgestrel oferece menor risco, enquanto os demais progestag&ecir
c;nios    parecem ter riscos semelhantes, superior a associa&ccedil;&atilde;o co
m levonorgestrel,    provavelmente porque este &uacute;ltimo &eacute; mais andro
g&ecirc;nico que    os demais, uma vez que progestag&ecirc;nios androg&ecirc;nic
os (levonorgestrel)    est&atilde;o associados a menor resist&ecirc;ncia &agrave
; prote&iacute;na C    do que os com menor pot&ecirc;ncia androg&ecirc;nica (ges
todeno e desogestrel)    e os antiandrog&ecirc;nicos (acetato de ciproterona e d
rosperinona)<sup>19</sup>.</font></p>     ^cY#aop01211.htm##
01233000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098900085002001301074#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#33#29#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Apesar dos dados    apresen
tados, isso n&atilde;o quer dizer que se deva sempre orientar o uso de    COC co
ntendo levonorgestrel, mas que se conhe&ccedil;am os riscos de TEV, bem    como 
os benef&iacute;cios adicionais de cada progestag&ecirc;nio, para uma prescri&cc
edil;&atilde;o    adequada aos anseios e caracter&iacute;sticas cl&iacute;nicas 
da paciente<sup>20</sup>.    Al&eacute;m disso, o ciclo grav&iacute;dico-puerper
al apresenta maior risco    de TEV do que qualquer formula&ccedil;&atilde;o cont
raceptiva apresentada<sup>21</sup>.    Entretanto, quando se estima que h&aacute
; no mundo cerca de 100 milh&otilde;es    de mulheres em uso de contracep&ccedil
;&atilde;o hormonal<sup>22</sup>, o conhecimento    de op&ccedil;&otilde;es meno
s trombog&ecirc;nicas torna-se de grande import&acirc;ncia,    especialmente em 
mulheres com outros fatores de risco associados para desenvolvimento    de TEV.<
/font></p>     ^cY#aop01211.htm##
00917000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067300085002001300758#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#34#30#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Quando administrados    iso
ladamente, os progestag&ecirc;nios afetam de forma m&iacute;nima o sistema    de
 coagula&ccedil;&atilde;o. Um aumento modesto e n&atilde;o significativo no    r
isco para TEV tem sido relatado em usu&aacute;rias de p&iacute;lulas contracepti
vas    somente de progestag&ecirc;nio (PP)<sup>23,24</sup>. Os progestag&ecirc;n
ios    isolados n&atilde;o s&atilde;o associados a altera&ccedil;&otilde;es marc
antes    nos par&acirc;metros de coagula&ccedil;&atilde;o ou fibrin&oacute;lise,
 podendo,    por isso, ser indicados para pacientes com risco para TEV<sup>7</su
p>.</font></p>     ^cY#aop01211.htm##
01120000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087600085002001300961#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#35#31#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Um estudo randomizado,    d
uplo-cego, comparou os efeitos no sistema hemost&aacute;tico de duas PP (desoges
trel    <i>versus</i> levonorgestrel) e mostrou que ambas apresentaram efeito fa
vor&aacute;vel    sobre este sistema<sup>25</sup>. Outro estudo recente tamb&eac
ute;m mostrou    resultados favor&aacute;veis na hemostasia em usu&aacute;rias d
as PP (desogestrel    <i>vs</i> levonorgestrel), com redu&ccedil;&atilde;o da re
sist&ecirc;ncia &agrave;    prote&iacute;na C ativada e aumento da prote&iacute;
na S15. Dessa forma, os    efeitos negativos dependentes do tipo de progestag&ec
irc;nio provocados pelos    COC sobre os par&acirc;metros de coagula&ccedil;&ati
lde;o e anticoagula&ccedil;&atilde;o    n&atilde;o foram observados com o uso de
 PP, seja de levonorgestrel ou de desogestrel.</font></p>     ^cY#aop01211.htm##
00853000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060900085002001300694#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#36#32#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nos &uacute;ltimos    20 an
os, t&ecirc;m sido desenvolvidos implantes subd&eacute;rmicos que mant&ecirc;m  
  libera&ccedil;&atilde;o de baixas doses de progestag&ecirc;nios. No Brasil,   
 dispomos do implante liberador de etonogestrel (Implanon<sup>&reg;</sup>, NV   
 Organon, Oss, <i>The Netherlands</i>). As vari&aacute;veis hemost&aacute;ticas 
   analisadas ou n&atilde;o se modificaram, ou sofreram altera&ccedil;&otilde;es
    discretas, sempre dentro dos valores de normalidade para os ensaios realizad
os<sup>26-29</sup>.</font></p>     ^cY#aop01211.htm##
03132000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704288800085002001302973#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#37#33#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">com rela&ccedil;&atilde;o  
  &agrave; via de administra&ccedil;&atilde;o, apesar da via transd&eacute;rmica
    em usu&aacute;rias de terapia de reposi&ccedil;&atilde;o hormonal (TH), dura
nte    a menopausa, parecer n&atilde;o aumentar o risco de TEV<sup>30</sup>, ess
es    dados n&atilde;o podem ser extrapolados para contracep&ccedil;&atilde;o, e
specialmente    porque em contracep&ccedil;&atilde;o &eacute; utilizado o EE, qu
e tem uma pot&ecirc;ncia    superior aos estrog&ecirc;nios utilizados em TH. Em 
novembro de 2005, o <i>US    Food and Drug Administration (FDA)</i> divulgou um 
comunicado de que o adesivo    contendo 0,75 mg + 6 mg de norelgestromin (Ortho-
Evra<sup>&reg;</sup> 20 mcg    de EE + 150 mg de norelgestrolmin/dia) liberava 6
0% a mais do que a quantidade    total de EE dispon&iacute;vel em um COC de 35 m
cg de EE<sup>31</sup> , o que    poderia alterar a frequ&ecirc;ncia de eventos a
dversos s&eacute;rios, como o    TEV. Posteriormente, foi realizado um estudo qu
e demonstrou que o adesivo com    libera&ccedil;&atilde;o di&aacute;ria de 20 mc
g de EE tem incid&ecirc;ncia de    TEV similar a de um COC com 35 mcg de EE, o q
ue significa que n&atilde;o devemos    usar esse m&eacute;todo para pacientes de
 alto risco para TEV, ao contr&aacute;rio    de TH transd&eacute;rmica<sup>32</s
up>. Outros m&eacute;todos de contracep&ccedil;&atilde;o    hormonal combinada n
&atilde;o oral, como o anel vaginal e os injet&aacute;veis    mensais, foram tes
tados quanto aos seus efeitos na hemostasia. O anel (15 mcg    de EE + 120 mcg d
e etonogestrel/dia) foi comparado ao COC contendo 30 mcg de    EE + 150 mcg de l
evonorgestrel, mostrando altera&ccedil;&otilde;es similares    na hemostasia<sup
>33</sup>. Recentemente, um estudo comparou o efeito das contracep&ccedil;&otild
e;es    combinadas oral e vaginal sobre as vari&aacute;veis hemost&aacute;ticas 
e observou    um efeito pr&oacute;-coagulante devido ao EE, independentemente da
 via de administra&ccedil;&atilde;o<sup>34</sup>.    Entretanto, ainda s&atilde;
o necess&aacute;rios estudos para avaliar o risco    de TEV com esse contracepti
vo vaginal. Os injet&aacute;veis combinados provocaram    menor impacto na hemos
tasia que as prepara&ccedil;&otilde;es orais<sup>35</sup>,    diferentemente de 
outras formula&ccedil;&otilde;es n&atilde;o orais (adesivo    e anel), provavelm
ente porque possuem estrog&ecirc;nios naturais (valerato de    estradiol ou cipi
onato de estradiol) em sua composi&ccedil;&atilde;o, em vez    do EE. Em termos 
de risco para trombose, um trabalho com amostra pequena para    esse desfecho mo
strou risco pequeno ou ausente de TEV, IAM e AVE<sup>36</sup>,    por&eacute;m a
inda n&atilde;o temos uma resposta definitiva se os combinados    injet&aacute;v
eis apresentam, de fato, aus&ecirc;ncia de risco para TEV.</font></p>     ^cY#ao
p01211.htm##
00643000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039900085002001300484#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#38#34#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Normalmente, os    eventos 
tromboemb&oacute;licos ocorrem dentro do primeiro ano de uso do contraceptivo   
 hormonal, especialmente ap&oacute;s o quarto m&ecirc;s do in&iacute;cio do uso<
sup>3,9,11</sup>.    Por&eacute;m, ap&oacute;s um ano, o tempo de uso de COC n&a
tilde;o altera o    risco para TEV<sup>3,9</sup>.</font></p>     ^cY#aop01211.ht
m##
01486000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704124200085002001301327#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#39#35#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em resumo, para    paciente
 com trombose pr&eacute;via ou trombofilia (herdada ou adquirida) &eacute;    pr
oscrito o uso de contracep&ccedil;&atilde;o hormonal combinada, independente    
da via administrada. Por outro lado, os progestag&ecirc;nios isolados (em qualqu
er    via de administra&ccedil;&atilde;o) e os m&eacute;todos n&atilde;o hormona
is    (condom e dispositivo intrauterino com cobre) s&atilde;o permitidos segund
os    crit&eacute;rios da OMS (<a href="/img/revistas/abc/2011nahead/aop01211t02
.jpg">tab. 2</a>). Em pacientes    de risco para trombose venosa (obesas, presen
&ccedil;a de s&iacute;ndrome metab&oacute;lica,    tabagistas, idade superior a 
40 anos e antecedente familiar de trombose) &eacute;    prefer&iacute;vel o uso 
de contracep&ccedil;&atilde;o com progestag&ecirc;nios    isolados, apesar de o 
uso de EE ser permitido (com exce&ccedil;&atilde;o de    tabagistas com idade <u
>&gt;</u> 35 anos). Nessas pacientes de risco &eacute;    prefer&iacute;vel o us
o de contracep&ccedil;&atilde;o combinada com levonorgestrel,    uma vez que ess
e progestag&ecirc;nio &eacute; o que apresenta menor risco de    TEV quando asso
ciado ao EE.</font></p>     ^cY#aop01211.htm##
00392000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014800085002001300233#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#40#36#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Contracep&ccedil;&atilde
;o    hormonal e trombose arterial</b></font></p>     ^cY#aop01211.htm##
00987000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704074300085002001300828#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#41#37#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Apesar de a ocorr&ecirc;nci
a    de TA ser infrequente em mulheres jovens, as mudan&ccedil;as comportamentai
s    - baixa frequ&ecirc;ncia de alimentos ricos em fibras, aumento da propor&cc
edil;&atilde;o    de gorduras saturadas e a&ccedil;&uacute;cares da dieta, assoc
iadas a um estilo    de vida sedent&aacute;rio - t&ecirc;m aumentado os riscos p
ara o seu aparecimento    durante a vida reprodutiva<sup>37</sup>. Dessa forma, 
em mulheres com fatores    de risco para doen&ccedil;a cardiovascular (DCV) (com
o fumantes, hipertensas,    obesas, portadoras de hipercolesterolemia ou diabete
 melito) os contraceptivos    hormonais devem ser prescritos com cautela.</font>
</p>     ^cY#aop01211.htm##
00706000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046200085002001300547#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#42#38#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Assim como para    TEV, o u
so de COC tamb&eacute;m est&aacute; associado &agrave; eleva&ccedil;&atilde;o   
 do risco para TA<sup>38-40</sup>. Esse risco est&aacute; diretamente relacionad
o    &agrave; dose do componente estrog&ecirc;nico, por&eacute;m mesmo em usu&aa
cute;rias    das p&iacute;lulas de baixa dosagem (EE&lt;50 mcg) observou-se aume
nto desse    risco<sup>41</sup>.</font></p>     ^cY#aop01211.htm##
00790000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054600085002001300631#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#43#39#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O uso de COC de    baixa do
sagem (EE&lt;50 mcg) aumenta o risco de trombose arterial em aproximadamente    
duas vezes entre usu&aacute;rias do m&eacute;todo, mesmo ap&oacute;s a corre&cce
dil;&atilde;o    das vari&aacute;veis confundidoras para fatores de risco de doe
n&ccedil;a cardiovascular<sup>42</sup>.    Ao contr&aacute;rio da TEV, o tipo de
 progestag&ecirc;nio associado ao EE n&atilde;o    modifica de forma significati
va o risco de TA<sup>38,40,41</sup>.</font></p>     ^cY#aop01211.htm##
01369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704112500085002001301210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#44#40#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O risco de IAM    entre usu
&aacute;rias de COC aumenta com a coexist&ecirc;ncia de fatores de    risco para
 DCV, como tabagismo, e esse efeito &eacute; mais pronunciado em mulheres    aci
ma dos 35 anos de idade. Em mulheres abaixo dos 35 anos e usu&aacute;rias    de 
COC, a incid&ecirc;ncia de IAM em tabagistas (<u>&gt;</u> 20 cigarros/dia)    &e
acute; 10 vezes maior que em n&atilde;o fumantes (3,5 por 100.000 <i>vs.</i>    
0,3 por 100.000, respectivamente)<sup>38</sup>. Em mulheres acima dos 35 anos   
 de idade em uso de COC, o risco para IAM &eacute; significativamente maior tant
o    em fumantes (40 por 100.000) quanto em n&atilde;o fumantes (3 por 100.000)<
sup>38</sup>.    Assim, idade superior a 35 anos e tabagismo merecem sempre cuid
ado especial    para escolha do contraceptivo. Da mesma forma que a idade e o ta
bagismo, outras    doen&ccedil;as que aumentam risco para DCV (como diabetes, hi
pertens&atilde;o)    tamb&eacute;m potencializam o risco de IAM em usu&aacute;ri
as de contracep&ccedil;&atilde;o    hormonal combinada.</font></p>     ^cY#aop01
211.htm##
00651000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040700085002001300492#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#45#41#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Dessa forma, pensando    em
 n&atilde;o aumentar de forma significativa o risco para IAM, at&eacute; o    pr
esente momento, o que importa &eacute; a dosagem do EE ser menor que 50 mcg    e
 identificar fatores de risco para DCV previamente &agrave; prescri&ccedil;&atil
de;o    do m&eacute;todo contraceptivo<sup>7,38-41</sup>.</font></p>     ^cY#aop
01211.htm##
01153000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704090900085002001300994#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#46#42#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Acidente vascular    encef&
aacute;lico (AVE) &eacute; outra doen&ccedil;a arterial bastante rara    em mulh
eres na idade reprodutiva<sup>43</sup>; entretanto, observa-se maior    incid&ec
irc;ncia de casos entre usu&aacute;rias de COC comparadas a n&atilde;o    usu&aa
cute;rias<sup>44,45</sup>. Ao analisar os artigos epidemiol&oacute;gicos    publ
icados, Heinemann<sup>46</sup> concluiu que altas doses de EE (<u>&gt;</u>50    
mcg) eram associadas a maior risco de AVE comparadas &agrave;s formula&ccedil;&o
tilde;es    com 50 mcg de EE (OR:5,3; IC95%: 2,6-11 <i>vs</i> OR: 1,53; IC95%: 0
,71-3,31)<sup>47</sup>.    Entretanto, os estudos n&atilde;o demonstraram difere
n&ccedil;a entre as formula&ccedil;&otilde;es    dos progestag&ecirc;nios de seg
unda e terceira gera&ccedil;&otilde;es<sup>47,48</sup>,    assim como para IAM.<
/font></p>     ^cY#aop01211.htm##
00833000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058900085002001300674#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#47#43#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Mais recentemente,    foi p
ublicado um estudo multic&ecirc;ntrico, caso-controle envolvendo 1.182    mulher
es saud&aacute;veis entre 18 e 49 anos de idade, que estimou o risco para    AVE
 2,3 vezes maior entre usu&aacute;rias de COC contendo &lt; 50 mcg de EE    (OR:
 2,3; IC95%: 1,6-3,3) comparadas a usu&aacute;rias de m&eacute;todos n&atilde;o 
   hormonais<sup>40</sup>. O risco para AVE, assim como nos estudos anteriores, 
   n&atilde;o foi relacionado ao progestag&ecirc;nio associado<sup>40,45</sup>.<
/font></p>     ^cY#aop01211.htm##
01552000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704130800085002001301393#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#48#44#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Estudos revelam    que a mi
gr&acirc;nea com aura duplica o risco para AVE comparada &agrave; sem    aura<su
p>49</sup>. Por ser comum em mulheres no per&iacute;odo reprodutivo<sup>50</sup>
,    deve-se estar atento &agrave; presen&ccedil;a dessa doen&ccedil;a (<a href=
"/img/revistas/abc/2011nahead/aop01211t02.jpg">tab.    2</a>). Ap&oacute;s a def
ini&ccedil;&atilde;o pelo neurologista das manifesta&ccedil;&otilde;es    neurol
&oacute;gicas que caracterizam a migr&acirc;nea, se houver quadro cl&iacute;nico
    de aura, os contraceptivos contendo EE s&atilde;o contraindicados em qualque
r    idade da vida reprodutiva feminina. Em rela&ccedil;&atilde;o aos progestag&
ecirc;nios    isolados e migr&acirc;nea, os estudos s&atilde;o muito escassos e 
a maioria    n&atilde;o distingue as formula&ccedil;&otilde;es orais, se combina
da ou de    progestag&ecirc;nio isolado<sup>51</sup>. Mas, na aus&ecirc;ncia de 
outros fatores    de risco para AVE, a OMS libera seu uso em mulheres com migr&a
circ;nea, com    exce&ccedil;&atilde;o &agrave;quelas que apresentarem a doen&cc
edil;a durante    o uso desse contraceptivo, quando esse deve ser suspenso<sup>7
</sup> (<a href="/img/revistas/abc/2011nahead/aop01211t02.jpg">tab.    2</a>).</
font></p>     ^cY#aop01211.htm##
00558000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031400085002001300399#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#49#45#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Apesar da baixa    incid&ec
irc;ncia de TA durante a vida reprodutiva, o que dificulta conclus&otilde;es    
fidedignas acerca dos estudos dispon&iacute;veis, n&atilde;o h&aacute; dados    
que indiquem a via mais segura<sup>52</sup>.</font></p>     ^cY#aop01211.htm##
01481000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704123700085002001301322#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#50#46#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">J&aacute; no caso    dos pr
ogestag&ecirc;nios isolados, a OMS &eacute; cautelosa na prescri&ccedil;&atilde;
o    desses na via injet&aacute;vel para mulheres com TA pr&eacute;via (<a href=
"/img/revistas/abc/2011nahead/aop01211t02.jpg">tab.    2</a>). O acetato de medr
oxiprogesterona de dep&oacute;sito (AMPD) inibe a ovula&ccedil;&atilde;o    e oc
asiona um decl&iacute;nio nos n&iacute;veis de estradiol, induzindo hipoestrogen
ismo<sup>53</sup>;    dessa forma, quando administrado de forma prolongada, pode
 alterar a fun&ccedil;&atilde;o    vascular<sup>54,55</sup>. Al&eacute;m disso, 
foram observadas em estudos longitudinais    e transversais eleva&ccedil;&atilde
;o nos n&iacute;veis de LDL e redu&ccedil;&atilde;o    do HDL colesterol em usu&
aacute;rias de AMPD, altera&ccedil;&otilde;es epidemiologicamente    associadas 
a DCV. Entretanto, essas altera&ccedil;&otilde;es no lipidograma    n&atilde;o f
oram relacionadas a eventos cl&iacute;nicos adversos<sup>56</sup>.    J&aacute; 
o implante, o sistema intrauterino liberador de levonorgestrel e PP    n&atilde;
o foram associados a efeitos adversos sobre o perfil lip&iacute;dico<sup>7,57-59
</sup>.</font></p>     ^cY#aop01211.htm##
01485000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704124100085002001301326#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#51#47#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Outra complica&ccedil;&atil
de;o    vascular arterial rara durante a vida reprodutiva, por&eacute;m com prog
n&oacute;stico    ruim, &eacute; a doen&ccedil;a perif&eacute;rica arterial (DPA
), com elevada    incid&ecirc;ncia de oclus&atilde;o vascular, amputa&ccedil;&at
ilde;o e morte.    Observou-se um risco tr&ecirc;s vezes maior para DPA entre us
u&aacute;rias de    COC comparadas a n&atilde;o usu&aacute;rias (OR:3,8; IC95%: 
2,4-5,8)<sup>60</sup>;    e esse risco foi maior, assim como nas demais doen&cce
dil;as arteriais, na presen&ccedil;a    de outros fatores de risco para DCV. Qua
ndo comparadas as tr&ecirc;s gera&ccedil;&otilde;es    das p&iacute;lulas contra
ceptivas separadamente <i>vs</i> n&atilde;o usu&aacute;rias    de contracep&cced
il;&atilde;o hormonal, encontrou-se um risco muito elevado    nas formula&ccedil
;&otilde;es com progestag&ecirc;nios de primeira gera&ccedil;&atilde;o    (lines
trenol e noretisterona) (OR:8,7, IC95%:3,6-21,3) e uma eleva&ccedil;&atilde;o   
 em torno de tr&ecirc;s vezes para os progestag&ecirc;nios de segunda (OR: 2,6; 
   IC95%: 1,4-4,9) e terceira gera&ccedil;&otilde;es (OR:3,0, IC95%: 1,4-6,6)<su
p>60</sup>.</font></p>     ^cY#aop01211.htm##
00672000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042800085002001300513#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#52#48#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As PP parecem n&atilde;o   
 aumentar o risco para DCV<sup>61,62</sup>. Uma meta-an&aacute;lise publicada   
 recentemente n&atilde;o encontrou associa&ccedil;&atilde;o significativa entre 
   contraceptivos contendo apenas progestag&ecirc;nios e AVE (OR: 0,96; IC95%:  
  0,70-1,31), apesar da baixa qualidade dos artigos selecionados<sup>62</sup>.</
font></p>     ^cY#aop01211.htm##
00914000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067000085002001300755#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#53#49#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Dessa forma, em    mulheres
 portadoras de cardiopatia isqu&ecirc;mica, AVE, migr&acirc;nea com    &aacute;u
rea ou com m&uacute;ltiplos fatores de risco para DCV (&gt; 35 anos    de idade,
 diab&eacute;ticas, tabagistas e hipertensas), deve-se optar por m&eacute;todos 
   contraceptivos n&atilde;o hormonais ou contraceptivos apenas de progestag&eci
rc;nio    (<a href="/img/revistas/abc/2011nahead/aop01211t02.jpg">tab. 2</a>). D
entre estes &uacute;ltimos,    os mais indicados s&atilde;o as PP, o implante li
berador de etonogestrel e o    sistema intrauterino liberador de levonorgestrel.
</font></p>     ^cY#aop01211.htm##
00424000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704018000085002001300265#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#54#50#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Contracep&ccedil;&atilde
;o    hormonal e hipertens&atilde;o arterial sist&ecirc;mica (HAS)</b></font></p
>     ^cY#aop01211.htm##
00978000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073400085002001300819#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#55#51#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As subst&acirc;ncias    pre
sentes nos COC tentam reproduzir as propriedades dos esteroides end&oacute;genos
.    Entretanto, o EE, pela sua elevada pot&ecirc;ncia biol&oacute;gica comparad
o    ao estradiol (mil vezes mais potente), exacerba a produ&ccedil;&atilde;o de
    angiotensinog&ecirc;nio hep&aacute;tico, que, por sua vez, causa eleva&ccedi
l;&atilde;o    da press&atilde;o arterial pelo sistema renina-angiotensina-aldos
terona<sup>63</sup>.    Al&eacute;m disso, o progestag&ecirc;nio associado ao EE
 presente nos COC &eacute;    similar, por&eacute;m n&atilde;o reproduz todas as
 caracter&iacute;sticas da    progesterona natural<sup>64</sup>.</font></p>     
^cY#aop01211.htm##
02108000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704186400085002001301949#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#56#52#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Apesar do desenvolvimento  
  de novos progestag&ecirc;nios somente a drospirenona mant&eacute;m o efeito   
 antimineralocorticoide<sup>65</sup> da progesterona natural; mesmo assim, ainda
    n&atilde;o &eacute; poss&iacute;vel determinar efeitos ben&eacute;ficos na P
A    em usu&aacute;rias hipertensas dessa formula&ccedil;&atilde;o anticonceptiv
a<sup>66</sup>.    Essa conclus&atilde;o difere da observada para TH na p&oacute
;s-menopausa, em    que o composto (drospirenona e estradiol) foi associado &agr
ave; redu&ccedil;&atilde;o    nos n&iacute;veis press&oacute;ricos em hipertensa
s<sup>67</sup>, o que n&atilde;o    se aplica para associa&ccedil;&atilde;o da d
rospirenona com EE na anticoncep&ccedil;&atilde;o.    Em contracep&ccedil;&atild
e;o, um artigo em normotensas mostrou que a PA reduziu    4 mmHg nas usu&aacute;
rias de EE+drospirenona em avalia&ccedil;&atilde;o pontual    ap&oacute;s seis m
eses de uso da medica&ccedil;&atilde;o<sup>68</sup>. Outro    artigo tamb&eacute
;m em avalia&ccedil;&atilde;o pontual de 160 mulheres normotensas    comparou os
 COC contendo drospirenona <i>versus</i> gestodeno mostrou redu&ccedil;&atilde;o
    da PA no grupo drospirenona ao longo do trabalho, por&eacute;m sem diferen&c
cedil;a    entre os grupos na avalia&ccedil;&atilde;o final, ap&oacute;s 12 mese
s<sup>69</sup>.    N&atilde;o h&aacute;, contudo, dados de seguran&ccedil;a dess
e contraceptivo    em hipertensas. Dessa forma, a drospirenona &eacute; melhor p
ara PA, por&eacute;m    seu uso com EE carece de dados de seguran&ccedil;a em po
rtadoras de HAS. Podemos    concluir que, at&eacute; o presente momento, n&atild
e;o h&aacute; diferen&ccedil;a    de seguran&ccedil;a entre os progestag&ecirc;n
ios em rela&ccedil;&atilde;o &agrave;    PA em contracep&ccedil;&atilde;o.</font
></p>     ^cY#aop01211.htm##
01061000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704081700085002001300902#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#57#53#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Lubianca e cols<sup>70</sup
>.    avaliaram, em estudo transversal, 171 mulheres com diagn&oacute;stico de H
AS    e observaram eleva&ccedil;&atilde;o de na press&atilde;o arterial diast&oa
cute;lica    (PAD), mesmo ap&oacute;s corre&ccedil;&otilde;es das vari&aacute;ve
is confundidoras<sup>70</sup>.    Os mesmos autores supracitados conduziram uma 
coorte com o objetivo de avaliar    se a interrup&ccedil;&atilde;o dos COC inter
feria nos n&iacute;veis de PA. Encontraram    um decl&iacute;nio na PAS (- 15,1 
&plusmn; 2,6 mmHg) e na PAD (- 10,4 &plusmn;    1,8 mmHg) ap&oacute;s seis meses
 de suspens&atilde;o do COC significativamente    maior quando comparado a mulhe
res que continuaram em uso do contraceptivo combinado<sup>71</sup>.</font></p>  
   ^cY#aop01211.htm##
00764000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052000085002001300605#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#58#54#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A via de administra&ccedil;
&atilde;o    na contracep&ccedil;&atilde;o hormonal n&atilde;o interfere na pres
s&atilde;o    arterial<sup>7</sup>. Ao contr&aacute;rio do observado para TH na 
p&oacute;s-menopausa,    em que n&atilde;o h&aacute; altera&ccedil;&atilde;o neg
ativa dos n&iacute;veis    press&oacute;ricos em mulheres climat&eacute;ricas hi
pertensas usu&aacute;rias    de TH transd&eacute;rmica comparadas ao placebo<sup
>72</sup>.</font></p>     ^cY#aop01211.htm##
00808000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056400085002001300649#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#59#55#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Apesar de os COC    induzir
em uma eleva&ccedil;&atilde;o m&eacute;dia nos n&iacute;veis da PA entre    2 a 
3 mmHg em mulheres saud&aacute;veis, na maioria dos casos n&atilde;o se    faz n
ecess&aacute;ria terapia anti-hipertensiva<sup>73</sup>. Entretanto, em    mulhe
res com diagn&oacute;stico pr&eacute;vio de HAS, deve-se evitar a prescri&ccedil
;&atilde;o    de contraceptivo contendo EE, pelo risco de piora de progn&oacute;
stico dessa    doen&ccedil;a e aumento de risco de TA.</font></p>     ^cY#aop012
11.htm##
00647000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040300085002001300488#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#60#56#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os estudos desenhados    pa
ra avaliar altera&ccedil;&otilde;es na PA e progestag&ecirc;nios isolados    s&a
tilde;o poucos, por&eacute;m consistentes de que n&atilde;o h&aacute; associa&cc
edil;&atilde;o    entre seu uso e hipertens&atilde;o em mulheres saud&aacute;vei
s durante seguimento    por dois anos<sup>7,74</sup>.</font></p>     ^cY#aop0121
1.htm##
01005000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076100085002001300846#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#61#57#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em resumo, em mulheres    h
ipertensas devemos orientar o uso de m&eacute;todos contraceptivos n&atilde;o   
 hormonais, ou hormonais que contenham somente progestag&ecirc;nio (<a href="/im
g/revistas/abc/2011nahead/aop01211t02.jpg">tab.    2</a>). Os contraceptivos com
binados, por qualquer via, al&eacute;m de interferirem    na PA, potencializam o
 risco de TA em pacientes j&aacute; predispostas. Em pacientes    hipertensas be
m controladas, com menos de 35 anos, pode-se usar o contraceptivo    combinado, 
por&eacute;m observando os crit&eacute;rios da OMS, as op&ccedil;&otilde;es    a
nteriores t&ecirc;m mais respaldo cient&iacute;fico e s&atilde;o mais seguras<su
p>75</sup>.</font></p>     ^cY#aop01211.htm##
00372000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012800085002001300213#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#62#58#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Resumo das recomenda&cce
dil;&otilde;es</b></font></p>     ^cY#aop01211.htm##
00868000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704062400085002001300709#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#63#59#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os benef&iacute;cios    do 
uso dos contraceptivos hormonais ultrapassam os riscos associados a esses    med
icamentos. Um bom aconselhamento contraceptivo &agrave;s mulheres deve incluir  
  todos os aspectos ben&eacute;ficos e poss&iacute;veis eventos adversos para,  
  nesse contexto, proporcionar uma escolha informada mais apropriada para cada  
  caso. A seguir, o resumo de algumas recomenda&ccedil;&otilde;es que devemos   
 sempre levar em considera&ccedil;&atilde;o na escolha contraceptiva de mulheres
    com fatores de risco para DCV:</font></p>     ^cY#aop01211.htm##
00450000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020600085002001300291#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#64#60#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os COC aumentam    risco de
 trombose venosa e arterial mesmo em mulheres sadias, por&eacute;m esse    risco
 &eacute; baixo;</font></p>     ^cY#aop01211.htm##
00500000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025600085002001300341#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#65#61#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As prepara&ccedil;&otilde;e
s    dispon&iacute;veis atualmente (EE&lt;50 mg) s&atilde;o consideradas de baix
o    risco para trombose venosa e arterial em pacientes sem risco;</font></p>   
  ^cY#aop01211.htm##
00731000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048700085002001300572#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#66#62#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O componente progestag&ecir
c;nico    associado altera o risco de TEV de um COC, as evid&ecirc;ncias atuais 
sugerem    que aqueles que cont&ecirc;m o levonorgestrel possuem o menor risco d
e TEV.    Para trombose arterial, o tipo de progestag&ecirc;nio n&atilde;o alter
a o risco    de trombose; assim, em mulheres saud&aacute;veis n&atilde;o h&aacut
e; uma op&ccedil;&atilde;o    que produza menores riscos;</font></p>     ^cY#aop
01211.htm##
00584000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034000085002001300425#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#67#63#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os contraceptivos    soment
e de progestag&ecirc;nio e os n&atilde;o hormonais n&atilde;o est&atilde;o    as
sociados a aumento de risco para TEV, sendo dessa forma indicados para pacientes
    de risco para TEV ou hist&oacute;ria pessoal pr&eacute;via de TEV;</font></p
>     ^cY#aop01211.htm##
00559000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031500085002001300400#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#68#64#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em pacientes com    hist&oa
cute;ria pr&eacute;via ou m&uacute;ltiplos fatores de risco para TA opta-se    p
elos contraceptivos n&atilde;o hormonais ou somente com progestag&ecirc;nio    (
excetuando-se o injet&aacute;vel trimestral);</font></p>     ^cY#aop01211.htm##
00440000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019600085002001300281#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#69#65#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O risco para TEV    ou TA i
ndepende da via de administra&ccedil;&atilde;o do contraceptivo hormonal    comb
inado;</font></p>     ^cY#aop01211.htm##
00821000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057700085002001300662#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#70#66#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os contraceptivos    hormon
ais combinados, por conterem o etinilestradiol, sempre alteram a PA, mesmo    em
 baixas doses. Em mulheres saud&aacute;veis, essa altera&ccedil;&atilde;o    n&a
tilde;o traz repercuss&otilde;es cl&iacute;nicas, por&eacute;m deve-se evitar   
 o seu uso em hipertensas. Assim, em mulheres com HAS, preferir os n&atilde;o   
 hormonais ou somente com progestag&ecirc;nio, pois o EE potencializa o risco   
 para trombose arterial e altera o controle da PA nessas pacientes.</font></p>  
   ^cY#aop01211.htm##
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#71#67#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    de
 Interesses</b></font></p>     ^cY#aop01211.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#72#68#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    haver
 conflito de interesses pertinentes.</font></p>     ^cY#aop01211.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#73#69#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01211.htm##
00397000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015300085002001300238#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#74#70#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    n&atil
de;o teve fontes de financiamento externas.</font></p>     ^cY#aop01211.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#75#71#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;o
    Acad&ecirc;mica</b></font></p>     ^cY#aop01211.htm##
00439000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019500085002001300280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#76#72#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o h&aacute;    vin
cula&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atil
de;o.</font></p>     ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#77#73#article#230#<p>&nbsp;<
/p>     ^cY#aop01211.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#78#74#article#230#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01211.htm##
00701000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704044300087002001300530#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#79#75#article#23
0#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Minist&eac
ute;rio    da Sa&uacute;de &#91;homepage na Internet&#93;. Pesquisa nacional de 
demografia    e sa&uacute;de da crian&ccedil;a e mulher (PNDS), 2006 &#91;citado
 2008 dez    17&#93;. Dispon&iacute;vel em: <a href="http://bvsms.saude.gov.br/b
vs/pnds/saude_nutricional.php" target="_blank">http://bvsms.saude.gov.br/bvs/pnd
s/saude_nutricional.php</a></font></p>     ^cY#aop01211.htm##
00550000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704029200087002001300379#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#80#76#article#23
0#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. World Heal
th    Organization. Reproductive Health and Research and John Hopkins Bloomberg 
School    of Public Health. Family planning: a global handbook for providers (20
08). Baltimore    and Geneva: CCP and WHO; 2008.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#81#77#article#230#</font></p
>     ^cY#aop01211.htm##
00605000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704034700087002001300434#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#82#78#article#23
0#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. World Heal
th    Organization Collaborative Study of Cardiovascular Disease and Steroid Hor
mone    Contraception Venous thromboembolic disease and combined oral contracept
ives:    results of international multicentre case-control study. Lancet. 1995; 
346 (8990):    1575-82.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#83#79#article#230#</font></p
>     ^cY#aop01211.htm##
00585000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032700087002001300414#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#84#80#article#23
0#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. World Heal
th    Organization Collaborative Study of Cardiovascular Disease and Steroid Hor
mone    Contraception. Effect of different progestagens in low oestrogen oral co
ntraceptives    on venous thromboembolic disease. Lancet. 1995; 346 (8990): 1582
-8.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#85#81#article#230#</font></p
>     ^cY#aop01211.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023200087002001300319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#86#82#article#23
0#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Khader YS,
 Rice    J, John L, Abueita O. Oral contraceptives use and the risk of myocardia
l infarction:    a meta-analysis. Contraception. 2003; 68 (1): 11-7.    ^cY#aop0
1211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#87#83#article#230#</font></p
>     ^cY#aop01211.htm##
00547000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028900087002001300376#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#88#84#article#23
0#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Girolami A
,    Scandellari R, Tezza F, Paternoster D, Girolami B. Arterial thrombosis in y
oung    women after ovarian stimulation: case report and review of the literatur
e. J    Thromb Thrombol. 2007; 24 (2): 169-7.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#89#85#article#230#</font></p
>     ^cY#aop01211.htm##
00438000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704018000087002001300267#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#90#86#article#23
0#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. World Heal
th    Organization. Medical eligibility criteria for contraceptive use. 4rd ed. 
Geneva;    2009.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#91#87#article#230#</font></p
>     ^cY#aop01211.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022800087002001300315#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#92#88#article#23
0#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Mammen EF.
 Oral    contraceptive pills and hormonal replacement therapy and thromboembolic
 disease.    Hematol Oncol Clin North Am. 2000; 14 (5): 1045-59.    ^cY#aop01211
.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#93#89#article#230#</font></p
>     ^cY#aop01211.htm##
00479000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022100087002001300308#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#94#90#article#23
0#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Rosendaal 
FR,    Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens a
nd    thrombosis. J Thromb Haemost. 2003; 1 (7): 1371-80.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#95#91#article#230#</font></p
>     ^cY#aop01211.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704021100088002001300299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#96#92#article#23
0#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Rosendaa
l FR.    Venous thrombosis: the role of genes, environment, and behavior. Hemato
logy    Am Soc Hematol Educ Program. 2005; 1-12.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#97#93#article#230#</font></p
>     ^cY#aop01211.htm##
00585000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704032600088002001300414#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#98#94#article#23
0#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. van Hylc
kama    Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The 
venous    thrombotic risk of oral contraceptives, effects of oestrogen dose and 
progestogen    type: results of the MEGA case-control study. BMJ. 2009; 339: b29
21.    ^cY#aop01211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#99#95#article#230#</font></p
>     ^cY#aop01211.htm##
00473000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704021300089002001300302#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#100#96#article#2
30#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Rosenda
al FR,    Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arte
rioscler    Thromb Vasc Biol. 2002; 22 (2): 201-10.    ^cY#aop01211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#101#97#article#230#</font></
p>     ^cY#aop01211.htm##
00487000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704022700089002001300316#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#102#98#article#2
30#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Kemmere
n JM,    Algra A, Grobbee DE. Third generation oral contraceptives and risk of v
enous    thrombosis: meta-analysis. BMJ. 2001; 323 (7305): 131-4.    ^cY#aop0121
1.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#103#99#article#230#</font></
p>     ^cY#aop01211.htm##
00510000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024900090002001300339#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#104#100#article#
230#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Schind
ler AE,    Campagnoli C, Druckmannc R, Huber J, Pasqualini JR, Schweppef KW, et 
al. Classification    and pharmacology of progestins. Maturitas. 2003; 61 (1-2):
 171-80.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#105#101#article#230#</font><
/p>     ^cY#aop01211.htm##
00610000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034900090002001300439#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#106#102#article#
230#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Kemmer
en JM,    Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, et al. Effect of sec
ond- and    third-generation oral contraceptives on the protein C system in the 
absence    or presence of the factor V Leiden mutation: a randomized trial. Bloo
d. 2004;    103 (3): 927-33.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#107#103#article#230#</font><
/p>     ^cY#aop01211.htm##
00464000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020300090002001300293#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#108#104#article#
230#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Conard
 J. Biological    coagulation findings in third-generation oral contraceptives. 
Hum Reprod Uptade.    1999; 5 (6): 672-80.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#109#105#article#230#</font><
/p>     ^cY#aop01211.htm##
00599000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033800090002001300428#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#110#106#article#
230#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Tans G
, Curvers    J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A rando
mized cross-over    study on the effects of levonorgestrel- and desogestrel-cont
aining oral contraceptives    on the anticoagulant pathways. Thromb Haemost. 200
0; 84 (1): 15-21.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#111#107#article#230#</font><
/p>     ^cY#aop01211.htm##
00595000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033400090002001300424#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#112#108#article#
230#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Tans G
, van    Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, et al.
 Activated    protein C resistance determined with a thrombin generation-based t
est predicts    for venous thrombosis in men and women. Br J Haematol. 2003; 122
 (3): 465-70.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#113#109#article#230#</font><
/p>     ^cY#aop01211.htm##
00565000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030400090002001300394#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#114#110#article#
230#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Odlind
 V, Milsom    I, Persson I, Victor A. Can changes in sex hormone 31. binding glo
bulin predict    the risk of venous thromboembolism with combined oral contracep
tive pills? Acta    Obstet Gynecol Scand. 2002; 81 (6): 482-90.    ^cY#aop01211.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#115#111#article#230#</font><
/p>     ^cY#aop01211.htm##
00468000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020700090002001300297#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#116#112#article#
230#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Vieira
 CS,    Oliveira LCO, S&aacute; MFS. Horm&ocirc;nio femininos e hemostasia. Rev 
Bras    Ginecol Obstet. 2007; 29 (10): 538-47.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#117#113#article#230#</font><
/p>     ^cY#aop01211.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027200090002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#118#114#article#
230#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Pomp E
R, Lenselink    AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period an
d prothrombotic    defects: risk of venous thrombosis in the MEGA study. J Throm
b Haemost. 2008;    6(4):632-7.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#119#115#article#230#</font><
/p>     ^cY#aop01211.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#120#116#article#
230#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. World 
Health    Organization. Cardiovascular disease and steroid hormone contraception
. Report    of a WHO Scientific group. Geneva: World Health Organization; 1998. 
(WHO Technical    Report Series, 877).    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#121#117#article#230#</font><
/p>     ^cY#aop01211.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020100090002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#122#118#article#
230#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Lowe G
DO. Venous    and arterial thrombosis: epidemiology and risk factors at various 
age. Maturitas.    2004; 47 (4): 259-63.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#123#119#article#230#</font><
/p>     ^cY#aop01211.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027200090002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#124#120#article#
230#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Conard
 J, Plu-Bureau    G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen
-only contraception    in women at high risk of venous thromboembolism. Contrace
ption. 2004; 70 (6):    437-41.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#125#121#article#230#</font><
/p>     ^cY#aop01211.htm##
00627000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036600090002001300456#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#126#122#article#
230#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Winkle
r UH,    Howie H, Buhler K, Korver T, Geurts TB, Coelingh Bennink HJ. A randomiz
ed controlled    double-blind study of the effects on hemostasis of two progesto
gen-only pills    containing 75 microgram desogestrel or 30 microgram levonorges
trel. Contraception.    1998; 57 (6): 385-92.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#127#123#article#230#</font><
/p>     ^cY#aop01211.htm##
00459000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019800090002001300288#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#128#124#article#
230#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Dorfli
nger    LJ. Metabolic effects of implantable steroid contraceptives for women. C
ontraception.    2002; 65 (1): 47-62.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#129#125#article#230#</font><
/p>     ^cY#aop01211.htm##
00600000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033900090002001300429#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#130#126#article#
230#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Egberg
 N, van    Beek A, Gunnervik C, Hulkko S, Hirvonen E, Larsson-Cohn U, et al. Eff
ects on    hemostatic system and liver function in relation to Implanon&acirc; a
nd Norplant&acirc;:    a prospective randomized clinical trial. Contraception. 1
998; 58 (2): 93-8.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#131#127#article#230#</font><
/p>     ^cY#aop01211.htm##
00558000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029700090002001300387#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#132#128#article#
230#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Vieira
 CS,    Ferriani RA, Garcia AA, Gomes MKO, Azevedo GD, Silva de S&aacute; MF. Tr
ansitory    reduction of platelet aggregation with the use of etonogestrel impla
nt in healthy    women. Thromb Haemost. 2005; 94: 682-3.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#133#129#article#230#</font><
/p>     ^cY#aop01211.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030500090002001300395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#134#130#article#
230#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Vieira
 CS,    Ferriani RA, Garcia AA, Pint&atilde;o MC, Azevedo GD, Gomes MK, et al. U
se of    the etonogestrel-releasing implant is associated with hypoactivation of
 the    coagulation cascade. Hum Reprod. 2007; 22 (8): 2196-201.    ^cY#aop01211
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#135#131#article#230#</font><
/p>     ^cY#aop01211.htm##
00615000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704035400090002001300444#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#136#132#article#
230#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Canoni
co M,    Oger E, Plu-Bureau G, Conard J, Meyer G, L&eacute;vesque H, et al. Horm
one therapy    and venous thromboembolism among postmenopausal women: impact of 
the route of    estrogen administration and progestogens: the ESTHER study. Circ
ulation. 2007;    115 (7): 840-5.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#137#133#article#230#</font><
/p>     ^cY#aop01211.htm##
00717000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704045600090002001300546#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#138#134#article#
230#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Food a
nd Drug    Administration. Center for Drug Evaluation and Research. Ortho Evra (
norelgestromin/ethinyl    estradiol) Information &#91;text on the Internet&#93;.
 2006 &#91;cited 2007    Jul 20&#93;. Available from: <a href="http://www.fda.go
v/cder/drug/infopage/orthoevra/default.htm" target="_blank">http://www.fda.gov/c
der/drug/infopage/orthoevra/default.htm</a></font></p>     ^cY#aop01211.htm##
00587000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032600090002001300416#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#139#135#article#
230#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Jick S
S, Kaye    JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in wo
men using    a contraceptive transdermal patch and oral contraceptives containin
g norgestimate    and 35 Ag of ethinyl estradiol. Contraception. 2006; 73 (3): 2
23-8.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#140#136#article#230#</font><
/p>     ^cY#aop01211.htm##
00592000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033100090002001300421#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#141#137#article#
230#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Magnus
d&oacute;ttir    EM, Bjarnad&oacute;ttir RI, Onundarson PT, Gudmundsd&oacute;tti
r BR, Geirsson    RT, Magnusd&oacute;ttir SD, et al. The contraceptive vaginal r
ing (NuvaRing)    and hemostasis: a comparative study. Contraception. 2004; 69 (
6): 461-7.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#142#138#article#230#</font><
/p>     ^cY#aop01211.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033700090002001300427#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#143#139#article#
230#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Sitruk
-Ware    R, Plu-Bureau G, Menard J, Conard J, Kumar S, Thalabard JC, et al. Effe
cts of    oral and transvaginal ethinyl estradiol on hemostatic factors and hepa
tic proteins    in a randomized, crossover study. J Clin Endocrinol Metab. 2007;
 92 (6): 2074-9.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#144#140#article#230#</font><
/p>     ^cY#aop01211.htm##
00852000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704059100090002001300681#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#145#141#article#
230#35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. World 
Health    Organization/United Nations Development Programme/United Nations Popul
ation    Fund/ World Bank Special Programme of Research, Development and Researc
h Training    in Human Reproduction, Task Force on Long-acting Systemic Agents f
or Fertility    Regulation. comparative study of the effects of two once-a-month
 injectable    contraceptives (Cyclofem&reg; and Mesigyna&reg;) and one oral con
traceptive    (Ortho-Novum 1/35&reg;) on coagulation and fibrinolysis. Contracep
tion. 2003;    68 (3): 159-76.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#146#142#article#230#</font><
/p>     ^cY#aop01211.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#147#143#article#
230#36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. World 
Health    Organization Collaborative Study of Cardiovascular Disease and Steroid
 Hormone    Contraception. Cardiovascular disease and use of oral and injectable
 progestogen    only contraceptives. Contraception. 1998; 57 (5): 315-24.    ^cY
#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#148#144#article#230#</font><
/p>     ^cY#aop01211.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025900090002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#149#145#article#
230#37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Sartor
elli    DS, Franco LJ. Tend&ecirc;ncias do diabetes mellitus no Brasil: o papel 
da transi&ccedil;&atilde;o    nutricional. Cad Sa&uacute;de P&uacute;blica. 2003
; 19 (1): S29-S36.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#150#146#article#230#</font><
/p>     ^cY#aop01211.htm##
00571000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031000090002001300400#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#151#147#article#
230#38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. WHO Co
llaborative    Study of Cardiovascular Disease and Steroid Hormone. Acute myocar
dial infarction    and combined oral contraceptives: results of an international
 multicentre case-control    study. Lancet. 1997; 349 (9060): 1202-9.    ^cY#aop
01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#152#148#article#230#</font><
/p>     ^cY#aop01211.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025900090002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#153#149#article#
230#39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Tanis 
BC, van    den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. O
ral contraceptives    and the risk of myocardial infarction. N Engl J Med. 2001;
 345 (25):1787-93.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#154#150#article#230#</font><
/p>     ^cY#aop01211.htm##
00593000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033200090002001300422#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#155#151#article#
230#40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Kemmer
en JM,    Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y
, et al.    Risk of arterial thrombosis in relation to oral contraceptives (RATI
O) study:    oral contraceptives and the risk of ischemic stroke. Stroke. 2002; 
33: 1202-8.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#156#152#article#230#</font><
/p>     ^cY#aop01211.htm##
00455000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019400090002001300284#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#157#153#article#
230#41#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">41. ESHRE 
Capri    Workshop Group. Hormones and cardiovascular health in women. Hum Reprod
 Update.    2006; 12 (5): 483-97.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#158#154#article#230#</font><
/p>     ^cY#aop01211.htm##
00602000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034100090002001300431#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#159#155#article#
230#42#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">42. World 
Health    Organization Collaborative Study of Cardiovascular Disease and Steroid
 Hormone    Contraception. Ischaemic stroke and combined oral contraceptives: re
sults of    an international, multicentre, case-control study. Lancet. 1996; 348
 (9026):    498-505.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#160#156#article#230#</font><
/p>     ^cY#aop01211.htm##
00510000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024900090002001300339#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#161#157#article#
230#43#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Practi
ce committee    of American Society for Reproductive Medicine. Hormonal contrace
ption: recent    advances and controversies. Fertil Steril. 2008; 90 (5 Suppl): 
S103-13.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#162#158#article#230#</font><
/p>     ^cY#aop01211.htm##
00471000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021000090002001300300#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#163#159#article#
230#44#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Gillum
 LA,    Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptive
s: a    meta-analysis. JAMA. 2000; 284 (1): 72-8.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#164#160#article#230#</font><
/p>     ^cY#aop01211.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029000090002001300380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#165#161#article#
230#45#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Chan W
S, Ray    J, Wai EK, Ginsburg S, Hannah ME, Corey PN, et al. Risk of stroke in w
omen exposed    to low-dose oral contraceptives: a critical evaluation of the ev
idence. Arch    Intern Med. 2004; 164 (7): 741-7.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#166#162#article#230#</font><
/p>     ^cY#aop01211.htm##
00442000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018100090002001300271#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#167#163#article#
230#46#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">46. Heinem
ann LA.    The changing scene-an unnecessary pill crisis. Hum Reprod Update. 199
9; 5 (6):    746-55.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#168#164#article#230#</font><
/p>     ^cY#aop01211.htm##
00624000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036300090002001300453#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#169#165#article#
230#47#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">47. Heinem
ann LA,    Lewis MA, Thorogood M, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher 
R. Case-control    study of oral contraceptives and risk of thromboembolic strok
e: results from    international study on oral contraceptives and health of youn
g women. BMJ. 1997;    315 (7121): 1502-4.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#170#166#article#230#</font><
/p>     ^cY#aop01211.htm##
00501000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024000090002001300330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#171#167#article#
230#48#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">48. Heinem
ann LA,    Lewis MA, Spitzer WO, Thorogood M, Guggenmoos-Holzmann I, Bruppacher 
R. Thromboembolic    stroke in young women. Contraception. 1998; 57 (1): 29-37. 
   ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#172#168#article#230#</font><
/p>     ^cY#aop01211.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031100090002001300401#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#173#169#article#
230#49#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">49. Chang 
CL, Donaghy    M, Poulter N. Migraine and stroke in young women: case-control st
udy. The World    Health Organization Collaborative Study of Cardiovascular Dise
ase and Steroid    Hormone Contraception. BMJ. 1999; 318 (7175): 13-8.    ^cY#ao
p01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#174#170#article#230#</font><
/p>     ^cY#aop01211.htm##
00410000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704014900090002001300239#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#175#171#article#
230#50#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">50. Rasmus
sen BK.    Epidemiology of headache. Cephalgia. 2001; 21 (7): 774-7.    ^cY#aop0
1211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#176#172#article#230#</font><
/p>     ^cY#aop01211.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020100090002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#177#173#article#
230#51#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">51. Massio
u H,    MacGregor EA. Evolution and treatment of migraine with oral contraceptiv
es.    Cephalalgia. 2000; 20 (3): 170-4.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#178#174#article#230#</font><
/p>     ^cY#aop01211.htm##
00485000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022400090002001300314#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#179#175#article#
230#52#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">52. Jick S
S, Jick    H. The contraceptive patch in relation to ischemic stroke and acute m
yocardial    infarction. Pharmacotherapy. 2007; 27 (2): 218-20.    ^cY#aop01211.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#180#176#article#230#</font><
/p>     ^cY#aop01211.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#181#177#article#
230#53#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">53. Miller
 L, Patton    DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA. Depomedroxyproges
terone-induced    hypoestrogenism and changes in vaginal flora and epithelium. O
bstet Gynecol.    2000; 96 (3): 431-9.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#182#178#article#230#</font><
/p>     ^cY#aop01211.htm##
00568000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030700090002001300397#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#183#179#article#
230#54#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">54. Kawano
 H, Motoyama    T, Hirai N, Yoshimura T, Kugiyama K, Ogawa H, et al. Effect of m
edroxyprogesterone    acetate plus estradiol on endothelium-dependent vasodilati
on in postmenopausal    women. Am J Cardiol. 2001; 87 (2): 238-40.    ^cY#aop012
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#184#180#article#230#</font><
/p>     ^cY#aop01211.htm##
00621000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036000090002001300450#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#185#181#article#
230#55#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">55. Sorens
en MB,    Collins P, Ong PJ, Webb CM, Hayward CS, Asbury EA, et al. Long-term us
e of contraceptive    depot medroxyprogesterone acetate in young women impairs a
rterial endothelial    function assessed by cardiovascular magnetic resonance. C
irculation. 2002; 106    (13): 1646-51.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#186#182#article#230#</font><
/p>     ^cY#aop01211.htm##
00482000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022100090002001300311#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#187#183#article#
230#56#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">56. Westho
ff C.    Depot medroxyprogesterone acetate contraception: metabolic parameters a
nd mood    changes. J Reprod Med. 1996; 41 (5 Suppl): 401-6.    ^cY#aop01211.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#188#184#article#230#</font><
/p>     ^cY#aop01211.htm##
00484000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022300090002001300313#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#189#185#article#
230#57#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">57. Suherm
an SK,    Affandi B, Korver T. The effects of Implanon on lipid metabolism in co
mparison    with Norplant. Contraception. 1999; 60 (5): 281-7.    ^cY#aop01211.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#190#186#article#230#</font><
/p>     ^cY#aop01211.htm##
00587000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032600090002001300416#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#191#187#article#
230#58#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">58. Innal 
MM, Yildirim    Y, Ertopcu K, Avci ME, Ozelmas I, Tinar S. Effect of the subderm
al contraceptive    etonogestrel. Implant (Implanon) on biochemical and hormonal
 parameters (three    years follow-up). Eur J Cont Reprod Health Care. 2008; 28:
 1-5.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#192#188#article#230#</font><
/p>     ^cY#aop01211.htm##
00652000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704039100090002001300481#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#193#189#article#
230#59#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">59. Morin-
Papunen    L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, et 
al. comparison    of metabolic and inflammatory outcomes in women who used oral 
contraceptives    and the levonorgestrel-releasing intrauterine device in a gene
ral population.    Am J Obstet Gynecol. 2008; 199 (5): 529.e1-529.e10.    ^cY#ao
p01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#194#190#article#230#</font><
/p>     ^cY#aop01211.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030600090002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#195#191#article#
230#60#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">60. Van De
n Bosch    MA, Kemmeren JM, Tanis BC, Mali WP, Helmerhorst FM, Rosendaal FR, et 
al. The    RATIO study: oral contraceptives and the risk of peripheral arterial 
disease    in young women. J Thromb Haemost. 2003; 1 (3): 439-44.    ^cY#aop0121
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#196#192#article#230#</font><
/p>     ^cY#aop01211.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033700090002001300427#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#197#193#article#
230#61#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">61. Heinem
ann LA,    Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives an
d cardiovascular    risk: results from the Transnational Study on Oral Contracep
tives and the Health    of Young Women. Eur J Contracept Reprod Health Care. 199
9; 4 (2): 67-73.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#198#194#article#230#</font><
/p>     ^cY#aop01211.htm##
00525000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026400090002001300354#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#199#195#article#
230#62#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">62. Chakht
oura    Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G. Proges
togen-only    contraceptives and the risk of stroke: a meta-analysis. Stroke. 20
09; 40 (4):    1059-62.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#200#196#article#230#</font><
/p>     ^cY#aop01211.htm##
00475000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021400090002001300304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#201#197#article#
230#63#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">63. Oelker
s WK.    Effects of estrogens and progestogens on the renin aldosterone system a
nd blood    pressure. Steroids. 1996; 61 (4): 166-71.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#202#198#article#230#</font><
/p>     ^cY#aop01211.htm##
00437000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704017600090002001300266#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#203#199#article#
230#64#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">64. Sitruk
-Ware    R. New progestagens for contraceptive use. Hum Reprod Update. 2006; 12 
(2):    169-78.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#204#200#article#230#</font><
/p>     ^cY#aop01211.htm##
00534000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027300090002001300363#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#205#201#article#
230#65#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">65. Palaci
os S,    Foidart JM, Genazzani AR. Advances in hormone replacement therapy with 
drospirenone,    a unique progestogen with aldosterone receptor antagonism. Matu
ritas. 2006;    55 (4): 297-307.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#206#202#article#230#</font><
/p>     ^cY#aop01211.htm##
00488000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022700090002001300317#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#207#203#article#
230#66#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">66. Oelker
s WH.    Drospirenone in combination with estrogens: for contraception and hormo
ne replacement    therapy. Climacteric. 2005; 8 (Suppl. 3): 19-27.    ^cY#aop012
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#208#204#article#230#</font><
/p>     ^cY#aop01211.htm##
00528000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026700090002001300357#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#209#205#article#
230#67#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">67. White 
WB, Hanes    V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenon
e and 17-beta-estradiol,    in postmenopausal women with hypertension. Hypertens
ion. 2006; 48 (2): 246-53.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#210#206#article#230#</font><
/p>     ^cY#aop01211.htm##
00639000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037800090002001300468#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#211#207#article#
230#68#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">68. Yildiz
han R,    Yildizhan B, Adali E, Yoruk P, Birol F, Suer N. Effects of two combine
d oral    contraceptives containing ethinylestradiol 30 mcg combined with either
 gestodene    or drospirenone on hemostatic parameters, lipid profiles and blood
 pressure.    Arch Gynecol Obstet. 2009; 280 (2): 255-61.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#212#208#article#230#</font><
/p>     ^cY#aop01211.htm##
00629000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036800090002001300458#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#213#209#article#
230#69#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">69. Suthip
ongse    W, Taneepanichskul S. An open-label randomized comparative study of ora
l contraceptives    between medications containing 3 mg drospirenone/30 microg e
thinylestradiol    and 150 microg levonogestrel/30 microg ethinylestradiol in Th
ai women. Contraception.    2004; 69 (1): 23-6.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#214#210#article#230#</font><
/p>     ^cY#aop01211.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024300090002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#215#211#article#
230#70#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">70. Lubian
ca JN,    Faccin CS, Fuchs FD. Oral contraceptives: a risk factor for uncontroll
ed blood    pressure among hypertensive women. Contraception. 2003; 67 (1): 19-2
4.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#216#212#article#230#</font><
/p>     ^cY#aop01211.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027100090002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#217#213#article#
230#71#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">71. Lubian
ca JN,    Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: an effectiv
e blood    pressure-lowering intervention in women with hypertension. J Hum Hype
rtens.    2005; 19 (6): 451-5.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#218#214#article#230#</font><
/p>     ^cY#aop01211.htm##
00599000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033800090002001300428#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#219#215#article#
230#72#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">72. de Car
valho    MN, Nobre F, Mendes MC, Dos Reis RM, Ferriani RA, Silva de S&aacute; MF
. Low-dose    transdermal hormone therapy does not interfere with the blood pres
sure of hypertensive    menopausal women: a pilot study. Blood Press Monit. 2008
; 13 (5): 277-83.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#220#216#article#230#</font><
/p>     ^cY#aop01211.htm##
00602000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034100090002001300431#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#221#217#article#
230#73#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">73. Du Y, 
Melchert    HU, Sch&auml;fer-Korting M. Use of oral contraceptives in Germany: p
revalence,    determinants and use-associated health correlates. Results of Nati
onal Health    Surveys from 1984 to 1999. Eur J Obstet Gynecol Reprod Biol. 2007
; 134 (1):    57-66.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#222#218#article#230#</font><
/p>     ^cY#aop01211.htm##
00483000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022200090002001300312#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#223#219#article#
230#74#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">74. Hussai
n SF.    Progestogen-only pills and high blood pressure: is there an association
? A literature    review. Contraception. 2004; 69 (2): 89-97.    ^cY#aop01211.ht
m##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#224#220#article#230#</font><
/p>     ^cY#aop01211.htm##
00464000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020300090002001300293#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#225#221#article#
230#75#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">75. Shufel
t CL,    Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J
 Am Coll    Cardiol. 2009; 53 (3): 221-31.    ^cY#aop01211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#226#222#article#230#</font><
/p>     ^cY#aop01211.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#227#223#article#230#<p>&nbsp
;</p>     ^cY#aop01211.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#228#224#article#230#<p>&nbsp
;</p>     ^cY#aop01211.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#229#225#article#230#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop01211.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004200087002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#230#226#article#230#<br>   <
/b> Milena Bastos Brito<b>    ^cY#aop01211.htm##
00337000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009100087002001300178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#231#227#article#230#<br>   <
/b> Av. dos Bandeirantes, 3900 - Campus Universit&aacute;rio - Monte Alegre    ^
cY#aop01211.htm##
00307000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006100087002001300148#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#232#228#article#230#<br>   1
4049-900 - Ribeir&atilde;o Preto, SP - Brasil    ^cY#aop01211.htm##
00418000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704017200087002001300259#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#233#229#article#230#<br>   E
-mail:<a href="mailto:milenabastos@usp.br">milenabastos@usp.br</a>, <a href="mai
lto:milenabastos22@yahoo.com.br">milenabastos22@yahoo.com.br</a></font></p>     
^cY#aop01211.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01211.htm#S#p#234#230#article#230#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 30/
10/09; revisado recebido em 27/01/10; aceito em 23/03/10.</font></p>     ^cY#aop
01211.htm##
00533000000000241000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170020000860180071001060650
00900177064000500186110000900191109001200200037005700212865000900269002001300278
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#235#1#articl
e#75#1#Ministério da Saúde#Pesquisa nacional de demografia e saúde da criança e 
mulher (PNDS)^lpt#20060000#2006#20081217#2008 dez 17#http://bvsms.saude.gov.br/b
vs/pnds/saude_nutricional.php#20110000#aop01211.htm##
00595000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170026000860180138001120650
00900250064000500259066001000264066000700274062001200281065000900293064000500302
865000900307002001300316#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
211.htm#S#c#236#2#article#75#2#World Health Organization#Reproductive Health and
 Research and John Hopkins Bloomberg School of Public Health: Family planning: a
 global handbook for providers^len#20080000#2008#Baltimore#Geneva#CCP and WHO#20
080000#2008#20110000#aop01211.htm##
00671000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840110026000860120204001120300
00700316065000900323064000500332031000400337032000500341014000800346865000900354
002001300363035001000376801000700386#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#237#3#article#75#3#World Health Organization#Collaborati
ve Study of Cardiovascular Disease and Steroid Hormone Contraception Venous thro
mboembolic disease and combined oral contraceptives: results of international mu
lticentre case-control study^len#Lancet#19950000#1995#346#8990#1575-82#20110000#
aop01211.htm#0099-5355#Lancet##
00654000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840110026000860120188001120300
00700300065000900307064000500316031000400321032000500325014000700330865000900337
002001300346035001000359801000700369#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#238#4#article#75#4#World Health Organization#Collaborati
ve Study of Cardiovascular Disease and Steroid Hormone Contraception: Effect of 
different progestagens in low oestrogen oral contraceptives on venous thromboemb
olic disease^len#Lancet#19950000#1995#346#8990#1582-8#20110000#aop01211.htm#0099
-5355#Lancet##
00629000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100014001030100
01400117010001700131012008300148030001400231065000900245064000500254031000300259
032000200262014000500264865000900269002001300278035001000291801001400301#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#239#5#article#75#5#^
rND^sKhader^nYS#^rND^sRice^nJ#^rND^sJohn^nL#^rND^sAbueita^nO#Oral contraceptives
 use and the risk of myocardial infarction: a meta-analysis^len#Contraception#20
030000#2003#68#1#11-7#20110000#aop01211.htm#0010-7824#Contraception##
00667000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100021001040100
01500125010002100140010001800161012010700179030001800286710000200304065000900306
064000500315031000300320032000200323014000600325865000900331002001300340#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#240#6#article#75#6#^
rND^sGirolami^nA#^rND^sScandellari^nR#^rND^sTezza^nF#^rND^sPaternoster^nD#^rND^s
Girolami^nB#Arterial thrombosis in young women after ovarian stimulation: case r
eport and review of the literature^len#J Thromb Thrombol#2#20070000#2007#24#2#16
9-7#20110000#aop01211.htm##
00444000000000229000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170026000860180055001120630
00400167066000700171065000900178064000500187865000900192002001300201#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#241#7#article#75#7#World
 Health Organization#Medical eligibility criteria for contraceptive use^len#4rd#
Geneva#20090000#2009#20110000#aop01211.htm##
00585000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860120089001030300
02800192065000900220064000500229031000300234032000200237014000800239865000900247
002001300256035001000269801002800279#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#242#8#article#75#8#^rND^sMammen^nEF#Oral contraceptive p
ills and hormonal replacement therapy and thromboembolic disease^len#Hematol Onc
ol Clin North Am#20000000#2000#14#5#1045-59#20110000#aop01211.htm#0889-8588#Hema
tol Oncol Clin North Am##
00584000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100028001060100
01600134010002200150012004300172030001700215710000200232065000900234064000500243
031000200248032000200250014000800252865000900260002001300269#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#243#9#article#75#9#^rND^sRosenda
al^nFR#^rND^sVan Hylckama Vlieg^nA#^rND^sTanis^nBC#^rND^sHelmerhorst^nFM#Estroge
ns, progestogens and thrombosis^len#J Thromb Haemost#2#20030000#2003#1#7#1371-80
#20110000#aop01211.htm##
00501000000000241000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880120068001080300
04000176710000200216065000900218064000500227014000500232865000900237002001300246
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#244#10#artic
le#75#10#^rND^sRosendaal^nFR#Venous thrombosis: the role of genes, environment, 
and behavior^len#Hematology Am Soc Hematol Educ Program.#2#20050000#2005#1-12#20
110000#aop01211.htm##
00719000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100028000880100022001160100
02400138010001700162010002000179012014200199030000400341065000900345064000500354
031000400359014000600363865000900369002001300378035001000391801000400401#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#245#11#article#75#11
#^rND^svan Hylckama Vlieg^nA#^rND^sHelmerhorst^nFM#^rND^sVandenbroucke^nJP#^rND^
sDoggen^nCJ#^rND^sRosendaal^nFR#The venous thrombotic risk of oral contraceptive
s, effects of oestrogen dose and progestogen type: results of the MEGA case-cont
rol study^len#BMJ#20090000#2009#339#b2921#20110000#aop01211.htm#0959-8138#BMJ##
00609000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100022001080100
02400130012003500154030003000189065000900219064000500228031000300233032000200236
014000700238865000900245002001300254035001000267801003000277#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#246#12#article#75#12#^rND^sRosen
daal^nFR#^rND^sHelmerhorst^nFM#^rND^sVandenbroucke^nJP#Female hormones and throm
bosis^len#Arterioscler Thromb Vasc Biol#20020000#2002#22#2#201-10#20110000#aop01
211.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00597000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01800122012008600140030000400226065000900230064000500239031000400244032000500248
014000600253865000900259002001300268035001000281801000400291#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#247#13#article#75#13#^rND^sKemme
ren^nJM#^rND^sAlgra^nA#^rND^sGrobbee^nDE#Third generation oral contraceptives an
d risk of venous thrombosis: meta-analysis^len#BMJ#20010000#2001#323#7305#131-4#
20110000#aop01211.htm#0959-8138#BMJ##
00690000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100020001080100
02000128010001500148010002100163010002000184810000600204012005000210030001000260
06500090027006400050027903100030028403200040028701400070029186500090029800200130
0307035001000320801001000330#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#248#14#article#75#14#^rND^sSchindler^nAE#^rND^sCampagnoli^nC#^rN
D^sDruckmannc^nR#^rND^sHuber^nJ#^rND^sPasqualini^nJR#^rND^sSchweppef^nKW#et al#C
lassification and pharmacology of progestins^len#Maturitas#20030000#2003#61#1-2#
171-80#20110000#aop01211.htm#0378-5122#Maturitas##
00780000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01800122010001400140010001600154010001700170810000600187012016600193030000600359
06500090036506400050037403100040037903200020038301400070038586500090039200200130
0401035001000414801000600424#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#249#15#article#75#15#^rND^sKemmeren^nJM#^rND^sAlgra^nA#^rND^sMei
jers^nJC#^rND^sTans^nG#^rND^sBouma^nBN#^rND^sCurvers^nJ#et al#Effect of second- 
and third-generation oral contraceptives on the protein C system in the absence 
or presence of the factor V Leiden mutation: a randomized trial^len#Blood#200400
00#2004#103#3#927-33#20110000#aop01211.htm#0006-4971#Blood##
00513000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120076001040300
01800180710000200198065000900200064000500209031000200214032000200216014000700218
865000900225002001300234#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
211.htm#S#c#250#16#article#75#16#^rND^sConard^nJ#Biological coagulation findings
 in third-generation oral contraceptives^len#Hum Reprod Uptade#2#19990000#1999#5
#6#672-80#20110000#aop01211.htm##
00781000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100017001020100
02000119010002000139010001800159010001600177810000600193012014500199030001500344
06500090035906400050036803100030037303200020037601400060037886500090038400200130
0393035001000406801001500416#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#251#17#article#75#17#^rND^sTans^nG#^rND^sCurvers^nJ#^rND^sMiddel
dorp^nS#^rND^sThomassen^nMC#^rND^sMeijers^nJC#^rND^sPrins^nMH#et al#A randomized
 cross-over study on the effects of levonorgestrel- and desogestrel-containing o
ral contraceptives on the anticoagulant pathways^len#Thromb Haemost#20000000#200
0#84#1#15-21#20110000#aop01211.htm#0340-6245#Thromb Haemost##
00776000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100028001020100
02000130010001700150010001800167010001600185810000600201012013200207030001400339
06500090035306400050036203100040036703200020037101400070037386500090038000200130
0389035001000402801001400412#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#252#18#article#75#18#^rND^sTans^nG#^rND^svan Hylckama Vlieg^nA#^
rND^sThomassen^nMC#^rND^sCurvers^nJ#^rND^sBertina^nRM#^rND^sRosing^nJ#et al#Acti
vated protein C resistance determined with a thrombin generation-based test pred
icts for venous thrombosis in men and women^len#Br J Haematol#20030000#2003#122#
3#465-70#20110000#aop01211.htm#0007-1048#Br J Haematol##
00712000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01700120010001600137012013500153030002600288065000900314064000500323031000300328
032000200331014000700333865000900340002001300349035001000362801002600372#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#253#19#article#75#19
#^rND^sOdlind^nV#^rND^sMilsom^nI#^rND^sPersson^nI#^rND^sVictor^nA#Can changes in
 sex hormone 31: binding globulin predict the risk of venous thromboembolism wit
h combined oral contraceptive pills?^len#Acta Obstet Gynecol Scand#20020000#2002
#81#6#482-90#20110000#aop01211.htm#0001-6349#Acta Obstet Gynecol Scand##
00584000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01400125012003600139030002400175065000900199064000500208031000300213032000300216
014000700219865000900226002001300235035001000248801002400258#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#254#20#article#75#20#^rND^sVieir
a^nCS#^rND^sOliveira^nLCO#^rND^sSá^nMFS#Hormônio femininos e hemostasia^lpt#Rev 
Bras Ginecol Obstet#20070000#2007#29#10#538-47#20110000#aop01211.htm#0100-7253#R
ev Bras Ginecol Obstet##
00635000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100020001030100
02000123010001700143012010800160030001700268710000200285065000900287064000500296
031000200301032000200303014000600305865000900311002001300320#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#255#21#article#75#21#^rND^sPomp^
nER#^rND^sLenselink^nAM#^rND^sRosendaal^nFR#^rND^sDoggen^nCJ#Pregnancy, the post
partum period and prothrombotic defects: risk of venous thrombosis in the MEGA s
tudy^len#J Thromb Haemost#2#20080000#2008#6#4#632-7#20110000#aop01211.htm##
00508000000000229000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170026000880180095001140660
00700209062002600216065000900242064000500251865000900256002001300265#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#256#22#article#75#22#Wor
ld Health Organization#Cardiovascular disease and steroid hormone contraception:
 Report of a WHO Scientific group^len#Geneva#World Health Organization#19980000#
1998#20110000#aop01211.htm##
00541000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120081001040300
01000185065000900195064000500204031000300209032000200212014000700214865000900221
002001300230035001000243801001000253#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#257#23#article#75#23#^rND^sLowe^nGDO#Venous and arterial
 thrombosis: epidemiology and risk factors at various age^len#Maturitas#20040000
#2004#47#4#259-63#20110000#aop01211.htm#0378-5122#Maturitas##
00703000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100020001040100
01400124010001900138010001900157010002000176012008300196030001400279065000900293
06400050030203100030030703200020031001400070031286500090031900200130032803500100
0341801001400351#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#258#24#article#75#24#^rND^sConard^nJ#^rND^sPlu-Bureau^nG#^rND^sBahi^nN#^rND^
sHorellou^nMH#^rND^sPelissier^nC#^rND^sThalabard^nJC#Progestogen-only contracept
ion in women at high risk of venous thromboembolism^len#Contraception#20040000#2
004#70#6#437-41#20110000#aop01211.htm#0010-7824#Contraception##
00794000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01600121010001600137010001700153010002700170012017300197030001400370065000900384
06400050039303100030039803200020040101400070040386500090041000200130041903500100
0432801001400442#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#259#25#article#75#25#^rND^sWinkler^nUH#^rND^sHowie^nH#^rND^sBuhler^nK#^rND^s
Korver^nT#^rND^sGeurts^nTB#^rND^sCoelingh Bennink^nHJ#A randomized controlled do
uble-blind study of the effects on hemostasis of two progestogen-only pills cont
aining 75 microgram desogestrel or 30 microgram levonorgestrel^len#Contraception
#19980000#1998#57#6#385-92#20110000#aop01211.htm#0010-7824#Contraception##
00542000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880120070001090300
01400179065000900193064000500202031000300207032000200210014000600212865000900218
002001300227035001000240801001400250#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#260#26#article#75#26#^rND^sDorflinger^nLJ#Metabolic effe
cts of implantable steroid contraceptives for women^len#Contraception#20020000#2
002#65#1#47-62#20110000#aop01211.htm#0010-7824#Contraception##
00769000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01900122010001600141010001800157010002200175810000600197012013200203030001400335
06500090034906400050035803100030036303200020036601400050036886500090037300200130
0382035001000395801001400405#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#261#27#article#75#27#^rND^sEgberg^nN#^rND^svan Beek^nA#^rND^sGun
nervik^nC#^rND^sHulkko^nS#^rND^sHirvonen^nE#^rND^sLarsson-Cohn^nU#et al#Effects 
on hemostatic system and liver function in relation to Implanonâ and Norplantâ: 
a prospective randomized clinical trial^len#Contraception#19980000#1998#58#2#93-
8#20110000#aop01211.htm#0010-7824#Contraception##
00712000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01700124010001700141010001800158010002200176012010300198030001500301065000900316
06400050032503100030033001400060033386500090033900200130034803500100036180100150
0371#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#262#28#a
rticle#75#28#^rND^sVieira^nCS#^rND^sFerriani^nRA#^rND^sGarcia^nAA#^rND^sGomes^nM
KO#^rND^sAzevedo^nGD#^rND^sSilva de Sá^nMF#Transitory reduction of platelet aggr
egation with the use of etonogestrel implant in healthy women^len#Thromb Haemost
#20050000#2005#94#682-3#20110000#aop01211.htm#0340-6245#Thromb Haemost##
00737000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01700124010001700141010001800158010001600176810000600192012010700198030001100305
06500090031606400050032503100030033003200020033301400090033586500090034400200130
0353035001000366801001100376#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#263#29#article#75#29#^rND^sVieira^nCS#^rND^sFerriani^nRA#^rND^sG
arcia^nAA#^rND^sPintão^nMC#^rND^sAzevedo^nGD#^rND^sGomes^nMK#et al#Use of the et
onogestrel-releasing implant is associated with hypoactivation of the coagulatio
n cascade^len#Hum Reprod#20070000#2007#22#8#2196-201#20110000#aop01211.htm#0268-
1161#Hum Reprod##
00784000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100014001060100
02000120010001600140010001500156010001800171810000600189012015700195030001200352
06500090036406400050037303100040037803200020038201400060038486500090039000200130
0399035001000412801001200422#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#264#30#article#75#30#^rND^sCanonico^nM#^rND^sOger^nE#^rND^sPlu-B
ureau^nG#^rND^sConard^nJ#^rND^sMeyer^nG#^rND^sLévesque^nH#et al#Hormone therapy 
and venous thromboembolism among postmenopausal women: impact of the route of es
trogen administration and progestogens: the ESTHER study^len#Circulation#2007000
0#2007#115#7#840-5#20110000#aop01211.htm#0009-7322#Circulation##
00579000000000241000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170070000880180062001580650
00900220064000500229110000900234109001200243037006000255865000900315002001300324
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#265#31#artic
le#75#31#Food and Drug Administration^dCenter for Drug Evaluation and Research#O
rtho Evra (norelgestromin/ethinyl estradiol) Information^len#20060000#2006#20070
720#2007 Jul 20#http://www.fda.gov/cder/drug/infopage/orthoevra/default.htm#2011
0000#aop01211.htm##
00721000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030100
01800118010001400136012017200150030001400322065000900336064000500345031000300350
032000200353014000600355865000900361002001300370035001000383801001400393#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#266#32#article#75#32
#^rND^sJick^nSS#^rND^sKaye^nJA#^rND^sRussmann^nS#^rND^sJick^nH#Risk of nonfatal 
venous thromboembolism in women using a contraceptive transdermal patch and oral
 contraceptives containing norgestimate and 35 Ag of ethinyl estradiol^len#Contr
aception#20060000#2006#73#3#223-8#20110000#aop01211.htm#0010-7824#Contraception#
#
00745000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100023001110100
02100134010002500155010001900180010002300199810000600222012008200228030001400310
06500090032406400050033303100030033803200020034101400060034386500090034900200130
0358035001000371801001400381#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#267#33#article#75#33#^rND^sMagnusdóttir^nEM#^rND^sBjarnadóttir^n
RI#^rND^sOnundarson^nPT#^rND^sGudmundsdóttir^nBR#^rND^sGeirsson^nRT#^rND^sMagnus
dóttir^nSD#et al#The contraceptive vaginal ring (NuvaRing) and hemostasis: a com
parative study^len#Contraception#20040000#2004#69#6#461-7#20110000#aop01211.htm#
0010-7824#Contraception##
00789000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100020001090100
01600129010001600145010001500161010002000176810000600196012013100202030002400333
06500090035706400050036603100030037103200020037401400070037686500090038300200130
0392035001000405801002400415#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#268#34#article#75#34#^rND^sSitruk-Ware^nR#^rND^sPlu-Bureau^nG#^r
ND^sMenard^nJ#^rND^sConard^nJ#^rND^sKumar^nS#^rND^sThalabard^nJC#et al#Effects o
f oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic prot
eins in a randomized, crossover study^len#J Clin Endocrinol Metab#20070000#2007#
92#6#2074-9#20110000#aop01211.htm#0021-972X#J Clin Endocrinol Metab##
00905000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110116000880120337002040300
01400541065000900555064000500564031000300569032000200572014000700574865000900581
002001300590035001000603801001400613#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#269#35#article#75#35#World Health Organization^d/United 
Nations Development Programme/United Nations Population Fund/ World Bank Special
#Programme of Research, Development and Research Training in Human Reproduction,
 Task Force on Long-acting Systemic Agents for Fertility Regulation.: comparativ
e study of the effects of two once-a-month injectable contraceptives (Cyclofem® 
and Mesigyna®) and one oral contraceptive (Ortho-Novum 1/35®) on coagulation and
 fibrinolysis^len#Contraception#20030000#2003#68#3#159-76#20110000#aop01211.htm#
0010-7824#Contraception##
00648000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110106000880120090001940300
01400284065000900298064000500307031000300312032000200315014000700317865000900324
002001300333035001000346801001400356#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#270#36#article#75#36#World Health Organization Collabora
tive Study of Cardiovascular Disease and Steroid Hormone Contraception#Cardiovas
cular disease and use of oral and injectable progestogen only contraceptives^len
#Contraception#19980000#1998#57#5#315-24#20110000#aop01211.htm#0010-7824#Contrac
eption##
00553000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100017001090120
08000126030001800206710000200224065000900226064000500235031000300240032000200243
014000800245865000900253002001300262#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#271#37#article#75#37#^rND^sSartorelli^nDS#^rND^sFranco^n
LJ#Tendências do diabetes mellitus no Brasil: o papel da transição nutricional^l
pt#Cad Saúde Pública#2#20030000#2003#19#1#S29-S36#20110000#aop01211.htm##
00638000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110071000880120125001590300
00700284065000900291064000500300031000400305032000500309014000700314865000900321
002001300330035001000343801000700353#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#272#38#article#75#38#WHO^dCollaborative Study of Cardiov
ascular Disease and Steroid Hormone#Acute myocardial infarction and combined ora
l contraceptives: results of an international multicentre case-control study^len
#Lancet#19970000#1997#349#9060#1202-9#20110000#aop01211.htm#0099-5355#Lancet##
00704000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100024001040100
01900128010001500147010002200162010001500184810000600199012006200205030001300267
06500090028006400050028903100040029403200030029801400080030186500090030900200130
0318035001000331801001300341#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#273#39#article#75#39#^rND^sTanis^nBC#^rND^svan den Bosch^nMA#^rN
D^sKemmeren^nJM#^rND^sCats^nVM#^rND^sHelmerhorst^nFM#^rND^sAlgra^nA#et al#Oral c
ontraceptives and the risk of myocardial infarction^len#N Engl J Med#20010000#20
01#345#25#1787-93#20110000#aop01211.htm#0028-4793#N Engl J Med##
00757000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
02400123010001700147010002200164010002300186810000600209012013400215030000700349
06500090035606400050036503100030037001400070037386500090038000200130038903500100
0402801000700412#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#274#40#article#75#40#^rND^sKemmeren^nJM#^rND^sTanis^nBC#^rND^svan den Bosch^
nMA#^rND^sBollen^nEL#^rND^sHelmerhorst^nFM#^rND^svan der Graaf^nY#et al#Risk of 
arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contr
aceptives and the risk of ischemic stroke^len#Stroke#20020000#2002#33#1202-8#201
10000#aop01211.htm#0039-2499#Stroke##
00535000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110027000880120048001150300
01800163065000900181064000500190031000300195032000200198014000700200865000900207
002001300216035001000229801001800239#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#275#41#article#75#41#ESHRE Capri Workshop Group#Hormones
 and cardiovascular health in women^len#Hum Reprod Update#20060000#2006#12#5#483
-97#20110000#aop01211.htm#1355-4786#Hum Reprod Update##
00665000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110106000880120116001940300
00700310065000900317064000500326031000400331032000500335014000800340865000900348
002001300357035001000370801000700380#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#276#42#article#75#42#World Health Organization Collabora
tive Study of Cardiovascular Disease and Steroid Hormone Contraception#Ischaemic
 stroke and combined oral contraceptives: results of an international, multicent
re, case-control study^len#Lancet#19960000#1996#348#9026#498-505#20110000#aop012
11.htm#0099-5355#Lancet##
00587000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110065000880120062001530300
01400215065000900229064000500238031000300243032000900246014000800255865000900263
002001300272035001000285801001400295#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#277#43#article#75#43#Practice committee of American Soci
ety for Reproductive Medicine#Hormonal contraception: recent advances and contro
versies^len#Fertil Steril#20080000#2008#90#5^sSuppl#S103-13#20110000#aop01211.ht
m#0015-0282#Fertil Steril##
00581000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01900126012006700145030000500212065000900217064000500226031000400231032000200235
014000500237865000900242002001300251035001000264801000500274#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#278#44#article#75#44#^rND^sGillu
m^nLA#^rND^sMamidipudi^nSK#^rND^sJohnston^nSC#Ischemic stroke risk with oral con
traceptives: a meta-analysis^len#JAMA#20000000#2000#284#1#72-8#20110000#aop01211
.htm#0098-7484#JAMA##
00734000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100013001030100
01400116010001800130010001700148010001600165810000600181012010700187030001600294
06500090031006400050031903100040032403200020032801400060033086500090033600200130
0345035001000358801001600368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#279#45#article#75#45#^rND^sChan^nWS#^rND^sRay^nJ#^rND^sWai^nEK#^
rND^sGinsburg^nS#^rND^sHannah^nME#^rND^sCorey^nPN#et al#Risk of stroke in women 
exposed to low-dose oral contraceptives: a critical evaluation of the evidence^l
en#Arch Intern Med#20040000#2004#164#7#741-7#20110000#aop01211.htm#0003-9926#Arc
h Intern Med##
00529000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880120050001080300
01800158065000900176064000500185031000200190032000200192014000700194865000900201
002001300210035001000223801001800233#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#280#46#article#75#46#^rND^sHeinemann^nLA#The changing sc
ene-an unnecessary pill crisis^len#Hum Reprod Update#19990000#1999#5#6#746-55#20
110000#aop01211.htm#1355-4786#Hum Reprod Update##
00781000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100016001080100
01900124010001800143010002900161010002000190012016300210030000400373065000900377
06400050038603100040039103200050039501400070040086500090040700200130041603500100
0429801000400439#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#281#47#article#75#47#^rND^sHeinemann^nLA#^rND^sLewis^nMA#^rND^sThorogood^nM#
^rND^sSpitzer^nWO#^rND^sGuggenmoos-Holzmann^nI#^rND^sBruppacher^nR#Case-control 
study of oral contraceptives and risk of thromboembolic stroke: results from int
ernational study on oral contraceptives and health of young women^len#BMJ#199700
00#1997#315#7121#1502-4#20110000#aop01211.htm#0959-8138#BMJ##
00674000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100016001080100
01800124010001900142010002900161010002000190012004100210030001400251065000900265
06400050027403100030027903200020028201400060028486500090029000200130029903500100
0312801001400322#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#282#48#article#75#48#^rND^sHeinemann^nLA#^rND^sLewis^nMA#^rND^sSpitzer^nWO#^
rND^sThorogood^nM#^rND^sGuggenmoos-Holzmann^nI#^rND^sBruppacher^nR#Thromboemboli
c stroke in young women^len#Contraception#19980000#1998#57#1#29-37#20110000#aop0
1211.htm#0010-7824#Contraception##
00678000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01700121012017000138030000400308065000900312064000500321031000400326032000500330
014000500335865000900340002001300349035001000362801000400372#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#283#49#article#75#49#^rND^sChang
^nCL#^rND^sDonaghy^nM#^rND^sPoulter^nN#Migraine and stroke in young women: case-
control study. The World Health Organization Collaborative Study of Cardiovascul
ar Disease and Steroid Hormone Contraception^len#BMJ#19990000#1999#318#7175#13-8
#20110000#aop01211.htm#0959-8138#BMJ##
00462000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880120029001080300
01000137710000200147065000900149064000500158031000300163032000200166014000600168
865000900174002001300183#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
211.htm#S#c#284#50#article#75#50#^rND^sRasmussen^nBK#Epidemiology of headache^le
n#Cephalgia#2#20010000#2001#21#7#774-7#20110000#aop01211.htm##
00561000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050120
06500125030001200190065000900202064000500211031000300216032000200219014000600221
865000900227002001300236035001000249801001200259#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01211.htm#S#c#285#51#article#75#51#^rND^sMassiou^nH#^rND^s
MacGregor^nEA#Evolution and treatment of migraine with oral contraceptives^len#C
ephalalgia#20000000#2000#20#3#170-4#20110000#aop01211.htm#0333-1024#Cephalalgia#
#
00588000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100014001030120
09100117030001600208065000900224064000500233031000300238032000200241014000700243
865000900250002001300259035001000272801001600282#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01211.htm#S#c#286#52#article#75#52#^rND^sJick^nSS#^rND^sJi
ck^nH#The contraceptive patch in relation to ischemic stroke and acute myocardia
l infarction^len#Pharmacotherapy#20070000#2007#27#2#218-20#20110000#aop01211.htm
#0277-0008#Pharmacotherapy##
00711000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01500121010001600136010001700152010002100169012009600190030001500286065000900301
06400050031003100030031503200020031801400060032086500090032600200130033503500100
0348801001500358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#287#53#article#75#53#^rND^sMiller^nL#^rND^sPatton^nDL#^rND^sMeier^nA#^rND^sT
hwin^nSS#^rND^sHooton^nTM#^rND^sEschenbach^nDA#Depomedroxyprogesterone-induced h
ypoestrogenism and changes in vaginal flora and epithelium^len#Obstet Gynecol#20
000000#2000#96#3#431-9#20110000#aop01211.htm#0029-7844#Obstet Gynecol##
00748000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01500122010001900137010001800156010001500174810000600189012011900195030001300314
06500090032706400050033603100030034103200020034401400070034686500090035300200130
0362035001000375801001300385#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#288#54#article#75#54#^rND^sKawano^nH#^rND^sMotoyama^nT#^rND^sHir
ai^nN#^rND^sYoshimura^nT#^rND^sKugiyama^nK#^rND^sOgawa^nH#et al#Effect of medrox
yprogesterone acetate plus estradiol on endothelium-dependent vasodilation in po
stmenopausal women^len#Am J Cardiol#20010000#2001#87#2#238-40#20110000#aop01211.
htm#0002-9149#Am J Cardiol##
00797000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070100
01400124010001500138010001800153010001700171810000600188012016800194030001200362
06500090037406400050038303100040038803200030039201400080039586500090040300200130
0412035001000425801001200435#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#289#55#article#75#55#^rND^sSorensen^nMB#^rND^sCollins^nP#^rND^sO
ng^nPJ#^rND^sWebb^nCM#^rND^sHayward^nCS#^rND^sAsbury^nEA#et al#Long-term use of 
contraceptive depot medroxyprogesterone acetate in young women impairs arterial 
endothelial function assessed by cardiovascular magnetic resonance^len#Circulati
on#20020000#2002#106#13#1646-51#20110000#aop01211.htm#0009-7322#Circulation##
00565000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880120091001060300
01300197065000900210064000500219031000300224032000900227014000600236865000900242
002001300251035001000264801001300274#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#290#56#article#75#56#^rND^sWesthoff^nC#Depot medroxyprog
esterone acetate contraception: metabolic parameters and mood changes^len#J Repr
od Med#19960000#1996#41#5^sSuppl#401-6#20110000#aop01211.htm#0024-7758#J Reprod 
Med##
00603000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070100
01600124012007600140030001400216065000900230064000500239031000300244032000200247
014000600249865000900255002001300264035001000277801001400287#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#291#57#article#75#57#^rND^sSuher
man^nSK#^rND^sAffandi^nB#^rND^sKorver^nT#The effects of Implanon on lipid metabo
lism in comparison with Norplant^len#Contraception#19990000#1999#60#5#281-7#2011
0000#aop01211.htm#0010-7824#Contraception##
00713000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01700122010001500139010001700154010001500171012013800186030003000324710000200354
065000900356064000500365031000300370014000400373865000900377002001300386#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#292#58#article#75#58
#^rND^sInnal^nMM#^rND^sYildirim^nY#^rND^sErtopcu^nK#^rND^sAvci^nME#^rND^sOzelmas
^nI#^rND^sTinar^nS#Effect of the subdermal contraceptive etonogestrel: Implant (
Implanon) on biochemical and hormonal parameters (three years follow-up)^len#Eur
 J Cont Reprod Health Care#2#20080000#2008#28#1-5#20110000#aop01211.htm##
00836000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100021001110100
01900132010001600151010001500167010002200182810000600204012016900210030002000379
06500090039906400050040803100040041303200020041701400150041986500090043400200130
0443035001000456801002000466#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01211.htm#S#c#293#59#article#75#59#^rND^sMorin-Papunen^nL#^rND^sMartikainen^nH
#^rND^sMcCarthy^nMI#^rND^sFranks^nS#^rND^sSovio^nU#^rND^sHartikainen^nAL#et al#c
omparison of metabolic and inflammatory outcomes in women who used oral contrace
ptives and the levonorgestrel-releasing intrauterine device in a general populat
ion^len#Am J Obstet Gynecol#20080000#2008#199#5#529.e1-529.e10#20110000#aop01211
.htm#0002-9378#Am J Obstet Gynecol##
00714000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100024000880100019001120100
01600131010001500147010002200162010002000184810000600204012010000210030001700310
71000020032706500090032906400050033803100020034303200020034501400070034786500090
0354002001300363#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#294#60#article#75#60#^rND^sVan Den Bosch^nMA#^rND^sKemmeren^nJM#^rND^sTanis^
nBC#^rND^sMali^nWP#^rND^sHelmerhorst^nFM#^rND^sRosendaal^nFR#et al#The RATIO stu
dy: oral contraceptives and the risk of peripheral arterial disease in young wom
en^len#J Thromb Haemost#2#20030000#2003#1#3#439-44#20110000#aop01211.htm##
00754000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
01600125010001500141012015600156030003600312065000900348064000500357031000200362
032000200364014000600366865000900372002001300381035001000394801003600404#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#295#61#article#75#61
#^rND^sHeinemann^nLA#^rND^sAssmann^nA#^rND^sDoMinh^nT#^rND^sGarbe^nE#Oral proges
togen-only contraceptives and cardiovascular risk: results from the Transnationa
l Study on Oral Contraceptives and the Health of Young Women^len#Eur J Contracep
t Reprod Health Care#19990000#1999#4#2#67-73#20110000#aop01211.htm#1362-5187#Eur
 J Contracept Reprod Health Care##
00688000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100018001080100
01600126010002000142010001900162010002000181012007600201030000700277065000900284
06400050029303100030029803200020030101400080030386500090031100200130032003500100
0333801000700343#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#296#62#article#75#62#^rND^sChakhtoura^nZ#^rND^sCanonico^nM#^rND^sGompel^nA#^
rND^sThalabard^nJC#^rND^sScarabin^nPY#^rND^sPlu-Bureau^nG#Progestogen-only contr
aceptives and the risk of stroke: a meta-analysis^len#Stroke#20090000#2009#40#4#
1059-62#20110000#aop01211.htm#0039-2499#Stroke##
00553000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880120093001060300
00900199065000900208064000500217031000300222032000200225014000700227865000900234
002001300243035001000256801000900266#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#297#63#article#75#63#^rND^sOelkers^nWK#Effects of estrog
ens and progestogens on the renin aldosterone system and blood pressure^len#Ster
oids#19960000#1996#61#4#166-71#20110000#aop01211.htm#0039-128X#Steroids##
00524000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880120043001090300
01800152065000900170064000500179031000300184032000200187014000700189865000900196
002001300205035001000218801001800228#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#298#64#article#75#64#^rND^sSitruk-Ware^nR#New progestage
ns for contraceptive use^len#Hum Reprod Update#20060000#2006#12#2#169-78#2011000
0#aop01211.htm#1355-4786#Hum Reprod Update##
00646000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
02000124012012100144030001000265065000900275064000500284031000300289032000200292
014000800294865000900302002001300311035001000324801001000334#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#299#65#article#75#65#^rND^sPalac
ios^nS#^rND^sFoidart^nJM#^rND^sGenazzani^nAR#Advances in hormone replacement the
rapy with drospirenone, a unique progestogen with aldosterone receptor antagonis
m^len#Maturitas#20060000#2006#55#4#297-307#20110000#aop01211.htm#0378-5122#Matur
itas##
00564000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880120098001060300
01200204065000900216064000500225031000200230032000400232014000600236865000900242
002001300251035001000264801001200274#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#300#66#article#75#66#^rND^sOelkers^nWH#Drospirenone in c
ombination with estrogens: for contraception and hormone replacement therapy^len
#Climacteric#20050000#2005#8#^s3#19-27#20110000#aop01211.htm#1369-7137#CLIMACTER
IC##
00664000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01700119010001400136012011600150030001300266065000900279064000500288031000300293
032000200296014000700298865000900305002001300314035001000327801001300337#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#301#67#article#75#67
#^rND^sWhite^nWB#^rND^sHanes^nV#^rND^sChauhan^nV#^rND^sPitt^nB#Effects of a new 
hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women wit
h hypertension^len#Hypertension#20060000#2006#48#2#246-53#20110000#aop01211.htm#
0194-911X#Hypertension##
00812000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
01500126010001500141010001500156010001400171012019000185030002000375065000900395
06400050040403100040040903200020041301400070041586500090042200200130043103500100
0444801002000454#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#302#68#article#75#68#^rND^sYildizhan^nR#^rND^sYildizhan^nB#^rND^sAdali^nE#^r
ND^sYoruk^nP#^rND^sBirol^nF#^rND^sSuer^nN#Effects of two combined oral contracep
tives containing ethinylestradiol 30 mcg combined with either gestodene or drosp
irenone on hemostatic parameters, lipid profiles and blood pressure^len#Arch Gyn
ecol Obstet#20090000#2009#280#2#255-61#20110000#aop01211.htm#0932-0067#Arch Gyne
col Obstet##
00724000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100025001090120
21600134030001400350065000900364064000500373031000300378032000200381014000500383
865000900388002001300397035001000410801001400420#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01211.htm#S#c#303#69#article#75#69#^rND^sSuthipongse^nW#^r
ND^sTaneepanichskul^nS#An open-label randomized comparative study of oral contra
ceptives between medications containing 3 mg drospirenone/30 microg ethinylestra
diol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women^len#C
ontraception#20040000#2004#69#1#23-6#20110000#aop01211.htm#0010-7824#Contracepti
on##
00623000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070100
01600124012009600140030001400236065000900250064000500259031000300264032000200267
014000600269865000900275002001300284035001000297801001400307#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#304#70#article#75#70#^rND^sLubia
nca^nJN#^rND^sFaccin^nCS#^rND^sFuchs^nFD#Oral contraceptives: a risk factor for 
uncontrolled blood pressure among hypertensive women^len#Contraception#20030000#
2003#67#1#19-24#20110000#aop01211.htm#0010-7824#Contraception##
00668000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01300125010001600138012011100154030001600265065000900281064000500290031000300295
032000200298014000600300865000900306002001300315035001000328801001600338#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#S#c#305#71#article#75#71
#^rND^sLubianca^nJN#^rND^sMoreira^nLB#^rND^sGus^nM#^rND^sFuchs^nFD#Stopping oral
 contraceptives: an effective blood pressure-lowering intervention in women with
 hypertension^len#J Hum Hypertens#20050000#2005#19#6#451-5#20110000#aop01211.htm
#0950-9240#J Hum Hypertens##
00766000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880100015001100100
01700125010001900142010001900161010002200180012013200202030001800334065000900352
06400050036103100030036603200020036901400070037186500090037800200130038703500100
0400801001800410#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01211.htm#
S#c#306#72#article#75#72#^rND^sde Carvalho^nMN#^rND^sNobre^nF#^rND^sMendes^nMC#^
rND^sDos Reis^nRM#^rND^sFerriani^nRA#^rND^sSilva de Sá^nMF#Low-dose transdermal 
hormone therapy does not interfere with the blood pressure of hypertensive menop
ausal women: a pilot study^len#Blood Press Monit#20080000#2008#13#5#277-83#20110
000#aop01211.htm#1359-5237#Blood Press Monit##
00729000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100012000880100019001000100
02500119012015900144030003300303065000900336064000500345031000400350032000200354
014000600356865000900362002001300371035001000384801003300394#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01211.htm#S#c#307#73#article#75#73#^rND^sDu^nY
#^rND^sMelchert^nHU#^rND^sSchäfer-Korting^nM#Use of oral contraceptives in Germa
ny: prevalence, determinants and use-associated health correlates. Results of Na
tional Health Surveys from 1984 to 1999^len#Eur J Obstet Gynecol Reprod Biol#200
70000#2007#134#1#57-66#20110000#aop01211.htm#0301-2115#Eur J Obstet Gynecol Repr
od Biol##
00566000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880120097001060300
01400203065000900217064000500226031000300231032000200234014000600236865000900242
002001300251035001000264801001400274#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01211.htm#S#c#308#74#article#75#74#^rND^sHussain^nSF#Progestogen-only 
pills and high blood pressure: is there an association? A literature review^len#
Contraception#20040000#2004#69#2#89-97#20110000#aop01211.htm#0010-7824#Contracep
tion##
00569000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100022001060120
05700128030001800185065000900203064000500212031000300217032000200220014000700222
865000900229002001300238035001000251801001800261#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01211.htm#S#c#309#75#article#75#75#^rND^sShufelt^nCL#^rND^
sBairey Merz^nCN#Contraceptive hormone use and cardiovascular disease^len#J Am C
oll Cardiol#20090000#2009#53#3#221-31#20110000#aop01211.htm#0735-1097#J Am Coll 
Cardiol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#o#1#1#
article#1#20110331#080919#aop01311.htm#257##
04220000000000661000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200880
01780120100002660100036003660100036004020100030004380100034004680700083005020831
30600585085000801891085003501899085002901934085003501963085003601998083128302034
08500080331708500290332508500270335408500260338108500360340705800370344311700080
34800720003034881120009034911110009035001160009035091150009035181140009035271130
00903536002001303545#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.
htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#23#nd#nd#Arq. Bras. Cardiol.#ah
ead#20110000#^f0^l0#0066-782X#20110225#Papel da titina na modulação da função ca
rdíaca e suas implicações fisiopatológicas^lpt#The role of titin in the modulati
on of cardiac function and its pathophysiological implications^len#^rND^1A01^nRi
cardo Castro^sFerreira#^rND^1A01^nRicardo Fontes^sCarvalho#^rND^1A01^nInês Falcã
o^sPires#^rND^1A01^nAdelino Leite^sMoreira#Universidade do Porto^iA01^1Faculdade
 de Medicina^2Serviço de Fisiologia^cPortugal#^lpt^aA titina é uma proteína sarc
omérica gigante que se estende desde a linha Z até a linha M. Em razão de sua lo
calização, representa um importante sensor biomecânico com um papel fundamental 
na manutenção da integridade estrutural do sarcômero. A titina funciona como uma
 "mola bidirecional" que regula o comprimento sarcomérico e realiza ajustes adeq
uados da tensão passiva sempre que o comprimento varia. Dessa forma, não só dete
rmina a rigidez ventricular e a função diastólica, como também influencia a funç
ão cardíaca sistólica, modulando o mecanismo de Frank-Starling. O miocárdio expr
essa duas isoformas dessa macromolécula: a N2B, mais rígida, e a isoforma N2BA, 
mais complacente. As alterações na expressão relativa das duas isoformas da titi
na ou alterações do seu estado de fosforilação têm sido implicadas na fisiopatol
ogia de várias doenças como a insuficiência cardíaca diastólica, a cardiomiopati
a dilatada, a cardiomiopatia isquêmica e a estenose aórtica. Neste artigo preten
de-se descrever sumariamente a estrutura e localização da titina, a sua relação 
com diferentes cardiomiopatias, e compreender de que forma as alterações dessa m
acromolécula influenciam a fisiopatologia da insuficiência cardíaca diastólica, 
salientando o potencial terapêutico da manipulação dessa macromolécula.#^dnd^i1#
^tm^lpt^kIsoformas de proteínas^i1#^tm^lpt^kmiosinas atriais^i1#^tm^lpt^kinsufic
iência cardíaca^i1#^tm^lpt^kcardiomiopatia dilatada^i1#^len^aTitin is a giant sa
rcomeric protein that extends from the Z-line to the M-line. Due to its location
, it represents an important biomechanical sensor, which has a crucial role in t
he maintenance of the sarcomere structural integrity. Titin works as a "bidireac
tional spring" that regulates the sarcomeric length and performs adequate adjust
ments of passive tension whenever the length varies. Therefore, it determines no
t only ventricular rigidity and diastolic function, but also systolic cardiac fu
nction, modulating the Frank-Starling mechanism. The myocardium expresses two is
oforms of this macromolecule: the N2B, more rigid and the isoform N2BA, more com
pliant. The alterations in the relative expression of the two titin isoforms or 
alterations in their state of phosphorylation have been implicated in the pathop
hysiology of several diseases, such as diastolic heart failure, dilated cardiomy
opathy, ischemic cardiomyopathy and aortic stenosis. The aim of this study is to
 describe, in brief, the structure and location of titin, its association with d
ifferent cardiomyopathies and understand how alterations in this macromolecule i
nfluence the pathophysiology of diastolic heart failure, emphasizing the therape
utic potential of the manipulation of this macromolecule.#^dnd^i2#^tm^len^kProte
in isoforms^i2#^tm^len^katrial myosins^i2#^tm^len^kheart failure^i2#^tm^len^kcar
diomyopathy, dilated^i2#Fundação para a Ciência e Tecnologia#vancouv#45#20090916
#16/09/09#20091105#05/11/09#20100126#26/01/10#aop01311.htm##
04234000000000661000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200950
01780120107002730100036003800100036004160100030004520100034004820700083005160831
30600599085000801905085003501913085002901948085003501977085003602012083128302048
08500080333108500290333908500270336808500260339508500360342105800370345711700080
34940720003035021120009035051110009035141160009035231150009035321140009035411130
00903550002001303559#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.
htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#23#nd#nd#Arq. Bras. Cardiol.#ah
ead#20110000#^f0^l0#0066-782X#20110225#<b>Papel da titina na modulação da função
 cardíaca e suas implicações fisiopatológicas</b>^lpt#<b>The role of titin in th
e modulation of cardiac function and its pathophysiological implications</b>^len
#^rND^1A01^nRicardo Castro^sFerreira#^rND^1A01^nRicardo Fontes^sCarvalho#^rND^1A
01^nInês Falcão^sPires#^rND^1A01^nAdelino Leite^sMoreira#Universidade do Porto^i
A01^1Faculdade de Medicina^2Serviço de Fisiologia^cPortugal#^lpt^aA titina é uma
 proteína sarcomérica gigante que se estende desde a linha Z até a linha M. Em r
azão de sua localização, representa um importante sensor biomecânico com um pape
l fundamental na manutenção da integridade estrutural do sarcômero. A titina fun
ciona como uma "mola bidirecional" que regula o comprimento sarcomérico e realiz
a ajustes adequados da tensão passiva sempre que o comprimento varia. Dessa form
a, não só determina a rigidez ventricular e a função diastólica, como também inf
luencia a função cardíaca sistólica, modulando o mecanismo de Frank-Starling. O 
miocárdio expressa duas isoformas dessa macromolécula: a N2B, mais rígida, e a i
soforma N2BA, mais complacente. As alterações na expressão relativa das duas iso
formas da titina ou alterações do seu estado de fosforilação têm sido implicadas
 na fisiopatologia de várias doenças como a insuficiência cardíaca diastólica, a
 cardiomiopatia dilatada, a cardiomiopatia isquêmica e a estenose aórtica. Neste
 artigo pretende-se descrever sumariamente a estrutura e localização da titina, 
a sua relação com diferentes cardiomiopatias, e compreender de que forma as alte
rações dessa macromolécula influenciam a fisiopatologia da insuficiência cardíac
a diastólica, salientando o potencial terapêutico da manipulação dessa macromolé
cula.#^dnd^i1#^tm^lpt^kIsoformas de proteínas^i1#^tm^lpt^kmiosinas atriais^i1#^t
m^lpt^kinsuficiência cardíaca^i1#^tm^lpt^kcardiomiopatia dilatada^i1#^len^aTitin
 is a giant sarcomeric protein that extends from the Z-line to the M-line. Due t
o its location, it represents an important biomechanical sensor, which has a cru
cial role in the maintenance of the sarcomere structural integrity. Titin works 
as a "bidireactional spring" that regulates the sarcomeric length and performs a
dequate adjustments of passive tension whenever the length varies. Therefore, it
 determines not only ventricular rigidity and diastolic function, but also systo
lic cardiac function, modulating the Frank-Starling mechanism. The myocardium ex
presses two isoforms of this macromolecule: the N2B, more rigid and the isoform 
N2BA, more compliant. The alterations in the relative expression of the two titi
n isoforms or alterations in their state of phosphorylation have been implicated
 in the pathophysiology of several diseases, such as diastolic heart failure, di
lated cardiomyopathy, ischemic cardiomyopathy and aortic stenosis. The aim of th
is study is to describe, in brief, the structure and location of titin, its asso
ciation with different cardiomyopathies and understand how alterations in this m
acromolecule influence the pathophysiology of diastolic heart failure, emphasizi
ng the therapeutic potential of the manipulation of this macromolecule.#^dnd^i2#
^tm^len^kProtein isoforms^i2#^tm^len^katrial myosins^i2#^tm^len^kheart failure^i
2#^tm^len^kcardiomyopathy, dilated^i2#Fundação para a Ciência e Tecnologia#vanco
uv#45#20090916#16/09/09#20091105#05/11/09#20100126#26/01/10#aop01311.htm##
04341000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120088001840120100002720100036003720100036004080100030004440100034004740700
08500508083130600593085000801899085003501907085002901942085003501971085003602006
08312830204208500080332508500290333308500270336208500260338908500360341505800370
34511170008034880720003034961120009034991110009035081160009035171150009035261140
00903535113000903544002001303553008008903566#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop01311.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#tab#
23#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110225#Papel da ti
tina na modulação da função cardíaca e suas implicações fisiopatológicas^lpt#The
 role of titin in the modulation of cardiac function and its pathophysiological 
implications^len#^rND^1A01^nRicardo Castro^sFerreira#^rND^1A01^nRicardo Fontes^s
Carvalho#^rND^1A01^nInês Falcão^sPires#^rND^1A01^nAdelino Leite^sMoreira#^iA01^1
Universidade do Porto^2Faculdade de Medicina^3Serviço de Fisiologia^cPortugal#^l
pt^aA titina é uma proteína sarcomérica gigante que se estende desde a linha Z a
té a linha M. Em razão de sua localização, representa um importante sensor biome
cânico com um papel fundamental na manutenção da integridade estrutural do sarcô
mero. A titina funciona como uma "mola bidirecional" que regula o comprimento sa
rcomérico e realiza ajustes adequados da tensão passiva sempre que o comprimento
 varia. Dessa forma, não só determina a rigidez ventricular e a função diastólic
a, como também influencia a função cardíaca sistólica, modulando o mecanismo de 
Frank-Starling. O miocárdio expressa duas isoformas dessa macromolécula: a N2B, 
mais rígida, e a isoforma N2BA, mais complacente. As alterações na expressão rel
ativa das duas isoformas da titina ou alterações do seu estado de fosforilação t
êm sido implicadas na fisiopatologia de várias doenças como a insuficiência card
íaca diastólica, a cardiomiopatia dilatada, a cardiomiopatia isquêmica e a esten
ose aórtica. Neste artigo pretende-se descrever sumariamente a estrutura e local
ização da titina, a sua relação com diferentes cardiomiopatias, e compreender de
 que forma as alterações dessa macromolécula influenciam a fisiopatologia da ins
uficiência cardíaca diastólica, salientando o potencial terapêutico da manipulaç
ão dessa macromolécula.#^dnd^i1#^tm^lpt^kIsoformas de proteínas^i1#^tm^lpt^kmios
inas atriais^i1#^tm^lpt^kinsuficiência cardíaca^i1#^tm^lpt^kcardiomiopatia dilat
ada^i1#^len^aTitin is a giant sarcomeric protein that extends from the Z-line to
 the M-line. Due to its location, it represents an important biomechanical senso
r, which has a crucial role in the maintenance of the sarcomere structural integ
rity. Titin works as a "bidireactional spring" that regulates the sarcomeric len
gth and performs adequate adjustments of passive tension whenever the length var
ies. Therefore, it determines not only ventricular rigidity and diastolic functi
on, but also systolic cardiac function, modulating the Frank-Starling mechanism.
 The myocardium expresses two isoforms of this macromolecule: the N2B, more rigi
d and the isoform N2BA, more compliant. The alterations in the relative expressi
on of the two titin isoforms or alterations in their state of phosphorylation ha
ve been implicated in the pathophysiology of several diseases, such as diastolic
 heart failure, dilated cardiomyopathy, ischemic cardiomyopathy and aortic steno
sis. The aim of this study is to describe, in brief, the structure and location 
of titin, its association with different cardiomyopathies and understand how alt
erations in this macromolecule influence the pathophysiology of diastolic heart 
failure, emphasizing the therapeutic potential of the manipulation of this macro
molecule.#^dnd^i2#^tm^len^kProtein isoforms^i2#^tm^len^katrial myosins^i2#^tm^le
n^kheart failure^i2#^tm^len^kcardiomyopathy, dilated^i2#Fundação para a Ciência 
e Tecnologia#vancouv#45#20090916#16/09/09#20091105#05/11/09#20100126#26/01/10#ao
p01311.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S006
6-782X2011005000023##
00495000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704025300083002001300336#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#5#1#article#208#<p><a name="
top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Papel   
 da titina na modula&ccedil;&atilde;o da fun&ccedil;&atilde;o card&iacute;aca   
 e suas implica&ccedil;&otilde;es fisiopatol&oacute;gicas</b></font></p>     ^cY
#aop01311.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#6#2#article#208#<p>&nbsp;</p
>     ^cY#aop01311.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#7#3#article#208#<p>&nbsp;</p
>     ^cY#aop01311.htm##
00441000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704019900083002001300282#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#8#4#article#208#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Ricardo Castro    Ferreira
; Ricardo Fontes Carvalho; In&ecirc;s Falc&atilde;o Pires; Adelino Leite    More
ira</b></font></p>     ^cY#aop01311.htm##
00413000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704017100083002001300254#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#9#5#article#208#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Servi&ccedil;o    de Fisiolog
ia Faculdade de Medicina da Universidade do Porto, Portugal</font></p>     ^cY#a
op01311.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#10#6#article#208#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01311.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#11#7#article#208#<p>&nbsp;</
p>     ^cY#aop01311.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#12#8#article#208#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01311.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#13#9#article#208#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop01311.htm##
01072000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704082800085002001300913#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#14#10#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina &eacute;    uma pr
ote&iacute;na sarcom&eacute;rica gigante que se estende desde a linha    Z at&ea
cute; a linha M. Em raz&atilde;o de sua localiza&ccedil;&atilde;o, representa   
 um importante sensor biomec&acirc;nico com um papel fundamental na manuten&cced
il;&atilde;o    da integridade estrutural do sarc&ocirc;mero. A titina funciona 
como uma "mola    bidirecional" que regula o comprimento sarcom&eacute;rico e re
aliza ajustes    adequados da tens&atilde;o passiva sempre que o comprimento var
ia. Dessa forma,    n&atilde;o s&oacute; determina a rigidez ventricular e a fun
&ccedil;&atilde;o    diast&oacute;lica, como tamb&eacute;m influencia a fun&cced
il;&atilde;o card&iacute;aca    sist&oacute;lica, modulando o mecanismo de Frank
-Starling.    ^cY#aop01311.htm##
00793000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054900085002001300634#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#15#11#article#208#<br>   O m
ioc&aacute;rdio expressa duas isoformas dessa macromol&eacute;cula: a N2B,    ma
is r&iacute;gida, e a isoforma N2BA, mais complacente. As altera&ccedil;&otilde;
es    na express&atilde;o relativa das duas isoformas da titina ou altera&ccedil
;&otilde;es    do seu estado de fosforila&ccedil;&atilde;o t&ecirc;m sido implic
adas na fisiopatologia    de v&aacute;rias doen&ccedil;as como a insufici&ecirc;
ncia card&iacute;aca diast&oacute;lica,    a cardiomiopatia dilatada, a cardiomi
opatia isqu&ecirc;mica e a estenose a&oacute;rtica.    ^cY#aop01311.htm##
00709000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046500085002001300550#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#16#12#article#208#<br>   Nes
te artigo pretende-se descrever sumariamente a estrutura e localiza&ccedil;&atil
de;o    da titina, a sua rela&ccedil;&atilde;o com diferentes cardiomiopatias, e
 compreender    de que forma as altera&ccedil;&otilde;es dessa macromol&eacute;c
ula influenciam    a fisiopatologia da insufici&ecirc;ncia card&iacute;aca diast
&oacute;lica, salientando    o potencial terap&ecirc;utico da manipula&ccedil;&a
tilde;o dessa macromol&eacute;cula.</font></p>     ^cY#aop01311.htm##
00489000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024500085002001300330#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#17#13#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Isoformas de prote&iacute;nas, miosinas atriais, insufici&ecirc;ncia card&iacute
;aca,    cardiomiopatia dilatada.</font></p> <hr size="1" noshade>     ^cY#aop01
311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#18#14#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#19#15#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#20#16#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01311.htm##
00739000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049500085002001300580#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#21#17#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina, descrita    inici
almente como conectina, &eacute; uma prote&iacute;na gigante com grande    elast
icidade e que pode ser encontrada apenas nos m&uacute;sculos card&iacute;aco    
e esquel&eacute;tico. Estruturalmente, est&aacute; localizada no interior dos   
 sarc&ocirc;meros, onde se liga a, e interage com, outras importantes prote&iacu
te;nas    miofilamentares, nomeadamente com a actina e a miosina.</font></p>    
 ^cY#aop01311.htm##
01158000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704091400085002001300999#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#22#18#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na &uacute;ltima    d&eacut
e;cada, tem sido demonstrado que a titina &eacute; uma prote&iacute;na    estrut
uralmente complexa que desempenha um papel importante no funcionamento    do m&u
acute;sculo estriado, particularmente do m&uacute;sculo card&iacute;aco.    Entr
e as suas diversas a&ccedil;&otilde;es destaca-se seu papel na manuten&ccedil;&a
tilde;o    da estrutura e arquitetura do sarc&ocirc;mero permitindo o correto al
inhamento    dos miofilamentos de actina e miosina, bem como sua fun&ccedil;&ati
lde;o "el&aacute;stica",    que permite a regula&ccedil;&atilde;o do comprimento
 e da distensibilidade do    sarc&ocirc;mero, influenciando, desse modo, n&atild
e;o s&oacute; a fun&ccedil;&atilde;o    card&iacute;aca diast&oacute;lica, como 
tamb&eacute;m a fun&ccedil;&atilde;o    sist&oacute;lica pela lei de Frank-Starl
ing.</font></p>     ^cY#aop01311.htm##
00766000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052200085002001300607#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#23#19#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">com este artigo    de revis
&atilde;o pretendemos rever a estrutura e as principais a&ccedil;&otilde;es    f
isiol&oacute;gicas da titina, nomeadamente a sua import&acirc;ncia na determina&
ccedil;&atilde;o    da fun&ccedil;&atilde;o card&iacute;aca diast&oacute;lica e 
sist&oacute;lica    e as implica&ccedil;&otilde;es das altera&ccedil;&otilde;es 
nessa macromol&eacute;cula    na fisiopatologia da insufici&ecirc;ncia card&iacu
te;aca (IC).</font></p>     ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#24#20#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00384000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014000085002001300225#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#25#21#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Estrutura e    localiza&
ccedil;&atilde;o da titina</b></font></p>     ^cY#aop01311.htm##
00784000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054000085002001300625#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#26#22#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina &eacute;    a maio
r prote&iacute;na encontrada nos mam&iacute;feros, variando entre 2970    e 3700
 kD, dependendo da isoforma<sup>1</sup>. &Eacute; codificada por um &uacute;nico
    gene, localizado no bra&ccedil;o longo do cromossoma 2, na regi&atilde;o 2q3
1,    constitu&iacute;do por 363 ex&otilde;es. No cora&ccedil;&atilde;o, a titin
a    possui duas isoformas, N2B e N2BA, que s&atilde;o geradas por <i>splicing</
i>    alternativo<sup>1</sup>.</font></p>     ^cY#aop01311.htm##
00887000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064300085002001300728#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#27#23#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina &eacute;    consti
tu&iacute;da majoritariamente por dois tipos de dom&iacute;nios: uns semelhantes
    &agrave; fibronectina-3 (chamados dom&iacute;nios Fn3), e outros semelhantes
    &agrave; imunoglobulina (dom&iacute;nios Ig). Al&eacute;m desses dom&iacute;
nios,    a titina cont&eacute;m ainda um dom&iacute;nio c&iacute;nase, localizad
o pr&oacute;ximo    do terminal carboxilo, e v&aacute;rias regi&otilde;es de seq
u&ecirc;ncia &uacute;nica<sup>1-3</sup>    (<a href="/img/revistas/abc/2011nahea
d/aop01311f01.jpg">fig. 1</a> e <a href="#f2">2</a>).</font></p>     ^cY#aop0131
1.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#28#24#article#208#<p><a name
="f2"></a></p>     ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#29#25#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#30#26#article#208#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01311f02.jpg"></p>     ^cY#aop
01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#31#27#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
03153000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704290900085002001302994#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#32#28#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina &eacute;    uma pr
ote&iacute;na intrassarcom&eacute;rica, com cerca de 1 &#181;m de comprimento,  
  que se estende desde a linha Z at&eacute; &agrave; linha M<sup>2</sup>. Desse 
   modo, a titina abrange quatro zonas do sarc&ocirc;mero, pelo que tradicionalm
ente    &eacute; dividida em quatro regi&otilde;es distintas designadas respecti
vamente    de regi&atilde;o da linha M, da banda A, da banda I e da linha Z (<a 
href="/img/revistas/abc/2011nahead/aop01311f01.jpg">fig.    1</a>). A regi&atild
e;o da linha Z cont&eacute;m o terminal amina, enquanto    na regi&atilde;o da l
inha M est&aacute; localizado o terminal carboxilo. como    veremos em seguida, 
na regi&atilde;o da linha Z a titina interage com outras    prote&iacute;nas, es
tando ainda envolvida em mecanismos de sinaliza&ccedil;&atilde;o    intracelular
, funcionando como um sensor biomec&acirc;nico<sup>4</sup>. A regi&atilde;o    d
a banda A cont&eacute;m a maior parte da mol&eacute;cula de titina que, nesse   
 local, &eacute; formada por repeti&ccedil;&otilde;es simples de dom&iacute;nios
    Ig e Fn3, e representa um componente integrante do filamento grosso (<a href
="/img/revistas/abc/2011nahead/aop01311f01.jpg">fig.    1</a>). Dessa forma, ess
a regi&atilde;o da titina n&atilde;o &eacute; extens&iacute;vel    e a sua const
itui&ccedil;&atilde;o &eacute; semelhante nas diferentes isoformas    da mol&eac
ute;cula (N2B e N2BA)<sup>5</sup>. Pelo contr&aacute;rio, a regi&atilde;o    da 
banda I &eacute; muito extens&iacute;vel, dada a sua capacidade de se alongar   
 ou enrolar, funcionando assim como uma liga&ccedil;&atilde;o "el&aacute;stica" 
   entre o filamento grosso e a linha Z (<a href="#f3">fig. 3</a>). Estruturalme
nte,    a por&ccedil;&atilde;o da titina presente na banda I &eacute; muito mais
 complexa    do que a regi&atilde;o da banda A, sendo constitu&iacute;da por dom
&iacute;nios    Ig, pela regi&atilde;o N2 e pelo segmento PEVK (rico nos amino&a
acute;cidos    prolina (P), glutamato (E), valina (V) e lisina (K))<sup>3,6</sup
> (<a href="#f2">fig.    2</a>). Al&eacute;m disso, &eacute; a regi&atilde;o da 
banda I que diferencia    as diferentes isoformas da titina<sup>6</sup>, uma vez
 que a sub-regi&atilde;o    N2 pode ter dois elementos distintos: N2A e/ou N2B (
<a href="#f2">fig. 2</a>).    O elemento N2A &eacute; composto por uma regi&atil
de;o com quatro dom&iacute;nios    Ig e uma regi&atilde;o &uacute;nica de 106 re
s&iacute;duos e o elemento N2B    &eacute; constitu&iacute;do por uma regi&atild
e;o com tr&ecirc;s dom&iacute;nios    Ig e uma regi&atilde;o &uacute;nica de 572
 res&iacute;duos. As sequ&ecirc;ncias    N2A est&atilde;o presentes quer no m&ua
cute;sculo card&iacute;aco quer no esquel&eacute;tico,    enquanto as sequ&ecirc
;ncias N2B s&atilde;o exclusivas do m&uacute;sculo card&iacute;aco<sup>6</sup>.<
/font></p>     ^cY#aop01311.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#33#29#article#208#<p><a name
="f3"></a></p>     ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#34#30#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#35#31#article#208#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01311f03.jpg"></p>     ^cY#aop
01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#36#32#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00376000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013200085002001300217#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#37#33#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Propriedades    el&aacut
e;sticas da titina</b></font></p>     ^cY#aop01311.htm##
00829000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058500085002001300670#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#38#34#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A principal caracter&iacute
;stica    da titina &eacute; a sua elevada elasticidade, que lhe permite distend
er-se    e encurtar-se regulando assim o comprimento do sarc&ocirc;mero e a fun&
ccedil;&atilde;o    muscular. Para comprimentos sarcom&eacute;ricos fisiol&oacut
e;gicos, a titina    constitui o principal determinante da tens&atilde;o passiva
 dos cardiomi&oacute;citos.    E, para comprimentos suprafisiol&oacute;gicos, o 
colag&ecirc;nio da matriz extracelular    adquire maior relevo<sup>2</sup>.</fon
t></p>     ^cY#aop01311.htm##
01336000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704109200085002001301177#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#39#35#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">como foi referido    anteri
ormente, as propriedades el&aacute;sticas da titina devem-se sobretudo    &agrav
e; regi&atilde;o na banda I, j&aacute; que, na banda A, a titina &eacute;    pra
ticamente inextens&iacute;vel<sup>7,8</sup>. A elasticidade da titina na    regi
&atilde;o da banda I &eacute; conferida por uma estrutura molecular constitu&iac
ute;da    por v&aacute;rios segmentos extens&iacute;veis, nomeadamente por um gr
ande n&uacute;mero    de segmentos Ig, por um segmento PEVK e pela regi&atilde;o
 N2 (<a href="/img/revistas/abc/2011nahead/aop01311f01.jpg">fig.    1</a>, <a hr
ef="#f2">2</a> e <a href="#f3">3</a>). O comportamento desses diferentes    segm
entos durante a distens&atilde;o muscular e o desenvolvimento de tens&atilde;o  
  passiva &eacute; complexo, uma vez que os v&aacute;rios segmentos t&ecirc;m   
 diferentes rela&ccedil;&otilde;es tens&atilde;o passiva-comprimento e, al&eacut
e;m    disso, cada um se distende em diferentes momentos conforme o comprimento 
do    sarc&ocirc;mero.</font></p>     ^cY#aop01311.htm##
01723000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704147900085002001301564#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#40#36#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na aus&ecirc;ncia    de for
&ccedil;as externas, os sarc&ocirc;meros dos cardiomi&oacute;citos t&ecirc;m    
um tamanho de 1,9 &#181;m, e nessas condi&ccedil;&otilde;es de repouso a titina 
   est&aacute; no seu estado contra&iacute;do (<a href="#f3">fig. 3</a>)<sup>2</
sup>    com o estiramento progressivo do sarc&ocirc;mero, inicialmente ocorre o 
alongamento    da sequ&ecirc;ncia I g, por meio do estiramento das liga&ccedil;&
otilde;es entre    os diferentes dom&iacute;nios Ig. S&oacute; a partir dos 2,15
 &#181;m &eacute;    que ocorre o alongamento dos segmentos PEVK, e posteriormen
te do segmento N2,    em especial por interm&eacute;dio do desenrolar dos seus d
om&iacute;nios<sup>8</sup>.    &Eacute; esse comportamento complexo observado na
 regi&atilde;o extens&iacute;vel    da titina que faz que a curva tens&atilde;o 
passiva-comprimento do sarc&ocirc;mero    n&atilde;o seja linear, ou seja, como 
se pode observar na <a href="/img/revistas/abc/2011nahead/aop01311f04.jpg">figur
a    4</a>, quanto maior o comprimento do sarc&ocirc;mero, maior &eacute; a incl
ina&ccedil;&atilde;o    da curva comprimento-tens&atilde;o passiva<sup>1-3,7</su
p>. Esse comportamento    permite que, durante o alongamento do sarc&ocirc;mero 
que ocorre durante a di&aacute;stole,    n&atilde;o se desenvolva uma tens&atild
e;o passiva excessiva, o que iria prejudicar    a fun&ccedil;&atilde;o diast&oac
ute;lica.</font></p>     ^cY#aop01311.htm##
01089000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704084500085002001300930#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#41#37#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina &eacute;    n&atil
de;o s&oacute; o principal determinante da tens&atilde;o passiva em resposta    
ao estiramento, como funciona tamb&eacute;m como uma mola el&aacute;stica bidire
cional.    Isso porque, pelo contr&aacute;rio, quando o comprimento do sarc&ocir
c;mero    &eacute; encurtado para valores inferiores ao comprimento de repouso, 
a titina    tamb&eacute;m gera uma for&ccedil;a el&aacute;stica que tem uma dire
&ccedil;&atilde;o    contr&aacute;ria &agrave; da tens&atilde;o passiva tradicio
nal. Essa for&ccedil;a,    designada "for&ccedil;a de restaura&ccedil;&atilde;o"
, permite o r&aacute;pido    restabelecimento do comprimento do sarc&ocirc;mero 
para os valores de repouso,    empurrando o filamento grosso para longe da linha
 Z<sup>9</sup>.</font></p>     ^cY#aop01311.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013500085002001300220#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#42#38#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>A titina no    m&uacute;
sculo card&iacute;aco</b></font></p>     ^cY#aop01311.htm##
00858000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704061400085002001300699#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#43#39#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No m&uacute;sculo    card&i
acute;aco existem duas isoformas de titina: a isoforma N2B e a isoforma    N2BA.
 A isoforma N2B &eacute; a mais pequena (2970 kDa) uma vez que na sub-regi&atild
e;o    N2 &eacute; constitu&iacute;da apenas pelo elemento N2B. Por sua vez, a i
soforma    N2BA tem maiores dimens&otilde;es (3200 a 3400 kDa) e cont&eacute;m a
mbos os    elementos: N2B e N2A. No ser humano, em cada metade do sarc&ocirc;mer
o est&atilde;o    presentes as isoformas N2BA e N2B, numa raz&atilde;o aproximad
a de 30/70<sup>10</sup>.</font></p>     ^cY#aop01311.htm##
01825000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704158100085002001301666#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#44#40#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A isoforma N2BA    possui m
ais um elemento extens&iacute;vel na regi&atilde;o da banda I, pelo    que essa 
isoforma &eacute; mais distens&iacute;vel e menos r&iacute;gida que    a N2B (<a
 href="#f2">fig. 2</a>). Desse modo, os cardiomi&oacute;citos que expressam    m
aiores quantidades da isoforma N2B possuem uma maior rigidez do que aqueles    q
ue expressam uma maior propor&ccedil;&atilde;o relativa da isoforma N2BA<sup>1,3
,11</sup>.    Adicionalmente, a propor&ccedil;&atilde;o relativa das diferentes 
isoformas    determina tamb&eacute;m o recolhimento el&aacute;stico ap&oacute;s 
a contra&ccedil;&atilde;o    ventricular. Os cardiomi&oacute;citos com um elevad
o grau de express&atilde;o    da isoforma N2B, mais r&iacute;gida, possuem tamb&
eacute;m maior for&ccedil;a    de restaura&ccedil;&atilde;o, ou seja, ap&oacute;
s a contra&ccedil;&atilde;o    o comprimento do sarc&ocirc;mero regressa mais ra
pidamente ao comprimento de    repouso. Isso ocorre porque, como a isoforma N2B 
&eacute; menos extens&iacute;vel,    n&atilde;o s&oacute; exerce uma maior tens&
atilde;o passiva durante o estiramento,    como tamb&eacute;m gera uma maior for
&ccedil;a para retomar o comprimento de    repouso ap&oacute;s a contra&ccedil;&
atilde;o. Desse modo, nos ventr&iacute;culos    com elevadas propor&ccedil;&otil
de;es da isoforma N2B, h&aacute; uma maior velocidade    de recolhimento el&aacu
te;stico, levando a um encurtamento da dura&ccedil;&atilde;o    da fase inicial 
da di&aacute;stole<sup>6</sup>.</font></p>     ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#45#41#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00402000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015800085002001300243#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#46#42#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Fun&ccedil;&otilde;es   
 da titina no m&uacute;sculo card&iacute;aco</b></font></p>     ^cY#aop01311.htm
##
00421000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017700085002001300262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#47#43#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>A titina como    determi
nante da fun&ccedil;&atilde;o card&iacute;aca diast&oacute;lica</b></font></p>  
   ^cY#aop01311.htm##
01016000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077200085002001300857#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#48#44#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os principais determinantes
    da fun&ccedil;&atilde;o card&iacute;aca diast&oacute;lica s&atilde;o o relax
amento    do mioc&aacute;rdio e as propriedades passivas do ventr&iacute;culo. E
nquanto    o relaxamento mioc&aacute;rdico &eacute; modulado pela carga, pela in
ativa&ccedil;&atilde;o    (associada &agrave; cin&eacute;tica do c&aacute;lcio e
 &agrave; dissocia&ccedil;&atilde;o    dos miofilamentos) e pela n&atilde;o unif
ormidade da parede ventricular, as    propriedades passivas mioc&aacute;rdicas s
&atilde;o influenciadas pela rigidez    mioc&aacute;rdica, pela espessura da par
ede do ventr&iacute;culo esquerdo e    pela geometria das c&acirc;maras card&iac
ute;acas<sup>12</sup>.</font></p>     ^cY#aop01311.htm##
00609000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036500085002001300450#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#49#45#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A disfun&ccedil;&atilde;o  
  diast&oacute;lica &eacute; causada por uma lentifica&ccedil;&atilde;o do relax
amento    mioc&aacute;rdico e/ou por altera&ccedil;&otilde;es das propriedades p
assivas    do ventr&iacute;culo, nomeadamente pelo aumento da rigidez ventricula
r<sup>12</sup>.</font></p>     ^cY#aop01311.htm##
00409000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016500085002001300250#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#50#46#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Influ&ecirc;ncia    da t
itina nas propriedade passivas do ventr&iacute;culo</b></font></p>     ^cY#aop01
311.htm##
00920000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067600085002001300761#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#51#47#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O aumento da rigidez    ven
tricular pode ser causado por altera&ccedil;&otilde;es das caracter&iacute;stica
s    intr&iacute;nsecas dos pr&oacute;prios cardiomi&oacute;citos - como por mod
ifica&ccedil;&otilde;es    na constitui&ccedil;&atilde;o das prote&iacute;nas do
 citosqueleto ou ent&atilde;o    das prote&iacute;nas endosarcom&eacute;ricas (c
omo altera&ccedil;&otilde;es    na titina ou na alfa-actinina) - ou por altera&c
cedil;&otilde;es da constitui&ccedil;&atilde;o    da matriz extracelular, nomead
amente pelo aumento da rede de colag&ecirc;neo    e fibrose extracelular<sup>12<
/sup>.</font></p>     ^cY#aop01311.htm##
01268000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704102400085002001301109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#52#48#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina &eacute;    um imp
ortante determinante da fun&ccedil;&atilde;o diast&oacute;lica, uma vez    que i
nfluencia a rigidez do cardiomi&oacute;cito e, dessa forma, as propriedades    p
assivas do ventr&iacute;culo. como foi visto anteriormente, atendendo &agrave;  
  sua localiza&ccedil;&atilde;o estrat&eacute;gica no sarc&ocirc;mero, e &agrave
;s    suas propriedades el&aacute;sticas &uacute;nicas, a titina &eacute; o prin
cipal    determinante da tens&atilde;o passiva do cardiomi&oacute;cito, para com
primentos    fisiol&oacute;gicos do sarc&ocirc;mero<sup>7,13</sup>, sendo a cont
ribui&ccedil;&atilde;o    relativa dos filamentos interm&eacute;dios e dos micro
t&uacute;bulos inferior    a 10%<sup>14</sup>. Para comprimentos superiores a 2,
3 mm, dificilmente atingidos    no cora&ccedil;&atilde;o intato, a tens&atilde;o
 passiva passa a ser determinada    essencialmente pelo colag&ecirc;nio e pela m
atriz extracelular<sup>7,11</sup>.</font></p>     ^cY#aop01311.htm##
00842000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059800085002001300683#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#53#49#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A import&acirc;ncia    da t
itina na determina&ccedil;&atilde;o da fun&ccedil;&atilde;o diast&oacute;lica   
 tem impacto no n&iacute;vel fisiopatol&oacute;gico, uma vez que, como veremos  
  mais &agrave; frente, foi demonstrado que doentes com IC diast&oacute;lica apr
esentam    uma altera&ccedil;&atilde;o na propor&ccedil;&atilde;o relativa das i
soformas    da titina, com aumento da isoforma N2B (mais r&iacute;gida) o que pa
rece explicar    o aumento da rigidez ventricular observado nesses doentes<sup>1
5</sup>.</font></p>     ^cY#aop01311.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#54#50#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Influ&ecirc;ncia    da t
itina no relaxamento ventricular</b></font></p>     ^cY#aop01311.htm##
00928000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068400085002001300769#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#55#51#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina n&atilde;o    dete
rmina apenas a rigidez ventricular. como foi referido anteriormente, a titina   
 possui propriedades el&aacute;sticas que funcionam de forma bidirecional, ou   
 seja, se por um lado gera tens&atilde;o passiva quando o m&uacute;sculo &eacute
;    estirado, por outro, quando h&aacute; encurtamento do sarc&ocirc;mero, a ti
tina    gera uma "for&ccedil;a de restaura&ccedil;&atilde;o", que tem uma dire&c
cedil;&atilde;o    oposta &agrave; da tens&atilde;o passiva e permite uma r&aacu
te;pida recupera&ccedil;&atilde;o    do comprimento de repouso do sarc&ocirc;mer
o<sup>9</sup>.</font></p>     ^cY#aop01311.htm##
00869000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704062500085002001300710#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#56#52#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em termos hemodin&acirc;mic
os,    essa "for&ccedil;a de restaura&ccedil;&atilde;o" gerada pela titina permi
te    aumentar a velocidade de relaxamento ventricular e permite a forma&ccedil;
&atilde;o    de um fen&ocirc;meno de "suc&ccedil;&atilde;o ventricular". Essa fo
r&ccedil;a    permite aumentar o enchimento ventricular, sobretudo na fase inici
al da di&aacute;stole,    o que pode ser particularmente importante nas situa&cc
edil;&otilde;es de exerc&iacute;cio    f&iacute;sico ou outras situa&ccedil;&oti
lde;es de taquicardia<sup>16</sup>.</font></p>     ^cY#aop01311.htm##
00906000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066200085002001300747#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#57#53#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Al&eacute;m disso,    ainda
 antes do in&iacute;cio da di&aacute;stole, a titina interv&eacute;m tamb&eacute
;m    na determina&ccedil;&atilde;o do fim da contra&ccedil;&atilde;o mioc&aacut
e;rdica,    um processo que tamb&eacute;m &eacute; dependente do comprimento do 
sarc&ocirc;mero.    Na verdade, quando h&aacute; o encurtamento do sarc&ocirc;me
ro para valores    inferiores ao comprimento de repouso a titina vai facilitar o
 processo de desativa&ccedil;&atilde;o    das pontes cruzadas, influenciando e d
eterminando o fim da contra&ccedil;&atilde;o    muscular<sup>9,16</sup>.</font><
/p>     ^cY#aop01311.htm##
00423000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017900085002001300264#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#58#54#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>A titina como    um dete
rminante da fun&ccedil;&atilde;o card&iacute;aca sist&oacute;lica</b></font></p>
     ^cY#aop01311.htm##
00615000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037100085002001300456#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#59#55#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina &eacute;    um imp
ortante determinante da fun&ccedil;&atilde;o card&iacute;aca diast&oacute;lica  
  mas influencia tamb&eacute;m a fun&ccedil;&atilde;o sist&oacute;lica, pelo efe
ito    que exerce na modula&ccedil;&atilde;o da rela&ccedil;&atilde;o de Frank-S
tarling<sup>17</sup>.</font></p>     ^cY#aop01311.htm##
00826000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058200085002001300667#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#60#56#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Segundo a Lei de    Frank-S
tarling, o aumento da pr&eacute;-carga, ou seja, o aumento do volume    teledias
t&oacute;lico melhora a fun&ccedil;&atilde;o sist&oacute;lica originando    um a
umento do volume de eje&ccedil;&atilde;o. A titina, como determinante da    rigi
dez ventricular e das propriedades passivas do ventr&iacute;culo, influencia    
a rela&ccedil;&atilde;o press&atilde;o-volume telediast&oacute;lica e, assim,   
 o enchimento ventricular e o volume telediast&oacute;lico<sup>18</sup>.</font><
/p>     ^cY#aop01311.htm##
01685000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704144100085002001301526#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#61#57#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em n&iacute;vel    celular,
 o mecanismo de Frank-Starling &eacute; explicado pela ocorr&ecirc;ncia    de um
 aumento da sensibilidade dos miofilamentos ao Ca<sup>2+</sup> em resposta    ao
 aumento do comprimento do sarc&ocirc;mero<sup>19</sup>. A titina desempenha    
um papel fundamental na regula&ccedil;&atilde;o desse mecanismo, uma vez que    
a tens&atilde;o passiva exercida pela titina determina diretamente o aumento    
da sensibilidade dos miofilamentos ao c&aacute;lcio<sup>17,20,21</sup>. Al&eacut
e;m    disso, a titina, como elemento estrutural do filamento grosso na regi&ati
lde;o    da banda A, &eacute; tamb&eacute;m capaz de influenciar diretamente a l
iga&ccedil;&atilde;o    entre os miofilamentos de actina e miosina, conforme o c
omprimento do sarc&ocirc;mero.    Ou seja, quando aumenta o comprimento do sarc&
ocirc;mero a titina parece potenciar    a liga&ccedil;&atilde;o entre os filamen
tos de actina e de miosina, com o consequente    aumento da for&ccedil;a de cont
ra&ccedil;&atilde;o<sup>22</sup>. Desse modo,    a titina &eacute; capaz de "pot
enciar" o ciclo das pontes cruzadas quando o    sarc&ocirc;mero &eacute; estirad
o, e que quando ele &eacute; encurtado para    dimens&otilde;es abaixo do seu co
mprimento de repouso, a titina &eacute; tamb&eacute;m    capaz de inibir a forma
&ccedil;&atilde;o das pontes cruzadas<sup>16</sup>.</font></p>     ^cY#aop01311.
htm##
00416000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017200085002001300257#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#62#58#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>A titina na    sinaliza&
ccedil;&atilde;o intracelular: um sensor biomec&acirc;nico</b></font></p>     ^c
Y#aop01311.htm##
00983000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073900085002001300824#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#63#59#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Al&eacute;m da    sua fun&c
cedil;&atilde;o estrutural e el&aacute;stica, a titina funciona tamb&eacute;m   
 como um sensor biomec&acirc;nico. Dada a sua capacidade de distender e encurtar
,    a titina &eacute; sens&iacute;vel ao grau de estiramento do cardiomi&oacute
;cito<sup>6,23</sup>    sendo depois capaz de transmitir esse sinal biomec&acirc
;nico pela liga&ccedil;&atilde;o    e intera&ccedil;&atilde;o que estabelece com
 v&aacute;rias prote&iacute;nas    estruturais e sinalizadoras. Essa sinaliza&cc
edil;&atilde;o ocorre sobretudo    em tr&ecirc;s regi&otilde;es principais: na l
inha Z, na parte central da banda    I e na linha M<sup>1,6,23</sup>.</font></p>
     ^cY#aop01311.htm##
01115000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087100085002001300956#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#64#60#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na regi&atilde;o    da linh
a Z a titina liga-se &agrave; prote&iacute;na teletonina (T-cap), que    funcion
a como um local de interliga&ccedil;&atilde;o entre a titina e v&aacute;rias    
outras mol&eacute;culas estruturais e de liga&ccedil;&atilde;o<sup>23,24</sup>. 
   Entre essas mol&eacute;culas encontram-se prote&iacute;nas presentes nos t&ua
cute;bulos    T e no ret&iacute;culo sarcoplasm&aacute;tico (RS), nomeadamente a
 anquirina    1 (sANK 1), a obscurina (RS) e canais de pot&aacute;ssio (minK/isk
). Dessa forma,    a titina interv&eacute;m n&atilde;o s&oacute; na manuten&cced
il;&atilde;o da    estrutura do sarc&ocirc;mero, como tamb&eacute;m da estrutura
 e correta organiza&ccedil;&atilde;o    dos t&uacute;bulos T e do ret&iacute;cul
o sarcoplasm&aacute;tico<sup>23,24</sup>.</font></p>     ^cY#aop01311.htm##
01825000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704158100085002001301666#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#65#61#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na regi&atilde;o    da linh
a Z formam-se complexos de prote&iacute;nas que funcionam como sinalizadores    
de tens&atilde;o e que respondem tanto &agrave; for&ccedil;a passiva, gerada    
pelos filamentos de titina durante o estiramento, como &agrave; for&ccedil;a    
ativa, transmitida pelos filamentos de actina<sup>23,24</sup>. Nesse n&iacute;ve
l,    existem v&aacute;rias prote&iacute;nas que ao interagirem com a titina par
ticipam    em seguida em cascatas de sinaliza&ccedil;&atilde;o intracelular, pro
movendo    a express&atilde;o de genes envolvidos na remodelagem card&iacute;aca
. Uma dessas    prote&iacute;nas &eacute; a MLP (muscle LIM prote&iacute;n - mem
bro da fam&iacute;lia    de prote&iacute;nas LIM), tendo sido mesmo observado qu
e muta&ccedil;&otilde;es    pontuais dessa prote&iacute;na podem participar no d
esenvolvimento quer da cardiomiopatia    hipertr&oacute;fica, quer da cardiomiop
atia dilatada<sup>24</sup>. Contudo,    n&atilde;o est&aacute; ainda estabelecid
o o mecanismo pelo qual a titina, interagindo    com a MLP, &eacute; capaz de re
gular a transcri&ccedil;&atilde;o gen&eacute;tica.    Aparentemente, quando dura
nte o estiramento se geram tens&otilde;es elevadas    no n&iacute;vel da linha Z
, ocorre a separa&ccedil;&atilde;o entre as liga&ccedil;&otilde;es    entre a ti
tina e o MLP que, uma vez livre, migra para o n&uacute;cleo, onde    vai promove
r a transcri&ccedil;&atilde;o de v&aacute;rios genes envolvidos na    remodelage
m card&iacute;aca<sup>24</sup>.</font></p>     ^cY#aop01311.htm##
01351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110700085002001301192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#66#62#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No n&iacute;vel    da regi&
atilde;o central da banda I, os elementos N2B e N2BA funcionam como    os locais
 de liga&ccedil;&atilde;o da titina a diversas prote&iacute;nas sinalizadoras.  
  A sequ&ecirc;ncia &uacute;nica N2B, exclusiva do m&uacute;sculo card&iacute;ac
o,    liga-se, por interm&eacute;dio de um membro da fam&iacute;lia de prote&iac
ute;nas    LIM (prote&iacute;nas que cont&ecirc;m dom&iacute;nios LIM - arranjo 
de oito    res&iacute;duos de ciste&iacute;na e histidina na configura&ccedil;&a
tilde;o    (C-X<sub>2</sub>-C-X<sub>16/23</sub>-H-X<sub>2</sub> -C-X<sub>2</sub>
-C-X<sub>2</sub>-C-X<sub>16/21</sub>    -C-X<sub>2/3</sub>-C/D/H)) conhecido com
o DRAL/FHL 2, a diversas enzimas metab&oacute;licas.    Em estados de maior nece
ssidade energ&eacute;tica a fun&ccedil;&atilde;o do    DRAL/FHL 2 como ponte de 
liga&ccedil;&atilde;o entre a titina e enzimas como    a creatinina c&iacute;nas
e ou a c&iacute;nase do adenilato adquire uma import&acirc;ncia    crescente aum
entando o aporte de ATP<sup>24</sup>.</font></p>     ^cY#aop01311.htm##
01136000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704089200085002001300977#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#67#63#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os ligandos da    titina na
 regi&atilde;o da banda I, assim como as prote&iacute;nas a eles associadas,    
tamb&eacute;m s&atilde;o encontrados no n&uacute;cleo, onde funcionam como regul
adores    da transcri&ccedil;&atilde;o e do ciclo celular, podendo tamb&eacute;m
 estar    envolvidos nas altera&ccedil;&otilde;es das propriedades passivas do c
ardiomi&oacute;cito    em longo prazo<sup>1</sup>. &Eacute; o exemplo da intera&
ccedil;&atilde;o com    a obscurina, uma prote&iacute;na com diversos dom&iacute
;nios de sinaliza&ccedil;&atilde;o.    Esse complexo titina-obscurina responde a
o estiramento do sarc&ocirc;mero, estando    envolvido na reestrutura&ccedil;&at
ilde;o sarcom&eacute;trica que ocorre por    exemplo na adapta&ccedil;&atilde;o 
muscular e na insufici&ecirc;ncia card&iacute;aca<sup>2</sup>.</font></p>     ^c
Y#aop01311.htm##
00598000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704035400085002001300439#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#68#64#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A regi&atilde;o    da titin
a adjacente &agrave; linha M tamb&eacute;m possui locais potencialmente    envol
vidos na sensibilidade dos miofilamentos para o Ca<sup>2+</sup> e participa    e
xtensamente nos mecanismos de sinaliza&ccedil;&atilde;o intracelular<sup>2,23</s
up>.</font></p>     ^cY#aop01311.htm##
00375000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013100085002001300216#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#69#65#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Outras fun&ccedil;&otild
e;es    da titina</b></font></p>     ^cY#aop01311.htm##
00639000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039500085002001300480#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#70#66#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Para al&eacute;m    das fun
&ccedil;&otilde;es j&aacute; referidas, come&ccedil;a a investigar-se    o envol
vimento da titina no processo de dobragem de prote&iacute;nas, na regula&ccedil;
&atilde;o    de express&atilde;o de genes e na regula&ccedil;&atilde;o de v&aacu
te;rios canais    i&ocirc;nicos<sup>23</sup>.</font></p>     ^cY#aop01311.htm##
00729000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048500085002001300570#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#71#67#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Al&eacute;m disso,    a tit
ina &eacute; ainda importante no processo de miofibrilog&ecirc;nese formando    
uma esp&eacute;cie de molde estrutural para a correta disposi&ccedil;&atilde;o  
  e organiza&ccedil;&atilde;o dos filamentos de actina e miosina<sup>25</sup>.  
  A perda da titina origina uma organiza&ccedil;&atilde;o anormal do sarc&ocirc;
mero    como foi demonstrado recentemente<sup>26</sup>.</font></p>     ^cY#aop01
311.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014300085002001300228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#72#68#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Modula&ccedil;&atilde;o 
   das propriedades da titina</b></font></p>     ^cY#aop01311.htm##
00699000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045500085002001300540#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#73#69#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina funciona    no sar
c&ocirc;mero como um elemento din&acirc;mico, cujas fun&ccedil;&otilde;es    pod
em ser moduladas, quer em curto, quer em longo prazos, por diversos fatores,    
o que permite ao mioc&aacute;rdio modificar a sua elasticidade em raz&atilde;o  
  das diversas altera&ccedil;&otilde;es hemodin&acirc;micas a que est&aacute;   
 sujeito<sup>11,27</sup>.</font></p>     ^cY#aop01311.htm##
01024000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078000085002001300865#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#74#70#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">como &eacute; demonstrado  
  na <a href="/img/revistas/abc/2011nahead/aop01311f04.jpg">figura 4</a>, a rigi
dez do m&uacute;sculo    card&iacute;aco varia em raz&atilde;o de altera&ccedil;
&otilde;es na composi&ccedil;&atilde;o    e no estado de fosforila&ccedil;&atild
e;o da titina. Tais altera&ccedil;&otilde;es    podem ocorrer em longo prazo, me
diante uma modifica&ccedil;&atilde;o da propor&ccedil;&atilde;o    relativa entr
e as duas isoformas da titina, ou, em curto prazo, por altera&ccedil;&otilde;es 
   p&oacute;s-translacionais, como a altera&ccedil;&atilde;o do estado de fosfor
ila&ccedil;&atilde;o    da titina ou da sua liga&ccedil;&atilde;o ao &iacute;on 
c&aacute;lcio<sup>11,27</sup>.</font></p>     ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#75#71#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00389000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014500085002001300230#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#76#72#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Mecanismos de    regula&
ccedil;&atilde;o em curto prazo</b></font></p>     ^cY#aop01311.htm##
00410000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016600085002001300251#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#77#73#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Altera&ccedil;&atilde;o 
   do estado de fosforila&ccedil;&atilde;o da Titina</b></font></p>     ^cY#aop0
1311.htm##
00915000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067100085002001300756#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#78#74#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O segmento N2B    da titina
 card&iacute;aca pode ser fosforilado pela prote&iacute;na c&iacute;nase    A (P
KA) originando uma diminui&ccedil;&atilde;o da sua tens&atilde;o passiva    (<a 
href="/img/revistas/abc/2011nahead/aop01311f04.jpg">fig. 4</a>)<sup>28,29</sup>.
 como seria de    esperar, foi tamb&eacute;m observado que a redu&ccedil;&atilde
;o da tens&atilde;o    passiva induzida pela fosforila&ccedil;&atilde;o da titin
a pela PKA &eacute;    mais pronunciada no m&uacute;sculo card&iacute;aco com n&
iacute;veis mais elevados    de express&atilde;o do segmento N2B<sup>30,31</sup>
.</font></p>     ^cY#aop01311.htm##
01105000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086100085002001300946#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#79#75#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A ativa&ccedil;&atilde;o   
 da PKA que ocorre, por exemplo, ap&oacute;s a estimula&ccedil;&atilde;o beta-ad
ren&eacute;rgica    constitui um dos principais mecanismos de regula&ccedil;&ati
lde;o fisiol&oacute;gica    em curto prazo da distensibilidade da titina. &Eacut
e; sabido que a estimula&ccedil;&atilde;o    simp&aacute;tica, para al&eacute;m 
dos seus efeitos cronotr&oacute;pico e inotr&oacute;pico    positivo, &eacute; t
amb&eacute;m capaz de melhorar a fun&ccedil;&atilde;o diast&oacute;lica,    aume
ntando n&atilde;o s&oacute; a velocidade de relaxamento ventricular, mas    tamb
&eacute;m a complac&ecirc;ncia ventricular. Este &uacute;ltimo efeito depende,  
  entre outros fatores, da fosforila&ccedil;&atilde;o da isoforma N2B da titina 
   pela PKA<sup>27,32,33</sup>.</font></p>     ^cY#aop01311.htm##
01109000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086500085002001300950#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#80#76#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os efeitos da fosforila&cce
dil;&atilde;o    da isoforma N2B pela PKA tamb&eacute;m se repercutem no n&iacut
e;vel na fase    final da s&iacute;stole, uma vez que a diminui&ccedil;&atilde;o
 da rigidez do    cardiomi&oacute;cito vai conduzir tamb&eacute;m a uma diminui&
ccedil;&atilde;o    da for&ccedil;a de restaura&ccedil;&atilde;o dos cardiomi&oa
cute;citos<sup>31</sup>.    Esse efeito, teoricamente pouco ben&eacute;fico, pod
e ser contraposto pelo fato    de a PKA acelerar a velocidade de relaxamento do 
mioc&aacute;rdio, por meio    da fosforila&ccedil;&atilde;o simult&acirc;nea do 
fosfolamban e da troponina<sup>34</sup>.    S&atilde;o necess&aacute;rios mais e
studos para compreender o papel da fosforila&ccedil;&atilde;o    da titina na fu
n&ccedil;&atilde;o card&iacute;aca.</font></p>     ^cY#aop01311.htm##
01034000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079000085002001300875#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#81#77#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Muito recentemente    foi t
amb&eacute;m demonstrado que quer a prote&iacute;na c&iacute;nase G (PKG)<sup>35
,36</sup>,    quer a isoforma alfa da prote&iacute;na c&iacute;nase C (PKC)<sup>
37</sup> promovem    igualmente a fosforila&ccedil;&atilde;o da titina. No caso 
da PKG a fosforila&ccedil;&atilde;o    d&aacute;-se no segmento PEVK da isoforma
 N2B, levando a uma diminui&ccedil;&atilde;o    da tens&atilde;o passiva cardiom
i&oacute;cit&aacute;ria<sup>35</sup>. J&aacute;    no caso da fosforila&ccedil;&
atilde;o pela PKC, essa ocorre no segmento PEVK    tanto da isoforma N2B como da
 N2BA e o efeito global dessa fosforila&ccedil;&atilde;o    &eacute; o aumento d
a tens&atilde;o passiva<sup>35-37</sup>.</font></p>     ^cY#aop01311.htm##
00609000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036500085002001300450#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#82#78#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em resumo, a titina    func
iona como uma "mola ajust&aacute;vel" que, por meio da fosforila&ccedil;&atilde;
o/desfosforila&ccedil;&atilde;o    sobretudo do seu segmento N2B, permite a adap
ta&ccedil;&atilde;o da fun&ccedil;&atilde;o    ventricular &agrave;s necessidade
s do organismo.</font></p>     ^cY#aop01311.htm##
00400000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015600085002001300241#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#83#79#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Regula&ccedil;&atilde;o 
   da titina pelo &iacute;on c&aacute;lcio</b></font></p>     ^cY#aop01311.htm##
01389000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704114500085002001301230#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#84#80#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O Ca<sup>2+</sup>    tem um
 papel importante como regulador da distensibilidade do cardiomi&oacute;cito,   
 sobretudo em raz&atilde;o da modula&ccedil;&atilde;o da intera&ccedil;&atilde;o
    entre a titina e os filamentos finos. Estudos revelam que o dom&iacute;nio P
EVK    na regi&atilde;o extens&iacute;vel da isoforma N2B se liga &agrave; F-act
ina    e que essa intera&ccedil;&atilde;o poder&aacute; contribuir para a rigide
z passiva    dos cardiomi&oacute;citos<sup>38</sup>. Embora o Ca<sup>2+</sup> is
oladamente    n&atilde;o interfira nessa liga&ccedil;&atilde;o, quando esse &iac
ute;on se    encontra ligado &agrave; prote&iacute;na S100A1, existente em eleva
das concentra&ccedil;&otilde;es    no mioc&aacute;rdio, essa intera&ccedil;&atil
de;o &eacute; inibida, diminuindo    a rigidez do cardiomi&oacute;cito. A observ
a&ccedil;&atilde;o do aumento da    rigidez do m&uacute;sculo card&iacute;aco pa
ralelamente ao decl&iacute;nio da    concentra&ccedil;&atilde;o de Ca<sup>2+</su
p> durante a di&aacute;stole suporta    esse mecanismo<sup>1,2,23,39</sup>.</fon
t></p>     ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#85#81#article#208#<p>&nbsp;<
/p>     ^cY#aop01311.htm##
00399000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015500085002001300240#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#86#82#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Mecanismos de    regula&
ccedil;&atilde;o da titina em longo prazo</b></font></p>     ^cY#aop01311.htm##
01344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110000085002001301185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#87#83#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">como foi anteriormente    r
eferido, os cardiomi&oacute;citos expressam as duas isoformas da titina, permiti
ndo-lhes    atingir um n&iacute;vel intermedi&aacute;rio de tens&atilde;o passiv
a (<a href="#f3">fig.    3</a>), que pode ser modificada conforme a propor&ccedi
l;&atilde;o relativa    de express&atilde;o N2B / N2BA. Uma maior express&atilde
;o da isoforma N2B est&aacute;    associada a um aumento da rigidez mioc&aacute;
rdica, enquanto o aumento da express&atilde;o    N2BA se associa a um aumento da
 sua complac&ecirc;ncia. Contudo, permanecem    por esclarecer os mecanismos mol
eculares subjacentes &agrave; express&atilde;o    preferencial de uma das isofor
mas. Sabe-se que em resposta a diferentes estados    hemodin&acirc;micos podem o
correr altera&ccedil;&otilde;es em longo prazo na    raz&atilde;o de express&ati
lde;o das duas isoformas da titina, o que, como veremos    em seguida, ocorre po
r exemplo na insufici&ecirc;ncia card&iacute;aca<sup>15</sup>    e na estenose a
&oacute;rtica<sup>40,41</sup>.</font></p>     ^cY#aop01311.htm##
00797000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055300085002001300638#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#88#84#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&Eacute; importante    refe
rir que, por meio da altera&ccedil;&atilde;o da propor&ccedil;&atilde;o    relat
iva das isoformas da titina, apenas s&atilde;o modificadas as propriedades    el
&aacute;sticas da titina, n&atilde;o sendo alteradas as suas propriedades    est
ruturais, uma vez que dessa forma s&oacute; a por&ccedil;&atilde;o da titina    
presente na banda I (ou seja, o componente distens&iacute;vel) &eacute; que    s
ofre altera&ccedil;&otilde;es<sup>11</sup>.</font></p>     ^cY#aop01311.htm##
00945000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704070100085002001300786#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#89#85#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em resumo, a fun&ccedil;&at
ilde;o    card&iacute;aca pode ser alterada por altera&ccedil;&otilde;es das pro
priedades    el&aacute;sticas da titina, que podem ocorrer tanto em curto como e
m longo prazos.    Tal como podemos ver na <a href="/img/revistas/abc/2011nahead
/aop01311f04.jpg">figura 4</a>, o aumento    da express&atilde;o da isoforma N2B
 est&aacute; associado a um aumento da rigidez    da titina. Essa rigidez pode s
er reduzida pela fosforila&ccedil;&atilde;o da    titina pela PKA ou PKG ou aume
ntada pela intera&ccedil;&atilde;o titina-actina,    que &eacute; inibida pelo c
omplexo Ca<sup>2+</sup>/S100A1.</font></p>     ^cY#aop01311.htm##
00386000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014200085002001300227#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#90#86#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Implica&ccedil;&otilde;e
s    fisiopatol&oacute;gicas</b></font></p>     ^cY#aop01311.htm##
00884000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064000085002001300725#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#91#87#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As altera&ccedil;&otilde;es
    da titina est&atilde;o envolvidas na fisiopatologia de algumas doen&ccedil;a
s    card&iacute;acas, nomeadamente na insufici&ecirc;ncia card&iacute;aca diast
&oacute;lica    (ICD) e na cardiomiopatia dilatada (CMD). H&aacute; cada vez mai
or evid&ecirc;ncia    de que as altera&ccedil;&otilde;es na raz&atilde;o de expr
ess&atilde;o das duas    isoformas da titina, bem como a altera&ccedil;&atilde;o
 do seu estado de fosforila&ccedil;&atilde;o    est&atilde;o na base do desenvol
vimento e progress&atilde;o dessas doen&ccedil;as.</font></p>     ^cY#aop01311.h
tm##
00432000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704018800085002001300273#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#92#88#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Altera&ccedil;&otilde;es
    na propor&ccedil;&atilde;o relativa das isoformas da titina (N2BA/N2B)</b></
font></p>     ^cY#aop01311.htm##
00858000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704061400085002001300699#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#93#89#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na disfun&ccedil;&atilde;o 
   diast&oacute;lica ocorre uma lentifica&ccedil;&atilde;o do relaxamento do mio
c&aacute;rdio    e/ou um aumento da rigidez ventricular. Num ventr&iacute;culo m
ais r&iacute;gido,    o aumento do volume de sangue durante a di&aacute;stole s&
oacute; &eacute; conseguido    &agrave; custa de um aumento das press&otilde;es 
de enchimento ventricular,    com aumento da rela&ccedil;&atilde;o press&atilde;
o-volume telediast&oacute;lica,    o que pode originar um quadro cl&iacute;nico 
de IC diast&oacute;lica.</font></p>     ^cY#aop01311.htm##
01223000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097900085002001301064#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#94#90#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A titina, como    principal
 determinante da tens&atilde;o passiva do cardiomi&oacute;cito, determina    a r
igidez ventricular. como foi demonstrado recentemente, os cardiomi&oacute;citos 
   extra&iacute;dos de biopsias endomioc&aacute;rdicas de doentes com ICD exibia
m    um aumento relativo da express&atilde;o da isoforma mais r&iacute;gida da t
itina,    N2B. Observou-se que, enquanto num cora&ccedil;&atilde;o humano saud&a
acute;vel    a raz&atilde;o N2BA/N2B normal &eacute; de cerca de 30/70<sup>10</s
up>, nos    doentes com ICD essa rela&ccedil;&atilde;o era de 17/83; e na IC sis
t&oacute;lica    a raz&atilde;o foi de 35/65<sup>15</sup>. Por&eacute;m, esse me
smo grupo demonstrou    recentemente que a hipofosforila&ccedil;&atilde;o do seg
mento N2B da titina    parece contribuir mais significativamente para o aumento 
da tens&atilde;o passiva    verificada nos casos de ICD<sup>41</sup>.</font></p>
     ^cY#aop01311.htm##
00593000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034900085002001300434#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#95#91#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em doentes com    cardiomio
patia dilatada e remodelagem exc&ecirc;ntrica foi observada uma altera&ccedil;&a
tilde;o    da rela&ccedil;&atilde;o entre as isoformas da titina, mas aqui com u
m aumento    relativo da isoforma mais distens&iacute;vel, a N2BA<sup>10</sup>.<
/font></p>     ^cY#aop01311.htm##
02537000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704229300085002001302378#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#96#92#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Numa fase inicial    da ins
ufici&ecirc;ncia card&iacute;aca sist&oacute;lica, altera&ccedil;&otilde;es    d
as isoformas da titina podem funcionar como um mecanismo de adapta&ccedil;&atild
e;o,    uma vez que o aumento da complac&ecirc;ncia ventricular permite um aumen
to do    volume telediast&oacute;lico, e consequentemente um aumento do d&eacute
;bito    card&iacute;aco de acordo com o mecanismo de Frank-Starling<sup>32</sup
>. Al&eacute;m    disso, prev&ecirc;-se que a menor for&ccedil;a de restaura&cce
dil;&atilde;o    desenvolvida pelos cardiomi&oacute;citos durante a s&iacute;sto
le (em raz&atilde;o    do aumento da propor&ccedil;&atilde;o da isoforma mais co
mplacente) permitiria    uma diminui&ccedil;&atilde;o do volume telessist&oacute
;lico final para qualquer    p&oacute;s-carga. Essa diminui&ccedil;&atilde;o oco
rreria pelo decr&eacute;scimo    da resist&ecirc;ncia ao encurtamento do cardiom
i&oacute;cito, aumentando assim    o volume de eje&ccedil;&atilde;o. De fato, es
t&aacute; provado que indiv&iacute;duos    com maior propor&ccedil;&atilde;o de 
N2BA t&ecirc;m melhor toler&acirc;ncia    ao exerc&iacute;cio em raz&atilde;o do
 aumento da press&atilde;o venosa de oxig&ecirc;nio<sup>10</sup>.    Esse efeito
 teoricamente ben&eacute;fico acaba por n&atilde;o ocorrer na pr&aacute;tica,   
 uma vez que, na IC sist&oacute;lica, a rela&ccedil;&atilde;o de Frank-Strarling
    est&aacute; alterada em consequ&ecirc;ncia da diminui&ccedil;&atilde;o da se
nsibilidade    dos miofilamentos para o Ca<sup>2+</sup>, em raz&atilde;o, nomead
amente, do    menor desenvolvimento de tens&atilde;o passiva na presen&ccedil;a 
de um aumento    da isoforma N2BA<sup>10</sup>. Finalmente, no cora&ccedil;&atil
de;o insuficiente    pode ocorrer um aumento da degrada&ccedil;&atilde;o da titi
na, o que poder&aacute;    igualmente contribuir para a atenua&ccedil;&atilde;o 
do mecanismo de Frank-Starling<sup>42</sup>.    Al&eacute;m disso, esse processo
 torna-se posteriormente desadaptativo, uma    vez que o aumento do volume teled
iast&oacute;lico do ventr&iacute;culo origina    mais estresse sobre as paredes 
ventriculares, estimulando e agravando o processo    de remodelagem card&iacute;
aca<sup>13,32,43</sup>.</font></p>     ^cY#aop01311.htm##
01280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704103600085002001301121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#97#93#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Tamb&eacute;m na    cardiom
iopatia isqu&ecirc;mica ocorre um aumento da raz&atilde;o N2BA/N2B, apesar    de
 geralmente ocorrer um aumento da rigidez ventricular<sup>44</sup>. Essa observa
&ccedil;&atilde;o,    aparentemente paradoxal, pode ser explicada pelo fato de, 
nessa situa&ccedil;&atilde;o,    o aumento da rigidez ventricular ser devido n&a
tilde;o a altera&ccedil;&otilde;es    a n&iacute;vel dos cardiomi&oacute;citos, 
mas a altera&ccedil;&otilde;es na    matriz extracelular com aumento da fibrose 
mioc&aacute;rdica. Aqui, o aumento    da isoforma N2BA da titina (menos r&iacute
;gida) pode mesmo ser um mecanismo    de compensa&ccedil;&atilde;o ao aumento da
 rigidez ventricular secund&aacute;rio    ao processo de fibrose. Na verdade, na
 cardiomiopatia isqu&ecirc;mica ocorre    mesmo uma diminui&ccedil;&atilde;o da 
tens&atilde;o passiva de cada cardiomi&oacute;cito,    provavelmente em raz&atil
de;o do aumento da isoforma N2BA<sup>10</sup>.</font></p>     ^cY#aop01311.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016700085002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#98#94#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Altera&ccedil;&otilde;es
    no estado de fosforila&ccedil;&atilde;o da titina</b></font></p>     ^cY#aop
01311.htm##
00881000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063700085002001300722#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#99#95#article#208#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">como abordado anteriormente
,    a titina pode tamb&eacute;m sofrer modula&ccedil;&atilde;o da sua rigidez m
ediante    altera&ccedil;&otilde;es p&oacute;s-translacionais, nomeadamente pela
 fosforila&ccedil;&atilde;o    do segmento N2B<sup>29</sup>. A titina pode ser f
osforilada pela prote&iacute;na    c&iacute;nase A (PKA) e pela prote&iacute;na 
c&iacute;nase G (PKG), levando    a uma diminui&ccedil;&atilde;o da sua rigidez<
sup>28,29,31,35</sup>, induzindo    assim, e de forma aguda, altera&ccedil;&otil
de;es em curto prazo na rigidez    ventricular.</font></p>     ^cY#aop01311.htm#
#
01506000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704126100086002001301347#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#100#96#article#208#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Essas descobertas    s&ati
lde;o particularmente relevantes, uma vez que podem inclusivamente ser    alvo d
e interven&ccedil;&atilde;o terap&ecirc;utica nos doentes com insufici&ecirc;nci
a    card&iacute;aca. Na verdade, o tratamento com PKA de cardiomi&oacute;citos 
extra&iacute;dos    de doentes com IC diast&oacute;lica permitiu uma redu&ccedil
;&atilde;o da sua    tens&atilde;o passiva, para valores semelhantes aos dos ind
iv&iacute;duos controle<sup>30</sup>.    Essa diminui&ccedil;&atilde;o da tens&a
tilde;o passiva foi diretamente proporcional    &agrave; rigidez inicial dos car
diomi&oacute;citos, o que &eacute; concordante    com a ideia de que o aumento d
a rigidez card&iacute;aca est&aacute; diretamente    relacionado n&atilde;o s&oa
cute; com altera&ccedil;&otilde;es da express&atilde;o    relativa das isoformas
, como tamb&eacute;m do estado de hipofosforila&ccedil;&atilde;o    da isoforma 
r&iacute;gida da titina. Tal como seria de esperar pela menor rigidez    dos car
diomi&oacute;citos provenientes de doentes com IC sist&oacute;lica, o    mesmo t
ratamento com PKA n&atilde;o causou uma queda t&atilde;o significativa    da ten
s&atilde;o passiva<sup>15</sup>.</font></p>     ^cY#aop01311.htm##
01025000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704078000086002001300866#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#101#97#article#208#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Tanto a estenose    a&oacu
te;rtica como a cardiomiopatia hipertensiva apresentam disfun&ccedil;&atilde;o  
  diast&oacute;lica, mas apenas na &uacute;ltima se verifica um aumento substanc
ial    da rigidez mioc&aacute;rdica. Em ambas os casos, a express&atilde;o relat
iva    das isoformas N2BA/N2B, assim como o seu grau de total de fosforila&ccedi
l;&atilde;o    s&atilde;o semelhantes. Contudo, na cardiomiopatia hipertensiva o
bservou-se    uma hipofosforila&ccedil;&atilde;o relativa da isoforma mais r&iac
ute;gida,    a N2B, tendo sido proposto como o mecanismo subjacente ao aumento d
a rigidez    mioc&aacute;rdica e disfun&ccedil;&atilde;o diast&oacute;lica nessa
 doen&ccedil;a<sup>40,45</sup>.</font></p>     ^cY#aop01311.htm##
00721000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704047600086002001300562#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#102#98#article#208#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Tamb&eacute;m na    cardio
miopatia dilatada parecem ocorrer altera&ccedil;&otilde;es na fosforila&ccedil;&
atilde;o    da titina. Nesses doentes foi observada uma diminui&ccedil;&atilde;o
 da atividade    da PKA card&iacute;aca, que poder&aacute; ser um mecanismo comp
ensador, em resposta    &agrave; elevada complac&ecirc;ncia observada nos cardio
mi&oacute;citos desses    doentes<sup>13</sup>.</font></p>     ^cY#aop01311.htm#
#
00802000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704055700086002001300643#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#103#99#article#208#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Em resumo, a titina,    po
r meio da modifica&ccedil;&atilde;o da express&atilde;o das suas isoformas    e/
ou do seu estado de fosforila&ccedil;&atilde;o, parece ser um elemento-chave    
na fisiopatologia de v&aacute;rias doen&ccedil;as card&iacute;acas. Al&eacute;m 
   disso, a titina pode ainda ser um potencial alvo de manipula&ccedil;&atilde;o
    farmacol&oacute;gica constituindo assim um novo alvo terap&ecirc;utico, sobr
etudo    na insufici&ecirc;ncia card&iacute;aca.</font></p>     ^cY#aop01311.htm
##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#104#100#article#208#<p>&nbsp
;</p>     ^cY#aop01311.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010400087002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#105#101#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Agradecimentos</b></fo
nt></p>     ^cY#aop01311.htm##
00443000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019700087002001300284#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#106#102#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Os autores agradecem    a
 preciosa ajuda de Pedro Daniel Miranda Couto na prepara&ccedil;&atilde;o das   
 figuras.</font></p>     ^cY#aop01311.htm##
00371000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704012500087002001300212#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#107#103#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    
de Interesses</b></font></p>     ^cY#aop01311.htm##
00392000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704014600087002001300233#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#108#104#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    hav
er conflito de interesses pertinentes.</font></p>     ^cY#aop01311.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704011300087002001300200#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#109#105#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiament
o</b></font></p>     ^cY#aop01311.htm##
00443000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019700087002001300284#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#110#106#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    foi 
parcialmente financiado pela Funda&ccedil;&atilde;o para a Ci&ecirc;ncia    e Te
cnologia.</font></p>     ^cY#aop01311.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704013300087002001300220#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#111#107#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde
;o    Acad&ecirc;mica</b></font></p>     ^cY#aop01311.htm##
00441000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019500087002001300282#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#112#108#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o h&aacute;    v
incula&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&at
ilde;o.</font></p>     ^cY#aop01311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#113#109#article#208#<p>&nbsp
;</p>     ^cY#aop01311.htm##
00353000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010700087002001300194#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#114#110#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b><
/font></p>     ^cY#aop01311.htm##
00475000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704021500089002001300304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#115#111#article#
208#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. LeWinter
 MM,    Wu Y, Labeit S, Granzier H. Cardiac titin: structure, functions and role
 in    disease. Clin Chim Acta. 2007; 375 (1-2): 1-9.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#116#112#article#208#</font><
/p>     ^cY#aop01311.htm##
00483000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704022300089002001300312#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#117#113#article#
208#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Granzier
 HL,    Labeit S. The giant protein titin: a major player in myocardial mechanic
s, signaling,    and disease. Circ Res. 2004; 94 (3): 284-95.    ^cY#aop01311.ht
m##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#118#114#article#208#</font><
/p>     ^cY#aop01311.htm##
00466000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704020600089002001300295#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#119#115#article#
208#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Tskhovre
bova    L, Trinick J. Properties of titin immunoglobulin and fibronectin-3 domai
ns.    J Biol Chem. 2004; 279 (45): 46351-4.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#120#116#article#208#</font><
/p>     ^cY#aop01311.htm##
00454000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704019400089002001300283#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#121#117#article#
208#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Tskhovre
bova    L, Trinick J. Titin: properties and family relationships. Nat Rev Mol Ce
ll Biol.    2003; 4 (9): 679-89.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#122#118#article#208#</font><
/p>     ^cY#aop01311.htm##
00428000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704016800089002001300257#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#123#119#article#
208#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Maruyama
 K.    Connectin/titin, giant elastic protein of muscle. Faseb J. 1997; 11 (5): 
341-5.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#124#120#article#208#</font><
/p>     ^cY#aop01311.htm##
00452000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704019200089002001300281#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#125#121#article#
208#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Granzier
 H,    Labeit S. Cardiac titin: an adjustable multi-functional spring. J Physiol
. 2002;    541 (Pt 2): 335-42.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#126#122#article#208#</font><
/p>     ^cY#aop01311.htm##
00582000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704032200089002001300411#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#127#123#article#
208#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Freiburg
 A,    Trombitas K, Hell W, Cazorla O, Fougerousse F, Centner T, et al. Series o
f exon-skipping    events in the elastic spring region of titin as the structura
l basis for myofibrillar    elastic diversity. Circ Res. 2000; 86 (11): 1114-21.
    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#128#124#article#208#</font><
/p>     ^cY#aop01311.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030700089002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#129#125#article#
208#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Linke WA
, Rudy    DE, Centner T, Gautel M, Witt C, Labeit S, et al. I-band titin in card
iac muscle    is a three-element molecular spring and is critical for maintainin
g thin filament    structure. J Cell Biol. 1999; 146 (3): 631-44.    ^cY#aop0131
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#130#126#article#208#</font><
/p>     ^cY#aop01311.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704020200089002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#131#127#article#
208#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Helmes M
, Trombitas    K, Granzier H. Titin develops restoring force in rat cardiac myoc
ytes. Circ    Res. 1996; 79 (3): 619-26.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#132#128#article#208#</font><
/p>     ^cY#aop01311.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030600090002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#133#129#article#
208#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Nagueh
 SF,    Shah G, Wu Y, Torre-Amione G, King NM, Lahmers S, et al. Altered titin e
xpression,    myocardial stiffness, and left ventricular function in patients wi
th dilated    cardiomyopathy. Circulation. 2004; 110 (2): 155-62.    ^cY#aop0131
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#134#130#article#208#</font><
/p>     ^cY#aop01311.htm##
00530000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026900090002001300359#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#135#131#article#
208#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Cazorl
a O,    Freiburg A, Helmes M, Centner T, McNabb M, Wu Y, et al. Differential exp
ression    of cardiac titin isoforms and modulation of cellular stiffness. Circ 
Res. 2000;    86 (1): 59-67.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#136#132#article#208#</font><
/p>     ^cY#aop01311.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020100090002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#137#133#article#
208#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Leite-
Moreira    AF. Current perspectives in diastolic dysfunction and diastolic heart
 failure.    Heart. 2006; 92 (5): 712-8.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#138#134#article#208#</font><
/p>     ^cY#aop01311.htm##
00501000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024000090002001300330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#139#135#article#
208#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Wu Y, 
Labeit    S, Lewinter MM, Granzier H. Titin: an endosarcomeric protein that modu
lates    myocardial stiffness in DCM. J Card Fail. 2002; 8 (6 Suppl): S276-286. 
   ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#140#136#article#208#</font><
/p>     ^cY#aop01311.htm##
00509000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024800090002001300338#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#141#137#article#
208#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Granzi
er HL,    Irving TC. Passive tension in cardiac muscle: contribution of collagen
, titin,    microtubules, and intermediate filaments. Biophys J. 1995; 68 (3): 1
027-44.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#142#138#article#208#</font><
/p>     ^cY#aop01311.htm##
00555000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029400090002001300384#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#143#139#article#
208#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. van He
erebeek    L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ,
 et al.    Myocardial structure and function differ in systolic and diastolic he
art failure.    Circulation. 2006; 113 (16): 1966-73.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#144#140#article#208#</font><
/p>     ^cY#aop01311.htm##
00497000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023600090002001300326#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#145#141#article#
208#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Helmes
 M, Lim    CC, Liao R, Bharti A, Cui L, Sawyer DB. Titin determines the Frank-St
arling    relation in early diastole. J Gen Physiol. 2003; 121 (2): 97-110.    ^
cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#146#142#article#208#</font><
/p>     ^cY#aop01311.htm##
00487000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022600090002001300316#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#147#143#article#
208#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Fukuda
 N, Granzier    HL. Titin/connectin-based modulation of the Frank-Starling mecha
nism of the    heart. J Muscle Res Motil. 2005; 26 (6-8): 319-23.    ^cY#aop0131
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#148#144#article#208#</font><
/p>     ^cY#aop01311.htm##
00457000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019600090002001300286#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#149#145#article#
208#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Katz A
M. Ernest    Henry Starling, his predecessors, and the "Law of the Heart". Circu
lation. 2002;    106 (23): 2986-92.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#150#146#article#208#</font><
/p>     ^cY#aop01311.htm##
00601000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034000090002001300430#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#151#147#article#
208#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Kentis
h JC,    Keurs HE, Ricciardi L, Bucx JJ, Noble MI. comparison between the sarcom
ere length-force    relations of intact and skinned trabeculae from rat right ve
ntricle. Influence    of calcium concentrations on these relations. Circ Res. 19
86; 58 (6): 755-68.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#152#148#article#208#</font><
/p>     ^cY#aop01311.htm##
00514000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025300090002001300343#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#153#149#article#
208#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Cazorl
a O,    Wu Y, Irving TC, Granzier H. Titin-based modulation of calcium sensitivi
ty of    active tension in mouse skinned cardiac myocytes. Circ Res. 2001; 88 (1
0): 1028-35.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#154#150#article#208#</font><
/p>     ^cY#aop01311.htm##
00523000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026200090002001300352#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#155#151#article#
208#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Fukuda
 N, Wu    Y, Farman G, Irving TC, Granzier H. Titin isoform variance and length 
dependence    of activation in skinned bovine cardiac muscle. J Physiol. 2003; 5
53 (Pt 1):    147-54.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#156#152#article#208#</font><
/p>     ^cY#aop01311.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#157#153#article#
208#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Fukuda
 N, Sasaki    D, Ishiwata S, Kurihara S. Length dependence of tension generation
 in rat skinned    cardiac muscle: role of titin in the Frank-Starling mechanism
 of the heart.    Circulation. 2001; 104 (14): 1639-45.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#158#154#article#208#</font><
/p>     ^cY#aop01311.htm##
00511000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025000090002001300340#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#159#155#article#
208#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Miller
 MK,    Granzier H, Ehler E, Gregorio CC. The sensitive giant: the role of titin
-based    stretch sensing complexes in the heart. Trends Cell Biol. 2004; 14 (3)
: 119-26.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#160#156#article#208#</font><
/p>     ^cY#aop01311.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025900090002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#161#157#article#
208#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Linke 
WA. Sense    and stretchability: the role of titin and titin-associated proteins
 in myocardial    stress-sensing and mechanical dysfunction. Cardiovasc Res. 200
8; 77 (4): 637-48.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#162#158#article#208#</font><
/p>     ^cY#aop01311.htm##
00471000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021000090002001300300#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#163#159#article#
208#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Gregor
io CC,    Granzier H, Sorimachi H, Labeit S. Muscle assembly: a titanic achievem
ent? Curr    Opin Cell Biol. 1999; 11 (1): 18-25.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#164#160#article#208#</font><
/p>     ^cY#aop01311.htm##
00578000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031700090002001300407#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#165#161#article#
208#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Udaka 
J, Ohmori    S, Terui T, Ohtsuki I, Ishiwata S, Kurihara S, et al. Disuse-induce
d preferential    loss of the giant protein titin depresses muscle performance v
ia abnormal sarcomeric    organization. J Gen Physiol. 2008; 131 (1): 33-41.    
^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#166#162#article#208#</font><
/p>     ^cY#aop01311.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020900090002001300299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#167#163#article#
208#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Granzi
er HL,    Labeit S. The giant muscle protein titin is an adjustable molecular sp
ring.    Exerc Sport Sci Rev. 2006; 34(2): 50-3.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#168#164#article#208#</font><
/p>     ^cY#aop01311.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029800090002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#169#165#article#
208#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Yamasa
ki R,    Wu Y, McNabb M, Greaser M, Labeit S, Granzier H. Protein kinase A phosp
horylates    titin's cardiac-specific N2B domain and reduces passive tension in 
rat cardiac    myocytes. Circ Res. 2002; 90 (11): 1181-8.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#170#166#article#208#</font><
/p>     ^cY#aop01311.htm##
00512000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025100090002001300341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#171#167#article#
208#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Kruger
 M, Linke    WA. Protein kinase-A phosphorylates titin in human heart muscle and
 reduces    myofibrillar passive tension. J Muscle Res Cell Motil. 2006; 27 (5-7
): 435-44.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#172#168#article#208#</font><
/p>     ^cY#aop01311.htm##
00507000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024600090002001300336#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#173#169#article#
208#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Borbel
y A,    van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, et al. Cardi
omyocyte    stiffness in diastolic heart failure. Circulation. 2005; 111 (6): 77
4-81.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#174#170#article#208#</font><
/p>     ^cY#aop01311.htm##
00527000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026600090002001300356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#175#171#article#
208#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Fukuda
 N, Wu    Y, Nair P, Granzier HL. Phosphorylation of titin modulates passive sti
ffness    of cardiac muscle in a titin isoform-dependent manner. J Gen Physiol. 
2005;    125 (3): 257-71.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#176#172#article#208#</font><
/p>     ^cY#aop01311.htm##
00457000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019600090002001300286#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#177#173#article#
208#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Lim CC
, Sawyer    DB. Modulation of cardiac function: titin springs into action. J Gen
 Physiol.    2005; 125 (3): 249-52.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#178#174#article#208#</font><
/p>     ^cY#aop01311.htm##
00590000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032900090002001300419#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#179#175#article#
208#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Falcao
-Pires    I, Fontes-Sousa AP, Bras-Silva C, Leite-Moreira A. Beta-adrenergic sti
mulation    acutely increases myocardial distensibility - A PKA, PKC and Na+/H+ 
exchanger    mediated effect (abstract). J Am Coll Cardiol. 2007; 49 (9 Suppl. A
): 408A.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#180#176#article#208#</font><
/p>     ^cY#aop01311.htm##
00423000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704016200090002001300252#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#181#177#article#
208#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Bers D
M. Cardiac    excitation-contraction coupling. Nature. 2002; 415 (6868): 198-205
.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#182#178#article#208#</font><
/p>     ^cY#aop01311.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029000090002001300380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#183#179#article#
208#35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Kruger
 M, Kotter    S, Grutzner A, Lang P, Andresen C, Redfield MM, et al. Protein kin
ase G modulates    human myocardial passive stiffness by phosphorylation of the 
titin springs.    Circ Res. 2009; 104 (1): 87-94.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#184#180#article#208#</font><
/p>     ^cY#aop01311.htm##
00573000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031200090002001300402#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#185#181#article#
208#36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Borbel
y A,    Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, et al. Hyp
ophosphorylation    of the stiff N2B titin isoform raises cardiomyocyte resting 
tension in failing    human myocardium. Circ Res. 2009; 104 (6): 780-6.    ^cY#a
op01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#186#182#article#208#</font><
/p>     ^cY#aop01311.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030000090002001300390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#187#183#article#
208#37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Hidalg
o C,    Hudson B, Bogomolovas J, Zhu Y, Anderson B, Greaser M, et al. PKC Phosph
orylation    of titin's PEVK element: a novel and conserved pathway for modulati
ng myocardial    stiffness. Circ Res. 2009; 105 (7): 631-8.    ^cY#aop01311.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#188#184#article#208#</font><
/p>     ^cY#aop01311.htm##
00562000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030100090002001300391#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#189#185#article#
208#38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Yamasa
ki R,    Berri M, Wu Y, Trombitas K, McNabb M, Kellermayer MS, et al. Titin-acti
n interaction    in mouse myocardium: passive tension modulation and its regulat
ion by calcium/S100A1.    Biophys J. 2001; 81 (4): 2297-313.    ^cY#aop01311.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#190#186#article#208#</font><
/p>     ^cY#aop01311.htm##
00522000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026100090002001300351#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#191#187#article#
208#39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Stuyve
rs BD,    Miura M, Jin JP, ter Keurs HE. Ca(2+)-dependence of diastolic properti
es of    cardiac sarcomeres: involvement of titin. Prog Biophys Mol Biol. 1998; 
69 (2-3):    425-43.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#192#188#article#208#</font><
/p>     ^cY#aop01311.htm##
00500000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023900090002001300329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#193#189#article#
208#40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Willia
ms L,    Howell N, Pagano D, Andreka P, Vertesaljai M, Pecor T, et al. Titin iso
form    expression in aortic stenosis. Clin Sci (Lond). 2009; 117 (6): 237-42.  
  ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#194#190#article#208#</font><
/p>     ^cY#aop01311.htm##
00500000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023900090002001300329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#195#191#article#
208#41#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Borbel
y A,    van Heerebeek L, Paulus WJ. Transcriptional and posttranslational modifi
cations    of titin: implications for diastole. Circ Res. 2009; 104 (1): 12-4.  
  ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#196#192#article#208#</font><
/p>     ^cY#aop01311.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027400090002001300364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#197#193#article#
208#42#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Morano
 I, Hadicke    K, Grom S, Koch A, Schwinger RH, Bohm M, et al. Titin, myosin lig
ht chains and    C-protein in the developing and failing human heart. J Mol Cell
 Cardiol. 1994;    26 (3): 361-8.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#198#194#article#208#</font><
/p>     ^cY#aop01311.htm##
00565000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030400090002001300394#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#199#195#article#
208#43#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Makare
nko I,    Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, et al. Passive sti
ffness    changes caused by upregulation of compliant titin isoforms in human di
lated    cardiomyopathy hearts. Circ Res. 2004; 95 (7): 708-16.    ^cY#aop01311.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#200#196#article#208#</font><
/p>     ^cY#aop01311.htm##
00509000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024800090002001300338#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#201#197#article#
208#44#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Neagoe
 C, Kulke    M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, et al. Titin i
soform switch    in ischemic human heart disease. Circulation. 2002; 106 (11): 1
333-41.    ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#202#198#article#208#</font><
/p>     ^cY#aop01311.htm##
00500000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023900090002001300329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#203#199#article#
208#45#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Warren
 CM,    Jordan MC, Roos KP, Krzesinski PR, Greaser ML. Titin isoform expression 
in normal    and hypertensive myocardium. Cardiovasc Res. 2003; 59 (1): 86-94.  
  ^cY#aop01311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#204#200#article#208#</font><
/p>     ^cY#aop01311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#205#201#article#208#<p>&nbsp
;</p>     ^cY#aop01311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#206#202#article#208#<p>&nbsp
;</p>     ^cY#aop01311.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#207#203#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop01311.htm##
00307000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006100087002001300148#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#208#204#article#208#<br>   <
/b> Ricardo Lu&iacute;s Castro Silva Ferreira    ^cY#aop01311.htm##
00337000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009100087002001300178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#209#205#article#208#<br>   S
ervi&ccedil;o de Fisiologia, Faculdade de Medicina da Universidade do Porto    ^
cY#aop01311.htm##
00316000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704007000087002001300157#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#210#206#article#208#<br>   A
lameda Prof. Hern&acirc;ni Monteiro - 4200-219 - Porto    ^cY#aop01311.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009300087002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#211#207#article#208#<br>   E
-mail: <a href="mailto:amoreira@med.up.pt">amoreira@med.up.pt</a></font></p>    
 ^cY#aop01311.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01311.htm#S#p#212#208#article#208#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 16/
09/09; revisado recebido em 05/11/09; aceito em 26/01/10.</font></p>     ^cY#aop
01311.htm##
00613000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100012001050100
01600117010001800133012006000151030001500211065000900226064000500235031000400240
032000400244014000400248865000900252002001300261035001000274801001500284#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#213#1#article#45#1#^
rND^sLeWinter^nMM#^rND^sWu^nY#^rND^sLabeit^nS#^rND^sGranzier^nH#Cardiac titin: s
tructure, functions and role in disease^len#Clin Chim Acta#20070000#2007#375#1-2
#1-9#20110000#aop01311.htm#0009-8981#Clin Chim Acta##
00579000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100016001050120
09200121030000900213065000900222064000500231031000300236032000200239014000700241
865000900248002001300257035001000270801000900280#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01311.htm#S#c#214#2#article#45#2#^rND^sGranzier^nHL#^rND^s
Labeit^nS#The giant protein titin: a major player in myocardial mechanics, signa
ling, and disease^len#Circ Res#20040000#2004#94#3#284-95#20110000#aop01311.htm#0
009-7330#Circ Res##
00565000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100022000860100017001080120
06500125030001200190065000900202064000500211031000400216032000300220014000800223
865000900231002001300240035001000253801001200263#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01311.htm#S#c#215#3#article#45#3#^rND^sTskhovrebova^nL#^rN
D^sTrinick^nJ#Properties of titin immunoglobulin and fibronectin-3 domains^len#J
 Biol Chem#20040000#2004#279#45#46351-4#20110000#aop01311.htm#0021-9258#J Biol C
hem##
00521000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100022000860100017001080120
04700125030002200172710000200194065000900196064000500205031000200210032000200212
014000700214865000900221002001300230#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#216#4#article#45#4#^rND^sTskhovrebova^nL#^rND^sTrinick^n
J#Titin: properties and family relationships^len#Nat Rev Mol Cell Biol#2#2003000
0#2003#4#9#679-89#20110000#aop01311.htm##
00508000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860120053001040300
00800157065000900165064000500174031000300179032000200182014000600184865000900190
002001300199035001000212801000800222#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#217#5#article#45#5#^rND^sMaruyama^nK#Connectin/titin, gi
ant elastic protein of muscle^len#Faseb J#19970000#1997#11#5#341-5#20110000#aop0
1311.htm#0892-6638#FASEB j##
00516000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100016001040120
05700120030001000177710000200187065000900189064000500198031000400203034000200207
014000700209865000900216002001300225#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#218#6#article#45#6#^rND^sGranzier^nH#^rND^sLabeit^nS#Car
diac titin: an adjustable multi-functional spring^len#J Physiol#2#20020000#2002#
541#2#335-42#20110000#aop01311.htm##
00758000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100019001040100
01400123010001700137010002100154010001700175810000600192012013200198030000900330
06500090033906400050034803100030035303200030035601400080035986500090036700200130
0376035001000389801000900399#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#219#7#article#45#7#^rND^sFreiburg^nA#^rND^sTrombitas^nK#^rND^sHe
ll^nW#^rND^sCazorla^nO#^rND^sFougerousse^nF#^rND^sCentner^nT#et al#Series of exo
n-skipping events in the elastic spring region of titin as the structural basis 
for myofibrillar elastic diversity^len#Circ Res#20000000#2000#86#11#1114-21#2011
0000#aop01311.htm#0009-7330#Circ Res##
00746000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100015001020100
01700117010001600134010001400150010001600164810000600180012012700186030001200313
06500090032506400050033403100040033903200020034301400070034586500090035200200130
0361035001000374801001200384#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#220#8#article#45#8#^rND^sLinke^nWA#^rND^sRudy^nDE#^rND^sCentner^
nT#^rND^sGautel^nM#^rND^sWitt^nC#^rND^sLabeit^nS#et al#I-band titin in cardiac m
uscle is a three-element molecular spring and is critical for maintaining thin f
ilament structure^len#J Cell Biol#19990000#1999#146#3#631-44#20110000#aop01311.h
tm#0021-9525#J Cell Biol##
00576000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100019001020100
01800121012005900139030000900198065000900207064000500216031000300221032000200224
014000700226865000900233002001300242035001000255801000900265#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01311.htm#S#c#221#9#article#45#9#^rND^sHelmes^
nM#^rND^sTrombitas^nK#^rND^sGranzier^nH#Titin develops restoring force in rat ca
rdiac myocytes^len#Circ Res#19960000#1996#79#3#619-26#20110000#aop01311.htm#0009
-7330#Circ Res##
00746000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100014001050100
01200119010002200131010001500153010001700168810000600185012012200191030001200313
06500090032506400050033403100040033903200020034301400070034586500090035200200130
0361035001000374801001200384#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#222#10#article#45#10#^rND^sNagueh^nSF#^rND^sShah^nG#^rND^sWu^nY#
^rND^sTorre-Amione^nG#^rND^sKing^nNM#^rND^sLahmers^nS#et al#Altered titin expres
sion, myocardial stiffness, and left ventricular function in patients with dilat
ed cardiomyopathy^len#Circulation#20040000#2004#110#2#155-62#20110000#aop01311.h
tm#0009-7322#Circulation##
00706000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01600123010001700139010001600156010001200172810000600184012009100190030000900281
06500090029006400050029903100030030403200020030701400060030986500090031500200130
0324035001000337801000900347#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#223#11#article#45#11#^rND^sCazorla^nO#^rND^sFreiburg^nA#^rND^sHe
lmes^nM#^rND^sCentner^nT#^rND^sMcNabb^nM#^rND^sWu^nY#et al#Differential expressi
on of cardiac titin isoforms and modulation of cellular stiffness^len#Circ Res#2
0000000#2000#86#1#59-67#20110000#aop01311.htm#0009-7330#Circ Res##
00537000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100024000880120078001120300
00600190065000900196064000500205031000300210032000200213014000600215865000900221
002001300230035001000243801000600253#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#224#12#article#45#12#^rND^sLeite-Moreira^nAF#Current per
spectives in diastolic dysfunction and diastolic heart failure^len#Heart#2006000
0#2006#92#5#712-8#20110000#aop01311.htm#1355-6037#Heart##
00637000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100012000880100016001000100
01900116010001800135012008000153030001200233065000900245064000500254031000200259
032000900261014000900270865000900279002001300288035001000301801001200311#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#225#13#article#45#13
#^rND^sWu^nY#^rND^sLabeit^nS#^rND^sLewinter^nMM#^rND^sGranzier^nH#Titin: an endo
sarcomeric protein that modulates myocardial stiffness in DCM^len#J Card Fail#20
020000#2002#8#6^sSuppl#S276-286#20110000#aop01311.htm#1071-9164#J Card Fail##
00606000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070120
11300124030001000237065000900247064000500256031000300261032000200264014000800266
865000900274002001300283035001000296801001000306#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01311.htm#S#c#226#14#article#45#14#^rND^sGranzier^nHL#^rND
^sIrving^nTC#Passive tension in cardiac muscle: contribution of collagen, titin,
 microtubules, and intermediate filaments^len#Biophys J#19950000#1995#68#3#1027-
44#20110000#aop01311.htm#0006-3495#Biophys J##
00734000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100017001110100
01800128010002000146010002400166010001800190810000600208012008500214030001200299
06500090031106400050032003100040032503200030032901400080033286500090034000200130
0349035001000362801001200372#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#227#15#article#45#15#^rND^svan Heerebeek^nL#^rND^sBorbely^nA#^rN
D^sNiessen^nHW#^rND^sBronzwaer^nJG#^rND^svan der Velden^nJ#^rND^sStienen^nGJ#et 
al#Myocardial structure and function differ in systolic and diastolic heart fail
ure^len#Circulation#20060000#2006#113#16#1966-73#20110000#aop01311.htm#0009-7322
#Circulation##
00670000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100014001040100
01400118010001600132010001300148010001700161012006700178030001400245065000900259
06400050026803100040027303200020027701400070027986500090028600200130029503500100
0308801001400318#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#
S#c#228#16#article#45#16#^rND^sHelmes^nM#^rND^sLim^nCC#^rND^sLiao^nR#^rND^sBhart
i^nA#^rND^sCui^nL#^rND^sSawyer^nDB#Titin determines the Frank-Starling relation 
in early diastole^len#J Gen Physiol#20030000#2003#121#2#97-110#20110000#aop01311
.htm#0022-1295#J Gen Physiol##
00554000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040120
08200123030001900205710000200224065000900226064000500235031000300240032000400243
014000700247865000900254002001300263#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#229#17#article#45#17#^rND^sFukuda^nN#^rND^sGranzier^nHL#
Titin/connectin-based modulation of the Frank-Starling mechanism of the heart^le
n#J Muscle Res Motil#2#20050000#2005#26#6-8#319-23#20110000#aop01311.htm##
00538000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880120072001030300
01200175065000900187064000500196031000400201032000300205014000800208865000900216
002001300225035001000238801001200248#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#230#18#article#45#18#^rND^sKatz^nAM#Ernest Henry Starlin
g, his predecessors, and the "Law of the Heart"^len#Circulation#20020000#2002#10
6#23#2986-92#20110000#aop01311.htm#0009-7322#Circulation##
00748000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01900122010001500141010001600156012017400172030000900346065000900355064000500364
03100030036903200020037201400070037486500090038100200130039003500100040380100090
0413#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#231#19#a
rticle#45#19#^rND^sKentish^nJC#^rND^sKeurs^nHE#^rND^sRicciardi^nL#^rND^sBucx^nJJ
#^rND^sNoble^nMI#comparison between the sarcomere length-force relations of inta
ct and skinned trabeculae from rat right ventricle: Influence of calcium concent
rations on these relations^len#Circ Res#19860000#1986#58#6#755-68#20110000#aop01
311.htm#0009-7330#Circ Res##
00646000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100012001050100
01700117010001800134012010200152030000900254065000900263064000500272031000300277
032000300280014000800283865000900291002001300300035001000313801000900323#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#232#20#article#45#20
#^rND^sCazorla^nO#^rND^sWu^nY#^rND^sIrving^nTC#^rND^sGranzier^nH#Titin-based mod
ulation of calcium sensitivity of active tension in mouse skinned cardiac myocyt
es^len#Circ Res#20010000#2001#88#10#1028-35#20110000#aop01311.htm#0009-7330#Circ
 Res##
00638000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100012001040100
01600116010001700132010001800149012009600167030001000263710000200273065000900275
064000500284031000400289034000200293014000700295865000900302002001300311#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#233#21#article#45#21
#^rND^sFukuda^nN#^rND^sWu^nY#^rND^sFarman^nG#^rND^sIrving^nTC#^rND^sGranzier^nH#
Titin isoform variance and length dependence of activation in skinned bovine car
diac muscle^len#J Physiol#2#20030000#2003#553#1#147-54#20110000#aop01311.htm##
00689000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01800120010001800138012013400156030001200290065000900302064000500311031000400316
032000300320014000800323865000900331002001300340035001000353801001200363#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#234#22#article#45#22
#^rND^sFukuda^nN#^rND^sSasaki^nD#^rND^sIshiwata^nS#^rND^sKurihara^nS#Length depe
ndence of tension generation in rat skinned cardiac muscle: role of titin in the
 Frank-Starling mechanism of the heart^len#Circulation#20010000#2001#104#14#1639
-45#20110000#aop01311.htm#0009-7322#Circulation##
00651000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01500123010001900138012008800157030001700245065000900262064000500271031000300276
032000200279014000700281865000900288002001300297035001000310801001700320#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#235#23#article#45#23
#^rND^sMiller^nMK#^rND^sGranzier^nH#^rND^sEhler^nE#^rND^sGregorio^nCC#The sensit
ive giant: the role of titin-based stretch sensing complexes in the heart^len#Tr
ends Cell Biol#20040000#2004#14#3#119-26#20110000#aop01311.htm#0962-8924#Trends 
Cell Biol##
00604000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120134001040300
01500238065000900253064000500262031000300267032000200270014000700272865000900279
002001300288035001000301801001500311#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#236#24#article#45#24#^rND^sLinke^nWA#Sense and stretchab
ility: the role of titin and titin-associated proteins in myocardial stress-sens
ing and mechanical dysfunction^len#Cardiovasc Res#20080000#2008#77#4#637-48#2011
0000#aop01311.htm#0008-6363#Cardiovasc Res##
00615000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01900125010001600144012004400160030002000204065000900224064000500233031000300238
032000200241014000600243865000900249002001300258035001000271801002000281#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#237#25#article#45#25
#^rND^sGregorio^nCC#^rND^sGranzier^nH#^rND^sSorimachi^nH#^rND^sLabeit^nS#Muscle 
assembly: a titanic achievement?^len#Curr Opin Cell Biol#19990000#1999#11#1#18-2
5#20110000#aop01311.htm#0955-0674#Curr Opin Cell Biol##
00759000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100016001030100
01500119010001700134010001800151010001800169810000600187012013000193030001400323
06500090033706400050034603100040035103200020035501400060035786500090036300200130
0372035001000385801001400395#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#238#26#article#45#26#^rND^sUdaka^nJ#^rND^sOhmori^nS#^rND^sTerui^
nT#^rND^sOhtsuki^nI#^rND^sIshiwata^nS#^rND^sKurihara^nS#et al#Disuse-induced pre
ferential loss of the giant protein titin depresses muscle performance via abnor
mal sarcomeric organization^len#J Gen Physiol#20080000#2008#131#1#33-41#20110000
#aop01311.htm#0022-1295#J Gen Physiol##
00578000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070120
06900123030002000192065000900212064000500221031000300226032000200229014000500231
865000900236002001300245035001000258801002000268#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01311.htm#S#c#239#27#article#45#27#^rND^sGranzier^nHL#^rND
^sLabeit^nS#The giant muscle protein titin is an adjustable molecular spring^len
#Exerc Sport Sci Rev#20060000#2006#34#2#50-3#20110000#aop01311.htm#0091-6331#Exe
rc Sport Sci Rev##
00724000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100012001060100
01600118010001700134010001600151010001800167012012400185030000900309065000900318
06400050032703100030033203200030033501400070033886500090034500200130035403500100
0367801000900377#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#
S#c#240#28#article#45#28#^rND^sYamasaki^nR#^rND^sWu^nY#^rND^sMcNabb^nM#^rND^sGre
aser^nM#^rND^sLabeit^nS#^rND^sGranzier^nH#Protein kinase A phosphorylates titin'
s cardiac-specific N2B domain and reduces passive tension in rat cardiac myocyte
s^len#Circ Res#20020000#2002#90#11#1181-8#20110000#aop01311.htm#0009-7330#Circ R
es##
00623000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040120
10500120030002400225065000900249064000500258031000300263032000400266014000700270
865000900277002001300286035001000299801002400309#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01311.htm#S#c#241#29#article#45#29#^rND^sKruger^nM#^rND^sL
inke^nWA#Protein kinase-A phosphorylates titin in human heart muscle and reduces
 myofibrillar passive tension^len#J Muscle Res Cell Motil#20060000#2006#27#5-7#4
35-44#20110000#aop01311.htm#0142-4319#J Muscle Res Cell Motil##
00689000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100024001050100
01400129010002000143010001400163010001800177810000600195012005500201030001200256
06500090026806400050027703100040028203200020028601400070028886500090029500200130
0304035001000317801001200327#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#242#30#article#45#30#^rND^sBorbely^nA#^rND^svan der Velden^nJ#^r
ND^sPapp^nZ#^rND^sBronzwaer^nJG#^rND^sEdes^nI#^rND^sStienen^nGJ#et al#Cardiomyoc
yte stiffness in diastolic heart failure^len#Circulation#20050000#2005#111#6#774
-81#20110000#aop01311.htm#0009-7322#Circulation##
00661000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100012001040100
01400116010001900130012011100149030001400260065000900274064000500283031000400288
032000200292014000700294865000900301002001300310035001000323801001400333#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#243#31#article#45#31
#^rND^sFukuda^nN#^rND^sWu^nY#^rND^sNair^nP#^rND^sGranzier^nHL#Phosphorylation of
 titin modulates passive stiffness of cardiac muscle in a titin isoform-dependen
t manner^len#J Gen Physiol#20050000#2005#125#3#257-71#20110000#aop01311.htm#0022
-1295#J Gen Physiol##
00558000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100017001020120
06200119030001400181065000900195064000500204031000400209032000200213014000700215
865000900222002001300231035001000244801001400254#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01311.htm#S#c#244#32#article#45#32#^rND^sLim^nCC#^rND^sSaw
yer^nDB#Modulation of cardiac function: titin springs into action^len#J Gen Phys
iol#20050000#2005#125#3#249-52#20110000#aop01311.htm#0022-1295#J Gen Physiol##
00722000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880100023001100100
02000133010002300153012013700176030001800313065000900331064000500340031000300345
032000500348014000500353865000900358002001300367035001000380801001800390#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#245#33#article#45#33
#^rND^sFalcao-Pires^nI#^rND^sFontes-Sousa^nAP#^rND^sBras-Silva^nC#^rND^sLeite-Mo
reira^nA#Beta-adrenergic stimulation acutely increases myocardial distensibility
 - A PKA, PKC and Na+/H+ exchanger mediated effect (abstract)^len#J Am Coll Card
iol#20070000#2007#49#9^sA#408A#20110000#aop01311.htm#0735-1097#J Am Coll Cardiol
##
00502000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880120044001030300
00700147065000900154064000500163031000400168032000500172014000800177865000900185
002001300194035001000207801000700217#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01311.htm#S#c#246#34#article#45#34#^rND^sBers^nDM#Cardiac excitation-c
ontraction coupling^len#Nature#20020000#2002#415#6868#198-205#20110000#aop01311.
htm#0028-0836#Nature##
00727000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01800120010001400138010001800152010001900170810000600189012010600195030000900301
06500090031006400050031903100040032403200020032801400060033086500090033600200130
0345035001000358801000900368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#247#35#article#45#35#^rND^sKruger^nM#^rND^sKotter^nS#^rND^sGrutz
ner^nA#^rND^sLang^nP#^rND^sAndresen^nC#^rND^sRedfield^nMM#et al#Protein kinase G
 modulates human myocardial passive stiffness by phosphorylation of the titin sp
rings^len#Circ Res#20090000#2009#104#1#87-94#20110000#aop01311.htm#0009-7330#Cir
c Res##
00749000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100022001050100
02300127010001700150010001400167010001600181810000600197012012000203030000900323
06500090033206400050034103100040034603200020035001400060035286500090035800200130
0367035001000380801000900390#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#248#36#article#45#36#^rND^sBorbely^nA#^rND^sFalcao-Pires^nI#^rND
^svan Heerebeek^nL#^rND^sHamdani^nN#^rND^sEdes^nI#^rND^sGavina^nC#et al#Hypophos
phorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension 
in failing human myocardium^len#Circ Res#20090000#2009#104#6#780-6#20110000#aop0
1311.htm#0009-7330#Circ Res##
00737000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
02100121010001300142010001800155010001700173810000600190012011500196030000900311
06500090032006400050032903100040033403200020033801400060034086500090034600200130
0355035001000368801000900378#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#249#37#article#45#37#^rND^sHidalgo^nC#^rND^sHudson^nB#^rND^sBogo
molovas^nJ#^rND^sZhu^nY#^rND^sAnderson^nB#^rND^sGreaser^nM#et al#PKC Phosphoryla
tion of titin's PEVK element: a novel and conserved pathway for modulating myoca
rdial stiffness^len#Circ Res#20090000#2009#105#7#631-8#20110000#aop01311.htm#000
9-7330#Circ Res##
00739000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01200121010001900133010001600152010002200168810000600190012011300196030001000309
06500090031906400050032803100030033303200020033601400090033886500090034700200130
0356035001000369801001000379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#250#38#article#45#38#^rND^sYamasaki^nR#^rND^sBerri^nM#^rND^sWu^n
Y#^rND^sTrombitas^nK#^rND^sMcNabb^nM#^rND^sKellermayer^nMS#et al#Titin-actin int
eraction in mouse myocardium: passive tension modulation and its regulation by c
alcium/S100A1^len#Biophys J#20010000#2001#81#4#2297-313#20110000#aop01311.htm#00
06-3495#Biophys J##
00664000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01400122010002000136012009000156030002200246065000900268064000500277031000300282
032000400285014000700289865000900296002001300305035001000318801002200328#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#251#39#article#45#39
#^rND^sStuyvers^nBD#^rND^sMiura^nM#^rND^sJin^nJP#^rND^ster Keurs^nHE#Ca(2+)-depe
ndence of diastolic properties of cardiac sarcomeres: involvement of titin^len#P
rog Biophys Mol Biol#19980000#1998#69#2-3#425-43#20110000#aop01311.htm#0079-6107
#Prog Biophys Mol Biol##
00650000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01600122010001700138010002100155010001500176810000600191012004800197030001600245
71000020026106500090026306400050027203100040027703200020028101400070028386500090
0290002001300299#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#
S#c#252#40#article#45#40#^rND^sWilliams^nL#^rND^sHowell^nN#^rND^sPagano^nD#^rND^
sAndreka^nP#^rND^sVertesaljai^nM#^rND^sPecor^nT#et al#Titin isoform expression i
n aortic stenosis^len#Clin Sci (Lond)#2#20090000#2009#117#6#237-42#20110000#aop0
1311.htm##
00614000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100023001050100
01700128012009200145030000900237065000900246064000500255031000400260032000200264
014000500266865000900271002001300280035001000293801000900303#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01311.htm#S#c#253#41#article#45#41#^rND^sBorbe
ly^nA#^rND^svan Heerebeek^nL#^rND^sPaulus^nWJ#Transcriptional and posttranslatio
nal modifications of titin: implications for diastole^len#Circ Res#20090000#2009
#104#1#12-4#20110000#aop01311.htm#0009-7330#Circ Res##
00721000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01400121010001400135010002000149010001400169810000600183012008700189030001900276
06500090029506400050030403100030030903200020031201400060031486500090032000200130
0329035001000342801001900352#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#254#42#article#45#42#^rND^sMorano^nI#^rND^sHadicke^nK#^rND^sGrom
^nS#^rND^sKoch^nA#^rND^sSchwinger^nRH#^rND^sBohm^nM#et al#Titin, myosin light ch
ains and C-protein in the developing and failing human heart^len#J Mol Cell Card
iol#19940000#1994#26#3#361-8#20110000#aop01311.htm#0022-2828#J Mol Cell Cardiol#
#
00741000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01600123010001600139010001500155010001900170810000600189012012000195030000900315
06500090032406400050033303100030033803200020034101400070034386500090035000200130
0359035001000372801000900382#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#255#43#article#45#43#^rND^sMakarenko^nI#^rND^sOpitz^nCA#^rND^sLe
ake^nMC#^rND^sNeagoe^nC#^rND^sKulke^nM#^rND^sGwathmey^nJK#et al#Passive stiffnes
s changes caused by upregulation of compliant titin isoforms in human dilated ca
rdiomyopathy hearts^len#Circ Res#20040000#2004#95#7#708-16#20110000#aop01311.htm
#0009-7330#Circ Res##
00691000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01900119010001900138010001900157010001700176810000600193012005700199030001200256
06500090026806400050027703100040028203200030028601400080028986500090029700200130
0306035001000319801001200329#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01311.htm#S#c#256#44#article#45#44#^rND^sNeagoe^nC#^rND^sKulke^nM#^rND^sdel Mo
nte^nF#^rND^sGwathmey^nJK#^rND^sde Tombe^nPP#^rND^sHajjar^nRJ#et al#Titin isofor
m switch in ischemic human heart disease^len#Circulation#20020000#2002#106#11#13
33-41#20110000#aop01311.htm#0009-7322#Circulation##
00656000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01500122010002100137010001800158012006700176030001500243065000900258064000500267
03100030027203200020027501400060027786500090028300200130029203500100030580100150
0315#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01311.htm#S#c#257#45#a
rticle#45#45#^rND^sWarren^nCM#^rND^sJordan^nMC#^rND^sRoos^nKP#^rND^sKrzesinski^n
PR#^rND^sGreaser^nML#Titin isoform expression in normal and hypertensive myocard
ium^len#Cardiovasc Res#20030000#2003#59#1#86-94#20110000#aop01311.htm#0008-6363#
Cardiovasc Res##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#o#1#1#
article#1#20110331#080923#aop01411.htm#273##
04382000000000577000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200930017301200740
02660100034003400700101003740831600004750850008020750850034020830850022021170850
02202139083148702161085000803648085002903656085002003685085002103705117000803726
07200030373411200090373711100090374611600090375511500090376411400090377311300090
3782002001303791#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#24#nd#nd#Arq. Bras. Cardiol.#ahead#20110
000#^f0^l0#0066-782X#20110225#Equações de referência para o teste de caminhada d
e seis minutos em indivíduos saudáveis^lpt#Reference equations for the 6-minute 
walk test in healthy individuals^len#^rND^1A01^nVictor Zuniga^sDourado#Universid
ade Federal de São Paulo^iA01^1Departamento de Ciências da Saúde^cSantos^sSão Pa
ulo^pBrasil#^lpt^aO teste de caminhada de 6 minutos (TC6) tem sido amplamente ut
ilizado no ambiente clínico. Algumas equações de referência para a previsão da d
istância percorrida no teste (DTC6) estão disponíveis na literatura. Esta revisã
o teve como objetivo discutir criticamente os achados da literatura, publicados 
em português e em inglês (LILACS, SCIELO, MEDLINE e PUBMED), que avaliaram os va
lores normais e elaboraram equações de referência para a previsão da DTC6 em ind
ivíduos saudáveis, comparando-os aos resultados recentemente obtidos em indivídu
os brasileiros. Idade, gênero, peso, estatura e índice de massa corporal foram o
s atributos demográficos e antropométricos mais frequentemente correlacionados c
om a DTC6. As equações resultantes desses atributos foram capazes de explicar en
tre 25-66,0% da variabilidade total da DTC6. Lamentavelmente, as equações estran
geiras não são adequadas para a população brasileira. Mesmo quando o teste é rea
lizado sob padronização rigorosa, a diferença de performance no TC6 entre estran
geiros e brasileiros permanece, indicando a necessidade dos valores de referênci
as específicos para cada população e/ou etnia. Nesse sentido, as equações desenv
olvidas recentemente no Brasil são, provavelmente, as mais apropriadas para inte
rpretar a performance de caminhada dos nossos compatriotas com doenças crônicas 
que afetam a capacidade para realizar exercícios. Estudos futuros com amostras s
ubstancialmente maiores (e.g. multicêntricos) e com técnica de amostragem random
izada são necessários para que os valores de referência da DTC6 sejam mais repre
sentativos.#^dnd^i1#^tm^lpt^kValores de referência^i1#^tm^lpt^kcaminhada^i1#^tm^
lpt^kexercício^i1#^len^aThe six-minute walk test (6MWT) has been broadly used in
 clinical settings. Several reference equations for prediction of the total dist
ance walked during the test (6MWD) are available in literature. The present revi
ew aimed to critically discuss studies, published in Portuguese and English (LIL
ACS, SCIELO, MEDLINE, PUBMED), which evaluated normal values and created referen
ce equations for predicting 6MWD in healthy subjects, comparing them with the re
sults that were recently obtained in Brazilian individuals. Age, sex, weight, he
ight and body mass index were the main demographic and anthropometric features m
ore often correlated with 6MWD. The equations derived from these characteristics
 were able to explain between 25 and 66% of the total variability in the 6MWD. U
nfortunately, the foreign equations were not applicable to the Brazilian populat
ion. Even when the 6MWT was performed following strict standardization, the diff
erence in 6MWT performance between foreign and Brazilian individuals remains, in
dicating the necessity of providing specific reference equations for each popula
tion and/or ethnic group. Accordingly, these equations developed in Brazil are p
robably the most appropriate for interpreting 6MWT performance in Brazilian pati
ents with chronic diseases affecting the exercise capacity. Future studies are n
ecessary with larger sample sizes (e.g. multicentric ones) and randomized design
 for the reference values of the 6MWD to be considered reliable.#^dnd^i2#^tm^len
^kReference values^i2#^tm^len^kwalking^i2#^tm^len^kexercise^i2#vancouv#56#200910
27#27/10/09#20100211#11/02/10#20100531#31/05/10#aop01411.htm##
04424000000000577000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201000017301200810
02730100034003540700101003880831621004890850008021100850034021180850022021520850
02202174083149402196085000803690085002903698085002003727085002103747117000803768
07200030377611200090377911100090378811600090379711500090380611400090381511300090
3824002001303833#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#24#nd#nd#Arq. Bras. Cardiol.#ahead#20110
000#^f0^l0#0066-782X#20110225#<b>Equações de referência para o teste de caminhad
a de seis minutos em indivíduos saudáveis</b>^lpt#<b>Reference equations for the
 6-minute walk test in healthy individuals</b>^len#^rND^1A01^nVictor Zuniga^sDou
rado#Universidade Federal de São Paulo^iA01^1Departamento de Ciências da Saúde^c
Santos^sSão Paulo^pBrasil#^lpt^aO teste de caminhada de 6 minutos (TC6) tem sido
 amplamente utilizado no ambiente clínico. Algumas equações de referência para a
 previsão da distância percorrida no teste (DTC6) estão disponíveis na literatur
a. Esta revisão teve como objetivo discutir criticamente os achados da literatur
a, publicados em português e em inglês (<i>LILACS, SCIELO, MEDLINE</i> e <i>PUBM
ED</i>), que avaliaram os valores normais e elaboraram equações de referência pa
ra a previsão da DTC6 em indivíduos saudáveis, comparando-os aos resultados rece
ntemente obtidos em indivíduos brasileiros. Idade, gênero, peso, estatura e índi
ce de massa corporal foram os atributos demográficos e antropométricos mais freq
uentemente correlacionados com a DTC6. As equações resultantes desses atributos 
foram capazes de explicar entre 25-66,0% da variabilidade total da DTC6. Lamenta
velmente, as equações estrangeiras não são adequadas para a população brasileira
. Mesmo quando o teste é realizado sob padronização rigorosa, a diferença de per
formance no TC6 entre estrangeiros e brasileiros permanece, indicando a necessid
ade dos valores de referências específicos para cada população e/ou etnia. Nesse
 sentido, as equações desenvolvidas recentemente no Brasil são, provavelmente, a
s mais apropriadas para interpretar a performance de caminhada dos nossos compat
riotas com doenças crônicas que afetam a capacidade para realizar exercícios. Es
tudos futuros com amostras substancialmente maiores (<i>e.g. multicêntricos</i>)
 e com técnica de amostragem randomizada são necessários para que os valores de 
referência da DTC6 sejam mais representativos.#^dnd^i1#^tm^lpt^kValores de refer
ência^i1#^tm^lpt^kcaminhada^i1#^tm^lpt^kexercício^i1#^len^aThe six-minute walk t
est (6MWT) has been broadly used in clinical settings. Several reference equatio
ns for prediction of the total distance walked during the test (6MWD) are availa
ble in literature. The present review aimed to critically discuss studies, publi
shed in Portuguese and English (LILACS, SCIELO, MEDLINE, PUBMED), which evaluate
d normal values and created reference equations for predicting 6MWD in healthy s
ubjects, comparing them with the results that were recently obtained in Brazilia
n individuals. Age, sex, weight, height and body mass index were the main demogr
aphic and anthropometric features more often correlated with 6MWD. The equations
 derived from these characteristics were able to explain between 25 and 66% of t
he total variability in the 6MWD. Unfortunately, the foreign equations were not 
applicable to the Brazilian population. Even when the 6MWT was performed followi
ng strict standardization, the difference in 6MWT performance between foreign an
d Brazilian individuals remains, indicating the necessity of providing specific 
reference equations for each population and/or ethnic group. Accordingly, these 
equations developed in Brazil are probably the most appropriate for interpreting
 6MWT performance in Brazilian patients with chronic diseases affecting the exer
cise capacity. Future studies are necessary with larger sample sizes (<i>e.g.</i
> multicentric ones) and randomized design for the reference values of the 6MWD 
to be considered reliable.#^dnd^i2#^tm^len^kReference values^i2#^tm^len^kwalking
^i2#^tm^len^kexercise^i2#vancouv#56#20091027#27/10/09#20100211#11/02/10#20100531
#31/05/10#aop01411.htm##
04519000000000601000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001200930
01790120074002720100034003460700103003800831609004830850008020920850034021000850
02202134085002202156083149402178085000803672085002903680085002003709085002103729
11700080375007200030375811200090376111100090377011600090377911500090378811400090
3797113000903806002001303815008008903828#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop01411.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#tab#24#nd#nd#
Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110225#Equações de referênc
ia para o teste de caminhada de seis minutos em indivíduos saudáveis^lpt#Referen
ce equations for the 6-minute walk test in healthy individuals^len#^rND^1A01^nVi
ctor Zuniga^sDourado#^iA01^1Universidade Federal de São Paulo^2Departamento de C
iências da Saúde^cSantos^sSão Paulo^pBrasil#^lpt^aO teste de caminhada de 6 minu
tos (TC6) tem sido amplamente utilizado no ambiente clínico. Algumas equações de
 referência para a previsão da distância percorrida no teste (DTC6) estão dispon
íveis na literatura. Esta revisão teve como objetivo discutir criticamente os ac
hados da literatura, publicados em português e em inglês (LILACS, SCIELO, MEDLIN
E e PUBMED), que avaliaram os valores normais e elaboraram equações de referênci
a para a previsão da DTC6 em indivíduos saudáveis, comparando-os aos resultados 
recentemente obtidos em indivíduos brasileiros. Idade, gênero, peso, estatura e 
índice de massa corporal foram os atributos demográficos e antropométricos mais 
frequentemente correlacionados com a DTC6. As equações resultantes desses atribu
tos foram capazes de explicar entre 25-66,0 por cento da variabilidade total da 
DTC6. Lamentavelmente, as equações estrangeiras não são adequadas para a populaç
ão brasileira. Mesmo quando o teste é realizado sob padronização rigorosa, a dif
erença de performance no TC6 entre estrangeiros e brasileiros permanece, indican
do a necessidade dos valores de referências específicos para cada população e/ou
 etnia. Nesse sentido, as equações desenvolvidas recentemente no Brasil são, pro
vavelmente, as mais apropriadas para interpretar a performance de caminhada dos 
nossos compatriotas com doenças crônicas que afetam a capacidade para realizar e
xercícios. Estudos futuros com amostras substancialmente maiores (e.g. multicênt
ricos) e com técnica de amostragem randomizada são necessários para que os valor
es de referência da DTC6 sejam mais representativos.#^dnd^i1#^tm^lpt^kValores de
 referência^i1#^tm^lpt^kcaminhada^i1#^tm^lpt^kexercício^i1#^len^aThe six-minute 
walk test (6MWT) has been broadly used in clinical settings. Several reference e
quations for prediction of the total distance walked during the test (6MWD) are 
available in literature. The present review aimed to critically discuss studies,
 published in Portuguese and English (LILACS, SCIELO, MEDLINE, PUBMED), which ev
aluated normal values and created reference equations for predicting 6MWD in hea
lthy subjects, comparing them with the results that were recently obtained in Br
azilian individuals. Age, sex, weight, height and body mass index were the main 
demographic and anthropometric features more often correlated with 6MWD. The equ
ations derived from these characteristics were able to explain between 25 and 66
 percent of the total variability in the 6MWD. Unfortunately, the foreign equati
ons were not applicable to the Brazilian population. Even when the 6MWT was perf
ormed following strict standardization, the difference in 6MWT performance betwe
en foreign and Brazilian individuals remains, indicating the necessity of provid
ing specific reference equations for each population and/or ethnic group. Accord
ingly, these equations developed in Brazil are probably the most appropriate for
 interpreting 6MWT performance in Brazilian patients with chronic diseases affec
ting the exercise capacity. Future studies are necessary with larger sample size
s (e.g. multicentric ones) and randomized design for the reference values of the
 6MWD to be considered reliable.#^dnd^i2#^tm^len^kReference values^i2#^tm^len^kw
alking^i2#^tm^len^kexercise^i2#vancouv#56#20091027#27/10/09#20100211#11/02/10#20
100531#31/05/10#aop01411.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sc
i_arttext&pid=S0066-782X2011005000024##
00478000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704023600083002001300319#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#5#1#article#213#<p><a name="
top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Equa&cce
dil;&otilde;es    de refer&ecirc;ncia para o teste de caminhada de seis minutos 
em indiv&iacute;duos    saud&aacute;veis</b></font></p>     ^cY#aop01411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#6#2#article#213#<p>&nbsp;</p
>     ^cY#aop01411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#7#3#article#213#<p>&nbsp;</p
>     ^cY#aop01411.htm##
00356000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704011400083002001300197#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#8#4#article#213#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Victor Zuniga    Dourado</
b></font></p>     ^cY#aop01411.htm##
00489000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704024700083002001300330#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#9#5#article#213#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Departamento de    Ci&ecirc;n
cias da Sa&uacute;de, Universidade Federal de S&atilde;o Paulo (UNIFESP),    Cam
pus Baixada Santista, Santos, S&atilde;o Paulo - Brasil</font></p>     ^cY#aop01
411.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#10#6#article#213#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01411.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#11#7#article#213#<p>&nbsp;</
p>     ^cY#aop01411.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#12#8#article#213#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01411.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#13#9#article#213#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop01411.htm##
00591000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034700085002001300432#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#14#10#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O teste de caminhada    de 
6 minutos (TC6) tem sido amplamente utilizado no ambiente cl&iacute;nico.    Alg
umas equa&ccedil;&otilde;es de refer&ecirc;ncia para a previs&atilde;o da    dis
t&acirc;ncia percorrida no teste (DTC6) est&atilde;o dispon&iacute;veis na    li
teratura.    ^cY#aop01411.htm##
00698000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045400085002001300539#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#15#11#article#213#<br>   Est
a revis&atilde;o teve como objetivo discutir criticamente os achados da literatu
ra,    publicados em portugu&ecirc;s e em ingl&ecirc;s (<i>LILACS, SCIELO, MEDLI
NE</i>    e <i>PUBMED</i>), que avaliaram os valores normais e elaboraram equa&c
cedil;&otilde;es    de refer&ecirc;ncia para a previs&atilde;o da DTC6 em indiv&
iacute;duos saud&aacute;veis,    comparando-os aos resultados recentemente obtid
os em indiv&iacute;duos brasileiros.    ^cY#aop01411.htm##
01307000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106300085002001301148#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#16#12#article#213#<br>   Ida
de, g&ecirc;nero, peso, estatura e &iacute;ndice de massa corporal foram    os a
tributos demogr&aacute;ficos e antropom&eacute;tricos mais frequentemente    cor
relacionados com a DTC6. As equa&ccedil;&otilde;es resultantes desses atributos 
   foram capazes de explicar entre 25-66,0% da variabilidade total da DTC6. Lame
ntavelmente,    as equa&ccedil;&otilde;es estrangeiras n&atilde;o s&atilde;o ade
quadas para    a popula&ccedil;&atilde;o brasileira. Mesmo quando o teste &eacut
e; realizado    sob padroniza&ccedil;&atilde;o rigorosa, a diferen&ccedil;a de p
erformance no    TC6 entre estrangeiros e brasileiros permanece, indicando a nec
essidade dos    valores de refer&ecirc;ncias espec&iacute;ficos para cada popula
&ccedil;&atilde;o    e/ou etnia. Nesse sentido, as equa&ccedil;&otilde;es desenv
olvidas recentemente    no Brasil s&atilde;o, provavelmente, as mais apropriadas
 para interpretar a    performance de caminhada dos nossos compatriotas com doen
&ccedil;as cr&ocirc;nicas    que afetam a capacidade para realizar exerc&iacute;
cios.    ^cY#aop01411.htm##
00518000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027400085002001300359#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#17#13#article#213#<br>   Est
udos futuros com amostras substancialmente maiores (<i>e.g. multic&ecirc;ntricos
</i>)    e com t&eacute;cnica de amostragem randomizada s&atilde;o necess&aacute
;rios    para que os valores de refer&ecirc;ncia da DTC6 sejam mais representati
vos.</font></p>     ^cY#aop01411.htm##
00433000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704018900085002001300274#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#18#14#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Valores de refer&ecirc;ncia, caminhada, exerc&iacute;cio.</font></p> <hr size="1
" noshade>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#19#15#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#20#16#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#21#17#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01411.htm##
00543000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029900085002001300384#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#22#18#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A aplica&ccedil;&atilde;o  
  dos testes de caminhada de campo em pacientes com doen&ccedil;as cardiorrespir
at&oacute;rias    resulta da adapta&ccedil;&atilde;o do teste de corrida de 12 m
inutos de Cooper<sup>1</sup>.</font></p>     ^cY#aop01411.htm##
01388000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704114400085002001301229#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#23#19#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Esse teste foi    desenvolv
ido com o objetivo de verificar o n&iacute;vel de condicionamento f&iacute;sico 
   de soldados das for&ccedil;as armadas americanas. Em sua forma original, o te
ste    consiste em correr a maior dist&acirc;ncia poss&iacute;vel em 12 minutos.
 Na    d&eacute;cada de 70, McGavin e cols.<sup>2</sup> modificaram o teste de c
orrida    de Cooper para um teste de caminhada de 12 minutos com o objetivo de a
valiar    a toler&acirc;ncia de pacientes com bronquite cr&ocirc;nica ao exerc&i
acute;cio.    O teste de caminhada de 12 minutos foi adaptado para dist&acirc;nc
ias mais curtas    (<i>e.g.</i> dois e 6 minutos), principalmente por ser extenu
ante para os pacientes<sup>3</sup>.    Por outro lado, o teste de dois minutos a
presentou responsividade limitada,    sobretudo para pacientes menos debilitados
<sup>4</sup>. Nesse sentido, o teste    de caminhada de 6 minutos (TC6) se torno
u o mais popular entre os testes com    dura&ccedil;&atilde;o controlada e consi
ste em caminhar o mais r&aacute;pido    poss&iacute;vel durante 6 minutos.</font
></p>     ^cY#aop01411.htm##
01211000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704096700085002001301052#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#24#20#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O TC6 foi originalmente    
desenvolvido para avaliar a capacidade funcional, monitorar a efetividade de    
tratamentos diversos e estabelecer o progn&oacute;stico de pacientes com doen&cc
edil;as    cardiorrespirat&oacute;rias<sup>5</sup>. Pacientes com tais disfun&cc
edil;&otilde;es    apresentam intoler&acirc;ncia ao exerc&iacute;cio devido ao m
au funcionamento    dos sistemas respirat&oacute;rio e/ou cardiovascular e &agra
ve; disfun&ccedil;&atilde;o    dos m&uacute;sculos esquel&eacute;ticos perif&eac
ute;ricos e respirat&oacute;rios<sup>6</sup>.    Contudo, mais recentemente, o t
este tem sido validado em diversas popula&ccedil;&otilde;es,    incluindo pacien
tes com fibromialgia, acidente vascular encef&aacute;lico, amputa&ccedil;&otilde
;es,    obesidade m&oacute;rbida, s&iacute;ndrome de <i>down</i>, <i>alzhaimer</
i>,    paralisia cerebral, entre outros<sup>5,7-12</sup>.</font></p>     ^cY#aop
01411.htm##
01103000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704085900085002001300944#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#25#21#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em pacientes com    doen&cc
edil;as cardiorrespirat&oacute;rias, o consumo de oxig&ecirc;nio no TC6    n&ati
lde;o difere significativamente do consumo m&aacute;ximo de oxig&ecirc;nio    (V
O<sub>2max</sub>) obtido em teste incremental de laborat&oacute;rio realizado   
 em cicloerg&ocirc;metro<sup>13</sup>. Sendo assim, &eacute; poss&iacute;vel    
estimar adequadamente o VO<sub>2max</sub> por meio da dist&acirc;ncia percorrida
    no TC6 (DTC6). Isto torna o TC6 uma ferramenta simples e menos onerosa de av
alia&ccedil;&atilde;o    da aptid&atilde;o cardiorrespirat&oacute;ria<sup>5</sup
>. O TC6 &eacute; mais    bem tolerado pelos pacientes e mais representativo das
 atividades da vida di&aacute;ria    em compara&ccedil;&atilde;o aos outros test
es de caminhada<sup>14</sup>.</font></p>     ^cY#aop01411.htm##
01344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110000085002001301185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#26#22#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Diversos fatores    demogr&
aacute;ficos, antropom&eacute;tricos, cl&iacute;nicos e fisiol&oacute;gicos    p
odem influenciar a DTC6 em indiv&iacute;duos saud&aacute;veis e em pacientes    
com doen&ccedil;as cr&ocirc;nicas. Os indiv&iacute;duos com menor estatura e    
as mulheres apresentam menor comprimento das passadas e, consequentemente, menor
    DTC6. Os idosos e os indiv&iacute;duos obesos comumente apresentam massa mag
ra    corporal reduzida e, consequentemente, menor DTC6. Os indiv&iacute;duos de
smotivados,    com preju&iacute;zo cognitivo, com artrite e outros dist&uacute;r
bios musculoesquel&eacute;ticos    tamb&eacute;m apresentam redu&ccedil;&atilde;
o da DTC6<sup>15,16</sup>. For&ccedil;a    muscular, sintomas de depress&atilde;
o, preju&iacute;zo da qualidade de vida    relacionada &agrave; sa&uacute;de, us
o de medicamentos, inflama&ccedil;&atilde;o    sist&ecirc;mica e fun&ccedil;&ati
lde;o pulmonar alterada s&atilde;o outros atributos    que influenciam a perform
ance no teste<sup>16-18</sup>.</font></p>     ^cY#aop01411.htm##
01710000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704146600085002001301551#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#27#23#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Devido ao seu car&aacute;te
r    de dura&ccedil;&atilde;o controlada, o TC6 sofre influ&ecirc;ncia de compli
cadores    externos, tais como o esfor&ccedil;o despendido e a motiva&ccedil;&at
ilde;o<sup>19</sup>.    Por esse motivo, as instru&ccedil;&otilde;es e o n&iacut
e;vel de encorajamento    devem ser cuidadosamente padronizados<sup>5</sup>. com
o a velocidade de caminhada    no TC6 &eacute; autocontrolada, a DTC6 &eacute; e
xtremamente vari&aacute;vel    em indiv&iacute;duos saud&aacute;veis<sup>5</sup>
. De fato, as equa&ccedil;&otilde;es    de regress&atilde;o publicadas na litera
tura para o TC6 apresentam grande variabilidade    em seus resultados. Isto se d
eve, provavelmente, &agrave;s diferen&ccedil;as    entre os protocolos de avalia
&ccedil;&atilde;o, bem como &agrave;s diferen&ccedil;as    populacionais<sup>20,
21</sup>. Embora pouco aplicado em popula&ccedil;&otilde;es    saud&aacute;veis<
sup>22</sup>, h&aacute; valores de refer&ecirc;ncia da DTC6    para crian&ccedil
;as e adolescentes<sup>23-27</sup>, para indiv&iacute;duos    adultos<sup>28-31<
/sup> e para idosos saud&aacute;veis<sup>16,20,21,28,32-35</sup>.    Alguns dess
es valores foram obtidos antes da publica&ccedil;&atilde;o do consenso    da <i>
American Thoracic Society</i> (ATS) para a realiza&ccedil;&atilde;o do    TC6<su
p>5</sup>, o que justifica, em parte, a grande variabilidade dos resultados.</fo
nt></p>     ^cY#aop01411.htm##
01684000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704144000085002001301525#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#28#24#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Entre as equa&ccedil;&otild
e;es    mais populares, est&atilde;o as desenvolvidas por Enright e Sherrill<sup
>20</sup>    e por Troosters e cols.<sup>21</sup>. Essas foram desenvolvidas ant
es da publica&ccedil;&atilde;o    do consenso da ATS<sup>5</sup> e oferecem resu
ltados substancialmente diferentes.    De fato, observamos recentemente que as e
qua&ccedil;&otilde;es estrangeiras    n&atilde;o foram adequadas para uma amostr
a da popula&ccedil;&atilde;o brasileira<sup>31</sup>.    Resultados semelhantes 
foram descritos em outras popula&ccedil;&otilde;es (<i>e.g.</i>,    australianos
, &aacute;rabes, tunisianos e cingapurianos)<sup>30,32,33,35</sup>.    A explica
&ccedil;&atilde;o para as diferentes performances encontradas em etnias    difer
entes n&atilde;o &eacute; simples. O n&iacute;vel de encorajamento, o compriment
o    e <i>layout</i> do percurso e o n&uacute;mero de testes realizados para fam
iliariza&ccedil;&atilde;o    influenciam significativamente a DTC6. Mesmo com es
sas vari&aacute;veis rigorosamente    controladas, a motiva&ccedil;&atilde;o dos
 indiv&iacute;duos durante o teste    tem contribui&ccedil;&atilde;o importante,
 uma vez que alguns estudos diferem    substancialmente na intensidade em que os
 indiv&iacute;duos realizaram o teste,    variando entre 44,0-81,0% da frequ&eci
rc;ncia card&iacute;aca m&aacute;xima    estimada.</font></p>     ^cY#aop01411.h
tm##
00831000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058700085002001300672#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#29#25#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Al&eacute;m disso,    as di
feren&ccedil;as demogr&aacute;ficas, antropom&eacute;tricas e nutricionais    ob
servadas entre as diversas etnias avaliadas devem ser consideradas. A maior    e
statura e a maior quantidade de massa magra observadas em caucasianos repercutem
    significativamente na DTC6. Por isso, a ATS estimula a comunidade cient&iacu
te;fica    a utilizar a padroniza&ccedil;&atilde;o do TC6 sugerida em seu consen
so e a    desenvolver valores de refer&ecirc;ncia da DTC6 em diversas etnias.</f
ont></p>     ^cY#aop01411.htm##
01241000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099700085002001301082#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#30#26#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A escolha equivocada    da 
equa&ccedil;&atilde;o de refer&ecirc;ncia pode resultar em erros potenciais    r
elacionados &agrave; interpreta&ccedil;&atilde;o do n&iacute;vel de aptid&atilde
;o    f&iacute;sica e da melhora da DTC6 ap&oacute;s interven&ccedil;&otilde;es 
em    pacientes com doen&ccedil;as cr&ocirc;nicas. Portanto, o conhecimento mais
 aprofundado    das condi&ccedil;&otilde;es em que cada equa&ccedil;&atilde;o de
 refer&ecirc;ncia    foi obtida se faz necess&aacute;rio. Desta forma, esta revi
s&atilde;o da literatura    teve como objetivo discutir criticamente os estudos 
publicados (<i>LILACS, SCIELO,    MEDLINE</i> e <i>PUBMED</i>) que avaliaram os 
valores normais e elaboraram equa&ccedil;&otilde;es    de refer&ecirc;ncia para 
a previs&atilde;o da DTC6 em indiv&iacute;duos saud&aacute;veis,    comparando-o
s aos resultados recentemente obtidos em indiv&iacute;duos brasileiros<sup>23,31
</sup>.</font></p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#31#27#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00388000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014400085002001300229#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#32#28#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Caracter&iacute;sticas  
  gerais dos indiv&iacute;duos</b></font></p>     ^cY#aop01411.htm##
00857000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704061300085002001300698#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#33#29#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Sob nosso conhecimento,    
h&aacute; 19 estudos que avaliaram os valores normais da DTC6. Dos tais, 15    e
studos avaliaram os atributos determinantes da DTC6 por meio de regress&atilde;o
    m&uacute;ltipla e elaboraram alguma equa&ccedil;&atilde;o de refer&ecirc;nci
a    (<a href="/img/revistas/abc/2011nahead/aop01411t01.jpg">Tabela 1</a>). Outr
os 4 estudos avaliaram    um n&uacute;mero razo&aacute;vel de indiv&iacute;duos,
 contudo n&atilde;o formularam    nenhuma equa&ccedil;&atilde;o de refer&ecirc;n
cia<sup>25,36-38</sup>.</font></p>     ^cY#aop01411.htm##
01235000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099100085002001301076#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#34#30#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Steffen e cols.<sup>36</sup
>,    Pires e cols.<sup>38</sup>, Roush e cols.<sup>37</sup> e Lammers e cols.<s
up>25</sup>    avaliaram a influ&ecirc;ncia do g&ecirc;nero, da idade e do &iacu
te;ndice da    massa corporal (IMC) na DTC6, respectivamente em indiv&iacute;duo
s entre 61    e 89 anos<sup>36</sup>, entre 18 e 80 anos<sup>38</sup>, entre 7 e
 9 anos<sup>37</sup>    e entre 4 e 11 anos<sup>25</sup>. Dos estudos que elabor
aram equa&ccedil;&otilde;es    de refer&ecirc;ncia, 4 foram realizados com crian
&ccedil;as e adolescentes<sup>23,24,26,27</sup>,    dos quais, um envolveu crian
&ccedil;as e adolescentes caucasianos austr&iacute;acos<sup>24</sup>,    um aval
iou crian&ccedil;as e adolescentes tunisianos<sup>27</sup>, um estudo    foi rea
lizado com crian&ccedil;as e adolescentes chineses<sup>26</sup> e outro    estud
o foi realizado com indiv&iacute;duos brasileiros entre 6 e 12 anos<sup>23</sup>
.</font></p>     ^cY#aop01411.htm##
01031000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078700085002001300872#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#35#31#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Dois estudos elaboraram    
equa&ccedil;&otilde;es de refer&ecirc;ncia em adultos italianos<sup>29</sup>    
e &aacute;rabes<sup>30</sup>. A maioria dos estudos avaliou indiv&iacute;duos   
 com idade <u>&gt;</u> 40 anos. Esses estudos foram realizados com indiv&iacute;
duos    estadunidenses<sup>16,20</sup>, belgas<sup>21</sup>, cingapurianos<sup>3
3</sup>,    australianos<sup>32</sup> e tunisianos<sup>34,35</sup>. Dois estudos
 avaliaram    indiv&iacute;duos em ampla faixa et&aacute;ria<sup>28,31</sup>, en
tre eles,    um estudo envolvendo indiv&iacute;duos estadunidenses<sup>28</sup> 
e outro envolvendo    indiv&iacute;duos de dois munic&iacute;pios brasileiros (S
antos/SP e Botucatu/SP)<sup>31</sup>.</font></p>     ^cY#aop01411.htm##
00797000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055300085002001300638#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#36#32#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os diversos estudos    publ
icados at&eacute; o momento s&atilde;o bastante heterog&ecirc;neos. Algumas    d
iferen&ccedil;as da DTC6 entre os estudos se devem &agrave; forma com que o    t
este foi realizado (<i>i.e.</i>, n&iacute;vel de encorajamento, comprimento    e
 <i>layout</i> do percurso, n&uacute;mero de testes realizados para familiariza&
ccedil;&atilde;o,    etc.). Contudo, outras caracter&iacute;sticas populacionais
 e cl&iacute;nicas    devem ser discutidas.</font></p>     ^cY#aop01411.htm##
01295000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704105100085002001301136#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#37#33#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os estudos envolvendo    pa
rticipantes adultos e idosos apresentaram, em sua grande maioria, valores    m&e
acute;dios do IMC representativos de sobrepeso. Poucos estudos utilizaram    o I
MC &gt; 35 kg/m<sup>2</sup> como crit&eacute;rio de exclus&atilde;o<sup>20,21,30
</sup>.    A obesidade aumenta a carga de trabalho para uma dada intensidade de 
exerc&iacute;cio,    reduzindo a DTC6. Os indiv&iacute;duos com IMC &gt; 30 kg/m
<sup>2</sup> caminharam    aproximadamente 85,0% da DTC6 percorrida por indiv&ia
cute;duos eutr&oacute;ficos    no estudo de Enright e cols.<sup>16</sup>. Embora
 o IMC seja um &iacute;ndice    cl&iacute;nico de obesidade &uacute;til, n&atild
e;o pode ser considerado como    o melhor &iacute;ndice para determina&ccedil;&a
tilde;o da quantidade de gordura    corporal. Adicionalmente, a rela&ccedil;&ati
lde;o entre a massa corporal e a    DTC6 costuma ser mais consistente que a corr
ela&ccedil;&atilde;o entre a DTC6    e o IMC<sup>16,20</sup>.</font></p>     ^cY
#aop01411.htm##
01217000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097300085002001301058#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#38#34#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Indiv&iacute;duos    com ou
tros fatores de risco cardiovascular, tais como a hipertens&atilde;o arterial   
 e o tabagismo, foram tamb&eacute;m inclu&iacute;dos em alguns estudos<sup>30-33
</sup>.    Indiv&iacute;duos com press&atilde;o arterial controlada por uso de m
edicamentos    e/ou &lt; 150/100 mmHg e os tabagistas sem altera&ccedil;&atilde;
o da fun&ccedil;&atilde;o    pulmonar e sem sintomas respirat&oacute;rios foram 
inclu&iacute;dos nesses estudos<sup>30-33</sup>.    A hipertens&atilde;o arteria
l e o tabagismo repercutem negativamente na DTC6<sup>16</sup>.    Participantes 
que apresentaram fatores de risco cardiovascular caminharam significativamente  
  menos no TC6 quando comparados aos indiv&iacute;duos sem fatores de risco<sup>
16,20</sup>.    O uso de medicamentos para doen&ccedil;as cardiovasculares tamb&
eacute;m pode    influenciar negativamente a DTC6<sup>39</sup>.</font></p>     ^
cY#aop01411.htm##
01563000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704131900085002001301404#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#39#35#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Diversos estudos    avaliar
am o n&iacute;vel de atividade f&iacute;sica habitual, contudo, sob nosso    con
hecimento, nenhum deles avaliou diretamente a quantidade e a intensidade    da a
tividade f&iacute;sica di&aacute;ria. Alguns question&aacute;rios internacionalm
ente    validados foram utilizados em alguns estudos<sup>31,35</sup>. Outros aut
ores    utilizaram instrumentos nacionais<sup>27,32,34</sup>. Em outros estudos,
 os    participantes foram simplesmente inquiridos sobre a participa&ccedil;&ati
lde;o    em atividades f&iacute;sicas esportivas ou vigorosas<sup>20,21,28,33,40
</sup>.    A quantifica&ccedil;&atilde;o da atividade f&iacute;sica di&aacute;ri
a por meio    de question&aacute;rios apresenta como principal vantagem o baixo 
custo e a    facilidade de aplica&ccedil;&atilde;o. Entretanto, tais instrumento
s sabidamente    dependem de fatores como: a percep&ccedil;&atilde;o e compreens
&atilde;o dos    indiv&iacute;duos sobre as informa&ccedil;&otilde;es, o delinea
mento do question&aacute;rio,    as caracter&iacute;sticas individuais (<i>e.g.,
</i> idade, cultura, escolaridade    e cogni&ccedil;&atilde;o) e o tipo de c&aac
ute;lculo utilizado para estimar    o gasto energ&eacute;tico di&aacute;rio<sup>
41</sup>.</font></p>     ^cY#aop01411.htm##
01169000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704092500085002001301010#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#40#36#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Embora alguns autores    te
nham afirmado que seus estudos foram realizados com indiv&iacute;duos sedent&aac
ute;rios<sup>29,34</sup>,    os question&aacute;rios t&ecirc;m capacidade limita
da para definir o sedentarismo    em todos os seus dom&iacute;nios (<i>e.g.,</i>
 quantidade e intensidade da atividade    f&iacute;sica di&aacute;ria)<sup>41</s
up>. De fato, a nossa experi&ecirc;ncia    em participantes brasileiros mostrou 
que a correla&ccedil;&atilde;o entre o    n&iacute;vel de atividade f&iacute;sic
a habitual, avaliado por meio do question&aacute;rio    de Baecke<sup>42</sup>, 
e a DTC6, embora significativa, apresentou-se fraca    (r = 0,25; p &lt; 0,01)<s
up>31</sup>. S&atilde;o necess&aacute;rios novos estudos    utilizando sensores 
de movimento para que uma amostra realmente sedent&aacute;ria    saud&aacute;vel
 seja avaliada.</font></p>     ^cY#aop01411.htm##
00999000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075500085002001300840#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#41#37#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil, a preval&ecirc;n
cia    de sobrepeso foi de 10,8% entre crian&ccedil;as, 9,9% nos adolescentes e 
28,3%    entre adultos e a de obesidade foi de 7,3%, 1,8% e 9,7%, respectivament
e. Preval&ecirc;ncia    conjunta de sobrepeso e obesidade na popula&ccedil;&atil
de;o brasileira &eacute;    maior no sexo feminino, sendo que mais da metade das
 mulheres das regi&otilde;es    Nordeste e Sudeste do Brasil, com idade entre 50
 e 69 anos, t&ecirc;m sobrepeso    e/ou obesidade<sup>43</sup>. O excesso de mas
sa corporal &eacute; um fator predisponente    para a hipertens&atilde;o, podend
o ser respons&aacute;vel por 20,0% a 30% dos    casos de hipertens&atilde;o arte
rial.</font></p>     ^cY#aop01411.htm##
01266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704102200085002001301107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#42#38#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Inqu&eacute;ritos    de bas
e populacional realizados em algumas cidades do Brasil mostram preval&ecirc;ncia
    de hipertens&atilde;o arterial (<u>&gt;</u> 140/90 mmHg) de 22,3% a 43,9%<su
p>44</sup>.    Quanto ao tabagismo, segundo dados divulgados em 2004, um ter&cce
dil;o da popula&ccedil;&atilde;o    adulta brasileira fuma, sendo 16,7 milh&otil
de;es de homens e 11,2 milh&otilde;es    de mulheres. Em jovens de 10 a 19 anos,
 revelou-se preval&ecirc;ncias de tabagismo    entre 8,9 e 12,1%<sup>45</sup>. A
 preval&ecirc;ncia de sedentarismo &eacute;    vari&aacute;vel e depende da meto
dologia utilizada para defini-lo e da amostra    estudada. Uma revis&atilde;o si
stem&aacute;tica da literatura mostrou que a    preval&ecirc;ncia de sedentarism
o no Brasil est&aacute; entre 26,7 e 78,2%.    Quando considerada apenas a ativi
dade f&iacute;sica realizada no tempo de lazer,    essa preval&ecirc;ncia varia 
entre 55,3 e 96,7%<sup>46</sup>.</font></p>     ^cY#aop01411.htm##
01052000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080800085002001300893#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#43#39#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Se por um lado,    a inclus
&atilde;o de participantes com os fatores de risco cardiovascular supracitados  
  torna o perfil saud&aacute;vel da amostra question&aacute;vel, por outro, a   
 inclus&atilde;o de indiv&iacute;duos com tais fatores de risco, devido &agrave;
    alta preval&ecirc;ncia dos mesmos, tornou as amostras mais representativas. 
   Al&eacute;m disso, entre diversas vari&aacute;veis demogr&aacute;ficas, antro
pom&eacute;tricas,    cl&iacute;nicas e fisiol&oacute;gicas, o IMC, a hipertens&
atilde;o, o tabagismo    e o n&iacute;vel de atividade f&iacute;sica habitual n&
atilde;o foram selecionados    como determinantes da DTC6, ap&oacute;s an&aacute
;lise de regress&atilde;o m&uacute;ltipla<sup>16,31</sup>.</font></p>     ^cY#ao
p01411.htm##
01394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704115000085002001301235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#44#40#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Outras caracter&iacute;stic
as    populacionais e cl&iacute;nicas devem ser consideradas. A DTC6 foi 132 m e
 30    m superior em indiv&iacute;duos com alta escolaridade e com melhor condi&
ccedil;&atilde;o    socioecon&ocirc;mica, respectivamente<sup>35</sup>. Ap&oacut
e;s ajuste para    a idade, o g&ecirc;nero, o peso, a estatura, entre outros fat
ores, os indiv&iacute;duos    estadunidenses afrodescendentes apresentaram pior 
performance no TC6, quando    comparados aos seus compatriotas caucasianos. Inve
stigadores no Jap&atilde;o<sup>47</sup>,    por outro lado, observaram que a DTC
6 percorrida pelos japoneses foi semelhante    &agrave; DTC6 relatada para indiv
&iacute;duos caucasianos<sup>20,21</sup>. Nesse    sentido, &eacute; coerente es
pecular que a pior condi&ccedil;&atilde;o socioecon&ocirc;mica,    o menor grau 
de escolaridade e a miscigena&ccedil;&atilde;o, comumente encontrados    na popu
la&ccedil;&atilde;o brasileira, podem explicar em parte a inadequa&ccedil;&atild
e;o    das equa&ccedil;&otilde;es estrangeiras em nossa popula&ccedil;&atilde;o.
</font></p>     ^cY#aop01411.htm##
00955000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071100085002001300796#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#45#41#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Recentemente, Bem    Saad e
 cols.<sup>35</sup> observaram que as mulheres que tiveram maior n&uacute;mero  
  de partos (7 &plusmn; 1) obtiveram uma menor DTC6, quando comparadas &agrave;s
    mulheres que tiveram menor n&uacute;mero de partos (3 &plusmn; 2)<sup>35</su
p>.    Sintomas de depress&atilde;o e menor cogni&ccedil;&atilde;o tamb&eacute;m
 foram    identificados como fatores que podem influenciar negativamente a DTC6<
sup>16</sup>.    Os aspectos cognitivo-comportamentais n&atilde;o foram devidame
nte valorizados    na grande maioria dos estudos que elaboraram equa&ccedil;&oti
lde;es de refer&ecirc;ncia    para o TC6.</font></p>     ^cY#aop01411.htm##
01155000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704091100085002001300996#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#46#42#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A evidente diversidade    p
opulacional utilizada para elabora&ccedil;&atilde;o das equa&ccedil;&otilde;es  
  de refer&ecirc;ncia, associada aos diferentes protocolos de realiza&ccedil;&at
ilde;o    do TC6, explica em grande parte a variabilidade dos resultados encontr
ados nos    diversos estudos. Nesse sentido, &eacute; coerente especular que a u
tiliza&ccedil;&atilde;o    das equa&ccedil;&otilde;es recentemente desenvolvidas
 com indiv&iacute;duos    brasileiros entre 6 e 84 anos<sup>23,31</sup> sejam as
 mais adequadas em nosso    meio. Esses estudos<sup>23,31</sup>, realizados nos 
estados de Rio Grande do    Sul e de S&atilde;o Paulo, seguiram rigorosamente as
 recomenda&ccedil;&otilde;es    da ATS<sup>5</sup>, o que reduz a influ&ecirc;nc
ia tanto do perfil populacional    quanto da padroniza&ccedil;&atilde;o do teste
.</font></p>     ^cY#aop01411.htm##
00572000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032800085002001300413#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#47#43#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Tendo em vista    que o Bra
sil &eacute; um pa&iacute;s de dimens&otilde;es continentais, &eacute;    recome
ndado que cl&iacute;nicos e/ou pesquisadores avaliem a utilidade dessas    equa&
ccedil;&otilde;es em outras regi&otilde;es do pa&iacute;s.</font></p>     ^cY#ao
p01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#48#44#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00354000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011000085002001300195#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#49#45#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Atributos associados</b>
</font></p>     ^cY#aop01411.htm##
01170000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704092600085002001301011#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#50#46#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A maioria dos estudos    en
fatizou as correla&ccedil;&otilde;es entre a DTC6 e a idade, o g&ecirc;nero,    
a estatura, o peso e o IMC (<a href="#t2">Tabela 2</a>). Esses atributos foram  
  priorizados devido &agrave; enorme facilidade de serem obtidos. Nesse sentido,
    as equa&ccedil;&otilde;es de refer&ecirc;ncia podem ser aplicadas sem a nece
ssidade    de equipamentos sofisticados. Para melhor interpreta&ccedil;&atilde;o
 das correla&ccedil;&otilde;es    descritas na literatura, utilizaremos a classi
fica&ccedil;&atilde;o proposta    por Lacasse e cols.<sup>48</sup>. Resumidament
e, coeficientes de correla&ccedil;&atilde;o    entre 0-0,20 s&atilde;o considera
dos n&atilde;o significativos, entre 0,21-0,35    s&atilde;o fracos, entre 0,36-
0,50 s&atilde;o moderados e superiores a 0,50    representam correla&ccedil;&oti
lde;es intensas.</font></p>     ^cY#aop01411.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#51#47#article#213#<p><a name
="t2"></a></p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#52#48#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#53#49#article#213#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01411t02.jpg"></p>     ^cY#aop
01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#54#50#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
01706000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704146200085002001301547#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#55#51#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A idade mostrou    influ&ec
irc;ncia significativa na DTC6 em diversos estudos. Em estudos envolvendo    adu
ltos e idosos saud&aacute;veis, a correla&ccedil;&atilde;o foi negativa<sup>20, 
   21</sup>. Nos estudos com crian&ccedil;as e adolescentes, a correla&ccedil;&a
tilde;o    foi positiva<sup>23,25-27</sup>. A correla&ccedil;&atilde;o entre ida
de e DTC6    n&atilde;o foi significativa apenas no estudo de Camarri e cols.<su
p>32</sup>    devido, provavelmente, &agrave; estreita faixa et&aacute;ria avali
ada (55-75    anos) e ao reduzido n&uacute;mero de indiv&iacute;duos avaliados (
n = 70). Em    alguns estudos, a correla&ccedil;&atilde;o foi forte<sup>21,23,25
,27,28</sup>    e, em outros, foi moderada<sup>26,29-31,33,35</sup>. Em alguns e
studos, a correla&ccedil;&atilde;o    foi significativa, contudo os autores n&at
ilde;o ofereceram os valores dos coeficientes    de correla&ccedil;&atilde;o<sup
>20,24</sup>. A menor dist&acirc;ncia percorrida    com o avan&ccedil;o da idade
 pode ser explicada por redu&ccedil;&otilde;es na    for&ccedil;a e massa muscul
ar e no consumo m&aacute;ximo de oxig&ecirc;nio,    inerentes ao envelhecimento<
sup>49,50</sup>. Por outro lado, a correla&ccedil;&atilde;o    positiva entre DT
C6 e idade antes dos 20 anos &eacute; resultado da maior matura&ccedil;&atilde;o
    dos adolescentes em rela&ccedil;&atilde;o &agrave;s crian&ccedil;as.</font><
/p>     ^cY#aop01411.htm##
01360000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704111600085002001301201#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#56#52#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A correla&ccedil;&atilde;o 
   encontrada entre a DTC6 e a estatura tem sido igualmente consistente. Alguns 
   estudos mostraram correla&ccedil;&otilde;es fortes<sup>21,25,27,32,35</sup>  
  e outros relataram correla&ccedil;&otilde;es moderadas<sup>23,26,28-31,33</sup
>.    Um estudo relatou correla&ccedil;&otilde;es significativas, contudo os aut
ores    n&atilde;o apresentaram os valores dos coeficientes de correla&ccedil;&a
tilde;o<sup>24</sup>.    De maneira semelhante, alguns autores relataram correla
&ccedil;&otilde;es significativas    entre o comprimento da perna e a DTC6<sup>2
4,32</sup>. Apenas o estudo de Enright    e Sherrill<sup>20</sup> n&atilde;o mos
trou correla&ccedil;&atilde;o significativa    entre a DTC6 e a estatura. A corr
ela&ccedil;&atilde;o consistente entre estatura    e dist&acirc;ncia percorrida 
pode ser atribu&iacute;da ao maior comprimento    das passadas em indiv&iacute;d
uos com maior estatura. O tamanho da passada &eacute;    um dos principais deter
minantes da velocidade da marcha<sup>51</sup>.</font></p>     ^cY#aop01411.htm##
00962000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071800085002001300803#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#57#53#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A correla&ccedil;&atilde;o 
   entre a DTC6 e o peso corporal, diferentemente, apresentou-se pouco consisten
te    em muitos estudos<sup>20,21,23,28,31,33</sup>. Gibbons e cols.<sup>28</sup
>    observaram que a idade e o g&ecirc;nero foram os atributos determinantes da
    DTC6. No estudo de Poh e cols.<sup>33</sup>, o peso corporal tamb&eacute;m n
&atilde;o    foi selecionado como determinante da DTC6. Em estudo brasileiro<sup
>31</sup>,    observamos, que a idade e o g&ecirc;nero foram os atributos determ
inantes da    DTC6. Adicionalmente, encontramos correla&ccedil;&atilde;o fraca e
ntre a DTC6    e o IMC (r = -0,27)<sup>31</sup>.</font></p>     ^cY#aop01411.htm
##
01242000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099800085002001301083#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#58#54#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Lammers e cols.<sup>25</sup
>    observaram que a idade, o peso e a estatura foram determinantes da DTC6 em 
crian&ccedil;as,    juntos explicando 44,0% da variabilidade total desta vari&aa
cute;vel. Apenas    a idade explicou 41,0% desses 44,0%<sup>25</sup>. Os autores
 observaram tamb&eacute;m    que a correla&ccedil;&atilde;o entre DTC6 e o peso 
corporal apresentou caracter&iacute;stica    linear somente at&eacute; os 30 kg<
sup>25</sup>. A partir desse ponto, houve    comportamento horizontal da rela&cc
edil;&atilde;o. Em indiv&iacute;duos idosos,    tal correla&ccedil;&atilde;o tam
b&eacute;m n&atilde;o foi linear, com ponto    de inflex&atilde;o em aproximadam
ente 82 kg, a partir do qual, a DTC6 come&ccedil;ou    a sofrer influ&ecirc;ncia
 negativa do peso corporal<sup>16</sup>. Quando significativa,    a correla&cced
il;&atilde;o entre DTC6 e peso costuma ser fraca ou moderada (r    = 0,25)<sup>3
2</sup>.</font></p>     ^cY#aop01411.htm##
00604000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036000085002001300445#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#59#55#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os resultados descritos    
anteriormente sugerem a pouca influ&ecirc;ncia do peso na DTC6. Contudo, &eacute
;    mais prov&aacute;vel que essa correla&ccedil;&atilde;o n&atilde;o tenha sid
o    bem detectada em regress&otilde;es lineares devido ao seu car&aacute;ter cu
rvilinear.</font></p>     ^cY#aop01411.htm##
00996000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075200085002001300837#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#60#56#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A influ&ecirc;ncia    do g&
ecirc;nero na DTC6 &eacute; consistente e tem sido descrita em diversos    estud
os. Em indiv&iacute;duos brasileiros adultos e idosos, os homens caminharam    e
m m&eacute;dia 61,5 m a mais que as mulheres<sup>31</sup>. Resultados semelhante
s    foram amplamente apresentados na literatura (<a href="#t3">Tabela 3</a>). P
or    outro lado, a dist&acirc;ncia percorrida por crian&ccedil;as n&atilde;o ap
resentou    influ&ecirc;ncia do g&ecirc;nero em alguns estudos<sup>23,25,27</sup
>. Tal resultado    pode ser facilmente explicado pela maior semelhan&ccedil;a m
usculoesquel&eacute;tica    encontrada entre os sexos antes da adolesc&ecirc;nci
a.</font></p>     ^cY#aop01411.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#61#57#article#213#<p><a name
="t3"></a></p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#62#58#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#63#59#article#213#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01411t03.jpg"></p>     ^cY#aop
01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#64#60#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
01315000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704107100085002001301156#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#65#61#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A influ&ecirc;ncia    do g&
ecirc;nero a partir da adolesc&ecirc;ncia pode ser atribu&iacute;da &agrave;    
maior for&ccedil;a e massa muscular e &agrave; maior estatura dos homens em    v
alores absolutos. Quando a influ&ecirc;ncia do g&ecirc;nero &eacute; avaliada   
 levando-se em considera&ccedil;&atilde;o a estatura, algumas equa&ccedil;&otild
e;es    de refer&ecirc;ncia preveem DTC6 semelhantes entre homens e mulheres. Po
r exemplo,    Enright e cols.<sup>16</sup> observaram em idosos assintom&aacute;
ticos que    as DTC6 de homens e mulheres idosos n&atilde;o foram significativam
ente diferentes    quando corrigidas pela estatura. A rela&ccedil;&atilde;o entr
e DTC6 e estatura    n&atilde;o &eacute; linear<sup>25</sup>. At&eacute; que m&e
acute;todos n&atilde;o    lineares sejam aplicados para comparar as diferen&cced
il;as relacionadas ao    g&ecirc;nero na DTC6, n&atilde;o &eacute; poss&iacute;v
el afirmar que homens    e mulheres apresentam performances semelhantes no teste
.</font></p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#66#62#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013500085002001300220#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#67#63#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Equa&ccedil;&otilde;es  
  de refer&ecirc;ncia</b></font></p>     ^cY#aop01411.htm##
01389000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704114500085002001301230#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#68#64#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Existem equa&ccedil;&otilde
;es    de refer&ecirc;ncia para a previs&atilde;o da DTC6 em diversas popula&cce
dil;&otilde;es    (<a href="/img/revistas/abc/2011nahead/aop01411t04.jpg">Tabela
 4</a>). com exce&ccedil;&atilde;o de    dois estudos que foram realizados com a
mostra randomizada<sup>20,32</sup> e    outros dois estudos de grande dimens&ati
lde;o<sup>16,26</sup>, os demais variam    em n&uacute;mero de indiv&iacute;duos
 e em faixa et&aacute;ria estudada, contudo,    apresentam delineamentos semelha
ntes. Na maioria dos estudos, as equa&ccedil;&otilde;es    de refer&ecirc;ncia f
oram obtidas mediante modelos de regress&atilde;o m&uacute;ltipla    linear, inc
luindo atributos demogr&aacute;ficos e antropom&eacute;tricos como    vari&aacut
e;veis independentes. Outras vari&aacute;veis, tais como os &iacute;ndices    es
pirom&eacute;tricos e a resposta da frequ&ecirc;ncia card&iacute;aca, foram    t
amb&eacute;m selecionados como determinantes em alguns estudos<sup>26,32,33</sup
>    (<a href="/img/revistas/abc/2011nahead/aop01411t04.jpg">Tabela 4</a>).</fon
t></p>     ^cY#aop01411.htm##
01217000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097300085002001301058#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#69#65#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em nossa opini&atilde;o,   
 essas &uacute;ltimas vari&aacute;veis s&atilde;o problem&aacute;ticas. Provavel
mente,    os pacientes com limita&ccedil;&atilde;o ventilat&oacute;ria n&atilde;
o apresentam    a mesma rela&ccedil;&atilde;o entre volume expirat&oacute;rio fo
r&ccedil;ado    no primeiro segundo e a DTC6 encontrada em indiv&iacute;duos sau
d&aacute;veis.    Outro problema &eacute; a utiliza&ccedil;&atilde;o de &iacute;
ndices que s&atilde;o    obtidos ao final do teste (e.g. a altera&ccedil;&atilde
;o absoluta da frequ&ecirc;ncia    card&iacute;aca ou o percentual da frequ&ecir
c;ncia card&iacute;aca m&aacute;xima<sup>26,33</sup>),    tendo em vista que os 
pacientes com doen&ccedil;as cardiopulmonares apresentam    respostas fisiol&oac
ute;gicas anormais durante o teste. Portanto, o uso de tais    &iacute;ndices po
de superestimar a capacidade de exerc&iacute;cio dos pacientes.</font></p>     ^
cY#aop01411.htm##
00819000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057500085002001300660#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#70#66#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A for&ccedil;a    muscular 
perif&eacute;rica foi tamb&eacute;m identificada como determinante    da DTC6<su
p>16</sup>. Infelizmente, esse &iacute;ndice necessita de equipamento    espec&i
acute;fico e calibra&ccedil;&atilde;o cuidadosa para que possa ser obtido.    Ne
sse sentido, as equa&ccedil;&otilde;es envolvendo somente atributos demogr&aacut
e;ficos    e antropom&eacute;tricos, tais como idade, g&ecirc;nero, peso e estat
ura, parecem    ser mais &uacute;teis no ambiente cl&iacute;nico.</font></p>    
 ^cY#aop01411.htm##
01123000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087900085002001300964#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#71#67#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Lamentavelmente,    as equa
&ccedil;&otilde;es desenvolvidas em popula&ccedil;&otilde;es estrangeiras    n&a
tilde;o foram adequadas para os brasileiros<sup>31</sup>. Observamos que    as e
qua&ccedil;&otilde;es desenvolvidas por Troosters e cols.<sup>21</sup>,    Chett
a e cols.<sup>29</sup>, Gibbons e cols.<sup>28</sup> e Camarri e cols.<sup>32</s
up>    superestimaram a DTC6 obtida em indiv&iacute;duos brasileiros saud&aacute
;veis    (<a href="/img/revistas/abc/2011nahead/aop01411t05.jpg">Tabela 5</a>). 
A causa para tal diferen&ccedil;a    &eacute; multifatorial. Tanto a padroniza&c
cedil;&atilde;o utilizada para o    teste (<a href="/img/revistas/abc/2011nahead
/aop01411t06.jpg">Tabela 6</a>) quanto diferen&ccedil;as    &eacute;tnico-popula
cionais e cl&iacute;nicas devem ser consideradas.</font></p>     ^cY#aop01411.ht
m##
01450000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704120600085002001301291#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#72#68#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Entre os estudos,    o comp
rimento do corredor utilizado variou entre 20 e 50 m, o n&uacute;mero    de test
es para familiariza&ccedil;&atilde;o variou entre um e quatro<sup>21,22,28,32</s
up>    e, em alguns estudos, o n&iacute;vel de encorajamento n&atilde;o seguiu a
s recomenda&ccedil;&otilde;es    da ATS<sup>5</sup>, sobretudo naqueles publicad
os antes de 2002<sup>20-22,32</sup>.    Por outro lado, observamos que a equa&cc
edil;&atilde;o desenvolvida por Enright    &amp; Sherrill<sup>20</sup> subestimo
u a DTC6 dos indiv&iacute;duos brasileiros,    provavelmente porque os autores r
ealizaram apenas um TC6 (<i>i.e.,</i> sem familiariza&ccedil;&atilde;o)    (<a h
ref="/img/revistas/abc/2011nahead/aop01411t06.jpg">Tabela 6</a>). Chetta e cols.
<sup>29</sup>    seguiram as recomenda&ccedil;&otilde;es da ATS e desenvolveram 
uma equa&ccedil;&atilde;o    que superestimaram discretamente (32 &plusmn; 71 m)
 nossos resultados em brasileiros    saud&aacute;veis<sup>31</sup>. Nesse caso, 
a diferen&ccedil;a &eacute; resultante,    provavelmente, das diferen&ccedil;as 
populacionais, as quais foram discutidas    previamente.</font></p>     ^cY#aop0
1411.htm##
01346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110200085002001301187#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#73#69#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Tal diferen&ccedil;a,    me
smo quando o TC6 &eacute; realizado sob padroniza&ccedil;&atilde;o rigorosa,    
enfatiza a necessidade da avalia&ccedil;&atilde;o dos valores de refer&ecirc;nci
a    espec&iacute;ficos para cada popula&ccedil;&atilde;o e/ou etnia. O perfil p
opulacional    e &eacute;tnico do nosso estudo<sup>31</sup> foi bastante amplo, 
o que pode    ser atribu&iacute;do &agrave; grande migra&ccedil;&atilde;o intern
a e externa    caracter&iacute;stica da regi&atilde;o sudeste do Brasil. H&aacut
e; alguns dados    na literatura que sugerem a influ&ecirc;ncia da etnia na perf
ormance em testes    de aptid&atilde;o f&iacute;sica<sup>52-54</sup>. Pouco se c
onhece a respeito    dos mecanismos fisiol&oacute;gicos dessa diferen&ccedil;a. 
Estudos preditivos    em popula&ccedil;&otilde;es estadunidenses e europeias enc
ontraram menores valores    nas minorias, tais como negras e latinas, embora a c
ondi&ccedil;&atilde;o socioecon&ocirc;mica    e nutricional sejam fatores confun
didores neste caso<sup>55</sup>.</font></p>     ^cY#aop01411.htm##
01308000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106400085002001301149#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#74#70#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A menor DTC6 encontrada    
para a popula&ccedil;&atilde;o brasileira pode ser atribu&iacute;da em parte    
ao perfil multirracial da popula&ccedil;&atilde;o urbana em nosso pa&iacute;s   
 e, portanto, seriam esperados valores inferiores aos encontrados nas popula&cce
dil;&otilde;es    predominantemente caucasianas. Outro aspecto que deve ser dest
acado &eacute;    a caracter&iacute;stica antropom&eacute;trica de cada popula&c
cedil;&atilde;o.    Observamos que nossa amostra da popula&ccedil;&atilde;o bras
ileira apresentou    estatura inferior e peso superior (para as mulheres) em com
para&ccedil;&atilde;o    ao descrito para indiv&iacute;duos italianos no estudo 
de Chetta e cols.<sup>29</sup>.    &Eacute; poss&iacute;vel que a DTC6 tamb&eacu
te;m apresente valores distintos    nas diversas regi&otilde;es do Brasil. Tavar
es e cols.<sup>56</sup> observaram    diferen&ccedil;as significativas no perfil
 antropom&eacute;trico e nutricional    entre as regi&otilde;es do Brasil.</font
></p>     ^cY#aop01411.htm##
00845000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060100085002001300686#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#75#71#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Finalmente, h&aacute;    de
 se considerar o n&iacute;vel de esfor&ccedil;o despendido pelos volunt&aacute;r
ios    nos diversos estudos. A frequ&ecirc;ncia card&iacute;aca atingida ao fina
l do    TC6 variou substancialmente entre n&iacute;veis moderados e intensos<sup
>20,32</sup>,    sugerindo que o esfor&ccedil;o foi subm&aacute;ximo em alguns e
studos, a despeito    da instru&ccedil;&atilde;o inicial enfatizando a caminhada
 da maior dist&acirc;ncia    poss&iacute;vel em 6 minutos sob incentivo verbal p
adronizado.</font></p>     ^cY#aop01411.htm##
01382000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704113800085002001301223#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#76#72#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Dois estudos, sob    nosso 
conhecimento, elaboraram equa&ccedil;&otilde;es de refer&ecirc;ncia para    a pr
evis&atilde;o da DTC6 na popula&ccedil;&atilde;o brasileira<sup>23,31</sup>.    
Iwama e cols.<sup>31</sup> avaliaram 134 indiv&iacute;duos saud&aacute;veis    b
rasileiros com idade <u>&gt;</u> 13 anos (73 mulheres). A m&eacute;dia da DTC6  
  foi significativamente superior nos homens (622 &plusmn; 80 <i>vs.</i> 551 &pl
usmn;    71 m, p &lt; 0,05). A DTC6 correlacionou-se significativamente (p &lt; 
0,05)    com a idade, a estatura, o IMC e o n&iacute;vel de atividade f&iacute;s
ica habitual<sup>42</sup>    (<a href="#t2">Tabela 2</a>). Idade e g&ecirc;nero 
foram selecionados como vari&aacute;veis    determinantes, juntas explicando 30,
0% da variabilidade total da DTC6. O poder    de previs&atilde;o descrito no est
udo de Iwama e cols.<sup>31</sup> para indiv&iacute;duos    brasileiros foi seme
lhante ao descrito na literatura utilizando atributos demogr&aacute;ficos    e a
ntropom&eacute;tricos (r<sup>2</sup> = 0,20 a 0,77)<sup>16,27</sup>.</font></p> 
    ^cY#aop01411.htm##
01701000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704145700085002001301542#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#77#73#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Oitenta e cinco    indiv&ia
cute;duos com caracter&iacute;sticas semelhantes &agrave; amostra inicial    for
am prospectivamente avaliados em outro centro de pesquisa brasileiro seguindo   
 as recomenda&ccedil;&otilde;es da ATS<sup>5</sup>. A diferen&ccedil;a entre    
a DTC6 avaliada e a DTC6 estimada pela equa&ccedil;&atilde;o desenvolvida n&atil
de;o    foi estatisticamente significativa (-3 &plusmn; 68 m; p = 0,938)<sup>31<
/sup>.    A DTC6 avaliada representou 99,6 &plusmn; 11,9% dos valores previstos<
sup>31</sup>.    Alguns autores avaliaram a aplicabilidade de equa&ccedil;&otild
e;es estrangeiras    e observaram resultados muito semelhantes<sup>32,33,35</sup
>. Priesnitz e cols.<sup>23</sup>    avaliaram 188 crian&ccedil;as e adolescente
s saud&aacute;veis entre 6 e 12 anos    (92 meninos), selecionados por conveni&e
circ;ncia em tr&ecirc;s escolas prim&aacute;rias    de Porto Alegre, RS, Brasil.
 Idade, estatura, diferen&ccedil;a absoluta da frequ&ecirc;ncia    card&iacute;a
ca antes e ap&oacute;s o TC6 (r = 0,30; p &lt; 0,0001) e o peso    (<a href="#t2
">Tabela 2</a>) foram os atributos significativamente correlacionados    com a D
TC6. Tais atributos explicaram 36,6% da variabilidade da DTC6. O g&ecirc;nero   
 e o IMC, no entanto, n&atilde;o foram selecionados como determinantes da DTC6  
  ap&oacute;s a an&aacute;lise de regress&atilde;o m&uacute;ltipla.</font></p>  
   ^cY#aop01411.htm##
00866000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704062200085002001300707#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#78#74#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A <a href="/img/revistas/ab
c/2011nahead/aop01411t07.jpg">Tabela    7</a> apresenta as equa&ccedil;&otilde;e
s de refer&ecirc;ncia desenvolvidas    na popula&ccedil;&atilde;o brasileira par
a crian&ccedil;as e adolescentes<sup>23</sup>    e para adultos e idosos<sup>31<
/sup>. Essas equa&ccedil;&otilde;es podem facilitar    a interpreta&ccedil;&atil
de;o da capacidade de exerc&iacute;cio dos pacientes    brasileiros. A validade 
de tais equa&ccedil;&otilde;es em nossa popula&ccedil;&atilde;o    deveria ser i
nvestigada em pesquisas futuras.</font></p>     ^cY#aop01411.htm##
01251000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704100700085002001301092#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#79#75#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Poucos estudos    avaliaram
 a validade das equa&ccedil;&otilde;es de refer&ecirc;ncia que propuseram<sup>21
,30,31,35.</sup>    Al&eacute;m do estudo brasileiro supracitado, desenvolvido p
or Iwama e cols.<sup>31,</sup>    Troosters e cols.<sup>21</sup> avaliaram prosp
ectivamente 20 indiv&iacute;duos    com as mesmas caracter&iacute;sticas demogr&
aacute;ficas e antropom&eacute;tricas    da amostra utilizada para o desenvolvim
ento da equa&ccedil;&atilde;o de refer&ecirc;ncia.    Mais recentemente, Ben Saa
d e cols.<sup>27,35</sup> validaram suas equa&ccedil;&otilde;es    em <sup>30-41
</sup> indiv&iacute;duos prospectivamente avaliados e Alameri e    cols.<sup>30<
/sup> validaram sua equa&ccedil;&atilde;o de maneira semelhante    em 59 indiv&i
acute;duos. Em todos os casos a confiabilidade das equa&ccedil;&otilde;es    foi
 aceit&aacute;vel e os autores as recomendaram para uso em popula&ccedil;&atilde
;o    semelhante.</font></p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#80#76#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00378000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013400085002001300219#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#81#77#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Estrat&eacute;gias    pa
ra pesquisas futuras</b></font></p>     ^cY#aop01411.htm##
01739000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704149500085002001301580#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#82#78#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">De todos os estudos    revi
sados que formularam equa&ccedil;&otilde;es de refer&ecirc;ncia, apenas    4 rea
lizaram algum tipo de randomiza&ccedil;&atilde;o da amostra. Os demais    estudo
s utilizaram amostragem de conveni&ecirc;ncia. Li e cols.<sup>26</sup>    desenv
olveram o estudo de maior dimens&atilde;o at&eacute; atualidade. Nesse    estudo
, escolas chinesas prim&aacute;rias e secund&aacute;rias foram randomizadas    p
ara a realiza&ccedil;&atilde;o das avalia&ccedil;&otilde;es. Alameri e cols.<sup
>30</sup>    randomizaram 80,0% da amostra para a elabora&ccedil;&atilde;o da eq
ua&ccedil;&atilde;o    de refer&ecirc;ncia. Os 20,0% restantes dos indiv&iacute;
duos fizeram parte    do estudo de valida&ccedil;&atilde;o cruzada da equa&ccedi
l;&atilde;o desenvolvida.    Embora as t&eacute;cnicas de amostragem desenvolvid
as por Li e cols.<sup>26</sup>    e por Alameri e cols.<sup>30</sup> sejam capaz
es de reduzir os vieses inerentes    &agrave; amostragem de conveni&ecirc;ncia, 
estes estudos n&atilde;o podem ser    classificados como randomizados. Li e cols
.<sup>26</sup> randomizaram as escolas,    contudo, dentro de cada escola, a sel
e&ccedil;&atilde;o foi realizada por conveni&ecirc;ncia.    De maneira semelhant
e, a randomiza&ccedil;&atilde;o realizada por Alameri e    cols.<sup>30</sup> mi
nimizou os vieses da amostragem de conveni&ecirc;ncia,    entretanto n&atilde;o 
os equacionou totalmente.</font></p>     ^cY#aop01411.htm##
00735000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049100085002001300576#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#83#79#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">At&eacute; o momento,    po
rtanto, apenas dois estudos podem ser considerados randomizados<sup>20,32</sup>.
    As limita&ccedil;&otilde;es pr&aacute;ticas, operacionais e econ&ocirc;micas
    podem explicar a aus&ecirc;ncia de estudo multic&ecirc;ntrico dos valores de
    refer&ecirc;ncia para a DTC6. Isto poderia ser importante, sobretudo em pa&i
acute;ses    com dimens&otilde;es continentais como o Brasil.</font></p>     ^cY
#aop01411.htm##
00584000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034000085002001300425#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#84#80#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Estudos futuros    com amos
tras substancialmente maiores (<i>e.g.,</i> multic&ecirc;ntricos) e    com t&eac
ute;cnica de amostragem randomizada s&atilde;o necess&aacute;rios para    que os
 valores de refer&ecirc;ncia da DTC6 sejam ainda mais representativos.</font></p
>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#85#81#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#86#82#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclus&otilde;es</b></f
ont></p>     ^cY#aop01411.htm##
01107000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086300085002001300948#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#87#83#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A DTC6 apresenta    grande 
variabilidade em indiv&iacute;duos saud&aacute;veis, no entanto, parte    import
ante desta variabilidade foi geralmente bem explicada por atributos demogr&aacut
e;ficos    e antropom&eacute;tricos. As equa&ccedil;&otilde;es desenvolvidas em 
popula&ccedil;&otilde;es    estrangeiras n&atilde;o foram adequadas para a popul
a&ccedil;&atilde;o brasileira.    As equa&ccedil;&otilde;es desenvolvidas no Bra
sil<sup>23,31</sup> s&atilde;o,    provavelmente, as mais apropriadas para inter
pretar a performance no TC6 dos    nossos pacientes com doen&ccedil;as cr&ocirc;
nicas que afetam a capacidade para    realizar exerc&iacute;cios. Contudo, &eacu
te; fortemente recomendado que tais    equa&ccedil;&otilde;es sejam validadas em
 outras regi&otilde;es do Brasil.</font></p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#88#84#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#89#85#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Agradecimentos</b></font
></p>     ^cY#aop01411.htm##
00734000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049000085002001300575#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#90#86#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&Agrave; Funda&ccedil;&atil
de;o    de Amparo &agrave; Pesquisa do Estado de S&atilde;o Paulo (FAPESP) pelo 
apoio    em forma de aux&iacute;lio financeiro (Processo nº. 2007/08673-3) para 
o desenvolvimento    dos valores de refer&ecirc;ncia relacionados ao teste de ca
minhada de 6 minutos    e ao teste de caminhada incremental (<i>incremental shut
tle walk test</i>) na    popula&ccedil;&atilde;o brasileira.</font></p>     ^cY#
aop01411.htm##
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#91#87#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    de
 Interesses</b></font></p>     ^cY#aop01411.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#92#88#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    haver
 conflito de interesses pertinentes.</font></p>     ^cY#aop01411.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#93#89#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01411.htm##
00397000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015300085002001300238#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#94#90#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    n&atil
de;o teve fontes de financiamento externas.</font></p>     ^cY#aop01411.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#95#91#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;o
    Acad&ecirc;mica</b></font></p>     ^cY#aop01411.htm##
00439000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019500085002001300280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#96#92#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o h&aacute;    vin
cula&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atil
de;o.</font></p>     ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#97#93#article#213#<p>&nbsp;<
/p>     ^cY#aop01411.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#98#94#article#213#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01411.htm##
00469000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704021100087002001300298#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#99#95#article#21
3#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Cooper KH.
 A    means of assessing maximal oxygen intake: correlation between field and tr
eadmill    testing. JAMA. 1968; 203 (3): 201-4.    ^cY#aop01411.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#100#96#article#213#</font></
p>     ^cY#aop01411.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704027400088002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#101#97#article#2
13#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. McGavin C
R,    Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked:
 comparison    of estimates of exercise performance in respiratory disease. Br M
ed J. 1978;    2 (6132): 241-3.    ^cY#aop01411.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#102#98#article#213#</font></
p>     ^cY#aop01411.htm##
00506000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704024700088002001300335#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#103#99#article#2
13#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Butland R
J,    Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walkin
g    tests in respiratory disease. Br Med J (Clin Res Ed). 1982; 284 (6329): 160
7-8.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#104#100#article#213#</font><
/p>     ^cY#aop01411.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704021000089002001300299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#105#101#article#
213#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Singh SJ
. Walking    for the assessment of patients with chronic obstructive pulmonary d
isease. Eur    Respir Mon. 2007; 40 (1): 148-64.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#106#102#article#213#</font><
/p>     ^cY#aop01411.htm##
00444000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704018400089002001300273#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#107#103#article#
213#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. ATS stat
ement:    guidelines for the six-minute walk test. Am J Respir Crit Care Med. 20
02; 166    (1): 111-7.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#108#104#article#213#</font><
/p>     ^cY#aop01411.htm##
00577000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704031700089002001300406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#109#105#article#
213#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Gosker H
R, Wouters    EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in ch
ronic obstructive    pulmonary disease and chronic heart failure: underlying mec
hanisms and therapy    perspectives. Am J Clin Nutr. 2000; 71 (5): 1033-47.    ^
cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#110#106#article#213#</font><
/p>     ^cY#aop01411.htm##
00522000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704026200089002001300351#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#111#107#article#
213#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. King S, 
Wessel    J, Bhambhani Y, Maikala R, Sholter D, Maksymowych W. Validity and reli
ability    of the 6 minute walk in persons with fibromyalgia. J Rheumatol. 1999;
 26 (10):    2233-7.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#112#108#article#213#</font><
/p>     ^cY#aop01411.htm##
00463000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704020300089002001300292#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#113#109#article#
213#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Lin SJ, 
Bose    NH. Six-minute walk test in persons with transtibial amputation. Arch Ph
ys Med    Rehabil. 2008; 89 (12): 2354-9.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#114#110#article#213#</font><
/p>     ^cY#aop01411.htm##
00525000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704026500089002001300354#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#115#111#article#
213#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Beriault
 K,    Carpentier AC, Gagnon C, Menard J, Baillargeon JP, Ardilouze JL, et al. R
eproducibility    of the 6-minute walk test in obese adults. Int J Sports Med. 2
009; 30 (10):    725-7.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#116#112#article#213#</font><
/p>     ^cY#aop01411.htm##
00553000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029200090002001300382#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#117#113#article#
213#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Vis JC
, Thoonsen    H, Duffels MG, de Bruin-Bon RA, Huisman SA, van Dijk AP, et al. Si
x-minute walk    test in patients with Down syndrome: validity and reproducibili
ty. Arch Phys    Med Rehabil. 2009; 90 (8): 1423-7.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#118#114#article#213#</font><
/p>     ^cY#aop01411.htm##
00597000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033600090002001300426#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#119#115#article#
213#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Ries J
D, Echternach    JL, Nof L, Gagnon Blodgett M. Test-retest reliability and minim
al detectable    change scores for the timed "up &amp; go" test, the six-minute 
walk test, and    gait speed in people with Alzheimer disease. Phys Ther. 2009; 
89 (6): 569-79.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#120#116#article#213#</font><
/p>     ^cY#aop01411.htm##
00472000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021100090002001300301#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#121#117#article#
213#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Maher 
CA, Williams    MT, Olds TS. The six-minute walk test for children with cerebral
 palsy. Int    J Rehabil Res. 2008; 31 (2): 185-8.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#122#118#article#213#</font><
/p>     ^cY#aop01411.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030600090002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#123#119#article#
213#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Troost
ers T,    Vilaro J, Rabinovich R, Casas A, Barbera JA, Rodriguez-Roisin R, et al
. Physiological    responses to the 6-min walk test in patients with chronic obs
tructive pulmonary    disease. Eur Respir J. 2002; 20 (3): 564-9.    ^cY#aop0141
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#124#120#article#213#</font><
/p>     ^cY#aop01411.htm##
00542000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028100090002001300371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#125#121#article#
213#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Solway
 S, Brooks    D, Lacasse Y, Thomas S. A qualitative systematic overview of the m
easurement    properties of functional walk tests used in the cardiorespiratory 
domain. Chest.    2001; 119 (1): 256-70.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#126#122#article#213#</font><
/p>     ^cY#aop01411.htm##
00410000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704014900090002001300239#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#127#123#article#
213#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Enrigh
t PL.    The six-minute walk test. Respir Care. 2003; 48 (8): 783-5.    ^cY#aop0
1411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#128#124#article#213#</font><
/p>     ^cY#aop01411.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026500090002001300355#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#129#125#article#
213#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Enrigh
t PL,    McBurnie MA, Bittner V, Tracy RP, McNamara R, Arnold A, et al. The 6-mi
n walk    test: a quick measure of functional status in elderly adults. Chest. 2
003; 123    (2): 387-98.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#130#126#article#213#</font><
/p>     ^cY#aop01411.htm##
00500000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023900090002001300329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#131#127#article#
213#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Gossel
ink R,    Troosters T, Decramer M. Peripheral muscle weakness contributes to exe
rcise    limitation in COPD. Am J Respir Crit Care Med. 1996; 153 (3): 976-80.  
  ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#132#128#article#213#</font><
/p>     ^cY#aop01411.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027800090002001300368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#133#129#article#
213#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Dourad
o VZ,    Antunes LC, Tanni SE, de Paiva SA, Padovani CR, Godoy I. Relationship o
f upper-limb    and thoracic muscle strength to 6-min walk distance in COPD pati
ents. Chest.    2006; 129 (3): 551-7.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#134#130#article#213#</font><
/p>     ^cY#aop01411.htm##
00612000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704035100090002001300441#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#135#131#article#
213#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Araujo
 CO,    Makdisse MR, Peres PA, Tebexreni AS, Ramos LR, Matsushita AM, et al. Dif
ferent    patterns for the 6-minute walk test as a test to measure exercise abil
ity in    elderly with and without clinically evident cardiopathy. Arq Bras Card
iol. 2006;    86 (3): 198-205.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#136#132#article#213#</font><
/p>     ^cY#aop01411.htm##
00484000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022300090002001300313#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#137#133#article#
213#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Enrigh
t PL,    Sherrill DL. Reference equations for the six-minute walk in healthy adu
lts.    Am J Respir Crit Care Med. 1998; 158 (5 Pt 1): 1384-7.    ^cY#aop01411.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#138#134#article#213#</font><
/p>     ^cY#aop01411.htm##
00471000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021000090002001300300#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#139#135#article#
213#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Troost
ers T,    Gosselink R, Decramer M. Six minute walking distance in healthy elderl
y subjects.    Eur Respir J. 1999; 14 (2): 270-4.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#140#136#article#213#</font><
/p>     ^cY#aop01411.htm##
00497000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023600090002001300326#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#141#137#article#
213#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Kervio
 G, Carre    F, Ville NS. Reliability and intensity of the six-minute walk test 
in healthy    elderly subjects. Med Sci Sports Exerc. 2003; 35 (1): 169-74.    ^
cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#142#138#article#213#</font><
/p>     ^cY#aop01411.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028400090002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#143#139#article#
213#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Priesn
itz CV,    Rodrigues GH, Stumpf Cda S, Viapiana G, Cabral CP, Stein RT, et al. R
eference    values for the 6-min walk test in healthy children aged 6-12 years. 
Pediatr    Pulmonol. 2009; 44 (12): 1174-9.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#144#140#article#213#</font><
/p>     ^cY#aop01411.htm##
00505000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024400090002001300334#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#145#141#article#
213#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Geiger
 R, Strasak    A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-minute
 walk test    in children and adolescents. J Pediatr. 2007; 150 (4): 395-9, e391
-2.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#146#142#article#213#</font><
/p>     ^cY#aop01411.htm##
00495000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023400090002001300324#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#147#143#article#
213#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Lammer
s AE,    Hislop AA, Flynn Y, Haworth SG. The 6-minute walk test: normal values f
or children    of 4-11 years of age. Arch Dis Child. 2008; 93 (6): 464-8.    ^cY
#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#148#144#article#213#</font><
/p>     ^cY#aop01411.htm##
00534000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027300090002001300363#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#149#145#article#
213#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Li AM,
 Yin    J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the six-
minute-walk    test in healthy children aged 7 to 16 years. Am J Respir Crit Car
e Med. 2007;    176 (2): 174-80.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#150#146#article#213#</font><
/p>     ^cY#aop01411.htm##
00542000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028100090002001300371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#151#147#article#
213#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Ben Sa
ad H,    Prefaut C, Missaoui R, Mohamed IH, Tabka Z, Hayot M. Reference equation
 for    6-min walk distance in healthy North African children 6-16 years old. Pe
diatr    Pulmonol. 2009; 44 (4): 316-24.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#152#148#article#213#</font><
/p>     ^cY#aop01411.htm##
00530000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026900090002001300359#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#153#149#article#
213#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Gibbon
s WJ,    Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetitio
n 6-minute    walk test in healthy adults older than 20 years. J Cardiopulm Reha
bil. 2001;    21 (2): 87-93.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#154#150#article#213#</font><
/p>     ^cY#aop01411.htm##
00516000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025500090002001300345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#155#151#article#
213#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Chetta
 A, Zanini    A, Pisi G, Aiello M, Tzani P, Neri M, et al. Reference values for 
the 6-min    walk test in healthy subjects 20-50 years old. Respir Med. 2006; 10
0 (9): 1573-8.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#156#152#article#213#</font><
/p>     ^cY#aop01411.htm##
00468000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020700090002001300297#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#157#153#article#
213#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Alamer
i H,    Al-Majed S, Al-Howaikan A. Six-min walk test in a healthy adult Arab pop
ulation.    Respir Med. 2009; 103 (7): 1041-6.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#158#154#article#213#</font><
/p>     ^cY#aop01411.htm##
00544000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028300090002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#159#155#article#
213#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Iwama 
AM, Andrade    GN, Shima P, Tanni SE, Godoy I, Dourado VZ. The six-minute walk t
est and body    weight-walk distance product in healthy Brazilian subjects. Braz
 J Med Biol    Res. 2009; 42 (11): 1080-5.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#160#156#article#213#</font><
/p>     ^cY#aop01411.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023700090002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#161#157#article#
213#32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Camarr
i B,    Eastwood PR, Cecins NM, Thompson PJ, Jenkins S. Six minute walk distance
 in    healthy subjects aged 55-75 years. Respir Med. 2006; 100 (4): 658-65.    
^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#162#158#article#213#</font><
/p>     ^cY#aop01411.htm##
00565000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030400090002001300394#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#163#159#article#
213#33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Poh H,
 Eastwood    PR, Cecins NM, Ho KT, Jenkins SC. Six-minute walk distance in healt
hy Singaporean    adults cannot be predicted using reference equations derived f
rom Caucasian    populations. Respirology. 2006; 11 (2): 211-6.    ^cY#aop01411.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#164#160#article#213#</font><
/p>     ^cY#aop01411.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027700090002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#165#161#article#
213#34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Masmou
di K,    Aouicha MS, Fki H, Dammak J, Zouari N. The six minute walk test: which 
predictive    values to apply for Tunisian subjects aged between 40 and 80 years
?. Tunis Med.    2008; 86 (1): 20-6.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#166#162#article#213#</font><
/p>     ^cY#aop01411.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#167#163#article#
213#35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Ben Sa
ad H,    Prefaut C, Tabka Z, Mtir AH, Chemit M, Hassaoune R, et al. 6-minute wal
k distance    in healthy North Africans older than 40 years: influence of parity
. Respir Med.    2009; 103 (1): 74-84.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#168#164#article#213#</font><
/p>     ^cY#aop01411.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#169#165#article#
213#36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Steffe
n TM,    Hacker TA, Mollinger L. Age- and gender-related test performance in com
munity-dwelling    elderly people: six-minute walk test, Berg Balance Scale, Tim
ed Up &amp; Go    Test, and gait speeds. Phys Ther. 2002; 82 (2): 128-37.    ^cY
#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#170#166#article#213#</font><
/p>     ^cY#aop01411.htm##
00768000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704050700090002001300597#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#171#167#article#
213#37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Roush 
J, Guy    J, Purvis M. Reference values and relationship of the six minute walk 
test and    body mass index in healthy third grade school children. The Internet
 Journal    of Allied Health Sciences and Practice. 2006; 4 (3): 1-6. &#91;Acess
ed on 2009    Nov 10&#93;. Available from: <a href="http://ijahsp.nova.edu/artic
les/vol4num3/rowsh.pdf" target="_blank">http://ijahsp.nova.edu/articles/vol4num3
/rowsh.pdf</a></font></p>     ^cY#aop01411.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027800090002001300368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#172#168#article#
213#38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Pires 
SR, Oliveira    AC, Parreira VF, Britto RR. Teste de caminhada de seis minutos e
m diferentes    faixas et&aacute;rias e &iacute;ndices de massa corporal. Rev Br
as Fisioter.    2007; 11 (2): 147-51.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#173#169#article#213#</font><
/p>     ^cY#aop01411.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026300090002001300353#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#174#170#article#
213#39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Lipkin
 DP,    Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assess
ing    exercise capacity in chronic heart failure. Br Med J (Clin Res Ed). 1986;
 292    (6521): 653-5.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#175#171#article#213#</font><
/p>     ^cY#aop01411.htm##
00484000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022300090002001300313#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#176#172#article#
213#40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Chetta
 A, Pisi    G, Aiello M, Tzani P, Olivieri D. The walking capacity assessment in
 the respiratory    patient. Respiration. 2009; 77 (4): 361-7.    ^cY#aop01411.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#177#173#article#213#</font><
/p>     ^cY#aop01411.htm##
00542000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028100090002001300371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#178#174#article#
213#41#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Pitta 
F, Troosters    T, Probst VS, Spruit MA, Decramer M, Gosselink R. Quantifying ph
ysical activity    in daily life with questionnaires and motion sensors in COPD.
 Eur Respir J.    2006; 27 (5): 1040-55.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#179#175#article#213#</font><
/p>     ^cY#aop01411.htm##
00516000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025500090002001300345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#180#176#article#
213#42#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Baecke
 JA,    Burema J, Frijters JE. A short questionnaire for the measurement of habi
tual    physical activity in epidemiological studies. Am J Clin Nutr. 1982; 36 (
5):    936-42.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#181#177#article#213#</font><
/p>     ^cY#aop01411.htm##
00502000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024100090002001300331#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#182#178#article#
213#43#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Abrant
es MM,    Lamounier JA, Colosimo EA. Overweight and obesity prevalence in Northe
ast and    Southeast Regions of Brazil. Rev Assoc Med Bras. 2003; 49 (2): 162-6.
    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#183#179#article#213#</font><
/p>     ^cY#aop01411.htm##
00637000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037600090002001300466#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#184#180#article#
213#44#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Mion J
r D,    Kohlmann Jr O, Machado CA, Amodeo C, Gomes MAG, Praxedes JN / Sociedade 
Brasileira    de Cardiologia / Sociedade Brasileira de Hipertens&atilde;o / Soci
edade Brasileira    de Nefrologia. V Diretrizes brasileiras de hipertens&atilde;
o arterial. Arq    Bras Cardiol. 2007; 89 (3): e24-e79.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#185#181#article#213#</font><
/p>     ^cY#aop01411.htm##
00578000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031700090002001300407#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#186#182#article#
213#45#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Araujo
 AJ,    Menezes AMB, D&oacute;rea AJPS, Torres BS, Viegas CAA, Silva CAR, et al.
 / Sociedade    Brasileira de Pneumologioa e Tisiologia. Diretrizes para cessa&c
cedil;&atilde;o    do tabagismo. J Bras Pneumol. 2004; 30 (Suppl 2): s1-s76.    
^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#187#183#article#213#</font><
/p>     ^cY#aop01411.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029000090002001300380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#188#184#article#
213#46#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">46. Hallal
 PC,    Dumith SC, Bastos JP, Reichert FF, Siqueira FV, Azevedo MR. Evolution of
 the    epidemiological research on physical activity in Brazil: a systematic re
view.    Rev Saude Publica. 2007; 41 (3): 453-60.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#189#185#article#213#</font><
/p>     ^cY#aop01411.htm##
00536000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027500090002001300365#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#190#186#article#
213#47#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">47. Teramo
to S,    Ohga E, Ishii T, Yamaguchi Y, Yamamoto H, Mastsuse T. Reference value o
f six-minute    walking distance in healthy middle-aged and older subjects. Eur 
Respir J. 2000;    15 (6): 1132-3.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#191#187#article#213#</font><
/p>     ^cY#aop01411.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023700090002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#192#188#article#
213#48#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">48. Lacass
e Y,    Wong E, Guyatt G. A systematic overview of the measurement properties of
 the    Chronic Respiratory Questionnaire. Can Respir J. 1997; 4 (3): 131-9.    
^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#193#189#article#213#</font><
/p>     ^cY#aop01411.htm##
00465000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020400090002001300294#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#194#190#article#
213#49#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">49. Fleg J
L, Lakatta    EG. Role of muscle loss in the age-associated reduction in VO2 max
. J Appl Physiol.    1988; 65 (3): 1147-51.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#195#191#article#213#</font><
/p>     ^cY#aop01411.htm##
00480000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021900090002001300309#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#196#192#article#
213#50#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">50. Evans 
WJ, Campbell    WW. Sarcopenia and age-related changes in body composition and f
unctional capacity.    J Nutr. 1993; 123 (2 Suppl): 465-8.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#197#193#article#213#</font><
/p>     ^cY#aop01411.htm##
00555000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029400090002001300384#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#198#194#article#
213#51#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">51. Callis
aya ML,    Blizzard L, Schmidt MD, McGinley JL, Srikanth VK. Sex modifies the re
lationship    between age and gait: a population-based study of older adults. J 
Gerontol A    Biol Sci Med Sci. 2008; 63 (2): 165-70.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#199#195#article#213#</font><
/p>     ^cY#aop01411.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030600090002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#200#196#article#
213#52#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">52. Miller
 GJ,    Saunders MJ, Gilson RJ, Ashcroft MT. Lung function of healthy boys and g
irls    in Jamaica in relation to ethnic composition, test exercise performance,
 and    habitual physical activity. Thorax. 1977; 32 (4): 486-96.    ^cY#aop0141
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#201#197#article#213#</font><
/p>     ^cY#aop01411.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025900090002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#202#198#article#
213#53#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">53. Whitro
w MJ,    Harding S. Ethnic differences in adolescent lung function: anthropometr
ic, socioeconomic,    and psychosocial factors. Am J Respir Crit Care Med. 2008;
 177 (11): 1262-7.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#203#199#article#213#</font><
/p>     ^cY#aop01411.htm##
00553000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029200090002001300382#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#204#200#article#
213#54#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">54. Neder 
JA, Nery    LE, Castelo A, Andreoni S, Lerario MC, Sachs A, et al. Prediction of
 metabolic    and cardiopulmonary responses to maximum cycle ergometry: a random
ised study.    Eur Respir J. 1999; 14 (6): 1304-13.    ^cY#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#205#201#article#213#</font><
/p>     ^cY#aop01411.htm##
00495000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023400090002001300324#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#206#202#article#
213#55#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">55. Lung f
unction    testing: selection of reference values and interpretative strategies.
 American    Thoracic Society. Am Rev Respir Dis. 1991; 144 (5): 1202-18.    ^cY
#aop01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#207#203#article#213#</font><
/p>     ^cY#aop01411.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031100090002001300401#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#208#204#article#
213#56#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">56. Tavare
s EL,    Anjos LA. Perfil antropom&eacute;trico da popula&ccedil;&atilde;o idosa
 brasileira:    resultados da pesquisa nacional sobre sa&uacute;de e nutri&ccedi
l;&atilde;o.    Cad Sa&uacute;de P&uacute;blica. 1999; 15 (4): 759-68.    ^cY#ao
p01411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#209#205#article#213#</font><
/p>     ^cY#aop01411.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#210#206#article#213#<p>&nbsp
;</p>     ^cY#aop01411.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#211#207#article#213#<p>&nbsp
;</p>     ^cY#aop01411.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#212#208#article#213#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop01411.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004100087002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#213#209#article#213#<br>   <
/b> Victor Zuniga Dourado    ^cY#aop01411.htm##
00290000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004400087002001300131#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#214#210#article#213#<br>   A
v. Ana Costa, 95 - 11060-001    ^cY#aop01411.htm##
00293000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004700087002001300134#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#215#211#article#213#<br>   S
antos, S&atilde;o Paulo, Brasil    ^cY#aop01411.htm##
00424000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704017800087002001300265#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#216#212#article#213#<br>   E
-mail: <a href="mailto:vzdourado@yahoo.com.br">vzdourado@yahoo.com.br</a>,    <a
 href="mailto:victor.dourado@unifesp.br">victor.dourado@unifesp.br</a></font></p
>     ^cY#aop01411.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01411.htm#S#p#217#213#article#213#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 27/
10/09; revisado recebido em 11/02/10; aceito em 31/05/10.</font></p>     ^cY#aop
01411.htm##
00545000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860120096001030300
00500199065000900204064000500213031000400218032000200222014000600224865000900230
002001300239035001000252801000500262#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01411.htm#S#c#218#1#article#56#1#^rND^sCooper^nKH#A means of assessing
 maximal oxygen intake: correlation between field and treadmill testing^len#JAMA
#19680000#1968#203#3#201-4#20110000#aop01411.htm#0098-7484#JAMA##
00663000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100018001040100
01400122010001800136012011800154030000900272065000900281064000500290031000200295
032000500297014000600302865000900308002001300317035001000330801000900340#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#219#2#article#56#2#^
rND^sMcGavin^nCR#^rND^sArtvinli^nM#^rND^sNaoe^nH#^rND^sMcHardy^nGJ#Dyspnoea, dis
ability, and distance walked: comparison of estimates of exercise performance in
 respiratory disease^len#Br Med J#19780000#1978#2#6132#241-3#20110000#aop01411.h
tm#0007-1447#Br Med J##
00671000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100014001040100
01600118010001900134010001700153012006700170030002300237065000900260064000500269
03100040027403200050027801400070028386500090029000200130029903500100031280100230
0322#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#220#3#ar
ticle#56#3#^rND^sButland^nRJ#^rND^sPang^nJ#^rND^sGross^nER#^rND^sWoodcock^nAA#^r
ND^sGeddes^nDM#Two-, six-, and 12-minute walking tests in respiratory disease^le
n#Br Med J (Clin Res Ed)#19820000#1982#284#6329#1607-8#20110000#aop01411.htm#026
7-0623#Br Med J (Clin Res Ed)##
00519000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860120086001020300
01500188710000200203065000900205064000500214031000300219032000200222014000700224
865000900231002001300240#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
411.htm#S#c#221#4#article#56#4#^rND^sSingh^nSJ#Walking for the assessment of pat
ients with chronic obstructive pulmonary disease^len#Eur Respir Mon#2#20070000#2
007#40#1#148-64#20110000#aop01411.htm##
00521000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840120059000860300026001450650
00900171064000500180031000400185032000200189014000600191865000900197002001300206
035001000219801002600229#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
411.htm#S#c#222#5#article#56#5#ATS statement: guidelines for the six-minute walk
 test^len#Am J Respir Crit Care Med#20020000#2002#166#1#111-7#20110000#aop01411.
htm#1073-449X#Am J Respir Crit Care Med##
00712000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030100
02400121010001700145012014700162030001500309065000900324064000500333031000300338
032000200341014000800343865000900351002001300360035001000373801001500383#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#223#6#article#56#6#^
rND^sGosker^nHR#^rND^sWouters^nEF#^rND^svan der Vusse^nGJ#^rND^sSchols^nAM#Skele
tal muscle dysfunction in chronic obstructive pulmonary disease and chronic hear
t failure: underlying mechanisms and therapy perspectives^len#Am J Clin Nutr#200
00000#2000#71#5#1033-47#20110000#aop01411.htm#0002-9165#Am J Clin Nutr##
00690000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100016001000100
01900116010001700135010001700152010002100169012007900190030001200269065000900281
06400050029003100030029503200030029801400070030186500090030800200130031703500100
0330801001200340#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#224#7#article#56#7#^rND^sKing^nS#^rND^sWessel^nJ#^rND^sBhambhani^nY#^rND^sMa
ikala^nR#^rND^sSholter^nD#^rND^sMaksymowych^nW#Validity and reliability of the 6
 minute walk in persons with fibromyalgia^len#J Rheumatol#19990000#1999#26#10#22
33-7#20110000#aop01411.htm#0315-162X#J Rheumatol##
00572000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100015001000120
06400115030002200179065000900201064000500210031000300215032000300218014000700221
865000900228002001300237035001000250801002200260#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01411.htm#S#c#225#8#article#56#8#^rND^sLin^nSJ#^rND^sBose^
nNH#Six-minute walk test in persons with transtibial amputation^len#Arch Phys Me
d Rehabil#20080000#2008#89#12#2354-9#20110000#aop01411.htm#0003-9993#Arch Phys M
ed Rehabil##
00709000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100021001040100
01600125010001600141010002200157010002000179810000600199012006200205030001700267
06500090028406400050029303100030029803200030030101400060030486500090031000200130
0319035001000332801001700342#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#226#9#article#56#9#^rND^sBeriault^nK#^rND^sCarpentier^nAC#^rND^s
Gagnon^nC#^rND^sMenard^nJ#^rND^sBaillargeon^nJP#^rND^sArdilouze^nJL#et al#Reprod
ucibility of the 6-minute walk test in obese adults^len#Int J Sports Med#2009000
0#2009#30#10#725-7#20110000#aop01411.htm#0172-4622#Int J sports Med##
00742000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100018001020100
01800120010002300138010001800161010001900179810000600198012008600204030002200290
06500090031206400050032103100030032603200020032901400070033186500090033800200130
0347035001000360801002200370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#227#10#article#56#10#^rND^sVis^nJC#^rND^sThoonsen^nH#^rND^sDuffe
ls^nMG#^rND^sde Bruin-Bon^nRA#^rND^sHuisman^nSA#^rND^svan Dijk^nAP#et al#Six-min
ute walk test in patients with Down syndrome: validity and reproducibility^len#A
rch Phys Med Rehabil#20090000#2009#90#8#1423-7#20110000#aop01411.htm#0003-9993#A
rch Phys Med Rehabil##
00723000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100021001030100
01300124010002500137012016900162030001000331065000900341064000500350031000300355
032000200358014000700360865000900367002001300376035001000389801001000399#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#228#11#article#56#11
#^rND^sRies^nJD#^rND^sEchternach^nJL#^rND^sNof^nL#^rND^sGagnon Blodgett^nM#Test-
retest reliability and minimal detectable change scores for the timed "up & go" 
test, the six-minute walk test, and gait speed in people with Alzheimer disease^
len#Phys Ther#20090000#2009#89#6#569-79#20110000#aop01411.htm#0031-9023#Phys The
r##
00595000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
01500123012006200138030001800200065000900218064000500227031000300232032000200235
014000600237865000900243002001300252035001000265801001800275#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#229#12#article#56#12#^rND^sMaher
^nCA#^rND^sWilliams^nMT#^rND^sOlds^nTS#The six-minute walk test for children wit
h cerebral palsy^len#Int J Rehabil Res#20080000#2008#31#2#185-8#20110000#aop0141
1.htm#0342-5282#Int J Rehabil Res##
00747000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
02000123010001500143010001800158010002600176810000600202012010600208030001300314
06500090032706400050033603100030034103200020034401400060034686500090035200200130
0361035001000374801001300384#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#230#13#article#56#13#^rND^sTroosters^nT#^rND^sVilaro^nJ#^rND^sRa
binovich^nR#^rND^sCasas^nA#^rND^sBarbera^nJA#^rND^sRodriguez-Roisin^nR#et al#Phy
siological responses to the 6-min walk test in patients with chronic obstructive
 pulmonary disease^len#Eur Respir J#20020000#2002#20#3#564-9#20110000#aop01411.h
tm#0903-1936#Eur Respir J##
00668000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01700120010001600137012013000153030000600283065000900289064000500298031000400303
032000200307014000700309865000900316002001300325035001000338801000600348#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#231#14#article#56#14
#^rND^sSolway^nS#^rND^sBrooks^nD#^rND^sLacasse^nY#^rND^sThomas^nS#A qualitative 
systematic overview of the measurement properties of functional walk tests used 
in the cardiorespiratory domain^len#Chest#20010000#2001#119#1#256-70#20110000#ao
p01411.htm#0012-3692#Chest##
00494000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880120029001060300
01200135065000900147064000500156031000300161032000200164014000600166865000900172
002001300181035001000194801001200204#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01411.htm#S#c#232#15#article#56#15#^rND^sEnright^nPL#The six-minute wa
lk test^len#Respir Care#20030000#2003#48#8#783-5#20110000#aop01411.htm#0020-1324
#Respir Care##
00699000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01700125010001600142010001800158010001600176810000600192012008000198030000600278
06500090028406400050029303100040029803200020030201400070030486500090031100200130
0320035001000333801000600343#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#233#16#article#56#16#^rND^sEnright^nPL#^rND^sMcBurnie^nMA#^rND^s
Bittner^nV#^rND^sTracy^nRP#^rND^sMcNamara^nR#^rND^sArnold^nA#et al#The 6-min wal
k test: a quick measure of functional status in elderly adults^len#Chest#2003000
0#2003#123#2#387-98#20110000#aop01411.htm#0012-3692#Chest##
00631000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
01800126012007400144030002600218065000900244064000500253031000400258032000200262
014000700264865000900271002001300280035001000293801002600303#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#234#17#article#56#17#^rND^sGosse
link^nR#^rND^sTroosters^nT#^rND^sDecramer^nM#Peripheral muscle weakness contribu
tes to exercise limitation in COPD^len#Am J Respir Crit Care Med#19960000#1996#1
53#3#976-80#20110000#aop01411.htm#1073-449X#Am J Respir Crit Care Med##
00701000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01600124010001900140010001900159010001500178012010000193030000600293065000900299
06400050030803100040031303200020031701400060031986500090032500200130033403500100
0347801000600357#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#235#18#article#56#18#^rND^sDourado^nVZ#^rND^sAntunes^nLC#^rND^sTanni^nSE#^rN
D^sde Paiva^nSA#^rND^sPadovani^nCR#^rND^sGodoy^nI#Relationship of upper-limb and
 thoracic muscle strength to 6-min walk distance in COPD patients^len#Chest#2006
0000#2006#129#3#551-7#20110000#aop01411.htm#0012-3692#Chest##
00793000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01600124010002000140010001600160010002100176810000600197012014700203030001700350
06500090036706400050037603100030038103200020038401400080038686500090039400200130
0403035001000416801001700426#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#236#19#article#56#19#^rND^sAraujo^nCO#^rND^sMakdisse^nMR#^rND^sP
eres^nPA#^rND^sTebexreni^nAS#^rND^sRamos^nLR#^rND^sMatsushita^nAM#et al#Differen
t patterns for the 6-minute walk test as a test to measure exercise ability in e
lderly with and without clinically evident cardiopathy^len#Arq Bras Cardiol#2006
0000#2006#86#3#198-205#20110000#aop01411.htm#0066-782X#Arq Bras Cardiol##
00606000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060120
06600125030002600191065000900217064000500226031000400231032000200235034000200237
014000700239865000900246002001300255035001000268801002600278#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#237#20#article#56#20#^rND^sEnrig
ht^nPL#^rND^sSherrill^nDL#Reference equations for the six-minute walk in healthy
 adults^len#Am J Respir Crit Care Med#19980000#1998#158#5#1#1384-7#20110000#aop0
1411.htm#1073-449X#Am J Respir Crit Care Med##
00589000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
01800126012006000144030001300204065000900217064000500226031000300231032000200234
014000600236865000900242002001300251035001000264801001300274#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#238#21#article#56#21#^rND^sTroos
ters^nT#^rND^sGosselink^nR#^rND^sDecramer^nM#Six minute walking distance in heal
thy elderly subjects^len#Eur Respir J#19990000#1999#14#2#270-4#20110000#aop01411
.htm#0903-1936#Eur Respir J##
00623000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01600119012008600135030002100221065000900242064000500251031000300256032000200259
014000700261865000900268002001300277035001000290801002100300#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#239#22#article#56#22#^rND^sKervi
o^nG#^rND^sCarre^nF#^rND^sVille^nNS#Reliability and intensity of the six-minute 
walk test in healthy elderly subjects^len#Med Sci Sports Exerc#20030000#2003#35#
1#169-74#20110000#aop01411.htm#0195-9131#Med Sci Sports Exerc##
00729000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100020001080100
02000128010001800148010001700166010001600183810000600199012008100205030001700286
06500090030306400050031203100030031703200030032001400070032386500090033000200130
0339035001000352801001700362#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#240#23#article#56#23#^rND^sPriesnitz^nCV#^rND^sRodrigues^nGH#^rN
D^sStumpf Cda^nS#^rND^sViapiana^nG#^rND^sCabral^nCP#^rND^sStein^nRT#et al#Refere
nce values for the 6-min walk test in healthy children aged 6-12 years^len#Pedia
tr Pulmonol#20090000#2009#44#12#1174-9#20110000#aop01411.htm#8755-6863#Pediatr P
ulmonol##
00685000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01500121010001600136010002100152010001700173810000600190012005300196030001000249
06500090025906400050026803100040027303200020027701400140027986500090029300200130
0302035001000315801001000325#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#241#24#article#56#24#^rND^sGeiger^nR#^rND^sStrasak^nA#^rND^sTrem
l^nB#^rND^sGasser^nK#^rND^sKleinsasser^nA#^rND^sFischer^nV#et al#Six-minute walk
 test in children and adolescents^len#J Pediatr#20070000#2007#150#4#395-9, e391-
2#20110000#aop01411.htm#0022-3476#J Pediatr##
00633000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01500123010001800138012007600156030001500232065000900247064000500256031000300261
032000200264014000600266865000900272002001300281035001000294801001500304#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#242#25#article#56#25
#^rND^sLammers^nAE#^rND^sHislop^nAA#^rND^sFlynn^nY#^rND^sHaworth^nSG#The 6-minut
e walk test: normal values for children of 4-11 years of age^len#Arch Dis Child#
20080000#2008#93#6#464-8#20110000#aop01411.htm#0003-9888#Arch Dis Child##
00727000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100013001010100
01300114010001300127010001500140010001400155810000600169012009100175030002600266
06500090029206400050030103100040030603200020031001400070031286500090031900200130
0328035001000341801002600351#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#243#26#article#56#26#^rND^sLi^nAM#^rND^sYin^nJ#^rND^sAu^nJT#^rND
^sSo^nHK#^rND^sTsang^nT#^rND^sWong^nE#et al#Standard reference for the six-minut
e-walk test in healthy children aged 7 to 16 years^len#Am J Respir Crit Care Med
#20070000#2007#176#2#174-80#20110000#aop01411.htm#1073-449X#Am J Respir Crit Car
e Med##
00715000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01800123010001800141010001500159010001500174012009600189030001700285065000900302
06400050031103100030031603200020031901400070032186500090032800200130033703500100
0350801001700360#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#244#27#article#56#27#^rND^sBen Saad^nH#^rND^sPrefaut^nC#^rND^sMissaoui^nR#^r
ND^sMohamed^nIH#^rND^sTabka^nZ#^rND^sHayot^nM#Reference equation for 6-min walk 
distance in healthy North African children 6-16 years old^len#Pediatr Pulmonol#2
0090000#2009#44#4#316-24#20110000#aop01411.htm#8755-6863#Pediatr Pulmonol##
00671000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01500124010001500139012010400154030002100258065000900279064000500288031000300293
032000200296014000600298865000900304002001300313035001000326801002100336#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#245#28#article#56#28
#^rND^sGibbons^nWJ#^rND^sFruchter^nN#^rND^sSloan^nS#^rND^sLevy^nRD#Reference val
ues for a multiple repetition 6-minute walk test in healthy adults older than 20
 years^len#J Cardiopulm Rehabil#20010000#2001#21#2#87-93#20110000#aop01411.htm#0
883-9212#J Cardiopulm Rehabil##
00697000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01400120010001600134010001500150010001400165810000600179012008100185030001100266
06500090027706400050028603100040029103200020029501400070029786500090030400200130
0313035001000326801001100336#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#246#29#article#56#29#^rND^sChetta^nA#^rND^sZanini^nA#^rND^sPisi^
nG#^rND^sAiello^nM#^rND^sTzani^nP#^rND^sNeri^nM#et al#Reference values for the 6
-min walk test in healthy subjects 20-50 years old^len#Respir Med#20060000#2006#
100#9#1573-8#20110000#aop01411.htm#0954-6111#Respir Med##
00584000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
02100123012005700144030001100201065000900212064000500221031000400226032000200230
014000700232865000900239002001300248035001000261801001100271#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#247#30#article#56#30#^rND^sAlame
ri^nH#^rND^sAl-Majed^nS#^rND^sAl-Howaikan^nA#Six-min walk test in a healthy adul
t Arab population^len#Respir Med#20090000#2009#103#7#1041-6#20110000#aop01411.ht
m#0954-6111#Respir Med##
00720000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01500122010001600137010001500153010001800168012009700186030002000283065000900303
06400050031203100030031703200030032001400070032386500090033000200130033903500100
0352801002000362#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#248#31#article#56#31#^rND^sIwama^nAM#^rND^sAndrade^nGN#^rND^sShima^nP#^rND^s
Tanni^nSE#^rND^sGodoy^nI#^rND^sDourado^nVZ#The six-minute walk test and body wei
ght-walk distance product in healthy Brazilian subjects^len#Braz J Med Biol Res#
20090000#2009#42#11#1080-5#20110000#aop01411.htm#0100-879X#Braz J Med Biol Res##
00650000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01700124010001900141010001700160012006600177030001100243065000900254064000500263
03100040026803200020027201400070027486500090028100200130029003500100030380100110
0313#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#249#32#a
rticle#56#32#^rND^sCamarri^nB#^rND^sEastwood^nPR#^rND^sCecins^nNM#^rND^sThompson
^nPJ#^rND^sJenkins^nS#Six minute walk distance in healthy subjects aged 55-75 ye
ars^len#Respir Med#20060000#2006#100#4#658-65#20110000#aop01411.htm#0954-6111#Re
spir Med##
00715000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100019001010100
01700120010001300137010001800150012014000168030001200308065000900320064000500329
03100030033403200020033701400060033986500090034500200130035403500100036780100120
0377#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#250#33#a
rticle#56#33#^rND^sPoh^nH#^rND^sEastwood^nPR#^rND^sCecins^nNM#^rND^sHo^nKT#^rND^
sJenkins^nSC#Six-minute walk distance in healthy Singaporean adults cannot be pr
edicted using reference equations derived from Caucasian populations^len#Respiro
logy#20060000#2006#11#2#211-6#20110000#aop01411.htm#1323-7799#RESPIROLOGY##
00686000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01300124010001600137010001600153012011500169030001000284065000900294064000500303
03100030030803200020031101400050031386500090031800200130032703500100034080100100
0350#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#251#34#a
rticle#56#34#^rND^sMasmoudi^nK#^rND^sAouicha^nMS#^rND^sFki^nH#^rND^sDammak^nJ#^r
ND^sZouari^nN#The six minute walk test: which predictive values to apply for Tun
isian subjects aged between 40 and 80 years?^len#Tunis Med#20080000#2008#86#1#20
-6#20110000#aop01411.htm#0041-4131#Tunis Med##
00718000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01500123010001500138010001600153010001900169810000600188012009400194030001100288
06500090029906400050030803100040031303200020031701400060031986500090032500200130
0334035001000347801001100357#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#252#35#article#56#35#^rND^sBen Saad^nH#^rND^sPrefaut^nC#^rND^sTa
bka^nZ#^rND^sMtir^nAH#^rND^sChemit^nM#^rND^sHassaoune^nR#et al#6-minute walk dis
tance in healthy North Africans older than 40 years: influence of parity^len#Res
pir Med#20090000#2009#103#1#74-84#20110000#aop01411.htm#0954-6111#Respir Med##
00683000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01900123012016100142030001000303065000900313064000500322031000300327032000200330
014000700332865000900339002001300348035001000361801001000371#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#253#36#article#56#36#^rND^sSteff
en^nTM#^rND^sHacker^nTA#^rND^sMollinger^nL#Age- and gender-related test performa
nce in community-dwelling elderly people: six-minute walk test, Berg Balance Sca
le, Timed Up & Go Test, and gait speeds^len#Phys Ther#20020000#2002#82#2#128-37#
20110000#aop01411.htm#0031-9023#Phys Ther##
00761000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100013001030100
01600116012012500132030006000257710000200317065000900319064000500328031000200333
03200020033501400040033711000090034110900120035003700510036286500090041300200130
0422#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#254#37#a
rticle#56#37#^rND^sRoush^nJ#^rND^sGuy^nJ#^rND^sPurvis^nM#Reference values and re
lationship of the six minute walk test and body mass index in healthy third grad
e school children^len#The Internet Journal of Allied Health Sciences and Practic
e#2#20060000#2006#4#3#1-6#20091110#2009 Nov 10#http://ijahsp.nova.edu/articles/v
ol4num3/rowsh.pdf#20110000#aop01411.htm##
00625000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
01900123010001700142012009600159030001800255710000200273065000900275064000500284
031000300289032000200292014000700294865000900301002001300310#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#255#38#article#56#38#^rND^sPires
^nSR#^rND^sOliveira^nAC#^rND^sParreira^nVF#^rND^sBritto^nRR#Teste de caminhada d
e seis minutos em diferentes faixas etárias e índices de massa corporal^lpt#Rev 
Bras Fisioter#2#20070000#2007#11#2#147-51#20110000#aop01411.htm##
00667000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01500123010002300138012008500161030002300246065000900269064000500278031000400283
032000500287014000600292865000900298002001300307035001000320801002300330#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#256#39#article#56#39
#^rND^sLipkin^nDP#^rND^sScriven^nAJ#^rND^sCrake^nT#^rND^sPoole-Wilson^nPA#Six mi
nute walking test for assessing exercise capacity in chronic heart failure^len#B
r Med J (Clin Res Ed)#19860000#1986#292#6521#653-5#20110000#aop01411.htm#0267-06
23#Br Med J (Clin Res Ed)##
00637000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100014001040100
01600118010001500134010001800149012006300167030001200230065000900242064000500251
03100030025603200020025901400060026186500090026700200130027603500100028980100120
0299#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#257#40#a
rticle#56#40#^rND^sChetta^nA#^rND^sPisi^nG#^rND^sAiello^nM#^rND^sTzani^nP#^rND^s
Olivieri^nD#The walking capacity assessment in the respiratory patient^len#Respi
ration#20090000#2009#77#4#361-7#20110000#aop01411.htm#0025-7931#Respiration##
00711000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01700122010001700139010001800156010001900174012009500193030001300288065000900301
06400050031003100030031503200020031801400080032086500090032800200130033703500100
0350801001300360#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#258#41#article#56#41#^rND^sPitta^nF#^rND^sTroosters^nT#^rND^sProbst^nVS#^rND
^sSpruit^nMA#^rND^sDecramer^nM#^rND^sGosselink^nR#Quantifying physical activity 
in daily life with questionnaires and motion sensors in COPD^len#Eur Respir J#20
060000#2006#27#5#1040-55#20110000#aop01411.htm#0903-1936#Eur Respir J##
00633000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01900121012010300140030001500243065000900258064000500267031000300272032000200275
014000700277865000900284002001300293035001000306801001500316#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#259#42#article#56#42#^rND^sBaeck
e^nJA#^rND^sBurema^nJ#^rND^sFrijters^nJE#A short questionnaire for the measureme
nt of habitual physical activity in epidemiological studies^len#Am J Clin Nutr#1
9820000#1982#36#5#936-42#20110000#aop01411.htm#0002-9165#Am J Clin Nutr##
00626000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100020001070100
01900127012008300146030001900229065000900248064000500257031000300262032000200265
014000600267865000900273002001300282035001000295801001900305#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#260#43#article#56#43#^rND^sAbran
tes^nMM#^rND^sLamounier^nJA#^rND^sColosimo^nEA#Overweight and obesity prevalence
 in Northeast and Southeast Regions of Brazil^len#Rev Assoc Med Bras#20030000#20
03#49#2#162-6#20110000#aop01411.htm#0004-5241#Rev Assoc Med Bras##
00816000000000373000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01800126010001600144010001700160011001200177011003600189011003600225011003500261
01200530029603000170034906500090036606400050037503100030038003200020038301400080
0385865000900393002001300402035001000415801001700425#2011nahead#V:\SciELO\serial
\abc\2011nahead\markup\aop01411.htm#S#c#261#44#article#56#44#^rND^sMion Jr^nD#^r
ND^sKohlmann Jr^nO#^rND^sMachado^nCA#^rND^sAmodeo^nC#^rND^sGomes^nMAG#Praxedes J
N#Sociedade Brasileira de Cardiologia#Sociedade Brasileira de Hipertensão#Socied
ade Brasileira de Nefrologia#V Diretrizes brasileiras de hipertensão arterial^lp
t#Arq Bras Cardiol#20070000#2007#89#3#e24-e79#20110000#aop01411.htm#0066-782X#Ar
q Bras Cardiol##
00700000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01800124010001700142010001800159010001700177810000600194012009500200030001500295
71000020031006500090031206400050032103100030032603200040032901400070033386500090
0340002001300349#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#262#45#article#56#45#^rND^sAraujo^nAJ#^rND^sMenezes^nAMB#^rND^sDórea^nAJPS#^
rND^sTorres^nBS#^rND^sViegas^nCAA#^rND^sSilva^nCAR#et al#/ Sociedade Brasileira 
de Pneumologioa e Tisiologia: Diretrizes para cessação do tabagismo^lpt#J Bras P
neumol#2#20040000#2004#30#^s2#s1-s76#20110000#aop01411.htm##
00725000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01700122010001900139010001900158010001800177012009800195030001800293065000900311
06400050032003100030032503200020032801400070033086500090033700200130034603500100
0359801001800369#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#263#46#article#56#46#^rND^sHallal^nPC#^rND^sDumith^nSC#^rND^sBastos^nJP#^rND
^sReichert^nFF#^rND^sSiqueira^nFV#^rND^sAzevedo^nMR#Evolution of the epidemiolog
ical research on physical activity in Brazil: a systematic review^len#Rev Saude 
Publica#20070000#2007#41#3#453-60#20110000#aop01411.htm#0034-8910#Rev Saude Publ
ica##
00705000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100014001060100
01500120010001900135010001800154010001800172012009300190030001300283065000900296
06400050030503100030031003200020031301400070031586500090032200200130033103500100
0344801001300354#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#
S#c#264#47#article#56#47#^rND^sTeramoto^nS#^rND^sOhga^nE#^rND^sIshii^nT#^rND^sYa
maguchi^nY#^rND^sYamamoto^nH#^rND^sMastsuse^nT#Reference value of six-minute wal
king distance in healthy middle-aged and older subjects^len#Eur Respir J#2000000
0#2000#15#6#1132-3#20110000#aop01411.htm#0903-1936#Eur Respir J##
00616000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100014001050100
01600119012009700135030001300232065000900245064000500254031000200259032000200261
014000600263865000900269002001300278035001000291801001300301#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01411.htm#S#c#265#48#article#56#48#^rND^sLacas
se^nY#^rND^sWong^nE#^rND^sGuyatt^nG#A systematic overview of the measurement pro
perties of the Chronic Respiratory Questionnaire^len#Can Respir J#19970000#1997#
4#3#131-9#20110000#aop01411.htm#1198-2241#Can Respir J##
00567000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100018001030120
06700121030001500188065000900203064000500212031000300217032000200220014000800222
865000900230002001300239035001000252801001500262#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01411.htm#S#c#266#49#article#56#49#^rND^sFleg^nJL#^rND^sLa
katta^nEG#Role of muscle loss in the age-associated reduction in VO2 max^len#J A
ppl Physiol#19880000#1988#65#3#1147-51#20110000#aop01411.htm#0021-8987#J Appl Ph
ysiol##
00575000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040120
08300123030000700206065000900213064000500222031000400227032000900231014000600240
865000900246002001300255035001000268801000700278#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01411.htm#S#c#267#50#article#56#50#^rND^sEvans^nWJ#^rND^sC
ampbell^nWW#Sarcopenia and age-related changes in body composition and functiona
l capacity^len#J Nutr#19930000#1993#123#2^sSuppl#465-8#20110000#aop01411.htm#002
2-3166#J Nutr##
00723000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100018001080100
01800126010001900144010001900163012009700182030003000279065000900309064000500318
03100030032303200020032601400070032886500090033500200130034403500100035780100300
0367#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#268#51#a
rticle#56#51#^rND^sCallisaya^nML#^rND^sBlizzard^nL#^rND^sSchmidt^nMD#^rND^sMcGin
ley^nJL#^rND^sSrikanth^nVK#Sex modifies the relationship between age and gait: a
 population-based study of older adults^len#J Gerontol A Biol Sci Med Sci#200800
00#2008#63#2#165-70#20110000#aop01411.htm#1079-5006#J Gerontol A Biol Sci Med Sc
i##
00694000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01700124010001900141012014800160030000700308065000900315064000500324031000300329
032000200332014000700334865000900341002001300350035001000363801000700373#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01411.htm#S#c#269#52#article#56#52
#^rND^sMiller^nGJ#^rND^sSaunders^nMJ#^rND^sGilson^nRJ#^rND^sAshcroft^nMT#Lung fu
nction of healthy boys and girls in Jamaica in relation to ethnic composition, t
est exercise performance, and habitual physical activity^len#Thorax#19770000#197
7#32#4#486-96#20110000#aop01411.htm#0040-6376#Thorax##
00633000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060120
10800123030002600231065000900257064000500266031000400271032000300275014000700278
865000900285002001300294035001000307801002600317#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01411.htm#S#c#270#53#article#56#53#^rND^sWhitrow^nMJ#^rND^
sHarding^nS#Ethnic differences in adolescent lung function: anthropometric, soci
oeconomic, and psychosocial factors^len#Am J Respir Crit Care Med#20080000#2008#
177#11#1262-7#20110000#aop01411.htm#1073-449X#Am J Respir Crit Care Med##
00733000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01700119010001800136010001800154010001500172810000600187012010500193030001300298
06500090031106400050032003100030032503200020032801400080033086500090033800200130
0347035001000360801001300370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01411.htm#S#c#271#54#article#56#54#^rND^sNeder^nJA#^rND^sNery^nLE#^rND^sCastel
o^nA#^rND^sAndreoni^nS#^rND^sLerario^nMC#^rND^sSachs^nA#et al#Prediction of meta
bolic and cardiopulmonary responses to maximum cycle ergometry: a randomised stu
dy^len#Eur Respir J#19990000#1999#14#6#1304-13#20110000#aop01411.htm#0903-1936#E
ur Respir J##
00564000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850120114000880300018002020650
00900220064000500229031000400234032000200238014000800240865000900248002001300257
035001000270801001800280#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
411.htm#S#c#272#55#article#56#55#Lung function testing: selection of reference v
alues and interpretative strategies. American Thoracic Society^len#Am Rev Respir
 Dis#19910000#1991#144#5#1202-18#20110000#aop01411.htm#0003-0805#Am Rev Respir D
is##
00580000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060120
11200122030001800234710000200252065000900254064000500263031000300268032000200271
014000700273865000900280002001300289#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01411.htm#S#c#273#56#article#56#56#^rND^sTavares^nEL#^rND^sAnjos^nLA#P
erfil antropométrico da população idosa brasileira: resultados da pesquisa nacio
nal sobre saúde e nutrição^lpt#Cad Saúde Pública#2#19990000#1999#15#4#759-68#201
10000#aop01411.htm##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#o#1#1#
article#1#20110331#080927#aop01511.htm#126##
04428000000000709000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200860
01780120085002640100045003490100039003940100055004330100035004880100047005230700
05100570070003600621070006900657083126500726085000801991085002701999085002802026
08500700205408500300212408500190215408312900217308500080346308500260347108500270
34970850069035240850028035930850019036211170008036400720003036481120009036511110
00903660116000903669115000903678114000903687113000903696002001303705#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#h#2#1#article#1#oa#pt#br1.
1#1#4.0#ILUS#TAB#26#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20
110304#Acesso radial em intervenções coronarianas percutâneas: panorama atual br
asileiro^lpt#Radial approach in percutaneous coronary interventions: current sta
tus in Brazil^len#^rND^1A01 A02 A03^nPedro Beraldo de^sAndrade#^rND^1A01 A02 A03
^nMarden André^sTebet#^rND^1A01 A02 A03^nMônoca Vieira Athanazio de^sAndrade#^rN
D^1A01 A02 A03^nAndré^sLabrunie#^rND^1A01 A02 A03^nLuiz Alberto Piva e^sMattos#H
ospital do Coração de Londrina^iA01^cLondrina^sPR#Santa Casa de Marília^iA02^cMa
rília#Instituto Dante Pazzanese de Cardiologia^iA03^cSão Paulo^sSP^pBrasil#^lpt^
aFUNDAMENTO: Embora a técnica radial exiba resultados incontestáveis na redução 
de complicações vasculares e ocorrência de sangramento grave quando comparada à 
técnica femoral, seu emprego permanece restrito a poucos centros que a elegeram 
como via de acesso preferencial. OBJETIVO: Avaliar o cenário atual das intervenç
ões coronarianas percutâneas no Brasil quanto à utilização da via de acesso radi
al. MÉTODOS: Análise dos dados cadastrados de forma espontânea na Central Nacion
al de Intervenções Cardiovasculares (CENIC) durante o quadriênio de 2005-2008, o
 que totaliza 83.376 procedimentos. RESULTADOS: A técnica radial foi utilizada e
m 12,6% dos procedimentos efetivados, e a técnica femoral, em 84,3%. Os 3,1% res
tantes foram representados pela dissecção ou punção braquial. Com uma taxa de su
cesso de 97,5%, a opção pelo acesso radial associou-se à redução significativa d
e complicações vasculares quando comparado ao femoral (2,5% versus 3,6%, p < 0,0
001). CONCLUSÃO: A utilização da técnica radial permanece baixa no Brasil. Ausên
cia de programas de treinamento, incertezas quanto à curva de aprendizagem e car
ência de estudos em larga escala, que corroboram os benefícios demonstrados até 
o momento, são possíveis justificativas para esses achados.#^dnd^i1#^tm^lpt^kArt
éria radial^i1#^tm^lpt^kartéria femoral^i1#^tm^lpt^kangioplastia transluminal pe
rcutânea coronariana^i1^smétodos#^tm^lpt^kregistros médicos^i1#^tm^lpt^kBrasil^i
1#^len^aBACKGROUND: Although the radial approach offers an unquestionable result
 in terms of reduction of vascular complications and occurrence of severe bleedi
ng in comparison to the femoral approach, so far it has only been used in few ce
nters which elected it as the preferential access. OBJECTIVE: To evaluate the cu
rrent status of percutaneous coronary interventions in Brazil, as regards the us
e of the radial approach. METHODS: Analysis of data spontaneously recorded in Ce
ntral Nacional de Intervenções Cardiovasculares - CENIC (National Center for Car
diovascular Interventions) from 2005 to 2008, in a total of 83,376 procedures. R
ESULTS: The radial approach was used in 12.6% of the procedures performed, and t
he femoral approach, in 84.3%. The remaining 3.1% corresponded to brachial arter
y dissection or puncture. With a success rate of 97.5%, the choice of the radial
 approach was associated with a significant reduction of vascular complications 
in comparison to the femoral approach (2.5% versus 3.6 %, p < 0.0001). CONCLUSIO
N: The radial approach remains uncommonly used in Brazil, and this is possibly e
xplained by the lack of training programs, uncertainties regarding the learning 
curve, and the lack of large-scale studies corroborating the benefits demonstrat
ed to date.#^dnd^i2#^tm^len^kRadial artery^i2#^tm^len^kfemoral artery^i2#^tm^len
^kangioplasty transluminal, percutaneous coronary^i2^smethods#^tm^len^kmedical r
ecords^i2#^tm^len^kBrazil^i2#vancouv#19#20100811#11/08/10#20100812#12/08/10#2010
0914#14/09/10#aop01511.htm##
04553000000000709000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201000
01780120099002780100045003770100039004220100055004610100035005160100047005510700
05100598070003600649070006900685083131000754085000802064085002702072085002802099
08500700212708500300219708500190222708313420224608500080358808500260359608500270
36220850069036490850028037180850019037461170008037650720003037731120009037761110
00903785116000903794115000903803114000903812113000903821002001303830#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#f#3#1#article#1#oa#pt#br1.
1#1#4.0#ILUS#TAB#26#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20
110304#<b>Acesso radial em intervenções coronarianas percutâneas</b>: <b>panoram
a atual brasileiro</b>^lpt#<b>Radial approach in percutaneous coronary intervent
ions</b>: <b>current status in Brazil</b>^len#^rND^1A01 A02 A03^nPedro Beraldo d
e^sAndrade#^rND^1A01 A02 A03^nMarden André^sTebet#^rND^1A01 A02 A03^nMônoca Viei
ra Athanazio de^sAndrade#^rND^1A01 A02 A03^nAndré^sLabrunie#^rND^1A01 A02 A03^nL
uiz Alberto Piva e^sMattos#Hospital do Coração de Londrina^iA01^cLondrina^sPR#Sa
nta Casa de Marília^iA02^cMarília#Instituto Dante Pazzanese de Cardiologia^iA03^
cSão Paulo^sSP^pBrasil#^lpt^a<b>FUNDAMENTO: </b>Embora a técnica radial exiba re
sultados incontestáveis na redução de complicações vasculares e ocorrência de sa
ngramento grave quando comparada à técnica femoral, seu emprego permanece restri
to a poucos centros que a elegeram como via de acesso preferencial. <b>OBJETIVO:
 </b>Avaliar o cenário atual das intervenções coronarianas percutâneas no Brasil
 quanto à utilização da via de acesso radial. <b>MÉTODOS: </b>Análise dos dados 
cadastrados de forma espontânea na Central Nacional de Intervenções Cardiovascul
ares (CENIC) durante o quadriênio de 2005-2008, o que totaliza 83.376 procedimen
tos. <b>RESULTADOS: </b>A técnica radial foi utilizada em 12,6% dos procedimento
s efetivados, e a técnica femoral, em 84,3%. Os 3,1% restantes foram representad
os pela dissecção ou punção braquial. Com uma taxa de sucesso de 97,5%, a opção 
pelo acesso radial associou-se à redução significativa de complicações vasculare
s quando comparado ao femoral (2,5% <i>versus</i> 3,6%, p &lt; 0,0001). <b>CONCL
USÃO: </b>A utilização da técnica radial permanece baixa no Brasil. Ausência de 
programas de treinamento, incertezas quanto à curva de aprendizagem e carência d
e estudos em larga escala, que corroboram os benefícios demonstrados até o momen
to, são possíveis justificativas para esses achados.#^dnd^i1#^tm^lpt^kArtéria ra
dial^i1#^tm^lpt^kartéria femoral^i1#^tm^lpt^kangioplastia transluminal percutâne
a coronariana^i1^smétodos#^tm^lpt^kregistros médicos^i1#^tm^lpt^kBrasil^i1#^len^
a<b>BACKGROUND: </b>Although the radial approach offers an unquestionable result
 in terms of reduction of vascular complications and occurrence of severe bleedi
ng in comparison to the femoral approach, so far it has only been used in few ce
nters which elected it as the preferential access. <b>OBJECTIVE: </b>To evaluate
 the current status of percutaneous coronary interventions in Brazil, as regards
 the use of the radial approach. <b>METHODS: </b>Analysis of data spontaneously 
recorded in <i>Central Nacional de Intervenções Cardiovasculares</i> - CENIC (Na
tional Center for Cardiovascular Interventions) from 2005 to 2008, in a total of
 83,376 procedures. <b>RESULTS: </b>The radial approach was used in 12.6% of the
 procedures performed, and the femoral approach, in 84.3%. The remaining 3.1% co
rresponded to brachial artery dissection or puncture. With a success rate of 97.
5%, the choice of the radial approach was associated with a significant reductio
n of vascular complications in comparison to the femoral approach (2.5% <i>versu
s</i> 3.6 %, p &lt; 0.0001). <b>CONCLUSION: </b>The radial approach remains unco
mmonly used in Brazil, and this is possibly explained by the lack of training pr
ograms, uncertainties regarding the learning curve, and the lack of large-scale 
studies corroborating the benefits demonstrated to date.#^dnd^i2#^tm^len^kRadial
 artery^i2#^tm^len^kfemoral artery^i2#^tm^len^kangioplasty transluminal, percuta
neous coronary^i2^smethods#^tm^len^kmedical records^i2#^tm^len^kBrazil^i2#vancou
v#19#20100811#11/08/10#20100812#12/08/10#20100914#14/09/10#aop01511.htm##
04649000000000733000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120086001840120085002700100045003550100039004000100055004390100035004940100
04700529070005300576070003800629070007100667083131900738085000802057085002702065
08500280209208500700212008500300219008500190222008313320223908500080357108500260
35790850027036050850069036320850028037010850019037291170008037480720003037561120
00903759111000903768116000903777115000903786114000903795113000903804002001303813
008008903826#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#l#
4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#tab#26#nd#nd#Arq. bras. cardiol#ahea
d#20110000#^f0^l0#0066-782X#20110304#Acesso radial em intervenções coronarianas 
percutâneas: panorama atual brasileiro^lpt#Radial approach in percutaneous coron
ary interventions: current status in Brazil^len#^rND^1A01 A02 A03^nPedro Beraldo
 de^sAndrade#^rND^1A01 A02 A03^nMarden André^sTebet#^rND^1A01 A02 A03^nMônoca Vi
eira Athanazio de^sAndrade#^rND^1A01 A02 A03^nAndré^sLabrunie#^rND^1A01 A02 A03^
nLuiz Alberto Piva e^sMattos#^iA01^1Hospital do Coração de Londrina^cLondrina^sP
R#^iA02^1Santa Casa de Marília^cMarília#^iA03^1Instituto Dante Pazzanese de Card
iologia^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: Embora a técnica radial exiba r
esultados incontestáveis na redução de complicações vasculares e ocorrência de s
angramento grave quando comparada à técnica femoral, seu emprego permanece restr
ito a poucos centros que a elegeram como via de acesso preferencial. OBJETIVO: A
valiar o cenário atual das intervenções coronarianas percutâneas no Brasil quant
o à utilização da via de acesso radial. MÉTODOS: Análise dos dados cadastrados d
e forma espontânea na Central Nacional de Intervenções Cardiovasculares (CENIC) 
durante o quadriênio de 2005-2008, o que totaliza 83.376 procedimentos. RESULTAD
OS: A técnica radial foi utilizada em 12,6 por cento dos procedimentos efetivado
s, e a técnica femoral, em 84,3 por cento. Os 3,1 por cento restantes foram repr
esentados pela dissecção ou punção braquial. Com uma taxa de sucesso de 97,5 por
 cento, a opção pelo acesso radial associou-se à redução significativa de compli
cações vasculares quando comparado ao femoral (2,5 por cento versus 3,6 por cent
o, p < 0,0001). CONCLUSÃO: A utilização da técnica radial permanece baixa no Bra
sil. Ausência de programas de treinamento, incertezas quanto à curva de aprendiz
agem e carência de estudos em larga escala, que corroboram os benefícios demonst
rados até o momento, são possíveis justificativas para esses achados.#^dnd^i1#^t
m^lpt^kArtéria radial^i1#^tm^lpt^kartéria femoral^i1#^tm^lpt^kangioplastia trans
luminal percutânea coronariana^i1^smétodos#^tm^lpt^kregistros médicos^i1#^tm^lpt
^kBrasil^i1#^len^aBACKGROUND: Although the radial approach offers an unquestiona
ble result in terms of reduction of vascular complications and occurrence of sev
ere bleeding in comparison to the femoral approach, so far it has only been used
 in few centers which elected it as the preferential access. OBJECTIVE: To evalu
ate the current status of percutaneous coronary interventions in Brazil, as rega
rds the use of the radial approach. METHODS: Analysis of data spontaneously reco
rded in Central Nacional de Intervenções Cardiovasculares - CENIC (National Cent
er for Cardiovascular Interventions) from 2005 to 2008, in a total of 83,376 pro
cedures. RESULTS: The radial approach was used in 12.6 percent of the procedures
 performed, and the femoral approach, in 84.3 percent. The remaining 3.1 percent
 corresponded to brachial artery dissection or puncture. With a success rate of 
97.5 percent, the choice of the radial approach was associated with a significan
t reduction of vascular complications in comparison to the femoral approach (2.5
 percent versus 3.6  percent, p < 0.0001). CONCLUSION: The radial approach remai
ns uncommonly used in Brazil, and this is possibly explained by the lack of trai
ning programs, uncertainties regarding the learning curve, and the lack of large
-scale studies corroborating the benefits demonstrated to date.#^dnd^i2#^tm^len^
kRadial artery^i2#^tm^len^kfemoral artery^i2#^tm^len^kangioplasty transluminal, 
percutaneous coronary^i2^smethods#^tm^len^kmedical records^i2#^tm^len^kBrazil^i2
#vancouv#19#20100811#11/08/10#20100812#12/08/10#20100914#14/09/10#aop01511.htm#I
nternet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X201100
5000026##
00452000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704021000083002001300293#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#5#1#article#103#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Acesso 
radial em interven&ccedil;&otilde;es coronarianas percut&acirc;neas: panorama at
ual brasileiro</b></font></p>     ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#6#2#article#103#<p>&nbsp;</p
>     ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#7#3#article#103#<p>&nbsp;</p
>     ^cY#aop01511.htm##
00476000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704023400083002001300317#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#8#4#article#103#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Pedro Beraldo de Andrade; 
Marden Andr&eacute; Tebet, M&ocirc;noca Vieira Athanazio de Andrade; Andr&eacute
; Labrunie; Luiz Alberto Piva e Mattos</b></font></p>     ^cY#aop01511.htm##
00503000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704026100083002001300344#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#9#5#article#103#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif">Hospital do Cora&ccedil;&atil
de;o de Londrina, Londrina, PR; Santa Casa de Mar&iacute;lia, Mar&iacute;lia, In
stituto Dante Pazzanese de Cardiologia, S&atilde;o Paulo, SP - Brasil</font></p>
     ^cY#aop01511.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#10#6#article#103#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#11#7#article#103#<p>&nbsp;</
p>     ^cY#aop01511.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#12#8#article#103#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01511.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#13#9#article#103#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>    
 ^cY#aop01511.htm##
00656000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041200085002001300497#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#14#10#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO: </b> Embora 
a t&eacute;cnica radial exiba resultados incontest&aacute;veis na redu&ccedil;&a
tilde;o de complica&ccedil;&otilde;es vasculares e ocorr&ecirc;ncia de sangramen
to grave quando comparada &agrave; t&eacute;cnica femoral, seu emprego permanece
 restrito a poucos centros que a elegeram como via de acesso preferencial.    ^c
Y#aop01511.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020100085002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#15#11#article#103#<br>   <b>
OBJETIVO: </b> Avaliar o cen&aacute;rio atual das interven&ccedil;&otilde;es cor
onarianas percut&acirc;neas no Brasil quanto &agrave; utiliza&ccedil;&atilde;o d
a via de acesso radial.    ^cY#aop01511.htm##
00498000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025400085002001300339#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#16#12#article#103#<br>   <b>
M&Eacute;TODOS: </b> An&aacute;lise dos dados cadastrados de forma espont&acirc;
nea na Central Nacional de Interven&ccedil;&otilde;es Cardiovasculares (CENIC) d
urante o quadri&ecirc;nio de 2005-2008, o que totaliza 83.376 procedimentos.    
^cY#aop01511.htm##
00737000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049300085002001300578#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#17#13#article#103#<br>   <b>
RESULTADOS: </b> A t&eacute;cnica radial foi utilizada em 12,6% dos procedimento
s efetivados, e a t&eacute;cnica femoral, em 84,3%. Os 3,1% restantes foram repr
esentados pela dissec&ccedil;&atilde;o ou pun&ccedil;&atilde;o braquial. Com uma
 taxa de sucesso de 97,5%, a op&ccedil;&atilde;o pelo acesso radial associou-se 
&agrave; redu&ccedil;&atilde;o significativa de complica&ccedil;&otilde;es vascu
lares quando comparado ao femoral (2,5% <i>versus</i> 3,6%, p &lt; 0,0001).    ^
cY#aop01511.htm##
00647000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040300085002001300488#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#18#14#article#103#<br>   <b>
CONCLUS&Atilde;O: </b> A utiliza&ccedil;&atilde;o da t&eacute;cnica radial perma
nece baixa no Brasil. Aus&ecirc;ncia de programas de treinamento, incertezas qua
nto &agrave; curva de aprendizagem e car&ecirc;ncia de estudos em larga escala, 
que corroboram os benef&iacute;cios demonstrados at&eacute; o momento, s&atilde;
o poss&iacute;veis justificativas para esses achados.</font></p>     ^cY#aop0151
1.htm##
00524000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028000085002001300365#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#19#15#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b> Art
&eacute;ria radial, art&eacute;ria femoral, angioplastia transluminal percut&aci
rc;nea coronariana/m&eacute;todos, registros m&eacute;dicos, Brasil.</font></p> 
<hr size="1" noshade>     ^cY#aop01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#20#16#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#21#17#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#22#18#article#103#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01511.htm##
01082000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083800085002001300923#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#23#19#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Inicialmente descrito em 19
48<sup>1</sup>, o acesso radial passou a despertar o interesse da comunidade car
diol&oacute;gica a partir das publica&ccedil;&otilde;es de Campeau<sup>2</sup> e
 Kiemeneij e Laarman<sup>3</sup>, em 1989 e 1993, que atestaram sua factibilidad
e na realiza&ccedil;&atilde;o de procedimentos coron&aacute;rios diagn&oacute;st
icos e terap&ecirc;uticos. Embora hoje a t&eacute;cnica se mostre madura, com re
sultados incontest&aacute;veis na redu&ccedil;&atilde;o de complica&ccedil;&otil
de;es vasculares e ocorr&ecirc;ncia de sangramento grave quando comparada &agrav
e; t&eacute;cnica femoral<sup>4,5</sup>, sua utiliza&ccedil;&atilde;o permanece 
restrita a poucos centros, cujos operadores a elegeram como via de acesso prefer
encial. </font></p>     ^cY#aop01511.htm##
01072000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704082800085002001300913#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#24#20#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No Brasil, dados relacionad
os ao final da d&eacute;cada de 1990 demonstravam que o acesso femoral preponder
ava sobre o radial, por ser empregado em 90% dos procedimentos, enquanto o &uacu
te;ltimo se restringia a 8% dos casos, com os 2% restantes representados pela t&
eacute;cnica de Sones ou pun&ccedil;&atilde;o braquial<sup>6</sup>. Por&eacute;m
, a disponibiliza&ccedil;&atilde;o crescente de novas e consistentes evid&ecirc;
ncias comprobat&oacute;rias dos benef&iacute;cios do emprego do acesso radial na
 realiza&ccedil;&atilde;o de interven&ccedil;&otilde;es coronarianas percut&acir
c;neas (ICP), sobretudo no cen&aacute;rio das s&iacute;ndromes isqu&ecirc;micas 
agudas, poderia impactar de forma positiva sua maior aceita&ccedil;&atilde;o. </
font></p>     ^cY#aop01511.htm##
00567000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032300085002001300408#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#25#21#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo &ea
cute; apresentar os resultados das ICP no Brasil, com enfoque na via de acesso u
tilizada, no quadri&ecirc;nio 2005-2008, segundo os dados da Central Nacional de
 Interven&ccedil;&otilde;es Cardiovasculares (CENIC).</font></p>     ^cY#aop0151
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#26#22#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#27#23#article#103#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos</b></font
></p>     ^cY#aop01511.htm##
00927000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068300085002001300768#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#28#24#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A CENIC &eacute; um &oacute
;rg&atilde;o oficial da Sociedade Brasileira de Hemodin&acirc;mica e Cardiologia
 Intervencionista (SBHCI), criada em 1991 para documentar o desempenho e a evolu
&ccedil;&atilde;o da especialidade no Brasil. Constitui-se em um banco de dados 
de contribui&ccedil;&atilde;o volunt&aacute;ria dos s&oacute;cios titulares e as
pirantes dessa sociedade, autorizados &agrave; pr&aacute;tica de ICP, e compreen
de as cinco regi&otilde;es geogr&aacute;ficas. Al&eacute;m disso, sua consist&ec
irc;ncia pode ser aferida por meio de publica&ccedil;&otilde;es pr&eacute;vias<s
up>7-9</sup>.</font></p>     ^cY#aop01511.htm##
00884000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064000085002001300725#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#29#25#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Seu centro coordenador loca
liza-se na sede da SBHCI em S&atilde;o Paulo, e sua sistem&aacute;tica de funcio
namento, por meio de coleta de dados em telefichas pr&eacute;-especificadas pree
nchidas de forma eletr&ocirc;nica, id&ecirc;nticas para todos os centros partici
pantes, j&aacute; foi descrita anteriormente<sup>10</sup>. Os dados acerca das I
CP passaram a ser coletados em 1992. Vale ressaltar que os novos instrumentos pe
rcut&acirc;neos, distintos da angioplastia coronariana com bal&atilde;o, foram i
ncorporados a partir do segundo semestre de 1995. </font></p>     ^cY#aop01511.h
tm##
01540000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704129600085002001301381#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#30#26#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Para a an&aacute;lise, fora
m utilizados os dados relacionados &agrave;s ICP efetivadas entre os anos de 200
5 e 2008. Adotaram-se os seguintes crit&eacute;rios e defini&ccedil;&otilde;es, 
estabelecidos pela CENIC, mas julgados pelos operadores: via de acesso (femoral,
 radial ou braquial); sucesso do procedimento (obten&ccedil;&atilde;o de les&ati
lde;o residual inferior a 50% nas interven&ccedil;&otilde;es sem o uso de <i>ste
nts</i> coron&aacute;rios e &lt; 30% naquelas em que se empregaram as endopr&oac
ute;teses); ocorr&ecirc;ncia de desfechos adversos graves at&eacute; o final da 
interna&ccedil;&atilde;o hospitalar - &oacute;bito, oclus&atilde;o aguda do vaso
 - (verifica&ccedil;&atilde;o de oclus&atilde;o do vaso dilatado at&eacute; 24h 
ap&oacute;s o procedimento); reinfarto; cirurgia de emerg&ecirc;ncia (realizada 
em decorr&ecirc;ncia de oclus&atilde;o aguda ou subaguda do vaso-alvo nas primei
ras 24h ap&oacute;s o procedimento ou desencadeada por outras modalidades de ins
ucesso da angioplastia, acompanhadas de isquemia aguda do mioc&aacute;rdio) e ou
tras complica&ccedil;&otilde;es (vasculares, com ou sem necessidade de transfus&
atilde;o sangu&iacute;nea e acidente vascular encef&aacute;lico). </font></p>   
  ^cY#aop01511.htm##
00934000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704069000085002001300775#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#31#27#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise estat&iacu
te;stica foi realizada com o programa de <i>software</i> SPSS, vers&atilde;o 12.
0 (SPSS Inc., Chicago, IL, USA). As vari&aacute;veis cont&iacute;nuas foram expr
essas em m&eacute;dia e desvio padr&atilde;o; as categ&oacute;ricas, em n&uacute
;meros absolutos e em percentual. A an&aacute;lise univariada das vari&aacute;ve
is categ&oacute;ricas foi efetivada por meio do teste qui-quadrado ou teste exat
o de Fisher; as vari&aacute;veis cont&iacute;nuas foram analisadas por meio do t
este <i>t </i>de <i>Student</i>. Foram considerados significativos os valores de
 p <u>&lt;</u> 0,05.</font></p>     ^cY#aop01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#32#28#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#33#29#article#103#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop01511.htm##
00521000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027700085002001300362#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#34#30#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Entre 1º de janeiro de 2005
 e 31 de dezembro de 2008, foram cadastradas, respectivamente, em cada ano: 27.2
66, 19.410, 21.321 e 15.379 ICP, totalizando 83.376 procedimentos no quadri&ecir
c;nio. </font></p>     ^cY#aop01511.htm##
00738000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049400085002001300579#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#35#31#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A utiliza&ccedil;&atilde;o 
da t&eacute;cnica radial no per&iacute;odo foi de 12,7% em 2005, 14,9% em 2006, 
11,2% em 2007 e 14% em 2008, perfazendo 10.555 procedimentos (<a href="/img/revi
stas/abc/2011nahead/aop01511fig01m.jpg">Figura 1</a>). Desses, a taxa de sucesso
 obtida foi de 97,5%, com 2,5% de complica&ccedil;&otilde;es vasculares, 0,4% de
 mortalidade, 0,3% de reinfarto e 0,04% de cirurgia emergencial.</font></p>     
^cY#aop01511.htm##
00744000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704050000085002001300585#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#36#32#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Comparado ao acesso femoral
 na realiza&ccedil;&atilde;o de ICP, o acesso radial associou-se &agrave; signif
icativa redu&ccedil;&atilde;o de complica&ccedil;&otilde;es vasculares, achado c
onsistente nos quatro anos analisados (<a href="/img/revistas/abc/2011nahead/aop
01511tab01m.jpg">Tabela 1</a>) bem como entre pacientes submetidos &agrave; ICP 
eletiva, prim&aacute;ria ou de resgate (<a href="#tab2">Tabela 2</a>).</font></p
>     ^cY#aop01511.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#37#33#article#103#<p><a name
="tab2"></a></p>     ^cY#aop01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#38#34#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#39#35#article#103#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01511tab02.jpg"></p>     ^cY#a
op01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#40#36#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00708000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046400085002001300549#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#41#37#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A constata&ccedil;&atilde;o
 na presente casu&iacute;stica de maior taxa de sucesso do procedimento, seja em
 car&aacute;ter eletivo, seja emergencial, e de redu&ccedil;&atilde;o de mortali
dade favor&aacute;veis &agrave; t&eacute;cnica radial refletem possivelmente a s
ele&ccedil;&atilde;o de pacientes com menor grau de complexidade e gravidade par
a o emprego dessa t&eacute;cnica. </font></p>     ^cY#aop01511.htm##
00620000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037600085002001300461#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#42#38#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O acesso femoral permanece 
a via preferencial para realiza&ccedil;&atilde;o de ICP no Brasil, com utiliza&c
cedil;&atilde;o em 84,3% dos casos. Desses, 3,6% s&atilde;o de complica&ccedil;&
otilde;es vasculares; 0,9%, de mortalidade; 0,4%, de reinfarto; e 0,06%, de ciru
rgia de emerg&ecirc;ncia. </font></p>     ^cY#aop01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#43#39#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#44#40#article#103#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop01511.htm##
01241000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099700085002001301082#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#45#41#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As estat&iacute;sticas alus
ivas ao quadri&ecirc;nio 2005-2008 apontam um discreto aumento no percentual de 
utiliza&ccedil;&atilde;o do acesso radial na realiza&ccedil;&atilde;o de ICP no 
Brasil, com eleva&ccedil;&atilde;o de 8% para 12,6% dos procedimentos, com queda
 concomitante de 90% para 84,3% de emprego da t&eacute;cnica femoral. Atestam ta
mb&eacute;m a superioridade do acesso radial na redu&ccedil;&atilde;o de complic
a&ccedil;&otilde;es vasculares, em conformidade com grandes casu&iacute;sticas c
omparativas entre as vias de acesso<sup>4,5</sup>. Os achados de maior taxa de s
ucesso e menor mortalidade hospitalar favor&aacute;veis &agrave; t&eacute;cnica 
refletem a poss&iacute;vel presen&ccedil;a de fatores n&atilde;o mensur&aacute;v
eis nesta an&aacute;lise, como sele&ccedil;&atilde;o de pacientes de menor gravi
dade cl&iacute;nica e grau de complexidade do procedimento na escolha do acesso 
radial.</font></p>     ^cY#aop01511.htm##
01066000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704082200085002001300907#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#46#42#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Gra&ccedil;as ao advento de
 dispositivos de oclus&atilde;o femoral, utiliza&ccedil;&atilde;o de introdutore
s e cateteres de menor di&acirc;metro e f&aacute;rmacos anticoagulantes com melh
or perfil de seguran&ccedil;a, a preval&ecirc;ncia de complica&ccedil;&otilde;es
 vasculares relacionadas &agrave; realiza&ccedil;&atilde;o de procedimentos coro
n&aacute;rios invasivos pela t&eacute;cnica femoral declinou na &uacute;ltima d&
eacute;cada<sup>11</sup>. Ainda assim, essa t&eacute;cnica sobrep&otilde;e-se &a
grave;quela observada com a t&eacute;cnica radial, sobretudo entre mulheres, ido
sos, portadores de doen&ccedil;a renal cr&ocirc;nica e pacientes submetidos &agr
ave; ICP na vig&ecirc;ncia de s&iacute;ndromes isqu&ecirc;micas agudas. </font><
/p>     ^cY#aop01511.htm##
01427000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704118300085002001301268#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#47#43#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Sabe-se que a ocorr&ecirc;n
cia de sangramento grave exibe estreita correla&ccedil;&atilde;o progn&oacute;st
ica, decorrente de maior mortalidade precoce e tardia<sup>12</sup>, e que compli
ca&ccedil;&otilde;es relacionadas &agrave; via de acesso arterial preponderam en
tre as principais causas de sangramento grave em ICP e s&iacute;ndromes isqu&eci
rc;micas agudas<sup>13</sup>. A op&ccedil;&atilde;o pelo acesso radial represent
aria uma medida simples e eficaz na redu&ccedil;&atilde;o desse desfecho. De fat
o, na meta-an&aacute;lise que envolveu 7.020 pacientes, esse desfecho demonstrou
 redu&ccedil;&atilde;o significativa de 73% na ocorr&ecirc;ncia de sangramento g
rave quando comparado &agrave; t&eacute;cnica femoral (0,05% <i>versus </i>2,3%,
 p &lt; 0,001)<sup>5</sup>. Achados semelhantes foram reportados em um registro 
canadense avaliando 38.872 ICP, em que o acesso radial promoveu redu&ccedil;&ati
lde;o significativa da necessidade de transfus&atilde;o (1,4% <i>versus </i>2,8%
, p &lt; 0,01), bem como de mortalidade aos trinta dias e um ano (RR = 0,83, IC 
de 95%: 0,71-0,98)<sup>14</sup>. </font></p>     ^cY#aop01511.htm##
00731000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048700085002001300572#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#48#44#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m dos benef&iacut
e;cios proporcionados na redu&ccedil;&atilde;o de complica&ccedil;&otilde;es vas
culares, sangramento grave e necessidade de transfus&atilde;o, o acesso radial a
ssocia-se ainda a maior conforto e prefer&ecirc;ncia por parte do paciente, poss
ibilidade de deambula&ccedil;&atilde;o precoce, redu&ccedil;&atilde;o do tempo d
e perman&ecirc;ncia hospitalar e dos custos<sup>15</sup>.</font></p>     ^cY#aop
01511.htm##
01368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704112400085002001301209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#49#45#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Diante do exposto, quais se
riam as raz&otilde;es para a baixa penetra&ccedil;&atilde;o atual do acesso radi
al? Dados do <i>National Cardiovascular Data Registry</i> (NCDC), que engloba ma
is de 2.400 hospitais norte-americanos, demonstram que seu emprego entre 2004-20
07 situou-se ao redor de 1,32%<sup>16</sup>, passando a apenas 2,3% entre 2005-2
009<sup>13</sup>. S&atilde;o poss&iacute;veis justificativas para esses achados 
estat&iacute;sticos: aus&ecirc;ncia de programas de treinamento e difus&atilde;o
 de conhecimentos acerca da t&eacute;cnica voltados a intervencionistas em ativi
dade e em forma&ccedil;&atilde;o<sup>17</sup>; incertezas quanto &agrave; curva 
de aprendizagem<sup>18</sup>, que, por sua vez, estaria associada &agrave; maior
 taxa de fal&ecirc;ncia da t&eacute;cnica e &agrave; maior exposi&ccedil;&atilde
;o radiol&oacute;gica<sup>19</sup>; car&ecirc;ncia de estudos em larga escala, m
ultic&ecirc;ntricos, capazes de reproduzir os excelentes resultados obtidos em c
entros dotados de grande experi&ecirc;ncia com a via. </font></p>     ^cY#aop015
11.htm##
00875000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063100085002001300716#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#50#46#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Com base nesses dados, pode
-se dizer que, al&eacute;m da reformula&ccedil;&atilde;o de programas de qualifi
ca&ccedil;&atilde;o profissional administrados por centros de treinamento devida
mente cadastrados e credenciados, grandes ensaios randomizados com casu&iacute;s
tica adequada e capazes de demonstrar redu&ccedil;&atilde;o de mortalidade e eve
ntos isqu&ecirc;micos com a utiliza&ccedil;&atilde;o do acesso radial se mostram
 necess&aacute;rios, para que se possa instituir uma mudan&ccedil;a no perfil da
 pr&aacute;tica intervencionista vigente.</font></p>     ^cY#aop01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#51#47#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#52#48#article#103#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Limita&ccedil;&otilde;es
</b></font></p>     ^cY#aop01511.htm##
01273000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704102900085002001301114#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#53#49#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O registro CENIC possibilit
a a an&aacute;lise de um grande n&uacute;mero consecutivo de pacientes submetido
s a ICP no pa&iacute;s. Contudo, por se tratar de um registro, apresenta limita&
ccedil;&otilde;es: o envio de dados &eacute; espont&acirc;neo, porque n&atilde;o
 contempla a totalidade de procedimentos efetivados no per&iacute;odo, embora o 
elevado n&uacute;mero de interven&ccedil;&otilde;es cadastradas, superior a 83.0
00, valide o estudo como representativo da realidade brasileira. Outras limita&c
cedil;&otilde;es podem ser relacionadas: o julgamento no preenchimento dos dados
, a despeito da normatiza&ccedil;&atilde;o existente, fica a crit&eacute;rio do 
operador; vari&aacute;veis relacionadas &agrave;s complexidades cl&iacute;nica e
 anat&ocirc;mica dos casos n&atilde;o foram aferidas, impossibilitando a compara
&ccedil;&atilde;o criteriosa no que tange ao sucesso do procedimento e &agrave; 
ocorr&ecirc;ncia de desfechos adversos.</font></p>     ^cY#aop01511.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#54#50#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Potencial Conflito de In
teresses</b></font></p>     ^cY#aop01511.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014300085002001300228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#55#51#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Declaro n&atilde;o haver co
nflito de interesses pertinentes.</font></p>     ^cY#aop01511.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#56#52#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01511.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015000085002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#57#53#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo n&atilde;
o teve fontes de financiamento externas.</font></p>     ^cY#aop01511.htm##
00374000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013000085002001300215#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#58#54#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vincula&ccedil;&atilde;o
 Acad&ecirc;mica</b></font></p>     ^cY#aop01511.htm##
00436000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019200085002001300277#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#59#55#article#103#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; vincul
a&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atilde;
o.</font></p>     ^cY#aop01511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#60#56#article#103#<p>&nbsp;<
/p>     ^cY#aop01511.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#61#57#article#103#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01511.htm##
00479000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022100087002001300308#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#62#58#article#10
3#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.	Radner S. 
Thoracal aortography by catheterization from the radial artery; preliminary repo
rt of a new technique. Acta Radiol. 1948; 29 (2): 178-80.    ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#63#59#article#103#</font></p
>     ^cY#aop01511.htm##
00448000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704019000087002001300277#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#64#60#article#10
3#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2.	Campeau L.
 Percutaneous radial artery approach for coronary angiography. Cathet Cardiovasc
 Diagn. 1989; 16 (1): 3-7.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#65#61#article#103# </font></
p>     ^cY#aop01511.htm##
00476000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704021800087002001300305#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#66#62#article#10
3#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3.	Kiemeneij 
F, Laarman GJ. Percutaneous transradial artery approach for coronary stent impla
ntation. Cathet Cardiovasc Diagn. 1993; 30 (2): 173-8.    ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#67#63#article#103#</font></p
>     ^cY#aop01511.htm##
00620000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704036200087002001300449#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#68#64#article#10
3#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4.	Agostoni P
, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M, et al. R
adial versus femoral approach for percutaneous coronary diagnostic and intervent
ional procedures; systematic overview and meta-analysis of randomized trials. J 
Am Coll Cardiol. 2004; 44 (2): 349-56.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#69#65#article#103# </font></
p>     ^cY#aop01511.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704034000087002001300427#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#70#66#article#10
3#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5.	Jolly SS, 
Amlani S, Hamon M, Yusuf S, Mehta SR. Radial versus femoral access for coronary 
angiography or intervention and the impact on major bleeding and ischemic events
: a systematic review and meta-analysis of randomized trials. Am Heart J. 2009; 
157 (1): 132-40.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#71#67#article#103# </font></
p>     ^cY#aop01511.htm##
00654000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704039600087002001300483#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#72#68#article#10
3#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6.	Mattos LA,
 Lemos Neto PA, Rassi A Jr, Marin-Neto JA, Sousa AGMR, Devito FS, et al. / Socie
dade Brasileira de Cardiologia. Diretrizes sobre interven&ccedil;&atilde;o coron
&aacute;ria percut&acirc;nea e m&eacute;todos adjuntos diagn&oacute;sticos em ca
rdiologia intervencionista. Arq Bras Cardiol. 2008; 91 (6 supl.1): 1-58.    ^cY#
aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#73#69#article#103# </font></
p>     ^cY#aop01511.htm##
00719000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704046100087002001300548#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#74#70#article#10
3#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7.	Sousa AG, 
Mattos LA, Campos Neto CM, Carvalho HG, Stella FP, Nunes G. Interven&ccedil;&oti
lde;es percut&acirc;neas para revasculariza&ccedil;&atilde;o do mioc&aacute;rdio
 no Brasil em 1996 e 1997 comparadas &agrave;s do bi&ecirc;nio 1992 e 1993. Rela
t&oacute;rio do Registro CENIC (Central Nacional de Interven&ccedil;&otilde;es C
ardiovasculares). Arq Bras Cardiol. 1998; 70 (6): 423-30.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#75#71#article#103# </font></
p>     ^cY#aop01511.htm##
00608000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704035000087002001300437#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#76#72#article#10
3#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8.	Mattos LA,
 Sousa AGMR, Pinto IMF, Campos Neto CM, Labrunie A, Alves CR et al. Primary coro
nary angioplasty in 9,434 patients during acute myocardial infarction: predictor
s of major in-hospital adverse events from 1996 to 2000 in Brazil. Arq Bras Card
iol. 2002; 79 (4): 405-18.    ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#77#73#article#103#</font></p
>     ^cY#aop01511.htm##
00661000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704040300087002001300490#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#78#74#article#10
3#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9.	Mattos LA,
 Sousa AGMR, Pinto IMF, Silva ER, Carneiro JK, Sousa JE, et al. Uma compara&cced
il;&atilde;o entre a interven&ccedil;&atilde;o coronariana percut&acirc;nea de r
esgate e prim&aacute;ria realizadas no infarto agudo do mioc&aacute;rdio: relato
 multic&ecirc;ntrico de 9.371 pacientes. Arq Bras Cardiol. 2004; 82 (5): 434-9. 
   ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#79#75#article#103# </font></
p>     ^cY#aop01511.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704033900088002001300427#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#80#76#article#10
3#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10.	Sousa AG
. Procedimentos percut&acirc;neos de interven&ccedil;&atilde;o cardiovascular no
 Brasil em 1992 e 1993. Relat&oacute;rio do Registro Nacional - Central Nacional
 de Interven&ccedil;&otilde;es Cardiovasculares (CENIC). Arq Bras Cardiol. 1994;
 62 (4): 217-23.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#81#77#article#103# </font></
p>     ^cY#aop01511.htm##
00590000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704033100088002001300419#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#82#78#article#10
3#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11.	Applegat
e RJ, Sacrinty MT, Kutcher MA, Kahl FR, Gandhi SK, Santos RM, et al. Trends in v
ascular complications after diagnostic cardiac and percutaneous coronary interve
ntion via the femoral artery, 1998 to 2007. JACC Cardiovasc Interv. 2008; 1 (3):
 317-26.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#83#79#article#103# </font></
p>     ^cY#aop01511.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704030000088002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#84#80#article#10
3#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12.	Doyle BJ
, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increas
ed mortality after percutaneous coronary intervention: implications for contempo
rary practice. J Am Coll Cardiol. 2009; 53 (22): 2019-27.    ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#85#81#article#103#</font></p
>     ^cY#aop01511.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704029200088002001300380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#86#82#article#10
3#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13.	Roe MT, 
Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, et al. Treatments, tre
nds, and outcomes of acute myocardial infarction and percutaneous coronary inter
vention. J Am Coll Cardiol. 2010; 56 (4): 254-63.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#87#83#article#103# </font></
p>     ^cY#aop01511.htm##
00645000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704038600088002001300474#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#88#84#article#10
3#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14.	Chase AJ
, Fretz EB, Warburton WP, Klinke WP, Carere RG, Pi D, et al. Association of the 
arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.
A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary 
intervention via the Arm or Leg). Heart. 2008; 94 (8): 1019-25.    ^cY#aop01511.
htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#89#85#article#103# </font></
p>     ^cY#aop01511.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704029800088002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#90#86#article#10
3#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15.	Cooper C
J, El-Shiekh RA, Cohen DJ, Blaesing L, Burket MW, Basuet A, et al. Effect of tra
nsradial access on quality of life and cost of cardiac catheterization: a random
ized comparison. Am Heart J. 1999; 138 (3 pt 1): 430-6.    ^cY#aop01511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#91#87#article#103# </font></
p>     ^cY#aop01511.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704029200088002001300380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#92#88#article#10
3#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16.	Rao SV, 
Ou FS, Wang TY, Roe MT, Brindis R, Rumsfeld JS, et al. Trends in the prevalence 
and outcomes of radial and femoral approaches to percutaneous coronary intervent
ion. JACC Cardiovasc Interv. 2008; 1 (4): 379-86.    ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#93#89#article#103#</font></p
>     ^cY#aop01511.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704030400088002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#94#90#article#10
3#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17.	Rao SV, 
Cohen MG, Kandzari DE, Bertrand OF, Gilchrist IC. The transradial approach to pe
rcutaneous coronary intervention: historical perspective, current concepts, and 
future directions. J Am Coll Cardiol. 2010; 55 (20): 2187-95.    ^cY#aop01511.ht
m##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#95#91#article#103#</font></p
>     ^cY#aop01511.htm##
00460000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704020100088002001300289#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#96#92#article#10
3#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18.	Louvard 
Y, Lefevre T, Morice MC. Radial approach: what about the learning curve? Cathet 
Cardiovasc Diagn. 1997; 42 (4): 467-8.    ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#97#93#article#103#</font></p
>     ^cY#aop01511.htm##
00639000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704038000088002001300468#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#98#94#article#10
3#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19.	Brassele
t C, Blanpain T, Tassan-Mangina S, Deschildre A, Duval S, Vitry F, et al. Compar
ison of operator radiation exposure with optimized radiation protection devices 
during coronary angiograms and ad hoc percutaneous coronary interventions by rad
ial and femoral routes. Eur Heart J. 2008; 29 (1): 63-70.    ^cY#aop01511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#99#95#article#103#</font></p
>     ^cY#aop01511.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002200086002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#100#96#article#103#<p>&nbsp;
</p>     ^cY#aop01511.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002200086002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#101#97#article#103#<p>&nbsp;
</p>     ^cY#aop01511.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704020000086002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#102#98#article#103#<p><a nam
e="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href
="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg"border="0"></a> <b>Corr
espond&ecirc;ncia: </b>    ^cY#aop01511.htm##
00285000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704004000086002001300126#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#103#99#article#103#<br>   Pe
dro Beraldo de Andrade     ^cY#aop01511.htm##
00307000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006100087002001300148#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#104#100#article#103#<br>   P
ra&ccedil;a Athos Fragata, 25/1101 - Fragata     ^cY#aop01511.htm##
00301000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005500087002001300142#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#105#101#article#103#<br>   1
7501-220 - Mar&iacute;lia, SP - Brasil     ^cY#aop01511.htm##
00417000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704017100087002001300258#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#106#102#article#103#<br>   E
-mail: <a href="mailto:pedroberaldo@gmail.com">pedroberaldo@gmail.com</a>, <a hr
ef="mailto:pedroberaldo@cardiol.br">pedroberaldo@cardiol.br</a></font></p>     ^
cY#aop01511.htm##
00408000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016200087002001300249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01511.htm#S#p#107#103#article#103#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 11/08/
10; revisado recebido em 12/08/10; aceito em 14/09/10.</font></p>     ^cY#aop015
11.htm##
00568000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860120106001020300
01200208065000900220064000500229031000300234032000200237014000700239865000900246
002001300255035001000268801001200278#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01511.htm#S#c#108#1#article#19#1#^rND^sRadner^nS#Thoracal aortography 
by catheterization from the radial artery; preliminary report of a new technique
^len#Acta Radiol#19480000#1948#29#2#178-80#20110000#aop01511.htm#0001-6926#Acta 
Radiol##
00549000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860120065001030300
02400168065000900192064000500201031000300206032000200209014000400211865000900215
002001300224035001000237801002400247#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01511.htm#S#c#109#2#article#19#2#^rND^sCampeau^nL#Percutaneous radial 
artery approach for coronary angiography^len#Cathet Cardiovasc Diagn#19890000#19
89#16#1#3-7#20110000#aop01511.htm#0098-6569#Cathet Cardiovasc Diagn##
00595000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100018001050120
07700123030002400200065000900224064000500233031000300238032000200241014000600243
865000900249002001300258035001000271801002400281#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01511.htm#S#c#110#3#article#19#3#^rND^sKiemeneij^nF#^rND^s
Laarman^nGJ#Percutaneous transradial artery approach for coronary stent implanta
tion^len#Cathet Cardiovasc Diagn#19930000#1993#30#2#173-8#20110000#aop01511.htm#
0098-6569#Cathet Cardiovasc Diagn##
00816000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100024001040100
02400128010002000152010001500172010001700187810000600204012016200210030001800372
06500090039006400050039903100030040403200020040701400070040986500090041600200130
0425035001000438801001800448#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01511.htm#S#c#111#4#article#19#4#^rND^sAgostoni^nP#^rND^sBiondi-Zoccai^nGG#^rN
D^sde Benedictis^nML#^rND^sRigattieri^nS#^rND^sTurri^nM#^rND^sAnselmi^nM#et al#R
adial versus femoral approach for percutaneous coronary diagnostic and intervent
ional procedures; systematic overview and meta-analysis of randomized trials^len
#J Am Coll Cardiol#20040000#2004#44#2#349-56#20110000#aop01511.htm#0735-1097#J A
m Coll Cardiol##
00758000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020100
01500118010001500133010001600148012018700164030001100351065000900362064000500371
03100040037603200020038001400070038286500090038900200130039803500100041180100110
0421#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#c#112#5#ar
ticle#19#5#^rND^sJolly^nSS#^rND^sAmlani^nS#^rND^sHamon^nM#^rND^sYusuf^nS#^rND^sM
ehta^nSR#Radial versus femoral access for coronary angiography or intervention a
nd the impact on major bleeding and ischemic events: a systematic review and met
a-analysis of randomized trials^len#Am Heart J#20090000#2009#157#1#132-40#201100
00#aop01511.htm#0002-8703#Am Heart J##
00765000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100021001030100
01800124010002100142010001800163010001700181810000600198012011800204030001700322
06500090033906400050034803100030035303200050035601400050036186500090036600200130
0375035001000388801001700398#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01511.htm#S#c#113#6#article#19#6#^rND^sMattos^nLA#^rND^sLemos Neto^nPA#^rND^sR
assi^nA Jr#^rND^sMarin-Neto^nJA#^rND^sSousa^nAGMR#^rND^sDevito^nFS#et al#Diretri
zes sobre intervenção coronária percutânea e métodos adjuntos diagnósticos em ca
rdiologia intervencionista^lpt#Arq Bras Cardiol#20080000#2008#91#6^s1#1-58#20110
000#aop01511.htm#0066-782X#Arq Bras Cardiol##
00828000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100017001020100
02200119010001900141010001700160010001500177012020600192030001700398065000900415
06400050042403100030042903200020043201400070043486500090044100200130045003500100
0463801001700473#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#
S#c#114#7#article#19#7#^rND^sSousa^nAG#^rND^sMattos^nLA#^rND^sCampos Neto^nCM#^r
ND^sCarvalho^nHG#^rND^sStella^nFP#^rND^sNunes^nG#Intervenções percutâneas para r
evascularização do miocárdio no Brasil em 1996 e 1997 comparadas às do biênio 19
92 e 1993: Relatório do Registro CENIC (Central Nacional de Intervenções Cardiov
asculares)^lpt#Arq Bras Cardiol#19980000#1998#70#6#423-30#20110000#aop01511.htm#
0066-782X#Arq Bras Cardiol##
00804000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030100
01700121010002200138010001800160010001600178810000600194012016200200030001700362
06500090037906400050038803100030039303200020039601400070039886500090040500200130
0414035001000427801001700437#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01511.htm#S#c#115#8#article#19#8#^rND^sMattos^nLA#^rND^sSousa^nAGMR#^rND^sPint
o^nIMF#^rND^sCampos Neto^nCM#^rND^sLabrunie^nA#^rND^sAlves^nCR#et al#Primary cor
onary angioplasty in 9,434 patients during acute myocardial infarction: predicto
rs of major in-hospital adverse events from 1996 to 2000 in Brazil^len#Arq Bras 
Cardiol#20020000#2002#79#4#405-18#20110000#aop01511.htm#0066-782X#Arq Bras Cardi
ol##
00802000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030100
01700121010001600138010001900154010001600173810000600189012016600195030001700361
06500090037806400050038703100030039203200020039501400060039786500090040300200130
0412035001000425801001700435#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01511.htm#S#c#116#9#article#19#9#^rND^sMattos^nLA#^rND^sSousa^nAGMR#^rND^sPint
o^nIMF#^rND^sSilva^nER#^rND^sCarneiro^nJK#^rND^sSousa^nJE#et al#Uma comparação e
ntre a intervenção coronariana percutânea de resgate e primária realizadas no in
farto agudo do miocárdio: relato multicêntrico de 9.371 pacientes^lpt#Arq Bras C
ardiol#20040000#2004#82#5#434-9#20110000#aop01511.htm#0066-782X#Arq Bras Cardiol
##
00651000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120177001040300
01700281065000900298064000500307031000300312032000200315014000700317865000900324
002001300333035001000346801001700356#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01511.htm#S#c#117#10#article#19#10#^rND^sSousa^nAG#Procedimentos percu
tâneos de intervenção cardiovascular no Brasil em 1992 e 1993: Relatório do Regi
stro Nacional - Central Nacional de Intervenções Cardiovasculares (CENIC)^lpt#Ar
q Bras Cardiol#19940000#1994#62#4#217-23#20110000#aop01511.htm#0066-782X#Arq Bra
s Cardiol##
00748000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100019001080100
01800127010001500145010001700160010001700177810000600194012013800200030002300338
71000020036106500090036306400050037203100020037703200020037901400070038186500090
0388002001300397#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#
S#c#118#11#article#19#11#^rND^sApplegate^nRJ#^rND^sSacrinty^nMT#^rND^sKutcher^nM
A#^rND^sKahl^nFR#^rND^sGandhi^nSK#^rND^sSantos^nRM#et al#Trends in vascular comp
lications after diagnostic cardiac and percutaneous coronary intervention via th
e femoral artery, 1998 to 2007^len#JACC Cardiovasc Interv#2#20080000#2008#1#3#31
7-26#20110000#aop01511.htm##
00708000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
02000120010002000140012013800160030001800298065000900316064000500325031000300330
032000300333014000800336865000900344002001300353035001000366801001800376#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#c#119#12#article#19#12
#^rND^sDoyle^nBJ#^rND^sRihal^nCS#^rND^sGastineau^nDA#^rND^sHolmes Jr^nDR#Bleedin
g, blood transfusion, and increased mortality after percutaneous coronary interv
ention: implications for contemporary practice^len#J Am Coll Cardiol#20090000#20
09#53#22#2019-27#20110000#aop01511.htm#0735-1097#J Am Coll Cardiol##
00747000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100020001020100
02000122010001700142010001800159010001300177810000600190012010700196030001800303
06500090032106400050033003100030033503200020033801400070034086500090034700200130
0356035001000369801001800379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01511.htm#S#c#120#13#article#19#13#^rND^sRoe^nMT#^rND^sMessenger^nJC#^rND^sWei
ntraub^nWS#^rND^sCannon^nCP#^rND^sFonarow^nGC#^rND^sDai^nD#et al#Treatments, tre
nds, and outcomes of acute myocardial infarction and percutaneous coronary inter
vention^len#J Am Coll Cardiol#20100000#2010#56#4#254-63#20110000#aop01511.htm#07
35-1097#J Am Coll Cardiol##
00829000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
02000120010001700140010001700157010001200174810000600186012021600192030000600408
06500090041406400050042303100030042803200020043101400080043386500090044100200130
0450035001000463801000600473#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01511.htm#S#c#121#14#article#19#14#^rND^sChase^nAJ#^rND^sFretz^nEB#^rND^sWarbu
rton^nWP#^rND^sKlinke^nWP#^rND^sCarere^nRG#^rND^sPi^nD#et al#Association of the 
arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.
A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary 
intervention via the Arm or Leg)^len#Heart#20080000#2008#94#8#1019-25#20110000#a
op01511.htm#1355-6037#Heart##
00755000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01600125010001800141010001700159010001600176810000600192012011300198030001100311
06500090032206400050033103100040033603200020034003400020034201400060034486500090
0350002001300359035001000372801001100382#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop01511.htm#S#c#122#15#article#19#15#^rND^sCooper^nCJ#^rND^sEl-Shiek
h^nRA#^rND^sCohen^nDJ#^rND^sBlaesing^nL#^rND^sBurket^nMW#^rND^sBasuet^nA#et al#E
ffect of transradial access on quality of life and cost of cardiac catheterizati
on: a randomized comparison^len#Am Heart J#19990000#1999#138#3#1#430-6#20110000#
aop01511.htm#0002-8703#Am Heart J##
00709000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100013001020100
01500115010001400130010001700144010001900161810000600180012011300186030002300299
71000020032206500090032406400050033303100020033803200020034001400070034286500090
0349002001300358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#
S#c#123#16#article#19#16#^rND^sRao^nSV#^rND^sOu^nFS#^rND^sWang^nTY#^rND^sRoe^nMT
#^rND^sBrindis^nR#^rND^sRumsfeld^nJS#et al#Trends in the prevalence and outcomes
 of radial and femoral approaches to percutaneous coronary intervention^len#JACC
 Cardiovasc Interv#2#20080000#2008#1#4#379-86#20110000#aop01511.htm##
00730000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100016001020100
01900118010001900137010002000156012013200176030001800308065000900326064000500335
03100030034003200030034301400080034686500090035400200130036303500100037680100180
0386#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01511.htm#S#c#124#17#a
rticle#19#17#^rND^sRao^nSV#^rND^sCohen^nMG#^rND^sKandzari^nDE#^rND^sBertrand^nOF
#^rND^sGilchrist^nIC#The transradial approach to percutaneous coronary intervent
ion: historical perspective, current concepts, and future directions^len#J Am Co
ll Cardiol#20100000#2010#55#20#2187-95#20110000#aop01511.htm#0735-1097#J Am Coll
 Cardiol##
00598000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01700122012005200139030002400191065000900215064000500224031000300229032000200232
014000600234865000900240002001300249035001000262801002400272#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01511.htm#S#c#125#18#article#19#18#^rND^sLouva
rd^nY#^rND^sLefevre^nT#^rND^sMorice^nMC#Radial approach: what about the learning
 curve?^len#Cathet Cardiovasc Diagn#19970000#1997#42#4#467-8#20110000#aop01511.h
tm#0098-6569#Cathet Cardiovasc Diagn##
00829000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
02400125010002000149010001500169010001500184810000600199012019300205030001200398
06500090041006400050041903100030042403200020042701400060042986500090043500200130
0444035001000457801001200467#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01511.htm#S#c#126#19#article#19#19#^rND^sBrasselet^nC#^rND^sBlanpain^nT#^rND^s
Tassan-Mangina^nS#^rND^sDeschildre^nA#^rND^sDuval^nS#^rND^sVitry^nF#et al#Compar
ison of operator radiation exposure with optimized radiation protection devices 
during coronary angiograms and ad hoc percutaneous coronary interventions by rad
ial and femoral routes^len#Eur Heart J#20080000#2008#29#1#63-70#20110000#aop0151
1.htm#0195-668X#Eur Heart J##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#o#1#1#
article#1#20110331#080939#aop01611.htm#270##
04107000000000601000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200680
01780120070002460100035003160100037003510700061003880831382004490850008018310850
02401839085002201863085002301885083144101908085000803349085002503357085002103382
08500240340311700080342707200030343511200090343811100090344711600090345611500090
3465114000903474113000903483002001303492#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop01611.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#25#nd#nd#Ar
q. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110304#Hipotensão pós-exercí
cio em indivíduos hipertensos: uma revisão^lpt#A review on post-exercise hypoten
sion in hypertensive individuals^len#^rND^1A01^nPaulo Gomes^sAnunciação#^rND^1A0
1^nMarcos Doederlein^sPolito#Universidade Estadual de Londrina^iA01^cLondrina^sP
R^pBrasil#^lpt^aApós uma sessão de exercícios físicos, pode ocorrer hipotensão p
ós-exercício (HPE). Esse efeito possui elevada relevância clínica em hipertensos
. Embora a literatura reporte vários estudos sobre o tema, ainda falta uma análi
se sobre o estado da arte, considerando-se os diferentes tipos de exercícios. As
sim, o objetivo deste estudo foi verificar, por meio de uma revisão na literatur
a, a relação entre o exercício aeróbio e o resistido na HPE em hipertensos. Para
 tanto, realizaram-se buscas nas bases Scielo e Medline, considerando os estudos
 em inglês e a amostra de humanos adultos hipertensos os principais critérios de
 inclusão. Foram encontrados 126 estudos. Porém, fizeram parte das análises 32 a
rtigos, dos quais cinco envolveram o exercício resistido, e 27, o exercício aeró
bio. Sobre o exercício resistido, embora os estudos utilizassem modelos diferent
es de prescrição, houve HPE principalmente no ambiente laboratorial. Após o exer
cício aeróbio, observou-se HPE por maiores períodos de tempo. Contudo, ocorrem c
onflitos sobre a melhor intensidade e duração para a prescrição dessa atividade.
 Portanto, aparentemente, ocorrem maiores reduções na pressão arterial após o ex
ercício aeróbio em comparação com o exercício resistido em hipertensos. Não obst
ante, para maiores conclusões, são necessários estudos que acompanhem a pressão 
arterial de forma ambulatorial.#^dnd^i1#^tm^lpt^kHipertensão^i1#^tm^lpt^kexercíc
io^i1#^tm^lpt^khipotensão^i1#^len^aPost-exercise hypotension (PEH) may follow a 
session of physical exercises. This effect has high clinical relevance for hyper
tensive individuals. Although there are several studies on the subject, an analy
sis is still lacking on a state-of-art approach considering different types of e
xercises. Using a review of literature, the aim of this paper was to verify the 
relationship between aerobic exercise and resistance exercise in PEH in hyperten
sive people. For the purpose of this study, Scielo and Medlinedatabases were sur
veyed, and the main inclusion criteria were studies on the subject in English la
nguage and a sample of hypertensive adults. One hundred and twenty-six studies w
ere found. However, only 32 papers, 5 of which on resistance exercise and 27 on 
aerobic exercise were used for this study. Although the studies surveyed used di
fferent prescription models for resistance exercise, PEH was observed mainly in 
the laboratory setting. After aerobic exercise, it was noted that PEH occurred f
or longer periods. However, there are differences of opinion as to the best inte
nsity and duration of the exercise to be prescribed. Therefore, in hypertensive 
individuals declines in arterial pressure following aerobic exercise are apparen
tly greater than those observed with resistance exercise. Nevertheless, in order
 to achieve sounder conclusions, further studies on ambulatory blood pressure mo
nitoring should be conducted.#^dnd^i2#^tm^len^kHypertension^i2#^tm^len^kexercise
^i2#^tm^len^khypotension^i2#vancouv#64#20091002#02/10/09#20091211#11/12/09#20100
212#12/02/10#aop01611.htm##
04142000000000601000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200820
01780120077002600100035003370100037003720700061004090831396004700850008018660850
02401874085002201898085002301920083144101943085000803384085002503392085002103417
08500240343811700080346207200030347011200090347311100090348211600090349111500090
3500114000903509113000903518002001303527#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop01611.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#25#nd#nd#Ar
q. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110304#<b>Hipotensão pós-exe
rcício em indivíduos hipertensos</b>: <b>uma revisão</b>^lpt#<b>A review on post
-exercise hypotension in hypertensive individuals</b>^len#^rND^1A01^nPaulo Gomes
^sAnunciação#^rND^1A01^nMarcos Doederlein^sPolito#Universidade Estadual de Londr
ina^iA01^cLondrina^sPR^pBrasil#^lpt^aApós uma sessão de exercícios físicos, pode
 ocorrer hipotensão pós-exercício (HPE). Esse efeito possui elevada relevância c
línica em hipertensos. Embora a literatura reporte vários estudos sobre o tema, 
ainda falta uma análise sobre o estado da arte, considerando-se os diferentes ti
pos de exercícios. Assim, o objetivo deste estudo foi verificar, por meio de uma
 revisão na literatura, a relação entre o exercício aeróbio e o resistido na HPE
 em hipertensos. Para tanto, realizaram-se buscas nas bases <i>Scielo</i> e <i>M
edline</i>, considerando os estudos em inglês e a amostra de humanos adultos hip
ertensos os principais critérios de inclusão. Foram encontrados 126 estudos. Por
ém, fizeram parte das análises 32 artigos, dos quais cinco envolveram o exercíci
o resistido, e 27, o exercício aeróbio. Sobre o exercício resistido, embora os e
studos utilizassem modelos diferentes de prescrição, houve HPE principalmente no
 ambiente laboratorial. Após o exercício aeróbio, observou-se HPE por maiores pe
ríodos de tempo. Contudo, ocorrem conflitos sobre a melhor intensidade e duração
 para a prescrição dessa atividade. Portanto, aparentemente, ocorrem maiores red
uções na pressão arterial após o exercício aeróbio em comparação com o exercício
 resistido em hipertensos. Não obstante, para maiores conclusões, são necessário
s estudos que acompanhem a pressão arterial de forma ambulatorial.#^dnd^i1#^tm^l
pt^kHipertensão^i1#^tm^lpt^kexercício^i1#^tm^lpt^khipotensão^i1#^len^aPost-exerc
ise hypotension (PEH) may follow a session of physical exercises. This effect ha
s high clinical relevance for hypertensive individuals. Although there are sever
al studies on the subject, an analysis is still lacking on a state-of-art approa
ch considering different types of exercises. Using a review of literature, the a
im of this paper was to verify the relationship between aerobic exercise and res
istance exercise in PEH in hypertensive people. For the purpose of this study, S
cielo and Medlinedatabases were surveyed, and the main inclusion criteria were s
tudies on the subject in English language and a sample of hypertensive adults. O
ne hundred and twenty-six studies were found. However, only 32 papers, 5 of whic
h on resistance exercise and 27 on aerobic exercise were used for this study. Al
though the studies surveyed used different prescription models for resistance ex
ercise, PEH was observed mainly in the laboratory setting. After aerobic exercis
e, it was noted that PEH occurred for longer periods. However, there are differe
nces of opinion as to the best intensity and duration of the exercise to be pres
cribed. Therefore, in hypertensive individuals declines in arterial pressure fol
lowing aerobic exercise are apparently greater than those observed with resistan
ce exercise. Nevertheless, in order to achieve sounder conclusions, further stud
ies on ambulatory blood pressure monitoring should be conducted.#^dnd^i2#^tm^len
^kHypertension^i2#^tm^len^kexercise^i2#^tm^len^khypotension^i2#vancouv#64#200910
02#02/10/09#20091211#11/12/09#20100212#12/02/10#aop01611.htm##
04228000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120068001840120070002520100035003220100037003570700063003940831382004570850
00801839085002401847085002201871085002301893083144101916085000803357085002503365
08500210339008500240341111700080343507200030344311200090344611100090345511600090
3464115000903473114000903482113000903491002001303500008008903513#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#l#4#1#article#1#^a2011#oa#pt#b
r1.1#1#4.0#ilus#tab#25#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#
20110304#Hipotensão pós-exercício em indivíduos hipertensos: uma revisão^lpt#A r
eview on post-exercise hypotension in hypertensive individuals^len#^rND^1A01^nPa
ulo Gomes^sAnunciação#^rND^1A01^nMarcos Doederlein^sPolito#^iA01^1Universidade E
stadual de Londrina^cLondrina^sPR^pBrasil#^lpt^aApós uma sessão de exercícios fí
sicos, pode ocorrer hipotensão pós-exercício (HPE). Esse efeito possui elevada r
elevância clínica em hipertensos. Embora a literatura reporte vários estudos sob
re o tema, ainda falta uma análise sobre o estado da arte, considerando-se os di
ferentes tipos de exercícios. Assim, o objetivo deste estudo foi verificar, por 
meio de uma revisão na literatura, a relação entre o exercício aeróbio e o resis
tido na HPE em hipertensos. Para tanto, realizaram-se buscas nas bases Scielo e 
Medline, considerando os estudos em inglês e a amostra de humanos adultos hipert
ensos os principais critérios de inclusão. Foram encontrados 126 estudos. Porém,
 fizeram parte das análises 32 artigos, dos quais cinco envolveram o exercício r
esistido, e 27, o exercício aeróbio. Sobre o exercício resistido, embora os estu
dos utilizassem modelos diferentes de prescrição, houve HPE principalmente no am
biente laboratorial. Após o exercício aeróbio, observou-se HPE por maiores perío
dos de tempo. Contudo, ocorrem conflitos sobre a melhor intensidade e duração pa
ra a prescrição dessa atividade. Portanto, aparentemente, ocorrem maiores reduçõ
es na pressão arterial após o exercício aeróbio em comparação com o exercício re
sistido em hipertensos. Não obstante, para maiores conclusões, são necessários e
studos que acompanhem a pressão arterial de forma ambulatorial.#^dnd^i1#^tm^lpt^
kHipertensão^i1#^tm^lpt^kexercício^i1#^tm^lpt^khipotensão^i1#^len^aPost-exercise
 hypotension (PEH) may follow a session of physical exercises. This effect has h
igh clinical relevance for hypertensive individuals. Although there are several 
studies on the subject, an analysis is still lacking on a state-of-art approach 
considering different types of exercises. Using a review of literature, the aim 
of this paper was to verify the relationship between aerobic exercise and resist
ance exercise in PEH in hypertensive people. For the purpose of this study, Scie
lo and Medlinedatabases were surveyed, and the main inclusion criteria were stud
ies on the subject in English language and a sample of hypertensive adults. One 
hundred and twenty-six studies were found. However, only 32 papers, 5 of which o
n resistance exercise and 27 on aerobic exercise were used for this study. Altho
ugh the studies surveyed used different prescription models for resistance exerc
ise, PEH was observed mainly in the laboratory setting. After aerobic exercise, 
it was noted that PEH occurred for longer periods. However, there are difference
s of opinion as to the best intensity and duration of the exercise to be prescri
bed. Therefore, in hypertensive individuals declines in arterial pressure follow
ing aerobic exercise are apparently greater than those observed with resistance 
exercise. Nevertheless, in order to achieve sounder conclusions, further studies
 on ambulatory blood pressure monitoring should be conducted.#^dnd^i2#^tm^len^kH
ypertension^i2#^tm^len^kexercise^i2#^tm^len^khypotension^i2#vancouv#64#20091002#
02/10/09#20091211#11/12/09#20100212#12/02/10#aop01611.htm#Internet^ihttp://www.s
cielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000025##
00449000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704020700083002001300290#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#5#1#article#202#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Hipoten
s&atilde;o p&oacute;s-exerc&iacute;cio em indiv&iacute;duos hipertensos: uma rev
is&atilde;o</b></font></p>     ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#6#2#article#202#<p>&nbsp;</p
>     ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#7#3#article#202#<p>&nbsp;</p
>     ^cY#aop01611.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704015200083002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#8#4#article#202#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Paulo Gomes Anuncia&ccedil
;&atilde;o; Marcos Doederlein Polito</b></font></p>     ^cY#aop01611.htm##
00382000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704014000083002001300223#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#9#5#article#202#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"> Universidade Estadual de Lon
drina, Londrina, PR - Brasil</font></p>     ^cY#aop01611.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#10#6#article#202#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01611.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#11#7#article#202#<p>&nbsp;</
p>     ^cY#aop01611.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#12#8#article#202#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01611.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#13#9#article#202#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>    
 ^cY#aop01611.htm##
00699000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045500085002001300540#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#14#10#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s uma sess&atilde
;o de exerc&iacute;cios f&iacute;sicos, pode ocorrer hipotens&atilde;o p&oacute;
s-exerc&iacute;cio (HPE). Esse efeito possui elevada relev&acirc;ncia cl&iacute;
nica em hipertensos. Embora a literatura reporte v&aacute;rios estudos sobre o t
ema, ainda falta uma an&aacute;lise sobre o estado da arte, considerando-se os d
iferentes tipos de exerc&iacute;cios.    ^cY#aop01611.htm##
00452000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020800085002001300293#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#15#11#article#202#<br>   Ass
im, o objetivo deste estudo foi verificar, por meio de uma revis&atilde;o na lit
eratura, a rela&ccedil;&atilde;o entre o exerc&iacute;cio aer&oacute;bio e o res
istido na HPE em hipertensos.     ^cY#aop01611.htm##
01050000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080600085002001300891#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#16#12#article#202#<br>   Par
a tanto, realizaram-se buscas nas bases <i>Scielo</i> e <i>Medline</i>, consider
ando os estudos em ingl&ecirc;s e a amostra de humanos adultos hipertensos os pr
incipais crit&eacute;rios de inclus&atilde;o. Foram encontrados 126 estudos. Por
&eacute;m, fizeram parte das an&aacute;lises 32 artigos, dos quais cinco envolve
ram o exerc&iacute;cio resistido, e 27, o exerc&iacute;cio aer&oacute;bio. Sobre
 o exerc&iacute;cio resistido, embora os estudos utilizassem modelos diferentes 
de prescri&ccedil;&atilde;o, houve HPE principalmente no ambiente laboratorial. 
Ap&oacute;s o exerc&iacute;cio aer&oacute;bio, observou-se HPE por maiores per&i
acute;odos de tempo. Contudo, ocorrem conflitos sobre a melhor intensidade e dur
a&ccedil;&atilde;o para a prescri&ccedil;&atilde;o dessa atividade.     ^cY#aop0
1611.htm##
00640000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039600085002001300481#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#17#13#article#202#<br>   Por
tanto, aparentemente, ocorrem maiores redu&ccedil;&otilde;es na press&atilde;o a
rterial ap&oacute;s o exerc&iacute;cio aer&oacute;bio em compara&ccedil;&atilde;
o com o exerc&iacute;cio resistido em hipertensos. N&atilde;o obstante, para mai
ores conclus&otilde;es, s&atilde;o necess&aacute;rios estudos que acompanhem a p
ress&atilde;o arterial de forma ambulatorial. </font></p>     ^cY#aop01611.htm##
00429000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704018500085002001300270#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#18#14#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b> Hip
ertens&atilde;o, exerc&iacute;cio, hipotens&atilde;o.</font></p> <hr size="1" no
shade>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#19#15#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#20#16#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#21#17#article#202#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01611.htm##
01040000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079600085002001300881#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#22#18#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A hipertens&atilde;o arteri
al (HA) atinge parte significativa da popula&ccedil;&atilde;o adulta mundial<sup
>1</sup> e &eacute; fator de risco para doen&ccedil;as card&iacute;acas e disfun
&ccedil;&atilde;o renal<sup>2</sup>. Mudan&ccedil;as no estilo de vida, como red
u&ccedil;&atilde;o no consumo de &aacute;lcool e tabaco, h&aacute;bitos alimenta
res adequados e manuten&ccedil;&atilde;o do peso corporal, s&atilde;o sugeridas 
como preven&ccedil;&atilde;o e tratamento n&atilde;o medicamentoso da HA<sup>2,3
</sup>. Al&eacute;m desses fatores, a pr&aacute;tica regular de exerc&iacute;cio
s f&iacute;sicos &eacute; recomendada como meio de reduzir os valores de press&a
tilde;o arterial (PA) de repouso<sup>4</sup>. </font></p>     ^cY#aop01611.htm##
01032000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078800085002001300873#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#23#19#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Independentemente da poss&i
acute;vel redu&ccedil;&atilde;o da PA de repouso em decorr&ecirc;ncia do exerc&i
acute;cio regular (efeito cr&ocirc;nico), pode existir redu&ccedil;&atilde;o aba
ixo dos valores de repouso nos momentos ap&oacute;s a realiza&ccedil;&atilde;o d
e uma sess&atilde;o de exerc&iacute;cios, o que se denomina hipotens&atilde;o p&
oacute;s-exerc&iacute;cio (HPE)<sup>5</sup>. Um dos primeiros dados cient&iacute
;ficos sobre a ocorr&ecirc;ncia desse fen&ocirc;meno foi descrito em 1981 por Wi
lliam Fitzgerald<sup>6</sup>, cuja PA encontrava-se sistematicamente reduzida ap
&oacute;s um exerc&iacute;cio aer&oacute;bio (corrida, 25 min, 70% da frequ&ecir
c;ncia card&iacute;aca m&aacute;xima).</font></p>     ^cY#aop01611.htm##
00790000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054600085002001300631#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#24#20#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A HPE pode ser considerada 
uma importante estrat&eacute;gia para auxiliar no controle da PA de repouso, pri
ncipalmente em hipertensos<sup>5</sup>. Sobre o exerc&iacute;cio f&iacute;sico, 
o aer&oacute;bio &eacute; o mais estudado e recomendado para promover HPE em hip
ertensos e normotensos<sup>7</sup>. Por&eacute;m, em hipertensos, informa&ccedil
;&otilde;es quanto ao efeito das vari&aacute;veis dura&ccedil;&atilde;o e intens
idade ainda s&atilde;o controversas.</font></p>     ^cY#aop01611.htm##
00916000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067200085002001300757#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#25#21#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m do exerc&iacute
;cio aer&oacute;bio, o exerc&iacute;cio resistido tamb&eacute;m &eacute; recomen
dado como parte de um programa de treinamento para hipertensos, como forma de au
mentar a for&ccedil;a muscular<sup>4</sup>. Contudo, pesquisas sobre a ocorr&eci
rc;ncia de HPE em hipertensos que empregaram esse modelo de exerc&iacute;cio, em
bora tenham mostrado resultados promissores, ainda s&atilde;o em pequeno n&uacut
e;mero<sup>8-12</sup>. Mais ainda, existem diferen&ccedil;as nos protocolos expe
rimentais, como carga, repeti&ccedil;&otilde;es e quantidade de exerc&iacute;cio
s.</font></p>     ^cY#aop01611.htm##
00762000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051800085002001300603#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#26#22#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Assim, considerando as pote
nciais lacunas identificadas no entendimento dos diferentes exerc&iacute;cios so
bre a HPE em hipertensos, torna-se relevante investigar essa tem&aacute;tica. Ne
sse contexto, o objetivo do presente estudo foi revisar a literatura sobre os ef
eitos dos exerc&iacute;cios aer&oacute;bio e resistido na HPE em hipertensos. Ad
icionalmente, mecanismos fisiol&oacute;gicos envolvidos foram apresentados e com
entados.</font></p>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#27#23#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00386000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014200085002001300227#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#28#24#article#202#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos de busca 
e inclus&atilde;o de artigos</b></font></p>     ^cY#aop01611.htm##
01093000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704084900085002001300934#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#29#25#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Foram realizadas buscas nas
 bases <i>Medline </i>e<i> Scielo</i> por dois pesquisadores independentes. No <
i>Medline</i>, para a busca das refer&ecirc;ncias relacionadas com o exerc&iacut
e;cio aer&oacute;bio, foram utilizados, separadamente, os termos <i>dynamic exer
cise </i>e<i> aerobic exercise</i>, associados com os termos <i>hypotension, hyp
ertension, post-exercise, postexercise, blood pressure </i>e<i> acute response <
/i>no t&iacute;tulo ou no resumo. Para a busca de refer&ecirc;ncias sobre o exer
c&iacute;cio resistido, foram utilizados, separadamente, os termos <i>resistance
 exercise</i> e <i>strength exercise</i>, seguidos dos demais termos j&aacute; d
escritos. No <i>Scielo</i>, a busca ocorreu com os termos descritos separadament
e no t&iacute;tulo.</font></p>     ^cY#aop01611.htm##
00980000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073600085002001300821#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#30#26#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os crit&eacute;rios de incl
us&atilde;o de artigos foram: 1) artigos que verificaram respostas da PA ap&oacu
te;s o exerc&iacute;cio aer&oacute;bio ou resistido por um per&iacute;odo m&iacu
te;nimo de 30 minutos; 2) dura&ccedil;&atilde;o do exerc&iacute;cio igual ou sup
erior a 15 minutos (para o exerc&iacute;cio aer&oacute;bio); 3) publica&ccedil;&
atilde;o em ingl&ecirc;s at&eacute; setembro de 2009; 4) amostra composta por ad
ultos e hipertensos, ou seja, m&eacute;dia de PA do grupo estudado maior ou igua
l a 140 mmHg para a press&atilde;o arterial sist&oacute;lica (PAS) ou 90 mmHg pa
ra a press&atilde;o arterial diast&oacute;lica (PAD)<sup>2</sup>. </font></p>   
  ^cY#aop01611.htm##
01439000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704119500085002001301280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#31#27#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s o filtro das bu
scas com as palavras-chave, foram encontrados 126 estudos. Desses, ainda foram e
xclu&iacute;dos os experimentos sobre efeito cr&ocirc;nico do exerc&iacute;cio, 
modelos animais, respostas da PA durante o exerc&iacute;cio, amostra normotensa/
pr&eacute;-hipertensa, estresse ortost&aacute;tico, revis&atilde;o de literatura
 e os que tiveram dura&ccedil;&atilde;o de exerc&iacute;cio menor que 15 min (<a
 href="/img/revistas/abc/2011nahead/aop01611fig01m.jpg">Figura 1</a>). Assim, 32
 estudos fizeram parte das refer&ecirc;ncias do presente estudo, dos quais, cinc
o abordaram o exerc&iacute;cio resistido (amostra total de 72 indiv&iacute;duos)
, e 27, o exerc&iacute;cio aer&oacute;bio (amostra total de 638 indiv&iacute;duo
s). Os principais achados dos estudos que envolveram exerc&iacute;cio resistido 
est&atilde;o resumidos na <a href="/img/revistas/abc/2011nahead/aop01611tab01m.j
pg">Tabela 1</a>. Al&eacute;m disso, a <a href="/img/revistas/abc/2011nahead/aop
01611tab02m.jpg">Tabela 2</a> apresenta os principais resultados dos estudos que
 abordaram o exerc&iacute;cio aer&oacute;bio.</font></p>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#32#28#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00389000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014500085002001300230#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#33#29#article#202#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Hipotens&atilde;o p&oacu
te;s-exerc&iacute;cio resistido</b></font></p>     ^cY#aop01611.htm##
01131000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704088700085002001300972#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#34#30#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Houve grande discrep&acirc;
ncia entre os protocolos de exerc&iacute;cios resistidos, em que a varia&ccedil;
&atilde;o ocorreu em rela&ccedil;&atilde;o &agrave; execu&ccedil;&atilde;o (conv
encional<sup>8,10,12</sup> e circuito<sup>9,11</sup>); &agrave; intensidade (des
de leves<sup>8,9,11</sup> a elevadas<sup>10,12</sup>), &agrave;s repeti&ccedil;&
otilde;es (entre 8 e 20) e ao intervalo de recupera&ccedil;&atilde;o (entre 30 e
 120 segundos). Por outro lado, o n&uacute;mero de exerc&iacute;cios utilizados 
apresentou pouca varia&ccedil;&atilde;o (entre 4 e 7), solicitando, principalmen
te, grandes grupos musculares. Assim, de forma geral, uma compara&ccedil;&atilde
;o entre os estudos fica fragilizada, haja visto a diversidade dos protocolos ut
ilizados na prescri&ccedil;&atilde;o do exerc&iacute;cio.</font></p>     ^cY#aop
01611.htm##
01242000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099800085002001301083#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#35#31#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em todos os estudos, foi ob
servada queda nos valores de PAS ap&oacute;s a sess&atilde;o de exerc&iacute;cio
. Tal redu&ccedil;&atilde;o ocorreu, principalmente, na primeira hora ap&oacute;
s a realiza&ccedil;&atilde;o da atividade e foi independente do protocolo empreg
ado. No estudo de Melo e cols.<sup>8</sup>, al&eacute;m de a queda ser verificad
a em todo o per&iacute;odo no ambiente laboratorial, a mesma perdurou por dez ho
ras quando a amostra foi liberada para as atividades di&aacute;rias, assemelhand
o-se a alguns estudos que envolvem o exerc&iacute;cio aer&oacute;bio<sup>13-16</
sup>. Vale ressaltar que, nesse experimento, a amostra utilizava medica&ccedil;&
atilde;o para o controle da PA (captopril). Esse resultado possui grande validad
e externa, pois o exerc&iacute;cio resistido aplicado concomitantemente ao uso d
o medicamento pode potencializar a dura&ccedil;&atilde;o da redu&ccedil;&atilde;
o da PA.</font></p>     ^cY#aop01611.htm##
01369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704112500085002001301210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#36#32#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o &a
grave; PAD, somente tr&ecirc;s estudos<sup>8,11,12</sup> verificaram HPE, apesar
 de utilizarem protocolos distintos. Moraes e cols.<sup>11</sup> observaram qued
a nos valores de PAD em momentos isolados (5º, 10º e 60º minutos) do per&iacute;
odo de acompanhamento ap&oacute;s circuito com pesos, fato esse que reduz a rele
v&acirc;ncia cl&iacute;nica da HPE por n&atilde;o causar queda constante na PA. 
Mediano e cols.<sup>12</sup>, utilizando o m&eacute;todo convencional, tamb&eacu
te;m verificaram redu&ccedil;&otilde;es em momentos isolados (30º e 50º minutos)
. Por&eacute;m, nesse estudo, foi empregada intensidade elevada (10RM), e os ind
iv&iacute;duos faziam uso de medicamento. A prescri&ccedil;&atilde;o de intensid
ade elevada reduz a validade externa, visto que, para indiv&iacute;duos hiperten
sos, a recomenda&ccedil;&atilde;o &eacute; de intensidade leve a moderada, pelo 
fato de provocar menores eleva&ccedil;&otilde;es nos valores de PA durante a rea
liza&ccedil;&atilde;o do exerc&iacute;cio<sup>4</sup>. </font></p>     ^cY#aop01
611.htm##
01470000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122600085002001301311#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#37#33#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m desses, um estu
do<sup>8</sup> observou diminui&ccedil;&atilde;o na PAD (45º e 75º minutos) em a
mbiente controlado. Contudo, os valores de PAD permaneceram reduzidos por dez ho
ras ap&oacute;s a realiza&ccedil;&atilde;o do exerc&iacute;cio em rela&ccedil;&a
tilde;o ao dia controle. Resultados como esse estudo<sup>8</sup> s&atilde;o rele
vantes, pois possibilitam aos indiv&iacute;duos hipertensos, por exemplo, menor 
tempo de exposi&ccedil;&atilde;o a valores press&oacute;ricos elevados, tanto pa
ra a PAS quanto para a PAD. Contudo, independentemente dos resultados descritos 
por Melo e cols.<sup>8</sup>, &eacute; importante considerar que a redu&ccedil;&
atilde;o da PA n&atilde;o ocorreu em rela&ccedil;&atilde;o aos valores de repous
o obtidos no dia de exerc&iacute;cio, mas somente em rela&ccedil;&atilde;o ao di
a em que n&atilde;o houve exerc&iacute;cio (controle). Dessa forma, considerando
 que a HPE &eacute; a redu&ccedil;&atilde;o da PA em rela&ccedil;&atilde;o aos v
alores pr&eacute;-exerc&iacute;cio, s&atilde;o necess&aacute;rios mais estudos q
ue investiguem a PA por longos per&iacute;odos para maiores esclarecimentos.</fo
nt></p>     ^cY#aop01611.htm##
01314000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704107000085002001301155#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#38#34#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Por fim, um estudo<sup>9</s
up> com indiv&iacute;duos treinados n&atilde;o observou redu&ccedil;&atilde;o na
 PAD. Considerando que o treinamento cr&ocirc;nico pode provocar ajustes hemodin
&acirc;micos no organismo<sup>17</sup>, &eacute; poss&iacute;vel que isso interf
ira sobre a HPE em indiv&iacute;duos treinados. Nesse sentido, o benef&iacute;ci
o causado pela pr&aacute;tica do exerc&iacute;cio j&aacute; teria sido adquirido
 pelo efeito cr&ocirc;nico e, dessa forma, n&atilde;o seria observado ap&oacute;
s uma &uacute;nica sess&atilde;o de exerc&iacute;cio. Por&eacute;m, n&atilde;o f
oram encontrados estudos que tenham analisado a influ&ecirc;ncia do estado de tr
einamento de hipertensos sobre a HPE, por isso, maiores infer&ecirc;ncias seriam
 especulativas. De forma semelhante, estudos<sup>18,19</sup> que envolvem normot
ensos treinados tamb&eacute;m n&atilde;o encontraram redu&ccedil;&otilde;es sign
ificativas na PAD ap&oacute;s uma sess&atilde;o de exerc&iacute;cios resistidos.
</font></p>     ^cY#aop01611.htm##
01812000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704156800085002001301653#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#39#35#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o ao
s mecanismos fisiol&oacute;gicos envolvidos na queda da PA ap&oacute;s o exerc&i
acute;cio resistido, foram encontrados somente dois estudos<sup>11,20</sup>, mas
 um<sup>11</sup> utilizou como amostra indiv&iacute;duos hipertensos, e o outro<
sup>20</sup>, normotensos. Moraes e cols.<sup>11</sup> identificaram que a HPE e
st&aacute; relacionada com a libera&ccedil;&atilde;o do vasodilatador calicre&ia
cute;na<sup>21</sup>. Por&eacute;m, essa subst&acirc;ncia &eacute; pouco estudad
a no contexto da HPE e n&atilde;o se sabe, por enquanto, sua real contribui&cced
il;&atilde;o na redu&ccedil;&atilde;o da PA ap&oacute;s o exerc&iacute;cio. Em n
ormotensos, Rezk e cols.<sup>20</sup> analisaram a resist&ecirc;ncia vascular pe
rif&eacute;rica (RVP) e o d&eacute;bito card&iacute;aco (DC) ap&oacute;s o exerc
&iacute;cio resistido com intensidades de 40 a 80% de 1RM. O exerc&iacute;cio de
 menor intensidade ocasionou HPE tanto para PAS e PAD, por&eacute;m o mecanismo 
observado foi a redu&ccedil;&atilde;o do DC com manuten&ccedil;&atilde;o da RVP.
 Em contrapartida, o exerc&iacute;cio de maior intensidade promoveu HPE somente 
para a PAS, a qual se relacionou principalmente com a redu&ccedil;&atilde;o do D
C, j&aacute; que a RVP aumentou ap&oacute;s a realiza&ccedil;&atilde;o do exerc&
iacute;cio. No entanto, foram utilizados como amostra jovens saud&aacute;veis, o
 que n&atilde;o permite, de forma segura, a extrapola&ccedil;&atilde;o dos dados
 para hipertensos.</font></p>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#40#36#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015000085002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#41#37#article#202#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Hipotens&atilde;o p&oacu
te;s-exerc&iacute;cio aer&oacute;bio</b></font></p>     ^cY#aop01611.htm##
00604000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036000085002001300445#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#42#38#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No exerc&iacute;cio aer&oac
ute;bio, a maioria dos estudos utilizou o cicloerg&ocirc;metro<sup>11,13-15,23-2
5,28-32,39,41-43</sup>, alguns utilizaram a esteira ergom&eacute;trica<sup>16,22
,26,27,33-38,40</sup>, e somente um estudo utilizou a corrida na &aacute;gua<sup
>36</sup>.</font></p>     ^cY#aop01611.htm##
01312000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106800085002001301153#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#43#39#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o &a
grave; HPE e exerc&iacute;cio aer&oacute;bio, observou-se que somente dois estud
os<sup>25,26</sup> n&atilde;o verificaram redu&ccedil;&otilde;es na PAS e PAD, t
anto em rela&ccedil;&atilde;o ao repouso quanto em rela&ccedil;&atilde;o ao dia 
controle. Al&eacute;m desses, alguns estudos<sup>11,22,33,34,36-40,42,43</sup> v
erificaram HPE em curtos per&iacute;odos de tempo (30-120 minutos), tanto para a
 PAS quanto para a PAD. Redu&ccedil;&otilde;es da PA por per&iacute;odos curtos 
causam menor impacto para a sa&uacute;de cardiovascular de um indiv&iacute;duo h
ipertenso, visto que a dura&ccedil;&atilde;o da queda da PA &eacute; o fator mai
s importante na ocorr&ecirc;ncia desse fen&ocirc;meno<sup>44</sup>. Por&eacute;m
, desses 11 estudos, oito<sup>22,33,34,36-40</sup> utilizaram o m&eacute;todo au
scultat&oacute;rio, e dois<sup>42,43</sup> utilizaram a medida intra-arterial da
 PA, o que impossibilita o acompanhamento da PA fora do ambiente laboratorial.</
font></p>     ^cY#aop01611.htm##
01140000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704089600085002001300981#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#44#40#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Nesse contexto, aproximadam
ente 50% dos estudos<sup>13-16,23,24,27-32,35,41</sup> que envolveram exerc&iacu
te;cio aer&oacute;bio verificaram redu&ccedil;&otilde;es na PAS e PAD por longos
 per&iacute;odos. Contudo, para a PAS, somente dois estudos<sup>14,15</sup> obse
rvaram redu&ccedil;&otilde;es em rela&ccedil;&atilde;o aos valores pr&eacute;-ex
erc&iacute;cio, fato que caracteriza o fen&ocirc;meno da HPE. Os resultados de a
lgumas pesquisas<sup>13,16,23,27,31,32,35</sup> foram significantes em rela&cced
il;&atilde;o ao dia controle, mas n&atilde;o em compara&ccedil;&atilde;o aos val
ores de repouso. Mais ainda, alguns estudos<sup>24,28-30,41</sup> encontraram au
mento nos valores de PAS em rela&ccedil;&atilde;o ao repouso, no entanto, esses 
valores foram menores em compara&ccedil;&atilde;o ao dia controle.</font></p>   
  ^cY#aop01611.htm##
01195000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704095100085002001301036#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#45#41#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Por outro lado, para a PAD,
 a HPE ocorreu em seis estudos<sup>14,15,24,28-30</sup>. Redu&ccedil;&otilde;es 
somente em rela&ccedil;&atilde;o ao dia controle foram verificadas em oito estud
os<sup>13,16,23,27,31,32,35,41</sup>, e, diferentemente da PAS, nenhum estudo ob
servou aumento em rela&ccedil;&atilde;o aos valores pr&eacute;-exerc&iacute;cio 
para a PAD. A compara&ccedil;&atilde;o da PA em rela&ccedil;&atilde;o ao dia con
trole &eacute; importante, pois permite visualizar o comportamento dos valores p
ress&oacute;ricos sem a realiza&ccedil;&atilde;o do exerc&iacute;cio. Todavia, c
omo j&aacute; citado, o conceito de HPE &eacute; a redu&ccedil;&atilde;o dos n&i
acute;veis de PA em rela&ccedil;&atilde;o aos valores de repouso e, dessa maneir
a, seria interessante quantificar e qualificar o comportamento da amostra no dia
 controle para maiores infer&ecirc;ncias.</font></p>     ^cY#aop01611.htm##
01275000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704103100085002001301116#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#46#42#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Parece n&atilde;o haver uma
 coes&atilde;o dos resultados obtidos nos estudos no que diz respeito &agrave; i
ntensidade e queda da PA ap&oacute;s o exerc&iacute;cio. Dessa forma, HPE pode s
er observada ap&oacute;s exerc&iacute;cio de baixa<sup>23,27,36,39</sup>, modera
da<sup>15,22,30,31</sup> e elevada intensidades<sup>35,38</sup>. Nesse sentido, 
alguns estudos<sup>13,14,16,24,28,29,34,41</sup> tentaram comparar diretamente a
 intensidade com a redu&ccedil;&atilde;o da PA, mas os resultados s&atilde;o con
flitantes. Algumas pesquisas<sup>16,34</sup> demonstraram que intensidades mais 
elevadas (70-75% do VO<sub>2m&aacute;x.</sub>) promovem maiores redu&ccedil;&oti
lde;es nos valores press&oacute;ricos do que intensidades mais leves (50% do VO<
sub>2m&aacute;x.</sub>). Em contrapartida, alguns estudos<sup>13,14,24,28,29,41<
/sup> n&atilde;o verificaram diferen&ccedil;as quanto &agrave; resposta da PA e 
&agrave; intensidade do exerc&iacute;cio.</font></p>     ^cY#aop01611.htm##
01084000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704084000085002001300925#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#47#43#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Vale ressaltar que alguns e
xperimentos<sup>32,33</sup> compararam o exerc&iacute;cio cont&iacute;nuo com o 
exerc&iacute;cio intervalado, sugerindo que o exerc&iacute;cio cont&iacute;nuo p
ossui pequena vantagem em rela&ccedil;&atilde;o ao exerc&iacute;cio intervalado.
 Portanto, n&atilde;o h&aacute; consenso na literatura a respeito da rela&ccedil
;&atilde;o de intensidade e HPE para indiv&iacute;duos hipertensos. No entanto, 
a recomenda&ccedil;&atilde;o do Col&eacute;gio Americano de Medicina do Esporte<
sup>4</sup> indica a prescri&ccedil;&atilde;o de intensidade leve/moderada (40-6
0% do VO<sub>2m&aacute;x.</sub>), justamente por provocar menores eleva&ccedil;&
otilde;es da PA durante o esfor&ccedil;o e, por isso, proporcionar maior seguran
&ccedil;a.</font></p>     ^cY#aop01611.htm##
02326000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704208200085002001302167#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#48#44#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Outra vari&aacute;vel que p
ode interferir na HPE &eacute; a dura&ccedil;&atilde;o do esfor&ccedil;o, por&ea
cute;m foi observada redu&ccedil;&atilde;o da PA tanto em exerc&iacute;cios com 
menor dura&ccedil;&atilde;o (15-20 minutos)<sup>30,41</sup> quanto com maiores d
ura&ccedil;&otilde;es (50 minutos)<sup>22,27,37,40</sup>. Bennett e cols.<sup>37
</sup> verificaram a resposta da PA com a realiza&ccedil;&atilde;o de exerc&iacu
te;cio intermitente, em que os indiv&iacute;duos exercitavam-se durante dez minu
tos e descansavam por tr&ecirc;s minutos. Essa rotina foi repetida cinco vezes, 
e, dessa forma, os autores verificaram que a queda da PA sofria influ&ecirc;ncia
 da dura&ccedil;&atilde;o do esfor&ccedil;o. Contudo, um estudo<sup>26</sup> emp
regou uma metodologia muito semelhante, mas n&atilde;o observou redu&ccedil;&ati
lde;o da PA ap&oacute;s o exerc&iacute;cio. Nesse contexto, estudos que comparam
 diretamente a resposta da PA com a dura&ccedil;&atilde;o do exerc&iacute;cio po
ssuem resultados conflitantes, j&aacute; que h&aacute; ind&iacute;cios de que ma
iores dura&ccedil;&otilde;es proporcionam maiores redu&ccedil;&otilde;es nos val
ores press&oacute;ricos<sup>45</sup>. Por outro lado, outros resultados sugerem 
n&atilde;o haver diferen&ccedil;a na HPE com a realiza&ccedil;&atilde;o de exerc
&iacute;cios com menores (dez minutos) ou maiores dura&ccedil;&otilde;es (30 min
utos)<sup>46</sup>. Guidry e cols.<sup>41</sup>, estudando indiv&iacute;duos hip
ertensos, observaram pequena vantagem para o exerc&iacute;cio de maior dura&cced
il;&atilde;o (30 minutos <i>versus </i>15 minutos) para a PAD. Portanto, parece 
n&atilde;o haver uma rela&ccedil;&atilde;o entre dura&ccedil;&atilde;o do exerc&
iacute;cio e HPE, por isso, mais estudos s&atilde;o necess&aacute;rios nesse con
texto, pois dois<sup>45,46</sup> dos tr&ecirc;s estudos que investigaram a influ
&ecirc;ncia da dura&ccedil;&atilde;o do esfor&ccedil;o sobre a HPE utilizaram co
mo amostra indiv&iacute;duos pr&eacute;-hipertensos.</font></p>     ^cY#aop01611
.htm##
01283000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704103900085002001301124#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#49#45#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os mecanismos envolvidos na
 queda da PA ap&oacute;s o exerc&iacute;cio aer&oacute;bio podem ser diferentes 
daqueles envolvidos em rela&ccedil;&atilde;o ao exerc&iacute;cio resistido. Curi
osamente, Rueckert e cols.<sup>38</sup> observaram um padr&atilde;o bif&aacute;s
ico na HPE, em que inicialmente a queda da PA &eacute; determinada pela redu&cce
dil;&atilde;o da RVP, seguida por diminui&ccedil;&atilde;o do DC. Al&eacute;m di
sso, alguns estudos<sup>23,34</sup> observaram que a HPE &eacute; determinada so
mente pela redu&ccedil;&atilde;o do DC, a qual est&aacute; relacionada com a red
u&ccedil;&atilde;o do volume sist&oacute;lico. Ademais, Hagberg e cols.<sup>34</
sup> verificaram que, em indiv&iacute;duos idosos, a HPE seja provavelmente medi
ada pela redu&ccedil;&atilde;o do DC, j&aacute; que, com o avan&ccedil;o da idad
e, ocorre aumento na rigidez arterial. Consequentemente, h&aacute; menor capacid
ade de vasodilata&ccedil;&atilde;o<sup>47</sup>. </font></p>     ^cY#aop01611.ht
m##
01925000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704168100085002001301766#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#50#46#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Por outro lado, alguns estu
dos<sup>15,39</sup> verificaram que a queda da PA tem influ&ecirc;ncia da diminu
i&ccedil;&atilde;o da RVP, a qual pode estar relacionada com a libera&ccedil;&at
ilde;o de subst&acirc;ncias vasodilatadoras como o &oacute;xido n&iacute;trico<s
up>44,48</sup>, prostaglandinas<sup>49,50</sup> e adenosina<sup>51</sup>. Contud
o, estudos que bloquearam a s&iacute;ntese de &oacute;xido n&iacute;trico e pros
taglandinas continuaram observando a queda da PA<sup>52,53</sup>. Mais ainda, a 
diminui&ccedil;&atilde;o da RVP pode estar atrelada a uma redu&ccedil;&atilde;o 
da atividade nervosa simp&aacute;tica, que foi observada tanto em humanos<sup>54
,55</sup> quanto em modelos animais<sup>56</sup>. Franklin e cols.<sup>57</sup> 
verificaram que a termorregula&ccedil;&atilde;o &eacute; outro fator que poderia
 estar relacionado com a ocorr&ecirc;ncia da HPE. No entanto, alguns estudos sug
erem que h&aacute; pouca contribui&ccedil;&atilde;o da termorregula&ccedil;&atil
de;o<sup>7</sup> e das circula&ccedil;&otilde;es espl&acirc;nica<sup>58</sup>, c
ut&acirc;nea<sup>59</sup> e cerebral<sup>60</sup> para a HPE. Por fim, outro mec
anismo que pode estar relacionado com a HPE &eacute; a fun&ccedil;&atilde;o baro
rreflexa, a qual parece estar aumentada ap&oacute;s uma sess&atilde;o de exerc&i
acute;cio<sup>61,62</sup>. Esse mecanismo age de duas maneiras, havendo diminui&
ccedil;&atilde;o da RVP e da frequ&ecirc;ncia card&iacute;aca com o aumento da P
A e, em contrapartida, aumento dessas vari&aacute;veis com a diminui&ccedil;&ati
lde;o dos valores press&oacute;ricos<sup>63</sup>. </font></p>     ^cY#aop01611.
htm##
00876000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063200085002001300717#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#51#47#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Portanto, n&atilde;o h&aacu
te; evid&ecirc;ncias sobre o exato mecanismo envolvido na HPE, pois parece haver
 contribui&ccedil;&atilde;o de v&aacute;rios fatores para a ocorr&ecirc;ncia do 
fen&ocirc;meno. Vale ressaltar que grande parte dos estudos que envolvem mecanis
mos relacionados com a queda da PA utilizou como amostra indiv&iacute;duos normo
tensos ou modelos animais. Dessa forma, os resultados devem ser analisados com c
erto cuidado, pois a extrapola&ccedil;&atilde;o dos resultados para a popula&cce
dil;&atilde;o hipertensa fica fragilizada.</font></p>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#52#48#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00416000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017200085002001300257#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#53#49#article#202#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Monitoriza&ccedil;&atild
e;o da press&atilde;o arterial p&oacute;s-exerc&iacute;cio</b></font></p>     ^c
Y#aop01611.htm##
01088000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704084400085002001300929#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#54#50#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Sobre a monitoriza&ccedil;&
atilde;o da PA ap&oacute;s exerc&iacute;cios aer&oacute;bio e com pesos, dois es
tudos<sup>9,12</sup> utilizaram somente o m&eacute;todo auscultat&oacute;rio ap&
oacute;s o exerc&iacute;cio resistido e oito estudos<sup>22,33,34,36-40</sup> ap
&oacute;s o exerc&iacute;cio aer&oacute;bio. Nesses experimentos, os pesquisador
es acompanharam a PA entre 30-120 minutos, e as medidas foram mensuradas, na mai
oria das vezes, a cada dez minutos. Al&eacute;m disso, dois estudos<sup>42,43</s
up> utilizaram a medida direta de PA. Esses procedimentos s&atilde;o interessant
es, pois permitem ao investigador analisar o comportamento cardiovascular na aus
&ecirc;ncia de vari&aacute;veis intervenientes, mas diminui a validade externa d
os resultados.</font></p>     ^cY#aop01611.htm##
01122000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087800085002001300963#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#55#51#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Por outro lado, tr&ecirc;s 
estudos<sup>8,10,11</sup> que envolveram exerc&iacute;cios com pesos e dezessete
<sup>11,13-16,23-32,35,41</sup> que empregaram o exerc&iacute;cio aer&oacute;bio
 utilizaram a monitoriza&ccedil;&atilde;o ambulatorial da press&atilde;o arteria
l (MAPA). Contudo, em alguns casos, a informa&ccedil;&atilde;o traduzida pelos r
esultados da MAPA pode causar confus&atilde;o no entendimento. Por exemplo, um e
studo<sup>32</sup> concluiu que a PA ficou reduzida significativamente na m&eacu
te;dia das 24 horas de monitoriza&ccedil;&atilde;o. No entanto, a redu&ccedil;&a
tilde;o significativa da PA ocorreu apenas nas medidas realizadas no per&iacute;
odo noturno. Dessa forma, pode parecer ao leitor que o exerc&iacute;cio proporci
onou redu&ccedil;&atilde;o em todas as 24 horas.</font></p>     ^cY#aop01611.htm
##
01012000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076800085002001300853#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#56#52#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m da an&aacute;li
se no per&iacute;odo de 24 horas, a MAPA pode ser utilizada pela divis&atilde;o 
dos per&iacute;odos do dia, isto &eacute;, 24 horas, vig&iacute;lia e sono<sup>2
,3</sup>. Dessa forma, a MAPA pode ser empregada para detec&ccedil;&atilde;o de 
pacientes com hipertens&atilde;o refrat&aacute;ria, por exemplo. Assim, a utiliz
a&ccedil;&atilde;o desse m&eacute;todo &eacute; bastante interessante, pois torn
a poss&iacute;vel a compara&ccedil;&atilde;o entre valores de PA no consult&oacu
te;rio e no per&iacute;odo de vig&iacute;lia, em que tais medidas comparativas p
odem favorecer a detec&ccedil;&atilde;o de hipertensos com efeito do avental bra
nco<sup>64</sup>. </font></p>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#57#53#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#58#54#article#202#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop01611.htm##
01333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704108900085002001301174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#59#55#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Aparentemente, o exerc&iacu
te;cio aer&oacute;bio proporciona redu&ccedil;&otilde;es de maior magnitude e du
ra&ccedil;&atilde;o na PA em compara&ccedil;&atilde;o ao exerc&iacute;cio resist
ido. No entanto, s&atilde;o necess&aacute;rios mais estudos que apliquem o exerc
&iacute;cio resistido em indiv&iacute;duos hipertensos. N&atilde;o h&aacute; um 
modelo de prescri&ccedil;&atilde;o para o exerc&iacute;cio com pesos que promova
 maiores redu&ccedil;&otilde;es nos valores press&oacute;ricos de hipertensos. C
ontudo, no que diz respeito &agrave; seguran&ccedil;a dos indiv&iacute;duos, a i
ntensidade deve ficar em torno de 50% de 1RM, com intervalos m&iacute;nimos de u
m minuto (entre as s&eacute;ries e os exerc&iacute;cios), e devem-se utilizar ex
erc&iacute;cios que solicitem principalmente os grandes grupos musculares. Al&ea
cute;m disso, deve-se evitar a utiliza&ccedil;&atilde;o de s&eacute;ries longas 
que levem at&eacute; a exaust&atilde;o, fato que pode causar maiores eleva&ccedi
l;&otilde;es na PA.</font></p>     ^cY#aop01611.htm##
00762000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051800085002001300603#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#60#56#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A prescri&ccedil;&atilde;o 
da maioria dos estudos em rela&ccedil;&atilde;o &agrave;s atividades aer&oacute;
bias variou entre 50-60% do VO<sub>2m&aacute;x.</sub>, com dura&ccedil;&otilde;e
s entre 30-45 minutos, sendo realizadas de forma cont&iacute;nua. Vale ressaltar
 que ainda h&aacute; resultados conflitantes em rela&ccedil;&atilde;o &agrave; m
elhor intensidade e &agrave; dura&ccedil;&atilde;o para esse modelo de exerc&iac
ute;cio.</font></p>     ^cY#aop01611.htm##
00977000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073300085002001300818#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#61#57#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O exato mecanismo envolvido
 na HPE permanece obscuro, havendo um mecanismo compensat&oacute;rio. Ou seja, a
 redu&ccedil;&atilde;o da PA deve-se &agrave; redu&ccedil;&atilde;o da RVP ou do
 DC, mas, quando n&atilde;o h&aacute; redu&ccedil;&atilde;o de uma dessas vari&a
acute;veis, ocorre uma compensa&ccedil;&atilde;o da outra, a fim de promover a r
edu&ccedil;&atilde;o dos n&iacute;veis de PA. Por fim, s&atilde;o necess&aacute;
rios estudos que investiguem o comportamento da PA, em rela&ccedil;&atilde;o aos
 valores pr&eacute;-exerc&iacute;cio, por longos per&iacute;odos de tempo, para 
proporcionar maiores esclarecimentos sobre essa quest&atilde;o.</font></p>     ^
cY#aop01611.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#62#58#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Potencial Conflito de In
teresses</b></font></p>     ^cY#aop01611.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014300085002001300228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#63#59#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Declaro n&atilde;o haver co
nflito de interesses pertinentes.</font></p>     ^cY#aop01611.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#64#60#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01611.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015000085002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#65#61#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo n&atilde;
o teve fontes de financiamento externas.</font></p>     ^cY#aop01611.htm##
00374000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013000085002001300215#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#66#62#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vincula&ccedil;&atilde;o
 Acad&ecirc;mica</b></font></p>     ^cY#aop01611.htm##
00474000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023000085002001300315#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#67#63#article#202#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Este artigo &eacute; parte 
de disserta&ccedil;&atilde;o de Mestrado de Paulo Gomes Anuncia&ccedil;&atilde;o
 pela Universidade Estadual de Londrina.</font></p>     ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#68#64#article#202#<p>&nbsp;<
/p>     ^cY#aop01611.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#69#65#article#202#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01611.htm##
00529000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027100087002001300358#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#70#66#article#20
2#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.	Cooper RS,
 Wolf-Maier K, Luke A, Adeyemo A, Banegas JR, Forrester T, et al. An internation
al comparative study of blood pressure in populations of European vs. African de
scent. BMC Med. 2005; 3: 2.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#71#67#article#202#</font></p
>     ^cY#aop01611.htm##
00582000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032400087002001300411#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#72#68#article#20
2#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2.	Chobanian 
AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Re
port of the Joint National Committee on Prevention, Detection, Evaluation, and T
reatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289 (6): 2560-72.
    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#73#69#article#202#</font></p
>     ^cY#aop01611.htm##
00461000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704020300087002001300290#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#74#70#article#20
2#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3.	Sociedade 
Brasileira de Cardiologia. V Diretrizes brasileiras de hipertens&atilde;o arteri
al. Arq Bras Cardiol. 2007; 89: e24-79.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#75#71#article#202#</font></p
>     ^cY#aop01611.htm##
00525000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704026700087002001300354#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#76#72#article#20
2#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4.	Pescatello
 LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA. American College of 
Sports Medicine position stand. Exercise and hypertension. Med Sci Sports Exerc.
 2004; 36 (10): 533-53.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#77#73#article#202#</font></p
>     ^cY#aop01611.htm##
00467000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704020900087002001300296#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#78#74#article#20
2#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5.	Kenney MJ,
 Seals DR. Postexercise hypotension: key features, mechanisms, and clinical sign
ificance. Hypertension. 1993; 22 (5): 653-64.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#79#75#article#202#</font></p
>     ^cY#aop01611.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704021200087002001300299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#80#76#article#20
2#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6.	Fitzgerald
 W. Labile hypertension and jogging: new diagnostic tool or spurious discovery? 
Br Med J (Clin Res Ed). 1981; 282 (6263): 542-4.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#81#77#article#202#</font></p
>     ^cY#aop01611.htm##
00461000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704020300087002001300290#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#82#78#article#20
2#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7.	MacDonald 
JR. Potential causes, mechanisms, and implications of post exercise hypotension.
 J Hum Hypertens. 2002; 16 (4): 225-36.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#83#79#article#202#</font></p
>     ^cY#aop01611.htm##
00544000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028600087002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#84#80#article#20
2#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8.	Melo CM, A
lencar Filho AC, Tinucci T, Mion D Jr, Forjaz CL. Postexercise hypotension induc
ed by low-intensity resistance exercise in hypertensive women receiving captopri
l. Blood Press Monit. 2006; 11 (4): 183-9.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#85#81#article#202#</font></p
>     ^cY#aop01611.htm##
00496000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023800087002001300325#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#86#82#article#20
2#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9.	Fisher MM.
 The effect of resistance exercise on recovery blood pressure in normotensive an
d borderline hypertensive women. J Strength Cond Res. 2001; 15 (2): 210-6.    ^c
Y#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#87#83#article#202#</font></p
>     ^cY#aop01611.htm##
00512000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704025300088002001300341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#88#84#article#20
2#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10.	Hardy DO
, Tucker LA. The effects of a single bout of strength training on ambulatory blo
od pressure levels in 24 mildly hypertensive men. Am J Health Promot. 1998; 13 (
2): 69-72.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#89#85#article#202#</font></p
>     ^cY#aop01611.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704027600088002001300364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#90#86#article#20
2#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11.	Moraes M
R, Bacurau RF, Ramalho JD, Reis FC, Casarini DE, Chagas JR, et al. Increase in k
inins on post-exercise hypotension in normotensive and hypertensive volunteers. 
Biol Chem. 2007; 388 (5): 533-40.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#91#87#article#202#</font></p
>     ^cY#aop01611.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704028100088002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#92#88#article#20
2#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12.	Mediano 
MFFP, Paravidino V, Sim&atilde;o R, Pontes FL, Polito MD. Subacute behavior of t
he blood pressure after power training in controlled hypertensive individuals. R
ev Bras Med Esporte. 2005; 11: 337-40.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#93#89#article#202#</font></p
>     ^cY#aop01611.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704030200088002001300390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#94#90#article#20
2#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13.	Blanchar
d BE, Tsongalis GJ, Guidry MA, LaBelle LA, Poulin M, Taylor AL, et al. RAAS poly
morphisms alter the acute blood pressure response to aerobic exercise among men 
with hypertension. Eur J Appl Physiol. 2006; 97 (1): 26-33.    ^cY#aop01611.htm#
#
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#95#91#article#202#</font></p
>     ^cY#aop01611.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704022700088002001300315#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#96#92#article#20
2#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14.	Pescatel
lo LS, Fargo AE, Leach CN Jr, Scherzer HH. Short-term effect of dynamic exercise
 on arterial blood pressure. Circulation. 1991; 83 (5): 1557-61.    ^cY#aop01611
.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#97#93#article#202#</font></p
>     ^cY#aop01611.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704027300088002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#98#94#article#20
2#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15.	Pescatel
lo LS, Miller B, Danias PG, Werner M, Hess M, Baker C, et al. Dynamic exercise n
ormalizes resting blood pressure in mildly hypertensive premenopausal women. Am 
Heart J. 1999;138 (5): 916-21.    ^cY#aop01611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#99#95#article#202#</font></p
>     ^cY#aop01611.htm##
00493000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704023300089002001300322#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#100#96#article#2
02#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16.	Quinn T
J. Twenty-four hour, ambulatory blood pressure responses following acute exercis
e: impact of exercise intensity. J Hum Hypertens. 2000; 14 (9): 547-53.    ^cY#a
op01611.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#101#97#article#202#</font></
p>     ^cY#aop01611.htm##
00464000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704020400089002001300293#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#102#98#article#2
02#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17.	Moyna N
M, Thompson PD. The effect of physical activity on endothelial function in man. 
Acta Physiol Scand. 2004; 180 (2): 113-23.    ^cY#aop01611.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#103#99#article#202#</font></
p>     ^cY#aop01611.htm##
00476000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021500090002001300305#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#104#100#article#
202#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18.	Brown 
SP, Clemons JM, He Q, Liu S. Effects of resistance exercise and cycling on recov
ery blood pressure. J Sports Sci. 1994; 12 (5): 463-8.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#105#101#article#202#</font><
/p>     ^cY#aop01611.htm##
00514000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025300090002001300343#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#106#102#article#
202#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19.	Roltsc
h MH, Mendez T, Wilund KR, Hagberg JM. Acute resistive exercise does not affect 
ambulatory blood pressure in young men and women. Med Sci Sports Exerc. 2001; 33
 (6): 881-6.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#107#103#article#202#</font><
/p>     ^cY#aop01611.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028400090002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#108#104#article#
202#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20.	Rezk C
C, Marrache RC, Tinucci T, Mion D Jr, Forjaz CL. Post-resistance exercise hypote
nsion, hemodynamics, and heart rate variability: influence of exercise intensity
. Eur J Appl Physiol. 2006; 98 (1): 105-12.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#109#105#article#202#</font><
/p>     ^cY#aop01611.htm##
00457000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019600090002001300286#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#110#106#article#
202#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21.	Pesque
ro JB, Bader M. Genetically altered animal models in the kallikrein-kinin system
. Biol Chem. 2006; 387 (2): 119-26.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#111#107#article#202#</font><
/p>     ^cY#aop01611.htm##
00503000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024200090002001300332#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#112#108#article#
202#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22.	Kaufma
n FL, Hughson RL, Schaman JP. Effect of exercise on recovery blood pressure in n
ormotensive and hypertensive subjects. Med Sci Sports Exerc. 1987; 19 (1): 17-20
.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#113#109#article#202#</font><
/p>     ^cY#aop01611.htm##
00527000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026600090002001300356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#114#110#article#
202#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23.	Brand&
atilde;o Rondon MU, Alves MJ, Braga AM, Teixeira OT, Barreto AC,  et al. Postexe
rcise blood pressure reduction in elderly hypertensive patients. J Am Coll Cardi
ol. 2002; 39 (4): 676-82.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#115#111#article#202#</font><
/p>     ^cY#aop01611.htm##
00582000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032100090002001300411#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#116#112#article#
202#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24.	Syme A
N, Blanchard BE, Guidry MA, Taylor AW, Vanheest JL, Hasson S, et al. Peak systol
ic blood pressure on a graded maximal exercise test and the blood pressure respo
nse to an acute bout of submaximal exercise. Am J Cardiol. 2006; 98 (7): 938-43.
    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#117#113#article#202#</font><
/p>     ^cY#aop01611.htm##
00531000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027000090002001300360#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#118#114#article#
202#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25.	Forjaz
 CL, Tinucci T, Ortega KC, Santaella DF, Mion D Jr, Negrao CE. Factors affecting
 post-exercise hypotension in normotensive and hypertensive humans. Blood Press 
Monit. 2000; 5 (5-6): 255-62.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#119#115#article#202#</font><
/p>     ^cY#aop01611.htm##
00525000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026400090002001300354#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#120#116#article#
202#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26.	Wallac
e JP, Bogle PG, King BA, Krasnoff JB, Jastremski CA. A comparison of 24-h averag
e blood pressures and blood pressure load following exercise. Am J Hypertens. 19
97; 10(7 pt 1): 728-34.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#121#117#article#202#</font><
/p>     ^cY#aop01611.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026300090002001300353#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#122#118#article#
202#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27.	Wallac
e JP, Bogle PG, King BA, Krasnoff JB, Jastremski CA. The magnitude and duration 
of ambulatory blood pressure reduction following acute exercise. J Hum Hypertens
. 1999; 13 (6): 361-6.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#123#119#article#202#</font><
/p>     ^cY#aop01611.htm##
00501000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024000090002001300330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#124#120#article#
202#28#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28.	Pescat
ello LS, Guidry MA, Blanchard BE, Kerr A, Taylor AL, Johnson AN, et al. Exercise
 intensity alters postexercise hypotension. J Hypertens. 2004; 22 (10): 1881-8. 
   ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#125#121#article#202#</font><
/p>     ^cY#aop01611.htm##
00600000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033900090002001300429#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#126#122#article#
202#29#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29.	Pescat
ello LS, Turner D, Rodriguez N, Blanchard BE, Tsongalis GJ, Maresh CM, et al. Di
etary calcium intake and renin angiotensin system polymorphisms alter the blood 
pressure response to aerobic exercise: a randomized control design. Nutr Metab (
Lond). 2007; 4: 1.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#127#123#article#202#</font><
/p>     ^cY#aop01611.htm##
00518000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025700090002001300347#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#128#124#article#
202#30#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30.	Brownl
ey KA, West SG, Hinderliter AL, Light KC. Acute aerobic exercise reduces ambulat
ory blood pressure in borderline hypertensive men and women. Am J Hypertens. 199
6; 9 (3): 200-6.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#129#125#article#202#</font><
/p>     ^cY#aop01611.htm##
00570000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030900090002001300399#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#130#126#article#
202#31#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31.	Ciolac
 EG, Guimaraes GV, D'Avila VM, Bortolotto LA, Doria EL, Bocchi EA. Acute aerobic
 exercise reduces 24-h ambulatory blood pressure levels in long-term-treated hyp
ertensive patients. Clinics (S&atilde;o Paulo). 2008; 63 (6): 753-8.    ^cY#aop0
1611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#131#127#article#202#</font><
/p>     ^cY#aop01611.htm##
00581000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032000090002001300410#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#132#128#article#
202#32#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32.	Ciolac
 EG, Guimaraes GV, D'Avila VM, Bortolotto LA, Doria EL, Bocchi EA. Acute effects
 of continuous and interval aerobic exercise on 24-h ambulatory blood pressure i
n long-term treated hypertensive patients. Int J Cardiol. 2009; 133 (3): 381-7. 
   ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#133#129#article#202#</font><
/p>     ^cY#aop01611.htm##
00602000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034100090002001300431#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#134#130#article#
202#33#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33.	Cunha 
GA, Rios ACS, Moreno JR, Braga PL, Campbell CSG, Sim&otilde;es HG, et al. Post-e
xercise hypotension in hypertensive individuals submitted to aerobic exercises o
f alternated intensities and constant intensity-exercise. Rev Bras Med Esporte. 
2006; 12 (6): 313-7.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#135#131#article#202#</font><
/p>     ^cY#aop01611.htm##
00492000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023100090002001300321#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#136#132#article#
202#34#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34.	Hagber
g JM, Montain SJ, Martin WH, 3rd. Blood pressure and hemodynamic responses after
 exercise in older hypertensives. J Appl Physiol. 1987; 63 (1): 270-6.    ^cY#ao
p01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#137#133#article#202#</font><
/p>     ^cY#aop01611.htm##
00548000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028700090002001300377#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#138#134#article#
202#35#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35.	Taylor
-Tolbert NS, Dengel DR, Brown MD, McCole SD, Pratley RE, Ferrell RE, et al. Ambu
latory blood pressure after acute exercise in older men with essential hypertens
ion. Am J Hypertens. 2000; 13 (1 pt 1): 44-51.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#139#135#article#202#</font><
/p>     ^cY#aop01611.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030500090002001300395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#140#136#article#
202#36#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36.	Pontes
 FL Jr, Bacurau RF, Moraes MR, Navarro F, Casarini DE, Pesquero JL, et al. Kalli
krein kinin system activation in post-exercise hypotension in water running of h
ypertensive volunteers. Int Immunopharmacol. 2008; 8 (2): 261-6.    ^cY#aop01611
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#141#137#article#202#</font><
/p>     ^cY#aop01611.htm##
00527000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026600090002001300356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#142#138#article#
202#37#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37.	Bennet
t T, Wilcox RG, Macdonald IA. Post-exercise reduction of blood pressure in hyper
tensive men is not due to acute impairment of baroreflex function. Clin Sci (Lon
d). 1984; 67 (1): 97-103.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#143#139#article#202#</font><
/p>     ^cY#aop01611.htm##
00517000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025600090002001300346#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#144#140#article#
202#38#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38.	Ruecke
rt PA, Slane PR, Lillis DL, Hanson P. Hemodynamic patterns and duration of post-
dynamic exercise hypotension in hypertensive humans. Med Sci Sports Exerc. 1996;
 28 (1): 24-32.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#145#141#article#202#</font><
/p>     ^cY#aop01611.htm##
00509000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024800090002001300338#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#146#142#article#
202#39#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39.	Clerou
x J, Kouame N, Nadeau A, Coulombe D, Lacourciere Y. Aftereffects of exercise on 
regional and systemic hemodynamics in hypertension. Hypertension. 1992; 19 (2): 
183-91.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#147#143#article#202#</font><
/p>     ^cY#aop01611.htm##
00472000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021100090002001300301#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#148#144#article#
202#40#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40.	Wilcox
 RG, Bennett T, Brown AM, Macdonald IA. Is exercise good for high blood pressure
? Br Med J (Clin Res Ed). 1982; 285 (6344): 767-9.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#149#145#article#202#</font><
/p>     ^cY#aop01611.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029900090002001300389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#150#146#article#
202#41#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">41.	Guidry
 MA, Blanchard BE, Thompson PD, Maresh CM, Seip RL, Taylor AL, et al. The influe
nce of short and long duration on the blood pressure response to an acute bout o
f dynamic exercise. Am Heart J. 2006; 151 (6): 1322.e5-12.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#151#147#article#202#</font><
/p>     ^cY#aop01611.htm##
00552000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029100090002001300381#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#152#148#article#
202#42#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">42.	MacDon
ald JR, Hogben CD, Tarnopolsky MA, MacDougall JD. Post exercise hypotension is s
ustained during subsequent bouts of mild exercise and simulated activities of da
ily living. J Hum Hypertens. 2001; 15 (8): 567-71.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#153#149#article#202#</font><
/p>     ^cY#aop01611.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030500090002001300395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#154#150#article#
202#43#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">43.	MacDon
ald JR, Rosenfeld JM, Tarnopolsky MA, Hogben CD, Ballantyne CS, MacDougall JD. P
ost exercise hypotension is not mediated by the serotonergic system in borderlin
e hypertensive individuals. J Hum Hypertens. 2002; 16 (1): 33-9.    ^cY#aop01611
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#155#151#article#202#</font><
/p>     ^cY#aop01611.htm##
00468000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020700090002001300297#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#156#152#article#
202#44#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">44.	Halliw
ill JR. Mechanisms and clinical implications of post-exercise hypotension in hum
ans. Exerc Sport Sci Rev. 2001; 29 (2): 65-70.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#157#153#article#202#</font><
/p>     ^cY#aop01611.htm##
00484000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022300090002001300313#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#158#154#article#
202#45#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">45.	Mach C
, Foster C, Brice G, Mikat RP, Porcari JP. Effect of exercise duration on postex
ercise hypotension. J Cardiopulm Rehabil. 2005; 25 (6): 366-9.    ^cY#aop01611.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#159#155#article#202#</font><
/p>     ^cY#aop01611.htm##
00476000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021500090002001300305#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#160#156#article#
202#46#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">46.	MacDon
ald JR, MacDougall JD, Hogben CD. The effects of exercise duration on post-exerc
ise hypotension. J Hum Hypertens. 2000; 14 (2): 125-9.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#161#157#article#202#</font><
/p>     ^cY#aop01611.htm##
00424000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704016300090002001300253#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#162#158#article#
202#47#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">47.	Brande
s RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005; 66 (2): 286-9
4.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#163#159#article#202#</font><
/p>     ^cY#aop01611.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027200090002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#164#160#article#
202#48#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">48.	Rao SP
, Collins HL, DiCarlo SE. Postexercise alpha-adrenergic receptor hyporesponsiven
ess in hypertensive rats is due to nitric oxide. Am J Physiol Regul Integr Comp 
Physiol. 2002; 282 (4): R960-8.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#165#161#article#202#</font><
/p>     ^cY#aop01611.htm##
00556000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029500090002001300385#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#166#162#article#
202#49#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">49.	Boushe
l R, Langberg H, Gemmer C, Olesen J, Crameri R, Scheede C, et al. Combined inhib
ition of nitric oxide and prostaglandins reduces human skeletal muscle blood flo
w during exercise. J Physiol. 2002; 543 (Pt 2): 691-8.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#167#163#article#202#</font><
/p>     ^cY#aop01611.htm##
00527000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026600090002001300356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#168#164#article#
202#50#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">50.	Duffy 
SJ, New G, Tran BT, Harper RW, Meredith IT. Relative contribution of vasodilator
 prostanoids and NO to metabolic vasodilation in the human forearm. Am J Physiol
. 1999; 276 (2): H663-70.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#169#165#article#202#</font><
/p>     ^cY#aop01611.htm##
00558000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029700090002001300387#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#170#166#article#
202#51#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">51.	Morten
sen SP, Nyberg M, Thaning P, Saltin B, Hellsten Y. Adenosine contributes to bloo
d flow regulation in the exercising human leg by increasing prostaglandin and ni
tric oxide formation. Hypertension. 2009; 53 (6): 993-9.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#171#167#article#202#</font><
/p>     ^cY#aop01611.htm##
00500000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023900090002001300329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#172#168#article#
202#52#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">52.	Halliw
ill JR, Minson CT, Joyner MJ. Effect of systemic nitric oxide synthase inhibitio
n on postexercise hypotension in humans. J Appl Physiol. 2000; 89 (5): 1830-6.  
  ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#173#169#article#202#</font><
/p>     ^cY#aop01611.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027200090002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#174#170#article#
202#53#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">53.	Lockwo
od JM, Pricher MP, Wilkins BW, Holowatz LA, Halliwill JR. Postexercise hypotensi
on is not explained by a prostaglandin-dependent peripheral vasodilation. J Appl
 Physiol. 2005; 98 (2): 447-53.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#175#171#article#202#</font><
/p>     ^cY#aop01611.htm##
00508000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024700090002001300337#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#176#172#article#
202#54#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">54.	Floras
 JS, Sinkey CA, Aylward PE, Seals DR, Thoren PN, Mark AL. Postexercise hypotensi
on and sympathoinhibition in borderline hypertensive men. Hypertension. 1989;14:
28-35.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#177#173#article#202#</font><
/p>     ^cY#aop01611.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022900090002001300319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#178#174#article#
202#55#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">55.	Halliw
ill JR, Taylor JA, Eckberg DL. Impaired sympathetic vascular regulation in human
s after acute dynamic exercise. J Physiol. 1996; 495 (Pt 1): 279-88.    ^cY#aop0
1611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#179#175#article#202#</font><
/p>     ^cY#aop01611.htm##
00494000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023300090002001300323#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#180#176#article#
202#56#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">56.	Kulics
 JM, Collins HL, DiCarlo SE. Postexercise hypotension is mediated by reductions 
in sympathetic nerve activity. Am J Physiol. 1999; 276 (1 pt 2): H27-32.    ^cY#
aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#181#177#article#202#</font><
/p>     ^cY#aop01611.htm##
00483000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022200090002001300312#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#182#178#article#
202#57#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">57.	Frankl
in PJ, Green DJ, Cable NT. The influence of thermoregulatory mechanisms on post-
exercise hypotension in humans. J Physiol. 1993; 470: 231-41.    ^cY#aop01611.ht
m##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#183#179#article#202#</font><
/p>     ^cY#aop01611.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027100090002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#184#180#article#
202#58#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">58.	Priche
r MP, Holowatz LA, Williams JT, Lockwood JM, Halliwill JR. Regional hemodynamics
 during postexercise hypotension. I. Splanchnic and renal circulations. J Appl P
hysiol. 2004; 97 (6): 2065-70.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#185#181#article#202#</font><
/p>     ^cY#aop01611.htm##
00492000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023100090002001300321#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#186#182#article#
202#59#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">59.	Wilkin
s BW, Minson CT, Halliwill JR. Regional hemodynamics during postexercise hypoten
sion. II. Cutaneous circulation. J Appl Physiol. 2004; 97 (6): 2071-6.    ^cY#ao
p01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#187#183#article#202#</font><
/p>     ^cY#aop01611.htm##
00505000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024400090002001300334#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#188#184#article#
202#60#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">60.	Willia
mson JW, McColl R, Mathews D. Changes in regional cerebral blood flow distributi
on during postexercise hypotension in humans. J Appl Physiol. 2004; 96 (2): 719-
24.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#189#185#article#202#</font><
/p>     ^cY#aop01611.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028500090002001300375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#190#186#article#
202#61#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">61.	Clerou
x J, Kouame N, Nadeau A, Coulombe D, Lacourciere Y. Baroreflex regulation of for
earm vascular resistance after exercise in hypertensive and normotensive humans.
 Am J Physiol. 1992; 263 (5 pt 2): H1523-31.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#191#187#article#202#</font><
/p>     ^cY#aop01611.htm##
00507000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024600090002001300336#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#192#188#article#
202#62#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">62.	Halliw
ill JR, Taylor JA, Hartwig TD, Eckberg DL. Augmented baroreflex heart rate gain 
after moderate-intensity, dynamic exercise. Am J Physiol. 1996; 270 (2 pt 2): R4
20-6.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#193#189#article#202#</font><
/p>     ^cY#aop01611.htm##
00506000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024500090002001300335#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#194#190#article#
202#63#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">63.	Kriege
r EM, Brum PC, Negrao CE. Role of arterial baroreceptor function on cardiovascul
ar adjustments to acute and chronic dynamic exercise. Biol Res. 1998; 31 (3): 27
3-9.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#195#191#article#202#</font><
/p>     ^cY#aop01611.htm##
00510000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024900090002001300339#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#196#192#article#
202#64#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">64.	Muxfel
dt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood press
ure monitoring pattern of resistant hypertension. Blood Press Monit. 2003; 8 (5)
: 181-5.    ^cY#aop01611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#197#193#article#202#</font><
/p>     ^cY#aop01611.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#198#194#article#202#<p>&nbsp
;</p>     ^cY#aop01611.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#199#195#article#202#<p>&nbsp
;</p>     ^cY#aop01611.htm##
00446000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020000087002001300287#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#200#196#article#202#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg"border="0"></a> <b>Cor
respond&ecirc;ncia: </b>    ^cY#aop01611.htm##
00285000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003900087002001300126#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#201#197#article#202#<br>   M
arcos Doederlein Polito    ^cY#aop01611.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010400087002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#202#198#article#202#<br>   D
epartamento de Educa&ccedil;&atilde;o F&iacute;sica - Universidade Estadual de L
ondrina     ^cY#aop01611.htm##
00294000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004800087002001300135#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#203#199#article#202#<br>   R
odovia Celso Garcia Cid, km 380     ^cY#aop01611.htm##
00293000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004700087002001300134#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#204#200#article#202#<br>   8
6051-980 - Londrina, PR, Brasil    ^cY#aop01611.htm##
00341000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009500087002001300182#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#205#201#article#202#<br>   E
-mail: <a href="mailto:marcospolito@uel.br">marcospolito@uel.br</a></font></p>  
   ^cY#aop01611.htm##
00409000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016300087002001300250#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01611.htm#S#p#206#202#article#202#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 02/10/
09; revisado recebido em 11/12/09;  aceito em 12/02/10.</font></p>     ^cY#aop01
611.htm##
00677000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100020001030100
01400123010001700137010001800154010001900172810000600191012010400197030000800301
71000020030906500090031106400050032003100020032501400020032786500090032900200130
0338#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#207#1#ar
ticle#64#1#^rND^sCooper^nRS#^rND^sWolf-Maier^nK#^rND^sLuke^nA#^rND^sAdeyemo^nA#^
rND^sBanegas^nJR#^rND^sForrester^nT#et al#An international comparative study of 
blood pressure in populations of European vs. African descent^len#BMC Med#2#2005
0000#2005#3#2#20110000#aop01611.htm##
00765000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100017001060100
01600123010001800139010001600157010001800173810000600191012014800197030000500345
06500090035006400050035903100040036403200020036801400080037086500090037800200130
0387035001000400801000500410#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01611.htm#S#c#208#2#article#64#2#^rND^sChobanian^nAV#^rND^sBakris^nGL#^rND^sBl
ack^nHR#^rND^sCushman^nWC#^rND^sGreen^nLA#^rND^sIzzo Jr^nJL#et al#The Seventh Re
port of the Joint National Committee on Prevention, Detection, Evaluation, and T
reatment of High Blood Pressure: the JNC 7 report^len#JAMA#20030000#2003#289#6#2
560-72#20110000#aop01611.htm#0098-7484#JAMA##
00531000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840110036000860120053001220300
01700175065000900192064000500201031000300206014000700209865000900216002001300225
035001000238801001700248#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
611.htm#S#c#209#3#article#64#3#Sociedade Brasileira de Cardiologia#V Diretrizes 
brasileiras de hipertensão arterial^lpt#Arq Bras Cardiol#20070000#2007#89#e24-79
#20110000#aop01611.htm#0066-782X#Arq Bras Cardiol##
00713000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100019001070100
01600126010001900142010001700161010001400178012008200192030002100274065000900295
06400050030403100030030903200030031201400070031586500090032200200130033103500100
0344801002100354#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#210#4#article#64#4#^rND^sPescatello^nLS#^rND^sFranklin^nBA#^rND^sFagard^nR#^
rND^sFarquhar^nWB#^rND^sKelley^nGA#^rND^sRay^nCA#American College of Sports Medi
cine position stand: Exercise and hypertension^len#Med Sci Sports Exerc#20040000
#2004#36#10#533-53#20110000#aop01611.htm#0195-9131#Med Sci Sports Exerc##
00575000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030120
08200119030001300201065000900214064000500223031000300228032000200231014000700233
865000900240002001300249035001000262801001300272#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01611.htm#S#c#211#5#article#64#5#^rND^sKenney^nMJ#^rND^sSe
als^nDR#Postexercise hypotension: key features, mechanisms, and clinical signifi
cance^len#Hypertension#19930000#1993#22#5#653-64#20110000#aop01611.htm#0194-911X
#Hypertension##
00567000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860120076001060300
02300182065000900205064000500214031000400219032000500223014000600228865000900234
002001300243035001000256801002300266#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01611.htm#S#c#212#6#article#64#6#^rND^sFitzgerald^nW#Labile hypertensi
on and jogging: new diagnostic tool or spurious discovery?#Br Med J (Clin Res Ed
)#19810000#1981#282#6263#542-4#20110000#aop01611.htm#0267-0623#Br Med J (Clin Re
s Ed)##
00554000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860120080001060300
01600186065000900202064000500211031000300216032000200219014000700221865000900228
002001300237035001000250801001600260#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01611.htm#S#c#213#7#article#64#7#^rND^sMacDonald^nJR#Potential causes,
 mechanisms, and implications of post exercise hypotension^len#J Hum Hypertens#2
0020000#2002#16#4#225-36#20110000#aop01611.htm#0950-9240#J Hum Hypertens##
00711000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100024001010100
01700125010001700142010001700159012011600176030001800292065000900310064000500319
03100030032403200020032701400060032986500090033500200130034403500100035780100180
0367#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#214#8#ar
ticle#64#8#^rND^sMelo^nCM#^rND^sAlencar Filho^nAC#^rND^sTinucci^nT#^rND^sMion Jr
^nD#^rND^sForjaz^nCL#Postexercise hypotension induced by low-intensity resistanc
e exercise in hypertensive women receiving captopril^len#Blood Press Monit#20060
000#2006#11#4#183-9#20110000#aop01611.htm#1359-5237#Blood Press Monit##
00553000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860120115001030300
02000218710000200238065000900240064000500249031000300254032000200257014000600259
865000900265002001300274#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
611.htm#S#c#215#9#article#64#9#^rND^sFisher^nMM#The effect of resistance exercis
e on recovery blood pressure in normotensive and borderline hypertensive women^l
en#J Strength Cond Res#2#20010000#2001#15#2#210-6#20110000#aop01611.htm##
00626000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040120
12000121030001900241065000900260064000500269031000300274032000200277014000600279
865000900285002001300294035001000307801001900317#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01611.htm#S#c#216#10#article#64#10#^rND^sHardy^nDO#^rND^sT
ucker^nLA#The effects of a single bout of strength training on ambulatory blood 
pressure levels in 24 mildly hypertensive men^len#Am J Health Promot#19980000#19
98#13#2#69-72#20110000#aop01611.htm#0890-1171#Am J Health Promot##
00723000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01800123010001500141010001900156010001700175810000600192012009600198030001000294
06500090030406400050031303100040031803200020032201400070032486500090033100200130
0340035001000353801001000363#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01611.htm#S#c#217#11#article#64#11#^rND^sMoraes^nMR#^rND^sBacurau^nRF#^rND^sRa
malho^nJD#^rND^sReis^nFC#^rND^sCasarini^nDE#^rND^sChagas^nJR#et al#Increase in k
inins on post-exercise hypotension in normotensive and hypertensive volunteers^l
en#Biol Chem#20070000#2007#388#5#533-40#20110000#aop01611.htm#1431-6730#Biol Che
m##
00714000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100020001080100
01500128010001700143010001700160012010400177030002100281065000900302064000500311
031000300316014000700319865000900326002001300335035001000348801004200358#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#218#12#article#64#12
#^rND^sMediano^nMFFP#^rND^sParavidino^nV#^rND^sSimão^nR#^rND^sPontes^nFL#^rND^sP
olito^nMD#Subacute behavior of the blood pressure after power training in contro
lled hypertensive individuals^len#Rev Bras Med Esporte#20050000#2005#11#337-40#2
0110000#aop01611.htm#1517-8692#Revista Brasileira de Medicina do Esporte##
00758000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100020001080100
01700128010001800145010001600163010001700179810000600196012011100202030001900313
06500090033206400050034103100030034603200020034901400060035186500090035700200130
0366035001000379801001900389#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01611.htm#S#c#219#13#article#64#13#^rND^sBlanchard^nBE#^rND^sTsongalis^nGJ#^rN
D^sGuidry^nMA#^rND^sLaBelle^nLA#^rND^sPoulin^nM#^rND^sTaylor^nAL#et al#RAAS poly
morphisms alter the acute blood pressure response to aerobic exercise among men 
with hypertension^len#Eur J Appl Physiol#20060000#2006#97#1#26-33#20110000#aop01
611.htm#0301-5548#Eur J Appl Physiol##
00629000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100016001090100
01900125010001900144012006900163030001200232065000900244064000500253031000300258
032000200261014000800263865000900271002001300280035001000293801001200303#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#220#14#article#64#14
#^rND^sPescatello^nLS#^rND^sFargo^nAE#^rND^sLeach Jr^nCN#^rND^sScherzer^nHH#Shor
t-term effect of dynamic exercise on arterial blood pressure^len#Circulation#199
10000#1991#83#5#1557-61#20110000#aop01611.htm#0009-7322#Circulation##
00722000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100016001090100
01700125010001600142010001400158010001500172810000600187012009800193030001100291
06500090030206400050031103100040031603200020032001400070032286500090032900200130
0338035001000351801001100361#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01611.htm#S#c#221#15#article#64#15#^rND^sPescatello^nLS#^rND^sMiller^nB#^rND^s
Danias^nPG#^rND^sWerner^nM#^rND^sHess^nM#^rND^sBaker^nC#et al#Dynamic exercise n
ormalizes resting blood pressure in mildly hypertensive premenopausal women^len#
Am Heart J#19990000#1999#138#5#916-21#20110000#aop01611.htm#0002-8703#Am Heart J
##
00585000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120113001040300
01600217065000900233064000500242031000300247032000200250014000700252865000900259
002001300268035001000281801001600291#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01611.htm#S#c#222#16#article#64#16#^rND^sQuinn^nTJ#Twenty-four hour, a
mbulatory blood pressure responses following acute exercise: impact of exercise 
intensity^len#J Hum Hypertens#20000000#2000#14#9#547-53#20110000#aop01611.htm#09
50-9240#J Hum Hypertens##
00577000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040120
06700123030001900190065000900209064000500218031000400223032000200227014000700229
865000900236002001300245035001000258801001900268#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01611.htm#S#c#223#17#article#64#17#^rND^sMoyna^nNM#^rND^sT
hompson^nPD#The effect of physical activity on endothelial function in man^len#A
cta Physiol Scand#20040000#2004#180#2#113-23#20110000#aop01611.htm#0001-6772#Act
a Physiol Scand##
00618000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01200122010001300134012007400147030001300221065000900234064000500243031000300248
032000200251014000600253865000900259002001300268035001000281801001300291#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#224#18#article#64#18
#^rND^sBrown^nSP#^rND^sClemons^nJM#^rND^sHe^nQ#^rND^sLiu^nS#Effects of resistanc
e exercise and cycling on recovery blood pressure^len#J Sports Sci#19940000#1994
#12#5#463-8#20110000#aop01611.htm#0264-0414#J Sports Sci##
00664000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01700122010001800139012009400157030002100251065000900272064000500281031000300286
032000200289014000600291865000900297002001300306035001000319801002100329#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#225#19#article#64#19
#^rND^sRoltsch^nMH#^rND^sMendez^nT#^rND^sWilund^nKR#^rND^sHagberg^nJM#Acute resi
stive exercise does not affect ambulatory blood pressure in young men and women^
len#Med Sci Sports Exerc#20010000#2001#33#6#881-6#20110000#aop01611.htm#0195-913
1#Med Sci Sports Exerc##
00711000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01700122010001700139010001700156012011600173030001900289065000900308064000500317
03100030032203200020032501400070032786500090033400200130034303500100035680100190
0366#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#226#20#a
rticle#64#20#^rND^sRezk^nCC#^rND^sMarrache^nRC#^rND^sTinucci^nT#^rND^sMion Jr^nD
#^rND^sForjaz^nCL#Post-resistance exercise hypotension, hemodynamics, and heart 
rate variability: influence of exercise intensity^len#Eur J Appl Physiol#2006000
0#2006#98#1#105-12#20110000#aop01611.htm#0301-5548#Eur J Appl Physiol##
00560000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070120
06900122030001000191065000900201064000500210031000400215032000200219014000700221
865000900228002001300237035001000250801001000260#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01611.htm#S#c#227#21#article#64#21#^rND^sPesquero^nJB#^rND
^sBader^nM#Genetically altered animal models in the kallikrein-kinin system^len#
Biol Chem#20060000#2006#387#2#119-26#20110000#aop01611.htm#1431-6730#Biol Chem##
00635000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01800124012009200142030002100234065000900255064000500264031000300269032000200272
014000600274865000900280002001300289035001000302801002100312#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#228#22#article#64#22#^rND^sKaufm
an^nFL#^rND^sHughson^nRL#^rND^sSchaman^nJP#Effect of exercise on recovery blood 
pressure in normotensive and hypertensive subjects^len#Med Sci Sports Exerc#1987
0000#1987#19#1#17-20#20110000#aop01611.htm#0195-9131#Med Sci Sports Exerc##
00695000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100025000880100016001130100
01600129010001900145010001800164810000600182012007500188030001800263065000900281
06400050029003100030029503200020029801400070030086500090030700200130031603500100
0329801001800339#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#229#23#article#64#23#^rND^sBrandão Rondon^nMU#^rND^sAlves^nMJ#^rND^sBraga^nA
M#^rND^sTeixeira^nOT#^rND^sBarreto^nAC#et al#Postexercise blood pressure reducti
on in elderly hypertensive patients^len#J Am Coll Cardiol#20020000#2002#39#4#676
-82#20110000#aop01611.htm#0735-1097#J Am Coll Cardiol##
00771000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100020001030100
01700123010001700140010001900157010001600176810000600192012013900198030001300337
06500090035006400050035903100030036403200020036701400070036986500090037600200130
0385035001000398801001300408#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01611.htm#S#c#230#24#article#64#24#^rND^sSyme^nAN#^rND^sBlanchard^nBE#^rND^sGu
idry^nMA#^rND^sTaylor^nAW#^rND^sVanheest^nJL#^rND^sHasson^nS#et al#Peak systolic
 blood pressure on a graded maximal exercise test and the blood pressure respons
e to an acute bout of submaximal exercise^len#Am J Cardiol#20060000#2006#98#7#93
8-43#20110000#aop01611.htm#0002-9149#Am J Cardiol##
00714000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01700122010002000139010001700159010001700176012008800193030001800281065000900299
06400050030803100020031303200040031501400070031986500090032600200130033503500100
0348801001800358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#231#25#article#64#25#^rND^sForjaz^nCL#^rND^sTinucci^nT#^rND^sOrtega^nKC#^rND
^sSantaella^nDF#^rND^sMion Jr^nD#^rND^sNegrao^nCE#Factors affecting post-exercis
e hypotension in normotensive and hypertensive humans^len#Blood Press Monit#2000
0000#2000#5#5-6#255-62#20110000#aop01611.htm#1359-5237#Blood Press Monit##
00697000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01500122010001900137010002100156012009200177030001500269065000900284064000500293
03100030029803200020030103400020030301400070030586500090031200200130032103500100
0334801001500344#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#232#26#article#64#26#^rND^sWallace^nJP#^rND^sBogle^nPG#^rND^sKing^nBA#^rND^s
Krasnoff^nJB#^rND^sJastremski^nCA#A comparison of 24-h average blood pressures a
nd blood pressure load following exercise^len#Am J Hypertens#19970000#1997#10#7#
1#728-34#20110000#aop01611.htm#0895-7061#Am J Hypertens##
00687000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01500122010001900137010002100156012009500177030001600272065000900288064000500297
03100030030203200020030501400060030786500090031300200130032203500100033580100160
0345#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#233#27#a
rticle#64#27#^rND^sWallace^nJP#^rND^sBogle^nPG#^rND^sKing^nBA#^rND^sKrasnoff^nJB
#^rND^sJastremski^nCA#The magnitude and duration of ambulatory blood pressure re
duction following acute exercise^len#J Hum Hypertens#19990000#1999#13#6#361-6#20
110000#aop01611.htm#0950-9240#J Hum Hypertens##
00689000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100017001090100
02000126010001400146010001700160010001800177810000600195012005500201030001200256
06500090026806400050027703100030028203200030028501400070028886500090029500200130
0304035001000317801001200327#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01611.htm#S#c#234#28#article#64#28#^rND^sPescatello^nLS#^rND^sGuidry^nMA#^rND^
sBlanchard^nBE#^rND^sKerr^nA#^rND^sTaylor^nAL#^rND^sJohnson^nAN#et al#Exercise i
ntensity alters postexercise hypotension^len#J Hypertens#20040000#2004#22#10#188
1-8#20110000#aop01611.htm#0263-6352#J Hypertens##
00746000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100016001090100
01900125010002000144010002000164010001700184810000600201012015300207030001800360
71000020037806500090038006400050038903100020039401400020039686500090039800200130
0407#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#235#29#a
rticle#64#29#^rND^sPescatello^nLS#^rND^sTurner^nD#^rND^sRodriguez^nN#^rND^sBlanc
hard^nBE#^rND^sTsongalis^nGJ#^rND^sMaresh^nCM#et al#Dietary calcium intake and r
enin angiotensin system polymorphisms alter the blood pressure response to aerob
ic exercise: a randomized control design^len#Nutr Metab (Lond)#2#20070000#2007#4
#1#20110000#aop01611.htm##
00662000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
02200122010001600144012010200160030001500262065000900277064000500286031000200291
032000200293014000600295865000900301002001300310035001000323801001500333#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#236#30#article#64#30
#^rND^sBrownley^nKA#^rND^sWest^nSG#^rND^sHinderliter^nAL#^rND^sLight^nKC#Acute a
erobic exercise reduces ambulatory blood pressure in borderline hypertensive men
 and women^len#Am J Hypertens#19960000#1996#9#3#200-6#20110000#aop01611.htm#0895
-7061#Am J Hypertens##
00707000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01700125010002100142010001600163010001700179012011600196030002000312710000200332
06500090033406400050034303100030034803200020035101400060035386500090035900200130
0368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#237#31#a
rticle#64#31#^rND^sCiolac^nEG#^rND^sGuimaraes^nGV#^rND^sD'Avila VM#^rND^sBortolo
tto^nLA#^rND^sDoria^nEL#^rND^sBocchi^nEA#Acute aerobic exercise reduces 24-h amb
ulatory blood pressure levels in long-term-treated hypertensive patients^len#Cli
nics (São Paulo)#2#20080000#2008#63#6#753-8#20110000#aop01611.htm##
00759000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01700125010002100142010001600163010001700179012013900196030001400335065000900349
06400050035803100040036303200020036701400060036986500090037500200130038403500100
0397801001400407#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#238#32#article#64#32#^rND^sCiolac^nEG#^rND^sGuimaraes^nGV#^rND^sD'Avila VM#^
rND^sBortolotto^nLA#^rND^sDoria^nEL#^rND^sBocchi^nEA#Acute effects of continuous
 and interval aerobic exercise on 24-h ambulatory blood pressure in long-term tr
eated hypertensive patients^len#Int J Cardiol#20090000#2009#133#3#381-7#20110000
#aop01611.htm#0167-5273#Int J Cardiol##
00813000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01700120010001600137010002000153010001700173810000600190012014700196030002100343
06500090036406400050037303100030037803200020038101400060038386500090038900200130
0398035001000411801004200421#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01611.htm#S#c#239#33#article#64#33#^rND^sCunha^nGA#^rND^sRios^nACS#^rND^sMoren
o^nJR#^rND^sBraga^nPL#^rND^sCampbell^nCSG#^rND^sSimões^nHG#et al#Post-exercise h
ypotension in hypertensive individuals submitted to aerobic exercises of alterna
ted intensities and constant intensity-exercise^len#Rev Bras Med Esporte#2006000
0#2006#12#6#313-7#20110000#aop01611.htm#1517-8692#Revista Brasileira de Medicina
 do Esporte##
00619000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
02300124012008300147030001500230065000900245064000500254031000300259032000200262
014000600264865000900270002001300279035001000292801001500302#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#240#34#article#64#34#^rND^sHagbe
rg^nJM#^rND^sMontain^nSJ#^rND^sMartin^nWH. 3rd.#Blood pressure and hemodynamic r
esponses after exercise in older hypertensives^len#J Appl Physiol#19870000#1987#
63#1#270-6#20110000#aop01611.htm#0021-8987#J Appl Physiol##
00748000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100025000880100017001130100
01600130010001700146010001800163010001800181810000600199012009200205030001500297
06500090031206400050032103100030032603200020032903400020033101400060033386500090
0339002001300348035001000361801001500371#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop01611.htm#S#c#241#35#article#64#35#^rND^sTaylor-Tolbert^nNS#^rND^s
Dengel^nDR#^rND^sBrown^nMD#^rND^sMcCole^nSD#^rND^sPratley^nRE#^rND^sFerrell^nRE#
et al#Ambulatory blood pressure after acute exercise in older men with essential
 hypertension^len#Am J Hypertens#20000000#2000#13#1#1#44-51#20110000#aop01611.ht
m#0895-7061#Am J Hypertens##
00722000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100018001080100
01700126010001700143010001900160010001900179810000600198012011200204030002000316
71000020033606500090033806400050034703100020035203200020035401400060035686500090
0362002001300371#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#242#36#article#64#36#^rND^sPontes Jr^nFL#^rND^sBacurau^nRF#^rND^sMoraes^nMR#
^rND^sNavarro^nF#^rND^sCasarini^nDE#^rND^sPesquero^nJL#et al#Kallikrein kinin sy
stem activation in post-exercise hypotension in water running of hypertensive vo
lunteers^len#Int Immunopharmacol#2#20080000#2008#8#2#261-6#20110000#aop01611.htm
##
00618000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
02000122012012000142030001600262710000200278065000900280064000500289031000300294
032000200297014000700299865000900306002001300315#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01611.htm#S#c#243#37#article#64#37#^rND^sBennett^nT#^rND^s
Wilcox^nRG#^rND^sMacdonald^nIA#Post-exercise reduction of blood pressure in hype
rtensive men is not due to acute impairment of baroreflex function^len#Clin Sci 
(Lond)#2#19840000#1984#67#1#97-103#20110000#aop01611.htm##
00667000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01700123010001600140012009800156030002100254065000900275064000500284031000300289
032000200292014000600294865000900300002001300309035001000322801002100332#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#244#38#article#64#38
#^rND^sRueckert^nPA#^rND^sSlane^nPR#^rND^sLillis^nDL#^rND^sHanson^nP#Hemodynamic
 patterns and duration of post-dynamic exercise hypotension in hypertensive huma
ns^len#Med Sci Sports Exerc#19960000#1996#28#1#24-32#20110000#aop01611.htm#0195-
9131#Med Sci Sports Exerc##
00669000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01600121010001800137010002100155012008300176030001300259065000900272064000500281
03100030028603200020028901400070029186500090029800200130030703500100032080100130
0330#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#245#39#a
rticle#64#39#^rND^sCleroux^nJ#^rND^sKouame^nN#^rND^sNadeau^nA#^rND^sCoulombe^nD#
^rND^sLacourciere^nY#Aftereffects of exercise on regional and systemic hemodynam
ics in hypertension^len#Hypertension#19920000#1992#19#2#183-91#20110000#aop01611
.htm#0194-911X#Hypertension##
00624000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01600122010002000138012004500158030002300203065000900226064000500235031000400240
032000500244014000600249865000900255002001300264035001000277801002300287#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#246#40#article#64#40
#^rND^sWilcox^nRG#^rND^sBennett^nT#^rND^sBrown^nAM#^rND^sMacdonald^nIA#Is exerci
se good for high blood pressure^len#Br Med J (Clin Res Ed)#19820000#1982#285#634
4#767-9#20110000#aop01611.htm#0267-0623#Br Med J (Clin Res Ed)##
00758000000000361000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01900125010001700144010001500161010001700176810000600193012011300199030001100312
06500090032306400050033203100040033703200020034102000050034301400050034886500090
0353002001300362035001000375801001100385#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop01611.htm#S#c#247#41#article#64#41#^rND^sGuidry^nMA#^rND^sBlanchar
d^nBE#^rND^sThompson^nPD#^rND^sMaresh^nCM#^rND^sSeip^nRL#^rND^sTaylor^nAL#et al#
The influence of short and long duration on the blood pressure response to an ac
ute bout of dynamic exercise^len#Am Heart J#20060000#2006#151#6#1322#5-12#201100
00#aop01611.htm#0002-8703#Am Heart J##
00697000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
02200125010002100147012012500168030001600293065000900309064000500318031000300323
032000200326014000700328865000900335002001300344035001000357801001600367#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#248#42#article#64#42
#^rND^sMacDonald^nJR#^rND^sHogben^nCD#^rND^sTarnopolsky^nMA#^rND^sMacDougall^nJD
#Post exercise hypotension is sustained during subsequent bouts of mild exercise
 and simulated activities of daily living^len#J Hum Hypertens#20010000#2001#15#8
#567-71#20110000#aop01611.htm#0950-9240#J Hum Hypertens##
00747000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100020001080100
02200128010001700150010002100167010002100188012011200209030001600321065000900337
06400050034603100030035103200020035401400050035686500090036100200130037003500100
0383801001600393#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#249#43#article#64#43#^rND^sMacDonald^nJR#^rND^sRosenfeld^nJM#^rND^sTarnopols
ky^nMA#^rND^sHogben^nCD#^rND^sBallantyne^nCS#^rND^sMacDougall^nJD#Post exercise 
hypotension is not mediated by the serotonergic system in borderline hypertensiv
e individuals^len#J Hum Hypertens#20020000#2002#16#1#33-9#20110000#aop01611.htm#
0950-9240#J Hum Hypertens##
00563000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880120080001080300
02000188065000900208064000500217031000300222032000200225014000600227865000900233
002001300242035001000255801002000265#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01611.htm#S#c#250#44#article#64#44#^rND^sHalliwill^nJR#Mechanisms and 
clinical implications of post-exercise hypotension in humans^len#Exerc Sport Sci
 Rev#20010000#2001#29#2#65-70#20110000#aop01611.htm#0091-6331#Exerc Sport Sci Re
v##
00652000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100016001020100
01500118010001600133010001800149012006000167030002100227065000900248064000500257
03100030026203200020026501400060026786500090027300200130028203500100029580100210
0305#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#251#45#a
rticle#64#45#^rND^sMach^nC#^rND^sFoster^nC#^rND^sBrice^nG#^rND^sMikat^nRP#^rND^s
Porcari^nJP#Effect of exercise duration on postexercise hypotension^len#J Cardio
pulm Rehabil#20050000#2005#25#6#366-9#20110000#aop01611.htm#0883-9212#J Cardiopu
lm Rehabil##
00603000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100021001080100
01700129012006600146030001600212065000900228064000500237031000300242032000200245
014000600247865000900253002001300262035001000275801001600285#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#252#46#article#64#46#^rND^sMacDo
nald^nJR#^rND^sMacDougall^nJD#^rND^sHogben^nCD#The effects of exercise duration 
on post-exercise hypotension^len#J Hum Hypertens#20000000#2000#14#2#125-9#201100
00#aop01611.htm#0950-9240#J Hum Hypertens##
00550000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01500123012002200138030001500160065000900175064000500184031000300189032000200192
014000700194865000900201002001300210035001000223801001500233#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#253#47#article#64#47#^rND^sBrand
es^nRP#^rND^sFleming^nI#^rND^sBusse^nR#Endothelial aging^len#Cardiovasc Res#2005
0000#2005#66#2#286-94#20110000#aop01611.htm#0008-6363#Cardiovasc Res##
00624000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100018001020100
01800120012010600138030003900244710000200283065000900285064000500294031000400299
032000200303014000700305865000900312002001300321#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01611.htm#S#c#254#48#article#64#48#^rND^sRao^nSP#^rND^sCol
lins^nHL#^rND^sDiCarlo^nSE#Postexercise alpha-adrenergic receptor hyporesponsive
ness in hypertensive rats is due to nitric oxide^len#Am J Physiol Regul Integr C
omp Physiol#2#20020000#2002#282#4#R960-8#20110000#aop01611.htm##
00709000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01600123010001600139010001700155010001700172810000600189012011600195030001000311
71000020032106500090032306400050033203100040033703400020034101400060034386500090
0349002001300358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#255#49#article#64#49#^rND^sBoushel^nR#^rND^sLangberg^nH#^rND^sGemmer^nC#^rND
^sOlesen^nJ#^rND^sCrameri^nR#^rND^sScheede^nC#et al#Combined inhibition of nitri
c oxide and prostaglandins reduces human skeletal muscle blood flow during exerc
ise^len#J Physiol#2#20020000#2002#543#2#691-8#20110000#aop01611.htm##
00687000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100013001040100
01500117010001700132010001900149012010700168030001300275065000900288064000500297
03100040030203200020030601400080030886500090031600200130032503500100033880100130
0348#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#256#50#a
rticle#64#50#^rND^sDuffy^nSJ#^rND^sNew^nG#^rND^sTran^nBT#^rND^sHarper^nRW#^rND^s
Meredith^nIT#Relative contribution of vasodilator prostanoids and NO to metaboli
c vasodilation in the human forearm^len#Am J Physiol#19990000#1999#276#2#H663-70
#20110000#aop01611.htm#0002-9513#Am J Physiol##
00718000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100016001080100
01700124010001600141010001800157012013400175030001300309065000900322064000500331
03100030033603200020033901400060034186500090034700200130035603500100036980100130
0379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#257#51#a
rticle#64#51#^rND^sMortensen^nSP#^rND^sNyberg^nM#^rND^sThaning^nP#^rND^sSaltin^n
B#^rND^sHellsten^nY#Adenosine contributes to blood flow regulation in the exerci
sing human leg by increasing prostaglandin and nitric oxide formation^len#Hypert
ension#20090000#2009#53#6#993-9#20110000#aop01611.htm#0194-911X#Hypertension##
00626000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
01700125012009400142030001500236065000900251064000500260031000300265032000200268
014000700270865000900277002001300286035001000299801001500309#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#258#52#article#64#52#^rND^sHalli
will^nJR#^rND^sMinson^nCT#^rND^sJoyner^nMJ#Effect of systemic nitric oxide synth
ase inhibition on postexercise hypotension in humans^len#J Appl Physiol#20000000
#2000#89#5#1830-6#20110000#aop01611.htm#0021-8987#J Appl Physiol##
00695000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01800125010001900143010002000162012009900182030001500281065000900296064000500305
03100030031003200020031301400070031586500090032200200130033103500100034480100150
0354#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#259#53#a
rticle#64#53#^rND^sLockwood^nJM#^rND^sPricher^nMP#^rND^sWilkins^nBW#^rND^sHolowa
tz^nLA#^rND^sHalliwill^nJR#Postexercise hypotension is not explained by a prosta
glandin-dependent peripheral vasodilation^len#J Appl Physiol#20050000#2005#98#2#
447-53#20110000#aop01611.htm#0021-8987#J Appl Physiol##
00678000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01800122010001600140010001700156010001500173012008300188030001300271065000900284
06400050029303100030029801400060030186500090030700200130031603500100032980100130
0339#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#260#54#a
rticle#64#54#^rND^sFloras^nJS#^rND^sSinkey^nCA#^rND^sAylward^nPE#^rND^sSeals^nDR
#^rND^sThoren^nPN#^rND^sMark^nAL#Postexercise hypotension and sympathoinhibition
 in borderline hypertensive men^len#Hypertension#19890000#1989#14#28-35#20110000
#aop01611.htm#0194-911X#Hypertension##
00578000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
01800125012008400143030001000227710000200237065000900239064000500248031000400253
034000200257014000700259865000900266002001300275#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01611.htm#S#c#261#55#article#64#55#^rND^sHalliwill^nJR#^rN
D^sTaylor^nJA#^rND^sEckberg^nDL#Impaired sympathetic vascular regulation in huma
ns after acute dynamic exercise^len#J Physiol#2#19960000#1996#495#1#279-88#20110
000#aop01611.htm##
00618000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01800123012008500141030001300226065000900239064000500248031000400253032000700257
014000700264865000900271002001300280035001000293801001300303#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#262#56#article#64#56#^rND^sKulic
s^nJM#^rND^sCollins^nHL#^rND^sDiCarlo^nSE#Postexercise hypotension is mediated b
y reductions in sympathetic nerve activity^len#Am J Physiol#19990000#1999#276#1 
Pt 2#H27-32#20110000#aop01611.htm#0002-9513#Am J Physiol##
00564000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01600123012008800139030001000227710000200237065000900239064000500248031000400253
014000700257865000900264002001300273#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01611.htm#S#c#263#57#article#64#57#^rND^sFranklin^nPJ#^rND^sGreen^nDJ#
^rND^sCable^nNT#The influence of thermoregulatory mechanisms on post-exercise hy
potension in humans^len#J Physiol#2#19930000#1993#470#231-41#20110000#aop01611.h
tm##
00694000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01900125010001900144010002000163012009600183030001500279065000900294064000500303
03100030030803200020031101400080031386500090032100200130033003500100034380100150
0353#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#264#58#a
rticle#64#58#^rND^sPricher^nMP#^rND^sHolowatz^nLA#^rND^sWilliams^nJT#^rND^sLockw
ood^nJM#^rND^sHalliwill^nJR#Regional hemodynamics during postexercise hypotensio
n: I. Splanchnic and renal circulations^len#J Appl Physiol#20040000#2004#97#6#20
65-70#20110000#aop01611.htm#0021-8987#J Appl Physiol##
00618000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
02000123012008500143030001500228065000900243064000500252031000300257032000200260
014000700262865000900269002001300278035001000291801001500301#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#265#59#article#64#59#^rND^sWilki
ns^nBW#^rND^sMinson^nCT#^rND^sHalliwill^nJR#Regional hemodynamics during postexe
rcise hypotension: II. Cutaneous circulation^len#J Appl Physiol#20040000#2004#97
#6#2071-6#20110000#aop01611.htm#0021-8987#J Appl Physiol##
00631000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100016001090100
01700125012009900142030001500241065000900256064000500265031000300270032000200273
014000700275865000900282002001300291035001000304801001500314#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#266#60#article#64#60#^rND^sWilli
amson^nJW#^rND^sMcColl^nR#^rND^sMathews^nD#Changes in regional cerebral blood fl
ow distribution during postexercise hypotension in humans^len#J Appl Physiol#200
40000#2004#96#2#719-24#20110000#aop01611.htm#0021-8987#J Appl Physiol##
00715000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01600121010001800137010002100155012011200176030001300288065000900301064000500310
03100040031503200020031903400020032101400090032386500090033200200130034103500100
0354801001300364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#
S#c#267#61#article#64#61#^rND^sCleroux^nJ#^rND^sKouame^nN#^rND^sNadeau^nA#^rND^s
Coulombe^nD#^rND^sLacourciere^nY#Baroreflex regulation of forearm vascular resis
tance after exercise in hypertensive and normotensive humans^len#Am J Physiol#19
920000#1992#263#5#2#H1523-31#20110000#aop01611.htm#0002-9513#Am J Physiol##
00658000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080100
01800125010001800143012008400161030001300245065000900258064000500267031000400272
03200020027603400020027801400070028086500090028700200130029603500100030980100130
0319#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#268#62#a
rticle#64#62#^rND^sHalliwill^nJR#^rND^sTaylor^nJA#^rND^sHartwig^nTD#^rND^sEckber
g^nDL#Augmented baroreflex heart rate gain after moderate-intensity, dynamic exe
rcise^len#Am J Physiol#19960000#1996#270#2#2#R420-6#20110000#aop01611.htm#0002-9
513#Am J Physiol##
00626000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01700121012011100138030000900249065000900258064000500267031000300272032000200275
014000600277865000900283002001300292035001000305801000900315#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01611.htm#S#c#269#63#article#64#63#^rND^sKrieg
er^nEM#^rND^sBrum^nPC#^rND^sNegrao^nCE#Role of arterial baroreceptor function on
 cardiovascular adjustments to acute and chronic dynamic exercise^len#Biol Res#1
9980000#1998#31#3#273-9#20110000#aop01611.htm#0716-9760#Biol Res##
00657000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01900123010001700142012009200159030001800251065000900269064000500278031000200283
032000200285014000600287865000900293002001300302035001000315801001800325#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01611.htm#S#c#270#64#article#64#64
#^rND^sMuxfeldt^nES#^rND^sBloch^nKV#^rND^sNogueira^nAR#^rND^sSalles^nGF#Twenty-f
our hour ambulatory blood pressure monitoring pattern of resistant hypertension^
len#Blood Press Monit#20030000#2003#8#5#181-5#20110000#aop01611.htm#1359-5237#Bl
ood Press Monit##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#o#1#1#
article#1#20110331#080942#aop01711.htm#147##
05511000000000757000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201180
01780120108002960100039004040100038004430100036004810100039005170100035005560100
04700591010004000638010004100678010004100719010004300760070006400803070007000867
08317990093708500080273608500270274408500350277108500290280608500290283508500360
28640831628029000850008045280850023045360850026045590850028045850850027046130850
03604640117000804676072000204684112000904686111000904695116000904704115000904713
114000904722113000904731002001304740#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01711.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#28#nd#nd#Arq. B
ras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110304#Transplante de células da
 medula óssea na insuficiência cardíaca chagásica: relato da primeira experiênci
a humana^lpt#Bone marrow cell transplantation in chagas' disease heart failure: 
report of the first human experience^len#^rND^1A01 A02^nFábio Vilas-Boas^sPinto#
^rND^1A01 A02^nGilson Soares^sFeitosa#^rND^1A01 A02^nMilena B. P.^sSoares#^rND^1
A01 A02^nJole Alves^sPinho-Filho#^rND^1A01 A02^nAugusto C. A.^sMota#^rND^1A01 A0
2^nAugusto José Gonçalves^sAlmeida#^rND^1A01 A02^nMarcus Vinícius^sAndrade#^rND^
1A01 A02^nHeitor Ghissoni^sCarvalho#^rND^1A01 A02^nAdriano Dourado^sOliveira#^rN
D^1A01 A02^nRicardo^sRibeiro-dos-Santos#Santa Casa de Misericórdia da Bahia^iA01
^1Hospital Santa Izabel#FIOCRUZ^iA02^1Centro de Pesquisas Gonçalo Moniz^cSalvado
r^sBA^pBrasil#^lpt^aFUNDAMENTO: Insuficiência cardíaca (IC) causada por Doença d
e Chagas (DC) é uma cardiomiopatia inflamatória progressiva que afeta milhões de
 pessoas na América Latina. Estudos com modelos de camundongo de IC devido à DC 
indicam que o transplante de células mononucleares derivadas da medula óssea (TC
DMO) pode reduzir a inflamação, fibrose e melhorar a função miocárdica. OBJETIVO
: O propósito desse estudo foi avaliar, pela primeira vez em seres humanos, a se
gurança e a eficácia de TCDMO no miocárdio de pacientes com IC devido à DC. MÉTO
DOS: Um total de 28 pacientes com IC devido à DC (média de idade de 52,2 ± 9,9 a
nos) com classe funcional NYHA III e IV foram submetidos à TCDMO através de inje
ção coronariana. Os efeitos na fração de ejeção do ventrículo esquerdo (FEVE), c
apacidade funcional, qualidade de vida, arritmias e parâmetros bioquímicos, imun
ológicos e neuro-humorais foram avaliados. RESULTADOS: Não houve complicações di
retamente relacionadas ao procedimento. A FEVE foi 20,1 ± 6,8% e 28,3 ± 7,9%, p 
< 0,03 a nível basal e 180 dias após o procedimento, respectivamente. No mesmo p
eríodo, melhoras significantes foram observadas na classe funcional NYHA (3,1 ± 
0,3 para 1,8 ± 0,5; p < 0,001), qualidade de vida (50,9 ± 11,7 para 25,1 ± 15,9;
 p < 0,001), e no teste de caminhada de seis minutos (355 ± 136 m para 437 ± 94 
m; p < 0,01). Não houve alterações nos marcadores de ativação imune ou neurohorm
onais. Nenhuma complicação foi registrada. CONCLUSÃO: Nossos dados sugerem que a
 injeção intracoronariana de células derivadas da medula óssea é segura e potenc
ialmente efetiva em pacientes com IC devido à DC. A extensão do benefício, entre
tanto, parece ser discreta e precisa ser confirmada em estudos clínicos maiores,
 randomizados, duplo-cegos, controlados com placebo.#^dnd^i1#^tm^lpt^kCélulas tr
onco^i1#^tm^lpt^kinsuficiência cardíaca^i1#^tm^lpt^kdoença de Chagas^i1#^tm^lpt^
kterapia tecidual^i1#^tm^lpt^kcardiomiopatia dilatada^i1#^len^aBACKGROUND: Heart
 failure due to Chagas' disease (HFCD) is a progressive inflammatory cardiomyopa
thy that affects millions of individuals in Latin America. Studies using mice mo
dels of HFCD indicate that bone marrow mononuclear cell transplantation (BMCT) m
ay reduce inflammation, fibrosis, and improve myocardial function. OBJECTIVE: Th
e purpose of this study was to evaluate, for the first time in humans, the safet
y and efficacy of BMCT to the myocardium of patients with HFCD. METHODS: A total
 of 28 HFCD patients (mean age 52.2 ± 9.9 years) with NYHA class III and IV were
 submitted to BMCT through intracoronary injection. Effects on the left ventricl
e ejection fraction (LVEF), functional capacity, quality-of-life, arrhythmias, b
iochemical, immunological, and neuro-humoral parameters, were evaluated. RESULTS
: There were no complications directly related to the procedure. LVEF was 20.1 ±
 6.8% and 28.3 ± 7.9%, p < 0.03 at baseline and 180 days after the procedure, re
spectively. In the same period, significant improvements were observed in the NY
HA class (3.1 ± 0.3 to 1.8 ± 0.5; p < 0.001), quality-of-life (50.9 ± 11.7 to 25
.1 ± 15.9; p < 0.001), and in the six-minute walking test (355 ± 136 m to 437 ± 
94 m; p < 0,01). There were no changes in markers of immune or neurohormonal act
ivation. No complications were registered. CONCLUSION: Our data suggest that the
 intracoronary injection of BMCT is safe and potentially effective in patients w
ith HFCD. The extent of the benefit, however, appears to be small and needs to b
e confirmed in a larger randomized, double blind, placebo controlled clinical tr
ial.#^dnd^i2#^tm^len^kStem cells^i2#^tm^len^kheart failure^i2#^tm^len^kChagas' d
isease^i2#^tm^len^ktissue therapy^i2#^tm^len^kcardiomyopathy, dilated^i2#vancouv
#9#20100810#10/08/10#20101013#13/10/10#20101019#19/10/10#aop01711.htm##
05633000000000757000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201320
01780120122003100100039004320100038004710100036005090100039005450100035005840100
04700619010004000666010004100706010004100747010004300788070006400831070007000895
08318460096508500080281108500270281908500350284608500290288108500290291008500360
29390831675029750850008046500850023046580850026046810850028047070850027047350850
03604762117000804798072000204806112000904808111000904817116000904826115000904835
114000904844113000904853002001304862#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01711.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#28#nd#nd#Arq. B
ras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110304#<b>Transplante de células
 da medula óssea na insuficiência cardíaca chagásica</b>: <b>relato da primeira 
experiência humana</b>^lpt#<b>Bone marrow cell transplantation in chagas' diseas
e heart failure</b>: <b>report of the first human experience</b>^len#^rND^1A01 A
02^nFábio Vilas-Boas^sPinto#^rND^1A01 A02^nGilson Soares^sFeitosa#^rND^1A01 A02^
nMilena B. P.^sSoares#^rND^1A01 A02^nJole Alves^sPinho-Filho#^rND^1A01 A02^nAugu
sto C. A.^sMota#^rND^1A01 A02^nAugusto José Gonçalves^sAlmeida#^rND^1A01 A02^nMa
rcus Vinícius^sAndrade#^rND^1A01 A02^nHeitor Ghissoni^sCarvalho#^rND^1A01 A02^nA
driano Dourado^sOliveira#^rND^1A01 A02^nRicardo^sRibeiro-dos-Santos#Santa Casa d
e Misericórdia da Bahia^iA01^1Hospital Santa Izabel#FIOCRUZ^iA02^1Centro de Pesq
uisas Gonçalo Moniz^cSalvador^sBA^pBrasil#^lpt^a<b>FUNDAMENTO: </b>Insuficiência
 cardíaca (IC) causada por Doença de Chagas (DC) é uma cardiomiopatia inflamatór
ia progressiva que afeta milhões de pessoas na América Latina. Estudos com model
os de camundongo de IC devido à DC indicam que o transplante de células mononucl
eares derivadas da medula óssea (TCDMO) pode reduzir a inflamação, fibrose e mel
horar a função miocárdica. <b>OBJETIVO: </b>O propósito desse estudo foi avaliar
, pela primeira vez em seres humanos, a segurança e a eficácia de TCDMO no miocá
rdio de pacientes com IC devido à DC. <b>MÉTODOS: </b>Um total de 28 pacientes c
om IC devido à DC (média de idade de 52,2 ± 9,9 anos) com classe funcional NYHA 
III e IV foram submetidos à TCDMO através de injeção coronariana. Os efeitos na 
fração de ejeção do ventrículo esquerdo (FEVE), capacidade funcional, qualidade 
de vida, arritmias e parâmetros bioquímicos, imunológicos e neuro-humorais foram
 avaliados. <b>RESULTADOS: </b>Não houve complicações diretamente relacionadas a
o procedimento. A FEVE foi 20,1 ± 6,8% e 28,3 ± 7,9%, p &lt; 0,03 a nível basal 
e 180 dias após o procedimento, respectivamente. No mesmo período, melhoras sign
ificantes foram observadas na classe funcional NYHA (3,1 ± 0,3 para 1,8 ± 0,5; p
 &lt; 0,001), qualidade de vida (50,9 ± 11,7 para 25,1 ± 15,9; p &lt; 0,001), e 
no teste de caminhada de seis minutos (355 ± 136 m para 437 ± 94 m; p &lt; 0,01)
. Não houve alterações nos marcadores de ativação imune ou neurohormonais. Nenhu
ma complicação foi registrada. <b>CONCLUSÃO: </b>Nossos dados sugerem que a inje
ção intracoronariana de células derivadas da medula óssea é segura e potencialme
nte efetiva em pacientes com IC devido à DC. A extensão do benefício, entretanto
, parece ser discreta e precisa ser confirmada em estudos clínicos maiores, rand
omizados, duplo-cegos, controlados com placebo.#^dnd^i1#^tm^lpt^kCélulas tronco^
i1#^tm^lpt^kinsuficiência cardíaca^i1#^tm^lpt^kdoença de Chagas^i1#^tm^lpt^ktera
pia tecidual^i1#^tm^lpt^kcardiomiopatia dilatada^i1#^len^a<b>BACKGROUND: </b>Hea
rt failure due to Chagas' disease (HFCD) is a progressive inflammatory cardiomyo
pathy that affects millions of individuals in Latin America. Studies using mice 
models of HFCD indicate that bone marrow mononuclear cell transplantation (BMCT)
 may reduce inflammation, fibrosis, and improve myocardial function. <b>OBJECTIV
E: </b>The purpose of this study was to evaluate, for the first time in humans, 
the safety and efficacy of BMCT to the myocardium of patients with HFCD. <b>METH
ODS: </b>A total of 28 HFCD patients (mean age 52.2 ± 9.9 years) with NYHA class
 III and IV were submitted to BMCT through intracoronary injection. Effects on t
he left ventricle ejection fraction (LVEF), functional capacity, quality-of-life
, arrhythmias, biochemical, immunological, and neuro-humoral parameters, were ev
aluated. <b>RESULTS: </b>There were no complications directly related to the pro
cedure. LVEF was 20.1 ± 6.8% and 28.3 ± 7.9%, p &lt; 0.03 at baseline and 180 da
ys after the procedure, respectively. In the same period, significant improvemen
ts were observed in the NYHA class (3.1 ± 0.3 to 1.8 ± 0.5; p &lt; 0.001), quali
ty-of-life (50.9 ± 11.7 to 25.1 ± 15.9; p &lt; 0.001), and in the six-minute wal
king test (355 ± 136 m to 437 ± 94 m; p &lt; 0,01). There were no changes in mar
kers of immune or neurohormonal activation. No complications were registered. <b
>CONCLUSION: </b>Our data suggest that the intracoronary injection of BMCT is sa
fe and potentially effective in patients with HFCD. The extent of the benefit, h
owever, appears to be small and needs to be confirmed in a larger randomized, do
uble blind, placebo controlled clinical trial.#^dnd^i2#^tm^len^kStem cells^i2#^t
m^len^kheart failure^i2#^tm^len^kChagas' disease^i2#^tm^len^ktissue therapy^i2#^
tm^len^kcardiomyopathy, dilated^i2#vancouv#9#20100810#10/08/10#20101013#13/10/10
#20101019#19/10/10#aop01711.htm##
05664000000000781000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120118001840120108003020100039004100100038004490100035004870100039005220100
03400561010004700595010004000642010004100682010004100723010004300764070006600807
07000720087308318170094508500080276208500270277008500350279708500290283208500290
28610850036028900831642029260850008045680850023045760850026045990850028046250850
02704653085003604680117000804716072000204724112000904726111000904735116000904744
115000904753114000904762113000904771002001304780008008904793#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01711.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1
#1#4.0#ilus#tab#28#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#2011
0304#Transplante de células da medula óssea na insuficiência cardíaca chagásica:
 relato da primeira experiência humana^lpt#Bone marrow cell transplantation in c
hagas' disease heart failure: report of the first human experience^len#^rND^1A01
 A02^nFábio Vilas-Boas^sPinto#^rND^1A01 A02^nGilson Soares^sFeitosa#^rND^1A01 A0
2^nMilena B. P^sSoares#^rND^1A01 A02^nJole Alves^sPinho-Filho#^rND^1A01 A02^nAug
usto C. A^sMota#^rND^1A01 A02^nAugusto José Gonçalves^sAlmeida#^rND^1A01 A02^nMa
rcus Vinícius^sAndrade#^rND^1A01 A02^nHeitor Ghissoni^sCarvalho#^rND^1A01 A02^nA
driano Dourado^sOliveira#^rND^1A01 A02^nRicardo^sRibeiro-dos-Santos#^iA01^1Santa
 Casa de Misericórdia da Bahia^2Hospital Santa Izabel#^iA02^1FIOCRUZ^2Centro de 
Pesquisas Gonçalo Moniz^cSalvador^sBA^pBrasil#^lpt^aFUNDAMENTO: Insuficiência ca
rdíaca (IC) causada por Doença de Chagas (DC) é uma cardiomiopatia inflamatória 
progressiva que afeta milhões de pessoas na América Latina. Estudos com modelos 
de camundongo de IC devido à DC indicam que o transplante de células mononuclear
es derivadas da medula óssea (TCDMO) pode reduzir a inflamação, fibrose e melhor
ar a função miocárdica. OBJETIVO: O propósito desse estudo foi avaliar, pela pri
meira vez em seres humanos, a segurança e a eficácia de TCDMO no miocárdio de pa
cientes com IC devido à DC. MÉTODOS: Um total de 28 pacientes com IC devido à DC
 (média de idade de 52,2 ± 9,9 anos) com classe funcional NYHA III e IV foram su
bmetidos à TCDMO através de injeção coronariana. Os efeitos na fração de ejeção 
do ventrículo esquerdo (FEVE), capacidade funcional, qualidade de vida, arritmia
s e parâmetros bioquímicos, imunológicos e neuro-humorais foram avaliados. RESUL
TADOS: Não houve complicações diretamente relacionadas ao procedimento. A FEVE f
oi 20,1 ± 6,8 por cento e 28,3 ± 7,9 por cento, p < 0,03 a nível basal e 180 dia
s após o procedimento, respectivamente. No mesmo período, melhoras significantes
 foram observadas na classe funcional NYHA (3,1 ± 0,3 para 1,8 ± 0,5; p < 0,001)
, qualidade de vida (50,9 ± 11,7 para 25,1 ± 15,9; p < 0,001), e no teste de cam
inhada de seis minutos (355 ± 136 m para 437 ± 94 m; p < 0,01). Não houve altera
ções nos marcadores de ativação imune ou neurohormonais. Nenhuma complicação foi
 registrada. CONCLUSÃO: Nossos dados sugerem que a injeção intracoronariana de c
élulas derivadas da medula óssea é segura e potencialmente efetiva em pacientes 
com IC devido à DC. A extensão do benefício, entretanto, parece ser discreta e p
recisa ser confirmada em estudos clínicos maiores, randomizados, duplo-cegos, co
ntrolados com placebo.#^dnd^i1#^tm^lpt^kCélulas tronco^i1#^tm^lpt^kinsuficiência
 cardíaca^i1#^tm^lpt^kdoença de Chagas^i1#^tm^lpt^kterapia tecidual^i1#^tm^lpt^k
cardiomiopatia dilatada^i1#^len^aBACKGROUND: Heart failure due to Chagas' diseas
e (HFCD) is a progressive inflammatory cardiomyopathy that affects millions of i
ndividuals in Latin America. Studies using mice models of HFCD indicate that bon
e marrow mononuclear cell transplantation (BMCT) may reduce inflammation, fibros
is, and improve myocardial function. OBJECTIVE: The purpose of this study was to
 evaluate, for the first time in humans, the safety and efficacy of BMCT to the 
myocardium of patients with HFCD. METHODS: A total of 28 HFCD patients (mean age
 52.2 ± 9.9 years) with NYHA class III and IV were submitted to BMCT through int
racoronary injection. Effects on the left ventricle ejection fraction (LVEF), fu
nctional capacity, quality-of-life, arrhythmias, biochemical, immunological, and
 neuro-humoral parameters, were evaluated. RESULTS: There were no complications 
directly related to the procedure. LVEF was 20.1 ± 6.8 percent and 28.3 ± 7.9 pe
rcent, p < 0.03 at baseline and 180 days after the procedure, respectively. In t
he same period, significant improvements were observed in the NYHA class (3.1 ± 
0.3 to 1.8 ± 0.5; p < 0.001), quality-of-life (50.9 ± 11.7 to 25.1 ± 15.9; p < 0
.001), and in the six-minute walking test (355 ± 136 m to 437 ± 94 m; p < 0,01).
 There were no changes in markers of immune or neurohormonal activation. No comp
lications were registered. CONCLUSION: Our data suggest that the intracoronary i
njection of BMCT is safe and potentially effective in patients with HFCD. The ex
tent of the benefit, however, appears to be small and needs to be confirmed in a
 larger randomized, double blind, placebo controlled clinical trial.#^dnd^i2#^tm
^len^kStem cells^i2#^tm^len^kheart failure^i2#^tm^len^kChagas' disease^i2#^tm^le
n^ktissue therapy^i2#^tm^len^kcardiomyopathy, dilated^i2#vancouv#9#20100810#10/0
8/10#20101013#13/10/10#20101019#19/10/10#aop01711.htm#Internet^ihttp://www.sciel
o.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000028##
00504000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704026200083002001300345#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#5#1#article#134#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Transpl
ante de c&eacute;lulas da medula &oacute;ssea na insufici&ecirc;ncia card&iacute
;aca chag&aacute;sica: relato da primeira experi&ecirc;ncia humana</b></font></p
>     ^cY#aop01711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#6#2#article#134#<p>&nbsp;</p
>     ^cY#aop01711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#7#3#article#134#<p>&nbsp;</p
>     ^cY#aop01711.htm##
00608000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704036600083002001300449#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#8#4#article#134#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>F&aacute;bio Vilas-Boas Pi
nto; Gilson Soares Feitosa; Milena B. P. Soares; Jole Alves Pinho-Filho; Augusto
 C. A. Mota; Augusto Jos&eacute; Gon&ccedil;alves Almeida; Marcus Vin&iacute;ciu
s Andrade; Heitor Ghissoni Carvalho; Adriano Dourado Oliveira; Ricardo Ribeiro-d
os-Santos</b> </font></p>     ^cY#aop01711.htm##
00470000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022800083002001300311#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#9#5#article#134#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif">Hospital Santa Izabel da Sant
a Casa de Miseric&oacute;rdia da Bahia, Centro de Pesquisas Gon&ccedil;alo Moniz
 - FIOCRUZ/BA, Salvador, BA - Brasil</font></p>     ^cY#aop01711.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#10#6#article#134#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01711.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#11#7#article#134#<p>&nbsp;</
p>     ^cY#aop01711.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#12#8#article#134#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01711.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#13#9#article#134#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>    
 ^cY#aop01711.htm##
00798000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055400085002001300639#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#14#10#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO: </b> Insufic
i&ecirc;ncia card&iacute;aca (IC) causada por Doen&ccedil;a de Chagas (DC) &eacu
te; uma cardiomiopatia inflamat&oacute;ria progressiva que afeta milh&otilde;es 
de pessoas na Am&eacute;rica Latina. Estudos com modelos de camundongo de IC dev
ido &agrave; DC indicam que o transplante de c&eacute;lulas mononucleares deriva
das da medula &oacute;ssea (TCDMO) pode reduzir a inflama&ccedil;&atilde;o, fibr
ose e melhorar a fun&ccedil;&atilde;o mioc&aacute;rdica.    ^cY#aop01711.htm##
00465000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022100085002001300306#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#15#11#article#134#<br>   <b>
OBJETIVO: </b> O prop&oacute;sito desse estudo foi avaliar, pela primeira vez em
 seres humanos, a seguran&ccedil;a e a efic&aacute;cia de TCDMO no mioc&aacute;r
dio de pacientes com IC devido &agrave; DC.    ^cY#aop01711.htm##
00737000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049300085002001300578#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#16#12#article#134#<br>   <b>
M&Eacute;TODOS: </b> Um total de 28 pacientes com IC devido &agrave; DC (m&eacut
e;dia de idade de 52,2 ± 9,9 anos) com classe funcional NYHA III e IV foram subm
etidos &agrave; TCDMO atrav&eacute;s de inje&ccedil;&atilde;o coronariana. Os ef
eitos na fra&ccedil;&atilde;o de eje&ccedil;&atilde;o do ventr&iacute;culo esque
rdo (FEVE), capacidade funcional, qualidade de vida, arritmias e par&acirc;metro
s bioqu&iacute;micos, imunol&oacute;gicos e neuro-humorais foram avaliados.    ^
cY#aop01711.htm##
00929000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068500085002001300770#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#17#13#article#134#<br>   <b>
RESULTADOS: </b> N&atilde;o houve complica&ccedil;&otilde;es diretamente relacio
nadas ao procedimento. A FEVE foi 20,1 ± 6,8% e 28,3 ± 7,9%, p &lt; 0,03 a n&iac
ute;vel basal e 180 dias ap&oacute;s o procedimento, respectivamente. No mesmo p
er&iacute;odo, melhoras significantes foram observadas na classe funcional NYHA 
(3,1 ± 0,3 para 1,8 ± 0,5; p &lt; 0,001), qualidade de vida (50,9 ± 11,7 para 25
,1 ± 15,9; p &lt; 0,001), e no teste de caminhada de seis minutos (355 ± 136 m p
ara 437 ± 94 m; p &lt; 0,01). N&atilde;o houve altera&ccedil;&otilde;es nos marc
adores de ativa&ccedil;&atilde;o imune ou neurohormonais. Nenhuma complica&ccedi
l;&atilde;o foi registrada.    ^cY#aop01711.htm##
00678000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043400085002001300519#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#18#14#article#134#<br>   <b>
CONCLUS&Atilde;O: </b> Nossos dados sugerem que a inje&ccedil;&atilde;o intracor
onariana de c&eacute;lulas derivadas da medula &oacute;ssea &eacute; segura e po
tencialmente efetiva em pacientes com IC devido &agrave; DC. A extens&atilde;o d
o benef&iacute;cio, entretanto, parece ser discreta e precisa ser confirmada em 
estudos cl&iacute;nicos maiores, randomizados, duplo-cegos, controlados com plac
ebo.</font></p>     ^cY#aop01711.htm##
00500000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025600085002001300341#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#19#15#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b> C&e
acute;lulas tronco, insufici&ecirc;ncia card&iacute;aca, doen&ccedil;a de Chagas
, terapia tecidual, cardiomiopatia dilatada.</font></p> <hr size="1" noshade>   
  ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#20#16#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#21#17#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#22#18#article#134#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01711.htm##
01691000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704144700085002001301532#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#23#19#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A Doen&ccedil;a de Chagas (
DC) &eacute; causada por uma infec&ccedil;&atilde;o pelo protozo&aacute;rio <i>T
rypanosoma cruzi</i>, e ainda afeta milh&otilde;es de pessoas na Am&eacute;rica 
Latina<sup>1,2</sup>. Devido &agrave; intensa imigra&ccedil;&atilde;o a partir d
e &aacute;reas end&ecirc;micas, a infec&ccedil;&atilde;o associada &agrave; tran
sfus&atilde;o tem sido recentemente identificada como uma amea&ccedil;a potencia
l nos Estados Unidos da Am&eacute;rica<sup>1</sup>. Dentre as suas muitas manife
sta&ccedil;&otilde;es, o envolvimento card&iacute;aco &eacute; bastante relevant
e, sendo frequente e habitualmente incapacitante<sup>1</sup>. Tem sido estimado 
que um quarto dos pacientes infectados eventualmente desenvolva a forma avan&cce
dil;ada da doen&ccedil;a card&iacute;aca, a qual apresenta caracter&iacute;stica
s da cardiomiopatia dilatada grave, com arritmias potencialmente fatais frequent
es e fen&ocirc;menos emb&oacute;licos pulmonares e sist&ecirc;micos<sup>1</sup>.
 As caracter&iacute;sticas macrosc&oacute;picas dessa condi&ccedil;&atilde;o inc
luem c&acirc;maras dilatadas, afetando as quatro c&acirc;maras, &aacute;reas loc
alizadas de aneurismas, especialmente na regi&atilde;o apical. As caracter&iacut
e;sticas microsc&oacute;picas dessa condi&ccedil;&atilde;o incluem focos dissemi
nados de inflama&ccedil;&atilde;o e fibrose<sup>1</sup>. </font></p>     ^cY#aop
01711.htm##
00994000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075000085002001300835#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#24#20#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O achado real do parasita n
essa forma tardia da doen&ccedil;a &eacute; pouco frequente, embora o uso de t&e
acute;cnicas altamente sens&iacute;veis permita o reconhecimento de partes do pa
rasita no mioc&aacute;rdio<sup>1</sup>. Esse achado e outros sugerem que o proce
sso auto-imune tem um papel principal na fase cr&ocirc;nica da doen&ccedil;a<sup
>1,2</sup>. No est&aacute;gio avan&ccedil;ado da doen&ccedil;a, o progn&oacute;s
tico &eacute; ruim e uma progress&atilde;o inexor&aacute;vel para a condi&ccedil
;&atilde;o refrat&aacute;ria &eacute; frequentemente observada, a despeito de to
dos os recursos terap&ecirc;uticos dispon&iacute;veis atualmente<sup>1,2</sup>. 
</font></p>     ^cY#aop01711.htm##
01319000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704107500085002001301160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#25#21#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Com o recente progresso na 
t&eacute;cnica de transplante de c&eacute;lulas derivadas de medula &oacute;ssea
 (TCDMO) direcionado &agrave; doen&ccedil;a card&iacute;aca isqu&ecirc;mica<sup>
1-3</sup>, nossa aten&ccedil;&atilde;o foi direcionada &agrave; possibilidade de
 empregar-se a mesma t&eacute;cnica na doen&ccedil;a card&iacute;aca chag&aacute
;sica. Experimentalmente, tem sido demonstrado que em camundongos cronicamente i
nfectados com a cepa colombiana de <i>T. cruzi</i>, a inje&ccedil;&atilde;o de c
&eacute;lulas aut&oacute;logas mononucleares de medula &oacute;ssea resultou em 
uma redu&ccedil;&atilde;o significante das c&eacute;lulas inflamat&oacute;rias e
 da fibrose intersticial no mioc&aacute;rdio<sup>1</sup>. Um estudo de refer&eci
rc;ncia, o transplante aut&oacute;logo simult&acirc;neo de c&eacute;lulas-tronco
 co-cultivadas e mioblastos esquel&eacute;ticos em um modelo experimental de car
diomiopatia dilatada causada por DC, mostrou ser funcionalmente efetivo<sup>1</s
up>. </font></p>     ^cY#aop01711.htm##
00990000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704074600085002001300831#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#26#22#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O Fator de estimula&ccedil;
&atilde;o de col&ocirc;nia por granul&oacute;cito (G-CSF) induz a mobiliza&ccedi
l;&atilde;o das c&eacute;lulas-tronco da medula &oacute;ssea para o sangue perif
&eacute;rico, tornando um grande n&uacute;mero de c&eacute;lulas-tronco dispon&i
acute;veis para repara&ccedil;&atilde;o de danos<sup>1</sup>. Assim, a experi&ec
irc;ncia anterior com TCDMO na doen&ccedil;a card&iacute;aca isqu&ecirc;mica, be
m como os resultados experimentais com ao modelo da DC definiu o cen&aacute;rio 
para nosso estudo-piloto de fase 1, sobre o uso de TCDMO em seres humanos com do
en&ccedil;a card&iacute;aca chag&aacute;sica avan&ccedil;ada<sup>1,2</sup>. </fo
nt></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#27#23#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#28#24#article#134#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos</b></font
></p>     ^cY#aop01711.htm##
01179000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704093500085002001301020#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#29#25#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">De Junho de 2003 a Junho de
 2006, conduzimos um estudo cl&iacute;nico de fase aberta, fase 1, para testar a
 viabilidade, seguran&ccedil;a e efic&aacute;cia potencial do transplante de c&e
acute;lulas derivadas da medula &oacute;ssea para o mioc&aacute;rdio de paciente
s com insufici&ecirc;ncia card&iacute;aca (IC) causada por cardiomiopatia chag&a
acute;sica. Os indiv&iacute;duos inclu&iacute;dos no estudo eram de ambos os sex
os, com idade variando de 20 a 70 anos e ICC causada por DC, com fra&ccedil;&ati
lde;o de eje&ccedil;&atilde;o do ventr&iacute;culo esquerdo (FEVE) &lt; 40% no e
cocardiograma, classe funcional III e IV (NYHA), recebiam terapia m&eacute;dica 
otimizada para ICC e haviam permanecido est&aacute;veis nessa condi&ccedil;&atil
de;o por pelo menos um m&ecirc;s antes do in&iacute;cio dos procedimentos de inv
estiga&ccedil;&atilde;o. </font></p>     ^cY#aop01711.htm##
01076000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083200085002001300917#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#30#26#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os pacientes exclu&iacute;d
os apresentavam condi&ccedil;&otilde;es sist&ecirc;micas que poderiam ter um imp
acto nos resultados do tratamento ou nas an&aacute;lises dos procedimentos de in
vestiga&ccedil;&atilde;o. Essas condi&ccedil;&otilde;es inclu&iacute;am infec&cc
edil;&otilde;es ou neoplasias, doen&ccedil;as auto-imunes, doen&ccedil;as hemato
l&oacute;gicas anteriores; doen&ccedil;as hep&aacute;ticas; insufici&ecirc;ncia 
renal moderada (creatinina &gt; 2 mg/dl); implanta&ccedil;&atilde;o de marcapass
o biventricular para ressincroniza&ccedil;&atilde;o card&iacute;aca nos 90 dias 
anteriores ao in&iacute;cio do estudo; mulheres em idade f&eacute;rtil e pacient
es com doen&ccedil;a arterial coronariana detectada por cineangiocoronariografia
. </font></p>     ^cY#aop01711.htm##
01251000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704100700085002001301092#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#31#27#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Uma avalia&ccedil;&atilde;o
 cl&iacute;nica foi realizada a n&iacute;vel basal e os seguintes dados cl&iacut
e;nicos e vari&aacute;veis foram registrados: a) classe funcional (CF) da NYHA; 
b) escore de qualidade de vida medido pelo question&aacute;rio "Minnesota Living
 with Heart Failure'<sup>1</sup>; c) vari&aacute;veis hematol&oacute;gicas e bio
qu&iacute;micas; d) eletrocardiograma (ECG) de 12 deriva&ccedil;&otilde;es; e) e
cocardiograma transtor&aacute;cico; f) teste de caminhada de 6 minutos (TC6M)<su
p>2</sup>; g) monitoriza&ccedil;&atilde;o por Holter de 24 horas. Ap&oacute;s o 
procedimento, os pacientes foram encaminhados &agrave; Unidade de Terapia Intens
iva (UTI), onde foram monitorados por pelo menos 24 horas. Em casos sem intercor
r&ecirc;ncias, os pacientes eram transferidos para o quarto, onde permaneciam po
r pelo menos cinco dias. Todas as avalia&ccedil;&otilde;es foram repetidas ap&oa
cute;s 180 dias. </font></p>     ^cY#aop01711.htm##
00954000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071000085002001300795#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#32#28#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Para verificar qualquer pos
sibilidade de dano mioc&aacute;rdico causado pela inje&ccedil;&atilde;o de c&eac
ute;lulas de medula &oacute;ssea, mensura&ccedil;&otilde;es seriadas (a cada sei
s horas durante as primeiras 24 horas) de marcadores de dano mioc&aacute;rdico (
CK-MB e troponina I), bem como eletrocardiogramas, foram realizados. Para invest
igar o desenvolvimento de arritmias card&iacute;acas como complica&ccedil;&atild
e;o da inje&ccedil;&atilde;o de c&eacute;lulas, os pacientes foram submetidos &a
grave; eletrocardiografia ambulatorial (Holter) de 24 horas antes do procediment
o e periodicamente ap&oacute;s o mesmo. </font></p>     ^cY#aop01711.htm##
00681000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043700085002001300522#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#33#29#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O protocolo do estudo foi a
provado pelo Comit&ecirc; de &Eacute;tica da institui&ccedil;&atilde;o e pela Co
miss&atilde;o Nacional de &Eacute;tica em Pesquisa. Os pacientes foram inclu&iac
ute;dos no estudo apenas ap&oacute;s terem sido totalmente informados sobre os p
rocedimentos do mesmo e ap&oacute;s assinar o Termo de Consentimento Livre e Inf
ormado.</font></p>     ^cY#aop01711.htm##
00400000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015600085002001300241#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#34#30#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Transplante de c&eacute;
lulas mononucleares de medula &oacute;ssea</b></font></p>     ^cY#aop01711.htm##
01290000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704104600085002001301131#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#35#31#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os pacientes foram encaminh
ados ao laborat&oacute;rio de cateterismo ap&oacute;s jejum de 12 horas. Uma amo
stra de 50 ml de conte&uacute;do de medula &oacute;ssea foi aspirada de cada pac
iente atrav&eacute;s de 5 pun&ccedil;&otilde;es nas cristas il&iacute;acas poste
riores direita e esquerda, sob anestesia local e seda&ccedil;&atilde;o intraveno
sa. O aspirado colhido foi filtrado para remo&ccedil;&atilde;o de debris da medu
la &oacute;ssea, como gordura e fragmentos &oacute;sseos (malha de a&ccedil;o in
oxid&aacute;vel, <i>Washington University</i>) e submetido a centrifuga&ccedil;&
atilde;o por gradiente de densidade com Ficoll Histopaque (Amersham Pharmacia, p
roduto licenciado para uso cl&iacute;nico em humanos). A fra&ccedil;&atilde;o mo
nonucleada celular isolada foi ent&atilde;o dilu&iacute;da em solu&ccedil;&atild
e;o fisiol&oacute;gica est&eacute;ril e novamente centrifugada. Uma amostra foi 
utilizada para contagem celular e teste de viabilidade. </font></p>     ^cY#aop0
1711.htm##
01052000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080800085002001300893#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#36#32#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ao final do processo, as am
ostras foram dilu&iacute;das em 20 ml de solu&ccedil;&atilde;o fisiol&oacute;gic
a. Imediatamente antes da inje&ccedil;&atilde;o intracoronariana, os pacientes f
oram submetidos &agrave; cateteriza&ccedil;&atilde;o card&iacute;aca esquerda co
m abordagem femoral, seguida por angiografia coronariana. Os pacientes foram exc
lu&iacute;dos se houvesse estenose &gt; 50% em qualquer art&eacute;ria coron&aac
ute;ria. A solu&ccedil;&atilde;o contendo as c&eacute;lulas foi injetada lentame
nte, durante 10 minutos, no sistema coronariano esquerdo e direito: 10 ml na art
&eacute;ria descendente anterior esquerda, 5 ml na art&eacute;ria coron&aacute;r
ia direita e 5 ml na art&eacute;ria circunflexa esquerda. </font></p>     ^cY#ao
p01711.htm##
00534000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029000085002001300375#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#37#33#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Vinte e cinco dias depois, 
os pacientes receberam inje&ccedil;&otilde;es di&aacute;rias subcut&acirc;neas d
e G-CSF (Granulokine<sup>&reg;</sup>) humano por cinco dias, a uma dose de 5 <i>
&#181;</i>g/kg/dia. </font></p>     ^cY#aop01711.htm##
01096000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704085200085002001300937#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#38#34#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O teste de caminhada de 6 m
inutos (TC6M) foi realizado de acordo com o protocolo utilizado por Bittner e co
ls.<sup>4</sup> no estudo SOLVD. Ap&oacute;s um per&iacute;odo de repouso de 15 
minutos, um novo teste foi realizado e a m&eacute;dia das dist&acirc;ncias camin
hadas nos dois testes foi usada como resultado. A qualidade de vida (QV) foi ava
liada atrav&eacute;s do question&aacute;rio de Minnesota (<i>Minnesota Living wi
th Heart Failure Questionnaire</i>). Todas as entrevistas foram realizadas pela 
mesma enfermeira pesquisadora. Os estudos ecocardiogr&aacute;ficos foram conduzi
dos pelo mesmo observador, cego para exames anteriores e para o <i>status</i> do
 paciente no protocolo. A FEVE foi calculada de acordo com a regra de Simpson mo
dificada<sup>2</sup>. </font></p>     ^cY#aop01711.htm##
00903000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704065900085002001300744#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#39#35#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">TNF-alfa, IL-1-beta, IL-6, 
MMP-2 e MMP-9 foram analisados atrav&eacute;s de kits de imunoensaio dispon&iacu
te;veis comercialmente (Quantikine, R&amp;D Systems, Minneapolis, MN, EUA). A va
sopressina foi analisada atrav&eacute;s de um kit EIA (Ann Arbor, MI, EUA). O pe
pt&iacute;deo natriur&eacute;tico do tipo B (BNP) foi medido usando-se imunoensa
io fluorescente r&aacute;pido (Biosite Diagnostics Incorporated, San Diego, Cali
fornia, USA). Todos os outros testes bioqu&iacute;micos e hematol&oacute;gicos f
oram realizados utilizando-se kits dispon&iacute;veis comercialmente.</font></p>
     ^cY#aop01711.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012300085002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#40#36#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lise estat&iac
ute;stica</b></font></p>     ^cY#aop01711.htm##
00958000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071400085002001300799#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#41#37#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise estat&iacu
te;stica foi realizada utilizando-se o <i>software</i> SPSS (<i>Statistical Pack
age for Social Sciences</i>) para Windows vers&atilde;o 9.0. As vari&aacute;veis
 cont&iacute;nuas foram apresentadas como m&eacute;dias ± desvios-padr&atilde;o.
 A distribui&ccedil;&atilde;o das vari&aacute;veis foi avaliada pelo teste de Ko
lmogorov-Smirnov. Como as vari&aacute;veis n&atilde;o apresentavam distribui&cce
dil;&atilde;o normal, testes n&atilde;o-param&eacute;tricos foram realizados. To
das as compara&ccedil;&otilde;es foram bicaudais. Valores de p &lt; 0,05 foram c
onsiderados estatisticamente significantes. </font></p>     ^cY#aop01711.htm##
00492000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024800085002001300333#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#42#38#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os autores tiveram acesso t
otal aos dados e s&atilde;o respons&aacute;veis por sua integridade. Todos os au
tores leram e concordam com o manuscrito como foi escrito.</font></p>     ^cY#ao
p01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#43#39#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#44#40#article#134#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop01711.htm##
00764000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052000085002001300605#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#45#41#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Durante o per&iacute;odo de
 estudo de seis meses, um total de 30 pacientes foram selecionados. Dois pacient
es foram exclu&iacute;dos ap&oacute;s a coleta de medula &oacute;ssea: um pacien
te devido &agrave; doen&ccedil;a arterial coronariana detectada durante a catete
riza&ccedil;&atilde;o e outro devido a problemas t&eacute;cnicos com o equipamen
to de cateteriza&ccedil;&atilde;o card&iacute;aca, o que impediu a inje&ccedil;&
atilde;o. </font></p>     ^cY#aop01711.htm##
01590000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704134600085002001301431#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#46#42#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As caracter&iacute;sticas b
asais da popula&ccedil;&atilde;o estudada s&atilde;o descritas na <a href="#tab1
">Tabela 1</a>. Como mostrado, os pacientes estavam no est&aacute;gio avan&ccedi
l;ado da doen&ccedil;a e apresentavam diversos marcadores de gravidade da doen&c
cedil;a. Todos os pacientes apresentavam classe funcional III e IV, a despeito d
e tratamento m&eacute;dico otimizado com regime multidrogas e altas doses de diu
r&eacute;ticos. Digoxina era utilizada por 95% dos pacientes, furosemida isolada
mente ou em combina&ccedil;&atilde;o com outros medicamentos era usada por 85% d
os pacientes, IECA ou BRA por 85% e beta-bloqueadores por 55% dos pacientes. A c
apacidade funcional era baixa, com base na pequena dist&acirc;ncia percorrida du
rante o teste de caminhada de seis minutos e a QV estava significantemente compr
ometida, como indicado pelos escores altos obtidos no question&aacute;rio de Min
nesota. A fun&ccedil;&atilde;o ventricular estava gravemente deprimida, com fra&
ccedil;&atilde;o de eje&ccedil;&atilde;o muito baixa e di&acirc;metro diast&oacu
te;lico do VE aumentado no ecocardiograma. A presen&ccedil;a de hiponatremia e d
isfun&ccedil;&atilde;o renal caracterizaram ainda mais a grave condi&ccedil;&ati
lde;o dessa popula&ccedil;&atilde;o.</font></p>     ^cY#aop01711.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#47#43#article#134#<p><a name
="tab1"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#48#44#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#49#45#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711tab01.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#50#46#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00955000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071100085002001300796#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#51#47#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o houve complica&c
cedil;&otilde;es diretamente relacionadas &agrave; aspira&ccedil;&atilde;o de co
nte&uacute;do da medula &oacute;ssea ou inje&ccedil;&atilde;o de c&eacute;lulas.
 Uma m&eacute;dia de 2,4 ± 1,2 x 10<sup>8</sup> c&eacute;lulas foram injetadas n
as art&eacute;rias coron&aacute;rias. Testes de viabilidade mostraram que 96 ± 6
,5 % das c&eacute;lulas eram vi&aacute;veis no momento da inje&ccedil;&atilde;o.
 Nenhuma altera&ccedil;&atilde;o significante nos marcadores de necrose mioc&aac
ute;rdica em 24 horas ou altera&ccedil;&otilde;es eletrocardiogr&aacute;ficas su
gestivas de isquemia ou infarto ocorreu. </font></p>     ^cY#aop01711.htm##
00759000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051500085002001300600#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#52#48#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A fim de verificar se o imp
lante mioc&aacute;rdico de c&eacute;lulas-tronco estava associado com arritmias,
 o perfil arritmog&ecirc;nico foi avaliado atrav&eacute;s do numero total de con
tra&ccedil;&otilde;es ventriculares prematuras em 24 horas, bem como seu padr&at
ilde;o de recorr&ecirc;ncia e agrupamento. Nenhuma altera&ccedil;&atilde;o signi
ficante foi encontrada no perfil arritmog&ecirc;nico (<a href="#tab2">Tabela 2</
a>). </font></p>     ^cY#aop01711.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#53#49#article#134#<p><a name
="tab2"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#54#50#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#55#51#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711tab02.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#56#52#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
01093000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704084900085002001300934#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#57#53#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Houve quatro mortes durante
 o per&iacute;odo de seis meses de seguimento: paciente 04, sexo masculino, idad
e 37, hemorragia pulmonar e insufici&ecirc;ncia respirat&oacute;ria; paciente 16
, sexo feminino, idade 34, morte s&uacute;bita; paciente 27, idade 69, sexo masc
ulino, insufici&ecirc;ncia card&iacute;aca terminal; paciente 7, idade 67, infec
&ccedil;&atilde;o respirat&oacute;ria complicada por insufici&ecirc;ncia renal e
 choque). Nenhuma associa&ccedil;&atilde;o causal direta foi encontrada entre as
 mortes e o transplante de c&eacute;lulas. N&atilde;o houve neoplasias, doen&cce
dil;as hematol&oacute;gicas, coagulopatias, ou qualquer outro tipo doen&ccedil;a
 que pudesse ser atribu&iacute;do &agrave; inje&ccedil;&atilde;o de c&eacute;lul
as ou seu implante.</font></p>     ^cY#aop01711.htm##
00504000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026000085002001300345#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#58#54#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"> A fun&ccedil;&atilde;o ven
tricular, avaliada pela FEVE, mostrou uma melhora significante, embora pequena, 
seis meses ap&oacute;s o procedimento (<a href="#fig1">Figura 1</a>). </font></p
>     ^cY#aop01711.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#59#55#article#134#<p><a name
="fig1"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#60#56#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#61#57#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711fig01.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#62#58#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00481000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023700085002001300322#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#63#59#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A QV avaliada pelo Question
&aacute;rio de Minnesota mostrou uma melhora acentuada no escore global ap&oacut
e;s seis meses (<a href="#fig2">Figura 2</a>). </font></p>     ^cY#aop01711.htm#
#
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#64#60#article#134#<p><a name
="fig2"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#65#61#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#66#62#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711fig02.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#67#63#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00504000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026000085002001300345#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#68#64#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A capacidade funcional, med
ida pela dist&acirc;ncia percorrida no TC6M, mostrou uma melhora significante, e
mbora pequena, ap&oacute;s seis meses (<a href="#fig3">Figura 3</a>). </font></p
>     ^cY#aop01711.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#69#65#article#134#<p><a name
="fig3"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#70#66#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#71#67#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711fig03.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#72#68#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00478000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023400085002001300319#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#73#69#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Uma diminui&ccedil;&atilde;
o significante na classe funcional m&eacute;dia da NYHA foi observada ap&oacute;
s seis meses (<a href="#fig4">Figura 4</a>).</font></p>     ^cY#aop01711.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#74#70#article#134#<p><a name
="fig4"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#75#71#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#76#72#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711fig04.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#77#73#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00514000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027000085002001300355#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#78#74#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise bioqu&iacu
te;mica mostrou um aumento acentuado na concentra&ccedil;&atilde;o de s&oacute;d
io s&eacute;rico durante o seguimento do estudo (<a href="#fig5">Figura 5</a>). 
</font></p>     ^cY#aop01711.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#79#75#article#134#<p><a name
="fig5"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#80#76#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#81#77#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711fig05.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#82#78#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00831000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058700085002001300672#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#83#79#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Entretanto, uma an&aacute;l
ise das concentra&ccedil;&otilde;es de vasopressina n&atilde;o mostrou qualquer 
altera&ccedil;&atilde;o significante, das suas concentra&ccedil;&otilde;es basai
s a 180 dias depois (193 ± 53 para 182 ± 44 pg/ml, p = 0,38). Houve uma tend&eci
rc;ncia de aumento nos n&iacute;veis de BNP (507 ± 523 para 720 ± 515 pg/ml; p =
 0,055), a qual n&atilde;o foi acompanhada por outras evid&ecirc;ncias de conges
t&atilde;o ou deteriora&ccedil;&atilde;o de fun&ccedil;&atilde;o ventricular.</f
ont></p>     ^cY#aop01711.htm##
00597000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704035300085002001300438#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#84#80#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Uma an&aacute;lise do <i>tu
rnover</i> da matriz extracelular mostrou um aumento significante nos n&iacute;v
eis de MMP-2 (<a href="#fig6">Figura 6</a>), mas n&atilde;o mostrou altera&ccedi
l;&otilde;es nos n&iacute;veis de MMP-9 (1,6 ± 1,8 para 2,3 ± 2,8 pg/ml, p = 0,2
0).</font></p>     ^cY#aop01711.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#85#81#article#134#<p><a name
="fig6"></a></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#86#82#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#87#83#article#134#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01711fig06.jpg"></p>     ^cY#a
op01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#88#84#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00609000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036500085002001300450#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#89#85#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Nenhuma diferen&ccedil;a si
gnificante nos n&iacute;veis plasm&aacute;ticos das citoquinas IL-1-beta (12 ± 1
4 para 13 ± 13 pg/ml, p = 0,54) e IL-6 (40 ± 74 para 28 ± 48 pg/ml, p = 0,21), b
em como nos n&iacute;veis de TNF-alfa (3,4 ± 3,5 para 3,8 ± 4,2 pg/ml, p = 0,38)
 foi observada.</font></p>     ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#90#86#article#134#<p>&nbsp;<
/p>     ^cY#aop01711.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#91#87#article#134#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop01711.htm##
00623000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037900085002001300464#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#92#88#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Esse estudo demonstra que a
 terapia celular realizada atrav&eacute;s de inje&ccedil;&atilde;o intracoronari
ana de c&eacute;lulas mononucleares derivadas de medula &oacute;ssea aut&oacute;
loga &eacute; vi&aacute;vel, segura e parece ser efetiva em pacientes com IC ava
n&ccedil;ada causada por DC. </font></p>     ^cY#aop01711.htm##
01025000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078100085002001300866#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#93#89#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Nesses pacientes selecionad
os, com IC grave, est&aacute;vel e adequadamente tratados, o procedimento foi be
m tolerado e n&atilde;o foram observados arritmias, dano agudo ao mioc&aacute;rd
io ou deteriora&ccedil;&atilde;o do desempenho card&iacute;aco ap&oacute;s a inj
e&ccedil;&atilde;o de c&eacute;lulas nas art&eacute;rias coron&aacute;rias. Esse
 achado &eacute; de grande relev&acirc;ncia, considerando que estudos anteriores
 que utilizaram c&eacute;lulas-tronco de m&uacute;sculo esquel&eacute;tico (c&ea
cute;lulas-sat&eacute;lite) apresentaram preocupa&ccedil;&otilde;es a respeito d
o desenvolvimento de arritmias em pacientes que foram submetidos a esse tipo de 
terapia celular<sup>2,3</sup>. </font></p>     ^cY#aop01711.htm##
01317000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704107300085002001301158#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#94#90#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A despeito de estarem receb
endo tratamento otimizado com regime multidrogas em doses adequadas, a CF dos pa
cientes e sua QV estavam gravemente comprometidas. Entretanto, houve melhoras co
nsistentes em v&aacute;rios dos par&acirc;metros avaliados. A QV melhorou de man
eira consistente, como demonstrado pela avalia&ccedil;&atilde;o feita atrav&eacu
te;s do question&aacute;rio de Minnesota, o que reflete n&atilde;o apenas os par
&acirc;metros referentes &agrave; dispn&eacute;ia, mas tamb&eacute;m os aspectos
 emocionais, psicol&oacute;gicos, econ&ocirc;micos e profissionais. O mesmo &eac
ute; verdadeiro em rela&ccedil;&atilde;o &agrave; vari&aacute;veis mais objetiva
s, como a dist&acirc;ncia percorrida durante o teste de caminhada de 6 minutos, 
que mede a capacidade de exerc&iacute;cio em n&iacute;veis sub-m&aacute;ximos. C
onsistente com as varia&ccedil;&otilde;es mencionadas acima, houve uma melhora s
ignificante na CF, avaliada atrav&eacute;s da classifica&ccedil;&atilde;o da NYH
A. </font></p>     ^cY#aop01711.htm##
01587000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704134300085002001301428#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#95#91#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os aumentos na FEVE foram s
imilares &agrave;queles descritos em estudos anteriores. Duas recentes revis&oti
lde;es sistem&aacute;ticas e meta-an&aacute;lises sobre terapia celular intracor
onariana mostraram que esse tipo de terapia resulta em um aumento modesto, embor
a significante, na FEVE, quando comparado com controles (3 para 4%)<sup>5,6</sup
>. No presente estudo, a FEVE m&eacute;dia aumentou 5%, correspondendo a aproxim
adamente 20% do aumento relativo, j&aacute; que a FEVE de nossos pacientes era s
ignificantemente mais baixa. A quest&atilde;o se um pequeno aumento na FEVE &eac
ute; de import&acirc;ncia cl&iacute;nica &eacute; um assunto importante. A maior
ia das interven&ccedil;&otilde;es salvadoras na cardiologia n&atilde;o aumenta a
 fra&ccedil;&atilde;o de eje&ccedil;&atilde;o de forma substancial. Os mecanismo
s por tr&aacute;s da melhora no desempenho ventricular s&atilde;o uma quest&atil
de;o a ser debatida. Dados recentes indicam que as c&eacute;lulas derivadas de m
edula &oacute;ssea adotam caracter&iacute;sticas hematopoi&eacute;ticas maduras<
sup>7,8</sup>. Outro mecanismo proposto &eacute; que o TCDMO pode exercer efeito
s anti-apopt&oacute;ticos par&aacute;crinos, induzindo modifica&ccedil;&otilde;e
s no ambiente imune<sup>8</sup>. </font></p>     ^cY#aop01711.htm##
00812000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056800085002001300653#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#96#92#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Considerando a bem-conhecid
a dificuldade em controlar a hiponatremia com o tratamento usual, &eacute; digno
 de nota a observa&ccedil;&atilde;o da normaliza&ccedil;&atilde;o do s&oacute;di
o s&eacute;rico elevado nesse estudo<sup>7,8</sup>. O mecanismo de corre&ccedil;
&atilde;o parece ser independente do n&iacute;vel de est&iacute;mulos de vasopre
ssina, considerando que os n&iacute;veis s&eacute;ricos de vasopressina permanec
eram elevados e precisam ser avaliados em outros estudos. </font></p>     ^cY#ao
p01711.htm##
00583000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033900085002001300424#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#97#93#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Um achado interessante de n
osso estudo foi o comportamento dos n&iacute;veis de BNP. A n&iacute;vel basal, 
os n&iacute;veis de BNP estavam elevados, embora quando considerada a gravidade 
da IC, seria esperado que estivessem ainda mais altos<sup>7,8</sup>. </font></p>
     ^cY#aop01711.htm##
01346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110200085002001301187#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#98#94#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">De certa forma surpreendent
e foi o fato de que, a despeito da melhora cl&iacute;nica consistente observada 
atrav&eacute;s de v&aacute;rios par&acirc;metros, seus n&iacute;veis n&atilde;o 
diminu&iacute;ram de forma correspondente. H&aacute; alguma documenta&ccedil;&at
ilde;o demonstrando que, ocasionalmente, em ventr&iacute;culos gravemente compro
metidos, o n&iacute;vel de BNP pode n&atilde;o aumentar como esperado<sup>7</sup
>. Os mecanismos considerados nessa situa&ccedil;&atilde;o podem implicar uma po
ss&iacute;vel exaust&atilde;o dos cardiomi&oacute;citos em produzir o BNP. Segui
ndo a mesma linha de pensamento, talvez o que tenhamos observado esteja de algum
a forma relacionada a algum grau de regenera&ccedil;&atilde;o de cardiomi&oacute
;citos, re-estabelecendo sua capacidade de produzir BNP, apesar da melhora cl&ia
cute;nica parcial. Entretanto, n&atilde;o podemos excluir a possibilidade da reg
enera&ccedil;&atilde;o de outros componentes celulares que tenham contribu&iacut
e;do para esse fato<sup>7</sup>.</font></p>     ^cY#aop01711.htm##
01012000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076800085002001300853#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#99#95#article#134#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Sabe-se que a inflama&ccedi
l;&atilde;o tem um papel principal na patog&ecirc;nese da DC<sup>9</sup>. Entret
anto, em nosso estudo, os biomarcadores inflamat&oacute;rios n&atilde;o mostrara
m altera&ccedil;&atilde;o em resposta ao TCDMO. Esse achado sugere que a terapia
 celular n&atilde;o teve efeito sobre os mecanismos de inflama&ccedil;&atilde;o 
ou ent&atilde;o, outras fontes de hiperprodu&ccedil;&atilde;o dessas substancias
 n&atilde;o s&atilde;o afetadas pela t&eacute;cnica utilizada. &Eacute; interess
ante registrar, entretanto, que os n&iacute;veis de MMP-2 aumentaram ap&oacute;s
 o TCDMO, o que pode se correlacionar com o aumento do turnover do col&aacute;ge
no<sup>7,8</sup>. </font></p>     ^cY#aop01711.htm##
00603000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704035800086002001300444#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#100#96#article#134#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">Considerando as caracter&i
acute;sticas do presente estudo, um estudo pioneiro de fase 1, a efic&aacute;cia
 do procedimento deve ser avaliada em um desenho mais adequado, o qual idealment
e incluir&aacute; um grupo controlado por placebo para fins de compara&ccedil;&a
tilde;o. </font></p>     ^cY#aop01711.htm##
00745000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704050000086002001300586#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#101#97#article#134#<p><font 
size="2" face="Verdana, Arial, Helvetica, sans-serif">De qualquer forma, demonst
ramos em seres humanos com IC avan&ccedil;ada causada por Doen&ccedil;a de Chaga
s, o uso potencial de uma nova forma de terapia que precisa ser confirmada por o
bserva&ccedil;&otilde;es futuras. Um estudo multic&ecirc;ntrico, randomizado, co
ntrolado por placebo, para testar os efeitos do TCDMO em IC chag&aacute;sica em 
300 pacientes, est&aacute; atualmente incluindo pacientes<sup>9</sup>. </font></
p>     ^cY#aop01711.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002200086002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#102#98#article#134#<p>&nbsp;
</p>     ^cY#aop01711.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704010400086002001300190#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#103#99#article#134#<p><font 
size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Agradecimentos</b></fon
t></p>     ^cY#aop01711.htm##
00647000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704040100087002001300488#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#104#100#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Os autores gostariam de a
gradecer a importante contribui&ccedil;&atilde;o de Cristiane Carvalho e Aline B
ernandes, do Hospital Santa Izabel e Daniele Brustollim do Centro de Pesquisas G
on&ccedil;alo Moniz, por sua ajuda na sele&ccedil;&atilde;o dos pacientes, colet
a de dados e manuseio de amostras biol&oacute;gicas. </font></p>     ^cY#aop0171
1.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704012200087002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#105#101#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Potencial Conflito de 
Interesses</b></font></p>     ^cY#aop01711.htm##
00389000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704014300087002001300230#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#106#102#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Declaro n&atilde;o haver 
conflito de interesses pertinentes.</font></p>     ^cY#aop01711.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704011300087002001300200#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#107#103#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fontes de Financiament
o</b></font></p>     ^cY#aop01711.htm##
00396000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704015000087002001300237#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#108#104#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo n&atild
e;o teve fontes de financiamento externas.</font></p>     ^cY#aop01711.htm##
00376000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704013000087002001300217#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#109#105#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vincula&ccedil;&atilde
;o Acad&ecirc;mica</b></font></p>     ^cY#aop01711.htm##
00438000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019200087002001300279#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#110#106#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; vinc
ula&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atild
e;o.</font></p>     ^cY#aop01711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#111#107#article#134#<p>&nbsp
;</p>     ^cY#aop01711.htm##
00353000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010700087002001300194#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#112#108#article#134#<p><font
 size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b><
/font></p>     ^cY#aop01711.htm##
00562000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030200089002001300391#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#113#109#article#
134#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.	Rector T
S, Kubo SK, Cohn JN. Patient's self-assessment of their congestive heart failure
, II: content, reliability and validity of a new measure. The Minnesota Living w
ith Heart Failure Questionnaire. Heart Fail. 1987;3:198-209.    ^cY#aop01711.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#114#110#article#134#</font><
/p>     ^cY#aop01711.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704022600089002001300315#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#115#111#article#
134#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2.	Murry CE
, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for re
pair of myocardial necrosis. J Clin Invest. 1996;98(11):2512-23.    ^cY#aop01711
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#116#112#article#134#</font><
/p>     ^cY#aop01711.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028600089002001300375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#117#113#article#
134#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3.	Menasche
 P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, et al. Autologous skel
etal myoblast transplantation for severe postinfarction left ventricular dysfunc
tion. J Am Coll Cardiol. 2003;41(7):1078-83.    ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#118#114#article#134#</font><
/p>     ^cY#aop01711.htm##
00555000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704029500089002001300384#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#119#115#article#
134#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4.	Bittner 
V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. Prediction 
of mortality with a 6-minute walk test in patients with left ventricular dysfunc
tion. SOLVD Investigators. JAMA. 1993;270(14):1702-7.    ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#120#116#article#134#</font><
/p>     ^cY#aop01711.htm##
00650000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704039000089002001300479#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#121#117#article#
134#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5.	Lipinski
 MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, et al. Impact
 of intracoronary cell therapy on left ventricular function in the setting of ac
ute myocardial infarction: a collaborative systematic review and meta-analysis o
f controlled clinical trials. J Am Coll Cardiol. 2007;50(18):1761-7.    ^cY#aop0
1711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#122#118#article#134#</font><
/p>     ^cY#aop01711.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704027800089002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#123#119#article#
134#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6.	Abdel-La
tif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornuz CA, et al. Adult bone m
arrow-derived cells for cardiac repair: a systematic review and meta-analysis. A
rch Intern Med. 2007;167(10):989-97.    ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#124#120#article#134#</font><
/p>     ^cY#aop01711.htm##
00569000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030900089002001300398#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#125#121#article#
134#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7.	Fielitz 
J, Leuschner M, Zurbrugg HR, Hannack B, Pregla R, Hetzer R, et al. Regulation of
 matrix metalloproteinases and their inhibitors in the left ventricular myocardi
um of patients with aortic stenosis. J Mol Med. 2004;82(12):809-20.    ^cY#aop01
711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#126#122#article#134#</font><
/p>     ^cY#aop01711.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028600089002001300375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#127#123#article#
134#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8.	Martos R
, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, et al. Diastolic heart f
ailure: evidence of increased myocardial collagen turnover linked to diastolic d
ysfunction. Circulation. 2007;115(7):888-95.    ^cY#aop01711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#128#124#article#134#</font><
/p>     ^cY#aop01711.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030100089002001300390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#129#125#article#
134#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9.	Andrade 
ZA, Andrade SG, Correa R, Sadigursky M, Ferrans VJ. Myocardial changes in acute 
Trypanosoma cruzi infection. Ultrastructural evidence of immune damage and the r
ole of microangioplasty. Am J. Pathol. 1994;144(6):1403-11.    ^cY#aop01711.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#130#126#article#134#</font><
/p>     ^cY#aop01711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#131#127#article#134#<p>&nbsp
;</p>     ^cY#aop01711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#132#128#article#134#<p>&nbsp
;</p>     ^cY#aop01711.htm##
00446000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020000087002001300287#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#133#129#article#134#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg"border="0"></a> <b>Cor
respond&ecirc;ncia: </b>    ^cY#aop01711.htm##
00290000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004400087002001300131#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#134#130#article#134#<br>   F
&aacute;bio Vilas-Boas Pinto    ^cY#aop01711.htm##
00296000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005000087002001300137#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#135#131#article#134#<br>   A
v. Sete de Setembro, 4161 - Barra     ^cY#aop01711.htm##
00294000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004800087002001300135#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#136#132#article#134#<br>   4
1140-900 - Salvador, BA - Brasil    ^cY#aop01711.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009900087002001300186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#137#133#article#134#<br>   E
-mail: <a href="mailto:fabiovboas@cardiol.br">fabiovboas@cardiol.br</a></font></
p>     ^cY#aop01711.htm##
00408000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016200087002001300249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01711.htm#S#p#138#134#article#134#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 10/08/
10; revisado recebido em 13/10/10; aceito em 19/10/10.</font></p>     ^cY#aop017
11.htm##
00644000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100017000850100015001020100
01500117012017500132030001100307710000200318065000900320064000500329031000200334
014000800336865000900344002001300353#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01711.htm#S#c#139#1#article#9#1#^rND^sRector^nTS#^rND^sKubo^nSK#^rND^s
Cohn^nJN#Patient's self-assessment of their congestive heart failure, II: conten
t, reliability and validity of a new measure. The Minnesota Living with Heart Fa
ilure Questionnaire^len#Heart Fail#2#19870000#1987#3#198-209#20110000#aop01711.h
tm##
00631000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100016000850100018001010100
01900119010001900138012007200157030001400229065000900243064000500252031000300257
032000300260014000800263865000900271002001300280035001000293801001400303#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#c#140#2#article#9#2#^r
ND^sMurry^nCE#^rND^sWiseman^nRW#^rND^sSchwartz^nSM#^rND^sHauschka^nSD#Skeletal m
yoblast transplantation for repair of myocardial necrosis^len#J Clin Invest#1996
0000#1996#98#11#2512-23#20110000#aop01711.htm#0021-9738#J Clin Invest##
00742000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100018000850100017001030100
01800120010001600138010001700154010001600171810000600187012010400193030001800297
06500090031506400050032403100030032903200020033201400080033486500090034200200130
0351035001000364801001800374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01711.htm#S#c#141#3#article#9#3#^rND^sMenasche^nP#^rND^sHagege^nAA#^rND^sVilqu
in^nJT#^rND^sDesnos^nM#^rND^sAbergel^nE#^rND^sPouzet^nB#et al#Autologous skeleta
l myoblast transplantation for severe postinfarction left ventricular dysfunctio
n^len#J Am Coll Cardiol#20030000#2003#41#7#1078-83#20110000#aop01711.htm#0735-10
97#J Am Coll Cardiol##
00717000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100017000850100017001020100
01500119010001700134010001900151010002100170810000600191012010000197030000500297
06500090030206400050031103100040031603200030032001400070032386500090033000200130
0339035001000352801000500362#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01711.htm#S#c#142#4#article#9#4#^rND^sBittner^nV#^rND^sWeiner^nDH#^rND^sYusuf^
nS#^rND^sRogers^nWJ#^rND^sMcIntyre^nKM#^rND^sBangdiwala^nSI#et al#Prediction of 
mortality with a 6-minute walk test in patients with left ventricular dysfunctio
n^len#JAMA#19930000#1993#270#14#1702-7#20110000#aop01711.htm#0098-7484#JAMA##
00846000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100019000850100024001040100
01600128010001700144010001700161010001800178810000600196012019900202030001800401
06500090041906400050042803100030043303200030043601400070043986500090044600200130
0455035001000468801001800478#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01711.htm#S#c#143#5#article#9#5#^rND^sLipinski^nMJ#^rND^sBiondi-Zoccai^nGG#^rN
D^sAbbate^nA#^rND^sKhianey^nR#^rND^sSheiban^nI#^rND^sBartunek^nJ#et al#Impact of
 intracoronary cell therapy on left ventricular function in the setting of acute
 myocardial infarction: a collaborative systematic review and meta-analysis of c
ontrolled clinical trials^len#J Am Coll Cardiol#20070000#2007#50#18#1761-7#20110
000#aop01711.htm#0735-1097#J Am Coll Cardiol##
00732000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100021000850100015001060100
01800121010001800139010001600157010001700173810000600190012009400196030001600290
06500090030606400050031503100040032003200030032401400070032786500090033400200130
0343035001000356801001600366#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01711.htm#S#c#144#6#article#9#6#^rND^sAbdel-Latif^nA#^rND^sBolli^nR#^rND^sTley
jeh^nIM#^rND^sMontori^nVM#^rND^sPerin^nEC#^rND^sHornuz^nCA#et al#Adult bone marr
ow-derived cells for cardiac repair: a systematic review and meta-analysis^len#A
rch Intern Med#20070000#2007#167#10#989-97#20110000#aop01711.htm#0003-9926#Arch 
Intern Med##
00757000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100017000850100019001020100
01900121010001700140010001600157010001600173810000600189012013300195030001000328
06500090033806400050034703100030035203200030035501400070035886500090036500200130
0374035001000387801001000397#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01711.htm#S#c#145#7#article#9#7#^rND^sFielitz^nJ#^rND^sLeuschner^nM#^rND^sZurb
rugg^nHR#^rND^sHannack^nB#^rND^sPregla^nR#^rND^sHetzer^nR#et al#Regulation of ma
trix metalloproteinases and their inhibitors in the left ventricular myocardium 
of patients with aortic stenosis^len#J Mol Med#20040000#2004#82#12#809-20#201100
00#aop01711.htm#0377-046X#J Mol Med##
00736000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100016000850100015001010100
01800116010002000134010001600154010001500170810000600185012011200191030001200303
06500090031506400050032403100040032903200020033301400070033586500090034200200130
0351035001000364801001200374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01711.htm#S#c#146#8#article#9#8#^rND^sMartos^nR#^rND^sBaugh^nJ#^rND^sLedwidge^
nM#^rND^sO'Loughlin^nC#^rND^sConlon^nC#^rND^sPatle^nA#et al#Diastolic heart fail
ure: evidence of increased myocardial collagen turnover linked to diastolic dysf
unction^len#Circulation#20070000#2007#115#7#888-95#20110000#aop01711.htm#0009-73
22#Circulation##
00691000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080002000811180002000830100018000850100018001030100
01600121010002000137010001900157012013600176030001300312710000200325065000900327
064000500336031000400341032000200345014000800347865000900355002001300364#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01711.htm#S#c#147#9#article#9#9#^r
ND^sAndrade^nZA#^rND^sAndrade^nSG#^rND^sCorrea^nR#^rND^sSadigursky^nM#^rND^sFerr
ans^nVJ.#Myocardial changes in acute Trypanosoma cruzi infection: Ultrastructura
l evidence of immune damage and the role of microangioplasty^len#Am J. Pathol#2#
19940000#1994#144#6#1403-11#20110000#aop01711.htm##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#o#1#1#
article#1#20110331#080946#aop01811.htm#176##
05595000000000745000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099121000300104049000300107158000300110030002000113
03200060013306500090013901400070014803500100015522300090016501200790017401200730
02530100026003260100033003520100034003850100023004190100034004420100020004760100
02500496010004200521010003500563070007200598070010600670070007100776070007600847
07001040092308318200102708500080284708500420285508500290289708500370292608500190
29630831650029820850008046320850043046400850031046830850039047140850018047531170
00804771072000304779112000904782111000904791116000904800115000904809114000904818
113000904827002001304836#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
811.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#29#nd#nd#Arq. Bras. Cardiol.#ah
ead#20110000#^f0^l0#0066-782X#20110304#Efeitos hemodinâmicos da sobrecarga ventr
icular direita aguda experimental^lpt#Hemodynamic effects of experimental acute 
right ventricular overload^len#^rND^nFlávio^sBrito Filho#^rND^nKleber Nogueira d
e^sCampos#^rND^nHumberto Alves de^sOliveira#^rND^nJosué^sFernandes#^rND^nCésar A
ugusto Melo e^sSilva#^rND^nEduardo^sGaio#^rND^nEdwin Roger^sParra#^rND^nPaulo He
nrique Cândido de^sCarvalho#^rND^nPaulo Manoel Pêgo^sFernandes#Hospital de Base 
do Distrito Federal^iA01^1Unidade de Cirurgia Torácica#Universidade de Brasília^
iA02^1Faculdade de Medicina^2Laboratório de Fisiologia Respiratória Experimental
#Centro de Treinamento e Ensino em Ciências da Saúde^iA03^cBrasília^sDF#Universi
dade de São Paulo^iA04^1Faculdade de Medicina^2Instituto do Coração#Universidade
 de São Paulo^iA05^1Faculdade de Medicina^2Departamento de Patologia^cSão Paulo^
sSP^pBrasil#^lpt^aFUNDAMENTO: A sobrecarga ventricular direita aguda está associ
ada a situações clínicas de elevada morbimortalidade, tais como: ressecções pulm
onares extensas, tromboembolismo pulmonar, transplante pulmonar e edema pulmonar
 das altitudes. Alguns pontos de sua fisiopatologia permanecem obscuros. OBJETIV
O: Avaliar os efeitos hemodinâmicos da sobrecarga ventricular direita aguda expe
rimental em suínos. MÉTODOS: A sobrecarga ventricular direita foi induzida pela 
oclusão das artérias pulmonares através de ligaduras. Vinte porcos foram utiliza
dos no estudo, sendo alocados em 04 grupos: um controle, não submetido à oclusão
 vascular pulmonar, e três de sobrecarga ventricular direita submetidos à oclusã
o das seguintes artérias pulmonares: SVD1 (artéria pulmonar esquerda); SVD2 (art
éria pulmonar esquerda e do lobo inferior direito) e SVD3 (artéria pulmonar esqu
erda, do lobo inferior direito e do lobo mediastinal), obstruindo a vasculatura 
pulmonar em 42, 76 e 82,0% respectivamente. Variáveis de hemodinâmica foram medi
das a cada 15 minutos durante a uma hora do estudo. Na análise estatística, fora
m utilizados ajustes de modelos lineares mistos com estrutura de variâncias e co
variâncias. RESULTADOS: Nas comparações intergrupais, houve aumento significativ
o da frequência cardíaca (p = 0,004), pressão arterial pulmonar média (p = 0,001
) e pressão capilar pulmonar (p < 0,0001). Houve redução significativa da pressã
o arterial média (p = 0,01) e do índice sistólico (p = 0,002). Não houve diferen
ça significativa no índice cardíaco (p = 0,94). CONCLUSÃO: Apesar da intensa sob
recarga ventricular direita promovida pela obstrução de 82,0% da vasculatura pul
monar e pelo aumento significativo da pressão arterial pulmonar não houve disfun
ção cardiovascular severa e/ou choque circulatório no período estudado.#^dnd^i1#
^tm^lpt^kDisfunção ventricular direita^i1#^tm^lpt^kembolia pulmonar^i1#^tm^lpt^k
cateterismo de Swan-Ganz^i1#^tm^lpt^ksuínos^i1#^len^aBACKGROUND: Acute right ven
tricular overload is associated with high morbidity and mortality clinical situa
tions such as: extensive lung resection, pulmonary thromboembolism, lung transpl
antation and high altitude pulmonary edema. Some points of its pathophysiology r
emain unclear. OBJECTIVE: To assess the hemodynamic effects of experimental acut
e right ventricular overload in pigs. METHODS: Right ventricular overload was in
duced through the occlusion of the pulmonary arteries using ligationss. Twenty p
igs were used in the study, divided into 04 groups: one control group not subjec
t to pulmonary vascular occlusion, and three right ventricular overload groups s
ubject to occlusion of the following pulmonary arteries: SVD1 (left pulmonary ar
tery); SVD2 (left pulmonary artery and right lower lobe) and SVD3 (left pulmonar
y artery, right lower lobe and mediastinal lobe), obstructing the pulmonary vasc
ulature in 42, 76 and 82.0% respectively. Hemodynamic variables were measured ev
ery 15 minutes during one hour of study. The statistical analysis employed mixed
 linear models with variance and covariance structures. RESULTS: Group compariso
ns revealed significant increases in heart rate (p = 0.004), mean pulmonary arte
ry pressure (p = 0.001) and pulmonary capillary wedge pressure (p < 0.0001). The
re was no significant difference in cardiac index (p = 0.94). CONCLUSION: Despit
e the severe right ventricular overload promoted by 82.0% obstruction of the pul
monary vasculature and the significant increase in pulmonary arterial pressure, 
there was no severe cardiovascular dysfunction and/or circulatory shock during t
he study period.#^dnd^i2#^tm^len^kVentricular dysfunction, right^i2#^tm^len^kpul
monary embolism^i2#^tm^len^kcatheterization, Swan-Ganz^i2#^tm^len^kswine^i2#vanc
ouv#27#20100731#31/07/10#20101015#15/10/10#20101028#28/10/10#aop01811.htm##
05685000000000745000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099121000300104049000300107158000300110030002000113
03200060013306500090013901400070014803500100015522300090016501200860017401200800
02600100026003400100033003660100034003990100023004330100034004560100020004900100
02500510010004200535010003500577070007200612070010600684070007100790070007600861
07001040093708318580104108500080289908500420290708500290294908500370297808500190
30150831688030340850008047220850043047300850031047730850039048040850018048431170
00804861072000304869112000904872111000904881116000904890115000904899114000904908
113000904917002001304926#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
811.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#29#nd#nd#Arq. Bras. Cardiol.#ah
ead#20110000#^f0^l0#0066-782X#20110304#<b>Efeitos hemodinâmicos da sobrecarga ve
ntricular direita aguda experimental</b>^lpt#<b>Hemodynamic effects of experimen
tal acute right ventricular overload</b>^len#^rND^nFlávio^sBrito Filho#^rND^nKle
ber Nogueira de^sCampos#^rND^nHumberto Alves de^sOliveira#^rND^nJosué^sFernandes
#^rND^nCésar Augusto Melo e^sSilva#^rND^nEduardo^sGaio#^rND^nEdwin Roger^sParra#
^rND^nPaulo Henrique Cândido de^sCarvalho#^rND^nPaulo Manoel Pêgo^sFernandes#Hos
pital de Base do Distrito Federal^iA01^1Unidade de Cirurgia Torácica#Universidad
e de Brasília^iA02^1Faculdade de Medicina^2Laboratório de Fisiologia Respiratóri
a Experimental#Centro de Treinamento e Ensino em Ciências da Saúde^iA03^cBrasíli
a^sDF#Universidade de São Paulo^iA04^1Faculdade de Medicina^2Instituto do Coraçã
o#Universidade de São Paulo^iA05^1Faculdade de Medicina^2Departamento de Patolog
ia^cSão Paulo^sSP^pBrasil#^lpt^a<b>FUNDAMENTO: </b>A sobrecarga ventricular dire
ita aguda está associada a situações clínicas de elevada morbimortalidade, tais 
como: ressecções pulmonares extensas, tromboembolismo pulmonar, transplante pulm
onar e edema pulmonar das altitudes. Alguns pontos de sua fisiopatologia permane
cem obscuros. <b>OBJETIVO: </b>Avaliar os efeitos hemodinâmicos da sobrecarga ve
ntricular direita aguda experimental em suínos. <b>MÉTODOS: </b>A sobrecarga ven
tricular direita foi induzida pela oclusão das artérias pulmonares através de li
gaduras. Vinte porcos foram utilizados no estudo, sendo alocados em 04 grupos: u
m controle, não submetido à oclusão vascular pulmonar, e três de sobrecarga vent
ricular direita submetidos à oclusão das seguintes artérias pulmonares: SVD1 (ar
téria pulmonar esquerda); SVD2 (artéria pulmonar esquerda e do lobo inferior dir
eito) e SVD3 (artéria pulmonar esquerda, do lobo inferior direito e do lobo medi
astinal), obstruindo a vasculatura pulmonar em 42, 76 e 82,0% respectivamente. V
ariáveis de hemodinâmica foram medidas a cada 15 minutos durante a uma hora do e
studo. Na análise estatística, foram utilizados ajustes de modelos lineares mist
os com estrutura de variâncias e covariâncias. <b>RESULTADOS: </b>Nas comparaçõe
s intergrupais, houve aumento significativo da frequência cardíaca (p = 0,004), 
pressão arterial pulmonar média (p = 0,001) e pressão capilar pulmonar (p &lt; 0
,0001). Houve redução significativa da pressão arterial média (p = 0,01) e do ín
dice sistólico (p = 0,002). Não houve diferença significativa no índice cardíaco
 (p = 0,94). <b>CONCLUSÃO: </b>Apesar da intensa sobrecarga ventricular direita 
promovida pela obstrução de 82,0% da vasculatura pulmonar e pelo aumento signifi
cativo da pressão arterial pulmonar não houve disfunção cardiovascular severa e/
ou choque circulatório no período estudado.#^dnd^i1#^tm^lpt^kDisfunção ventricul
ar direita^i1#^tm^lpt^kembolia pulmonar^i1#^tm^lpt^kcateterismo de Swan-Ganz^i1#
^tm^lpt^ksuínos^i1#^len^a<b>BACKGROUND: </b>Acute right ventricular overload is 
associated with high morbidity and mortality clinical situations such as: extens
ive lung resection, pulmonary thromboembolism, lung transplantation and high alt
itude pulmonary edema. Some points of its pathophysiology remain unclear. <b>OBJ
ECTIVE: </b>To assess the hemodynamic effects of experimental acute right ventri
cular overload in pigs. <b>METHODS: </b>Right ventricular overload was induced t
hrough the occlusion of the pulmonary arteries using ligationss. Twenty pigs wer
e used in the study, divided into 04 groups: one control group not subject to pu
lmonary vascular occlusion, and three right ventricular overload groups subject 
to occlusion of the following pulmonary arteries: SVD1 (left pulmonary artery); 
SVD2 (left pulmonary artery and right lower lobe) and SVD3 (left pulmonary arter
y, right lower lobe and mediastinal lobe), obstructing the pulmonary vasculature
 in 42, 76 and 82.0% respectively. Hemodynamic variables were measured every 15 
minutes during one hour of study. The statistical analysis employed mixed linear
 models with variance and covariance structures. <b>RESULTS: </b>Group compariso
ns revealed significant increases in heart rate (p = 0.004), mean pulmonary arte
ry pressure (p = 0.001) and pulmonary capillary wedge pressure (p &lt; 0.0001). 
There was no significant difference in cardiac index (p = 0.94). <b>CONCLUSION: 
</b>Despite the severe right ventricular overload promoted by 82.0% obstruction 
of the pulmonary vasculature and the significant increase in pulmonary arterial 
pressure, there was no severe cardiovascular dysfunction and/or circulatory shoc
k during the study period.#^dnd^i2#^tm^len^kVentricular dysfunction, right^i2#^t
m^len^kpulmonary embolism^i2#^tm^len^kcatheterization, Swan-Ganz^i2#^tm^len^kswi
ne^i2#vancouv#27#20100731#31/07/10#20101015#15/10/10#20101028#28/10/10#aop01811.
htm##
05779000000000769000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106121000300111049000300114158000300117
03000190012003200060013906500090014501400070015403500100016122300090017101200790
01800120073002590100026003320100033003580100034003910100023004250100034004480100
02000482010002500502010004200527010003500569070007400604070010800678070007300786
07001010085907001060096008318380106608500080290408500420291208500290295408500370
29830850019030200831664030390850008047030850043047110850031047540850039047850850
01804824117000804842072000304850112000904853111000904862116000904871115000904880
114000904889113000904898002001304907008008904920#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01811.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#
29#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110304#Efeitos hem
odinâmicos da sobrecarga ventricular direita aguda experimental^lpt#Hemodynamic 
effects of experimental acute right ventricular overload^len#^rND^nFlávio^sBrito
 Filho#^rND^nKleber Nogueira de^sCampos#^rND^nHumberto Alves de^sOliveira#^rND^n
Josué^sFernandes#^rND^nCésar Augusto Melo e^sSilva#^rND^nEduardo^sGaio#^rND^nEdw
in Roger^sParra#^rND^nPaulo Henrique Cândido de^sCarvalho#^rND^nPaulo Manoel Pêg
o^sFernandes#^iA01^1Hospital de Base do Distrito Federal^2Unidade de Cirurgia To
rácica#^iA02^1Universidade de Brasília^2Faculdade de Medicina^3Laboratório de Fi
siologia Respiratória Experimental#^iA03^1Centro de Treinamento e Ensino em Ciên
cias da Saúde^cBrasília^sDF#^iA04^1Universidade de São Paulo^2Faculdade de Medic
ina^3Instituto do Coração^cSão Paulo^sSP^pBrasil#^iA05^1Universidade de São Paul
o^2Faculdade de Medicina^3Departamento de Patologia^cSão Paulo^sSP^pBrasil#^lpt^
aFUNDAMENTO: A sobrecarga ventricular direita aguda está associada a situações c
línicas de elevada morbimortalidade, tais como: ressecções pulmonares extensas, 
tromboembolismo pulmonar, transplante pulmonar e edema pulmonar das altitudes. A
lguns pontos de sua fisiopatologia permanecem obscuros. OBJETIVO: Avaliar os efe
itos hemodinâmicos da sobrecarga ventricular direita aguda experimental em suíno
s. MÉTODOS: A sobrecarga ventricular direita foi induzida pela oclusão das artér
ias pulmonares através de ligaduras. Vinte porcos foram utilizados no estudo, se
ndo alocados em 04 grupos: um controle, não submetido à oclusão vascular pulmona
r, e três de sobrecarga ventricular direita submetidos à oclusão das seguintes a
rtérias pulmonares: SVD1 (artéria pulmonar esquerda); SVD2 (artéria pulmonar esq
uerda e do lobo inferior direito) e SVD3 (artéria pulmonar esquerda, do lobo inf
erior direito e do lobo mediastinal), obstruindo a vasculatura pulmonar em 42, 7
6 e 82,0 por cento respectivamente. Variáveis de hemodinâmica foram medidas a ca
da 15 minutos durante a uma hora do estudo. Na análise estatística, foram utiliz
ados ajustes de modelos lineares mistos com estrutura de variâncias e covariânci
as. RESULTADOS: Nas comparações intergrupais, houve aumento significativo da fre
quência cardíaca (p = 0,004), pressão arterial pulmonar média (p = 0,001) e pres
são capilar pulmonar (p < 0,0001). Houve redução significativa da pressão arteri
al média (p = 0,01) e do índice sistólico (p = 0,002). Não houve diferença signi
ficativa no índice cardíaco (p = 0,94). CONCLUSÃO: Apesar da intensa sobrecarga 
ventricular direita promovida pela obstrução de 82,0 por cento da vasculatura pu
lmonar e pelo aumento significativo da pressão arterial pulmonar não houve disfu
nção cardiovascular severa e/ou choque circulatório no período estudado.#^dnd^i1
#^tm^lpt^kDisfunção ventricular direita^i1#^tm^lpt^kembolia pulmonar^i1#^tm^lpt^
kcateterismo de Swan-Ganz^i1#^tm^lpt^ksuínos^i1#^len^aBACKGROUND: Acute right ve
ntricular overload is associated with high morbidity and mortality clinical situ
ations such as: extensive lung resection, pulmonary thromboembolism, lung transp
lantation and high altitude pulmonary edema. Some points of its pathophysiology 
remain unclear. OBJECTIVE: To assess the hemodynamic effects of experimental acu
te right ventricular overload in pigs. METHODS: Right ventricular overload was i
nduced through the occlusion of the pulmonary arteries using ligationss. Twenty 
pigs were used in the study, divided into 04 groups: one control group not subje
ct to pulmonary vascular occlusion, and three right ventricular overload groups 
subject to occlusion of the following pulmonary arteries: SVD1 (left pulmonary a
rtery); SVD2 (left pulmonary artery and right lower lobe) and SVD3 (left pulmona
ry artery, right lower lobe and mediastinal lobe), obstructing the pulmonary vas
culature in 42, 76 and 82.0 percent respectively. Hemodynamic variables were mea
sured every 15 minutes during one hour of study. The statistical analysis employ
ed mixed linear models with variance and covariance structures. RESULTS: Group c
omparisons revealed significant increases in heart rate (p = 0.004), mean pulmon
ary artery pressure (p = 0.001) and pulmonary capillary wedge pressure (p < 0.00
01). There was no significant difference in cardiac index (p = 0.94). CONCLUSION
: Despite the severe right ventricular overload promoted by 82.0 percent obstruc
tion of the pulmonary vasculature and the significant increase in pulmonary arte
rial pressure, there was no severe cardiovascular dysfunction and/or circulatory
 shock during the study period.#^dnd^i2#^tm^len^kVentricular dysfunction, right^
i2#^tm^len^kpulmonary embolism^i2#^tm^len^kcatheterization, Swan-Ganz^i2#^tm^len
^kswine^i2#vancouv#27#20100731#31/07/10#20101015#15/10/10#20101028#28/10/10#aop0
1811.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-
782X2011005000029##
00431000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704018900083002001300272#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#5#1#article#145#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Efeitos
 hemodin&acirc;micos da sobrecarga ventricular direita aguda experimental</b></f
ont></p>     ^cY#aop01811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#6#2#article#145#<p>&nbsp;</p
>     ^cY#aop01811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#7#3#article#145#<p>&nbsp;</p
>     ^cY#aop01811.htm##
00582000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704034000083002001300423#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#8#4#article#145#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fl&aacute;vio Brito Filho;
 Kleber Nogueira de Campos; Humberto Alves de Oliveira; Josu&eacute; Fernandes; 
C&eacute;sar Augusto Melo e Silva; Eduardo Gaio, Edwin Roger Parra; Paulo Henriq
ue C&acirc;ndido de Carvalho; Paulo Manoel P&ecirc;go Fernandes </b></font></p> 
    ^cY#aop01811.htm##
00398000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704015600083002001300239#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#9#5#article#145#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Unidade de Cirurg
ia Tor&aacute;cica, Hospital de Base do Distrito Federal    ^cY#aop01811.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704015100084002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#10#6#article#145#<br>   <sup
>II</sup>Laborat&oacute;rio de Fisiologia Respirat&oacute;ria Experimental, Facu
ldade de Medicina da Universidade de Bras&iacute;lia    ^cY#aop01811.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012500084002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#11#7#article#145#<br>   <sup
>III</sup>Centro de Treinamento e Ensino em Ci&ecirc;ncias da Sa&uacute;de - CET
REX, Bras&iacute;lia, DF;     ^cY#aop01811.htm##
00364000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012100084002001300205#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#12#8#article#145#<br>   <sup
>IV</sup>Instituto do Cora&ccedil;&atilde;o, Faculdade de Medicina da Universida
de de S&atilde;o Paulo    ^cY#aop01811.htm##
00397000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704015400084002001300238#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#13#9#article#145#<br>   <sup
>V</sup>Departamento de Patologia, Faculdade de Medicina da Universidade de S&at
ilde;o Paulo, S&atilde;o Paulo, SP - Brasil</font></p>     ^cY#aop01811.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012400085002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#14#10#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&
ecirc;ncia</a></font></p>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#15#11#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#16#12#article#145#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop01811.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#17#13#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>   
  ^cY#aop01811.htm##
00659000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041500085002001300500#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#18#14#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO: </b> A sobre
carga ventricular direita aguda est&aacute; associada a situa&ccedil;&otilde;es 
cl&iacute;nicas de elevada morbimortalidade, tais como: ressec&ccedil;&otilde;es
 pulmonares extensas, tromboembolismo pulmonar, transplante pulmonar e edema pul
monar das altitudes. Alguns pontos de sua fisiopatologia permanecem obscuros.   
 ^cY#aop01811.htm##
00386000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014200085002001300227#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#19#15#article#145#<br>   <b>
OBJETIVO: </b> Avaliar os efeitos hemodin&acirc;micos da sobrecarga ventricular 
direita aguda experimental em su&iacute;nos.    ^cY#aop01811.htm##
01194000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704095000085002001301035#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#20#16#article#145#<br>   <b>
M&Eacute;TODOS: </b> A sobrecarga ventricular direita foi induzida pela oclus&at
ilde;o das art&eacute;rias pulmonares atrav&eacute;s de ligaduras. Vinte porcos 
foram utilizados no estudo, sendo alocados em 04 grupos: um controle, n&atilde;o
 submetido &agrave; oclus&atilde;o vascular pulmonar, e tr&ecirc;s de sobrecarga
 ventricular direita submetidos &agrave; oclus&atilde;o das seguintes art&eacute
;rias pulmonares: SVD1 (art&eacute;ria pulmonar esquerda); SVD2 (art&eacute;ria 
pulmonar esquerda e do lobo inferior direito) e SVD3 (art&eacute;ria pulmonar es
querda, do lobo inferior direito e do lobo mediastinal), obstruindo a vasculatur
a pulmonar em 42, 76 e 82,0% respectivamente. Vari&aacute;veis de hemodin&acirc;
mica foram medidas a cada 15 minutos durante a uma hora do estudo. Na an&aacute;
lise estat&iacute;stica, foram utilizados ajustes de modelos lineares mistos com
 estrutura de vari&acirc;ncias e covari&acirc;ncias.    ^cY#aop01811.htm##
00743000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049900085002001300584#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#21#17#article#145#<br>   <b>
RESULTADOS: </b> Nas compara&ccedil;&otilde;es intergrupais, houve aumento signi
ficativo da frequ&ecirc;ncia card&iacute;aca (p = 0,004), press&atilde;o arteria
l pulmonar m&eacute;dia (p = 0,001) e press&atilde;o capilar pulmonar (p &lt; 0,
0001). Houve redu&ccedil;&atilde;o significativa da press&atilde;o arterial m&ea
cute;dia (p = 0,01) e do &iacute;ndice sist&oacute;lico (p = 0,002). N&atilde;o 
houve diferen&ccedil;a significativa no &iacute;ndice card&iacute;aco (p = 0,94)
.    ^cY#aop01811.htm##
00605000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036100085002001300446#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#22#18#article#145#<br>   <b>
CONCLUS&Atilde;O: </b> Apesar da intensa sobrecarga ventricular direita promovid
a pela obstru&ccedil;&atilde;o de 82,0% da vasculatura pulmonar e pelo aumento s
ignificativo da press&atilde;o arterial pulmonar n&atilde;o houve disfun&ccedil;
&atilde;o cardiovascular severa e/ou choque circulat&oacute;rio no per&iacute;od
o estudado.</font></p>     ^cY#aop01811.htm##
00476000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023200085002001300317#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#23#19#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b> Dis
fun&ccedil;&atilde;o ventricular direita, embolia pulmonar, cateterismo de Swan-
Ganz, su&iacute;nos.</font></p> <hr size="1" noshade>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#24#20#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#25#21#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#26#22#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01811.htm##
01119000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087500085002001300960#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#27#23#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O estudo da sobrecarga vent
ricular direita aguda (SVD) desperta o interesse da comunidade cient&iacute;fica
, n&atilde;o somente por sua relev&acirc;ncia cl&iacute;nica, mas tamb&eacute;m 
pelo seu importante significado biol&oacute;gico, visto que a SVD tamb&eacute;m 
est&aacute; presente em situa&ccedil;&otilde;es fisiol&oacute;gicas, como, por e
xemplo, no exerc&iacute;cio f&iacute;sico<sup>1</sup>. No contexto cl&iacute;nic
o, a principal causa de SVD aguda &eacute; o aumento da imped&acirc;ncia vascula
r pulmonar, que ocorre em diversas situa&ccedil;&otilde;es, tais como: nas resse
c&ccedil;&otilde;es pulmonares extensas<sup>2</sup>, no transplante pulmonar<sup
>3</sup>, no tromboembolismo pulmonar (TEP)<sup>4</sup> e no edema pulmonar das 
grandes altitudes<sup>5</sup>, entre outras. </font></p>     ^cY#aop01811.htm##
01681000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704143700085002001301522#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#28#24#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O aumento da imped&acirc;nc
ia vascular pulmonar tende a promover hipertens&atilde;o e dilata&ccedil;&atilde
;o da c&acirc;mara ventricular direita, que pode reduzir seu volume sist&oacute;
lico e, consequentemente, o d&eacute;bito card&iacute;aco pelo alinhamento ventr
icular em s&eacute;rie<sup>6</sup>. A SVD intensa promove desvio do septo interv
entricular e seu cavalgamento para o lado esquerdo, com consequente redu&ccedil;
&atilde;o da c&acirc;mara ventricular esquerda, reduzindo sua complac&ecirc;ncia
 e gerando disfun&ccedil;&atilde;o biventricular<sup>4</sup>. A disfun&ccedil;&a
tilde;o ventricular direita n&atilde;o &eacute; causada apenas pela sobrecarga p
ress&oacute;rica, mas tamb&eacute;m pela redu&ccedil;&atilde;o da oxigena&ccedil
;&atilde;o do mioc&aacute;rdio, que nesse contexto &eacute; causada por dois fat
ores: (i) hipoperfus&atilde;o coronariana promovida pela redu&ccedil;&atilde;o n
o d&eacute;bito card&iacute;aco; e (ii), redu&ccedil;&atilde;o do fluxo sangu&ia
cute;neo subendoc&aacute;rdico, causado pela compress&atilde;o da art&eacute;ria
 coron&aacute;ria direita devido &agrave; distens&atilde;o e hipertens&atilde;o 
ventricular direita. Al&eacute;m disso, a redu&ccedil;&atilde;o na oferta de oxi
g&ecirc;nio ao mioc&aacute;rdio pode causar isquemia, com agravamento da disfun&
ccedil;&atilde;o cardiovascular<sup>4,7</sup>. </font></p>     ^cY#aop01811.htm#
#
01355000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704111100085002001301196#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#29#25#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O grau de toler&acirc;ncia 
do sistema cardiovascular &agrave; SVD aguda ainda &eacute; controverso. Em rela
&ccedil;&atilde;o aos n&iacute;veis press&oacute;ricos, alguns autores<sup>8,9</
sup> citam que 40 mmHg &eacute; o n&iacute;vel press&oacute;rico m&aacute;ximo q
ue o ventr&iacute;culo direito suporta na aus&ecirc;ncia de cardiopatia pr&eacut
e;via. H&aacute; evid&ecirc;ncias que, durante o exerc&iacute;cio f&iacute;sico 
intenso, os n&iacute;veis press&oacute;ricos na art&eacute;ria pulmonar (AP) se 
aproximam de 40 mmHg, sem que ocorra disfun&ccedil;&atilde;o cardiovascular<sup>
1</sup>. Hultgren e cols.<sup>10</sup> demonstraram que alguns pacientes com ede
ma pulmonar das grandes altitudes apresentam n&iacute;veis press&oacute;ricos de
 AP maiores que 50 mmHg. Um paciente, deste trabalho em particular, apresentou p
ress&atilde;o arterial pulmonar m&eacute;dia (PAP) pr&oacute;xima aos n&iacute;v
eis sist&ecirc;micos (117 mmHg), sem que houvesse disfun&ccedil;&atilde;o cardio
vascular e/ou choque circulat&oacute;rio.</font></p>     ^cY#aop01811.htm##
01381000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704113700085002001301222#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#30#26#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o &a
grave; toler&acirc;ncia do sistema cardiovascular ao percentual de obstru&ccedil
;&atilde;o vascular pulmonar, a literatura &eacute; controversa. P&oacute;voa e 
cols.<sup>11</sup> citam que a obstru&ccedil;&atilde;o vascular pulmonar acima d
e 40,0% promove instabilidade hemodin&acirc;mica no TEP. Nesse mesmo contexto, S
imeke cols.<sup>12</sup> citam que a instabilidade hemodin&acirc;mica ocorre com
 obstru&ccedil;&atilde;o acima de 50,0%. Num contexto distinto, Hsiae cols.<sup>
13</sup> demonstraram que ressec&ccedil;&otilde;es pulmonares extensas podem ser
 realizadas em c&atilde;es, sem que ocorra disfun&ccedil;&atilde;o cardiovascula
r. No nosso trabalho, 58,0% do par&ecirc;nquima pulmonar dos animais foram resse
cados em tempo &uacute;nico, e 70,0% de forma sequencial, com intervalo de 3-4 s
emanas. Apesar de tratarem de situa&ccedil;&otilde;es distintas, os tr&ecirc;s e
xemplos descritos acima demonstram que alguns efeitos hemodin&acirc;micos import
antes da sobrecarga ventricular direita aguda permanecem obscuros. </font></p>  
   ^cY#aop01811.htm##
00493000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024900085002001300334#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#31#27#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O objetivo do presente trab
alho &eacute; avaliar sistematicamente tais efeitos, bem como sua evolu&ccedil;&
atilde;o temporal num modelo de SVD aguda em su&iacute;nos.</font></p>     ^cY#a
op01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#32#28#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#33#29#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos</b></font
></p>     ^cY#aop01811.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012400085002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#34#30#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Modelo de SVD e animais 
utilizados</b></font></p>     ^cY#aop01811.htm##
00979000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073500085002001300820#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#35#31#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A SVD foi induzida em su&ia
cute;nos atrav&eacute;s da oclus&atilde;o das art&eacute;rias pulmonares pelo m&
eacute;todo de ligaduras, ap&oacute;s dissec&ccedil;&atilde;o e isolamento dos s
eus ramos. O grau de oclus&atilde;o vascular pulmonar promovido pelas ligaduras,
 nos diversos grupos do estudo, foi estimado em percentual; assumindo que a vasc
ulatura pulmonar dos su&iacute;nos e, consequentemente, o fluxo sangu&iacute;neo
 sejam proporcionais ao peso dos respectivos lobos. A configura&ccedil;&atilde;o
 anat&ocirc;mica e os pesos percentuais do par&ecirc;nquima pulmonar dos su&iacu
te;nos est&atilde;o demonstrados na <a href="#fig1">Figura 1</a>.</font></p>    
 ^cY#aop01811.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#36#32#article#145#<p><a name
="fig1"></a></p>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#37#33#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#38#34#article#145#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01811fig01.jpg"></p>     ^cY#a
op01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#39#35#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
01914000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704167000085002001301755#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#40#36#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Vinte porcos <i>Large White
,</i> machos, pesando em m&eacute;dia 21,3 kg ± 0,7 (EP) foram entubados, ap&oac
ute;s indu&ccedil;&atilde;o anest&eacute;sica com tiopental s&oacute;dico (7 mg.
kg<sup>-1</sup>) e fentanil (15 <i>&#181;</i>cg.kg<sup>-1</sup>) endovenoso em <
i>bolus</i> e submetidos &agrave; ventila&ccedil;&atilde;o mec&acirc;nica (VC 10
 ml kg<sup>-1</sup>, PEEP 5 cmH<sub>2</sub>O, FR 25 ipm e FiO<sub>2</sub> de 100
,0%). A manuten&ccedil;&atilde;o anest&eacute;sica foi feita atrav&eacute;s da i
nfus&atilde;o venosa cont&iacute;nua de fentanil (20-40 <i>&#181;</i>cg.kg<sup>-
1</sup>h<sup>-1</sup>) associado &agrave; tiopental s&oacute;dico (7-14 mg.kg<su
p>-1</sup>.h<sup>-1</sup>), veiculados em solu&ccedil;&atilde;o fisiol&oacute;gi
ca a 0,9% e pancur&ocirc;nio (0,3 mg.kg<sup>-1</sup>) em <i>bolus</i>. Em seguid
a, os animais foram submetidos &agrave; toracotomia bilateral transesternal, com
 dissec&ccedil;&atilde;o e reparo das art&eacute;rias pulmonares, e alocados ran
domicamente em 4 grupos (n = 5), sendo um controle (C) e tr&ecirc;s de sobrecarg
a ventricular direita (SVD1, SVD2 e SVD3). O grupo C n&atilde;o foi submetido &a
grave; oclus&atilde;o vascular pulmonar. Os grupos de sobrecarga ventricular dir
eita foram submetidos &agrave; oclus&atilde;o das seguintes art&eacute;rias pulm
onares: SVD1 (art&eacute;ria pulmonar esquerda); SVD2 (art&eacute;ria pulmonar e
squerda e do lobo inferior direito) e SVD3 (art&eacute;ria pulmonar esquerda, do
 lobo inferior direito e do lobo mediastinal) (<a href="/img/revistas/abc/2011na
head/aop01811fig02m.jpg">Figura 2</a>). </font></p>     ^cY#aop01811.htm##
00851000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060700085002001300692#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#41#37#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Todos os animais receberam 
cuidados de acordo com as normas estabelecidas no "<i>Guide for the Care and Use
 of Laboratory Animals' </i>(<i>Institute of Laboratory Animal Resources, Nation
al Academy of Sciences</i>, <i>Washington</i>, D. C. 1996) e seguido os Princ&ia
cute;pios &Eacute;ticos na Experimenta&ccedil;&atilde;o Animal do Col&eacute;gio
 Brasileiro de Experimenta&ccedil;&atilde;o Animal (COBEA), sendo o trabalho apr
ovado pelo Comit&ecirc; de &Eacute;tica no Uso Animal da Universidade de Bras&ia
cute;lia, Brasil.</font></p>     ^cY#aop01811.htm##
00354000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011000085002001300195#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#42#38#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Desenho experimental</b>
</font></p>     ^cY#aop01811.htm##
00530000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028600085002001300371#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#43#39#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A coleta dos dados foi real
izada em 05 tempos com intervalos de 15 minutos, totalizando uma hora de estudo,
 conforme demonstrado na <a href="/img/revistas/abc/2011nahead/aop01811fig03m.jp
g">Figura 3</a>.</font></p>     ^cY#aop01811.htm##
00360000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011600085002001300201#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#44#40#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vari&aacute;veis estudad
as</b></font></p>     ^cY#aop01811.htm##
00506000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026200085002001300347#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#45#41#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Press&atilde;o arterial 
m&eacute;dia (PAM), press&atilde;o arterial pulmonar m&eacute;dia (PAP), press&a
tilde;o capilar pulmonar (PCP) e press&atilde;o venosa central (PVC)</b></font><
/p>     ^cY#aop01811.htm##
00920000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067600085002001300761#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#46#42#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A PAM foi obtida atrav&eacu
te;s do cateterismo da art&eacute;ria femoral direita, sendo o cateter conectado
 a um transdutor de press&atilde;o e ao monitor card&iacute;aco multiparam&eacut
e;trico (Dixtal DX 2010<sup>&reg;</sup>, Manaus, AM, Brasil). A PAP e a PVC fora
m mensuradas atrav&eacute;s do cateter de art&eacute;ria pulmonar (Edwards<sup>&
reg;</sup> 131HF7, Irvine, CA, USA) conectado ao monitor citado. A PCP foi mensu
rada pelo m&eacute;todo de oclus&atilde;o, atrav&eacute;s da insufla&ccedil;&ati
lde;o do balonete situado na extremidade distal do cateter da art&eacute;ria pul
monar.</font></p>     ^cY#aop01811.htm##
00482000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023800085002001300323#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#47#43#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Frequ&ecirc;ncia card&ia
cute;aca (FC), d&eacute;bito card&iacute;aco (DC), &iacute;ndice card&iacute;aco
 (IC) e &iacute;ndice sist&oacute;lico (IS)</b> </font></p>     ^cY#aop01811.htm
##
00928000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068400085002001300769#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#48#44#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A FC foi obtida atrav&eacut
e;s do monitor multiparam&eacute;trico e do ox&iacute;metro de pulso conectado n
a orelha esquerda do animal. O DC foi obtido pelo m&eacute;todo de termodilui&cc
edil;&atilde;o e calculado no monitor multiparam&eacute;trico atrav&eacute;s da 
equa&ccedil;&atilde;o de Stewart-Hamilton modificada. O IC foi calculado atrav&e
acute;s do monitor citado anteriormente a partir da divis&atilde;o dos valores d
o DC pela superf&iacute;cie corp&oacute;rea do animal. A superf&iacute;cie corp&
oacute;rea (SC) dos su&iacute;nos foi obtida atrav&eacute;s da seguinte formula<
sup>14 </sup>:</font></p>     ^cY#aop01811.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010100085002001300186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#49#45#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><i>SC = K.p2/3</i></font></
p>     ^cY#aop01811.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014300085002001300228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#50#46#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><i>K = Constante igual a 0,
09 para animais acima de 4 kg</i></font></p>     ^cY#aop01811.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012300085002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#51#47#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><i>p = Peso do animal em qu
ilogramas</i></font></p>     ^cY#aop01811.htm##
00461000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704021700085002001300302#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#52#48#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O IS foi obtido indiretamen
te atrav&eacute;s da divis&atilde;o do &iacute;ndice card&iacute;aco pela frequ&
ecirc;ncia card&iacute;aca.</font></p>     ^cY#aop01811.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012300085002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#53#49#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lise estat&iac
ute;stica</b></font></p>     ^cY#aop01811.htm##
01145000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704090100085002001300986#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#54#50#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As vari&aacute;veis foram a
nalisadas segundo sua distribui&ccedil;&atilde;o, atrav&eacute;s do teste de nor
malidade de Shapiro Wilk. A homogeneidade das vari&acirc;ncias entre os grupos f
oi avaliada pelo teste de Levene. A partir dessa an&aacute;lise, o modelo de aju
stes lineares mistos com estrutura de vari&acirc;ncias e covari&acirc;ncias foi 
utilizado. Os c&aacute;lculos foram realizados com o pacote estat&iacute;stico <
i>SPSS</i> (<i>Statistical Package for the Social Sciences</i>), vers&atilde;o 1
3.0 para <i>Windows</i>. Todos os dados s&atilde;o apresentados como m&eacute;di
a <img src="/img/revistas/abc/2011nahead/aop01811car01.jpg" align="absmiddle"> ±
 erro padr&atilde;o (EP), sendo adotado um valor arbitr&aacute;rio de </font>&#9
45;<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> = 0,05.</font></
p>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#55#51#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#56#52#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop01811.htm##
00616000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037200085002001300457#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#57#53#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A PAM n&atilde;o apresentou
 varia&ccedil;&atilde;o significativa ao longo do estudo (p = 0,27). Nas compara
&ccedil;&otilde;es intergrupais, a PAM em SVD3 foi significativamente menor do q
ue em SVD1 (p = 0,03) (<a href="/img/revistas/abc/2011nahead/html/aop01811fig04.
html">Figura 4-A</a>).</font></p>     ^cY#aop01811.htm##
00640000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039600085002001300481#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#58#54#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A PVC apresentou significat
iva eleva&ccedil;&atilde;o ao longo do estudo no grupo SVD3 (p = 0,01). Entretan
to, as compara&ccedil;&otilde;es das PVCs intergrupais n&atilde;o revelaram dife
ren&ccedil;as significativas (p = 0,07) (<a href="/img/revistas/abc/2011nahead/h
tml/aop01811fig04.html#fig4b">Figura 4-B</a>).</font></p>     ^cY#aop01811.htm##
00672000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042800085002001300513#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#59#55#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A PAP apresentou significat
iva eleva&ccedil;&atilde;o ao longo do estudo nos grupos SVD2 e SVD3 (p &lt; 0,0
001). Nas compara&ccedil;&otilde;es intergrupais, a PAP em SVD3 foi significativ
amente maior do que em C e SVD1, com p-valor de 0,001 e 0,02, respectivamente (<
a href="/img/revistas/abc/2011nahead/html/aop01811fig05.html">Figura 5-A</a>).</
font></p>     ^cY#aop01811.htm##
00724000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048000085002001300565#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#60#56#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A PCP, de forma similar &ag
rave; PAP, apresentou significativa eleva&ccedil;&atilde;o ao longo do estudo no
s grupos SVD2 e SVD3 (p &lt; 0,0001). Nas compara&ccedil;&otilde;es intergrupais
, a PCP em SVD3 foi significativamente maior do que em C e SVD1, com p-valor de 
0,002 em ambas as compara&ccedil;&otilde;es (<a href="/img/revistas/abc/2011nahe
ad/html/aop01811fig05.html#fig5b">Figura 5-B</a>).</font></p>     ^cY#aop01811.h
tm##
00668000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042400085002001300509#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#61#57#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O IS apresentou significati
va redu&ccedil;&atilde;o ao longo do estudo nos grupos C, SVD2 e SVD3 (p = 0,001
). Nas compara&ccedil;&otilde;es intergrupais, o IS em SVD3 foi significativamen
te menor do que em C e SVD1, com p-valor de 0,01 e 0,005, respectivamente (<a hr
ef="/img/revistas/abc/2011nahead/html/aop01811fig06.html">Figura 6-A</a>).</font
></p>     ^cY#aop01811.htm##
00719000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047500085002001300560#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#62#58#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A FC apresentou estabilidad
e nos grupos C e SVD1 e significativa eleva&ccedil;&atilde;o nos grupos SVD2 e S
VD3 ao longo do estudo (p = 0,04). Nas compara&ccedil;&otilde;es intergrupais, a
 FC em SVD3 foi significativamente maior do que em C e SVD1, com p-valor de 0,01
 em ambas as compara&ccedil;&otilde;es (<a href="/img/revistas/abc/2011nahead/ht
ml/aop01811fig06.html#fig6b">Figura 6-B</a>).</font></p>     ^cY#aop01811.htm##
00691000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044700085002001300532#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#63#59#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O IC apresentou redu&ccedil
;&atilde;o similar nos 04 grupos ao longo do estudo (p = 0,005). Apesar da grand
e oclus&atilde;o vascular pulmonar nos grupos SVD2 e SVD3, o IC n&atilde;o apres
entou diferen&ccedil;as significativas nas compara&ccedil;&otilde;es intergrupai
s, com p-valor de 0,94 (<a href="/img/revistas/abc/2011nahead/aop01811fig07m.jpg
">Figura 7</a>). </font></p>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#64#60#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#65#61#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop01811.htm##
00883000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063900085002001300724#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#66#62#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A SVD &eacute; caracterizad
a pelo o aumento da carga volum&eacute;trica e/ou press&oacute;rica imposta ao v
entr&iacute;culo direito<sup>15</sup>. A SVD est&aacute; presente no exerc&iacut
e;cio f&iacute;sico e em diversas situa&ccedil;&otilde;es cl&iacute;nicas, tais 
como: nas ressec&ccedil;&otilde;es pulmonares extensas, no transplante pulmonar,
 no TEP e no edema pulmonar das grandes altitudes. A SVD pode causar instabilida
de hemodin&acirc;mica, dependendo de sua intensidade e do <i>status</i> cardiova
scular pr&eacute;vio dos pacientes<sup>4,6</sup>.</font></p>     ^cY#aop01811.ht
m##
01487000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704124300085002001301328#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#67#63#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No presente trabalho, o gra
u de oclus&atilde;o vascular pulmonar foi estimado pelo peso do par&ecirc;nquima
 pulmonar submetido &agrave;s ligaduras, atrav&eacute;s da assun&ccedil;&atilde;
o que a vasculatura pulmonar e, consequentemente, o fluxo sangu&iacute;neo sejam
 proporcionais ao peso percentual dos respectivos lobos. De forma similar, em an
imais, o peso do par&ecirc;nquima pulmonar j&aacute; foi utilizado previamente c
omo m&eacute;todo para quantifica&ccedil;&atilde;o do volume pulmonar<sup>16</su
p>. Em rela&ccedil;&atilde;o &agrave; distribui&ccedil;&atilde;o regional do flu
xo sangu&iacute;neo pulmonar, j&aacute; foi demonstrado que a estrutura vascular
 pulmonar &eacute; o fator mais importante<sup>17</sup>. Portanto, os lobos pulm
onares mais pesados provavelmente apresentam maior percentual de vasculatura e, 
consequentemente, maior fluxo sangu&iacute;neo em rela&ccedil;&atilde;o aos lobo
s pulmonares com menor peso. Entretanto, ressaltamos que a quantifica&ccedil;&at
ilde;o do percentual de oclus&atilde;o vascular pulmonar utilizada no presente t
rabalho &eacute; apenas uma estimativa e n&atilde;o uma medida direta, podendo s
er imprecisa.</font></p>     ^cY#aop01811.htm##
01831000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704158700085002001301672#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#68#64#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No presente trabalho, o IS 
apresentou tend&ecirc;ncia de redu&ccedil;&atilde;o ao longo do estudo, por&eacu
te;m de maior intensidade nos grupos SVD2 e SVD3, sendo significativamente menor
 em SVD3, quando comparado aos dos grupos C e SVD1. Tal resultado indica que, no
s grupos de maior SVD, houve queda do volume sist&oacute;lico, podendo ser expli
cada pelo menor enchimento ventricular esquerdo. Em situa&ccedil;&otilde;es de S
VD, o menor enchimento ventricular esquerdo pode ocorrer por dois fatores. O pri
meiro &eacute; resultante da redu&ccedil;&atilde;o do volume sist&oacute;lico ve
ntricular direito causado pelo aumento da p&oacute;s-carga, em decorr&ecirc;ncia
 do aumento da imped&acirc;ncia vascular pulmonar consequente &agrave;s oclus&ot
ilde;es vasculares, ou seja, pelo alinhamento ventricular em s&eacute;rie<sup>6,
7</sup>. O segundo fator &eacute; decorrente da redu&ccedil;&atilde;o da complac
&ecirc;ncia ventricular esquerda causada pelo desvio do septo interventricular, 
que ocorre nas grandes dilata&ccedil;&otilde;es do ventr&iacute;culo direito dur
ante aumentos s&uacute;bitos da p&oacute;s-carga (mecanismo de interdepend&ecirc
;ncia das c&acirc;maras card&iacute;acas)<sup>18,19</sup>. No presente trabalho,
 n&atilde;o dispomos de imagens das c&acirc;maras ventriculares para confirmar e
ssa hip&oacute;tese. Foi observado tamb&eacute;m aumento significativo da FC nos
 grupos SVD2 e SVD3 ao longo do estudo, sendo a FC no grupo SVD3 significativame
nte maior do que nos grupos C e SVD1.</font></p>     ^cY#aop01811.htm##
00492000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024800085002001300333#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#69#65#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O IC apresentou redu&ccedil
;&atilde;o similar em todos os grupos ao longo do estudo sem diferen&ccedil;as s
ignificativas nas compara&ccedil;&otilde;es intergrupais. </font></p>     ^cY#ao
p01811.htm##
01462000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704121800085002001301303#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#70#66#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A redu&ccedil;&atilde;o sim
ilar do IC nos diversos grupos do estudo, inclusive no controle, n&atilde;o era 
um achado esperado, e indica que a redu&ccedil;&atilde;o do IC observada nos v&a
acute;rios grupos n&atilde;o pode ser atribu&iacute;da exclusivamente &agrave; S
VD. &Eacute; poss&iacute;vel que no presente estudo a redu&ccedil;&atilde;o do I
C possa ser atribu&iacute;da, pelo menos em parte, &agrave; depress&atilde;o mio
c&aacute;rdica promovida pelos agentes anest&eacute;sicos, principalmente os bar
bit&uacute;ricos que deprimem o sistema cardiovascular por dois mecanismos: o pr
imeiro, atrav&eacute;s do efeito inotr&oacute;pico negativo direito; o segundo, 
pela depress&atilde;o do sistema nervoso simp&aacute;tico<sup>20,21</sup>. O fat
o de n&atilde;o ter havido diferen&ccedil;as significativas no IC intergrupal in
dica que a intensidade da SVD, mesmo aquela mais extrema no grupo SVD3 (com 82,0
% de oclus&atilde;o vascular pulmonar), n&atilde;o comprometeu agudamente a fun&
ccedil;&atilde;o card&iacute;aca. Se o efeito existiu, foi sutil a ponto de n&at
ilde;o ter gerado diferen&ccedil;as significativas entre os grupos. </font></p> 
    ^cY#aop01811.htm##
00965000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704072100085002001300806#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#71#67#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Apesar da magnitude da oclu
s&atilde;o vascular pulmonar nos grupos SVD2 e SVD3, a PVC apresentou tend&ecirc
;ncia significativa de eleva&ccedil;&atilde;o apenas no grupo SVD3. Entretanto, 
nas compara&ccedil;&otilde;es intergrupais, n&atilde;o houve diferen&ccedil;as s
ignificativas. Esse achado indica que o aumento da imped&acirc;ncia vascular pul
monar, capaz de promover aumento na press&atilde;o ventricular direita, ocorreu 
apenas em graus mais extremos de oclus&atilde;o da vasculatura pulmonar, revelan
do uma toler&acirc;ncia consider&aacute;vel do ventr&iacute;culo direito &agrave
; oclus&atilde;o aguda do leito vascular pulmonar. </font></p>     ^cY#aop01811.
htm##
01557000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704131300085002001301398#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#72#68#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Segundo Woode cols.<sup>6</
sup>, durante o TEP agudo em pacientes sem doen&ccedil;a cardiopulmonar pr&eacut
e;via, ocorre eleva&ccedil;&atilde;o da press&atilde;o atrial direita com oclus&
atilde;o vascular pulmonar em torno de 40,0%. Em contraste, no presente trabalho
, a eleva&ccedil;&atilde;o da press&atilde;o atrial direita e da PVC s&oacute; f
oi observada no grupo SVD3, cuja oclus&atilde;o vascular pulmonar foi de 82,0%. 
Segundo outros autores<sup>11,12,22</sup>, o TEP com oclus&atilde;o vascular aci
ma de 30-50,0% promove disfun&ccedil;&atilde;o cardiovascular e instabilidade he
modin&acirc;mica. Por&eacute;m, no presente trabalho, n&atilde;o houve disfun&cc
edil;&atilde;o cardiovascular nem instabilidade hemodin&acirc;mica significativa
, mesmo com 82,0% de oclus&atilde;o vascular pulmonar no grupo SVD3. Entretanto,
 ressaltamos que, nos paciente com TEP agudo, o aumento da imped&acirc;ncia vasc
ular pulmonar n&atilde;o ocorre apenas pelo fator obstrutivo. Existem tamb&eacut
e;m os efeitos dos fatores humorais derivados das plaquetas, liberados pelos &ec
irc;mbolos, que promovem vasoconstric&ccedil;&atilde;o pulmonar reflexa e contri
buem, de forma significativa, para o aumento da imped&acirc;ncia vascular pulmon
ar.</font></p>     ^cY#aop01811.htm##
00732000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048800085002001300573#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#73#69#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Como esperado, a PAP e a PC
P apresentaram significativa eleva&ccedil;&atilde;o nos grupos SVD2 e SVD3 ap&oa
cute;s as ligaduras vasculares. Nas compara&ccedil;&otilde;es intergrupais, tal 
achado foi confirmado, sendo a PAP e a PCP significativamente maiores no grupo S
VD3 do que nos grupos C e SVD1. Esses resultados podem ser atribu&iacute;dos ao 
hiperfluxo na microvasculatura pulmonar<sup>1,5,23</sup>. </font></p>     ^cY#ao
p01811.htm##
01686000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704144200085002001301527#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#74#70#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Uma quest&atilde;o relevant
e refere-se ao local ou segmento da microvasculatura pulmonar na qual ocorre o a
umento da imped&acirc;ncia em situa&ccedil;&otilde;es de hiperfluxo. Sabe-se que
 a sobrecarga de fluxo reduz a resist&ecirc;ncia na por&ccedil;&atilde;o arteria
l da microvasculatura pulmonar, atrav&eacute;s do recrutamento e da distensibili
dade dos seus capilares<sup>24,25</sup>. Na por&ccedil;&atilde;o venosa da micro
vasculatura pulmonar, tal capacidade adaptativa pode ser limitada, podendo ser u
m local significativo de gera&ccedil;&atilde;o de imped&acirc;ncia na vasculatur
a pulmonar como sugerido por Hultgren<sup>5</sup>. Os resultados de Younese cols
.<sup>23</sup>, por sua vez, demonstram que, durante o hiperfluxo pulmonar exper
imental, o gradiente press&oacute;rico entre os capilares pulmonares e o &aacute
;trio esquerdo aumenta significativamente em fun&ccedil;&atilde;o do aumento do 
fluxo, revelando que o hiperfluxo induz a aumento significativo da resist&ecirc;
ncia no seguimento venoso da vasculatura pulmonar. Esses resultados s&atilde;o c
orroborados pelos estudos de Hyman<sup>26</sup>, que demonstrou que, durante o h
iperfluxo, as veias pulmonares de pequeno calibre (2 mm) apresentam aumento pres
s&oacute;rico significativo, em fun&ccedil;&atilde;o do aumento do fluxo, sem qu
e haja hipertens&atilde;o do &aacute;trio esquerdo. </font></p>     ^cY#aop01811
.htm##
01667000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704142300085002001301508#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#75#71#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">&Eacute; poss&iacute;vel qu
e, no presente estudo, o aumento press&oacute;rico no seguimento arterial da vas
culatura pulmonar tenha ocorrido quando a capacidade de recrutamento dos capilar
es pulmonares foi excedida e que, pela raz&atilde;o descrita acima, este aumento
 press&oacute;rico n&atilde;o tenha sido transmitido completamente ao segmento v
enoso de maior calibre. Assim, neste trabalho, a medida da press&atilde;o arteri
al pulmonar oclusiva deve ser interpretada com cautela, pois pode refletir t&ati
lde;o somente os valores da PCP. Younese cols.<sup>23</sup> e Bshoutye cols.<sup
>27</sup> demonstraram tamb&eacute;m que, em situa&ccedil;&otilde;es de hiperflu
xo, os valores da press&atilde;o arterial pulmonar oclusiva est&atilde;o muito m
ais pr&oacute;ximos dos valores do componente arterial do que do venoso. Outros 
autores<sup>5,24 </sup>tamb&eacute;m demonstraram que durante o hiperfluxo exper
imental n&atilde;o foi observado aumento na press&atilde;o atrial esquerda, apes
ar da significativa eleva&ccedil;&atilde;o na press&atilde;o arterial pulmonar. 
Portanto, neste estudo e em situa&ccedil;&otilde;es de hiperfluxo, a press&atild
e;o arterial pulmonar oclusiva estima predominantemente os valores da press&atil
de;o capilar pulmonar e n&atilde;o pode ser utilizada como estimativa de press&a
tilde;o do &aacute;trio esquerdo.</font></p>     ^cY#aop01811.htm##
01174000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704093000085002001301015#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#76#72#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o ao
 grau de toler&acirc;ncia do ventr&iacute;culo direito e o s&uacute;bito aumento
 da press&atilde;o vascular pulmonar, Baruzzi e cols.<sup>8</sup> e McIntyre e c
ols.<sup>9</sup> citam que o ventr&iacute;culo direito &eacute; incapaz de supor
tar eleva&ccedil;&otilde;es agudas da PAP, acima de 40 mmHg. Entretanto, no pres
ente trablho, n&atilde;o foi observado disfun&ccedil;&atilde;o cardiovascular si
gnificativa nos animais do grupo SVD3, cuja m&eacute;dia da PAP foi de 46 mmHg. 
Os resultados do presente trabalho indicam que, em animais com cora&ccedil;&otil
de;es previamente normais, apenas o fator obstrutivo n&atilde;o justifica a disf
un&ccedil;&atilde;o cardiovascular e o choque circulat&oacute;rio, eventualmente
 observados em situa&ccedil;&otilde;es de obstru&ccedil;&atilde;o aguda do leito
 vascular pulmonar. </font></p>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#77#73#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#78#74#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop01811.htm##
00931000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068700085002001300772#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#79#75#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No presente trabalho, o aum
ento da PVC, indicando aumento da press&atilde;o no ventr&iacute;culo direito, s
&oacute; foi observado no grau mais extremo de oclus&atilde;o vascular pulmonar 
(82,0%). Apesar da intensa SVD, promovida pela oclus&atilde;o vascular pulmonar 
de 82,0%, e do significativo aumento da PAP, n&atilde;o houve disfun&ccedil;&ati
lde;o cardiovascular significativa e/ou choque circulat&oacute;rio no per&iacute
;odo estudado. Os resultados deste estudo demonstraram uma surpreendente toler&a
circ;ncia do sistema cardiovascular &agrave; SVD aguda, ao longo de uma hora no 
modelo utilizado.</font></p>     ^cY#aop01811.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#80#76#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Potencial Conflito de In
teresses</b></font></p>     ^cY#aop01811.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014300085002001300228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#81#77#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Declaro n&atilde;o haver co
nflito de interesses pertinentes.</font></p>     ^cY#aop01811.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#82#78#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01811.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015000085002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#83#79#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo n&atilde;
o teve fontes de financiamento externas.</font></p>     ^cY#aop01811.htm##
00374000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013000085002001300215#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#84#80#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vincula&ccedil;&atilde;o
 Acad&ecirc;mica</b></font></p>     ^cY#aop01811.htm##
00436000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019200085002001300277#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#85#81#article#145#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; vincul
a&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atilde;
o.</font></p>     ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#86#82#article#145#<p>&nbsp;<
/p>     ^cY#aop01811.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#87#83#article#145#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01811.htm##
00517000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704025900087002001300346#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#88#84#article#14
5#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.	Wagner PD,
 Gale GE, Moon RE, Torre-Bueno JR, Stolp BW, Saltzman HA. Pulmonary gas exchange
 in humans exercising at a sea level and simulated altitude. J Appl Physiol. 198
6;61(1):260-70.    ^cY#aop01811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#89#85#article#145#</font></p
>     ^cY#aop01811.htm##
00481000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022300087002001300310#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#90#86#article#14
5#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2.	Waller DA,
 Keavey P, Woodfine L, Dark JH. Pulmonary endothelial permeability changes after
 major lung resection. Ann Thorac Surg. 1996;61(5):1435-40.    ^cY#aop01811.htm#
#
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#91#87#article#145#</font></p
>     ^cY#aop01811.htm##
00428000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704017000087002001300257#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#92#88#article#14
5#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3.	Della Rocc
a G, Coccia C. Nitric oxide in thoracic surgery. Minerva Anestesiol. 2005;71(6):
313-8.    ^cY#aop01811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#93#89#article#145#</font></p
>     ^cY#aop01811.htm##
00492000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023400087002001300321#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#94#90#article#14
5#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4.	Kreit JW. 
The impact of right ventricular dysfunction on the prognosis and therapy of norm
otensive patients with pulmonary embolism. Chest. 2004;125(4):1539-45.    ^cY#ao
p01811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#95#91#article#145#</font></p
>     ^cY#aop01811.htm##
00423000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704016500087002001300252#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#96#92#article#14
5#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5.	Hultgren H
N. High-altitude pulmonary edema: current concepts. Annu Rev Med. 1996;47:267-84
.    ^cY#aop01811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#97#93#article#145#</font></p
>     ^cY#aop01811.htm##
00502000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704024400087002001300331#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#98#94#article#14
5#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6.	Wood KE. M
ajor pulmonary embolism: review of a pathophysiologic approach to the golden hou
r of hemodynamically significant pulmonary embolism. Chest. 2002;121(3):877-905.
    ^cY#aop01811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#99#95#article#145#</font></p
>     ^cY#aop01811.htm##
00471000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704021200088002001300300#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#100#96#article#1
45#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7.	Goldhaber
 SZ, Elliott CG. Acute pulmonary embolism: part I. Epidemiology, pathophysiology
 and diagnosis. Circulation. 2003;108(22):2726-9.    ^cY#aop01811.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#101#97#article#145#</font></
p>     ^cY#aop01811.htm##
00466000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704020700088002001300295#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#102#98#article#1
45#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8.	Baruzzi A
CA, Knobel M, Knobel E. Right ventricle in pulmonary hypertension. Rev Soc Cardi
ol Estado de S&atilde;o Paulo. 2000;5:636-9.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#103#99#article#145# </font><
/p>     ^cY#aop01811.htm##
00471000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704021100089002001300300#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#104#100#article#
145#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9.	McIntyre
 KM, Sasahara AA. Determinants of right ventricular function and hemodynamics af
ter pulmonary embolism. Chest. 1974;65(5):534-43.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#105#101#article#145#</font><
/p>     ^cY#aop01811.htm##
00467000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020600090002001300296#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#106#102#article#
145#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10.	Hultgr
en HN, Lopez CE, Lundberg E, Miller H. Physiologic studies of pulmonary edema at
 high altitude. Circulation. 1964;29:393-408.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#107#103#article#145#</font><
/p>     ^cY#aop01811.htm##
00473000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021200090002001300302#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#108#104#article#
145#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11.	P&oacu
te;voa R, Kasinski N. Pulmonary hypertension in pulmonary tromboembolism. Rev So
c Cardiol Estado de S&atilde;o Paulo. 2000;5:590-8.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#109#105#article#145#</font><
/p>     ^cY#aop01811.htm##
00516000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025500090002001300345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#110#106#article#
145#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12.	Simek 
M, Nemec P, Cermak M, Prikrylov&aacute; K. Intraoperative massive pulmonary embo
lism during coronary artery bypass grafting. Interact CardioVasc Thorac Surg. 20
05;4(4):283-4.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#111#107#article#145#</font><
/p>     ^cY#aop01811.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026300090002001300353#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#112#108#article#
145#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13.	Hsia C
CW, Dane DM, Estrera AS, Wagner HE, Wagner PD, Johnson Jr RL. Shifting sources o
f functional limitation following extensive (70%) lung resection. J Appl Physiol
. 2008;104(4):1060-79.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#113#109#article#145#</font><
/p>     ^cY#aop01811.htm##
00647000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704038600090002001300476#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#114#110#article#
145#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14.	Otsuki
 DA. Hemodilui&ccedil;&atilde;o normovol&ecirc;mica aguda: estudo experimental c
omparativo utilizando amido hidroxiet&iacute;lico a 6% ou solu&ccedil;&atilde;o 
de Ringer lactato &#91;tese&#93;. S&atilde;o Paulo: Faculdade de Medicina Veteri
n&aacute;ria e Zootecnia. Universidade de S&atilde;o Paulo; 2004.    ^cY#aop0181
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#115#111#article#145#</font><
/p>     ^cY#aop01811.htm##
00508000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024700090002001300337#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#116#112#article#
145#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15.	Santam
ore WP, Gray L Jr. Significant left ventricular contributions to right ventricul
ar systolic function. Mechanism and clinical implications. Chest. 1995;107(4):11
34-45.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#117#113#article#145#</font><
/p>     ^cY#aop01811.htm##
00556000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029500090002001300385#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#118#114#article#
145#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16.	Fusco 
LB, Fonseca MH, P&ecirc;go-Fernandes PM, Pazetti R, Capelozzi V, Jatene FB, et a
l. Cirurgia de redu&ccedil;&atilde;o do volume pulmonar em modelo experimental d
e enfisema em ratos. J Bras Pneumol. 2005;31(1):34-40.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#119#115#article#145#</font><
/p>     ^cY#aop01811.htm##
00457000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019600090002001300286#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#120#116#article#
145#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17.	Hlasta
la MP, Glenny RW. Vascular structure determines pulmonary blood flow distributio
n. News Physiol Sci. 1999;14:182-6.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#121#117#article#145#</font><
/p>     ^cY#aop01811.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028500090002001300375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#122#118#article#
145#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18.	Dell'I
talia LJ, Pearce DJ, Blackwell GG, Singleton HR, Bishop SP, Pohost GM. Right and
 left ventricular volumes and function after acute pulmonary hypertension in int
act dogs. J Appl Physiol. 1995;78(6):2320-7.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#123#119#article#145#</font><
/p>     ^cY#aop01811.htm##
00477000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021600090002001300306#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#124#120#article#
145#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19.	Belenk
ie I, Dani R, Smith ER, Tyberg JV. Ventricular interaction during experimental a
cute pulmonary embolism. Circulation. 1988;78(3):761-8.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#125#121#article#145#</font><
/p>     ^cY#aop01811.htm##
00485000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022400090002001300314#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#126#122#article#
145#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20.	Neukir
chen M, Kienbaum P. Sympathetic nervous system: evaluation and importance for cl
inical general anesthesia. Anesthesiology. 2008;109(6):1113-31.    ^cY#aop01811.
htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#127#123#article#145#</font><
/p>     ^cY#aop01811.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022500090002001300315#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#128#124#article#
145#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21.	Wada R
D, Harashima H, Ebling WF, Osaki EWAS, Stanski DR. Effects of thiopental on regi
onal blood flows in the rat. Anesthesiology. 1996;84(3):596-604.    ^cY#aop01811
.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#129#125#article#145#</font><
/p>     ^cY#aop01811.htm##
00507000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024600090002001300336#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#130#126#article#
145#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22.	Ocak I
, Fuhrman C. CT angiography findings of the left atrium and the right ventricle 
in patients with massive pulmonary embolism. AJR.Am J Roentgenol. 2008;191(4):10
72-6.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#131#127#article#145#</font><
/p>     ^cY#aop01811.htm##
00493000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023200090002001300322#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#132#128#article#
145#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23.	Younes
 M, Bshouty Z, Ali J. Longitudinal distribution of pulmonary vascular resistance
 with very high pulmonary blood flow. J App Physiol. 1987;62(1):344-58.    ^cY#a
op01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#133#129#article#145#</font><
/p>     ^cY#aop01811.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029800090002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#134#130#article#
145#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24.	Nagasa
ka Y, Ishigaki M, Okazaki H, Huang J, Matsuda M, Noguchi T, et al. Effect of pul
monary blood flow on microvascular pressure profile determined by micropuncture 
in perfused cat lungs. J Appl Physiol. 1994;77(4):1834-9.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#135#131#article#145#</font><
/p>     ^cY#aop01811.htm##
00407000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704014600090002001300236#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#136#132#article#
145#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25.	Levitz
ky MG. Pulmonary physiology. 6th ed. New York: McGraw-Hill; 2003.    ^cY#aop0181
1.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#137#133#article#145# </font>
</p>     ^cY#aop01811.htm##
00461000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020000090002001300290#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#138#134#article#
145#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26.	Hyman 
AL. Effects of large increases in pulmonary blood flow on pulmonary venous press
ure. J Appl Physiol. 1969;27(2):179-85.    ^cY#aop01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#139#135#article#145#</font><
/p>     ^cY#aop01811.htm##
00491000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023000090002001300320#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#140#136#article#
145#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27.	Bshout
y Z, Ali J, Younes M. Arterial occlusion versus isofiltration pulmonary capillar
y pressures during very high flow. J Appl Physiol. 1987;62(3):1174-8.    ^cY#aop
01811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#141#137#article#145#</font><
/p>     ^cY#aop01811.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#142#138#article#145#<p>&nbsp
;</p>     ^cY#aop01811.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#143#139#article#145#<p>&nbsp
;</p>     ^cY#aop01811.htm##
00446000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020000087002001300287#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#144#140#article#145#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg"border="0"></a> <b>Cor
respond&ecirc;ncia: </b>    ^cY#aop01811.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004100087002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#145#141#article#145#<br>   F
l&aacute;vio Brito Filho     ^cY#aop01811.htm##
00300000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005400087002001300141#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#146#142#article#145#<br>   S
QN 309, Bloco K, apt. 503 - Asa Norte     ^cY#aop01811.htm##
00302000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005600087002001300143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#147#143#article#145#<br>   7
0755-110 - Bras&iacute;lia, DF - Brasil     ^cY#aop01811.htm##
00429000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704018300087002001300270#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#148#144#article#145#<br>   E
-mail: <a href="mailto:flavio@cirurgiatoracicadf.com.br">flavio@cirurgiatoracica
df.com.br</a>, <a href="mailto:fbtorax@hotmail.com">fbtorax@hotmail.com</a></fon
t></p>     ^cY#aop01811.htm##
00408000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016200087002001300249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01811.htm#S#p#149#145#article#145#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 31/07/
10; revisado recebido em 15/10/10; aceito em 28/10/10.</font></p>     ^cY#aop018
11.htm##
00702000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100015001030100
01500118010002200133010001600155010001900171012008600190030001500276065000900291
06400050030003100030030503200020030801400070031086500090031700200130032603500100
0339801001500349#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#
S#c#150#1#article#27#1#^rND^sWagner^nPD#^rND^sGale^nGE#^rND^sMoon^nRE#^rND^sTorr
e-Bueno^nJR#^rND^sStolp^nBW#^rND^sSaltzman^nHA#Pulmonary gas exchange in humans 
exercising at a sea level and simulated altitude^len#J Appl Physiol#19860000#198
6#61#1#260-70#20110000#aop01811.htm#0021-8987#J Appl Physiol##
00631000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030100
01800119010001500137012007400152030001600226065000900242064000500251031000300256
032000200259014000800261865000900269002001300278035001000291801001600301#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#c#151#2#article#27#2#^
rND^sWaller^nDA#^rND^sKeavey^nP#^rND^sWoodfine^nL#^rND^sDark^nJH#Pulmonary endot
helial permeability changes after major lung resection^len#Ann Thorac Surg#19960
000#1996#61#5#1435-40#20110000#aop01811.htm#0003-4975#Ann Thorac Surg##
00545000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100016001070120
03700123030001900160065000900179064000500188031000300193032000200196014000600198
865000900204002001300213035001000226801001900236#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01811.htm#S#c#152#3#article#27#3#^rND^sDella Rocca^nG#^rND
^sCoccia^nC#Nitric oxide in thoracic surgery^len#Minerva Anestesiol#20050000#200
5#71#6#313-8#20110000#aop01811.htm#0375-9393#Minerva anestesiol##
00578000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860120126001020300
00600228065000900234064000500243031000400248032000200252014000800254865000900262
002001300271035001000284801000600294#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01811.htm#S#c#153#4#article#27#4#^rND^sKreit^nJW#The impact of right v
entricular dysfunction on the prognosis and therapy of normotensive patients wit
h pulmonary embolism^len#Chest#20040000#2004#125#4#1539-45#20110000#aop01811.htm
#0012-3692#Chest##
00505000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860120052001050300
01300157065000900170064000500179031000300184014000700187865000900194002001300203
035001000216801001300226#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
811.htm#S#c#154#5#article#27#5#^rND^sHultgren^nHN#High-altitude pulmonary edema:
 current concepts^len#Annu Rev Med#19960000#1996#47#267-84#20110000#aop01811.htm
#0066-4219#Annu Rev Med##
00588000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860120137001010300
00600238065000900244064000500253031000400258032000200262014000800264865000900272
002001300281035001000294801000600304#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01811.htm#S#c#155#6#article#27#6#^rND^sWood^nKE#Major pulmonary emboli
sm: review of a pathophysiologic approach to the golden hour of hemodynamically 
significant pulmonary embolism^len#Chest#20020000#2002#121#3#877-905#20110000#ao
p01811.htm#0012-3692#Chest##
00580000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100018001060120
08200124030001200206065000900218064000500227031000400232032000300236014000700239
865000900246002001300255035001000268801001200278#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01811.htm#S#c#156#7#article#27#7#^rND^sGoldhaber^nSZ#^rND^
sElliott^nCG#Acute pulmonary embolism: part I. Epidemiology, pathophysiology and
 diagnosis^len#Circulation#20030000#2003#108#22#2726-9#20110000#aop01811.htm#000
9-7322#Circulation##
00543000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100016001050100
01600121012004600137030003600183710000200219065000900221064000500230031000200235
014000600237865000900243002001300252#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01811.htm#S#c#157#8#article#27#8#^rND^sBaruzzi^nACA#^rND^sKnobel^nM#^r
ND^sKnobel^nE#Right ventricle in pulmonary hypertension^len#Rev Soc Cardiol Esta
do de São Paulo#2#20000000#2000#5#636-9#20110000#aop01811.htm##
00573000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100019001050120
08900124030000600213065000900219064000500228031000300233032000200236014000700238
865000900245002001300254035001000267801000600277#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01811.htm#S#c#158#9#article#27#9#^rND^sMcIntyre^nKM#^rND^s
Sasahara^nAA#Determinants of right ventricular function and hemodynamics after p
ulmonary embolism^len#Chest#19740000#1974#65#5#534-43#20110000#aop01811.htm#0012
-3692#Chest##
00600000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01800123010001600141012006000157030001200217065000900229064000500238031000300243
014000800246865000900254002001300263035001000276801001200286#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01811.htm#S#c#159#10#article#27#10#^rND^sHultg
ren^nHN#^rND^sLopez^nCE#^rND^sLundberg^nE#^rND^sMiller^nH#Physiologic studies of
 pulmonary edema at high altitude^len#Circulation#19640000#1964#29#393-408#20110
000#aop01811.htm#0009-7322#Circulation##
00524000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100018001030120
05500121030003600176710000200212065000900214064000500223031000200228014000600230
865000900236002001300245#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
811.htm#S#c#160#11#article#27#11#^rND^sPóvoa^nR#^rND^sKasinski^nN#Pulmonary hype
rtension in pulmonary tromboembolism^len#Rev Soc Cardiol Estado de São Paulo#2#2
0000000#2000#5#590-8#20110000#aop01811.htm##
00621000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030100
01600118010002000134012008500154030003200239710000200271065000900273064000500282
031000200287032000200289014000600291865000900297002001300306#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01811.htm#S#c#161#12#article#27#12#^rND^sSimek
^nM#^rND^sNemec^nP#^rND^sCermak^nM#^rND^sPrikrylová^nK#Intraoperative massive pu
lmonary embolism during coronary artery bypass grafting^len#Interact CardioVasc 
Thorac Surg#2#20050000#2005#4#4#283-4#20110000#aop01811.htm##
00707000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01800119010001700137010001700154010002100171012008700192030001500279065000900294
06400050030303100040030803200020031201400080031486500090032200200130033103500100
0344801001500354#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#
S#c#162#13#article#27#13#^rND^sHsia^nCCW#^rND^sDane^nDM#^rND^sEstrera^nAS#^rND^s
Wagner^nHE#^rND^sWagner^nPD#^rND^sJohnson Jr^nRL#Shifting sources of functional 
limitation following extensive (70%) lung resection^len#J Appl Physiol#20080000#
2008#104#4#1060-79#20110000#aop01811.htm#0021-8987#J Appl Physiol##
00591000000000229000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160018000880180136001060660
01000242062007300252065000900325064000500334865000900339002001300348#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#c#163#14#article#27#14#^rN
D^sOtsuki^nDA.#Hemodiluição normovolêmica aguda: estudo experimental comparativo
 utilizando amido hidroxietílico a 6% ou solução de Ringer lactato^lpt#São Paulo
#Faculdade de Medicina Veterinária e Zootecnia. Universidade de São Paulo#200400
00#2004#20110000#aop01811.htm##
00610000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080120
12300125030000600248065000900254064000500263031000400268032000200272014000800274
865000900282002001300291035001000304801000600314#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01811.htm#S#c#164#15#article#27#15#^rND^sSantamore^nWP#^rN
D^sGray Jr^nL#Significant left ventricular contributions to right ventricular sy
stolic function: Mechanism and clinical implications^len#Chest#19950000#1995#107
#4#1134-45#20110000#aop01811.htm#0012-3692#Chest##
00695000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
02500122010001700147010001900164010001700183810000600200012008700206030001500293
71000020030806500090031006400050031903100030032403200020032701400060032986500090
0335002001300344#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#
S#c#165#16#article#27#16#^rND^sFusco^nLB#^rND^sFonseca^nMH#^rND^sPêgo-Fernandes^
nPM#^rND^sPazetti^nR#^rND^sCapelozzi^nV#^rND^sJatene^nFB#et al#Cirurgia de reduç
ão do volume pulmonar em modelo experimental de enfisema em ratos^lpt#J Bras Pne
umol#2#20050000#2005#31#1#34-40#20110000#aop01811.htm##
00522000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070120
06800124030001700192710000200209065000900211064000500220031000300225014000600228
865000900234002001300243#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
811.htm#S#c#166#17#article#27#17#^rND^sHlastala^nMP#^rND^sGlenny^nRW#Vascular st
ructure determines pulmonary blood flow distribution^len#News Physiol Sci#2#1999
0000#1999#14#182-6#20110000#aop01811.htm##
00729000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880100017001100100
02000127010002000147010001700167010001700184012010200201030001500303065000900318
06400050032703100030033203200020033501400070033786500090034400200130035303500100
0366801001500376#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#
S#c#167#18#article#27#18#^rND^sDell'Italia^nLJ#^rND^sPearce^nDJ#^rND^sBlackwell^
nGG#^rND^sSingleton^nHR#^rND^sBishop^nSP#^rND^sPohost^nGM#Right and left ventric
ular volumes and function after acute pulmonary hypertension in intact dogs^len#
J Appl Physiol#19950000#1995#78#6#2320-7#20110000#aop01811.htm#0021-8987#J Appl 
Physiol##
00621000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100014001060100
01600120010001700136012007300153030001200226065000900238064000500247031000300252
032000200255014000600257865000900263002001300272035001000285801001200295#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#c#168#19#article#27#19
#^rND^sBelenkie^nI#^rND^sDani^nR#^rND^sSmith^nER#^rND^sTyberg^nJV#Ventricular in
teraction during experimental acute pulmonary embolism^len#Circulation#19880000#
1988#78#3#761-8#20110000#aop01811.htm#0009-7322#Circulation##
00596000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100018001080120
09000126030001500216065000900231064000500240031000400245032000200249014000800251
865000900259002001300268035001000281801001500291#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01811.htm#S#c#169#20#article#27#20#^rND^sNeukirchen^nM#^rN
D^sKienbaum^nP#Sympathetic nervous system: evaluation and importance for clinica
l general anesthesia^len#Anesthesiology#20080000#2008#109#6#1113-31#20110000#aop
01811.htm#0003-3022#Anesthesiology##
00651000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01700122010001800139010001800157012006100175030001500236065000900251064000500260
03100030026503200020026801400080027086500090027800200130028703500100030080100150
0310#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#c#170#21#a
rticle#27#21#^rND^sWada^nRD#^rND^sHarashima^nH#^rND^sEbling^nWF#^rND^sOsaki^nEWA
S#^rND^sStanski^nDR#Effects of thiopental on regional blood flows in the rat^len
#Anesthesiology#19960000#1996#84#3#596-604#20110000#aop01811.htm#0003-3022#Anest
hesiology##
00583000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100017001020120
11500119030002000234710000200254065000900256064000500265031000400270032000200274
014000700276865000900283002001300292#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01811.htm#S#c#171#22#article#27#22#^rND^sOcak^nI#^rND^sFuhrman^nC#CT a
ngiography findings of the left atrium and the right ventricle in patients with 
massive pulmonary embolism^len#AJR.Am J Roentgenol#2#20080000#2008#191#4#1072-6#
20110000#aop01811.htm##
00587000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01300121012009900134030001400233710000200247065000900249064000500258031000300263
032000200266014000700268865000900275002001300284#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01811.htm#S#c#172#23#article#27#23#^rND^sYounes^nM#^rND^sB
shouty^nZ#^rND^sAli^nJ#Longitudinal distribution of pulmonary vascular resistanc
e with very high pulmonary blood flow^len#J App Physiol#2#19870000#1987#62#1#344
-58#20110000#aop01811.htm##
00753000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01700124010001500141010001700156010001700173810000600190012011900196030001500315
06500090033006400050033903100030034403200020034701400070034986500090035600200130
0365035001000378801001500388#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01811.htm#S#c#173#24#article#27#24#^rND^sNagasaka^nY#^rND^sIshigaki^nM#^rND^sO
kazaki^nH#^rND^sHuang^nJ#^rND^sMatsuda^nM#^rND^sNoguchi^nT#et al#Effect of pulmo
nary blood flow on microvascular pressure profile determined by micropuncture in
 perfused cat lungs^len#J Appl Physiol#19940000#1994#77#4#1834-9#20110000#aop018
11.htm#0021-8987#J Appl Physiol##
00433000000000241000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160019000880180025001070630
00200132066000900134062001200143065000900155064000500164865000900169002001300178
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01811.htm#S#c#174#25#artic
le#27#25#^rND^sLevitzky^nMG#Pulmonary physiology^len#6#New York#McGraw-Hill#2003
0000#2003#20110000#aop01811.htm##
00554000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120084001040300
01500188065000900203064000500212031000300217032000200220014000700222865000900229
002001300238035001000251801001500261#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop01811.htm#S#c#175#26#article#27#26#^rND^sHyman^nAL#Effects of large in
creases in pulmonary blood flow on pulmonary venous pressure^len#J Appl Physiol#
19690000#1969#27#2#179-85#20110000#aop01811.htm#0021-8987#J Appl Physiol##
00620000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100013001050100
01600118012009600134030001500230065000900245064000500254031000300259032000200262
014000700264865000900271002001300280035001000293801001500303#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01811.htm#S#c#176#27#article#27#27#^rND^sBshou
ty^nZ#^rND^sAli^nJ#^rND^sYounes^nM#Arterial occlusion versus isofiltration pulmo
nary capillary pressures during very high flow^len#J Appl Physiol#19870000#1987#
62#3#1174-8#20110000#aop01811.htm#0021-8987#J Appl Physiol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#o#1#1#
article#1#20110331#080952#aop01911.htm#182##
05511000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200980
01780120104002760100033003800100028004130100030004410100021004710100037004920100
02900529070006500558070010400623083193400727085000802661085002602669085003102695
08500220272608500290274808318480277708500080462508500250463308500300465808500230
46880850036047111170008047470720003047551120009047581110009047671160009047761150
00904785114000904794113000904803002001304812#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop01911.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#27#nd#n
d#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110304#Prevalência e cor
relatos de doença vascular no exame de ultrassom em pacientes em hemodiálise^lpt
#Prevalence and correlates of vascular disease at ultrasound examination in pati
ents on hemodialysis^len#^rND^nSebastião Baptista^sMiguel#^rND^nJair Baptista^sM
iguel#^rND^nLuis Guilhermo^sVelarde#^rND^nElisa^sSampaio#^rND^nJorge Paulo Strog
off de^sMatos#^rND^nJocemir Ronaldo^sLugon#Clinefron Clínica de Doenças Renais^i
A01^cSanto Antonio de Pádua#Universidade Federal Fluminense^iA02^1Faculdade de M
edicina^2Divisão de Nefrologia^cNiterói^sRJ^pBrasil#^lpt^aFUNDAMENTO: Pacientes 
em hemodiálise (HD) apresentam risco aumentado de morte cardiovascular. A espess
ura íntima-média (EIM) e a presença de calcificações arteriais são fatores de ri
sco bem conhecidos para morte cardiovascular em pacientes em HD. OBJETIVO: Avali
ar a prevalência de EIM e calcificações em pacientes em HD e correlacionar achad
os de imagem com dados clínicos e laboratoriais. MÉTODOS: Estudo transversal de 
75 pacientes em HD por &gt; 12 meses. Os pacientes foram submetidos à ultrassono
grafia (US) modo-B para determinação da EIM do terço distal das artérias carótid
as comuns. As calcificações arteriais foram avaliadas por US de artérias carótid
as, femorais e tibiais e consideradas positivas se calcificações fossem encontra
das em qualquer sítio arterial. RESULTADOS: Os pacientes tinham 52 ± 13 anos, 57
% eram do sexo masculino e 16% eram diabéticos. EIM &gt; 0,9 mm foi encontrada e
m 57% dos cases e calcificações arteriais na US em 48%. Envelhecimento (décadas)
 e tabagismo estavam associados com aumento da EIM (odds ratio ajustado [aOR] = 
3,4, p < 0,001; aOR = 4,4, p = 0,045, respectivamente) e presença de calcificaçõ
es vasculares (aOR = 3,0, p < 0,001; aOR = 6,8, p = 0,011, respectivamente). Alt
os níveis de hormônio paratireoidiano intacto (iPTH) (por 100 pg/ml) estavam ass
ociados de forma significante com aumento na EIM (aOR = 1,7, p = 0,021), mas não
 com calcificação vascular. Em contraste, diabete e tempo de diálise (anos) fora
m determinantes significantes para calcificações na US (aOR = 15,0, p = 0,009; a
OR = 1,39, p = 0,020), mas não para o aumento da EIM. CONCLUSÃO: EIM aumentada e
 calcificações à US são achados comuns em pacientes em HD. Envelhecimento e taba
gismo são determinantes consistentes para ambas as alterações de imagem. Aumento
 nos níveis de iPTH está associado com aumento na EIM. Diabete e tempo de diális
e aumentam de forma substancial o risco de calcificação arterial.#^dnd^i1#^tm^lp
t^kDiálise renal^i1#^tm^lpt^kdoenças vasculares^i1#^tm^lpt^kcalcinose^i1#^tm^lpt
^kultrassonografia^i1#^len^aBACKGROUND: Patients on hemodialysis present an incr
eased risk of cardiovascular death. Intimal media thickness (IMT) and presence o
f arterial calcifications are well-known risk factors for cardiovascular death i
n hemodialysis patients. OBJECTIVE: To assess the prevalence of IMT and arterial
 calcifications in HD patients and to correlate image findings with clinical and
 laboratory data. METHODS: Cross-sectional study involving 75 patients on dialys
is for &gt;12 months. Patients underwent B-mode ultrasound scan (US) for determi
nation of IMT of the distal third of the common carotid arteries. Arterial calci
fications were assessed by US of carotids, femoral and tibial arteries, and labe
led positive if calcification was found in any arterial site. RESULTS: Patients 
were 52±13 years old, 57% were males and 16% were diabetics. IMT &gt; 0.9 mm was
 found in 57% of cases and arterial calcifications at US in 48%. Aging (decades)
 and smoking were associated with both increased IMT (adjusted odds ratio [aOR] 
= 3.4, p < 0.001; aOR = 4.4, p = 0.045, respectively) and presence of vascular c
alcifications (aOR = 3.0, p < 0.001; aOR = 6.8, p = 0.011, respectively). High i
ntact parathyroid hormone levels (per each 100 pg/ml) were significantly associa
ted with increased IMT (aOR = 1.7, p = 0.021), but not with vascular calcificati
on. In contrast, Diabetes and time on dialysis (years) were significant determin
ants for calcifications at US (aOR = 15.0, p = 0.009; aOR = 1.39, p = 0.020), bu
t not for increased IMT. CONCLUSION: Increased IMT and calcifications at US are 
common findings in hemodialysis patients. Aging and smoking are consistent deter
minants for both image alterations. Parathyroid hormone elevation is associated 
with increased IMT. Diabetes and time on dialysis substantially increase the ris
k for arterial calcification.#^dnd^i2#^tm^len^kHemodialysis^i2#^tm^len^kvascular
 diseases^i2#^tm^len^kcalcinosis^i2#^tm^len^kDoppler ultrasonography^i2#vancouv#
30#20100705#05/07/10#20101020#20/10/10#20101130#30/11/10#aop01911.htm##
05621000000000685000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201050
01780120111002830100033003940100028004270100030004550100021004850100037005060100
02900543070006500572070010400637083198200741085000802723085002602731085003102757
08500220278808500290281008318960283908500080473508500250474308500300476808500230
47980850036048211170008048570720003048651120009048681110009048771160009048861150
00904895114000904904113000904913002001304922#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop01911.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#27#nd#n
d#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110304#<b>Prevalência e 
correlatos de doença vascular no exame de ultrassom em pacientes em hemodiálise<
/b>^lpt#<b>Prevalence and correlates of vascular disease at ultrasound examinati
on in patients on hemodialysis</b>^len#^rND^nSebastião Baptista^sMiguel#^rND^nJa
ir Baptista^sMiguel#^rND^nLuis Guilhermo^sVelarde#^rND^nElisa^sSampaio#^rND^nJor
ge Paulo Strogoff de^sMatos#^rND^nJocemir Ronaldo^sLugon#Clinefron Clínica de Do
enças Renais^iA01^cSanto Antonio de Pádua#Universidade Federal Fluminense^iA02^1
Faculdade de Medicina^2Divisão de Nefrologia^cNiterói^sRJ^pBrasil#^lpt^a<b>FUNDA
MENTO: </b>Pacientes em hemodiálise (HD) apresentam risco aumentado de morte car
diovascular. A espessura íntima-média (EIM) e a presença de calcificações arteri
ais são fatores de risco bem conhecidos para morte cardiovascular em pacientes e
m HD. <b>OBJETIVO: </b>Avaliar a prevalência de EIM e calcificações em pacientes
 em HD e correlacionar achados de imagem com dados clínicos e laboratoriais. <b>
MÉTODOS: </b>Estudo transversal de 75 pacientes em HD por &gt; 12 meses. Os paci
entes foram submetidos à ultrassonografia (US) modo-B para determinação da EIM d
o terço distal das artérias carótidas comuns. As calcificações arteriais foram a
valiadas por US de artérias carótidas, femorais e tibiais e consideradas positiv
as se calcificações fossem encontradas em qualquer sítio arterial. <b>RESULTADOS
: </b>Os pacientes tinham 52 ± 13 anos, 57% eram do sexo masculino e 16% eram di
abéticos. EIM <u>&gt;</u> 0,9 mm foi encontrada em 57% dos cases e calcificações
 arteriais na US em 48%. Envelhecimento (décadas) e tabagismo estavam associados
 com aumento da EIM (odds ratio ajustado [aOR] = 3,4, p &lt; 0,001; aOR = 4,4, p
 = 0,045, respectivamente) e presença de calcificações vasculares (aOR = 3,0, p 
&lt; 0,001; aOR = 6,8, p = 0,011, respectivamente). Altos níveis de hormônio par
atireoidiano intacto (iPTH) (por 100 pg/ml) estavam associados de forma signific
ante com aumento na EIM (aOR = 1,7, p = 0,021), mas não com calcificação vascula
r. Em contraste, diabete e tempo de diálise (anos) foram determinantes significa
ntes para calcificações na US (aOR = 15,0, p = 0,009; aOR = 1,39, p = 0,020), ma
s não para o aumento da EIM. <b>CONCLUSÃO: </b>EIM aumentada e calcificações à U
S são achados comuns em pacientes em HD. Envelhecimento e tabagismo são determin
antes consistentes para ambas as alterações de imagem. Aumento nos níveis de iPT
H está associado com aumento na EIM. Diabete e tempo de diálise aumentam de form
a substancial o risco de calcificação arterial.#^dnd^i1#^tm^lpt^kDiálise renal^i
1#^tm^lpt^kdoenças vasculares^i1#^tm^lpt^kcalcinose^i1#^tm^lpt^kultrassonografia
^i1#^len^a<b>BACKGROUND: </b>Patients on hemodialysis present an increased risk 
of cardiovascular death. Intimal media thickness (IMT) and presence of arterial 
calcifications are well-known risk factors for cardiovascular death in hemodialy
sis patients. <b>OBJECTIVE: </b>To assess the prevalence of IMT and arterial cal
cifications in HD patients and to correlate image findings with clinical and lab
oratory data. <b>METHODS: </b>Cross-sectional study involving 75 patients on dia
lysis for &gt;12 months. Patients underwent B-mode ultrasound scan (US) for dete
rmination of IMT of the distal third of the common carotid arteries. Arterial ca
lcifications were assessed by US of carotids, femoral and tibial arteries, and l
abeled positive if calcification was found in any arterial site. <b>RESULTS: </b
>Patients were 52±13 years old, 57% were males and 16% were diabetics. IMT <u>&g
t;</u> 0.9 mm was found in 57% of cases and arterial calcifications at US in 48%
. Aging (decades) and smoking were associated with both increased IMT (adjusted 
odds ratio [aOR] = 3.4, p &lt; 0.001; aOR = 4.4, p = 0.045, respectively) and pr
esence of vascular calcifications (aOR = 3.0, p &lt; 0.001; aOR = 6.8, p = 0.011
, respectively). High intact parathyroid hormone levels (per each 100 pg/ml) wer
e significantly associated with increased IMT (aOR = 1.7, p = 0.021), but not wi
th vascular calcification. In contrast, Diabetes and time on dialysis (years) we
re significant determinants for calcifications at US (aOR = 15.0, p = 0.009; aOR
 = 1.39, p = 0.020), but not for increased IMT. <b>CONCLUSION: </b>Increased IMT
 and calcifications at US are common findings in hemodialysis patients. Aging an
d smoking are consistent determinants for both image alterations. Parathyroid ho
rmone elevation is associated with increased IMT. Diabetes and time on dialysis 
substantially increase the risk for arterial calcification.#^dnd^i2#^tm^len^kHem
odialysis^i2#^tm^len^kvascular diseases^i2#^tm^len^kcalcinosis^i2#^tm^len^kDoppl
er ultrasonography^i2#vancouv#30#20100705#05/07/10#20101020#20/10/10#20101130#30
/11/10#aop01911.htm##
05698000000000709000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120098001840120104002820100033003860100028004190100030004470100021004770100
03700498010002900535070006700564070010600631083197000737085000802707085002602715
08500310274108500220277208500290279408318760282308500080469908500250470708500300
47320850023047620850036047851170008048210720003048291120009048321110009048411160
00904850115000904859114000904868113000904877002001304886008008904899#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#l#4#1#article#1#^a2011#oa#
pt#br1.1#1#4.0#ilus#tab#27#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-7
82X#20110304#Prevalência e correlatos de doença vascular no exame de ultrassom e
m pacientes em hemodiálise^lpt#Prevalence and correlates of vascular disease at 
ultrasound examination in patients on hemodialysis^len#^rND^nSebastião Baptista^
sMiguel#^rND^nJair Baptista^sMiguel#^rND^nLuis Guilhermo^sVelarde#^rND^nElisa^sS
ampaio#^rND^nJorge Paulo Strogoff de^sMatos#^rND^nJocemir Ronaldo^sLugon#^iA01^1
Clinefron Clínica de Doenças Renais^cSanto Antonio de Pádua#^iA02^1Universidade 
Federal Fluminense^2Faculdade de Medicina^3Divisão de Nefrologia^cNiterói^sRJ^pB
rasil#^lpt^aFUNDAMENTO: Pacientes em hemodiálise (HD) apresentam risco aumentado
 de morte cardiovascular. A espessura íntima-média (EIM) e a presença de calcifi
cações arteriais são fatores de risco bem conhecidos para morte cardiovascular e
m pacientes em HD. OBJETIVO: Avaliar a prevalência de EIM e calcificações em pac
ientes em HD e correlacionar achados de imagem com dados clínicos e laboratoriai
s. MÉTODOS: Estudo transversal de 75 pacientes em HD por &gt; 12 meses. Os pacie
ntes foram submetidos à ultrassonografia (US) modo-B para determinação da EIM do
 terço distal das artérias carótidas comuns. As calcificações arteriais foram av
aliadas por US de artérias carótidas, femorais e tibiais e consideradas positiva
s se calcificações fossem encontradas em qualquer sítio arterial. RESULTADOS: Os
 pacientes tinham 52 ± 13 anos, 57 por cento eram do sexo masculino e 16 por cen
to eram diabéticos. EIM &gt; 0,9 mm foi encontrada em 57 por cento dos cases e c
alcificações arteriais na US em 48 por cento. Envelhecimento (décadas) e tabagis
mo estavam associados com aumento da EIM (odds ratio ajustado [aOR] = 3,4, p < 0
,001; aOR = 4,4, p = 0,045, respectivamente) e presença de calcificações vascula
res (aOR = 3,0, p < 0,001; aOR = 6,8, p = 0,011, respectivamente). Altos níveis 
de hormônio paratireoidiano intacto (iPTH) (por 100 pg/ml) estavam associados de
 forma significante com aumento na EIM (aOR = 1,7, p = 0,021), mas não com calci
ficação vascular. Em contraste, diabete e tempo de diálise (anos) foram determin
antes significantes para calcificações na US (aOR = 15,0, p = 0,009; aOR = 1,39,
 p = 0,020), mas não para o aumento da EIM. CONCLUSÃO: EIM aumentada e calcifica
ções à US são achados comuns em pacientes em HD. Envelhecimento e tabagismo são 
determinantes consistentes para ambas as alterações de imagem. Aumento nos nívei
s de iPTH está associado com aumento na EIM. Diabete e tempo de diálise aumentam
 de forma substancial o risco de calcificação arterial.#^dnd^i1#^tm^lpt^kDiálise
 renal^i1#^tm^lpt^kdoenças vasculares^i1#^tm^lpt^kcalcinose^i1#^tm^lpt^kultrasso
nografia^i1#^len^aBACKGROUND: Patients on hemodialysis present an increased risk
 of cardiovascular death. Intimal media thickness (IMT) and presence of arterial
 calcifications are well-known risk factors for cardiovascular death in hemodial
ysis patients. OBJECTIVE: To assess the prevalence of IMT and arterial calcifica
tions in HD patients and to correlate image findings with clinical and laborator
y data. METHODS: Cross-sectional study involving 75 patients on dialysis for &gt
;12 months. Patients underwent B-mode ultrasound scan (US) for determination of 
IMT of the distal third of the common carotid arteries. Arterial calcifications 
were assessed by US of carotids, femoral and tibial arteries, and labeled positi
ve if calcification was found in any arterial site. RESULTS: Patients were 52±13
 years old, 57 percent were males and 16 percent were diabetics. IMT &gt; 0.9 mm
 was found in 57 percent of cases and arterial calcifications at US in 48 percen
t. Aging (decades) and smoking were associated with both increased IMT (adjusted
 odds ratio [aOR] = 3.4, p < 0.001; aOR = 4.4, p = 0.045, respectively) and pres
ence of vascular calcifications (aOR = 3.0, p < 0.001; aOR = 6.8, p = 0.011, res
pectively). High intact parathyroid hormone levels (per each 100 pg/ml) were sig
nificantly associated with increased IMT (aOR = 1.7, p = 0.021), but not with va
scular calcification. In contrast, Diabetes and time on dialysis (years) were si
gnificant determinants for calcifications at US (aOR = 15.0, p = 0.009; aOR = 1.
39, p = 0.020), but not for increased IMT. CONCLUSION: Increased IMT and calcifi
cations at US are common findings in hemodialysis patients. Aging and smoking ar
e consistent determinants for both image alterations. Parathyroid hormone elevat
ion is associated with increased IMT. Diabetes and time on dialysis substantiall
y increase the risk for arterial calcification.#^dnd^i2#^tm^len^kHemodialysis^i2
#^tm^len^kvascular diseases^i2#^tm^len^kcalcinosis^i2#^tm^len^kDoppler ultrasono
graphy^i2#vancouv#30#20100705#05/07/10#20101020#20/10/10#20101130#30/11/10#aop01
911.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-7
82X2011005000027##
00464000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022200083002001300305#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#5#1#article#148#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Preval&
ecirc;ncia e correlatos de doen&ccedil;a vascular no exame de ultrassom em pacie
ntes em hemodi&aacute;lise</b></font></p>     ^cY#aop01911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#6#2#article#148#<p>&nbsp;</p
>     ^cY#aop01911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#7#3#article#148#<p>&nbsp;</p
>     ^cY#aop01911.htm##
00479000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704023700083002001300320#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#8#4#article#148#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Sebasti&atilde;o Baptista 
Miguel; Jair Baptista Miguel; Luis Guilhermo Velarde; Elisa Sampaio; Jorge Paulo
 Strogoff de Matos; Jocemir Ronaldo Lugon</b></font></p>     ^cY#aop01911.htm##
00406000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704016400083002001300247#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#9#5#article#148#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Clinefron, Cl&iac
ute;nica de Doen&ccedil;as Renais, Santo Antonio de P&aacute;dua    ^cY#aop01911
.htm##
00395000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704015200084002001300236#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#10#6#article#148#<br>   <sup
>II</sup>Faculdade de Medicina, Universidade Federal Fluminense, Divis&atilde;o 
de Nefrologia Niter&oacute;i, RJ - Brasil</font></p>     ^cY#aop01911.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#11#7#article#148#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop01911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#12#8#article#148#<p>&nbsp;</
p>     ^cY#aop01911.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#13#9#article#148#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop01911.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#14#10#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>   
  ^cY#aop01911.htm##
00618000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037400085002001300459#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#15#11#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO: </b> Pacient
es em hemodi&aacute;lise (HD) apresentam risco aumentado de morte cardiovascular
. A espessura &iacute;ntima-m&eacute;dia (EIM) e a presen&ccedil;a de calcifica&
ccedil;&otilde;es arteriais s&atilde;o fatores de risco bem conhecidos para mort
e cardiovascular em pacientes em HD.    ^cY#aop01911.htm##
00437000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019300085002001300278#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#16#12#article#148#<br>   <b>
OBJETIVO: </b> Avaliar a preval&ecirc;ncia de EIM e calcifica&ccedil;&otilde;es 
em pacientes em HD e correlacionar achados de imagem com dados cl&iacute;nicos e
 laboratoriais.    ^cY#aop01911.htm##
00747000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704050300085002001300588#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#17#13#article#148#<br>   <b>
M&Eacute;TODOS: </b> Estudo transversal de 75 pacientes em HD por &gt; 12 meses.
 Os pacientes foram submetidos &agrave; ultrassonografia (US) modo-B para determ
ina&ccedil;&atilde;o da EIM do ter&ccedil;o distal das art&eacute;rias car&oacut
e;tidas comuns. As calcifica&ccedil;&otilde;es arteriais foram avaliadas por US 
de art&eacute;rias car&oacute;tidas, femorais e tibiais e consideradas positivas
 se calcifica&ccedil;&otilde;es fossem encontradas em qualquer s&iacute;tio arte
rial.    ^cY#aop01911.htm##
01220000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097600085002001301061#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#18#14#article#148#<br>   <b>
RESULTADOS: </b> Os pacientes tinham 52 ± 13 anos, 57% eram do sexo masculino e 
16% eram diab&eacute;ticos. EIM <u>&gt;</u> 0,9 mm foi encontrada em 57% dos cas
es e calcifica&ccedil;&otilde;es arteriais na US em 48%. Envelhecimento (d&eacut
e;cadas) e tabagismo estavam associados com aumento da EIM (odds ratio ajustado 
&#91;aOR&#93; = 3,4, p &lt; 0,001; aOR = 4,4, p = 0,045, respectivamente) e pres
en&ccedil;a de calcifica&ccedil;&otilde;es vasculares (aOR = 3,0, p &lt; 0,001; 
aOR = 6,8, p = 0,011, respectivamente). Altos n&iacute;veis de horm&ocirc;nio pa
ratireoidiano intacto (iPTH) (por 100 pg/ml) estavam associados de forma signifi
cante com aumento na EIM (aOR = 1,7, p = 0,021), mas n&atilde;o com calcifica&cc
edil;&atilde;o vascular. Em contraste, diabete e tempo de di&aacute;lise (anos) 
foram determinantes significantes para calcifica&ccedil;&otilde;es na US (aOR = 
15,0, p = 0,009; aOR = 1,39, p = 0,020), mas n&atilde;o para o aumento da EIM.  
  ^cY#aop01911.htm##
00701000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045700085002001300542#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#19#15#article#148#<br>   <b>
CONCLUS&Atilde;O: </b> EIM aumentada e calcifica&ccedil;&otilde;es &agrave; US s
&atilde;o achados comuns em pacientes em HD. Envelhecimento e tabagismo s&atilde
;o determinantes consistentes para ambas as altera&ccedil;&otilde;es de imagem. 
Aumento nos n&iacute;veis de iPTH est&aacute; associado com aumento na EIM. Diab
ete e tempo de di&aacute;lise aumentam de forma substancial o risco de calcifica
&ccedil;&atilde;o arterial.</font></p>     ^cY#aop01911.htm##
00450000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020600085002001300291#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#20#16#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave: </b> Di&
aacute;lise renal, doen&ccedil;as vasculares, calcinose, ultrassonografia.</font
></p> <hr size="1" noshade>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#21#17#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#22#18#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#23#19#article#148#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop01911.htm##
01547000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704130300085002001301388#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#24#20#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Pacientes com doen&ccedil;a
 renal cr&ocirc;nica terminal (DRCT) apresentam alta taxa de mortalidade, princi
palmente relacionada &agrave; doen&ccedil;a cardiovascular (DCV)<sup>1</sup>. O 
desenvolvimento de estrat&eacute;gias n&atilde;o-invasivas para detec&ccedil;&at
ilde;o precoce de doen&ccedil;a vascular pode fornecer oportunidade para uma abo
rdagem precoce de pacientes. A ultrassonografia (US) modo B, que tem o potencial
 de detec&ccedil;&atilde;o de est&aacute;gios iniciais de doen&ccedil;a vascular
, pode ser usada para medir a espessura &iacute;ntima-m&eacute;dia (EIM), consid
erada um marcador de aterosclerose e para detec&ccedil;&atilde;o de calcifica&cc
edil;&otilde;es arteriais<sup>2</sup>, que tem demonstrado uma associa&ccedil;&a
tilde;o com menor taxa de sobrevida em di&aacute;lise<sup>3,4</sup>. Atualmente,
 outros m&eacute;todos diagn&oacute;sticos est&atilde;o dispon&iacute;veis para 
identifica&ccedil;&atilde;o de calcifica&ccedil;&otilde;es arteriais no ambiente
 cl&iacute;nico, incluindo raios-x, ecocardiografia e tomografia computadorizada
 por feixe de el&eacute;trons<sup>5-7</sup>. Entretanto a US modo B &eacute; uma
 t&eacute;cnica de baixo custo e de f&aacute;cil execu&ccedil;&atilde;o. </font>
</p>     ^cY#aop01911.htm##
00556000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031200085002001300397#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#25#21#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os objetivos do presente es
tudo foram avaliar a preval&ecirc;ncia do aumento da EIM e presen&ccedil;a de ca
lcifica&ccedil;&otilde;es utilizando a US modo B e correlacionar os achados com 
os dados cl&iacute;nicos e laboratoriais. </font></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#26#22#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#27#23#article#148#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos</b></font
></p>     ^cY#aop01911.htm##
00818000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057400085002001300659#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#28#24#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Este &eacute; um estudo tra
nsversal, unic&ecirc;ntrico, no qual pacientes de um &uacute;nico centro de di&a
acute;lise, com idade entre 18 e 75 anos, que estavam sendo submetidos &agrave; 
di&aacute;lise por pelo menos 12 meses foram convidados a participar do estudo. 
O estudo foi aprovado pelo Comit&ecirc; de &Eacute;tica local e todos os pacient
es assinaram o Termo de Consentimento Livre e Informado. A avalia&ccedil;&atilde
;o foi realizada entre Mar&ccedil;o de 2006 e Setembro de 2007. </font></p>     
^cY#aop01911.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#29#25#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Estudos de imagem</b></f
ont></p>     ^cY#aop01911.htm##
01740000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704149600085002001301581#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#30#26#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A US modo B foi realizada s
empre pelo mesmo m&eacute;dico com experi&ecirc;ncia na &aacute;rea, utilizando 
aparelhos de US de modo B de alta resolu&ccedil;&atilde;o com transdutor de 7,5 
MHz (Medison 8000 e Esaote Caris Plus). As medidas da EIM forma realizadas no te
r&ccedil;o distal das art&eacute;rias car&oacute;tidas comuns, como sugerido ant
eriormente<sup>2</sup>. Casos com qualquer valor <u>&gt;</u>0,9mm, um valor de c
orte anteriormente associado com aumento da incid&ecirc;ncia de eventos cardiova
sculares em uma popula&ccedil;&atilde;o n&atilde;o submetida &agrave; di&aacute;
lise<sup>8,9</sup>, foram considerados positivos. Na avalia&ccedil;&atilde;o ult
rassonogr&aacute;fica de calcifica&ccedil;&otilde;es vasculares, uma parede vasc
ular altamente ecog&ecirc;nica ou estrutura intraluminal produzindo ecos brilhan
tes com sombreamento foram considerados calcifica&ccedil;&otilde;es<sup>10</sup>
. Os locais investigados foram: o ter&ccedil;o distal das art&eacute;rias car&oa
cute;tidas comuns; car&oacute;tida e ter&ccedil;o proximal dos ramos interno e e
xterno; toda a extens&atilde;o das art&eacute;rias femorais comuns; ter&ccedil;o
 proximal das art&eacute;rias femorais profundas e superficiais; e metade distal
 das art&eacute;rias tibiais posteriores<sup>10</sup>. Se uma calcifica&ccedil;&
atilde;o fosse encontrada em qualquer s&iacute;tio arterial, o caso era consider
ado positivo<sup>11</sup>.</font></p>     ^cY#aop01911.htm##
00392000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014800085002001300233#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#31#27#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Dados demogr&aacute;fico
s, cl&iacute;nicos e laboratoriais</b></font></p>     ^cY#aop01911.htm##
02011000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704176700085002001301852#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#32#28#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Dados demogr&aacute;ficos e
 cl&iacute;nicos foram obtidos atrav&eacute;s de exame de prontu&aacute;rios. Hi
pertens&atilde;o foi definida como press&atilde;o arterial sist&oacute;lica (PAS
) pr&eacute;-di&aacute;lise atual <u>&gt;</u> 140 mmHg e/ou press&atilde;o arter
ial diast&oacute;lica (PAD) <u>&gt;</u> 90 mmHg e/ou uso de medicamentos anti-hi
pertensivos. Os pacientes foram classificados como diab&eacute;ticos se apresent
assem diabete anteriormente &agrave; terapia de substitui&ccedil;&atilde;o renal
 (TSR). N&iacute;veis de hemoglobina, creatinina e Kt/V equilibrado (eKt/V) repr
esentam a m&eacute;dia das tr&ecirc;s &uacute;ltimas determina&ccedil;&otilde;es
 antes da avalia&ccedil;&atilde;o. Para melhor estimar o impacto dos dist&uacute
;rbios de metabolismo mineral em nossos achados, a exposi&ccedil;&atilde;o cumul
ativa foi avaliada atrav&eacute;s do c&aacute;lculo da m&eacute;dia de todos os 
valores s&eacute;ricos de c&aacute;lcio, f&oacute;sforo e horm&ocirc;nio paratir
eoidiano intacto (i-PTH) durante um per&iacute;odo de 36 meses exatamente antes 
da avalia&ccedil;&atilde;o, ou desde o in&iacute;cio da di&aacute;lise para paci
entes em TSR por menos de 3 anos. Os n&iacute;veis s&eacute;ricos de c&aacute;lc
io e f&oacute;sforo foram medidos mensalmente e os n&iacute;veis de i-PTH a cada
 seis meses. An&aacute;lises de sangue de rotina foram realizadas no mesmo labor
at&oacute;rio. Um ensaio imunoturbidim&eacute;trico ultra-sens&iacute;vel para p
rote&iacute;na C-reativa (PCR) foi realizado especificamente para o estudo e os 
valores mostrados correspondem &agrave; uma &uacute;nica determina&ccedil;&atild
e;o, feita quando da inclus&atilde;o no presente estudo. </font></p>     ^cY#aop
01911.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012300085002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#33#29#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lise estat&iac
ute;stica</b></font></p>     ^cY#aop01911.htm##
01408000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704116400085002001301249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#34#30#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Vari&aacute;veis cont&iacut
e;nuas s&atilde;o apresentadas como m&eacute;dias ± DP ou mediana e varia&ccedil
;&atilde;o, como apropriado. Vari&aacute;veis categ&oacute;ricas s&atilde;o most
radas como frequ&ecirc;ncias. Diferen&ccedil;as entre as frequ&ecirc;ncias foram
 analisadas pelo teste de Qui-quadrado. As associa&ccedil;&otilde;es entre as va
ri&aacute;veis foram avaliadas por an&aacute;lise de regress&atilde;o log&iacute
;stica com procedimento <i>backward</i>, na qual todas as vari&aacute;veis poten
cialmente relevantes eram inclu&iacute;das na primeira fase. Somente vari&aacute
;veis que apresentavam valores de p &lt; 0,10 foram mantidas na fase seguinte. E
m caso de colinearidade significante entre duas vari&aacute;veis, somente a mais
 relevante persistia na fase seguinte. As decis&otilde;es sobre quais vari&aacut
e;veis a serem exclu&iacute;das da an&aacute;lise em cada fase foram realizadas 
pelo <i>software</i>. Valores de p &lt; 0,05 foram considerados significantes. O
 <i>software</i> SPSS, vers&atilde;o 17.0 foi utilizado na an&aacute;lise estat&
iacute;stica. </font></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#35#31#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#36#32#article#148#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop01911.htm##
01242000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099800085002001301083#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#37#33#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">De 128 pacientes em hemodi&
aacute;lise, 75 foram inclu&iacute;dos no presente estudo. As principais raz&oti
lde;es para exclus&atilde;o foram: tempo de di&aacute;lise &lt; 1 ano (18 pacien
tes); idade &gt; 75 anos (14 pacientes); e recusa em participar do estudo (12 pa
cientes). Os pacientes inclu&iacute;dos no estudo tinham 52 ± 13 anos, 43 (57%) 
eram do sexo masculino, estavam h&aacute; 59 ± 34 meses em hemodi&aacute;lise (H
D) e 12 (16%) eram diab&eacute;ticos. As caracter&iacute;sticas demogr&aacute;fi
cas e cl&iacute;nicas dos pacientes s&atilde;o mostradas na <a href="#tab1">Tabe
la 1</a>. Os pacientes apresentavam uma ampla varia&ccedil;&atilde;o de idade (<
a href="#fig1">Figura 1</a>) e tempo de di&aacute;lise. Quarenta pacientes (53%)
 estavam sob HD por menos de 5 anos, 30 (40%) por 5 a 10 anos e 5 (7%) por mais 
de 10 anos. Os dados laboratoriais s&atilde;o mostrados na <a href="#tab2">Tabel
a 2</a>.</font></p>     ^cY#aop01911.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#38#34#article#148#<p><a name
="tab1"></a></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#39#35#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#40#36#article#148#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01911tab01.jpg"></p>     ^cY#a
op01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#41#37#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#42#38#article#148#<p><a name
="fig1"></a></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#43#39#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#44#40#article#148#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01911fig01.jpg"></p>     ^cY#a
op01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#45#41#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#46#42#article#148#<p><a name
="tab2"></a></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#47#43#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#48#44#article#148#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01911tab02.jpg"></p>     ^cY#a
op01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#49#45#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00799000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055500085002001300640#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#50#46#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A US modo B foi realizada e
m todos os 75 pacientes. EIM aumentada estava presente em 43 (57%) e calcifica&c
cedil;&otilde;es arteriais foram detectadas em 36 pacientes (48%), <a href="#tab
3">Tabela 3</a>. Calcifica&ccedil;&otilde;es estavam presentes em mais de tr&eci
rc;s art&eacute;rias em 23 desses 36 pacientes e 33 deles tamb&eacute;m apresent
avam aumento da EIM. Dez pacientes (22%) com aumento da EIM n&atilde;o apresenta
vam calcifica&ccedil;&otilde;es &agrave; US. </font></p>     ^cY#aop01911.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#51#47#article#148#<p><a name
="tab3"></a></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#52#48#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#53#49#article#148#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01911tab03.jpg"></p>     ^cY#a
op01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#54#50#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
01749000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704150500085002001301590#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#55#51#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em busca de determinantes d
os achados de imagem, dois modelos de an&aacute;lise de regress&atilde;o condici
onal com procedimento <i>backward</i> foram desenvolvidos utilizando em cada um 
deles EIM <u>&gt;</u> 0,9 mm e calcifica&ccedil;&otilde;es &agrave; US como as v
ari&aacute;veis dependentes. Os dados cl&iacute;nicos e laboratoriais foram util
izados como as vari&aacute;veis independentes. Idade (odds ratio ajustado &#91;a
OR&#93; = 3,36 por d&eacute;cada, p &lt; 0,001), tabagismo (aOR = 4,49, p = 0,04
6), e altos n&iacute;veis de iPTH (1,67 por 100 pg/ml) estavam significantemente
 associados com EIM <u>&gt;</u> 0,9 mm (<a href="#tab4">Tabela 4</a>). Idade (aO
R= 2,96 por d&eacute;cada, p &lt; 0,001) e tabagismo (aOR = 6,77, p = 0,011) tam
b&eacute;m estavam associados com calcifica&ccedil;&otilde;es &agrave; US (<a hr
ef="#tab5">Tabela 5</a>). Diabete (aOR = 1,67, p = 0,021) e tempo de di&aacute;l
ise (aOR = 1,39, p = 0,020) estavam associados com risco significante para calci
fica&ccedil;&otilde;es &agrave; US (aOR = 1,67, p = 0,021 e aOR = 1,39, p = 0,02
0, respectivamente), mas n&atilde;o com aumento da EIM. N&iacute;veis de f&oacut
e;sforo, c&aacute;lcio, produto Ca x P e iPTH n&atilde;o foram identificados com
o fatores de risco para calcifica&ccedil;&atilde;o vascular &agrave; US. N&iacut
e;veis de PCR n&atilde;o estavam associados com EIM <u>&gt;</u> 0,9 mm ou calcif
ica&ccedil;&otilde;es &agrave; US. </font></p>     ^cY#aop01911.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#56#52#article#148#<p><a name
="tab4"></a></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#57#53#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#58#54#article#148#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01911tab04.jpg"></p>     ^cY#a
op01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#59#55#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#60#56#article#148#<p><a name
="tab5"></a></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#61#57#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#62#58#article#148#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop01911tab05.jpg"></p>     ^cY#a
op01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#63#59#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00855000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704061100085002001300696#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#64#60#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"> Para melhor explicar a rel
a&ccedil;&atilde;o entre os n&iacute;veis de iPTH e a EIM, um modelo adicional d
e an&aacute;lise de regress&atilde;o multivariada foi utilizado, no qual os n&ia
cute;veis de iPTH foram estratificados em tr&ecirc;s faixas categ&oacute;ricas: 
&lt; 150 pg/ml, 150 - 300 pg/ml e &gt; 300 pg/ml. Nessa an&aacute;lise, um risco
 elevado significante estava restrito &agrave; faixa mais alta (&gt; 300 pg/ml),
 em compara&ccedil;&atilde;o com a faixa m&eacute;dia (aOR = 6,26 &#91;1,05 - 37
,50&#93;, p = 0,045).</font></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#65#61#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#66#62#article#148#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop01911.htm##
01198000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704095400085002001301039#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#67#63#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Sabe-se que pacientes com d
oen&ccedil;a renal cr&ocirc;nica terminal (DRCT) tem um risco elevado de doen&cc
edil;a cardiovascular (DCV), o que representa a maior causa de morte nessa popul
a&ccedil;&atilde;o<sup>1</sup>. A doen&ccedil;a arterial &eacute; generalizada e
 a presen&ccedil;a de defeitos estruturais da car&oacute;tida<sup>2,8</sup>, bem
 como doen&ccedil;a vascular perif&eacute;rica<sup>2,12</sup> est&atilde;o forte
mente correlacionadas com doen&ccedil;a coronariana e mortalidade. O objetivo de
sse estudo foi avaliar doen&ccedil;a vascular em pacientes com DRCT atrav&eacute
;s do uso de estudos de imagem n&atilde;o-invasivos e correlacionar os achados c
om os dados cl&iacute;nicos e laboratoriais. O perfil de nossos pacientes &eacut
e; aproximadamente similar &agrave; popula&ccedil;&atilde;o geral submetida &agr
ave; di&aacute;lise no Brasil<sup>13</sup>. </font></p>     ^cY#aop01911.htm##
01270000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704102600085002001301111#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#68#64#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A frequ&ecirc;ncia de EIM <
u>&gt;</u> 0,9 mm, um conhecido marcador de aterosclerose, foi muito alta, afeta
ndo 43 (57%) dos pacientes. Embora v&aacute;rios estudos j&aacute; tenham avalia
do a quest&atilde;o da determina&ccedil;&atilde;o da EIM em pacientes com DRCT<s
up>14,15</sup>, n&atilde;o encontramos a incid&ecirc;ncia de EIM <u>&gt;</u> 0,9
 mm em uma amostra n&atilde;o-selecionada submetida &agrave; HD para compara&cce
dil;&atilde;o apropriada de preval&ecirc;ncia. Deve ser enfatizado que a taxa de
 57% foi obtida com um ponto de corte de 0,9 mm, que est&aacute; associado com a
umento da incid&ecirc;ncia de eventos cardiovasculares<sup>8</sup>, mas que &eac
ute;, de alguma forma, conservador. Em um estudo recente, por exemplo, foi demon
strado que os limites superiores (percentil 97,5) da EIM em uma popula&ccedil;&a
tilde;o saud&aacute;vel com idade de 50 a 59 anos e 60 a 75 anos, eram 0,71 e 0,
81 mm, respectivamente<sup>16</sup>.</font></p>     ^cY#aop01911.htm##
01029000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078500085002001300870#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#69#65#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Calcifica&ccedil;&otilde;es
 &agrave; US tamb&eacute;m foram achados comuns, afetando 36 (48%) dos pacientes
, uma propor&ccedil;&atilde;o compar&aacute;vel &agrave;quelas relatadas em estu
dos anteriores, as quais variavam de 50 a 64%<sup>17-19</sup>. Trinta e tr&ecirc
;s de nossos 36 pacientes com calcifica&ccedil;&otilde;es tamb&eacute;m apresent
avam aumento da EIM, enquanto 10 pacientes com aumento da EIM n&atilde;o apresen
tavam calcifica&ccedil;&otilde;es &agrave; US. Esses achados s&atilde;o consiste
ntes com o presente cen&aacute;rio de que o aumento da EIM pode ser visto como u
m marcador pr&eacute;-cl&iacute;nico da aterosclerose que precede a forma&ccedil
;&atilde;o da placa<sup>2,20</sup>.</font></p>     ^cY#aop01911.htm##
02967000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704272300085002001302808#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#70#66#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A fim de verificar determin
antes potenciais de achados de imagem em nosso estudo, utilizamos dois modelos d
e an&aacute;lise de regress&atilde;o log&iacute;stica, usando dados cl&iacute;ni
cos e laboratoriais selecionados como vari&aacute;veis independentes contra cada
 um dos achados de imagem. A idade uniformemente influenciou os par&acirc;metros
 de imagem de forma que cada d&eacute;cada de idade estava associada com um aume
nto de aproximadamente 3 vezes a chance de haver um achado positivo nos par&acir
c;metros de imagem estudados. Esse achado &eacute; consistente com a extensa inf
orma&ccedil;&atilde;o dispon&iacute;vel na literatura, enfatizando o papel da id
ade no desenvolvimento da doen&ccedil;a vascular<sup>16,21</sup>. Da mesma forma
, o tabagismo influenciou ambos os par&acirc;metros de imagem, com um aumento de
 4 vezes a chance de EIM positiva e uma aumento de quase 7 vezes a chance de cal
cifica&ccedil;&atilde;o. Estudos avaliando o fumo como fator de risco para calci
fica&ccedil;&atilde;o vascular em pacientes com DRCT s&atilde;o escassos, mas o 
h&aacute;bito de fumar &eacute; um fator de risco tradicional para DCV, com o ri
sco sendo fortemente dose-relacionado<sup>22</sup>. Os efeitos do tempo de di&aa
cute;lise, bem como os da diabete, entretanto, somente foram vistos com a presen
&ccedil;a de calcifica&ccedil;&otilde;es. Um estudo recente mostrou que paciente
s em HD tem aproximadamente um risco oito vezes aumentado de apresentar calcific
a&ccedil;&atilde;o vascular, quando comparados com indiv&iacute;duos na popula&c
cedil;&atilde;o geral<sup>23</sup>. Diabete &eacute; um fator de risco bem conhe
cido para calcifica&ccedil;&otilde;es vasculares<sup>24</sup> e a aus&ecirc;ncia
 de sua influ&ecirc;ncia na EIM aumentada permite especular se o ambiente ur&eci
rc;mico pode prevalecer sobre dist&uacute;rbios do metabolismo da glicose na fas
e inicial das anormalidades estruturais vasculares em pacientes com DRCT<sup>25<
/sup>. Entretanto, deve-se ter cautela em rela&ccedil;&atilde;o a essa quest&ati
lde;o, considerando que o tamanho da amostra pode ter contribu&iacute;do para a 
falta de impacto desse fator sobre o aumento da EIM. Altos n&iacute;veis de iPTH
 estavam associados com aumento da EIM. A fim de melhor esclarecer essa quest&at
ilde;o, utilizamos um modelo de regress&atilde;o adicional usando estratifica&cc
edil;&atilde;o dos n&iacute;veis de iPTH. Associa&ccedil;&otilde;es significante
s entre n&iacute;veis de iPTH e aumento da EIM estavam restritas &agrave; compar
a&ccedil;&atilde;o entre o grupo com n&iacute;veis de iPTH &gt; 300 pg/ml e o gr
upo com n&iacute;veis de i-PTH entre 150 e 300 pg/ml.</font></p>     ^cY#aop0191
1.htm##
01157000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704091300085002001300998#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#71#67#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">&Eacute; interessante notar
 que n&atilde;o encontramos uma correla&ccedil;&atilde;o entre calcifica&ccedil;
&otilde;es vasculares e dist&uacute;rbios cumulativos do metabolismo mineral em 
nosso estudo. Entretanto, esse achado n&atilde;o pode ser visto como um argument
o contra o papel relatado da sobrecarga de fosfato no desenvolvimento da calcifi
ca&ccedil;&atilde;o vascular<sup>26,27</sup>, considerando que os n&iacute;veis 
s&eacute;ricos de fosfato podem n&atilde;o ser um marcador preciso da carga oral
 de fosfato<sup>28</sup>. Al&eacute;m disso, n&atilde;o refuta a extensa literat
ura que coloca os dist&uacute;rbios de metabolismo mineral como fatores de risco
 cruciais para a alta mortalidade cardiovascular de pacientes com DRCT<sup>29,30
</sup>, considerando que a mortalidade n&atilde;o foi analisada no presente estu
do.</font></p>     ^cY#aop01911.htm##
00526000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028200085002001300367#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#72#68#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">&Eacute; digno de nota o fa
to de que, em concord&acirc;ncia com nossos achados, a aus&ecirc;ncia de correla
&ccedil;&atilde;o entre o produto Ca x P e a EIM j&aacute; havia sido relatada<s
up>15</sup>.</font></p>     ^cY#aop01911.htm##
01078000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083400085002001300919#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#73#69#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Nosso estudo apresenta limi
ta&ccedil;&otilde;es e os dados negativos devem ser interpretados com cuidado. A
 caracter&iacute;stica transversal do desenho e pequeno tamanho da amostra podem
 ter contribu&iacute;do para a falta de signific&acirc;ncia de alguns dados esta
t&iacute;sticos. Entretanto, os achados positivos refor&ccedil;am o papel de alg
uns fatores de risco tradicionais como envelhecimento, tabagismo e diabete como 
determinantes de doen&ccedil;a vascular na popula&ccedil;&atilde;o com doen&cced
il;a renal em est&aacute;gio final (DREF). Eles tamb&eacute;m mostram que alguns
 fatores n&atilde;o-tradicionais como tempo de di&aacute;lise e aumento nos n&ia
cute;veis de iPTH podem ter impacto nas anormalidades vasculares em tais pacient
es. </font></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#74#70#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#75#71#article#148#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclus&otilde;es</b></f
ont></p>     ^cY#aop01911.htm##
00835000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059100085002001300676#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#76#72#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ambos o aumento na espessur
a &iacute;ntima-m&eacute;dia (EIM) e calcifica&ccedil;&otilde;es na ultrassonogr
afia s&atilde;o achados comuns em pacientes submetidos &agrave; di&aacute;lise, 
mas o aumento na EIM foi mais frequente. Tabagismo foi um determinante consisten
te para ambos os achados de imagens. O maior impacto foi visto com o envelhecime
nto, de forma que cada d&eacute;cada de idade estava associada com um aumento de
 3 vezes a chance de haver um achado positivo em qualquer dos estudos de imagem.
 </font></p>     ^cY#aop01911.htm##
00436000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019200085002001300277#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#77#73#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Diabete e tempo de di&aacut
e;lise substancialmente aumentaram o risco de calcifica&ccedil;&atilde;o arteria
l.</font></p>     ^cY#aop01911.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#78#74#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Potencial Conflito de In
teresses</b></font></p>     ^cY#aop01911.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014300085002001300228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#79#75#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Declaro n&atilde;o haver co
nflito de interesses pertinentes.</font></p>     ^cY#aop01911.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#80#76#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop01911.htm##
00394000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015000085002001300235#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#81#77#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo n&atilde;
o teve fontes de financiamento externas.</font></p>     ^cY#aop01911.htm##
00374000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013000085002001300215#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#82#78#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vincula&ccedil;&atilde;o
 Acad&ecirc;mica</b></font></p>     ^cY#aop01911.htm##
00468000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022400085002001300309#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#83#79#article#148#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Este artigo &eacute; parte 
de disserta&ccedil;&atilde;o de Mestrado de Sebasti&atilde;o Baptista Miguel pel
a Universidade Federal Fluminense.</font></p>     ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#84#80#article#148#<p>&nbsp;<
/p>     ^cY#aop01911.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#85#81#article#148#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop01911.htm##
00481000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022300087002001300310#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#86#82#article#14
8#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.	Foley RN, 
Parfrey PS, Sarnak M. Clinical epidemiology of cardiovascular disease in chronic
 renal disease. Am J Kidney Dis. 1998;32(5 Suppl. 3):112-9.    ^cY#aop01911.htm#
#
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#87#83#article#148#</font></p
>     ^cY#aop01911.htm##
00562000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704030400087002001300391#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#88#84#article#14
8#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2.	Van der Me
er IM, Bots ML, Hofman A, del Sol AL, van der Kuip DA, Witterman JC. Predictive 
value of non-invasive measures of atherosclerosis for incident myocardial infarc
tion. The Rotterdam study. Circulation. 2004;109(9):1089-94.    ^cY#aop01911.htm
##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#89#85#article#148#</font></p
>     ^cY#aop01911.htm##
00579000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032100087002001300408#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#90#86#article#14
8#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3.	Papagianni
 A, Dovas S, Bantis C, Belechri AM, Kalovoulos M, Dimitriadis C, et al. Carotid 
atherosclerosis and endothelial cell adhesion molecules as predictors of long-te
rm outcome in chronic hemodialysis patients. Am J Nephrol. 2008;28(2):265-74.   
 ^cY#aop01911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#91#87#article#148#</font></p
>     ^cY#aop01911.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704024000087002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#92#88#article#14
8#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4.	Benedetto 
FA, Tripepi G, Mallamaci F, Zoccali C. Rate of atherosclerotic plaque formation 
predicts cardiovascular events in ESRD. J Am Soc Nephrol. 2008;19(4):757-63.    
^cY#aop01911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#93#89#article#148#</font></p
>     ^cY#aop01911.htm##
00485000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022700087002001300314#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#94#90#article#14
8#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5.	Adrag&atil
de;o T, Fraz&atilde;o JM. Cardiovascular risk in dialysis patients: an X-ray vis
ion on vascular calcifications. Kidney Int. 2008;74(12):1505-7.    ^cY#aop01911.
htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#95#91#article#148#</font></p
>     ^cY#aop01911.htm##
00593000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704033500087002001300422#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#96#92#article#14
8#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6.	Wang AY, W
ang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an im
portant predictor for all-cause mortality and cardiovascular mortality in long-t
erm peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003;14
(1):159-68.    ^cY#aop01911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#97#93#article#148#</font></p
>     ^cY#aop01911.htm##
00638000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704038000087002001300467#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#98#94#article#14
8#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7.	Haydar AA,
 Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ. Coronary artery calcif
ication is related to coronary atherosclerosis in chronic renal disease patients
: a study comparing EBCT-generated coronary artery calcium scores and coronary a
ngiography. Nephrol Dial Transplant. 2004;19(9):2307-12.    ^cY#aop01911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#99#95#article#148#</font></p
>     ^cY#aop01911.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704028100088002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#100#96#article#1
48#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8.	Price JF,
 Tzoulaki I, Lee AJ, Fowkes FG. Ankle brachial index and intima media thickness 
predict cardiovascular events similarly and increased prediction when combined. 
J Clin Epidemiol. 2007;60(10):1067-75.    ^cY#aop01911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#101#97#article#148#</font></
p>     ^cY#aop01911.htm##
00548000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704028900088002001300377#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#102#98#article#1
48#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9.	Savage T,
 Clarke AL, Giles M, Tomson CR, Raine AE. Calcified plaque is common in the caro
tid and femoral arteries of dialysis patients without clinical vascular disease.
 Nephrol Dial Transplant. 1998; 13(8):2004-12.    ^cY#aop01911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#103#99#article#148#</font></
p>     ^cY#aop01911.htm##
00503000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024200090002001300332#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#104#100#article#
148#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10.	Guerin
 AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcif
ications in end-stage renal disease. Nephrol Dial Transplant. 2000;15(7):1014-21
.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#105#101#article#148#</font><
/p>     ^cY#aop01911.htm##
00523000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026200090002001300352#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#106#102#article#
148#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11.	Blache
r J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arte
rial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension
. 2001; 38(4):938-42.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#107#103#article#148#</font><
/p>     ^cY#aop01911.htm##
00604000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034300090002001300433#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#108#104#article#
148#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12.	Pearte
 CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Power NR, et al. Characteristic
s and baseline clinical predictors of future fatal versus non-fatal coronary hea
rt disease events in older adults: the Cardiovascular Health Study. Circulation.
 2006;113(18):2177-85.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#109#105#article#148#</font><
/p>     ^cY#aop01911.htm##
00521000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026000090002001300350#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#110#106#article#
148#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13.	Sesso 
R, Lopes AA, Thom&eacute; FS, Bevilacqua JL, Rom&atilde;o Jr JE, Lugon J. Relat&
oacute;rio do Censo Brasileiro de Di&aacute;lise, 2008. J Bras Nefrol 2008; 30(4
):233-8</font></p>     ^cY#aop01911.htm##
00562000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030100090002001300391#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#111#107#article#
148#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14.	Ohkuma
 T, Minagawa T, Takada N, Ohno M, Oda H, Ohashi H. C-reactive protein, lipoprote
in(a), homocysteine, and male sex contribute to carotid atherosclerosis in perit
oneal dialysis patients. Am J Kidney Dis. 2003;42(6):355-61.    ^cY#aop01911.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#112#108#article#148#</font><
/p>     ^cY#aop01911.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029900090002001300389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#113#109#article#
148#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15.	Zoccal
i C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, et al. Asymmetri
c dimethylarginine, C-reactive protein, and carotid intima-media thickness in en
d-stage renal disease. J Am Soc Nephrol. 2002;13(2):490-6.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#114#110#article#148#</font><
/p>     ^cY#aop01911.htm##
00564000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030300090002001300393#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#115#111#article#
148#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16.	Lim TK
, Lim E, Dwivedi G, Kooner J, Senior R. Normal value of carotid intima-media thi
ckness - a surrogate marker of atherosclerosis: quantitative assessment by B-mod
e carotid ultrasound. J Am Soc Echocardiogr. 2008;21(2):112-6.    ^cY#aop01911.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#116#112#article#148#</font><
/p>     ^cY#aop01911.htm##
00451000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019000090002001300280#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#117#113#article#
148#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17.	London
 GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. 
Semin Dial. 2003;16(2):85-94.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#118#114#article#148#</font><
/p>     ^cY#aop01911.htm##
00542000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028100090002001300371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#119#115#article#
148#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18.	Wang A
Y, Ho SS, Wang M, Liu EK, Ho S, Lui SF, et al. Cardiac valvular calcification as
 a marker of atherosclerosis and arterial calcification in end-stage renal disea
se. Arch Intern Med. 2005;165(3):327-32.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#120#116#article#148#</font><
/p>     ^cY#aop01911.htm##
00586000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032500090002001300415#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#121#117#article#
148#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19.	Yildiz
 A, Memisoglu E, Oflaz H, Yazic H, Pusuraglu H, Akkaya V, et al. Atherosclerosis
 and vascular calcification are independent predictors of left ventricular hyper
trophy in chronic haemodialysis patients. Nephrol Dial Transplant. 2005;20(4):76
0-7.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#122#118#article#148#</font><
/p>     ^cY#aop01911.htm##
00630000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036900090002001300459#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#123#119#article#
148#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20.	Zureik
 M, Ducimeti&egrave;re P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C, et al.
 Common carotid intima-media thickness predicts occurrence of carotid atheroscle
rotic plaques: longitudinal results from the Aging Vascular Study (EVA) study. A
rterioscler Thromb Vasc Biol. 2000;20(6):1622-9.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#124#120#article#148#</font><
/p>     ^cY#aop01911.htm##
00628000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036700090002001300457#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#125#121#article#
148#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21.	Juonal
a M, K&auml;h&ouml;nen M, Laitinen T, Hutri-Kahonen N, Jokinen E, Taittonen L, e
t al. Effect of age and sex on carotid intima-media thickness, elasticity and br
achial endothelial function in healthy adults: the cardiovascular risk in Young 
Finns Study. Eur Heart J. 2008;29(9):1198-206.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#126#122#article#148#</font><
/p>     ^cY#aop01911.htm##
00579000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031800090002001300408#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#127#123#article#
148#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22.	Ockene
 IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a stateme
nt for healthcare professionals from the American Heart Association. American He
art Association.Task Force on Risk Reduction. Circulation. 1997;96(9):3243-7.   
 ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#128#124#article#148#</font><
/p>     ^cY#aop01911.htm##
00569000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030800090002001300398#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#129#125#article#
148#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23.	Coll B
, Betriu A, Mart&iacute;nez-Alonso M, Amoldo ML, Arcidiacono MV, Borras M, et al
. Large artery calcification on dialysis patients is located in the intima and r
elated to atherosclerosis. Clin J Am Soc Nephrol. 2010, Oct 7 &#91;    ^cY#aop01
911.htm##
00292000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004600087002001300133#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#130#126#article#148#Epub ahe
ad of print&#93;. </font></p>     ^cY#aop01911.htm##
00517000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025600090002001300346#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#131#127#article#
148#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24.	London
 GM, Marchais SJ, Gu&eacute;rin AP, Metivier F. Arteriosclerosis, vascular calci
fications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens. 200
5;14(6):525-31.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#132#128#article#148#</font><
/p>     ^cY#aop01911.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033700090002001300427#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#133#129#article#
148#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25.	Jono S
, Nishizawa Y, Shioi A, Morili H. Parathyroid hormone-related peptide as a local
 regulator of vascular calcification: its inhibitory action on in vitro calcific
ation by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 199
7;17(6):1135-42.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#134#130#article#148#</font><
/p>     ^cY#aop01911.htm##
00552000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029100090002001300381#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#135#131#article#
148#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26.	Shigem
atsu T, Kono T, Satoh K, Yokoyama K, Yoshida T, Hosoya T, et al. Phosphate overl
oad accelerates vascular calcium deposition in end-stage renal disease patients.
 Nephron Dial Transplant. 2003;18(Suppl. 3):S86-9.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#136#132#article#148#</font><
/p>     ^cY#aop01911.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027400090002001300364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#137#133#article#
148#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27.	Neves 
KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalh&atilde;es AO, et a
l. Vascular calcification: contribution of parathyroid hormone in renal failure.
 Kidney Int. 2007;71(12):1262-70.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#138#134#article#148#</font><
/p>     ^cY#aop01911.htm##
00581000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032000090002001300410#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#139#135#article#
148#28#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28.	El-Abb
adi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al. Phosphate feeding 
induces arterial medial calcification in uremic mice: role of serum phosphorus, 
fibroblast growth factor-23, and osteopontin. Kidney Int. 2009;75(12):1297-307. 
   ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#140#136#article#148#</font><
/p>     ^cY#aop01911.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027700090002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#141#137#article#
148#29#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29.	Block 
GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperp
arathyroidism in dialysis patients: Recommendations for a change in management. 
Am J Kidney Dis. 2000;35(6):1226-37.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#142#138#article#148#</font><
/p>     ^cY#aop01911.htm##
00534000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027300090002001300363#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#143#139#article#
148#30#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30.	Kesten
baum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum p
hosphate levels and mortality risk among people with chronic kidney disease. J A
m Soc Nephrol. 2005;16(2):520-8.    ^cY#aop01911.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#144#140#article#148#</font><
/p>     ^cY#aop01911.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#145#141#article#148#<p>&nbsp
;</p>     ^cY#aop01911.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#146#142#article#148#<p>&nbsp
;</p>     ^cY#aop01911.htm##
00446000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020000087002001300287#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#147#143#article#148#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg"border="0"></a> <b>Cor
respond&ecirc;ncia: </b>    ^cY#aop01911.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004100087002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#148#144#article#148#<br>   J
ocemir Ronaldo Lugon <b>     ^cY#aop01911.htm##
00299000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005300087002001300140#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#149#145#article#148#<br>   <
/b>Rua Haddock Lobo 369/309 - Tijuca     ^cY#aop01911.htm##
00300000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005400087002001300141#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#150#146#article#148#<br>   2
0260-131 - Rio de Janeiro, RJ - Brasil    ^cY#aop01911.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009300087002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#151#147#article#148#<br>   E
-mail: <a href="mailto:jocerl@huap.uff.br">jocerl@huap.uff.br</a></font></p>    
 ^cY#aop01911.htm##
00408000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016200087002001300249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop01911.htm#S#p#152#148#article#148#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 05/07/
10; revisado recebido em 20/10/10; aceito em 30/11/10.</font></p>     ^cY#aop019
11.htm##
00608000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01700120012007700137030001600214065000900230064000500239031000300244032000500247
014000600252865000900258002001300267035001000280801001600290#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01911.htm#S#c#153#1#article#30#1#^rND^sFoley^n
RN#^rND^sParfrey^nPS#^rND^sSarnak^nM.#Clinical epidemiology of cardiovascular di
sease in chronic renal disease^len#Am J Kidney Dis#19980000#1998#32#5^s3#112-9#2
0110000#aop01911.htm#0272-6386#Am J Kidney Dis##
00749000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100023000860100016001090100
01700125010001900142010002400161010002100185012012100206030001200327065000900339
06400050034803100040035303200020035701400080035986500090036700200130037603500100
0389801001200399#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#
S#c#154#2#article#30#2#^rND^sVan der Meer^nIM#^rND^sBots^nML.#^rND^sHofman^nA.#^
rND^sdel Sol^nAL.#^rND^svan der Kuip^nDA.#^rND^sWitterman^nJC.#Predictive value 
of non-invasive measures of atherosclerosis for incident myocardial infarction: 
The Rotterdam study^len#Circulation#20040000#2004#109#9#1089-94#20110000#aop0191
1.htm#0009-7322#Circulation##
00773000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100015001060100
01600121010001900137010002000156010002100176810000600197012013600203030001300339
06500090035206400050036103100030036603200020036901400070037186500090037800200130
0387035001000400801001300410#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#155#3#article#30#3#^rND^sPapagianni^nA#^rND^sDovas^nS#^rND^sBant
is^nC#^rND^sBelechri^nAM#^rND^sKalovoulos^nM#^rND^sDimitriadis^nC#et al#Carotid 
atherosclerosis and endothelial cell adhesion molecules as predictors of long-te
rm outcome in chronic hemodialysis patients^len#Am J Nephrol#20080000#2008#28#2#
265-74#20110000#aop01911.htm#0250-8095#Am J Nephrol##
00649000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100017001060100
01900123010001700142012008400159030001700243065000900260064000500269031000300274
032000200277014000700279865000900286002001300295035001000308801001700318#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#156#4#article#30#4#^
rND^sBenedetto^nFA#^rND^sTripepi^nG#^rND^sMallamaci^nF#^rND^sZoccali^nC#Rate of 
atherosclerotic plaque formation predicts cardiovascular events in ESRD^len#J Am
 Soc Nephrol#20080000#2008#19#4#757-63#20110000#aop01911.htm#1046-6673#J Am Soc 
Nephrol##
00580000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030120
08900120030001100209065000900220064000500229031000300234032000300237014000700240
865000900247002001300256035001000269801001100279#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01911.htm#S#c#157#5#article#30#5#^rND^sAdragão^nT#^rND^sFr
azão^nJM#Cardiovascular risk in dialysis patients: an X-ray vision on vascular c
alcifications^len#Kidney Int#20080000#2008#74#12#1505-7#20110000#aop01911.htm#00
85-2538#Kidney int##
00791000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100014001010100
01300115010001400128010001300142010001400155810000600169012017400175030001700349
06500090036606400050037503100030038003200020038301400070038586500090039200200130
0401035001000414801001700424#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#158#6#article#30#6#^rND^sWang^nAY#^rND^sWang^nM#^rND^sWoo^nJ#^rN
D^sLam^nCW#^rND^sLi^nPK#^rND^sLui^nSF#et al#Cardiac valve calcification as an im
portant predictor for all-cause mortality and cardiovascular mortality in long-t
erm peritoneal dialysis patients: a prospective study^len#J Am Soc Nephrol#20030
000#2003#14#1#159-68#20110000#aop01911.htm#1046-6673#J Am Soc Nephrol##
00832000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030100
01600121010001700137010001600154010002000170012019700190030002400387065000900411
06400050042003100030042503200020042801400080043086500090043800200130044703500100
0460801002400470#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#
S#c#159#7#article#30#7#^rND^sHaydar^nAA#^rND^sHujairi^nNM#^rND^sCovic^nAA#^rND^s
Pereira^nD#^rND^sRubens^nM#^rND^sGoldsmith^nDJ#Coronary artery calcification is 
related to coronary atherosclerosis in chronic renal disease patients: a study c
omparing EBCT-generated coronary artery calcium scores and coronary angiography^
len#Nephrol Dial Transplant#20040000#2004#19#9#2307-12#20110000#aop01911.htm#093
1-0509#Nephrol Dial Transplant##
00690000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01400120010001700134012013100151030001700282065000900299064000500308031000300313
032000300316014000800319865000900327002001300336035001000349801001700359#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#160#8#article#30#8#^
rND^sPrice^nJF#^rND^sTzoulaki^nI#^rND^sLee^nAJ#^rND^sFowkes^nFG#Ankle brachial i
ndex and intima media thickness predict cardiovascular events similarly and incr
eased prediction when combined^len#J Clin Epidemiol#20070000#2007#60#10#1067-75#
20110000#aop01911.htm#0895-4356#J Clin Epidemiol##
00722000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100017001020100
01500119010001700134010001600151012012200167030002400289065000900313064000500322
03100030032703200020033001400080033286500090034000200130034903500100036280100240
0372#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#161#9#ar
ticle#30#9#^rND^sSavage^nT#^rND^sClarke^nAL#^rND^sGiles^nM#^rND^sTomson^nCR#^rND
^sRaine^nAE#Calcified plaque is common in the carotid and femoral arteries of di
alysis patients without clinical vascular disease^len#Nephrol Dial Transplant#19
980000#1998#13#8#2004-12#20110000#aop01911.htm#0931-0509#Nephrol Dial Transplant
##
00659000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01900122010001800141012007900159030002400238065000900262064000500271031000300276
032000200279014000800281865000900289002001300298035001000311801002400321#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#162#10#article#30#10
#^rND^sGuerin^nAP#^rND^sLondon^nGM#^rND^sMarchais^nSJ#^rND^sMetivier^nF#Arterial
 stiffening and vascular calcifications in end-stage renal disease^len#Nephrol D
ial Transplant#20000000#2000#15#7#1014-21#20110000#aop01911.htm#0931-0509#Nephro
l Dial Transplant##
00685000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01700122010001900139010001700158012010000175030001300275065000900288064000500297
03100030030203200020030501400070030786500090031400200130032303500100033680100130
0346#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#163#11#a
rticle#30#11#^rND^sBlacher^nJ#^rND^sGuerin^nAP#^rND^sPannier^nB#^rND^sMarchais^n
SJ#^rND^sLondon^nGM#Arterial calcifications, arterial stiffness, and cardiovascu
lar risk in end-stage renal disease^len#Hypertension#20010000#2001#38#4#938-42#2
0110000#aop01911.htm#0194-911X#Hypertension##
00794000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050100
01700123010001600140010001600156010001600172810000600188012016500194030001200359
06500090037106400050038003100040038503200030038901400080039286500090040000200130
0409035001000422801001200432#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#164#12#article#30#12#^rND^sPearte^nCA#^rND^sFurberg^nCD#^rND^sO'
Meara ES#^rND^sPsaty^nBM#^rND^sKuller^nL#^rND^sPower^nNR#et al#Characteristics a
nd baseline clinical predictors of future fatal versus non-fatal coronary heart 
disease events in older adults: the Cardiovascular Health Study^len#Circulation#
20060000#2006#113#18#2177-85#20110000#aop01911.htm#0009-7322#Circulation##
00664000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100016001030100
01600119010002100135010001900156010001500175012005100190030001400241065000900255
06400050026403100030026903200020027201400060027486500090028000200130028903500100
0302801001400312#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#
S#c#165#13#article#30#13#^rND^sSesso^nR#^rND^sLopes^nAA#^rND^sThomé^nFS#^rND^sBe
vilacqua^nJL#^rND^sRomão Jr^nJE#^rND^sLugon^nJ#Relatório do Censo Brasileiro de 
Diálise, 2008^lpt#J Bras Nefrol#20080000#2008#30#4#233-8#20110000#aop01911.htm#0
101-2800#J Bras Nefrol##
00746000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01600122010001400138010001300152010001600165012013700181030001600318065000900334
06400050034303100030034803200020035101400070035386500090036000200130036903500100
0382801001600392#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#
S#c#166#14#article#30#14#^rND^sOhkuma^nT#^rND^sMinagawa^nT#^rND^sTakada^nN#^rND^
sOhno^nM#^rND^sOda^nH#^rND^sOhashi^nH#C-reactive protein, lipoprotein(a), homocy
steine, and male sex contribute to carotid atherosclerosis in peritoneal dialysi
s patients^len#Am J Kidney Dis#20030000#2003#42#6#355-61#20110000#aop01911.htm#0
272-6386#Am J Kidney Dis##
00756000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01400125010001900139010001700158010001900175810000600194012011500200030001700315
06500090033206400050034103100030034603200020034901400060035186500090035700200130
0366035001000379801001700389#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#167#15#article#30#15#^rND^sZoccali^nC#^rND^sBenedetto^nFA#^rND^s
Maas^nR#^rND^sMallamaci^nF#^rND^sTripepi^nG#^rND^sMalatino^nLS#et al#Asymmetric 
dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-
stage renal disease^len#J Am Soc Nephrol#20020000#2002#13#2#490-6#20110000#aop01
911.htm#1046-6673#J Am Soc Nephrol##
00736000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100013001020100
01700115010001600132010001600148012014500164030002200309065000900331064000500340
03100030034503200020034801400060035086500090035600200130036503500100037880100220
0388#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#168#16#a
rticle#30#16#^rND^sLim^nTK#^rND^sLim^nE#^rND^sDwivedi^nG#^rND^sKooner^nJ#^rND^sS
enior^nR#Normal value of carotid intima-media thickness - a surrogate marker of 
atherosclerosis: quantitative assessment by B-mode carotid ultrasound^len#J Am S
oc Echocardiogr#20080000#2008#21#2#112-6#20110000#aop01911.htm#0894-7317#J Am So
c Echocardiogr##
00509000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120078001050300
01100183710000200194065000900196064000500205031000300210032000200213014000600215
865000900221002001300230#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01
911.htm#S#c#169#17#article#30#17#^rND^sLondon^nGM#Cardiovascular disease in chro
nic renal failure: pathophysiologic aspects^len#Semin Dial#2#20030000#2003#16#2#
85-94#20110000#aop01911.htm##
00737000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100013001030100
01400116010001400130010001200144010001400156810000600170012012000176030001600296
06500090031206400050032103100040032603200020033001400070033286500090033900200130
0348035001000361801001600371#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#170#18#article#30#18#^rND^sWang^nAY#^rND^sHo^nSS#^rND^sWang^nM#^
rND^sLiu^nEK#^rND^sHo^nS#^rND^sLui^nSF#et al#Cardiac valvular calcification as a
 marker of atherosclerosis and arterial calcification in end-stage renal disease
^len#Arch Intern Med#20050000#2005#165#3#327-32#20110000#aop01911.htm#0003-9926#
Arch Intern Med##
00789000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
01500123010001500138010001900153010001600172810000600188012014000194030002400334
06500090035806400050036703100030037203200020037501400060037786500090038300200130
0392035001000405801002400415#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#171#19#article#30#19#^rND^sYildiz^nA#^rND^sMemisoglu^nE#^rND^sOf
laz^nH#^rND^sYazic^nH#^rND^sPusuraglu^nH#^rND^sAkkaya^nV#et al#Atherosclerosis a
nd vascular calcification are independent predictors of left ventricular hypertr
ophy in chronic haemodialysis patients^len#Nephrol Dial Transplant#20050000#2005
#20#4#760-7#20110000#aop01911.htm#0931-0509#Nephrol Dial Transplant##
00832000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100021001040100
01800125010001700143010002300160010001400183810000600197012016100203030003000364
06500090039406400050040303100030040803200020041101400070041386500090042000200130
0429035001000442801003000452#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#172#20#article#30#20#^rND^sZureik^nM#^rND^sDucimetière^nP#^rND^s
Touboul^nPJ#^rND^sCourbon^nD#^rND^sBonithon-Kopp^nC#^rND^sBerr^nC#et al#Common c
arotid intima-media thickness predicts occurrence of carotid atherosclerotic pla
ques: longitudinal results from the Aging Vascular Study (EVA) study^len#Arterio
scler Thromb Vasc Biol#20000000#2000#20#6#1622-9#20110000#aop01911.htm#1079-5642
#Arterioscler Thromb Vasc Biol##
00809000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01800122010002300140010001700163010001900180810000600199012017000205030001200375
06500090038706400050039603100030040103200020040401400090040686500090041500200130
0424035001000437801001200447#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#173#21#article#30#21#^rND^sJuonala^nM#^rND^sKähönen^nM#^rND^sLai
tinen^nT#^rND^sHutri-Kahonen^nN#^rND^sJokinen^nE#^rND^sTaittonen^nL#et al#Effect
 of age and sex on carotid intima-media thickness, elasticity and brachial endot
helial function in healthy adults: the cardiovascular risk in Young Finns Study^
len#Eur Heart J#20080000#2008#29#9#1198-206#20110000#aop01911.htm#0195-668X#Eur 
Heart J##
00687000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050120
19300122030001200315065000900327064000500336031000300341032000200344014000700346
865000900353002001300362035001000375801001200385#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01911.htm#S#c#174#22#article#30#22#^rND^sOckene^nIS#^rND^s
Miller^nNH#Cigarette smoking, cardiovascular disease, and stroke: a statement fo
r healthcare professionals from the American Heart Association. American Heart A
ssociation.Task Force on Risk Reduction^len#Circulation#19970000#1997#96#9#3243-
7#20110000#aop01911.htm#0009-7322#Circulation##
00681000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100016001020100
02500118010001700143010002200160010001600182810000600198012010800204030002200312
710000200334065000900336064001200345865000900357002001300366#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop01911.htm#S#c#175#23#article#30#23#^rND^sColl^
nB#^rND^sBetriu^nA#^rND^sMartínez-Alonso^nM#^rND^sAmoldo^nML#^rND^sArcidiacono^n
MV#^rND^sBorras^nM#et al#Large artery calcification on dialysis patients is loca
ted in the intima and related to atherosclerosis^len#Clin J Am Soc Nephrol#2#201
01007#2010, Oct 7#20110000#aop01911.htm##
00670000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01700124010001800141012008300159030002800242065000900270064000500279031000300284
032000200287014000700289865000900296002001300305035001000318801002800328#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#176#24#article#30#24
#^rND^sLondon^nGM#^rND^sMarchais^nSJ#^rND^sGuérin^nAP#^rND^sMetivier^nF#Arterios
clerosis, vascular calcifications and cardiovascular disease in uremia^len#Curr 
Opin Nephrol Hypertens#20050000#2005#14#6#525-31#20110000#aop01911.htm#1062-4821
#Curr Opin Nephrol Hypertens##
00760000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100019001020100
01500121010001600136012017500152030003000327065000900357064000500366031000300371
032000200374014000800376865000900384002001300393035001000406801003000416#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#S#c#177#25#article#30#25
#^rND^sJono^nS#^rND^sNishizawa^nY#^rND^sShioi^nA#^rND^sMorili^nH#Parathyroid hor
mone-related peptide as a local regulator of vascular calcification: its inhibit
ory action on in vitro calcification by bovine vascular smooth muscle cells^len#
Arterioscler Thromb Vasc Biol#19970000#1997#17#6#1135-42#20110000#aop01911.htm#1
079-5642#Arterioscler Thromb Vasc Biol##
00706000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100014001080100
01500122010001800137010001700155010001600172810000600188012009900194030002400293
71000020031706500090031906400050032803100030033303200040033601400060034086500090
0346002001300355#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop01911.htm#
S#c#178#26#article#30#26#^rND^sShigematsu^nT#^rND^sKono^nT#^rND^sSatoh^nK#^rND^s
Yokoyama^nK#^rND^sYoshida^nT#^rND^sHosoya^nT#et al#Phosphate overload accelerate
s vascular calcium deposition in end-stage renal disease patients^len#Nephron Di
al Transplant#2#20030000#2003#18#^s3#S86-9#20110000#aop01911.htm##
00718000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100020001040100
01900124010002000143010001600163010002000179810000600199012008100205030001100286
06500090029706400050030603100030031103200030031401400080031786500090032500200130
0334035001000347801001100357#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#179#27#article#30#27#^rND^sNeves^nKR#^rND^sGraciolli^nFG#^rND^sd
os Reis^nLM#^rND^sGraciolli^nRG#^rND^sNeves^nCL#^rND^sMagalhães^nAO#et al#Vascul
ar calcification: contribution of parathyroid hormone in renal failure^len#Kidne
y Int#20070000#2007#71#12#1262-70#20110000#aop01911.htm#0085-2538#Kidney int##
00771000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100014001080100
01500122010001500137010001800152010001500170810000600185012014700191030001100338
06500090034906400050035803100030036303200030036601400090036986500090037800200130
0387035001000400801001100410#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#180#28#article#30#28#^rND^sEl-Abbadi^nMM#^rND^sPai^nAS#^rND^sLea
f^nEM#^rND^sYang^nHY#^rND^sBartley^nBA#^rND^sQuan^nKK#et al#Phosphate feeding in
duces arterial medial calcification in uremic mice: role of serum phosphorus, fi
broblast growth factor-23, and osteopontin^len#Kidney Int#20090000#2009#75#12#12
97-307#20110000#aop01911.htm#0085-2538#Kidney int##
00650000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040120
15000119030001600269065000900285064000500294031000300299032000200302014000800304
865000900312002001300321035001000334801001600344#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop01911.htm#S#c#181#29#article#30#29#^rND^sBlock^nGA#^rND^sP
ort^nFK#Re-evaluation of risks associated with hyperphosphatemia and hyperparath
yroidism in dialysis patients: Recommendations for a change in management^len#Am
 J Kidney Dis#20000000#2000#35#6#1226-37#20110000#aop01911.htm#0272-6386#Am J Ki
dney Dis##
00730000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100018001080100
01700126010002000143010001800163010001500181810000600196012008700202030001700289
06500090030606400050031503100030032003200020032301400060032586500090033100200130
0340035001000353801001700363#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op01911.htm#S#c#182#30#article#30#30#^rND^sKestenbaum^nB#^rND^sSampson^nJN#^rND^
sRudser^nKD#^rND^sPatterson^nDJ#^rND^sSeliger^nSL#^rND^sYoung^nB#et al#Serum pho
sphate levels and mortality risk among people with chronic kidney disease^len#J 
Am Soc Nephrol#20050000#2005#16#2#520-8#20110000#aop01911.htm#1046-6673#J Am Soc
 Nephrol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#o#1#1#
article#1#20110331#080959#aop02011.htm#226##
04853000000000637000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104038000400108121000300112049000300115
15800030011803000200012103200060014106500090014701400070015603500100016322300090
01730120104001820120103002860100031003890100031004200700085004510831658005360850
00802194085003102202085003902233085002402272085002302296083169502319085000804014
08500310402208500360405308500220408908500260411111700080413707200030414511200090
4148111000904157116000904166115000904175114000904184113000904193002001304202#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#h#2#1#article#1#tr
#pt#br1.1#1#4.0#ILUS#GRA#TAB#32#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#
0066-782X#20110311#Proteína C-reativa e prognóstico em síndromes coronarianas ag
udas: revisão sistemática e metanálise^lpt#C-Reactive protein and outcomes in ac
ute coronary syndromes: a systematic review and meta-analysis^len#^rND^1A01^nLuí
s C. L.^sCorreia#^rND^1A01^nJ Péricles^sEsteves#Universidade Federal da Bahia^iA
01^1Escola Bahiana de Medicina^cSalvador^sBA^pBrasil#^lpt^aA despeito da associa
ção entre proteína C-reativa de alta sensibilidade (PCR) e eventos recorrentes e
m síndromes coronarianas agudas sem supradesnível do segmento ST (SCA), a medida
 rotineira deste marcador não tem sido recomendada. No intuito de avaliar se as 
evidências científicas atuais justificam a incorporação da PCR para estratificaç
ão de risco na admissão hospitalar de pacientes com SCA, realizamos revisão sist
emática e metanálise dos trabalhos indexados no MEDLINE, SCIELO ou LILACS, com o
s seguintes critérios de inclusão: desenho de coorte prospectiva e avaliação do 
valor prognóstico da PCR, mensurada por método de alta sensibilidade, no momento
 da admissão hospitalar de pacientes com SCA. Dezenove estudos preencheram os cr
itérios de inclusão. Em relação ao seguimento de longo prazo, houve associação c
onsistente entre PCR e eventos cardiovasculares, com odds ratio (OR) global de 4
,6 (95% IC = 2,3-7,6) e OR global multivariado de 2,5 (95% IC = 1,8-3,4). Quanto
 ao curto prazo, 9 estudos foram positivos e 6 estudos negativos, com OR global 
de 1,65 (95% IC = 1,2-2,3). O OR global multivariado não foi obtido para o segui
mento de curto prazo, pois esta medida foi descrita em apenas três trabalhos het
erogêneos. Somente dois trabalhos, de curto prazo, fizeram análise do valor pred
itor incremental da PCR em relação a modelos multivariados, com resultados contr
aditórios. Em conclusão, a escassez de avaliação do valor incremental da PCR, al
iada a resultados controversos quanto ao valor preditor independente para evento
s de curto prazo, não recomenda a utilização rotineira de PCR para estratificaçã
o de risco na admissão de SCA.#^dnd^i1#^tm^lpt^kProteína C-Reativa^i1#^tm^lpt^ks
índrome coronariana aguda^i1#^tm^lpt^kprognóstico^i1#^tm^lpt^kmetanálise^i1#^len
^aDespite the association between high-sensitivity C-reactive protein (CRP) and 
recurrent events in non-ST elevation acute coronary syndromes (ACS), routine det
ermination of this marker has not been recommended. In order to verify whether t
he current scientific evidence justifies the inclusion of CRP for risk stratific
ation at hospital admission of patients with ACS, we carried out a systematic re
view and meta-analysis of the studies indexed in MEDLINE, SciELO or LILACS, with
 the following inclusion criteria: prospective cohort design and assessment of t
he prognostic value of CPR, as measured using a high-sensitivity method at the m
oment of hospital admission of patients with ACS. Nineteen studies met the inclu
sion criteria. In relation to the long-term follow-up, there was a consistent as
sociation between CRP and cardiovascular events, with an overall odds ratio (OR)
 of 4.6 (95% CI = 2.3 - 7.6) and overall multivariate OR of 2.5 (95% CI = 1.8-3.
4). As for the short-term, nine studies were positive and six were negative, wit
h an overall OR of 1.65 (95% CI = 1.2-2.3). The overall multivariate OR was not 
obtained for the short-term follow-up, because this measurement was described on
ly in three heterogeneous studies. Only two short-term studies analyzed the incr
emental predictive value of CRP in relation to multivariate models, with contrad
icting results. In conclusion, the small number of assessments of the incrementa
l value of CRP, in conjunction with controversial results regarding the independ
ent predictive value of CRP for short-term events does not support the recommend
ation of the routine use of CRP for risk stratification at admission of patients
 with ACS.#^dnd^i2#^tm^len^kC-Reactive protein^i2#^tm^len^kacute coronary syndro
me^i2#^tm^len^kprognosis^i2#^tm^len^kmeta-analysis^i2#vancouv#36#20100111#11/01/
10#20100414#14/04/10#20100517#17/05/10#aop02011.htm##
04902000000000637000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104038000400108121000300112049000300115
15800030011803000200012103200060014106500090014701400070015603500100016322300090
01730120118001820120117003000100031004170100031004480700085004790831679005640850
00802243085003102251085003902282085002402321085002302345083169502368085000804063
08500310407108500360410208500220413808500260416011700080418607200030419411200090
4197111000904206116000904215115000904224114000904233113000904242002001304251#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#f#3#1#article#1#tr
#pt#br1.1#1#4.0#ILUS#GRA#TAB#32#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#
0066-782X#20110311#<b>Proteína C-reativa e prognóstico em síndromes coronarianas
 agudas</b>: <b>revisão sistemática e metanálise</b>^lpt#<b>C-Reactive protein a
nd outcomes in acute coronary syndromes</b>: <b>a systematic review and meta-ana
lysis</b>^len#^rND^1A01^nLuís C. L.^sCorreia#^rND^1A01^nJ Péricles^sEsteves#Univ
ersidade Federal da Bahia^iA01^1Escola Bahiana de Medicina^cSalvador^sBA^pBrasil
#^lpt^aA despeito da associação entre proteína C-reativa de alta sensibilidade (
PCR) e eventos recorrentes em síndromes coronarianas agudas sem supradesnível do
 segmento ST (SCA), a medida rotineira deste marcador não tem sido recomendada. 
No intuito de avaliar se as evidências científicas atuais justificam a incorpora
ção da PCR para estratificação de risco na admissão hospitalar de pacientes com 
SCA, realizamos revisão sistemática e metanálise dos trabalhos indexados no <i>M
EDLINE</i>, <i>SCIELO</i> ou LILACS, com os seguintes critérios de inclusão: des
enho de coorte prospectiva e avaliação do valor prognóstico da PCR, mensurada po
r método de alta sensibilidade, no momento da admissão hospitalar de pacientes c
om SCA. Dezenove estudos preencheram os critérios de inclusão. Em relação ao seg
uimento de longo prazo, houve associação consistente entre PCR e eventos cardiov
asculares, com <i>odds ratio</i> (OR) global de 4,6 (95% IC = 2,3-7,6) e OR glob
al multivariado de 2,5 (95% IC = 1,8-3,4). Quanto ao curto prazo, 9 estudos fora
m positivos e 6 estudos negativos, com OR global de 1,65 (95% IC = 1,2-2,3). O O
R global multivariado não foi obtido para o seguimento de curto prazo, pois esta
 medida foi descrita em apenas três trabalhos heterogêneos. Somente dois trabalh
os, de curto prazo, fizeram análise do valor preditor incremental da PCR em rela
ção a modelos multivariados, com resultados contraditórios. Em conclusão, a esca
ssez de avaliação do valor incremental da PCR, aliada a resultados controversos 
quanto ao valor preditor independente para eventos de curto prazo, não recomenda
 a utilização rotineira de PCR para estratificação de risco na admissão de SCA.#
^dnd^i1#^tm^lpt^kProteína C-Reativa^i1#^tm^lpt^ksíndrome coronariana aguda^i1#^t
m^lpt^kprognóstico^i1#^tm^lpt^kmetanálise^i1#^len^aDespite the association betwe
en high-sensitivity C-reactive protein (CRP) and recurrent events in non-ST elev
ation acute coronary syndromes (ACS), routine determination of this marker has n
ot been recommended. In order to verify whether the current scientific evidence 
justifies the inclusion of CRP for risk stratification at hospital admission of 
patients with ACS, we carried out a systematic review and meta-analysis of the s
tudies indexed in MEDLINE, SciELO or LILACS, with the following inclusion criter
ia: prospective cohort design and assessment of the prognostic value of CPR, as 
measured using a high-sensitivity method at the moment of hospital admission of 
patients with ACS. Nineteen studies met the inclusion criteria. In relation to t
he long-term follow-up, there was a consistent association between CRP and cardi
ovascular events, with an overall odds ratio (OR) of 4.6 (95% CI = 2.3 - 7.6) an
d overall multivariate OR of 2.5 (95% CI = 1.8-3.4). As for the short-term, nine
 studies were positive and six were negative, with an overall OR of 1.65 (95% CI
 = 1.2-2.3). The overall multivariate OR was not obtained for the short-term fol
low-up, because this measurement was described only in three heterogeneous studi
es. Only two short-term studies analyzed the incremental predictive value of CRP
 in relation to multivariate models, with contradicting results. In conclusion, 
the small number of assessments of the incremental value of CRP, in conjunction 
with controversial results regarding the independent predictive value of CRP for
 short-term events does not support the recommendation of the routine use of CRP
 for risk stratification at admission of patients with ACS.#^dnd^i2#^tm^len^kC-R
eactive protein^i2#^tm^len^kacute coronary syndrome^i2#^tm^len^kprognosis^i2#^tm
^len^kmeta-analysis^i2#vancouv#36#20100111#11/01/10#20100414#14/04/10#20100517#1
7/05/10#aop02011.htm##
05021000000000661000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111038000400115121000300119
04900030012215800030012503000190012803200060014706500090015301400070016203500100
01692230009001790120104001880120103002920100030003950100031004250700087004560831
68500543085000802228085003102236085003902267085002402306085002302330083171602353
08500080406908500310407708500360410808500220414408500260416611700080419207200030
42001120009042031110009042121160009042211150009042301140009042391130009042480020
01304257008008904270#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.
htm#S#l#4#1#article#1#^a2011#tr#pt#br1.1#1#4.0#ilus#gra#tab#32#nd#nd#Arq. bras. 
cardiol#ahead#20110000#^f0^l0#0066-782X#20110311#Proteína C-reativa e prognóstic
o em síndromes coronarianas agudas: revisão sistemática e metanálise^lpt#C-React
ive protein and outcomes in acute coronary syndromes: a systematic review and me
ta-analysis^len#^rND^1A01^nLuís C. L^sCorreia#^rND^1A01^nJ Péricles^sEsteves#^iA
01^1Universidade Federal da Bahia^2Escola Bahiana de Medicina^cSalvador^sBA^pBra
sil#^lpt^aA despeito da associação entre proteína C-reativa de alta sensibilidad
e (PCR) e eventos recorrentes em síndromes coronarianas agudas sem supradesnível
 do segmento ST (SCA), a medida rotineira deste marcador não tem sido recomendad
a. No intuito de avaliar se as evidências científicas atuais justificam a incorp
oração da PCR para estratificação de risco na admissão hospitalar de pacientes c
om SCA, realizamos revisão sistemática e metanálise dos trabalhos indexados no M
EDLINE, SCIELO ou LILACS, com os seguintes critérios de inclusão: desenho de coo
rte prospectiva e avaliação do valor prognóstico da PCR, mensurada por método de
 alta sensibilidade, no momento da admissão hospitalar de pacientes com SCA. Dez
enove estudos preencheram os critérios de inclusão. Em relação ao seguimento de 
longo prazo, houve associação consistente entre PCR e eventos cardiovasculares, 
com odds ratio (OR) global de 4,6 (95 por cento IC = 2,3-7,6) e OR global multiv
ariado de 2,5 (95 por cento IC = 1,8-3,4). Quanto ao curto prazo, 9 estudos fora
m positivos e 6 estudos negativos, com OR global de 1,65 (95 por cento IC = 1,2-
2,3). O OR global multivariado não foi obtido para o seguimento de curto prazo, 
pois esta medida foi descrita em apenas três trabalhos heterogêneos. Somente doi
s trabalhos, de curto prazo, fizeram análise do valor preditor incremental da PC
R em relação a modelos multivariados, com resultados contraditórios. Em conclusã
o, a escassez de avaliação do valor incremental da PCR, aliada a resultados cont
roversos quanto ao valor preditor independente para eventos de curto prazo, não 
recomenda a utilização rotineira de PCR para estratificação de risco na admissão
 de SCA.#^dnd^i1#^tm^lpt^kProteína C-Reativa^i1#^tm^lpt^ksíndrome coronariana ag
uda^i1#^tm^lpt^kprognóstico^i1#^tm^lpt^kmetanálise^i1#^len^aDespite the associat
ion between high-sensitivity C-reactive protein (CRP) and recurrent events in no
n-ST elevation acute coronary syndromes (ACS), routine determination of this mar
ker has not been recommended. In order to verify whether the current scientific 
evidence justifies the inclusion of CRP for risk stratification at hospital admi
ssion of patients with ACS, we carried out a systematic review and meta-analysis
 of the studies indexed in MEDLINE, SciELO or LILACS, with the following inclusi
on criteria: prospective cohort design and assessment of the prognostic value of
 CPR, as measured using a high-sensitivity method at the moment of hospital admi
ssion of patients with ACS. Nineteen studies met the inclusion criteria. In rela
tion to the long-term follow-up, there was a consistent association between CRP 
and cardiovascular events, with an overall odds ratio (OR) of 4.6 (95 percent CI
 = 2.3 - 7.6) and overall multivariate OR of 2.5 (95 percent CI = 1.8-3.4). As f
or the short-term, nine studies were positive and six were negative, with an ove
rall OR of 1.65 (95 percent CI = 1.2-2.3). The overall multivariate OR was not o
btained for the short-term follow-up, because this measurement was described onl
y in three heterogeneous studies. Only two short-term studies analyzed the incre
mental predictive value of CRP in relation to multivariate models, with contradi
cting results. In conclusion, the small number of assessments of the incremental
 value of CRP, in conjunction with controversial results regarding the independe
nt predictive value of CRP for short-term events does not support the recommenda
tion of the routine use of CRP for risk stratification at admission of patients 
with ACS.#^dnd^i2#^tm^len^kC-Reactive protein^i2#^tm^len^kacute coronary syndrom
e^i2#^tm^len^kprognosis^i2#^tm^len^kmeta-analysis^i2#vancouv#36#20100111#11/01/1
0#20100414#14/04/10#20100517#17/05/10#aop02011.htm#Internet^ihttp://www.scielo.b
r/scielo.php?script=sci_arttext&pid=S0066-782X2011005000032##
00464000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022200083002001300305#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#5#1#article#186#<p><font siz
e="4" face="verdana"><b><a name="tx"></a>Prote&iacute;na C&#45;reativa e progn&o
acute;stico em s&iacute;ndromes coronarianas agudas: revis&atilde;o sistem&aacut
e;tica e metan&aacute;lise</b></font></p>     ^cY#aop02011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#6#2#article#186#<p>&nbsp;</p
>     ^cY#aop02011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#7#3#article#186#<p>&nbsp;</p
>     ^cY#aop02011.htm##
00354000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704011200083002001300195#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#8#4#article#186#<p><font siz
e="2" face="Verdana"><b>Lu&iacute;s C. L. Correia; J P&eacute;ricles Esteves</b>
</font></p>     ^cY#aop02011.htm##
00381000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704013900083002001300222#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#9#5#article#186#<p><font siz
e="2" face="Verdana"> Escola Bahiana de Medicina, Universidade Federal da Bahia,
 Salvador, BA &#150; Brasil</font></p>     ^cY#aop02011.htm##
00335000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009200084002001300176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#10#6#article#186#<p><font si
ze="2" face="Verdana"><a href="#nt">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop02011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#11#7#article#186#<p>&nbsp;</
p>     ^cY#aop02011.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#12#8#article#186#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop02011.htm##
00309000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704006600084002001300150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#13#9#article#186#<p><font si
ze="2" face="verdana"><b>RESUMO</b></font></p>     ^cY#aop02011.htm##
00563000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031900085002001300404#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#14#10#article#186#<p><font s
ize="2" face="Verdana">A despeito da associa&ccedil;&atilde;o entre prote&iacute
;na C&#45;reativa de alta sensibilidade (PCR) e eventos recorrentes em s&iacute;
ndromes coronarianas agudas sem supradesn&iacute;vel do segmento ST (SCA), a med
ida rotineira deste marcador n&atilde;o tem sido recomendada.    ^cY#aop02011.ht
m##
00931000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068700085002001300772#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#15#11#article#186#<br> No in
tuito de avaliar se as evid&ecirc;ncias cient&iacute;ficas atuais justificam a i
ncorpora&ccedil;&atilde;o da PCR para estratifica&ccedil;&atilde;o de risco na a
dmiss&atilde;o hospitalar de pacientes com SCA, realizamos revis&atilde;o sistem
&aacute;tica e metan&aacute;lise dos trabalhos indexados no <I>MEDLINE</I>, <I>S
CIELO</I> ou LILACS, com os seguintes crit&eacute;rios de inclus&atilde;o: desen
ho de coorte prospectiva e avalia&ccedil;&atilde;o do valor progn&oacute;stico d
a PCR, mensurada por m&eacute;todo de alta sensibilidade, no momento da admiss&a
tilde;o hospitalar de pacientes com SCA. Dezenove estudos preencheram os crit&ea
cute;rios de inclus&atilde;o.    ^cY#aop02011.htm##
00982000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073800085002001300823#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#16#12#article#186#<br> Em re
la&ccedil;&atilde;o ao seguimento de longo prazo, houve associa&ccedil;&atilde;o
 consistente entre PCR e eventos cardiovasculares, com <I>odds ratio</I> (OR) gl
obal de 4,6 (95% IC = 2,3&#150;7,6) e OR global multivariado de 2,5 (95% IC = 1,
8&#150;3,4). Quanto ao curto prazo, 9 estudos foram positivos e 6 estudos negati
vos, com OR global de 1,65 (95% IC = 1,2&#45;2,3). O OR global multivariado n&at
ilde;o foi obtido para o seguimento de curto prazo, pois esta medida foi descrit
a em apenas tr&ecirc;s trabalhos heterog&ecirc;neos. Somente dois trabalhos, de 
curto prazo, fizeram an&aacute;lise do valor preditor incremental da PCR em rela
&ccedil;&atilde;o a modelos multivariados, com resultados contradit&oacute;rios.
    ^cY#aop02011.htm##
00591000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034700085002001300432#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#17#13#article#186#<br> Em co
nclus&atilde;o, a escassez de avalia&ccedil;&atilde;o do valor incremental da PC
R, aliada a resultados controversos quanto ao valor preditor independente para e
ventos de curto prazo, n&atilde;o recomenda a utiliza&ccedil;&atilde;o rotineira
 de PCR para estratifica&ccedil;&atilde;o de risco na admiss&atilde;o de SCA.</f
ont></p>     ^cY#aop02011.htm##
00450000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020600085002001300291#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#18#14#article#186#<p><font s
ize="2" face="Verdana"><b>Palavras&#45;chave:</b> Prote&iacute;na C&#45;Reativa,
 s&iacute;ndrome coronariana aguda, progn&oacute;stico, metan&aacute;lise.</font
></p> <hr size="1" noshade>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#19#15#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#20#16#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#21#17#article#186#<p><font s
ize="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop020
11.htm##
01318000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704107400085002001301159#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#22#18#article#186#<p><font s
ize="2" face="Verdana">Em pacientes acometidos de s&iacute;ndromes coronarianas 
agudas (SCA), a instabiliza&ccedil;&atilde;o da placa ateroscler&oacute;tica &ea
cute; acompanhada de exacerba&ccedil;&atilde;o da inflama&ccedil;&atilde;o<SUP>1
</SUP>. O fen&ocirc;meno inflamat&oacute;rio dificulta a estabiliza&ccedil;&atil
de;o da placa, o que teoricamente torna tais pacientes mais vulner&aacute;veis a
 eventos coronarianos recorrentes<SUP>2</SUP>. Esse processo vascular &eacute; u
niversal, n&atilde;o se limita ao local da ruptura de placa, acomete todo o leit
o coron&aacute;rio e, em n&iacute;vel sist&ecirc;mico, pode ser detectado pela m
edida dos marcadores inflamat&oacute;rios plasm&aacute;ticos<SUP>3</SUP>. Esse &
eacute; o racional mecan&iacute;stico para o valor progn&oacute;stico dos marcad
ores inflamat&oacute;rios em pacientes com s&iacute;ndromes coronarianas agudas.
 Dentre os marcadores inflamat&oacute;rios, o mais estudado &eacute; a medida de
 prote&iacute;na C&#45;reativa, por m&eacute;todo de alta sensibilidade<SUP>4</S
UP>.</font></p>     ^cY#aop02011.htm##
01174000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704093000085002001301015#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#23#19#article#186#<p><font s
ize="2" face="Verdana">Ao longo dos &uacute;ltimos 15 anos, v&aacute;rias public
a&ccedil;&otilde;es indicaram que a medida de prote&iacute;na C&#45;reativa apre
senta valor preditor independente para eventos coronarianos recorrentes em pacie
ntes com SCA sem supradesn&iacute;vel do segmento ST<SUP>5</SUP>. No entanto, es
sa conduta n&atilde;o ganhou ader&ecirc;ncia na pr&aacute;tica cl&iacute;nica, a
ssim como a recomenda&ccedil;&atilde;o para dosagem deste marcador n&atilde;o fo
i incorporada nas diretrizes brasileiras<SUP>6</SUP>, americanas<SUP>5,7</SUP> o
u europeias<SUP>8</SUP>. Sendo assim, esta revis&atilde;o sistem&aacute;tica tem
 o objetivo de avaliar se as evid&ecirc;ncias atuais justificam a incorpora&cced
il;&atilde;o da prote&iacute;na C&#45;reativa para estratifica&ccedil;&atilde;o 
de risco na admiss&atilde;o hospitalar de pacientes com SCA sem supradesn&iacute
;vel do segmento ST.</font></p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#24#20#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00318000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007400085002001300159#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#25#21#article#186#<p><font s
ize="3" face="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#aop02011.htm##
00326000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008200085002001300167#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#26#22#article#186#<p><font s
ize="2" face="Verdana"><b>Pesquisa da Literatura</b></font></p>     ^cY#aop02011
.htm##
01018000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077400085002001300859#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#27#23#article#186#<p><font s
ize="2" face="Verdana">A base de dados <I>MEDLINE</I> (<I>Medical Literature Ana
lysis and Retrieval System</I>) foi a principal fonte para revis&atilde;o sistem
atizada de trabalhos sobre o tema. Para pesquisa de trabalhos n&atilde;o indexad
os ao <I>MEDLINE</I> e realizados na Am&eacute;rica Latina, foram utilizadas as 
bases de dados <I>SCIELO</I> (<I>Scientific Electronic Library Online</I>) e LIL
ACS (Literatura Latino&#45;Americana e do Caribe em Ci&ecirc;ncias da Sa&uacute;
de), aplicando&#45;se as mesmas palavras&#45;chave do <I>MEDLINE</I>. As refer&e
circ;ncias de cada artigo original e de artigos de revis&atilde;o foram checadas
 a fim de selecionar estudos que n&atilde;o tenham sido identificados pela pesqu
isa nas bases de dados. </font></p>     ^cY#aop02011.htm##
01214000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097000085002001301055#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#28#24#article#186#<p><font s
ize="2" face="Verdana">Inicialmente, o dicion&aacute;rio <I>MeSH</I> (<I>Medical
 Subject Heading Terms)</I> foi utilizado para defini&ccedil;&atilde;o dos termo
s para pesquisa nos t&iacute;tulos dos trabalhos. O termo <I>c&#45;reactive prot
ein</I> foi escolhidos para combina&ccedil;&atilde;o com os termos <I>acute coro
nary syndromes</I>, <I>myocardial infarction</I> e <I>unstable angina, </I>resul
tando em um total de tr&ecirc;s combina&ccedil;&otilde;es de dois termos, utiliz
ando&#45;se a preposi&ccedil;&atilde;o <I>AND.</I> Ap&oacute;s leitura dos t&iac
ute;tulos e dos resumos encontrados, os estudos com as seguintes caracter&iacute
;sticas foram selecionados: desenho de coorte prospectiva em pacientes com SCA s
em supradesn&iacute;vel do segmento ST e avalia&ccedil;&atilde;o do valor progn&
oacute;stico da prote&iacute;na C&#45;reativa, mensurada por m&eacute;todo de al
ta sensibilidade, no momento da admiss&atilde;o hospitalar. </font></p>     ^cY#
aop02011.htm##
00373000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012900085002001300214#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#29#25#article#186#<p><font s
ize="2" face="Verdana">Trabalhos com evidentes vieses metodol&oacute;gicos foram
 exclu&iacute;dos. </font></p>     ^cY#aop02011.htm##
00323000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007900085002001300164#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#30#26#article#186#<p><font s
ize="2" face="Verdana"><b>Desfechos avaliados</b></font></p>     ^cY#aop02011.ht
m##
01045000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080100085002001300886#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#31#27#article#186#<p><font s
ize="2" face="Verdana">Os seguintes desfechos foram considerados: morte ou event
os cardiovasculares combinados. Houve varia&ccedil;&atilde;o dos estudos quanto 
&agrave; defini&ccedil;&atilde;o de desfechos combinados, sendo que a maioria co
nsiderou <I>morte cardiovascular</I> e <I>infarto</I>, ou <I>morte cardiovascula
r</I>, <I>infarto</I> e <I>angina recorrente</I>. Esses estudos foram avaliados 
em conjunto, uniformizando qualquer uma dessas combina&ccedil;&otilde;es como <I
>eventos cardiovasculares</I>. Desfechos em seguimento de curto prazo foram defi
nidos como ocorridos durante a hospitaliza&ccedil;&atilde;o ou em tempo m&aacute
;ximo de 30 dias. Desfechos em seguimento de longo prazo foram definidos como m&
iacute;nimos de tr&ecirc;s meses de acompanhamento.</font></p>     ^cY#aop02011.
htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#32#28#article#186#<p><font s
ize="2" face="Verdana"><b>An&aacute;lise dos dados</b></font></p>     ^cY#aop020
11.htm##
00671000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042700085002001300512#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#33#29#article#186#<p><font s
ize="2" face="Verdana">Inicialmente, as caracter&iacute;sticas dos diferentes es
tudos foram apresentadas em forma de tabela. Foram descritos de forma separada e
studos que avaliaram eventos em seguimento de curto prazo (<u>&lt;</u> 30 dias) 
e estudos que avaliaram eventos em seguimento de longo prazo (<u>&gt;</u> 3 mese
s). Alguns avaliaram ambos os desfechos, portanto, constam nas duas tabelas. </f
ont></p>     ^cY#aop02011.htm##
01029000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078500085002001300870#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#34#30#article#186#<p><font s
ize="2" face="Verdana">Na an&aacute;lise univariada, foram combinados os estudos
 que relataram a incid&ecirc;ncia absoluta de eventos de acordo com um ponto de 
corte da prote&iacute;na C&#45;reativa. Trabalhos que se limitaram a avaliar a p
rote&iacute;na C&#45;reativa como vari&aacute;vel cont&iacute;nua n&atilde;o for
am inclu&iacute;dos na metan&aacute;lise. No come&ccedil;o, os resultados dos di
ferentes estudos foram comparados pela estat&iacute;stica Q de Cochrane, sendo p
 &lt; 0,05 indicativo de heterogeneidade. Em caso de heterogeneidade, os estudos
 foram combinados pelo modelo de efeito rand&ocirc;mico (m&eacute;todo de DerSim
onian e Laird). Do contr&aacute;rio, foi utilizado o modelo de efeito fixo (m&ea
cute;todo de Mantel&#45;Haenszel). </font></p>     ^cY#aop02011.htm##
00991000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704074700085002001300832#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#35#31#article#186#<p><font s
ize="2" face="Verdana">Os resultados combinados foram descritos em <I>odds ratio
</I> (OR) e 95% intervalo de confian&ccedil;a (IC). Al&eacute;m disso, foram obt
idas curvas <I>ROC</I> sumarizadas (sROC), com descri&ccedil;&atilde;o da estat&
iacute;stica&#45;C (&aacute;rea abaixo da curva) sumarizada e respectivo 95% IC.
 O "efeito de limiar" dos pontos de corte da prote&iacute;na C&#45;reativa foi a
valiado, em cada trabalho, pela correla&ccedil;&atilde;o de Spearman entre sensi
bilidade e especificidade. Para an&aacute;lise de sensibilidade, as influ&ecirc;
ncias de diferen&ccedil;as metodol&oacute;gicas nos resultados da metan&aacute;l
ise foram testadas conjuntamente por m&eacute;todo de metarregress&atilde;o. </f
ont></p>     ^cY#aop02011.htm##
00907000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066300085002001300748#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#36#32#article#186#<p><font s
ize="2" face="Verdana">Para analisar conjuntamente os dados das an&aacute;lises 
multivariadas, foram combinadas os OR descritos em cada trabalho. Os estudos que
 descreveram a an&aacute;lise multivariada por risco relativo ou <I>hazard ratio
</I> n&atilde;o foram combinados. Para an&aacute;lise estat&iacute;stica, foi ut
ilizado o programa Meta&#45;DiSc, Vers&atilde;o 1.4 (<I>Universidad Complutense,
 Madri, Espanha</I>)<SUP>9</SUP>, exceto para a combina&ccedil;&atilde;o dos <I>
odds ratio</I>, quando se utilizou o programa <I>Comprehensive Meta Analysis</I>
, Vers&atilde;o 2 (<I>Biostat, Inc, Englewood, NJ, EUA</I>)<SUP>10</SUP>.</font>
</p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#37#33#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00314000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007000085002001300155#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#38#34#article#186#<p><font s
ize="3" face="Verdana"><b>Resultados</b></font></p>     ^cY#aop02011.htm##
00337000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009300085002001300178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#39#35#article#186#<p><font s
ize="2" face="Verdana"><b>Sele&ccedil;&atilde;o dos estudos</b></font></p>     ^
cY#aop02011.htm##
01261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704101700085002001301102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#40#36#article#186#<p><font s
ize="2" face="Verdana">A pesquisa de artigos publicados at&eacute; maio de 2009 
resultou em 288 trabalhos, sendo 259 exclu&iacute;dos pela leitura do t&iacute;t
ulo, que indicava n&atilde;o se tratar de trabalhos avaliando o valor progn&oacu
te;stico da prote&iacute;na C&#45;reativa em pacientes com SCA sem supradesn&iac
ute;vel do segmento ST. Dos 29 trabalhos restantes, 7 foram exclu&iacute;dos por
 serem artigos de revis&atilde;o e um por ser publicado em revista japonesa, com
 vers&atilde;o integral apenas naquele idioma<SUP>11</SUP>. Outros dois artigos 
foram exclu&iacute;dos por problemas metodol&oacute;gicos: um artigo japon&ecirc
;s, pois apenas avaliou prote&iacute;na C&#45;reativa combinada ao amiloide s&ea
cute;rico A<SUP>12</SUP>; e um artigo chileno que apenas trata prote&iacute;na C
&#45;reativa como vari&aacute;vel cont&iacute;nua e, no modelo multivariado, con
templa apenas tr&ecirc;s biomarcadores, sem ajustar para as vari&aacute;veis cl&
iacute;nicas<SUP>13</SUP>. </font></p>     ^cY#aop02011.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016700085002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#41#37#article#186#<p><font s
ize="2" face="Verdana">Sendo assim, 19 estudos participaram desta revis&atilde;o
 sistem&aacute;tica &#150; <a href="#fig01">Figura 1</a>.</font></p>     ^cY#aop
02011.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#42#38#article#186#<p><a name
="fig01"></a></p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#43#39#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#44#40#article#186#<p align="
center"><img src="/img/revistas/abc/2011nahead/a20fig01.jpg"></p>     ^cY#aop020
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#45#41#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00338000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009400085002001300179#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#46#42#article#186#<p><font s
ize="2" face="Verdana"><b>Caracter&iacute;sticas dos estudos</b></font></p>     
^cY#aop02011.htm##
01273000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704102900085002001301114#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#47#43#article#186#<p><font s
ize="2" face="Verdana">Dezenove estudos foram selecionados, 15 realizados por gr
upos da Am&eacute;rica do Norte ou Europa<SUP>1,14&#45;27</SUP>, tr&ecirc;s do B
rasil<SUP>28&#45;30</SUP> e um da Argentina<SUP>31</SUP>. Todos esses trabalhos 
foram publicados em revistas com fator de impacto <u>&gt;</u> 3, exceto dois est
udos brasileiros<SUP>28,29</SUP>. O primeiro estudo data de 1994, realizado por 
Liuzzo e cols.<SUP>14</SUP> e publicado no <I>New England Journal of Medicine</I
>. Embora de pequeno tamanho amostral, apenas 32 pacientes com angina inst&aacut
e;vel, o impacto de tal trabalho deve&#45;se &agrave; original ideia de predizer
 eventos cardiovasculares a partir do <I>status</I> inflamat&oacute;rio de pacie
ntes com SCA. A demonstra&ccedil;&atilde;o de que a medida de prote&iacute;na C&
#45;reativa predizia eventos hospitalares serviu de base para a realiza&ccedil;&
atilde;o dos outros 18 estudos, cujas publica&ccedil;&otilde;es sucessivas inici
aram&#45;se tr&ecirc;s anos mais tarde.</font></p>     ^cY#aop02011.htm##
01100000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704085600085002001300941#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#48#44#article#186#<p><font s
ize="2" face="Verdana">Predominantemente, as amostras populacionais de tais estu
dos consistiram de pacientes com SCA sem supradesn&iacute;vel do segmento ST e 6
 trabalhos inclu&iacute;ram tamb&eacute;m infarto com supradesn&iacute;vel do ST
<SUP>21,23&#45;26,28</SUP>. O tamanho amostral dos trabalhos cresceu ao longo do
s anos, variando de 32 a 7.108 pacientes (m&eacute;dia 1.123 &plusmn; 1.674), 7 
deles com mais de 1.000 pacientes<SUP>20,21,23&#45;27</SUP>, totalizando 21.339 
indiv&iacute;duos estudados. Todos os estudos mediram prote&iacute;na C&#45;reat
iva por m&eacute;todo de alta sensibilidade, 11 deles utilizaram nefelometria<SU
P>14&#45;19,21&#45;24,26,28&#45;30</SUP>, tr&ecirc;s turbidimetria<SUP>1,25,27</
SUP>, um luminometria<SUP>20</SUP> e dois ELISA (<I>Enzyme Linked Immuno Sorbent
 Assay</I>)<SUP>31</SUP>. </font></p>     ^cY#aop02011.htm##
00517000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027300085002001300358#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#49#45#article#186#<p><font s
ize="2" face="Verdana">Desta forma, podemos concluir que h&aacute; um significat
ivo n&uacute;mero de trabalhos e pacientes estudados, com t&eacute;cnicas adequa
das de mensura&ccedil;&atilde;o da prote&iacute;na C&#45;reativa plasm&aacute;ti
ca.</font></p>     ^cY#aop02011.htm##
00384000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014000085002001300225#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#50#46#article#186#<p><font s
ize="2" face="Verdana"> <b>Prote&iacute;na C&#45;reativa: predi&ccedil;&atilde;o
 de eventos em longo prazo</b></font></p>     ^cY#aop02011.htm##
00769000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052500085002001300610#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#51#47#article#186#<p><font s
ize="2" face="Verdana">Oito trabalhos avaliaram o valor progn&oacute;stico da pr
ote&iacute;na C&#45;reativa em rela&ccedil;&atilde;o a eventos recorrentes em se
guimento m&iacute;nimo de tr&ecirc;s meses, com seguimento m&eacute;dio de 13 &p
lusmn; 11 meses. Todos os estudos demonstraram associa&ccedil;&atilde;o signific
ativa da prote&iacute;na C&#45;reativa com eventos cardiovasculares<SUP>1,18,19,
22&#45;24,27,31</SUP> &#150; <a href="/img/revistas/abc/2011nahead/a20tab01.jpg"
>Tabela 1</a>. </font></p>     ^cY#aop02011.htm##
01363000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704111900085002001301204#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#52#48#article#186#<p><font s
ize="2" face="Verdana">Quanto ao agrupamento metanal&iacute;tico dos resultados 
dos trabalhos, os estudos de Bogaty e cols.<SUP>23</SUP> e Scirica e cols.<SUP>2
4</SUP> n&atilde;o foram inclu&iacute;dos, pois a prote&iacute;na C&#45;reativa 
foi avaliada como vari&aacute;vel num&eacute;rica, n&atilde;o sendo descritas as
 incid&ecirc;ncia de eventos de acordo com subgrupos definidos pelos valores des
te marcador. Sendo assim, 6 estudos tiveram seus resultados de longo prazo combi
nados. Em todos esses trabalhos, houve associa&ccedil;&atilde;o positiva e estat
isticamente significante entre prote&iacute;na C&#45;reativa e desfecho, por&eac
ute;m a an&aacute;lise de heterogeneidade mostrou diferen&ccedil;a quantitativa 
(p = 0,007), ou seja, em rela&ccedil;&atilde;o &agrave; magnitude da associa&cce
dil;&atilde;o. A combina&ccedil;&atilde;o dos estudos pelo modelo rand&ocirc;mic
o resultou em OR de 4,6 (95% IC = 2,3 &#150; 7,6) &#150; <a href="#fig02">Figura
 2</a>. A curva sROC apresentou estat&iacute;stica&#45;C de 0,75 (95% IC = 0,65 
&#45; 0,85) &#150; <a href="#fig03">Figura 3</a>.</font></p>     ^cY#aop02011.ht
m##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#53#49#article#186#<p><a name
="fig02"></a></p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#54#50#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#55#51#article#186#<p align="
center"><img src="/img/revistas/abc/2011nahead/a20fig02.jpg"></p>     ^cY#aop020
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#56#52#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#57#53#article#186#<p><a name
="fig03"></a></p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#58#54#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#59#55#article#186#<p align="
center"><img src="/img/revistas/abc/2011nahead/a20fig03.jpg"></p>     ^cY#aop020
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#60#56#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00387000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014300085002001300228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#61#57#article#186#<p><font s
ize="2" face="Verdana"><b>An&aacute;lise de sensibilidade da predi&ccedil;&atild
e;o de eventos em longo prazo</b></font></p>     ^cY#aop02011.htm##
01278000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704103400085002001301119#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#62#58#article#186#<p><font s
ize="2" face="Verdana">Duas caracter&iacute;sticas variaram significativamente e
ntre os trabalhos da metan&aacute;lise. Primeiro, a forma de determina&ccedil;&a
tilde;o do ponto de corte da prote&iacute;na C&#45;reativa: tr&ecirc;s estudos i
dentificaram o ponto de corte pela curva ROC, encontrando 15 mg/l<SUP>31</SUP>, 
10 mg/l<SUP>19</SUP>, 11 mg/l<SUP>22</SUP>, respectivamente. Os outros tr&ecirc;
s trabalhos elegeram o ponto de corte de forma arbitr&aacute;ria, respectivament
e, 5 mg/l<SUP>18</SUP>, 10 mg/l<SUP>1</SUP> e 10 mg/l<SUP>27</SUP>. De acordo co
m an&aacute;lise de metarregress&atilde;o, n&atilde;o houve influ&ecirc;ncia da 
forma de determina&ccedil;&atilde;o do ponto de corte no resultado dos trabalhos
 (OR = 0,1; 95% IC = 0 &#150; 36; p = 0,23). Al&eacute;m disso, n&atilde;o houve
 associa&ccedil;&atilde;o linear entre sensibilidade e especificidade (p = 0,40)
, indicando aus&ecirc;ncia de influ&ecirc;ncia dos valores dos pontos de corte n
o resultado dos estudos (efeito de limiar). </font></p>     ^cY#aop02011.htm##
00712000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046800085002001300553#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#63#59#article#186#<p><font s
ize="2" face="Verdana">A segunda caracter&iacute;stica que variou entre os estud
os foi a defini&ccedil;&atilde;o de desfechos, com dois estudos da metan&aacute;
lise avaliando apenas morte<SUP>1,27</SUP> e 4 avaliando desfechos combinados<SU
P>18,19,22,31</SUP>. Da mesma forma, a an&aacute;lise de metarregress&atilde;o n
&atilde;o mostrou influ&ecirc;ncia do tipo de desfecho nos resultados (OR = 0,35
; 95% IC = 0,02 &#150; 4,5; p = 0,27).</font></p>     ^cY#aop02011.htm##
00383000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013900085002001300224#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#64#60#article#186#<p><font s
ize="2" face="Verdana"><b>Prote&iacute;na C&#45;reativa: predi&ccedil;&atilde;o 
de eventos em curto prazo</b></font></p>     ^cY#aop02011.htm##
01165000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704092100085002001301006#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#65#61#article#186#<p><font s
ize="2" face="Verdana">Quanto &agrave; predi&ccedil;&atilde;o de eventos at&eacu
te; 30 dias, 15 estudos fizeram esta avalia&ccedil;&atilde;o<SUP>14&#45;17,19&#4
5;21,25&#45;31</SUP>. Ao contr&aacute;rio do seguimento tardio, os resultados do
s trabalhos foram conflitantes: 9 estudos positivos<SUP>14,17,20,21,25&#45;27,30
</SUP> e 6 estudos negativos<SUP>15,16,19,28,29,31</SUP> &#150; <a href="/img/re
vistas/abc/2011nahead/a20tab02.jpg">Tabela 2</a>. O grupo de estudos positivos p
ossuiu em m&eacute;dia maior tamanho amostral (1.911 &plusmn; 2.197 pacientes), 
sendo 6 dos 7 trabalhos com mais de 1.000 pacientes. Por outro lado, o grupo de 
estudos negativos possuiu uma m&eacute;dia de tamanho amostral de 225 &plusmn; 1
10 pacientes, o maior deles com 447 indiv&iacute;duos. Isto sugere que os result
ados negativos de tais estudos podem ser decorrentes de reduzido poder estat&iac
ute;stico. </font></p>     ^cY#aop02011.htm##
01381000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704113700085002001301222#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#66#62#article#186#<p><font s
ize="2" face="Verdana">Abordagem metanal&iacute;tica foi realizada com os 12 est
udos que compararam a incid&ecirc;ncia de eventos entre dois grupos dicotomizado
s de acordo com o valor da prote&iacute;na C&#45;reativa<SUP>14&#45;17,19,20,25&
#45;27,29&#45;31</SUP>. O estudo de Duarte e cols.<SUP>28</SUP> n&atilde;o entro
u na an&aacute;lise, pois avaliou a prote&iacute;na C&#45;reativa como vari&aacu
te;vel cont&iacute;nua. O segundo estudo de Oltrona e cols.<SUP>21</SUP> e o est
udo de Scirica e cols.<SUP>24</SUP> n&atilde;o participaram da metan&aacute;lise
, pois reportam resultados apenas em risco relativo, sem detalhar as incid&ecirc
;ncias absolutas dos eventos. A metan&aacute;lise mostrou heterogeneidade signif
icativa entre os estudos (p = 0,002), por este motivo o OR foi calculado pelo m&
eacute;todo de efeito rand&ocirc;mico, resultando em 1,65 (95% IC = 1,20 &#45; 2
,27), confirmando a predi&ccedil;&atilde;o de eventos hospitalares &#150; <a hre
f="#fig04">Figura 4</a>. A curva sROC apresentou estat&iacute;stica&#45;C de 0,5
7 (95% IC = 0,54 &#45; 0,60) &#150; <a href="#fig05">Figura 5</a>. </font></p>  
   ^cY#aop02011.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#67#63#article#186#<p><a name
="fig04"></a></p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#68#64#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#69#65#article#186#<p align="
center"><img src="/img/revistas/abc/2011nahead/a20fig04.jpg"></p>     ^cY#aop020
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#70#66#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#71#67#article#186#<p><a name
="fig05"></a></p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#72#68#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#73#69#article#186#<p align="
center"><img src="/img/revistas/abc/2011nahead/a20fig05.jpg"></p>     ^cY#aop020
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#74#70#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00384000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014000085002001300225#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#75#71#article#186#<p><font s
ize="2" face="Verdana"><b>An&aacute;lise de sensibilidade: predi&ccedil;&atilde;
o de eventos a curto prazo</b></font></p>     ^cY#aop02011.htm##
01107000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086300085002001300948#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#76#72#article#186#<p><font s
ize="2" face="Verdana">Tr&ecirc;s caracter&iacute;sticas variaram significativam
ente entre os trabalhos. Primeiro, a forma de determina&ccedil;&atilde;o do pont
o de corte da prote&iacute;na C&#45;reativa: 4 estudos identificaram o ponto de 
corte pela curva ROC<SUP>19,26,30,31</SUP> e outros 8 trabalhos elegeram o ponto
 de corte de forma arbitr&aacute;ria<SUP>14&#45;17,20,25,27,29</SUP>. De acordo 
com an&aacute;lise de metarregress&atilde;o, n&atilde;o houve influ&ecirc;ncia d
a forma de determina&ccedil;&atilde;o do ponto de corte no resultado dos trabalh
os (OR = 1,34; 95% IC = 0,52 &#150; 3,47; p = 0,49). Al&eacute;m disso, n&atilde
;o houve associa&ccedil;&atilde;o linear entre sensibilidade e especificidade (p
 = 0,55), indicando aus&ecirc;ncia de influ&ecirc;ncia dos valores dos pontos de
 corte no resultado dos estudos. </font></p>     ^cY#aop02011.htm##
00750000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704050600085002001300591#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#77#73#article#186#<p><font s
ize="2" face="Verdana">A segunda caracter&iacute;stica que variou entre os estud
os foi a defini&ccedil;&atilde;o de desfechos, com tr&ecirc;s estudos da metan&a
acute;lise avaliando apenas morte<SUP>17,25,27</SUP> e os 9 demais avaliando des
fechos combinados<SUP>14&#45;16,19,20,26,29&#45;31</SUP>. Da mesma forma, a an&a
acute;lise de metarregress&atilde;o n&atilde;o mostrou influ&ecirc;ncia do tipo 
de desfecho nos resultados (OR = 0,35; 95% IC = 0,02 &#150; 4,5; p = 0,27). </fo
nt></p>     ^cY#aop02011.htm##
00649000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040500085002001300490#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#78#74#article#186#<p><font s
ize="2" face="Verdana">Por fim, infarto com supradesn&iacute;vel do ST foi inclu
&iacute;do em dois estudos<SUP>25,26</SUP>, enquanto os 10 demais analisaram ape
nas SCA sem supradesn&iacute;vel do ST. Essa caracter&iacute;stica tamb&eacute;m
 n&atilde;o teve influ&ecirc;ncia nos resultados (OR = 0,70; 95% IC = 0,36 &#150
; 1,35; p = 0,25) &#150; <a href="#tab03">Tabela 3</a>.</font></p>     ^cY#aop02
011.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#79#75#article#186#<p><a name
="tab03"></a></p>     ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#80#76#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#81#77#article#186#<p align="
center"><img src="/img/revistas/abc/2011nahead/a20tab03.jpg"></p>     ^cY#aop020
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#82#78#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00364000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012000085002001300205#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#83#79#article#186#<p><font s
ize="2" face="Verdana"><b>Valor preditor independente da prote&iacute;na C&#45;r
eativa</b></font></p>     ^cY#aop02011.htm##
00924000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068000085002001300765#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#84#80#article#186#<p><font s
ize="2" face="Verdana">A maioria dos estudos, excetuando&#45;se os tr&ecirc;s in
iciais<SUP>14,15,17</SUP>, ajustou o valor preditor da prote&iacute;na C&#45;rea
tiva para vari&aacute;veis cl&iacute;nicas e laboratoriais. Em 5 estudos, covari
&aacute;veis importantes foram omitidas do modelo estat&iacute;stico<SUP>16,18,2
5,28,32</SUP>, enquanto que, em outros 11 trabalhos, a an&aacute;lise multivaria
da foi adequada<SUP>1,19&#45;24,26,27,31</SUP>. Merecem destaque os estudos de F
oussas e cols.<SUP>26</SUP> e Correia e cols.<SUP>30</SUP>, os &uacute;nicos a a
justar o valor da prote&iacute;na C&#45;reativa para um escore de risco validado
, o TIMI. </font></p>     ^cY#aop02011.htm##
00981000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073700085002001300822#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#85#81#article#186#<p><font s
ize="2" face="Verdana">Dos 8 estudos que avaliaram o valor progn&oacute;stico em
 longo prazo, 6 confirmaram valor preditor independente por an&aacute;lise multi
variada<SUP>1,18,19,22,24,27</SUP> e um deles n&atilde;o fez esta avalia&ccedil;
&atilde;o<SUP>31</SUP>. Por outro lado, o recente estudo de Bogaty e cols.<SUP>2
3</SUP>, em uma coorte de 1.210 pacientes com SCA, negou a associa&ccedil;&atild
e;o multivariada da prote&iacute;na C&#45;reativa com eventos recorrentes a long
o prazo, tendo este trabalho recebido aten&ccedil;&atilde;o por seu resultado ne
gativo<SUP>23</SUP>. Devido ao dado in&eacute;dito de aus&ecirc;ncia de valor pr
editor independente, esse estudo merece ser discutido com detalhe. </font></p>  
   ^cY#aop02011.htm##
01635000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704139100085002001301476#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#86#82#article#186#<p><font s
ize="2" face="Verdana">Primeiro, analisando quest&otilde;es metodol&oacute;gicas
, n&atilde;o encontrarmos superioridade do estudo de Bogaty e cols.<SUP>23</SUP>
 em rela&ccedil;&atilde;o aos demais estudos. Segundo, est&aacute; demonstrado q
ue o valor preditor da prote&iacute;na C&#45;reativa em pacientes com angina ins
t&aacute;vel ou infarto sem supradesn&iacute;vel do ST &eacute; superior &agrave
; capacidade preditora em infarto com supradesn&iacute;vel do segmento ST, onde 
o maior grau de necrose influencia a medida de prote&iacute;na C&#45;reativa<SUP
>25</SUP>. Desta forma, o fato de 30,0% dos pacientes apresentarem infarto com s
upradesn&iacute;vel do segmento ST pode ter contribu&iacute;do para o resultado 
negativo de Bogaty e cols.<SUP>23</SUP>. Terceiro, nesse estudo, a prote&iacute;
na C&#45;reativa apresentou predi&ccedil;&atilde;o significativa na an&aacute;li
se univariada, por&eacute;m perdeu signific&acirc;ncia na an&aacute;lise multiva
riada. Ao contr&aacute;rio dos demais estudos, a medida de prote&iacute;na C&#45
;reativa foi inserida como vari&aacute;vel cont&iacute;nua na regress&atilde;o l
og&iacute;stica, o que reduz sua for&ccedil;a de predi&ccedil;&atilde;o ao ser a
valiada junto a outras vari&aacute;veis categ&oacute;ricas. Isto pode ter sido o
 principal motivo do resultado negativo do estudo de Bogaty e cols.<SUP>23</SUP>
.</font></p>     ^cY#aop02011.htm##
00642000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039800085002001300483#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#87#83#article#186#<p><font s
ize="2" face="Verdana">Cinco estudos de longo prazo reportaram medidas de associ
a&ccedil;&atilde;o provenientes da an&aacute;lise multivariada. Tr&ecirc;s deles
 utilizaram OR, permitindo a combina&ccedil;&atilde;o dos dados. Estes tr&ecirc;
s estudos apresentaram homogeneidade (p = 0,14) e o m&eacute;todo de efeito fixo
 resultou em OR = 2,5 (95% IC = 1,8 &#150; 3,4).</font></p>     ^cY#aop02011.htm
##
00811000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056700085002001300652#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#88#84#article#186#<p><font s
ize="2" face="Verdana">Em rela&ccedil;&atilde;o ao valor preditor independente d
a prote&iacute;na C&#45;reativa para eventos de curto prazo, 10 estudos realizar
am an&aacute;lise multivariada e apenas 4 indicaram valor preditor independente,
 evidenciando dados controversos. Apenas tr&ecirc;s estudos descreveram OR multi
variada e, devido &agrave; heterogeneidade do resultado entre os trabalhos, opto
u&#45;se por n&atilde;o combin&aacute;&#45;los, pois haveria alto potencial de v
i&eacute;s de sele&ccedil;&atilde;o nesta an&aacute;lise.</font></p>     ^cY#aop
02011.htm##
00354000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011000085002001300195#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#89#85#article#186#<p><font s
ize="2" face="Verdana"><b>Valor incremental da prote&iacute;na C&#45;reativa</b>
</font></p>     ^cY#aop02011.htm##
01472000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122800085002001301313#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#90#86#article#186#<p><font s
ize="2" face="Verdana">Dos 19 artigos selecionados, apenas dois quantificaram o 
valor incremental da prote&iacute;na C&#45;reativa, ambos relativos ao valor pre
ditor de curto prazo. No primeiro, Oltrona e cols.<SUP>15</SUP> n&atilde;o encon
traram aumento da estat&iacute;stica&#45;C ap&oacute;s adi&ccedil;&atilde;o de p
rote&iacute;na C&#45;reativa em modelo de regress&atilde;o log&iacute;stica. O e
studo de Oltrona e cols.<SUP>15 </SUP>possui grande tamanho amostral (N = 1.773)
 e vantagem de contemplar grande quantidade de covari&aacute;veis<SUP>21</SUP>. 
Por outro lado, Oltrona e cols.<SUP>15 </SUP>t&ecirc;m a desvantagem de ter incl
u&iacute;do tamb&eacute;m infarto com supradesn&iacute;vel do ST, o que teoricam
ente reduz o valor preditor da prote&iacute;na C&#45;reativa. A abordagem de Olt
rona e cols.<SUP>15</SUP>, em avaliar o quanto a prote&iacute;na C&#45;reativa a
diciona a um modelo preditor derivado da pr&oacute;pria amostra do estudo, embor
a estatisticamente correta, torna mais dif&iacute;cil encontrar valor preditor a
dicional de um biomarcador. Isto porque o modelo preditor multivariado est&aacut
e; otimizado por ter sido derivado da pr&oacute;pria popula&ccedil;&atilde;o. </
font></p>     ^cY#aop02011.htm##
00740000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049600085002001300581#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#91#87#article#186#<p><font s
ize="2" face="Verdana">No segundo trabalho, Correia e cols.<SUP>30</SUP> selecio
nam especificamente pacientes com SCA sem supradesn&iacute;vel do ST e avaliam o
 valor incremental em rela&ccedil;&atilde;o a um escore de risco validado, o TIM
I. Embora de pequeno tamanho amostral, ap&oacute;s incorporar a informa&ccedil;&
atilde;o da prote&iacute;na C&#45;reativa, esse estudo demonstrou um incremento 
na estat&iacute;stica&#45;C do TIMI da ordem de 0,06<SUP>30</SUP>.</font></p>   
  ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#92#88#article#186#<p>&nbsp;<
/p>     ^cY#aop02011.htm##
00320000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007600085002001300161#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#93#89#article#186#<p><font s
ize="3" face="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#aop02011.htm##
00731000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048700085002001300572#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#94#90#article#186#<p><font s
ize="2" face="Verdana">A presente revis&atilde;o sistem&aacute;tica tem o objeti
vo de avaliar se h&aacute; evid&ecirc;ncias que indiquem a utiliza&ccedil;&atild
e;o da prote&iacute;na C&#45;reativa como preditor de risco na admiss&atilde;o d
e pacientes com SCA sem supradesn&iacute;vel do segmento ST. Esse marcador tem s
ido avaliado quanto ao valor progn&oacute;stico referente ao curto prazo (hospit
alar ou 30 dias) ou longo prazo (&gt; tr&ecirc;s meses). </font></p>     ^cY#aop
02011.htm##
01353000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110900085002001301194#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#95#91#article#186#<p><font s
ize="2" face="Verdana">Observa&#45;se que, no longo prazo, evid&ecirc;ncias demo
nstrando associa&ccedil;&atilde;o entre o valor da prote&iacute;na C&#45;reativa
 e a incid&ecirc;ncia de desfechos s&atilde;o consistentes nas an&aacute;lises u
nivariada e multivariada. Por outro lado, os resultados de curto prazo s&atilde;
o qualitativamente heterog&ecirc;neos, ou seja, parte indica aus&ecirc;ncia de a
ssocia&ccedil;&atilde;o e outra parte sugere associa&ccedil;&atilde;o entre prot
e&iacute;na C&#45;reativa e desfechos. Na presente metan&aacute;lise, o efeito m
&eacute;dio dos estudos de curto prazo indica associa&ccedil;&atilde;o univariad
a entre prote&iacute;na C&#45;reativa e risco cardiovascular<SUP>32</SUP>. Por&e
acute;m, as an&aacute;lises multivariadas desses estudos s&atilde;o conflitantes
 e os resultados n&atilde;o puderam ser combinados, pois a minoria reportou o <I
>odds ratio</I> multivariado. Dessa forma, a presente an&aacute;lise demonstra v
alor progn&oacute;stico de longo prazo e indica controv&eacute;rsia quanto ao va
lor progn&oacute;stico de curto prazo. </font></p>     ^cY#aop02011.htm##
01573000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704132900085002001301414#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#96#92#article#186#<p><font s
ize="2" face="Verdana">Embora a predi&ccedil;&atilde;o de risco independente sej
a uma condi&ccedil;&atilde;o necess&aacute;ria na valida&ccedil;&atilde;o de um 
novo marcador, esta n&atilde;o &eacute; uma condi&ccedil;&atilde;o suficiente. I
nterromper a avalia&ccedil;&atilde;o do preditor em tal etapa, considerando&#45;
o validado para a utiliza&ccedil;&atilde;o cl&iacute;nica &eacute; um equ&iacute
;voco comum. Nem todo preditor independente incrementa de forma clinicamente rel
evante a acur&aacute;cia progn&oacute;stica dos modelos cl&aacute;ssicos de pred
i&ccedil;&atilde;o<SUP>33</SUP>. Isto origina uma quest&atilde;o importante: o n
ovo marcador de risco tem utilidade incremental aos modelos aplicados na pr&aacu
te;tica cl&iacute;nica? Essa resposta deve ser obtida pela compara&ccedil;&atild
e;o do desempenho de um modelo preditor que utiliza vari&aacute;veis usuais com 
o desempenho de um modelo alternativo resultante da incorpora&ccedil;&atilde;o d
o novo marcador ao modelo cl&aacute;ssico. Ou seja, ao inserir uma nova vari&aac
ute;vel a um escore de risco, o quanto melhora o desempenho deste escore? A form
a mais comum de se avaliar esta quest&atilde;o &eacute; a medida do incremento d
a estat&iacute;stica&#45;C ap&oacute;s incorpora&ccedil;&atilde;o do novo biomar
cador<SUP>34</SUP>.</font></p>     ^cY#aop02011.htm##
01029000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078500085002001300870#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#97#93#article#186#<p><font s
ize="2" face="Verdana">Na presente revis&atilde;o, apenas dois estudos avaliaram
 tal quest&atilde;o, com resultados conflitantes, um negativo<SUP>21</SUP> e out
ro positivo<SUP>30</SUP>. Embora o estudo de Correia e cols.<SUP>30</SUP>, cujos
 resultados foram positivos, tenha as vantagens metodol&oacute;gicas relatadas n
os resultados desta revis&atilde;o sistem&aacute;tica, o estudo negativo de Oltr
ona e cols.<SUP>21</SUP> tem um tamanho amostral 20 vezes maior do que o primeir
o, devendo seu resultado ser tamb&eacute;m valorizado. Portanto, n&atilde;o h&aa
cute; evid&ecirc;ncias conclusivas quanto ao valor incremental (utilidade cl&iac
ute;nica) da prote&iacute;na C&#45;reativa em rela&ccedil;&atilde;o &agrave; pre
di&ccedil;&atilde;o de risco usual.</font></p>     ^cY#aop02011.htm##
01297000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704105300085002001301138#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#98#94#article#186#<p><font s
ize="2" face="Verdana">Na escassez de avalia&ccedil;&atilde;o incremental, podem
os inferir se o valor adicional estar&aacute; presente, baseado na for&ccedil;a 
de associa&ccedil;&atilde;o entre prote&iacute;na C&#45;reativa e desfechos. &Ea
cute; descrito que, para promover um aumento clinicamente relevante na estat&iac
ute;stica&#45;C (&gt; 0,05), um marcador geralmente necessita de <I>odds ratio</
I> &gt; 3<SUP>35</SUP>. Na presente an&aacute;lise, o <I>odds ratio</I> conjunto
 de 4,6 para o longo prazo parece um n&uacute;mero favor&aacute;vel. Por&eacute;
m, esse &eacute; o <I>odds ratio</I> univariado, provavelmente superestimado em 
rela&ccedil;&atilde;o ao valor multivariado. Al&eacute;m disso, o limite inferio
r do intervalo de confian&ccedil;a &eacute; 2,3, o que deixa d&uacute;vida quant
o ao valor incremental. Mais incerto ainda seria o valor incremental de curto pr
azo, pois o <I>odds ratio</I> da metan&aacute;lise foi de 1,6, sugerindo aus&eci
rc;ncia de valor incremental da prote&iacute;na C&#45;reativa. </font></p>     ^
cY#aop02011.htm##
00985000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704074100085002001300826#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#99#95#article#186#<p><font s
ize="2" face="Verdana">Devemos salientar que o racioc&iacute;nio relatado &eacut
e; inferencial e a resposta definitiva de tal quest&atilde;o vir&aacute; com an&
aacute;lises futuras do valor incremental, que pode ser realizada nos pr&oacute;
prios bancos de dados dos estudos publicados. A import&acirc;ncia desse tipo de 
an&aacute;lise &eacute; exemplificada pela quest&atilde;o da prote&iacute;na C&#
45;reativa como preditor de risco em indiv&iacute;duos aparentemente saud&aacute
;veis. Naquele caso, a dosagem de prote&iacute;na C&#45;reativa n&atilde;o incre
menta a estat&iacute;stica&#45;C do escore de Framingham, embora tenha associa&c
cedil;&atilde;o independente com eventos cardiovasculares<SUP>36</SUP>.</font></
p>     ^cY#aop02011.htm##
01063000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704081800086002001300904#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#100#96#article#186#<p><font 
size="2" face="Verdana">As diferen&ccedil;as metodol&oacute;gicas dos diferentes
 estudos representam potenciais vieses nos resultados desta revis&atilde;o siste
m&aacute;tica. Por exemplo, h&aacute; grande varia&ccedil;&atilde;o dos pontos d
e corte, dos tipos de desfechos utilizados e das popula&ccedil;&otilde;es&#45;al
vo entre os estudos. No entanto, as an&aacute;lises de sensibilidade indicaram q
ue tais caracter&iacute;sticas n&atilde;o influenciaram nos resultados da metan&
aacute;lise. Outra limita&ccedil;&atilde;o &eacute; a aus&ecirc;ncia de informa&
ccedil;&otilde;es relativas ao <I>odds ratio</I> da maioria dos estudos, o que i
mpediu que estes fossem corretamente combinados quanto &agrave; avalia&ccedil;&a
tilde;o do valor preditor independente (an&aacute;lise multivariada).</font></p>
     ^cY#aop02011.htm##
00822000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704057700086002001300663#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#101#97#article#186#<p><font 
size="2" face="Verdana">Os <I>guidelines</I> atuais sobre SCA sem supradesn&iacu
te;vel do segmento ST n&atilde;o se posicionam claramente quanto &agrave; utiliz
a&ccedil;&atilde;o da prote&iacute;na C&#45;reativa. A diretriz brasileira nem m
esmo menciona marcadores inflamat&oacute;rios, enquanto os <I>guidelines</I> ame
ricano e europeu descrevem os trabalhos que mostram associa&ccedil;&atilde;o ent
re prote&iacute;na C&#45;reativa e progn&oacute;stico, por&eacute;m n&atilde;o d
e forma conclusiva do ponto de vista de recomenda&ccedil;&atilde;o. </font></p> 
    ^cY#aop02011.htm##
00812000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704056700086002001300653#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#102#98#article#186#<p><font 
size="2" face="Verdana">Portanto, a presente revis&atilde;o sistem&aacute;tica p
reenche esta lacuna com a seguinte conclus&atilde;o: a despeito da consistente a
ssocia&ccedil;&atilde;o entre a medida da prote&iacute;na C&#45;reativa na admis
s&atilde;o e o progn&oacute;stico de longo prazo de pacientes com SCA, a falta d
e informa&ccedil;&otilde;es definitivas quanto ao seu valor progn&oacute;stico i
ncremental impede que a dosagem rotineira deste biomarcador seja recomendada em 
pacientes com SCA sem supradesn&iacute;vel do segmento ST.</font></p>     ^cY#ao
p02011.htm##
00337000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704009200086002001300178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#103#99#article#186#<p><font 
size="2" face="Verdana"><b>Potencial Conflito de Interesses</b></font></p>     ^
cY#aop02011.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704011300087002001300200#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#104#100#article#186#<p><font
 size="2" face="Verdana">Declaro n&atilde;o haver conflito de interesses pertine
ntes.</font></p>     ^cY#aop02011.htm##
00329000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704008300087002001300170#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#105#101#article#186#<p><font
 size="2" face="Verdana"><b>Fontes de Financiamento</b></font></p>     ^cY#aop02
011.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704012000087002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#106#102#article#186#<p><font
 size="2" face="Verdana">O presente estudo n&atilde;o teve fontes de financiamen
to externas.</font></p>     ^cY#aop02011.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010000087002001300187#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#107#103#article#186#<p><font
 size="2" face="Verdana"><b>Vincula&ccedil;&atilde;o Acad&ecirc;mica</b></font><
/p>     ^cY#aop02011.htm##
00422000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704017600087002001300263#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#108#104#article#186#<p><font
 size="2" face="Verdana">Este artigo &eacute; parte de tese de livre doc&ecirc;n
cia de Lu&iacute;s C. L. Correia pela Universidade Federal da Bahia.</font></p> 
    ^cY#aop02011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#109#105#article#186#<p>&nbsp
;</p>     ^cY#aop02011.htm##
00323000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704007700087002001300164#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#110#106#article#186#<p><font
 size="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop02011.ht
m##
00596000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704033600089002001300425#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#111#107#article#
186#1#<p><font size="2" face="Verdana">1.  Lindahl B, Toss H, Siegbahn A, Venge 
P, Wallentin L. Markers of myocardial damage and inflammation in relation to lon
g&#45;term mortality in unstable coronary artery disease. FRISC Study Group. Fra
gmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343 (16)
: 1139&#45;47.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#112#108#article#186#</font><
/p>     ^cY#aop02011.htm##
00409000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704014900089002001300238#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#113#109#article#
186#2#<p><font size="2" face="Verdana">2.  Libby P, Ridker PM, Maseri A. Inflamm
ation and atherosclerosis. Circulation. 2002; 105 (9): 1135&#45;43.    ^cY#aop02
011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#114#110#article#186#</font><
/p>     ^cY#aop02011.htm##
00460000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704020000089002001300289#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#115#111#article#
186#3#<p><font size="2" face="Verdana">3.  Buffon A, Biasucci LM, Liuzzo G, D'On
ofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. 
N Engl J Med. 2002; 347 (1): 5&#45;12.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#116#112#article#186#</font><
/p>     ^cY#aop02011.htm##
00458000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704019800089002001300287#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#117#113#article#
186#4#<p><font size="2" face="Verdana">4.  Rifai N, Tracy RP, Ridker PM. Clinica
l efficacy of an automated high&#45;sensitivity C&#45;reactive protein assay. Cl
in Chem. 1999; 45 (12): 2136&#45;41.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#118#114#article#186#</font><
/p>     ^cY#aop02011.htm##
00617000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704035700089002001300446#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#119#115#article#
186#5#<p><font size="2" face="Verdana">5.  Morrow DA, Cannon CP, Jesse RL, Newby
 LK, Ravkilde J, Storrow AB, et al; NACB WRITING GROUP. National Academy of Clin
ical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characterist
ics and Utilization of Biochemical Markers in Acute Coronary Syndromes. Circulat
ion. 2007; 115 (13): e356&#45;e375.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#120#116#article#186#</font><
/p>     ^cY#aop02011.htm##
00561000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030100089002001300390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#121#117#article#
186#6#<p><font size="2" face="Verdana">6.   Nicolau JC, Timerman A, Piegas LS, M
arin Neto JA, Rassi A Jr. Guidelines for unstable angina and non&#45;ST&#45;segm
ent elevation myocardial infarction of the Brazilian Society of Cardiology (II E
dition,2007). Arq Bras Cardiol. 2007; 89 (4): e89&#45;e131.    ^cY#aop02011.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#122#118#article#186#</font><
/p>     ^cY#aop02011.htm##
01116000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704085600089002001300945#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#123#119#article#
186#7#<p><font size="2" face="Verdana">7.  Anderson JL, Adams CD, Antman EM, Bri
dges CR, Califf RM, Casey DEJ, et al. ACC/AHA 2007 Guidelines for the Management
 of Patients With Unstable Angina/Non&#45;ST&#45;Elevation Myocardial Infarction
: A Report of the American College of Cardiology/American Heart Association Task
 Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines f
or the Management of Patients With Unstable Angina/Non&#45;ST&#45;Elevation Myoc
ardial Infarction) Developed in Collaboration with the American College of Emerg
ency Physicians, the Society for Cardiovascular Angiography and Interventions, a
nd the Society of Thoracic Surgeons Endorsed by the American Association of Card
iovascular and Pulmonary Rehabilitation and the Society for Academic Emergency M
edicine. J Am Coll Cardiol. 2007; 50 (7): e1&#45;e157.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#124#120#article#186#</font><
/p>     ^cY#aop02011.htm##
00683000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704042300089002001300512#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#125#121#article#
186#8#<p><font size="2" face="Verdana">8.  Bassand JP, Hamm CW, Ardissino D, Boe
rsma E, Budaj A, Fernandez&#45;Aviles F, et al. Guidelines for the diagnosis and
 treatment of non&#45;ST&#45;segment elevation acute coronary syndromes: The Tas
k Force for the Diagnosis and Treatment of Non&#45;ST&#45;Segment Elevation Acut
e Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007; 2
8 (13): 1598&#45;660.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#126#122#article#186#</font><
/p>     ^cY#aop02011.htm##
00464000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704020400089002001300293#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#127#123#article#
186#9#<p><font size="2" face="Verdana">9.  Zamora J, Abraira V, Muriel A, Khan K
, Coomarasamy A. Meta&#45;DiSc: a software for meta&#45;analysis of test accurac
y data. BMC Med Res Methodol. 2006; 6: 31.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#128#124#article#186#</font><
/p>     ^cY#aop02011.htm##
00460000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019900090002001300289#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#129#125#article#
186#10#<p><font size="2" face="Verdana">10.  Bax L, Yu LM, Ikeda N, Moons KG. A 
systematic comparison of software dedicated to meta&#45;analysis of causal studi
es. BMC Med Res Methodol. 2007; 7: 40.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#130#126#article#186#</font><
/p>     ^cY#aop02011.htm##
00482000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022100090002001300311#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#131#127#article#
186#11#<p><font size="2" face="Verdana">11.  Tanaka H, Tsurumi Y, Kasanuki H. Pr
ognostic value of C&#45;reactive protein and troponin T level in patients with u
nstable angina pectoris. J Cardiol. 2006; 47 (4): 173&#45;9.    ^cY#aop02011.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#132#128#article#186#</font><
/p>     ^cY#aop02011.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#133#129#article#
186#12#<p><font size="2" face="Verdana">12.  Kosuge M, Ebina T, Ishikawa T, Hibi
 K, Tsukahara K, Okuda J, et al. Serum amyloid A is a better predictor of clinic
al outcomes than C&#45;reactive protein in non&#45;ST&#45;segment elevation acut
e coronary syndromes. Circ J. 2007; 71 (2): 186&#45;90.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#134#130#article#186#</font><
/p>     ^cY#aop02011.htm##
00531000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027000090002001300360#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#135#131#article#
186#13#<p><font size="2" face="Verdana">13.  Baeza VR, Corbalan HR, Castro GP, A
cevedo BM, Quiroga GT, Viviani GP. Coronary biomarkers and long&#45;term clinica
l outcome in acute coronary syndrome without ST segment elevation. Rev Med Chil.
 2005; 133 (11): 1285&#45;93.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#136#132#article#186#</font><
/p>     ^cY#aop02011.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026500090002001300355#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#137#133#article#
186#14#<p><font size="2" face="Verdana">14.  Liuzzo G, Biasucci LM, Gallimore JR
, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C&#45;reactive
 protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 19
94; 331 (7): 417&#45;24.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#138#134#article#186#</font><
/p>     ^cY#aop02011.htm##
00508000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024700090002001300337#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#139#135#article#
186#15#<p><font size="2" face="Verdana">15.  Oltrona L, Ardissino D, Merlini PA,
 Spinola A, Chiodo F, Pezzano A. C&#45;reactive protein elevation and early outc
ome in patients with unstable angina pectoris. Am J Cardiol. 1997; 80 (8): 1002&
#45;6.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#140#136#article#186#</font><
/p>     ^cY#aop02011.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#141#137#article#
186#16#<p><font size="2" face="Verdana">16.  Benamer H, Steg PG, Benessiano J, V
icaut E, Gaultier CJ, Boccara A, et al. Comparison of the prognostic value of C&
#45;reactive protein and troponin I in patients with unstable angina pectoris. A
m J Cardiol. 1998; 82 (7): 845&#45;50.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#142#138#article#186#</font><
/p>     ^cY#aop02011.htm##
00621000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036000090002001300450#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#143#139#article#
186#17#<p><font size="2" face="Verdana">17.  Morrow DA, Rifai N, Antman EM, Wein
er DL, McCabe CH, Cannon CP, et al. C&#45;reactive protein is a potent predictor
 of mortality independently of and in combination with troponin T in acute coron
ary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am 
Coll Cardiol. 1998; 31 (7): 1460&#45;5.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#144#140#article#186#</font><
/p>     ^cY#aop02011.htm##
00577000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031600090002001300406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#145#141#article#
186#18#<p><font size="2" face="Verdana">18.  de Winter RJ, Bholasingh R, Lijmer 
JG, Koster RW, Gorgels JP, Schouten Y, et al.. Independent prognostic value of C
&#45;reactive protein and troponin I in patients with unstable angina or non&#45
;Q&#45;wave myocardial infarction. Cardiovasc Res. 1999; 42 (1): 240&#45;5.    ^
cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#146#142#article#186#</font><
/p>     ^cY#aop02011.htm##
00630000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036900090002001300459#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#147#143#article#
186#19#<p><font size="2" face="Verdana">19.  Heeschen C, Hamm CW, Bruemmer J, Si
moons ML. Predictive value of C&#45;reactive protein and troponin T in patients 
with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7
E3 AntiPlatelet Therapy in Unstable angina Refractory to standard treatment tria
l. J Am Coll Cardiol. 2000; 35 (6): 1535&#45;42.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#148#144#article#186#</font><
/p>     ^cY#aop02011.htm##
00594000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033300090002001300423#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#149#145#article#
186#20#<p><font size="2" face="Verdana">20.  James SK, Armstrong P, Barnathan E,
 Califf R, Lindahl B, Siegbahn A, et al. Troponin and C&#45;reactive protein hav
e different relations to subsequent mortality and myocardial infarction after ac
ute coronary syndrome: a GUSTO&#45;IV substudy. J Am Coll Cardiol. 2003; 41 (6):
 916&#45;24.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#150#146#article#186#</font><
/p>     ^cY#aop02011.htm##
00541000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028000090002001300370#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#151#147#article#
186#21#<p><font size="2" face="Verdana">21.  Oltrona L, Ottani F, Galvani M. Cli
nical significance of a single measurement of troponin&#45;I and C&#45;reactive 
protein at admission in 1773 consecutive patients with acute coronary syndromes.
 Am Heart J. 2004; 148 (3): 405&#45;15.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#152#148#article#186#</font><
/p>     ^cY#aop02011.htm##
00569000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030800090002001300398#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#153#149#article#
186#22#<p><font size="2" face="Verdana">22.  Bodi V, Sanchis J, Llacer A, Facila
 L, Nunez J, Bertomeu V, et al. Risk stratification in non&#45;ST elevation acut
e coronary syndromes: predictive power of troponin I, C&#45;reactive protein, fi
brinogen and homocysteine. Int J Cardiol. 2005; 98 (2): 277&#45;83.    ^cY#aop02
011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#154#150#article#186#</font><
/p>     ^cY#aop02011.htm##
00661000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704040000090002001300490#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#155#151#article#
186#23#<p><font size="2" face="Verdana">23.  Bogaty P, Boyer L, Simard S, Dauwe 
F, Dupuis R, Verret B, et al. Clinical utility of C&#45;reactive protein measure
d at admission, hospital discharge, and 1 month later to predict outcome in pati
ents with acute coronary disease. The RISCA (recurrence and inflammation in the 
acute coronary syndromes) study. J Am Coll Cardiol. 2008; 51 (24): 2339&#45;46. 
   ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#156#152#article#186#</font><
/p>     ^cY#aop02011.htm##
00516000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025500090002001300345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#157#153#article#
186#24#<p><font size="2" face="Verdana">24.  Scirica BM, Morrow DA, Cannon CP, d
e Lemos JA, Murphy S, Sabatine MS, et al. Clinical application of C&#45;reactive
 protein across the spectrum of acute coronary syndromes. Clin Chem. 2007; 53 (1
): 1800&#45;7.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#158#154#article#186#</font><
/p>     ^cY#aop02011.htm##
00794000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704053300090002001300623#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#159#155#article#
186#25#<p><font size="2" face="Verdana">25.  Kuch B, von Scheidt W, Kling B, Hei
er M, Hoermann A, Meisinger C. Differential impact of admission C&#45;reactive p
rotein levels on 28&#45;day mortality risk in patients with ST&#45;elevation ver
sus non&#45;ST&#45;elevation myocardial infarction (from the Monitoring Trends a
nd Determinants on Cardiovascular Diseases &#91;MONICA&#93;/Cooperative Health R
esearch in the Region of Augsburg &#91;KORA&#93; Augsburg Myocardial Infarction 
Registry). Am J Cardiol. 2008; 102 (9): 1125&#45;30.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#160#156#article#186#</font><
/p>     ^cY#aop02011.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031100090002001300401#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#161#157#article#
186#26#<p><font size="2" face="Verdana">26.  Foussas SG, Zairis MN, Lyras AG, Pa
tsourakos NG, Tsirimpis VG, Katsaros K, et al. Early prognostic usefulness of C&
#45;reactive protein added to the Thrombolysis In Myocardial Infarction risk sco
re in acute coronary syndromes. Am J Cardiol. 2005; 96 (4): 533&#45;7.    ^cY#ao
p02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#162#158#article#186#</font><
/p>     ^cY#aop02011.htm##
00592000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033100090002001300421#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#163#159#article#
186#27#<p><font size="2" face="Verdana">27.  Mueller C, Buettner HJ, Hodgson JM,
 Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long&#45;term morta
lity after Non&#45;ST elevation acute coronary syndrome treated with a very earl
y invasive strategy in 1042 consecutive patients. Circulation. 2002; 105 (12): 1
412&#45;5.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#164#160#article#186#</font><
/p>     ^cY#aop02011.htm##
00506000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024500090002001300335#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#165#161#article#
186#28#<p><font size="2" face="Verdana">28.  Duarte ER, Pellanda LC, Portal VL. 
Inflammatory, lipid, and metabolic profile in acute ischemic syndrome: correlati
on with hospital and posthospital events. Arq Bras Cardiol. 2005; 84 (2): 122&#4
5;9.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#166#162#article#186#</font><
/p>     ^cY#aop02011.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023700090002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#167#163#article#
186#29#<p><font size="2" face="Verdana">29.  Manenti ER, Bodanese LC, Camey SA, 
Polanczyk CA. Prognostic value of serum biomarkers in association with TIMI risk
 score for acute coronary syndromes. Clin Cardiol. 2006; 29 (9): 405&#45;10.    
^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#168#164#article#186#</font><
/p>     ^cY#aop02011.htm##
00577000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031600090002001300406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#169#165#article#
186#30#<p><font size="2" face="Verdana">30.  Correia LC, Lima JC, Rocha MS, D'Ol
iveira JA, Pericles EJ. Does high&#45;sensitivity C&#45;reactive protein add pro
gnostic value to the TIMI&#45;Risk Score in individuals with non&#45;ST elevatio
n acute coronary syndromes? Clin Chim Acta. 2007; 375 (1&#45;2): 124&#45;8.    ^
cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#170#166#article#186#</font><
/p>     ^cY#aop02011.htm##
00513000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025200090002001300342#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#171#167#article#
186#31#<p><font size="2" face="Verdana">31.  Ferreiros ER, Boissonnet CP, Pizarr
o R, Merletti PF, Corrado G, Cagide A, et al.  Independent prognostic value of e
levated C&#45;reactive protein in unstable angina. Circulation. 1999;100 (19): 1
958&#45;63.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#172#168#article#186#</font><
/p>     ^cY#aop02011.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#173#169#article#
186#32#<p><font size="2" face="Verdana">32.  Biasucci LM, Liuzzo G, Grillo RL, C
aligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C&#45;reactive prote
in at discharge in patients with unstable angina predict recurrent instability. 
Circulation. 1999; 99 (7): 855&#45;60.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#174#170#article#186#</font><
/p>     ^cY#aop02011.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020100090002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#175#171#article#
186#33#<p><font size="2" face="Verdana">33.  O'Donoghue M, Morrow DA. The future
 of biomarkers in the management of patients with acute coronary syndromes. Curr
 Opin Cardiol. 2008; 23 (4): 309&#45;14.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#176#172#article#186#</font><
/p>     ^cY#aop02011.htm##
00414000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704015300090002001300243#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#177#173#article#
186#34#<p><font size="2" face="Verdana">34.  Wilson PW. Challenges to improve co
ronary heart disease risk assessment. JAMA. 2009; 302 (21): 2369&#45;70.    ^cY#
aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#178#174#article#186#</font><
/p>     ^cY#aop02011.htm##
00498000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023700090002001300327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#179#175#article#
186#35#<p><font size="2" face="Verdana">35.  Lloyd&#45;Jones DM, Liu K, Tian L, 
Greenland P. Narrative review: assessment of C&#45;reactive protein in risk pred
iction for cardiovascular disease. Ann Intern Med. 2006; 145 (1): 35&#45;42.    
^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#180#176#article#186#</font><
/p>     ^cY#aop02011.htm##
00508000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024700090002001300337#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#181#177#article#
186#36#<p><font size="2" face="Verdana">36.  Wang TJ, Gona P, Larson MG, Tofler 
GH, Levy D, Newton&#45;Cheh C, et al. Multiple biomarkers for the prediction of 
first major cardiovascular events and death. N Engl J Med. 2006; 355 (25): 2631&
#45;9.    ^cY#aop02011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#182#178#article#186#</font><
/p>     ^cY#aop02011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#183#179#article#186#<p>&nbsp
;</p>     ^cY#aop02011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#184#180#article#186#<p>&nbsp
;</p>     ^cY#aop02011.htm##
00412000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016600087002001300253#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#185#181#article#186#<p><font
 size="2" face="Verdana"><b><a name="nt"></a><a href="#tx"><img src="/img/revist
as/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:</b>    ^cY#ao
p02011.htm##
00286000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004000087002001300127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#186#182#article#186#<br>   L
u&iacute;s C. L. Correia    ^cY#aop02011.htm##
00311000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006500087002001300152#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#187#183#article#186#<br>   A
v. Princesa Leopoldina 19/402 &#150; Gra&ccedil;a    ^cY#aop02011.htm##
00303000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005700087002001300144#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#188#184#article#186#<br>   4
0150080 &#150; Salvador, BA &#150; Brasil    ^cY#aop02011.htm##
00415000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016900087002001300256#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#189#185#article#186#<br>   E
&#45;mail: <a href="mailto:lccorreia@cardiol.br">lccorreia@cardiol.br</a>, <a hr
ef="mailto:lccorreia@terra.com.br">lccorreia@terra.com.br</a></font></p>     ^cY
#aop02011.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704013300087002001300220#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02011.htm#S#p#190#186#article#186#<p><font
 size="2" face="Verdana"> Artigo recebido em 11/01/10; revisado recebido em 14/0
4/10; aceito em 17/05/10.</font></p>     ^cY#aop02011.htm##
00777000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100014001030100
01800117010001500135010001900150012019500169030001300364065000900377064000500386
03100040039103200030039501400080039886500090040600200130041503500100042880100130
0438#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#c#191#1#ar
ticle#36#1#^rND^sLindahl^nB#^rND^sToss^nH#^rND^sSiegbahn^nA#^rND^sVenge^nP#^rND^
sWallentin^nL#Markers of myocardial damage and inflammation in relation to long-
term mortality in unstable coronary artery disease: FRISC Study Group. Fragmin d
uring Instability in Coronary Artery Disease^len#N Engl J Med#20000000#2000#343#
16#1139-47#20110000#aop02011.htm#0028-4793#N Engl J Med##
00557000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100017001010100
01600118012003700134030001200171065000900183064000500192031000400197032000200201
014000800203865000900211002001300220035001000233801001200243#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02011.htm#S#c#192#2#article#36#2#^rND^sLibby^n
P#^rND^sRidker^nPM#^rND^sMaseri^nA#Inflammation and atherosclerosis^len#Circulat
ion#20020000#2002#105#9#1135-43#20110000#aop02011.htm#0009-7322#Circulation##
00663000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100019001020100
01600121010001900137010001400156010001600170012005600186030001300242065000900255
06400050026403100040026903200020027301400050027586500090028000200130028903500100
0302801001300312#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#
S#c#193#3#article#36#3#^rND^sBuffon^nA#^rND^sBiasucci^nLM#^rND^sLiuzzo^nG#^rND^s
D'Onofrio^nG#^rND^sCrea^nF#^rND^sMaseri^nA#Widespread coronary inflammation in u
nstable angina^len#N Engl J Med#20020000#2002#347#1#5-12#20110000#aop02011.htm#0
028-4793#N Engl J Med##
00596000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100016001010100
01700117012008000134030001000214065000900224064000500233031000300238032000300241
014000800244865000900252002001300261035001000274801001000284#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02011.htm#S#c#194#4#article#36#4#^rND^sRifai^n
N#^rND^sTracy^nRP#^rND^sRidker^nPM#Clinical efficacy of an automated high-sensit
ivity C-reactive protein assay^len#Clin Chem#19990000#1999#45#12#2136-41#2011000
0#aop02011.htm#0009-9147#Clin Chem##
00848000000000361000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030100
01600120010001600136010001800152010001800170010002600188810000600214012017900220
03000120039906500090041106400050042003100040042503200030042901400100043286500090
0442002001300451035001000464801001200474#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop02011.htm#S#c#195#5#article#36#5#^rND^sMorrow^nDA#^rND^sCannon^nCP
#^rND^sJesse^nRL#^rND^sNewby^nLK#^rND^sRavkilde^nJ#^rND^sStorrow^nAB#^rND^sNACB 
WRITING^nGROUP#et al#National Academy of Clinical Biochemistry Laboratory Medici
ne Practice Guidelines: Clinical Characteristics and Utilization of Biochemical 
Markers in Acute Coronary Syndromes^len#Circulation#20070000#2007#115#13#e356-e3
75#20110000#aop02011.htm#0009-7322#Circulation##
00741000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100018001040100
01700122010002100139010001800160012014300178030001700321065000900338064000500347
03100030035203200020035501400090035786500090036600200130037503500100038880100170
0398#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#c#196#6#ar
ticle#36#6#^rND^sNicolau^nJC#^rND^sTimerman^nA#^rND^sPiegas^nLS#^rND^sMarin Neto
^nJA#^rND^sRassi Jr^nA#Guidelines for unstable angina and non-ST-segment elevati
on myocardial infarction of the Brazilian Society of Cardiology (II Edition,2007
)^len#Arq Bras Cardiol#20070000#2007#89#4#e89-e131#20110000#aop02011.htm#0066-78
2X#Arq Bras Cardiol##
01319000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100016001050100
01700121010001800138010001700156010001700173810000600190012067800196030001800874
06500090089206400050090103100030090603200020090901400080091186500090091900200130
0928035001000941801001800951#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#197#7#article#36#7#^rND^sAnderson^nJL#^rND^sAdams^nCD#^rND^sAntm
an^nEM#^rND^sBridges^nCR#^rND^sCaliff^nRM#^rND^sCasey^nDEJ#et al#ACC/AHA 2007 Gu
idelines for the Management of Patients With Unstable Angina/Non-ST-Elevation My
ocardial Infarction: A Report of the American College of Cardiology/American Hea
rt Association Task Force on Practice Guidelines (Writing Committee to Revise th
e 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Ele
vation Myocardial Infarction) Developed in Collaboration with the American Colle
ge of Emergency Physicians, the Society for Cardiovascular Angiography and Inter
ventions, and the Society of Thoracic Surgeons Endorsed by the American Associat
ion of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic 
Emergency Medicine^len#J Am Coll Cardiol#20070000#2007#50#7#e1-e157#20110000#aop
02011.htm#0735-1097#J Am Coll Cardiol##
00876000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100015001040100
01900119010001700138010001500155010002600170810000600196012023900202030001200441
06500090045306400050046203100030046703200030047001400090047386500090048200200130
0491035001000504801001200514#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#198#8#article#36#8#^rND^sBassand^nJP#^rND^sHamm^nCW#^rND^sArdiss
ino^nD#^rND^sBoersma^nE#^rND^sBudaj^nA#^rND^sFernandez-Aviles^nF#et al#Guideline
s for the diagnosis and treatment of non-ST-segment elevation acute coronary syn
dromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevati
on Acute Coronary Syndromes of the European Society of Cardiology^len#Eur Heart 
J#20070000#2007#28#13#1598-660#20110000#aop02011.htm#0195-668X#Eur Heart J##
00602000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100017001020100
01600119010001400135010002100149012006600170030002100236710000200257065000900259
064000500268031000200273014000300275865000900278002001300287#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02011.htm#S#c#199#9#article#36#9#^rND^sZamora^
nJ#^rND^sAbraira^nV#^rND^sMuriel^nA#^rND^sKhan^nK#^rND^sCoomarasamy^nA#Meta-DiSc
: a software for meta-analysis of test accuracy data^len#BMC Med Res Methodol#2#
20060000#2006#6#31#20110000#aop02011.htm##
00584000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100013001010100
01500114010001600129012008500145030002100230710000200251065000900253064000500262
031000200267014000300269865000900272002001300281#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02011.htm#S#c#200#10#article#36#10#^rND^sBax^nL#^rND^sYu^n
LM#^rND^sIkeda^nN#^rND^sMoons^nKG#A systematic comparison of software dedicated 
to meta-analysis of causal studies^len#BMC Med Res Methodol#2#20070000#2007#7#40
#20110000#aop02011.htm##
00624000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01800121012010600139030001000245065000900255064000500264031000300269032000200272
014000600274865000900280002001300289035001000302801001000312#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02011.htm#S#c#201#11#article#36#11#^rND^sTanak
a^nH#^rND^sTsurumi^nY#^rND^sKasanuki^nH#Prognostic value of C-reactive protein a
nd troponin T level in patients with unstable angina pectoris^len#J Cardiol#2006
0000#2006#47#4#173-9#20110000#aop02011.htm#0914-5087#J Cardiol##
00726000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01800119010001400137010001900151010001500170810000600185012014000191030000700331
71000020033806500090034006400050034903100030035403200020035701400070035986500090
0366002001300375#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#
S#c#202#12#article#36#12#^rND^sKosuge^nM#^rND^sEbina^nT#^rND^sIshikawa^nT#^rND^s
Hibi^nK#^rND^sTsukahara^nK#^rND^sOkuda^nJ#et al#Serum amyloid A is a better pred
ictor of clinical outcomes than C-reactive protein in non-ST-segment elevation a
cute coronary syndromes^len#Circ J#2#20070000#2007#71#2#186-90#20110000#aop02011
.htm##
00730000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
01700123010001800140010001800158010001800176012011100194030001300305065000900318
06400050032703100040033203200030033601400080033986500090034700200130035603500100
0369801001300379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#
S#c#203#13#article#36#13#^rND^sBaeza^nVR#^rND^sCorbalan^nHR#^rND^sCastro^nGP#^rN
D^sAcevedo^nBM#^rND^sQuiroga^nGT#^rND^sViviani^nGP#Coronary biomarkers and long-
term clinical outcome in acute coronary syndrome without ST segment elevation^le
n#Rev Med Chil#20050000#2005#133#11#1285-93#20110000#aop02011.htm#0034-9887#Rev 
Med Chil##
00736000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
02000123010001700143010001800160010001600178810000600194012010100200030001300301
06500090031406400050032303100040032803200020033201400070033486500090034100200130
0350035001000363801001300373#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#204#14#article#36#14#^rND^sLiuzzo^nG#^rND^sBiasucci^nLM#^rND^sGa
llimore^nJR#^rND^sGrillo^nRL#^rND^sRebuzzi^nAG#^rND^sPepys^nMB#et al#The prognos
tic value of C-reactive protein and serum amyloid a protein in severe unstable a
ngina^len#N Engl J Med#19940000#1994#331#7#417-24#20110000#aop02011.htm#0028-479
3#N Engl J Med##
00707000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01800124010001700142010001600159010001700175012009300192030001300285065000900298
06400050030703100030031203200020031501400070031786500090032400200130033303500100
0346801001300356#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#
S#c#205#15#article#36#15#^rND^sOltrona^nL#^rND^sArdissino^nD#^rND^sMerlini^nPA#^
rND^sSpinola^nA#^rND^sChiodo^nF#^rND^sPezzano^nA#C-reactive protein elevation an
d early outcome in patients with unstable angina pectoris^len#Am J Cardiol#19970
000#1997#80#8#1002-6#20110000#aop02011.htm#0002-9149#Am J Cardiol##
00750000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
02000120010001600140010001900156010001700175810000600192012011800198030001300316
06500090032906400050033803100030034303200020034601400070034886500090035500200130
0364035001000377801001300387#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#206#16#article#36#16#^rND^sBenamer^nH#^rND^sSteg^nPG#^rND^sBenes
siano^nJ#^rND^sVicaut^nE#^rND^sGaultier^nCJ#^rND^sBoccara^nA#et al#Comparison of
 the prognostic value of C-reactive protein and troponin I in patients with unst
able angina pectoris^len#Am J Cardiol#19980000#1998#82#7#845-50#20110000#aop0201
1.htm#0002-9149#Am J Cardiol##
00836000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01700120010001700137010001700154010001700171810000600188012019800194030001800392
06500090041006400050041903100030042403200020042701400070042986500090043600200130
0445035001000458801001800468#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#207#17#article#36#17#^rND^sMorrow^nDA#^rND^sRifai^nN#^rND^sAntma
n^nEM#^rND^sWeiner^nDL#^rND^sMcCabe^nCH#^rND^sCannon^nCP#et al#C-reactive protei
n is a potent predictor of mortality independently of and in combination with tr
oponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myoca
rdial Infarction^len#J Am Coll Cardiol#19980000#1998#31#7#1460-5#20110000#aop020
11.htm#0735-1097#J Am Coll Cardiol##
00780000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100020001080100
01700128010001700145010001800162010001800180810000600198012013900204030001500343
06500090035806400050036703100030037203200020037501400060037786500090038300200130
0392035001000405801001500415#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#208#18#article#36#18#^rND^sde Winter^nRJ#^rND^sBholasingh^nR#^rN
D^sLijmer^nJG#^rND^sKoster^nRW#^rND^sGorgels^nJP#^rND^sSchouten^nY#et al#Indepen
dent prognostic value of C-reactive protein and troponin I in patients with unst
able angina or non-Q-wave myocardial infarction^len#Cardiovasc Res#19990000#1999
#42#1#240-5#20110000#aop02011.htm#0008-6363#Cardiovasc Res##
00798000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01800121010001800139012023200157030001800389065000900407064000500416031000300421
032000200424014000800426865000900434002001300443035001000456801001800466#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#c#209#19#article#36#19
#^rND^sHeeschen^nC#^rND^sHamm^nCW#^rND^sBruemmer^nJ#^rND^sSimoons^nML#Predictive
 value of C-reactive protein and troponin T in patients with unstable angina: a 
comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy 
in Unstable angina Refractory to standard treatment trial^len#J Am Coll Cardiol#
20000000#2000#35#6#1535-42#20110000#aop02011.htm#0735-1097#J Am Coll Cardiol##
00805000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
01900123010001600142010001700158010001800175810000600193012016200199030001800361
06500090037906400050038803100030039303200020039601400070039886500090040500200130
0414035001000427801001800437#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#210#20#article#36#20#^rND^sJames^nSK#^rND^sArmstrong^nP#^rND^sBa
rnathan^nE#^rND^sCaliff^nR#^rND^sLindahl^nB#^rND^sSiegbahn^nA#et al#Troponin and
 C-reactive protein have different relations to subsequent mortality and myocard
ial infarction after acute coronary syndrome: a GUSTO-IV substudy^len#J Am Coll 
Cardiol#20030000#2003#41#6#916-24#20110000#aop02011.htm#0735-1097#J Am Coll Card
iol##
00680000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01700121012015900138030001100297065000900308064000500317031000400322032000200326
014000700328865000900335002001300344035001000357801001100367#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02011.htm#S#c#211#21#article#36#21#^rND^sOltro
na^nL#^rND^sOttani^nF#^rND^sGalvani^nM#Clinical significance of a single measure
ment of troponin-I and C-reactive protein at admission in 1773 consecutive patie
nts with acute coronary syndromes^len#Am Heart J#20040000#2004#148#3#405-15#2011
0000#aop02011.htm#0002-8703#Am Heart J##
00776000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100017001020100
01600119010001600135010001500151010001800166810000600184012015000190030001400340
06500090035406400050036303100030036803200020037101400070037386500090038000200130
0389035001000402801001400412#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#212#22#article#36#22#^rND^sBodi^nV#^rND^sSanchis^nJ#^rND^sLlacer
^nA#^rND^sFacila^nL#^rND^sNunez^nJ#^rND^sBertomeu^nV#et al#Risk stratification i
n non-ST elevation acute coronary syndromes: predictive power of troponin I, C-r
eactive protein, fibrinogen and homocysteine^len#Int J Cardiol#20050000#2005#98#
2#277-83#20110000#aop02011.htm#0167-5273#Int J Cardiol##
00876000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01600119010001500135010001600150010001600166810000600182012024200188030001800430
06500090044806400050045703100030046203200030046501400080046886500090047600200130
0485035001000498801001800508#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#213#23#article#36#23#^rND^sBogaty^nP#^rND^sBoyer^nL#^rND^sSimard
^nS#^rND^sDauwe^nF#^rND^sDupuis^nR#^rND^sVerret^nB#et al#Clinical utility of C-r
eactive protein measured at admission, hospital discharge, and 1 month later to 
predict outcome in patients with acute coronary disease: The RISCA (recurrence a
nd inflammation in the acute coronary syndromes) study^len#J Am Coll Cardiol#200
80000#2008#51#24#2339-46#20110000#aop02011.htm#0735-1097#J Am Coll Cardiol##
00723000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01700123010001900140010001600159010001900175810000600194012009500200030001000295
06500090030506400050031403100030031903200020032201400070032486500090033100200130
0340035001000353801001000363#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#214#24#article#36#24#^rND^sScirica^nBM#^rND^sMorrow^nDA#^rND^sCa
nnon^nCP#^rND^sde Lemos^nJA#^rND^sMurphy^nS#^rND^sSabatine^nMS#et al#Clinical ap
plication of C-reactive protein across the spectrum of acute coronary syndromes^
len#Clin Chem#20070000#2007#53#1#1800-7#20110000#aop02011.htm#0009-9147#Clin Che
m##
00929000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100021001020100
01500123010001500138010001800153010001900171012034700190030001400537710000200551
06500090055306400050056203100040056703200020057101400080057386500090058100200130
0590#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#c#215#25#a
rticle#36#25#^rND^sKuch^nB#^rND^svon Scheidt^nW#^rND^sKling^nB#^rND^sHeier^nM#^r
ND^sHoermann^nA#^rND^sMeisinger^nC#Differential impact of admission C-reactive p
rotein levels on 28-day mortality risk in patients with ST-elevation versus non-
ST-elevation myocardial infarction (from the Monitoring Trends and Determinants 
on Cardiovascular Diseases [MONICA]/Cooperative Health Research in the Region of
 Augsburg [KORA] Augsburg Myocardial Infarction Registry)^len#Am J Cardiol.#2#20
080000#2008#102#9#1125-30#20110000#aop02011.htm##
00782000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01600123010002200139010002000161010001800181810000600199012014400205030001300349
06500090036206400050037103100030037603200020037901400060038186500090038700200130
0396035001000409801001300419#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#216#26#article#36#26#^rND^sFoussas^nSG#^rND^sZairis^nMN#^rND^sLy
ras^nAG#^rND^sPatsourakos^nNG#^rND^sTsirimpis^nVG#^rND^sKatsaros^nK#et al#Early 
prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocard
ial Infarction risk score in acute coronary syndromes^len#Am J Cardiol#20050000#
2005#96#4#533-7#20110000#aop02011.htm#0002-9149#Am J Cardiol##
00797000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01800124010001600142010002100158010001700179810000600196012016100202030001200363
06500090037506400050038403100040038903200030039301400070039686500090040300200130
0412035001000425801001200435#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#217#27#article#36#27#^rND^sMueller^nC#^rND^sBuettner^nHJ#^rND^sH
odgson^nJM#^rND^sMarsch^nS#^rND^sPerruchoud^nAP#^rND^sRoskamm^nH#et al#Inflammat
ion and long-term mortality after Non-ST elevation acute coronary syndrome treat
ed with a very early invasive strategy in 1042 consecutive patients^len#Circulat
ion#20020000#2002#105#12#1412-5#20110000#aop02011.htm#0009-7322#Circulation##
00659000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01700124012012500141030001700266065000900283064000500292031000300297032000200300
014000600302865000900308002001300317035001000330801001700340#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02011.htm#S#c#218#28#article#36#28#^rND^sDuart
e^nER#^rND^sPellanda^nLC#^rND^sPortal^nVL#Inflammatory, lipid, and metabolic pro
file in acute ischemic syndrome: correlation with hospital and posthospital even
ts^len#Arq Bras Cardiol#20050000#2005#84#2#122-9#20110000#aop02011.htm#0066-782X
#Arq Bras Cardiol##
00665000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01600125010002000141012010600161030001300267065000900280064000500289031000300294
032000200297014000700299865000900306002001300315035001000328801001300338#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#c#219#29#article#36#29
#^rND^sManenti^nER#^rND^sBodanese^nLC#^rND^sCamey^nSA#^rND^sPolanczyk^nCA#Progno
stic value of serum biomarkers in association with TIMI risk score for acute cor
onary syndromes^len#Clin Cardiol#20060000#2006#29#9#405-10#20110000#aop02011.htm
#0160-9289#Clin Cardiol##
00744000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01600121010002100137010001900158012015100177030001500328065000900343064000500352
03100040035703200040036101400060036586500090037100200130038003500100039380100150
0403#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#c#220#30#a
rticle#36#30#^rND^sCorreia^nLC#^rND^sLima^nJC#^rND^sRocha^nMS#^rND^sD'Oliveira^n
JA#^rND^sPericles^nEJ#Does high-sensitivity C-reactive protein add prognostic va
lue to the TIMI-Risk Score in individuals with non-ST elevation acute coronary s
yndromes^len#Clin Chim Acta#20070000#2007#375#1-2#124-8#20110000#aop02011.htm#00
09-8981#Clin Chim Acta##
00722000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100021001080100
01700129010001900146010001700165010001600182810000600198012008300204030001200287
06500090029906400050030803100040031303200030031701400080032086500090032800200130
0337035001000350801001200360#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#221#31#article#36#31#^rND^sFerreiros^nER#^rND^sBoissonnet^nCP#^r
ND^sPizarro^nR#^rND^sMerletti^nPF#^rND^sCorrado^nG#^rND^sCagide^nA#et al#Indepen
dent prognostic value of elevated C-reactive protein in unstable angina^len#Circ
ulation#19990000#1999#100#19#1958-63#20110000#aop02011.htm#0009-7322#Circulation
##
00749000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01700123010001900140010001800159010001600177810000600193012011800199030001200317
06500090032906400050033803100030034303200020034601400070034886500090035500200130
0364035001000377801001200387#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#222#32#article#36#32#^rND^sBiasucci^nLM#^rND^sLiuzzo^nG#^rND^sGr
illo^nRL#^rND^sCaligiuri^nG#^rND^sRebuzzi^nAG#^rND^sBuffon^nA#et al#Elevated lev
els of C-reactive protein at discharge in patients with unstable angina predict 
recurrent instability^len#Circulation#19990000#1999#99#7#855-60#20110000#aop0201
1.htm#0009-7322#Circulation##
00598000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100017001080120
08900125030001800214065000900232064000500241031000300246032000200249014000700251
865000900258002001300267035001000280801001800290#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02011.htm#S#c#223#33#article#36#33#^rND^sO'Donoghue^nM#^rN
D^sMorrow^nDA#The future of biomarkers in the management of patients with acute 
coronary syndromes^len#Curr Opin Cardiol#20080000#2008#23#4#309-14#20110000#aop0
2011.htm#0268-4705#Curr Opin Cardiol##
00519000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120065001050300
00500170065000900175064000500184031000400189032000300193014000800196865000900204
002001300213035001000226801000500236#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02011.htm#S#c#224#34#article#36#34#^rND^sWilson^nPW#Challenges to impr
ove coronary heart disease risk assessment^len#JAMA#20090000#2009#302#21#2369-70
#20110000#aop02011.htm#0098-7484#JAMA##
00659000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880100013001100100
01400123010001900137012010100156030001500257065000900272064000500281031000400286
032000200290014000600292865000900298002001300307035001000320801001500330#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02011.htm#S#c#225#35#article#36#35
#^rND^sLloyd-Jones^nDM#^rND^sLiu^nK#^rND^sTian^nL#^rND^sGreenland^nP#Narrative r
eview: assessment of C-reactive protein in risk prediction for cardiovascular di
sease^len#Ann Intern Med#20060000#2006#145#1#35-42#20110000#aop02011.htm#0003-48
19#Ann Intern Med##
00718000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100014001030100
01700117010001700134010001400151010002100165810000600186012009000192030001300282
06500090029506400050030403100040030903200030031301400070031686500090032300200130
0332035001000345801001300355#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02011.htm#S#c#226#36#article#36#36#^rND^sWang^nTJ#^rND^sGona^nP#^rND^sLarson^n
MG#^rND^sTofler^nGH#^rND^sLevy^nD#^rND^sNewton-Cheh^nC#et al#Multiple biomarkers
 for the prediction of first major cardiovascular events and death^len#N Engl J 
Med#20060000#2006#355#25#2631-9#20110000#aop02011.htm#0028-4793#N Engl J Med##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#o#1#1#
article#1#20110331#081003#aop02111.htm#167##
05058000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201130017301201040
02860100031003900100039004210100029004600100030004890100035005190100028005540100
02900582070010600611070006700717070005900784083162400843085000802467085003502475
08500230251008500220253308500260255508315850258108500080416608500330417408500250
42070850023042320850027042551170008042820720003042901120009042931110009043021160
00904311115000904320114000904329113000904338002001304347#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02111.htm#S#h#2#1#article#1#tr#pt#br1.1#1#4.0#TAB#
31#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110318#Associação
 do índice tornozelo-braço com inflamação e alterações minerais ósseas em pacien
tes em hemodiálise^lpt#Association of ankle-arm index with inflammation and mine
ral bone disorder in hemodialysis patients^len#^rND^1A01 A02^nJair B.^sMiguel#^r
ND^1A01^nJorge P. Strogoff de^sMatos#^rND^1A03^nFrederico^sRuzany#^rND^1A02^nCla
udia S.^sMiguel#^rND^1A02^nSebastião J. S.^sMiguel#^rND^1A01^nLuiz T.^sNaveiro#^
rND^1A01^nJocemir R.^sLugon#Universidade Federal Fluminense^iA01^1Departmento de
 Medicina^2Divisão de Nefrologia^cNiteroi^sRJ^pBrasil#Clínica de Doenças Renais^
iA02^cSanto Antônio de Pádua^sRJ^pBrasil#Clínica de Doenças Renais^iA03^cRio de 
Janeiro^sRJ^pBrasil#^lpt^aFUNDAMENTO: O índice tornozelo-braço (ITB) reduzido, i
nflamação e distúrbio mineral ósseo (DMO) estão associados com aumento no risco 
de morte e complicações cardiovasculares em pacientes em hemodiálise (HD), mas a
 relação entre esses fatores necessita ser elucidada. OBJETIVO: Avaliar a associ
ação entre ITB anormal e DMO com inflamação em pacientes em HD. MÉTODOS: Esta an
álise transversal avaliou 478 pacientes em HD por pelo menos 1 ano. O ITB foi av
aliado através de um Doppler portátil e manômetro de coluna de mercúrio. Os paci
entes foram divididos em três grupos, de acordo com o ITB (baixo: <0,9, normal: 
0,9 a 1,3, e alto: &gt;1,3). As medidas de proteína C-reativa foram utilizadas c
omo marcador inflamatório, enquanto a DMO foi avaliada através dos níveis de cál
cio, fósforo e hormônio paratireoidiano intacto (iPTH). RESULTADOS: Os participa
ntes tinham 54 (18 a 75) anos, 56% eram do sexo masculino, 17% eram diabéticos e
 estavam em HM por 5 (1 a 35) anos. A prevalência de ITB baixo, normal e alto AA
I foi 26,8%, 64,6% e 8,6%, respectivamente. Usando um modelo de regressão logíst
ica condicional com procedimento backward, idade (p<0,001), diabetes (p= 0,001),
 e níveis de proteína C-reativa &gt;6 mg/L (p= 0,006) estavam associados com a p
resença de ITB baixo, enquanto o sexo masculino (p<0,001), diabetes (p= 0,001) e
 produto cálcio x fósforo elevado (p= 0,026) estavam associados com ITB alto. CO
NCLUSÃO: Em pacientes em HD, a presença de diabetes estava associada com ITB alt
o e baixo. O risco de ter ITB baixo parece aumentar com a idade e inflamação, en
quanto a DMO estava associada com ITB alto.#^dnd^i1#^tm^lpt^kÍndice tornozelo-br
aço^i1#^tm^lpt^kinflamação^i1#^tm^lpt^kcalcinose^i1#^tm^lpt^kdiálise renal^i1#^l
en^aBACKGROUND: Reduced ankle-arm index (AAI), inflammation and mineral bone dis
order (MBD) are all associated with increased risk of death and cardiovascular c
omplications in patients on hemodialysis (HD), but the association between them 
deserves clarification. OBJECTIVE: To evaluate the association between abnormal 
AAI with MBD and inflammation in patients on HD. METHODS: This was a cross-secti
onal analysis of 478 patients on hemodialysis for at least one year. The AAI was
 evaluated using a portable Doppler and mercury column manometer. Patients were 
divided into 3 groups, according to AAI (low: <0.9, normal: 0.9 to 1.3, and high
: &gt;1.3). C-reactive protein measurement was used as an inflammatory marker, w
hereas MBD was evaluated by calcium, phosphorus and intact parathyroid hormone l
evels. RESULTS: Participants were 54 (18 to 75) years old, 56% males, 17% diabet
ics, and had been on hemodialysis for a mean of 5 (1 to 35) years. The prevalenc
e of low, normal and high AAI was 26.8%, 64.6% and 8.6%, respectively. Using a b
ackward conditional logistic regression model, age (p<0.001), diabetes (p= 0.001
), and C-reactive protein levels &gt;6 mg/L (p= 0.006) were associated with the 
presence of low AAI, whereas male gender (p<0.001), diabetes (p= 0.001) and elev
ated calcium x phosphorus product (p= 0.026) were associated with high AAI. CONC
LUSION: In patients on hemodialysis, the presence of diabetes was associated wit
h both low and high AAI. The risk of having low AAI seems to be increased by agi
ng and inflammation, whereas BMD was associated with high AAI.#^dnd^i2#^tm^len^k
Ankle brachial index^i2#^tm^len^kinflammation^i2#^tm^len^kcalcinosis^i2#^tm^len^
krenal dialysis^i2#vancouv#25#20100816#16/08/10#20101020#20/10/10#20101027#27/10
/10#aop02111.htm##
05181000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201200017301201110
02930100031004040100039004350100029004740100030005030100035005330100028005680100
02900596070010600625070006700731070005900798083168200857085000802539085003502547
08500230258208500220260508500260262708316360265308500080428908500330429708500250
43300850023043550850027043781170008044050720003044131120009044161110009044251160
00904434115000904443114000904452113000904461002001304470#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02111.htm#S#f#3#1#article#1#tr#pt#br1.1#1#4.0#TAB#
31#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110318#<b>Associa
ção do índice tornozelo-braço com inflamação e alterações minerais ósseas em pac
ientes em hemodiálise</b>^lpt#<b>Association of ankle-arm index with inflammatio
n and mineral bone disorder in hemodialysis patients</b>^len#^rND^1A01 A02^nJair
 B.^sMiguel#^rND^1A01^nJorge P. Strogoff de^sMatos#^rND^1A03^nFrederico^sRuzany#
^rND^1A02^nClaudia S.^sMiguel#^rND^1A02^nSebastião J. S.^sMiguel#^rND^1A01^nLuiz
 T.^sNaveiro#^rND^1A01^nJocemir R.^sLugon#Universidade Federal Fluminense^iA01^1
Departmento de Medicina^2Divisão de Nefrologia^cNiteroi^sRJ^pBrasil#Clínica de D
oenças Renais^iA02^cSanto Antônio de Pádua^sRJ^pBrasil#Clínica de Doenças Renais
^iA03^cRio de Janeiro^sRJ^pBrasil#^lpt^a<b>FUNDAMENTO:</b> O índice tornozelo-br
aço (ITB) reduzido, inflamação e distúrbio mineral ósseo (DMO) estão associados 
com aumento no risco de morte e complicações cardiovasculares em pacientes em he
modiálise (HD), mas a relação entre esses fatores necessita ser elucidada. <b>OB
JETIVO:</b> Avaliar a associação entre ITB anormal e DMO com inflamação em pacie
ntes em HD. <b>MÉTODOS:</b> Esta análise transversal avaliou 478 pacientes em HD
 por pelo menos 1 ano. O ITB foi avaliado através de um Doppler portátil e manôm
etro de coluna de mercúrio. Os pacientes foram divididos em três grupos, de acor
do com o ITB (baixo: &lt;0,9, normal: 0,9 a 1,3, e alto: &gt;1,3). As medidas de
 proteína C-reativa foram utilizadas como marcador inflamatório, enquanto a DMO 
foi avaliada através dos níveis de cálcio, fósforo e hormônio paratireoidiano in
tacto (iPTH). <b>RESULTADOS:</b> Os participantes tinham 54 (18 a 75) anos, 56% 
eram do sexo masculino, 17% eram diabéticos e estavam em HM por 5 (1 a 35) anos.
 A prevalência de ITB baixo, normal e alto AAI foi 26,8%, 64,6% e 8,6%, respecti
vamente. Usando um modelo de regressão logística condicional com procedimento <i
>backward</i>, idade (p&lt;0,001), diabetes (p= 0,001), e níveis de proteína C-r
eativa <u>&gt;</u>6 mg/L (p= 0,006) estavam associados com a presença de ITB bai
xo, enquanto o sexo masculino (p&lt;0,001), diabetes (p= 0,001) e produto cálcio
 x fósforo elevado (p= 0,026) estavam associados com ITB alto. <b>CONCLUSÃO:</b>
 Em pacientes em HD, a presença de diabetes estava associada com ITB alto e baix
o. O risco de ter ITB baixo parece aumentar com a idade e inflamação, enquanto a
 DMO estava associada com ITB alto.#^dnd^i1#^tm^lpt^kÍndice tornozelo-braço^i1#^
tm^lpt^kinflamação^i1#^tm^lpt^kcalcinose^i1#^tm^lpt^kdiálise renal^i1#^len^a<b>B
ACKGROUND:</b> Reduced ankle-arm index (AAI), inflammation and mineral bone diso
rder (MBD) are all associated with increased risk of death and cardiovascular co
mplications in patients on hemodialysis (HD), but the association between them d
eserves clarification. <b>OBJECTIVE:</b> To evaluate the association between abn
ormal AAI with MBD and inflammation in patients on HD. <b>METHODS:</b> This was 
a cross-sectional analysis of 478 patients on hemodialysis for at least one year
. The AAI was evaluated using a portable Doppler and mercury column manometer. P
atients were divided into 3 groups, according to AAI (low: &lt;0.9, normal: 0.9 
to 1.3, and high: &gt;1.3). C-reactive protein measurement was used as an inflam
matory marker, whereas MBD was evaluated by calcium, phosphorus and intact parat
hyroid hormone levels. <b>RESULTS:</b> Participants were 54 (18 to 75) years old
, 56% males, 17% diabetics, and had been on hemodialysis for a mean of 5 (1 to 3
5) years. The prevalence of low, normal and high AAI was 26.8%, 64.6% and 8.6%, 
respectively. Using a backward conditional logistic regression model, age (p&lt;
0.001), diabetes (p= 0.001), and C-reactive protein levels <u>&gt;</u>6 mg/L (p=
 0.006) were associated with the presence of low AAI, whereas male gender (p&lt;
0.001), diabetes (p= 0.001) and elevated calcium x phosphorus product (p= 0.026)
 were associated with high AAI. <b>CONCLUSION:</b> In patients on hemodialysis, 
the presence of diabetes was associated with both low and high AAI. The risk of 
having low AAI seems to be increased by aging and inflammation, whereas BMD was 
associated with high AAI.#^dnd^i2#^tm^len^kAnkle brachial index^i2#^tm^len^kinfl
ammation^i2#^tm^len^kcalcinosis^i2#^tm^len^krenal dialysis^i2#vancouv#25#2010081
6#16/08/10#20101020#20/10/10#20101027#27/10/10#aop02111.htm##
05258000000000721000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001201130
01790120104002920100030003960100039004260100029004650100029004940100034005230100
02700557010002800584070010800612070006900720070006100789083166900850085000802519
08500350252708500230256208500220258508500260260708316200263308500080425308500330
42610850025042940850023043190850027043421170008043690720003043771120009043801110
00904389116000904398115000904407114000904416113000904425002001304434008008904447
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#l#4#1#article#
1#^a2011#tr#pt#br1.1#1#4.0#tab#31#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0
#0066-782X#20110318#Associação do índice tornozelo-braço com inflamação e altera
ções minerais ósseas em pacientes em hemodiálise^lpt#Association of ankle-arm in
dex with inflammation and mineral bone disorder in hemodialysis patients^len#^rN
D^1A01 A02^nJair B^sMiguel#^rND^1A01^nJorge P. Strogoff de^sMatos#^rND^1A03^nFre
derico^sRuzany#^rND^1A02^nClaudia S^sMiguel#^rND^1A02^nSebastião J. S^sMiguel#^r
ND^1A01^nLuiz T^sNaveiro#^rND^1A01^nJocemir R^sLugon#^iA01^1Universidade Federal
 Fluminense^2Departmento de Medicina^3Divisão de Nefrologia^cNiteroi^sRJ^pBrasil
#^iA02^1Clínica de Doenças Renais^cSanto Antônio de Pádua^sRJ^pBrasil#^iA03^1Clí
nica de Doenças Renais^cRio de Janeiro^sRJ^pBrasil#^lpt^aFUNDAMENTO: O índice to
rnozelo-braço (ITB) reduzido, inflamação e distúrbio mineral ósseo (DMO) estão a
ssociados com aumento no risco de morte e complicações cardiovasculares em pacie
ntes em hemodiálise (HD), mas a relação entre esses fatores necessita ser elucid
ada. OBJETIVO: Avaliar a associação entre ITB anormal e DMO com inflamação em pa
cientes em HD. MÉTODOS: Esta análise transversal avaliou 478 pacientes em HD por
 pelo menos 1 ano. O ITB foi avaliado através de um Doppler portátil e manômetro
 de coluna de mercúrio. Os pacientes foram divididos em três grupos, de acordo c
om o ITB (baixo: <0,9, normal: 0,9 a 1,3, e alto: &gt;1,3). As medidas de proteí
na C-reativa foram utilizadas como marcador inflamatório, enquanto a DMO foi ava
liada através dos níveis de cálcio, fósforo e hormônio paratireoidiano intacto (
iPTH). RESULTADOS: Os participantes tinham 54 (18 a 75) anos, 56 por cento eram 
do sexo masculino, 17 por cento eram diabéticos e estavam em HM por 5 (1 a 35) a
nos. A prevalência de ITB baixo, normal e alto AAI foi 26,8 por cento, 64,6 por 
cento e 8,6 por cento, respectivamente. Usando um modelo de regressão logística 
condicional com procedimento backward, idade (p<0,001), diabetes (p= 0,001), e n
íveis de proteína C-reativa &gt;6 mg/L (p= 0,006) estavam associados com a prese
nça de ITB baixo, enquanto o sexo masculino (p<0,001), diabetes (p= 0,001) e pro
duto cálcio x fósforo elevado (p= 0,026) estavam associados com ITB alto. CONCLU
SÃO: Em pacientes em HD, a presença de diabetes estava associada com ITB alto e 
baixo. O risco de ter ITB baixo parece aumentar com a idade e inflamação, enquan
to a DMO estava associada com ITB alto.#^dnd^i1#^tm^lpt^kÍndice tornozelo-braço^
i1#^tm^lpt^kinflamação^i1#^tm^lpt^kcalcinose^i1#^tm^lpt^kdiálise renal^i1#^len^a
BACKGROUND: Reduced ankle-arm index (AAI), inflammation and mineral bone disorde
r (MBD) are all associated with increased risk of death and cardiovascular compl
ications in patients on hemodialysis (HD), but the association between them dese
rves clarification. OBJECTIVE: To evaluate the association between abnormal AAI 
with MBD and inflammation in patients on HD. METHODS: This was a cross-sectional
 analysis of 478 patients on hemodialysis for at least one year. The AAI was eva
luated using a portable Doppler and mercury column manometer. Patients were divi
ded into 3 groups, according to AAI (low: <0.9, normal: 0.9 to 1.3, and high: &g
t;1.3). C-reactive protein measurement was used as an inflammatory marker, where
as MBD was evaluated by calcium, phosphorus and intact parathyroid hormone level
s. RESULTS: Participants were 54 (18 to 75) years old, 56 percent males, 17 perc
ent diabetics, and had been on hemodialysis for a mean of 5 (1 to 35) years. The
 prevalence of low, normal and high AAI was 26.8 percent, 64.6 percent and 8.6 p
ercent, respectively. Using a backward conditional logistic regression model, ag
e (p<0.001), diabetes (p= 0.001), and C-reactive protein levels &gt;6 mg/L (p= 0
.006) were associated with the presence of low AAI, whereas male gender (p<0.001
), diabetes (p= 0.001) and elevated calcium x phosphorus product (p= 0.026) were
 associated with high AAI. CONCLUSION: In patients on hemodialysis, the presence
 of diabetes was associated with both low and high AAI. The risk of having low A
AI seems to be increased by aging and inflammation, whereas BMD was associated w
ith high AAI.#^dnd^i2#^tm^len^kAnkle brachial index^i2#^tm^len^kinflammation^i2#
^tm^len^kcalcinosis^i2#^tm^len^krenal dialysis^i2#vancouv#25#20100816#16/08/10#2
0101020#20/10/10#20101027#27/10/10#aop02111.htm#Internet^ihttp://www.scielo.br/s
cielo.php?script=sci_arttext&pid=S0066-782X2011005000031##
00501000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704025900083002001300342#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#5#1#article#138#<p><font siz
e="4" face="verdana"><b><a name="tx"></a>Associa&ccedil;&atilde;o do &iacute;ndi
ce tornozelo&#45;bra&ccedil;o com inflama&ccedil;&atilde;o e altera&ccedil;&otil
de;es minerais &oacute;sseas em pacientes em hemodi&aacute;lise</b></font></p>  
   ^cY#aop02111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#6#2#article#138#<p>&nbsp;</p
>     ^cY#aop02111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#7#3#article#138#<p>&nbsp;</p
>     ^cY#aop02111.htm##
00543000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704030100083002001300384#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#8#4#article#138#<p><font siz
e="2" face="Verdana"><b>Jair B. Miguel<SUP>I,II</SUP>;  Jorge P. Strogoff de Mat
os<SUP>I</SUP>;  Frederico Ruzany<SUP>III</SUP>; Claudia S. Miguel<SUP>II</SUP>;
  Sebasti&atilde;o J. S. Miguel<SUP>II</SUP>;  Luiz T. Naveiro<SUP>I</SUP>;  Joc
emir R. Lugon<SUP>I</SUP></b></font></p>     ^cY#aop02111.htm##
00408000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704016600083002001300249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#9#5#article#138#<p><font siz
e="2" face="Verdana"> <sup>I</sup>Divis&atilde;o de Nefrologia, Departmento de M
edicina, Universidade Federal Fluminense, Niteroi, RJ &#45; Brasil    ^cY#aop021
11.htm##
00375000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704013200084002001300216#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#10#6#article#138#<br>   <sup
>II</sup>Clinefron, Cl&iacute;nica de Doen&ccedil;as Renais, Santo Ant&ocirc;nio
 de P&aacute;dua, RJ &#45; Brasil    ^cY#aop02111.htm##
00361000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704011800084002001300202#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#11#7#article#138#<br>   <sup
>III</sup>CDR, Cl&iacute;nica de Doen&ccedil;as Renais, Rio de Janeiro, RJ &#45;
 Brasil</font></p>     ^cY#aop02111.htm##
00335000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009200084002001300176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#12#8#article#138#<p><font si
ze="2" face="Verdana"><a href="#nt">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop02111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#13#9#article#138#<p>&nbsp;</
p>     ^cY#aop02111.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#14#10#article#138#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop02111.htm##
00310000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704006600085002001300151#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#15#11#article#138#<p><font s
ize="2" face="VERDANA"><B>RESUMO</B></font></p>     ^cY#aop02111.htm##
00647000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040300085002001300488#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#16#12#article#138#<p><font s
ize="2" face="Verdana"><b>FUNDAMENTO:</b> O &iacute;ndice tornozelo&#45;bra&cced
il;o (ITB) reduzido, inflama&ccedil;&atilde;o e dist&uacute;rbio mineral &oacute
;sseo (DMO) est&atilde;o associados com aumento no risco de morte e complica&cce
dil;&otilde;es cardiovasculares em pacientes em hemodi&aacute;lise (HD), mas a r
ela&ccedil;&atilde;o entre esses fatores necessita ser elucidada.    ^cY#aop0211
1.htm##
00383000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013900085002001300224#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#17#13#article#138#<br>   <b>
OBJETIVO:</b> Avaliar a associa&ccedil;&atilde;o entre ITB anormal e DMO com inf
lama&ccedil;&atilde;o em pacientes em HD.    ^cY#aop02111.htm##
00839000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059500085002001300680#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#18#14#article#138#<br>   <b>
M&Eacute;TODOS:</b> Esta an&aacute;lise transversal avaliou 478 pacientes em HD 
por pelo menos 1 ano. O ITB foi avaliado atrav&eacute;s de um Doppler port&aacut
e;til e man&ocirc;metro de coluna de merc&uacute;rio. Os pacientes foram dividid
os em tr&ecirc;s grupos, de acordo com o ITB (baixo: &lt;0,9, normal: 0,9 a 1,3,
 e alto: &gt;1,3). As medidas de prote&iacute;na C&#45;reativa foram utilizadas 
como marcador inflamat&oacute;rio, enquanto a DMO foi avaliada atrav&eacute;s do
s n&iacute;veis de c&aacute;lcio, f&oacute;sforo e horm&ocirc;nio paratireoidian
o intacto (iPTH).    ^cY#aop02111.htm##
00933000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068900085002001300774#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#19#15#article#138#<br>   <b>
RESULTADOS:</b> Os participantes tinham 54 (18 a 75) anos, 56% eram do sexo masc
ulino, 17% eram diab&eacute;ticos e estavam em HM por 5 (1 a 35) anos. A preval&
ecirc;ncia de ITB baixo, normal e alto AAI foi 26,8%, 64,6% e 8,6%, respectivame
nte. Usando um modelo de regress&atilde;o log&iacute;stica condicional com proce
dimento <I>backward</I>, idade (p&lt;0,001), diabetes (p= 0,001), e n&iacute;vei
s de prote&iacute;na C&#45;reativa <u>&gt;</u>6 mg/L (p= 0,006) estavam associad
os com a presen&ccedil;a de ITB baixo, enquanto o sexo masculino (p&lt;0,001), d
iabetes (p= 0,001) e produto c&aacute;lcio x f&oacute;sforo elevado (p= 0,026) e
stavam associados com ITB alto.    ^cY#aop02111.htm##
00511000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026700085002001300352#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#20#16#article#138#<br>   <b>
CONCLUS&Atilde;O:</b> Em pacientes em HD, a presen&ccedil;a de diabetes estava a
ssociada com ITB alto e baixo. O risco de ter ITB baixo parece aumentar com a id
ade e inflama&ccedil;&atilde;o, enquanto a DMO estava associada com ITB alto.</f
ont></p>     ^cY#aop02111.htm##
00447000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020300085002001300288#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#21#17#article#138#<p><font s
ize="2" face="Verdana"><b>Palavras&#45;chave: </b> &Iacute;ndice tornozelo&#45;b
ra&ccedil;o, inflama&ccedil;&atilde;o, calcinose, di&aacute;lise renal.</font></
p> <hr size="1" noshade>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#22#18#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#23#19#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#24#20#article#138#<p><font s
ize="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop021
11.htm##
01472000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122800085002001301313#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#25#21#article#138#<p><font s
ize="2" face="Verdana">A taxa de mortalidade em pacientes com Doen&ccedil;a Rena
l Cr&ocirc;nica (DRC) terminal &eacute; muito alta e a maior causa de morte &eac
ute; doen&ccedil;a cardiovascular (DCV)<SUP>1</SUP>. Esse impacto da DCV tem sid
o atribu&iacute;do &agrave; fatores de risco tradicionais e n&atilde;o&#45;tradi
cionais, que est&atilde;o relacionados &agrave; doen&ccedil;a renal cr&ocirc;nic
a e/ou procedimento de di&aacute;lise. Idade, diabetes mellitus e tabagismo s&at
ilde;o fatores tradicionais tamb&eacute;m aplic&aacute;veis &agrave; pacientes e
m di&aacute;lise<SUP>2</SUP>. Entre os fatores de risco n&atilde;o&#45;tradicion
ais, dist&uacute;rbio mineral &oacute;sseo (DMO), incluindo altos n&iacute;veis 
de f&oacute;sforo, produto c&aacute;lcio x f&oacute;sforo alto e n&iacute;veis s
&eacute;ricos extremos de horm&ocirc;nio paratireoidiano intacto (iPTH) tem sido
 associados com aumento do risco de mortalidade cardiovascular<SUP>3&#45;5</SUP>
. Outro fator de risco n&atilde;o&#45;tradicional para morte cardiovascular &eac
ute; a microinflama&ccedil;&atilde;o, geralmente avaliada atrav&eacute;s dos n&i
acute;veis s&eacute;ricos de prote&iacute;na C&#45;reativa (PCR)<SUP>6</SUP>. </
font></p>     ^cY#aop02111.htm##
01532000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704128800085002001301373#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#26#22#article#138#<p><font s
ize="2" face="Verdana">Al&eacute;m de doen&ccedil;a arterial coronariana e doen&
ccedil;a vascular cerebral, doen&ccedil;a arterial perif&eacute;rica (DAP) tamb&
eacute;m &eacute; altamente prevalente em pacientes em di&aacute;lise e sua pres
en&ccedil;a tem sido associada com alta mortalidade<SUP>7&#45;10</SUP>. O &iacut
e;ndice tornozelo&#45;bra&ccedil;o (ITB) tem sido utilizado como uma ferramenta 
diagn&oacute;stica para DAP<SUP>11</SUP>. O &iacute;ndice &eacute; baseado no fa
to de que a press&atilde;o arterial sist&oacute;lica nas pernas &eacute; geralme
nte igual ou levemente mais alta do que nos membros superiores de indiv&iacute;d
uos saud&aacute;veis. Na presen&ccedil;a de uma estenose arterial, uma redu&cced
il;&atilde;o na press&atilde;o ocorre em posi&ccedil;&atilde;o distal &agrave; l
es&atilde;o<SUP>12</SUP>. Quando a angiografia era utilizada como o padr&atilde;
o&#45;ouro, uma raz&atilde;o ITB &lt; 0.9 era considerada de alta sensibilidade 
e especificidade no diagn&oacute;stico de DAP<SUP>11</SUP>. Al&eacute;m disso, u
m ITB baixo apresenta uma forte correla&ccedil;&atilde;o com doen&ccedil;a arter
ial em outros s&iacute;tios e tem se mostrado um bom preditor de mortalidade na 
popula&ccedil;&atilde;o em geral<SUP>7&#45;10,13,14</SUP>.</font></p>     ^cY#ao
p02111.htm##
00630000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038600085002001300471#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#27#23#article#138#<p><font s
ize="2" face="Verdana">Tanto o ITB baixo quanto o alto tem se mostrado fortes pr
editores de morte em pacientes em hemodi&aacute;lise (HD)<SUP>7&#45;10,13,14</SU
P>. &Eacute; presum&iacute;vel considerar que um ITB alto em pacientes com DRC t
erminal pode ser devido &agrave; calcifica&ccedil;&atilde;o vascular e rigidez d
a parede arterial associada com DMO.</font></p>     ^cY#aop02111.htm##
00538000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029400085002001300379#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#28#24#article#138#<p><font s
ize="2" face="Verdana">O objetivo desse estudo foi avaliar a associa&ccedil;&ati
lde;o entre valores de ITB altos e baixos em pacientes em HD, com v&aacute;rios 
fatores de risco cardiovasculares n&atilde;o&#45;tradicionais, a saber, inflama&
ccedil;&atilde;o e DMO. </font></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#29#25#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00330000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008600085002001300171#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#30#26#article#138#<p><font s
ize="3" face="Verdana"><b>Materiais e m&eacute;todos</b></font></p>     ^cY#aop0
2111.htm##
01040000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079600085002001300881#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#31#27#article#138#<p><font s
ize="2" face="Verdana">Esse &eacute; um estudo transversal e multic&ecirc;ntrico
, realizado em seis cl&iacute;nicas de di&aacute;lise no estado do Rio de Janeir
o, Brasil. O estudo foi aprovado pelo Comit&ecirc; de &Eacute;tica local e todos
 os pacientes assinaram o termo de consentimento informado. Os estudos de imagen
s e medidas do ITB foram realizados entre mar&ccedil;o de 2006 e setembro de 200
7. Todos os pacientes com idade de 18 a 75 anos, que estavam em HD por pelo meno
s 12 meses foram convidados a participar do estudo. Os crit&eacute;rios de exclu
s&atilde;o foram: diagn&oacute;stico de neoplasia, presen&ccedil;a de teste anti
&#45;HIV positivo, fibrila&ccedil;&atilde;o atrial, amputa&ccedil;&atilde;o bila
teral de membros inferiores e dem&ecirc;ncia. </font></p>     ^cY#aop02111.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010300085002001300188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#32#28#article#138#<p><font s
ize="2" face="Verdana"><b>O &iacute;ndice tornozelo&#45;bra&ccedil;o </b></font>
</p>     ^cY#aop02111.htm##
01994000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704175000085002001301835#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#33#29#article#138#<p><font s
ize="2" face="Verdana">Os pacientes foram avaliados uma vez para obten&ccedil;&a
tilde;o do &iacute;ndice tornozelo&#45;bra&ccedil;o (ITB). As medidas foram real
izadas antes da sess&atilde;o de HD, ap&oacute;s 5 minutos na posi&ccedil;&atild
e;o supina. O ITB, definido como a raz&atilde;o entre a press&atilde;o arterial 
sist&oacute;lica do tornozelo e a do bra&ccedil;o, foi medido por tr&ecirc;s obs
ervadores treinados (um m&eacute;dico e dois estudantes de Medicina), com base n
a informa&ccedil;&atilde;o de que a variabilidade inter&#45;observador e intra&#
45;observador para medida de press&atilde;o arterial por Doppler &eacute; insign
ificante<SUP>7,15</SUP>. Nos membros inferiores, as art&eacute;rias posteriores 
tibiais foram utilizadas, considerando que a art&eacute;ria <I>dorsalis pedis</I
> est&aacute; congenitamente ausente em 4 a 12% da popula&ccedil;&atilde;o<SUP>1
1</SUP>. A press&atilde;o arterial sist&oacute;lica (PAS) foi medida duas vezes 
em cada s&iacute;tio, em uma sucess&atilde;o alternada e r&aacute;pida, a fim de
 obter&#45;se um valor m&eacute;dio. Manguitos padr&atilde;o para medir a PA for
am aplicados ao bra&ccedil;o e &agrave; cada tornozelo (com a extremidade inferi
or da p&ecirc;ra posicionada exatamente acima dos mal&eacute;olos). Ap&oacute;s 
a palpa&ccedil;&atilde;o das art&eacute;rias, gel para ultrassom foi aplicado e 
um estetosc&oacute;pio Doppler (10 MHz, Super Dupplex, Huntleigh Technology Inc.
, Manalapan NJ, EUA) foi utilizado para avaliar a PAS. A PAS no membro superior 
foi medida na arterial braquial do bra&ccedil;o contralateral ao acesso vascular
. Para calcular o ITB, a menor m&eacute;dia dos tornozelos foi dividida pela m&e
acute;dia do bra&ccedil;o<SUP>16</SUP>. </font></p>     ^cY#aop02111.htm##
00600000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704035600085002001300441#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#34#30#article#138#<p><font s
ize="2" face="Verdana">Para avaliar a rela&ccedil;&atilde;o entre o ITB e os dad
os demogr&aacute;ficos, cl&iacute;nicos e laboratoriais, a popula&ccedil;&atilde
;o foi dividida em tr&ecirc;s grupos, de acordo com os valores do ITB: grupo com
 ITB baixo (&lt;0,9), grupo com ITB normal (0,9 a 1,3) e grupo com ITB alto (&gt
;1,3).</font></p>     ^cY#aop02111.htm##
00362000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011800085002001300203#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#35#31#article#138#<p><font s
ize="2" face="Verdana"><b>Dados demogr&aacute;ficos, cl&iacute;nicos e laborator
iais</b></font></p>     ^cY#aop02111.htm##
01720000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704147600085002001301561#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#36#32#article#138#<p><font s
ize="2" face="Verdana">Dados cl&iacute;nicos e demogr&aacute;ficos foram obtidos
 atrav&eacute;s de uma entrevista cl&iacute;nica estruturada e o banco de dados 
utilizado em todas as seis cl&iacute;nicas de di&aacute;lise. Esses dados inclue
m sexo, idade, etnia, tempo de di&aacute;lise, doen&ccedil;a renal prim&aacute;r
ia, acesso vascular, tabagismo atual (sim/n&atilde;o) e uso de medicamentos (ace
tato de c&aacute;lcio, carbonato de c&aacute;lcio, calcitriol, sevelamer e eritr
opoetina). Comorbidades foram definidas como: hipertens&atilde;o (PAS pr&eacute;
&#45;di&aacute;lise <u>&gt;</u>140 mmHg e/ou press&atilde;o arterial diast&oacut
e;lica (PAD) <u>&gt;</u>90 mmHg e/ou uso de medica&ccedil;&otilde;es anti&#45;hi
pertensivas); doen&ccedil;a arterial coronariana (angina de esfor&ccedil;o, uso 
atual de vasodilatador coron&aacute;rio, infarto do mioc&aacute;rdio pr&eacute;v
io e cirurgia de revasculariza&ccedil;&atilde;o ou angioplastia pr&eacute;vias);
 sequelas de derrame; DAP (uso atual de vasodilatador perif&eacute;rico, cirurgi
a de revasculariza&ccedil;&atilde;o de membro inferior ou angioplastia ou amputa
&ccedil;&atilde;o n&atilde;o&#45;traum&aacute;tica de membro inferior); diabetes
 mellitus (nefropatia diab&eacute;tica como doen&ccedil;a renal prim&aacute;ria 
ou diagn&oacute;stico cl&iacute;nico ap&oacute;s in&iacute;cio da terapia de sub
stitui&ccedil;&atilde;o renal) paratireoidectomia; e soropositividade para hepat
ite C.</font></p>     ^cY#aop02111.htm##
01437000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704119300085002001301278#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#37#33#article#138#<p><font s
ize="2" face="Verdana">Valores de hemoglobina, creatinina e Kt/V equilibrado (eK
t/V) foram definidos atrav&eacute;s da m&eacute;dia das tr&ecirc;s ultimas medid
as mais pr&oacute;ximas &agrave; medida do ITB. A fim de melhor analisar o impac
to da DMO nos achados, exposi&ccedil;&atilde;o cumulativa foi avaliada atrav&eac
ute;s do c&aacute;lculo da m&eacute;dia de todas as medidas dos valores s&eacute
;ricos para c&aacute;lcio, f&oacute;sforo e horm&ocirc;nio paratireoidiano intac
to (iPTH) durante um per&iacute;odo de 36 meses exatamente anterior &agrave; ava
lia&ccedil;&atilde;o do ITB ou desde o in&iacute;cio da HD em pacientes submetid
os a terapia de substitui&ccedil;&atilde;o renal por menos de 3 anos. Os n&iacut
e;veis s&eacute;ricos de c&aacute;lcio e f&oacute;sforo foram medidos mensalment
e, os n&iacute;veis de iPTH, a cada seis meses. As an&aacute;lises de sangue de 
rotina foram realizadas no mesmo laborat&oacute;rio. Um ensaio imunoturbidim&eac
ute;trico de alta sensibilidade para prote&iacute;na C&#45;reativa (PCR) foi esp
ecificamente utilizado para o estudo e os valores mostrados foram determinados n
a mesma &eacute;poca que o ITB foi medido. </font></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#38#34#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00337000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009300085002001300178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#39#35#article#138#<p><font s
ize="3" face="Verdana"><b>An&aacute;lise estat&iacute;stica</b></font></p>     ^
cY#aop02111.htm##
01623000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704137900085002001301464#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#40#36#article#138#<p><font s
ize="2" face="Verdana">As vari&aacute;veis cont&iacute;nuas foram apresentadas c
omo m&eacute;dia &plusmn; DP, se os dados seguissem uma distribui&ccedil;&atilde
;o normal e como mediana e varia&ccedil;&atilde;o se a distribui&ccedil;&atilde;
o dos dados fosse n&atilde;o&#45;Gaussiana. As vari&aacute;veis categ&oacute;ric
as foram mostradas como freq&uuml;&ecirc;ncias. As diferen&ccedil;as entre os gr
upos ITB foram avaliadas atrav&eacute;s do teste ANOVA one&#45;way, complementad
o pelo teste de Bonferroni ou Kruskal&#45;Wallis ANOVA complementado pelo teste 
de Dunn, quando apropriado. A an&aacute;lise das freq&uuml;&ecirc;ncias foi real
izada atrav&eacute;s do teste exato de Fisher. A associa&ccedil;&atilde;o entre 
as vari&aacute;veis e o risco de apresentar ITB baixo foi estudada atrav&eacute;
s de regress&atilde;o log&iacute;stica condicional com t&eacute;cnica <I>backwar
d</I>. Idade, sexo, diabetes, tabagismo, tempo de di&aacute;lise, albumina s&eac
ute;rica, PCR, c&aacute;lcio, f&oacute;sforo, produto c&aacute;lcio x f&oacute;s
foro e iPTH foram inclu&iacute;dos na fase inicial. A mesma an&aacute;lise foi r
ealizada para avaliar as vari&aacute;veis associadas com o risco de apresentar I
TB alto. Um valor de P&lt;0,05 foi considerado significante. O software SPSS, ve
rs&atilde;o 17.0 foi utilizada na an&aacute;lise estat&iacute;stica. </font></p>
     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#41#37#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00314000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007000085002001300155#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#42#38#article#138#<p><font s
ize="3" face="Verdana"><b>Resultados</b></font></p>     ^cY#aop02111.htm##
01189000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704094500085002001301030#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#43#39#article#138#<p><font s
ize="2" face="Verdana">De um total de 1.170 pacientes com DRC terminal em HD de 
manuten&ccedil;&atilde;o nas seis cl&iacute;nicas, 478 pacientes foram inclu&iac
ute;dos no estudo. As caracter&iacute;sticas gerais dos pacientes s&atilde;o mos
tradas na <a href="#tab01">Tabela 1</a>. A mediana da idade era 53,6 (18 a 75) a
nos; 56% dos pacientes eram do sexo masculino, 16,9% eram diab&eacute;ticos e 50
,6% tinham hipertens&atilde;o como doen&ccedil;a renal prim&aacute;ria. A median
a do tempo de di&aacute;lise era de 59 (12 a 427) meses, com 27% dos pacientes e
m di&aacute;lise por menos de 3 anos. Os valores dos par&acirc;metros laboratori
ais selecionados foram: eKt/V 1,51&plusmn;0,40; hemoglobina 11,4&plusmn;1,6 g/dl
; albumina s&eacute;rica 3,8&plusmn;0,3 g/dl; PCR 4,7 (0,1 &#45; 150) mg/l; &iac
ute;on c&aacute;lcio 4,6&plusmn;0,3 mg/dl; f&oacute;sforo 5,4&plusmn;1,2 mg/dL; 
e i&#45;PTH 370 (10 a 2.500) pg/ml.</font></p>     ^cY#aop02111.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#44#40#article#138#<p><a name
="tab01"></a></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#45#41#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#46#42#article#138#<p align="
center"><img src="/img/revistas/abc/2011nahead/a21tab01.jpg"></p>     ^cY#aop021
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#47#43#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00474000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704023000085002001300315#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#48#44#article#138#<p><font s
ize="2" face="Verdana">As preval&ecirc;ncias de ITB baixo, normal e alto foram 2
6,8%, 64,6% e 8,6%, respectivamente. A <a href="#tab02">Tabela 2</a> mostra as c
aracter&iacute;sticas de cada grupo ITB.</font></p>     ^cY#aop02111.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#49#45#article#138#<p><a name
="tab02"></a></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#50#46#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#51#47#article#138#<p align="
center"><img src="/img/revistas/abc/2011nahead/a21tab02.jpg"></p>     ^cY#aop021
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#52#48#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
01029000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704078500085002001300870#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#53#49#article#138#<p><font s
ize="2" face="Verdana">Pacientes no grupo ITB baixo eram significantemente mais 
velhos do que aqueles nos grupos ITB normal e ITB alto. O sexo masculino prevale
ceu no grupo com ITB alto, quando comparado aos grupos ITB normal e baixo. As pr
eval&ecirc;ncias de diabetes, DAP e amputa&ccedil;&atilde;o n&atilde;o&#45;traum
&aacute;tica foram significantemente mais baixas no grupo ITB normal do que no g
rupo ITB baixo e ITB alto. Doen&ccedil;a arterial coronariana (DAC) e sequela de
 derrame foram mais frequentes no grupo com ITB baixo do que no grupo com ITB no
rmal. Nenhuma diferen&ccedil;a foi observada em rela&ccedil;&atilde;o &agrave;s 
medidas de press&atilde;o arterial ou press&atilde;o de pulso entre os grupos de
 ITB (dados n&atilde;o mostrados). </font></p>     ^cY#aop02111.htm##
00958000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071400085002001300799#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#54#50#article#138#<p><font s
ize="2" face="Verdana">Os achados laboratoriais por grupo de ITB s&atilde;o most
rados na <a href="#tab03">Tabela 3</a>. O grupo com ITB baixo mostrava n&iacute;
veis mais altos de PCR e mais baixos de albumina s&eacute;rica do que o grupo co
m ITB normal. Os n&iacute;veis de creatinina s&eacute;rica eram mais baixos no g
rupo com ITB baixo, quando comparado aos grupos com ITB normal e alto. O grupo c
om ITB alto apresentava aumento nos n&iacute;veis de f&oacute;sforo s&eacute;ric
o e produto c&aacute;lcio x f&oacute;sforo, quando comparado aos grupos com ITB 
normal e alto. O grupo com ITB alto apresentava aumento dos n&iacute;veis de iPT
H, quando comparado ao grupo com baixo ITB. </font></p>     ^cY#aop02111.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#55#51#article#138#<p><a name
="tab03"></a></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#56#52#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#57#53#article#138#<p align="
center"><img src="/img/revistas/abc/2011nahead/a21tab03.jpg"></p>     ^cY#aop021
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#58#54#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00684000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044000085002001300525#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#59#55#article#138#<p><font s
ize="2" face="Verdana">Na an&aacute;lise de regress&atilde;o, apenas idade, diab
etes e n&iacute;veis elevados de PCR estavam significantemente associados com o 
risco de apresentar ITB baixo (<a href="#tab04">Tabela 4</a>), enquanto as vari&
aacute;veis associadas com o risco de apresentar ITB baixo eram sexo masculino, 
diabetes e produto c&aacute;lcio x f&oacute;sforo elevado (<a href="#tab05">Tabe
la 5</a>).</font></p>     ^cY#aop02111.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#60#56#article#138#<p><a name
="tab04"></a></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#61#57#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#62#58#article#138#<p align="
center"><img src="/img/revistas/abc/2011nahead/a21tab04.jpg"></p>     ^cY#aop021
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#63#59#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#64#60#article#138#<p><a name
="tab05"></a></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#65#61#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#66#62#article#138#<p align="
center"><img src="/img/revistas/abc/2011nahead/a21tab05.jpg"></p>     ^cY#aop021
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#67#63#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00320000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007600085002001300161#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#68#64#article#138#<p><font s
ize="3" face="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#aop02111.htm##
00442000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019800085002001300283#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#69#65#article#138#<p><font s
ize="2" face="Verdana">No presente estudo, a alta preval&ecirc;ncia de ITB anorm
al, na maioria ITB baixo, foi observada em pacientes em HD de manuten&ccedil;&at
ilde;o. </font></p>     ^cY#aop02111.htm##
00599000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704035500085002001300440#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#70#66#article#138#<p><font s
ize="2" face="Verdana">A mensura&ccedil;&atilde;o do ITB &eacute; um teste f&aac
ute;cil, confi&aacute;vel e n&atilde;o&#45;invasivo, o qual &eacute; um marcador
 de doen&ccedil;a vascular ateroscler&oacute;tica, bem como um preditor de morta
lidade na popula&ccedil;&atilde;o em geral e em pacientes em HD<SUP>9,10,13,14</
SUP>.</font></p>     ^cY#aop02111.htm##
00928000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068400085002001300769#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#71#67#article#138#<p><font s
ize="2" face="Verdana">As doen&ccedil;as cardiovasculares tem sido apontadas com
o a principal causa de morte em pacientes em di&aacute;lise<SUP>1</SUP>. Ambos o
s fatores de risco tradicionais e n&atilde;o&#45;tradicionais relacionados &agra
ve; doen&ccedil;a renal cr&ocirc;nica e/ou procedimento de di&aacute;lise est&at
ilde;o envolvidos nesse processo. Entre os fatores de risco de DCV n&atilde;o&#4
5;tradicionais, a DMO, inflama&ccedil;&atilde;o e tempo de di&aacute;lise tem si
do amplamente explorados<SUP>3&#45;6</SUP>. Entretanto, uma liga&ccedil;&atilde;
o entre ITB anormal e tais fatores de risco n&atilde;o&#45;tradicionais est&aacu
te; faltando. </font></p>     ^cY#aop02111.htm##
00469000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022500085002001300310#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#72#68#article#138#<p><font s
ize="2" face="Verdana">Enfatizando o papel do ITB como marcador substituto de at
erosclerose generalizada, observamos que o grupo com ITB baixo apresentava uma p
reval&ecirc;ncia mais alta de DCV. </font></p>     ^cY#aop02111.htm##
01126000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704088200085002001300967#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#73#69#article#138#<p><font s
ize="2" face="Verdana">Como esperado, observou&#45;se que diabetes estava associ
ada com aumento no risco de baixo ITB. No presente estudo, a diabetes tamb&eacut
e;m estava associada com aumento no risco de ITB alto. Isso pode ser atribu&iacu
te;do &agrave; maior preval&ecirc;ncia de calcifica&ccedil;&atilde;o vascular em
 tais pacientes, o que promove rigidez arterial e press&atilde;o arterial mais e
levada nos membros inferiores<SUP>10</SUP>. A predomin&acirc;ncia de pacientes m
ais velhos no grupo com ITB baixo em nosso estudo est&aacute; de acordo com estu
dos anteriores que avaliaram popula&ccedil;&otilde;es em geral e aquelas em HD<S
UP>9,10,13,14</SUP>. Observamos que o risco de apresentar ITB baixo quase dobra 
para cada d&eacute;cada adicional. Esse achado refor&ccedil;a idade como um fato
r de risco tradicional para DAP em pacientes em HD. </font></p>     ^cY#aop02111
.htm##
01231000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098700085002001301072#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#74#70#article#138#<p><font s
ize="2" face="Verdana">Os pacientes com ITB baixo apresentaram n&iacute;veis de 
PCR mais altos e n&iacute;veis s&eacute;ricos mais baixos de albumina e creatini
na. Esses achados n&atilde;o s&atilde;o inesperados, considerando que a associa&
ccedil;&atilde;o de desnutri&ccedil;&atilde;o e inflama&ccedil;&atilde;o com doe
n&ccedil;a ateroscler&oacute;tica e DAP, em popula&ccedil;&otilde;es em geral e 
em HD, &eacute; bem conhecida<SUP>17&#45;19</SUP>. Na an&aacute;lise de regress&
atilde;o, o n&iacute;vel da PCR <u>&gt;</u>6 mg/l foi a &uacute;nica vari&aacute
;vel laboratorial associada com o risco de apresentar ITB baixo. Pacientes em HD
 geralmente apresentam n&iacute;veis de PCR muito mais altos do que aqueles vist
os na popula&ccedil;&atilde;o em geral. Assim, n&iacute;veis de PCR <u>&gt;</u> 
6 mg/dl foi uma defini&ccedil;&atilde;o pr&eacute;&#45;especificada de anormalid
ade adotada pelas cl&iacute;nicas de di&aacute;lise participantes do estudo. </f
ont></p>     ^cY#aop02111.htm##
01988000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704174400085002001301829#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#75#71#article#138#<p><font s
ize="2" face="Verdana">O n&iacute;vel de fosfato s&eacute;rico foi mais alto em 
pacientes com ITB alto, provavelmente refletindo seu papel na calcifica&ccedil;&
atilde;o vascular, j&aacute; que art&eacute;rias calcificadas s&atilde;o mais r&
iacute;gidas e apresentam press&atilde;o arterial mais elevada<SUP>10</SUP>. Nen
huma diferen&ccedil;a foi observada nos n&iacute;veis s&eacute;ricos de c&aacute
;lcio de acordo com a classifica&ccedil;&atilde;o do ITB. Na an&aacute;lise de r
egress&atilde;o, a &uacute;nica vari&aacute;vel laboratorial associada com o ris
co de apresentar ITB alto foi o produto c&aacute;lcio x f&oacute;sforo. Nenhum m
arcador de DMO foi associado com o risco de ter ITB baixo. Deve ser enfatizado q
ue, no presente estudo, utilizamos as m&eacute;dias das medidas de c&aacute;lcio
, fosfato e iPTH realizadas ao longo de um per&iacute;odo de 36 meses anterior &
agrave; avalia&ccedil;&atilde;o do ITB ou desde o in&iacute;cio da terapia de su
bstitui&ccedil;&atilde;o renal para aqueles indiv&iacute;duos em HD h&aacute; me
nos de 3 anos. Defici&ecirc;ncia de vitamina D tem sido reconhecida como um fato
r de risco n&atilde;o&#45;tradicional para aterosclerose e desfechos cardiovascu
lares adversos<SUP>20</SUP>. A defici&ecirc;ncia de 25&#45;hidroxivitamina D e s
ua forma ativa 1,25&#45;dihidroxivitamina D &eacute; altamente prevalente em pac
ientes em HD<SUP>21,22</SUP>. Acreditamos que algumas anormalidades vasculares o
bservadas em nosso estudo poderiam ser pelo menos parcialmente atribu&iacute;das
 &agrave; defici&ecirc;ncia de vitamina D. Como n&atilde;o foi poss&iacute;vel m
edir os n&iacute;veis s&eacute;ricos de vitamina D, essa quest&atilde;o n&atilde
;o foi analisada em nosso estudo. </font></p>     ^cY#aop02111.htm##
00856000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704061200085002001300697#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#76#72#article#138#<p><font s
ize="2" face="Verdana">Nenhuma associa&ccedil;&atilde;o foi detectada entre o te
mpo de di&aacute;lise e o risco de apresentar ITB alto ou baixo. Por conseguinte
, a DAP n&atilde;o parece ser uma complica&ccedil;&atilde;o da insufici&ecirc;nc
ia renal e/ou terapia de apoio, mas uma consequ&ecirc;ncia de outras condi&ccedi
l;&otilde;es, principalmente envelhecimento e diabetes. Achado similar foi demon
strado por Cheung e cols.<SUP>10</SUP>, mas n&atilde;o por Rajagopalan e cols.<S
UP>8</SUP>, que observaram uma correla&ccedil;&atilde;o positiva entre tempo de 
di&aacute;lise e DAP. </font></p>     ^cY#aop02111.htm##
00796000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055200085002001300637#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#77#73#article#138#<p><font s
ize="2" face="Verdana">Em nossa an&aacute;lise, a hipertens&atilde;o n&atilde;o 
estava associada com ITB alto ou baixo, uma observa&ccedil;&atilde;o tamb&eacute
;m relatada por Cheung e cols.<SUP>2 </SUP>e Jaar e cols.<SUP>23</SUP>. A hipert
ens&atilde;o est&aacute; amplamente presente em pacientes em HD, com uma preval&
ecirc;ncia que pode chegar a 80% em algumas popula&ccedil;&otilde;es, tornando a
 identifica&ccedil;&atilde;o de seu efeito sobre um subgrupo espec&iacute;fico d
if&iacute;cil de demonstrar<SUP>24</SUP>. </font></p>     ^cY#aop02111.htm##
00544000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030000085002001300385#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#78#74#article#138#<p><font s
ize="2" face="Verdana">Deve ser enfatizado que Rajagopalan e cols.<SUP>8</SUP> o
bservaram uma associa&ccedil;&atilde;o positiva entre hipertens&atilde;o e DAP, 
demonstrando que os dados, em rela&ccedil;&atilde;o a essa quest&atilde;o, n&ati
lde;o s&atilde;o consensuais. </font></p>     ^cY#aop02111.htm##
00711000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046700085002001300552#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#79#75#article#138#<p><font s
ize="2" face="Verdana">Surpreendentemente, n&atilde;o observamos uma associa&cce
dil;&atilde;o entre tabagismo e risco de ITB anormal. Talvez a baixa preval&ecir
c;ncia de tabagismo em nossa popula&ccedil;&atilde;o possa ter abrandado esse ef
eito. A rela&ccedil;&atilde;o entre tabagismo e DAP em pacientes em HD foi demon
strada por Cheung e cols.<SUP>2</SUP> e Rajagopalan e cols.<SUP>8</SUP>, mas n&a
tilde;o por Ono e cols.<SUP>10</SUP>.</font></p>     ^cY#aop02111.htm##
00767000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052300085002001300608#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#80#76#article#138#<p><font s
ize="2" face="Verdana">Observamos uma predomin&acirc;ncia de indiv&iacute;duos d
o sexo masculino entre os pacientes com ITB alto. Achados similares foram tamb&e
acute;m descritos por Ono e cols.<SUP>10</SUP> e O'Hare e cols.<SUP>17</SUP>. Em
 nosso estudo, o risco ajustado de apresentar ITB alto &gt;1,3 foi 4,4 vezes mai
s alto no sexo masculino, quando comparado ao feminino. As raz&otilde;es para ta
l diferen&ccedil;a n&atilde;o s&atilde;o claras e merecem investiga&ccedil;&atil
de;o futura. </font></p>     ^cY#aop02111.htm##
00813000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056900085002001300654#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#81#77#article#138#<p><font s
ize="2" face="Verdana">Nosso estudo apresenta limita&ccedil;&otilde;es. Como &ea
cute; um estudo observacional, uma rela&ccedil;&atilde;o causal entre inflama&cc
edil;&atilde;o e ITB reduzido n&atilde;o pode ser estabelecida. Outra limita&cce
dil;&atilde;o foi o fato de termos realizado apenas uma &uacute;nica medida da P
CR, apesar de informa&ccedil;&otilde;es anteriores de que esse par&acirc;metro p
ode apresentar instabilidade ao longo do tempo, refletindo mudan&ccedil;as trans
it&oacute;rias no estado inflamat&oacute;rio<SUP>25</SUP>. </font></p>     ^cY#a
op02111.htm##
00956000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071200085002001300797#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#82#78#article#138#<p><font s
ize="2" face="Verdana">Em conclus&atilde;o, o presente estudo avaliou um grande 
n&uacute;mero de pacientes em HD de manuten&ccedil;&atilde;o a fim de analisar a
 associa&ccedil;&atilde;o entre os fatores de risco tradicionais e n&atilde;o&#4
5;tradicionais para doen&ccedil;a cardiovascular e &iacute;ndice tornozelo&#45;b
ra&ccedil;o. Diabetes estava associada com &iacute;ndice tornozelo&#45;bra&ccedi
l;o alto e baixo. Idade mais avan&ccedil;ada e inflama&ccedil;&atilde;o estavam 
associadas com o risco de apresentar &iacute;ndice tornozelo&#45;bra&ccedil;o ba
ixo, enquanto o dist&uacute;rbio mineral &oacute;sseo estava associado com &iacu
te;ndice tornozelo&#45;bra&ccedil;o alto. </font></p>     ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#83#79#article#138#<p>&nbsp;<
/p>     ^cY#aop02111.htm##
00321000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007700085002001300162#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#84#80#article#138#<p><font s
ize="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop02111.htm#
#
00456000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704019800087002001300285#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#85#81#article#13
8#1#<p><font size="2" face="Verdana">1. Foley RN, Parfrey PS, Sarnak M. Clinical
 epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Di
s. 1998;32(5 Suppl. 3):S112&#45;9.    ^cY#aop02111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#86#82#article#138# </font></
p>     ^cY#aop02111.htm##
00481000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022300087002001300310#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#87#83#article#13
8#2#<p><font size="2" face="Verdana">2. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, H
eyka RJ, Rocao MV, et al. Atherosclerotic cardiovascular disease risks in chroni
c hemodialysis patients. Kidney Int. 2000;58(1):353&#45;62.    ^cY#aop02111.htm#
#
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#88#84#article#138# </font></
p>     ^cY#aop02111.htm##
00530000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027200087002001300359#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#89#85#article#13
8#3#<p><font size="2" face="Verdana">3. Block GA, Hulbert&#45;Shearon TE, Levin 
NW, Port FK. Association of serum phosphorus and calcium x phosphate product wit
h mortality risk in chronic hemodialysis patients: A national study. Am J Kidney
 Dis. 1998;31(4):601&#45;17.    ^cY#aop02111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#90#86#article#138#</font></p
>     ^cY#aop02111.htm##
00485000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022700087002001300314#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#91#87#article#13
8#4#<p><font size="2" face="Verdana">4. Block GA, Klassen PS, Lazarus JM, Ofsthu
n N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in main
tenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208&#45;18.    ^cY#aop02111.
htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#92#88#article#138# </font></
p>     ^cY#aop02111.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028700087002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#93#89#article#13
8#5#<p><font size="2" face="Verdana">5. Ganesh SK, Stack AG, Levin NW, Hulbert&#
45;Shearon T, Port FK. Association of elevated serum PO4, Ca x PO4 product, and 
parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients
. J Am Soc Nephrol. 2001;12(10):2131&#45;8.    ^cY#aop02111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#94#90#article#138# </font></
p>     ^cY#aop02111.htm##
00483000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022500087002001300312#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#95#91#article#13
8#6#<p><font size="2" face="Verdana">6. Yeun JY, Levine RA, Mantadilok V, Kaysen
 GA. C&#45;reactive protein predicts all cause and cardiovascular mortality in h
emodialysis patients. Am J Kidney Dis. 2000;35(3):469&#45;76.    ^cY#aop02111.ht
m##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#96#92#article#138# </font></
p>     ^cY#aop02111.htm##
00492000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023400087002001300321#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#97#93#article#13
8#7#<p><font size="2" face="Verdana">7. Fishbane S, Youn S, Kowalski EJ, Frei GL
. Ankle&#45;arm blood pressure index as a marker for atherosclerotic vascular di
seases in hemodialysis patients. Am J Kidney Dis. 1995;25(1):34&#45;9.    ^cY#ao
p02111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#98#94#article#138# </font></
p>     ^cY#aop02111.htm##
00583000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032500087002001300412#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#99#95#article#13
8#8#<p><font size="2" face="Verdana">8. Rajagopalan S, Dellegrottaglie S, Furnis
 AL, Gillespie BW, Satayathum S, Lameire N, et al. Peripheral arterial disease i
n patients with end&#45;stage renal disease: observations from the Dialysis Outc
omes and Practice Patterns Study (DOPPS). Circulation. 2006; 114(18):1914&#45;22
.    ^cY#aop02111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#100#96#article#138#</font></
p>     ^cY#aop02111.htm##
00482000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704022300088002001300311#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#101#97#article#1
38#9#<p><font size="2" face="Verdana">9. Fishbane S, Youn S, Flaster E, Adam G, 
Maesaka JK. Ankle&#45;arm blood pressure index as a predictor of mortality in he
modialysis patients. Am J Kidney Dis. 1996;27(5):668&#45;72.    ^cY#aop02111.htm
##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#102#98#article#138#</font></
p>     ^cY#aop02111.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704027200089002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#103#99#article#1
38#10#<p><font size="2" face="Verdana">10. Ono K, Tsuchida A, Kawai H, Matsuo H,
 Wakamatsu R, Maezawa A, et al. Ankle&#45;brachial blood pressure index predicts
 all&#45;cause and cardiovascular mortality in hemodialysis patients. J Am Soc N
ephrol. 2003;14(6):1591&#45;8.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#104#100#article#138#</font><
/p>     ^cY#aop02111.htm##
00447000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018600090002001300276#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#105#101#article#
138#11#<p><font size="2" face="Verdana">11. Fowkes FG. The measurement of athero
sclerotic peripheral arterial disease in epidemiological surveys. Int J Epidemio
l. 1988;17(2):248&#45;54.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#106#102#article#138#</font><
/p>     ^cY#aop02111.htm##
00463000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020200090002001300292#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#107#103#article#
138#12#<p><font size="2" face="Verdana">12. Donnelly R, Hinwood D, London NJ, AB
C of arterial and venous disease: noninvasive methods of arterial and venous ass
essment. BMJ. 2000;320(7236):698&#45;701.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#108#104#article#138#</font><
/p>     ^cY#aop02111.htm##
00548000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028700090002001300377#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#109#105#article#
138#13#<p><font size="2" face="Verdana">13. Newman AB, Shemanski L, Manolio TA, 
Cushman M, Mittelmark M, Pollak JF, et al Ankle&#45;arm index as a predictor of 
cardiovascular disease and mortality in the cardiovascular health study. Arterio
scler Thromb Vasc Biol. 1999;19(3):538&#45;45.    ^cY#aop02111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#110#106#article#138# </font>
</p>     ^cY#aop02111.htm##
00460000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019900090002001300289#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#111#107#article#
138#14#<p><font size="2" face="Verdana">14. Vogt MT, Cauley JA, Newman AB, Kulle
r LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elder
ly women. JAMA. 1993;270(4):465&#45;9.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#112#108#article#138#</font><
/p>     ^cY#aop02111.htm##
00475000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021400090002001300304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#113#109#article#
138#15#<p><font size="2" face="Verdana">15. Newman AB, Sutton&#45;Tyrel K, Vogt 
MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/a
rm blood pressure index. JAMA. 1993;270(4):487&#45;9.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#114#110#article#138#</font><
/p>     ^cY#aop02111.htm##
00603000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034200090002001300432#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#115#111#article#
138#16#<p><font size="2" face="Verdana">16. Orchard TJ, Strandness DE Jr. Assess
ment of peripheral vascular disease in diabetes: report and recommendations of a
n international workshop sponsored by the American Diabetes and the American Hea
rt Association September 18&#150;20, 1992 New Orleans, Louisiana. Circulation. 1
993;88(2):819&#45;28.    ^cY#aop02111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#116#112#article#138# </font>
</p>     ^cY#aop02111.htm##
00516000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025500090002001300345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#117#113#article#
138#17#<p><font size="2" face="Verdana">17. O'Hare AM, Katz R, Shlipak MG, Cushm
an M, Newman AB. Mortality and cardiovascular risk across the ankle&#45;arm inde
x spectrum: results from the Cardiovascular Health Study. Circulation. 2006;113(
3):388&#45;93.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#118#114#article#138#</font><
/p>     ^cY#aop02111.htm##
00491000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023000090002001300320#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#119#115#article#
138#18#<p><font size="2" face="Verdana">18. Ridker PM, Cushman M, Stampfer MJ, T
racy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular dis
ease in apparently healthy men. N Engl J Med. 1997;336(14):973&#45;9.    ^cY#aop
02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#120#116#article#138#</font><
/p>     ^cY#aop02111.htm##
00479000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021800090002001300308#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#121#117#article#
138#19#<p><font size="2" face="Verdana">19. Zimmermann J, Herrlinger S, Pruy A, 
Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in 
hemodialysis patients. Kidney Int. 1999;55(2):648&#45;58.    ^cY#aop02111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#122#118#article#138# </font>
</p>     ^cY#aop02111.htm##
00544000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028300090002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#123#119#article#
138#20#<p><font size="2" face="Verdana">20. Kendrick J, Targher G, Smits G, Chon
chol M. 25&#45;Hydroxyvitamin D deficiency is independently associated with card
iovascular disease in the Third National Health and Nutrition Examination Survey
. Atherosclerosis. 2009;205(1):255&#45;60.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#124#120#article#138#</font><
/p>     ^cY#aop02111.htm##
00523000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026200090002001300352#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#125#121#article#
138#21#<p><font size="2" face="Verdana">21. Del Valle E, Negri AL, Aguirre C, Fr
adinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and defici
ency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2
007;11(3):315&#45;21.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#126#122#article#138#</font><
/p>     ^cY#aop02111.htm##
00554000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029300090002001300383#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#127#123#article#
138#22#<p><font size="2" face="Verdana">22. Matias PJ, Jorge C, Ferreira C, Borg
es M, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis 
patients: effects on mineral metabolism, inflammation, and cardiac dimension par
ameters. Clin J Am Soc Nephrol. 2010;5(5):905&#45;1.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#128#124#article#138#</font><
/p>     ^cY#aop02111.htm##
00543000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028200090002001300372#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#129#125#article#
138#23#<p><font size="2" face="Verdana">23. Jaar BG, Plantinga LC, Astor BC, Fin
k NE, Longenecker C, Tracy RP, et al. Novel and traditional cardiovascular risk 
factors for peripheral arterial disease in incident&#45;dialysis patients. Adv C
hronic Kidney Dis. 2007;14(3):304&#45;13.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#130#126#article#138#</font><
/p>     ^cY#aop02111.htm##
00511000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025000090002001300340#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#131#127#article#
138#24#<p><font size="2" face="Verdana">24. Agarwal R, Nissenson AR, Batlle D, C
oyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertensio
n in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):2
91&#45;7.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#132#128#article#138#</font><
/p>     ^cY#aop02111.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024300090002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#133#129#article#
138#25#<p><font size="2" face="Verdana">25. Dummer CD, Thom&eacute; FS, Veronese
 FV. Doen&ccedil;a renal cr&ocirc;nica, inflama&ccedil;&atilde;o e aterosclerose
: novos conceitos de um velho problema. Rev Assoc Med Bras. 2007;53(5):446&#45;5
0.    ^cY#aop02111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#134#130#article#138#</font><
/p>     ^cY#aop02111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#135#131#article#138#<p>&nbsp
;</p>     ^cY#aop02111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#136#132#article#138#<p>&nbsp
;</p>     ^cY#aop02111.htm##
00412000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016600087002001300253#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#137#133#article#138#<p><font
 size="2" face="Verdana"><b><a name="nt"></a><a href="#tx"><img src="/img/revist
as/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:</b>    ^cY#ao
p02111.htm##
00283000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003700087002001300124#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#138#134#article#138#<br>   J
ocemir Ronaldo Lugon     ^cY#aop02111.htm##
00302000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005600087002001300143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#139#135#article#138#<br>   R
ua Haddock Lobo 369/309   &#150; Tijuca     ^cY#aop02111.htm##
00313000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006700087002001300154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#140#136#article#138#<br>   2
0260&#45;131 &#45; Rio de Janeiro, RJ &#150; Brasil    ^cY#aop02111.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009800087002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#141#137#article#138#<br>   E
&#45;mail: <a href="mailto:jocerl@huap.uff.br">jocerl@huap.uff.br</a> </font></p
>     ^cY#aop02111.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704013300087002001300220#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02111.htm#S#p#142#138#article#138#<p><font
 size="2" face="Verdana"> Artigo recebido em 16/08/10; revisado recebido em 20/1
0/10; aceito em 27/10/10.</font></p>     ^cY#aop02111.htm##
00579000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01600120012007700136030001700213710000200230065000900232064000500241031000300246
032001100249014000700260865000900267002001300276#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02111.htm#S#c#143#1#article#25#1#^rND^sFoley^nRN#^rND^sPar
frey^nPS#^rND^sSarnak^nM#Clinical epidemiology of cardiovascular disease in chro
nic renal disease^len#Am J Kidney Dis.#2#19980000#1998#32#3^s5 Suppl#S112-9#2011
0000#aop02111.htm##
00699000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030100
01300120010001600133010001600149010001600165810000600181012008200187030001100269
06500090028006400050028903100030029403200020029701400070029986500090030600200130
0315035001000328801001100338#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02111.htm#S#c#144#2#article#25#2#^rND^sCheung^nAK#^rND^sSarnak^nMJ#^rND^sYan^n
G#^rND^sDwyer^nJT#^rND^sHeyka^nRJ#^rND^sRocao^nMV#et al#Atherosclerotic cardiova
scular disease risks in chronic hemodialysis patients^len#Kidney Int#20000000#20
00#58#1#353-62#20110000#aop02111.htm#0085-2538#Kidney int##
00702000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100026001020100
01600128010001500144012013900159030001600298065000900314064000500323031000300328
032000200331014000700333865000900340002001300349035001000362801001600372#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#145#3#article#25#3#^
rND^sBlock^nGA#^rND^sHulbert-Shearon^nTE#^rND^sLevin^nNW#^rND^sPort^nFK#Associat
ion of serum phosphorus and calcium x phosphate product with mortality risk in c
hronic hemodialysis patients: A national study^len#Am J Kidney Dis#19980000#1998
#31#4#601-17#20110000#aop02111.htm#0272-6386#Am J Kidney Dis##
00698000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01800120010001700138010001700155010001800172012007700190030001700267065000900284
06400050029303100030029803200020030101400080030386500090031100200130032003500100
0333801001700343#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#
S#c#146#4#article#25#4#^rND^sBlock^nGA#^rND^sKlassen^nPS#^rND^sLazarus^nJM#^rND^
sOfsthun^nN#^rND^sLowrie^nEG#^rND^sChertow^nGM#Mineral metabolism, mortality, an
d morbidity in maintenance hemodialysis^len#J Am Soc Nephrol#20040000#2004#15#8#
2208-18#20110000#aop02111.htm#1046-6673#J Am Soc Nephrol##
00736000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030100
01600119010002500135010001500160012014200175030001700317065000900334064000500343
03100030034803200030035101400070035486500090036100200130037003500100038380100170
0393#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#147#5#ar
ticle#25#5#^rND^sGanesh^nSK#^rND^sStack^nAG#^rND^sLevin^nNW#^rND^sHulbert-Shearo
n^nT#^rND^sPort^nFK#Association of elevated serum PO4, Ca x PO4 product, and par
athyroid hormone with cardiac mortality risk in chronic hemodialysis patients^le
n#J Am Soc Nephrol#20010000#2001#12#10#2131-8#20110000#aop02111.htm#1046-6673#J 
Am Soc Nephrol##
00655000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100017001010100
02000118010001700138012009600155030001600251065000900267064000500276031000300281
032000200284014000700286865000900293002001300302035001000315801001600325#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#148#6#article#25#6#^
rND^sYeun^nJY#^rND^sLevine^nRA#^rND^sMantadilok^nV#^rND^sKaysen^nGA#C-reactive p
rotein predicts all cause and cardiovascular mortality in hemodialysis patients^
len#Am J Kidney Dis#20000000#2000#35#3#469-76#20110000#aop02111.htm#0272-6386#Am
 J Kidney Dis##
00664000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100014001040100
01900118010001500137012011000152030001600262065000900278064000500287031000300292
032000200295014000500297865000900302002001300311035001000324801001600334#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#149#7#article#25#7#^
rND^sFishbane^nS#^rND^sYoun^nS#^rND^sKowalski^nEJ#^rND^sFrei^nGL#Ankle-arm blood
 pressure index as a marker for atherosclerotic vascular diseases in hemodialysi
s patients^len#Am J Kidney Dis#19950000#1995#25#1#34-9#20110000#aop02111.htm#027
2-6386#Am J Kidney Dis##
00797000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100025001070100
01700132010002000149010002000169010001700189810000600206012015000212030001200362
06500090037406400050038303100040038803200030039201400080039586500090040300200130
0412035001000425801001200435#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02111.htm#S#c#150#8#article#25#8#^rND^sRajagopalan^nS#^rND^sDellegrottaglie^nS
#^rND^sFurnis^nAL#^rND^sGillespie^nBW#^rND^sSatayathum^nS#^rND^sLameire^nN#et al
#Peripheral arterial disease in patients with end-stage renal disease: observati
ons from the Dialysis Outcomes and Practice Patterns Study (DOPPS)^len#Circulati
on#20060000#2006#114#18#1914-22#20110000#aop02111.htm#0009-7322#Circulation##
00671000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100014001040100
01700118010001400135010001800149012008800167030001600255065000900271064000500280
03100030028503200020028801400070029086500090029700200130030603500100031980100160
0329#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#151#9#ar
ticle#25#9#^rND^sFishbane^nS#^rND^sYoun^nS#^rND^sFlaster^nE#^rND^sAdam^nG#^rND^s
Maesaka^nJK#Ankle-arm blood pressure index as a predictor of mortality in hemodi
alysis patients^len#Am J Kidney Dis#19960000#1996#27#5#668-72#20110000#aop02111.
htm#0272-6386#Am J Kidney Dis##
00747000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100018001010100
01500119010001600134010001900150010001700169810000600186012011300192030001700305
06500090032206400050033103100030033603200020033901400070034186500090034800200130
0357035001000370801001700380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02111.htm#S#c#152#10#article#25#10#^rND^sOno^nK#^rND^sTsuchida^nA#^rND^sKawai^
nH#^rND^sMatsuo^nH#^rND^sWakamatsu^nR#^rND^sMaezawa^nA#et al#Ankle-brachial bloo
d pressure index predicts all-cause and cardiovascular mortality in hemodialysis
 patients^len#J Am Soc Nephrol#20030000#2003#14#6#1591-8#20110000#aop02111.htm#1
046-6673#J Am Soc Nephrol##
00567000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120094001050300
01600199065000900215064000500224031000300229032000200232014000700234865000900241
002001300250035001000263801001600273#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02111.htm#S#c#153#11#article#25#11#^rND^sFowkes^nFG#The measurement of
 atherosclerotic peripheral arterial disease in epidemiological surveys^len#Int 
J Epidemiol#19880000#1988#17#2#248-54#20110000#aop02111.htm#0300-5771#Int J Epid
emiol##
00607000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01700123012009400140030000400234065000900238064000500247031000400252032000500256
014000800261865000900269002001300278035001000291801000400301#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02111.htm#S#c#154#12#article#25#12#^rND^sDonne
lly^nR#^rND^sHinwood^nD#^rND^sLondon^nNJ#ABC of arterial and venous disease: non
invasive methods of arterial and venous assessment^len#BMJ#20000000#2000#320#723
6#698-701#20110000#aop02111.htm#0959-8138#BMJ##
00785000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01800124010001700142010002000159010001700179810000600196012011500202030003000317
06500090034706400050035603100030036103200020036401400070036686500090037300200130
0382035001000395801003000405#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02111.htm#S#c#155#13#article#25#13#^rND^sNewman^nAB#^rND^sShemanski^nL#^rND^sM
anolio^nTA#^rND^sCushman^nM#^rND^sMittelmark^nM#^rND^sPollak^nJF#et al#Ankle-arm
 index as a predictor of cardiovascular disease and mortality in the cardiovascu
lar health study^lunknown#Arterioscler Thromb Vasc Biol#19990000#1999#19#3#538-4
5#20110000#aop02111.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00641000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01700120010001700137010001700154012007600171030000500247065000900252064000500261
03100040026603200020027001400060027286500090027800200130028703500100030080100050
0310#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#156#14#a
rticle#25#14#^rND^sVogt^nMT#^rND^sCauley^nJA#^rND^sNewman^nAB#^rND^sKuller^nLH#^
rND^sHulley^nSB#Decreased ankle/arm blood pressure index and mortality in elderl
y women^len#JAMA#19930000#1993#270#4#465-9#20110000#aop02111.htm#0098-7484#JAMA#
#
00634000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100022001050100
01500127010001700142012009300159030000500252065000900257064000500266031000400271
032000200275014000600277865000900283002001300292035001000305801000500315#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#157#15#article#25#15
#^rND^sNewman^nAB#^rND^sSutton-Tyrel^nK#^rND^sVogt^nMT#^rND^sKuller^nLH#Morbidit
y and mortality in hypertensive adults with a low ankle/arm blood pressure index
^len#JAMA#19930000#1993#270#4#487-9#20110000#aop02111.htm#0098-7484#JAMA##
00732000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100024001060120
23000130030001200360065000900372064000500381031000300386032000200389014000700391
865000900398002001300407035001000420801001200430#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02111.htm#S#c#158#16#article#25#16#^rND^sOrchard^nTJ#^rND^
sStrandness Jr^nDE#Assessment of peripheral vascular disease in diabetes: report
 and recommendations of an international workshop sponsored by the American Diab
etes and the American Heart Association September 18-20, 1992 New Orleans, Louis
iana^len#Circulation#19930000#1993#88#2#819-28#20110000#aop02111.htm#0009-7322#C
irculation##
00699000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100014001040100
01800118010001700136010001700153012012000170030001200290065000900302064000500311
03100040031603200020032001400070032286500090032900200130033803500100035180100120
0361#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#159#17#a
rticle#25#17#^rND^sO'Hare AM#^rND^sKatz^nR#^rND^sShlipak^nMG#^rND^sCushman^nM#^r
ND^sNewman^nAB#Mortality and cardiovascular risk across the ankle-arm index spec
trum: results from the Cardiovascular Health Study^len#Circulation#20060000#2006
#113#3#388-93#20110000#aop02111.htm#0009-7322#Circulation##
00680000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01900122010001600141010002000157012009200177030001300269065000900282064000500291
03100040029603200030030001400060030386500090030900200130031803500100033180100130
0341#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#160#18#a
rticle#25#18#^rND^sRidker^nPM#^rND^sCushman^nM#^rND^sStampfer^nMJ#^rND^sTracy^nR
P#^rND^sHennekens^nCH#Inflammation, aspirin, and the risk of cardiovascular dise
ase in apparently healthy men^len#N Engl J Med#19970000#1997#336#14#973-9#201100
00#aop02111.htm#0028-4793#N Engl J Med##
00666000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100020001080100
01400128010001700142010001600159012008500175030001100260065000900271064000500280
03100030028503200020028801400070029086500090029700200130030603500100031980100110
0329#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#161#19#a
rticle#25#19#^rND^sZimmermann^nJ#^rND^sHerrlinger^nS#^rND^sPruy^nA#^rND^sMetzger
^nT#^rND^sWanner^nC#Inflammation enhances cardiovascular risk and mortality in h
emodialysis patients^len#Kidney Int#19990000#1999#55#2#648-58#20110000#aop02111.
htm#0085-2538#Kidney int##
00714000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01500123010001800138012015300156030001600309065000900325064000500334031000400339
032000200343014000700345865000900352002001300361035001000374801001600384#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#162#20#article#25#20
#^rND^sKendrick^nJ#^rND^sTargher^nG#^rND^sSmits^nG#^rND^sChonchol^nM#25-Hydroxyv
itamin D deficiency is independently associated with cardiovascular disease in t
he Third National Health and Nutrition Examination Survey^len#Atherosclerosis#20
090000#2009#205#1#255-60#20110000#aop02111.htm#0021-9150#Atherosclerosis##
00679000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01700123010001900140010002000159012012300179030001300302710000200315065000900317
064000500326031000300331032000200334014000700336865000900343002001300352#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#S#c#163#21#article#25#21
#^rND^sDel Valle^nE#^rND^sNegri^nAL#^rND^sAguirre^nC#^rND^sFradinger^nE#^rND^sZa
nchetta^nJR#Prevalence of 25(OH) vitamin D insufficiency and deficiency in chron
ic kidney disease stage 5 patients on hemodialysis^len#Hemodial Int#2#20070000#2
007#11#3#315-21#20110000#aop02111.htm##
00739000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01800120010001600138010001500154010001600169810000600185012014000191030002200331
71000020035306500090035506400050036403100020036903200020037101400060037386500090
0379002001300388#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#
S#c#164#22#article#25#22#^rND^sMatias^nPJ#^rND^sJorge^nC#^rND^sFerreira^nC#^rND^
sBorges^nM#^rND^sAires^nI#^rND^sAmaral^nT#et al#Cholecalciferol supplementation 
in hemodialysis patients: effects on mineral metabolism, inflammation, and cardi
ac dimension parameters^len#Clin J Am Soc Nephrol#2#20100000#2010#5#5#905-1#2011
0000#aop02111.htm##
00724000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100020001030100
01600123010001500139010002100154010001600175810000600191012011600197030002300313
71000020033606500090033806400050034703100030035203200020035501400070035786500090
0364002001300373#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#
S#c#165#23#article#25#23#^rND^sJaar^nBG#^rND^sPlantinga^nLC#^rND^sAstor^nBC#^rND
^sFink^nNE#^rND^sLongenecker^nC#^rND^sTracy^nRP#et al#Novel and traditional card
iovascular risk factors for peripheral arterial disease in incident-dialysis pat
ients^len#Adv Chronic Kidney Dis#2#20070000#2007#14#3#304-13#20110000#aop02111.h
tm##
00714000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050100
01600125010001600141010001600157010001800173012010900191030000900300065000900309
06400050031803100040032303200020032701400060032986500090033500200130034403500100
0357801000900367#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02111.htm#
S#c#166#24#article#25#24#^rND^sAgarwal^nR#^rND^sNissenson^nAR#^rND^sBatlle^nD#^r
ND^sCoyne^nDW#^rND^sTrout^nJR#^rND^sWarnock^nDG#Prevalence, treatment, and contr
ol of hypertension in chronic hemodialysis patients in the United States^len#Am 
J Med#20030000#2003#115#4#291-7#20110000#aop02111.htm#0002-9343#Am J Med##
00629000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01900121012009100140030001900231065000900250064000500259031000300264032000200267
014000700269865000900276002001300285035001000298801001900308#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02111.htm#S#c#167#25#article#25#25#^rND^sDumme
r^nCD#^rND^sThomé^nFS#^rND^sVeronese^nFV#Doença renal crônica, inflamação e ater
osclerose: novos conceitos de um velho problema^lpt#Rev Assoc Med Bras#20070000#
2007#53#5#446-50#20110000#aop02111.htm#0004-5241#Rev Assoc Med Bras##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#o#1#1#
article#1#20110331#081012#aop02311.htm#238##
04651000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801200690
01770120068002460100032003140100025003460100028003710100028003990100032004270100
03000459010002500489010002600514070006200540083165400602085000802256085004302264
08500220230708500240232908500250235308315080237808500080388608500370389408500200
3931085002503951085002503976117000804001072000304009002001304012#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#h#2#1#article#1#tr#pt#br1.1#1#
4.0#GRA#TAB#30#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#2011031
8#Perfil cardiovascular em pacientes com apneia obstrutiva do sono^lpt#Cardiovas
cular profile in patients with obstructive sleep apnea^len#^rND^1A01^nFátima Dum
as^sCintra#^rND^1A01^nSergio^sTufik#^rND^1A01^nAngelo de^sPaola#^rND^1A01^nMárci
a C.^sFeres#^rND^1A01^nLuciane^sMelo-Fujita#^rND^1A01^nWercules^sOliveira#^rND^1
A01^nCamila^sRizzi#^rND^1A01^nDalva^sPoyares#Universidade Federal de São Paulo^i
A01^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: Apneia Obstrutiva do Sono (AOS) é u
m fator de risco para várias condições cardiovasculares incluindo aumento na mor
talidade cardiovascular. Sendo assim, é essencial o conhecimento das principais 
repercussões cardiovasculares dos distúrbios respiratórios do sono durante uma a
valiação clínica. OBJETIVO: Analisar as características cardiovasculares de paci
entes com AOS. MÉTODOS: Pacientes submetidos a polissonografia basal foram conse
cutivamente selecionados do banco de dados do Instituto do Sono entre março de 2
007 e março de 2009. Todos os pacientes foram orientados a comparecer ao ambulat
ório para coleta de sangue, exame físico, eletrocardiograma de 12 derivações, es
pirometria, teste cardiopulmonar em esteira ergométrica e ecocardiograma transto
rácico. O estudo foi aprovado pelo comitê de ética e pesquisa e registrado no si
te http://clinicaltrials.gov/ sob o número: NCT00768625. RESULTADOS: Foram anali
sados 261 pacientes e 108 controles. As principais características dos pacientes
 com AOS foram: obesidade, hipertensão, baixos níveis plasmáticos de lipoproteín
as de alta densidade (HDL) e aumento no diâmetro do átrio esquerdo quando compar
ados com controles (3,75 ± 0,42; 3,61 ± 0,41, p = 0,001), respectivamente. Essas
 características associadas correspondem a um acréscimo de 16,6 vezes na probabi
lidade de ocorrência de AOS independentemente do relato de algum sintoma dessa d
esordem, como sonolência ou ronco. CONCLUSÃO: Na amostra avaliada, o perfil card
iovascular dos pacientes com AOS mais encontrado foi: obesidade, hipertensão art
erial, baixos níveis plasmáticos de HDL e átrio esquerdo com diâmetro aumentado.
#^dnd^i1#^tm^lpt^kApneia do sono tipo obstrutiva^i1#^tm^lpt^kobesidade^i1#^tm^lp
t^khipertensão^i1#^tm^lpt^kdislipidemia^i1#^len^aBACKGROUND: Obstructive Sleep A
pnea (OSA) is a risk factor for several cardiovascular conditions including incr
eased cardiovascular mortality. It is therefore essential to know the major card
iovascular effects of sleep-disordered breathing during a clinical evaluation. O
BJECTIVE: To analyze the cardiovascular characteristics of patients with OSA. ME
THODS: Patients underwent baseline polysomnography and were consecutively select
ed from the database of the Sleep Institute between March 2007 and March 2009. A
ll patients were instructed to attend the clinic for blood collection, physical 
examination, 12-lead electrocardiogram, spirometry, cardiopulmonary exercise tes
ting on a treadmill and transthoracic echocardiography. The study was approved b
y the Research Ethics Committee and recorded at http://clinicaltrials.gov/ under
 number: NCT00768625. RESULTS: We analyzed 261 patients and 108 controls. The ma
in characteristics of patients with OSA were: obesity, hypertension, low plasma 
levels of high density lipoprotein (HDL) and increased left atrial diameter comp
ared with controls (3.75 ± 0.42; 3.61 ± 0.41, p = 0.001), respectively. These as
sociated characteristics correspond to a 16.6 increase in the likelihood of OSA 
regardless of reporting any symptoms of this disorder, such as sleepiness or sno
ring. CONCLUSION: In the sample studied, the mostly found cardiovascular profile
 of patients with OSA was: obesity, hypertension, low plasma levels of HDL and l
eft atrial diameter increased.#^dnd^i2#^tm^len^kSleep apnea^i2^sobstructive#^tm^
len^kobesity^i2#^tm^len^khypertension^i2#^tm^len^kdyslipidemia^i2#vancouv#40#aop
02311.htm##
04849000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801200760
01770120075002530100032003280100025003600100028003850100028004130100032004410100
03000473010002500503010002600528070006200554083174600616085000802362085004302370
08500220241308500240243508500250245908316000248408500080408408500370409208500200
4129085002504149085002504174117000804199072000304207002001304210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#f#3#1#article#1#tr#pt#br1.1#1#
4.0#GRA#TAB#30#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#2011031
8#<b>Perfil cardiovascular em pacientes com apneia obstrutiva do sono</b>^lpt#<b
>Cardiovascular profile in patients with obstructive sleep apnea</b>^len#^rND^1A
01^nFátima Dumas^sCintra#^rND^1A01^nSergio^sTufik#^rND^1A01^nAngelo de^sPaola#^r
ND^1A01^nMárcia C.^sFeres#^rND^1A01^nLuciane^sMelo-Fujita#^rND^1A01^nWercules^sO
liveira#^rND^1A01^nCamila^sRizzi#^rND^1A01^nDalva^sPoyares#Universidade Federal 
de São Paulo^iA01^cSão Paulo^sSP^pBrasil#^lpt^a<b>FUNDAMENTO:</b> Apneia Obstrut
iva do Sono (AOS) é um fator de risco para várias condições cardiovasculares inc
luindo aumento na mortalidade cardiovascular. Sendo assim, é essencial o conheci
mento das principais repercussões cardiovasculares dos distúrbios respiratórios 
do sono durante uma avaliação clínica. <b>OBJETIVO:</b> Analisar as característi
cas cardiovasculares de pacientes com AOS. <b>MÉTODOS:</b> Pacientes submetidos 
a polissonografia basal foram consecutivamente selecionados do banco de dados do
 Instituto do Sono entre março de 2007 e março de 2009. Todos os pacientes foram
 orientados a comparecer ao ambulatório para coleta de sangue, exame físico, ele
trocardiograma de 12 derivações, espirometria, teste cardiopulmonar em esteira e
rgométrica e ecocardiograma transtorácico. O estudo foi aprovado pelo comitê de 
ética e pesquisa e registrado no site <a href="http://clinicaltrials.gov/" targe
t="_blank">http://clinicaltrials.gov/</a> sob o número: NCT00768625. <b>RESULTAD
OS:</b> Foram analisados 261 pacientes e 108 controles. As principais caracterís
ticas dos pacientes com AOS foram: obesidade, hipertensão, baixos níveis plasmát
icos de lipoproteínas de alta densidade (HDL) e aumento no diâmetro do átrio esq
uerdo quando comparados com controles (3,75 ± 0,42; 3,61 ± 0,41, p = 0,001), res
pectivamente. Essas características associadas correspondem a um acréscimo de 16
,6 vezes na probabilidade de ocorrência de AOS independentemente do relato de al
gum sintoma dessa desordem, como sonolência ou ronco. <b>CONCLUSÃO:</b> Na amost
ra avaliada, o perfil cardiovascular dos pacientes com AOS mais encontrado foi: 
obesidade, hipertensão arterial, baixos níveis plasmáticos de HDL e átrio esquer
do com diâmetro aumentado.#^dnd^i1#^tm^lpt^kApneia do sono tipo obstrutiva^i1#^t
m^lpt^kobesidade^i1#^tm^lpt^khipertensão^i1#^tm^lpt^kdislipidemia^i1#^len^a<b>BA
CKGROUND:</b> Obstructive Sleep Apnea (OSA) is a risk factor for several cardiov
ascular conditions including increased cardiovascular mortality. It is therefore
 essential to know the major cardiovascular effects of sleep-disordered breathin
g during a clinical evaluation. <b>OBJECTIVE:</b> To analyze the cardiovascular 
characteristics of patients with OSA. <b>METHODS:</b> Patients underwent baselin
e polysomnography and were consecutively selected from the database of the Sleep
 Institute between March 2007 and March 2009. All patients were instructed to at
tend the clinic for blood collection, physical examination, 12-lead electrocardi
ogram, spirometry, cardiopulmonary exercise testing on a treadmill and transthor
acic echocardiography. The study was approved by the Research Ethics Committee a
nd recorded at <a href="http://clinicaltrials.gov/" target="_blank">http://clini
caltrials.gov/</a> under number: NCT00768625. <b>RESULTS:</b> We analyzed 261 pa
tients and 108 controls. The main characteristics of patients with OSA were: obe
sity, hypertension, low plasma levels of high density lipoprotein (HDL) and incr
eased left atrial diameter compared with controls (3.75 ± 0.42; 3.61 ± 0.41, p =
 0.001), respectively. These associated characteristics correspond to a 16.6 inc
rease in the likelihood of OSA regardless of reporting any symptoms of this diso
rder, such as sleepiness or snoring. <b>CONCLUSION:</b> In the sample studied, t
he mostly found cardiovascular profile of patients with OSA was: obesity, hypert
ension, low plasma levels of HDL and left atrial diameter increased.#^dnd^i2#^tm
^len^kSleep apnea^i2^sobstructive#^tm^len^kobesity^i2#^tm^len^khypertension^i2#^
tm^len^kdyslipidemia^i2#vancouv#40#aop02311.htm##
04771000000000649000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106038000400110121000300114049000300117
15800030012003000190012303200060014206500090014801400070015703500100016422300090
01740120069001830120068002520100032003200100025003520100028003770100027004050100
03200432010003000464010002500494010002600519070006400545083165400609085000802263
08500430227108500220231408500240233608500250236008315080238508500080389308500370
39010850020039380850025039580850025039831170008040080720003040160020013040190080
08904032#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#l#4#1#
article#1#^a2011#tr#pt#br1.1#1#4.0#gra#tab#30#nd#nd#Arq. bras. cardiol#ahead#201
10000#^f0^l0#0066-782X#20110318#Perfil cardiovascular em pacientes com apneia ob
strutiva do sono^lpt#Cardiovascular profile in patients with obstructive sleep a
pnea^len#^rND^1A01^nFátima Dumas^sCintra#^rND^1A01^nSergio^sTufik#^rND^1A01^nAng
elo de^sPaola#^rND^1A01^nMárcia C^sFeres#^rND^1A01^nLuciane^sMelo-Fujita#^rND^1A
01^nWercules^sOliveira#^rND^1A01^nCamila^sRizzi#^rND^1A01^nDalva^sPoyares#^iA01^
1Universidade Federal de São Paulo^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: Apne
ia Obstrutiva do Sono (AOS) é um fator de risco para várias condições cardiovasc
ulares incluindo aumento na mortalidade cardiovascular. Sendo assim, é essencial
 o conhecimento das principais repercussões cardiovasculares dos distúrbios resp
iratórios do sono durante uma avaliação clínica. OBJETIVO: Analisar as caracterí
sticas cardiovasculares de pacientes com AOS. MÉTODOS: Pacientes submetidos a po
lissonografia basal foram consecutivamente selecionados do banco de dados do Ins
tituto do Sono entre março de 2007 e março de 2009. Todos os pacientes foram ori
entados a comparecer ao ambulatório para coleta de sangue, exame físico, eletroc
ardiograma de 12 derivações, espirometria, teste cardiopulmonar em esteira ergom
étrica e ecocardiograma transtorácico. O estudo foi aprovado pelo comitê de étic
a e pesquisa e registrado no site http://clinicaltrials.gov/ sob o número: NCT00
768625. RESULTADOS: Foram analisados 261 pacientes e 108 controles. As principai
s características dos pacientes com AOS foram: obesidade, hipertensão, baixos ní
veis plasmáticos de lipoproteínas de alta densidade (HDL) e aumento no diâmetro 
do átrio esquerdo quando comparados com controles (3,75 ± 0,42; 3,61 ± 0,41, p =
 0,001), respectivamente. Essas características associadas correspondem a um acr
éscimo de 16,6 vezes na probabilidade de ocorrência de AOS independentemente do 
relato de algum sintoma dessa desordem, como sonolência ou ronco. CONCLUSÃO: Na 
amostra avaliada, o perfil cardiovascular dos pacientes com AOS mais encontrado 
foi: obesidade, hipertensão arterial, baixos níveis plasmáticos de HDL e átrio e
squerdo com diâmetro aumentado.#^dnd^i1#^tm^lpt^kApneia do sono tipo obstrutiva^
i1#^tm^lpt^kobesidade^i1#^tm^lpt^khipertensão^i1#^tm^lpt^kdislipidemia^i1#^len^a
BACKGROUND: Obstructive Sleep Apnea (OSA) is a risk factor for several cardiovas
cular conditions including increased cardiovascular mortality. It is therefore e
ssential to know the major cardiovascular effects of sleep-disordered breathing 
during a clinical evaluation. OBJECTIVE: To analyze the cardiovascular character
istics of patients with OSA. METHODS: Patients underwent baseline polysomnograph
y and were consecutively selected from the database of the Sleep Institute betwe
en March 2007 and March 2009. All patients were instructed to attend the clinic 
for blood collection, physical examination, 12-lead electrocardiogram, spirometr
y, cardiopulmonary exercise testing on a treadmill and transthoracic echocardiog
raphy. The study was approved by the Research Ethics Committee and recorded at h
ttp://clinicaltrials.gov/ under number: NCT00768625. RESULTS: We analyzed 261 pa
tients and 108 controls. The main characteristics of patients with OSA were: obe
sity, hypertension, low plasma levels of high density lipoprotein (HDL) and incr
eased left atrial diameter compared with controls (3.75 ± 0.42; 3.61 ± 0.41, p =
 0.001), respectively. These associated characteristics correspond to a 16.6 inc
rease in the likelihood of OSA regardless of reporting any symptoms of this diso
rder, such as sleepiness or snoring. CONCLUSION: In the sample studied, the most
ly found cardiovascular profile of patients with OSA was: obesity, hypertension,
 low plasma levels of HDL and left atrial diameter increased.#^dnd^i2#^tm^len^kS
leep apnea^i2^sobstructive#^tm^len^kobesity^i2#^tm^len^khypertension^i2#^tm^len^
kdyslipidemia^i2#vancouv#40#aop02311.htm#Internet^ihttp://www.scielo.br/scielo.p
hp?script=sci_arttext&pid=S0066-782X2011005000030##
00383000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704014100083002001300224#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#5#1#article#194#<p><font siz
e="4" face="verdana"><b><a name="tx"></a>Perfil cardiovascular em pacientes com 
apneia obstrutiva do sono</b></font></p>     ^cY#aop02311.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#6#2#article#194#<p>&nbsp;</p
>     ^cY#aop02311.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#7#3#article#194#<p>&nbsp;</p
>     ^cY#aop02311.htm##
00456000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704021400083002001300297#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#8#4#article#194#<p><font siz
e="2" face="Verdana"><b>F&aacute;tima Dumas Cintra; Sergio Tufik; Angelo de Paol
a; M&aacute;rcia C. Feres; Luciane Melo&#45;Fujita; Wercules Oliveira; Camila Ri
zzi; Dalva Poyares</b></font></p>     ^cY#aop02311.htm##
00372000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704013000083002001300213#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#9#5#article#194#<p><font siz
e="2" face="Verdana"> Universidade Federal de S&atilde;o Paulo, S&atilde;o Paulo
, SP &#150; Brasil</font></p>     ^cY#aop02311.htm##
00335000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009200084002001300176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#10#6#article#194#<p><font si
ze="2" face="Verdana"><a href="#nt">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop02311.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#11#7#article#194#<p>&nbsp;</
p>     ^cY#aop02311.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#12#8#article#194#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop02311.htm##
00309000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704006600084002001300150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#13#9#article#194#<p><font si
ze="2" face="verdana"><b>RESUMO</b></font></p>     ^cY#aop02311.htm##
00673000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042900085002001300514#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#14#10#article#194#<p><font s
ize="2" face="Verdana"><b>FUNDAMENTO:</b> Apneia Obstrutiva do Sono (AOS) &eacut
e; um fator de risco para v&aacute;rias condi&ccedil;&otilde;es cardiovasculares
 incluindo aumento na mortalidade cardiovascular. Sendo assim, &eacute; essencia
l o conhecimento das principais repercuss&otilde;es cardiovasculares dos dist&ua
cute;rbios respirat&oacute;rios do sono durante uma avalia&ccedil;&atilde;o cl&i
acute;nica.    ^cY#aop02311.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010500085002001300190#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#15#11#article#194#<br>   <b>
OBJETIVO:</b> Analisar as caracter&iacute;sticas cardiovasculares de pacientes c
om AOS.    ^cY#aop02311.htm##
00927000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068300085002001300768#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#16#12#article#194#<br>   <b>
M&Eacute;TODOS:</b> Pacientes submetidos a polissonografia basal foram consecuti
vamente selecionados do banco de dados do Instituto do Sono entre mar&ccedil;o d
e 2007 e mar&ccedil;o de 2009. Todos os pacientes foram orientados a comparecer 
ao ambulat&oacute;rio para coleta de sangue, exame f&iacute;sico, eletrocardiogr
ama de 12 deriva&ccedil;&otilde;es, espirometria, teste cardiopulmonar em esteir
a ergom&eacute;trica e ecocardiograma transtor&aacute;cico. O estudo foi aprovad
o pelo comit&ecirc; de &eacute;tica e pesquisa e registrado no site <a href="htt
p://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a> sob o n&
uacute;mero: NCT00768625.    ^cY#aop02311.htm##
00891000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064700085002001300732#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#17#13#article#194#<br>   <b>
RESULTADOS:</b> Foram analisados 261 pacientes e 108 controles. As principais ca
racter&iacute;sticas dos pacientes com AOS foram: obesidade, hipertens&atilde;o,
 baixos n&iacute;veis plasm&aacute;ticos de lipoprote&iacute;nas de alta densida
de (HDL) e aumento no di&acirc;metro do &aacute;trio esquerdo quando comparados 
com controles (3,75 &plusmn; 0,42; 3,61 &plusmn; 0,41, p = 0,001), respectivamen
te. Essas caracter&iacute;sticas associadas correspondem a um acr&eacute;scimo d
e 16,6 vezes na probabilidade de ocorr&ecirc;ncia de AOS independentemente do re
lato de algum sintoma dessa desordem, como sonol&ecirc;ncia ou ronco.    ^cY#aop
02311.htm##
00524000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028000085002001300365#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#18#14#article#194#<br>   <b>
CONCLUS&Atilde;O:</b> Na amostra avaliada, o perfil cardiovascular dos pacientes
 com AOS mais encontrado foi: obesidade, hipertens&atilde;o arterial, baixos n&i
acute;veis plasm&aacute;ticos de HDL e &aacute;trio esquerdo com di&acirc;metro 
aumentado.</font></p>     ^cY#aop02311.htm##
00421000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017700085002001300262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#19#15#article#194#<p><font s
ize="2" face="Verdana"><b>Palavras&#45;chave:</b> Apneia do sono tipo obstrutiva
, obesidade, hipertens&atilde;o, dislipidemia</font></p> <hr size="1" noshade>  
   ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#20#16#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#21#17#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#22#18#article#194#<p><font s
ize="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop023
11.htm##
01428000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704118400085002001301269#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#23#19#article#194#<p><font s
ize="2" face="Verdana">A Apneia Obstrutiva do Sono (AOS) &eacute; uma condi&cced
il;&atilde;o comum causada por colapso intermitente da via a&eacute;rea durante 
o sono que resulta em hip&oacute;xia repetitiva, despertar, piora na qualidade d
e sono e sonol&ecirc;ncia excessiva diurna. AOS &eacute; um fator de risco para 
v&aacute;rias condi&ccedil;&otilde;es cardiovasculares como hipertens&atilde;o a
rterial<SUP>1,2</SUP>, insufici&ecirc;ncia card&iacute;aca congestiva<SUP>3</SUP
>, acidente vascular cerebral<SUP>4</SUP>, doen&ccedil;a arterial coronariana<SU
P>5</SUP>, s&iacute;ndrome metab&oacute;lica<SUP>6</SUP> e arritmias card&iacute
;acas<SUP>7</SUP>. Recentemente, a AOS foi associada ao aumento na mortalidade c
ardiovascular<SUP>8&#45;10</SUP> em pacientes com a forma grave da doen&ccedil;a
 sem tratamento. Al&eacute;m disso, tratamento adequado com CPAP (<I>Continuos P
ositive Airway Pressure</I>) pode melhorar a sobrevida<SUP>8</SUP>. Dessa forma,
 torna&#45;se essencial o conhecimento das principais repercuss&otilde;es cardio
vasculares dos dist&uacute;rbios respirat&oacute;rios do sono durante uma avalia
&ccedil;&atilde;o cl&iacute;nica. </font></p>     ^cY#aop02311.htm##
00830000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058600085002001300671#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#24#20#article#194#<p><font s
ize="2" face="Verdana">Al&eacute;m disso, &eacute; relatada baixa taxa de diagn&
oacute;stico realizada por cardiologistas<SUP>11</SUP>. Isso pode ser parcialmen
te explicado pelo fato de invent&aacute;rios de investiga&ccedil;&atilde;o de di
st&uacute;rbios do sono n&atilde;o serem inclu&iacute;dos nas avalia&ccedil;&oti
lde;es cardiol&oacute;gicas e as caracter&iacute;sticas cardiovasculares desses 
pacientes ainda estarem em investiga&ccedil;&atilde;o. Sendo assim, o objetivo d
este estudo &eacute; analisar o perfil cardiovascular de pacientes com AOS. </fo
nt></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#25#21#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00318000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007400085002001300159#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#26#22#article#194#<p><font s
ize="3" face="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#aop02311.htm##
00327000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008300085002001300168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#27#23#article#194#<p><font s
ize="2" face="Verdana"><b>Popula&ccedil;&atilde;o</b></font></p>     ^cY#aop0231
1.htm##
01206000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704096200085002001301047#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#28#24#article#194#<p><font s
ize="2" face="Verdana">Pacientes submetidos a polissonografia basal foram consec
utivamente selecionados do banco de dados do Instituto do Sono, S&atilde;o Paulo
, Brasil, entre mar&ccedil;o de 2007 e mar&ccedil;o de 2009. Os crit&eacute;rios
 de inclus&atilde;o foram: idade superior a 30 anos, sedent&aacute;rios, aus&eci
rc;ncia de hospitaliza&ccedil;&otilde;es recentes ou troca de medica&ccedil;&oti
lde;es. Foram considerados crit&eacute;rios de exclus&atilde;o: IMC&gt;40, doen&
ccedil;a pulmonar cr&ocirc;nica definida como FEV1/FVC abaixo de 0,7<SUP>12</SUP
> durante a espirometria, tabagismo, doen&ccedil;as sist&ecirc;micas graves e gr
avidez. Um &iacute;ndice de apneia/hipopneia (IAH) &gt;5 foi considerado diagn&o
acute;stico para AOS. O grupo controle foi formado por pacientes com IAH &lt;5. 
Pacientes foram divididos de acordo com o IAH em: leve (5 a 15 eventos/h); moder
ado (15 a 30 eventos/h) e grave (&gt;30 eventos/h). </font></p>     ^cY#aop02311
.htm##
00933000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068900085002001300774#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#29#25#article#194#<p><font s
ize="2" face="Verdana">Todos os participantes foram orientados a evitar cafe&iac
ute;na e fumo e a comparecerem ao servi&ccedil;o com 8 horas de jejum para a col
eta de sangue, exame f&iacute;sico, preenchimento da escala de sonol&ecirc;ncia 
de Epworth (ESE), eletrocardiograma de 12 deriva&ccedil;&otilde;es, espirometria
, teste cardiopulmonar em esteira ergom&eacute;trica, e ecocardiograma transtor&
aacute;cico. O estudo foi aprovado pelo comit&ecirc; de &eacute;tica da Universi
dade Federal de S&atilde;o Paulo e registrado no site <u><a href="http://clinica
ltrials.gov/" target="_blank">http://clinicaltrials.gov/</a></u> sob o n&uacute;
mero: NCT00768625. </font></p>     ^cY#aop02311.htm##
00319000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007500085002001300160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#30#26#article#194#<p><font s
ize="2" face="Verdana"><b>Polissonografia</b></font></p>     ^cY#aop02311.htm##
00758000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051400085002001300599#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#31#27#article#194#<p><font s
ize="2" face="Verdana">A polissonografia foi realizada utilizando o sistema digi
tal EMBLA<SUP>&reg;</SUP> (17 canais, Medicare Medical Devices). As seguintes va
ri&aacute;veis foram monitoradas: eletroencefalograma (4 canais: C3&#45;A2, C4&#
45;A1, O1&#45;A2, O2&#45;A1), eletro&#45;oculograma,  (2 canais: LOC&#45;A2, ROC
&#45;A1), eletromiograma (2 canais: submentoniano e m&uacute;sculo tibial anteri
or), eletrocardiograma (1 canal), ronco e sensor de posi&ccedil;&atilde;o corpor
al. </font></p>     ^cY#aop02311.htm##
01092000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704084800085002001300933#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#32#28#article#194#<p><font s
ize="2" face="Verdana">O fluxo a&eacute;reo foi monitorado utilizando um termist
or e c&acirc;nula e o esfor&ccedil;o respirat&oacute;rio, atrav&eacute;s de cint
as tor&aacute;cicas e abdominais. A satura&ccedil;&atilde;o de oxig&ecirc;nio e 
o pulso foram registrados por ox&iacute;metro de pulso (Nonin&reg;, model 9500, 
Plymouth, USA). Todas as polissonografias foram executadas e analisadas por t&ea
cute;cnicos segundo as diretrizes para estudos do sono<SUP>13</SUP>, e foram rev
isados por um m&eacute;dico especialista em fisiologia do sono. Os despertares f
oram definidos de acordo com diretrizes da Sleep Disorders Atlas Task Force of t
he American Sleep Disorders Association<SUP>14</SUP>, e os eventos respirat&oacu
te;rios classificados usando crit&eacute;rios da American Academy of Sleep Medic
ine<SUP>15</SUP>. </font></p>     ^cY#aop02311.htm##
00325000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008100085002001300166#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#33#29#article#194#<p><font s
ize="2" face="Verdana"><b>Testes laboratoriais </b></font></p>     ^cY#aop02311.
htm##
00631000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038700085002001300472#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#34#30#article#194#<p><font s
ize="2" face="Verdana">Foram coletados 30 ml de sangue venoso para determina&cce
dil;&atilde;o dos seguintes par&acirc;metros: <I>Brain Natriuretc Peptide</I> (B
NP), hemograma, velocidade de hemossedimenta&ccedil;&atilde;o (VHS), glicemia de
 jejum, colesterol e fra&ccedil;&otilde;es, triglic&eacute;rides, ureia, creatin
ina, s&oacute;dio e pot&aacute;ssio. </font></p>     ^cY#aop02311.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010300085002001300188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#35#31#article#194#<p><font s
ize="2" face="Verdana"><b>Avalia&ccedil;&atilde;o cardiol&oacute;gica</b></font>
</p>     ^cY#aop02311.htm##
01419000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704117500085002001301260#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#36#32#article#194#<p><font s
ize="2" face="Verdana">Pacientes e controles foram submetidos a avalia&ccedil;&a
tilde;o cardiol&oacute;gica, em at&eacute; tr&ecirc;s meses ap&oacute;s a realiz
a&ccedil;&atilde;o da polissonografia, incluindo: exame f&iacute;sico, press&ati
lde;o arterial, eletrocardiograma (ECG) com 12 deriva&ccedil;&otilde;es e &iacut
e;ndice tornozelo&#45;bra&ccedil;o (ITB). O ECG de 12 deriva&ccedil;&otilde;es f
oi realizado com avalia&ccedil;&otilde;es de frequ&ecirc;ncia card&iacute;aca ba
sal e intervalo de QT corrigida pela frequ&ecirc;ncia card&iacute;aca (QTc) usan
do a "f&oacute;rmula de <I>Bazzet</I>". O ITB foi obtido ap&oacute;s 10 min de r
epouso na posi&ccedil;&atilde;o supina e a press&atilde;o sist&oacute;lica reali
zada pelo Doppler no tornozelo, na art&eacute;ria tibial e na art&eacute;ria bra
quial. A press&atilde;o arterial sist&oacute;lica mais elevada em cada perna foi
 ent&atilde;o dividida pela press&atilde;o m&eacute;dia sist&oacute;lica em ambo
s os bra&ccedil;os. Em caso de uma diferen&ccedil;a de <u>&gt;</u>10 mmHg entre 
os dois bra&ccedil;os, o procedimento foi repetido, considerando&#45;se a m&eacu
te;dia das duas medidas. </font></p>     ^cY#aop02311.htm##
00462000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704021800085002001300303#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#37#33#article#194#<p><font s
ize="2" face="Verdana">Par&acirc;metros antropom&eacute;tricos como peso, altura
, circunfer&ecirc;ncia abdominal e &Iacute;ndice de Massa Corp&oacute;rea (IMC) 
foram tamb&eacute;m obtidos.</font></p>     ^cY#aop02311.htm##
00354000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011000085002001300195#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#38#34#article#194#<p><font s
ize="2" face="Verdana"><b>Teste cardiopulmonar em esteira ergom&eacute;trica</b>
</font></p>     ^cY#aop02311.htm##
01015000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077100085002001300856#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#39#35#article#194#<p><font s
ize="2" face="Verdana">Uma subgrupo de 70 homens n&atilde;o obesos, definidos co
m um &Iacute;ndice de Massa Corporal (IMC) &lt;28, foi selecionado e submetido a
o teste cardiopulmonar (ErgoPC13, Micromed &reg;, Bras&iacute;lia, Brasil), sob 
monitoriza&ccedil;&atilde;o eletrocardiogr&aacute;fica, press&oacute;rica e com 
ox&iacute;metro de pulso (Nonin &reg;, modelo 9500, Plymouth, EUA), sendo analis
adas as seguintes vari&aacute;veis: consumo de oxig&ecirc;nio (VO<SUB>2</SUB>), 
produ&ccedil;&atilde;o de di&oacute;xido de carbono (VCO<SUB>2</SUB>), ventila&c
cedil;&atilde;o/ minuto (VE), frequ&ecirc;ncia respirat&oacute;ria (RR), e o vol
ume corrente (VC) atrav&eacute;s de uma m&aacute;scara (Vista CPX &reg;, Vacumed
, Ventura, CA, EUA). </font></p>     ^cY#aop02311.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009500085002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#40#36#article#194#<p><font s
ize="2" face="Verdana"><b>Ecocardiograma transtor&aacute;cico</b></font></p>    
 ^cY#aop02311.htm##
01019000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077500085002001300860#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#41#37#article#194#<p><font s
ize="2" face="Verdana">Todos os pacientes foram submetidos a ecocardiografia tra
nstor&aacute;cica bidimensional (iE33 &#45;Philips Electronics,&Ograve; Holanda)
, de acordo com as diretrizes da American Society of Echocardiography<SUP>16</SU
P>. Medidas lineares dos di&acirc;metros sist&oacute;licos e diast&oacute;licos 
finais do ventr&iacute;culo esquerdo foram obtidas, assim como a sua fra&ccedil;
&atilde;o de eje&ccedil;&atilde;o, utilizando&#45;se o m&eacute;todo de Teichhol
z. O di&acirc;metro &acirc;ntero&#45;posterior do &aacute;trio esquerdo foi medi
do da borda posterior da parede da raiz a&oacute;rtica at&eacute; a borda poster
ior do &aacute;trio esquerdo no final da s&iacute;stole ventricular, num corte p
araesternal longitudinal.</font></p>     ^cY#aop02311.htm##
00317000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007300085002001300158#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#42#38#article#194#<p><font s
ize="2" face="Verdana"><b>Espirometria </b></font></p>     ^cY#aop02311.htm##
00809000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056500085002001300650#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#43#39#article#194#<p><font s
ize="2" face="Verdana">Foram realizados testes de fun&ccedil;&atilde;o pulmonar 
com espir&ocirc;metro computadorizado (Koko, Pulmonary Data Service Instrumentat
ion, Inc., Louisville, KY, EUA), seguindo as recomenda&ccedil;&otilde;es vigente
s<SUP>12</SUP> para excluir a doen&ccedil;a pulmonar. O volume expirat&oacute;ri
o for&ccedil;ado no primeiro segundo (VEF1), a capacidade vital for&ccedil;ada (
CVF) e a rela&ccedil;&atilde;o VEF1/CVF foram avaliados para cada individuo e re
gistrados em valores absolutos e percentual do predito.</font></p>     ^cY#aop02
311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#44#40#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00338000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009400085002001300179#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#45#41#article#194#<p><font s
ize="3" face="Verdana"><b>An&aacute;lise estat&iacute;stica </b></font></p>     
^cY#aop02311.htm##
00569000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032500085002001300410#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#46#42#article#194#<p><font s
ize="2" face="Verdana">Os resultados foram apresentados com m&eacute;dia e desvi
o&#45;padr&atilde;o. Os grupos foram comparados usando testes de ANOVA e Chi qua
drado. Teste Post hoc de Bonferroni foram aplicados quando necess&aacute;rios. V
alor de p &lt; ou = 0,05 foi considerado significante. </font></p>     ^cY#aop02
311.htm##
00621000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037700085002001300462#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#47#43#article#194#<p><font s
ize="2" face="Verdana">Foi usada regress&atilde;o log&iacute;stica para estimar 
a raz&atilde;o de chance (<I>Odds Ratios</I>). O modelo final foi aplicado aos p
acientes com AOS moderada e severa (IAH &gt;15), incluindo as vari&aacute;veis q
ue permaneceram significativas ap&oacute;s ajuste para fatores de confus&atilde;
o, como: IMC, sexo e idade.</font></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#48#44#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00314000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007000085002001300155#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#49#45#article#194#<p><font s
ize="3" face="Verdana"><b>Resultados</b></font></p>     ^cY#aop02311.htm##
00578000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033400085002001300419#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#50#46#article#194#<p><font s
ize="2" face="Verdana">Foram selecionados 380 indiv&iacute;duos. Onze foram excl
u&iacute;dos; 2, em raz&atilde;o de hist&oacute;ria de asma br&ocirc;nquica; 8, 
por tabagismo; e 1, por suspeita cl&iacute;nica de angina inst&aacute;vel. Um to
tal de 261 pacientes (IAH &gt;5) e 108 controles foi analisado. </font></p>     
^cY#aop02311.htm##
00758000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051400085002001300599#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#51#47#article#194#<p><font s
ize="2" face="Verdana">As caracter&iacute;sticas basais da popula&ccedil;&atilde
;o s&atilde;o apresentadas na <a href="#tab01">Tabela 1</a>. N&atilde;o houve di
feren&ccedil;as quanto a idade, sexo, frequ&ecirc;ncia de hipertens&atilde;o art
erial ou diabetes. Pacientes com AOS apresentaram maior IMC (29,6 &plusmn; 5,9; 
27,1 &plusmn; 4,3) e circunfer&ecirc;ncia abdominal (98,7 &plusmn; 14,2; 91,0 &p
lusmn; 11,1) quando comparados com o grupo controle (p &lt; 0,001), respectivame
nte.</font></p>     ^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#52#48#article#194#<p><a name
="tab01"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#53#49#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#54#50#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23tab01.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#55#51#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00798000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055400085002001300639#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#56#52#article#194#<p><font s
ize="2" face="Verdana"> Os par&acirc;metros polissonogr&aacute;ficos s&atilde;o 
apresentados na <a href="#tab02">Tabela 2</a>. Como esperado, o IAH foi maior em
 pacientes com AOS quando comparados com controles (28,0 &plusmn; 22,2 e 2,9 &pl
usmn; 1,4, respectivamente, p &lt; 0,001). A porcentagem de sono REM e est&aacut
e;gio 1 do sono NREM diferiu entre os grupos (pacientes: 96,9 &plusmn; 15,4; con
troles: 99,9 &plusmn; 5,9, p = 0,05 e pacientes: 5,3 &plusmn; 4,8; controles: 4,
2 &plusmn; 3,1, p = 0,02, respectivamente). </font></p>     ^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#57#53#article#194#<p><a name
="tab02"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#58#54#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#59#55#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23tab02.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#60#56#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00898000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704065400085002001300739#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#61#57#article#194#<p><font s
ize="2" face="Verdana">A satura&ccedil;&atilde;o m&iacute;nima foi menor nos pac
ientes do que controles (82,9 &plusmn; 1,4, 89,4 &plusmn; 3,8, respectivamente, 
p &lt; 0,001). A lat&ecirc;ncia do sono REM foi maior em pacientes com AOS do qu
e os controles (121,1 &plusmn; 73,3, 104,8 &plusmn; 57,8, p = 0,04). Pacientes c
om AOS foram caracterizados por n&iacute;veis elevados de press&atilde;o arteria
l sist&oacute;lica e diast&oacute;lica, quando comparados ao grupo controle. A f
requ&ecirc;ncia card&iacute;aca basal, o intervalo QT corrigido e o ITB n&atilde
;o apresentaram diferen&ccedil;as (<a href="#tab03">tab. 3</a>).</font></p>     
^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#62#58#article#194#<p><a name
="tab03"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#63#59#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#64#60#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23tab03.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#65#61#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00583000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033900085002001300424#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#66#62#article#194#<p><font s
ize="2" face="Verdana">O di&acirc;metro do &aacute;trio esquerdo foi maior em pa
cientes com AOS quando comparados com os controles (3,75 &plusmn; 0,42 e 3,61 &p
lusmn; 0,41, respectivamente, p = 0,001). Outros par&acirc;metros ecocardiogr&aa
cute;ficos n&atilde;o apresentaram diferen&ccedil;as significativas. </font></p>
     ^cY#aop02311.htm##
01018000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077400085002001300859#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#67#63#article#194#<p><font s
ize="2" face="Verdana">As an&aacute;lises sangu&iacute;neas entre os grupos est&
atilde;o apresentadas na <a href="#tab04">Tabela 4</a>. Foi observado maior glic
emia em pacientes comparados aos controles (110,51 &plusmn; 30,79 e 103,24 &plus
mn; 22,40, respectivamente, p = 0,002). A <a href="#fig01">fig. 1A</a> mostra o 
n&iacute;vel de glicemia de jejum de acordo com a gravidade da AOS. Lipoprote&ia
cute;na de alta densidade (HDL) foi menor em pacientes com AOS comparados aos co
ntroles (53,25 &plusmn; 11,43 e 56,80 &plusmn; 14,23, respectivamente, p = 0,001
). An&aacute;lises <I>post hoc </I>novamente mostraram uma diferen&ccedil;a sign
ificativa entre pacientes com AOS graves e controles (p = 0,001) e AOS moderada 
e controles (p = 0,002).</font></p>     ^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#68#64#article#194#<p><a name
="tab04"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#69#65#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#70#66#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23tab04.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#71#67#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#72#68#article#194#<p><a name
="fig01"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#73#69#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#74#70#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23fig01.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#75#71#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00393000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014900085002001300234#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#76#72#article#194#<p><font s
ize="2" face="Verdana">A <a href="#fig01">fig. 1B</a> mostra os n&iacute;veis de
 HDL de acordo com a gravidade da AOS. </font></p>     ^cY#aop02311.htm##
01431000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704118700085002001301272#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#77#73#article#194#<p><font s
ize="2" face="Verdana">O teste ergoespirom&eacute;trico foi realizado em 44 paci
entes n&atilde;o obesos, com AOS, e 26 controles. N&atilde;o foram encontradas d
iferen&ccedil;as quanto a idade (51,13 &plusmn; 8,59, 48,16 &plusmn; 9,16, p = 0
,18), IMC (25,49 &plusmn; 2,35, 25,27 &plusmn; 1,85, p = 0,69), press&atilde;o a
rterial sist&oacute;lica (123,48 &plusmn; 14,74, 120,60 &plusmn; 11,30, p = 0,40
), press&atilde;o arterial diast&oacute;lica (81,27 &plusmn; 8,93, 82,00 &plusmn
; 8,29, respectivamente, p = 0,74), ou frequ&ecirc;ncia card&iacute;aca (78,41 &
plusmn; 14,42, 79,64 &plusmn; 10,39, p = 0,71) entre os grupos. Os dados relacio
nados ao pico de esfor&ccedil;o s&atilde;o apresentados na <a href="#tab05">Tabe
la 5</a>. N&atilde;o houve diferen&ccedil;a nas vari&aacute;veis analisadas. Cas
os de isquemia do mioc&aacute;rdio ou arritmia card&iacute;aca n&atilde;o foram 
observados. Associa&ccedil;&otilde;es univariadas entre as caracter&iacute;stica
s cardiovasculares e AOS s&atilde;o apresentadas na <a href="#tab06">Tabela 6</a
>. A <a href="#tab07">Tabela 7</a> mostra a raz&atilde;o de chance, ap&oacute;s 
o ajuste para fatores confundidores. </font></p>     ^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#78#74#article#194#<p><a name
="tab05"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#79#75#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#80#76#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23tab05.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#81#77#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#82#78#article#194#<p><a name
="tab06"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#83#79#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#84#80#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23tab06.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#85#81#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003600085002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#86#82#article#194#<p><a name
="tab07"></a></p>     ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#87#83#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00328000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008400085002001300169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#88#84#article#194#<p align="
center"><img src="/img/revistas/abc/2011nahead/a23tab07.jpg"></p>     ^cY#aop023
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#89#85#article#194#<p>&nbsp;<
/p>     ^cY#aop02311.htm##
00321000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704007700085002001300162#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#90#86#article#194#<p><font s
ize="3" face="Verdana"><b>Discuss&atilde;o </b></font></p>     ^cY#aop02311.htm#
#
01102000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704085800085002001300943#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#91#87#article#194#<p><font s
ize="2" face="Verdana">A AOS est&aacute; relacionada a v&aacute;rios mecanismos 
fisiopatol&oacute;gicos deflagrados pela hip&oacute;xia<SUP>17&#45;19</SUP> e fr
agmenta&ccedil;&atilde;o do sono<SUP>9,20,21</SUP>; incluindo ativa&ccedil;&atil
de;o simp&aacute;tica<SUP>17,22</SUP>, inflama&ccedil;&atilde;o<SUP>23,24</SUP>,
 disfun&ccedil;&atilde;o endotelial<SUP>25&#45;27</SUP>,  altera&ccedil;&atilde;
o na coagulabilidade<SUP>28</SUP>, dentre outros. Esses mecanismos podem levar a
 consequ&ecirc;ncias cardiovasculares, como hipertens&atilde;o arterial<SUP>29</
SUP>, arritmias card&iacute;acas<SUP>30</SUP>, s&iacute;ndrome metab&oacute;lica
<SUP>31</SUP> e insufici&ecirc;ncia card&iacute;aca<SUP>32</SUP>. Portanto, &eac
ute; dif&iacute;cil determinar uma caracter&iacute;stica cardiovascular &uacute;
nica nos pacientes com AOS. </font></p>     ^cY#aop02311.htm##
01042000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079800085002001300883#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#92#88#article#194#<p><font s
ize="2" face="Verdana">Este &eacute; o primeiro estudo que avaliou simultaneamen
te as caracter&iacute;sticas cardiovasculares em pacientes com AOS, incluindo a 
contribui&ccedil;&atilde;o individual de cada par&acirc;metro analisado, tais co
mo: dados cl&iacute;nicos, antropom&eacute;tricos, ecocardiogr&aacute;ficos e ca
rdiopulmonares. Como resultado, o perfil cardiovascular dos pacientes com AOS in
clui: obesidade, hipertens&atilde;o, baixos n&iacute;veis plasm&aacute;ticos de 
HDL e aumento do di&acirc;metro do &aacute;trio esquerdo. Juntas, essas caracter
&iacute;sticas correspondem a 16,6 vezes mais chance para ocorr&ecirc;ncia de OS
A, independentemente de investiga&ccedil;&atilde;o de qualquer sintoma dessa des
ordem (por exemplo, sonol&ecirc;ncia ou ronco). </font></p>     ^cY#aop02311.htm
##
01193000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704094900085002001301034#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#93#89#article#194#<p><font s
ize="2" face="Verdana">Como esperado, as vari&aacute;veis de polissonografias di
feriram entre indiv&iacute;duos AOS e n&atilde;o AOS. Indiv&iacute;duos AOS apre
sentaram menor satura&ccedil;&atilde;o de oxig&ecirc;nio e maiores IAH, est&aacu
te;gio 1 do sono n&atilde;o REM e lat&ecirc;ncia do sono REM. O &uacute;ltimo ac
hado &eacute; provavelmente associado com a diminui&ccedil;&atilde;o do sono REM
 nesse grupo. Interessantemente, o grupo AOS n&atilde;o foi significativamente m
ais sonolento do que indiv&iacute;duos n&atilde;o AOS. Acreditamos que uma poss&
iacute;vel explica&ccedil;&atilde;o para esse achado &eacute; que a escala de so
nol&ecirc;ncia de Epworth n&atilde;o est&aacute; adequadamente adaptada &agrave;
 nossa popula&ccedil;&atilde;o. No entanto, a pontua&ccedil;&atilde;o m&eacute;d
ia do grupo AOS foi ligeiramente superior ao dos n&atilde;o AOS e ficou acima do
 valor limite para a sonol&ecirc;ncia. </font></p>     ^cY#aop02311.htm##
01206000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704096200085002001301047#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#94#90#article#194#<p><font s
ize="2" face="Verdana">A hipertens&atilde;o arterial &eacute; a mais comum conse
qu&ecirc;ncia de AOS na pr&aacute;tica cl&iacute;nica. Peppard e cols.<SUP>29</S
UP> encontraram uma rela&ccedil;&atilde;o entre dist&uacute;rbios respirat&oacut
e;rios do sono e hipertens&atilde;o, ap&oacute;s ajuste para h&aacute;bitos, ida
de, sexo, tabagismo e uso de &aacute;lcool. Pacientes com sono leve e com grave 
transtorno respirat&oacute;rio tiveram cerca de duas a tr&ecirc;s vezes maior ch
ance de apresentar hipertens&atilde;o arterial quando comparados com indiv&iacut
e;duos sem apneia ou hipopneia. Em um estudo caso&#45;controle<SUP>33</SUP>, os 
investigadores estudaram a associa&ccedil;&atilde;o entre hipertens&atilde;o res
istente e dist&uacute;rbios do sono avaliado pelo Question&aacute;rio de Berlim 
e pela ESE, e demonstraram que alto risco para o diagn&oacute;stico de AOS foi a
ltamente associado a hipertens&atilde;o resistente. </font></p>     ^cY#aop02311
.htm##
01076000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083200085002001300917#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#95#91#article#194#<p><font s
ize="2" face="Verdana">Quando, por&eacute;m, a hipertens&atilde;o arterial foi c
onsiderada isoladamente, nossos resultados mostraram que o risco de um diagn&oac
ute;stico de AOS aumentou apenas 1,8 vez. Embora a hipertens&atilde;o arterial s
eja a consequ&ecirc;ncia mais comum da AOS, a obesidade &eacute; um achado muito
 frequente nesses pacientes; assim, a possibilidade de ocorr&ecirc;ncia de AOS &
eacute; reduzida quando a amostra &eacute; ajustada. Baixos n&iacute;veis de HDL
 isoladamente correspondem a 2,7 vezes mais chances para o diagn&oacute;stico de
 AOS. Quando o c&aacute;lculo leva em considera&ccedil;&atilde;o a hipertens&ati
lde;o e os n&iacute;veis mais baixos de HDL em conjunto, no entanto, ocorre um a
umento na probabilidade de AOS em 4,8 vezes em nosso estudo, para ambos os sexos
. </font></p>     ^cY#aop02311.htm##
01244000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704100000085002001301085#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#96#92#article#194#<p><font s
ize="2" face="Verdana">A rela&ccedil;&atilde;o entre o HDL&#45;colesterol e AOS 
tem sido estudada. Tan e cols.<SUP>34</SUP> mostraram altera&ccedil;&atilde;o no
 HDL em pacientes com AOS, sendo o IAH o principal determinante dessa altera&cce
dil;&atilde;o. Em protocolos experimentais, Savransky e cols.<SUP>35</SUP> inves
tigaram se a hip&oacute;xia intermitente cr&ocirc;nica poderia induzir a aterosc
lerose em camundongos. Nove em cada dez ratos expostos a hip&oacute;xia intermit
ente e uma dieta rica em colesterol desenvolveram les&otilde;es ateroscler&oacut
e;ticas, juntamente com aumentos significativos nos n&iacute;veis de colesterol 
total e LDL&#45;colesterol e uma diminui&ccedil;&atilde;o nos n&iacute;veis de H
DL&#45;colesterol. Por sua vez, nossos achados n&atilde;o foram reproduzidos por
 outros autores. Kono e cols.<SUP>36</SUP> n&atilde;o encontraram diferen&ccedil
;as nos n&iacute;veis de HDL&#45;colesterol em pacientes com AOS comparados aos 
controles.</font></p>     ^cY#aop02311.htm##
02453000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704220900085002001302294#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#97#93#article#194#<p><font s
ize="2" face="Verdana">Outro achado interessante &eacute; o aumento significativ
o do di&acirc;metro do &aacute;trio esquerdo nos indiv&iacute;duos AOS, em compa
ra&ccedil;&atilde;o com os n&atilde;o AOS. Os mecanismos envolvidos na amplia&cc
edil;&atilde;o do &aacute;trio esquerdo permanecem sob investiga&ccedil;&atilde;
o. Oliveira e cols.<SUP>37</SUP> relataram um preju&iacute;zo na fun&ccedil;&ati
lde;o ventricular esquerda diast&oacute;lica em indiv&iacute;duos com AOS n&atil
de;o hipertensos. O aumento na press&atilde;o de enchimento ventricular esquerdo
 poderia dificultar o esvaziamento atrial esquerdo, o que acabaria por iniciar u
m processo de remodela&ccedil;&atilde;o estrutural e funcional no &aacute;trio e
squerdo. Orban e cols.<SUP>38</SUP> estudaram as altera&ccedil;&otilde;es agudas
 nos di&acirc;metros card&iacute;acos esquerdos durante uma simula&ccedil;&atild
e;o de AOS utilizando a manobra de Mueller. Imposi&ccedil;&atilde;o repentina da
 press&atilde;o negativa intrator&aacute;cica grave levou a uma queda abrupta do
 volume atrial esquerdo e uma redu&ccedil;&atilde;o no desempenho sist&oacute;li
co do ventr&iacute;culo esquerdo. As mudan&ccedil;as repetidas da p&oacute;s&#45
;carga e volumes de c&acirc;mara podem ter aumentado o di&acirc;metro do &aacute
;trio esquerdo em nosso grupo de pacientes, uma vez que a dimens&atilde;o do &aa
cute;trio esquerdo pode ser contemplada como uma express&atilde;o morfol&oacute;
gica do aumento das press&otilde;es de enchimento ventricular, que por sua vez e
st&aacute; diretamente relacionado ao aumento da p&oacute;s&#45;carga<SUP>39</SU
P>. Al&eacute;m disso, Khan e cols.<SUP>40</SUP> identificaram retrospectivament
e 47 pacientes com AOS recebendo CPAP que tinham ecocardiograma realizado antes 
e depois da polissonografia. O volume do &aacute;trio esquerdo n&atilde;o diminu
iu significativamente (p = 0,65) com uso de CPAP, ao passo que houve aumento des
sa cavidade (p &lt; 0,006) nos pacientes que abandonaram o tratamento. Al&eacute
;m disso, no grupo n&atilde;o tratado, o aumento do volume do &aacute;trio esque
rdo n&atilde;o foi associado a altera&ccedil;&otilde;es significativas na press&
atilde;o arterial. </font></p>     ^cY#aop02311.htm##
01114000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087000085002001300955#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#98#94#article#194#<p><font s
ize="2" face="Verdana">As medidas antropom&eacute;tricas mostraram uma diferen&c
cedil;a significativa no IMC, bem como a circunfer&ecirc;ncia abdominal entre os
 grupos.  H&aacute; um crescente debate sobre o papel da obesidade na OSA, com f
oco espec&iacute;fico sobre se a obesidade &eacute; parte da s&iacute;ndrome OSA
. A raz&atilde;o de chance da obesidade para a AOS foi de 1,9, semelhante &agrav
e; da hipertens&atilde;o. Dessa forma, se a equipe m&eacute;dica cardiol&oacute;
gica analisar o IMC por si s&oacute;, pode estar subestimando a suspeita de AOS.
 &Eacute; importante salientar que o grupo controle foi formado por indiv&iacute
;duos sem AOS (AIH &lt; 5), o que &eacute; considerado uma limita&ccedil;&atilde
;o do estudo, uma vez que poderia incluir algumas formas leves de dist&uacute;rb
ios respirat&oacute;rios durante o sono.</font></p>     ^cY#aop02311.htm##
00697000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045300085002001300538#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#99#95#article#194#<p><font s
ize="2" face="Verdana">Como conclus&atilde;o, um marcador &uacute;nico e poderos
o &eacute; improv&aacute;vel que seja encontrado em uma doen&ccedil;a multifator
ial como a AOS. Assim, as associa&ccedil;&otilde;es de caracter&iacute;sticas co
mo obesidade, hipertens&atilde;o arterial, baixos n&iacute;veis plasm&aacute;tic
os de HDL e aumento do di&acirc;metro do AE representam o perfil cardiovascular 
dos pacientes com AOS. </font></p>     ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002200086002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#100#96#article#194#<p>&nbsp;
</p>     ^cY#aop02311.htm##
00319000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704007400086002001300160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#101#97#article#194#<p><font 
size="3" face="Verdana"><b>Agradecimentos</b></font></p>     ^cY#aop02311.htm##
00531000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704028600086002001300372#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#102#98#article#194#<p><font 
size="2" face="Verdana">Este estudo foi realizado com suporte da Funda&ccedil;&a
tilde;o de Amparo &agrave; Pesquisa do Estado de S&atilde;o Paulo (Fapesp), e da
 Associa&ccedil;&atilde;o Fundo de Incentivo a Psicofarmacologia (AFIP), S&atild
e;o Paulo, Brasil</font></p>     ^cY#aop02311.htm##
00337000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704009200086002001300178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#103#99#article#194#<p><font 
size="2" face="Verdana"><b>Potencial Conflito de Interesses</b></font></p>     ^
cY#aop02311.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704011300087002001300200#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#104#100#article#194#<p><font
 size="2" face="Verdana">Declaro n&atilde;o haver conflito de interesses pertine
ntes.</font></p>     ^cY#aop02311.htm##
00329000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704008300087002001300170#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#105#101#article#194#<p><font
 size="2" face="Verdana"><b>Fontes de Financiamento</b></font></p>     ^cY#aop02
311.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010500087002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#106#102#article#194#<p><font
 size="2" face="Verdana">O presente estudo foi financiado pela FAPESP / AFIP.</f
ont></p>     ^cY#aop02311.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010000087002001300187#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#107#103#article#194#<p><font
 size="2" face="Verdana"><b>Vincula&ccedil;&atilde;o Acad&ecirc;mica</b></font><
/p>     ^cY#aop02311.htm##
00437000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019100087002001300278#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#108#104#article#194#<p><font
 size="2" face="Verdana">Este artigo &eacute; parte de disserta&ccedil;&atilde;o
 de Mestrado de F&aacute;tima Cintra pela Universidade Federal de S&atilde;o Pau
lo.</font></p>     ^cY#aop02311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#109#105#article#194#<p>&nbsp
;</p>     ^cY#aop02311.htm##
00323000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704007700087002001300164#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#110#106#article#194#<p><font
 size="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop02311.ht
m##
00544000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028400089002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#111#107#article#
194#1#<p><font size="2" face="Verdana">1.  Nieto FJ, Young TB, Lind BK, Shahar E
, Samet JM, Redline S, et al. Association of sleep&#45;disordered breathing, sle
ep apnea, and hypertension in a large community&#45;based study. Sleep Heart Hea
lth Study. JAMA. 2000;283(14):1829&#45;36.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#112#108#article#194#</font><
/p>     ^cY#aop02311.htm##
00478000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704021800089002001300307#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#113#109#article#
194#2#<p><font size="2" face="Verdana">2. Peppard PE, Young T, Palta M, Skatrud 
J. Prospective study of the association between sleep&#45;disordered breathing a
nd hypertension. N Engl J Med. 2000;342(19):1378&#45;84.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#114#110#article#194#</font><
/p>     ^cY#aop02311.htm##
00547000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028700089002001300376#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#115#111#article#
194#3#<p><font size="2" face="Verdana">3. Shahar E, Whitney CW, Redline S, Lee E
T, Newman AB, Javier Nieto F, et al. Sleep&#45;disordered breathing and cardiova
scular disease: cross&#45;sectional results of the Sleep Heart Health Study. Am 
J Respir Crit Care Med 2001;163(1):19&#45;25.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#116#112#article#194#</font><
/p>     ^cY#aop02311.htm##
00531000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704027100089002001300360#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#117#113#article#
194#4#<p><font size="2" face="Verdana">4. Dziewas R, Humpert M, Hopmann B, Klosk
a SP, L&uuml;demann P, Ritter M, et al. Increased prevalence of sleep apnea in p
atients with recurring ischemic stroke compared with first stroke victims. J Neu
rol. 2005;252(11):1394&#45;8.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#118#114#article#194#</font><
/p>     ^cY#aop02311.htm##
00521000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704026100089002001300350#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#119#115#article#
194#5#<p><font size="2" face="Verdana">5. Sorajja D, Gami AS, Somers VK, Behrenb
eck TR, Garcia&#45;Touchard A, Lopez&#45;Jimenez F. Independent association betw
een obstructive sleep apnea and subclinical coronary artery disease. Chest. 2008
;133(4):927&#45;33.    ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#120#116#article#194# </font>
</p>     ^cY#aop02311.htm##
00507000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704024700089002001300336#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#121#117#article#
194#6#<p><font size="2" face="Verdana">6. Coughlin SR, Mawdsley L, Mugarza JA, C
alverley PM, Wilding JP. Obstructive sleep apnoea is independently associated wi
th an increased prevalence of metabolic syndrome. Eur Heart J. 2004;25(9):735&#4
5;41.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#122#118#article#194#</font><
/p>     ^cY#aop02311.htm##
00616000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704035600089002001300445#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#123#119#article#
194#7#<p><font size="2" face="Verdana">7. Simantirakis EN, Schiza SI, Marketou M
E, Chrysostomakis SI, Chlouverakis GI, Klapsinos NC, et al. Severe bradyarrhythm
ias in patients with sleep apnoea: the effect of continuous positive airway pres
sure treatment: a long&#45;term evaluation using an insertable loop recorder. Eu
r Heart J. 2004;25(12):1070&#45;6.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#124#120#article#194#</font><
/p>     ^cY#aop02311.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030300089002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#125#121#article#
194#8#<p><font size="2" face="Verdana">8. Marin JM, Carrizo SJ, Vicente E, Agust
i AG. Long&#45;term cardiovascular outcomes in men with obstructive sleep apnea&
#45;hypopnoea with or without treatment with continuous positive airway pressure
: an observational study. Lancet. 2005;365(9464):1046&#45;53.    ^cY#aop02311.ht
m##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#126#122#article#194#</font><
/p>     ^cY#aop02311.htm##
00499000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704023900089002001300328#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#127#123#article#
194#9#<p><font size="2" face="Verdana">9. Marshall NS, Wong KK, Liu PY, Cullen S
R, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all&#
45;cause mortality: the Busselton Health Study. Sleep 2008;31(8):1079&#45;85.   
 ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#128#124#article#194#</font><
/p>     ^cY#aop02311.htm##
00514000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025300090002001300343#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#129#125#article#
194#10#<p><font size="2" face="Verdana">10. Young T, Finn L, Peppard PE, Szklo&#
45;Coxe M, Austin D, Nieto FJ, et al. Sleep disordered breathing and mortality: 
eighteen&#45;year follow&#45;up of the Wisconsin sleep cohort. Sleep. 2008;31(8)
:1071&#45;8.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#130#126#article#194#</font><
/p>     ^cY#aop02311.htm##
00502000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024100090002001300331#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#131#127#article#
194#11#<p><font size="2" face="Verdana">11. Namen AM, Dunagan DP, Fleischer A, T
illett J, Barnett M, McCall WV, et al. Increased physician&#45;reported sleep ap
nea: the National Ambulatory Medical Care Survey. Chest. 2002;121(6):1741&#45;7.
    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#132#128#article#194#</font><
/p>     ^cY#aop02311.htm##
00428000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704016700090002001300257#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#133#129#article#
194#12#<p><font size="2" face="Verdana">12. Standardization of Spirometry, 1994 
Update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(3):1107&#
45;36.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#134#130#article#194#</font><
/p>     ^cY#aop02311.htm##
00522000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026100090002001300351#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#135#131#article#
194#13#<p><font size="2" face="Verdana">13. Rechtschaffen A, Kales A. A manual o
f standardized terminology, technique and scoring system for sleep stages of hum
an sleep, Los Angeles Brain Information Service, Brain Information Institute, Lo
s Angeles, CA; 1968.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#136#132#article#194#</font><
/p>     ^cY#aop02311.htm##
00481000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022000090002001300310#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#137#133#article#
194#14#<p><font size="2" face="Verdana">14. EEG arousals: scoring rules and exam
ples: a preliminary report from Sleep Disorders Atlas Task Force of the American
 Sleep Disorders Association. Sleep. 1992;15(2):173&#45;84.    ^cY#aop02311.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#138#134#article#194#</font><
/p>     ^cY#aop02311.htm##
00537000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027600090002001300366#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#139#135#article#
194#15#<p><font size="2" face="Verdana">15. Sleep&#45;related breathing disorder
s in adults: recommendations for syndrome definition and measurement techniques 
in clinical research. The report of an American Academy of Sleep Medicine Task F
orce. Sleep. 1999;22(5):667&#45;89.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#140#136#article#194#</font><
/p>     ^cY#aop02311.htm##
01063000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704080200090002001300892#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#141#137#article#
194#16#<p><font size="2" face="Verdana">16. Douglas PS, Khandheria B, Stainback 
RF, Weissman NJ, Brindis RG, Patel MR, et al. ACCF/ASE/ACEP/ ASNC/SCAI/SCCT/SCMR
 2007 appropriateness criteria for transthoracic and transesophageal echocardiog
raphy: a report of the American College of Cardiology Foundation Quality Strateg
ic Directions Committee Appropriateness Criteria Working Group, American Society
 of Echocardiography, American College of Emergency Physicians, American Society
 of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions
, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascu
lar Magnetic Resonance endorsed by the American College of Chest Physicians and 
the Society of Critical Care Medicine. J Am Coll Cardiol. 2007;50(2):187&#45;204
.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#142#138#article#194#</font><
/p>     ^cY#aop02311.htm##
00550000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028900090002001300379#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#143#139#article#
194#17#<p><font size="2" face="Verdana">17. Peled N, Greenberg A, Pillar G, Zind
er O, Levi N, Lavie P. Contributions of hypoxia and respiratory disturbance inde
x to sympathetic activation and blood pressure in obstructive sleep apnea syndro
me. Am J Hypertens. 1998;11(11 Pt 1):1284&#45;9.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#144#140#article#194#</font><
/p>     ^cY#aop02311.htm##
00459000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019800090002001300288#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#145#141#article#
194#18#<p><font size="2" face="Verdana">18. Fletcher EC. Cardiovascular conseque
nces of obstructive sleep apnea: experimental hypoxia and sympathetic activity. 
Sleep. 2000;23(Suppl. 4):S127&#45;31.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#146#142#article#194#</font><
/p>     ^cY#aop02311.htm##
00475000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021400090002001300304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#147#143#article#
194#19#<p><font size="2" face="Verdana">19. Remsburg S, Launois SH, Weiss JW. Pa
tients with obstructive sleep apnea have an abnormal peripheral vascular respons
e to hypoxia. J Appl Physiol. 1999;87(3):1148&#45;53.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#148#144#article#194#</font><
/p>     ^cY#aop02311.htm##
00583000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032200090002001300412#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#149#145#article#
194#20#<p><font size="2" face="Verdana">20. Bennett LS, Barbour C, Langford B, S
tradling JR, Davies RJ. Health status in obstructive sleep apnea: relationship w
ith sleep fragmentation and daytine sleepiness, and effects of continuous positi
ve airway pressure treatment. Am J Respir Crit Care Med. 1999;159(6):1884&#45;90
.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#150#146#article#194#</font><
/p>     ^cY#aop02311.htm##
00464000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020300090002001300293#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#151#147#article#
194#21#<p><font size="2" face="Verdana">21. Colt HG, Haas H, Rich GB. Hypoxemia 
vs sleep fragmentation as cause of excessive daytime sleepiness in obstructive s
leep apnea. Chest. 1991;100(6):1542&#45;8.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#152#148#article#194#</font><
/p>     ^cY#aop02311.htm##
00525000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026400090002001300354#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#153#149#article#
194#22#<p><font size="2" face="Verdana">22. Guilleminault C, Poyares D, Rosa A, 
Huang YS. Heart rate variability, sympathetic and vagal balance and EEG arousals
 in upper airway resistance and mild obstructive sleep apnea syndromes. Sleep Me
d. 2005;6(5):451&#45;7.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#154#150#article#194#</font><
/p>     ^cY#aop02311.htm##
00430000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704016900090002001300259#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#155#151#article#
194#23#<p><font size="2" face="Verdana">23. Patel AD, Cohen Z. Inflammation and 
obstructive sleep apnea: thinking outside of the fat. Respiration. 2008;76(4):37
5&#45;6.    ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#156#152#article#194# </font>
</p>     ^cY#aop02311.htm##
00522000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026100090002001300351#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#157#153#article#
194#24#<p><font size="2" face="Verdana">24. Jelic S, Padeletti M, Kawut SM, Higg
ins C, Canfield SM, Onat D, et al. Inflammation, oxidative stress, and repair ca
pacity of the vascular endothelium in obstructive sleep apnea. Circulation. 2008
;117(17):2270&#45;8.    ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#158#154#article#194# </font>
</p>     ^cY#aop02311.htm##
00512000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025100090002001300341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#159#155#article#
194#25#<p><font size="2" face="Verdana">25. Chung S, Yoon IY, Shin YK, Lee CH, K
im JW, Lee T, et al. Endothelial dysfunction and C&#45;reactive protein in relat
ion with the severity of obstructive sleep apnea syndrome. Sleep. 2007;30(8):997
&#45;1001.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#160#156#article#194#</font><
/p>     ^cY#aop02311.htm##
00500000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023900090002001300329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#161#157#article#
194#26#<p><font size="2" face="Verdana">26. El Solh AA, Akinnusi ME, Baddoura FH
, Mankowski CR. Endothelial cell apoptosis in obstructive sleep apnea: a link to
 endothelial dysfunction. Am J Respir Crit Care Med. 2007;175(11):1186&#45;91.  
  ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#162#158#article#194# </font>
</p>     ^cY#aop02311.htm##
00516000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025500090002001300345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#163#159#article#
194#27#<p><font size="2" face="Verdana">27. Itzhaki S, Lavie L, Pillar G, Tal G,
 Lavie P. Endothelial dysfunction in obstructive sleep apnea measured by periphe
ral arterial tone response in the finger to reactive hyperemia. Sleep. 2005;28(5
):594&#45;600.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#164#160#article#194#</font><
/p>     ^cY#aop02311.htm##
00472000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021100090002001300301#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#165#161#article#
194#28#<p><font size="2" face="Verdana">28&#45; Al Lawati NM, Ayas NT. Hypercoag
ulability: another potential mechanism of obstructive sleep apnea&#45;related ca
rdiovascular disease? Lung. 2008;186(4):195&#45;6.    ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#166#162#article#194# </font>
</p>     ^cY#aop02311.htm##
00484000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022300090002001300313#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#167#163#article#
194#29#<p><font size="2" face="Verdana">29&#45; Peppard PE, Young T, Palta M, Sk
atrud J. Prospective study of the association between sleep&#45;disordered breat
hing and hypertension. N Engl J Med. 2000;342(19):1378&#45;84.    ^cY#aop02311.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#168#164#article#194#</font><
/p>     ^cY#aop02311.htm##
00459000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019800090002001300288#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#169#165#article#
194#30#<p><font size="2" face="Verdana">30&#45; Miller WP. Cardiac arrhythmias a
nd conduction disturbances in the sleep apnea syndrome: prevalence and significa
nce. Am J Med. 1982;73(3):317&#45;21.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#170#166#article#194#</font><
/p>     ^cY#aop02311.htm##
00476000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021500090002001300305#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#171#167#article#
194#31#<p><font size="2" face="Verdana">31&#45; Yeh SY, Rahangdale S, Malhotra A
. Metabolic syndrome, obstructive sleep apnea, and continuous positive airway pr
essure: a weighty issue. Chest. 2008;134(4):675&#45;6.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#172#168#article#194#</font><
/p>     ^cY#aop02311.htm##
00512000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025100090002001300341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#173#169#article#
194#32#<p><font size="2" face="Verdana">32&#45; Laaban JP, Pascal&#45;Sebaoun S,
 Bloch E, Orvoen&#45;Frija E, Oppert JM, Huchon G. Left ventricular systolic dys
function in patients with obstructive sleep apnea syndrome. Chest. 2002;122(4):1
133&#45;8.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#174#170#article#194#</font><
/p>     ^cY#aop02311.htm##
00590000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032900090002001300419#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#175#171#article#
194#33#<p><font size="2" face="Verdana">33&#45; Gus M, Gon&ccedil;alves SC, Mart
inez D, de Abreu Silva EO, Moreira LB, Fuchs SC, et al. Risk for obstructive sle
ep apnea by Berlin Questionnaire, but not daytime sleepiness, is associated with
 resistant hypertension: a case&#45;control study. Am J Hypertens. 2008;21(7):83
2&#45;5.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#176#172#article#194#</font><
/p>     ^cY#aop02311.htm##
00449000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018800090002001300278#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#177#173#article#
194#34#<p><font size="2" face="Verdana">34&#45; Tan KC, Chow WS, Lam JC, Lam B, 
Wong WK, Tam S, et al. HDL dysfunction in obstructive sleep apnea. Atheroscleros
is. 2006;184(2):377&#45;82.    ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#178#174#article#194# </font>
</p>     ^cY#aop02311.htm##
00489000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022800090002001300318#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#179#175#article#
194#35#<p><font size="2" face="Verdana">35&#45; Savransky V, Nanayakkara A, Li J
, Bevans S, Smith PL, Rodriguez A, et al. Chronic intermittent hypoxia induces a
therosclerosis. Am J Respir Crit Care Med. 2007;175(12):1290&#45;7.    ^cY#aop02
311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#180#176#article#194# </font>
</p>     ^cY#aop02311.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024300090002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#181#177#article#
194#36#<p><font size="2" face="Verdana">36&#45; Kono M, Tatsumi K, Saibara T, Na
kamura A, Tanabe N, Takiguchi Y, et al. Obstructive sleep apnea syndrome is asso
ciated with some components of metabolic syndrome. Chest. 2007;131(5):1387&#45;9
2.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#182#178#article#194#</font><
/p>     ^cY#aop02311.htm##
00587000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032600090002001300416#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#183#179#article#
194#37#<p><font size="2" face="Verdana">37&#45; Oliveira W, Campos O, Bezerra Li
ra&#45;Filho E, Cintra FD, Vieira M, Ponchirolli A, et al. Left atrial volume an
d function in patients with obstructive sleep apnea assessed by real&#45;time th
ree&#45;dimensional echocardiography. J Am Soc Echocardiogr. 2008;21(12):1355&#4
5;61.    ^cY#aop02311.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#184#180#article#194# </font>
</p>     ^cY#aop02311.htm##
00646000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704038500090002001300475#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#185#181#article#
194#38#<p><font size="2" face="Verdana">38&#45; Orban M, Bruce CJ, Pressman GS, 
Leinveber P, Romero&#45;Corral A, Korinek J, et al. Dynamic changes of left vent
ricular performance and left atrial volume induced by the mueller maneuver in he
althy young adults and implications for obstructive sleep apnea, atrial fibrilla
tion, and heart failure. Am J Cardiol. 2008;102(11):1557&#45;61.    ^cY#aop02311
.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#186#182#article#194# </font>
</p>     ^cY#aop02311.htm##
00541000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028000090002001300370#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#187#183#article#
194#39#<p><font size="2" face="Verdana">39&#45; Cho IJ, Pyun WB, Shin GJ. The In
fluence of the left ventricular geometry on the left atrial size and left ventri
cular filling pressure in hypertensive patients, as assessed by echocardiography
. Korean Circ J. 2009;39(4):145&#45;50.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#188#184#article#194#</font><
/p>     ^cY#aop02311.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024300090002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#189#185#article#
194#40#<p><font size="2" face="Verdana">40&#45; Khan A, Latif F, Hawkins B, Tawk
 M, Sivaram CA, Kinasewitz G. Effects of obstructive sleep apnea treatment on le
ft atrial volume and left atrial volume index. Sleep Breath. 2008;12(2):141&#45;
7.    ^cY#aop02311.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#190#186#article#194#</font><
/p>     ^cY#aop02311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#191#187#article#194#<p>&nbsp
;</p>     ^cY#aop02311.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#192#188#article#194#<p>&nbsp
;</p>     ^cY#aop02311.htm##
00412000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016600087002001300253#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#193#189#article#194#<p><font
 size="2" face="Verdana"><b><a name="nt"></a><a href="#tx"><img src="/img/revist
as/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:</b>    ^cY#ao
p02311.htm##
00280000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003400087002001300121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#194#190#article#194#<br>   F
atima Dumas Cintra    ^cY#aop02311.htm##
00338000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009200087002001300179#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#195#191#article#194#<br>   A
v. Marcos Penteado de Ulhoa Rodrigues, 1001 &#45; 91B &#150; Tambor&eacute;     
^cY#aop02311.htm##
00326000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704008000087002001300167#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#196#192#article#194#<br>   0
6543&#45;001 &#45; Santana de Parna&iacute;ba, SP &#150; Brasil     ^cY#aop02311
.htm##
00434000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704018800087002001300275#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#197#193#article#194#<br>   E
&#45;mail: <a href="mailto:fatimacintra@cardiol.br">fatimacintra@cardiol.br</a>,
 <a href="mailto:fatimacintra@interair.com.br">fatimacintra@interair.com.br</a> 
</font></p>     ^cY#aop02311.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704013300087002001300220#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02311.htm#S#p#198#194#article#194#<p><font
 size="2" face="Verdana"> Artigo recebido em 28/04/10; revisado recebido em 07/1
2/10; aceito em 13/12/10.</font></p>     ^cY#aop02311.htm##
00745000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020100
01500118010001600133010001600149010001700165810000600182012013600188030000500324
06500090032906400050033803100040034303200030034701400080035086500090035800200130
0367035001000380801000500390#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#199#1#article#40#1#^rND^sNieto^nFJ#^rND^sYoung^nTB#^rND^sLind^nB
K#^rND^sShahar^nE#^rND^sSamet^nJM#^rND^sRedline^nS#et al#Association of sleep-di
sordered breathing, sleep apnea, and hypertension in a large community-based stu
dy: Sleep Heart Health Study^len#JAMA#20000000#2000#283#14#1829-36#20110000#aop0
2311.htm#0098-7484#JAMA##
00645000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100015001040100
01500119010001700134012009300151030001300244065000900257064000500266031000400271
032000300275014000800278865000900286002001300295035001000308801001300318#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#200#2#article#40#2#^
rND^sPeppard^nPE#^rND^sYoung^nT#^rND^sPalta^nM#^rND^sSkatrud^nJ#Prospective stud
y of the association between sleep-disordered breathing and hypertension^len#N E
ngl J Med#20000000#2000#342#19#1378-84#20110000#aop02311.htm#0028-4793#N Engl J 
Med##
00771000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01700120010001400137010001700151010002200168810000600190012011500196030002600311
06500090033706400050034603100040035103200020035501400060035786500090036300200130
0372035001000385801002600395#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#201#3#article#40#3#^rND^sShahar^nE#^rND^sWhitney^nCW#^rND^sRedli
ne^nS#^rND^sLee^nET#^rND^sNewman^nAB#^rND^sJavier Nieto^nF#et al#Sleep-disordere
d breathing and cardiovascular disease: cross-sectional results of the Sleep Hea
rt Health Study^len#Am J Respir Crit Care Med#20010000#2001#163#1#19-25#20110000
#aop02311.htm#1073-449X#Am J Respir Crit Care Med##
00740000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030100
01700120010001700137010001800154010001600172810000600188012011800194030000900312
06500090032106400050033003100040033503200030033901400070034286500090034900200130
0358035001000371801000900381#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#202#4#article#40#4#^rND^sDziewas^nR#^rND^sHumpert^nM#^rND^sHopma
nn^nB#^rND^sKloska^nSP#^rND^sLüdemann^nP#^rND^sRitter^nM#et al#Increased prevale
nce of sleep apnea in patients with recurring ischemic stroke compared with firs
t stroke victims^len#J Neurol#20050000#2005#252#11#1394-8#20110000#aop02311.htm#
0340-5354#J Neurol##
00713000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100015001030100
01700118010002100135010002500156010002300181012010000204030000600304065000900310
06400050031903100040032403200020032801400070033086500090033700200130034603500100
0359801000600369#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#
S#c#203#5#article#40#5#^rND^sSorajja^nD#^rND^sGami^nAS#^rND^sSomers^nVK#^rND^sBe
hrenbeck^nTR#^rND^sGarcia-Touchard^nA#^rND^sLopez-Jimenez^nF#Independent associa
tion between obstructive sleep apnea and subclinical coronary artery disease^len
#Chest#20080000#2008#133#4#927-33#20110000#aop02311.htm#0012-3692#Chest##
00695000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100018001050100
01800123010002000141010001800161012010800179030001200287065000900299064000500308
03100030031303200020031601400070031886500090032500200130033403500100034780100120
0357#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#204#6#ar
ticle#40#6#^rND^sCoughlin^nSR#^rND^sMawdsley^nL#^rND^sMugarza^nJA#^rND^sCalverle
y^nPM#^rND^sWilding^nJP#Obstructive sleep apnoea is independently associated wit
h an increased prevalence of metabolic syndrome^len#Eur Heart J#20040000#2004#25
#9#735-41#20110000#aop02311.htm#0195-668X#Eur Heart J##
00829000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100023000860100017001090100
01900126010002500145010002300170010002000193810000600213012017700219030001200396
06500090040806400050041703100030042203200030042501400070042886500090043500200130
0444035001000457801001200467#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#205#7#article#40#7#^rND^sSimantirakis^nEN#^rND^sSchiza^nSI#^rND^
sMarketou^nME#^rND^sChrysostomakis^nSI#^rND^sChlouverakis^nGI#^rND^sKlapsinos^nN
C#et al#Severe bradyarrhythmias in patients with sleep apnoea: the effect of con
tinuous positive airway pressure treatment: a long-term evaluation using an inse
rtable loop recorder^len#Eur Heart J#20040000#2004#25#12#1070-6#20110000#aop0231
1.htm#0195-668X#Eur Heart J##
00720000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01700120010001700137012017500154030000700329065000900336064000500345031000400350
032000500354014000800359865000900367002001300376035001000389801000700399#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#206#8#article#40#8#^
rND^sMarin^nJM#^rND^sCarrizo^nSJ#^rND^sVicente^nE#^rND^sAgusti^nAG#Long-term car
diovascular outcomes in men with obstructive sleep apnea-hypopnoea with or witho
ut treatment with continuous positive airway pressure: an observational study^le
n#Lancet#20050000#2005#365#9464#1046-53#20110000#aop02311.htm#0099-5355#Lancet##
00696000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100015001050100
01400120010001700134010001800151010002000169012009800189030000600287065000900293
06400050030203100030030703200020031001400080031286500090032000200130032903500100
0342801000600352#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#
S#c#207#9#article#40#9#^rND^sMarshall^nNS#^rND^sWong^nKK#^rND^sLiu^nPY#^rND^sCul
len^nSR#^rND^sKnuiman^nMW#^rND^sGrunstein^nRR#Sleep apnea as an independent risk
 factor for all-cause mortality: the Busselton Health Study^len#Sleep#20080000#2
008#31#8#1079-85#20110000#aop02311.htm#0161-8105#Sleep##
00713000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100014001030100
01800117010002000135010001600155010001600171810000600187012010000193030000600293
06500090029906400050030803100030031303200020031601400070031886500090032500200130
0334035001000347801000600357#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#208#10#article#40#10#^rND^sYoung^nT#^rND^sFinn^nL#^rND^sPeppard^
nPE#^rND^sSzklo-Coxe^nM#^rND^sAustin^nD#^rND^sNieto^nFJ#et al#Sleep disordered b
reathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort^le
n#Sleep#20080000#2008#31#8#1071-8#20110000#aop02311.htm#0161-8105#Sleep##
00709000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01900122010001700141010001700158010001700175810000600192012009000198030000600288
06500090029406400050030303100040030803200020031201400070031486500090032100200130
0330035001000343801000600353#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#209#11#article#40#11#^rND^sNamen^nAM#^rND^sDunagan^nDP#^rND^sFle
ischer^nA#^rND^sTillett^nJ#^rND^sBarnett^nM#^rND^sMcCall^nWV#et al#Increased phy
sician-reported sleep apnea: the National Ambulatory Medical Care Survey^len#Che
st#20020000#2002#121#6#1741-7#20110000#aop02311.htm#0012-3692#Chest##
00550000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110042000880120030001300300
02600160065000900186064000500195031000400200032000200204014000800206865000900214
002001300223035001000236801002600246#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02311.htm#S#c#210#12#article#40#12#Standardization of Spirometry.1994 
Update#American Thoracic Society^len#Am J Respir Crit Care Med#19950000#1995#152
#3#1107-36#20110000#aop02311.htm#1073-449X#Am J Respir Crit Care Med##
00586000000000241000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160023000880160015001110180
10300126066001200229062006700241065000900308064000500317865000900322002001300331
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#211#13#artic
le#40#13#^rND^sRechtschaffen^nA#^rND^sKales^nA#A manual of standardized terminol
ogy, technique and scoring system for sleep stages of human sleep^len#Los Angele
s#Los Angeles Brain Information Service, Brain Information Institute#19680000#19
68#20110000#aop02311.htm##
00573000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850120149000880300006002370650
00900243064000500252031000300257032000200260014000700262865000900269002001300278
035001000291801000600301#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02
311.htm#S#c#212#14#article#40#14#EEG arousals: scoring rules and examples: a pre
liminary report from Sleep Disorders Atlas Task Force of the American Sleep Diso
rders Association^len#Sleep#19920000#1992#15#2#173-84#20110000#aop02311.htm#0161
-8105#Sleep##
00625000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850120201000880300006002890650
00900295064000500304031000300309032000200312014000700314865000900321002001300330
035001000343801000600353#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02
311.htm#S#c#213#15#article#40#15#Sleep-related breathing disorders in adults: re
commendations for syndrome definition and measurement techniques in clinical res
earch. The report of an American Academy of Sleep Medicine Task Force^len#Sleep#
19990000#1999#22#5#667-89#20110000#aop02311.htm#0161-8105#Sleep##
01286000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100020001060100
02000126010001900146010001800165010001600183810000600199012063600205030001800841
06500090085906400050086803100030087303200020087601400080087886500090088600200130
0895035001000908801001800918#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#214#16#article#40#16#^rND^sDouglas^nPS#^rND^sKhandheria^nB#^rND^
sStainback^nRF#^rND^sWeissman^nNJ#^rND^sBrindis^nRG#^rND^sPatel^nMR#et al#ACCF/A
SE/ACEP/ ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and
 transesophageal echocardiography: a report of the American College of Cardiolog
y Foundation Quality Strategic Directions Committee Appropriateness Criteria Wor
king Group, American Society of Echocardiography, American College of Emergency 
Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular A
ngiography and Interventions, Society of Cardiovascular Computed Tomography, and
 the Society for Cardiovascular Magnetic Resonance endorsed by the American Coll
ege of Chest Physicians and the Society of Critical Care Medicine^len#J Am Coll 
Cardiol#20070000#2007#50#2#187-204#20110000#aop02311.htm#0735-1097#J Am Coll Car
diol##
00759000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01600122010001600138010001400154010001500168012014400183030001500327065000900342
06400050035103100030035603200080035901400070036786500090037400200130038303500100
0396801001500406#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#
S#c#215#17#article#40#17#^rND^sPeled^nN#^rND^sGreenberg^nA#^rND^sPillar^nG#^rND^
sZinder^nO#^rND^sLevi^nN#^rND^sLavie^nP#Contributions of hypoxia and respiratory
 disturbance index to sympathetic activation and blood pressure in obstructive s
leep apnea syndrome^len#Am J Hypertens#19980000#1998#11#11 Pt 1#1284-9#20110000#
aop02311.htm#0895-7061#Am J Hypertens##
00546000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880120106001070300
00700213710000200220065000900222064000500231031000300236032001100239014000800250
865000900258002001300267#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02
311.htm#S#c#216#18#article#40#18#^rND^sFletcher^nEC#Cardiovascular consequences 
of obstructive sleep apnea: experimental hypoxia and sympathetic activity^len#Sl
eep.#2#20000000#2000#23#^sSuppl. 4#S127-31#20110000#aop02311.htm##
00630000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01600124012009900140030001500239065000900254064000500263031000300268032000200271
014000800273865000900281002001300290035001000303801001500313#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02311.htm#S#c#217#19#article#40#19#^rND^sRemsb
urg^nS#^rND^sLaunois^nSH#^rND^sWeiss^nJW#Patients with obstructive sleep apnea h
ave an abnormal peripheral vascular response to hypoxia^len#J Appl Physiol#19990
000#1999#87#3#1148-53#20110000#aop02311.htm#0021-8987#J Appl Physiol##
00785000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01800123010002000141010001700161012016900178030002600347065000900373064000500382
03100040038703200020039101400080039386500090040100200130041003500100042380100260
0433#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#218#20#a
rticle#40#20#^rND^sBennett^nLS#^rND^sBarbour^nC#^rND^sLangford^nB#^rND^sStradlin
g^nJR#^rND^sDavies^nRJ#Health status in obstructive sleep apnea: relationship wi
th sleep fragmentation and daytine sleepiness, and effects of continuous positiv
e airway pressure treatment^len#Am J Respir Crit Care Med#19990000#1999#159#6#18
84-90#20110000#aop02311.htm#1073-449X#Am J Respir Crit Care Med##
00610000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100014001030100
01500117012010500132030000600237065000900243064000500252031000400257032000200261
014000700263865000900270002001300279035001000292801000600302#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02311.htm#S#c#219#21#article#40#21#^rND^sColt^
nHG#^rND^sHaas^nH#^rND^sRich^nGB#Hypoxemia vs sleep fragmentation as cause of ex
cessive daytime sleepiness in obstructive sleep apnea^len#Chest#19910000#1991#10
0#6#1542-8#20110000#aop02311.htm#0012-3692#Chest##
00663000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100017001110100
01400128010001600142012014500158030001000303710000200313065000900315064000500324
031000200329032000200331014000600333865000900339002001300348#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02311.htm#S#c#220#22#article#40#22#^rND^sGuill
eminault^nC#^rND^sPoyares^nD#^rND^sRosa^nA#^rND^sHuang^nYS#Heart rate variabilit
y, sympathetic and vagal balance and EEG arousals in upper airway resistance and
 mild obstructive sleep apnea syndromes^len#Sleep Med#2#20050000#2005#6#5#451-7#
20110000#aop02311.htm##
00564000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040120
07400119030001200193065000900205064000500214031000300219032000200222014000600224
865000900230002001300239035001000252801001200262#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02311.htm#S#c#221#23#article#40#23#^rND^sPatel^nAD#^rND^sC
ohen^nZ#Inflammation and obstructive sleep apnea: thinking outside of the fat^le
n#Respiration#20080000#2008#76#4#375-6#20110000#aop02311.htm#0025-7931#Respirati
on##
00739000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01600122010001700138010001900155010001400174810000600188012011100194030001200305
06500090031706400050032603100040033103200030033501400070033886500090034500200130
0354035001000367801001200377#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#222#24#article#40#24#^rND^sJelic^nS#^rND^sPadeletti^nM#^rND^sKaw
ut^nSM#^rND^sHiggins^nC#^rND^sCanfield^nSM#^rND^sOnat^nD#et al#Inflammation, oxi
dative stress, and repair capacity of the vascular endothelium in obstructive sl
eep apnea^len#Circulation#20080000#2008#117#17#2270-8#20110000#aop02311.htm#0009
-7322#Circulation##
00719000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030100
01500118010001400133010001400147010001300161810000600174012011700180030000600297
06500090030306400050031203100030031703200020032001400090032286500090033100200130
0340035001000353801000600363#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#223#25#article#40#25#^rND^sChung^nS#^rND^sYoon^nIY#^rND^sShin^nY
K#^rND^sLee^nCH#^rND^sKim^nJW#^rND^sLee^nT#et al#Endothelial dysfunction and C-r
eactive protein in relation with the severity of obstructive sleep apnea syndrom
e^len#Sleep#20070000#2007#30#8#997-1001#20110000#aop02311.htm#0161-8105#Sleep##
00684000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01900125010002000144012009300164030002600257065000900283064000500292031000400297
032000300301014000800304865000900312002001300321035001000334801002600344#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#224#26#article#40#26
#^rND^sEl Solh^nAA#^rND^sAkinnusi^nME#^rND^sBaddoura^nFH#^rND^sMankowski^nCR#End
othelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfun
ction^len#Am J Respir Crit Care Med#20070000#2007#175#11#1186-91#20110000#aop023
11.htm#1073-449X#Am J Respir Crit Care Med##
00698000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01600120010001300136010001500149012013700164030000600301065000900307064000500316
03100030032103200020032401400080032686500090033400200130034303500100035680100060
0366#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#225#27#a
rticle#40#27#^rND^sItzhaki^nS#^rND^sLavie^nL#^rND^sPillar^nG#^rND^sTal^nG#^rND^s
Lavie^nP#Endothelial dysfunction in obstructive sleep apnea measured by peripher
al arterial tone response in the finger to reactive hyperemia^len#Sleep#20050000
#2005#28#5#594-600#20110000#aop02311.htm#0161-8105#Sleep##
00592000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100015001080120
11100123030000500234065000900239064000500248031000400253032000200257014000600259
865000900265002001300274035001000287801000500297#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02311.htm#S#c#226#28#article#40#28#^rND^sAl Lawati^nNM#^rN
D^sAyas^nNT#Hypercoagulability: another potential mechanism of obstructive sleep
 apnea-related cardiovascular disease?^len#Lung#20080000#2008#186#4#195-6#201100
00#aop02311.htm#0341-2040#Lung##
00647000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01500121010001700136012009300153030001300246065000900259064000500268031000400273
032000300277014000800280865000900288002001300297035001000310801001300320#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#227#29#article#40#29
#^rND^sPeppard^nPE#^rND^sYoung^nT#^rND^sPalta^nM#^rND^sSkatrud^nJ#Prospective st
udy of the association between sleep-disordered breathing and hypertension^len#N
 Engl J Med#20000000#2000#342#19#1378-84#20110000#aop02311.htm#0028-4793#N Engl 
J Med##
00568000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120109001050300
00900214065000900223064000500232031000300237032000200240014000700242865000900249
002001300258035001000271801000900281#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02311.htm#S#c#228#30#article#40#30#^rND^sMiller^nWP#Cardiac arrhythmia
s and conduction disturbances in the sleep apnea syndrome: prevalence and signif
icance^len#Am J Med#19820000#1982#73#3#317-21#20110000#aop02311.htm#0002-9343#Am
 J Med##
00618000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100020001020100
01800122012010600140030000600246065000900252064000500261031000400266032000200270
014000600272865000900278002001300287035001000300801000600310#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02311.htm#S#c#229#31#article#40#31#^rND^sYeh^n
SY#^rND^sRahangdale^nS#^rND^sMalhotra^nA#Metabolic syndrome, obstructive sleep a
pnea, and continuous positive airway pressure: a weighty issue^len#Chest#2008000
0#2008#134#4#675-6#20110000#aop02311.htm#0012-3692#Chest##
00700000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100024001050100
01500129010002200144010001700166010001600183012009200199030000600291065000900297
06400050030603100040031103200020031501400070031786500090032400200130033303500100
0346801000600356#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#
S#c#230#32#article#40#32#^rND^sLaaban^nJP#^rND^sPascal-Sebaoun^nS#^rND^sBloch^nE
#^rND^sOrvoen-Frija^nE#^rND^sOppert^nJM#^rND^sHuchon^nG#Left ventricular systoli
c dysfunction in patients with obstructive sleep apnea syndrome^len#Chest#200200
00#2002#122#4#1133-8#20110000#aop02311.htm#0012-3692#Chest##
00797000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100020001010100
01800121010002600139010001900165010001600184810000600200012015400206030001500360
06500090037506400050038403100030038903200020039201400060039486500090040000200130
0409035001000422801001500432#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#231#33#article#40#33#^rND^sGus^nM#^rND^sGonçalves^nSC#^rND^sMart
inez^nD#^rND^sde Abreu Silva^nEO.#^rND^sMoreira^nLB.#^rND^sFuchs^nSC#et al#Risk 
for obstructive sleep apnea by Berlin Questionnaire, but not daytime sleepiness,
 is associated with resistant hypertension: a case-control study^len#Am J Hypert
ens#20080000#2008#21#7#832-5#20110000#aop02311.htm#0895-7061#Am J Hypertens##
00666000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100015001020100
01400117010001300131010001500144010001300159810000600172012004700178030001600225
06500090024106400050025003100040025503200020025901400070026186500090026800200130
0277035001000290801001600300#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#232#34#article#40#34#^rND^sTan^nKC#^rND^sChow^nWS#^rND^sLam^nJC#
^rND^sLam^nB#^rND^sWong^nWK#^rND^sTam^nS#et al#HDL dysfunction in obstructive sl
eep apnea^len#Atherosclerosis#20060000#2006#184#2#377-82#20110000#aop02311.htm#0
021-9150#Atherosclerosis##
00716000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100021001070100
01200128010001600140010001600156010001900172810000600191012005700197030002600254
06500090028006400050028903100040029403200030029801400070030186500090030800200130
0317035001000330801002600340#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#233#35#article#40#35#^rND^sSavransky^nV#^rND^sNanayakkara^nA#^rN
D^sLi^nJ#^rND^sBevans^nS#^rND^sSmith^nPL#^rND^sRodriguez^nA#et al#Chronic interm
ittent hypoxia induces atherosclerosis^len#Am J Respir Crit Care Med#20070000#20
07#175#12#1290-7#20110000#aop02311.htm#1073-449X#Am J Respir Crit Care Med##
00711000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100017001020100
01700119010001800136010001600154010001900170810000600189012009400195030000600289
06500090029506400050030403100040030903200020031301400080031586500090032300200130
0332035001000345801000600355#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#234#36#article#40#36#^rND^sKono^nM#^rND^sTatsumi^nK#^rND^sSaibar
a^nT#^rND^sNakamura^nA#^rND^sTanabe^nN#^rND^sTakiguchi^nY#et al#Obstructive slee
p apnea syndrome is associated with some components of metabolic syndrome^len#Ch
est#20070000#2007#131#5#1387-92#20110000#aop02311.htm#0012-3692#Chest##
00798000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
02800122010001700150010001600167010002100183810000600204012013400210030002200344
06500090036606400050037503100030038003200030038301400080038686500090039400200130
0403035001000416801002200426#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#235#37#article#40#37#^rND^sOliveira^nW#^rND^sCampos^nO#^rND^sBez
erra Lira-Filho^nE#^rND^sCintra^nFD#^rND^sVieira^nM#^rND^sPonchirolli^nA#et al#L
eft atrial volume and function in patients with obstructive sleep apnea assessed
 by real-time three-dimensional echocardiography^len#J Am Soc Echocardiogr#20080
000#2008#21#12#1355-61#20110000#aop02311.htm#0894-7317#J Am Soc Echocardiogr##
00856000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100016001030100
01900119010001900138010002300157010001700180810000600197012021600203030001300419
06500090043206400050044103100040044603200030045001400080045386500090046100200130
0470035001000483801001300493#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02311.htm#S#c#236#38#article#40#38#^rND^sOrban^nM#^rND^sBruce^nCJ#^rND^sPressm
an^nGS#^rND^sLeinveber^nP#^rND^sRomero-Corral^nA#^rND^sKorinek^nJ#et al#Dynamic 
changes of left ventricular performance and left atrial volume induced by the mu
eller maneuver in healthy young adults and implications for obstructive sleep ap
nea, atrial fibrillation, and heart failure^len#Am J Cardiol#20080000#2008#102#1
1#1557-61#20110000#aop02311.htm#0002-9149#Am J Cardiol##
00657000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100015001020100
01500117012017100132030001400303710000200317065000900319064000500328031000300333
032000200336014000700338865000900345002001300354#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02311.htm#S#c#237#39#article#40#39#^rND^sCho^nIJ#^rND^sPyu
n^nWB#^rND^sShin^nGJ#The Influence of the left ventricular geometry on the left 
atrial size and left ventricular filling pressure in hypertensive patients, as a
ssessed by echocardiography^len#Korean Circ J#2#20090000#2009#39#4#145-50#201100
00#aop02311.htm##
00674000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100015001020100
01700117010001400134010001800148010002000166012010000186030001300286710000200299
06500090030106400050031003100030031503200020031801400060032086500090032600200130
0335#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02311.htm#S#c#238#40#a
rticle#40#40#^rND^sKhan^nA#^rND^sLatif^nF#^rND^sHawkins^nB#^rND^sTawk^nM#^rND^sS
ivaram^nCA#^rND^sKinasewitz^nG#Effects of obstructive sleep apnea treatment on l
eft atrial volume and left atrial volume index^len#Sleep Breath#2#20080000#2008#
12#2#141-7#20110000#aop02311.htm##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#o#1#1#
article#1#20110331#081015#aop02411.htm#166##
05644000000000721000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200920017301200890
02650100052003540100038004060100033004440100036004770100027005130100040005400100
04300580010003800623010005000661010003900711070007000750070006400820083191200884
08500080279608500370280408500340284108500240287508500240289908317980292308500080
47210850034047290850036047630850023047990850022048221170008048440720003048521120
00904855111000904864116000904873115000904882114000904891113000904900002001304909
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#h#2#1#article#
1#oa#pt#br1.1#1#4.0#TAB#37#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-
782X#20110401#Prevalência e valor prognóstico da dissincronia ventricular na car
diomiopatia chagásica^lpt#Prevalence and prognostic value of ventricular dyssync
hrony in chagas cardiomyopathy^len#^rND^1A01 A02^nJussara de Oliveira Pinheiro^s
Duarte#^rND^1A02^nLuiz Pereira de^sMagalhães#^rND^1A02^nOto Oliveira^sSantana#^r
ND^1A01^nLeandro Barros da^sSilva#^rND^1A02^nMonique^sSimões#^rND^1A02^nDarluce 
Oliveira de^sAzevedo#^rND^1A02^nOctávio Alencar^sBarbosa Júnior#^rND^1A02^nAlexs
andro Alves^sFagundes#^rND^1A02^nFrancisco José Farias Borges dos^sReis#^rND^1A0
1^nLuis Cláudio Lemos^sCorreia#Escola Bahiana de Medicina e Saúde Pública^iA01^c
Salvador^sBA^pBrasil#Universitário Professor Edgar Santos^iA02^cSalvador^sBA^pBr
asil#^lpt^aFUNDAMENTO: A cardiomiopatia chagásica é uma causa importante de insu
ficiência cardíaca na América Latina. A dissincronia ventricular pode ser um fat
or de descompensação no curso da doença, mas não há dados sobre sua prevalência 
e principais implicações prognósticas, ainda. OBJETIVO: Descrever a prevalência 
e valores prognósticos da dissincronia ventricular na cardiomiopatia chagásica. 
MÉTODOS: 56 pacientes com cardiomiopatia chagásica foram selecionados consecutiv
amente através de dois testes sorológicos positivos e uma fração de ejeção (FE) 
< 45% no ecocardiograma. O ecocardiograma avaliou a presença de dissincronia int
raventricular utilizando três critérios e dissincronia interventricular utilizan
do 1 critério. Os pacientes foram seguidos por 21 ± 14 meses e os eventos cardía
cos foram definidos como a combinação de morte e hospitalização. RESULTADOS: A m
édia da idade da população era de 56 ± 10 anos, sendo 50% do sexo masculino. A F
E média era de 30 ± 8% e 87% dos pacientes apresentavam classe funcional I/II (N
YHA). A prevalência de dissincronia interventricular era de 34% (IC95%: 22%-48%)
 e a dissincronia intraventricular tinha uma prevalência de 85% (IC95%: 75%-93%)
. A prevalência de dissincronia intraventricular era similar em pacientes com du
ração do QRS < 0,12 s ou &gt; 0,12 s (85% e 89%, respectivamente, p = 0,66). Vin
te eventos foram registrados. A incidência de eventos combinados foi similar em 
pacientes com ou sem dissincronia intraventricular (35% versus 38%, p = 0,9) e a
queles com ou sem dissincronia interventricular (39% versus 34%, p = 0,73). CONC
LUSÃO: Pacientes com cardiomiopatia chagásica apresentam alta prevalência de dis
sincronia intraventricular e moderada prevalência de dissincronia interventricul
ar. A alta prevalência independe da largura do QRS. A dissincronia ventricular n
ão tem qualquer valor prognóstico em pacientes com cardiomiopatia chagásica.#^dn
d^i1#^tm^lpt^kCardiomiopatia chagásica^i1#^tm^lpt^kdisfunção ventricular^i1#^tm^
lpt^kprevalência^i1#^tm^lpt^kprognóstico^i1#^len^aBACKGROUND: Chagas cardiomyopa
thy is one important cause of heart failure in Latin America. Ventricular dyssyn
chrony may be a factor of decompensation in the course of this disease, but ther
e are no data on its prevalence and its main prognostic implications yet. OBJECT
IVE: Describe prevalence and prognostic value of ventricular dyssynchrony in Cha
gas cardiomyopathy. METHODS: 56 patients with Chagas cardiomyopathy were consecu
tively selected by two positive serologies and an ejection fraction < 45% in the
 echocardiogram. The echocardiogram evaluated the presence of intraventricular d
yssynchrony using 3 criteria and interventricular dyssynchrony using 1 criterion
. Patients were followed for 21 ± 14 months and cardiac events were defined as t
he combination of death and hospitalization. RESULTS: The average age of the pop
ulation was 56 ± 10 years, 50% males. Mean ejection fraction was 30 ± 8% and 87%
 presented functional class I/II (NYHA). The prevalence of interventricular dyss
ynchrony was 34% (95% CI: 22%-48%) and intraventricular dyssynchrony had a preva
lence of 85% (95% CI: 75%-93%). The prevalence of intraventricular dyssynchrony 
was similar among patients with QRS duration < 0.12 s or &gt; 0.12 s (85% and 89
%, respectively, p = 0.66). Twenty events were recorded. The incidence of combin
ed events was similar in patients with or without intraventricular dyssynchrony 
(35% versus 38%, p = 0.9) and those with or without interventricular dyssynchron
y (39% versus 34%, p = 0.73). CONCLUSION: Patients with Chagas cardiomyopathy ha
ve high intraventricular and moderate interventricular prevalence of dyssynchron
y. The high prevalence is independent from the QRS width. The ventricular dyssyn
chrony does not have any prognostic value in patients with Chagas cardiomyopathy
.#^dnd^i2#^tm^len^kChagas cardiomyopathy^i2#^tm^len^kventricular dysfunction^i2#
^tm^len^kprevalence^i2#^tm^len^kprognosis^i2#vancouv#25#20100501#01/05/10#201009
02#02/09/10#20100921#21/09/10#aop02411.htm##
05754000000000721000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200990017301200960
02720100052003680100038004200100033004580100036004910100027005270100040005540100
04300594010003800637010005000675010003900725070007000764070006400834083196700898
08500080286508500370287308500340291008500240294408500240296808318390299208500080
48310850034048390850036048730850023049090850022049321170008049540720003049621120
00904965111000904974116000904983115000904992114000905001113000905010002001305019
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#f#3#1#article#
1#oa#pt#br1.1#1#4.0#TAB#37#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-
782X#20110401#<b>Prevalência e valor prognóstico da dissincronia ventricular na 
cardiomiopatia chagásica</b>^lpt#<b>Prevalence and prognostic value of ventricul
ar dyssynchrony in chagas cardiomyopathy</b>^len#^rND^1A01 A02^nJussara de Olive
ira Pinheiro^sDuarte#^rND^1A02^nLuiz Pereira de^sMagalhães#^rND^1A02^nOto Olivei
ra^sSantana#^rND^1A01^nLeandro Barros da^sSilva#^rND^1A02^nMonique^sSimões#^rND^
1A02^nDarluce Oliveira de^sAzevedo#^rND^1A02^nOctávio Alencar^sBarbosa Júnior#^r
ND^1A02^nAlexsandro Alves^sFagundes#^rND^1A02^nFrancisco José Farias Borges dos^
sReis#^rND^1A01^nLuis Cláudio Lemos^sCorreia#Escola Bahiana de Medicina e Saúde 
Pública^iA01^cSalvador^sBA^pBrasil#Universitário Professor Edgar Santos^iA02^cSa
lvador^sBA^pBrasil#^lpt^a<b>FUNDAMENTO: </b>A cardiomiopatia chagásica é uma cau
sa importante de insuficiência cardíaca na América Latina. A dissincronia ventri
cular pode ser um fator de descompensação no curso da doença, mas não há dados s
obre sua prevalência e principais implicações prognósticas, ainda. <b>OBJETIVO:<
/b> Descrever a prevalência e valores prognósticos da dissincronia ventricular n
a cardiomiopatia chagásica. <b>MÉTODOS:</b> 56 pacientes com cardiomiopatia chag
ásica foram selecionados consecutivamente através de dois testes sorológicos pos
itivos e uma fração de ejeção (FE) &lt; 45% no ecocardiograma. O ecocardiograma 
avaliou a presença de dissincronia intraventricular utilizando três critérios e 
dissincronia interventricular utilizando 1 critério. Os pacientes foram seguidos
 por 21 ± 14 meses e os eventos cardíacos foram definidos como a combinação de m
orte e hospitalização. <b>RESULTADOS:</b> A média da idade da população era de 5
6 ± 10 anos, sendo 50% do sexo masculino. A FE média era de 30 ± 8% e 87% dos pa
cientes apresentavam classe funcional I/II (NYHA). A prevalência de dissincronia
 interventricular era de 34% (IC95%: 22%-48%) e a dissincronia intraventricular 
tinha uma prevalência de 85% (IC95%: 75%-93%). A prevalência de dissincronia int
raventricular era similar em pacientes com duração do QRS &lt; 0,12 s ou &gt; 0,
12 s (85% e 89%, respectivamente, p = 0,66). Vinte eventos foram registrados. A 
incidência de eventos combinados foi similar em pacientes com ou sem dissincroni
a intraventricular (35% <i>versus</i> 38%, p = 0,9) e aqueles com ou sem dissinc
ronia interventricular (39% <i>versus</i> 34%, p = 0,73). <b>CONCLUSÃO:</b> Paci
entes com cardiomiopatia chagásica apresentam alta prevalência de dissincronia i
ntraventricular e moderada prevalência de dissincronia interventricular. A alta 
prevalência independe da largura do QRS. A dissincronia ventricular não tem qual
quer valor prognóstico em pacientes com cardiomiopatia chagásica.#^dnd^i1#^tm^lp
t^kCardiomiopatia chagásica^i1#^tm^lpt^kdisfunção ventricular^i1#^tm^lpt^kpreval
ência^i1#^tm^lpt^kprognóstico^i1#^len^a<b>BACKGROUND:</b> Chagas cardiomyopathy 
is one important cause of heart failure in Latin America. Ventricular dyssynchro
ny may be a factor of decompensation in the course of this disease, but there ar
e no data on its prevalence and its main prognostic implications yet. <b>OBJECTI
VE:</b> Describe prevalence and prognostic value of ventricular dyssynchrony in 
Chagas cardiomyopathy. <b>METHODS:</b> 56 patients with Chagas cardiomyopathy we
re consecutively selected by two positive serologies and an ejection fraction &l
t; 45% in the echocardiogram. The echocardiogram evaluated the presence of intra
ventricular dyssynchrony using 3 criteria and interventricular dyssynchrony usin
g 1 criterion. Patients were followed for 21 ± 14 months and cardiac events were
 defined as the combination of death and hospitalization. <b>RESULTS:</b> The av
erage age of the population was 56 ± 10 years, 50% males. Mean ejection fraction
 was 30 ± 8% and 87% presented functional class I/II (NYHA). The prevalence of i
nterventricular dyssynchrony was 34% (95% CI: 22%-48%) and intraventricular dyss
ynchrony had a prevalence of 85% (95% CI: 75%-93%). The prevalence of intraventr
icular dyssynchrony was similar among patients with QRS duration &lt; 0.12 s or 
&gt; 0.12 s (85% and 89%, respectively, p = 0.66). Twenty events were recorded. 
The incidence of combined events was similar in patients with or without intrave
ntricular dyssynchrony (35% versus 38%, p = 0.9) and those with or without inter
ventricular dyssynchrony (39% versus 34%, p = 0.73). <b>CONCLUSION:</b> Patients
 with Chagas cardiomyopathy have high intraventricular and moderate interventric
ular prevalence of dyssynchrony. The high prevalence is independent from the QRS
 width. The ventricular dyssynchrony does not have any prognostic value in patie
nts with Chagas cardiomyopathy.#^dnd^i2#^tm^len^kChagas cardiomyopathy^i2#^tm^le
n^kventricular dysfunction^i2#^tm^len^kprevalence^i2#^tm^len^kprognosis^i2#vanco
uv#25#20100501#01/05/10#20100902#02/09/10#20100921#21/09/10#aop02411.htm##
06055000000000745000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001200920
01790120089002710100052003600100038004120100033004500100036004830100027005190100
04000546010004300586010003800629010005000667010003900717070007200756070006600828
08320740089408500080296808500370297608500340301308500240304708500240307108319240
30950850008050190850034050270850036050610850023050970850022051201170008051420720
00305150112000905153111000905162116000905171115000905180114000905189113000905198
002001305207008008905220#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02
411.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#tab#37#nd#nd#Arq. bras. cardi
ol#ahead#20110000#^f0^l0#0066-782X#20110401#Prevalência e valor prognóstico da d
issincronia ventricular na cardiomiopatia chagásica^lpt#Prevalence and prognosti
c value of ventricular dyssynchrony in chagas cardiomyopathy^len#^rND^1A01 A02^n
Jussara de Oliveira Pinheiro^sDuarte#^rND^1A02^nLuiz Pereira de^sMagalhães#^rND^
1A02^nOto Oliveira^sSantana#^rND^1A01^nLeandro Barros da^sSilva#^rND^1A02^nMoniq
ue^sSimões#^rND^1A02^nDarluce Oliveira de^sAzevedo#^rND^1A02^nOctávio Alencar^sB
arbosa Júnior#^rND^1A02^nAlexsandro Alves^sFagundes#^rND^1A02^nFrancisco José Fa
rias Borges dos^sReis#^rND^1A01^nLuis Cláudio Lemos^sCorreia#^iA01^1Escola Bahia
na de Medicina e Saúde Pública^cSalvador^sBA^pBrasil#^iA02^1Universitário Profes
sor Edgar Santos^cSalvador^sBA^pBrasil#^lpt^aFUNDAMENTO: A cardiomiopatia chagás
ica é uma causa importante de insuficiência cardíaca na América Latina. A dissin
cronia ventricular pode ser um fator de descompensação no curso da doença, mas n
ão há dados sobre sua prevalência e principais implicações prognósticas, ainda. 
OBJETIVO: Descrever a prevalência e valores prognósticos da dissincronia ventric
ular na cardiomiopatia chagásica. MÉTODOS: 56 pacientes com cardiomiopatia chagá
sica foram selecionados consecutivamente através de dois testes sorológicos posi
tivos e uma fração de ejeção (FE) < 45 por cento no ecocardiograma. O ecocardiog
rama avaliou a presença de dissincronia intraventricular utilizando três critéri
os e dissincronia interventricular utilizando 1 critério. Os pacientes foram seg
uidos por 21 ± 14 meses e os eventos cardíacos foram definidos como a combinação
 de morte e hospitalização. RESULTADOS: A média da idade da população era de 56 
± 10 anos, sendo 50 por cento do sexo masculino. A FE média era de 30 ± 8 por ce
nto e 87 por cento dos pacientes apresentavam classe funcional I/II (NYHA). A pr
evalência de dissincronia interventricular era de 34 por cento (IC95 por cento: 
22 por cento-48 por cento) e a dissincronia intraventricular tinha uma prevalênc
ia de 85 por cento (IC95 por cento: 75 por cento-93 por cento). A prevalência de
 dissincronia intraventricular era similar em pacientes com duração do QRS < 0,1
2 s ou &gt; 0,12 s (85 por cento e 89 por cento, respectivamente, p = 0,66). Vin
te eventos foram registrados. A incidência de eventos combinados foi similar em 
pacientes com ou sem dissincronia intraventricular (35 por cento versus 38 por c
ento, p = 0,9) e aqueles com ou sem dissincronia interventricular (39 por cento 
versus 34 por cento, p = 0,73). CONCLUSÃO: Pacientes com cardiomiopatia chagásic
a apresentam alta prevalência de dissincronia intraventricular e moderada preval
ência de dissincronia interventricular. A alta prevalência independe da largura 
do QRS. A dissincronia ventricular não tem qualquer valor prognóstico em pacient
es com cardiomiopatia chagásica.#^dnd^i1#^tm^lpt^kCardiomiopatia chagásica^i1#^t
m^lpt^kdisfunção ventricular^i1#^tm^lpt^kprevalência^i1#^tm^lpt^kprognóstico^i1#
^len^aBACKGROUND: Chagas cardiomyopathy is one important cause of heart failure 
in Latin America. Ventricular dyssynchrony may be a factor of decompensation in 
the course of this disease, but there are no data on its prevalence and its main
 prognostic implications yet. OBJECTIVE: Describe prevalence and prognostic valu
e of ventricular dyssynchrony in Chagas cardiomyopathy. METHODS: 56 patients wit
h Chagas cardiomyopathy were consecutively selected by two positive serologies a
nd an ejection fraction < 45 percent in the echocardiogram. The echocardiogram e
valuated the presence of intraventricular dyssynchrony using 3 criteria and inte
rventricular dyssynchrony using 1 criterion. Patients were followed for 21 ± 14 
months and cardiac events were defined as the combination of death and hospitali
zation. RESULTS: The average age of the population was 56 ± 10 years, 50 percent
 males. Mean ejection fraction was 30 ± 8 percent and 87 percent presented funct
ional class I/II (NYHA). The prevalence of interventricular dyssynchrony was 34 
percent (95 percent CI: 22 percent-48 percent) and intraventricular dyssynchrony
 had a prevalence of 85 percent (95 percent CI: 75 percent-93 percent). The prev
alence of intraventricular dyssynchrony was similar among patients with QRS dura
tion < 0.12 s or &gt; 0.12 s (85 percent and 89 percent, respectively, p = 0.66)
. Twenty events were recorded. The incidence of combined events was similar in p
atients with or without intraventricular dyssynchrony (35 percent versus 38 perc
ent, p = 0.9) and those with or without interventricular dyssynchrony (39 percen
t versus 34 percent, p = 0.73). CONCLUSION: Patients with Chagas cardiomyopathy 
have high intraventricular and moderate interventricular prevalence of dyssynchr
ony. The high prevalence is independent from the QRS width. The ventricular dyss
ynchrony does not have any prognostic value in patients with Chagas cardiomyopat
hy.#^dnd^i2#^tm^len^kChagas cardiomyopathy^i2#^tm^len^kventricular dysfunction^i
2#^tm^len^kprevalence^i2#^tm^len^kprognosis^i2#vancouv#25#20100501#01/05/10#2010
0902#02/09/10#20100921#21/09/10#aop02411.htm#Internet^ihttp://www.scielo.br/scie
lo.php?script=sci_arttext&pid=S0066-782X2011005000037##
00460000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704021800083002001300301#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#5#1#article#137#<p><a name="
top"></a><font face="verdana, arial, helvetica, sans-serif" size="4"><b>Preval&e
circ;ncia    e valor progn&oacute;stico da dissincronia ventricular na cardiomio
patia chag&aacute;sica</b></font></p>     ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#6#2#article#137#<p>&nbsp;</p
>     ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#7#3#article#137#<p>&nbsp;</p
>     ^cY#aop02411.htm##
00803000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704056100083002001300644#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#8#4#article#137#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Jussara de Oliveira    Pin
heiro Duarte<sup>I, II</sup>; Luiz Pereira de Magalh&atilde;es<sup>II</sup>;    
Oto Oliveira Santana<sup>II</sup>; Leandro Barros da Silva<sup>I</sup>; Monique 
   Sim&otilde;es<sup>II</sup>; Darluce Oliveira de Azevedo<sup>II</sup>; Oct&aac
ute;vio    Alencar Barbosa J&uacute;nior<sup>II</sup>; Alexsandro Alves Fagundes
<sup>II</sup>;    Francisco Jos&eacute; Farias Borges dos Reis<sup>II</sup>; Lui
s Cl&aacute;udio    Lemos Correia<sup>I</sup></b></font></p>     ^cY#aop02411.ht
m##
00407000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704016500083002001300248#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#9#5#article#137#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Escola    Bahiana
 de Medicina e Sa&uacute;de P&uacute;blica, Salvador, BA - Brasil    ^cY#aop0241
1.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012500084002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#10#6#article#137#<br>   <sup
>II</sup>Hospital Universit&aacute;rio Professor Edgar Santos - UFBA, Salvador, 
   BA - Brasil</font></p>     ^cY#aop02411.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#11#7#article#137#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop02411.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#12#8#article#137#<p>&nbsp;</
p>     ^cY#aop02411.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#13#9#article#137#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop02411.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#14#10#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>   
  ^cY#aop02411.htm##
00708000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046400085002001300549#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#15#11#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>FUNDAMENTO:    </b> A ca
rdiomiopatia chag&aacute;sica &eacute; uma causa importante de insufici&ecirc;nc
ia    card&iacute;aca na Am&eacute;rica Latina. A dissincronia ventricular pode 
ser    um fator de descompensa&ccedil;&atilde;o no curso da doen&ccedil;a, mas n
&atilde;o    h&aacute; dados sobre sua preval&ecirc;ncia e principais implica&cc
edil;&otilde;es    progn&oacute;sticas, ainda.    ^cY#aop02411.htm##
00402000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015800085002001300243#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#16#12#article#137#<br>   <b>
OBJETIVO:</b> Descrever a preval&ecirc;ncia e valores progn&oacute;sticos    da 
dissincronia ventricular na cardiomiopatia chag&aacute;sica.    ^cY#aop02411.htm
##
00879000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063500085002001300720#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#17#13#article#137#<br>   <b>
M&Eacute;TODOS:</b> 56 pacientes com cardiomiopatia chag&aacute;sica foram    se
lecionados consecutivamente atrav&eacute;s de dois testes sorol&oacute;gicos    
positivos e uma fra&ccedil;&atilde;o de eje&ccedil;&atilde;o (FE) &lt; 45% no   
 ecocardiograma. O ecocardiograma avaliou a presen&ccedil;a de dissincronia intr
aventricular    utilizando tr&ecirc;s crit&eacute;rios e dissincronia interventr
icular utilizando    1 crit&eacute;rio. Os pacientes foram seguidos por 21 &plus
mn; 14 meses e os    eventos card&iacute;acos foram definidos como a combina&cce
dil;&atilde;o de    morte e hospitaliza&ccedil;&atilde;o.    ^cY#aop02411.htm##
01123000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087900085002001300964#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#18#14#article#137#<br>   <b>
RESULTADOS:</b> A m&eacute;dia da idade da popula&ccedil;&atilde;o era de    56 
&plusmn; 10 anos, sendo 50% do sexo masculino. A FE m&eacute;dia era de 30    &p
lusmn; 8% e 87% dos pacientes apresentavam classe funcional I/II (NYHA). A    pr
eval&ecirc;ncia de dissincronia interventricular era de 34% (IC95%: 22%-48%)    
e a dissincronia intraventricular tinha uma preval&ecirc;ncia de 85% (IC95%:    
75%-93%). A preval&ecirc;ncia de dissincronia intraventricular era similar em   
 pacientes com dura&ccedil;&atilde;o do QRS &lt; 0,12 s ou &gt; 0,12 s (85% e   
 89%, respectivamente, p = 0,66). Vinte eventos foram registrados. A incid&ecirc
;ncia    de eventos combinados foi similar em pacientes com ou sem dissincronia 
intraventricular    (35% <i>versus</i> 38%, p = 0,9) e aqueles com ou sem dissin
cronia interventricular    (39% <i>versus</i> 34%, p = 0,73).    ^cY#aop02411.ht
m##
00663000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041900085002001300504#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#19#15#article#137#<br>   <b>
CONCLUS&Atilde;O:</b> Pacientes com cardiomiopatia chag&aacute;sica apresentam  
  alta preval&ecirc;ncia de dissincronia intraventricular e moderada preval&ecir
c;ncia    de dissincronia interventricular. A alta preval&ecirc;ncia independe d
a largura    do QRS. A dissincronia ventricular n&atilde;o tem qualquer valor pr
ogn&oacute;stico    em pacientes com cardiomiopatia chag&aacute;sica.</font></p>
     ^cY#aop02411.htm##
00487000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024300085002001300328#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#20#16#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Cardiomiopatia chag&aacute;sica, disfun&ccedil;&atilde;o ventricular, preval&eci
rc;ncia,    progn&oacute;stico.</font></p> <hr size="1" noshade>     ^cY#aop0241
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#21#17#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#22#18#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#23#19#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop02411.htm##
02450000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704220600085002001302291#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#24#20#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Atualmente, &eacute;    est
imado que 10 a 18 milh&otilde;es de pessoas estejam infectadas com a Doen&ccedil
;a    de Chagas (DC) na Am&eacute;rica Latina<sup>1</sup>. A mortalidade devido 
&agrave;    cardiomiopatia chag&aacute;sica est&aacute; intimamente ligada ao gr
au de envolvimento    mioc&aacute;rdico<sup>2</sup>. Al&eacute;m disso, o risco 
de morte n&atilde;o    &eacute; o mesmo para todos os pacientes e muitos autores
 tem tentando identificar    caracter&iacute;sticas cl&iacute;nicas que apontem 
os pacientes com maior risco.    Recentemente, Rassi e cols.<sup>3</sup> publico
u um escore de risco com boa    acur&aacute;cia progn&oacute;stica, levando em c
onsidera&ccedil;&atilde;o o    sexo, a baixa voltagem no eletrocardiograma, card
iomegalia no raio X de t&oacute;rax,    taquicardia ventricular n&atilde;o-suste
ntada, classe funcional e fra&ccedil;&atilde;o    de eje&ccedil;&atilde;o reduzi
da no ecocardiograma. Al&eacute;m da quantifica&ccedil;&atilde;o    do grau de d
isfun&ccedil;&atilde;o ventricular, o ecocardiograma recentemente    emergiu com
o uma ferramenta para determinar a presen&ccedil;a de dissincronia    ventricula
r, a qual est&aacute; relacionada &agrave; um pior progn&oacute;stico    em card
iomiopatias devido &agrave; outras etiologias<sup>4-6</sup>. O valor    progn&oa
cute;stico da dissincronia ventricular em pacientes com cardiomiopatia    chag&a
acute;sica n&atilde;o &eacute; conhecido. Recentemente, um estudo controverso   
 chamado "PROSPECT" descreveu o valor e a alta variabilidade inter-observador   
 do ecocardiograma durante a an&aacute;lise da dissincronia, e isso &eacute;    
um t&oacute;pico a ser analisado nesse estudo com pacientes chag&aacute;sicos<su
p>7</sup>.    Dada a necessidade de novos marcadores de risco nessa doen&ccedil;
a que possam    adicionar valor progn&oacute;stico ao escore de Rassi e a falta 
de dados sobre    a preval&ecirc;ncia de dissincronia ventricular nessa popula&c
cedil;&atilde;o,    avaliamos a dissincronia por ecocardiograma em 56 indiv&iacu
te;duos com cardiomiopatia    chag&aacute;sica, que foram acompanhados por 21 &p
lusmn; 14 meses.</font></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#25#21#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#26#22#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&eacute;todos</b></font
></p>     ^cY#aop02411.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012600085002001300211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#27#23#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Popula&ccedil;&atilde;o 
   do estudo</b></font></p>     ^cY#aop02411.htm##
01337000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704109300085002001301178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#28#24#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O estudo foi conduzido    n
a Cl&iacute;nica de Cardiomiopatia da Universidade Federal da Bahia. A cardiomio
patia    chag&aacute;sica foi definida como dois testes sorol&oacute;gicos posit
ivos    para Doen&ccedil;a de Chagas (imunofluoresc&ecirc;ncia e hemaglutina&cce
dil;&atilde;o)    e fra&ccedil;&atilde;o de eje&ccedil;&atilde;o (FE) &lt; 45% n
o ecocardiograma.    Novos pacientes com essas caracter&iacute;sticas foram cons
ecutivamente selecionados    de junho de 2005 a agosto de 2008. O estudo foi apr
ovado pelo Comit&ecirc; de    &Eacute;tica local. Todos os pacientes assinaram o
 Termo de Consentimento Livre    e Informado. Pacientes com condi&ccedil;&otilde
;es card&iacute;acas associadas    (cardiopatia hipertensiva, valvar ou isqu&eci
rc;mica) foram exclu&iacute;dos.    Pacientes com fibrila&ccedil;&atilde;o atria
l ou extra-s&iacute;stoles frequentes    foram exclu&iacute;dos por que essas ar
ritmias podem prejudicar a avalia&ccedil;&atilde;o    da dissincronia atrav&eacu
te;s do ecocardiograma.</font></p>     ^cY#aop02411.htm##
00356000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011200085002001300197#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#29#25#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Protocolo do    estudo</
b></font></p>     ^cY#aop02411.htm##
02278000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704203400085002001302119#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#30#26#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Um sistema de ultrassom    
dispon&iacute;vel comercialmente (Vingmed system FiVi/Seven, General Electric-Vi
ngmed,    Milwaukee, WI, EUA<i>)</i> foi utilizado. Imagens foram obtidas com um
 transdutor    de 3,5 MHz, a uma profundidade de 16 cm nos cortes paraesternal e
 apical. Os    par&acirc;metros do Doppler tecidual foram medidos a partir de im
agens coloridas    de tr&ecirc;s batimentos card&iacute;acos consecutivos atrav&
eacute;s de an&aacute;lise    <i>off-line</i>. O observador n&atilde;o estava ci
ente da condi&ccedil;&atilde;o    cl&iacute;nica dos pacientes. A dissincronia i
ntraventricular foi definida pelos    seguintes crit&eacute;rios: 1) desvio-padr
&atilde;o (DP) do atraso entre o in&iacute;cio    da onda R no eletrocardiograma
 e o pico da velocidade da onda S medida nos 12    segmentos do ventr&iacute;cul
o esquerdo &gt; 33 ms<sup>8-10</sup>; 2) intervalo    m&aacute;ximo (IM) medido 
entre quaisquer 2 segmentos &gt; 100 ms<sup>11</sup>;    3) atraso entre os segm
entos septo-basal e basal-lateral (SLD) &gt; 60 ms<sup>12</sup>.    Para dissinc
ronia interventricular, o Doppler pulsado foi usado. Foi determinada    como a d
iferen&ccedil;a nos intervalos de tempo da onda Q at&eacute; o in&iacute;cio    
do fluxo na art&eacute;ria pulmonar, comparada com o intervalo de tempo da onda 
   Q at&eacute; o in&iacute;cio do fluxo a&oacute;rtico, respectivamente. Um val
or    &gt; 40 ms &eacute; considerado anormal<sup>13</sup>. A FE foi calculada a
trav&eacute;s    do m&eacute;todo de Simpson modificado. Al&eacute;m disso, um r
egistro de Holter    de 24 horas foi realizado em todos os pacientes. O escore d
e Rassi foi calculado    como previamente validado<sup>3</sup>. Resumidamente, e
sse escore leva em considera&ccedil;&atilde;o    o sexo, baixa voltagem no eletr
ocardiograma, cardiomegalia no raio-X de t&oacute;rax,    taquicardia ventricula
r n&atilde;o-sustentada, classe funcional III/IV e FE    reduzida no ecocardiogr
ama.</font></p>     ^cY#aop02411.htm##
00672000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042800085002001300513#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#31#27#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os pacientes foram    monit
orados de forma regular, a cada 3 meses, atrav&eacute;s de consultas ambulatoria
is    e liga&ccedil;&otilde;es telef&ocirc;nicas. Eventos cl&iacute;nicos tais c
omo    morte total, morte cardiovascular e hospitaliza&ccedil;&atilde;o devido &
agrave;    insufici&ecirc;ncia card&iacute;aca ou arritmias foram registrados.</
font></p>     ^cY#aop02411.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012600085002001300211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#32#28#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    estat&
iacute;stica</b></font></p>     ^cY#aop02411.htm##
02641000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704239700085002001302482#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#33#29#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A frequ&ecirc;ncia    relat
iva de dissincronia interventricular e intraventricular foi descrita com    inte
rvalo de confian&ccedil;a de 95%. A fim de identificar os preditores na    an&aa
cute;lise univariada, dados cl&iacute;nicos, eletrocardiogr&aacute;ficos    e ec
ocardiogr&aacute;ficos, incluindo crit&eacute;rios de dissincronia, foram    com
parados entre pacientes com e sem eventos. As vari&aacute;veis categ&oacute;rica
s    foram comparadas atrav&eacute;s do Teste Qui-quadrado de Pearson e as vari&
aacute;veis    num&eacute;ricas pelo teste <i>t</i> de <i>Student</i> ou teste d
e Mann-Whitney;    as vari&aacute;veis associadas com eventos (p <i><u>&lt;</u><
/i> 0,10) foram    inclu&iacute;das na an&aacute;lise de regress&atilde;o log&ia
cute;stica para    avaliar os preditores independentes. O escore de Rassi foi es
colhido ao inv&eacute;s    de preditores independentes. Com base em um estudo pi
loto de 28 indiv&iacute;duos,    onde havia uma preval&ecirc;ncia de 70% de diss
incronia, 56 indiv&iacute;duos    foram considerados suficientes, dado um erro d
e precis&atilde;o de &plusmn;    12% e intervalo de confian&ccedil;a de 95%. Em 
rela&ccedil;&atilde;o ao valor    progn&oacute;stico, com base no estudo de Rass
i e cols., para definir os fatores    progn&oacute;sticos independentes na DC e 
em caso de eventos combinados, foi    estimado um risco absoluto de 40%. Assim, 
56 pacientes tamb&eacute;m foram considerados    suficientes, dos quais 39 apres
entavam dissincronia e 17 n&atilde;o apresentavam    dissincronia. Para o grupo 
com dissincronia, esse risco chega a 60% e para o    grupo sem dissincronia, ess
e risco seria de 20%. Um poder de 80% e um alfa igual    a 5% foram dados ao est
udo. Na an&aacute;lise de variabilidade intra-observador    e inter-observador, 
o coeficiente de variabilidade (CV) foi calculado entre    as medidas em rela&cc
edil;&atilde;o aos crit&eacute;rios de dissincronia intraventricular    e interv
entricular. Para essa an&aacute;lise, cerca de 10% da amostra foi utilizada,    
um total de 6 pacientes, com dois observadores avaliando os &uacute;ltimos seis 
   pacientes do estudo. Um valor de p &lt; 0,05 foi considerado significante. O 
   <i>software</i> SPSS 14.0 para Windows (<i>SPSS Inc, Chicago, II)</i> foi uti
lizado    na an&aacute;lise estat&iacute;stica.</font></p>     ^cY#aop02411.htm#
#
00544000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030000085002001300385#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#34#30#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o havia    rela&cc
edil;&otilde;es financeiras ou pessoais entre os autores e outros indiv&iacute;d
uos    ou organiza&ccedil;&otilde;es que pudessem influenciar suas a&ccedil;&oti
lde;es    de forma inadequada.</font></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#35#31#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#36#32#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Resultados</b></font></p
>     ^cY#aop02411.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#37#33#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Caracter&iacute;sticas  
  basais</b></font></p>     ^cY#aop02411.htm##
01976000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704173200085002001301817#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#38#34#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Um grupo de 56    pacientes
 com cardiomiopatia chag&aacute;sica foi estudado, com m&eacute;dia    de idade 
de 56 &plusmn; 10 anos (36 a 79 anos), sendo 50% do sexo masculino,    82% de as
cend&ecirc;ncia africana. Eles haviam sido tratados de forma efetiva    em rela&
ccedil;&atilde;o &agrave; press&atilde;o arterial, frequ&ecirc;ncia    card&iacu
te;aca, fun&ccedil;&atilde;o renal e eletr&oacute;litos. Em geral,    os pacient
es estavam sendo submetidos &agrave; tratamento m&eacute;dico com    inibidores 
de enzima conversora de angiotensina, beta-bloqueadores e bloqueadores    de ald
osterona, com 93% de uso regular de medicamentos e 87% apresentando classe    fu
ncional I/II. Essa boa classe funcional pode ser explicada pela cl&iacute;nica  
  espec&iacute;fica (Cl&iacute;nica de Cardiomiopatia), com diferentes profissio
nais    da sa&uacute;de e o uso regular dos medicamentos. Um n&uacute;mero signi
ficante    de pacientes era portador de marca-passo (25%), 23% apresentava bloqu
eio de    ramo direito e 14% apresentava bloqueio de ramo esquerdo. O grau de di
sfun&ccedil;&atilde;o    ventricular esquerda era grave, medido pela fra&ccedil;
&atilde;o de eje&ccedil;&atilde;o    do ventr&iacute;culo esquerdo de 30 &plusmn
; 8%. As cavidades apresentavam-se    dilatadas, com uma m&eacute;dia de di&acir
c;metro diast&oacute;lico ventricular    esquerdo de 66 &plusmn; 8 mm. Dist&uacu
te;rbios segmentares de contratilidade    ventricular eram muito comuns nessa po
pula&ccedil;&atilde;o (73%) e o segmento    mais comumente afetado era o segment
o posterior (56%). Essas caracter&iacute;sticas    s&atilde;o mostradas na <a hr
ef="#t1">Tabela 1</a>.</font></p>     ^cY#aop02411.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#39#35#article#137#<p><a name
="t1"></a></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#40#36#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#41#37#article#137#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02411t01.jpg"></p>     ^cY#aop
02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#42#38#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012600085002001300211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#43#39#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Preval&ecirc;ncia    de 
dissincronia</b></font></p>     ^cY#aop02411.htm##
02180000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704193600085002001302021#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#44#40#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Quando quaisquer    dos tr&
ecirc;s crit&eacute;rios eram considerados, uma preval&ecirc;ncia significante  
  de 85% (IC95%: 75% - 93%) de dissincronia intraventricular era observada. Com 
   base no desvio padr&atilde;o de 12 segmentos isoladamente, havia uma preval&e
circ;ncia    de 75% (IC95%: 62% - 86%), o crit&eacute;rio de intervalo m&aacute;
ximo estava    presente em 79% (IC95%: 65% - 88%) e o atraso septo-lateral, em m
enor propor&ccedil;&atilde;o,    48% (IC95%: 35% - 62%). A preval&ecirc;ncia de 
dissincronia interventricular    era 34% (IC95%: 22% -48%) <b>-</b> <a href="#t2
">Tabela 2</a>. A dissincronia    intraventricular permaneceu alta independente 
da largura do QRS. Estava presente    em 89% (IC95%: 74% - 97%) dos pacientes co
m QRS &gt; 0,12 s e em 84% (IC95%:    62% - 96%) dos pacientes com QRS &lt; 0,12
 s (p = 0,66) - <a href="/img/revistas/abc/2011nahead/aop02411t03.jpg">Tabela   
 3</a>. Quando os tr&ecirc;s crit&eacute;rios eram analisados separadamente,    
nenhuma diferen&ccedil;a significante foi observada em rela&ccedil;&atilde;o    
&agrave; porcentagem, considerando a largura do QRS nos dois grupos - desvio-pad
r&atilde;o    - 81% <i>vs</i> 70% (p = 0,31), intervalo m&aacute;ximo - 81% <i>v
s</i> 75%    (p = 0,85) e atraso septo-lateral - 47% <i>vs</i> 50% (p = 0,78). A
 dissincronia    interventricular era similar entre os subgrupos de QRS &lt; ou 
&gt; 0,12 s (15%    <i>vs</i> 44%, p = 0,30). A <a href="/img/revistas/abc/2011n
ahead/aop02411t03.jpg">Tabela 3</a> mostra    a m&eacute;dia dos 4 crit&eacute;r
ios e valores de p. Quando a porcentagem foi    comparada, n&atilde;o houve dife
ren&ccedil;a. Mas quando as m&eacute;dias foram    comparadas, o valor foi signi
ficante no crit&eacute;rio do desvio-padr&atilde;o    (p = 0,03) e quase signifi
cante no crit&eacute;rio da diferen&ccedil;a VE-VD    (p = 0,052).</font></p>   
  ^cY#aop02411.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#45#41#article#137#<p><a name
="t2"></a></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#46#42#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#47#43#article#137#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02411t02.jpg"></p>     ^cY#aop
02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#48#44#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
01225000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098100085002001301066#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#49#45#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No momento da avalia&ccedil
;&atilde;o    da dissincronia, todos os pacientes com marca-passo apresentavam e
stimula&ccedil;&atilde;o    ventricular, com o eletrodo ventricular no &aacute;p
ice do VD. Em rela&ccedil;&atilde;o    &agrave; pacientes portadores de marca-pa
sso, a dissincronia intraventricular    n&atilde;o apresentou diferen&ccedil;a q
uando as porcentagens e as m&eacute;dias    foram comparadas (p = 0,09). Entreta
nto, em rela&ccedil;&atilde;o &agrave; dissincronia    interventricular, houve d
iferen&ccedil;a quando as porcentagens (57% <i>vs</i>    24%, p = 0,04), e as m&
eacute;dias (26 &plusmn; 22 ms <i>vs</i> 48 &plusmn;    33 ms, p = 0,007) foram 
comparadas. Quando os pacientes sem marca-passo (n =    42) foram analisados, a 
preval&ecirc;ncia de dissincronia intraventricular foi    de 90% e a de dissincr
onia interventricular foi 24%, o que pode explicar esses    resultados.</font></
p>     ^cY#aop02411.htm##
00771000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052700085002001300612#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#50#46#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Outra observa&ccedil;&atild
e;o    &eacute; que os dist&uacute;rbios segmentares de contratilidade ventricul
ar    foram significantemente mais prevalentes em pacientes com dissincronia int
raventricular    quando comparados com o grupo sem dissincronia (81% <i>versus</
i> 57%, p = 0,01).    Os dist&uacute;rbios segmentares de contratilidade ventric
ular foram um preditor    de dissincronia intraventricular (an&aacute;lise multi
variada, p=0,01).</font></p>     ^cY#aop02411.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#51#47#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Valor progn&oacute;stico
    da dissincronia</b></font></p>     ^cY#aop02411.htm##
01037000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079300085002001300878#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#52#48#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Durante um per&iacute;odo  
  de seguimento de 21 &plusmn; 14 meses, 20 eventos foram registrados (11 mortes
    e 9 hospitaliza&ccedil;&otilde;es). A incid&ecirc;ncia de eventos combinados
    entre pacientes com e sem dissincronia intraventricular era similar (35% <i>
vs</i>    38%, p = 0,9). Quando somente mortes foram consideradas, a incid&ecirc
;ncia    foi de 19% e 25%, respectivamente (p = 0,68). Na an&aacute;lise de pres
en&ccedil;a    ou aus&ecirc;ncia de dissincronia interventricular, a incid&ecirc
;ncia de eventos    foi de 39% e 34%, respectivamente (p = 0,73). Quando somente
 mortes foram consideradas,    a incid&ecirc;ncia era de 28% comparada com 16% e
m pacientes sem dissincronia    (p = 0,29).</font></p>     ^cY#aop02411.htm##
01063000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704081900085002001300904#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#53#49#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Na an&aacute;lise    univar
iada, as seguintes vari&aacute;veis eram prevalentes em indiv&iacute;duos    com
 eventos quando comparados &agrave;queles livres de eventos: classe funcional   
 III / IV (30% <i>vs</i> 6%, p = 0,02), &iacute;ndice cardiotor&aacute;cico &gt;
    50% (70% <i>vs</i> 36%, p = 0,02). A m&eacute;dia do escore de Rassi era mai
s    alta em pacientes com eventos (8) quando comparada com os pacientes remanes
centes    (6, p = 0,01) e a FE era mais baixa em pacientes com eventos (27% &plu
smn; 7%    <i>vs</i> 32% &plusmn; 8%, p = 0,02). Quando examinamos os quatro cri
t&eacute;rios    para dissincronia, o atraso septo-lateral e a diferen&ccedil;a 
VD-VE mostraram    um valor de p = 0,10 (<a href="#t4">Tabela 4</a>).</font></p>
     ^cY#aop02411.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#54#50#article#137#<p><a name
="t4"></a></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#55#51#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#56#52#article#137#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02411t04.jpg"></p>     ^cY#aop
02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#57#53#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00837000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059300085002001300678#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#58#54#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    multiva
riada por regress&atilde;o log&iacute;stica mostrou que o escore de Rassi    foi
 o &uacute;nico preditor de eventos combinados (<i>odds ratio - OR</i>-1.19;    
IC95%: 1,02 a 1,40, p=0,01). As vari&aacute;veis de dissincronia - atraso septo-
lateral    (intraventricular) e diferen&ccedil;a VD-VE (interventricular) n&atil
de;o foram    significantes- atraso septo-lateral - OR = 0,98 (IC95%: 0,97-1.00)
 e diferen&ccedil;a    VE-VD -1,01 (IC95%: 0,98-1,04) - <a href="#t5">Tabela 5</
a>.</font></p>     ^cY#aop02411.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#59#55#article#137#<p><a name
="t5"></a></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#60#56#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#61#57#article#137#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02411t05.jpg"></p>     ^cY#aop
02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#62#58#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00386000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014200085002001300227#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#63#59#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Variabilidade    inter-o
bservador e intra-observador</b></font></p>     ^cY#aop02411.htm##
00918000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067400085002001300759#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#64#60#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Para as vari&aacute;veis   
 desvio-padr&atilde;o e intervalo m&aacute;ximo, havia uma baixa variabilidade  
  intra-observador (9 e 10%, respectivamente) e uma moderada variabilidade inter
-observador    (23 e 18%, respectivamente). Em rela&ccedil;&atilde;o ao atraso s
epto-lateral    e a diferen&ccedil;a VE-VD, ambas as variabilidades intra-observ
ador e inter-observador    eram moderadas a altas (23 a 64%). A variabilidade in
tra-observador (9 a 27%)    era muito mais baixa quando comparada &agrave; varia
bilidade inter-observador    (18 a 64%) em qualquer uma das quatro vari&aacute;v
eis.</font></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#65#61#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#66#62#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop02411.htm##
00789000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054500085002001300630#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#67#63#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Esse &eacute; o    primeiro
 estudo a avaliar a preval&ecirc;ncia de dissincronia ventricular e    suas impl
ica&ccedil;&otilde;es cl&iacute;nicas em indiv&iacute;duos com cardiomiopatia   
 chag&aacute;sica. Primeiramente, observamos que a dissincronia &eacute; uma    
condi&ccedil;&atilde;o altamente prevalente; segundo, a presen&ccedil;a de dissi
ncronia    pode n&atilde;o afetar o progn&oacute;stico de indiv&iacute;duos com 
cardiomiopatia    chag&aacute;sica.</font></p>     ^cY#aop02411.htm##
01917000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704167300085002001301758#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#68#64#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A preval&ecirc;ncia    de 8
5% de dissincronia intraventricular deve ser considerada significantemente    al
ta, especialmente quando comparada com outras etiologias, tais como cardiomiopat
ia    isqu&ecirc;mica e dilatada, com uma preval&ecirc;ncia relatada de 58% em p
acientes    com bloqueio do ramo esquerdo e 42% em pacientes com bloqueio do ram
o direito    associado com bloqueio divisional<sup>14</sup>. Poss&iacute;veis ex
plica&ccedil;&otilde;es    para essa preval&ecirc;ncia mais alta em pacientes ch
ag&aacute;sicos seriam    as altera&ccedil;&otilde;es segmentares secund&aacute;
rias &agrave; &aacute;reas    de fibrose associadas com o processo inflamat&oacu
te;rio cr&ocirc;nico e difuso,    que &eacute; persistente e inerente &agrave; e
ssa doen&ccedil;a<sup>15,16</sup>.    Em rela&ccedil;&atilde;o &agrave; dissincr
onia interventricular, nossos achados    foram similares &agrave;queles relatado
s em outras etiologias<sup>17</sup>.    Nessa popula&ccedil;&atilde;o, nenhuma d
iferen&ccedil;a significante foi observada    em rela&ccedil;&atilde;o &agrave; 
preval&ecirc;ncia baseada na largura do QRS,    apenas em alguns valores de m&ea
cute;dias de crit&eacute;rios de dissincronia    intraventricular. Em rela&ccedi
l;&atilde;o ao crit&eacute;rio interventricular,    essa diferen&ccedil;a era ma
is evidente, mas sem atingir signific&acirc;ncia    estat&iacute;stica, apenas e
m pacientes com marca-passo. Na literatura, a preval&ecirc;ncia    de dissincron
ia intraventricular e interventricular tem rela&ccedil;&atilde;o    com a largur
a do QRS em outras etiologias<sup>17</sup>.</font></p>     ^cY#aop02411.htm##
01689000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704144500085002001301530#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#69#65#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O grau de fibrose    em pac
ientes com Doen&ccedil;a de Chagas (DC) contradiz os benef&iacute;cios    da res
sincroniza&ccedil;&atilde;o, como o relatado para cardiomiopatias isqu&ecirc;mic
as    com &aacute;reas de cicatrizes transmurais<sup>18,19</sup>. O crit&eacute;
rio    septo-lateral nessa popula&ccedil;&atilde;o era menos prevalente, mas n&a
tilde;o    havia rela&ccedil;&atilde;o com a &aacute;rea de fibrose. Essa medida
 &eacute;    feita na &aacute;rea anterior, uma &aacute;rea que n&atilde;o &eacu
te; normalmente    afetada pela DC. Por outro lado, todos os outros crit&eacute;
rios foram altamente    prevalentes e poderiam ser um fator em favor da terapia,
 j&aacute; bem estabelecida    em grandes estudos cl&iacute;nicos em outras etio
logias (CARE-HF e COMPANION)<sup>20-23</sup>    e em pequenos estudos na popula&
ccedil;&atilde;o chag&aacute;sica. Silva e cols.<sup>24</sup>    descreveram uma
 popula&ccedil;&atilde;o de 29 pacientes, metade dos quais chag&aacute;sicos,   
 que receberam terapia de ressincroniza&ccedil;&atilde;o e evolu&iacute;ram com 
   melhora cl&iacute;nica e da fra&ccedil;&atilde;o de eje&ccedil;&atilde;o (FE)
.    Esses indiv&iacute;duos podem se beneficiar com a terapia, mas isso n&atild
e;o    pode ser declarado nesse momento e um novo estudo cl&iacute;nico &eacute;
 necess&aacute;rio    para definir essa quest&atilde;o.</font></p>     ^cY#aop02
411.htm##
02402000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704215800085002001302243#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#70#66#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Dados anteriores    relatar
am uma rela&ccedil;&atilde;o entre a dissincronia e um pior progn&oacute;stico  
  em outras cardiomiopatias. Cho e cols.<sup>6</sup> avaliaram a dissincronia   
 em 106 pacientes com insufici&ecirc;ncia card&iacute;aca e verificaram que a   
 dissincronia era um forte preditor de eventos cl&iacute;nicos graves. De forma 
   similar, Bader e cols.<sup>4</sup>, ao descreverem um grupo de 104 pacientes,
    mostraram que a presen&ccedil;a de dissincronia intraventricular &eacute; um
    fator determinante de eventos card&iacute;acos adversos, independentemente d
a    FE e do QRS. Em oposi&ccedil;&atilde;o, no presente estudo, a dissincronia 
n&atilde;o    mostrou ser um marcador em pacientes com cardiomiopatia chag&aacut
e;sica. Poss&iacute;veis    explica&ccedil;&otilde;es podem ser a alta preval&ec
irc;ncia, com quase todos    apresentando dissincronia, e provavelmente a espera
da variabilidade do m&eacute;todo    usado para avaliar a dissincronia. Ao anali
sar a exatid&atilde;o das medidas    de dissincronia, podemos observar uma varia
bilidade intra-observador mais baixa    quando comparada &agrave; variabilidade 
inter-observador. Essas medidas refletem,    de certa forma, a alta variabilidad
e desses valores, j&aacute; bem estabelecidos    na literatura<sup>7-25</sup>. A
 recente publica&ccedil;&atilde;o do estudo PROSPECT    mostrou um baixo valor p
reditivo do ecocardiograma em rela&ccedil;&atilde;o    &agrave; dissincronia. Es
se estudo corrente mostrou um resultado bastante similar    em rela&ccedil;&atil
de;o &agrave; variabilidade, considerando a mesma vari&aacute;vel.    Al&eacute;
m disso, pode explicar o resultado negativo em rela&ccedil;&atilde;o    ao progn
&oacute;stico. Uma sugest&atilde;o &eacute; que os crit&eacute;rios    de ecocar
diograma na cardiomiopatia chag&aacute;sica poderiam ser diferentes    dos crit&
eacute;rios utilizados em outras cardiomiopatias. Isso pode ser observado    qua
ndo da avalia&ccedil;&atilde;o dos altos valores de m&eacute;dias em pacientes  
  com doen&ccedil;a de Chagas e QRS &lt; 0,12 s.</font></p>     ^cY#aop02411.htm
##
01478000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704123400085002001301319#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#71#67#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Optou-se por incluir    pac
ientes com marca-passo por que eles s&atilde;o muito comuns na pr&aacute;tica   
 cl&iacute;nica e refletem uma importante porcentagem de pacientes com DC. Quand
o    os pacientes sem marca-passo foram analisados, a preval&ecirc;ncia de dissi
ncronia    intraventricular permaneceu alta. A maior limita&ccedil;&atilde;o des
se estudo    poderia ser a variabilidade do m&eacute;todo de avalia&ccedil;&atil
de;o da dissincronia.    O n&uacute;mero de pacientes pode ser uma quest&atilde;
o, mas os n&uacute;meros    de eventos cl&iacute;nicos s&atilde;o altos. Ao fina
l do estudo, foi observado    que apenas 8 pacientes n&atilde;o apresentavam dis
sincronia, o que levou &agrave;    um poder estat&iacute;stico menor do que o an
teriormente calculado. Al&eacute;m    disso, ele reflete um grupo selecionado de
 pacientes Chag&aacute;sicos com a    forma avan&ccedil;ada da doen&ccedil;a, co
m fortes marcadores progn&oacute;sticos,    n&atilde;o refletindo a popula&ccedi
l;&atilde;o chag&aacute;sica como um todo.    Entretanto, esses resultados podem
 ter implica&ccedil;&otilde;es terap&ecirc;uticas,    como mencionado anteriorme
nte.</font></p>     ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#72#68#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#73#69#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop02411.htm##
00620000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037600085002001300461#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#74#70#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em conclus&atilde;o,    os 
pacientes com cardiomiopatia chag&aacute;sica apresentam alta preval&ecirc;ncia 
   de dissincronia intraventricular e moderada preval&ecirc;ncia interventricula
r.    A alta preval&ecirc;ncia independe da largura do QRS e continua alta no su
bgrupo    sem marca-passo.</font></p>     ^cY#aop02411.htm##
00582000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033800085002001300423#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#75#71#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nesse grupo de    pacientes
 selecionados com cardiomiopatia chag&aacute;sica, n&atilde;o observamos    o va
lor progn&oacute;stico da dissincronia ventricular. Estudos mais amplos    s&ati
lde;o necess&aacute;rios para melhor investigar essa quest&atilde;o.</font></p> 
    ^cY#aop02411.htm##
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#76#72#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    de
 Interesses</b></font></p>     ^cY#aop02411.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#77#73#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    haver
 conflito de interesses pertinentes.</font></p>     ^cY#aop02411.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#78#74#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop02411.htm##
00397000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015300085002001300238#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#79#75#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    n&atil
de;o teve fontes de financiamento externas.</font></p>     ^cY#aop02411.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#80#76#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;o
    Acad&ecirc;mica</b></font></p>     ^cY#aop02411.htm##
00578000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033400085002001300419#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#81#77#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Este artigo &eacute;    par
te de disserta&ccedil;&atilde;o de Mestrado de Jussara de Oliveira Pinheiro    D
uarte pela Escola Bahiana de Medicina e Sa&uacute;de P&uacute;blica - Funda&cced
il;&atilde;o    Bahiana para o Desenvolvimento da Ci&ecirc;ncia.</font></p>     
^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#82#78#article#137#<p>&nbsp;<
/p>     ^cY#aop02411.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#83#79#article#137#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop02411.htm##
00478000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022000087002001300307#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#84#80#article#13
7#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. World Heal
th    Organization. Control of Chagas' diseases: second report of the WHO Expert
 Comitee.    Geneva; 2002 (Technical Report Series 905).    ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#85#81#article#137#</font></p
>     ^cY#aop02411.htm##
00452000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704019400087002001300281#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#86#82#article#13
7#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Marin-Neto
 JA,    Sim&otilde;es MA, Sarabanda AVL. Cardiopatia chag&aacute;sica. Arq Bras 
Cardiol.    1999;72(3):247-63.    ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#87#83#article#137#</font></p
>     ^cY#aop02411.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027700087002001300364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#88#84#article#13
7#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Rassi Jr A
,    Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and v
alidation    of a risk score for predicting death in Chagas' heart disease. N En
gl J Med.    2006;355(8):799-808.    ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#89#85#article#137#</font></p
>     ^cY#aop02411.htm##
00579000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032100087002001300408#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#90#86#article#13
7#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Bader H, G
arrigue    S, Lafitte S, Reuter S, Jais P, Haissaguerre M, et al. Intra-left ven
tricular    electromechanical asynchrony: a new independent predictor of severe 
cardiac    events in heart failure patients. J Am Cardiol. 2004;43(2):248-56.   
 ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#91#87#article#137#</font></p
>     ^cY#aop02411.htm##
00623000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704036500087002001300452#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#92#88#article#13
7#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Fauchier L
,    Marie O, Casset-Senon D, Babuty D, Cosnay P, Fauchier JP. Interventricular 
and    intraventricular dyssynchrony in idiopathic dilated cardiomyopathy: a pro
gnostic    study with fourier phase analysis of radionuclide angiocintigraphy. J
 Am Coll    Cardiol. 2002;40(11):2022-30.    ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#93#89#article#137#</font></p
>     ^cY#aop02411.htm##
00574000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704031600087002001300403#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#94#90#article#13
7#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Cho GY, So
ng    JK, Park WJ, Han SW, Choi SH, Doo YC, et al. Mechanical dyssynchrony asses
sed    by tissue Doppler imaging is a powerful predictor of mortality in congest
ive    heart failure with normal QRS. J Am Cardiol. 2005;46(12):2237-43.    ^cY#
aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#95#91#article#137#</font></p
>     ^cY#aop02411.htm##
00510000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704025200087002001300339#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#96#92#article#13
7#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Chung ES, 
Leon    AR, Tavazzi L, Sun J-P, Nihoyannopoulos P, Merlino J, et al. Result of t
he predictors    of response to CRT (PROSPECT) trial. Circulation. 2008;117(20):
2608-16.    ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#97#93#article#137#</font></p
>     ^cY#aop02411.htm##
00593000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704033500087002001300422#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#98#94#article#13
7#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Yu CM, Fun
g    WH, Lin H, Zhang Q, Sanderson JE, Lau SP. Predictors of left ventricular re
verse    remodeling after cardiac resynchronization therapy for heart failure se
condary    to idiopathic dialed or ischemic cardiomyophaty. Am J Cardiol. 2003;9
1(6):684-8.    ^cY#aop02411.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#99#95#article#137#</font></p
>     ^cY#aop02411.htm##
00624000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704036500088002001300453#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#100#96#article#1
37#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Yu CM, Fu
ng    WH, Chan CK, Chan YS, Zhang Q, Lin H, et al. Comparison of efficacy of rev
erse    remodeling and clinical improvement for relatively narrow and wide QRS c
omplexes    after cardiac resynchronization therapy for heart failure. J Cardiov
asc Electrophysiol.    2004;15(9):1058-65.    ^cY#aop02411.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#101#97#article#137#</font></
p>     ^cY#aop02411.htm##
00651000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704039100089002001300480#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#102#98#article#1
37#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Yu CM, 
Fung    WH, Zhang Q, Chan CK, Chan YS, Lin H, et al. Tissue Doppler imaging is s
uperior    to strain rate imaging and postsystolic shortening on the prediction 
of reverse    remodelling in both ischemic and non-ischemic heart failure after 
cardiac resynchronization    therapy. Circulation. 2004;110(1):66-73.    ^cY#aop
02411.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#103#99#article#137#</font></
p>     ^cY#aop02411.htm##
00473000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021200090002001300302#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#104#100#article#
137#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Yu CM,
 Bax    JJ, Gorcsan J 3rd. Critical appraisal of methods to assess mechanical dy
ssynchrony.    Curr Opin Cardiol. 2009;24(1):18-28.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#105#101#article#137#</font><
/p>     ^cY#aop02411.htm##
00610000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034900090002001300439#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#106#102#article#
137#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Bax JJ
, Marwick    TH, Molhoek SG, Bleeker JB, Van Erven L, Boersma E, et al. Left ven
tricular    dyssynchrony predicts benefit of cardiac resynchronization therapy i
n patients    with end stage heart failure before pacemaker implantation. Am J C
ardiol. 2003;92(10):1238-40.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#107#103#article#137#</font><
/p>     ^cY#aop02411.htm##
00618000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704035700090002001300447#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#108#104#article#
137#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Zamora
no J,    P&eacute;res de Isla LP, Roque C, Khanhderia RC. The role of echocardio
graphy    in the assessment of mechanical dyssynchrony and its importance in pre
dicting    response to prognosis after cardiac resynchronization therapy. J Am S
oc Echocardiogr.    2007;20(1):91-9.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#109#105#article#137#</font><
/p>     ^cY#aop02411.htm##
00711000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704045000090002001300540#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#110#106#article#
137#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Haghjo
o M,    Bagherzadeh A, Farahani MM, Haghighi ZO, Sadr-Ameli MA. Significance of 
QRS    morphology in determining the prevalence of mechanical dyssynchrony in he
art    failure patient eligible for cardiac resynchronization: particular focus 
on    patients with right bundle block with and without coexistent left-sided co
nduction    defects. Europace. 2008;10(5):566-71.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#111#107#article#137#</font><
/p>     ^cY#aop02411.htm##
00518000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025700090002001300347#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#112#108#article#
137#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Rochit
te CE,    Nacif MS, Oliveira Junior AC, Siqueira-Batista R, Marchiori E, Uellend
ahl M,    et al. Cardiac magnetic resonance in Chagas' disease. Artif Organs. 20
07;31(4):259-67.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#113#109#article#137#</font><
/p>     ^cY#aop02411.htm##
00588000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032700090002001300417#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#114#110#article#
137#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Rochit
te CE,    Oliveira PF, Andrade JM, Ianni BM, Parga JR, &Aacute;vila LF, et al. M
yocardial    delayed enhancement by magnetic resonance imaging in patients with 
Chagas disease:    a marker of disease severity. J Am Coll Cardiol. 2005;46(8):1
553-8.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#115#111#article#137#</font><
/p>     ^cY#aop02411.htm##
00573000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031200090002001300402#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#116#112#article#
137#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Haghjo
o M,    Bagherzadeh A, Fazelifar AF, Haghighi ZO, Esmaielzadeh M, Alisadeh A, et
 al.    Prevalence of mechanical dyssynchrony in heart failure patients with dif
ferent    QRS durations. Pacing Clin Electrophysiol. 2007;30(5):616-22.    ^cY#a
op02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#117#113#article#137#</font><
/p>     ^cY#aop02411.htm##
00576000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031500090002001300405#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#118#114#article#
137#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Bleeke
r GB,    Kaandorp TAM, Lamb HJ, Boersma E, Steendijk P, Roos A, et al. Effects o
f posterolateral    scar tissue on clinical and echocardiographic improvement af
ter cardiac resynchronization    therapy. Circulation. 2006;113(7):969-76.    ^c
Y#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#119#115#article#137#</font><
/p>     ^cY#aop02411.htm##
00585000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032400090002001300414#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#120#116#article#
137#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Ypenbu
rg C,    Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, et
 al.    Impact of viability and scar tissue on response to cardiac resynchroniza
tion    therapy in ischaemic heart failure patients. Eur Heart J. 2007;28(1):33-
41.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#121#117#article#137#</font><
/p>     ^cY#aop02411.htm##
00556000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029500090002001300385#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#122#118#article#
137#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Clelan
d JGF,    Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. Th
e effect    of cardiac resynchronization on morbidity and mortality in heart fai
lure (CARE-HF).    N Engl J Med. 2005;352(15):1539-49.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#123#119#article#137#</font><
/p>     ^cY#aop02411.htm##
00631000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037000090002001300460#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#124#120#article#
137#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Clelan
d JGF,    Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M, et al. Pr
edicting    the long-term effects of cardiac resynchronization therapy on mortal
ity from    baselines variables and the early response: a report from the CARE-H
F Trial.    J Am Coll Cardiol. 2008;52(6):438-45.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#125#121#article#137#</font><
/p>     ^cY#aop02411.htm##
00579000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031800090002001300408#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#126#122#article#
137#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Bristo
w MR,    Saxon MD, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-res
ynchronization    therapy with and without an implantable defibrillator in advan
ced chronic heart    failure(COMPANION). N Engl J Med. 2004;350(21):2140-550.   
 ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#127#123#article#137#</font><
/p>     ^cY#aop02411.htm##
00581000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032000090002001300410#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#128#124#article#
137#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Anand 
IS, Carson    P, Galle E, Song R, Boehmer J, Ghali JK, et al. Cardiac resyncroni
zation therapy    reduces the risk of hospitalization in patients with advanced 
heart failure:    results from COMPANION trial. Circulation 2009;119(7):969-77. 
   ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#129#125#article#137#</font><
/p>     ^cY#aop02411.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030600090002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#130#126#article#
137#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Silva 
RT, Martinelli    FM, Lima CEB, Daniela GMC, Nishi&oacute;ka SAD, Pedrosa AA, et
 al. Functional    behavior of patients with conventional pacemaker undergoing c
ardiac resynchronization.    Arq Bras Cardiol. 2008;90(2):138-43.    ^cY#aop0241
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#131#127#article#137#</font><
/p>     ^cY#aop02411.htm##
00525000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026400090002001300354#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#132#128#article#
137#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Bax JJ
, Gorcsan    J. Echocardiography and noninvasive imaging in cardiac resynchroniz
ation therapy:    Results of the PROSPECT study in perspective. J Am Coll Cardio
l. 2009;53(21):1933-43.    ^cY#aop02411.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#133#129#article#137#</font><
/p>     ^cY#aop02411.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#134#130#article#137#<p>&nbsp
;</p>     ^cY#aop02411.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#135#131#article#137#<p>&nbsp
;</p>     ^cY#aop02411.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#136#132#article#137#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop02411.htm##
00299000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005300087002001300140#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#137#133#article#137#<br>   <
/b> Luis Cl&aacute;udio Lemos Correia    ^cY#aop02411.htm##
00292000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004600087002001300133#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#138#134#article#137#<br>   A
v. Princesa Leopoldina, 19/402    ^cY#aop02411.htm##
00294000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004800087002001300135#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#139#135#article#137#<br>   4
0150-080 - Salvador, BA - Brasil    ^cY#aop02411.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010100087002001300188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#140#136#article#137#<br>   E
-mail: <a href="mailto:lccorreia@terra.com.br">lccorreia@terra.com.br</a></font>
</p>     ^cY#aop02411.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02411.htm#S#p#141#137#article#137#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 01/
05/10; revisado recebido em 02/09/10; aceito em 21/09/10.</font></p>     ^cY#aop
02411.htm##
00446000000000217000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170026000860180073001120660
00700185065000900192064000500201865000900206002001300215#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02411.htm#S#c#142#1#article#25#1#World Health Orga
nization#Control of Chagas' diseases: second report of the WHO Expert Comitee^le
n#Geneva#20020000#2002#20110000#aop02411.htm##
00565000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100017001070100
02100124012002600145030001700171065000900188064000500197031000300202032000200205
014000700207865000900214002001300223035001000236801001700246#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02411.htm#S#c#143#2#article#25#2#^rND^sMarin-N
eto^nJA#^rND^sSimões^nMA#^rND^sSarabanda^nAVL#Cardiopatia chagásica^lpt#Arq Bras
 Cardiol#19990000#1999#72#3#247-63#20110000#aop02411.htm#0066-782X#Arq Bras Card
iol##
00720000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100015001040100
01700119010001700136010001600153010001600169810000600185012009300191030001300284
06500090029706400050030603100040031103200020031501400080031786500090032500200130
0334035001000347801001300357#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#144#3#article#25#3#^rND^sRassi Jr^nA#^rND^sRassi^nA#^rND^sLittle
^nWC#^rND^sXavier^nSS#^rND^sRassi^nSG#^rND^sRassi^nAG#et al#Development and vali
dation of a risk score for predicting death in Chagas' heart disease^len#N Engl 
J Med#20060000#2006#355#8#799-808#20110000#aop02411.htm#0028-4793#N Engl J Med##
00731000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100018001010100
01700119010001600136010001400152010002200166810000600188012013600194030001300330
71000020034306500090034506400050035403100030035903200020036201400070036486500090
0371002001300380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#
S#c#145#4#article#25#4#^rND^sBader^nH#^rND^sGarrigue^nS#^rND^sLafitte^nS#^rND^sR
euter^nS#^rND^sJais^nP#^rND^sHaissaguerre^nM#et al#Intra-left ventricular electr
omechanical asynchrony: a new independent predictor of severe cardiac events in 
heart failure patients^len#J Am Cardiol#2#20040000#2004#43#2#248-56#20110000#aop
02411.htm##
00799000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100015001040100
02200119010001600141010001600157010001900173012017300192030001800365065000900383
06400050039203100030039703200030040001400080040386500090041100200130042003500100
0433801001800443#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#
S#c#146#5#article#25#5#^rND^sFauchier^nL#^rND^sMarie^nO#^rND^sCasset-Senon^nD#^r
ND^sBabuty^nD#^rND^sCosnay^nP#^rND^sFauchier^nJP#Interventricular and intraventr
icular dyssynchrony in idiopathic dilated cardiomyopathy: a prognostic study wit
h fourier phase analysis of radionuclide angiocintigraphy^len#J Am Coll Cardiol#
20020000#2002#40#11#2022-30#20110000#aop02411.htm#0735-1097#J Am Coll Cardiol##
00726000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100015001000100
01500115010001400130010001500144010001400159810000600173012014400179030001300323
71000020033606500090033806400050034703100030035203200030035501400080035886500090
0366002001300375#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#
S#c#147#6#article#25#6#^rND^sCho^nGY#^rND^sSong^nJK#^rND^sPark^nWJ#^rND^sHan^nSW
#^rND^sChoi^nSH#^rND^sDoo^nYC#et al#Mechanical dyssynchrony assessed by tissue D
oppler imaging is a powerful predictor of mortality in congestive heart failure 
with normal QRS^len#J Am Cardiol#2#20050000#2005#46#12#2237-43#20110000#aop02411
.htm##
00697000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100015001020100
01700117010001500134010002500149010001700174810000600191012006500197030001200262
06500090027406400050028303100040028803200030029201400080029586500090030300200130
0312035001000325801001200335#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#148#7#article#25#7#^rND^sChung^nES#^rND^sLeon^nAR#^rND^sTavazzi^
nL#^rND^sSun^nJ-P#^rND^sNihoyannopoulos^nP#^rND^sMerlino^nJ#et al#Result of the 
predictors of response to CRT (PROSPECT) trial^len#Circulation#20080000#2008#117
#20#2608-16#20110000#aop02411.htm#0009-7322#Circulation##
00767000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100013000860100015000990100
01300114010001500127010002000142010001400162012017000176030001300346065000900359
06400050036803100030037303200020037601400060037886500090038400200130039303500100
0406801001300416#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#
S#c#149#8#article#25#8#^rND^sYu^nCM#^rND^sFung^nWH#^rND^sLin^nH#^rND^sZhang^nQ#^
rND^sSanderson^nJE#^rND^sLau^nSP#Predictors of left ventricular reverse remodeli
ng after cardiac resynchronization therapy for heart failure secondary to idiopa
thic dialed or ischemic cardiomyophaty^len#Am J Cardiol#20030000#2003#91#6#684-8
#20110000#aop02411.htm#0002-9149#Am J Cardiol##
00820000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100013000860100015000990100
01500114010001500129010001500144010001300159810000600172012017700178030002800355
06500090038306400050039203100030039703200020040001400080040286500090041000200130
0419035001000432801002800442#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#150#9#article#25#9#^rND^sYu^nCM#^rND^sFung^nWH#^rND^sChan^nCK#^r
ND^sChan^nYS#^rND^sZhang^nQ#^rND^sLin^nH#et al#Comparison of efficacy of reverse
 remodeling and clinical improvement for relatively narrow and wide QRS complexe
s after cardiac resynchronization therapy for heart failure^len#J Cardiovasc Ele
ctrophysiol#20040000#2004#15#9#1058-65#20110000#aop02411.htm#1045-3873#J Cardiov
asc Electrophysiol##
00831000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100015001010100
01500116010001500131010001500146010001300161810000600174012021900180030001200399
06500090041106400050042003100040042503200020042901400060043186500090043700200130
0446035001000459801001200469#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#151#10#article#25#10#^rND^sYu^nCM#^rND^sFung^nWH#^rND^sZhang^nQ#
^rND^sChan^nCK#^rND^sChan^nYS#^rND^sLin^nH#et al#Tissue Doppler imaging is super
ior to strain rate imaging and postsystolic shortening on the prediction of reve
rse remodelling in both ischemic and non-ischemic heart failure after cardiac re
synchronization therapy^len#Circulation#20040000#2004#110#1#66-73#20110000#aop02
411.htm#0009-7322#Circulation##
00600000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100014001010100
02200115012006800137030001800205065000900223064000500232031000300237032000200240
014000600242865000900248002001300257035001000270801001800280#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02411.htm#S#c#152#11#article#25#11#^rND^sYu^nC
M#^rND^sBax^nJJ#^rND^sGorcsan^nJ 3rd.#Critical appraisal of methods to assess me
chanical dyssynchrony^len#Curr Opin Cardiol#20090000#2009#24#1#18-28#20110000#ao
p02411.htm#0268-4705#Curr Opin Cardiol##
00793000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100018001020100
01800120010001800138010001900156010001700175810000600192012015900198030001300357
06500090037006400050037903100030038403200030038701400080039086500090039800200130
0407035001000420801001300430#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#153#12#article#25#12#^rND^sBax^nJJ#^rND^sMarwick^nTH#^rND^sMolho
ek^nSG#^rND^sBleeker^nJB#^rND^sVan Erven^nL#^rND^sBoersma^nE#et al#Left ventricu
lar dyssynchrony predicts benefit of cardiac resynchronization therapy in patien
ts with end stage heart failure before pacemaker implantation^len#Am J Cardiol#2
0030000#2003#92#10#1238-40#20110000#aop02411.htm#0002-9149#Am J Cardiol##
00753000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100024001060100
01500130010002100145012017300166030002200339065000900361064000500370031000300375
032000200378014000500380865000900385002001300394035001000407801002200417#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#c#154#13#article#25#13
#^rND^sZamorano^nJ#^rND^sPéres de Isla^nLP#^rND^sRoque^nC#^rND^sKhanhderia^nRC#T
he role of echocardiography in the assessment of mechanical dyssynchrony and its
 importance in predicting response to prognosis after cardiac resynchronization 
therapy^len#J Am Soc Echocardiogr#20070000#2007#20#1#91-9#20110000#aop02411.htm#
0894-7317#J Am Soc Echocardiogr##
00826000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01900126010001900145010002100164012026800185030000900453710000200462065000900464
064000500473031000300478032000200481014000700483865000900490002001300499#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02411.htm#S#c#155#14#article#25#14
#^rND^sHaghjoo^nM#^rND^sBagherzadeh^nA#^rND^sFarahani^nMM#^rND^sHaghighi^nZO#^rN
D^sSadr-Ameli^nMA#Significance of QRS morphology in determining the prevalence o
f mechanical dyssynchrony in heart failure patient eligible for cardiac resynchr
onization: particular focus on patients with right bundle block with and without
 coexistent left-sided conduction defects^len#Europace#2#20080000#2008#10#5#566-
71#20110000#aop02411.htm##
00704000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
02600123010002600149010001900175010002000194810000600214012005000220030001300270
06500090028306400050029203100030029703200020030001400070030286500090030900200130
0318035001000331801001300341#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#156#15#article#25#15#^rND^sRochitte^nCE#^rND^sNacif^nMS#^rND^sOl
iveira Junior^nAC#^rND^sSiqueira-Batista^nR#^rND^sMarchiori^nE#^rND^sUellendahl^
nM#et al#Cardiac magnetic resonance in Chagas' disease^len#Artif Organs#20070000
#2007#31#4#259-67#20110000#aop02411.htm#0160-564X#Artif Organs##
00769000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
01800126010001600144010001600160010001600176810000600192012012700198030001800325
06500090034306400050035203100030035703200020036001400070036286500090036900200130
0378035001000391801001800401#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#157#16#article#25#16#^rND^sRochitte^nCE#^rND^sOliveira^nPF#^rND^
sAndrade^nJM#^rND^sIanni^nBM#^rND^sParga^nJR#^rND^sÁvila^nLF#et al#Myocardial de
layed enhancement by magnetic resonance imaging in patients with Chagas disease:
 a marker of disease severity^len#J Am Coll Cardiol#20050000#2005#46#8#1553-8#20
110000#aop02411.htm#0735-1097#J Am Coll Cardiol##
00770000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
02000126010001900146010002200165010001800187810000600205012009700211030002700308
06500090033506400050034403100030034903200020035201400070035486500090036100200130
0370035001000383801002700393#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#158#17#article#25#17#^rND^sHaghjoo^nM#^rND^sBagherzadeh^nA#^rND^
sFazelifar^nAF#^rND^sHaghighi^nZO#^rND^sEsmaielzadeh^nM#^rND^sAlisadeh^nA#et al#
Prevalence of mechanical dyssynchrony in heart failure patients with different Q
RS durations^len#Pacing Clin Electrophysiol#20070000#2007#30#5#616-22#20110000#a
op02411.htm#0147-8389#Pacing Clin Electrophysiol##
00758000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100020001060100
01500126010001700141010001900158010001400177810000600191012012800197030001200325
06500090033706400050034603100040035103200020035501400070035786500090036400200130
0373035001000386801001200396#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#159#18#article#25#18#^rND^sBleeker^nGB#^rND^sKaandorp^nTAM#^rND^
sLamb^nHJ#^rND^sBoersma^nE#^rND^sSteendijk^nP#^rND^sRoos^nA#et al#Effects of pos
terolateral scar tissue on clinical and echocardiographic improvement after card
iac resynchronization therapy^len#Circulation#20060000#2006#113#7#969-76#2011000
0#aop02411.htm#0009-7322#Circulation##
00767000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01800124010001900142010001700161010002700178810000600205012012500211030001200336
06500090034806400050035703100030036203200020036501400060036786500090037300200130
0382035001000395801001200405#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#160#19#article#25#19#^rND^sYpenburg^nC#^rND^sSchalij^nMJ#^rND^sB
leeker^nGB#^rND^sSteendijk^nP#^rND^sBoersma^nE#^rND^sDibbets-Schneider^nP#et al#
Impact of viability and scar tissue on response to cardiac resynchronization the
rapy in ischaemic heart failure patients^len#Eur Heart J#20070000#2007#28#1#33-4
1#20110000#aop02411.htm#0195-668X#Eur Heart J##
00739000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01700125010002000142010001400162010002200176810000600198012009800204030001300302
06500090031506400050032403100040032903200030033301400080033686500090034400200130
0353035001000366801001300376#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#161#20#article#25#20#^rND^sCleland^nJGF#^rND^sDaubert^nJC#^rND^s
Erdmann^nE#^rND^sFreemantle^nN#^rND^sGras^nD#^rND^sKappenberger^nL#et al#The eff
ect of cardiac resynchronization on morbidity and mortality in heart failure (CA
RE-HF)^len#N Engl J Med#20050000#2005#352#15#1539-49#20110000#aop02411.htm#0028-
4793#N Engl J Med##
00816000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100020001070100
01400127010001800141010001700159010002200176810000600198012016800204030001800372
06500090039006400050039903100030040403200020040701400070040986500090041600200130
0425035001000438801001800448#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#162#21#article#25#21#^rND^sCleland^nJGF#^rND^sFreemantle^nN#^rND
^sGhio^nS#^rND^sFruhwald^nF#^rND^sShankar^nA#^rND^sMarijanowski^nM#et al#Predict
ing the long-term effects of cardiac resynchronization therapy on mortality from
 baselines variables and the early response: a report from the CARE-HF Trial^len
#J Am Coll Cardiol#20080000#2008#52#6#438-45#20110000#aop02411.htm#0735-1097#J A
m Coll Cardiol##
00762000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01700122010001700139010001500156010001800171810000600189012012900195030001300324
06500090033706400050034603100040035103200030035501400090035886500090036700200130
0376035001000389801001300399#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#163#22#article#25#22#^rND^sBristow^nMR#^rND^sSaxon^nMD#^rND^sBoe
hmer^nJ#^rND^sKrueger^nS#^rND^sKass^nDA#^rND^sDe Marco^nT#et al#Cardiac-resynchr
onization therapy with and without an implantable defibrillator in advanced chro
nic heart failure(COMPANION)^len#N Engl J Med#20040000#2004#350#21#2140-550#2011
0000#aop02411.htm#0028-4793#N Engl J Med##
00764000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01500120010001400135010001700149010001600166810000600182012014300188030001200331
06500090034306400050035203100040035703200020036101400070036386500090037000200130
0379035001000392801001200402#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#164#23#article#25#23#^rND^sAnand^nIS#^rND^sCarson^nP#^rND^sGalle
^nE#^rND^sSong^nR#^rND^sBoehmer^nJ#^rND^sGhali^nJK#et al#Cardiac resyncronizatio
n therapy reduces the risk of hospitalization in patients with advanced heart fa
ilure: results from COMPANION trial^len#Circulation#20090000#2009#119#7#969-77#2
0110000#aop02411.htm#0009-7322#Circulation##
00747000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100021001040100
01600125010001900141010002000160010001800180810000600198012010100204030001700305
06500090032206400050033103100030033603200020033901400070034186500090034800200130
0357035001000370801001700380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02411.htm#S#c#165#24#article#25#24#^rND^sSilva^nRT#^rND^sMartinelli^nFM#^rND^s
Lima^nCEB#^rND^sDaniela^nGMC#^rND^sNishióka^nSAD#^rND^sPedrosa^nAA#et al#Functio
nal behavior of patients with conventional pacemaker undergoing cardiac resynchr
onization^len#Arq Bras Cardiol#20080000#2008#90#2#138-43#20110000#aop02411.htm#0
066-782X#Arq Bras Cardiol##
00633000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100017001020120
12800119030001800247065000900265064000500274031000300279032000300282014000800285
865000900293002001300302035001000315801001800325#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02411.htm#S#c#166#25#article#25#25#^rND^sBax^nJJ#^rND^sGor
csan^nJ#Echocardiography and noninvasive imaging in cardiac resynchronization th
erapy: Results of the PROSPECT study in perspective^len#J Am Coll Cardiol#200900
00#2009#53#21#1933-43#20110000#aop02411.htm#0735-1097#J Am Coll Cardiol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#o#1#1#
article#1#20110331#081018#aop02511.htm#202##
04706000000000601000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200870017301200980
02600100035003580100025003930700069004180831639004870850008021260850061021340850
03502195085003902230085002802269083160102297085000803898085005903906085003303965
08500280399811700080402607200030403411200090403711100090404611600090405511500090
4064114000904073113000904082002001304091#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop02511.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#35#nd#nd#Arq. Br
as. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#Intervenção coronariana pe
rcutânea no Brasil: resultados do Sistema Único de Saúde^lpt#Percutaneous corona
ry intervention in Brazil: results from the Brazilian Public Health System^len#^
rND^1A01^nLeopoldo Soares^sPiegas#^rND^1A01^nNagib^sHaddad#Instituto Dante Pazza
nese de Cardiologia^iA01^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: O Sistema Únic
o de Saúde (SUS) realiza aproximadamente 80% das intervenções coronarianas percu
tâneas (ICP) no Brasil. O conhecimento desses dados permitirá planejar adequadam
ente o tratamento da doença arterial coronariana (DAC). OBJETIVO: Analisar e dis
cutir os resultados das ICP realizadas pelo SUS. MÉTODOS: Foram avaliados os dad
os do SIH/DATASUS disponibilizados para consulta pública. RESULTADOS: Entre os a
nos de 2005 a 2008 foram realizados 166.514 procedimentos em 180 hospitais. A mo
rtalidade hospitalar média foi de 2,33%, variando de 0% a 11,35%, sendo mais bai
xa no Sudeste, 2,03% e mais alta na região Norte, 3,64% (p < 0,001). A mortalida
de foi de 2,33% nos 45 (25%) hospitais de maior volume, responsáveis por 101.218
 (60,8%) das ICP, 2,29% nos 90 (50%) de médio volume com 50.067 (34,9%) ICP e 2,
52% nos 45 (25%) de pequeno volume com 7.229 (4,3%) ICP (p &gt; 0,05). A mortali
dade foi maior no gênero feminino (p < 0,0001), e nas idades &gt; 65 a (p < 0,00
1). No diagnóstico de angina (79.324, 47,64%) a mortalidade foi de 1,03% e no de
 IAM (33.286, 32,30%) 6,35% (p < 0,0000001). No implante único de stent, o mais 
frequente (102.165, 61,36%), a mortalidade foi de 1,20%, e na ICP primária (27.1
25, 16,29%), 6,96%. CONCLUSÃO: Embora crescente, ainda é baixo o número de ICP n
o país. Os hospitais de grande volume, em menor número, foram responsáveis pela 
maior parte dos procedimentos. O implante único de stent por internação foi o pr
ocedimento reportado mais empregado. As mortalidades tiveram grande variabilidad
e entre os hospitais. A ICP primária foi a responsável pela maior taxa de mortal
idade.#^dnd^i1#^tm^lpt^kAngioplastia transluminal percutânea coronariana^i1#^tm^
lpt^kSistema Único de Saúde^i1#^tm^lpt^kinfarto agudo do miocárdio^i1#^tm^lpt^ka
ngina pectoris^i1#^len^aBACKGROUND: The Brazilian Public Health System (SUS) hol
ds approximately 80% of percutaneous coronary interventions (PCI) in Brazil. Bei
ng aware of these data will enable to design a proper plan for the treatment of 
coronary artery disease (CAD). OBJECTIVE: To review and discuss the results of P
CIs performed by the SUS. METHODS: We reviewed data from SIH/DATASUS available f
or public consultation. RESULTS: From 2005 to 2008, 166,514 procedures were perf
ormed in 180 hospitals. Average hospital mortality was 2.33%, ranging from 0% to
 11.35%, being lower in the Southeast, 2.03% and higher in the northern region, 
3.64% (p < 0.001). The mortality rate was 2.33% in 45 (25%) higher-volume hospit
als, accounting for 101,218 (60.8%) of the PCIs, 2.29% in 90 (50%) medium-volume
 hospitals with 50,067 (34.9%) PCIs and 2.52% in 45 (25%) small-volume hospitals
 with 7,229 (4.3%) PCIs (p &gt; 0.05). Mortality was higher in females (p < 0.00
01) and at ages &gt; 65 to = (p < 0.001). In the diagnosis of angina (79,324, 47
.64%) mortality was 1.03%, and AMI (33,286, 32.30%) 6.35% (p < 0.0000001). In th
e single stent implantation, the most common (102,165, 61.36%), mortality was 1.
20%, and primary PCI (27,125, 16.29%), 6.96%. CONCLUSION: Although it is growing
, the number of PCIs in Brazil is still low. High-volume hospitals, in smaller n
umbers, accounted for most procedures. Single stent implantation through hospita
l admission was reported to be most commonly used procedure. Mortality rates wer
e highly variable among the hospitals. Primary PCI was responsible for the highe
st mortality rate.#^dnd^i2#^tm^len^kAngioplasty transluminal percutaneous corona
ry^i2#^tm^len^kSingle Health System^i2#^tm^len^kangina pectoris^i2#vancouv#31#20
100908#08/09/10#20101104#04/11/10#20101117#17/11/10#aop02511.htm##
04884000000000601000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201010017301201120
02740100035003860100025004210700069004460831714005150850008022290850061022370850
03502298085003902333085003502372083166202407085000804069085005904077085003304136
08500350416911700080420407200030421211200090421511100090422411600090423311500090
4242114000904251113000904260002001304269#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop02511.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#35#nd#nd#Arq. Br
as. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#<b>Intervenção coronariana
 percutânea no Brasil</b>: <b>resultados do Sistema Único de Saúde</b>^lpt#<b>Pe
rcutaneous coronary intervention in Brazil</b>: <b>results from the Brazilian Pu
blic Health System</b>^len#^rND^1A01^nLeopoldo Soares^sPiegas#^rND^1A01^nNagib^s
Haddad#Instituto Dante Pazzanese de Cardiologia^iA01^cSão Paulo^sSP^pBrasil#^lpt
^a<b>FUNDAMENTO: </b>O Sistema Único de Saúde (SUS) realiza aproximadamente 80% 
das intervenções coronarianas percutâneas (ICP) no Brasil. O conhecimento desses
 dados permitirá planejar adequadamente o tratamento da doença arterial coronari
ana (DAC). <b>OBJETIVO: </b>Analisar e discutir os resultados das ICP realizadas
 pelo SUS. <b>MÉTODOS: </b>Foram avaliados os dados do SIH/DATASUS disponibiliza
dos para consulta pública. <b>RESULTADOS: </b>Entre os anos de 2005 a 2008 foram
 realizados 166.514 procedimentos em 180 hospitais. A mortalidade hospitalar méd
ia foi de 2,33%, variando de 0% a 11,35%, sendo mais baixa no Sudeste, 2,03% e m
ais alta na região Norte, 3,64% (p &lt; 0,001). A mortalidade foi de 2,33% nos 4
5 (25%) hospitais de maior volume, responsáveis por 101.218 (60,8%) das ICP, 2,2
9% nos 90 (50%) de médio volume com 50.067 (34,9%) ICP e 2,52% nos 45 (25%) de p
equeno volume com 7.229 (4,3%) ICP (p &gt; 0,05). A mortalidade foi maior no gên
ero feminino (p &lt; 0,0001), e nas idades <u>&gt;</u> 65 a (p <u>&lt;</u> 0,001
). No diagnóstico de angina (79.324, 47,64%) a mortalidade foi de 1,03% e no de 
IAM (33.286, 32,30%) 6,35% (p &lt; 0,0000001). No implante único de <i>stent</i>
, o mais frequente (102.165, 61,36%), a mortalidade foi de 1,20%, e na ICP primá
ria (27.125, 16,29%), 6,96%. <b>CONCLUSÃO:</b> Embora crescente, ainda é baixo o
 número de ICP no país. Os hospitais de grande volume, em menor número, foram re
sponsáveis pela maior parte dos procedimentos. O implante único de <i>stent</i> 
por internação foi o procedimento reportado mais empregado. As mortalidades tive
ram grande variabilidade entre os hospitais. A ICP primária foi a responsável pe
la maior taxa de mortalidade.#^dnd^i1#^tm^lpt^kAngioplastia transluminal percutâ
nea coronariana^i1#^tm^lpt^kSistema Único de Saúde^i1#^tm^lpt^kinfarto agudo do 
miocárdio^i1#^tm^lpt^kangina <i>pectoris</i>^i1#^len^a<b>BACKGROUND:</b> The Bra
zilian Public Health System (SUS) holds approximately 80% of percutaneous corona
ry interventions (PCI) in Brazil. Being aware of these data will enable to desig
n a proper plan for the treatment of coronary artery disease (CAD). <b>OBJECTIVE
:</b> To review and discuss the results of PCIs performed by the SUS. <b>METHODS
:</b> We reviewed data from SIH/DATASUS available for public consultation. <b>RE
SULTS:</b> From 2005 to 2008, 166,514 procedures were performed in 180 hospitals
. Average hospital mortality was 2.33%, ranging from 0% to 11.35%, being lower i
n the Southeast, 2.03% and higher in the northern region, 3.64% (p &lt; 0.001). 
The mortality rate was 2.33% in 45 (25%) higher-volume hospitals, accounting for
 101,218 (60.8%) of the PCIs, 2.29% in 90 (50%) medium-volume hospitals with 50,
067 (34.9%) PCIs and 2.52% in 45 (25%) small-volume hospitals with 7,229 (4.3%) 
PCIs (p &gt; 0.05). Mortality was higher in females (p &lt; 0.0001) and at ages 
<u>&gt;</u> 65 to = (p <u>&lt;</u> 0.001). In the diagnosis of angina (79,324, 4
7.64%) mortality was 1.03%, and AMI (33,286, 32.30%) 6.35% (p &lt; 0.0000001). I
n the single stent implantation, the most common (102,165, 61.36%), mortality wa
s 1.20%, and primary PCI (27,125, 16.29%), 6.96%. <b>CONCLUSION:</b> Although it
 is growing, the number of PCIs in Brazil is still low. High-volume hospitals, i
n smaller numbers, accounted for most procedures. Single stent implantation thro
ugh hospital admission was reported to be most commonly used procedure. Mortalit
y rates were highly variable among the hospitals. Primary PCI was responsible fo
r the highest mortality rate.#^dnd^i2#^tm^len^kAngioplasty transluminal percutan
eous coronary^i2#^tm^len^kSingle Health System^i2#^tm^len^k<i>angina pectoris</i
>^i2#vancouv#31#20100908#08/09/10#20101104#04/11/10#20101117#17/11/10#aop02511.h
tm##
05195000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001200870
01790120098002660100035003640100025003990700071004240831846004950850008023410850
06102349085003502410085003902445085002802484083176202512085000804274085005904282
08500330434108500280437411700080440207200030441011200090441311100090442211600090
4431115000904440114000904449113000904458002001304467008008904480#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#l#4#1#article#1#^a2011#oa#pt#b
r1.1#1#4.0#tab#35#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110
401#Intervenção coronariana percutânea no Brasil: resultados do Sistema Único de
 Saúde^lpt#Percutaneous coronary intervention in Brazil: results from the Brazil
ian Public Health System^len#^rND^1A01^nLeopoldo Soares^sPiegas#^rND^1A01^nNagib
^sHaddad#^iA01^1Instituto Dante Pazzanese de Cardiologia^cSão Paulo^sSP^pBrasil#
^lpt^aFUNDAMENTO: O Sistema Único de Saúde (SUS) realiza aproximadamente 80 por 
cento das intervenções coronarianas percutâneas (ICP) no Brasil. O conhecimento 
desses dados permitirá planejar adequadamente o tratamento da doença arterial co
ronariana (DAC). OBJETIVO: Analisar e discutir os resultados das ICP realizadas 
pelo SUS. MÉTODOS: Foram avaliados os dados do SIH/DATASUS disponibilizados para
 consulta pública. RESULTADOS: Entre os anos de 2005 a 2008 foram realizados 166
.514 procedimentos em 180 hospitais. A mortalidade hospitalar média foi de 2,33 
por cento, variando de 0 por cento a 11,35 por cento, sendo mais baixa no Sudest
e, 2,03 por cento e mais alta na região Norte, 3,64 por cento (p < 0,001). A mor
talidade foi de 2,33 por cento nos 45 (25 por cento) hospitais de maior volume, 
responsáveis por 101.218 (60,8 por cento) das ICP, 2,29 por cento nos 90 (50 por
 cento) de médio volume com 50.067 (34,9 por cento) ICP e 2,52 por cento nos 45 
(25 por cento) de pequeno volume com 7.229 (4,3 por cento) ICP (p &gt; 0,05). A 
mortalidade foi maior no gênero feminino (p < 0,0001), e nas idades &gt; 65 a (p
 < 0,001). No diagnóstico de angina (79.324, 47,64 por cento) a mortalidade foi 
de 1,03 por cento e no de IAM (33.286, 32,30 por cento) 6,35 por cento (p < 0,00
00001). No implante único de stent, o mais frequente (102.165, 61,36 por cento),
 a mortalidade foi de 1,20 por cento, e na ICP primária (27.125, 16,29 por cento
), 6,96 por cento. CONCLUSÃO: Embora crescente, ainda é baixo o número de ICP no
 país. Os hospitais de grande volume, em menor número, foram responsáveis pela m
aior parte dos procedimentos. O implante único de stent por internação foi o pro
cedimento reportado mais empregado. As mortalidades tiveram grande variabilidade
 entre os hospitais. A ICP primária foi a responsável pela maior taxa de mortali
dade.#^dnd^i1#^tm^lpt^kAngioplastia transluminal percutânea coronariana^i1#^tm^l
pt^kSistema Único de Saúde^i1#^tm^lpt^kinfarto agudo do miocárdio^i1#^tm^lpt^kan
gina pectoris^i1#^len^aBACKGROUND: The Brazilian Public Health System (SUS) hold
s approximately 80 percent of percutaneous coronary interventions (PCI) in Brazi
l. Being aware of these data will enable to design a proper plan for the treatme
nt of coronary artery disease (CAD). OBJECTIVE: To review and discuss the result
s of PCIs performed by the SUS. METHODS: We reviewed data from SIH/DATASUS avail
able for public consultation. RESULTS: From 2005 to 2008, 166,514 procedures wer
e performed in 180 hospitals. Average hospital mortality was 2.33 percent, rangi
ng from 0 percent to 11.35 percent, being lower in the Southeast, 2.03 percent a
nd higher in the northern region, 3.64 percent (p < 0.001). The mortality rate w
as 2.33 percent in 45 (25 percent) higher-volume hospitals, accounting for 101,2
18 (60.8 percent) of the PCIs, 2.29 percent in 90 (50 percent) medium-volume hos
pitals with 50,067 (34.9 percent) PCIs and 2.52 percent in 45 (25 percent) small
-volume hospitals with 7,229 (4.3 percent) PCIs (p &gt; 0.05). Mortality was hig
her in females (p < 0.0001) and at ages &gt; 65 to = (p < 0.001). In the diagnos
is of angina (79,324, 47.64 percent) mortality was 1.03 percent, and AMI (33,286
, 32.30 percent) 6.35 percent (p < 0.0000001). In the single stent implantation,
 the most common (102,165, 61.36 percent), mortality was 1.20 percent, and prima
ry PCI (27,125, 16.29 percent), 6.96 percent. CONCLUSION: Although it is growing
, the number of PCIs in Brazil is still low. High-volume hospitals, in smaller n
umbers, accounted for most procedures. Single stent implantation through hospita
l admission was reported to be most commonly used procedure. Mortality rates wer
e highly variable among the hospitals. Primary PCI was responsible for the highe
st mortality rate.#^dnd^i2#^tm^len^kAngioplasty transluminal percutaneous corona
ry^i2#^tm^len^kSingle Health System^i2#^tm^len^kangina pectoris^i2#vancouv#31#20
100908#08/09/10#20101104#04/11/10#20101117#17/11/10#aop02511.htm#Internet^ihttp:
//www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000035##
00472000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704023000083002001300313#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#5#1#article#167#<p><a name="
top"></a><font face="verdana, arial, helvetica, sans-serif" size="4"><b>Interven
&ccedil;&atilde;o    coronariana percut&acirc;nea no Brasil. Resultados do Siste
ma &Uacute;nico de    Sa&uacute;de</b></font></p>     ^cY#aop02511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#6#2#article#167#<p>&nbsp;</p
>     ^cY#aop02511.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#7#3#article#167#<p>&nbsp;</p
>     ^cY#aop02511.htm##
00371000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704012900083002001300212#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#8#4#article#167#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Leopoldo Soares    Piegas;
 Nagib Haddad</b></font></p>     ^cY#aop02511.htm##
00399000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704015700083002001300240#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#9#5#article#167#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Instituto Dante    Pazzanese 
de Cardiologia, S&atilde;o Paulo, SP - Brasil</font></p>     ^cY#aop02511.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#10#6#article#167#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop02511.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#11#7#article#167#<p>&nbsp;</
p>     ^cY#aop02511.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#12#8#article#167#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop02511.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#13#9#article#167#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop02511.htm##
00624000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038000085002001300465#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#14#10#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>FUNDAMENTO:    </b> O Si
stema &Uacute;nico de Sa&uacute;de (SUS) realiza aproximadamente 80%    das inte
rven&ccedil;&otilde;es coronarianas percut&acirc;neas (ICP) no Brasil.    O conh
ecimento desses dados permitir&aacute; planejar adequadamente o tratamento    da
 doen&ccedil;a arterial coronariana (DAC).    ^cY#aop02511.htm##
00342000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009800085002001300183#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#15#11#article#167#<br>   <b>
OBJETIVO: </b> Analisar e discutir os resultados das ICP realizadas pelo    SUS.
    ^cY#aop02511.htm##
00372000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012800085002001300213#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#16#12#article#167#<br>   <b>
M&Eacute;TODOS: </b> Foram avaliados os dados do SIH/DATASUS disponibilizados   
 para consulta p&uacute;blica.    ^cY#aop02511.htm##
01229000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098500085002001301070#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#17#13#article#167#<br>   <b>
RESULTADOS: </b> Entre os anos de 2005 a 2008 foram realizados 166.514 procedime
ntos    em 180 hospitais. A mortalidade hospitalar m&eacute;dia foi de 2,33%, va
riando    de 0% a 11,35%, sendo mais baixa no Sudeste, 2,03% e mais alta na regi
&atilde;o    Norte, 3,64% (p &lt; 0,001). A mortalidade foi de 2,33% nos 45 (25%
) hospitais    de maior volume, respons&aacute;veis por 101.218 (60,8%) das ICP,
 2,29% nos    90 (50%) de m&eacute;dio volume com 50.067 (34,9%) ICP e 2,52% nos
 45 (25%)    de pequeno volume com 7.229 (4,3%) ICP (p &gt; 0,05). A mortalidade
 foi maior    no g&ecirc;nero feminino (p &lt; 0,0001), e nas idades <u>&gt;</u>
 65 a (p <u>&lt;</u>    0,001). No diagn&oacute;stico de angina (79.324, 47,64%)
 a mortalidade foi de    1,03% e no de IAM (33.286, 32,30%) 6,35% (p &lt; 0,0000
001). No implante &uacute;nico    de <i>stent</i>, o mais frequente (102.165, 61
,36%), a mortalidade foi de 1,20%,    e na ICP prim&aacute;ria (27.125, 16,29%),
 6,96%.    ^cY#aop02511.htm##
00763000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051900085002001300604#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#18#14#article#167#<br>   <b>
CONCLUS&Atilde;O:</b> Embora crescente, ainda &eacute; baixo o n&uacute;mero    
de ICP no pa&iacute;s. Os hospitais de grande volume, em menor n&uacute;mero,   
 foram respons&aacute;veis pela maior parte dos procedimentos. O implante &uacut
e;nico    de <i>stent</i> por interna&ccedil;&atilde;o foi o procedimento report
ado mais    empregado. As mortalidades tiveram grande variabilidade entre os hos
pitais.    A ICP prim&aacute;ria foi a respons&aacute;vel pela maior taxa de mor
talidade.</font></p>     ^cY#aop02511.htm##
00531000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028700085002001300372#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#19#15#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Angioplastia transluminal percut&acirc;nea coronariana, Sistema &Uacute;nico    
de Sa&uacute;de, infarto agudo do mioc&aacute;rdio, angina <i>pectoris</i>.</fon
t></p> <hr size="1" noshade>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#20#16#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#21#17#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#22#18#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop02511.htm##
01553000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704130900085002001301394#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#23#19#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A introdu&ccedil;&atilde;o 
   da interven&ccedil;&atilde;o coronariana percut&acirc;nea (ICP), utilizando  
  um cateter bal&atilde;o, por Andreas Gruentzig<sup>1</sup>, em 1977, revolucio
nou    o tratamento da doen&ccedil;a arterial coronariana (DAC). Les&otilde;es c
oronarianas    at&eacute; ent&atilde;o s&oacute; abordadas por procedimento cir&
uacute;rgico,    envolvendo uma toracotomia, passaram a ser tratadas com um cate
ter bal&atilde;o    levado at&eacute; o sistema coronariano por simples pun&cced
il;&atilde;o arterial    perif&eacute;rica. A reestenose coronariana, complica&c
cedil;&atilde;o comum    nos anos iniciais, foi reduzida com o implante dos <i>s
tents</i> coronarianos    utilizados a partir de 1986<sup>2</sup>, procedimento 
que veio a se tornar padr&atilde;o.    Os <i>stents</i> n&atilde;o recobertos, i
nicialmente empregados, foram substitu&iacute;dos,    a partir de 2001, por <i>s
tents</i> farmacol&oacute;gicos, elu&iacute;dos primeiro    com sirolimus<sup>3<
/sup>, seguido pelo paclitaxel<sup>4</sup>, e posteriormente    por outros difer
entes f&aacute;rmacos<sup>5,6</sup> que, se n&atilde;o aboliram    a reestenose 
e a necessidade de reinterven&ccedil;&atilde;o, tornaram-na menos    frequente.<
/font></p>     ^cY#aop02511.htm##
01113000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086900085002001300954#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#24#20#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Estima-se que atualmente   
 sejam implantados anualmente 2 a 3 milh&otilde;es de <i>stents</i> no mundo,   
 sendo que aproximadamente 70% s&atilde;o elu&iacute;dos com f&aacute;rmacos.   
 A limita&ccedil;&atilde;o para seu emprego &eacute; o custo, principalmente    
nos pa&iacute;ses com dificuldades econ&ocirc;micas para manter seus sistemas   
 de sa&uacute;de. No Brasil, at&eacute; o momento, esse tipo de <i>stent</i>    
n&atilde;o &eacute; reembols&aacute;vel pelo Sistema &Uacute;nico de Sa&uacute;d
e    (SUS). Os <i>stents</i> n&atilde;o farmacol&oacute;gicos s&atilde;o reembol
s&aacute;veis,    entretanto seu n&uacute;mero por paciente &eacute; controlado,
 sendo permitido    o implante de at&eacute; dois <i>stents</i> em 20% do total 
de procedimentos    por servi&ccedil;o.</font></p>     ^cY#aop02511.htm##
00687000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044300085002001300528#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#25#21#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">S&atilde;o in&uacute;meros 
   os resultados relacionados ao implante de <i>stents</i> publicados no exterio
r    e no Brasil, por&eacute;m em nosso pa&iacute;s tem se publicado estat&iacut
e;sticas    isoladas de algumas institui&ccedil;&otilde;es, pouco abrangentes e 
geralmente    provenientes dos servi&ccedil;os de lideran&ccedil;a e maior exper
i&ecirc;ncia.</font></p>     ^cY#aop02511.htm##
00566000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032200085002001300407#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#26#22#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os <i>stents</i>    convenc
ionais foram incorporados aos tratamentos fornecidos pelo SUS em dezembro    de 
1999. At&eacute; ent&atilde;o, o principal procedimento dispon&iacute;vel,    er
a a revasculariza&ccedil;&atilde;o cir&uacute;rgica.</font></p>     ^cY#aop02511
.htm##
01887000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704164300085002001301728#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#27#23#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Uma oportunidade    &uacute
;nica de se conhecerem os n&uacute;meros nacionais &eacute; analisar    o DATASU
S<sup>7</sup>, acess&iacute;vel pela internet e de dom&iacute;nio p&uacute;blico
.    DATASUS &eacute; o departamento de inform&aacute;tica do SUS. &Eacute; um &
oacute;rg&atilde;o    da Secretaria Executiva do Minist&eacute;rio da Sa&uacute;
de com a responsabilidade    de coletar, processar e disseminar informa&ccedil;&
otilde;es sobre sa&uacute;de.    Esse banco de dados &eacute; alimentado pelo si
stema de informa&ccedil;&otilde;es    hospitalares (SIH). Apesar das limita&cced
il;&otilde;es inerentes &agrave;s    caracter&iacute;sticas administrativas, e a
o fato de n&atilde;o ser universal,    pois abrange somente as interna&ccedil;&o
tilde;es pagas pelo SUS, o SIH/SUS    apresenta v&aacute;rias vantagens: tem col
eta rotineira em um grande n&uacute;mero    de unidades hospitalares, &eacute; d
isponibilizado ao p&uacute;blico interessado    em pouco tempo, abrange aproxima
damente 80% das interna&ccedil;&otilde;es brasileiras    e conta com informa&cce
dil;&otilde;es epidemiol&oacute;gicas importantes, as    quais permitem in&uacut
e;meras an&aacute;lises da situa&ccedil;&atilde;o de    morbidade hospitalar e d
e avalia&ccedil;&atilde;o de servi&ccedil;os. Esse banco    de dados funciona co
mo um registro, com uma caracter&iacute;stica muito especial,    todos os proced
imentos realizados dentro do SUS s&atilde;o obrigatoriamente    anotados, caso c
ontr&aacute;rio n&atilde;o haver&aacute; ressarcimento dos custos    do tratamen
to executado.</font></p>     ^cY#aop02511.htm##
01804000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704156000085002001301645#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#28#24#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Estima-se que o    SUS seja
 respons&aacute;vel por 80% das ICP realizadas no pa&iacute;s, sendo    as mesma
s cadastradas para fins de ressarcimento dos custos pelos hospitais,    p&uacute
;blicos, privados ou filantr&oacute;picos, prestadores desse servi&ccedil;o.    
As contas s&atilde;o auditadas e os valores da Autoriza&ccedil;&atilde;o de    I
nterna&ccedil;&atilde;o Hospitalar (AIH), perman&ecirc;ncia hospitalar e mortali
dade,    entre outras informa&ccedil;&otilde;es, s&atilde;o integradas ao SIH, e
stando    dispon&iacute;veis para consulta p&uacute;blica no DATASUS. S&atilde;o
 escassos,    sen&atilde;o inexistentes, os dados relativos &agrave;s ICP realiz
adas pelos    planos de sa&uacute;de privados. Segundo as informa&ccedil;&otilde
;es da Ag&ecirc;ncia    Nacional de Sa&uacute;de Suplementar, &oacute;rg&atilde;
o governamental que    regula os planos de sa&uacute;de, no ano de 2009, apenas 
42.310.415 brasileiros    possu&iacute;am algum tipo de plano de sa&uacute;de pr
ivado. Isso traduz uma    taxa de cobertura de planos de sa&uacute;de de 21,3% (
raz&atilde;o expressa    em porcentagem, entre o n&uacute;mero de benefici&aacut
e;rios e a popula&ccedil;&atilde;o    do pa&iacute;s)<sup>8</sup>. Assim, a an&a
acute;lise dessas informa&ccedil;&otilde;es    nos d&aacute; uma vis&atilde;o, s
e n&atilde;o da totalidade dos procedimentos,    mas do total da popula&ccedil;&
atilde;o atendida pelo sistema, mais de tr&ecirc;s    quartos da existente no pa
&iacute;s.</font></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#29#25#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#30#26#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&eacute;todos</b></font
></p>     ^cY#aop02511.htm##
00648000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040400085002001300489#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#31#27#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os dados analisados    de I
CP foram obtidos por interm&eacute;dio do SIH/DATASUS<sup>7</sup>. Foram    cons
iderados os dados relativos aos anos de 2005, 2006, 2007 e 2008, por serem    os
 mais recentes dispon&iacute;veis e expressarem as indica&ccedil;&otilde;es    e
 t&eacute;cnicas praticadas atualmente no pa&iacute;s.</font></p>     ^cY#aop025
11.htm##
01472000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122800085002001301313#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#32#28#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os procedimentos    foram c
lassificados utilizando-se os c&oacute;digos da tabela SUS, mantendo-se    a nom
enclatura original dos procedimentos: 48030066 - angioplastia coronariana;    48
030074 - angioplastia coronariana com implante de pr&oacute;tese intraluminal;  
  48030082 - angioplastia coronariana com implante de dupla pr&oacute;tese intra
luminal;    48030090 - angioplastia em enxerto coronariano; 48030104 - angioplas
tia coronariana    em enxertos coronarianos com implante de pr&oacute;tese; 4803
0112 - angioplastia    coronariana prim&aacute;ria (incluso cateterismo). A part
ir do ano de 2008 foram    mudados os c&oacute;digos que passaram a ter nova num
era&ccedil;&atilde;o: 0406030014    - angioplastia coronariana; 0406030022 - ang
ioplastia coronariana com implante    de dupla pr&oacute;tese intraluminal arter
ial; 0406030030 - angioplastia coronariana    com implante de pr&oacute;tese int
raluminal arterial; 0406030049 - angioplastia    coronariana prim&aacute;ria (in
clui cateterismo); 0406030065 - angioplastia    em enxerto coronariano; 04060300
73 - angioplastia em enxerto coronariano (com    implante de pr&oacute;teses).</
font></p>     ^cY#aop02511.htm##
00632000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038800085002001300473#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#33#29#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Utilizaram-se os    c&oacut
e;digos referentes ao quadro cl&iacute;nico de apresenta&ccedil;&atilde;o,    ag
rupando-os como angina, IAM e outras anginas (em alguns poucos casos com dados  
  incompletos, n&atilde;o foi poss&iacute;vel estabelecer o diagn&oacute;stico, 
   sendo classificados como Ignorado):</font></p>     ^cY#aop02511.htm##
00588000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034400085002001300429#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#34#30#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Angina -</i>    angina i
nst&aacute;vel, angina <i>pectoris</i> com espasmo documentado, outras    formas
 de doen&ccedil;a isqu&ecirc;mica aguda do cora&ccedil;&atilde;o; doen&ccedil;a 
   isqu&ecirc;mica aguda do cora&ccedil;&atilde;o n&atilde;o especificada.</font
></p>     ^cY#aop02511.htm##
01077000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083300085002001300918#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#35#31#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>IAM -</i> infarto    agu
do transmural da parede anterior do mioc&aacute;rdio; Infarto agudo transmural  
  da parede inferior do mioc&aacute;rdio; infarto agudo transmural do mioc&aacut
e;rdio    outras localiza&ccedil;&otilde;es; infarto agudo transmural do mioc&aa
cute;rdio    com localiza&ccedil;&atilde;o n&atilde;o especificada; infarto agud
o subendoc&aacute;rdico    do mioc&aacute;rdio; infarto agudo do mioc&aacute;rdi
o n&atilde;o especificado;    infarto do mioc&aacute;rdio recorrente de parede a
nterior; infarto do mioc&aacute;rdio    recorrente de parede inferior; infarto d
o mioc&aacute;rdio recorrente de outras    localiza&ccedil;&otilde;es; infarto d
o mioc&aacute;rdio recorrente localiza&ccedil;&atilde;o    n&atilde;o especifica
da.</font></p>     ^cY#aop02511.htm##
01050000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080600085002001300891#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#36#32#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Outras anginas    <b>-</
b></i> outras formas de angina <i>pectoris</i>; angina <i>pectoris</i>    n&atil
de;o especificada; trombose coronariana que n&atilde;o resulta em infarto    do 
mioc&aacute;rdio; doen&ccedil;a cardiovascular ateroscler&oacute;tica, descrita 
   desta maneira; doen&ccedil;a ateroscler&oacute;tica do cora&ccedil;&atilde;o;
    infarto antigo do mioc&aacute;rdio; aneurisma card&iacute;aco; aneurisma de 
   art&eacute;ria coron&aacute;ria; miocardiopatia isqu&ecirc;mica; isquemia mio
c&aacute;rdica    silenciosa; outras formas de doen&ccedil;a isqu&ecirc;mica cr&
ocirc;nica do    cora&ccedil;&atilde;o; doen&ccedil;a isqu&ecirc;mica cr&ocirc;n
ica do cora&ccedil;&atilde;o    n&atilde;o especificada.</font></p>     ^cY#aop0
2511.htm##
00651000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040700085002001300492#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#37#33#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A indica&ccedil;&atilde;o  
  do procedimento foi classificada como eletiva, urg&ecirc;ncia/emerg&ecirc;ncia
    e outras, conforme a classifica&ccedil;&atilde;o utilizada para preenchiment
o    da AIH formul&aacute;rio fonte, de onde as informa&ccedil;&otilde;es s&atil
de;o    extra&iacute;das para abastecer o banco de dados.</font></p>     ^cY#aop
02511.htm##
00547000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030300085002001300388#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#38#34#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A tabela SUS classifica    
os diferentes procedimentos como: ICP isolada, ICP + duplo <i>stent</i>, ICP    
+ um <i>stent</i>, ICP prim&aacute;ria, ICP em enxerto coronariano, ICP + <i>ste
nt</i>    em enxerto coronariano.</font></p>     ^cY#aop02511.htm##
00504000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026000085002001300345#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#39#35#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Foram exclu&iacute;dos    o
s hospitais que realizaram 48 ou menos angioplastias no per&iacute;odo de 4    a
nos, ou seja que n&atilde;o realizaram mais de um procedimento mensal.</font></p
>     ^cY#aop02511.htm##
00928000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068400085002001300769#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#40#36#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Para analisar os    dados, 
de acordo com o volume de ICP, foram calculados os percentis 25 e 75,    da dist
ribui&ccedil;&atilde;o do n&uacute;mero de procedimentos realizados por    esses
 hospitais, entre 2005 a 2008, encontrando-se os valores P<sub>25</sub>    = 331
 e P<sub>75</sub> = 1.064. Foram, ent&atilde;o, classificados como hospitais    
de pequeno volume de atendimento, aqueles que atenderam 331 pacientes ou menos  
  para ICP; como hospitais de m&eacute;dio volume, aqueles que atenderam entre  
  332 e 1.063 pacientes; e de grande volume, aqueles que atenderam 1.064 pacient
es    ou mais.</font></p>     ^cY#aop02511.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012600085002001300211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#41#37#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>An&aacute;lise    estat&
iacute;stica</b></font></p>     ^cY#aop02511.htm##
00924000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068000085002001300765#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#42#38#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As vari&aacute;veis    qual
itativas s&atilde;o apresentadas em porcentagens e as compara&ccedil;&otilde;es 
   foram realizadas pelo teste de </font><font size="2">&#967;</font><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><sup>2</sup>    (qui-quadrado).
 As vari&aacute;veis quantitativas s&atilde;o apresentadas com    m&eacute;dias,
 desvios-padr&atilde;o, m&iacute;nimos e m&aacute;ximos e as compara&ccedil;&oti
lde;es    de m&eacute;dias pelo teste <i>t</i> de <i>Student</i> e an&aacute;lis
e de vari&acirc;ncia.    Foi estipulado o n&iacute;vel de signific&acirc;ncia p 
&lt; 0,05.</font></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#43#39#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#44#40#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Resultados</b></font></p
>     ^cY#aop02511.htm##
00901000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704065700085002001300742#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#45#41#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Entre 2005 e 2008    foram 
realizadas 166.514 ICP nos 180 hospitais que realizaram mais de um procedimento 
   mensal m&eacute;dio. Foram assim exclu&iacute;dos 23 hospitais de muito peque
no    volume que realizaram um total de 437 interven&ccedil;&otilde;es. Em 2005 
foram    35.717 (21,4%) procedimentos, em 2006, 41.693 (25,0%), em 2007, 43.124 
(25,9%)    e em 2008, 45.980 (27,6%). Tomando-se por base o ano de 2007, em que 
o sistema    internou 1.157.509 pacientes por causa circulat&oacute;ria, a ICP s
eria respons&aacute;vel    por 3,73% das interna&ccedil;&otilde;es.</font></p>  
   ^cY#aop02511.htm##
00768000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052400085002001300609#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#46#42#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A mortalidade hospitalar   
 global foi de 2,33% e permaneceu est&aacute;vel no per&iacute;odo &#91;(2,22%  
  no ano de 2005, 2,29% em 2006, 2,46% em 2007 e 2,32% em 2008 (p &gt; 0,05)&#93
;.    A menor encontrada foi na regi&atilde;o Sudeste, 2,03%, e a maior na regi&
atilde;o    Norte, 3,64%, havendo diferen&ccedil;a significativa entre as 5 regi
&otilde;es    fisiogr&aacute;ficas do pa&iacute;s (p &lt; 0,001) (<a href="#t1">
Tabela 1</a>).</font></p>     ^cY#aop02511.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#47#43#article#167#<p><a name
="t1"></a></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#48#44#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#49#45#article#167#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02511t01.jpg"></p>     ^cY#aop
02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#50#46#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00804000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056000085002001300645#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#51#47#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A mortalidade hospitalar   
 conforme o volume de produ&ccedil;&atilde;o hospitalar pode ser observada na   
 <a href="#t2">Tabela 2</a>. Os 45 hospitais (25%) considerados de pequeno volum
e    foram respons&aacute;veis por 7.229 (4,3%) das ICP; os 90 (50%) de m&eacute
;dio    volume, respons&aacute;veis por 58.067 (34,9%) e os 45 (25%) de grande v
olume,    respons&aacute;veis por 101.218 (60,8%). As mortalidades foram respect
ivamente    de 2,52%, 2,29% e 2,33% (p &gt; 0,05).</font></p>     ^cY#aop02511.h
tm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#52#48#article#167#<p><a name
="t2"></a></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#53#49#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#54#50#article#167#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02511t02.jpg"></p>     ^cY#aop
02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#55#51#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00501000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025700085002001300342#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#56#52#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A mortalidade conforme    o
 g&ecirc;nero e idade &eacute; mostrada na <a href="#t3">Tabela 3</a>. Foi    me
nor no g&ecirc;nero masculino e na faixa et&aacute;ria 0 a 64 anos.</font></p>  
   ^cY#aop02511.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#57#53#article#167#<p><a name
="t3"></a></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#58#54#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#59#55#article#167#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02511t03.jpg"></p>     ^cY#aop
02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#60#56#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00514000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027000085002001300355#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#61#57#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A mortalidade nos    180 ho
spitais analisados variou de 0% a 11,35%, com m&eacute;dia de 2,33% e    mediana
 de 2,15% (<a href="/img/revistas/abc/2011nahead/aop02511f01.jpg">Figura 1</a>).
</font></p>     ^cY#aop02511.htm##
00723000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047900085002001300564#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#62#58#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A mortalidade nos    22 hos
pitais, com produ&ccedil;&atilde;o superior a 400 procedimentos anuais,    ou 1.
600 no per&iacute;odo analisado, variou entre 0,37% e 7,83% (<a href="/img/revis
tas/abc/2011nahead/aop02511f02.jpg">Figura    2</a>). Esses hospitais em conjunt
o realizaram 71.412 (43%) dos procedimentos,    com produ&ccedil;&atilde;o indiv
idual variando entre 1.605 e 8.638 procedimentos.</font></p>     ^cY#aop02511.ht
m##
00993000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704074900085002001300834#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#63#59#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A mortalidade conforme    o
 quadro cl&iacute;nico de apresenta&ccedil;&atilde;o foi de 1,03% na angina,    
de 6,35% no IAM e de 1,75% em outras anginas (p &lt; 0,0000001) (<a href="#t4">T
abela    4</a>). A mortalidade tamb&eacute;m variou conforme a indica&ccedil;&at
ilde;o,    eletiva, 0,86%, emerg&ecirc;ncia, 3,25% e outras (casos n&atilde;o ca
racterizados),    0,79% (p &lt; 0,0000001) (<a href="#t5">Tabela 5</a>). Os proc
edimentos empregados    influ&iacute;ram na mortalidade conforme observado na <a
 href="#t6">Tabela 6</a>,    sendo as maiores mortalidades na ICP prim&aacute;ri
a, 6,97% e na ICP isolada    em enxerto coronariano, 17,65% (p &lt; 0,0000001).<
/font></p>     ^cY#aop02511.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#64#60#article#167#<p><a name
="t4"></a></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#65#61#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#66#62#article#167#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02511t04.jpg"></p>     ^cY#aop
02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#67#63#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#68#64#article#167#<p><a name
="t5"></a></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#69#65#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#70#66#article#167#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02511t05.jpg"></p>     ^cY#aop
02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#71#67#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#72#68#article#167#<p><a name
="t6"></a></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#73#69#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#74#70#article#167#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02511t06.jpg"></p>     ^cY#aop
02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#75#71#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00633000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038900085002001300474#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#76#72#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Embora neste estudo    o vo
lume total de procedimentos n&atilde;o tenha influenciado a mortalidade,    obse
rvaram-se nos procedimentos eletivos nos hospitais de pequeno, m&eacute;dio    e
 grande volume, diferen&ccedil;as resultando em mortalidades de 1,51%, 0,84%    
e 0,82% respectivamente (p &lt; 0,001).</font></p>     ^cY#aop02511.htm##
00529000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028500085002001300370#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#77#73#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A m&eacute;dia    de perman
&ecirc;ncia hospitalar, de acordo com o volume de ICP, n&atilde;o variou    e fo
i de 4,15 dias nos de pequeno, 3,84 dias nos de m&eacute;dio e de 4,01 nos    de
 grande volume.</font></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#78#74#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#79#75#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop02511.htm##
00655000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041100085002001300496#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#80#76#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A ICP tornou-se    um dos t
ratamentos mais utilizados na DAC, aliviando a angina, melhorando a    qualidade
 de vida e, mesmo, reduzindo a mortalidade nos casos agudos. Nos &uacute;ltimos 
   anos foi o m&eacute;todo mais comumente empregado para revasculariza&ccedil;&
atilde;o    coronariana, superando a cirurgia<sup>9-11</sup>.</font></p>     ^cY
#aop02511.htm##
01614000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704137000085002001301455#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#81#77#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Como acontece com    todo p
rocedimento que se inicia, o n&uacute;mero de complica&ccedil;&otilde;es    e &o
acute;bitos se reduz &agrave; medida que as experi&ecirc;ncias se acumulam.    A
 tomada de decis&atilde;o para um tratamento, tanto pelos pacientes como pelos  
  m&eacute;dicos leva em considera&ccedil;&atilde;o a experi&ecirc;ncia e os res
ultados    obtidos, de prefer&ecirc;ncia locais. Apesar do tremendo desenvolvime
nto alcan&ccedil;ado    por essa t&eacute;cnica nos &uacute;ltimos anos, a gravi
dade dos pacientes &agrave;    ela habitualmente submetidos ainda &eacute; preoc
upa&ccedil;&atilde;o pelo risco    sempre presente associado de mortalidade. Do 
ponto de vista de sa&uacute;de    p&uacute;blica &eacute; importante o conhecime
nto de informa&ccedil;&otilde;es    sobre a perman&ecirc;ncia hospitalar, custos
 envolvidos e dos resultados em    diferentes regi&otilde;es, hospitais e mesmo 
equipes, se poss&iacute;vel. Em    nosso pa&iacute;s &eacute; necess&aacute;rio 
conhecer a efici&ecirc;ncia e efetividade    dos procedimentos realizados para q
ue a tomada de decis&otilde;es, tanto individual    quanto coletiva, seja sempre
 a mais correta poss&iacute;vel. Em nosso meio,    muito desses dados, embora di
spon&iacute;veis, ainda n&atilde;o tinham sido    avaliados.</font></p>     ^cY#
aop02511.htm##
01160000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704091600085002001301001#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#82#78#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os dados analisados    de I
CP foram obtidos por interm&eacute;dio do SIH/DATASUS. No mundo, o SUS &eacute; 
   um dos maiores sistemas p&uacute;blicos de assist&ecirc;ncia &agrave; sa&uacu
te;de,    tendo sido respons&aacute;vel por 11.107.155 interna&ccedil;&otilde;es
 no ano    de 2008<sup>12</sup> para uma popula&ccedil;&atilde;o de 189.335.191 
de indiv&iacute;duos,    resultando um percentual anual de interna&ccedil;&otild
e;es de 6% da popula&ccedil;&atilde;o    n&atilde;o coberta por planos privados 
de sa&uacute;de. Estima-se ser respons&aacute;vel    por 80% das interven&ccedil
;&otilde;es realizadas anualmente, considerando-se    que na popula&ccedil;&atil
de;o brasileira os planos privados foram respons&aacute;veis    por 20,61% da co
bertura em sa&uacute;de no ano de 2008<sup>13</sup> e em 2009    por 21,3<sup>8<
/sup>.</font></p>     ^cY#aop02511.htm##
02125000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704188100085002001301966#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#83#79#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No per&iacute;odo    analis
ado, foram realizadas 166.514 ICP, resultando numa m&eacute;dia anual    de 41.6
28 procedimentos ou 22/100.000 habitantes. Um crescimento de 29% quando    compa
rado com o ano de 2005. &Eacute; de se destacar que 25% dos hospitais (grande   
 volume) realizaram 61% dos procedimentos e 25% (pequeno volume) apenas 4%. &Eac
ute;    dif&iacute;cil estimar-se o n&uacute;mero de reinterna&ccedil;&otilde;es
 programadas    para colocar-se um novo <i>stent</i>, n&atilde;o liberado pelo S
US na primeira    interna&ccedil;&atilde;o, visto o sistema limitar em 20% por h
ospital o implante    de dois <i>stents</i>. Na Esc&oacute;cia<sup>14</sup>, em 
2009, foram feitos    99,4 procedimentos para cada grupo de 100.000 habitantes, 
enquanto no Reino    Unido, segundo a <i>British Cardiovascular Intervention Soc
iety</i><sup>15</sup>,    em 2007, foram 73.692 interven&ccedil;&otilde;es ou 12
1,6/100.000 habitantes.    J&aacute; no Canad&aacute;, a recomenda&ccedil;&atild
e;o do <i>Cardiac Care    Network of Ont&aacute;rio</i><sup>16</sup> era de atin
gir na prov&iacute;ncia    um m&iacute;nimo de 221 interven&ccedil;&otilde;es no
 per&iacute;odo 2005/6,    crescendo a 260/100.000 habitantes em 2008/9. A &uacu
te;ltima estat&iacute;stica    dispon&iacute;vel, referente ao ano de 2008 no Ca
nad&aacute;, registra 168/100.000    habitantes<sup>17</sup>. Nos Estados Unidos
, a <i>American Heart Associatio</i>n<sup>18</sup>    estimou que em 2006 foram 
realizadas 1.313.000 ICP, ou seja 440/100.000 habitantes.    Comparando nossos n
&uacute;meros com os do exterior conclui-se que aqui se realizam    menos interv
en&ccedil;&otilde;es, mesmo sabendo-se que os n&uacute;meros do    SUS n&atilde;
o incluem 20% das interven&ccedil;&otilde;es que se estima sejam    realizadas f
ora do SUS.</font></p>     ^cY#aop02511.htm##
01302000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704105800085002001301143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#84#80#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A mortalidade m&eacute;dia 
   de 2,33% variou nas diferentes regi&otilde;es do pa&iacute;s. Foi maior na re
gi&atilde;o    Norte, respons&aacute;vel por menos de 4% dos procedimentos, e me
nor na regi&atilde;o    Sudeste, respons&aacute;vel por quase metade dos procedi
mentos realizados. &Eacute;    de se supor que essas diferen&ccedil;as sejam exp
licadas pela maior experi&ecirc;ncia    das regi&otilde;es com maior volume de i
nterven&ccedil;&otilde;es. Esses dados    est&atilde;o de acordo com o que a lit
eratura registra, quanto maior a experi&ecirc;ncia,    melhores os resultados<su
p>19</sup>. Em 8.735 angioplastias coronarianas (7,5    a 15,5/100.000 h no per&
iacute;odo) realizadas pelo SUS no Estado do Rio de    Janeiro, entre 1999 e 200
3, a mortalidade encontrada foi de 1,9%, observando-se    varia&ccedil;&atilde;o
 entre 0 e 6,5% nos 14 hospitais (12 com mais de 200 procedimentos    no per&iac
ute;odo) que realizaram essa interven&ccedil;&atilde;o<sup>20</sup>.</font></p> 
    ^cY#aop02511.htm##
00848000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060400085002001300689#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#85#81#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O <i>National Cardiovascula
r    Data Registry</i> nos Estados Unidos, registro patrocinado pelo <i>American
    College of Cardiology</i> e a <i>Society for Cardiovascular Angiography and 
   Interventions</i>, buscando um modelo de risco contempor&acirc;neo analisou  
  os dados de 588.398 procedimentos de ICP realizados entre 2004 e 2007, relatan
do    uma mortalidade hospitalar total de 1,27%, variando de 0,65% para os casos
 eletivos    a 4,81% para os casos de IAM com supradesnivelamento do segmento ST
<sup>21</sup>.</font></p>     ^cY#aop02511.htm##
01308000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106400085002001301149#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#86#82#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Diferente do observado    e
m rela&ccedil;&atilde;o &agrave;s regi&otilde;es fisiogr&aacute;ficas, n&atilde;
o    se observou diferen&ccedil;as nas mortalidades nos hospitais de grande, m&e
acute;dio    e pequeno volume, embora, em n&uacute;meros absolutos, esses &uacut
e;ltimos    tiveram o maior percentual de &oacute;bitos. H&aacute; muito a liter
atura mostra    uma rela&ccedil;&atilde;o inversa entre o volume e a evolu&ccedi
l;&atilde;o    nas diferentes formas de tratamento que empregam procedimentos e 
a ICP se insere    nesse paradigma<sup>22</sup>. A explica&ccedil;&atilde;o mais
 plaus&iacute;vel    seria a experi&ecirc;ncia. Grupos mais experientes, que pro
vavelmente tamb&eacute;m    passaram por uma curva de aprendizado, possuem uma e
quipe mais capacitada a    ter sucesso, menores taxas de complica&ccedil;&atilde
;o e menor mortalidade.    &Eacute; certo que a sele&ccedil;&atilde;o dos pacien
tes e a gravidade dos mesmos    tamb&eacute;m pode influir nos resultados.</font
></p>     ^cY#aop02511.htm##
01332000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704108800085002001301173#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#87#83#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As mortalidades    foram ma
iores nos idosos<sup>21,23</sup> e nas mulheres<sup>21,24</sup>. Assim    como n
a DAC, as mortalidades na ICP relacionam-se &agrave; idade, com incremento    co
nforme a faixa et&aacute;ria<sup>25</sup>, e ao g&ecirc;nero. Recente revis&atil
de;o    de 588.398 procedimentos do <i>National Cardiovascular Data Registry</i>
, banco    de dados organizado pelas sociedades americanas, <i>American College 
of Cardiology</i>    e <i>Society for Cardiovascular Angiography and Interventio
n</i> confirmam esses    achados. Idosos <i>versus</i> n&atilde;o idosos, 2,25% 
<i>versus</i> 0,76%,    g&ecirc;nero feminino versus masculino, 1,63% versus 1,0
4%<sup>21</sup>. A literatura    registra que de 1,3 milh&otilde;es de procedime
ntos realizados nos Estados Unidos    em 2006 apenas 35% foram em mulheres a des
peito dos conhecidos benef&iacute;cios    desse tratamento, particularmente em s
&iacute;ndromes coronarianas agudas com    ou sem supradesnivelamento do segment
o ST<sup>26</sup>.</font></p>     ^cY#aop02511.htm##
01690000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704144600085002001301531#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#88#84#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Observou-se grande    dispa
ridade nas mortalidades entre os hospitais. Mesmo quando analisados aqueles    c
om mais de 400 ICP por ano, experi&ecirc;ncia m&iacute;nima necess&aacute;ria   
 por centro, preconizada pelas diretrizes, ainda se observa, em alguns hospitais
,    mortalidades mais elevadas do que as esperadas, quando comparadas com outro
s    hospitais nacionais. A literatura situa a mortalidade em ICP em torno de 2%
.    No Canad&aacute;, em 23 hospitais, a mortalidade n&atilde;o ajustada em 127
.103    ICP foi de 1,4%<sup>27</sup>. Em um registro canadense, coletado na prov
&iacute;ncia    canadense de <i>British Columbia</i>, que comparou a evolu&ccedi
l;&atilde;o    de 32.899 ICP, sendo 26.350 nos anos 2000 a 2004 e 6.549 no ano d
e 2005, a mortalidade    global em 30 dias foi de 1,5%, sendo 1,5% no primeiro p
er&iacute;odo analisado    e 1,4% (confirmar o valor das porcentagens) no segund
o<sup>28</sup>. Dados do    <i>New York's Percutaneous Coronary Interventions Re
porting System</i> referentes    ao per&iacute;odo 1998 a 2000 com 107.713 casos
, relatam uma mortalidade hospitalar    de 0,79%, sendo de 1,23% em 2.435 pacien
tes tratados nos hospitais que tinham    um volume inferior a 400 procedimentos/
ano e 0,78% (confirmar o valor das porcentagens)    em 105.278 pacientes nos hos
pitais com volume superior a 400 casos/ano<sup>19</sup>.</font></p>     ^cY#aop0
2511.htm##
02368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704212400085002001302209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#89#85#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Embora as informa&ccedil;&o
tilde;es    dispon&iacute;veis para an&aacute;lise no DATASUS n&atilde;o contemp
lem vari&aacute;veis    cl&iacute;nicas, disp&otilde;e-se dos dados relativos ao
 quadro cl&iacute;nico    de apresenta&ccedil;&atilde;o e indica&ccedil;&atilde;
o para o tratamento, essa    &uacute;ltima se eletiva ou de emerg&ecirc;ncia. A 
mortalidade &eacute; baixa    quando a indica&ccedil;&atilde;o &eacute; por angi
na, enquanto nos casos catalogados    como infarto (angioplastia prim&aacute;ria
) &eacute; cerca de seis vezes maior.    O Registro SOLACI, registro espont&acir
c;neo e n&atilde;o obrigat&oacute;rio    da Sociedade Latino Americana de Cardio
logia Intervencionista, relatou no per&iacute;odo    de 2007 a 2008, 13.925 inte
rven&ccedil;&otilde;es de angioplastia prim&aacute;ria    com uma mortalidade ho
spitalar de 4,5%<sup>29</sup>. Dados do <i>New York State    PCI Registry</i>, r
egistro mandat&oacute;rio e controlado desse estado americano,    mostram uma in
tera&ccedil;&atilde;o entre volume hospitalar e experi&ecirc;ncia    do m&eacute
;dico. Nesse estudo foram comparadas as mortalidades hospitalares    de 7.321 pa
cientes submetidos &agrave; angioplastias prim&aacute;rias, realizadas    em hos
pitais de grande volume para esse tipo de procedimento (&gt; 50 casos/ano)    e 
pequeno volume, e m&eacute;dicos com grande volume (&gt; 10 casos/ano) e pequeno
    volume, mostrando que no grupo de maior volume (hospitais e m&eacute;dicos) 
   os resultados s&atilde;o melhores do que nos de pequeno volume (3,2% <i>versu
s</i>    6,7%, p = 0,03, n&atilde;o-ajustado; 3,8% <i>versus</i> 8,4%, p=0,09, a
justado)<sup>30</sup>.    O <i>National Cardiovascular Data Registry CathPCI,</i
> programa nacional americano,    volunt&aacute;rio de melhoria de qualidade, pa
trocinado pelo <i>American College    of Cardiology,</i> reporta no primeiro sem
estre de 2009 uma mortalidade hospitalar    ajustada de 2% para s&iacute;ndrome 
coronariana aguda e de 0,5% para n&atilde;o    s&iacute;ndrome coronariana aguda
<sup>31</sup>.</font></p>     ^cY#aop02511.htm##
00640000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039600085002001300481#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#90#86#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A realiza&ccedil;&atilde;o 
   do procedimento em situa&ccedil;&otilde;es de emerg&ecirc;ncia traz maior mor
talidade    do que na eletiva, o que &eacute; esperado pela gravidade dos pacien
tes atendidos    de emerg&ecirc;ncia, geralmente internados com quadro cl&iacute
;nico de s&iacute;ndrome    coronariana aguda.</font></p>     ^cY#aop02511.htm##
00998000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075400085002001300839#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#91#87#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A ICP mais usada    foi o i
mplante de um <i>stent</i>, 60% dos pacientes foram dessa forma tratados.    N&a
tilde;o surpreende que a utiliza&ccedil;&atilde;o de <i>stent</i> &uacute;nico  
  tenha sido o procedimento mais empregado pois o sistema n&atilde;o permite o  
  uso de <i>stents</i> m&uacute;ltiplos em mais do que 20% dos casos que realiza
m    esse tipo de tratamento. Nesse grupo que recebeu <i>stent</i> &uacute;nico 
observou-se    menor mortalidade. Nesse banco de dados n&atilde;o &eacute; poss&
iacute;vel    identificar pacientes que eletivamente reinternaram para receber u
m segundo    <i>stent</i>, n&atilde;o liberado na primeira interna&ccedil;&atild
e;o.</font></p>     ^cY#aop02511.htm##
00530000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028600085002001300371#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#92#88#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A angioplastia    isolada, 
sem emprego de <i>stents</i> foi utilizada numa minoria de casos, assim    como 
as interven&ccedil;&otilde;es em enxertos coronarianos, com ou sem implante    d
e <i>stents</i>.</font></p>     ^cY#aop02511.htm##
01011000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076700085002001300852#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#93#89#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">De acordo com esse    banco
 de dados, a interven&ccedil;&atilde;o catalogada como ICP prim&aacute;ria,    q
ue por defini&ccedil;&atilde;o caracteriza ICP no tratamento do infarto agudo,  
  foi frequente e a mortalidade alta, cerca de seis vezes a encontrada nos impla
ntes    de <i>stents</i> em pacientes sem infarto. Embora poss&iacute;vel o rela
to nesse    diagn&oacute;stico de outras formas de SCA que n&atilde;o o infarto 
com supradesnivelamento    do segmento ST, casos de resgate p&oacute;s trombol&i
acute;ticos, erroneamente    informados como ICP prim&aacute;ria, retardos prolo
ngados ou casos complicados    com choque cardiog&ecirc;nico, ainda assim a mort
alidade foi alta.</font></p>     ^cY#aop02511.htm##
00541000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029700085002001300382#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#94#90#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A perman&ecirc;ncia    hosp
italar m&eacute;dia por procedimento situou-se em torno de 4 dias, um pouco    a
baixo da m&eacute;dia geral de perman&ecirc;ncia hospitalar no SUS que &eacute; 
   de 5,9 dias<sup>7</sup>.</font></p>     ^cY#aop02511.htm##
00644000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040000085002001300485#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#95#91#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O custo m&eacute;dio    por
 interna&ccedil;&atilde;o de R$ 5.135,15 foi muito superior aos valores pagos   
 por AIH no sistema que &eacute; de R$ 672,35<sup>7</sup>. Deve ser considerado 
   que nesse valor est&aacute; inclu&iacute;do o custo da pr&oacute;tese, respon
s&aacute;vel    por mais da metade do valor final.</font></p>     ^cY#aop02511.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#96#92#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#97#93#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Limita&ccedil;&otilde;es
</b></font></p>     ^cY#aop02511.htm##
01312000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106800085002001301153#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#98#94#article#167#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A principal limita&ccedil;&
atilde;o    desse estudo est&aacute; no fato do SIH/DATASUS n&atilde;o disponibi
lizar informa&ccedil;&otilde;es    cl&iacute;nicas dos pacientes submetidos a IC
P. N&atilde;o apenas a idade, o    g&ecirc;nero, o diagn&oacute;stico de interna
&ccedil;&atilde;o e a condi&ccedil;&atilde;o    de realiza&ccedil;&atilde;o do p
rocedimento s&atilde;o respons&aacute;veis pelo    resultado hospitalar. A falta
 dessas informa&ccedil;&otilde;es impede um ajuste    de mortalidade pela gravid
ade dos pacientes entre os diferentes hospitais, embora    seja de se esperar qu
e, pelo menos nos hospitais de grande volume, eventuais    diferen&ccedil;as que
 possam existir estejam uniformizadas pelo grande volume    atendido e n&atilde;
o tenham impacto cl&iacute;nico significativo. Tamb&eacute;m    a atua&ccedil;&a
tilde;o de v&aacute;rias equipes em alguns hospitais, nem sempre    com resultad
os semelhante, &eacute; outro fator que pode influenciar resultados    locais.</
font></p>     ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#99#95#article#167#<p>&nbsp;<
/p>     ^cY#aop02511.htm##
00352000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704010700086002001300193#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#100#96#article#167#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclus&otilde;es</b></
font></p>     ^cY#aop02511.htm##
01867000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704162200086002001301708#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#101#97#article#167#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">Comparado com os    pa&iac
ute;ses mais industrializados e com mais recursos dispon&iacute;veis para    sa&
uacute;de, ainda &eacute; baixo o n&uacute;mero de procedimentos de ICP realizad
os    no pa&iacute;s. Hospitais de grande volume, em menor n&uacute;mero, s&atil
de;o    os respons&aacute;veis pela maior parte da produ&ccedil;&atilde;o, o que
 faz    pensar que uma melhor gest&atilde;o dos recursos p&uacute;blicos despend
idos,    priorizando esses hospitais e a regionaliza&ccedil;&atilde;o poderia to
rnar    o sistema mais eficiente. As mortalidades tem grande variabilidade e na 
m&eacute;dia    s&atilde;o mais elevadas do que as encontradas em outros pa&iacu
te;ses, embora    em muitos centros os resultados alcan&ccedil;ados estejam equi
parados aos melhores    resultados publicados na literatura internacional. A des
peito dos hospitais    com maior volume terem uma menor mortalidade m&eacute;dia
, n&atilde;o se conseguiu    encontrar diferen&ccedil;a quando comparada aos de 
menor volume, talvez por    n&atilde;o haver ajuste das vari&aacute;veis cl&iacu
te;nicas. Essas diferen&ccedil;as    aparecem quando se analisa o grupo de indic
a&ccedil;&atilde;o eletiva. Os procedimentos    realizados de emerg&ecirc;ncia, 
grupo mais frequente, e a ICP prim&aacute;ria    tiveram as maiores mortalidades
. O procedimento respons&aacute;vel pelo maior    n&uacute;mero de casos foi o i
mplante &uacute;nico de <i>stent</i>, embora como    mencionado, o SUS limite em
 20% o n&uacute;mero de dois <i>stents</i> por interven&ccedil;&atilde;o.</font>
</p>     ^cY#aop02511.htm##
00968000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704072300086002001300809#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#102#98#article#167#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">A ICP &eacute;    um proce
dimento de excelentes resultados e a cada ano mais empregado, embora    em n&uac
ute;mero inferior ao empregado em outros pa&iacute;ses. Em nosso pa&iacute;s,   
 os resultados ainda diferem bastante entre os hospitais, mesmo entre os de gran
de    volume, impondo-se um melhor controle de qualidade, na tentativa de unifor
mizar    resultados futuros. Ser&aacute; necess&aacute;rio discutir a situa&cced
il;&atilde;o    dos hospitais com pequeno volume, visto que este &eacute; um pro
cedimento de    custo alto e que necessita de melhores equipamentos e pessoal es
pecializado    que, no caso, s&atilde;o subutilizados.</font></p>     ^cY#aop025
11.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704012500086002001300211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#103#99#article#167#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    d
e Interesses</b></font></p>     ^cY#aop02511.htm##
00392000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704014600087002001300233#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#104#100#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    hav
er conflito de interesses pertinentes.</font></p>     ^cY#aop02511.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704011300087002001300200#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#105#101#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiament
o</b></font></p>     ^cY#aop02511.htm##
00399000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704015300087002001300240#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#106#102#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    n&at
ilde;o teve fontes de financiamento externas.</font></p>     ^cY#aop02511.htm##
00379000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704013300087002001300220#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#107#103#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde
;o    Acad&ecirc;mica</b></font></p>     ^cY#aop02511.htm##
00441000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019500087002001300282#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#108#104#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o h&aacute;    v
incula&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&at
ilde;o.</font></p>     ^cY#aop02511.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#109#105#article#167#<p>&nbsp
;</p>     ^cY#aop02511.htm##
00353000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010700087002001300194#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#110#106#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b><
/font></p>     ^cY#aop02511.htm##
00478000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704021800089002001300307#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#111#107#article#
167#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Gruentzi
g AR,    Myler RK, Hanna ES, Turina MI. Coronary transluminal angioplasty. &#91;
Abstract&#93;.    Circulation. 1977;56(Suppl. 3):III-84.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#112#108#article#167#</font><
/p>     ^cY#aop02511.htm##
00522000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704026200089002001300351#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#113#109#article#
167#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Sigwart 
U, Puel    J, Mircovitcht V, Joffre F, Kappenberger L. Intravascular stents to p
revent    occlusion and restenosis after transluminal angioplasty. N Engl J Med.
 1987;316(12):701-6.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#114#110#article#167#</font><
/p>     ^cY#aop02511.htm##
00734000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704047400089002001300563#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#115#111#article#
167#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Morice M
C, Serruys    PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. RAVEL Stud
y Group. Randomized    Study with the Sirolimus-Coated Bx Velocity Balloon-Expan
dable Stent in the    Treatment of Patients with de Novo Native Coronary Artery 
Lesions. A randomized    comparison of a sirolimus-eluting stent with a standard
 stent for coronary revascularization.    Surg Neurol. 2003;59(3):146-7.    ^cY#
aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#116#112#article#167#</font><
/p>     ^cY#aop02511.htm##
00602000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704034200089002001300431#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#117#113#article#
167#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Grube E,
 Silber    S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I
: six-and    twelve-month results from a randomized, double-blind trial on a slo
w-release    paclitaxel-eluting stent for de novo coronary lesions. N Engl J Med
. 2008;358(4):405-7.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#118#114#article#167#</font><
/p>     ^cY#aop02511.htm##
00570000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704031000089002001300399#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#119#115#article#
167#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Kedhi E,
 Joesoef    KS, McFadden E, Wassing J, Van Mieghem C, Goedhart D, et al. Second-
generation    everolimus-eluting and paclitaxel-eluting stents in real-life prac
tice (COMPARE):    a randomized trial. Lancet. 2010;375(9710):201-9.    ^cY#aop0
2511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#120#116#article#167#</font><
/p>     ^cY#aop02511.htm##
00521000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704026100089002001300350#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#121#117#article#
167#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Semiys P
W, Silber    S, Garg S, Van Geuns RJ, Richardt G, Buszman PA, et al. Comparison 
of zotarolimus-eluting    and everolimus-eluting coronary stents. N Engl J Med. 
2010;363(2):136-46.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#122#118#article#167#</font><
/p>     ^cY#aop02511.htm##
00614000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704035400089002001300443#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#123#119#article#
167#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Minist&e
acute;rio    da Sa&uacute;de. DATASUS. (Departamento de Inform&aacute;tica do SU
S). &#91;Acesso    em 2010 abr 10&#93;. Dispon&iacute;vel em <a href="http://www
2.datasus.gov.br/DATASUS/index.php" target="_blank">http://www2.datasus.gov.br/D
ATASUS/index.php</a></font></p>     ^cY#aop02511.htm##
00617000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704035700089002001300446#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#124#120#article#
167#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Minist&e
acute;rio    da Sa&uacute;de. Agencia Nacional de Sa&uacute;de Suplementar. Info
rma&ccedil;&atilde;o    em sa&uacute;de suplementar. &#91;Acesso em 2010 abr 10&
#93;. Dispon&iacute;vel    em <a href="http://www.ans.gov.br" target="_blank">ht
tp://www.ans.gov.br</a></font></p>     ^cY#aop02511.htm##
00586000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704032600089002001300415#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#125#121#article#
167#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Movahed 
MR,    Ramaraj R, Jamal MM, Hashemzadeh M. Nationwide trends in the utilization 
of    multivessel percutaneous coronary intervention (MVPCI) in the United State
s    across different gender and ethniticities. J Interv Cardiol. 2009;22(3):247
-51.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#126#122#article#167#</font><
/p>     ^cY#aop02511.htm##
00607000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034600090002001300436#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#127#123#article#
167#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Movahe
d MR,    Hashemzadeh M, Jammal MM, Ramaraj R. Decreasing in-hospital mortality o
f patients    undergoing percutaneous coronary intervention with persistent high
er mortality    rates in women and minorities in the United States. J Invasive C
ardiol. 2010;22(2):58-60.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#128#124#article#167#</font><
/p>     ^cY#aop02511.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026500090002001300355#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#129#125#article#
167#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Piegas
 LS,    Bittar OJNV, Haddad N. Cirurgia de revasculariza&ccedil;&atilde;o mioc&a
acute;rdica:    resultados do Sistema &Uacute;nico de Sa&uacute;de. Arq Bras Car
diol. 2009;93(5):555-60.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#130#126#article#167#</font><
/p>     ^cY#aop02511.htm##
00654000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704039300090002001300483#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#131#127#article#
167#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Minist
&eacute;rio    da Sa&uacute;de. Indicadores e dados b&aacute;sicos - Brasil - 20
08. Rede interagencial    de informa&ccedil;&otilde;es para a sa&uacute;de. &#91
;Acesso em 2010 abr 10&#93;.    Dispon&iacute;vel em <a href="http://tabnet.data
sus.gov.br" target="_blank">http://tabnet.datasus.gov.br</a></font></p>     ^cY#
aop02511.htm##
00650000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704038900090002001300479#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#132#128#article#
167#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Minist
&eacute;rio    da Sa&uacute;de. Agencia Nacional de Sa&uacute;de Suplementar. AN
S lan&ccedil;a    norma de fiscaliza&ccedil;&atilde;o pr&oacute;-ativa: dados ge
rais. &#91;Acesso    em 2010 mar 15&#93;. Dispon&iacute;vel em <a href="http://w
ww.ans.gov.br" target="_blank">http://www.ans.gov.br</a></font></p>     ^cY#aop0
2511.htm##
00616000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704035500090002001300445#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#133#129#article#
167#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Nation
al Services    Scotland. Public Health Information for Scotland. Coronary heart 
disease statistics.    &#91;Access on 2010 Mar 15&#93;. Available from <a href="
http://www.isdscotland.org/isd/6060.html" target="_blank">http://www.isdscotland
.org/isd/6060.html</a></font></p>     ^cY#aop02511.htm##
00554000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029300090002001300383#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#134#130#article#
167#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Britis
h Cardiovascular    Intervention Society. &#91;Access on 2010 May 8&#93;. Availa
ble from <a href="http://www.bcis.org.uk/pages/default.asp" target="_blank">http
://www.bcis.org.uk/pages/default.asp</a></font></p>     ^cY#aop02511.htm##
00608000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034700090002001300437#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#135#131#article#
167#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Canadi
an Institute    for Health Information. Health System Characteristics. Percutane
ous Coronary    Intervention Rate. &#91;Access on 2010 Feb 20&#93;. Available fr
om <a href="http://secure.cihi.ca/cihiweb/" target="_blank">http://secure.cihi.c
a/cihiweb/</a></font></p>     ^cY#aop02511.htm##
00564000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030300090002001300393#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#136#132#article#
167#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Canadi
an Institute    for Health Information. Indicator Reports 2008. &#91;Access on 2
010 Mar 15&#93;.    Available from <a href="http://secure.cihi.ca/hireports/" ta
rget="_blank">http://secure.cihi.ca/hireports/</a></font></p>     ^cY#aop02511.h
tm##
00658000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704039700090002001300487#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#137#133#article#
167#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Americ
an Heart    Association. Heart disease &amp; stroke statistics. 2010 Update. (At
-A-Glance    Version). &#91;Access on 2010 Mar 15&#93;. Available from <a href="
http://www.americanheart.org/presenter.jhtm?identifier=120026" target="_blank">h
ttp://www.americanheart.org/presenter.jhtm?identifier=120026</a></font></p>     
^cY#aop02511.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027700090002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#138#134#article#
167#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Hannan
 EL,    Wu C, Walford G, King SB 3rd, Holmes DR Jr, Ambrose JA, et al. Volume-ou
tcome    relationships for percutaneous coronary interventions in the stent era.
 Circulation.    2005;112(8):1171-9.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#139#135#article#167#</font><
/p>     ^cY#aop02511.htm##
00550000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028900090002001300379#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#140#136#article#
167#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Godoy 
PH, Klein    CH, Souza-e-Silva N, Oliveira GM. Hospital case fatality associated
 with coronary    angioplasty in Rio de Janeiro State, Brazil, 1999-2003. Cad Sa
&uacute;de P&uacute;blica.    2007;23(4):845-51.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#141#137#article#167#</font><
/p>     ^cY#aop02511.htm##
00639000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037800090002001300468#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#142#138#article#
167#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Peters
on ED,    Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, et al. NCDR Registry Pa
rticipants.    Contemporary mortality risk prediction for percutaneous coronary 
intervention:    results from 588,398 procedures in the National Cardiovascular 
Data Registry.    J Am Coll Cardiol. 2010;55(18):1923-32.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#143#139#article#167#</font><
/p>     ^cY#aop02511.htm##
00506000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024500090002001300335#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#144#140#article#
167#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Luft H
S, Bunker    JP, Enthoven AC. Should operations be regionalized? The empirical r
elation between    surgical volume and mortality. N Engl J Med. 1979;301(25):136
4-9.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#145#141#article#167#</font><
/p>     ^cY#aop02511.htm##
00574000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031300090002001300403#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#146#142#article#
167#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Singh 
M, Rihal    CS, Gersh BJ, Roger VL, Bell MR, Lennon RJ, et al. Mortality differe
nces between    men and women after percutaneous coronary interventions: a 25-ye
ar, single-center    experience. J Am Coll Cardiol. 2008;51(24):2313-20.    ^cY#
aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#147#143#article#167#</font><
/p>     ^cY#aop02511.htm##
00458000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019700090002001300287#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#148#144#article#
167#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Lansky
 AJ.    Outcomes of percutaneous and surgical revascularization in women. Prog C
ardiovasc    Dis. 2004;46(4):305-19.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#149#145#article#167#</font><
/p>     ^cY#aop02511.htm##
00633000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037200090002001300462#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#150#146#article#
167#25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Feldma
n DN,    Gade CL, Slotwiner AJ, Parikh M, Bergman G, Wong SC, et al. Comparison 
of outcomes    of percutaneous coronary interventions in patients of three age g
roups (&lt;60,    60 to 80, and &gt; 80 years) (from the New York State Angiopla
sty Registry).    Am J Cardiol. 2006;98(10):1334-9.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#151#147#article#167#</font><
/p>     ^cY#aop02511.htm##
00457000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019600090002001300286#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#152#148#article#
167#26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Jacobs
 AK.    Coronary intervention in 2009: are women no different than men? Circ Car
diovasc    Interv. 2009;2(1):69-78.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#153#149#article#167#</font><
/p>     ^cY#aop02511.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026300090002001300353#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#154#150#article#
167#27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Jamal 
SM, Shrive    FM, Ghali WA, Knudtson ML, Eisenberg MJ. In-hospital outcomes afte
r percutaneous    coronary intervention in Canada:1992/93 to 2000/01. Can J Card
iol. 2003;19(7):782-9.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#155#151#article#167#</font><
/p>     ^cY#aop02511.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#156#152#article#
167#28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Hambur
ger JN,    Walsh SJ, Khurana R, Ding L, Gao M, Humphries KH, et al. Percutaneous
 coronary    intervention and 30-day mortality. The British Columbia PCI Risk Sc
ore. Cathet    Cardiovasc Intervent. 2009;74(3):377-85.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#157#153#article#167#</font><
/p>     ^cY#aop02511.htm##
00599000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033800090002001300428#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#158#154#article#
167#29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Sousa 
AGMR,    Sousa JEMR, Costa Junior JR, Abizaid AAC, Buitr&oacute;n F, Marchant E,
 et al.    Perfil demogr&aacute;fico e resultados imediatos dos pacientes submet
idos a    angioplastia prim&aacute;ria no Registro SOLACI. Rev Bras Cardiol Inva
s. 2009;17:335-9.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#159#155#article#167#</font><
/p>     ^cY#aop02511.htm##
00552000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029100090002001300381#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#160#156#article#
167#30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Sriniv
as VS,    Hailpern SM, Koss E, Monrad ES, Alderman MH. Effect of physician volum
e on the    relationship between hospital volume and mortality during primary an
gioplasty.    J Am Coll Cardiol. 2009;53(7):574-9.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#161#157#article#167#</font><
/p>     ^cY#aop02511.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029800090002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#162#158#article#
167#31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Roe MT
, Messenger    JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, et al. Treatments
, trends, and    outcomes of acute myocardial infarction and percutaneous corona
ry intervention.    J Am Coll Cardiol. 2010;56(4):254-63.    ^cY#aop02511.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#163#159#article#167#</font><
/p>     ^cY#aop02511.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#164#160#article#167#<p>&nbsp
;</p>     ^cY#aop02511.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#165#161#article#167#<p>&nbsp
;</p>     ^cY#aop02511.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#166#162#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop02511.htm##
00295000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004900087002001300136#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#167#163#article#167#<br>   <
/b> Leopoldo Soares Piegas</font>    ^cY#aop02511.htm##
00362000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704011600087002001300203#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#168#164#article#167#<br>   <
font face="Verdana, Arial, Helvetica, sans-serif" size="2">Av. Dr. Dante Pazzane
se,    500 12º andar    ^cY#aop02511.htm##
00302000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005600087002001300143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#169#165#article#167#<br>   0
4012-909 - S&atilde;o Paulo, SP - Brasil    ^cY#aop02511.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009300087002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#170#166#article#167#<br>   E
-mail: <a href="mailto:lpiegas@uol.com.br">lpiegas@uol.com.br</a></font></p>    
 ^cY#aop02511.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02511.htm#S#p#171#167#article#167#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 08/
09/10; revisado recebido em 04/11/10; aceito em 17/11/10.</font></p>     ^cY#aop
02511.htm##
00591000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100016001060100
01600122010001700138012003800155030001200193065000900205064000500214031000300219
032000400222014000700226865000900233002001300242035001000255801001200265#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#c#172#1#article#31#1#^
rND^sGruentzig^nAR#^rND^sMyler^nRK#^rND^sHanna^nES#^rND^sTurina^nMI#Coronary tra
nsluminal angioplasty^len#Circulation#19770000#1977#56#^s3#III-84#20110000#aop02
511.htm#0009-7322#Circulation##
00679000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100014001030100
02100117010001600138010002200154012009200176030001300268065000900281064000500290
03100040029503200030029901400060030286500090030800200130031703500100033080100130
0340#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#c#173#2#ar
ticle#31#2#^rND^sSigwart^nU#^rND^sPuel^nJ#^rND^sMircovitcht^nV#^rND^sJoffre^nF#^
rND^sKappenberger^nL#Intravascular stents to prevent occlusion and restenosis af
ter transluminal angioplasty^len#N Engl J Med#19870000#1987#316#12#701-6#2011000
0#aop02511.htm#0028-4793#N Engl J Med##
00910000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100018001030100
01600121010001700137010002100154010001500175810000600190012028300196030001200479
06500090049106400050050003100030050503200020050801400060051086500090051600200130
0525035001000538801001200548#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#174#3#article#31#3#^rND^sMorice^nMC#^rND^sSerruys^nPW#^rND^sSous
a^nJE#^rND^sFajadet^nJ#^rND^sBan Hayashi^nE#^rND^sPerin^nM#et al#RAVEL Study Gro
up: Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable St
ent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A 
randomized comparison of a sirolimus-eluting stent with a standard stent for cor
onary revascularization^len#Surg Neurol#20030000#2003#59#3#146-7#20110000#aop025
11.htm#0090-3019#Surg Neurol##
00785000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100016001010100
02000117010001700137010002100154010001800175810000600193012015200199030001300351
06500090036406400050037303100040037803200020038201400060038486500090039000200130
0399035001000412801001300422#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#175#4#article#31#4#^rND^sGrube^nE#^rND^sSilber^nS#^rND^sHauptman
n^nKE#^rND^sMueller^nR#^rND^sBuellesfeld^nL#^rND^sGerckens^nU#et al#TAXUS I: six
-and twelve-month results from a randomized, double-blind trial on a slow-releas
e paclitaxel-eluting stent for de novo coronary lesions^len#N Engl J Med#2008000
0#2008#358#4#405-7#20110000#aop02511.htm#0028-4793#N Engl J Med##
00747000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100018001010100
01800119010001700137010002100154010001800175810000600193012012300199030000700322
06500090032906400050033803100040034303200050034701400060035286500090035800200130
0367035001000380801000700390#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#176#5#article#31#5#^rND^sKedhi^nE#^rND^sJoesoef^nKS#^rND^sMcFadd
en^nE#^rND^sWassing^nJ#^rND^sVan Mieghem^nC#^rND^sGoedhart^nD#et al#Second-gener
ation everolimus-eluting and paclitaxel-eluting stents in real-life practice (CO
MPARE): a randomized trial^len#Lancet#20100000#2010#375#9710#201-9#20110000#aop0
2511.htm#0099-5355#Lancet##
00707000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030100
01400119010002000133010001800153010001800171810000600189012007700195030001300272
06500090028506400050029403100040029903200020030301400070030586500090031200200130
0321035001000334801001300344#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#177#6#article#31#6#^rND^sSemiys^nPW#^rND^sSilber^nS#^rND^sGarg^n
S#^rND^sVan Geuns^nRJ#^rND^sRichardt^nG#^rND^sBuszman^nPA#et al#Comparison of zo
tarolimus-eluting and everolimus-eluting coronary stents^len#N Engl J Med#201000
00#2010#363#2#136-46#20110000#aop02511.htm#0028-4793#N Engl J Med##
00409000000000205000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170029000861100009001151090
01200124037004500136865000900181002001300190#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop02511.htm#S#c#178#7#article#31#7#Ministério da Saúde^dDATASUS#
20100410#2010 abr 10#http://www2.datasus.gov.br/DATASUS/index.php#20110000#aop02
511.htm##
00464000000000217000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170059000860180036001451100
00900181109001200190037002200202865000900224002001300233#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02511.htm#S#c#179#8#article#31#8#Ministério da Saú
de^dAgencia Nacional de Saúde Suplementar#Informação em saúde suplementar^lpt#20
100410#2010 abr 10#http://www.ans.gov.br#20110000#aop02511.htm##
00726000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100017001040100
01600121010002100137012016200158030001700320065000900337064000500346031000300351
032000200354014000700356865000900363002001300372035001000385801001700395#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#c#180#9#article#31#9#^
rND^sMovahed^nMR#^rND^sRamaraj^nR#^rND^sJamal^nMM#^rND^sHashemzadeh^nM#Nationwid
e trends in the utilization of multivessel percutaneous coronary intervention (M
VPCI) in the United States across different gender and ethniticities^len#J Inter
v Cardiol#20090000#2009#22#3#247-51#20110000#aop02511.htm#0896-4327#J Interv Car
diol##
00749000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100021001060100
01700127010001700144012017900161030001900340065000900359064000500368031000300373
032000200376014000600378865000900384002001300393035001000406801001900416#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#c#181#10#article#31#10
#^rND^sMovahed^nMR#^rND^sHashemzadeh^nM#^rND^sJammal^nMM#^rND^sRamaraj^nR#Decrea
sing in-hospital mortality of patients undergoing percutaneous coronary interven
tion with persistent higher mortality rates in women and minorities in the Unite
d States^len#J Invasive Cardiol#20100000#2010#22#2#58-60#20110000#aop02511.htm#1
042-3931#J Invasive Cardiol##
00616000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01600124012008200140030001700222065000900239064000500248031000300253032000200256
014000700258865000900265002001300274035001000287801001700297#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02511.htm#S#c#182#11#article#31#11#^rND^sPiega
s^nLS#^rND^sBittar^nOJNV#^rND^sHaddad^nN#Cirurgia de revascularização miocárdica
: resultados do Sistema Único de Saúde^lpt#Arq Bras Cardiol#20090000#2009#93#5#5
55-60#20110000#aop02511.htm#0066-782X#Arq Bras Cardiol##
00494000000000217000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170020000880180096001081100
00900204109001200213037002900225865000900254002001300263#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02511.htm#S#c#183#12#article#31#12#Ministério da S
aúde#Indicadores e dados básicos - Brasil - 2008: Rede interagencial de informaç
ões para a saúde^len#20100410#2010 abr 10#http://tabnet.datasus.gov.br#20110000#
aop02511.htm##
00490000000000217000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170059000880180060001471100
00900207109001200216037002200228865000900250002001300259#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02511.htm#S#c#184#13#article#31#13#Ministério da S
aúde^dAgencia Nacional de Saúde Suplementar#ANS lança norma de fiscalização pró-
ativa: dados gerais^len#20100315#2010 mar 15#http://www.ans.gov.br#20110000#aop0
2511.htm##
00495000000000217000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170027000880180078001151100
00900193109001200202037004100214865000900255002001300264#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02511.htm#S#c#185#14#article#31#14#National Servic
es Scotland#Public Health Information for Scotland: Coronary heart disease stati
stics^len#20100315#2010 Mar 15#http://www.isdscotland.org/isd/6060.html#20110000
#aop02511.htm##
00421000000000205000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170044000881100009001321090
01100141037004100152865000900193002001300202#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop02511.htm#S#c#186#15#article#31#15#British Cardiovascular Inte
rvention Society#20100508#2010 May 8#http://www.bcis.org.uk/pages/default.asp#20
110000#aop02511.htm##
00497000000000217000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170042000880180075001301100
00900205109001200214037003100226865000900257002001300266#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02511.htm#S#c#187#16#article#31#16#Canadian Instit
ute for Health Information#Health System Characteristics: Percutaneous Coronary 
Intervention Rate^len#20100220#2010 Feb 20#http://secure.cihi.ca/cihiweb/#201100
00#aop02511.htm##
00451000000000217000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170042000880180027001301100
00900157109001200166037003300178865000900211002001300220#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02511.htm#S#c#188#17#article#31#17#Canadian Instit
ute for Health Information#Indicator Reports 2008^len#20100315#2010 Mar 15#http:
//secure.cihi.ca/hireports/#20110000#aop02511.htm##
00489000000000217000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170027000880180051001151100
00900166109001200175037006200187865000900249002001300258#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02511.htm#S#c#189#18#article#31#18#American Heart 
Association#Heart disease & stroke statistics: 2010 Update^len#20100315#2010 Mar
 15#http://www.americanheart.org/presenter.jhtm?identifier=120026#20110000#aop02
511.htm##
00720000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100012001050100
01700117010001900134010002000153010001800173810000600191012009000197030001200287
06500090029906400050030803100040031303200020031701400070031986500090032600200130
0335035001000348801001200358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#190#19#article#31#19#^rND^sHannan^nEL#^rND^sWu^nC#^rND^sWalford^
nG#^rND^sKing SB^n3rd#^rND^sHolmes DR^nJr#^rND^sAmbrose^nJA#et al#Volume-outcome
 relationships for percutaneous coronary interventions in the stent era^len#Circ
ulation#20050000#2005#112#8#1171-9#20110000#aop02511.htm#0009-7322#Circulation##
00639000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
02300120010001900143012010700162030001800269710000200287065000900289064000500298
031000300303032000200306014000700308865000900315002001300324#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02511.htm#S#c#191#20#article#31#20#^rND^sGodoy
^nPH#^rND^sKlein^nCH#^rND^sSouza-e-Silva^nN#^rND^sOliveira^nGM#Hospital case fat
ality associated with coronary angioplasty in Rio de Janeiro State, Brazil, 1999
-2003^len#Cad Saúde Pública#2#20070000#2007#23#4#845-51#20110000#aop02511.htm##
00824000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100013001070100
01700120010001800137010001500155010001400170810000600184012018800190030001800378
06500090039606400050040503100030041003200030041301400080041686500090042400200130
0433035001000446801001800456#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#192#21#article#31#21#^rND^sPeterson^nED#^rND^sDai^nD#^rND^sDeLon
g^nER#^rND^sBrennan^nJM#^rND^sSingh^nM#^rND^sRao^nSV#et al#NCDR Registry Partici
pants: Contemporary mortality risk prediction for percutaneous coronary interven
tion: results from 588,398 procedures in the National Cardiovascular Data Regist
ry^len#J Am Coll Cardiol#20100000#2010#55#18#1923-32#20110000#aop02511.htm#0735-
1097#J Am Coll Cardiol##
00628000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01900120012010100139030001300240065000900253064000500262031000400267032000300271
014000700274865000900281002001300290035001000303801001300313#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02511.htm#S#c#193#22#article#31#22#^rND^sLuft^
nHS#^rND^sBunker^nJP#^rND^sEnthoven^nAC#Should operations be regionalized?: The 
empirical relation between surgical volume and mortality^len#N Engl J Med#197900
00#1979#301#25#1364-9#20110000#aop02511.htm#0028-4793#N Engl J Med##
00762000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100016001030100
01600119010001600135010001500151010001700166810000600183012012700189030001800316
06500090033406400050034303100030034803200030035101400080035486500090036200200130
0371035001000384801001800394#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#194#23#article#31#23#^rND^sSingh^nM#^rND^sRihal^nCS#^rND^sGersh^
nBJ#^rND^sRoger^nVL#^rND^sBell^nMR#^rND^sLennon^nRJ#et al#Mortality differences 
between men and women after percutaneous coronary interventions: a 25-year, sing
le-center experience^len#J Am Coll Cardiol#20080000#2008#51#24#2313-20#20110000#
aop02511.htm#0735-1097#J Am Coll Cardiol##
00550000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120069001050300
02000174065000900194064000500203031000300208032000200211014000700213865000900220
002001300229035001000242801002000252#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02511.htm#S#c#195#24#article#31#24#^rND^sLansky^nAJ#Outcomes of percut
aneous and surgical revascularization in women^len#Prog Cardiovasc Dis#20040000#
2004#46#4#305-19#20110000#aop02511.htm#0033-0620#Prog Cardiovasc Dis##
00810000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
02000121010001600141010001700157010001500174810000600189012018000195030001300375
06500090038806400050039703100030040203200030040501400070040886500090041500200130
0424035001000437801001300447#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#196#25#article#31#25#^rND^sFeldman^nDN#^rND^sGade^nCL#^rND^sSlot
winer^nAJ#^rND^sParikh^nM#^rND^sBergman^nG#^rND^sWong^nSC#et al#Comparison of ou
tcomes of percutaneous coronary interventions in patients of three age groups (<
60, 60 to 80, and &gt; 80 years) (from the New York State Angioplasty Registry)^
len#Am J Cardiol#20060000#2006#98#10#1334-9#20110000#aop02511.htm#0002-9149#Am J
 Cardiol##
00510000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120068001050300
02300173710000200196065000900198064000500207031000200212032000200214014000600216
865000900222002001300231#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02
511.htm#S#c#197#26#article#31#26#^rND^sJacobs^nAK#Coronary intervention in 2009:
 are women no different than men?^len#Circ Cardiovasc Interv#2#20090000#2009#2#1
#69-78#20110000#aop02511.htm##
00683000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01600121010001900137010002000156012009600176030001400272065000900286064000500295
03100030030003200020030301400060030586500090031100200130032003500100033380100140
0343#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#c#198#27#a
rticle#31#27#^rND^sJamal^nSM#^rND^sShrive^nFM#^rND^sGhali^nWA#^rND^sKnudtson^nML
#^rND^sEisenberg^nMJ#In-hospital outcomes after percutaneous coronary interventi
on in Canada: 1992/93 to 2000/01^len#Can J Cardiol#20030000#2003#19#7#782-9#2011
0000#aop02511.htm#0828-282X#Can J Cardiol##
00707000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100016001080100
01700124010001400141010001300155010002000168810000600188012009700194030002800291
71000020031906500090032106400050033003100030033503200020033801400070034086500090
0347002001300356#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#
S#c#199#28#article#31#28#^rND^sHamburger^nJN#^rND^sWalsh^nSJ#^rND^sKhurana^nR#^r
ND^sDing^nL#^rND^sGao^nM#^rND^sHumphries^nKH#et al#Percutaneous coronary interve
ntion and 30-day mortality: The British Columbia PCI Risk Score^len#Cathet Cardi
ovasc Intervent#2#20090000#2009#74#3#377-85#20110000#aop02511.htm##
00717000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
02300124010001900147010001700166010001800183810000600201012011400207030002300321
71000020034406500090034606400050035503100030036001400060036386500090036900200130
0378#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#c#200#29#a
rticle#31#29#^rND^sSousa^nAGMR#^rND^sSousa^nJEMR#^rND^sCosta Junior^nJR#^rND^sAb
izaid^nAAC#^rND^sBuitrón^nF#^rND^sMarchant^nE#et al#Perfil demográfico e resulta
dos imediatos dos pacientes submetidos a angioplastia primária no Registro SOLAC
I^lpt#Rev Bras Cardiol Invas#2#20090000#2009#17#335-9#20110000#aop02511.htm##
00711000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
01400126010001700140010001900157012011600176030001800292065000900310064000500319
03100030032403200020032701400060032986500090033500200130034403500100035780100180
0367#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02511.htm#S#c#201#30#a
rticle#31#30#^rND^sSrinivas^nVS#^rND^sHailpern^nSM#^rND^sKoss^nE#^rND^sMonrad^nE
S#^rND^sAlderman^nMH#Effect of physician volume on the relationship between hosp
ital volume and mortality during primary angioplasty^len#J Am Coll Cardiol#20090
000#2009#53#7#574-9#20110000#aop02511.htm#0735-1097#J Am Coll Cardiol##
00747000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100020001020100
02000122010001700142010001800159010001300177810000600190012010700196030001800303
06500090032106400050033003100030033503200020033801400070034086500090034700200130
0356035001000369801001800379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02511.htm#S#c#202#31#article#31#31#^rND^sRoe^nMT#^rND^sMessenger^nJC#^rND^sWei
ntraub^nWS#^rND^sCannon^nCP#^rND^sFonarow^nGC#^rND^sDai^nD#et al#Treatments, tre
nds, and outcomes of acute myocardial infarction and percutaneous coronary inter
vention^len#J Am Coll Cardiol#20100000#2010#56#4#254-63#20110000#aop02511.htm#07
35-1097#J Am Coll Cardiol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#o#1#1#
article#1#20110331#081020#aop02611.htm#160##
05654000000000733000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201030017301201130
02760100034003890100027004230100038004500100036004880100040005240100027005640100
02500591070012200616070006900738070011100807070014300918083179401061085000802855
08500250286308500220288808500410291008500360295108500210298708316920300808500080
47000850026047080850023047340850033047570850030047900850022048201170008048420720
00304850112000904853111000904862116000904871115000904880114000904889113000904898
002001304907#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#h#
2#1#article#1#oa#pt#br1.1#1#4.0#TAB#34#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#
^f0^l0#0066-782X#20110401#Doença periodontal em portadoras de valvopatia durante
 a gravidez: estudo clínico e microbiológico^lpt#Periodontal disease in pregnant
 patients with rheumatic valvular disease: clinical and microbiological study^le
n#^rND^1A01^nWalkiria Samuel^sÁvila#^rND^1A02^nLilia^sTimerman#^rND^1A03^nGiusep
pe Alexandre^sRomito#^rND^1A03^nSílvia Linard^sMarcelino#^rND^1A01^nItamara Lúci
a Itagiba^sNeves#^rND^1A04^nMarcelo^sZugaib#^rND^1A01^nMax^sGrinberg#Universidad
e de São Paulo^iA01^1Faculdade de Medicina^2Hospital das Clínicas^3Instituto do 
Coração^cSão Paulo^sSP^pBrasil#Instituto Dante Pazzanese de Cardiologia^iA02^cSã
o Paulo^sSP^pBrasil#Universidade de São Paulo^iA03^1Faculdade de Odontologia^2De
partamento de Estomatologia^cSão Paulo^sSP^pBrasil#Universidade de São Paulo^iA0
4^1Faculdade de Medicina^2Hospital das Clínicas^3Departamento de Obstetrícia e G
inecologia^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: A doença periodontal represe
nta risco à gestante portadora de valvopatia reumática, seja para contrair endoc
ardite infecciosa, seja por propiciar complicações obstétricas. OBJETIVO: Estuda
r a frequência da doença periodontal em portadoras de valvopatia reumática duran
te a gravidez. MÉTODOS: Foram estudadas 140 gestantes, comparáveis quanto a idad
e e o nível socioeconômico, divididas em: 70 portadoras de doença valvar reumáti
ca e 70 mulheres saudáveis. Todas se submeteram a: 1) avaliação clínica odontoló
gica que incluiu a análise dos seguintes parâmetros: 1.1) profundidade à sondage
m, 1.2) distância da linha esmalte-cemento à margem gengival, 1.3) nível clínico
 de inserção, 1.4) índice de sangramento, 1.5) índice de placa bacteriana, e, 1.
6) comprometimento de furca; e, 2) exame microbiológico nas amostras de saliva e
 do cone que considerou o controle positivo para as cepas das bactérias Porphyro
monas gingivalis, Tannerella forsithia e Aggregobacter actinomycetemcomitans. RE
SULTADOS: A lesão valvar mitral foi prevalente (65 casos = 92,8%) dentre as gest
antes cardiopatas. A comparação entre os grupos mostrou não haver diferenças ent
re idade e a paridade, e embora tenham sido verificadas diferenças entre as medi
das da distância da linha esmalte-cemento à margem gengival (p = 0,01) e o índic
e de placa (p=0,04), a frequência da doença periodontal identificada em 20 (14,3
%) gestantes, não foi diferente entre os grupos (p = 0,147). O exame microbiológ
ico mostrou uma proporção maior da bactéria P. gingivalis na saliva de gestantes
 saudáveis (p = 0,004). CONCLUSÃO: O estudo clínico e microbiológico periodontal
 durante a gravidez demonstrou igual frequência da doença periodontal em portado
ras de valvopatia reumática quando comparada às mulheres saudáveis.#^dnd^i1#^tm^
lpt^kPeriodontite^i1#^tm^lpt^kgengivite^i1#^tm^lpt^kdoenças das valvas cardíacas
^i1#^tm^lpt^kdoença valvar reumática^i1#^tm^lpt^kgravidez^i1#^len^aBACKGROUND: T
he periodontal disease during pregnancy of women with rheumatic valve disease im
ply infective endocarditis risks and higher rate of preterm birth and low birth 
weight. OBJECTIVE: To study the periodontal disease rate of women with rheumatic
 valve disease during pregnancy. METHODS: We studied 140 pregnant women who incl
uded 70 patients with rheumatic valve disease and 70 healthy women. The periodon
tal examination included: 1) periodontal clinical exam regard the follow variabl
es: a) probing depth; b) gingival margin; c) clinical attachment level; d) bleed
ing on probing; e) plaque index and f) gingival index; and 2) microbiological te
st was performed in samples serum and gingival crevicular fluid and considered p
ositive controls to Porphyromonas gingivalis, Tannerella forsithia e Aggregobact
er actinomycetemcomitans. RESULTS: Age and parity were similar between groups; a
s single or combined the mitral valve disease was prevalent among the rheumatic 
valve lesion in 45 (32.1%) e 20 (28.5%) cases, respectively. Among the periodont
al variables gingival margin (p=0.01) and plaque index (p=0.04) were different b
etween groups. The periodontal disease was identified in 20 (14,3%) pregnant wom
en, seven (10%) of them were patients with valve rheumatic disease and the remai
n 13 (18,6%) were healthy women, its percentual was not different between groups
 (p=0,147). Microbiological analyses of oral samples showed higher percentual of
 P. gingivalis in healthy pregnant women (p=0.004). CONCLUSION: The clinical and
 microbiological study during pregnancy showed comparable incidence of periodont
al disease between women with rheumatic valve disease and healthy women.#^dnd^i2
#^tm^len^kPeriodontitis^i2#^tm^len^kgengivitis^i2#^tm^len^kheart valve diseases^
i2#^tm^len^krheumatic disease^i2#^tm^len^kpregnancy^i2#vancouv#21#20100224#24/02
/10#20100726#26/07/10#20100728#28/07/10#aop02611.htm##
05794000000000733000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201170017301201270
02900100034004170100027004510100038004780100036005160100040005520100027005920100
02500619070012200644070006900766070011100835070014300946083185701089085000802946
08500250295408500220297908500410300108500360304208500210307808317410309908500080
48400850026048480850023048740850033048970850030049300850022049601170008049820720
00304990112000904993111000905002116000905011115000905020114000905029113000905038
002001305047#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#f#
3#1#article#1#oa#pt#br1.1#1#4.0#TAB#34#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#
^f0^l0#0066-782X#20110401#<b>Doença periodontal em portadoras de valvopatia dura
nte a gravidez</b>: <b>estudo clínico e microbiológico</b>^lpt#<b>Periodontal di
sease in pregnant patients with rheumatic valvular disease</b>: <b>clinical and 
microbiological study</b>^len#^rND^1A01^nWalkiria Samuel^sÁvila#^rND^1A02^nLilia
^sTimerman#^rND^1A03^nGiuseppe Alexandre^sRomito#^rND^1A03^nSílvia Linard^sMarce
lino#^rND^1A01^nItamara Lúcia Itagiba^sNeves#^rND^1A04^nMarcelo^sZugaib#^rND^1A0
1^nMax^sGrinberg#Universidade de São Paulo^iA01^1Faculdade de Medicina^2Hospital
 das Clínicas^3Instituto do Coração^cSão Paulo^sSP^pBrasil#Instituto Dante Pazza
nese de Cardiologia^iA02^cSão Paulo^sSP^pBrasil#Universidade de São Paulo^iA03^1
Faculdade de Odontologia^2Departamento de Estomatologia^cSão Paulo^sSP^pBrasil#U
niversidade de São Paulo^iA04^1Faculdade de Medicina^2Hospital das Clínicas^3Dep
artamento de Obstetrícia e Ginecologia^cSão Paulo^sSP^pBrasil#^lpt^a<b>FUNDAMENT
O: </b>A doença periodontal representa risco à gestante portadora de valvopatia 
reumática, seja para contrair endocardite infecciosa, seja por propiciar complic
ações obstétricas. <b>OBJETIVO:</b> Estudar a frequência da doença periodontal e
m portadoras de valvopatia reumática durante a gravidez. <b>MÉTODOS:</b> Foram e
studadas 140 gestantes, comparáveis quanto a idade e o nível socioeconômico, div
ididas em: 70 portadoras de doença valvar reumática e 70 mulheres saudáveis. Tod
as se submeteram a: 1) avaliação clínica odontológica que incluiu a análise dos 
seguintes parâmetros: 1.1) profundidade à sondagem, 1.2) distância da linha esma
lte-cemento à margem gengival, 1.3) nível clínico de inserção, 1.4) índice de sa
ngramento, 1.5) índice de placa bacteriana, e, 1.6) comprometimento de furca; e,
 2) exame microbiológico nas amostras de saliva e do cone que considerou o contr
ole positivo para as cepas das bactérias <i>Porphyromonas gingivalis</i>, <i>Tan
nerella forsithia</i> e <i>Aggregobacter actinomycetemcomitans</i>. <b>RESULTADO
S:</b> A lesão valvar mitral foi prevalente (65 casos = 92,8%) dentre as gestant
es cardiopatas. A comparação entre os grupos mostrou não haver diferenças entre 
idade e a paridade, e embora tenham sido verificadas diferenças entre as medidas
 da distância da linha esmalte-cemento à margem gengival (p = 0,01) e o índice d
e placa (p=0,04), a frequência da doença periodontal identificada em 20 (14,3%) 
gestantes, não foi diferente entre os grupos (p = 0,147). O exame microbiológico
 mostrou uma proporção maior da bactéria <i>P. gingivalis</i> na saliva de gesta
ntes saudáveis (p = 0,004). <b>CONCLUSÃO:</b> O estudo clínico e microbiológico 
periodontal durante a gravidez demonstrou igual frequência da doença periodontal
 em portadoras de valvopatia reumática quando comparada às mulheres saudáveis.#^
dnd^i1#^tm^lpt^kPeriodontite^i1#^tm^lpt^kgengivite^i1#^tm^lpt^kdoenças das valva
s cardíacas^i1#^tm^lpt^kdoença valvar reumática^i1#^tm^lpt^kgravidez^i1#^len^a<b
>BACKGROUND:</b> The periodontal disease during pregnancy of women with rheumati
c valve disease imply infective endocarditis risks and higher rate of preterm bi
rth and low birth weight. <b>OBJECTIVE:</b> To study the periodontal disease rat
e of women with rheumatic valve disease during pregnancy. <b>METHODS:</b> We stu
died 140 pregnant women who included 70 patients with rheumatic valve disease an
d 70 healthy women. The periodontal examination included: 1) periodontal clinica
l exam regard the follow variables: a) probing depth; b) gingival margin; c) cli
nical attachment level; d) bleeding on probing; e) plaque index and f) gingival 
index; and 2) microbiological test was performed in samples serum and gingival c
revicular fluid and considered positive controls to Porphyromonas gingivalis, <i
>Tannerella forsithia</i> e <i>Aggregobacter actinomycetemcomitans</i>. <b>RESUL
TS:</b> Age and parity were similar between groups; as single or combined the mi
tral valve disease was prevalent among the rheumatic valve lesion in 45 (32.1%) 
e 20 (28.5%) cases, respectively. Among the periodontal variables gingival margi
n (p=0.01) and plaque index (p=0.04) were different between groups. The periodon
tal disease was identified in 20 (14,3%) pregnant women, seven (10%) of them wer
e patients with valve rheumatic disease and the remain 13 (18,6%) were healthy w
omen, its percentual was not different between groups (p=0,147). Microbiological
 analyses of oral samples showed higher percentual of P. gingivalis in healthy p
regnant women (p=0.004). <b>CONCLUSION:</b> The clinical and microbiological stu
dy during pregnancy showed comparable incidence of periodontal disease between w
omen with rheumatic valve disease and healthy women.#^dnd^i2#^tm^len^kPeriodonti
tis^i2#^tm^len^kgengivitis^i2#^tm^len^kheart valve diseases^i2#^tm^len^krheumati
c disease^i2#^tm^len^kpregnancy^i2#vancouv#21#20100224#24/02/10#20100726#26/07/1
0#20100728#28/07/10#aop02611.htm##
05834000000000757000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001201030
01790120113002820100034003950100027004290100038004560100036004940100040005300100
02700570010002500597070012400622070007100746070011300817070014500930083181201075
08500080288708500250289508500220292008500410294208500360298308500210301908317270
30400850008047670850026047750850023048010850033048240850030048570850022048871170
00804909072000304917112000904920111000904929116000904938115000904947114000904956
113000904965002001304974008008904987#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02611.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#tab#34#nd#nd#Arq.
 bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110401#Doença periodontal em po
rtadoras de valvopatia durante a gravidez: estudo clínico e microbiológico^lpt#P
eriodontal disease in pregnant patients with rheumatic valvular disease: clinica
l and microbiological study^len#^rND^1A01^nWalkiria Samuel^sÁvila#^rND^1A02^nLil
ia^sTimerman#^rND^1A03^nGiuseppe Alexandre^sRomito#^rND^1A03^nSílvia Linard^sMar
celino#^rND^1A01^nItamara Lúcia Itagiba^sNeves#^rND^1A04^nMarcelo^sZugaib#^rND^1
A01^nMax^sGrinberg#^iA01^1Universidade de São Paulo^2Faculdade de Medicina^3Hosp
ital das Clínicas. Instituto do Coração^cSão Paulo^sSP^pBrasil#^iA02^1Instituto 
Dante Pazzanese de Cardiologia^cSão Paulo^sSP^pBrasil#^iA03^1Universidade de São
 Paulo^2Faculdade de Odontologia^3Departamento de Estomatologia^cSão Paulo^sSP^p
Brasil#^iA04^1Universidade de São Paulo^2Faculdade de Medicina^3Hospital das Clí
nicas. Departamento de Obstetrícia e Ginecologia^cSão Paulo^sSP^pBrasil#^lpt^aFU
NDAMENTO: A doença periodontal representa risco à gestante portadora de valvopat
ia reumática, seja para contrair endocardite infecciosa, seja por propiciar comp
licações obstétricas. OBJETIVO: Estudar a frequência da doença periodontal em po
rtadoras de valvopatia reumática durante a gravidez. MÉTODOS: Foram estudadas 14
0 gestantes, comparáveis quanto a idade e o nível socioeconômico, divididas em: 
70 portadoras de doença valvar reumática e 70 mulheres saudáveis. Todas se subme
teram a: 1) avaliação clínica odontológica que incluiu a análise dos seguintes p
arâmetros: 1.1) profundidade à sondagem, 1.2) distância da linha esmalte-cemento
 à margem gengival, 1.3) nível clínico de inserção, 1.4) índice de sangramento, 
1.5) índice de placa bacteriana, e, 1.6) comprometimento de furca; e, 2) exame m
icrobiológico nas amostras de saliva e do cone que considerou o controle positiv
o para as cepas das bactérias Porphyromonas gingivalis, Tannerella forsithia e A
ggregobacter actinomycetemcomitans. RESULTADOS: A lesão valvar mitral foi preval
ente (65 casos = 92,8 por cento) dentre as gestantes cardiopatas. A comparação e
ntre os grupos mostrou não haver diferenças entre idade e a paridade, e embora t
enham sido verificadas diferenças entre as medidas da distância da linha esmalte
-cemento à margem gengival (p = 0,01) e o índice de placa (p=0,04), a frequência
 da doença periodontal identificada em 20 (14,3 por cento) gestantes, não foi di
ferente entre os grupos (p = 0,147). O exame microbiológico mostrou uma proporçã
o maior da bactéria P. gingivalis na saliva de gestantes saudáveis (p = 0,004). 
CONCLUSÃO: O estudo clínico e microbiológico periodontal durante a gravidez demo
nstrou igual frequência da doença periodontal em portadoras de valvopatia reumát
ica quando comparada às mulheres saudáveis.#^dnd^i1#^tm^lpt^kPeriodontite^i1#^tm
^lpt^kgengivite^i1#^tm^lpt^kdoenças das valvas cardíacas^i1#^tm^lpt^kdoença valv
ar reumática^i1#^tm^lpt^kgravidez^i1#^len^aBACKGROUND: The periodontal disease d
uring pregnancy of women with rheumatic valve disease imply infective endocardit
is risks and higher rate of preterm birth and low birth weight. OBJECTIVE: To st
udy the periodontal disease rate of women with rheumatic valve disease during pr
egnancy. METHODS: We studied 140 pregnant women who included 70 patients with rh
eumatic valve disease and 70 healthy women. The periodontal examination included
: 1) periodontal clinical exam regard the follow variables: a) probing depth; b)
 gingival margin; c) clinical attachment level; d) bleeding on probing; e) plaqu
e index and f) gingival index; and 2) microbiological test was performed in samp
les serum and gingival crevicular fluid and considered positive controls to Porp
hyromonas gingivalis, Tannerella forsithia e Aggregobacter actinomycetemcomitans
. RESULTS: Age and parity were similar between groups; as single or combined the
 mitral valve disease was prevalent among the rheumatic valve lesion in 45 (32.1
 percent) e 20 (28.5 percent) cases, respectively. Among the periodontal variabl
es gingival margin (p=0.01) and plaque index (p=0.04) were different between gro
ups. The periodontal disease was identified in 20 (14,3 percent) pregnant women,
 seven (10 percent) of them were patients with valve rheumatic disease and the r
emain 13 (18,6 percent) were healthy women, its percentual was not different bet
ween groups (p=0,147). Microbiological analyses of oral samples showed higher pe
rcentual of P. gingivalis in healthy pregnant women (p=0.004). CONCLUSION: The c
linical and microbiological study during pregnancy showed comparable incidence o
f periodontal disease between women with rheumatic valve disease and healthy wom
en.#^dnd^i2#^tm^len^kPeriodontitis^i2#^tm^len^kgengivitis^i2#^tm^len^kheart valv
e diseases^i2#^tm^len^krheumatic disease^i2#^tm^len^kpregnancy^i2#vancouv#21#201
00224#24/02/10#20100726#26/07/10#20100728#28/07/10#aop02611.htm#Internet^ihttp:/
/www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000034##
00476000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704023400083002001300317#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#5#1#article#135#<p><a name="
top"></a><font face="verdana, arial, helvetica, sans-serif" size="4"><b>Doen&cce
dil;a    periodontal em portadoras de valvopatia durante a gravidez - estudo cl&
iacute;nico    e microbiol&oacute;gico</b></font></p>     ^cY#aop02611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#6#2#article#135#<p>&nbsp;</p
>     ^cY#aop02611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#7#3#article#135#<p>&nbsp;</p
>     ^cY#aop02611.htm##
00600000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704035800083002001300441#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#8#4#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Walkiria Samuel    &Aacute
;vila<sup>I</sup>; Lilia Timerman<sup>II</sup>; Giuseppe Alexandre Romito<sup>II
I</sup>;    S&iacute;lvia Linard Marcelino<sup>III</sup>; Itamara L&uacute;cia I
tagiba Neves<sup>I</sup>;    Marcelo Zugaib<sup>IV</sup>; Max Grinberg<sup>I</su
p></b></font></p>     ^cY#aop02611.htm##
00490000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704024800083002001300331#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#9#5#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    do C
ora&ccedil;&atilde;o do Hospital das Cl&iacute;nicas da Faculdade de Medicina   
 da Universidade de S&atilde;o Paulo - S&atilde;o Paulo, SP - Brasil    ^cY#aop0
2611.htm##
00346000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704010300084002001300187#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#10#6#article#135#<br>   <sup
>II</sup>Instituto Dante Pazzanese de Cardiologia - S&atilde;o Paulo, SP    - Br
asil    ^cY#aop02611.htm##
00432000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704018900084002001300273#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#11#7#article#135#<br>   <sup
>III</sup>Disciplina de Periodontia do Departamento de Estomatologia da    Facul
dade de Odontologia da Universidade de S&atilde;o Paulo - S&atilde;o Paulo,    S
P - Brasil    ^cY#aop02611.htm##
00462000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704021900084002001300303#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#12#8#article#135#<br>   <sup
>IV</sup>Departamento de Obstetr&iacute;cia e Ginecologia do Hospital das    Cl&
iacute;nicas da Faculdade de Medicina da Universidade de S&atilde;o Paulo    - S
&atilde;o Paulo, SP - Brasil</font></p>     ^cY#aop02611.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#13#9#article#135#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#14#10#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#15#11#article#135#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop02611.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#16#12#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>   
  ^cY#aop02611.htm##
00557000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031300085002001300398#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#17#13#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>FUNDAMENTO:    </b> A do
en&ccedil;a periodontal representa risco &agrave; gestante portadora    de valvo
patia reum&aacute;tica, seja para contrair endocardite infecciosa, seja    por p
ropiciar complica&ccedil;&otilde;es obst&eacute;tricas.    ^cY#aop02611.htm##
00399000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015500085002001300240#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#18#14#article#135#<br>   <b>
OBJETIVO:</b> Estudar a frequ&ecirc;ncia da doen&ccedil;a periodontal em    port
adoras de valvopatia reum&aacute;tica durante a gravidez.    ^cY#aop02611.htm##
01184000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704094000085002001301025#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#19#15#article#135#<br>   <b>
M&Eacute;TODOS:</b> Foram estudadas 140 gestantes, compar&aacute;veis quanto    
a idade e o n&iacute;vel socioecon&ocirc;mico, divididas em: 70 portadoras de   
 doen&ccedil;a valvar reum&aacute;tica e 70 mulheres saud&aacute;veis. Todas    
se submeteram a: 1) avalia&ccedil;&atilde;o cl&iacute;nica odontol&oacute;gica  
  que incluiu a an&aacute;lise dos seguintes par&acirc;metros: 1.1) profundidade
    &agrave; sondagem, 1.2) dist&acirc;ncia da linha esmalte-cemento &agrave; ma
rgem    gengival, 1.3) n&iacute;vel cl&iacute;nico de inser&ccedil;&atilde;o, 1.
4) &iacute;ndice    de sangramento, 1.5) &iacute;ndice de placa bacteriana, e, 1
.6) comprometimento    de furca; e, 2) exame microbiol&oacute;gico nas amostras 
de saliva e do cone    que considerou o controle positivo para as cepas das bact
&eacute;rias <i>Porphyromonas    gingivalis</i>, <i>Tannerella forsithia</i> e <
i>Aggregobacter actinomycetemcomitans</i>.    ^cY#aop02611.htm##
00999000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075500085002001300840#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#20#16#article#135#<br>   <b>
RESULTADOS:</b> A les&atilde;o valvar mitral foi prevalente (65 casos = 92,8%)  
  dentre as gestantes cardiopatas. A compara&ccedil;&atilde;o entre os grupos   
 mostrou n&atilde;o haver diferen&ccedil;as entre idade e a paridade, e embora  
  tenham sido verificadas diferen&ccedil;as entre as medidas da dist&acirc;ncia 
   da linha esmalte-cemento &agrave; margem gengival (p = 0,01) e o &iacute;ndic
e    de placa (p=0,04), a frequ&ecirc;ncia da doen&ccedil;a periodontal identifi
cada    em 20 (14,3%) gestantes, n&atilde;o foi diferente entre os grupos (p = 0
,147).    O exame microbiol&oacute;gico mostrou uma propor&ccedil;&atilde;o maio
r da bact&eacute;ria    <i>P. gingivalis</i> na saliva de gestantes saud&aacute;
veis (p = 0,004).    ^cY#aop02611.htm##
00545000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030100085002001300386#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#21#17#article#135#<br>   <b>
CONCLUS&Atilde;O:</b> O estudo cl&iacute;nico e microbiol&oacute;gico periodonta
l    durante a gravidez demonstrou igual frequ&ecirc;ncia da doen&ccedil;a perio
dontal    em portadoras de valvopatia reum&aacute;tica quando comparada &agrave;
s mulheres    saud&aacute;veis.</font></p>     ^cY#aop02611.htm##
00496000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025200085002001300337#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#22#18#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Periodontite, gengivite, doen&ccedil;as das valvas card&iacute;acas, doen&ccedil
;a    valvar reum&aacute;tica, gravidez.</font></p> <hr size="1" noshade>     ^c
Y#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#23#19#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#24#20#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#25#21#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop02611.htm##
00904000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066000085002001300745#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#26#22#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A doen&ccedil;a    periodon
tal compreende um amplo espectro de altera&ccedil;&otilde;es dos tecidos    peri
odont&iacute;ticos de origem inflamat&oacute;ria e/ou infecciosa que podem    ac
ontecer durante a gravidez, quando modifica&ccedil;&otilde;es fisiol&oacute;gica
s    da cavidade oral, atribu&iacute;veis a mecanismos hormonais da gesta&ccedil
;&atilde;o,    causam o que se denomina gengivite grav&iacute;dica<sup>1</sup>, 
caracterizada    por inflama&ccedil;&atilde;o de gengiva, cemento e ligamento pe
riodontal, e    que predisp&otilde;e a gestante &agrave; periodontite.</font></p
>     ^cY#aop02611.htm##
00850000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060600085002001300691#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#27#23#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A periodontite    que acome
te cerca de 15,0% da popula&ccedil;&atilde;o brasileira<sup>2,3</sup>    &eacute
; uma situa&ccedil;&atilde;o cl&iacute;nica mais grave, porque, al&eacute;m    d
e comprometer o osso alveolar, associa-se a micro-organismos, na maioria bacilos
    anaer&oacute;bicos gram-negativos, destacando-se as bact&eacute;rias <i>Porp
hyromonas    gingivalis (P. gingivalis), Tannerella forsythia</i> (<i>T. forsyth
ia),</i>    e <i>Aggregobacter actinomycetemcomitans (A. actinomycetemcomitans)<
/i><sup>4</sup>.</font></p>     ^cY#aop02611.htm##
00680000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043600085002001300521#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#28#24#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No &acirc;mbito    da gravi
dez, o permanente estado inflamat&oacute;rio e infeccioso da cavidade    oral<su
p>5</sup> representa riscos potenciais, seja por favorecer a infec&ccedil;&atild
e;o    por endocardite infecciosa, seja por propiciar complica&ccedil;&otilde;es
 obst&eacute;tricas,    tais como aborto espont&acirc;neo e prematuridade<sup>6<
/sup>.</font></p>     ^cY#aop02611.htm##
00507000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026300085002001300348#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#29#25#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nesse sentido,    o objetiv
o deste trabalho foi estudar a frequ&ecirc;ncia da doen&ccedil;a periodontal    
em mulheres portadoras de valvopatia reum&aacute;tica durante a gravidez.</font>
</p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#30#26#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#31#27#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&eacute;todos</b></font
></p>     ^cY#aop02611.htm##
01083000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704083900085002001300924#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#32#28#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No per&iacute;odo    de jan
eiro de 2005 a julho de 2008, realizou-se um estudo transversal que selecionou  
  140 mulheres gr&aacute;vidas com idades entre 18 e 35 anos, atendidas consecut
ivamente    pelo Sistema &Uacute;nico de Sa&uacute;de (SUS). O grupo de portador
as de doen&ccedil;a    valvar reum&aacute;tica foi composto por 70 gestantes ate
ndidas no ambulat&oacute;rio    de Cardiopatia e Gravidez da Unidade de Cardiopa
tias Valvares do Instituto do    Cora&ccedil;&atilde;o (InCor). O grupo de mulhe
res saud&aacute;veis correspondeu    a 70 gestantes acompanhadas no ambulat&oacu
te;rio de pr&eacute;-natal do Centro    de Sa&uacute;de Geraldo de Paula Souza, 
da Faculdade de Sa&uacute;de P&uacute;blica    da Universidade de S&atilde;o Pau
lo (USP).</font></p>     ^cY#aop02611.htm##
01429000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704118500085002001301270#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#33#29#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Quando da inclus&atilde;o  
  no estudo, os grupos de gestantes reum&aacute;ticas e gestantes saud&aacute;ve
is    foram compar&aacute;veis quanto &agrave; idade, n&iacute;veis socioecon&oc
irc;mico    e cultural, e idade gestacional. Todas as pacientes obedeceram a um 
protocolo    que incluiu avalia&ccedil;&atilde;o cl&iacute;nica peri&oacute;dica
 e exame    cl&iacute;nico odontol&oacute;gico, que visou a identifica&ccedil;&a
tilde;o    de doen&ccedil;a periodontal e o estudo microbiol&oacute;gico da cavi
dade oral.    No grupo das gestantes reum&aacute;ticas, dentre as medica&ccedil;
&otilde;es    de indica&ccedil;&atilde;o cardiol&oacute;gica, foi mantida a apli
ca&ccedil;&atilde;o    intramuscular de penicilina G benzatina, na dose de 1.200
.000 UI a cada 21 dias,    para profilaxia secund&aacute;ria da doen&ccedil;a re
um&aacute;tica. N&atilde;o    foram inclu&iacute;das mulheres com outras morbida
des, tais como hipertens&atilde;o    arterial, diabete melito, doen&ccedil;as in
fecciosas, ou aquelas que tivessem    utilizado antibi&oacute;ticos num per&iacu
te;odo inferior a tr&ecirc;s meses.</font></p>     ^cY#aop02611.htm##
01343000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704109900085002001301184#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#34#30#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Entre os dados    da anamne
se, destacou-se, para o estudo, o questionamento sobre os h&aacute;bitos    da h
igiene bucal. As pacientes foram submetidas &agrave; avalia&ccedil;&atilde;o    
cl&iacute;nica periodontal que utilizou o espelho cl&iacute;nico e uma sonda    
milimetrada para registro dos seguintes par&acirc;metros: a) profundidade cl&iac
ute;nica    de sondagem (PCS) que corresponde &agrave; dist&acirc;ncia (mm) comp
reendida    entre a margem gengival e o fundo do sulco gengival ou da bolsa peri
odontal;    b) dist&acirc;ncia da linha esmalte-cemento &agrave; margem gengival
 (LEC/MG);    c) n&iacute;vel cl&iacute;nico de inser&ccedil;&atilde;o (NCI) que
 &eacute;    a diferen&ccedil;a aritm&eacute;tica dos valores de PCS e LEC/MG; d
) &iacute;ndice    de sangramento (IS) nas 4 faces de cada dente avaliado; e) &i
acute;ndice de    placa bacteriana (IP); e f) comprometimento de furca. O diagn&
oacute;stico de    doen&ccedil;a periodontal firmou-se nos crit&eacute;rios de T
onetti e Claffey<sup>7</sup>.</font></p>     ^cY#aop02611.htm##
00773000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052900085002001300614#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#35#31#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Para a an&aacute;lise    mi
crobiol&oacute;gica das amostras de saliva e do cone, foram aplicadas as t&eacut
e;cnicas    de extra&ccedil;&atilde;o do &aacute;cido desoxirribonucleico (DNA) 
e da rea&ccedil;&atilde;o    de polimerase em cadeia. Os controles positivos for
am cepas cultivadas das bact&eacute;rias    <i>P. gingivalis</i>, <i>T. forsythi
a</i> e <i>A. actinomycetemcomitans</i>,    de acordo com a t&eacute;cnica de As
himoto<sup>8</sup>.</font></p>     ^cY#aop02611.htm##
01309000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106500085002001301150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#36#32#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    estat&i
acute;stica dos resultados utilizou as frequ&ecirc;ncias absolutas e    relativa
s dos dados, as medidas de tend&ecirc;ncia central (m&eacute;dia e mediana)    e
 a dispers&atilde;o dos valores (m&iacute;nimo, m&aacute;ximo e desvio-padr&atil
de;o).    Os testes de associa&ccedil;&atilde;o (qui-quadrado de Pearson e exato
 de Fisher)    foram calculados para avaliar a rela&ccedil;&atilde;o entre a pre
sen&ccedil;a    de doen&ccedil;a periodontal e as vari&aacute;veis qualitativas.
 Na avalia&ccedil;&atilde;o    da condi&ccedil;&atilde;o periodontal, foram cons
iderados os par&acirc;metros    cl&iacute;nicos: PCS, NCI, LEC/MG, IS e IP. Os t
estes n&atilde;o param&eacute;tricos    de Mann-Whitney e qui-quadrado de Pearso
n foram utilizados para a compara&ccedil;&atilde;o    entre as gestantes reum&aa
cute;ticas e as saud&aacute;veis. Adotou-se o n&iacute;vel    de signific&acirc;
ncia de 5,0% para rejei&ccedil;&atilde;o da hip&oacute;tese    de nulidade.</fon
t></p>     ^cY#aop02611.htm##
00943000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704069900085002001300784#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#37#33#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O estudo foi aprovado    pe
las Comiss&otilde;es de &Eacute;tica em Pesquisa do Hospital das Cl&iacute;nicas
    da Faculdade de Medicina (CAPPesp - processo nº 199/05) e do InCor (processo
    nº 2557-04/177) da Universidade de S&atilde;o Paulo, e pelo Comit&ecirc; de 
   &Eacute;tica em Pesquisa do Instituto Dante Pazzanese de Cardiologia. As paci
entes    foram inclu&iacute;das no protocolo ap&oacute;s obten&ccedil;&atilde;o 
da assinatura    do Termo de Consentimento Livre e Esclarecido, de acordo com as
 normas da Resolu&ccedil;&atilde;o    nº 196, de 10 de outubro de 1996, do Conse
lho Nacional de Sa&uacute;de.</font></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#38#34#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#39#35#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Resultados</b></font></p
>     ^cY#aop02611.htm##
01042000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079800085002001300883#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#40#36#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Eram primigestas    61 paci
entes (43,6%) e a m&eacute;dia da idade materna n&atilde;o foi diferente    (p &
lt; 0,451) entre os grupos, sendo de 27 &plusmn; 4,6 anos nas reum&aacute;ticas 
   e de 27 &plusmn; 5,1 anos nas mulheres saud&aacute;veis. A an&aacute;lise da 
   distribui&ccedil;&atilde;o da les&atilde;o valvar no grupo de gestantes reum&
aacute;ticas    mostrou que 45 (32,1%) delas apresentavam valvopatia mitral, 5 (
3,6%) valvopatia    a&oacute;rtica e 20 (28,5%), les&atilde;o combinada mitral e
 a&oacute;rtica.    Quinze das 70 gestantes reum&aacute;ticas j&aacute; haviam s
ido submetidas &agrave;    cirurgia card&iacute;aca de substitui&ccedil;&atilde;
o valvar por pr&oacute;tese    biol&oacute;gica.</font></p>     ^cY#aop02611.htm
##
00374000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013000085002001300215#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#41#37#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Exame cl&iacute;nico-odo
ntol&oacute;gico</b></font></p>     ^cY#aop02611.htm##
01000000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075600085002001300841#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#42#38#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    das inf
orma&ccedil;&otilde;es dos h&aacute;bitos de higiene bucal mostrou que    o uso 
de fio dental foi maior (p = 0,02) no grupo das gestantes reum&aacute;ticas    (
48 = 68,5%) quando comparado ao saud&aacute;vel (32 = 45,7%), enquanto que    o 
h&aacute;bito de enxaguar a boca com antiss&eacute;ptico foi 2,3 vezes maior    
entre as gestantes saud&aacute;veis. Os exames odontol&oacute;gico e microbiol&o
acute;gico    foram realizados em idade gestacional semelhante (p = 0,801), send
o em m&eacute;dia    durante a 27,8ª &plusmn; 6,6 semana de gesta&ccedil;&atilde
;o no grupo de reum&aacute;ticas    e na 29,8ª &plusmn; 7,6 semana no saud&aacut
e;vel.</font></p>     ^cY#aop02611.htm##
00945000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704070100085002001300786#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#43#39#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A m&eacute;dia    do n&uacu
te;mero de dentes preservados foi de 24,1 dentes no grupo das reum&aacute;ticas 
   e 24,0 no grupo saud&aacute;vel. A doen&ccedil;a periodontal foi identificada
    em 20 (14,3%) gestantes, sendo que 7 (10%) delas eram reum&aacute;ticas e 13
    (18,6%) saud&aacute;veis, n&atilde;o havendo diferen&ccedil;a estat&iacute;s
tica    (p = 0,147) na compara&ccedil;&atilde;o entre os grupos. A an&aacute;lis
e dos    par&acirc;metros periodontais demonstrados na <a href="#t1">Tabela 1</a
> verificou    diferen&ccedil;as entre os grupos quanto &agrave;s medidas LEC/MG
 (p = 0,01)    e IP (p = 0,04).</font></p>     ^cY#aop02611.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#44#40#article#135#<p><a name
="t1"></a></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#45#41#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#46#42#article#135#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02611t01.jpg"></p>     ^cY#aop
02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#47#43#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00361000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011700085002001300202#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#48#44#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Exame microbiol&oacute;g
ico</b></font></p>     ^cY#aop02611.htm##
01146000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704090200085002001300987#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#49#45#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    compara
tiva entre os grupos mostrou que a propor&ccedil;&atilde;o da <i>P. gingivalis</
i>    foi significativamente maior na saliva de gestantes saud&aacute;veis em co
mpara&ccedil;&atilde;o    &agrave;s reum&aacute;ticas (p = 0,004), mas n&atilde;
o houve diferen&ccedil;a    quanto &agrave;s bact&eacute;rias <i>T. forsythia e 
A. actinomycetemcomitans</i>    tanto nas amostras de saliva quanto nas do cone 
(<a href="#t2">Tabela 2</a>).    An&aacute;lise da distribui&ccedil;&atilde;o do
s tipos de bact&eacute;rias entre    as 20 gestantes que apresentaram doen&ccedi
l;a periodontal mostrou que a propor&ccedil;&atilde;o    de <i>P. gingivalis</i>
 e de <i>A. actinomycetemcomitans</i> foi significativamente    maior nas amostr
as de saliva e do cone, respectivamente (<a href="#t3">Tabela    3</a>).</font><
/p>     ^cY#aop02611.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#50#46#article#135#<p><a name
="t2"></a></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#51#47#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#52#48#article#135#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02611t02.jpg"></p>     ^cY#aop
02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#53#49#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#54#50#article#135#<p><a name
="t3"></a></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#55#51#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#56#52#article#135#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02611t03.jpg"></p>     ^cY#aop
02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#57#53#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#58#54#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Dados obst&eacute;tricos
</b></font></p>     ^cY#aop02611.htm##
01199000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704095500085002001301040#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#59#55#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o houve    complic
a&ccedil;&atilde;o obst&eacute;trica materna durante a gesta&ccedil;&atilde;o   
 e o parto. A idade gestacional do parto, calculada em semanas de gesta&ccedil;&
atilde;o,    variou entre 36 e 42 anos (m&eacute;dia = 38,54 &plusmn; 6,65) nas 
gestantes    reum&aacute;ticas e entre 32 e 42 anos (m&eacute;dia = 39,28 &plusm
n; 7,65)    nas saud&aacute;veis. O peso dos rec&eacute;m-nascidos variou entre 
3.017 e    4.488 g (m&eacute;dia = 3.069 g &plusmn; 455) no grupo de gestantes r
eum&aacute;ticas,    e entre 3.290 e 4.260 g (m&eacute;dia = 3.286 g &plusmn; 45
5) no das saud&aacute;veis.    A an&aacute;lise comparativa mostrou que a idade 
gestacional do parto e o peso    dos rec&eacute;m-nascidos foram menores no grup
o das gestantes reum&aacute;ticas,    com signific&acirc;ncia estat&iacute;stica
 (respectivamente p = 0,0036 e p =    0,034).</font></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#60#56#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#61#57#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop02611.htm##
00539000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029500085002001300380#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#62#58#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    prov&e
circ; dados originais aos conhecimentos atuais sobre o envolvimento da    doen&c
cedil;a periodontal em duas situa&ccedil;&otilde;es especiais: gravidez    e val
vopatia reum&aacute;tica.</font></p>     ^cY#aop02611.htm##
00879000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063500085002001300720#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#63#59#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Modifica&ccedil;&otilde;es 
   hormonais da gesta&ccedil;&atilde;o, mudan&ccedil;as no estilo de alimenta&cc
edil;&atilde;o    e higiene bucal prec&aacute;ria s&atilde;o fatores que favorec
em a manifesta&ccedil;&atilde;o    da gengivite grav&iacute;dica, habitual no ci
clo grav&iacute;dico-puerperal<sup>9,10</sup>.    Acresce que a falta de acesso 
ao tratamento odontol&oacute;gico e os mitos sobre    a seguran&ccedil;a no trat
amento dent&aacute;rio predisp&otilde;em &agrave;    doen&ccedil;a periodontal d
urante a gesta&ccedil;&atilde;o<sup>11</sup>.</font></p>     ^cY#aop02611.htm##
01275000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704103100085002001301116#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#64#60#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Embora a popula&ccedil;&ati
lde;o    considerada neste estudo estivesse exposta a todos esses fatores, o reg
istro    de 14,0% de doen&ccedil;a periodontal n&atilde;o foi diferente do perce
ntual    encontrado na popula&ccedil;&atilde;o geral<sup>12</sup>. Entre as expl
ica&ccedil;&otilde;es    para tal achado est&atilde;o as caracter&iacute;sticas 
da casu&iacute;stica:    pacientes jovens (m&eacute;dia de idade de 27 anos) que
 sabidamente<sup>13</sup>    apresentam menor risco de doen&ccedil;a periodontal
 quando comparadas aos idosos;    exclus&atilde;o de tabagistas e de portadoras 
de diabete melito, condi&ccedil;&otilde;es    de reconhecido e elevado risco par
a doen&ccedil;a periodontal na popula&ccedil;&atilde;o    geral<sup>14,15</sup>.
 Deve-se ressaltar, entretanto, que os conhecimentos atuais    carecem de mais e
studos sobre a incid&ecirc;ncia da doen&ccedil;a periodontal    em cardiopatas p
ortadores de valvopatia reum&aacute;tica.</font></p>     ^cY#aop02611.htm##
00824000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058000085002001300665#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#65#61#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    mostro
u que a propor&ccedil;&atilde;o de 13 (18,6%) casos de doen&ccedil;a periodontal
    no grupo saud&aacute;vel e 7 (10,0%) no grupo de reum&aacute;ticas n&atilde;
o    resultou em signific&acirc;ncia estat&iacute;stica. Entretanto, verificou-s
e    no exame cl&iacute;nico que par&acirc;metros, como a dist&acirc;ncia entre 
a    linha esmalte-cemento (LEC) e a margem gengival (MG) e o &iacute;ndice de p
laca    bacteriana (IP), foram diferentes na gestante saud&aacute;vel.</font></p
>     ^cY#aop02611.htm##
00838000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059400085002001300679#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#66#62#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Tais achados talvez    poss
am ser explicados pela melhor higiene bucal efetuada pelas gestantes reum&aacute
;ticas,    as quais utilizavam fio dental com maior frequ&ecirc;ncia. Embora de 
n&iacute;vel    socioecon&ocirc;mico semelhante, as mulheres com valvopatia s&at
ilde;o, provavelmente,    mais bem informadas sobre os potenciais riscos card&ia
cute;acos associados &agrave;    m&aacute; sa&uacute;de bucal, fruto da educa&cc
edil;&atilde;o continuada recebida    no decorrer do seguimento cardiol&oacute;g
ico.</font></p>     ^cY#aop02611.htm##
00781000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053700085002001300622#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#67#63#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nesse sentido,    tem sido 
refor&ccedil;ado na pr&aacute;tica di&aacute;ria que o estado inflamat&oacute;ri
o    e infeccioso cr&ocirc;nico da boca contribui para a bacteriemia intermitent
e    e para o risco de endocardite infecciosa em portadores de valvopatias. De f
ato,    Hull<sup>16</sup> e Holmstrup<sup>17</sup> demonstraram que a cavidade b
ucal    &eacute; a principal porta de entrada para agentes etiol&oacute;gicos da
 endocardite    infecciosa.</font></p>     ^cY#aop02611.htm##
01057000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704081300085002001300898#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#68#64#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No que diz respeito    aos 
tipos de agentes microbianos na doen&ccedil;a periodontal, as dificuldades    no
 reconhecimento de sua especificidade fundamentam-se no expressivo n&uacute;mero
    de esp&eacute;cies, observando-se que cerca de 300 a 400 delas s&atilde;o en
contradas    no biofilme bacteriano<sup>18</sup>. Desse espectro, possivelmente,
 algo entre    10 a 20 esp&eacute;cies participam da patogenicidade e da destrui
&ccedil;&atilde;o    period&ocirc;ntica na doen&ccedil;a periodontal<sup>19</sup
>, prevalecendo bacilos    anaer&oacute;bicos gram-negativos, dentre eles o <i>A
. actinomycetemcomitans    (grupo Hacek), a P. gingivalis e a P. intermedia,</i>
 com predom&iacute;nio    nas amostras de gengiva<sup>20</sup>.</font></p>     ^
cY#aop02611.htm##
00721000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047700085002001300562#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#69#65#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A identifica&ccedil;&atilde
;o    de maior propor&ccedil;&atilde;o de <i>P. gingivalis</i> na saliva de gest
antes    saud&aacute;veis em compara&ccedil;&atilde;o &agrave; reum&aacute;tica 
(54,3%    <i>vs</i> 29,20%; p = 0,004) refor&ccedil;a a explica&ccedil;&atilde;o
 sobre    a melhor condi&ccedil;&atilde;o bucal das pacientes cardiopatas compar
ada &agrave;    das gestantes saud&aacute;veis.</font></p>     ^cY#aop02611.htm#
#
00833000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704058900085002001300674#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#70#66#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Considere-se, entretanto,  
  a poss&iacute;vel influ&ecirc;ncia positiva da penicilina benzatina no grupo  
  das gestantes reum&aacute;ticas. Assim, a recomenda&ccedil;&atilde;o de manter
    a administra&ccedil;&atilde;o desse antibi&oacute;tico a cada 21 dias, duran
te    a gravidez, com o intuito de prevenir novos surtos reum&aacute;ticos, pode
 representar    um benef&iacute;cio adicional na melhoria da sa&uacute;de oral e
 na preven&ccedil;&atilde;o    da doen&ccedil;a periodontal durante a gravidez.<
/font></p>     ^cY#aop02611.htm##
00752000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704050800085002001300593#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#71#67#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No presente estudo,    a pr
eval&ecirc;ncia da <i>P. gingivalis</i> nas amostras de saliva nas pacientes    
que tiveram a doen&ccedil;a periodontal corrobora os relatos de Dietrich e Takeu
chi<sup>19</sup>,    que demonstraram ser a <i>P. gingivalis</i> um agente pat&o
acute;geno de forte    virul&ecirc;ncia e que a sua detec&ccedil;&atilde;o deve 
ser utilizada como    indicador cl&iacute;nico para doen&ccedil;a periodontal.</
font></p>     ^cY#aop02611.htm##
00954000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071000085002001300795#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#72#68#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Quanto &agrave;    evolu&cc
edil;&atilde;o obst&eacute;trica, nossos resultados n&atilde;o permitiram    cor
relacionar a doen&ccedil;a periodontal com os efeitos adversos para a gravidez. 
   Embora a literatura tenha chamado a aten&ccedil;&atilde;o para a associa&cced
il;&atilde;o    de doen&ccedil;a periodontal com o baixo peso ao nascer e a prem
aturidade, em    decorr&ecirc;ncia do estado sist&ecirc;mico inflamat&oacute;rio
, ainda n&atilde;o    h&aacute; evid&ecirc;ncias suficientes para permitir a cor
rela&ccedil;&atilde;o    de efeitos da doen&ccedil;a periodontal com desfechos o
bst&eacute;tricos adversos<sup>21</sup>.</font></p>     ^cY#aop02611.htm##
00810000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056600085002001300651#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#73#69#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Por outro lado,    a signif
icativa propor&ccedil;&atilde;o de rec&eacute;m-nascidos de baixo peso    e a me
nor idade gestacional quando do parto, verificadas no grupo de gestantes    reum
&aacute;ticas, s&atilde;o explicadas pelas restri&ccedil;&otilde;es ao d&eacute;
bito    card&iacute;aco materno e ao fluxo placent&aacute;rio, acrescidas da a&c
cedil;&atilde;o    da eventual terap&ecirc;utica com diur&eacute;ticos e betablo
queadores utilizados    nas gestantes reum&aacute;ticas.</font></p>     ^cY#aop0
2611.htm##
00673000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042900085002001300514#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#74#70#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">No &acirc;mbito    materno,
 a aus&ecirc;ncia de complica&ccedil;&otilde;es no ciclo grav&iacute;dico-puerpe
ral    &eacute; atribu&iacute;vel &agrave; n&atilde;o inclus&atilde;o de pacient
es    portadoras de hipertens&atilde;o arterial, diabete melito e outras morbida
des,    aliada ao rigor da assist&ecirc;ncia pr&eacute;-natal multidisciplinar.<
/font></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#75#71#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#76#72#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop02611.htm##
00614000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037000085002001300455#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#77#73#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O estudo cl&iacute;nico-mic
robiol&oacute;gico    da cavidade oral durante a gravidez demonstrou que a frequ
&ecirc;ncia da doen&ccedil;a    periodontal em mulheres portadoras de valvopatia
 reum&aacute;tica n&atilde;o    foi diferente quando comparada &agrave;s gestant
es saud&aacute;veis.</font></p>     ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#78#74#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#79#75#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Agradecimentos</b></font
></p>     ^cY#aop02611.htm##
00469000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022500085002001300310#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#80#76#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A pesquisa teve    apoio fi
nanceiro da Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa do Estado    de S
&atilde;o Paulo (processo 57931-2).</font></p>     ^cY#aop02611.htm##
00625000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038100085002001300466#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#81#77#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&Agrave; equipe    do atend
imento de pr&eacute;-natal do Centro de Sa&uacute;de Geraldo de Paula    Souza d
a Faculdade de Sa&uacute;de P&uacute;blica da Universidade de S&atilde;o    Paul
o pelo apoio &agrave; forma&ccedil;&atilde;o da casu&iacute;stica que incluiu   
 as gestantes saud&aacute;veis.</font></p>     ^cY#aop02611.htm##
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#82#78#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Potencial Conflito    de
 Interesses</b></font></p>     ^cY#aop02611.htm##
00390000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014600085002001300231#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#83#79#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Declaro n&atilde;o    haver
 conflito de interesses pertinentes.</font></p>     ^cY#aop02611.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#84#80#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop02611.htm##
00375000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013100085002001300216#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#85#81#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    foi fi
nanciado pela FAPESP.</font></p>     ^cY#aop02611.htm##
00377000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013300085002001300218#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#86#82#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;o
    Acad&ecirc;mica</b></font></p>     ^cY#aop02611.htm##
00407000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016300085002001300248#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#87#83#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Este artigo &eacute;    par
te de tese de Doutorado de Lilia Timerman pelo Incor.</font></p>     ^cY#aop0261
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#88#84#article#135#<p>&nbsp;<
/p>     ^cY#aop02611.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#89#85#article#135#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop02611.htm##
00583000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032500087002001300412#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#90#86#article#13
5#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Raber-Durl
acher    JE, van Steengergen TJ, Van Der Velden U, de Graaff J, Abracham-Inpijn 
L. Experimental    gingivitis during pregnancy and post-partum: clinical, endocr
inological and    microbiological aspects. J Clin Periodontal. 1994;21(8):549-58
.    ^cY#aop02611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#91#87#article#135#</font></p
>     ^cY#aop02611.htm##
00478000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022000087002001300307#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#92#88#article#13
5#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Abegg C. O
ral    hygiene habits among Brazilian adults in an urban area of southern Brazil
. Rev    Sa&uacute;de P&uacute;blica. 1997;31(6):586-93.    ^cY#aop02611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#93#89#article#135#</font></p
>     ^cY#aop02611.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704020400087002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#94#90#article#13
5#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Gjermo P, 
Rosing    CK, Susin C, Oppermann R. Periodontal diseases in Central and South Am
erica.    Periodontol 2000;2002;29:70-8.    ^cY#aop02611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#95#91#article#135#</font></p
>     ^cY#aop02611.htm##
00641000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704038300087002001300470#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#96#92#article#13
5#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Sanz M, La
u    L, Herrera D, Morillo JM, Silva A. Methods of detection of Actinobacillus a
ctinomycetemcomitans,    Porphyromonas gingivalis and Tannerella forsythensis in
 periodontal microbiology,    with special emphasis on advanced molecular techni
ques: a review. J Clin Periodontol.    2004;31(12):1034-47.    ^cY#aop02611.htm#
#
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#97#93#article#135#</font></p
>     ^cY#aop02611.htm##
00464000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704020600087002001300293#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#98#94#article#13
5#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Mombelli A
.    Periodontitis as an infectious disease: specific features and their implica
tions.    Oral Dis. 2003;9(Suppl. 1):6-10.    ^cY#aop02611.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#99#95#article#135#</font></p
>     ^cY#aop02611.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704027300088002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#100#96#article#1
35#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Agueda A,
 Ramon    JM, Manau C, Guerrero A, Echeverria JJ. Periodontal disease as a risk 
factor    for adverse pregnancy outcomes: a prospective cohort study. J Clin Per
iodontol.    2008;35(1):16-22.    ^cY#aop02611.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#101#97#article#135#</font></
p>     ^cY#aop02611.htm##
00611000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704035200088002001300440#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#102#98#article#1
35#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Tonetti M
S,    Claffey N. Advances in the progression of periodontitis and proposal of de
finitions    of a periodontitis case and disease progression for use in risk fac
tor research.    In: 5th European Workshop in Periodontology. J Clin Periodontol
. 2005;32(Suppl.    6):210-3.    ^cY#aop02611.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#103#99#article#135#</font></
p>     ^cY#aop02611.htm##
00568000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030800089002001300397#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#104#100#article#
135#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Ashimoto
 A,    Chen C, Bakker I, Slots J. Polymerase chain reaction detection of 8 putat
ive    periodontal pathogens in subgingival plaque of gingivitis and advanced pe
riodontitis    lesions. Oral Microbiol Immunol. 1996;11(4):266-73.    ^cY#aop026
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#105#101#article#135#</font><
/p>     ^cY#aop02611.htm##
00481000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704022100089002001300310#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#106#102#article#
135#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Kinane D
F PM,    Peterson M, Stathopoulou PG. Environment and other modifying factors of
 the    periodontal disease. J Periodontol. 2006;40:107-19.    ^cY#aop02611.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#107#103#article#135#</font><
/p>     ^cY#aop02611.htm##
00521000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026000090002001300350#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#108#104#article#
135#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Yalcin
 FEE,    Soydinc M, Basegmez C, Issever H, Isik G, Berber L, et al. The effect o
f sociocultural    status on periodontal conditions in pregnancy. J Periodontol.
 2002;73(2):178-82.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#109#105#article#135#</font><
/p>     ^cY#aop02611.htm##
00426000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704016500090002001300255#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#110#106#article#
135#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Bogges
s, KA.    Maternal oral healthy in pregnancy. Obstetric Gynecol. 2008;111(4):976
-86.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#111#107#article#135#</font><
/p>     ^cY#aop02611.htm##
00457000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019600090002001300286#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#112#108#article#
135#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Oliver
 RC,    Brown LJ, Loe H. Periodontal diseases in the United States population. J
 Periodontol.    1998;69(2):269-78.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#113#109#article#135#</font><
/p>     ^cY#aop02611.htm##
00544000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028300090002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#114#110#article#
135#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Dietri
ch T,    Jimenez M, Krall Kaye EA, Vokonas PS, Garcia RI. Age-dependent associat
ions    between chronic periodontitis/edentulism and risk of coronary heart dise
ase.    Circulation. 2008;117(13):1668-74.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#115#111#article#135#</font><
/p>     ^cY#aop02611.htm##
00434000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704017300090002001300263#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#116#112#article#
135#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Haber 
J, Kent    RL. Cigarette smoking in a periodontal practice. J Periodontol. 1992;
63(2):100-6.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#117#113#article#135#</font><
/p>     ^cY#aop02611.htm##
00446000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018500090002001300275#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#118#114#article#
135#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Kinane
 DF,    Chestnutt IG. Relationship of diabetes to periodontitis. Curr Opin Perio
dontol.    1997;4:29-34.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#119#115#article#135#</font><
/p>     ^cY#aop02611.htm##
00450000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018900090002001300279#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#120#116#article#
135#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Hull M
W, Chow    AW. An approach to oral infections and their management. Curr Infect 
Dis Rep.    2005;7(1):17-27.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#121#117#article#135#</font><
/p>     ^cY#aop02611.htm##
00478000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704021700090002001300307#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#122#118#article#
135#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Holmst
rup P,    Poulsen AH, Andersen L, Skuldbol T, Fiehn NE. Oral infections and syst
emic diseases.    Dent Clin North Am. 2003;47(3):575-98.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#123#119#article#135#</font><
/p>     ^cY#aop02611.htm##
00444000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018300090002001300273#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#124#120#article#
135#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Darvea
u RJP,    Tanner A, Page RC. The microbial challenge in periodontitis. Periodont
ol 2000;1997;14:12-32.    ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#125#121#article#135#</font><
/p>     ^cY#aop02611.htm##
00579000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031800090002001300408#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#126#122#article#
135#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Takeuc
hi Y,    Umeda M, Sakamoto M, Benno Y, Huang Y, Ishikawa I. Treponema socranskii
, Treponema    denticola, and Porphyromonas gingivalis are associated with sever
ity of periodontal    tissue destruction. J Periodontol. 2001;72(10):1354-63.   
 ^cY#aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#127#123#article#135#</font><
/p>     ^cY#aop02611.htm##
00643000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704038200090002001300472#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#128#124#article#
135#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Yano-H
iguchi    K, Takamatsu N, He T, Umeda M, Ishikawa I. Prevalence of Bacteroides f
orsythus,    Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans i
n subgingival    microflora of Japanese patients with adult and rapidly progress
ive periodontitis.    J Clin Periodontol. 2000;27(8):597-602.    ^cY#aop02611.ht
m##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#129#125#article#135#</font><
/p>     ^cY#aop02611.htm##
00494000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023300090002001300323#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#130#126#article#
135#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Xiong 
X, Buekens    P, Fraser WD, Beck J, Offenbacher J. Periodontal disease and adver
se pregnancy    outcomes: a systematic review. BJOG. 2006;113(2):135-43.    ^cY#
aop02611.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#131#127#article#135#</font><
/p>     ^cY#aop02611.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#132#128#article#135#<p>&nbsp
;</p>     ^cY#aop02611.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#133#129#article#135#<p>&nbsp
;</p>     ^cY#aop02611.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#134#130#article#135#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop02611.htm##
00294000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004800087002001300135#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#135#131#article#135#<br>   <
/b> Walkiria Samuel &Aacute;vila    ^cY#aop02611.htm##
00298000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005200087002001300139#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#136#132#article#135#<br>   R
ua Apiac&aacute;s, 688/31 - Perdizes    ^cY#aop02611.htm##
00302000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005600087002001300143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#137#133#article#135#<br>   0
5017-020 - S&atilde;o Paulo, SP - Brasil    ^cY#aop02611.htm##
00405000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704015900087002001300246#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#138#134#article#135#<br>   E
-mail: <a href="mailto:wsavila@cardiol.br">wsavila@cardiol.br</a>, <a href="mail
to:walkiria@incor.usp.br">walkiria@incor.usp.br</a></font></p>     ^cY#aop02611.
htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02611.htm#S#p#139#135#article#135#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 24/
02/10; revisado recebido em 26/07/10; aceito em 28/07/10.</font></p>     ^cY#aop
02611.htm##
00706000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100026000860100026001120100
02400138010001900162010002500181012011700206030001900323710000200342065000900344
064000500353031000300358032000200361014000700363865000900370002001300379#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#140#1#article#21#1#^
rND^sRaber-Durlacher^nJE#^rND^svan Steengergen^nTJ#^rND^sVan Der Velden^nU#^rND^
sde Graaff^nJ#^rND^sAbracham-Inpijn^nL#Experimental gingivitis during pregnancy 
and post-partum: clinical, endocrinological and microbiological aspects^len#J Cl
in Periodontal#2#19940000#1994#21#8#549-58#20110000#aop02611.htm##
00518000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860120083001010300
01800184710000200202065000900204064000500213031000300218032000200221014000700223
865000900230002001300239#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02
611.htm#S#c#141#2#article#21#2#^rND^sAbegg^nC#Oral hygiene habits among Brazilia
n adults in an urban area of southern Brazil^len#Rev Saúde Pública#2#19970000#19
97#31#6#586-93#20110000#aop02611.htm##
00593000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100017001020100
01500119010001900134012005400153030001200207710000200219065000900221064000500230
065000900235064000500244031000300249014000500252865000900257002001300266#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#142#3#article#21#3#^
rND^sGjermo^nP#^rND^sRosing^nCK#^rND^sSusin^nC#^rND^sOppermann^nR#Periodontal di
seases in Central and South America^len#Periodontol#2#20000000#2000#20020000#200
2#29#70-8#20110000#aop02611.htm##
00800000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100014000860100013001000100
01700113010001800130010001500148012021300163030001900376065000900395064000500404
03100030040903200030041201400080041586500090042300200130043203500100044580100190
0455#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#143#4#ar
ticle#21#4#^rND^sSanz^nM#^rND^sLau^nL#^rND^sHerrera^nD#^rND^sMorillo^nJM#^rND^sS
ilva^nA#Methods of detection of Actinobacillus actinomycetemcomitans, Porphyromo
nas gingivalis and Tannerella forsythensis in periodontal microbiology, with spe
cial emphasis on advanced molecular techniques: a review^len#J Clin Periodontol#
20040000#2004#31#12#1034-47#20110000#aop02611.htm#0303-6979#J Clin Periodontol##
00542000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860120085001040300
00900189065000900198064000500207031000200212032000400214014000500218865000900223
002001300232035001000245801000900255#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02611.htm#S#c#144#5#article#21#5#^rND^sMombelli^nA#Periodontitis as an
 infectious disease: specific features and their implications^len#Oral Dis#20030
000#2003#9#^s1#6-10#20110000#aop02611.htm#1354-523X#Oral Dis##
00693000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020100
01500118010001800133010002100151012010000172030001900272065000900291064000500300
03100030030503200020030801400060031086500090031600200130032503500100033880100190
0348#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#145#6#ar
ticle#21#6#^rND^sAgueda^nA#^rND^sRamon^nJM#^rND^sManau^nC#^rND^sGuerrero^nA#^rND
^sEcheverria^nJJ#Periodontal disease as a risk factor for adverse pregnancy outc
omes: a prospective cohort study^len#J Clin Periodontol#20080000#2008#35#1#16-22
#20110000#aop02611.htm#0303-6979#J Clin Periodontol##
00667000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100017001040120
15700121030006000278710000200338065000900340064000500349031000300354032000400357
014000600361865000900367002001300376#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02611.htm#S#c#146#7#article#21#7#^rND^sTonetti^nMS#^rND^sClaffey^nN#Ad
vances in the progression of periodontitis and proposal of definitions of a peri
odontitis case and disease progression for use in risk factor research^len#5th E
uropean Workshop in Periodontology. J Clin Periodontol#2#20050000#2005#32#^s6#21
0-3#20110000#aop02611.htm##
00714000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100014001040100
01600118010001500134012014700149030002300296065000900319064000500328031000300333
032000200336014000700338865000900345002001300354035001000367801002300377#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#147#8#article#21#8#^
rND^sAshimoto^nA#^rND^sChen^nC#^rND^sBakker^nI#^rND^sSlots^nJ#Polymerase chain r
eaction detection of 8 putative periodontal pathogens in subgingival plaque of g
ingivitis and advanced periodontitis lesions^len#Oral Microbiol Immunol#19960000
#1996#11#4#266-73#20110000#aop02611.htm#0902-0055#Oral Microbiol Immunol##
00592000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100018001060100
02300124012007100147030001400218065000900232064000500241031000300246014000700249
865000900256002001300265035001000278801001400288#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02611.htm#S#c#148#9#article#21#9#^rND^sKinane DF^nPM#^rND^
sPeterson^nM#^rND^sStathopoulou^nPG#Environment and other modifying factors of t
he periodontal disease^len#J Periodontol#20060000#2006#40#107-19#20110000#aop026
11.htm#0022-3492#J Periodontol##
00708000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01800123010001700141010001400158010001600172810000600188012007800194030001400272
06500090028606400050029503100030030003200020030301400070030586500090031200200130
0321035001000334801001400344#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02611.htm#S#c#149#10#article#21#10#^rND^sYalcin^nFEE#^rND^sSoydinc^nM#^rND^sBa
segmez^nC#^rND^sIssever^nH#^rND^sIsik^nG#^rND^sBerber^nL#et al#The effect of soc
iocultural status on periodontal conditions in pregnancy^len#J Periodontol#20020
000#2002#73#2#178-82#20110000#aop02611.htm#0022-3492#J Periodontol##
00481000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880120039001070300
01800146710000200164065000900166064000500175031000400180032000200184014000700186
865000900193002001300202#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02
611.htm#S#c#150#11#article#21#11#^rND^sBoggess^nKA.#Maternal oral healthy in pre
gnancy^len#Obstetric Gynecol#2#20080000#2008#111#4#976-86#20110000#aop02611.htm#
#
00579000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01300121012005700134030001400191065000900205064000500214031000300219032000200222
014000700224865000900231002001300240035001000253801001400263#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02611.htm#S#c#151#12#article#21#12#^rND^sOlive
r^nRC#^rND^sBrown^nLJ#^rND^sLoe^nH#Periodontal diseases in the United States pop
ulation^len#J Periodontol#19980000#1998#69#2#269-78#20110000#aop02611.htm#0022-3
492#J Periodontol##
00697000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
02100123010001800144010001700162012010700179030001200286065000900298064000500307
03100040031203200030031601400080031986500090032700200130033603500100034980100120
0359#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#152#13#a
rticle#21#13#^rND^sDietrich^nT#^rND^sJimenez^nM#^rND^sKrall Kaye^nEA#^rND^sVokon
as^nPS#^rND^sGarcia^nRI#Age-dependent associations between chronic periodontitis
/edentulism and risk of coronary heart disease^len#Circulation#20080000#2008#117
#13#1668-74#20110000#aop02611.htm#0009-7322#Circulation##
00541000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030120
04800118030001400166065000900180064000500189031000300194032000200197014000600199
865000900205002001300214035001000227801001400237#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02611.htm#S#c#153#14#article#21#14#^rND^sHaber^nJ#^rND^sKe
nt^nRL#Cigarette smoking in a periodontal practice^len#J Periodontol#19920000#19
92#63#2#100-6#20110000#aop02611.htm#0022-3492#J Periodontol##
00547000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100020001050120
04600125030002200171065000900193064000500202031000200207014000600209865000900215
002001300224035001000237801002200247#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02611.htm#S#c#154#15#article#21#15#^rND^sKinane^nDF#^rND^sChestnutt^nI
G#Relationship of diabetes to periodontitis^len#Curr Opin Periodontol#19970000#1
997#4#29-34#20110000#aop02611.htm#1065-626X#Curr Opin Periodontol##
00520000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030120
05600118030002000174710000200194065000900196064000500205031000200210032000200212
014000600214865000900220002001300229#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02611.htm#S#c#155#16#article#21#16#^rND^sHull^nMW#^rND^sChow^nAW#An ap
proach to oral infections and their management^len#Curr Infect Dis Rep#2#2005000
0#2005#7#1#17-27#20110000#aop02611.htm##
00641000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01800125010001800143010001600161012004200177030001900219065000900238064000500247
03100030025203200020025501400070025786500090026400200130027303500100028680100190
0296#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#156#17#a
rticle#21#17#^rND^sHolmstrup^nP#^rND^sPoulsen^nAH#^rND^sAndersen^nL#^rND^sSkuldb
ol^nT#^rND^sFiehn^nNE#Oral infections and systemic diseases^len#Dent Clin North 
Am#20030000#2003#47#3#575-98#20110000#aop02611.htm#0011-8532#Dent Clin North Am#
#
00558000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01500123012004500138030001200183710000200195065000900197064000500206065000900211
064000500220031000300225014000600228865000900234002001300243#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02611.htm#S#c#157#18#article#21#18#^rND^sDarve
au^nRJP#^rND^sTanner^nA#^rND^sPage^nRC#The microbial challenge in periodontitis^
len#Periodontol#2#20000000#2000#19970000#1997#14#12-32#20110000#aop02611.htm##
00752000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01800121010001500139010001500154010001800169012013900187030001400326065000900340
06400050034903100030035403200030035701400080036086500090036800200130037703500100
0390801001400400#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#
S#c#158#19#article#21#19#^rND^sTakeuchi^nY#^rND^sUmeda^nM#^rND^sSakamoto^nM#^rND
^sBenno^nY#^rND^sHuang^nY#^rND^sIshikawa^nI#Treponema socranskii, Treponema dent
icola, and Porphyromonas gingivalis are associated with severity of periodontal 
tissue destruction^len#J Periodontol#20010000#2001#72#10#1354-63#20110000#aop026
11.htm#0022-3492#J Periodontol##
00800000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880100019001100100
01200129010001500141010001800156012020300174030001900377065000900396064000500405
03100030041003200020041301400080041586500090042300200130043203500100044580100190
0455#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#159#20#a
rticle#21#20#^rND^sYano-Higuchi^nK#^rND^sTakamatsu^nN#^rND^sHe^nT#^rND^sUmeda^nM
#^rND^sIshikawa^nI#Prevalence of Bacteroides forsythus, Porphyromonas gingivalis
 and Actinobacillus actinomycetemcomitans in subgingival microflora of Japanese 
patients with adult and rapidly progressive periodontitis^len#J Clin Periodontol
#20000000#2000#27#8#597-602#20110000#aop02611.htm#0303-6979#J Clin Periodontol##
00618000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01700120010001400137010002100151012007600172030000500248710000200253065000900255
064000500264031000400269032000200273014000700275865000900282002001300291#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02611.htm#S#c#160#21#article#21#21
#^rND^sXiong^nX#^rND^sBuekens^nP#^rND^sFraser^nWD#^rND^sBeck^nJ#^rND^sOffenbache
r^nJ#Periodontal disease and adverse pregnancy outcomes: a systematic review^len
#BJOG#2#20060000#2006#113#2#135-43#20110000#aop02611.htm##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#o#1#1#
article#1#20110331#081023#aop02711.htm#157##
05723000000000769000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801201030
01770120101002800100024003810100028004050100022004330100025004550100022004800100
02900502010003000531070006400561070007100625070003100696070006800727070006300795
07000570085808318600091508500080277508500340278308500350281708500400285208500350
28920850061029270831691029880850008046790850027046870850032047140850038047460850
03204784085005904816117000804875072000304883112000904886111000904895116000904904
115000904913114000904922113000904931002001304940#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02711.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#33#n
d#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#Desfechos clín
icos por região geográfica em pacientes com implante de stent eluidor de Zotarol
imus^lpt#Clinical outcomes by geographic region for patients implanted with the 
zotarolimus-eluting stent^len#^rND^1A01^nChaim^sLotan#^rND^1A02^nIan T.^sMeredit
h#^rND^1A03^nAjay^sJain#^rND^1A04^nFausto^sFeres#^rND^1A05^nA.^sFirszt#^rND^1A06
^nA. Frutos^sGarcia#^rND^1A03^nMartin T.^sRothman#Hadassah-Hebrew University Med
ical Centre^iA01^1Heart Institute#Monash University^iA02^1Monash Heart Medical C
entre^cJerusalem^pIsrael#The London Chest Hospital^iA03#Instituto Dante Pazzanes
e de Cardiologia^iA04^cLondres^pReino Unido#Instituto Nacional de Cirugia Cardia
ca^iA05^cSão Paulo^pBrasil#Hospital de San Juan de Alicante^iA06^cAlicante^pEspa
nha#^lpt^aFUNDAMENTO: Diferenças entre regiões geográficas em relação à caracter
ísticas de pacientes e desfechos, particularmente em síndromes coronarianas agud
as, tem sido demonstradas em testes clínicos. Os desfechos clínicos após interve
nções coronarianas percutâneas com o stent eluidor de Zotarolimus em uma populaç
ão real foram analisados com o tempo. OBJETIVO: A influência da localização geog
ráfica sobre os desfechos clínicos com o stent eluidor de Zotarolimus foi avalia
da em três regiões: Pacífico Asiático, Europa e América Latina. MÉTODOS: Um tota
l de 8.314 pacientes (6.572 da Europa, 1.522 do Pacífico Asiático e 220 da Améri
ca Latina) foram acompanhados por 1 ano; 2.116 desses (1.613, 316, e 187, respec
tivamente) foram acompanhados por 2 anos. Características dos pacientes e lesões
, terapia antiplaquetária dupla e desfechos clínicos foram comparados entre a Am
érica Latina e as outras duas regiões. RESULTADOS: Os pacientes da América Latin
a apresentavam a maior proporção de fatores de risco e infarto do miocárdio prév
io. O uso da terapia antiplaquetária dupla declinou rapidamente na América Latin
a, de 44,9% em 6 meses para 22,5% em 1 ano e 7,8% em 2 anos (Europa: 87,4%, 61,5
%, 19,7%; Pacífico Asiático: 82,4%, 67,0%, 45,7%, respectivamente). Não houve di
ferenças significantes entre a América Latina e a Europa ou Pacífico Asiático pa
ra qualquer desfecho em qualquer ponto do tempo. A incidência de trombose de ste
nt provável e definitiva pelo Academic Research Consortium foi baixa (<1,2%) ent
re todos os pacientes em 1 ano e 2 anos. CONCLUSÃO: Os desfechos clínicos foram 
comparáveis entre os pacientes da América Latina e Europa, e América Latina e Pa
cífico Asiático, a despeito dos subgrupos clínicos menos favoráveis na América L
atina, perfil de risco mais elevado e menor uso acentuado de terapia antiplaquet
ária dupla com o tempo.#^dnd^i1#^tm^lpt^kStents farmacológicos^i1#^tm^lpt^kestud
os multicêntricos^i1#^tm^lpt^koclusão de enxerto vascular^i1#^tm^lpt^kreestenose
 coronariana^i1#^tm^lpt^kangioplastia transluminal percutânea coronariana^i1#^le
n^aBACKGROUND: Differences between geographic regions in patient characteristics
 and outcomes, particularly for acute coronary syndromes, have been demonstrated
 in clinical trials. Clinical outcomes after percutaneous coronary interventions
 with the Zotarolimus-eluting stent in a real-world population were assessed ove
r time. OBJECTIVE: The influence of geographic location on clinical outcomes wit
h the Zotarolimus-eluting stent was assessed in 3 regions: Asia Pacific, Europe,
 and Latin America. METHODS: A total of 8,314 patients (6,572 Europe, 1,522 Asia
 Pacific, and 220 Latin America) were followed for 1 year; 2,116 of these (1,613
, 316, and 187, respectively) were followed for 2 years. Patient and lesion char
acteristics, dual antiplatelet therapy, and clinical outcomes were compared betw
een Latin America and the other regions. RESULTS: Patients in Latin America had 
the highest proportions of risk factors and prior myocardial infarction. Dual an
tiplatelet therapy usage rapidly declined in Latin America, from 44.9% at 6 mont
hs to 22.5% at 1 year and 7.8% at 2 years (Europe: 87.4%, 61.5%, 19.7%; Asia Pac
ific: 82.4%, 67.0%, 45.7%). There were no significant differences between Latin 
America and Europe or Asia Pacific for any outcome at either time point. The inc
idence of Academic Research Consortium definite and probable stent thrombosis wa
s low (<1.2%) among all patients at 1 year and 2 years. CONCLUSION: Clinical out
comes were comparable between patients in Latin America and Europe, and Latin Am
erica and Asia Pacific, despite less favorable clinical subsets in Latin America
, a higher risk profile, and markedly lower use of dual antiplatelet therapy ove
r time.#^dnd^i2#^tm^len^kEluting stents^i2#^tm^len^kmulticenter studies^i2#^tm^l
en^kcraft occlusion, vascular^i2#^tm^len^kcoronary restenosis^i2#^tm^len^kangiop
lasty transluminal percutaneous coronary^i2#vancouv#11#20100826#26/08/10#2010082
6#26/08/10#20101004#04/10/10#aop02711.htm##
05869000000000769000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801201170
01770120108002940100024004020100028004260100022004540100025004760100022005010100
02900523010003000552070006400582070007100646070003100717070006800748070006300816
07000570087908319330093608500080286908500410287708500350291808500400295308500350
29930850061030280831736030890850008048250850027048330850032048600850038048920850
03204930085005904962117000805021072000305029112000905032111000905041116000905050
115000905059114000905068113000905077002001305086#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02711.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#33#n
d#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#<b>Desfechos c
línicos por região geográfica em pacientes com implante de <i>stent</i> eluidor 
de Zotarolimus</b>^lpt#<b>Clinical outcomes by geographic region for patients im
planted with the zotarolimus-eluting stent</b>^len#^rND^1A01^nChaim^sLotan#^rND^
1A02^nIan T.^sMeredith#^rND^1A03^nAjay^sJain#^rND^1A04^nFausto^sFeres#^rND^1A05^
nA.^sFirszt#^rND^1A06^nA. Frutos^sGarcia#^rND^1A03^nMartin T.^sRothman#Hadassah-
Hebrew University Medical Centre^iA01^1Heart Institute#Monash University^iA02^1M
onash Heart Medical Centre^cJerusalem^pIsrael#The London Chest Hospital^iA03#Ins
tituto Dante Pazzanese de Cardiologia^iA04^cLondres^pReino Unido#Instituto Nacio
nal de Cirugia Cardiaca^iA05^cSão Paulo^pBrasil#Hospital de San Juan de Alicante
^iA06^cAlicante^pEspanha#^lpt^a<b>FUNDAMENTO: </b>Diferenças entre regiões geogr
áficas em relação à características de pacientes e desfechos, particularmente em
 síndromes coronarianas agudas, tem sido demonstradas em testes clínicos. Os des
fechos clínicos após intervenções coronarianas percutâneas com o <i>stent</i> el
uidor de Zotarolimus em uma população real foram analisados com o tempo. <b>OBJE
TIVO:</b> A influência da localização geográfica sobre os desfechos clínicos com
 o <i>stent</i> eluidor de Zotarolimus foi avaliada em três regiões: Pacífico As
iático, Europa e América Latina. <b>MÉTODOS:</b> Um total de 8.314 pacientes (6.
572 da Europa, 1.522 do Pacífico Asiático e 220 da América Latina) foram acompan
hados por 1 ano; 2.116 desses (1.613, 316, e 187, respectivamente) foram acompan
hados por 2 anos. Características dos pacientes e lesões, terapia antiplaquetári
a dupla e desfechos clínicos foram comparados entre a América Latina e as outras
 duas regiões. <b>RESULTADOS: </b>Os pacientes da América Latina apresentavam a 
maior proporção de fatores de risco e infarto do miocárdio prévio. O uso da tera
pia antiplaquetária dupla declinou rapidamente na América Latina, de 44,9% em 6 
meses para 22,5% em 1 ano e 7,8% em 2 anos (Europa: 87,4%, 61,5%, 19,7%; Pacífic
o Asiático: 82,4%, 67,0%, 45,7%, respectivamente). Não houve diferenças signific
antes entre a América Latina e a Europa ou Pacífico Asiático para qualquer desfe
cho em qualquer ponto do tempo. A incidência de trombose de <i>stent</i> prováve
l e definitiva pelo <i>Academic Research Consortium</i> foi baixa (<u>&lt;</u>1,
2%) entre todos os pacientes em 1 ano e 2 anos. <b>CONCLUSÃO: </b>Os desfechos c
línicos foram comparáveis entre os pacientes da América Latina e Europa, e Améri
ca Latina e Pacífico Asiático, a despeito dos subgrupos clínicos menos favorávei
s na América Latina, perfil de risco mais elevado e menor uso acentuado de terap
ia antiplaquetária dupla com o tempo.#^dnd^i1#^tm^lpt^k<i>Stents</i> farmacológi
cos^i1#^tm^lpt^kestudos multicêntricos^i1#^tm^lpt^koclusão de enxerto vascular^i
1#^tm^lpt^kreestenose coronariana^i1#^tm^lpt^kangioplastia transluminal percutân
ea coronariana^i1#^len^a<b>BACKGROUND:</b> Differences between geographic region
s in patient characteristics and outcomes, particularly for acute coronary syndr
omes, have been demonstrated in clinical trials. Clinical outcomes after percuta
neous coronary interventions with the Zotarolimus-eluting stent in a real-world 
population were assessed over time. <b>OBJECTIVE:</b> The influence of geographi
c location on clinical outcomes with the Zotarolimus-eluting stent was assessed 
in 3 regions: Asia Pacific, Europe, and Latin America. <b>METHODS:</b> A total o
f 8,314 patients (6,572 Europe, 1,522 Asia Pacific, and 220 Latin America) were 
followed for 1 year; 2,116 of these (1,613, 316, and 187, respectively) were fol
lowed for 2 years. Patient and lesion characteristics, dual antiplatelet therapy
, and clinical outcomes were compared between Latin America and the other region
s. <b>RESULTS:</b> Patients in Latin America had the highest proportions of risk
 factors and prior myocardial infarction. Dual antiplatelet therapy usage rapidl
y declined in Latin America, from 44.9% at 6 months to 22.5% at 1 year and 7.8% 
at 2 years (Europe: 87.4%, 61.5%, 19.7%; Asia Pacific: 82.4%, 67.0%, 45.7%). The
re were no significant differences between Latin America and Europe or Asia Paci
fic for any outcome at either time point. The incidence of Academic Research Con
sortium definite and probable stent thrombosis was low (<u>&lt;</u>1.2%) among a
ll patients at 1 year and 2 years. <b>CONCLUSION:</b> Clinical outcomes were com
parable between patients in Latin America and Europe, and Latin America and Asia
 Pacific, despite less favorable clinical subsets in Latin America, a higher ris
k profile, and markedly lower use of dual antiplatelet therapy over time.#^dnd^i
2#^tm^len^kEluting stents^i2#^tm^len^kmulticenter studies^i2#^tm^len^kcraft occl
usion, vascular^i2#^tm^len^kcoronary restenosis^i2#^tm^len^kangioplasty translum
inal percutaneous coronary^i2#vancouv#11#20100826#26/08/10#20100826#26/08/10#201
01004#04/10/10#aop02711.htm##
06011000000000793000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106038000400110121000300114049000300117
15800030012003000190012303200060014206500090014801400070015703500100016422300090
01740120103001830120101002860100024003870100027004110100022004380100025004600100
02100485010002900506010002900535070006600564070007300630070003300703070007000736
07000650080607000590087108319500093008500080288008500340288808500350292208500400
29570850035029970850061030320831761030930850008048540850027048620850032048890850
03804921085003204959085005904991117000805050072000305058112000905061111000905070
116000905079115000905088114000905097113000905106002001305115008008905128#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#l#4#1#article#1#^a2011
#oa#pt#br1.1#1#4.0#gra#tab#33#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#006
6-782X#20110401#Desfechos clínicos por região geográfica em pacientes com implan
te de stent eluidor de Zotarolimus^lpt#Clinical outcomes by geographic region fo
r patients implanted with the zotarolimus-eluting stent^len#^rND^1A01^nChaim^sLo
tan#^rND^1A02^nIan T^sMeredith#^rND^1A03^nAjay^sJain#^rND^1A04^nFausto^sFeres#^r
ND^1A05^nA^sFirszt#^rND^1A06^nA. Frutos^sGarcia#^rND^1A03^nMartin T^sRothman#^iA
01^1Hadassah-Hebrew University Medical Centre^2Heart Institute#^iA02^1Monash Uni
versity^2Monash Heart Medical Centre^cJerusalem^pIsrael#^iA03^1The London Chest 
Hospital#^iA04^1Instituto Dante Pazzanese de Cardiologia^cLondres^pReino Unido#^
iA05^1Instituto Nacional de Cirugia Cardiaca^cSão Paulo^pBrasil#^iA06^1Hospital 
de San Juan de Alicante^cAlicante^pEspanha#^lpt^aFUNDAMENTO: Diferenças entre re
giões geográficas em relação à características de pacientes e desfechos, particu
larmente em síndromes coronarianas agudas, tem sido demonstradas em testes clíni
cos. Os desfechos clínicos após intervenções coronarianas percutâneas com o sten
t eluidor de Zotarolimus em uma população real foram analisados com o tempo. OBJ
ETIVO: A influência da localização geográfica sobre os desfechos clínicos com o 
stent eluidor de Zotarolimus foi avaliada em três regiões: Pacífico Asiático, Eu
ropa e América Latina. MÉTODOS: Um total de 8.314 pacientes (6.572 da Europa, 1.
522 do Pacífico Asiático e 220 da América Latina) foram acompanhados por 1 ano; 
2.116 desses (1.613, 316, e 187, respectivamente) foram acompanhados por 2 anos.
 Características dos pacientes e lesões, terapia antiplaquetária dupla e desfech
os clínicos foram comparados entre a América Latina e as outras duas regiões. RE
SULTADOS: Os pacientes da América Latina apresentavam a maior proporção de fator
es de risco e infarto do miocárdio prévio. O uso da terapia antiplaquetária dupl
a declinou rapidamente na América Latina, de 44,9 por cento em 6 meses para 22,5
 por cento em 1 ano e 7,8 por cento em 2 anos (Europa: 87,4 por cento, 61,5 por 
cento, 19,7 por cento; Pacífico Asiático: 82,4 por cento, 67,0 por cento, 45,7 p
or cento, respectivamente). Não houve diferenças significantes entre a América L
atina e a Europa ou Pacífico Asiático para qualquer desfecho em qualquer ponto d
o tempo. A incidência de trombose de stent provável e definitiva pelo Academic R
esearch Consortium foi baixa (<1,2 por cento) entre todos os pacientes em 1 ano 
e 2 anos. CONCLUSÃO: Os desfechos clínicos foram comparáveis entre os pacientes 
da América Latina e Europa, e América Latina e Pacífico Asiático, a despeito dos
 subgrupos clínicos menos favoráveis na América Latina, perfil de risco mais ele
vado e menor uso acentuado de terapia antiplaquetária dupla com o tempo.#^dnd^i1
#^tm^lpt^kStents farmacológicos^i1#^tm^lpt^kestudos multicêntricos^i1#^tm^lpt^ko
clusão de enxerto vascular^i1#^tm^lpt^kreestenose coronariana^i1#^tm^lpt^kangiop
lastia transluminal percutânea coronariana^i1#^len^aBACKGROUND: Differences betw
een geographic regions in patient characteristics and outcomes, particularly for
 acute coronary syndromes, have been demonstrated in clinical trials. Clinical o
utcomes after percutaneous coronary interventions with the Zotarolimus-eluting s
tent in a real-world population were assessed over time. OBJECTIVE: The influenc
e of geographic location on clinical outcomes with the Zotarolimus-eluting stent
 was assessed in 3 regions: Asia Pacific, Europe, and Latin America. METHODS: A 
total of 8,314 patients (6,572 Europe, 1,522 Asia Pacific, and 220 Latin America
) were followed for 1 year; 2,116 of these (1,613, 316, and 187, respectively) w
ere followed for 2 years. Patient and lesion characteristics, dual antiplatelet 
therapy, and clinical outcomes were compared between Latin America and the other
 regions. RESULTS: Patients in Latin America had the highest proportions of risk
 factors and prior myocardial infarction. Dual antiplatelet therapy usage rapidl
y declined in Latin America, from 44.9 percent at 6 months to 22.5 percent at 1 
year and 7.8 percent at 2 years (Europe: 87.4 percent, 61.5 percent, 19.7 percen
t; Asia Pacific: 82.4 percent, 67.0 percent, 45.7 percent). There were no signif
icant differences between Latin America and Europe or Asia Pacific for any outco
me at either time point. The incidence of Academic Research Consortium definite 
and probable stent thrombosis was low (<1.2 percent) among all patients at 1 yea
r and 2 years. CONCLUSION: Clinical outcomes were comparable between patients in
 Latin America and Europe, and Latin America and Asia Pacific, despite less favo
rable clinical subsets in Latin America, a higher risk profile, and markedly low
er use of dual antiplatelet therapy over time.#^dnd^i2#^tm^len^kEluting stents^i
2#^tm^len^kmulticenter studies^i2#^tm^len^kcraft occlusion, vascular^i2#^tm^len^
kcoronary restenosis^i2#^tm^len^kangioplasty transluminal percutaneous coronary^
i2#vancouv#11#20100826#26/08/10#20100826#26/08/10#20101004#04/10/10#aop02711.htm
#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011
005000033##
00482000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704024000083002001300323#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#5#1#article#142#<p><a name="
top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Desfecho
s    cl&iacute;nicos por regi&atilde;o geogr&aacute;fica em pacientes com implan
te    de <i>stent</i> eluidor de Zotarolimus</b></font></p>     ^cY#aop02711.htm
##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#6#2#article#142#<p>&nbsp;</p
>     ^cY#aop02711.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#7#3#article#142#<p>&nbsp;</p
>     ^cY#aop02711.htm##
00530000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704028800083002001300371#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#8#4#article#142#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Chaim Lotan<sup>I</sup>;  
  Ian T. Meredith<sup>II</sup>; Ajay Jain<sup>III</sup>; Fausto Feres<sup>IV</su
p>;    A. Firszt<sup>V</sup>; A. Frutos Garcia<sup>VI</sup>; Martin T. Rothman<s
up>III</sup></b></font></p>     ^cY#aop02711.htm##
00386000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704014400083002001300227#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#9#5#article#142#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Heart    Institut
e, Hadassah-Hebrew University Medical Centre    ^cY#aop02711.htm##
00336000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009300084002001300177#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#10#6#article#142#<br>   <sup
>II</sup>Jerusalem, Israel, Monash Heart Medical Centre, Monash University    ^c
Y#aop02711.htm##
00355000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704011200084002001300196#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#11#7#article#142#<br>   <sup
>III</sup>Melbourne, Australia, The London Chest Hospital, Barts, and The    Lon
don NHS Trust    ^cY#aop02711.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009000084002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#12#8#article#142#<br>   <sup
>IV</sup>Londres, Reino Unido, Instituto Dante Pazzanese de Cardiologia    ^cY#a
op02711.htm##
00334000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009100084002001300175#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#13#9#article#142#<br>   <sup
>V</sup>S&atilde;o Paulo, Brasil, Instituto Nacional de Cirugia Cardiaca    ^cY#
aop02711.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011500085002001300200#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#14#10#article#142#<br>   <su
p>VI</sup>Montevideo, Uruguai, Hospital de San Juan de Alicante, Alicante,    Es
panha</font></p>     ^cY#aop02711.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012400085002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#15#11#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&
ecirc;ncia</a></font></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#16#12#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704004400085002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#17#13#article#142#<p>&nbsp;<
/p> <hr size="1" noshade>     ^cY#aop02711.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#18#14#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>   
  ^cY#aop02711.htm##
00806000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056200085002001300647#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#19#15#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>FUNDAMENTO:    </b> Dife
ren&ccedil;as entre regi&otilde;es geogr&aacute;ficas em rela&ccedil;&atilde;o  
  &agrave; caracter&iacute;sticas de pacientes e desfechos, particularmente em  
  s&iacute;ndromes coronarianas agudas, tem sido demonstradas em testes cl&iacut
e;nicos.    Os desfechos cl&iacute;nicos ap&oacute;s interven&ccedil;&otilde;es 
coronarianas    percut&acirc;neas com o <i>stent</i> eluidor de Zotarolimus em u
ma popula&ccedil;&atilde;o    real foram analisados com o tempo.    ^cY#aop02711
.htm##
00535000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704029100085002001300376#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#20#16#article#142#<br>   <b>
OBJETIVO:</b> A influ&ecirc;ncia da localiza&ccedil;&atilde;o geogr&aacute;fica 
   sobre os desfechos cl&iacute;nicos com o <i>stent</i> eluidor de Zotarolimus 
   foi avaliada em tr&ecirc;s regi&otilde;es: Pac&iacute;fico Asi&aacute;tico,  
  Europa e Am&eacute;rica Latina.    ^cY#aop02711.htm##
00725000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048100085002001300566#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#21#17#article#142#<br>   <b>
M&Eacute;TODOS:</b> Um total de 8.314 pacientes (6.572 da Europa, 1.522 do    Pa
c&iacute;fico Asi&aacute;tico e 220 da Am&eacute;rica Latina) foram acompanhados
    por 1 ano; 2.116 desses (1.613, 316, e 187, respectivamente) foram acompanha
dos    por 2 anos. Caracter&iacute;sticas dos pacientes e les&otilde;es, terapia
 antiplaquet&aacute;ria    dupla e desfechos cl&iacute;nicos foram comparados en
tre a Am&eacute;rica Latina    e as outras duas regi&otilde;es.    ^cY#aop02711.
htm##
01070000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704082600085002001300911#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#22#18#article#142#<br>   <b>
RESULTADOS: </b> Os pacientes da Am&eacute;rica Latina apresentavam a maior    p
ropor&ccedil;&atilde;o de fatores de risco e infarto do mioc&aacute;rdio pr&eacu
te;vio.    O uso da terapia antiplaquet&aacute;ria dupla declinou rapidamente na
 Am&eacute;rica    Latina, de 44,9% em 6 meses para 22,5% em 1 ano e 7,8% em 2 a
nos (Europa: 87,4%,    61,5%, 19,7%; Pac&iacute;fico Asi&aacute;tico: 82,4%, 67,
0%, 45,7%, respectivamente).    N&atilde;o houve diferen&ccedil;as significantes
 entre a Am&eacute;rica Latina    e a Europa ou Pac&iacute;fico Asi&aacute;tico 
para qualquer desfecho em qualquer    ponto do tempo. A incid&ecirc;ncia de trom
bose de <i>stent</i> prov&aacute;vel    e definitiva pelo <i>Academic Research C
onsortium</i> foi baixa (<u>&lt;</u>1,2%)    entre todos os pacientes em 1 ano e
 2 anos.    ^cY#aop02711.htm##
00670000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042600085002001300511#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#23#19#article#142#<br>   <b>
CONCLUS&Atilde;O: </b> Os desfechos cl&iacute;nicos foram compar&aacute;veis    
entre os pacientes da Am&eacute;rica Latina e Europa, e Am&eacute;rica Latina   
 e Pac&iacute;fico Asi&aacute;tico, a despeito dos subgrupos cl&iacute;nicos    
menos favor&aacute;veis na Am&eacute;rica Latina, perfil de risco mais elevado  
  e menor uso acentuado de terapia antiplaquet&aacute;ria dupla com o tempo.</fo
nt></p>     ^cY#aop02711.htm##
00564000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032000085002001300405#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#24#20#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
<i>Stents</i> farmacol&oacute;gicos, estudos multic&ecirc;ntricos, oclus&atilde;
o    de enxerto vascular, reestenose coronariana, angioplastia transluminal perc
ut&acirc;nea    coronariana.</font></p> <hr size="1" noshade>     ^cY#aop02711.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#25#21#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#26#22#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#27#23#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Sum&aacute;rio</b></font
></p>     ^cY#aop02711.htm##
01097000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704085300085002001300938#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#28#24#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Resultados do Registro    E
-Five indicam que a localiza&ccedil;&atilde;o geogr&aacute;fica n&atilde;o    af
eta os desfechos cl&iacute;nicos em pacientes tratados com o <i>stent</i>    elu
idor de Zotarolimus. Pacientes na Am&eacute;rica Latina apresentaram a maior    
propor&ccedil;&atilde;o de fatores de risco e infarto do mioc&aacute;rdio pr&eac
ute;vio.    O uso da terapia antiplaquet&aacute;ria dupla declinou rapidamente n
a Am&eacute;rica    Latina, quando comparado &agrave; Europa e Pac&iacute;fico A
si&aacute;tico para    qualquer desfecho em qualquer ponto do tempo. A incid&eci
rc;ncia de trombose    de <i>stent</i> prov&aacute;vel e definitiva pelo <i>Acad
emic Research Consortium</i>    foi baixa (<u>&lt;</u>1,2%) entre todos os pacie
ntes em 1 ano e 2 anos.</font></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#29#25#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#30#26#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop02711.htm##
01607000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704136300085002001301448#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#31#27#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As diferen&ccedil;as    int
ernacionais em rela&ccedil;&atilde;o &agrave; caracter&iacute;sticas de paciente
s    e desfecho cl&iacute;nico tem sido demonstradas em testes cl&iacute;nicos c
ardiovasculares,    especificamente na popula&ccedil;&atilde;o com s&iacute;ndro
me coronariana aguda    (SCA)<sup>1,2</sup>. Em estudos trombol&iacute;ticos, pa
cientes nos Estados    Unidos (EUA) apresentaram tend&ecirc;ncia &agrave; menor 
tempo de tratamento,    classe de Killip mais baixa e maior propor&ccedil;&atild
e;o de infarto mioc&aacute;rdico    (IM) inferior do que pacientes n&atilde;o-or
igin&aacute;rios dos EUA. Em estudos    comparando pacientes da Am&eacute;rica d
o Norte e Europa Oriental, os pacientes    norte-americanos apresentavam maior t
end&ecirc;ncia a ser do sexo masculino    e apresentar menos comorbidades, inclu
indo hipertens&atilde;o, angina, insufici&ecirc;ncia    card&iacute;aca e achado
s eletrocardiogr&aacute;ficos anormais, quando comparados    &agrave;queles orig
in&aacute;rios da Europa Oriental. V&aacute;rios estudos    sobre o IM com eleva
&ccedil;&atilde;o do segmento ST demonstraram maiores taxas    de mortalidade em
 outros pa&iacute;ses que n&atilde;o os EUA, quando comparados    a estes, parti
cularmente na Am&eacute;rica Latina (AL)<sup>1</sup>.</font></p>     ^cY#aop0271
1.htm##
00848000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060400085002001300689#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#32#28#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Poucos dados est&atilde;o  
  dispon&iacute;veis sobre as diferen&ccedil;as internacionais no uso de <i>sten
ts</i>    farmacol&oacute;gicos. Austin e cols.<sup>3</sup> demonstraram uma amp
la varia&ccedil;&atilde;o    na aplica&ccedil;&atilde;o de <i>stents</i> farmaco
l&oacute;gicos em quatro    pa&iacute;ses diferentes (EUA, Canad&aacute;, Reino 
Unido e B&eacute;lgica),    mas n&atilde;o relataram diferen&ccedil;as em rela&c
cedil;&atilde;o &agrave;    caracter&iacute;sticas dos pacientes ou desfechos cl
&iacute;nicos.</font></p>     ^cY#aop02711.htm##
01367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704112300085002001301208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#33#29#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O Registro E-Five,    um gr
ande registro prospectivo, n&atilde;o-randomizado, multic&ecirc;ntrico    e inte
rnacional, avaliou a seguran&ccedil;a e a efic&aacute;cia do <i>stent</i>    elu
idor de Zotarolimus Endeavor (ZES; Medtronic CardioVascular, Santa Rosa,    Cali
f&oacute;rnia, EUA) em pacientes reais com doen&ccedil;a arterial coronariana   
 sintom&aacute;tica submetidos a interven&ccedil;&atilde;o coronariana percut&ac
irc;nea    (ICP)<sup>4</sup>. O tamanho dessa coorte global fornece uma oportuni
dade &uacute;nica    de explorar a exist&ecirc;ncia de diferen&ccedil;as geogr&a
acute;ficas e se    tais diferen&ccedil;as podem influenciar os desfechos cl&iac
ute;nicos em pacientes    submetidos &agrave; ICP e implante de <i>stent</i> for
a dos limites de um estudo    cl&iacute;nico. Al&eacute;m disso, essa coorte per
mite a an&aacute;lise de diferentes    pr&aacute;ticas, geograficamente falando,
 em rela&ccedil;&atilde;o ao uso da    terapia antiplaquet&aacute;ria dupla (DAP
T) e se h&aacute; qualquer impacto    cl&iacute;nico.</font></p>     ^cY#aop0271
1.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#34#30#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#35#31#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&eacute;todos</b></font
></p>     ^cY#aop02711.htm##
00365000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012100085002001300206#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#36#32#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Desenho e objetivo    do
 estudo</b></font></p>     ^cY#aop02711.htm##
01340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704109600085002001301181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#37#33#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O Registro E-Five    &eacut
e; um registro prospectivo, n&atilde;o-randomizado, multic&ecirc;ntrico,    cond
uzido em 37 pa&iacute;ses ao redor do mundo. Para esse estudo, selecionamos    t
r&ecirc;s regi&otilde;es - Pac&iacute;fico Asi&aacute;tico (PA), Uni&atilde;o   
 Europ&eacute;ia (EU) e Am&eacute;rica Latina (AL) - com base na localiza&ccedil
;&atilde;o    f&iacute;sica. Nenhuma tentativa foi feita para assegurar a iguald
ade entre    o n&uacute;mero de pacientes inclu&iacute;dos em cada regi&atilde;o
 ou entre    pa&iacute;ses-membros. Um total de 8.314 pacientes adultos inclu&ia
cute;dos    no estudo, que contou com a participa&ccedil;&atilde;o de 118 centro
s, foi acompanhado    por um ano. Adicionalmente, um subgrupo de 2.116 pacientes
 de 26 centros foi    acompanhado por dois anos. Esses centros foram selecionado
s com base na inclus&atilde;o    e disposi&ccedil;&atilde;o em continuar o segui
mento. Os desfechos foram avaliados    ap&oacute;s 1 ano e 2 anos ap&oacute;s pa
ra as respectivas coortes.</font></p>     ^cY#aop02711.htm##
00982000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073800085002001300823#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#38#34#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As an&aacute;lises    foram
 realizadas para determinar as diferen&ccedil;as nas caracter&iacute;sticas    d
emogr&aacute;ficas e basais entre pacientes de cada regi&atilde;o e a potencial 
   influ&ecirc;ncia dessas diferen&ccedil;as sobre os desfechos cl&iacute;nicos,
    incluindo eventos card&iacute;acos adversos maiores (MACE), morte card&iacut
e;aca,    IM, revasculariza&ccedil;&atilde;o da les&atilde;o-alvo (RLA), revascu
lariza&ccedil;&atilde;o    do vaso-alvo (RVA) e a incid&ecirc;ncia de trombose d
e <i>stent</i> prov&aacute;vel    e definitiva, de acordo com a defini&ccedil;&a
tilde;o do <i>Academic Research    Consortium</i> (ARC)<sup>5</sup>.</font></p> 
    ^cY#aop02711.htm##
00382000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013800085002001300223#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#39#35#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Popula&ccedil;&atilde;o 
   do estudo e protocolo</b></font></p>     ^cY#aop02711.htm##
00654000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041000085002001300495#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#40#36#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O Registro E-Five    cont&e
acute;m dados de pacientes adultos submetidos &agrave; ICP de um &uacute;nico   
 vaso ou multivaso. Pacientes eleg&iacute;veis apresentavam les&otilde;es-alvo  
  apropriadas para interven&ccedil;&atilde;o com <i>stent</i>. Detalhes do proto
colo    do estudo foram relatados anteriormente<sup>4</sup>.</font></p>     ^cY#
aop02711.htm##
00664000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042000085002001300505#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#41#37#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Todos os pacientes    compl
etaram as visitas de acompanhamento na alta hospitalar, em 30 dias, 6 meses    e
 1 ano e os centros selecionados acompanharam pacientes por at&eacute; 2 anos   
 (<a href="#f1">Figura 1</a>). Visitas ambulatoriais foram o meio preferido de  
  acompanhamento, embora contatos telef&ocirc;nicos fossem permitidos.</font></p
>     ^cY#aop02711.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#42#38#article#142#<p><a name
="f1"></a></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#43#39#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#44#40#article#142#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02711f01.jpg"></p>     ^cY#aop
02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#45#41#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
01366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704112200085002001301207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#46#42#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os pa&iacute;ses    inclu&i
acute;dos na regi&atilde;o AL foram Brasil, Chile, M&eacute;xico, e Uruguai.    
A regi&atilde;o PA incluiu Austr&aacute;lia, China, Hong Kong, &Iacute;ndia,    
Cor&eacute;ia, Mal&aacute;sia, Nova Zel&acirc;ndia, Singapura e Tail&acirc;ndia.
    A regi&atilde;o EU incluiu &Aacute;ustria, B&eacute;lgica, Bulg&aacute;ria, 
   Republica Tcheca, Egito, Est&ocirc;nia, Finl&acirc;ndia, Alemanha, Gr&eacute;
cia,    Hungria, Israel, It&aacute;lia, Let&ocirc;nia, Pa&iacute;ses Baixos, Nor
uega,    Pol&ocirc;nia, Portugal, Rom&ecirc;nia, S&eacute;rvia, Eslov&aacute;qui
a, Espanha,    Su&iacute;&ccedil;a, Turquia e o Reino Unido. Esse estudo foi con
duzido sob    as diretrizes &eacute;ticas da Declara&ccedil;&atilde;o de Helsink
i. Antes do    in&iacute;cio da pesquisa em qualquer dos locais de estudo, o mes
mo foi aprovado    por um comit&ecirc; de &eacute;tica m&eacute;dica para proteg
er seres humanos,    dependendo das exig&ecirc;ncias regionais. Consentimento li
vre e informado foi    obtido de todos os pacientes.</font></p>     ^cY#aop02711
.htm##
00375000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013100085002001300216#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#47#43#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descri&ccedil;&atilde;o 
   do dispositivo</b></font></p>     ^cY#aop02711.htm##
01256000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704101200085002001301097#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#48#44#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O Endeavor ZES    (Medtroni
c) consiste em <i>stent</i> de liga de cobalto com exterior recoberto    por pol
&iacute;mero, eluidor do medicamento antiproliferativo Zotarolimus (10    </font
><font size="2">&#956;</font><font face="Verdana, Arial, Helvetica, sans-serif" 
size="2">g/mm    de comprimento de <i>stent</i>). A elui&ccedil;&atilde;o de Zot
arolimus &eacute;    projetada para inibir a prolifera&ccedil;&atilde;o de c&eac
ute;lulas de m&uacute;sculo    liso; o revestimento de pol&iacute;mero de fosfor
ilcolina &eacute; projetado    para simular hem&aacute;cias, dessa forma mimetiz
ando a membrana celular natural<sup>6</sup>.    Essas caracter&iacute;sticas for
am projetadas para reduzir a resposta biol&oacute;gica    t&iacute;pica ao impla
nte de um dispositivo e aumentar a seguran&ccedil;a a    longo prazo. O ZES est&
aacute; dispon&iacute;vel em di&acirc;metros de 2,25    mm a 4,0 mm e em comprim
entos de 8 mm a 30 mm.</font></p>     ^cY#aop02711.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012400085002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#49#45#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Coleta e gerenciamento  
  de dados</b></font></p>     ^cY#aop02711.htm##
00811000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056700085002001300652#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#50#46#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A captura de dados    eletr
&ocirc;nicos atrav&eacute;s de formul&aacute;rios baseados na web foi completada
    em todos os locais do estudo. Para assegurar o controle de qualidade, a moni
toriza&ccedil;&atilde;o    aleat&oacute;ria dos locais do estudo foi conduzida a
 intervalos pr&eacute;-especificados.    Aproximadamente 10% dos dados do estudo
 foram revisados para monitorar ader&ecirc;ncia    e para assegurar relatos prec
isos de eventos, bem como a acur&aacute;cia dos    dados.</font></p>     ^cY#aop
02711.htm##
00734000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049000085002001300575#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#51#47#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os dados designados    para
 coleta basal inclu&iacute;ram crit&eacute;rios de elegibilidade, caracter&iacut
e;sticas    demogr&aacute;ficas, fatores de risco card&iacute;aco, estado card&i
acute;aco    atual, caracter&iacute;sticas da les&atilde;o e resultados da angio
grafia pr&eacute;-procedimento.    Os investigadores conduziram um exame visual 
da les&atilde;o para estimar suas    caracter&iacute;sticas.</font></p>     ^cY#
aop02711.htm##
00750000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704050600085002001300591#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#52#48#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Desfechos cl&iacute;nicos  
  documentados comparados entre as regi&otilde;es inclu&iacute;ram MACE, morte, 
   morte card&iacute;aca, IM, RLA, RVA, RVA (les&atilde;o n&atilde;o-alvo) e fal
ha    do vaso alvo (FVA). O uso da medica&ccedil;&atilde;o antiplaquet&aacute;ri
a    foi documentado ap&oacute;s 30 dias, 6 meses e 1 ano para todos os paciente
s    e ap&oacute;s 2 anos para aqueles inclu&iacute;dos na coorte de 2 anos.</fo
nt></p>     ^cY#aop02711.htm##
00870000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704062600085002001300711#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#53#49#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Eventos como MACE    e trom
bose de <i>stent</i> foram revisados por um comit&ecirc; central de eventos    c
l&iacute;nicos (Cardialysis, Roterd&atilde;, Pa&iacute;ses Baixos). Eventos    d
e trombose de <i>stent</i> foram avaliados usando as defini&ccedil;&otilde;es   
 do <i>Academic Research Consortium</i> (ARC). O gerenciamento de dados para    
esse estudo e a monitoriza&ccedil;&atilde;o do estudo foram completados pela    
equipe do Medtronic CardioVascular ou organiza&ccedil;&atilde;o de pesquisa    c
ontratada, designada pela Medtronic.</font></p>     ^cY#aop02711.htm##
00355000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011100085002001300196#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#54#50#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Desfecho do    estudo</b
></font></p>     ^cY#aop02711.htm##
00645000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040100085002001300486#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#55#51#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O desfecho prim&aacute;rio 
   para o Registro E-Five geral foi a taxa de MACE, definida como morte, IM (Ond
a    Q e sem onda Q), cirurgia de revasculariza&ccedil;&atilde;o emergente ou RL
A    (repeti&ccedil;&atilde;o da ICP ou cirurgia de revasculariza&ccedil;&atilde
;o    do mioc&aacute;rdio &#91;CRM&#93;) em um ano.</font></p>     ^cY#aop02711.
htm##
00751000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704050700085002001300592#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#56#52#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Reportamos aqui    os desfe
chos cl&iacute;nicos de MACE, morte por todas as causas, morte card&iacute;aca, 
   IM, RLA, RVA e FVA ap&oacute;s 1 ano e 2 anos de acompanhamento para cada uma
    das tr&ecirc;s regi&otilde;es. As taxas de trombose de <i>stent</i> prov&aac
ute;vel    e definitiva definidas pelo ARC foram analisadas para eventos precoce
s (0 a    30 dias), tardios (31 a 365 dias) e muito tardios (366 a 730 dias).</f
ont></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#57#53#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00372000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012800085002001300213#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#58#54#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>An&aacute;lises    estat
&iacute;sticas</b></font></p>     ^cY#aop02711.htm##
01634000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704139000085002001301475#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#59#55#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As caracter&iacute;sticas  
  dos pacientes, les&otilde;es e procedimentos foram registradas em cada local  
  do estudo e resumidas por regi&atilde;o para a popula&ccedil;&atilde;o geral  
  em 1 ano e para a coorte de acompanhamento de longo prazo em 2 anos. Porcentag
ens    s&atilde;o relatadas para vari&aacute;veis categ&oacute;ricas e m&eacute;
dias    e desvios-padr&atilde;o para vari&aacute;veis cont&iacute;nuas. A terapi
a antiplaquet&aacute;ria    foi detalhada em 30 dias, 6 meses e 1 ano para todos
 os pacientes e 2 anos para    a coorte menor. Todos os desfechos cl&iacute;nico
s (incluindo MACE, morte por    todas as causas, morte por complica&ccedil;&otil
de;es card&iacute;acas, IM,    RLA, RVA, FVA e trombose de <i>stent</i> prov&aac
ute;vel e definitiva definidas    pelo ARC) foram compilados por regi&atilde;o p
ara todos os pacientes dispon&iacute;veis    nos momentos 1 ano e 2 anos. Embora
 a regi&atilde;o AL tivesse o menor n&uacute;mero    de pacientes, ela represent
ou uma popula&ccedil;&atilde;o especial de pacientes    com maior n&uacute;mero 
de fatores de risco card&iacute;aco e maior taxa de    MI pr&eacute;vios, mas a 
menor dura&ccedil;&atilde;o de uso da DAPT; assim,    utilizamos essa regi&atild
e;o como o comparador de refer&ecirc;ncia para as    outras duas regi&otilde;es.
</font></p>     ^cY#aop02711.htm##
00689000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044500085002001300530#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#60#56#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As vari&aacute;veis    basa
is foram comparadas como se segue: um teste <i>t</i> bilateral foi utilizado    
para calcular valores de p para vari&aacute;veis cont&iacute;nuas e o teste    E
xato de Fisher foi usado para determinar os valores de p para vari&aacute;veis  
  categ&oacute;ricas. Um valor de p &lt; 0,05 foi considerado estatisticamente  
  significante.</font></p>     ^cY#aop02711.htm##
01365000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704112100085002001301206#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#61#57#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A fim de fazer    o ajuste 
para diferen&ccedil;as nas caracter&iacute;sticas basais nas coortes    de 1 ano
 e 2 anos, os desfechos cl&iacute;nicos em 1 ano e 2 anos foram comparados    da
 seguinte forma: valores de p foram baseados em regress&atilde;o log&iacute;stic
a    ajustada para escores de propens&atilde;o, que foram calculados usando as s
eguintes    vari&aacute;veis basais: idade, sexo, MI pr&eacute;vio, angioplastia
 coronariana    transluminal percut&acirc;nea pr&eacute;via, CRM pr&eacute;via, 
diabete, infarto    agudo do mioc&aacute;rdio (&lt; 72 horas), hipertens&atilde;
o, hipercolesterolemia,    tabagismo, art&eacute;ria descendente anterior esquer
da (<i>vs</i> art&eacute;ria    descendente anterior n&atilde;o-esquerda), class
e B2/C (<i>vs</i> classe A/B1),    comprimento de les&atilde;o <u>&gt;</u> 27 mm
 (se qualquer les&atilde;o for    <u>&gt;</u> 27 mm, <i>vs</i> &lt; 27 mm) e di&
acirc;metro do vaso de refer&ecirc;ncia    &gt; 3,5 mm (se qualquer les&atilde;o
 for &gt; 3,5 mm, <i>vs</i> <u>&lt;</u>    3,5 mm).</font></p>     ^cY#aop02711.
htm##
00469000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022500085002001300310#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#62#58#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O Registro E-Five    &eacut
e; financiado pelo Medtronic Bakken Research Center, Medtronic CardioVascular,  
  Maastricht, Pa&iacute;ses Baixos.</font></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#63#59#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#64#60#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Resultados</b></font></p
>     ^cY#aop02711.htm##
00419000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017500085002001300260#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#65#61#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Dados demogr&aacute;fico
s    dos pacientes e caracter&iacute;sticas das les&otilde;es</b></font></p>    
 ^cY#aop02711.htm##
02007000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704176300085002001301848#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#66#62#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Popula&ccedil;&atilde;o 
   geral -</i> a m&eacute;dia da idade de todos os pacientes inclu&iacute;dos no
    Registro E-Five era 63,3 anos. Pacientes na regi&atilde;o EU eram mais velho
s    do que os pacientes na regi&atilde;o AL (64,2 <i>vs</i> 61,3 anos, p &lt; 0
,001)    e pacientes na regi&atilde;o AL eram mais velhos do que n&atilde;o regi
&atilde;o    PA, embora essa diferen&ccedil;a n&atilde;o tenha sido estatisticam
ente significante    (61,3 <i>vs</i> 59,9 anos) (<a href="/img/revistas/abc/2011
nahead/aop02711t01.jpg">Tabela 1</a>).    A maioria dos pacientes em todas as re
gi&otilde;es era do sexo masculino: EU,    76,8%; PA, 77,1%; e AL, 70,0%. As com
orbidades mais comuns eram hipercolesterolemia    e hipertens&atilde;o. A preval
&ecirc;ncia de hipercolesterolemia era significantemente    mais alta na regi&at
ilde;o AL do que na EU (75,0% <i>vs</i> 66.3%, p = 0.007)    e PA (75,0% <i>vs</
i> 47,6%, p &lt; 0,001). A preval&ecirc;ncia de hipertens&atilde;o    era signif
icantemente maior na regi&atilde;o AL do que na PA (76,4% <i>vs</i>    63,0%, p 
&lt; 0,001) ou EU (76,4% <i>vs</i> 69,6%, p = 0,036). A taxa de IM    pr&eacute;
vio tamb&eacute;m era mais alta na regi&atilde;o AL do que na EU (47,3%    <i>vs
</i> 31,8%, p &lt; 0,001) e PA (47,3% <i>vs</i> 31,5%, p &lt; 0,001), bem    com
o a taxa de CRM pr&eacute;via (AL <i>vs</i> EU: 10,0% <i>vs</i> 8,3%, p =    0,3
84; AL <i>vs</i> PA, 10,0% <i>vs</i> 4,0%, p &lt; 0,001). A preval&ecirc;ncia   
 de diabete melito era more consistente entre as regi&otilde;es, com aproximadam
ente    um ter&ccedil;o dos pacientes afetados: AL, 34,5%; PA, 37,4%; e EU, 31,6
% (p    = NS para AL <i>vs</i> EU e AL <i>vs</i> PA).</font></p>     ^cY#aop0271
1.htm##
00981000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073700085002001300822#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#67#63#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A localiza&ccedil;&atilde;o
    dos vasos-alvo apresentou varia&ccedil;&atilde;o entre as regi&otilde;es e e
st&aacute;    detalhada na <a href="/img/revistas/abc/2011nahead/aop02711t01.jpg
">Tabela 1</a>. O di&acirc;metro    do vaso de refer&ecirc;ncia era similar para
 pacientes nas regi&otilde;es AL    e PA, mas menor para os pacientes da regi&at
ilde;o EU. Havia uma taxa significantemente    menor de les&otilde;es classe C (
sistema <i>American College of Cardiology/American    Heart Association</i>) na 
regi&atilde;o AL, quando comparada com as regi&otilde;es    EU (10,7% <i>vs</i> 
24,5%, p &lt; 0,001) e PA (10,7% <i>vs</i> 30,2%, p &lt;    0,001).</font></p>  
   ^cY#aop02711.htm##
01323000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704107900085002001301164#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#68#64#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Coorte de 2    anos</i> 
- os dados demogr&aacute;ficos basais para esse subgrupo de pacientes    acompan
hados por 2 anos era similar aos dados para a popula&ccedil;&atilde;o    geral (
<a href="#t2">Tabela 2</a>). Pacientes da regi&atilde;o AL eram significantement
e    mais jovens do os pacientes da regi&atilde;o EU (61,3 <i>vs</i> 63,2 anos, 
p    = 0,02), mas significantemente mais velhos do que os pacientes da regi&atil
de;o    PA (61,3 <i>vs</i> 56,7 anos, p &lt; 0,001). Na coorte de 2 anos, havia 
um n&uacute;mero    significantemente menor de indiv&iacute;duos do sexo masculi
no na regi&atilde;o    AL do que na PA (69,0% <i>vs</i> 83,5%, p &lt; 0,001) e E
U (69,0% <i>vs</i>    77,1%, p = 0,018). A regi&atilde;o AL tamb&eacute;m aprese
ntava as maiores taxas    de fatores de risco card&iacute;aco comuns, incluindo 
hipertens&atilde;o, hipercolesterolemia,    IM pr&eacute;vio, CRM pr&eacute;via,
 angina inst&aacute;vel e diabete, quando    comparada com as outras duas regi&o
tilde;es.</font></p>     ^cY#aop02711.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#69#65#article#142#<p><a name
="t2"></a></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#70#66#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#71#67#article#142#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02711t02.jpg"></p>     ^cY#aop
02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#72#68#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
01503000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704125900085002001301344#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#73#69#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">As caracter&iacute;sticas  
  da les&atilde;o-alvo na coorte de 2 anos foram similares &agrave;quelas observ
adas    nos pacientes da popula&ccedil;&atilde;o geral de 1 ano. A localiza&cced
il;&atilde;o    do vaso, comprimento da les&atilde;o e a propor&ccedil;&atilde;o
 de les&otilde;es    classe B2 e C eram todas significantemente diferentes entre
 as regi&otilde;es    AL e EU e entre AL e PA (<a href="#t2">Tabela 2</a>). Os p
acientes da regi&atilde;o    AL tinham maior probabilidade de apresentar les&oti
lde;es classe B2 do que os    pacientes da PA (54,5% <i>vs</i> 27,6%, p &lt; 0,0
01) e EU (54,5% <i>vs</i>    36,7%, p &lt; 0,001) e significantemente menor prob
abilidade de apresentar les&otilde;es    classe C do que os pacientes da regi&at
ilde;o PA (10,3% <i>vs</i> 37,2%, p &lt;    0,001) e EU (10,3% <i>vs</i> 25,9%, 
p &lt; 0,001). O di&acirc;metro do vaso    de referencia era similar entre as re
gi&otilde;es AL, EU e PA, enquanto o comprimento    da les&atilde;o era novament
e mais curto na regi&atilde;o AL (16,94 &plusmn;    8,46 mm), quando comparado c
om as regi&otilde;es EU (18,85 &plusmn; 10,72 mm,    p = 0,001) e PA (21,75 &plu
smn; 11,01 mm, p &lt; 0,001).</font></p>     ^cY#aop02711.htm##
00364000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012000085002001300205#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#74#70#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Terapia antiplaquet&aacu
te;ria</b></font></p>     ^cY#aop02711.htm##
01504000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704126000085002001301345#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#75#71#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A terapia antiplaquet&aacut
e;ria    p&oacute;s-procedimento, que foi baseada na pr&aacute;tica cl&iacute;ni
ca padr&atilde;o,    era comum em todas as regi&otilde;es. Embora a maioria dos 
pacientes continuasse    a receber aspirina durante o per&iacute;odo de acompanh
amento de 2 anos, as    taxas de uso de terapia antiplaquet&aacute;ria dupla (DA
PT) diminu&iacute;ram    consideravelmente com o tempo (<a href="/img/revistas/a
bc/2011nahead/aop02711t03.jpg">Tabela 3</a>).    Particularmente, o maior e mais
 r&aacute;pido decl&iacute;nio no uso da DAPT    foi visto nos pacientes da regi
&atilde;o da AL aos 6 meses, 44,9% dos pacientes    da regi&atilde;o AL estavam 
recebendo DAPT, enquanto 87,4% dos pacientes na    regi&atilde;o EU e 82,4% dos 
pacientes na regi&atilde;o PA continuavam a receber    DAPT. Ap&oacute;s 1 ano, 
apenas 22,5% de todos os pacientes da AL ainda estavam    usando DAPT, comparado
s com 61,5% dos pacientes da regi&atilde;o EU e 67,0%    dos pacientes da regi&a
tilde;o PA. Entre os pacientes acompanhados por 2 anos,    o uso da DAPT diminui
u para 7,8% na regi&atilde;o AL, 19,7% na EU e 45,7% na    PA ap&oacute;s 2 anos
 (<a href="#f2">Figura 2</a>).</font></p>     ^cY#aop02711.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#76#72#article#142#<p><a name
="f2"></a></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#77#73#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#78#74#article#142#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02711f02.jpg"></p>     ^cY#aop
02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#79#75#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00359000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011500085002001300200#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#80#76#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Desfechos cl&iacute;nico
s</b></font></p>     ^cY#aop02711.htm##
01633000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704138900085002001301474#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#81#77#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Desfechos gerais    ap&o
acute;s 1 ano</i> - n&atilde;o houve diferen&ccedil;as estatisticamente    signi
ficantes na maioria dos desfechos cl&iacute;nicos ap&oacute;s 1 ano entre    as 
regi&otilde;es AL, EU ou PA (<a href="/img/revistas/abc/2011nahead/aop02711t03.j
pg">Tabela 3</a>).    A taxa de 1 ano de MACE foi 4,3% para a regi&atilde;o AL, 
6,2% para PA e 7,9%    para EU (p = NS para ambos AL <i>vs</i> EU e AL <i>vs</i>
 PA). N&atilde;o houve    eventos de IM na regi&atilde;o AL e taxas de apenas 1,
6% na regi&atilde;o EU    e 1,9% na regi&atilde;o PA (p = NS para AL <i>vs</i> E
U e AL <i>vs</i> PA).    Morte card&iacute;aca e IM foram estatisticamente difer
entes para AL, quando    comparados com PA (0,5% <i>vs</i> 3,5%, p = 0,039), mas
 n&atilde;o para AL comparada    com EU. As taxas de trombose de <i>stent</i> pr
ov&aacute;vel e definitiva definidas    pelo ARC precoce (0 a 30 dias) e tardia 
(31 a 365 dias) foram baixas em todas    as regi&otilde;es e, mais uma vez, n&at
ilde;o houve diferen&ccedil;a significante    entre a regi&otilde;es AL, EU e PA
. N&atilde;o houve trombose de <i>stent</i>    prov&aacute;vel e definitiva defi
nidas pelo ARC tardia na regi&atilde;o AL,    comparada &agrave; uma taxa de 0,5
% na regi&atilde;o EU (p = 0,977) e 0,2% na    PA no mesmo momento (p = 0,968).<
/font></p>     ^cY#aop02711.htm##
01509000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704126500085002001301350#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#82#78#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Desfechos na    coorte d
e 2 anos</i> - similar aos resultados da coorte geral do Registro E-Five,    aco
mpanhada por 1 ano, n&atilde;o houve diferen&ccedil;as estatisticamente signific
antes    nos desfechos cl&iacute;nicos na regi&atilde;o AL comparada &agrave; EU
 ou PA    ap&oacute;s 2 anos de acompanhamento (<a href="/img/revistas/abc/2011n
ahead/aop02711t04.jpg">Tabela    4</a>). As taxas de MACE ap&oacute;s 2 anos for
am 6,3% na regi&atilde;o AL,    4,5% na PA e 9,5% na EU. Em todos os grandes end
points card&iacute;acos, os    desfechos e as taxas de preval&ecirc;ncia aos 2 a
nos foram similares &agrave;s    taxas observadas em 1 ano. As taxas de RVA fora
m similares nas regi&otilde;es    AL e EU (6,8% <i>vs</i> 6,6%, p = 0,795); entr
etanto, a taxa de RVA foram mais    baixas na regi&atilde;o PA do que na AL, emb
ora a diferen&ccedil;a n&atilde;o    tivesse alcan&ccedil;ado signific&acirc;nci
a estat&iacute;stica (6,8% <i>vs</i>    1,9%, p = 0,052). N&atilde;o houve tromb
ose de <i>stent</i> prov&aacute;vel    e definitiva definidas pelo ARC muito tar
dia (366 a 730 dias) na regi&atilde;o    AL ou PA na coorte de 2 anos e somente 
2 casos (0,1%) na regi&atilde;o EU.</font></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#83#79#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#84#80#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop02711.htm##
01581000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704133700085002001301422#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#85#81#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O desfecho prim&aacute;rio 
   de MACE aos 12 meses e o desfecho secund&aacute;rio de MACE na coorte de 2 an
os,    al&eacute;m de morte card&iacute;aca, IM, RLA, RVA e trombose de <i>stent
</i>    prov&aacute;vel e definitiva nos mesmos momentos, foram similares entre 
as regi&otilde;es    AL e EU e entre as regi&otilde;es AL e PA, a despeito de co
nsider&aacute;vel    varia&ccedil;&atilde;o nos fatores de risco card&iacute;aco
, caracter&iacute;sticas    de les&atilde;o e uso de DAPT. Ap&oacute;s 1 ano, a 
taxa mais baixa de MACE    foi observada na regi&atilde;o AL, muito embora essa 
regi&atilde;o tivesse a    menor taxa de uso de DAPT naquele momento. Na coorte 
menor de 2 anos, a menor    taxa de MACE foi observada na regi&atilde;o PA. Paci
entes na regi&atilde;o AL    apresentavam maior incid&ecirc;ncia de IM pr&eacute
;vio, angina inst&aacute;vel    e revasculariza&ccedil;&atilde;o pr&eacute;via (
ICP e CRM) e maiores taxas de    hipertens&atilde;o, hipercolesterolemia e diabe
te. &Eacute; poss&iacute;vel    que pacientes com maior incid&ecirc;ncia de fato
res de risco card&iacute;aco    tenham recebido tratamentos secund&aacute;rios p
reventivos mais rigorosos, embora    esses dados n&atilde;o estejam dispon&iacut
e;veis para an&aacute;lise.</font></p>     ^cY#aop02711.htm##
02007000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704176300085002001301848#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#86#82#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Dentro do Registro    E-Fiv
e, os eventos de trombose de <i>stent</i> foram adjudicados para confirmar    de
sfechos por-protocolo e definidos pelo ARC. Como relatado anteriormente<sup>4</s
up>,    a ocorr&ecirc;ncia de trombose de <i>stent</i> prov&aacute;vel e definit
iva    definidas pelo ARC foram mais comuns precocemente (0 a 30 dias) do que ta
rdiamente    (31 a 365 dias). O mesmo foi observado em rela&ccedil;&atilde;o ao 
subgrupo    de pacientes acompanhado por 2 anos para todas as regi&otilde;es, co
m taxas    extremamente baixas de trombose de <i>stent</i> prov&aacute;vel e def
initiva    definidas pelo ARC sendo relatadas. A interrup&ccedil;&atilde;o preco
ce da DAPT    pode estar relacionada ao aumento do risco de trombose de <i>stent
</i><sup>7</sup>    e a dura&ccedil;&atilde;o ideal da DAPT que &eacute; segura 
e efetiva na redu&ccedil;&atilde;o    de trombose tardia de <i>stent</i> permane
ce uma quest&atilde;o importante a    ser respondida<sup>8,9</sup>. A despeito d
as baixas taxas de uso prolongado    de DAPT na regi&atilde;o AL, as taxas de tr
ombose de <i>stent</i> n&atilde;o    foram significantemente diferentes daquelas
 relatadas nas outras duas regi&otilde;es.    Os pacientes da regi&atilde;o AL a
presentavam les&otilde;es mais curtas e menos    complexas, o que pode diminuir 
o risco de trombose de <i>stent</i><sup>7</sup>.    Ainda n&atilde;o est&aacute;
 claro como esses m&uacute;ltiplos fatores (interrup&ccedil;&atilde;o    precoce
 da DAPT, les&otilde;es menos complexas e maior n&uacute;mero de comorbidades)  
  podem ter interagido e influenciado o risco de trombose de <i>stent</i>. Esse 
   achado precisa ser investigado em estudos futuros.</font></p>     ^cY#aop0271
1.htm##
00790000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054600085002001300631#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#87#83#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&Eacute; interessante    no
tar que estudos cl&iacute;nicos prospectivos em andamento est&atilde;o avaliando
    a dura&ccedil;&atilde;o ideal da DAPT. Um desses estudos &eacute; o estudo O
PTIMIZE    para ZES, que randomizou 3.120 pacientes para 3 meses <i>versus</i> 1
2 meses    de DAPT e relatar&aacute; seus desfechos de 1 ano em rela&ccedil;&ati
lde;o &agrave;    morte, IM, derrame, sangramento maior e trombose de <i>stent</
i> definida pelo    ARC<sup>9</sup>.</font></p>     ^cY#aop02711.htm##
01309000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106500085002001301150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#88#84#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em contraste com    esses a
chados, outras an&aacute;lises de varia&ccedil;&atilde;o internacional    tem mo
strado diferen&ccedil;as nos desfechos cl&iacute;nicos por regi&atilde;o    geog
r&aacute;fica. No estudo <i>Platelet IIb/IIIa in Unstable Angina: Receptor    Su
ppression Using Integrilin Therapy</i> (PURSUIT), a inclus&atilde;o na AL    era
 um preditor independente de mortalidade em 30 dias (<i>odds ratio (OR)</i>:    
2,42, IC95%: 1,60-3,67) e 6 meses (OR: 2,5, IC95%: 1,8-3,4)<sup>10</sup>. Esse  
  achado foi observado mesmo ap&oacute;s o ajuste para diferen&ccedil;as no risc
o    basal, sugerindo que as diferen&ccedil;as em desfecho podem ter sido causad
as    por padr&otilde;es mais conservadores de pr&aacute;tica cl&iacute;nica (po
r    ex., menor uso de terapias baseadas em evid&ecirc;ncia para infarto agudo d
o    mioc&aacute;rdio, menor e mais tardio uso de procedimentos de revasculariza
&ccedil;&atilde;o    e menor uso de manejo invasivo, tal como angiografia).</fon
t></p>     ^cY#aop02711.htm##
00848000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060400085002001300689#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#89#85#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Outros estudos    de SCA ta
mb&eacute;m relataram uma mortalidade significantemente mais alta entre    pacie
ntes inclu&iacute;dos em centros da regi&atilde;o AL. Nesses estudos, a    morta
lidade variou de 10,4% a 12,4% na regi&atilde;o AL, comparada com 5,7%    a 7,8%
 nos EUA e Europa<sup>1</sup>. Uma das hip&oacute;teses consideradas &eacute;   
 que as baixas taxas de angiografia coronariana e revasculariza&ccedil;&atilde;o
    possam explicar essas diferen&ccedil;as observadas no desfecho cl&iacute;nic
o<sup>1</sup>.</font></p>     ^cY#aop02711.htm##
00717000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047300085002001300558#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#90#86#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">&Eacute; digno    de nota, 
entretanto, que Cardoso e cols.<sup>11</sup> avaliaram o uso de <i>stents</i>   
 farmacol&oacute;gicos no Brasil de 2000 a 2005 e observaram um aumento progress
ivo    no uso (de 0,14% para 14%) e, ap&oacute;s 2001, um aumento nas taxas de s
ucesso    (de 96,58% para 99,56%) e uma diminui&ccedil;&atilde;o nas taxas de mo
rtalidade    hospitalar (1,59% para 0,21%).</font></p>     ^cY#aop02711.htm##
01018000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077400085002001300859#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#91#87#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nossos achados    do Regist
ro E-Five de que o uso de DAPT foi mais baixo na regi&atilde;o AL s&atilde;o    
consistentes com outros relatos. No estudo PURSUIT, pacientes na regi&atilde;o  
  AL apresentavam uma probabilidade significantemente menor de receber ticlopidi
na,    heparina, inibidores de enzima conversora de angiotensina, beta-bloqueado
res    orais, agentes hipolipemiantes, e nitratos orais durante a estadia hospit
alar.    Eles tamb&eacute;m recebiam menos prescri&ccedil;&otilde;es de medicame
ntos    ap&oacute;s alta hospitalar baseados em evid&ecirc;ncia, incluindo agent
es antiplaquet&aacute;rios,    beta-bloqueadores, agentes hipolipemiantes e nitr
atos orais<sup>10</sup>.</font></p>     ^cY#aop02711.htm##
01289000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704104500085002001301130#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#92#88#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o est&aacute;    c
laro porque nenhuma diferen&ccedil;a em desfechos cl&iacute;nicos foi observada 
   no grupo AL no Registro E-Five. &Eacute; poss&iacute;vel que haja menos oport
unidade    para varia&ccedil;&atilde;o na pr&aacute;tica em ICP e implanta&ccedi
l;&atilde;o    de <i>stent</i>, quando comparada com o manejo da SCA, onde difer
en&ccedil;as    foram observadas. &Eacute; tamb&eacute;m admiss&iacute;vel que o
s centros da    regi&atilde;o AL que participaram do E-Five tivessem mais experi
&ecirc;ncia    cl&iacute;nica do que os locais participantes dos estudos de SCA,
 de forma que    as varia&ccedil;&otilde;es na pr&aacute;tica que pudessem ter i
nfluenciado o    desfecho foram m&iacute;nimas. Finalmente, os pacientes inclu&i
acute;dos no    E-Five podem ter apresentado menor risco de eventos do que pacie
ntes nos estudos    de SCA, diminuindo a probabilidade que uma diferen&ccedil;a 
em eventos cl&iacute;nicos    possa ter sido observada.</font></p>     ^cY#aop02
711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#93#89#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#94#90#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Limita&ccedil;&otilde;es
</b></font></p>     ^cY#aop02711.htm##
01738000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704149400085002001301579#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#95#91#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Deve ser observado    que o
 desenho ou poder originais desse estudo n&atilde;o s&atilde;o adequados    para
 a avalia&ccedil;&atilde;o de subgrupos regionais. As regi&otilde;es AL    e PA 
juntas tem menos pacientes do que a regi&atilde;o EU e podem n&atilde;o    ser r
epresentativas de todos os pacientes que se apresentaram para implanta&ccedil;&a
tilde;o    de <i>stent</i> eluidor de f&aacute;rmaco nessas regi&otilde;es. Em n
ossa an&aacute;lise,    embora tenhamos ajustado para diferen&ccedil;as basais n
os testes de compara&ccedil;&atilde;o    de desfecho entre regi&otilde;es, outro
s fatores relativos a pacientes que n&atilde;o    foram considerados podem ter a
fetado os desfechos, independentemente da regi&atilde;o    geogr&aacute;fica. A 
coorte de pacientes de 2 anos &eacute; um subgrupo da popula&ccedil;&atilde;o   
 geral do E-Five; assim, compara&ccedil;&otilde;es formais de caracter&iacute;st
icas    basais de pacientes e les&otilde;es para os dois grupos n&atilde;o s&ati
lde;o    apropriadas, embora seja importante, de qualquer forma, mostrar as simi
laridades    gerais dos grupos de pacientes em 1 e 2 anos. Finalmente, considera
ndo que o    seguimento pode ser feito atrav&eacute;s de contato telef&ocirc;nic
o, informa&ccedil;&otilde;es    extensas sobre terapias m&eacute;dicas e interve
n&ccedil;&otilde;es espec&iacute;ficas    para cada regi&atilde;o n&atilde;o est
avam dispon&iacute;veis.</font></p>     ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#96#92#article#142#<p>&nbsp;<
/p>     ^cY#aop02711.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#97#93#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop02711.htm##
01072000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704082800085002001300913#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#98#94#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Resultados regionais    do 
Registro E-Five sugerem que, a despeito da diferen&ccedil;as em caracter&iacute;
sticas    de pacientes e les&otilde;es e uso de DAPT entre regi&otilde;es geogr&
aacute;ficas    distintas, os desfechos, incluindo taxas de MACE, morte card&iac
ute;aca, IM    e trombose de <i>stent</i> prov&aacute;vel e definitiva definida 
pelo ARC, s&atilde;o    similares. Embora o uso de DAPT em regi&otilde;es AL ten
ha sido menor do que    50% do uso nas outras regi&otilde;es, isso n&atilde;o re
sultou em aumento das    taxas de MACE ou trombose tardia de <i>stent</i>. Os ou
tros desfechos card&iacute;acos    e de les&otilde;es em 1 ano e 2 anos foram co
mpar&aacute;veis entre as regi&otilde;es    da AL e regi&otilde;es da EU e PA.</
font></p>     ^cY#aop02711.htm##
01045000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080100085002001300886#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#99#95#article#142#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Esses dados sugerem    que 
diferen&ccedil;as consider&aacute;veis na complexidade da les&atilde;o e    cond
i&ccedil;&otilde;es de comorbidade em regi&otilde;es demogr&aacute;ficas    dive
rsas n&atilde;o s&atilde;o traduzidas em diferen&ccedil;as nos desfechos    ap&o
acute;s a ICP. Pode ser que os riscos de interrup&ccedil;&atilde;o prematura    
da DAPT sejam parcialmente mitigados atrav&eacute;s da anatomia de les&otilde;es
    mais simples. Esses resultados fornecem evid&ecirc;ncias da seguran&ccedil;a
    e efetividade do Endeavor ZES em pacientes reais, a despeito de diferen&cced
il;as    potenciais em termos de pacientes, les&otilde;es e pr&aacute;ticas entr
e as    grandes regi&otilde;es demogr&aacute;ficas.</font></p>     ^cY#aop02711.
htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704011300086002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#100#96#article#142#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fontes de Financiamento
</b></font></p>     ^cY#aop02711.htm##
00461000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704021600086002001300302#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#101#97#article#142#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    foi f
inanciado pela Medtronic Bakken Research Center, Medtronic CardioVascular,    Ma
astricht e The Netherlands.</font></p>     ^cY#aop02711.htm##
00378000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704013300086002001300219#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#102#98#article#142#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Vincula&ccedil;&atilde;
o    Acad&ecirc;mica</b></font></p>     ^cY#aop02711.htm##
00440000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704019500086002001300281#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#103#99#article#142#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o h&aacute;    vi
ncula&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&ati
lde;o.</font></p>     ^cY#aop02711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#104#100#article#142#<p>&nbsp
;</p>     ^cY#aop02711.htm##
00353000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010700087002001300194#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#105#101#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b><
/font></p>     ^cY#aop02711.htm##
00454000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704019400089002001300283#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#106#102#article#
142#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. O'Shea J
C, Califf    RM. International differences in cardiovascular clinical trials. Am
 Heart J.    2001;141(5):866-74.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#107#103#article#142#</font><
/p>     ^cY#aop02711.htm##
00585000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704032500089002001300414#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#108#104#article#
142#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Chang WC
, Midodzi    WK, Westerhout CM, Boersma E, Cooper J, Barnathan ES, et al. Are in
ternational    differences in the outcomes of acute coronary syndromes apparent 
or real? A    multilevel analysis. J Epidemiol Community Health. 2005;59(5):427-
33.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#109#105#article#142#</font><
/p>     ^cY#aop02711.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704024400089002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#110#106#article#
142#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Austin D
, Oldroyd    KG, Holmes DR Jr, Rihal CS, Galbraith PD, Ghali WA, et al. Drug-elu
ting stents:    a study of international practice. Am Heart J. 2009;158(4):576-8
4.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#111#107#article#142#</font><
/p>     ^cY#aop02711.htm##
00606000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704034600089002001300435#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#112#108#article#
142#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Lotan C,
 Meredith    IT, Mauri L, Liu M, Rothman MT, for the E-Five Investigators. Safet
y and effectiveness    of the Endeavor zotarolimus-eluting stent in real-world c
linical practice: 12-month    data from the E-Five registry. JACC Cardiovasc Int
erv. 2009;2(12):1227-35.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#113#109#article#142#</font><
/p>     ^cY#aop02711.htm##
00568000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704030800089002001300397#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#114#110#article#
142#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Cutlip D
E, Windecker    S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. for the Academi
c Research Consortium.    Clinical end points in coronary stent trials: a case f
or standardized definitions.    Circulation. 2007;115(17):2344-51.    ^cY#aop027
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#115#111#article#142#</font><
/p>     ^cY#aop02711.htm##
00446000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704018600089002001300275#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#116#112#article#
142#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Burke SE
, Kuntz    RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv
 Rev. 2006;58(3):437-46.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#117#113#article#142#</font><
/p>     ^cY#aop02711.htm##
00548000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028800089002001300377#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#118#114#article#
142#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Iakavou 
I, Schimdt    T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence,
 predictors,    and outcome of thrombosis after successful implantation of drug-
eluting stents.    JAMA. 2005;293(17):2126-30.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#119#115#article#142#</font><
/p>     ^cY#aop02711.htm##
00649000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704038900089002001300478#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#120#116#article#
142#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Waksman 
R, Buch    AN, Torguson R, Xue Z, Smith K, Javaid A, et al; for the REWARDS Regi
stry. Long-term    clinical outcomes and thrombosis rates of sirolimus-eluting v
ersus paclitaxel-eluting    stents in an unselected population with coronary art
ery disease (REWARDS registry).    Am J Cardiol. 2007;100(1):45-51.    ^cY#aop02
711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#121#117#article#142#</font><
/p>     ^cY#aop02711.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028600089002001300375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#122#118#article#
142#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Kandzari
 DE,    Angiolillo DJ, Price MJ, Teirstein PS. Identifying the "optimal" duratio
n of    dual antiplatelet therapy after drug-eluting stent revascularization. JA
CC Cardiovasc    Interv. 2009;2(12):1279-85.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#123#119#article#142#</font><
/p>     ^cY#aop02711.htm##
00690000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704042900090002001300519#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#124#120#article#
142#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Cohen 
MG, Pacchiana    CM, Corbal&aacute;n R, Perez JE, Ponte CI, Oropeza ES, et al. V
ariation in patient    management and outcomes for acute coronary syndromes in L
atin America and North    America: results from the Platelet IIb/IIIa in Unstabl
e Angina: Receptor Suppression    Using Integrilin Therapy (PURSUIT) trial. Am H
eart J. 2001;141(3):391-401.    ^cY#aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#125#121#article#142#</font><
/p>     ^cY#aop02711.htm##
00574000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031300090002001300403#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#126#122#article#
142#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Cardos
o CO,    Quadros AS, Mattos LA, Gottschall CA, Sarmento-Leite RE, Marin-Neto JA.
 Use    of drug-eluting stents in Brazil: the CENIC (National Registry of Cardio
vascular    Interventions) Registry. Arq Bras Cardiol. 2007;89(6):323-7.    ^cY#
aop02711.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#127#123#article#142#</font><
/p>     ^cY#aop02711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#128#124#article#142#<p>&nbsp
;</p>     ^cY#aop02711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#129#125#article#142#<p>&nbsp
;</p>     ^cY#aop02711.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#130#126#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop02711.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003100087002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#131#127#article#142#<br>   <
/b> Chaim Lotan    ^cY#aop02711.htm##
00291000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004500087002001300132#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#132#128#article#142#<br>   K
iryat Hadassah - P.O.B. 12000    ^cY#aop02711.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004100087002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#133#129#article#142#<br>   9
1120 - Jerusalem - Israel    ^cY#aop02711.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010500087002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#134#130#article#142#<br>   E
-mail: <a href="mailto:jane.moore@medtronic.com">jane.moore@medtronic.com</a></f
ont></p>     ^cY#aop02711.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#135#131#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 26/
08/10; revisado recebido em 26/08/10; aceito em 04/10/10.</font></p>     ^cY#aop
02711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#136#132#article#142#<p>&nbsp
;</p>     ^cY#aop02711.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#137#133#article#142#<p>&nbsp
;</p>     ^cY#aop02711.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010400087002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#138#134#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Ap&ecirc;ndice</b></fo
nt></p>     ^cY#aop02711.htm##
00401000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704015500087002001300242#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#139#135#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Investigadores    e in
stitui&ccedil;&otilde;es do Registro E-Five</b></font></p>     ^cY#aop02711.htm#
#
01021000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704077500087002001300862#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#140#136#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Australia</b>:    S. W
orthley, Royal Adelaide, Adelaide / D. Muller, St. Vincent's Sydney, Sydney/    
D. Walters, The Prince Charles Hospital, Brisbane; &Aacute;ustria: O. Luha,    U
niversit&auml;tsklinik Graz, Graz / D. Glogar, AKH Wien, Vienna / M. Pichler,   
 Salzburger Landeskliniken, Salzburg / O. Pachinger, Landeskrankenhaus Innsbruck
-    Universit&auml;tskliniken, Innsbruck / G. Zenker, Allg. &ouml;ffentl. Lande
skrankenhaus    Bruck a.d. Mur, Bruck an der Mur / G. Gaul, Hanusch-Krankenhaus,
 Vienna / F.    Leisch, AKH Linz, Linz; B&eacute;lgica: P. Decroly, RHMS Baudour
, Baudour /    N. Debbas, UCL Saint-Luc, Bruxelles / M. Vrolix, Ziekenhuis Oost-
Limburg (St.    Jan), Genk;</font></p>     ^cY#aop02711.htm##
02971000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704272500087002001302812#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#141#137#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Brasil</b>:    F. Fere
s, Instituto Dante Pazzanese de Cardiologia, S&atilde;o Paulo / P.S.    Oliveira
, Instituto Nacional de Cardiologia de Laranjeiras, Rio de Janeiro /    C.R. Cos
tantini, Hospital Cardiol&oacute;gico Costantini, Curitiba, PR; Chile:    A. Mar
t&iacute;nez, Pontificada Universidad Cat&oacute;lica de Chile, Santaigo;    Chi
na: R. Gao, Beijing Fuwai Hospital, Beijing / S. Lu, Beijing Anzhen Hospital,   
 Beijing / Y. Han, The General Hospital of Shenyang Military Command, Shenyang  
  / J. Ge, Zhongshan Hospital of Fudan University, Shanghai / L. Wang, Beijing  
  Chaoyang Hospital, Beijing / T. Jiang, Affiliated Hospital of Armed Police For
ces    Medical University, Tianjin / Y. Sun, Shengjing Hospital of China Medical
 University,    Shenyang; Rep&uacute;blica Tcheca: J. Kovac, Regional Hospital K
arlovy Vary,    Karlovy Vary / P. Kala, University Hospital Brno, Brno / Z. Couf
al, Bata District    Hospital Zlin, Zlin / L. Groch, St. Anna University Hospita
l, Brno; Egito: H.    Ragy, Hayat Hospital, Cairo; Est&ocirc;nia: T. Hermlin, Ta
rtu University Hospital,    Tartu / S. Margus, East Tallinn Central Hospital, Ta
llinn; Finl&acirc;ndia:    A. Ylitalo, Satakunnan keskussairaala, Pori; Alemanha
: J. Brachmann, Klinikum    Coburg, Coburg / R. Zahn, Klinikum Nuernberg, N&uuml
;rnberg / C. Hehrlein, Universit&auml;tsklinik    Freiburg, Freiburg / C. Tiefen
bacher, Universit&auml;tsklinik Heidelberg, Heidelberg    / J. Haase, Rotes Kreu
z, Frankfurt / C. Butter, Evangelisch-Freikirchliches    Herzzentrum Bernau, Ber
nau / R. Birkemeyer, Medizinische Klinik Villingen Schweningen,    Villingen Sch
weningen / A. Els&auml;sser, Kerckhoff-Klinik GmbH, Bad Nauheim    / C. Nienaber
, University of Rostock, Rostock / H. Heuer, Johanneshospital Dortmund,    Dortm
und / P. Schuster, St. Marienhospital, Siegen / B. Hennen, Stadtkrankenhaus    P
irmasens, Pirmasens / K.F. Appel, Ambulantes Herzzentrum Kassel, Kassel / J.    
Kreuzer, St. Vincenz Krankenhaus, Limburg / P. Schwimmbeck, Klinikum Leverkusen,
    Leverkusen / T. M&uuml;nzel, Johannes Gutenberg Universit&auml;t Mainz, Main
z    / W. Motz, Klinikgruppe Dr. Guth - Klinikum Karlsburg, Karlsburg / T. Heitz
er,    Universit&auml;tskrankenhaus Eppendorf, Hamburg / F. Hartmann, Universit&
auml;tsklinikum    L&uuml;beck, L&uuml;beck / M. Wiemer, Herz- und Diabeteszentr
um Bad Oeynhausen,    Bad Oeynhausen / P. Sick, Krankenhaus der barmherzigen Bru
eder Regensburg, Regensburg    / E. Freiherr von Hodenberg, Herzzentrum Lahr/Bad
en, Lahr / B. Strauer, Universit&auml;tsklinikum    D&uuml;sseldorf, D&uuml;ssel
dorf / H. Sievert, St. Katharinen-Krankenhaus, Frankfurt;</font></p>     ^cY#aop
02711.htm##
00984000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704073800087002001300825#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#142#138#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Gr&eacute;cia</b>:    
D. Sionis, 1st IKA, Athens / C. Stefanadis, Hippokratio, Athens / D. Alexopoulos
,    University Hospital of Patra, Patra / S. Hatzimiltiades, Ahepa University H
ospital,    Thessaloniki / D. Cokkinos, Onassis Cardiac Surgery Center, Athens /
 L. Karagounis,    Interbalcan Medical Center, Thessaloniki / D. Katritsis, Euro
clinic, Athens;    Hong Kong: Kam-Tim Chan, Queen Elizabeth Hospital, Hong Kong 
/ Shu-Kin Li, Pamela    Youde Nethersole Eastern Hospital, Hong Kong / Wai-Luen,
 Stephen Lee, Queen    Mary Hospital, Hong Kong / Chee Wo Wu, Princess Margaret 
Hospital, Hong Kong    / Sum-Kin Leung, Kwong Wah Hospital, Hong Kong;</font></p
>     ^cY#aop02711.htm##
00930000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704068400087002001300771#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#143#139#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Hungria</b>:    G. Fon
tos, Gottsegen National Hearth Institute, Budapest / D. Apr&oacute;, Balatonf&uu
ml;redi    &Aacute;llami Szivkorhaz, Balatonf&uuml;red; &Iacute;ndia: P. Chandra
 / Max    Devika Devi Heart &amp; Vascular Institute, New Delhi / N. Sinha, SGPG
I Lucknow,    Lucknow / P. Rath, Apollo Hospital Jubilee Hills Hyderabad, Hydera
bad / B. Goyal,    Bombay Hospital &amp; Medical Research Center, Bombay / K. Pa
rikh, The Heart    Clinic, Ahmedabad / S. Hiremath, Ruby Hall Clinic, Pune / T. 
Patel, Sterling    Hospital, Ahmedabad; Irlanda: G. Manoharan, Royal Victoria Ho
spital, Belfast;</font></p>     ^cY#aop02711.htm##
03202000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704295600087002001303043#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#144#140#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Israel</b>:    C. Lota
n, Hadassah Medical Center, Jerusalem / Y. Rozenman, Wolfson Medical    Center, 
Holon / V. Guetta, Sheba Medical Center, Tel Hashomer / R. Krakover,    Asaf Har
ofe M.C., Zorifin / B. Lewis, Carmel M.C., Haifa / R. Kornowski, Rabin    Medica
l Center, Belinson Campus, Petach Tikva / Y. Almagor, Shaare Zedek Medical    Ce
nter, Jerusalem / S. Banai, Tel Aviv Sourasky Medical Center, Tel Aviv / E.    N
ikolsky, Rambam Medical Center, Haifa / Y. Turgeman, Emek Medical Center, Afula;
    It&aacute;lia: L. Palscia, Civile Dello Spirito Santo Hospital, Pescara / R.
    Violini, S. Camillo - Forlanini Hospital, Roma / L. Bolognese, New S. Donato
    Hospital, Arezzo / A. Manari, Arcispedale S. Maria Nuova, Reggio Emilia / P.
    Presbitero, Istituto Clinico Humanitas, Rozzano / A. Colombo, San Raffaele H
ospital,    Milano / G. Bernardi, S. Maria Della Misericordia Hospital, Udine / 
C. Tamburino,    A.O. Vittorio Emanuele Ferrarotto S. Bambino, Catania / C. Indo
lfi, Azienda    Ospedaliera Mater Domini, Catanzaro / S. De Servi, Ospedale Civi
le, Legnano    / F. Piscione, Universit&agrave; Degli Studi Federico II, Napoli 
/ B. Tuccillo,    Ospedale S. Maria di Loreto Mare, Napoli / R. Piva, A.O. Osped
ali Riuniti Umberti    I - Lancisi - Salesi, Torrette di Ancona / P. Rubino, Cas
a Di Cura Montevergine,    Mercogliano / A. Bartorelli, Centro Cardiologico Monz
ino, Milano / R. Mongiardo,    A.O. Policlinico Gemelli, Roma / C. Briguori, Cas
a di Cura Mediterranea, Napoli;    Cor&eacute;ia: Seung-Jung Park, Asan Medical 
Center, Seoul; Let&ocirc;nia: A.    Erglis, P.Stradins University Hospital, Riga
 / A. Kalnins, Clinical Hospital    Gailezers, Riga; Mal&aacute;sia: R. Zambahar
i, National Heart Institute (IJN),    Kuala Lumpur / Kui Hian Sim, Sarawak Gener
al Hospital, Kuching, Sarawak / O.    Maskon, Hospital Universiti Kebangsaan Mal
aysia, Kuala Lumpur / O. Ismail, Penang    General Hospital, Pulau Pinang / Wan 
Azman Wan Ahmad, University Malaya Medical    Centre, Kuala Lumpur / Mohd Aminud
din Mohd Sani, Kedah Medical Center, Alor    Setar; M&eacute;xico: E. Ban Hayash
i, Instituto Nacional de Cardiologia, Mexico,    DF; Pa&iacute;ses Baixos: P. De
n Heijer, Amphia Hospital, Breda / R.W.M. Hautvast,    MCAlkmaar, Alkmaar / C. S
chotborgh, Hagaziekenhuis - Leyenburg, Den Haag / R.    de Winter, AMC, Amsterda
m / J. Louwerenburg, Medisch Spectrum Twente, Enschede    / J. Bronzwaer, VUMC, 
Amsterdam; Nova Zel&acirc;ndia: G. Devlin, Waikato Hospital,    Hamilton / M. Si
mmonds, Wellington Hospital, Wellington / W. Jaffe, Ascot Hospital,    Auckland 
/ M. Abernethy, Wakefield Hospital, Wellington / G. Wilkins, Mercy    Heart Cent
re Dunedin, Dunedin: Noruega: S. Rotevatn, Haukeland Universitetssykehus,    Ber
gen / D. Nilsen, Stavanger Universitetssjukehus, Stavanger / J. Mannsverk,    Un
iversitetssykehuset i Nord Norge, Troms&oslash;;</font></p>     ^cY#aop02711.htm
##
01100000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704085400087002001300941#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#145#141#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Pol&ocirc;nia</b>:    
M. Lesiak, University Hospital No 1, Poznan / J. Rzezniczak, Szpital Miejski    
i. Strusia, Poznan / J. Hiczkiewicz, Wielospecjalistyczny Szpital SPZOZ w Nowej 
   Soli, Nowa Sol; Portugal: M.S. Almeida, Hospital Santa Cruz, Carnaxide / J.L.
    Palos, Unidade de Interven&ccedil;&atilde;o Cardiovascular, Alvor / H. Carva
lho,    SMIC - Servi&ccedil;o Medico de Imagem Computorizada, SA, Porto / R. Fer
reira,    Hospital de Santa Marta, Lisboa / M. Ad&atilde;o, Hospital Pulido Vale
nte, Lisbon;    Rom&ecirc;nia: R. Capalneanu, Institutul Inimii Cluj, Cluj Napoc
a; S&eacute;rvia:    M. Ostojic, Clinical Center of Serbia, Belgrade; Singapura:
 S. T. Lim, National    Heart Center, Singapore; Eslov&aacute;quia: M. Studencan
, VUSCH a.s., Ko&#154;ice;</font></p>     ^cY#aop02711.htm##
03492000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704324600087002001303333#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02711.htm#S#p#146#142#article#142#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Espanha</b>:    A. Mer
ch&aacute;n Herrera, Hospital Infanta Cristina, Badajoz / F. Goicolea,    Hospit
al Puerta de Hierro, Madrid / M. Sabate Tenas, Hospital de la Santa Creu    i Sa
nt Pau, Barcelona / E. Garc&iacute;a Fern&aacute;ndez, Hospital General    Unive
rsitario Gregorio Mara&ntilde;&oacute;n, Madrid / J. Moreu Burgos, Hospital    V
irgen de la Salud, Toledo / A. Bethencourt Gonzalez, Hospital Universitario    S
on Dureta, Palma de Mallorca / F. Fern&aacute;ndez - V&aacute;zquez, Hospital   
 de Le&oacute;n, Le&oacute;n / J. Diaz Fern&aacute;ndez, Hosp. Juan Ram&oacute;n
    J&iacute;menez, Huelva / A. Sanchez Gonzalez, Hosp. Virgen del Rocio, Sevill
a    / M. Vald&eacute;s Ch&aacute;varri, Hosp. Virgen de la Arrixaca, Murcia / J
.M.    Ruiz Nodar, Hosp. General de Alicante, Alicante / A.R. Cequier Fillat, Ho
spital    Bellvitge, Barcelona / L. Mart&iacute;nez Elbal, Hospital Universitari
o de La    Princesa, Madrid / J.M. Hern&aacute;ndez Garc&iacute;a, Hosp. Univers
itario    Virgen de la Victoria M&aacute;laga, M&aacute;laga / I. Santos Rodr&ia
cute;guez,    Hosp. Universitario Salamanca, Salamanca / J.M. Duran Hern&aacute;
ndez, Hospital    General Yag&uuml;e, Burgos / A. Frutos Garc&iacute;a, Hospital
 de San Juan de    Alicante, Alicante / A. Rinc&oacute;n de Arellano Castellv&ia
cute;, Universitario    Dr. Peset, Valencia / J. Fern&aacute;ndez Portales, Fern
&aacute;ndez Portales,    C&aacute;ceres / F. Pic&oacute; Aracil, Hospital Sta. 
Mar&iacute;a de Rosell,    Cartagena / F. J&iacute;menez Cabrera, Hospital Unive
rsitario Insular Gran Canario,    Las Palmas / H. P&eacute;rez Hern&aacute;ndez,
 Hosp. Univ. Ntra. Sra. de la    Candelaria, Santa Cruz de Tenerife / F. Bosa Oj
eda, Hospital Universitario de    Canarias, Santa Cruz de Tenerife / L.M. Teruel
 Gila, Hospital General de Catalu&ntilde;a,    Barcelona / J. Balaguer Recena, H
ospital General Universitario de Guadalajara,    Guadalajara / J.A. Ferrer, Ccv.
 Sant Jordi, Barcelona / A. Serra Pe&ntilde;aranda,    Hospital del Mar, Barcelo
na / V. Fern&aacute;ndez Vallejo, Hosp. General Ciudad    Real, Ciudad Real / R.
 Ruiz Salmeron, Hospital Virgen de la Macarena, Sevilla    / J.R. Rumoroso Cueva
s, Galdacano, Bilbao / A. I&ntilde;iguez Romo, Hosp. Mexoeiro,    Vigo Pontevedr
a; Su&iacute;&ccedil;a: F.R. Eberli, University Hospital Z&uuml;rich,    Z&uuml;
rich; Tailandia: W. Buddhari, King Chualongkorn Memorial Hospital, Bangkok    / 
D. Tresukosol, Siriraj Hospital, Bangkok; Turquia: O. Sancaktar, Medical Park   
 Hospital, Istanbul / M. Akin, Ege Saglik Hastanesi, Izmir; Reino Unido: N. West
,    Cheltenham General Hospital, Cheltenham / P. Ludman, Queen Elizabeth Hospit
al,    Birmingham / M. Rothman, London Chest Hospital, London / M. de Belder, Ja
mes    Cook University Hospital, Middlesbrough / R.A. Henderson, Nottingham City
 Hospital,    Nottingham / J.P. Greenwood, Leeds General Infirmary, Leeds / G. H
aywood, Derriford    Hospital, Plymouth / S. Brecker, St. Georges Hospital, Lond
on / D. Dymond, St.    Bartholomew's, London / P. Glennon, Walsgrave Hospital, C
oventry, West Midlands;    Uruguai: A. Firszt, Instituto Nacional de Cirugia Car
diaca, Montevideo.</font></p>     ^cY#aop02711.htm##
00555000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030120
06400120030001100184065000900195064000500204031000400209032000200213014000700215
865000900222002001300231035001000244801001100254#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02711.htm#S#c#147#1#article#11#1#^rND^sO'Shea^nJC#^rND^sCa
liff^nRM#International differences in cardiovascular clinical trials^len#Am Hear
t J#20010000#2001#141#5#866-74#20110000#aop02711.htm#0002-8703#Am Heart J##
00785000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
02100120010001700141010001600158010002000174810000600194012011900200030002900319
06500090034806400050035703100030036203200020036501400070036786500090037400200130
0383035001000396801002900406#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02711.htm#S#c#148#2#article#11#2#^rND^sChang^nWC#^rND^sMidodzi^nWK#^rND^sWeste
rhout^nCM#^rND^sBoersma^nE#^rND^sCooper^nJ#^rND^sBarnathan^nES#et al#Are interna
tional differences in the outcomes of acute coronary syndromes apparent or real?
: A multilevel analysis^len#J Epidemiol Community Health#20050000#2005#59#5#427-
33#20110000#aop02711.htm#0141-7681#J Epidemiol Community Health##
00688000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
02000120010001600140010002000156010001600176810000600192012005900198030001100257
06500090026806400050027703100040028203200020028601400070028886500090029500200130
0304035001000317801001100327#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02711.htm#S#c#149#3#article#11#3#^rND^sAustin^nD#^rND^sOldroyd^nKG#^rND^sHolme
s^nDR Jr#^rND^sRihal^nCS#^rND^sGalbraith^nPD#^rND^sGhali^nWA#et al#Drug-eluting 
stents: a study of international practice^len#Am Heart J#20090000#2009#158#4#576
-84#20110000#aop02711.htm#0002-8703#Am Heart J##
00727000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100019001010100
01500120010001300135010001800148012017300166030002300339710000200362065000900364
064000500373031000200378032000300380014000800383865000900391002001300400#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#S#c#150#4#article#11#4#^
rND^sLotan^nC#^rND^sMeredith^nIT#^rND^sMauri^nL#^rND^sLiu^nM#^rND^sRothman^nMT#f
or the E-Five Investigators: Safety and effectiveness of the Endeavor zotarolimu
s-eluting stent in real-world clinical practice: 12-month data from the E-Five r
egistry^len#JACC Cardiovasc Interv#2#20090000#2009#2#12#1227-35#20110000#aop0271
1.htm##
00750000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100019001030100
01600122010001400138010001600152010001700168810000600185012012400191030001200315
06500090032706400050033603100040034103200030034501400080034886500090035600200130
0365035001000378801001200388#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02711.htm#S#c#151#5#article#11#5#^rND^sCutlip^nDE#^rND^sWindecker^nS#^rND^sMeh
ran^nR#^rND^sBoam^nA#^rND^sCohen^nDJ#^rND^svan Es^nGA#et al#for the Academic Res
earch Consortium: Clinical end points in coronary stent trials: a case for stand
ardized definitions^len#Circulation#20070000#2007#115#17#2344-51#20110000#aop027
11.htm#0009-7322#Circulation##
00537000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020100
01900118012004100137030001900178710000200197065000900199064000500208031000300213
032000200216014000700218865000900225002001300234#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02711.htm#S#c#152#6#article#11#6#^rND^sBurke^nSE#^rND^sKun
tz^nRE#^rND^sSchwartz^nLB#Zotarolimus (ABT-578) eluting stents^len#Adv Drug Deli
v Rev#2#20060000#2006#58#3#437-46#20110000#aop02711.htm##
00723000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030100
01900120010001200139010002000151010001900171810000600190012010600196030000500302
06500090030706400050031603100040032103200030032501400080032886500090033600200130
0345035001000358801000500368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02711.htm#S#c#153#7#article#11#7#^rND^sIakavou^nI#^rND^sSchimdt^nT#^rND^sBoniz
zoni^nE#^rND^sGe^nL#^rND^sSangiorgi^nGM#^rND^sStankovic^nG#et al#Incidence, pred
ictors, and outcome of thrombosis after successful implantation of drug-eluting 
stents^len#JAMA#20050000#2005#293#17#2126-30#20110000#aop02711.htm#0098-7484#JAM
A##
00803000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100015001030100
01800118010001300136010001500149010001600164810000600180012018300186030001300369
06500090038206400050039103100040039603200020040001400060040286500090040800200130
0417035001000430801001300440#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02711.htm#S#c#154#8#article#11#8#^rND^sWaksman^nR#^rND^sBuch^nAN#^rND^sTorguso
n^nR#^rND^sXue^nZ#^rND^sSmith^nK#^rND^sJavaid^nA#et al#Long-term clinical outcom
es and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in
 an unselected population with coronary artery disease (REWARDS registry)^len#Am
 J Cardiol#20070000#2007#100#1#45-51#20110000#aop02711.htm#0002-9149#Am J Cardio
l##
00649000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100021001050100
01600126010002000142012011100162030002300273710000200296065000900298064000500307
031000200312032000300314014000800317865000900325002001300334#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02711.htm#S#c#155#9#article#11#9#^rND^sKandzar
i^nDE#^rND^sAngiolillo^nDJ#^rND^sPrice^nMJ#^rND^sTeirstein^nPS#Identifying the "
optimal" duration of dual antiplatelet therapy after drug-eluting stent revascul
arization^len#JACC Cardiovasc Interv#2#20090000#2009#2#12#1279-85#20110000#aop02
711.htm##
00861000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100020001040100
01800124010001600142010001600158010001800174810000600192012023100198030001100429
06500090044006400050044903100040045403200020045801400080046086500090046800200130
0477035001000490801001100500#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02711.htm#S#c#156#10#article#11#10#^rND^sCohen^nMG#^rND^sPacchiana^nCM#^rND^sC
orbalán^nR#^rND^sPerez^nJE#^rND^sPonte^nCI#^rND^sOropeza^nES#et al#Variation in 
patient management and outcomes for acute coronary syndromes in Latin America an
d North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor
 Suppression Using Integrilin Therapy (PURSUIT) trial^len#Am Heart J#20010000#20
01#141#3#391-401#20110000#aop02711.htm#0002-8703#Am Heart J##
00750000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01700124010002100141010002500162010002100187012011300208030001700321065000900338
06400050034703100030035203200020035501400060035786500090036300200130037203500100
0385801001700395#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02711.htm#
S#c#157#11#article#11#11#^rND^sCardoso^nCO#^rND^sQuadros^nAS#^rND^sMattos^nLA#^r
ND^sGottschall^nCA#^rND^sSarmento-Leite^nRE#^rND^sMarin-Neto^nJA#Use of drug-elu
ting stents in Brazil: the CENIC (National Registry of Cardiovascular Interventi
ons) Registry^len#Arq Bras Cardiol#20070000#2007#89#6#323-7#20110000#aop02711.ht
m#0066-782X#Arq Bras Cardiol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#o#1#1#
article#1#20110331#081025#aop02811.htm#151##
05552000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801201000
01770120095002770100033003720100047004050100033004520100031004850100037005160100
03600553070009100589083194800680085000802628085002102636085002602657085003502683
08500340271808500340275208318370278608500080462308500220463108500240465308500310
46770850029047080850039047371170008047760720003047841120009047871110009047961160
00904805115000904814114000904823113000904832002001304841#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02811.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#GRA#
TAB#36#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#Curva 
de referência da área do septo interventricular fetal pelo método STIC: estudo p
reliminar^lpt#Reference curve of the fetal ventricular septum area by the STIC m
ethod: preliminary study^len#^rND^1A01^nLiliam Cristine^sRolo#^rND^1A01^nLuciano
 Marcondes Machado^sNardozza#^rND^1A01^nEdward^sAraujo Júnior#^rND^1A01^nChristi
ane^sSimioni#^rND^1A01^nMarina Maccagnano^sZamith#^rND^1A01^nAntonio Fernandes^s
Moron#Universidade Federal de São Paulo^iA01^1Departamento de Obstetrícia^cSão P
aulo^sSP^pBrasil#^lpt^aFUNDAMENTO: A detecção precoce de alterações septais, tai
s como a hipertrofia septal comumente presente em fetos de mães diabéticas, cont
ribuiria para a redução das altas taxas de mortalidade infantil. OBJETIVO: Deter
minar intervalos de referência para a área do septo interventricular fetal por m
eio da ultrassonografia tridimensional (US3D) utilizando o método STIC (Spatio-T
emporal Image Correlation). MÉTODOS: Realizou-se um estudo de corte transversal 
com 69 gestantes normais entre a 18ª e 33ª semanas de gestação. Utilizou-se como
 referência o plano de quatro câmaras com a ROI (Região de Interesse) posicionad
a a partir dos ventrículos, sendo a área do septo delimitada de modo manual. Par
a se avaliar a correlação da área do septo interventricular com a idade gestacio
nal (IG), construíram-se diagramas de dispersão e calculou-se o coeficiente de c
orrelação de Pearson (r), sendo o ajuste realizado pelo coeficiente de determina
ção (R²). Foram calculadas médias, medianas, desvios-padrão (dp), valores máximo
 e mínimo. Para o cálculo da reprodutibilidade intraobservador, utilizou-se o co
eficiente de correlação intraclasse (CCI). Obteve-se a medida da espessura do se
pto interventricular e ela foi correlacionada com a IG e a área septal obtida pe
lo modo renderizado em 52 pacientes utilizando-se o CCI. RESULTADOS: A área do s
epto interventricular foi altamente correlacionada com a idade gestacional (r = 
0,81), e a média aumentou de 0,47 cm² na 18ª para 2,42 cm² na 33ª semana de gest
ação. A reprodutibilidade intraobservador foi excelente com CCI = 0,994. Não se 
observou correlação significativa entre a medida do septo interventricular e a I
G (R² = 0,200), assim como não houve correlação com a área do septo obtida pelo 
modo renderizado com CCI = 0,150. CONCLUSÃO: Intervalos de referência para a áre
a do septo interventricular entre a 18ª e 33ª semanas de gestação foram determin
ados e se mostraram altamente reprodutíveis.#^dnd^i1#^tm^lpt^kGravidez^i1#^tm^lp
t^kcoração fetal^i1#^tm^lpt^ksepto interventricular^i1#^tm^lpt^kvalores de refer
ência^i1#^tm^lpt^kimagem tridimensional^i1#^len^aBACKGROUND: Early detection of 
septal changes such as septal hypertrophy commonly present in fetuses of diabeti
c mothers would help reduce the high rates of infant mortality. OBJECTIVE: Deter
mine reference ranges for the fetal ventricular septal area through three-dimens
ional ultrasound (US3D) using the STIC method (Spatio-Temporal Image Correlation
). METHODS: We conducted a cross-sectional study with 69 pregnant women between 
the 18th and 33rd weeks of pregnancy. We used as a reference the four-chamber pl
ane with the ROI (Region of Interest) positioned from the ventricles; the septum
 area were manually marked. To assess the correlation of the interventricular se
ptum area with gestational age (GA), we constructed scatter plots and calculated
 Pearson's correlation coefficient (r), and the adjustment was performed by the 
coefficient of determination (R²). We calculated averages, medians, standard dev
iations (sd), as well as maximum and minimum values. To calculate the intraobser
ver reproducibility, we used the intraclass correlation coefficient (ICC). The i
nterventricular septum thickness was measured and it was correlated with gestati
onal age and the septal area rendered in 52 patients using the ICC. RESULTS: The
 interventricular septum area was highly correlated with gestational age (r = 0.
81), and the average increased from 0.47 cm² in the 18th week to 2.42 cm² in the
 33rd of gestation. The intraobserver reproducibility was excellent with ICC = 0
.994. No significant correlation was observed between the interventricular septu
m measurement and the GA (R² = 0.200), as well as there was no correlation with 
the septal area rendered with ICC = 0.150. CONCLUSION: Reference intervals for t
he interventricular septum area between the 18th and the 33rd pregnancy week wer
e determined to be highly reproducible.#^dnd^i2#^tm^len^kPregnancy^i2#^tm^len^kf
etal heart^i2#^tm^len^kventricular septum^i2#^tm^len^kreference values^i2#^tm^le
n^kimaging, three-dimensional^i2#vancouv#24#20100729#29/07/10#20101117#17/11/10#
20101214#14/12/10#aop02811.htm##
05789000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099038000400103121000300107049000300110158000300113
03000200011603200060013606500090014201400070015103500100015822300090016801201140
01770120109002910100033004000100047004330100033004800100031005130100037005440100
03600581070009100617083202300708085000802731085002102739085002602760085003502786
08500340282108500340285508319710288908500080486008500220486808500240489008500310
49140850029049450850039049741170008050130720003050211120009050241110009050331160
00905042115000905051114000905060113000905069002001305078#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02811.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#GRA#
TAB#36#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#<b>Cur
va de referência da área do septo interventricular fetal pelo método STIC</b>: <
b>estudo preliminar</b>^lpt#<b>Reference curve of the fetal ventricular septum a
rea by the STIC method</b>: <b>preliminary study</b>^len#^rND^1A01^nLiliam Crist
ine^sRolo#^rND^1A01^nLuciano Marcondes Machado^sNardozza#^rND^1A01^nEdward^sArau
jo Júnior#^rND^1A01^nChristiane^sSimioni#^rND^1A01^nMarina Maccagnano^sZamith#^r
ND^1A01^nAntonio Fernandes^sMoron#Universidade Federal de São Paulo^iA01^1Depart
amento de Obstetrícia^cSão Paulo^sSP^pBrasil#^lpt^a<b>FUNDAMENTO: </b>A detecção
 precoce de alterações septais, tais como a hipertrofia septal comumente present
e em fetos de mães diabéticas, contribuiria para a redução das altas taxas de mo
rtalidade infantil. <b>OBJETIVO: </b>Determinar intervalos de referência para a 
área do septo interventricular fetal por meio da ultrassonografia tridimensional
 (US3D) utilizando o método STIC (<i>Spatio-Temporal Image Correlation</i>). <b>
MÉTODOS: </b>Realizou-se um estudo de corte transversal com 69 gestantes normais
 entre a 18ª e 33ª semanas de gestação. Utilizou-se como referência o plano de q
uatro câmaras com a ROI (Região de Interesse) posicionada a partir dos ventrícul
os, sendo a área do septo delimitada de modo manual. Para se avaliar a correlaçã
o da área do septo interventricular com a idade gestacional (IG), construíram-se
 diagramas de dispersão e calculou-se o coeficiente de correlação de Pearson (r)
, sendo o ajuste realizado pelo coeficiente de determinação (R<sup>2</sup>). For
am calculadas médias, medianas, desvios-padrão (dp), valores máximo e mínimo. Pa
ra o cálculo da reprodutibilidade intraobservador, utilizou-se o coeficiente de 
correlação intraclasse (CCI). Obteve-se a medida da espessura do septo intervent
ricular e ela foi correlacionada com a IG e a área septal obtida pelo modo rende
rizado em 52 pacientes utilizando-se o CCI. <b>RESULTADOS: </b>A área do septo i
nterventricular foi altamente correlacionada com a idade gestacional (r = 0,81),
 e a média aumentou de 0,47 cm<sup>2</sup> na 18ª para 2,42 cm<sup>2</sup> na 33
ª semana de gestação. A reprodutibilidade intraobservador foi excelente com CCI 
= 0,994. Não se observou correlação significativa entre a medida do septo interv
entricular e a IG (R² = 0,200), assim como não houve correlação com a área do se
pto obtida pelo modo renderizado com CCI = 0,150. <b>CONCLUSÃO: </b>Intervalos d
e referência para a área do septo interventricular entre a 18ª e 33ª semanas de 
gestação foram determinados e se mostraram altamente reprodutíveis.#^dnd^i1#^tm^
lpt^kGravidez^i1#^tm^lpt^kcoração fetal^i1#^tm^lpt^ksepto interventricular^i1#^t
m^lpt^kvalores de referência^i1#^tm^lpt^kimagem tridimensional^i1#^len^a<b>BACKG
ROUND:</b> Early detection of septal changes such as septal hypertrophy commonly
 present in fetuses of diabetic mothers would help reduce the high rates of infa
nt mortality. <b>OBJECTIVE:</b> Determine reference ranges for the fetal ventric
ular septal area through three-dimensional ultrasound (US3D) using the STIC meth
od (Spatio-Temporal Image Correlation). <b>METHODS:</b> We conducted a cross-sec
tional study with 69 pregnant women between the 18<sup>th</sup> and 33<sup>rd</s
up> weeks of pregnancy. We used as a reference the four-chamber plane with the R
OI (Region of Interest) positioned from the ventricles; the septum area were man
ually marked. To assess the correlation of the interventricular septum area with
 gestational age (GA), we constructed scatter plots and calculated Pearson's cor
relation coefficient (r), and the adjustment was performed by the coefficient of
 determination (R<sup>2</sup>). We calculated averages, medians, standard deviat
ions (sd), as well as maximum and minimum values. To calculate the intraobserver
 reproducibility, we used the intraclass correlation coefficient (ICC). The inte
rventricular septum thickness was measured and it was correlated with gestationa
l age and the septal area rendered in 52 patients using the ICC. <b>RESULTS:</b>
 The interventricular septum area was highly correlated with gestational age (r 
= 0.81), and the average increased from 0.47 cm<sup>2</sup> in the 18<sup>th</su
p> week to 2.42 cm<sup>2</sup> in the 33<sup>rd</sup> of gestation. The intraobs
erver reproducibility was excellent with ICC = 0.994. No significant correlation
 was observed between the interventricular septum measurement and the GA (R² = 0
.200), as well as there was no correlation with the septal area rendered with IC
C = 0.150. <b>CONCLUSION:</b> Reference intervals for the interventricular septu
m area between the 18<sup>th</sup> and the 33<sup>rd</sup> pregnancy week were d
etermined to be highly reproducible.#^dnd^i2#^tm^len^kPregnancy^i2#^tm^len^kfeta
l heart^i2#^tm^len^kventricular septum^i2#^tm^len^kreference values^i2#^tm^len^k
imaging, three-dimensional^i2#vancouv#24#20100729#29/07/10#20101117#17/11/10#201
01214#14/12/10#aop02811.htm##
05673000000000721000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106038000400110121000300114049000300117
15800030012003000190012303200060014206500090014801400070015703500100016422300090
01740120100001830120095002830100033003780100047004110100033004580100031004910100
03700522010003600559070009300595083194800688085000802636085002102644085002602665
08500350269108500340272608500340276008318370279408500080463108500220463908500240
46610850031046850850029047160850039047451170008047840720003047921120009047951110
00904804116000904813115000904822114000904831113000904840002001304849008008904862
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#l#4#1#article#
1#^a2011#oa#pt#br1.1#1#4.0#gra#tab#36#nd#nd#Arq. bras. cardiol#ahead#20110000#^f
0^l0#0066-782X#20110401#Curva de referência da área do septo interventricular fe
tal pelo método STIC: estudo preliminar^lpt#Reference curve of the fetal ventric
ular septum area by the STIC method: preliminary study^len#^rND^1A01^nLiliam Cri
stine^sRolo#^rND^1A01^nLuciano Marcondes Machado^sNardozza#^rND^1A01^nEdward^sAr
aujo Júnior#^rND^1A01^nChristiane^sSimioni#^rND^1A01^nMarina Maccagnano^sZamith#
^rND^1A01^nAntonio Fernandes^sMoron#^iA01^1Universidade Federal de São Paulo^2De
partamento de Obstetrícia^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: A detecção pr
ecoce de alterações septais, tais como a hipertrofia septal comumente presente e
m fetos de mães diabéticas, contribuiria para a redução das altas taxas de morta
lidade infantil. OBJETIVO: Determinar intervalos de referência para a área do se
pto interventricular fetal por meio da ultrassonografia tridimensional (US3D) ut
ilizando o método STIC (Spatio-Temporal Image Correlation). MÉTODOS: Realizou-se
 um estudo de corte transversal com 69 gestantes normais entre a 18ª e 33ª seman
as de gestação. Utilizou-se como referência o plano de quatro câmaras com a ROI 
(Região de Interesse) posicionada a partir dos ventrículos, sendo a área do sept
o delimitada de modo manual. Para se avaliar a correlação da área do septo inter
ventricular com a idade gestacional (IG), construíram-se diagramas de dispersão 
e calculou-se o coeficiente de correlação de Pearson (r), sendo o ajuste realiza
do pelo coeficiente de determinação (R²). Foram calculadas médias, medianas, des
vios-padrão (dp), valores máximo e mínimo. Para o cálculo da reprodutibilidade i
ntraobservador, utilizou-se o coeficiente de correlação intraclasse (CCI). Obtev
e-se a medida da espessura do septo interventricular e ela foi correlacionada co
m a IG e a área septal obtida pelo modo renderizado em 52 pacientes utilizando-s
e o CCI. RESULTADOS: A área do septo interventricular foi altamente correlaciona
da com a idade gestacional (r = 0,81), e a média aumentou de 0,47 cm² na 18ª par
a 2,42 cm² na 33ª semana de gestação. A reprodutibilidade intraobservador foi ex
celente com CCI = 0,994. Não se observou correlação significativa entre a medida
 do septo interventricular e a IG (R² = 0,200), assim como não houve correlação 
com a área do septo obtida pelo modo renderizado com CCI = 0,150. CONCLUSÃO: Int
ervalos de referência para a área do septo interventricular entre a 18ª e 33ª se
manas de gestação foram determinados e se mostraram altamente reprodutíveis.#^dn
d^i1#^tm^lpt^kGravidez^i1#^tm^lpt^kcoração fetal^i1#^tm^lpt^ksepto interventricu
lar^i1#^tm^lpt^kvalores de referência^i1#^tm^lpt^kimagem tridimensional^i1#^len^
aBACKGROUND: Early detection of septal changes such as septal hypertrophy common
ly present in fetuses of diabetic mothers would help reduce the high rates of in
fant mortality. OBJECTIVE: Determine reference ranges for the fetal ventricular 
septal area through three-dimensional ultrasound (US3D) using the STIC method (S
patio-Temporal Image Correlation). METHODS: We conducted a cross-sectional study
 with 69 pregnant women between the 18th and 33rd weeks of pregnancy. We used as
 a reference the four-chamber plane with the ROI (Region of Interest) positioned
 from the ventricles; the septum area were manually marked. To assess the correl
ation of the interventricular septum area with gestational age (GA), we construc
ted scatter plots and calculated Pearson's correlation coefficient (r), and the 
adjustment was performed by the coefficient of determination (R²). We calculated
 averages, medians, standard deviations (sd), as well as maximum and minimum val
ues. To calculate the intraobserver reproducibility, we used the intraclass corr
elation coefficient (ICC). The interventricular septum thickness was measured an
d it was correlated with gestational age and the septal area rendered in 52 pati
ents using the ICC. RESULTS: The interventricular septum area was highly correla
ted with gestational age (r = 0.81), and the average increased from 0.47 cm² in 
the 18th week to 2.42 cm² in the 33rd of gestation. The intraobserver reproducib
ility was excellent with ICC = 0.994. No significant correlation was observed be
tween the interventricular septum measurement and the GA (R² = 0.200), as well a
s there was no correlation with the septal area rendered with ICC = 0.150. CONCL
USION: Reference intervals for the interventricular septum area between the 18th
 and the 33rd pregnancy week were determined to be highly reproducible.#^dnd^i2#
^tm^len^kPregnancy^i2#^tm^len^kfetal heart^i2#^tm^len^kventricular septum^i2#^tm
^len^kreference values^i2#^tm^len^kimaging, three-dimensional^i2#vancouv#24#2010
0729#29/07/10#20101117#17/11/10#20101214#14/12/10#aop02811.htm#Internet^ihttp://
www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000036##
00471000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022900083002001300312#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#5#1#article#123#<p><a name="
top"></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Curva   
 de refer&ecirc;ncia da &aacute;rea do septo interventricular fetal pelo m&eacut
e;todo    STIC: estudo preliminar</b></font></p>     ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#6#2#article#123#<p>&nbsp;</p
>     ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#7#3#article#123#<p>&nbsp;</p
>     ^cY#aop02811.htm##
00494000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704025200083002001300335#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#8#4#article#123#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Liliam Cristine    Rolo; L
uciano Marcondes Machado Nardozza; Edward Araujo J&uacute;nior; Christiane    Si
mioni; Marina Maccagnano Zamith; Antonio Fernandes Moron</b></font></p>     ^cY#
aop02811.htm##
00439000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704019700083002001300280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#9#5#article#123#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Departamento de    Obstetr&ia
cute;cia - Universidade Federal de S&atilde;o Paulo, S&atilde;o Paulo,    SP - B
rasil</font></p>     ^cY#aop02811.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#10#6#article#123#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&e
circ;ncia</a></font></p>     ^cY#aop02811.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#11#7#article#123#<p>&nbsp;</
p>     ^cY#aop02811.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#12#8#article#123#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop02811.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#13#9#article#123#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>    
 ^cY#aop02811.htm##
00589000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034500085002001300430#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#14#10#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>FUNDAMENTO:    </b> A de
tec&ccedil;&atilde;o precoce de altera&ccedil;&otilde;es septais, tais    como a
 hipertrofia septal comumente presente em fetos de m&atilde;es diab&eacute;ticas
,    contribuiria para a redu&ccedil;&atilde;o das altas taxas de mortalidade in
fantil.    ^cY#aop02811.htm##
00502000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025800085002001300343#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#15#11#article#123#<br>   <b>
OBJETIVO: </b> Determinar intervalos de refer&ecirc;ncia para a &aacute;rea    d
o septo interventricular fetal por meio da ultrassonografia tridimensional    (U
S3D) utilizando o m&eacute;todo STIC (<i>Spatio-Temporal Image Correlation</i>).
    ^cY#aop02811.htm##
01398000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704115400085002001301239#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#16#12#article#123#<br>   <b>
M&Eacute;TODOS: </b> Realizou-se um estudo de corte transversal com 69 gestantes
    normais entre a 18ª e 33ª semanas de gesta&ccedil;&atilde;o. Utilizou-se com
o    refer&ecirc;ncia o plano de quatro c&acirc;maras com a ROI (Regi&atilde;o d
e    Interesse) posicionada a partir dos ventr&iacute;culos, sendo a &aacute;rea
    do septo delimitada de modo manual. Para se avaliar a correla&ccedil;&atilde
;o    da &aacute;rea do septo interventricular com a idade gestacional (IG), con
stru&iacute;ram-se    diagramas de dispers&atilde;o e calculou-se o coeficiente 
de correla&ccedil;&atilde;o    de Pearson (r), sendo o ajuste realizado pelo coe
ficiente de determina&ccedil;&atilde;o    (R<sup>2</sup>). Foram calculadas m&ea
cute;dias, medianas, desvios-padr&atilde;o    (dp), valores m&aacute;ximo e m&ia
cute;nimo. Para o c&aacute;lculo da reprodutibilidade    intraobservador, utiliz
ou-se o coeficiente de correla&ccedil;&atilde;o intraclasse    (CCI). Obteve-se 
a medida da espessura do septo interventricular e ela foi correlacionada    com 
a IG e a &aacute;rea septal obtida pelo modo renderizado em 52 pacientes    util
izando-se o CCI.    ^cY#aop02811.htm##
00845000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060100085002001300686#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#17#13#article#123#<br>   <b>
RESULTADOS: </b> A &aacute;rea do septo interventricular foi altamente correlaci
onada    com a idade gestacional (r = 0,81), e a m&eacute;dia aumentou de 0,47 c
m<sup>2</sup>    na 18ª para 2,42 cm<sup>2</sup> na 33ª semana de gesta&ccedil;&
atilde;o. A reprodutibilidade    intraobservador foi excelente com CCI = 0,994. 
N&atilde;o se observou correla&ccedil;&atilde;o    significativa entre a medida 
do septo interventricular e a IG (R&sup2; = 0,200),    assim como n&atilde;o hou
ve correla&ccedil;&atilde;o com a &aacute;rea do septo    obtida pelo modo rende
rizado com CCI = 0,150.    ^cY#aop02811.htm##
00496000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025200085002001300337#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#18#14#article#123#<br>   <b>
CONCLUS&Atilde;O: </b> Intervalos de refer&ecirc;ncia para a &aacute;rea    do s
epto interventricular entre a 18ª e 33ª semanas de gesta&ccedil;&atilde;o    for
am determinados e se mostraram altamente reprodut&iacute;veis.</font></p>     ^c
Y#aop02811.htm##
00493000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024900085002001300334#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#19#15#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Palavras-chave:    </b> 
Gravidez, cora&ccedil;&atilde;o fetal, septo interventricular, valores    de ref
er&ecirc;ncia, imagem tridimensional.</font></p> <hr size="1" noshade>     ^cY#a
op02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#20#16#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#21#17#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#22#18#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop02811.htm##
00840000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059600085002001300681#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#23#19#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O aumento progressivo    da
 demanda de oxig&ecirc;nio em raz&atilde;o do r&aacute;pido crescimento do    em
bri&atilde;o durante as fases iniciais da embriog&ecirc;nese determina a precoce
    forma&ccedil;&atilde;o card&iacute;aca por volta do 22º-23º dias de gesta&cc
edil;&atilde;o<sup>1</sup>.    Progressivamente, o cora&ccedil;&atilde;o primiti
vo fetal sofre uma s&eacute;rie    de processos remodeladores capazes de modific
ar a sua anatomia, at&eacute; atingir    a forma funcional que conhecemos<sup>1<
/sup>.</font></p>     ^cY#aop02811.htm##
01022000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077800085002001300863#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#24#20#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O cora&ccedil;&atilde;o,   
 quando j&aacute; composto de suas quatro c&acirc;maras (&aacute;trios e ventr&i
acute;culos),    apresenta no interior de seus ventr&iacute;culos o septo interv
entricular (IV)    divisor, formado a partir da fus&atilde;o das paredes mediais
: a parte muscular    do septo IV. Dentro dos ventr&iacute;culos, com a cavita&c
cedil;&atilde;o dos    mesmos, os feixes musculares ser&atilde;o formados e esse
s originam os m&uacute;sculos    papilares e as cordas tend&iacute;neas<sup>1</s
up>, com fun&ccedil;&atilde;o    de compet&ecirc;ncia valvar, impedindo o prolap
so das c&uacute;spides durante    a s&iacute;stole card&iacute;aca e o refluxo s
angu&iacute;neo<sup>2</sup>.</font></p>     ^cY#aop02811.htm##
01066000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704082200085002001300907#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#25#21#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em 50% dos casos,    as mal
forma&ccedil;&otilde;es card&iacute;acas s&atilde;o consideradas defeitos    mai
ores, fatores determinantes da eleva&ccedil;&atilde;o da taxa da mortalidade    
infantil precoce e tardia<sup>3,4</sup>, evidenciando a necessidade do rastreame
nto    e diagn&oacute;stico precoce de tais cardiopatias. Apesar da ampla aplica
&ccedil;&atilde;o    da ultrassonografia convencional no rastreamento de cardiop
atias cong&ecirc;nitas,    a detec&ccedil;&atilde;o pr&eacute;-natal ainda apres
enta lacunas diagn&oacute;sticas,    o que impulsiona o desenvolvimento de novas
 t&eacute;cnicas de aquisi&ccedil;&atilde;o    de imagem para um melhor rastream
ento card&iacute;aco durante a rotina do pr&eacute;-natal<sup>5-7</sup>.</font><
/p>     ^cY#aop02811.htm##
01155000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704091100085002001300996#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#26#22#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Nas &uacute;ltimas    d&eac
ute;cadas, com o desenvolvimento da ultrassonografia tridimensional (US3D)    e 
da tecnologia do <i>Spatio-Temporal Image Correlation</i> (STIC), surgiu uma    
nova forma de an&aacute;lise card&iacute;aca pr&eacute;-natal. Tal t&eacute;cnic
a    permite a obten&ccedil;&atilde;o do volume card&iacute;aco e seu armazename
nto    para posterior reconstru&ccedil;&atilde;o e an&aacute;lise da sua anatomi
a,    apresentando a imagem no modo multiplanar e de superf&iacute;cie (renderiz
ada),    identificando-se as c&acirc;maras card&iacute;acas, as v&aacute;lvulas 
atrioventriculares    e semilunares, al&eacute;m do posicionamento dos vasos e s
uas correla&ccedil;&otilde;es,    podendo-se tamb&eacute;m acompanhar o moviment
o card&iacute;aco pelo uso da    t&eacute;cnica do <i>cineloop</i><sup>7-9</sup>
.</font></p>     ^cY#aop02811.htm##
01386000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704114200085002001301227#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#27#23#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Apesar dos in&uacute;meros 
   trabalhos desenvolvidos com a t&eacute;cnica de STIC, n&atilde;o se encontra 
   na literatura a sua aplica&ccedil;&atilde;o na avalia&ccedil;&atilde;o da med
ida    da &aacute;rea do septo interventricular em cora&ccedil;&otilde;es de fet
os    normais e/ou cardiopatas. Essa medida seria uma forma de analisar diretame
nte    os defeitos septais, que s&atilde;o os defeitos card&iacute;acos cong&eci
rc;nitos    mais comumente encontrados, perfazendo cerca de 30% das doen&ccedil;
as card&iacute;acas,    em especial os defeitos membran&aacute;ceos<sup>1</sup>,
 al&eacute;m de analisar    indiretamente as demais malforma&ccedil;&otilde;es c
ard&iacute;acas (como as    estenoses valvares com consequentes hipertrofias ven
triculares dentre outras).    Al&eacute;m disso, a medida da &aacute;rea valvar 
possibilitar&aacute; a detec&ccedil;&atilde;o    precoce da hipertrofia septal n
os fetos de gestantes diab&eacute;ticas, rastreando    fetos com maior probabili
dade de desenvolvimento de macrossomia e cardiomiopatia<sup>10,11</sup>.</font><
/p>     ^cY#aop02811.htm##
00569000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032500085002001300410#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#28#24#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Este estudo tem    por obje
tivo determinar valores de refer&ecirc;ncia para a &aacute;rea do septo    inter
ventricular de fetos normais entre a 18ª e a 33ª semanas de gesta&ccedil;&atilde
;o    por meio da US3D utilizando o m&eacute;todo STIC.</font></p>     ^cY#aop02
811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#29#25#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#30#26#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&eacute;todos</b></font
></p>     ^cY#aop02811.htm##
00801000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055700085002001300642#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#31#27#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Realizou-se um    estudo do
 tipo corte transversal, entre dezembro de 2009 e maio de 2010, com    69 gestan
tes entre a 18ª e a 33ª semanas completas de gesta&ccedil;&atilde;o.    Este est
udo foi aprovado pelo Comit&ecirc; de &Eacute;tica em Pesquisa da Universidade  
  Federal de S&atilde;o Paulo (Unifesp) sob o n<sup>0</sup> 0135/10, e as pacien
tes    que concordaram na participa&ccedil;&atilde;o volunt&aacute;ria assinaram
 Termo    de Consentimento Livre e Esclarecido.</font></p>     ^cY#aop02811.htm#
#
02066000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704182200085002001301907#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#32#28#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Todas as pacientes    foram
 selecionadas no setor de pr&eacute;-natal de baixo risco do Departamento    de 
Obstetr&iacute;cia da Unifesp, sendo essas oriundas do Sistema &Uacute;nico    d
e Sa&uacute;de do munic&iacute;pio e da regi&atilde;o metropolitana da cidade   
 de S&atilde;o Paulo. Os crit&eacute;rios de inclus&atilde;o foram os seguintes:
    gesta&ccedil;&atilde;o &uacute;nica com embri&atilde;o vivo e idade gestacio
nal    determinada pela data da &uacute;ltima menstrua&ccedil;&atilde;o (DUM) e 
confirmada    por ultrassonografia realizada at&eacute; a 10ª semana utilizando 
como par&acirc;metro    o Comprimento Cabe&ccedil;a-N&aacute;dega (CCN). Os crit
&eacute;rios de exclus&atilde;o    foram: oligo&acirc;mnio &#91;&Iacute;ndice de
 L&iacute;quido Amni&oacute;tico    (ILA) abaixo do percentil 5 para a idade ges
tacional, segundo tabela proposta    por Moore e Cayle<sup>12</sup>; feto posici
onado com o dorso anterior (entre    11 e 1h); fetos com peso estimado abaixo e/
ou acima de dois desvios-padr&atilde;o    da m&eacute;dia, de acordo com a tabel
a proposta de Hadlock; gestantes portadoras    de doen&ccedil;as cr&ocirc;nicas 
que pudessem afetar o crescimento e desenvolvimento    fetal, tais como hiperten
s&atilde;o arterial, diabete melito, colagenoses, entre    outras; atenua&ccedil
;&atilde;o intensa do feixe sonoro por condi&ccedil;&otilde;es    tais como obes
idade materna e cicatrizes abdominais; malforma&ccedil;&atilde;o    fetal diagno
sticada &agrave; ultrassonografia morfol&oacute;gica de 1º e 2º    trimestres; p
acientes tabagistas e/ou usu&aacute;rias de drogas il&iacute;citas.    Todas as 
gestantes foram submetidas a ecocardiografia fetal realizada entre    20 e 24 se
manas de gesta&ccedil;&atilde;o.</font></p>     ^cY#aop02811.htm##
01062000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704081800085002001300903#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#33#29#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Todos os exames    foram re
alizados no Setor de Cardiologia Fetal do Departamento de Obstetr&iacute;cia    
da Unifesp, sendo esses realizados por apenas um examinador (LCR) com experi&eci
rc;ncia    de tr&ecirc;s anos em US3D em obstetr&iacute;cia. Todos os exames for
am realizados    em um aparelho da marca Voluson 730 Expert (General Eletric Med
ical Systems,    Kretztechnic, Zipf, Austria) equipado com um transdutor convexo
 volum&eacute;trico    (RAB4-8P). As an&aacute;lises <i>off-line</i> para a mens
ura&ccedil;&atilde;o    das &aacute;reas do septo interventricular foram realiza
das pelo mesmo examinador    utilizando o <i>software</i> 4D <i>View</i> vers&at
ilde;o 9.0 (GE, Medical Systems    Kretztechnic, GmbH &amp; Co OHG).</font></p> 
    ^cY#aop02811.htm##
01345000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110100085002001301186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#34#30#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os volumes card&iacute;acos
    foram colhidos no corte das 4 c&acirc;maras card&iacute;acas com o dorso fet
al,    se poss&iacute;vel, na posi&ccedil;&atilde;o de 6 horas, utilizando-se um
 &acirc;ngulo    de abertura entre 20 e 40<sup>0</sup> e um tempo de aquisi&cced
il;&atilde;o    entre 10 e 15 segundos. Ap&oacute;s a varredura tridimensional, 
a imagem foi    apresentada na tela do aparelho na forma de tr&ecirc;s planos or
togonais: axial    (A), sagital (B) e coronal (C). Antes de se iniciar as avalia
&ccedil;&otilde;es,    foi utilizada a padroniza&ccedil;&atilde;o proposta por P
aladini<sup>13</sup>    para a orienta&ccedil;&atilde;o de volumes obtidos pelo 
STIC, ou seja, para    fetos em apresenta&ccedil;&atilde;o cef&aacute;lica, o la
do esquerdo do cora&ccedil;&atilde;o    coincide com o lado esquerdo da tela, en
quanto para os fetos p&eacute;lvicos,    o lado esquerdo do cora&ccedil;&atilde;
o coincide com o lado direito da tela;    devendo-se o plano A ser rodado 180<su
p>0</sup> em torno do eixo "Y".</font></p>     ^cY#aop02811.htm##
01920000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704167600085002001301761#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#35#31#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">O plano das quatro    c&aci
rc;maras card&iacute;acas (A) foi selecionado como referencial, sendo esse    ro
dado em torno do eixo "Z", de forma que o &aacute;pice card&iacute;aco se    dep
usesse em 6 horas; em seguida, foi ativada a tecla RENDER, com ponto de refer&ec
irc;ncia    da caixa disposta no ter&ccedil;o m&eacute;dio do septo interventric
ular. Tr&ecirc;s    planos virtuais para avalia&ccedil;&atilde;o do septo interv
entricular foram    utilizados. Dois planos foram determinados pelo posicionamen
to da linha verde    (ativa) da caixa de renderiza&ccedil;&atilde;o paralelo &ag
rave; borda externa    do septo interventricular, com o ponto m&eacute;dio manti
do no seu ter&ccedil;o    m&eacute;dio. Utilizou-se a op&ccedil;&atilde;o seis d
a ROI <i>selection</i>,    delimitando-se a regi&atilde;o do septo; por conven&c
cedil;&atilde;o, optou-se    pela sua visibiliza&ccedil;&atilde;o atrav&eacute;s
 do lado do ventr&iacute;culo    esquerdo. A imagem renderizada foi magnificada 
e ent&atilde;o a tecla MEASURE    foi acionada e a op&ccedil;&atilde;o TRACE ARE
A foi selecionada para se delimitar    manualmente a &aacute;rea septal em cm&su
p2;. A mensura&ccedil;&atilde;o da    &aacute;rea septal foi realizada durante a
 fase inicial da di&aacute;stole ventricular,    momento em que o septo encontra
va-se menos contra&iacute;do (<a href="/img/revistas/abc/2011nahead/aop02811f01.
jpg">Figura    1</a>). A medida bidimensional da espessura septal tamb&eacute;m 
foi obtida    no plano de quatro c&acirc;maras em mm (<a href="/img/revistas/abc
/2011nahead/aop02811f02.jpg">Figura    2</a>).</font></p>     ^cY#aop02811.htm##
02508000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704226400085002001302349#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#36#32#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Os dados foram    armazenad
os em planilha do programa Excel (Microsoft, Redmond, WA, USA) e analisados    p
or meio de um programa estat&iacute;stico <i>Statistical Package for the Social 
   Sciences</i> (SPSS) for Windows vers&atilde;o 15.0 (SPSS Inc., Chicago, IL,  
  USA). Foram calculadas m&eacute;dias, medianas, desvios-padr&atilde;o (dp),   
 valores m&aacute;ximo e m&iacute;nimo para cada intervalo gestacional avaliado,
    bem como os percentis 5, 25, 50, 75 e 95. Para se avaliar a correla&ccedil;&
atilde;o    entre as &aacute;reas do septo interventricular com a idade gestacio
nal (IG),    foram determinados diagramas de dispers&atilde;o obtendo-se &iacute
;ndice de    correla&ccedil;&atilde;o de Pearson (r), sendo o ajuste da equa&cce
dil;&atilde;o    determinado pelo coeficiente de determina&ccedil;&atilde;o (R<s
up>2</sup>).    Para a constru&ccedil;&atilde;o de intervalos de refer&ecirc;nci
a das &aacute;reas    do septo interventricular em fun&ccedil;&atilde;o da idade
 gestacional, seguiu-se    o modelo de regress&atilde;o linear simples<sup>14</s
up>, utilizando-se o m&eacute;todo    de Altman<sup>15</sup> com n&iacute;vel de
 signific&acirc;ncia de p &lt; 0,05.    Para se avaliar a medida da espessura se
ptal em fun&ccedil;&atilde;o da idade    gestacional utilizou-se tamb&eacute;m a
 regress&atilde;o linear. Para se avaliar    a correla&ccedil;&atilde;o entre a 
medida da espessura bidimensional do septo    interventricular e a sua &aacute;r
ea, utilizou-se o coeficiente de correla&ccedil;&atilde;o    intraclasse (CCI). 
Para o c&aacute;lculo da reprodutibilidade intraobservador,    o mesmo examinado
r (LCR) realizou uma segunda medida da &aacute;rea septal de    40 fetos, medida
s essas blindadas dos resultados da primeira. Para tanto, tamb&eacute;m    se ut
ilizou o CCI e o gr&aacute;fico de Bland-Altman<sup>16</sup>. Os gr&aacute;ficos
    de Bland-Altman plotam as m&eacute;dias duas medidas, realizadas por um mesm
o    examinador, contra a diferen&ccedil;a de suas m&eacute;dias com intervalo d
e    95% de confian&ccedil;a de 1,96 dp da m&eacute;dia. Em todas as an&aacute;l
ises    ser&aacute; utilizado n&iacute;vel de signific&acirc;ncia de 0,05.</font
></p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#37#33#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#38#34#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Resultados</b></font></p
>     ^cY#aop02811.htm##
00774000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053000085002001300615#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#39#35#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Foram avaliadas    69 gesta
ntes portando fetos normais entre a 18ª e a 33ª semanas completas da    gesta&cc
edil;&atilde;o, e todas preencheram os crit&eacute;rios de inclus&atilde;o    e 
foram alocadas na an&aacute;lise estat&iacute;stica final. A idade materna    em
 m&eacute;dia foi de 29,8 anos com dp &plusmn; 5,1, com m&eacute;dia de 1,4    g
esta&ccedil;&otilde;es (dp &plusmn; 0,5) e paridade m&eacute;dia de 0,3 partos  
  (dp &plusmn; 0,5).</font></p>     ^cY#aop02811.htm##
00897000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704065300085002001300738#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#40#36#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A &aacute;rea m&eacute;dia 
   da &aacute;rea septal foi de 0,47 &plusmn; 0,10 cm<sup>2</sup> (variando de  
  0,36 - 0,59 cm<sup>2</sup>) na 18ª semana para 2,42 &plusmn; 1,13 cm<sup>2</su
p>    (variando de 1,26 - 3,92 cm<sup>2</sup>) na 33ª semana de gesta&ccedil;&at
ilde;o.    A <a href="#t1">tabela 1</a> mostra m&eacute;dias, medianas, desvios-
padr&atilde;o    e valores m&iacute;nimos e m&aacute;ximos da &aacute;rea do sep
to interventricular,    enquanto a <a href="#t2">tabela 2</a> mostra os percenti
s 5, 25, 50, 75 e 95    em cada intervalo gestacional avaliado.</font></p>     ^
cY#aop02811.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#41#37#article#123#<p><a name
="t1"></a></p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#42#38#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#43#39#article#123#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02811t01.jpg"></p>     ^cY#aop
02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#44#40#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#45#41#article#123#<p><a name
="t2"></a></p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#46#42#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#47#43#article#123#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02811t02.jpg"></p>     ^cY#aop
02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#48#44#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00670000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042600085002001300511#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#49#45#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A &aacute;rea septal    apr
esentou forte correla&ccedil;&atilde;o com a idade gestacional (r = 0,81).    Fo
ram realizados modelos de regress&atilde;o polinomial, sendo o melhor ajuste    
com a equa&ccedil;&atilde;o exponencial: &aacute;rea do septo interventricular  
  = 0,125 x IG + 0,043, com R<sup>2</sup>=0,65 (<a href="#f3">Figura 3</a>).</fo
nt></p>     ^cY#aop02811.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#50#46#article#123#<p><a name
="f3"></a></p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#51#47#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#52#48#article#123#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02811f03.jpg"></p>     ^cY#aop
02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#53#49#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00917000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067300085002001300758#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#54#50#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em 52 pacientes,    a medid
a da espessura septal foi obtida no modo bidimensional, mas n&atilde;o    aprese
ntou correla&ccedil;&atilde;o significativa com a idade gestacional (R&sup2;    
= 0,20), mostrando um padr&atilde;o praticamente linear entre a 18ª e a 33ª    s
emanas completas de gesta&ccedil;&atilde;o (<a href="#f4">Figura 4</a>). Al&eacu
te;m    disso, n&atilde;o houve correla&ccedil;&atilde;o estatisticamente signif
icante    entre a medida da espessura e da &aacute;rea septal no intervalo gesta
cional    estudado com CCI= 0,150 &#91;95% IC -0,480; 0,512&#93;, com p &lt; 0,0
05.</font></p>     ^cY#aop02811.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#55#51#article#123#<p><a name
="f4"></a></p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#56#52#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#57#53#article#123#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02811f04.jpg"></p>     ^cY#aop
02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#58#54#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00742000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049800085002001300583#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#59#55#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Observou-se uma    excelent
e reprodutibilidade intraobservador para a medida da &aacute;rea do    septo int
erventricular, com CCI= 0,994 (IC 95% 0,988 - 0,997). O gr&aacute;fico    de Bla
nd-Altman comprovou essa boa reprodutibilidade com diferen&ccedil;a m&eacute;dia
    entre as medidas de 0,01 cm<sup>2</sup> (dp &plusmn; 0,06 cm<sup>2</sup> e I
C    95% &plusmn; 0,12 cm<sup>2</sup>) (<a href="#f5">Figura 5</a>).</font></p> 
    ^cY#aop02811.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003300085002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#60#56#article#123#<p><a name
="f5"></a></p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#61#57#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00331000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008700085002001300172#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#62#58#article#123#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop02811f05.jpg"></p>     ^cY#aop
02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#63#59#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#64#60#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop02811.htm##
02084000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704184000085002001301925#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#65#61#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A tecnologia STIC    tem es
tado dispon&iacute;vel em alguns aparelhos de US3D em meados da d&eacute;cada   
 de 2010. STIC consiste na aquisi&ccedil;&atilde;o do volume do cora&ccedil;&ati
lde;o    fetal com suas conex&otilde;es vasculares, permitindo a sua avalia&cced
il;&atilde;o    nos modo multiplanar ou renderizado na forma de uma sequ&ecirc;n
cia "cineloop"    de um ciclo card&iacute;aco completo. Para a aquisi&ccedil;&at
ilde;o do volume,    deve-se selecionar uma regi&atilde;o de interesse (ROI), qu
e determina a altura    e largura do volume, que englobe todo o cora&ccedil;&ati
lde;o com suas conex&otilde;es    vasculares. Sempre que poss&iacute;vel, a aqui
si&ccedil;&atilde;o deve ser realizada    com o feto em dorso posterior (6 horas
) e na aus&ecirc;ncia de movimentos respirat&oacute;rios    maternos. O &acirc;n
gulo de aquisi&ccedil;&atilde;o, que determina a profundidade    do volume, vari
a de acordo com a idade gestacional, e &acirc;ngulos entre 20    e 25<sup>0</sup
> s&atilde;o suficientes em fetos no segundo trimestre. O tempo    de aquisi&cce
dil;&atilde;o &eacute; determinado pelo operador, variando de 7,5    a 15 segund
os, e corresponde &agrave; velocidade com que o transdutor varre    a ROI. Ao vo
lume em escala de cinzas, pode-se associar o modo Doppler colorido,    al&eacute
;m de p&oacute;s-processamentos como o "inversion mode" e o "B-flow    imaging"<
sup>8,17</sup>. A vantagem do STIC em rela&ccedil;&atilde;o &agrave;    ecocardi
ografia bidimensional &eacute; ser um m&eacute;todo menos dependente    do opera
dor, possibilitando a identifica&ccedil;&atilde;o de anormalidades nas    vias d
e sa&iacute;da do cora&ccedil;&atilde;o fetal por examinadores com pouca    a in
termedi&aacute;ria experi&ecirc;ncia<sup>18</sup>.</font></p>     ^cY#aop02811.h
tm##
01771000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704152700085002001301612#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#66#62#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o   
 &agrave; renderiza&ccedil;&atilde;o de estruturas card&iacute;acas, Yagel e    
cols.<sup>19</sup> avaliaram 136 gestantes, sendo 35 portando fetos com anomalia
s    card&iacute;acas, utilizando a renderiza&ccedil;&atilde;o para obter planos
    para avalia&ccedil;&atilde;o dos septos interatrial e interventricular, &aci
rc;nulo    das valvas atrioventriculares e alinhamento dos grandes vasos. Em 13 
fetos com    anomalias card&iacute;acas, o plano do septo interventricular melho
rou a avalia&ccedil;&atilde;o    do defeito septal, e em 4 o plano do septo inte
ratrial contribuiu para avalia&ccedil;&atilde;o    do forame oval. Em 5 casos, o
 plano do &acirc;nulo das valvas atrioventriculares    imediatamente distais &ag
rave;s valvas semilunares (coronal AV) melhorou a avalia&ccedil;&atilde;o    do 
alinhamento dos grandes vasos em rela&ccedil;&atilde;o ao &acirc;nulo das    val
vas atrioventriculares, e em 3 a avalia&ccedil;&atilde;o das valvas semilunares,
    com ou sem mau alinhamento dos grandes vasos. Recentemente, Paladini e cols.
<sup>20</sup>    avaliaram uma s&eacute;rie de 30 casos de defeitos parciais do 
septo atrioventricular    fetal utilizando a ecocardiografia, e em 14 desses cas
os associou-se o STIC.    Em todos os casos os marcadores ecocardiogr&aacute;fic
os para essa anomalia    foram: defeito do septo atrial ostium primum e perda da
 apar&ecirc;ncia normal    das valvas atrioventriculares.</font></p>     ^cY#aop
02811.htm##
01230000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098600085002001301071#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#67#63#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">A medida da &aacute;rea    
do septo interventricular &eacute; de particular import&acirc;ncia em fetos    d
e risco para miocardiopatias hipertr&oacute;ficas, como os filhos de m&atilde;es
    diab&eacute;ticas, nos quais h&aacute; importante espessamento do septo inte
rventricular,    podendo causar obstru&ccedil;&otilde;es no trato de sa&iacute;d
a do ventr&iacute;culo    esquerdo<sup>21</sup>. A gravidade dos sintomas de ins
ufici&ecirc;ncia respirat&oacute;ria    e fal&ecirc;ncia card&iacute;aca congest
iva se correlacionam com a severidade    da miocardiopatia hipertr&oacute;fica<s
up>22,23</sup>. Tradicionalmente a medida    da espessura do septo interventricu
lar fetal tem sido realizada pela ecocardiografia    bidimensional utilizando o 
modo M<sup>10,11,24</sup>; contudo, tal medida apresenta    imprecis&otilde;es, 
pois o septo interventricular n&atilde;o &eacute; uma estrutura    uniforme.</fo
nt></p>     ^cY#aop02811.htm##
01230000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098600085002001301071#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#68#64#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Neste estudo, utilizou-se  
  a t&eacute;cnica STIC para mensura&ccedil;&atilde;o da &aacute;rea do septo   
 interventricular, metodologia at&eacute; o momento in&eacute;dita na literatura
.    A &aacute;rea do septo mostrou-se fortemente correlacionada com a idade ges
tacional,    al&eacute;m de comprovada reprodutibilidade intraobservador. J&aacu
te; a medida    da espessura septal mostrou fraca correla&ccedil;&atilde;o com a
 idade gestacional,    mostrando um padr&atilde;o praticamente linear da medida 
entre a 18ª e a 33ª    semanas completas de gesta&ccedil;&atilde;o, sem apresent
ar correla&ccedil;&atilde;o    estatisticamente significante com &aacute;rea obt
ida pelo STIC. Tal resultado    torna a &aacute;rea septal um poss&iacute;vel pa
r&acirc;metro ultrassonogr&aacute;fico    mais fidedigno que a medida da espessu
ra do septo interventricular no diagn&oacute;stico    de hipertrofia septal.</fo
nt></p>     ^cY#aop02811.htm##
00718000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047400085002001300559#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#69#65#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">Em s&iacute;ntese,    este 
estudo determinou valores de refer&ecirc;ncia para a &aacute;rea do septo    int
erventricular fetal que poder&atilde;o ser aplicados em fetos de risco para    h
ipertrofia septal, como os filhos de m&atilde;es diab&eacute;ticas, favorecendo 
   a detec&ccedil;&atilde;o precoce de altera&ccedil;&otilde;es funcionais e mor
fol&oacute;gicas    card&iacute;acas fetais.</font></p>     ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#70#66#article#123#<p>&nbsp;<
/p>     ^cY#aop02811.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#71#67#article#123#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="3"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop02811.htm##
00425000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704016700087002001300254#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#72#68#article#12
3#1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Moore KL, 
Persaud    TVN. Embriologia b&aacute;sica. Rio de Janeiro: Saunders/Elsevier; 20
08.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#73#69#article#123#</font></p
>     ^cY#aop02811.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704030500087002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#74#70#article#12
3#2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Hansen DE,
 Cahill    PD, DeCampli WM, Harrison DC, Derby GC, Mitchell RS. Valvular-ventric
ular intereaction:    importance of the mitral apparatus in canine left ventricu
lar systolic performance.    Circulation. 1986;73(6):1310-20.    ^cY#aop02811.ht
m##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#75#71#article#123#</font></p
>     ^cY#aop02811.htm##
00615000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704035700087002001300444#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#76#72#article#12
3#3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. McElhinney
 DB,    Silverman NH, Brook MM, Hanley FL, Stanger P. Asymmetrically short tendi
nous    cords causing congenital tricuspid regurgitation: improved understanding
 of    tricuspid valvular dysplasia in the era of color flow echocardiography. C
ardiol    Young. 1999;9(3):300-4.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#77#73#article#123#</font></p
>     ^cY#aop02811.htm##
00531000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027300087002001300360#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#78#74#article#12
3#4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Minami K, 
Kado    H, Sai S, Tatewaki H, Shiokawa Y, Nakashima A, et al. Midterm results of
 mitral    valve repair with artificial chordae in children. J Thorac Cardiovasc
 Surg.    2005;129(2):336-42.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#79#75#article#123#</font></p
>     ^cY#aop02811.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704030500087002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#80#76#article#12
3#5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. St&uuml;mp
flen    I, St&uuml;mpflen A, Wimmer M, Bernaschek G. Effect of detailed echocard
iography    as part of routine prenatal ultrasonographic screening on detection 
of congenital    heart disease. Lancet. 1996;348(9031):854-7.    ^cY#aop02811.ht
m##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#81#77#article#123#</font></p
>     ^cY#aop02811.htm##
00491000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023300087002001300320#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#82#78#article#12
3#6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Berghella 
V,    Pagotto L, Kaufman M, Huhta JC, Wapner RJ. Accuracy of prenatal diagnosis 
of    congenital heart defects. Fetal Diagn Ther. 2001; 16(6):407-12.    ^cY#aop
02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#83#79#article#123#</font></p
>     ^cY#aop02811.htm##
00489000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023100087002001300318#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#84#80#article#12
3#7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Kurjak A, 
Chervenak    FA. Donald School Textbook of Ultrasound in Obstetrics and Ginecolo
gy. New Delhi:    Jaypee Brothers Medical Publishers (P) Ltd; 2008.    ^cY#aop02
811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#85#81#article#123#</font></p
>     ^cY#aop02811.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704030800087002001300395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#86#82#article#12
3#8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Gon&ccedil
;alves    LF, Lee W, Chaiworapongsa T, Espinoza J, Schoen MJ, Falkensammer P, et
 al. Four-dimensional    ultrasonography of the fetal heart with spatiotemporal 
image correlation. Am    J Obstet Gynecol. 2003;189(6):1792-802.    ^cY#aop02811
.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#87#83#article#123#</font></p
>     ^cY#aop02811.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704026600087002001300353#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#88#84#article#12
3#9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Devore GR,
 Falkensammer    P, Sklansky MS, Platt LD. Spatio-temporal image correlation (ST
IC): new technology    for evaluation of the fetal heart. Ultrasound Obstet Gyne
col. 2003;22(4):380-7.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#89#85#article#123#</font></p
>     ^cY#aop02811.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704027900088002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#90#86#article#12
3#10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Macklon 
NS,    Hop WC, Wladimiroff JW. Fetal cardiac function and septal thickness in di
abetic    pregnancy: a controlled observational and reproducibility study. Br J 
Obstet    Gynaecol. 1998;5(6):661-6.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#91#87#article#123#</font></p
>     ^cY#aop02811.htm##
00608000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704034900088002001300437#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#92#88#article#12
3#11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Bethune 
M,    Bell R. Evaluation of the measurement of the fetal fat layer, interventric
ular    septum and abdominal circumference percentile in the prediction of macro
somia    in pregnancies affected by gestational diabetes. Ultrasound Obstet Gyne
col.    2003;22(6):586-90.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#93#89#article#123#</font></p
>     ^cY#aop02811.htm##
00435000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704017600088002001300264#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#94#90#article#12
3#12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Moore KL
. Anatomia    orientada para a cl&iacute;nica. 2ª ed. Rio de Janeiro: Guanabara 
Koogan; 1990.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#95#91#article#123#</font></p
>     ^cY#aop02811.htm##
00528000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704026900088002001300357#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#96#92#article#12
3#13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Paladini
 D.    Standardization of on-screen fetal heart orientation prior to storage of 
spatio-temporal    image correlation (STIC) volume datasets. Ultrasound Obstet G
ynecol. 2007;29(6):605-11.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#97#93#article#123#</font></p
>     ^cY#aop02811.htm##
00480000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704022100088002001300309#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#98#94#article#12
3#14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Hsieh FY
, Bloch    DA, Larsen MD. A simple method of sample size calculation for linear 
and logistic    regression. Stat Med. 1998;17(14):1623-34.    ^cY#aop02811.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002000085002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#99#95#article#123#</font></p
>     ^cY#aop02811.htm##
00454000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704019400089002001300283#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#100#96#article#1
23#15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Altman 
DG.    Construction of age-related reference centiles using absolute residuals. 
Stat    Med. 1993;12(10):917-24.    ^cY#aop02811.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#101#97#article#123#</font></
p>     ^cY#aop02811.htm##
00479000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704021900089002001300308#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#102#98#article#1
23#16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Bland J
M, Altman    DG. Statistical methods for assessing agreement between two methods
 of clinical    measurement. Lancet. 1986;1(8476):307-10.    ^cY#aop02811.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002000086002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#103#99#article#123#</font></
p>     ^cY#aop02811.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027800090002001300368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#104#100#article#
123#17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Vin&at
ilde;ls    F, Poblete P, Giuliano A. Spatio-temporal image correlation (STIC): a
 new tool    for the prenatal screening of congenital heart defects. Ultrasound 
Obstet Gynecol.    2003;22(4):388-94.    ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#105#101#article#123#</font><
/p>     ^cY#aop02811.htm##
00586000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032500090002001300415#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#106#102#article#
123#18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Paladi
ni D,    Sglavo G, Greco E, Nappi C. Cardiac screening by STIC: can sonologists 
performing    the 20-week anomaly can pick up outflow tract abnormalities by scr
olling the    A-plane of STIC volumes? Ultrasound Obstet Gynecol. 2008;32(7):865
-70.    ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#107#103#article#123#</font><
/p>     ^cY#aop02811.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#108#104#article#
123#19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Yagel 
S, Benachi    A, Bonnet D, Dumez Y, Hochner-Celnikier D, Cohen SM, et al. Render
ing in fetal    cardiac scanning: the intracardiac septa and the coronal atriove
ntricular valve    planes. Ultrasound Obstet Gynecol. 2006; 28(3):266-74.    ^cY
#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#109#105#article#123#</font><
/p>     ^cY#aop02811.htm##
00590000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032900090002001300419#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#110#106#article#
123#20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Paladi
ni D,    Volpe P, Sglavo G, Russo MG, De Robertis V, Penner I, et al. Partial at
rioventricular    septal defect in the fetus: diagnostic features and associatio
ns in a multicenter    series of 30 cases. Ultrasound Obstet Gynecol. 2009;34(3)
:268-73.    ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#111#107#article#123#</font><
/p>     ^cY#aop02811.htm##
00484000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022300090002001300313#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#112#108#article#
123#21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Abu-Su
laiman    RM, Subaih B. Congenital heart disease in infants of diabetic mothers:
 echocardiograph    study. Pediatr Cardiol. 2004;25(2):137-40.    ^cY#aop02811.h
tm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#113#109#article#123#</font><
/p>     ^cY#aop02811.htm##
00482000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022100090002001300311#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#114#110#article#
123#22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Gutges
ell HP,    Speer ME, Rosenberg HS. Characterization of the cardiomyopathy in inf
ants of    diabetic mothers. Circulation. 1980;61(2):441-50.    ^cY#aop02811.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#115#111#article#123#</font><
/p>     ^cY#aop02811.htm##
00466000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020500090002001300295#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#116#112#article#
123#23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Reller
 MD,    Kaplan S. Hypertrophic cardiomyopathy in infants of diabetic mothers: an
 update.    Am J Perinatol. 1988;5(4):353-8.    ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#117#113#article#123#</font><
/p>     ^cY#aop02811.htm##
00516000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025500090002001300345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#118#114#article#
123#24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Wong M
L, Wong    WH, Cheung YF. Fetal myocardial performance in pregnancies complicate
d by gestational    impaired glucose tolerance. Ultrasound Obstet Gynecol. 2007;
29(4):395-400.    ^cY#aop02811.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002000087002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#119#115#article#123#</font><
/p>     ^cY#aop02811.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#120#116#article#123#<p>&nbsp
;</p>     ^cY#aop02811.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#121#117#article#123#<p>&nbsp
;</p>     ^cY#aop02811.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704019900087002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#122#118#article#123#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a hre
f="#top"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a>    <b>
 Correspond&ecirc;ncia:    ^cY#aop02811.htm##
00293000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004700087002001300134#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#123#119#article#123#<br>   <
/b> Edward Araujo J&uacute;nior    ^cY#aop02811.htm##
00313000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006700087002001300154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#124#120#article#123#<br>   R
ua Napole&atilde;o de Barros, 875 - Vila Clementino    ^cY#aop02811.htm##
00302000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005600087002001300143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#125#121#article#123#<br>   0
4024-002 - S&atilde;o Paulo, SP - Brasil    ^cY#aop02811.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010300087002001300190#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#126#122#article#123#<br>   E
-mail: <a href="mailto:araujojred@terra.com.br">araujojred@terra.com.br</a></fon
t></p>     ^cY#aop02811.htm##
00411000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016500087002001300252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02811.htm#S#p#127#123#article#123#<p><font
 face="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo recebido    em 29/
07/10; revisado recebido em 17/11/10; aceito em 14/12/10.</font></p>     ^cY#aop
02811.htm##
00467000000000253000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840160016000860160019001020180
02300121066001500144062000900159062000900168065000900177064000500186865000900191
002001300200#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#
128#1#article#24#1#^rND^sMoore^nKL#^rND^sPersaud^nTVN#Embriologia básica^lpt#Rio
 de Janeiro#Saunders#Elsevier#20080000#2008#20110000#aop02811.htm##
00736000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030100
01900120010001900139010001600158010001900174012012200193030001200315065000900327
06400050033603100030034103200020034401400080034686500090035400200130036303500100
0376801001200386#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#
S#c#129#2#article#24#2#^rND^sHansen^nDE#^rND^sCahill^nPD#^rND^sDeCampli^nWM#^rND
^sHarrison^nDC#^rND^sDerby^nGC#^rND^sMitchell^nRS#Valvular-ventricular intereact
ion: importance of the mitral apparatus in canine left ventricular systolic perf
ormance^len#Circulation#19860000#1986#73#6#1310-20#20110000#aop02811.htm#0009-73
22#Circulation##
00769000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100021000860100020001070100
01600127010001700143010001700160012018200177030001400359065000900373064000500382
03100020038703200020038901400060039186500090039700200130040603500100041980100140
0429#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#130#3#ar
ticle#24#3#^rND^sMcElhinney^nDB#^rND^sSilverman^nNH#^rND^sBrook^nMM#^rND^sHanley
^nFL#^rND^sStanger^nP#Asymmetrically short tendinous cords causing congenital tr
icuspid regurgitation: improved understanding of tricuspid valvular dysplasia in
 the era of color flow echocardiography^len#Cardiol Young#19990000#1999#9#3#300-
4#20110000#aop02811.htm#1047-9511#Cardiol Young##
00728000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100014001020100
01300116010001800129010001800147010001900165810000600184012007900190030002500269
06500090029406400050030303100040030803200020031201400070031486500090032100200130
0330035001000343801002500353#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02811.htm#S#c#131#4#article#24#4#^rND^sMinami^nK#^rND^sKado^nH#^rND^sSai^nS#^r
ND^sTatewaki^nH#^rND^sShiokawa^nY#^rND^sNakashima^nA#et al#Midterm results of mi
tral valve repair with artificial chordae in children^len#J Thorac Cardiovasc Su
rg#20050000#2005#129#2#336-42#20110000#aop02811.htm#0022-5223#J Thorac Cardiovas
c Surg##
00685000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100019001050100
01600124010002000140012013600160030000700296065000900303064000500312031000400317
032000500321014000600326865000900332002001300341035001000354801000700364#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#132#5#article#24#5#^
rND^sStümpflen^nI#^rND^sStümpflen^nA#^rND^sWimmer^nM#^rND^sBernaschek^nG#Effect 
of detailed echocardiography as part of routine prenatal ultrasonographic screen
ing on detection of congenital heart disease^len#Lancet#19960000#1996#348#9031#8
54-7#20110000#aop02811.htm#0099-5355#Lancet##
00653000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100017001050100
01700122010001600139010001700155012006300172030001700235065000900252064000500261
03100030026603200020026901400070027186500090027800200130028703500100030080100170
0310#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#133#6#ar
ticle#24#6#^rND^sBerghella^nV#^rND^sPagotto^nL#^rND^sKaufman^nM#^rND^sHuhta^nJC#
^rND^sWapner^nRJ#Accuracy of prenatal diagnosis of congenital heart defects^len#
Fetal Diagn Ther#20010000#2001#16#6#407-12#20110000#aop02811.htm#1015-3837#Fetal
 Diagn Ther##
00515000000000241000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840160016000860160020001020180
07000122066001000192062003500202065000900237064000500246865000900251002001300260
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#134#7#articl
e#24#7#^rND^sKurjak^nA#^rND^sChervenak^nFA#Donald School Textbook of Ultrasound 
in Obstetrics and Ginecology^len#New Delhi#Jaypee Brothers Medical Publishers#20
080000#2008#20110000#aop02811.htm##
00751000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100013001060100
02400119010001800143010001700161010002200178810000600200012009400206030002000300
06500090032006400050032903100040033403200020033801400090034086500090034900200130
0358035001000371801002000381#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02811.htm#S#c#135#8#article#24#8#^rND^sGonçalves^nLF#^rND^sLee^nW#^rND^sChaiwo
rapongsa^nT#^rND^sEspinoza^nJ#^rND^sSchoen^nMJ#^rND^sFalkensammer^nP#et al#Four-
dimensional ultrasonography of the fetal heart with spatiotemporal image correla
tion^len#Am J Obstet Gynecol#20030000#2003#189#6#1792-802#20110000#aop02811.htm#
0002-9378#Am J Obstet Gynecol##
00678000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100022001030100
01900125010001600144012009500160030002600255065000900281064000500290031000300295
032000200298014000600300865000900306002001300315035001000328801002600338#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#136#9#article#24#9#^
rND^sDevore^nGR#^rND^sFalkensammer^nP#^rND^sSklansky^nMS#^rND^sPlatt^nLD#Spatio-
temporal image correlation (STIC): new technology for evaluation of the fetal he
art^len#Ultrasound Obstet Gynecol#20030000#2003#22#4#380-7#20110000#aop02811.htm
#0960-7692#Ultrasound Obstet Gynecol##
00666000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100014001060100
02200120012012400142030002100266065000900287064000500296031000200301032000200303
014000600305865000900311002001300320035001000333801002100343#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02811.htm#S#c#137#10#article#24#10#^rND^sMackl
on^nNS#^rND^sHop^nWC#^rND^sWladimiroff^nJW#Fetal cardiac function and septal thi
ckness in diabetic pregnancy: a controlled observational and reproducibility stu
dy^len#Br J Obstet Gynaecol#19980000#1998#5#6#661-6#20110000#aop02811.htm#0306-5
456#Br J Obstet Gynaecol##
00720000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100014001050120
20100119030002600320065000900346064000500355031000300360032000200363014000700365
865000900372002001300381035001000394801002600404#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02811.htm#S#c#138#11#article#24#11#^rND^sBethune^nM#^rND^s
Bell^nR#Evaluation of the measurement of the fetal fat layer, interventricular s
eptum and abdominal circumference percentile in the prediction of macrosomia in 
pregnancies affected by gestational diabetes^len#Ultrasound Obstet Gynecol#20030
000#2003#22#6#586-90#20110000#aop02811.htm#0960-7692#Ultrasound Obstet Gynecol##
00455000000000241000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850160016000880180038001040630
00300142066001500145062001700160065000900177064000500186865000900191002001300200
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#139#12#artic
le#24#12#^rND^sMoore^nKL#Anatomia orientada para a clínica^lpt#2ª#Rio de Janeiro
#Guanabara Koogan#19900000#1990#20110000#aop02811.htm##
00628000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880120134001060300
02600240065000900266064000500275031000300280032000200283014000700285865000900292
002001300301035001000314801002600324#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02811.htm#S#c#140#13#article#24#13#^rND^sPaladini^nD#Standardization o
f on-screen fetal heart orientation prior to storage of spatio-temporal image co
rrelation (STIC) volume datasets^len#Ultrasound Obstet Gynecol#20070000#2007#29#
6#605-11#20110000#aop02811.htm#0960-7692#Ultrasound Obstet Gynecol##
00599000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01700120012008200137030000900219065000900228064000500237031000300242032000300245
014000800248865000900256002001300265035001000278801000900288#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02811.htm#S#c#141#14#article#24#14#^rND^sHsieh
^nFY#^rND^sBloch^nDA#^rND^sLarsen^nMD#A simple method of sample size calculation
 for linear and logistic regression^len#Stat Med#19980000#1998#17#14#1623-34#201
10000#aop02811.htm#0277-6715#Stat Med##
00536000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120076001050300
00900181065000900190064000500199031000300204032000300207014000700210865000900217
002001300226035001000239801000900249#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02811.htm#S#c#142#15#article#24#15#^rND^sAltman^nDG#Construction of ag
e-related reference centiles using absolute residuals^len#Stat Med#19930000#1993
#12#10#917-24#20110000#aop02811.htm#0277-6715#Stat Med##
00577000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040120
09200121030000700213065000900220064000500229031000200234032000500236014000700241
865000900248002001300257035001000270801000700280#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02811.htm#S#c#143#16#article#24#16#^rND^sBland^nJM#^rND^sA
ltman^nDG#Statistical methods for assessing agreement between two methods of cli
nical measurement^len#Lancet#19860000#1986#1#8476#307-10#20110000#aop02811.htm#0
099-5355#Lancet##
00663000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040100
01800121012011200139030002600251065000900277064000500286031000300291032000200294
014000700296865000900303002001300312035001000325801002600335#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02811.htm#S#c#144#17#article#24#17#^rND^sVinãl
s^nF#^rND^sPoblete^nP#^rND^sGiuliano^nA#Spatio-temporal image correlation (STIC)
: a new tool for the prenatal screening of congenital heart defects^len#Ultrasou
nd Obstet Gynecol#20030000#2003#22#4#388-94#20110000#aop02811.htm#0960-7692#Ultr
asound Obstet Gynecol##
00736000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01500122010001500137012016000152030002600312065000900338064000500347031000300352
032000200355014000700357865000900364002001300373035001000386801002600396#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02811.htm#S#c#145#18#article#24#18
#^rND^sPaladini^nD#^rND^sSglavo^nG#^rND^sGreco^nE#^rND^sNappi^nC#Cardiac screeni
ng by STIC: can sonologists performing the 20-week anomaly can pick up outflow t
ract abnormalities by scrolling the A-plane of STIC volumes?^len#Ultrasound Obst
et Gynecol#20080000#2008#32#7#865-70#20110000#aop02811.htm#0960-7692#Ultrasound 
Obstet Gynecol##
00770000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01600120010001500136010002700151010001600178810000600194012011000200030002600310
06500090033606400050034503100030035003200020035301400070035586500090036200200130
0371035001000384801002600394#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02811.htm#S#c#146#19#article#24#19#^rND^sYagel^nS#^rND^sBenachi^nA#^rND^sBonne
t^nD#^rND^sDumez^nY#^rND^sHochner-Celnikier^nD#^rND^sCohen^nSM#et al#Rendering i
n fetal cardiac scanning: the intracardiac septa and the coronal atrioventricula
r valve planes^len#Ultrasound Obstet Gynecol#20060000#2006#28#3#266-74#20110000#
aop02811.htm#0960-7692#Ultrasound Obstet Gynecol##
00786000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01600121010001600137010002100153010001600174810000600190012013000196030002600326
06500090035206400050036103100030036603200020036901400070037186500090037800200130
0387035001000400801002600410#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02811.htm#S#c#147#20#article#24#20#^rND^sPaladini^nD#^rND^sVolpe^nP#^rND^sSgla
vo^nG#^rND^sRusso^nMG#^rND^sDe Robertis^nV#^rND^sPenner^nI#et al#Partial atriove
ntricular septal defect in the fetus: diagnostic features and associations in a 
multicenter series of 30 cases^len#Ultrasound Obstet Gynecol#20090000#2009#34#3#
268-73#20110000#aop02811.htm#0960-7692#Ultrasound Obstet Gynecol##
00590000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100016001110120
08300127030001600210065000900226064000500235031000300240032000200243014000700245
865000900252002001300261035001000274801001600284#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02811.htm#S#c#148#21#article#24#21#^rND^sAbu-Sulaiman^nRM#
^rND^sSubaih^nB#Congenital heart disease in infants of diabetic mothers: echocar
diograph study^len#Pediatr Cardiol#20040000#2004#25#2#137-40#20110000#aop02811.h
tm#0172-0643#Pediatr Cardiol##
00602000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100016001080100
02000124012007400144030001200218065000900230064000500239031000300244032000200247
014000700249865000900256002001300265035001000278801001200288#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02811.htm#S#c#149#22#article#24#22#^rND^sGutge
sell^nHP#^rND^sSpeer^nME#^rND^sRosenberg^nHS#Characterization of the cardiomyopa
thy in infants of diabetic mothers^len#Circulation#19800000#1980#61#2#441-50#201
10000#aop02811.htm#0009-7322#Circulation##
00571000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050120
07400121030001500195065000900210064000500219031000200224032000200226014000600228
865000900234002001300243035001000256801001500266#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02811.htm#S#c#150#23#article#24#23#^rND^sReller^nMD#^rND^s
Kaplan^nS#Hypertrophic cardiomyopathy in infants of diabetic mothers: an update^
len#Am J Perinatol#19880000#1988#5#4#353-8#20110000#aop02811.htm#0735-1631#Am J 
Perinatol##
00650000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030100
01700118012010200135030002600237065000900263064000500272031000300277032000200280
014000800282865000900290002001300299035001000312801002600322#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02811.htm#S#c#151#24#article#24#24#^rND^sWong^
nML#^rND^sWong^nWH#^rND^sCheung^nYF#Fetal myocardial performance in pregnancies 
complicated by gestational impaired glucose tolerance^len#Ultrasound Obstet Gyne
col#20070000#2007#29#4#395-400#20110000#aop02811.htm#0960-7692#Ultrasound Obstet
 Gynecol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#o#1#1#
article#1#20110331#081818#aop03011.htm#193##
04298000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200760017301200730
02490100039003220100032003610100034003930700054004270831470004810850008019510850
04001959085003201999085003202031085002902063083136802092085000803460085003803468
08500310350608500320353708500250356911700080359407200030360211200090360511100090
3614116000903623115000903632114000903641113000903650002001303659#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#h#2#1#article#1#oa#pt#br1.1#1#
4.0#TAB#39#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#Pr
editores de função ventricular esquerda global na síndrome metabólica^lpt#Predic
tors of global left ventricular function in metabolic syndrome^len#^rND^1A01^nBr
anislava Aleksa^sIvanovic#^rND^1A01^nMarijana Vaso^sTadic#^rND^1A01^nDragan Voji
slav^sSimic#Clinical Centre of Serbia^iA01^1Clinic for Cardiology#^lpt^aFUNDAMEN
TO: A síndrome metabólica (SM) representa um conjunto de fatores de risco cardio
vascular que agem de forma sinérgica. OBJETIVO: O objetivo desse estudo foi dete
rminar quais parâmetros estavam associados de forma independente à função global
 do ventrículo esquerdo (VE) em indivíduos com SM, estimada através do índice Te
i. MÉTODOS: O estudo incluiu 234 indivíduos com SM e 96 controles ajustados por 
idade. A SM foi definida pela presença de três ou mais critérios da ATP-NCEP III
. Todos os indivíduos foram submetidos a testes laboratoriais e ecocardiograma b
idimensional e com Doppler pulsátil e tecidual. Intervalos de tempo apropriados 
no Doppler tecidual para a estimativa do índice Tei também foram avaliados. RESU
LTADOS: O índice Tei estava aumentado em todos os indivíduos com SM (0,35 ± 0,05
 vs 0,49 ± 0,10, p < 0,001). Análise de regressão múltipla dos parâmetros clínic
os mostrou que a pressão arterial sistólica (&#946;= 0,289, p < 0,001), glicemia
 de jejum (&#946;= 0,205, p = 0,009), índice de massa do VE (&#946;= 0,301, p < 
0,001), E/e'septal (&#946;= 0,267, p < 0,001) e e'septal (&#946;= -0,176, p = 0,
011) estavam independentemente associados com a função ventricular esquerda glob
al estimada pelo índice Tei. CONCLUSÃO: A SM teve um impacto significante na fun
ção global do VE. A pressão arterial sistólica, glicemia de jejum, índice de mas
sa do VE E/e'septal, e e'septal estavam independentemente associados com a funçã
o global do VE.#^dnd^i1#^tm^lpt^kFunção ventricular esquerda^i1#^tm^lpt^ksindrom
e metabólica^i1#^tm^lpt^kisquemia miocárdica^i1#^tm^lpt^kfatores de risco^i1#^le
n^aBACKGROUND: The metabolic syndrome (MS) represents a cluster of cardiovascula
r risk factors that act synergistically. OBJECTIVE: The aim of this study was to
 determine which parameters were independently associated with the global left v
entricular (LV) function in subjects with MS estimated with the Tei index. METHO
DS: The study included 234 subjects with MS and 96 controls adjusted by age. MS 
was defined by the presence of three or more of ATP- NCEP III criteria. All subj
ects underwent laboratory blood tests and two-dimensional, pulsed and tissue Dop
pler echocardiography. Appropriate tissue Doppler time intervals for the estimat
ion of the Tei index were also assessed. RESULTS: The Tei index was increased in
 subjects with MS (0.35 ± 0.05 vs 0.49 ± 0.10, p < 0.001). Multiple regression a
nalysis of the clinical parameters showed that systolic blood pressure (&#946;= 
0.289, p < 0.001), fasting glucose (&#946;= 0.205, p = 0.009), LV mass index (&#
946;= 0.301, p < 0.001), E/e'septal (&#946;= 0.267, p < 0.001), and e'septal (&#
946;= -0.176, p = 0.011) were independently associated with the global left vent
ricular function estimated by Tei index. CONCLUSION: MS has a significant impact
 on LV global function. Systolic blood pressure, fasting glucose, LV mass index,
 E/e'septal, and e'septal were independently associated with the LV global funct
ion.#^dnd^i2#^tm^len^kVentricular function left^i2#^tm^len^kmetabolic syndrome^i
2#^tm^len^kmyocardial ischemia^i2#^tm^len^krisk factors^i2#vancouv#29#20100714#1
4/07/10#20101025#25/10/10#20101203#03/12/10#aop03011.htm##
04508000000000625000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200830017301200800
02560100039003360100032003750100034004070700054004410831568004950850008020630850
04002071085003202111085003202143085002902175083146602204085000803670085003803678
08500310371608500320374708500250377911700080380407200030381211200090381511100090
3824116000903833115000903842114000903851113000903860002001303869#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#f#3#1#article#1#oa#pt#br1.1#1#
4.0#TAB#39#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#<b
>Preditores de função ventricular esquerda global na síndrome metabólica</b>^lpt
#<b>Predictors of global left ventricular function in metabolic syndrome</b>^len
#^rND^1A01^nBranislava Aleksa^sIvanovic#^rND^1A01^nMarijana Vaso^sTadic#^rND^1A0
1^nDragan Vojislav^sSimic#Clinical Centre of Serbia^iA01^1Clinic for Cardiology#
^lpt^a<b>FUNDAMENTO:</b> A síndrome metabólica (SM) representa um conjunto de fa
tores de risco cardiovascular que agem de forma sinérgica. <b>OBJETIVO:</b> O ob
jetivo desse estudo foi determinar quais parâmetros estavam associados de forma 
independente à função global do ventrículo esquerdo (VE) em indivíduos com SM, e
stimada através do índice Tei. <b>MÉTODOS:</b> O estudo incluiu 234 indivíduos c
om SM e 96 controles ajustados por idade. A SM foi definida pela presença de trê
s ou mais critérios da ATP-NCEP III. Todos os indivíduos foram submetidos a test
es laboratoriais e ecocardiograma bidimensional e com Doppler pulsátil e tecidua
l. Intervalos de tempo apropriados no Doppler tecidual para a estimativa do índi
ce Tei também foram avaliados. <b>RESULTADOS:</b> O índice Tei estava aumentado 
em todos os indivíduos com SM (0,35 ± 0,05 <i>vs</i> 0,49 ± 0,10, p &lt; 0,001).
 Análise de regressão múltipla dos parâmetros clínicos mostrou que a pressão art
erial sistólica (&#946;= 0,289, p &lt; 0,001), glicemia de jejum (&#946;= 0,205,
 p = 0,009), índice de massa do VE (&#946;= 0,301, p &lt; 0,001), E/e'<sub>septa
l</sub> (&#946;= 0,267, p &lt; 0,001) e e'<sub>septal</sub> (&#946;= -0,176, p =
 0,011) estavam independentemente associados com a função ventricular esquerda g
lobal estimada pelo índice Tei. <b>CONCLUSÃO:</b> A SM teve um impacto significa
nte na função global do VE. A pressão arterial sistólica, glicemia de jejum, índ
ice de massa do VE E/e'<sub>septal</sub>, e e'<sub>septal</sub> estavam independ
entemente associados com a função global do VE.#^dnd^i1#^tm^lpt^kFunção ventricu
lar esquerda^i1#^tm^lpt^ksindrome metabólica^i1#^tm^lpt^kisquemia miocárdica^i1#
^tm^lpt^kfatores de risco^i1#^len^a<b>BACKGROUND:</b> The metabolic syndrome (MS
) represents a cluster of cardiovascular risk factors that act synergistically. 
<b>OBJECTIVE:</b> The aim of this study was to determine which parameters were i
ndependently associated with the global left ventricular (LV) function in subjec
ts with MS estimated with the Tei index. <b>METHODS:</b> The study included 234 
subjects with MS and 96 controls adjusted by age. MS was defined by the presence
 of three or more of ATP- NCEP III criteria. All subjects underwent laboratory b
lood tests and two-dimensional, pulsed and tissue Doppler echocardiography. Appr
opriate tissue Doppler time intervals for the estimation of the Tei index were a
lso assessed. <b>RESULTS:</b> The Tei index was increased in subjects with MS (0
.35 ± 0.05 <i>vs</i> 0.49 ± 0.10, p &lt; 0.001). Multiple regression analysis of
 the clinical parameters showed that systolic blood pressure (&#946;= 0.289, p &
lt; 0.001), fasting glucose (&#946;= 0.205, p = 0.009), LV mass index (&#946;= 0
.301, p &lt; 0.001), E/e'<sub>septal</sub> (&#946;= 0.267, p &lt; 0.001), and e'
<sub>septal</sub> (&#946;= -0.176, p = 0.011) were independently associated with
 the global left ventricular function estimated by Tei index. <b>CONCLUSION:</b>
 MS has a significant impact on LV global function. Systolic blood pressure, fas
ting glucose, LV mass index, E/e'<sub>septal</sub>, and e'<sub>septal</sub> were
 independently associated with the LV global function.#^dnd^i2#^tm^len^kVentricu
lar function left^i2#^tm^len^kmetabolic syndrome^i2#^tm^len^kmyocardial ischemia
^i2#^tm^len^krisk factors^i2#vancouv#29#20100714#14/07/10#20101025#25/10/10#2010
1203#03/12/10#aop03011.htm##
04419000000000649000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001200760
01790120073002550100039003280100032003670100034003990700056004330831470004890850
00801959085004001967085003202007085003202039085002902071083136802100085000803468
08500380347608500310351408500320354508500250357711700080360207200030361011200090
36131110009036221160009036311150009036401140009036491130009036580020013036670080
08903680#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#l#4#1#
article#1#^a2011#oa#pt#br1.1#1#4.0#tab#39#nd#nd#Arq. bras. cardiol#ahead#2011000
0#^f0^l0#0066-782X#20110401#Preditores de função ventricular esquerda global na 
síndrome metabólica^lpt#Predictors of global left ventricular function in metabo
lic syndrome^len#^rND^1A01^nBranislava Aleksa^sIvanovic#^rND^1A01^nMarijana Vaso
^sTadic#^rND^1A01^nDragan Vojislav^sSimic#^iA01^1Clinical Centre of Serbia^2Clin
ic for Cardiology#^lpt^aFUNDAMENTO: A síndrome metabólica (SM) representa um con
junto de fatores de risco cardiovascular que agem de forma sinérgica. OBJETIVO: 
O objetivo desse estudo foi determinar quais parâmetros estavam associados de fo
rma independente à função global do ventrículo esquerdo (VE) em indivíduos com S
M, estimada através do índice Tei. MÉTODOS: O estudo incluiu 234 indivíduos com 
SM e 96 controles ajustados por idade. A SM foi definida pela presença de três o
u mais critérios da ATP-NCEP III. Todos os indivíduos foram submetidos a testes 
laboratoriais e ecocardiograma bidimensional e com Doppler pulsátil e tecidual. 
Intervalos de tempo apropriados no Doppler tecidual para a estimativa do índice 
Tei também foram avaliados. RESULTADOS: O índice Tei estava aumentado em todos o
s indivíduos com SM (0,35 ± 0,05 vs 0,49 ± 0,10, p < 0,001). Análise de regressã
o múltipla dos parâmetros clínicos mostrou que a pressão arterial sistólica (&#9
46;= 0,289, p < 0,001), glicemia de jejum (&#946;= 0,205, p = 0,009), índice de 
massa do VE (&#946;= 0,301, p < 0,001), E/e'septal (&#946;= 0,267, p < 0,001) e 
e'septal (&#946;= -0,176, p = 0,011) estavam independentemente associados com a 
função ventricular esquerda global estimada pelo índice Tei. CONCLUSÃO: A SM tev
e um impacto significante na função global do VE. A pressão arterial sistólica, 
glicemia de jejum, índice de massa do VE E/e'septal, e e'septal estavam independ
entemente associados com a função global do VE.#^dnd^i1#^tm^lpt^kFunção ventricu
lar esquerda^i1#^tm^lpt^ksindrome metabólica^i1#^tm^lpt^kisquemia miocárdica^i1#
^tm^lpt^kfatores de risco^i1#^len^aBACKGROUND: The metabolic syndrome (MS) repre
sents a cluster of cardiovascular risk factors that act synergistically. OBJECTI
VE: The aim of this study was to determine which parameters were independently a
ssociated with the global left ventricular (LV) function in subjects with MS est
imated with the Tei index. METHODS: The study included 234 subjects with MS and 
96 controls adjusted by age. MS was defined by the presence of three or more of 
ATP- NCEP III criteria. All subjects underwent laboratory blood tests and two-di
mensional, pulsed and tissue Doppler echocardiography. Appropriate tissue Dopple
r time intervals for the estimation of the Tei index were also assessed. RESULTS
: The Tei index was increased in subjects with MS (0.35 ± 0.05 vs 0.49 ± 0.10, p
 < 0.001). Multiple regression analysis of the clinical parameters showed that s
ystolic blood pressure (&#946;= 0.289, p < 0.001), fasting glucose (&#946;= 0.20
5, p = 0.009), LV mass index (&#946;= 0.301, p < 0.001), E/e'septal (&#946;= 0.2
67, p < 0.001), and e'septal (&#946;= -0.176, p = 0.011) were independently asso
ciated with the global left ventricular function estimated by Tei index. CONCLUS
ION: MS has a significant impact on LV global function. Systolic blood pressure,
 fasting glucose, LV mass index, E/e'septal, and e'septal were independently ass
ociated with the LV global function.#^dnd^i2#^tm^len^kVentricular function left^
i2#^tm^len^kmetabolic syndrome^i2#^tm^len^kmyocardial ischemia^i2#^tm^len^krisk 
factors^i2#vancouv#29#20100714#14/07/10#20101025#25/10/10#20101203#03/12/10#aop0
3011.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-
782X2011005000039##
00450000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704020800083002001300291#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#5#1#article#160#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Predito
res de fun&ccedil;&atilde;o ventricular esquerda global na s&iacute;ndrome metab
&oacute;lica</b></font></p>     ^cY#aop03011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#6#2#article#160#<p>&nbsp;</p
>     ^cY#aop03011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#7#3#article#160#<p>&nbsp;</p
>     ^cY#aop03011.htm##
00403000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704016100083002001300244#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#8#4#article#160#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Branislava Aleksa Ivanovic
; Marijana Vaso Tadic; Dragan Vojislav Simic </b></font></p>     ^cY#aop03011.ht
m##
00373000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704013100083002001300214#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#9#5#article#160#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif">Clinic for Cardiology, Clinic
al Centre of Serbia</font></p>     ^cY#aop03011.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#10#6#article#160#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop03011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#11#7#article#160#<p>&nbsp;</
p>     ^cY#aop03011.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#12#8#article#160#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop03011.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#13#9#article#160#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>    
 ^cY#aop03011.htm##
00469000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022500085002001300310#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#14#10#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO:</b> A s&iacu
te;ndrome metab&oacute;lica (SM) representa um conjunto de fatores de risco card
iovascular que agem de forma sin&eacute;rgica.     ^cY#aop03011.htm##
00526000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028200085002001300367#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#15#11#article#160#<br>   <b>
OBJETIVO:</b> O objetivo desse estudo foi determinar quais par&acirc;metros esta
vam associados de forma independente &agrave; fun&ccedil;&atilde;o global do ven
tr&iacute;culo esquerdo (VE) em indiv&iacute;duos com SM, estimada atrav&eacute;
s do &iacute;ndice Tei.     ^cY#aop03011.htm##
00720000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704047600085002001300561#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#16#12#article#160#<br>   <b>
M&Eacute;TODOS:</b> O estudo incluiu 234 indiv&iacute;duos com SM e 96 controles
 ajustados por idade. A SM foi definida pela presen&ccedil;a de tr&ecirc;s ou ma
is crit&eacute;rios da ATP-NCEP III. Todos os indiv&iacute;duos foram submetidos
 a testes laboratoriais e ecocardiograma bidimensional e com Doppler puls&aacute
;til e tecidual. Intervalos de tempo apropriados no Doppler tecidual para a esti
mativa do &iacute;ndice Tei tamb&eacute;m foram avaliados.    ^cY#aop03011.htm##
01245000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704100100085002001301086#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#17#13#article#160#<br>   <b>
RESULTADOS:</b> O &iacute;ndice Tei estava aumentado em todos os indiv&iacute;du
os com SM (0,35 ± 0,05 <i>vs</i> 0,49 ± 0,10, p &lt; 0,001). An&aacute;lise de r
egress&atilde;o m&uacute;ltipla dos par&acirc;metros cl&iacute;nicos mostrou que
 a press&atilde;o arterial sist&oacute;lica (</font>&#946;<font size="2" face="V
erdana, Arial, Helvetica, sans-serif">= 0,289, p &lt; 0,001), glicemia de jejum 
(</font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">= 0,20
5, p = 0,009), &iacute;ndice de massa do VE (</font>&#946;<font size="2" face="V
erdana, Arial, Helvetica, sans-serif">= 0,301, p &lt; 0,001), E/e'<sub>septal</s
ub> (</font>&#946;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">= 
0,267, p &lt; 0,001) e e'<sub>septal</sub> (</font>&#946;<font size="2" face="Ve
rdana, Arial, Helvetica, sans-serif">= -0,176, p = 0,011) estavam independenteme
nte associados com a fun&ccedil;&atilde;o ventricular esquerda global estimada p
elo &iacute;ndice Tei.     ^cY#aop03011.htm##
00583000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704033900085002001300424#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#18#14#article#160#<br>   <b>
CONCLUS&Atilde;O:</b> A SM teve um impacto significante na fun&ccedil;&atilde;o 
global do VE. A press&atilde;o arterial sist&oacute;lica, glicemia de jejum, &ia
cute;ndice de massa do VE E/e'<sub>septal</sub>, e e'<sub>septal</sub> estavam i
ndependentemente associados com a fun&ccedil;&atilde;o global do VE. </font></p>
     ^cY#aop03011.htm##
00489000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024500085002001300330#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#19#15#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> Fun&
ccedil;&atilde;o ventricular esquerda, sindrome metab&oacute;lica, isquemia mioc
&aacute;rdica, fatores de risco. </font></p> <hr size="1" noshade>     ^cY#aop03
011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#20#16#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#21#17#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#22#18#article#160#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop03011.htm##
01581000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704133700085002001301422#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#23#19#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O &iacute;ndice de desempen
ho mioc&aacute;rdico (&iacute;ndice Tei) reflete as fun&ccedil;&otilde;es sist&o
acute;lica e diast&oacute;lica dos ventr&iacute;culos esquerdo e direito<sup>1</
sup>. Pode ser deficiente em pacientes com v&aacute;rios fatores de risco, tais 
como hipertens&atilde;o<sup>2</sup>, diabete<sup>3</sup> e obesidade<sup>4</sup>
. A influ&ecirc;ncia da s&iacute;ndrome metab&oacute;lica (SM) na fun&ccedil;&at
ilde;o global do ventr&iacute;culo esquerdo (VE) ainda n&atilde;o foi determinad
a de forma completa. H&aacute; diferentes opini&otilde;es sobre esse problema; p
or um lado h&aacute; autores que acreditam que a SM &eacute; um conjunto de fato
res de risco e, sendo assim, a altera&ccedil;&atilde;o na fun&ccedil;&atilde;o g
lobal do VE &eacute; uma consequ&ecirc;ncia esperada e l&oacute;gica<sup>5,6</su
p>. Por outro lado, alguns investigadores mostraram que o &iacute;ndice Tei n&at
ilde;o est&aacute; alterado de forma significativa em pacientes com alta preval&
ecirc;ncia de obesidade, hipertens&atilde;o e diabete, os quais s&atilde;o fator
es de risco importantes da s&iacute;ndrome metab&oacute;lica<sup>7</sup>. Poucos
 estudos analisaram o impacto dos fatores de risco individuais da SM na fun&cced
il;&atilde;o global do VE. </font></p>     ^cY#aop03011.htm##
00632000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038800085002001300473#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#24#20#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O objetivo do presente estu
do foi determinar quais par&acirc;metros cl&iacute;nicos e ecocardiogr&aacute;fi
cos se correlacionam com a fun&ccedil;&atilde;o global do VE em pacientes com SM
 e tamb&eacute;m identificar quais par&acirc;metros estavam associados de forma 
independente com o &iacute;ndice Tei. </font></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#25#21#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010100085002001300186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#26#22#article#160#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Metodologia</b></font></
p>     ^cY#aop03011.htm##
01776000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704153200085002001301617#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#27#23#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A investiga&ccedil;&atilde;
o incluiu 330 indiv&iacute;duos divididos em dois grupos: o primeiro grupo consi
stia em 234 indiv&iacute;duos (125 mulheres e 109 homens) com SM, enquanto o gru
po controle consistia em 96 indiv&iacute;duos (52 mulheres e 44 homens) sem fato
res de risco de SM. Pacientes com sinais cl&iacute;nicos ou laboratoriais de ins
ufici&ecirc;ncia card&iacute;aca, doen&ccedil;a arterial coronariana, les&atilde
;o cerebrovascular anterior, doen&ccedil;a valvar card&iacute;aca, hipertens&ati
lde;o secund&aacute;ria ou outras doen&ccedil;as cr&ocirc;nicas tais como cirros
e hep&aacute;tica, insufici&ecirc;ncia renal ou doen&ccedil;as endocrinol&oacute
;gicas (exceto diabete melito tipo 2) foram exclu&iacute;dos do estudo. SM foi d
efinida pela presen&ccedil;a de tr&ecirc;s ou mais crit&eacute;rios do <i>Third 
Report of the National  Cholesterol Education Program (NCEP) Expert Panel on  de
tection, evaluation, and treatment of high blood cholesterol  in adults (Adult T
reatment Panel III - NCEP-ATP-III)</i> de 2001<sup>8</sup>: obesidade abdominal 
(circunfer&ecirc;ncia da cintura <u>&gt;</u> 102 cm em homens e <u>&gt;</u> 88 c
m em mulheres), triglic&eacute;rides de jejum <u>&gt;</u> 150 mg/dl, n&iacute;ve
is diminu&iacute;dos de HDL colesterol (&lt;40mg/dl em homens e &lt; 50 mg/dl em
 mulheres), press&atilde;o arterial elevada (<u>&gt;</u> 130/85 mmHg ou terapia 
anti-hipertensiva) e glicemia de jejum <u>&gt;</u> 110 mg/dl. </font></p>     ^c
Y#aop03011.htm##
00909000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066500085002001300750#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#28#24#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As medidas antropom&eacute;
tricas (altura, peso, circunfer&ecirc;ncia da cintura) foram obtidas de todos os
 indiv&iacute;duos inclu&iacute;dos no estudo a fim de calcular a &aacute;rea de
 superf&iacute;cie corporal (ASC) e &iacute;ndice de massa corporal (IMC). Em re
la&ccedil;&atilde;o &agrave; an&aacute;lise laboratorial, utilizamos os n&iacute
;veis de glicemia de jejum, hemoglobina glicosilada, colesterol total e lipoprot
e&iacute;na de alta e baixa densidade colesterol (HDL e LDL, respectivamente), t
riglic&eacute;rides, &aacute;cido &uacute;rico e creatinina s&eacute;rica. </fon
t></p>     ^cY#aop03011.htm##
00613000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036900085002001300454#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#29#25#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os valores da press&atilde;
o arterial (PA) foram obtidos atrav&eacute;s da medida do valor m&eacute;dio de 
duas medi&ccedil;&otilde;es consecutivas na posi&ccedil;&atilde;o sentada com um
 intervalo de cinco minutos, pela manh&atilde;, utilizando um esfigmoman&ocirc;m
etro convencional. </font></p>     ^cY#aop03011.htm##
00820000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057600085002001300661#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#30#26#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O diagn&oacute;stico de dia
bete foi baseado nos crit&eacute;rios da Organiza&ccedil;&atilde;o Mundial da Sa
&uacute;de (OMS) publicados em 2006<sup>9</sup> e hipertens&atilde;o arterial fo
i estabelecida de acordo com as recomenda&ccedil;&otilde;es da <i>European Assoc
iation for  Hypertension </i>em 2007<sup>10</sup>. O protocolo foi aprovado pelo
 Comit&ecirc; de &Eacute;tica da Faculdade de Medicina da Universidade de Belgra
do. Consentimento informado foi obtido de todos os participantes. </font></p>   
  ^cY#aop03011.htm##
00349000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010500085002001300190#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#31#27#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Ecocardiografia</b></fon
t></p>     ^cY#aop03011.htm##
01240000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099600085002001301081#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#32#28#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O exame ecocardiogr&aacute;
fico foi realizado com o ecocardiografo Acuson Sequoia 256 com um transdutor de 
2 a 4 MHz. Os valores de todos os par&acirc;metros ecocardiogr&aacute;ficos fora
m obtidos como o valor m&eacute;dio de cinco ciclos card&iacute;acos consecutivo
s. O di&acirc;metro sist&oacute;lico final do VE (DSFVE) e o di&acirc;metro dias
t&oacute;lico final do VE (DDFVE), a espessura da parede posterior (EPP) do VE e
 a do septo interventricular (ESI) foram determinados de acordo com as recomenda
&ccedil;&otilde;es da <i>American Society of  Echocardiography</i><sup>11</sup>.
 Os volumes finais sist&oacute;lico e diast&oacute;lico do VE e par&acirc;metros
 da fun&ccedil;&atilde;o sist&oacute;lica (fra&ccedil;&atilde;o de eje&ccedil;&a
tilde;o - FE e encurtamento fracional - EF) foram estimados pela f&oacute;rmula 
de Teichholz. A espessura relativa da parede (ERP) foi calculada como (2x PWT)/D
DFVE. </font></p>     ^cY#aop03011.htm##
00858000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704061400085002001300699#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#33#29#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A massa ventricular esquerd
a (MVE) foi calculada atrav&eacute;s da f&oacute;rmula de Penn: MVE = 1.04x&#91;
(DDFVE + EPPD + ESI)<sup>3</sup> - (DDFVE)<sup>3</sup> - 13,6 g<sup>12</sup>. O 
&iacute;ndice de massa do VE (massa do VE/Alt<sup>2,7</sup>) foi calculado como 
a raz&atilde;o entre a massa ventricular esquerda e a altura<sup>2,7</sup>. Hipe
rtrofia ventricular esquerda foi definida como massa VE/Alt<sup>2,7</sup> <u>&gt
;</u> 51 g/m<sup>2,7</sup> para homens e <u>&gt;</u> 49,5 g/m<sup>2,7</sup> para
 mulheres<sup>13</sup>. </font></p>     ^cY#aop03011.htm##
01307000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106300085002001301148#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#34#30#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise das veloci
dades de fluxo transmitral foi obtida por Doppler puls&aacute;til no corte apica
l quatro c&acirc;maras com o volume da amostra posicionado na borda dos folhetos
 da valva mitral<sup>14</sup>. As medidas inclu&iacute;ram as velocidades diast&
oacute;lica inicial transmitral (onda E) e atrial (onda A) para calcular a raz&a
tilde;o E/A e o tempo de desacelera&ccedil;&atilde;o (TD) da onda E<sup>13</sup>
. A imagem do Doppler tecidual foi utilizada para obter as velocidades mioc&aacu
te;rdicas do VE no corte apical quatro c&acirc;maras com volume de amostra de 2 
mm posicionado no segmento septal do anel mitral durante a di&aacute;stole inici
al (e&acute;<sub>septal</sub>) e s&iacute;stole (s<sub>septal</sub>)<sup>14</sup
>. A raz&atilde;o E/e&acute;<sub>septal</sub> foi determinada atrav&eacute;s de 
valores previamente estimados de velocidades de fluxo E e e'<sub>septal</sub> na
 di&aacute;stole inicial obtidas por Doppler tecidual e puls&aacute;til. </font>
</p>     ^cY#aop03011.htm##
00917000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067300085002001300758#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#35#31#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os par&acirc;metros necess&
aacute;rios para calcular o &iacute;ndice Tei foram obtidos atrav&eacute;s de Do
ppler tecidual no corte apical de quatro c&acirc;maras<sup>15</sup>. Um volume d
e amostra de 2 mm foi posicionado no canto lateral do anel mitral. O tempo de co
ntra&ccedil;&atilde;o isovolum&eacute;trica (TCIV) e o tempo de relaxamento isov
olum&eacute;trico (TRIV) foram medidos do final do padr&atilde;o de velocidade d
o anel mitral at&eacute; o in&iacute;cio da onda S e do final da onda S at&eacut
e; o in&iacute;cio do padr&atilde;o de velocidade do anel mitral, respectivament
e. </font></p>     ^cY#aop03011.htm##
00473000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022900085002001300314#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#36#32#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O tempo de eje&ccedil;&atil
de;o (TE) foi definido como a dura&ccedil;&atilde;o do fluxo de sa&iacute;da do 
VE no perfil de velocidade do Doppler. </font></p>     ^cY#aop03011.htm##
00443000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019900085002001300284#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#37#33#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O &iacute;ndice Tei foi cal
culado de acordo com a f&oacute;rmula: &Iacute;ndice Tei = (TCIV + TRIV)/TE<sup>
1</sup>. </font></p>     ^cY#aop03011.htm##
00369000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012500085002001300210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#38#34#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lises estat&ia
cute;sticas</b></font></p>     ^cY#aop03011.htm##
01753000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704150900085002001301594#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#39#35#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Vari&aacute;veis cont&iacut
e;nuas foram apresentadas como m&eacute;dias ± desvios-padr&atilde;o (DP) e comp
aradas atrav&eacute;s de teste <i>t</i> para duas amostras independentes, consid
erando que apresentavam distribui&ccedil;&atilde;o normal. Diferen&ccedil;as ent
re propor&ccedil;&otilde;es foram comparadas usando teste &chi;<sup>2</sup>. O c
oeficiente de correla&ccedil;&atilde;o de Pearson foi utilizado para determinar 
a correla&ccedil;&atilde;o entre o &iacute;ndice Tei e a diferentes par&acirc;me
tros cl&iacute;nicos e ecocardiogr&aacute;ficos. O mesmo teste foi usado para de
terminar a correla&ccedil;&atilde;o entre esses par&acirc;metros e intervalos do
 Doppler tecidual que eram necess&aacute;rios para o c&aacute;lculo do &iacute;n
dice Tei (TRIV, TCIV e TE). A an&aacute;lise de regress&atilde;o m&uacute;ltipla
 <i>stepwise</i> determinou quais par&acirc;metros, cl&iacute;nicos e ecocardiog
r&aacute;ficos, estavam associados de forma independente com o &iacute;ndice Tei
 ou seus componentes (TRIV, TCIV e TE). A frequ&ecirc;ncia card&iacute;aca (FC) 
e a vari&aacute;vel cujo valor de <i>p</i> era <u>&lt;</u> 0.10 foram inclu&iacu
te;das nos modelos de regress&atilde;o <i>stepwise</i>. Tamb&eacute;m determinam
os quais componentes da SM se correlacionavam e quais componentes estavam indepe
ndentemente associados com o &iacute;ndice Tei. Um valor de p &lt; 0,05 foi cons
iderado estatisticamente significante. </font></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#40#36#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#41#37#article#160#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop03011.htm##
01045000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704080100085002001300886#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#42#38#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o havia diferen&cc
edil;a estatisticamente significante na m&eacute;dia da idade entre os indiv&iac
ute;duos com SM e os controles (52 ± 9 <i>vs</i> 54 ± 9 anos, p &gt; 0,05). Todo
s os par&acirc;metros cl&iacute;nicos do grupo de estudo s&atilde;o mostrados na
 <a href="#tab1">Tabela 1</a>. Os valores de todos os par&acirc;metros da SM era
m significantemente mais altos nos pacientes com SM do que nos controles (<a hre
f="#tab1">Tabela 1</a>). Tamb&eacute;m observamos que os n&iacute;veis de hemogl
obina glicosilada, acido &uacute;rico, creatinina s&eacute;rica, LDL-colesterol 
e colesterol total eram significantemente mais altos na popula&ccedil;&atilde;o 
de pacientes com SM (<a href="#tab1">Tabela 1</a>).</font></p>     ^cY#aop03011.
htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#43#39#article#160#<p><a name
="tab1"></a></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#44#40#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#45#41#article#160#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03011tab01.jpg"></p>     ^cY#a
op03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#46#42#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00807000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704056300085002001300648#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#47#43#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o havia diferen&cc
edil;a estatisticamente significante entre os grupos estudados em rela&ccedil;&a
tilde;o &agrave; di&acirc;metro do VE, FE e EF (<a href="#tab2">Tabela 2</a>). A
 espessura relativa da parede e o &iacute;ndice de massa do VE estavam significa
ntemente aumentados no grupo com SM (<a href="#tab2">Tabela 2</a>). Comparado ao
 grupo controle, o grupo SM apresentava uma porcentagem significantemente maior 
de hipertrofia do VE (<a href="#tab2">Tabela 2</a>). </font></p>     ^cY#aop0301
1.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#48#44#article#160#<p><a name
="tab2"></a></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#49#45#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#50#46#article#160#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03011tab02.jpg"></p>     ^cY#a
op03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#51#47#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00774000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053000085002001300615#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#52#48#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O par&acirc;metro da fun&cc
edil;&atilde;o sist&oacute;lica obtido atrav&eacute;s de Doppler tecidual (s<sub
>septal</sub>) demonstrou fun&ccedil;&atilde;o sist&oacute;lica do VE normal em 
indiv&iacute;duos com SM. Entretanto, os par&acirc;metros da fun&ccedil;&atilde;
o diast&oacute;lica do VE, como E/A, TD, e'<sub>septal</sub> e E/e'<sub>septal</
sub> apresentavam-se significantemente deteriorados no grupo com SM (<a href="#t
ab2">Tabela 2</a>). </font></p>     ^cY#aop03011.htm##
00664000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042000085002001300505#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#53#49#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os par&acirc;metros necess&
aacute;rios para o c&aacute;lculo do &iacute;ndice Tei tamb&eacute;m estavam alt
erados em indiv&iacute;duos com SM. O TRIV e TCIV apresentavam-se significanteme
nte prolongados, enquanto o TE estava encurtado no grupo SM, o que determinava o
 valor aumentado do &iacute;ndice Tei (<a href="#tab2">Tabela 2</a>). </font></p
>     ^cY#aop03011.htm##
01596000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704135200085002001301437#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#54#50#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">An&aacute;lises de correla&
ccedil;&atilde;o univariada mostraram que FC, press&atilde;o arterial sist&oacut
e;lica (PAS), press&atilde;o arterial diast&oacute;lica (PAD), n&iacute;veis de 
glicose, triglic&eacute;rides, colesterol total e creatinina s&eacute;rica e val
ores de circunfer&ecirc;ncia da cintura (CC) estavam associados com a fun&ccedil
;&atilde;o global do VE estimada pelo &iacute;ndice Tei (<a href="#tab3">Tabela 
3</a>). Entre os par&acirc;metros ecocardiogr&aacute;ficos, as an&aacute;lises d
e correla&ccedil;&atilde;o univariada demonstraram que a espessura relativa da p
arede, di&acirc;metro atrial esquerdo, &iacute;ndice de massa do VE, raz&atilde;
o E/A, s<sub>septal</sub>, e'<sub>septal</sub> e raz&atilde;o E/e'<sub>septal</s
ub> se correlacionavam com o &iacute;ndice de desempenho mioc&aacute;rdico do VE
 (<a href="#tab3">Tabela 3</a>). A an&aacute;lise de regress&atilde;o m&uacute;l
tipla dos par&acirc;metros cl&iacute;nicos e ecocardiogr&aacute;ficos demonstrou
 que a PAS, n&iacute;vel de glicose, &iacute;ndice de massa do VE, e'<sub>septal
</sub> e raz&atilde;o E/e'<sub>septal</sub> estavam associados de forma independ
ente com a fun&ccedil;&atilde;o global do VE estimada atrav&eacute;s do &iacute;
ndice Tei (<a href="#tab4">Tabela 4</a>). </font></p>     ^cY#aop03011.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#55#51#article#160#<p><a name
="tab3"></a></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#56#52#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#57#53#article#160#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03011tab03.jpg"></p>     ^cY#a
op03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#58#54#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#59#55#article#160#<p><a name
="tab4"></a></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#60#56#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#61#57#article#160#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03011tab04.jpg"></p>     ^cY#a
op03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#62#58#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00506000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026200085002001300347#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#63#59#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m disso, determin
amos quais par&acirc;metros estavam associados com todos os intervalos de tempo 
usados na equa&ccedil;&atilde;o do &iacute;ndice Tei (TRIV, TCIV e TE). </font><
/p>     ^cY#aop03011.htm##
01039000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079500085002001300880#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#64#60#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise univariada
 dos par&acirc;metros cl&iacute;nicos e ecocardiogr&aacute;ficos no grupo SM mos
trou que a PAS, n&iacute;veis de glicemia de jejum, CC, espessura relativa da pa
rede, di&acirc;metro atrial esquerdo, &iacute;ndice de massa do VE, raz&atilde;o
 E/A, tempo de desacelera&ccedil;&atilde;o (TD), e'<sub>septal</sub> e raz&atild
e;o E/e'<sub>septal</sub> estavam associados com o TRIV (<a href="/img/revistas/
abc/2011nahead/aop03011tab05m.jpg">Tabela 5</a>). Al&eacute;m disso, todos esses
 par&acirc;metros, exceto o di&acirc;metro atrial esquerdo, raz&atilde;o E/A e T
D, estavam independentemente associados com o TRIV (<a href="/img/revistas/abc/2
011nahead/aop03011tab06m.jpg">Tabela 6</a>). </font></p>     ^cY#aop03011.htm##
00890000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064600085002001300731#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#65#61#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise de correla
&ccedil;&atilde;o mostrou que a PAS, PAD, n&iacute;veis de glicemia de jejum, CC
, espessura relativa da parede, di&acirc;metro atrial esquerdo, &iacute;ndice de
 massa do VE, raz&atilde;o E/A, TD, e'<sub>septal</sub> e raz&atilde;o E/e'<sub>
septal</sub> estavam associados com o TCIV (<a href="/img/revistas/abc/2011nahea
d/aop03011tab05m.jpg">Tabela 5</a>). Todos os par&acirc;metros mencionados, exce
to a PAD, estavam associados de forma independente com o TCIV (<a href="/img/rev
istas/abc/2011nahead/aop03011tab06m.jpg">Tabela 6</a>). </font></p>     ^cY#aop0
3011.htm##
00844000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704060000085002001300685#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#66#62#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise univariada
 tamb&eacute;m demonstrou que a PAS, di&acirc;metro atrial esquerdo, &iacute;ndi
ce de massa do VE, FE, s<sub>septal</sub>, TD, e'<sub>septal</sub> e raz&atilde;
o E/e'<sub>septal</sub> estavam associados com o TE (<a href="/img/revistas/abc/
2011nahead/aop03011tab05m.jpg">Tabela 5</a>). Entretanto, apenas a PAS, &iacute;
ndice de massa do VE, FE e s<sub>septal</sub> estavam associados de forma indepe
ndente com o TE (<a href="/img/revistas/abc/2011nahead/aop03011tab06m.jpg">Tabel
a 6</a>). </font></p>     ^cY#aop03011.htm##
00692000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704044800085002001300533#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#67#63#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise de correla
&ccedil;&atilde;o mostrou que todos os componentes da SM, exceto o HDL-colestero
l, estavam associados com o &iacute;ndice Tei, mas apenas a PAS, n&iacute;veis d
e glicemia de jejum e triglic&eacute;rides estavam associados de forma independe
nte com esse par&acirc;metro da fun&ccedil;&atilde;o global do VE (<a href="#tab
7">Tabela 7</a>). </font></p>     ^cY#aop03011.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#68#64#article#160#<p><a name
="tab7"></a></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#69#65#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#70#66#article#160#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03011tab07.jpg"></p>     ^cY#a
op03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#71#67#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#72#68#article#160#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o </b></f
ont></p>     ^cY#aop03011.htm##
00522000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027800085002001300363#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#73#69#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O &iacute;ndice Tei &eacute
; um par&acirc;metro ecocardiogr&aacute;fico especial que simultaneamente mostra
 as fun&ccedil;&otilde;es sist&oacute;lica e diast&oacute;lica de um ventr&iacut
e;culo. </font></p>     ^cY#aop03011.htm##
00871000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704062700085002001300712#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#74#70#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; um con
senso sobre o impacto da idade e FC no &iacute;ndice Tei<sup>2,3,5,7,16</sup>. N
osso estudo mostrou que o &iacute;ndice da fun&ccedil;&atilde;o global do VE era
 independente da idade, o que &eacute; muito importante para a avalia&ccedil;&at
ilde;o da fun&ccedil;&atilde;o global do VE em pacientes de diferentes idades. P
or outro lado, esse estudo mostrou que a FC se correlacionava com o &iacute;ndic
e Tei, embora n&atilde;o de forma independente. Resultados similares foram obtid
os em outros estudos<sup>2,17</sup>. </font></p>     ^cY#aop03011.htm##
00637000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039300085002001300478#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#75#71#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A hipertens&atilde;o arteri
al altera a estrutura mioc&aacute;rdica, primariamente devido ao ac&uacute;mulo 
anormal de col&aacute;geno no espa&ccedil;o extracelular, resultando em uma dimi
nui&ccedil;&atilde;o da complac&ecirc;ncia e aparecimento de disfun&ccedil;&atil
de;o diast&oacute;lica do VE<sup>18</sup>. </font></p>     ^cY#aop03011.htm##
01104000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704086000085002001300945#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#76#72#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; um con
senso universal sobre a influ&ecirc;ncia da PAS e da PAD na fun&ccedil;&atilde;o
 ventricular global do VE e o &iacute;ndice Tei. Alguns autores mostraram que o 
&iacute;ndice Tei se correlaciona com a press&atilde;o arterial<sup>5,15,19</sup
>, enquanto outros discordam<sup>2,17</sup>. Nosso estudo mostrou que a PAS e a 
PAD se correlacionaram com o &iacute;ndice de desempenho mioc&aacute;rdico, mas 
apenas a PAS estava associada de forma independente com o &iacute;ndice Tei. O m
esmo resultado foi obtido quando consideramos apenas os crit&eacute;rios da SM. 
Al&eacute;m disso, a PAS mostrou ser o preditor independente mais forte do &iacu
te;ndice Tei entre os crit&eacute;rios da SM com maior signific&acirc;ncia estat
&iacute;stica (p &lt; 0,001). </font></p>     ^cY#aop03011.htm##
01726000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704148200085002001301567#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#77#73#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A resist&ecirc;ncia &agrave
; insulina subjacente &agrave; diabete melito tipo 2 e SM leva &agrave; altera&c
cedil;&otilde;es significantes na estrutura e fun&ccedil;&atilde;o do VE. Basica
mente, ela leva &agrave; ativa&ccedil;&atilde;o do sistema nervoso simp&aacute;t
ico e do sistema renina-angiotensina-aldosterona (SRAA), causando redu&ccedil;&a
tilde;o no n&uacute;mero de mitoc&ocirc;ndrias, elementos contr&aacute;teis, den
sidade da rede capilar, e induz fibrose extracelular e apoptose<sup>20</sup>. To
das essas altera&ccedil;&otilde;es resultam no aparecimento de disfun&ccedil;&at
ilde;o diast&oacute;lica do VE e, subsequentemente, hipertrofia do VE. Pattoneri
 e cols. <sup>3</sup> mostraram que indiv&iacute;duos recentemente diagnosticado
s com diabete melito tipo 2 apresentavam fun&ccedil;&atilde;o global do VE anorm
al. H&aacute; um dilema em rela&ccedil;&atilde;o a se os n&iacute;veis de glicos
e e hemoglobina glicada afetam ou n&atilde;o a fun&ccedil;&atilde;o global do VE
. Estudos tem confirmado que essa rela&ccedil;&atilde;o existe<sup>3,5,19</sup>,
 o que tamb&eacute;m foi o resultado de nosso estudo. A an&aacute;lise separada 
da influ&ecirc;ncia dos componentes da SM em nosso estudo tamb&eacute;m demonstr
ou que os n&iacute;veis de glicemia de jejum, al&eacute;m da PAS e n&iacute;veis
 de triglic&eacute;rides, estavam associados de forma independente com o &iacute
;ndice Tei. </font></p>     ^cY#aop03011.htm##
00919000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067500085002001300760#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#78#74#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os estudos que investigaram
 os efeitos individuais e simult&acirc;neos da hipertens&atilde;o e diabete na f
un&ccedil;&atilde;o global do VE n&atilde;o chegaram a um acordo sobre se esses 
fatores sinergisticamente levam &agrave; maior dano no VE. Cho e cols. <sup>21</
sup> mostraram que os efeitos simult&acirc;neos desses fatores alteravam a fun&c
cedil;&atilde;o global do VE mais do que os fatores individuais separadamente. O
utros autores discordam e acreditam que as diferen&ccedil;as entre os efeitos in
dividuais e simult&acirc;neos desses dois fatores n&atilde;o existem<sup>3,17</s
up>. </font></p>     ^cY#aop03011.htm##
01936000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704169200085002001301777#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#79#75#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; consen
so absoluto sobre o impacto da obesidade no &iacute;ndice Tei. Levent e cols. <s
up>4</sup> estudaram o efeito da hipertens&atilde;o e obesidade em crian&ccedil;
as e mostrou que crian&ccedil;as obesas, mas normotensas, tinham um &iacute;ndic
e Tei mais alto, quando comparadas ao grupo controle, o que confirmava dano &agr
ave; fun&ccedil;&atilde;o global do VE, enquanto crian&ccedil;as com ambos os fa
tores de risco apresentavam um n&iacute;vel ainda maior de disfun&ccedil;&atilde
;o, o que indicava um poss&iacute;vel efeito sinerg&iacute;stico desses fatores.
 O estudo em uma popula&ccedil;&atilde;o adulta confirmou que a obesidade prejud
icava a fun&ccedil;&atilde;o mioc&aacute;rdica global pela diminui&ccedil;&atild
e;o do &iacute;ndice Tei, isto &eacute;, mostrando a melhora na fun&ccedil;&atil
de;o mioc&aacute;rdica com a redu&ccedil;&atilde;o do peso<sup>22</sup>. H&aacut
e; um estudo controverso que mostrou que a obesidade n&atilde;o piorava, mas sim
 melhorava a fun&ccedil;&atilde;o global do VE<sup>23</sup>. Entretanto, os auto
res n&atilde;o sugeriram poss&iacute;veis mecanismos para esse efeito "protetor"
 do aumento do peso corporal. Nosso estudo mostrou que o IMC n&atilde;o se corre
lacionava com &iacute;ndice Tei, em contraste com a CC, que era um preditor inde
pendente da fun&ccedil;&atilde;o global do VE. Esses achados eram esperados, poi
s n&atilde;o havia diferen&ccedil;a significante no IMC entre os grupos SM e con
trole, enquanto a CC era significantemente maior nos indiv&iacute;duos com SM. V
oulgari e cols. <sup>19</sup> obtiveram resultados similares. </font></p>     ^c
Y#aop03011.htm##
01611000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704136700085002001301452#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#80#76#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Nesse estudo, mostramos que
 os n&iacute;veis de LDL e HDL-colesterol n&atilde;o se correlacionavam com o &i
acute;ndice Tei, enquanto os n&iacute;veis de colesterol total e triglic&eacute;
rides se correlacionavam com esse par&acirc;metro. Os n&iacute;veis de triglic&e
acute;rides n&atilde;o se associavam de forma independente com o &iacute;ndice T
ei, quando todos os par&acirc;metros cl&iacute;nicos e ecocardiogr&aacute;ficos 
eram considerados. Entretanto, quando somente os crit&eacute;rios da SM eram con
siderados, os n&iacute;veis de triglic&eacute;rides associavam-se de forma indep
endente com esse &iacute;ndice, o que est&aacute; de acordo com os achados de ou
tros autores<sup>5,19</sup>. de las Fuentes e cols. <sup>24</sup> foram os prime
iros a mostrar que indiv&iacute;duos com n&iacute;veis de triglic&eacute;rides (
TG) aumentados apresentavam fun&ccedil;&atilde;o diast&oacute;lica do VE signifi
cantemente deficiente e aumento da massa do VE, quando comparados ao grupo contr
ole. Isso pode ser explicado pelo fato de que os TG acumulados no espa&ccedil;o 
extracelular reduzem a complac&ecirc;ncia do VE, tendo como consequ&ecirc;ncia s
eus efeitos lipot&oacute;xicos nos cardiomi&oacute;citos e alto consumo de energ
ia, que &eacute; necess&aacute;rio para seu metabolismo. </font></p>     ^cY#aop
03011.htm##
00761000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051700085002001300602#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#81#77#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Nosso estudo tamb&eacute;m 
mostrou que a fun&ccedil;&atilde;o renal estimada atrav&eacute;s da creatinina s
&eacute;rica estava elevada em indiv&iacute;duos com SM e se correlacionava com 
o &iacute;ndice Tei, o que est&aacute; de acordo com alguns autores<sup>25</sup>
, mas contradit&oacute;rio para outros<sup>26</sup>. Entretanto, a creatinina s&
eacute;rica n&atilde;o estava associada de forma independente com o &iacute;ndic
e Tei. </font></p>     ^cY#aop03011.htm##
01678000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704143400085002001301519#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#82#78#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A rela&ccedil;&atilde;o ent
re v&aacute;rios par&acirc;metros ecocardiogr&aacute;ficos e o &iacute;ndice Tei
 foi avaliada em pacientes com hipertens&atilde;o, diabete ou aqueles que aprese
ntavam ambos os fatores de risco<sup>2,3,17</sup>; entretanto, essa avalia&ccedi
l;&atilde;o n&atilde;o havia ainda sido realizada em indiv&iacute;duos com SM. A
 maioria dos autores acredita que a fun&ccedil;&atilde;o global do VE deficiente
 na SM &eacute; na verdade uma consequ&ecirc;ncia do dano &agrave; fun&ccedil;&a
tilde;o diast&oacute;lica<sup>5,6,19</sup>, que &eacute;, em sua maior parte, o 
resultado da identifica&ccedil;&atilde;o da fun&ccedil;&atilde;o sist&oacute;lic
a do VE realizada apenas com a fra&ccedil;&atilde;o de eje&ccedil;&atilde;o sist
&oacute;lica e/ou o encurtamento fracional do VE. Entretanto, h&aacute; estudos 
mostrando que esses par&acirc;metros tamb&eacute;m poderiam estar alterados em i
ndiv&iacute;duos com SM<sup>26</sup>. O estudo de imagem por Doppler tecidual in
troduziu novos par&acirc;metros da fun&ccedil;&atilde;o sist&oacute;lica do VE, 
que mostrou estar deficiente no grupo com SM<sup>27</sup>. Nosso estudo mostrou 
que a fun&ccedil;&atilde;o sist&oacute;lica do VE estimada atrav&eacute;s da FE 
e s<sub>septal</sub> estava preservada no grupo com SM, embora com signific&acir
c;ncia estat&iacute;stica lim&iacute;trofe. </font></p>     ^cY#aop03011.htm##
01508000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704126400085002001301349#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#83#79#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Todos os par&acirc;metros d
a fun&ccedil;&atilde;o diast&oacute;lica do VE avaliados em nosso estudo (E/A, T
D, e'<sub>septal</sub> e raz&atilde;o E/e'<sub>septal</sub>) confirmaram a exist
&ecirc;ncia de disfun&ccedil;&atilde;o diast&oacute;lica. A espessura relativa d
a parede e o &iacute;ndice de massa do VE, o di&acirc;metro atrial esquerdo, a r
az&atilde;o E/A, s<sub>septal</sub>, e'<sub>septal</sub> e a raz&atilde;o E/e'<s
ub> septal</sub> se correlacionaram com a fun&ccedil;&atilde;o global do VE esti
mada atrav&eacute;s do &iacute;ndice Tei; entretanto, o &iacute;ndice de massa d
o VE, e'<sub>septal</sub> e raz&atilde;o E/e'<sub>septal</sub> estavam associado
s de forma independente com o &iacute;ndice Tei. Resultados similares foram obti
dos por Masugata e cols. <sup>2</sup> em pacientes com hipertens&atilde;o. Ander
sen e cols. <sup>17</sup> descobriram uma correla&ccedil;&atilde;o entre o &iacu
te;ndice Tei e o TD e a raz&atilde;o E/A ratio em pacientes com hipertens&atilde
;o e diabete, enquanto Pattoneri e cols. <sup>3</sup> encontraram uma correla&cc
edil;&atilde;o entre o TCIV e o TE com esse &iacute;ndice em pacientes com diabe
te de diagn&oacute;stico recente. </font></p>     ^cY#aop03011.htm##
01745000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704150100085002001301586#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#84#80#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m disso, estudamo
s o impacto de diferentes par&acirc;metros cl&iacute;nicos e ecocardiogr&aacute;
ficos no grupo SM sobre os intervalos do Doppler tecidual necess&aacute;rios par
a o c&aacute;lculo do &iacute;ndice Tei (TRIV, TCIV e TE). A PAS, glicemia de je
jum, CC, espessura relativa da parede, &iacute;ndice de massa do VE, e'<sub>sept
al</sub> e raz&atilde;o E/e'<sub>septal</sub> estavam associados de forma indepe
ndente com o TRIV. A an&aacute;lise multivariada mostrou que a PAS, PAD, glicemi
a de jejum, &iacute;ndice de massa do VE, e'<sub>septal</sub> e raz&atilde;o E/e
'<sub>septal</sub> estavam associados de forma independente com o TCIV. Esses pa
r&acirc;metros representam, simultaneamente, as fun&ccedil;&otilde;es sist&oacut
e;lica e diast&oacute;lica do VE na equa&ccedil;&atilde;o do &iacute;ndice de Te
i. Por outro lado, o TE, um par&acirc;metro da fun&ccedil;&atilde;o sist&oacute;
lica nessa equa&ccedil;&atilde;o, estava associado de forma independente com a P
AS, &iacute;ndice de massa do VE, FE e s<sub>septal</sub>. Aparentemente, quase 
os mesmos fatores que est&atilde;o associados com TRIV, TCIV e TE na SM se corre
lacionaram com o &iacute;ndice Tei como par&acirc;metro da fun&ccedil;&atilde;o 
global do VE. Esses achados s&atilde;o importantes, pois demonstramos que n&atil
de;o &eacute; necess&aacute;rio determinar fatores de risco para componentes ind
ividuais do &iacute;ndice Tei. </font></p>     ^cY#aop03011.htm##
01008000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704076400085002001300849#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#85#81#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Considerando que a fun&cced
il;&atilde;o sist&oacute;lica do VE estava preservada em indiv&iacute;duos com S
M em nosso estudo, enquanto, por outro lado, a fun&ccedil;&atilde;o diast&oacute
;lica estava deficiente, a conclus&atilde;o l&oacute;gica &eacute; que o dano &a
grave; fun&ccedil;&atilde;o global do VE &eacute; na verdade o resultado de alte
ra&ccedil;&otilde;es na fun&ccedil;&atilde;o diast&oacute;lica. Entretanto, um g
rupo de estudo maior possivelmente teria demonstrado que a fun&ccedil;&atilde;o 
sist&oacute;lica do VE tamb&eacute;m estava alterada em indiv&iacute;duos com SM
, considerando que o valor estat&iacute;stico em nosso estudo foi lim&iacute;tro
fe (p=0,075). </font></p>     ^cY#aop03011.htm##
01561000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704131700085002001301402#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#86#82#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A limita&ccedil;&atilde;o d
o presente estudo consistiu em um grande n&uacute;mero de indiv&iacute;duos com 
SM e hipertens&atilde;o arterial, que era controlada atrav&eacute;s do uso de di
ferentes medicamentos que poderiam afetar o &iacute;ndice Tei e a interpreta&cce
dil;&atilde;o dos resultados. Outra limita&ccedil;&atilde;o &eacute; o fato de q
ue poucos estudos cl&iacute;nicos utilizaram a imagem do Doppler tecidual para o
bter par&acirc;metros de fun&ccedil;&atilde;o sist&oacute;lica, diast&oacute;lic
a e global do VE; sendo assim, n&atilde;o pudemos realizar uma compara&ccedil;&a
tilde;o completa desses par&acirc;metros. Estudos diagn&oacute;sticos demonstrar
am que o &iacute;ndice Tei obtido por Doppler puls&aacute;til e tecidual apresen
tavam valores similares e embora tenha sido demonstrado que os valores determina
dos pelo Doppler tecidual s&atilde;o mais precisos e apresentam melhor correla&c
cedil;&atilde;o com as medidas invasivas obtidas durante a cateteriza&ccedil;&at
ilde;o card&iacute;aca, a compara&ccedil;&atilde;o &eacute; bastante razo&aacute
;vel<sup>28</sup>. A terceira limita&ccedil;&atilde;o &eacute; relativa &agrave;
 depend&ecirc;ncia da pr&eacute;-carga que o &iacute;ndice Tei apresenta<sup>29<
/sup>. </font></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#87#83#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#88#84#article#160#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop03011.htm##
01382000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704113800085002001301223#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#89#85#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A s&iacute;ndrome metab&oac
ute;lica leva &agrave; dano card&iacute;aco subcl&iacute;nico, reduzindo a fun&c
cedil;&atilde;o global do VE. O &iacute;ndice Tei &eacute; uma maneira relativam
ente simples de estimar a fun&ccedil;&atilde;o global do VE e portanto, um par&a
circ;metro valioso na pr&aacute;tica cl&iacute;nica rotineira. A an&aacute;lise 
de regress&atilde;o m&uacute;ltipla dos par&acirc;metros cl&iacute;nicos mostrou
 que a PAS, glicemia de jejum, &iacute;ndice de massa do VE, raz&atilde;o E/e'<s
ub>septal</sub>, e e'<sub>septal</sub> estavam associados de forma independente 
com a fun&ccedil;&atilde;o global do VE estimada atrav&eacute;s do &iacute;ndice
 Tei. Tamb&eacute;m demonstramos que quase os mesmos fatores que est&atilde;o as
sociados com o TRIV, TCIV e TE no grupo com SM tamb&eacute;m est&atilde;o associ
ados com o &iacute;ndice Tei. A fun&ccedil;&atilde;o diast&oacute;lica deficient
e do VE &eacute; a principal raz&atilde;o para a deteriora&ccedil;&atilde;o da f
un&ccedil;&atilde;o global do VE na SM, de acordo com nosso estudo. </font></p> 
    ^cY#aop03011.htm##
00604000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704036000085002001300445#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#90#86#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Al&eacute;m disso, mostramo
s que, entre os componentes da SM, apenas a press&atilde;o arterial sist&oacute;
lica, glicemia de jejum e n&iacute;veis de triglic&eacute;rides estavam associad
os de forma independente com a fun&ccedil;&atilde;o global do ventr&iacute;culo 
esquerdo. </font></p>     ^cY#aop03011.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012200085002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#91#87#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Potencial Conflito de In
teresses</b></font></p>     ^cY#aop03011.htm##
00388000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704014400085002001300229#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#92#88#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Declaro n&atilde;o haver co
nflito de interesses pertinentes. </font></p>     ^cY#aop03011.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011300085002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#93#89#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fontes de Financiamento<
/b></font></p>     ^cY#aop03011.htm##
00395000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704015100085002001300236#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#94#90#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo n&atilde;
o teve fontes de financiamento externas. </font></p>     ^cY#aop03011.htm##
00374000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704013000085002001300215#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#95#91#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vincula&ccedil;&atilde;o
 Acad&ecirc;mica</b></font></p>     ^cY#aop03011.htm##
00437000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019300085002001300278#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#96#92#article#160#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; vincul
a&ccedil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atilde;
o. </font></p>     ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#97#93#article#160#<p>&nbsp;<
/p>     ^cY#aop03011.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#98#94#article#160#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop03011.htm##
00597000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704033900087002001300426#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#99#95#article#16
0#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Tei C, Lin
g LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al. New index of combined sy
stolic and diastolic myocardial performance: a simple and reproducible measure o
f cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol. 199
5;26(6):357-66.    ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#100#96#article#160# </font><
/p>     ^cY#aop03011.htm##
00550000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704029100088002001300379#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#101#97#article#1
60#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Masugata 
H, Senda S, Goda F, Yamasami A, Okuyama H, Kohno T, et al. Independent determina
nts of the Tei index in hypertensive patients with preserved left ventricular sy
stolic function. Int Heart J. 2009;50(3):331-40.    ^cY#aop03011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#102#98#article#160# </font><
/p>     ^cY#aop03011.htm##
00564000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000200086704030500088002001300393#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#103#99#article#1
60#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Pattoneri
 P, Sozzi FB, Catellani E, Piazza A, Iotti R, Michelini M, et al. Myocardial inv
olvement during the early course of type 2 diabetes mellitus: usefulness of myoc
ardial performance index. Cardiovasc Ultrasound. 2008;6:27-33.    ^cY#aop03011.h
tm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#104#100#article#160# </font>
</p>     ^cY#aop03011.htm##
00549000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704028900089002001300378#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#105#101#article#
160#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Levent E
, G&ouml;k&#351;en D, Ozy&uuml;rek AR, Darcan S, Coker M. Usefulness of the myoc
ardial performance index (MPI) for assessing ventricular function in obese pedia
tric patients. Turk J Pediatr. 2005;47(1):34-8.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#106#102#article#160# </font>
</p>     ^cY#aop03011.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704027500089002001300364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#107#103#article#
160#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Masugata
 H, Senda S, Goda F, Yoshihara Y, Yoshikawa K, Fujita N, et al. Left ventricular
 diastolic dysfunction as assessed by echocardiography in metabolic syndrome. Hy
pertens Res. 2006;29(11):897-903.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#108#104#article#160# </font>
</p>     ^cY#aop03011.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704027800089002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#109#105#article#
160#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Turhan H
, Yasar AS, Yagmur J, Kurtoglu E, Yetkin E. The impact of metabolic syndrome on 
left ventricular function: evaluated by using the index of myocardial performanc
e. Int J Cardiol. 2009;132(3):382-6.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#110#106#article#160# </font>
</p>     ^cY#aop03011.htm##
00590000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704033000089002001300419#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#111#107#article#
160#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Mishra R
K, Kizer JR, Palmieri V, Roman MJ, Galloway JM, Fabsitz RR, et al. Utility of th
e myocardial performance index in a population with high prevalences of obesity,
 diabetes, and hypertension: the Strong Heart Study. Echocardiography. 2007;24(4
):340-7.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#112#108#article#160# </font>
</p>     ^cY#aop03011.htm##
00570000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704031000089002001300399#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#113#109#article#
160#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Executiv
e Summary of the Third Report of the National Cholesterol Education Program (NCE
P) Expert Panel on detection, evaluation, and treatment of high blood cholestero
l in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.    ^cY#aop0
3011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#114#110#article#160# </font>
</p>     ^cY#aop03011.htm##
00497000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000200087704023700089002001300326#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#115#111#article#
160#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. WHO Guid
eline Development Committee. Definition and diagnosis of diabetes mellitus and i
ntermediate hyperglicaemia. Report of a WHO/IDF Consultation, Geneve; 2006.    ^
cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#116#112#article#160# </font>
</p>     ^cY#aop03011.htm##
00659000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704039800090002001300488#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#117#113#article#
160#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Mancia
 G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guide
lines for the Management of Arterial Hypertension: The Task Force for the Manage
ment of Arterial Hypertension of the European Society of Hypertension (ESH) and 
of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.   
 ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#118#114#article#160# </font>
</p>     ^cY#aop03011.htm##
00672000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704041100090002001300501#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#119#115#article#
160#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Schill
er NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommen
dations for quantitation of the left ventricle by two-dimensional echocardiograp
hy. American Society of Echocardiography committee on standards, subcommittee on
 quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr. 1989;2(
5):358-67.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#120#116#article#160# </font>
</p>     ^cY#aop03011.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022900090002001300319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#121#117#article#
160#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Devere
ux RB, Reichek N. Echocardiographic determination of left ventricular mass in ma
n: anatomic validation of the method. Circulation. 1977;55(4):613-8.    ^cY#aop0
3011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#122#118#article#160# </font>
</p>     ^cY#aop03011.htm##
00588000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032700090002001300417#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#123#119#article#
160#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. de Sim
one G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left v
entricular mass and body size in normotensive children and adults: assessment of
 allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20(5):12
51-60.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#124#120#article#160# </font>
</p>     ^cY#aop03011.htm##
00639000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037800090002001300468#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#125#121#article#
160#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Quinon
es MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantific
ation of Doppler echocardiography: a report from the Doppler quantification task
 force of the nomenclature and standards committee of the American Society of Ec
hocardiography. J Am Soc Echocardiogr. 2002;15(2):167-84.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#126#122#article#160# </font>
</p>     ^cY#aop03011.htm##
00483000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022200090002001300312#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#127#123#article#
160#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Keser 
N, Yildiz S, Kurtoglu N, Dindar I. Modified TEI index: a promising parameter in 
essential hypertension? Echocardiography. 2005;22(4):296-304.    ^cY#aop03011.ht
m##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#128#124#article#160# </font>
</p>     ^cY#aop03011.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022900090002001300319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#129#125#article#
160#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Spence
r K, Kirkpatrick J, Mor-Avi V, Decara J, Lang R. Age dependency of the Tei index
 of myocardial performance. J Am Soc Echocardiogr. 2004;17(4):350-2.    ^cY#aop0
3011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#130#126#article#160# </font>
</p>     ^cY#aop03011.htm##
00558000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029700090002001300387#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#131#127#article#
160#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Anders
en NH, Poulsen SH, Helleberg K, Ivarsen P, Knudsen ST, Mogensen CE. Impact of es
sential hypertension and diabetes mellitus on left ventricular systolic and dias
tolic performance. Eur J Echocardiogr. 2003;4(4):306-12.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#132#128#article#160# </font>
</p>     ^cY#aop03011.htm##
00448000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018700090002001300277#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#133#129#article#
160#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Berk B
C, Fujiwara K, Lehoux S. ECM remodelling in hypertensive heart disease. J Clin I
nvest. 2007;117(3):568-75.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#134#130#article#160# </font>
</p>     ^cY#aop03011.htm##
00543000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028200090002001300372#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#135#131#article#
160#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Voulga
ri C, Moyssakis I, Papazafiropoulou A, Perrea D, Kyriaki D, Katsilambros N, et a
l. The impact of metabolic syndrome on left ventricular myocardial performance. 
Diabetes Metab Res Rev. 2010;26(2):121-7.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#136#132#article#160# </font>
</p>     ^cY#aop03011.htm##
00494000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023300090002001300323#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#137#133#article#
160#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Marwic
k T. Diastolic disturbances in diabetes mellitus. In: Smiseth OA, Tendera M. (ed
s. ). Diastolic heart failure. London: Springer-Verlag; 2008. p. 271-84.    ^cY#
aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#138#134#article#160# </font>
</p>     ^cY#aop03011.htm##
00527000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026600090002001300356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#139#135#article#
160#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Cho KI
, Park JH, Lee CK, Kim SH, Ahan JM, Kim S, et al. Isolated and combined influenc
es of diabetes and hypertension on the myocardial function and geometry. Korean 
Circ J. 2006;36(6):411-7.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#140#136#article#160# </font>
</p>     ^cY#aop03011.htm##
00497000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023600090002001300326#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#141#137#article#
160#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Dayi S
U, Kasikcioglu H, Uslu N, Tartan Z, Uyarel H, Terzi S, et al. Influence of weigh
t loss on myocardial performance index. Heart and Vessels. 2006;21(2):84-8.    ^
cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#142#138#article#160# </font>
</p>     ^cY#aop03011.htm##
00517000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025600090002001300346#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#143#139#article#
160#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Valoci
k G, Mitro P, Zapachova J, Majercak I, Mudrakova K. Relation of various degrees 
of body mass index to systolic and diastolic dysfunctions. Bratisl Lek Listy. 20
08;109(2):52-6.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#144#140#article#160# </font>
</p>     ^cY#aop03011.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028400090002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#145#141#article#
160#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. de las
 Fuentes L, Waggoner AD, Brown AL, D&aacute;vila-Rom&aacute;n VG. Plasma triglyc
eride level is an independent predictor of altered left ventricular relaxation. 
J Am Soc Echocardiogr. 2005;18(12):1285-91.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#146#142#article#160# </font>
</p>     ^cY#aop03011.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#147#143#article#
160#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. de Sim
one G, Devereux RB, Chinali M, Roman MJ, Lee ET, Resnick HE, et al. Metabolic sy
ndrome and left ventricular hypertrophy in the prediction of cardiovascular even
ts: the Strong Heart Study. Nutr Metab Cardiovasc Dis. 2009;19(2):98-104.    ^cY
#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#148#144#article#160# </font>
</p>     ^cY#aop03011.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030600090002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#149#145#article#
160#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Chinal
i M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al. Comparison of ca
rdiac structure and function in American Indians with and without the metabolic 
syndrome (the Strong Heart Study). Am J Cardiol. 2004;93(1):40-4.    ^cY#aop0301
1.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#150#146#article#160# </font>
</p>     ^cY#aop03011.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030200090002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#151#147#article#
160#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. de las
 Fuentes L, Brown A, Mathews S, Waggoner A, Soto P, Gropler R, et al. Metabolic 
syndrome is associated with abnormal left ventricular diastolic function indepen
dent of left ventricular mass. Eur Heart J. 2007,28(5):553-9.    ^cY#aop03011.ht
m##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#152#148#article#160# </font>
</p>     ^cY#aop03011.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#153#149#article#
160#28#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Su HM,
 Lin TH, Voon WC, Lee KT, Chu CS, Yen HW, et al. Correlation of Tei index obtain
ed from tissue Doppler echocardiography with invasive measurements of left ventr
icular performance. Echocardiography. 2007;24(3):252-7.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#154#150#article#160# </font>
</p>     ^cY#aop03011.htm##
00524000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026300090002001300353#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#155#151#article#
160#29#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Barber
ato SH, Pecoits Filho R. Influence of preload reduction on Tei index and other D
oppler echocardiographic parameters of left ventricular function. Arq Bras Cardi
ol. 2006;86(6):425-31.    ^cY#aop03011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#156#152#article#160# </font>
</p>     ^cY#aop03011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#157#153#article#160#<p>&nbsp
;</p>     ^cY#aop03011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#158#154#article#160#<p>&nbsp
;</p>     ^cY#aop03011.htm##
00447000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020100087002001300288#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#159#155#article#160#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a> <b>Co
rrespond&ecirc;ncia:</b>     ^cY#aop03011.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004100087002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#160#156#article#160#<br>   B
ranislava Aleksa Ivanovic    ^cY#aop03011.htm##
00305000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005900087002001300146#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#161#157#article#160#<br>   B
ul.Mihaila Pupina 151 - 11070 Novi Beograd     ^cY#aop03011.htm##
00286000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004000087002001300127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#162#158#article#160#<br>   1
1000 - Belgrade - Serbia    ^cY#aop03011.htm##
00329000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704008300087002001300170#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#163#159#article#160#<br>   E
-mail: <a href="mailto:lole@scnet.rs">lole@scnet.rs</a></font></p>     ^cY#aop03
011.htm##
00409000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016300087002001300250#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03011.htm#S#p#164#160#article#160#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 14/07/
10; revisado recebido em 25/10/10; aceito em 03/12/10. </font></p>     ^cY#aop03
011.htm##
00788000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100013000860100015000990100
01600114010001700130010001300147010002100160810000600181012017300187030001000360
06500090037006400050037903100030038403200020038701400070038986500090039600200130
0405035001000418801001000428#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#165#1#article#29#1#^rND^sTei^nC#^rND^sLing^nLH#^rND^sHodge^nDO#^
rND^sBailey^nKR#^rND^sOh^nJK#^rND^sRodeheffer^nRJ#et al#New index of combined sy
stolic and diastolic myocardial performance: a simple and reproducible measure o
f cardiac function-a study in normals and dilated cardiomyopathy^len#J Cardiol#1
9950000#1995#26#6#357-66#20110000#aop03011.htm#0914-5087#J Cardiol##
00710000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100015001040100
01400119010001800133010001700151010001500168810000600183012012100189030001200310
71000020032206500090032406400050033303100030033803200020034101400070034386500090
0350002001300359#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#
S#c#166#2#article#29#2#^rND^sMasugata^nH#^rND^sSenda^nS#^rND^sGoda^nF#^rND^sYama
sami^nA#^rND^sOkuyama^nH#^rND^sKohno^nT#et al#Independent determinants of the Te
i index in hypertensive patients with preserved left ventricular systolic functi
on^len#Int Heart J#2#20090000#2009#50#3#331-40#20110000#aop03011.htm##
00713000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100016001050100
01900121010001600140010001500156010001900171810000600190012012300196030002200319
71000020034106500090034306400050035203100020035701400060035986500090036500200130
0374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#167#3#ar
ticle#29#3#^rND^sPattoneri^nP#^rND^sSozzi^nFB#^rND^sCatellani^nE#^rND^sPiazza^nA
#^rND^sIotti^nR#^rND^sMichelini^nM#et al#Myocardial involvement during the early
 course of type 2 diabetes mellitus: usefulness of myocardial performance index^
len#Cardiovasc Ultrasound#2#20080000#2008#6#27-33#20110000#aop03011.htm##
00704000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100021001020100
01800123010001600141010001500157012012000172030001500292065000900307064000500316
03100030032103200020032401400050032686500090033100200130034003500100035380100150
0363#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#168#4#ar
ticle#29#4#^rND^sLevent^nE#^rND^sGök&#351;en^nD#^rND^sOzyürek^nAR#^rND^sDarcan^n
S#^rND^sCoker^nM#Usefulness of the myocardial performance index (MPI) for assess
ing ventricular function in obese pediatric patients^len#Turk J Pediatr#20050000
#2005#47#1#34-8#20110000#aop03011.htm#0041-4301#Turk J Pediatr##
00728000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100015001040100
01400119010001900133010001900152010001600171810000600187012009700193030001400290
06500090030406400050031303100030031803200030032101400080032486500090033200200130
0341035001000354801001400364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#169#5#article#29#5#^rND^sMasugata^nH#^rND^sSenda^nS#^rND^sGoda^n
F#^rND^sYoshihara^nY#^rND^sYoshikawa^nK#^rND^sFujita^nN#et al#Left ventricular d
iastolic dysfunction as assessed by echocardiography in metabolic syndrome^len#H
ypertens Res#20060000#2006#29#11#897-903#20110000#aop03011.htm#0916-9636#Hyperte
ns Res##
00702000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020100
01600118010001800134010001600152012012200168030001400290065000900304064000500313
03100040031803200020032201400060032486500090033000200130033903500100035280100140
0362#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#170#6#ar
ticle#29#6#^rND^sTurhan^nH#^rND^sYasar^nAS#^rND^sYagmur^nJ#^rND^sKurtoglu^nE#^rN
D^sYetkin^nE#The impact of metabolic syndrome on left ventricular function: eval
uated by using the index of myocardial performance^len#Int J Cardiol#20090000#20
09#132#3#382-6#20110000#aop03011.htm#0167-5273#Int J Cardiol##
00786000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030100
01800119010001600137010001900153010001800172810000600190012014900196030001700345
06500090036206400050037103100030037603200020037901400060038186500090038700200130
0396035001000409801001700419#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#171#7#article#29#7#^rND^sMishra^nRK#^rND^sKizer^nJR#^rND^sPalmie
ri^nV#^rND^sRoman^nMJ#^rND^sGalloway^nJM#^rND^sFabsitz^nRR#et al#Utility of the 
myocardial performance index in a population with high prevalences of obesity, d
iabetes, and hypertension: the Strong Heart Study^len#Echocardiography#20070000#
2007#24#4#340-7#20110000#aop03011.htm#0263-5453#ECHOCARDIOGRAPHY##
00635000000000265000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840120212000860300005002980650
00900303064000500312031000400317032000300321014000800324865000900332002001300341
035001000354801000500364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03
011.htm#S#c#172#8#article#29#8#Executive Summary of the Third Report of the Nati
onal Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation,
 and treatment of high blood cholesterol in adults (Adult Treatment Panel III)^l
en#JAMA#20010000#2001#285#19#2486-97#20110000#aop03011.htm#0098-7484#JAMA##
00511000000000229000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170036000860180099001220660
01700221062000700238065000900245064000500254865000900259002001300268#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#173#9#article#29#9#WHO G
uideline Development Committee#Definition and diagnosis of diabetes mellitus and
 intermediate hyperglicaemia.Report of a WHO/^len#IDF Consultation#Geneve#200600
00#2006#20110000#aop03011.htm##
00850000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
02000123010001700143010001600160010001700176810000600193012021800199030001200417
06500090042906400050043803100030044303200020044601400080044886500090045600200130
0465035001000478801001200488#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#174#10#article#29#10#^rND^sMancia^nG#^rND^sDe Backer^nG#^rND^sDo
miniczak^nA#^rND^sCifkova^nR#^rND^sFagard^nR#^rND^sGermano^nG#et al#2007 Guideli
nes for the Management of Arterial Hypertension: The Task Force for the Manageme
nt of Arterial Hypertension of the European Society of Hypertension (ESH) and of
 the European Society of Cardiology (ESC)^len#J Hypertens#20070000#2007#25#6#110
5-87#20110000#aop03011.htm#0263-6352#J Hypertens##
00873000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01800122010001700140010001800157010002000175810000600195012022100201030002200422
06500090044406400050045303100020045803200020046001400070046286500090046900200130
0478035001000491801002200501#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#175#11#article#29#11#^rND^sSchiller^nNB#^rND^sShah^nPM#^rND^sCra
wford^nM#^rND^sDeMaria^nA#^rND^sDevereux^nR#^rND^sFeigenbaum^nH#et al#Recommenda
tions for quantitation of the left ventricle by two-dimensional echocardiography
: American Society of Echocardiography committee on standards, subcommittee on q
uantitation of two-dimensional echocardiograms^len#J Am Soc Echocardiogr#1989000
0#1989#2#5#358-67#20110000#aop03011.htm#0894-7317#J Am Soc Echocardiogr##
00598000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070120
10300124030001200227065000900239064000500248031000300253032000200256014000600258
865000900264002001300273035001000286801001200296#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03011.htm#S#c#176#12#article#29#12#^rND^sDevereux^nRB#^rND
^sReichek^nN#Echocardiographic determination of left ventricular mass in man: an
atomic validation of the method^len#Circulation#19770000#1977#55#4#613-8#2011000
0#aop03011.htm#0009-7322#Circulation##
00785000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01900125010001600144010001600160010002100176810000600197012013700203030001800340
06500090035806400050036703100030037203200020037501400080037786500090038500200130
0394035001000407801001800417#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#177#13#article#29#13#^rND^sde Simone^nG#^rND^sDaniels^nSR#^rND^s
Devereux^nRB#^rND^sMeyer^nRA#^rND^sRoman^nMJ#^rND^sde Divitiis^nO#et al#Left ven
tricular mass and body size in normotensive children and adults: assessment of a
llometric relations and impact of overweight^len#J Am Coll Cardiol#19920000#1992
#20#5#1251-60#20110000#aop03011.htm#0735-1097#J Am Coll Cardiol##
00811000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01800122010001800140010001700158012020800175030002200383065000900405064000500414
03100030041903200020042201400070042486500090043100200130044003500100045380100220
0463#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#178#14#a
rticle#29#14#^rND^sQuinones^nMA#^rND^sOtto^nCM#^rND^sStoddard^nM#^rND^sWaggoner^
nA#^rND^sZoghbi^nWA#Recommendations for quantification of Doppler echocardiograp
hy: a report from the Doppler quantification task force of the nomenclature and 
standards committee of the American Society of Echocardiography^len#J Am Soc Ech
ocardiogr#20020000#2002#15#2#167-84#20110000#aop03011.htm#0894-7317#J Am Soc Ech
ocardiogr##
00633000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100016001030100
01800119010001600137012007300153030001700226065000900243064000500252031000300257
032000200260014000800262865000900270002001300279035001000292801001700302#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#179#15#article#29#15
#^rND^sKeser^nN#^rND^sYildiz^nS#^rND^sKurtoglu^nN#^rND^sDindar^nI#Modified TEI i
ndex: a promising parameter in essential hypertension?^len#Echocardiography#2005
0000#2005#22#4#296-304#20110000#aop03011.htm#0263-5453#ECHOCARDIOGRAPHY##
00662000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01700126010001600143010001400159012006200173030002200235065000900257064000500266
03100030027103200020027401400060027686500090028200200130029103500100030480100220
0314#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#180#16#a
rticle#29#16#^rND^sSpencer^nK#^rND^sKirkpatrick^nJ#^rND^sMor-Avi^nV#^rND^sDecara
^nJ#^rND^sLang^nR#Age dependency of the Tei index of myocardial performance^len#
J Am Soc Echocardiogr#20040000#2004#17#4#350-2#20110000#aop03011.htm#0894-7317#J
 Am Soc Echocardiogr##
00706000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01900125010001700144010001800161010001900179012011400198030001900312710000200331
06500090033306400050034203100020034703200020034901400070035186500090035800200130
0367#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#181#17#a
rticle#29#17#^rND^sAndersen^nNH#^rND^sPoulsen^nSH#^rND^sHelleberg^nK#^rND^sIvars
en^nP#^rND^sKnudsen^nST#^rND^sMogensen^nCE#Impact of essential hypertension and 
diabetes mellitus on left ventricular systolic and diastolic performance^len#Eur
 J Echocardiogr#2#20030000#2003#4#4#306-12#20110000#aop03011.htm##
00576000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100018001030100
01600121012005000137030001400187065000900201064000500210031000400215032000200219
014000700221865000900228002001300237035001000250801001400260#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop03011.htm#S#c#182#18#article#29#18#^rND^sBerk^
nBC#^rND^sFujiwara^nK#^rND^sLehoux^nS#ECM remodelling in hypertensive heart dise
ase^len#J Clin Invest#20070000#2007#117#3#568-75#20110000#aop03011.htm#0021-9738
#J Clin Invest##
00702000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
02600125010001600151010001700167010002200184810000600206012008000212030002300292
71000020031506500090031706400050032603100030033103200020033401400060033686500090
0342002001300351#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#
S#c#183#19#article#29#19#^rND^sVoulgari^nC#^rND^sMoyssakis^nI#^rND^sPapazafiropo
ulou^nA#^rND^sPerrea^nD#^rND^sKyriaki^nD#^rND^sKatsilambros^nN#et al#The impact 
of metabolic syndrome on left ventricular myocardial performance^len#Diabetes Me
tab Res Rev#2#20100000#2010#26#2#121-7#20110000#aop03011.htm##
00560000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880120048001050160
01800153016001700171018002800188066000700216062001600223014000700239065000900246
064000500255865000900260002001300269#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop03011.htm#S#c#184#20#article#29#20#^rND^sMarwick^nT#Diastolic disturba
nces in diabetes mellitus^len#^rND^sSmiseth^nOA#^rND^sTendera^nM#Diastolic heart
 failure^len#London#Springer-Verlag#271-84#20080000#2008#20110000#aop03011.htm##
00686000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100015001020100
01400117010001400131010001500145010001300160810000600173012010600179030001400285
71000020029906500090030106400050031003100030031503200020031801400060032086500090
0326002001300335#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#
S#c#185#21#article#29#21#^rND^sCho^nKI#^rND^sPark^nJH#^rND^sLee^nCK#^rND^sKim^nS
H#^rND^sAhan^nJM#^rND^sKim^nS#et al#Isolated and combined influences of diabetes
 and hypertension on the myocardial function and geometry^len#Korean Circ J#2#20
060000#2006#36#6#411-7#20110000#aop03011.htm##
00694000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100021001030100
01400124010001600138010001600154010001500170810000600185012006100191030001800252
06500090027006400050027903100030028403200020028701400050028986500090029400200130
0303035001000316801001800326#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#186#22#article#29#22#^rND^sDayi^nSU#^rND^sKasikcioglu^nH#^rND^sU
slu^nN#^rND^sTartan^nZ#^rND^sUyarel^nH#^rND^sTerzi^nS#et al#Influence of weight 
loss on myocardial performance index^len#Heart and Vessels#20060000#2006#21#2#84
-8#20110000#aop03011.htm#0910-8327#Heart and Vessels##
00685000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01900120010001800139010001900157012009000176030001800266065000900284064000500293
03100040029803200020030201400050030486500090030900200130031803500100033180100180
0341#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#S#c#187#23#a
rticle#29#23#^rND^sValocik^nG#^rND^sMitro^nP#^rND^sZapachova^nJ#^rND^sMajercak^n
I#^rND^sMudrakova^nK#Relation of various degrees of body mass index to systolic 
and diastolic dysfunctions^len#Bratisl Lek Listy#20080000#2008#109#2#52-6#201100
00#aop03011.htm#0006-9248#Bratisl Lek Listy##
00621000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110054000880120097001420300
02200239065000900261064000500270031000300275032000300278014000800281865000900289
002001300298035001000311801002200321#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop03011.htm#S#c#188#24#article#29#24#de las Fuentes L.Waggoner AD.Brown 
AL.Dávila-Román VG#Plasma triglyceride level is an independent predictor of alte
red left ventricular relaxation^len#J Am Soc Echocardiogr#20050000#2005#18#12#12
85-91#20110000#aop03011.htm#0894-7317#J Am Soc Echocardiogr##
00734000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
01700126010001600143010001400159010001800173810000600191012012300197030002600320
71000020034606500090034806400050035703100030036203200020036501400070036786500090
0374002001300383#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03011.htm#
S#c#189#25#article#29#25#^rND^sde Simone^nG#^rND^sDevereux^nRB#^rND^sChinali^nM#
^rND^sRoman^nMJ#^rND^sLee^nET#^rND^sResnick^nHE#et al#Metabolic syndrome and lef
t ventricular hypertrophy in the prediction of cardiovascular events: the Strong
 Heart Study^len#Nutr Metab Cardiovasc Dis#2#20090000#2009#19#2#98-104#20110000#
aop03011.htm##
00759000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01700124010001600141010001600157010001400173810000600187012013400193030001300327
06500090034006400050034903100030035403200020035701400050035986500090036400200130
0373035001000386801001300396#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#190#26#article#29#26#^rND^sChinali^nM#^rND^sDevereux^nRB#^rND^sH
oward^nBV#^rND^sRoman^nMJ#^rND^sBella^nJN#^rND^sLiu^nJE#et al#Comparison of card
iac structure and function in American Indians with and without the metabolic sy
ndrome (the Strong Heart Study)^len#Am J Cardiol#20040000#2004#93#1#40-4#2011000
0#aop03011.htm#0002-9149#Am J Cardiol##
00754000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100024000880100015001120100
01700127010001800144010001400162010001700176810000600193012012400199030001200323
06500090033506400050034403100030034903200020035201400060035486500090036000200130
0369035001000382801001200392#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#191#27#article#29#27#^rND^sde las Fuentes^nL#^rND^sBrown^nA#^rND
^sMathews^nS#^rND^sWaggoner^nA#^rND^sSoto^nP#^rND^sGropler^nR#et al#Metabolic sy
ndrome is associated with abnormal left ventricular diastolic function independe
nt of left ventricular mass^len#Eur Heart J#20070000#2007#28#5#553-9#20110000#ao
p03011.htm#0195-668X#Eur Heart J##
00753000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100013000880100014001010100
01500115010001400130010001400144010001400158810000600172012013400178030001700312
06500090032906400050033803100030034303200020034601400060034886500090035400200130
0363035001000376801001700386#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03011.htm#S#c#192#28#article#29#28#^rND^sSu^nHM#^rND^sLin^nTH#^rND^sVoon^nWC#^
rND^sLee^nKT#^rND^sChu^nCS#^rND^sYen^nHW#et al#Correlation of Tei index obtained
 from tissue Doppler echocardiography with invasive measurements of left ventric
ular performance^len#Echocardiography#20070000#2007#24#3#252-7#20110000#aop03011
.htm#0263-5453#ECHOCARDIOGRAPHY##
00637000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100023001080120
12400131030001700255065000900272064000500281031000300286032000200289014000700291
865000900298002001300307035001000320801001700330#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03011.htm#S#c#193#29#article#29#29#^rND^sBarberato^nSH#^rN
D^sPecoits Filho^nR#Influence of preload reduction on Tei index and other Dopple
r echocardiographic parameters of left ventricular function^len#Arq Bras Cardiol
#20060000#2006#86#6#425-31#20110000#aop03011.htm#0066-782X#Arq Bras Cardiol##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#o#1#1#
article#1#20110331#081828#aop03111.htm#124##
05276000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201070
01780120099002850100030003840100029004140100036004430100024004790100032005030700
09500535070010100630083178400731085000802515085002902523085003602552085002902588
08500360261708316680265308500080432108500270432908500340435608500280439008500340
44180580012044520580036044641170008045000720003045081120009045111110009045201160
00904529115000904538114000904547113000904556002001304565#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop03111.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS
#TAB#38#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#Preci
são do aparelho Omron HEM-705 CP na medida de pressão arterial em grandes estudo
s epidemiológicos^lpt#Accuracy of the Omron HEM-705 CP for blood pressure measur
ement in large epidemiologic studies^len#^rND^1A01^nLina M.^sVera-Cala#^rND^1A01
^nMyriam^sOrostegui#^rND^1A01^nLaura I.^sValencia-Angel#^rND^1A01^nNahyr^sLópez#
^rND^1A02^nLeonelo E.^sBautista#Universidad Industrial de Santander^iA01^1Depart
amento de Salud Pública^cBucaramanga^pColombia#University of Wisconsin^iA02^1Med
ical School^2Department of Population Health Sciences^cMadison^pUSA#^lpt^aFUNDAM
ENTO: A medida precisa da pressão arterial (PA) é de grande importância na pesqu
isa da hipertensão. No contexto de estudos clínicos e epidemiológicos, dispositi
vos oscilométricos frequentemente oferecem importantes vantagens para superar al
gumas das limitações do método auscultatório. Embora sua acurácia tenha sido ava
liada em estudos múltiplos no ambiente clínico, há pouca evidência de seu desemp
enho em grandes estudos epidemiológicos. OBJETIVO: Avaliamos a precisão do Omron
 HEM-705-CP, um dispositivo automático para medida de PA, quando comparado com o
 método padrão auscultatório com esfigmomanômetro de mercúrio em um grande estud
o de coorte. MÉTODOS: Três medidas auscultatórias foram obtidas, seguidas por du
as mensurações com o dispositivo Omron em 1.084 indivíduos. O viés foi estimado 
como a média de duas medidas pelo dispositivo Omron menos a média das duas últim
as medidas auscultatórias, com seus correspondentes limites de concordância (LC)
 de 95%. RESULTADOS: O dispositivo Omron superestimou a pressão arterial sistóli
ca (PAS) por 1,8 mmHg (LC:-10,1, 13,7) e subestimou a pressão arterial diastólic
a (PAD) por 1,6 mmHg (LC:-12,3, 9,2). O viés foi significantemente maior em home
ns. O viés na PAS aumentou com a idade e diminuiu com o nível da PA, enquanto o 
viés na PAD diminuiu com a idade e aumentou com o nível da PA. A sensibilidade e
 a especificidade do dispositivo Omron para detectar hipertensão foram 88,2% e 9
8,6%, respectivamente. O uso das medidas do dispositivo Omron resultou em viés m
ínimo na estimativa dos efeitos de vários fatores. CONCLUSÃO: Nossos resultados 
demonstraram que o dispositivo Omron HEM-705-CP pode ser utilizado para medir a 
PA em grandes estudos epidemiológicos sem comprometer a validade do estudo ou su
a precisão.#^dnd^i1#^tm^lpt^kPressão arterial^i1#^tm^lpt^kequipamentos de mediçã
o^i1#^tm^lpt^kensaios clínicos^i1#^tm^lpt^kestudos epidemiológicos^i1#^len^aBACK
GROUND: Accurate measurement of blood pressure is of utmost importance in hypert
ension research. In the context of epidemiologic and clinical studies, oscillome
tric devices offer important advantages to overcome some of the limitations of t
he auscultatory method. Even though their accuracy has been evaluated in multipl
e studies in the clinical setting, there is little evidence of their performance
 in large epidemiologic studies. OBJECTIVE: We evaluated the accuracy of the Omr
on HEM-705-CP, an automatic device for blood pressure (BP) measurement, as compa
red to the standard auscultatory method with a mercury sphygmomanometer in a lar
ge cohort study. METHODS: We made three auscultatory measurements, followed by t
wo measurements with the Omron device in 1,084 subjects. Bias was estimated as t
he average of the two Omron minus the average of the last two auscultatory measu
rements, with its corresponding 95% limits of agreement (LA). RESULTS: The Omron
 overestimated systolic blood pressure (SBP) by 1.8 mmHg (LA:-10.1, 13.7) and un
derestimated diastolic blood pressure (DBP) by 1.6 mmHg (LA:-12.3, 9.2). Bias wa
s significantly larger in men. Bias in SBP increased with age and decreased with
 BP level, while bias in DBP decreased with age and increased with BP level. The
 sensitivity and specificity of the Omron to detect hypertension were 88.2% and 
98.6%, respectively. Minimum bias in the estimates of the effects of several fac
tors resulted from the use of Omron measurements. CONCLUSION: Our results showed
 that the Omron HEM-705-CP could be used for measuring BP in large epidemiology 
studies without compromising study validity or precision.#^dnd^i2#^tm^len^kBlood
 pressure^i2#^tm^len^kmeasurement equipment^i2#^tm^len^kclinical trials^i2#^tm^l
en^kepidemiologic studies^i2#COLCIENCIAS#Universidad Industrial de Santander#van
couv#19#20100217#17/02/10#20101007#07/10/10#20101130#30/11/10#aop03111.htm##
05360000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201140
01780120106002920100030003980100029004280100036004570100024004930100032005170700
09500549070010100644083181900745085000802564085002902572085003602601085002902637
08500360266608317030270208500080440508500270441308500340444008500280447408500340
45020580012045360580036045481170008045840720003045921120009045951110009046041160
00904613115000904622114000904631113000904640002001304649#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop03111.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS
#TAB#38#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#<b>Pr
ecisão do aparelho Omron HEM-705 CP na medida de pressão arterial em grandes est
udos epidemiológicos</b>^lpt#<b>Accuracy of the Omron HEM-705 CP for blood press
ure measurement in large epidemiologic studies</b>^len#^rND^1A01^nLina M.^sVera-
Cala#^rND^1A01^nMyriam^sOrostegui#^rND^1A01^nLaura I.^sValencia-Angel#^rND^1A01^
nNahyr^sLópez#^rND^1A02^nLeonelo E.^sBautista#Universidad Industrial de Santande
r^iA01^1Departamento de Salud Pública^cBucaramanga^pColombia#University of Wisco
nsin^iA02^1Medical School^2Department of Population Health Sciences^cMadison^pUS
A#^lpt^a<b>FUNDAMENTO:</b> A medida precisa da pressão arterial (PA) é de grande
 importância na pesquisa da hipertensão. No contexto de estudos clínicos e epide
miológicos, dispositivos oscilométricos frequentemente oferecem importantes vant
agens para superar algumas das limitações do método auscultatório. Embora sua ac
urácia tenha sido avaliada em estudos múltiplos no ambiente clínico, há pouca ev
idência de seu desempenho em grandes estudos epidemiológicos. <b>OBJETIVO:</b> A
valiamos a precisão do Omron HEM-705-CP, um dispositivo automático para medida d
e PA, quando comparado com o método padrão auscultatório com esfigmomanômetro de
 mercúrio em um grande estudo de coorte. <b>MÉTODOS:</b> Três medidas auscultató
rias foram obtidas, seguidas por duas mensurações com o dispositivo Omron em 1.0
84 indivíduos. O viés foi estimado como a média de duas medidas pelo dispositivo
 Omron menos a média das duas últimas medidas auscultatórias, com seus correspon
dentes limites de concordância (LC) de 95%. <b>RESULTADOS:</b> O dispositivo Omr
on superestimou a pressão arterial sistólica (PAS) por 1,8 mmHg (LC:-10,1, 13,7)
 e subestimou a pressão arterial diastólica (PAD) por 1,6 mmHg (LC:-12,3, 9,2). 
O viés foi significantemente maior em homens. O viés na PAS aumentou com a idade
 e diminuiu com o nível da PA, enquanto o viés na PAD diminuiu com a idade e aum
entou com o nível da PA. A sensibilidade e a especificidade do dispositivo Omron
 para detectar hipertensão foram 88,2% e 98,6%, respectivamente. O uso das medid
as do dispositivo Omron resultou em viés mínimo na estimativa dos efeitos de vár
ios fatores. <b>CONCLUSÃO:</b> Nossos resultados demonstraram que o dispositivo 
Omron HEM-705-CP pode ser utilizado para medir a PA em grandes estudos epidemiol
ógicos sem comprometer a validade do estudo ou sua precisão.#^dnd^i1#^tm^lpt^kPr
essão arterial^i1#^tm^lpt^kequipamentos de medição^i1#^tm^lpt^kensaios clínicos^
i1#^tm^lpt^kestudos epidemiológicos^i1#^len^a<b>BACKGROUND:</b> Accurate measure
ment of blood pressure is of utmost importance in hypertension research. In the 
context of epidemiologic and clinical studies, oscillometric devices offer impor
tant advantages to overcome some of the limitations of the auscultatory method. 
Even though their accuracy has been evaluated in multiple studies in the clinica
l setting, there is little evidence of their performance in large epidemiologic 
studies. <b>OBJECTIVE:</b> We evaluated the accuracy of the Omron HEM-705-CP, an
 automatic device for blood pressure (BP) measurement, as compared to the standa
rd auscultatory method with a mercury sphygmomanometer in a large cohort study. 
<b>METHODS:</b> We made three auscultatory measurements, followed by two measure
ments with the Omron device in 1,084 subjects. Bias was estimated as the average
 of the two Omron minus the average of the last two auscultatory measurements, w
ith its corresponding 95% limits of agreement (LA). <b>RESULTS:</b> The Omron ov
erestimated systolic blood pressure (SBP) by 1.8 mmHg (LA:-10.1, 13.7) and under
estimated diastolic blood pressure (DBP) by 1.6 mmHg (LA:-12.3, 9.2). Bias was s
ignificantly larger in men. Bias in SBP increased with age and decreased with BP
 level, while bias in DBP decreased with age and increased with BP level. The se
nsitivity and specificity of the Omron to detect hypertension were 88.2% and 98.
6%, respectively. Minimum bias in the estimates of the effects of several factor
s resulted from the use of Omron measurements. <b>CONCLUSION:</b> Our results sh
owed that the Omron HEM-705-CP could be used for measuring BP in large epidemiol
ogy studies without compromising study validity or precision.#^dnd^i2#^tm^len^kB
lood pressure^i2#^tm^len^kmeasurement equipment^i2#^tm^len^kclinical trials^i2#^
tm^len^kepidemiologic studies^i2#COLCIENCIAS#Universidad Industrial de Santander
#vancouv#19#20100217#17/02/10#20101007#07/10/10#20101130#30/11/10#aop03111.htm##
05444000000000721000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120107001840120099002910100029003900100029004190100035004480100024004830100
03100507070009700538070010300635083181100738085000802549085002902557085003602586
08500290262208500360265108316890268708500080437608500270438408500340441108500280
44450850034044730580012045070580036045191170008045550720003045631120009045661110
00904575116000904584115000904593114000904602113000904611002001304620008008904633
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#l#4#1#article#
1#^a2011#oa#pt#br1.1#1#4.0#ilus#tab#38#nd#nd#Arq. bras. cardiol#ahead#20110000#^
f0^l0#0066-782X#20110401#Precisão do aparelho Omron HEM-705 CP na medida de pres
são arterial em grandes estudos epidemiológicos^lpt#Accuracy of the Omron HEM-70
5 CP for blood pressure measurement in large epidemiologic studies^len#^rND^1A01
^nLina M^sVera-Cala#^rND^1A01^nMyriam^sOrostegui#^rND^1A01^nLaura I^sValencia-An
gel#^rND^1A01^nNahyr^sLópez#^rND^1A02^nLeonelo E^sBautista#^iA01^1Universidad In
dustrial de Santander^2Departamento de Salud Pública^cBucaramanga^pColombia#^iA0
2^1University of Wisconsin^2Medical School^3Department of Population Health Scie
nces^cMadison^pUSA#^lpt^aFUNDAMENTO: A medida precisa da pressão arterial (PA) é
 de grande importância na pesquisa da hipertensão. No contexto de estudos clínic
os e epidemiológicos, dispositivos oscilométricos frequentemente oferecem import
antes vantagens para superar algumas das limitações do método auscultatório. Emb
ora sua acurácia tenha sido avaliada em estudos múltiplos no ambiente clínico, h
á pouca evidência de seu desempenho em grandes estudos epidemiológicos. OBJETIVO
: Avaliamos a precisão do Omron HEM-705-CP, um dispositivo automático para medid
a de PA, quando comparado com o método padrão auscultatório com esfigmomanômetro
 de mercúrio em um grande estudo de coorte. MÉTODOS: Três medidas auscultatórias
 foram obtidas, seguidas por duas mensurações com o dispositivo Omron em 1.084 i
ndivíduos. O viés foi estimado como a média de duas medidas pelo dispositivo Omr
on menos a média das duas últimas medidas auscultatórias, com seus correspondent
es limites de concordância (LC) de 95 por cento. RESULTADOS: O dispositivo Omron
 superestimou a pressão arterial sistólica (PAS) por 1,8 mmHg (LC:-10,1, 13,7) e
 subestimou a pressão arterial diastólica (PAD) por 1,6 mmHg (LC:-12,3, 9,2). O 
viés foi significantemente maior em homens. O viés na PAS aumentou com a idade e
 diminuiu com o nível da PA, enquanto o viés na PAD diminuiu com a idade e aumen
tou com o nível da PA. A sensibilidade e a especificidade do dispositivo Omron p
ara detectar hipertensão foram 88,2 por cento e 98,6 por cento, respectivamente.
 O uso das medidas do dispositivo Omron resultou em viés mínimo na estimativa do
s efeitos de vários fatores. CONCLUSÃO: Nossos resultados demonstraram que o dis
positivo Omron HEM-705-CP pode ser utilizado para medir a PA em grandes estudos 
epidemiológicos sem comprometer a validade do estudo ou sua precisão.#^dnd^i1#^t
m^lpt^kPressão arterial^i1#^tm^lpt^kequipamentos de medição^i1#^tm^lpt^kensaios 
clínicos^i1#^tm^lpt^kestudos epidemiológicos^i1#^len^aBACKGROUND: Accurate measu
rement of blood pressure is of utmost importance in hypertension research. In th
e context of epidemiologic and clinical studies, oscillometric devices offer imp
ortant advantages to overcome some of the limitations of the auscultatory method
. Even though their accuracy has been evaluated in multiple studies in the clini
cal setting, there is little evidence of their performance in large epidemiologi
c studies. OBJECTIVE: We evaluated the accuracy of the Omron HEM-705-CP, an auto
matic device for blood pressure (BP) measurement, as compared to the standard au
scultatory method with a mercury sphygmomanometer in a large cohort study. METHO
DS: We made three auscultatory measurements, followed by two measurements with t
he Omron device in 1,084 subjects. Bias was estimated as the average of the two 
Omron minus the average of the last two auscultatory measurements, with its corr
esponding 95 percent limits of agreement (LA). RESULTS: The Omron overestimated 
systolic blood pressure (SBP) by 1.8 mmHg (LA:-10.1, 13.7) and underestimated di
astolic blood pressure (DBP) by 1.6 mmHg (LA:-12.3, 9.2). Bias was significantly
 larger in men. Bias in SBP increased with age and decreased with BP level, whil
e bias in DBP decreased with age and increased with BP level. The sensitivity an
d specificity of the Omron to detect hypertension were 88.2 percent and 98.6 per
cent, respectively. Minimum bias in the estimates of the effects of several fact
ors resulted from the use of Omron measurements. CONCLUSION: Our results showed 
that the Omron HEM-705-CP could be used for measuring BP in large epidemiology s
tudies without compromising study validity or precision.#^dnd^i2#^tm^len^kBlood 
pressure^i2#^tm^len^kmeasurement equipment^i2#^tm^len^kclinical trials^i2#^tm^le
n^kepidemiologic studies^i2#COLCIENCIAS#Universidad Industrial de Santander#vanc
ouv#19#20100217#17/02/10#20101007#07/10/10#20101130#30/11/10#aop03111.htm#Intern
et^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X20110050000
38##
00474000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704023200083002001300315#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#5#1#article#101#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Precis&
atilde;o do aparelho Omron HEM-705 CP na medida de press&atilde;o arterial em gr
andes estudos epidemiol&oacute;gicos</b></font></p>     ^cY#aop03111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#6#2#article#101#<p>&nbsp;</p
>     ^cY#aop03111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#7#3#article#101#<p>&nbsp;</p
>     ^cY#aop03111.htm##
00494000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704025200083002001300335#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#8#4#article#101#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Lina M. Vera-Cala<sup>I</s
up>; Myriam Orostegui<sup>I</sup>; Laura I. Valencia-Angel<sup>I</sup>; Nahyr L&
oacute;pez<sup>I</sup>; Leonelo E. Bautista<sup>II</sup></b></font></p>     ^cY#
aop03111.htm##
00421000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704017900083002001300262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#9#5#article#101#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Departamento de S
alud P&uacute;blica, Universidad Industrial de Santander, Bucaramanga, Colombia 
   ^cY#aop03111.htm##
00380000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704013700084002001300221#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#10#6#article#101#<br>   <sup
>II</sup>Department of Population Health Sciences,  University of Wisconsin, Med
ical School, Madison - USA</font></p>     ^cY#aop03111.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#11#7#article#101#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#12#8#article#101#<p>&nbsp;</
p>     ^cY#aop03111.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#13#9#article#101#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop03111.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#14#10#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>   
  ^cY#aop03111.htm##
00886000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704064200085002001300727#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#15#11#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO:</b> A medida
 precisa da press&atilde;o arterial (PA) &eacute; de grande import&acirc;ncia na
 pesquisa da hipertens&atilde;o. No contexto de estudos cl&iacute;nicos e epidem
iol&oacute;gicos, dispositivos oscilom&eacute;tricos frequentemente oferecem imp
ortantes vantagens para superar algumas das limita&ccedil;&otilde;es do m&eacute
;todo auscultat&oacute;rio. Embora sua acur&aacute;cia tenha sido avaliada em es
tudos m&uacute;ltiplos no ambiente cl&iacute;nico, h&aacute; pouca evid&ecirc;nc
ia de seu desempenho em grandes estudos epidemiol&oacute;gicos.     ^cY#aop03111
.htm##
00526000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704028200085002001300367#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#16#12#article#101#<br>   <b>
OBJETIVO:</b> Avaliamos a precis&atilde;o do Omron HEM-705-CP, um dispositivo au
tom&aacute;tico para medida de PA, quando comparado com o m&eacute;todo padr&ati
lde;o auscultat&oacute;rio com esfigmoman&ocirc;metro de merc&uacute;rio em um g
rande estudo de coorte.     ^cY#aop03111.htm##
00663000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041900085002001300504#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#17#13#article#101#<br>   <b>
M&Eacute;TODOS:</b> Tr&ecirc;s medidas auscultat&oacute;rias foram obtidas, segu
idas por duas mensura&ccedil;&otilde;es com o dispositivo Omron em 1.084 indiv&i
acute;duos. O vi&eacute;s foi estimado como a m&eacute;dia de duas medidas pelo 
dispositivo Omron menos a m&eacute;dia das duas &uacute;ltimas medidas auscultat
&oacute;rias, com seus correspondentes limites de concord&acirc;ncia (LC) de 95%
.    ^cY#aop03111.htm##
00959000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071500085002001300800#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#18#14#article#101#<br>   <b>
RESULTADOS:</b> O dispositivo Omron superestimou a press&atilde;o arterial sist&
oacute;lica (PAS) por 1,8 mmHg (LC:-10,1, 13,7) e subestimou a press&atilde;o ar
terial diast&oacute;lica (PAD) por 1,6 mmHg (LC:-12,3, 9,2). O vi&eacute;s foi s
ignificantemente maior em homens. O vi&eacute;s na PAS aumentou com a idade e di
minuiu com o n&iacute;vel da PA, enquanto o vi&eacute;s na PAD diminuiu com a id
ade e aumentou com o n&iacute;vel da PA. A sensibilidade e a especificidade do d
ispositivo Omron para detectar hipertens&atilde;o foram 88,2% e 98,6%, respectiv
amente. O uso das medidas do dispositivo Omron resultou em vi&eacute;s m&iacute;
nimo na estimativa dos efeitos de v&aacute;rios fatores.     ^cY#aop03111.htm##
00500000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025600085002001300341#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#19#15#article#101#<br>   <b>
CONCLUS&Atilde;O:</b> Nossos resultados demonstraram que o dispositivo Omron HEM
-705-CP pode ser utilizado para medir a PA em grandes estudos epidemiol&oacute;g
icos sem comprometer a validade do estudo ou sua precis&atilde;o. </font></p>   
  ^cY#aop03111.htm##
00493000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024900085002001300334#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#20#16#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> Pres
s&atilde;o arterial, equipamentos de medi&ccedil;&atilde;o, ensaios cl&iacute;ni
cos, estudos epidemiol&oacute;gicos. </font></p> <hr size="1" noshade>     ^cY#a
op03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#21#17#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#22#18#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#23#19#article#101#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop03111.htm##
02063000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704181900085002001301904#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#24#20#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A medida precisa da press&a
tilde;o arterial &eacute; de grande import&acirc;ncia na pesquisa da hipertens&a
tilde;o. Embora o m&eacute;todo auscultat&oacute;rio com esfigmoman&ocirc;metro 
tenha sido o padr&atilde;o de ouro para a medida de press&atilde;o h&aacute; mai
s de um s&eacute;culo, a t&eacute;cnica tem importantes limita&ccedil;&otilde;es
 no contexto de estudos epidemiol&oacute;gicos e cl&iacute;nicos<sup>1-3</sup>. 
Primeiramente, o treinamento e a certifica&ccedil;&atilde;o de examinadores para
 medir a press&atilde;o arterial s&atilde;o tarefas complexas e que demandam tem
po. Segundo, a acur&aacute;cia do m&eacute;todo pode ser comprometida por vi&eac
ute;s do examinador, particularmente a prefer&ecirc;ncia por d&iacute;gitos term
inais. Terceiro, existe um potencial para contamina&ccedil;&atilde;o ambiental d
evido a derrames de merc&uacute;rio. Aparelhos autom&aacute;ticos de medida de p
ress&atilde;o tem sido desenvolvidos como forma de superar algumas das limita&cc
edil;&otilde;es do m&eacute;todo auscultat&oacute;rio. Particularmente, aparelho
s oscilom&eacute;tricos oferecem importantes vantagens em grandes estudos porque
 s&atilde;o baratos, requerem pouco treinamento para uso, n&atilde;o usam merc&u
acute;rio e limitam o potencial para vi&eacute;s do examinador. Contudo, o desem
penho dos aparelhos oscilom&eacute;tricos tem sido vari&aacute;vel, e &eacute; s
abido que cada aparelho deve ser avaliado no contexto e popula&ccedil;&atilde;o 
nos quais ser&aacute; utilizado<sup>1-5</sup>. A acur&aacute;cia dos aparelhos o
scilom&eacute;tricos foi avaliada em m&uacute;ltiplos estudos no ambiente cl&iac
ute;nico, mas h&aacute; poucas evid&ecirc;ncias de seu desempenho em grandes est
udos epidemiol&oacute;gicos. </font></p>     ^cY#aop03111.htm##
00561000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031700085002001300402#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#25#21#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O objetivo deste estudo foi
 avaliar a acur&aacute;cia do aparelho oscilom&eacute;trico Omron HEM-705 VP com
parado ao m&eacute;todo auscultat&oacute;rio com esfigmoman&ocirc;metro no conte
xto de um grande estudo epidemiol&oacute;gico. </font></p>     ^cY#aop03111.htm#
#
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#26#22#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#27#23#article#101#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos</b></font
></p>     ^cY#aop03111.htm##
00875000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063100085002001300716#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#28#24#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Este estudo foi aninhado no
 estudo <i>Incidence of  Cardiovascular Diseases and their Risk Factors </i>(INE
FAC), um estudo de coorte em uma amostragem aleat&oacute;ria de indiv&iacute;duo
s de 15 a 64 anos de idade de Bucaramanga, Colombia (n = 1.634). Utilizamos dado
s de 1.084 indiv&iacute;duos com uma circunfer&ecirc;ncia de bra&ccedil;o entre 
25 e 32 cm que completaram uma primeira avalia&ccedil;&atilde;o de acompanhament
o (&#8776;6 anos) e tiveram tanto medidas auscultat&oacute;rias quanto oscilom&e
acute;tricas da press&atilde;o arterial. </font></p>     ^cY#aop03111.htm##
01819000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704157500085002001301660#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#29#25#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As medidas de press&atilde;
o arterial foram feitas entre 6 e 9 horas da manh&atilde; e os participantes abs
tiveram-se de fumar e se exercitar nas 12 horas anteriores ao exame. De acordo c
om as diretrizes da American Heart Association<sup>6</sup>, todas as medidas for
am obtidas ap&oacute;s 5 minutos de descanso, com o participante confortavelment
e sentado, com os p&eacute;s retos apoiados no ch&atilde;o e as costas e bra&cce
dil;o apoiados, e com a fossa antecubital ao n&iacute;vel do cora&ccedil;&atilde
;o. A m&aacute;xima insufla&ccedil;&atilde;o do manguito foi calculada adicionan
do-se 30 mmHg &agrave; press&atilde;o de oblitera&ccedil;&atilde;o do pulso, e o
 manguito foi esvaziado a uma taxa constante de 2 a 4 mm por segundo. Todos os e
xaminadores receberam 40 horas de treinamento no in&iacute;cio do estudo e foram
 certificados a cada 3-4 meses. Eles foram supervisionados de perto por um m&eac
ute;dico treinado para assegurar a ader&ecirc;ncia ao protocolo de estudo. Os da
dos de press&atilde;o arterial foram analisados periodicamente para controle de 
qualidade e para detectar e corrigir potenciais desvios de protocolo. Dois exami
nadores independentes fizeram medidas auscultat&oacute;rias de press&atilde;o ar
terial em cada participante, seguido por duas medidas adicionais com o Omron HEM
-705 CP tiradas por um terceiro examinador. A m&eacute;dia das duas &uacute;ltim
as medidas auscultat&oacute;rias e as duas medidas oscilom&eacute;tricas foram u
sadas na an&aacute;lise. </font></p>     ^cY#aop03111.htm##
01738000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704149400085002001301579#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#30#26#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A acur&aacute;cia do aparel
ho oscilom&eacute;trico foi avaliada usando-se os crit&eacute;rios de protocolo 
definidos pela <i>British Hypertension  Society</i> (BHS)<sup>2,4</sup> e a <i>A
merican Association for the Advancement  of Medical Instrumentation </i>(AAMI)<s
up>2,7</sup> para valida&ccedil;&atilde;o de aparelhos medidores de press&atilde
;o arterial. O vi&eacute;s foi estimado como a m&eacute;dia das duas medidas de 
aparelho Omron HEM-705 CP menos a m&eacute;dia das duas &uacute;ltimas medidas a
uscultat&oacute;rias, com seus correspondentes limites de concord&acirc;ncia (LC
), como definido por Bland e Altman<sup>8</sup>. Tamb&eacute;m calculamos o tama
nho do vi&eacute;s em grupos de participantes definidos pelas caracter&iacute;st
icas conhecidas por estarem associadas &agrave; press&atilde;o arterial (sexo, i
dade, &iacute;ndice de massa corporal) e utilizamos curvas ROC para estimar a va
lidade do Omron HEM-705 CP na identifica&ccedil;&atilde;o dos participantes com 
hipertens&atilde;o (press&atilde;o arterial sist&oacute;lica <u>&gt;</u> 140 mmH
g ou press&atilde;o arterial diast&oacute;lica <u>&gt;</u> 90 mmHg). Finalmente,
 utilizamos regress&atilde;o linear e log&iacute;stica para estimar e comparar a
 magnitude dos efeitos da idade, sexo e &iacute;ndice de massa corporal na press
&atilde;o arterial e hipertens&atilde;o, ao usar medidas oscilom&eacute;tricas e
 auscultat&oacute;rias. </font></p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#31#27#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#32#28#article#101#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop03111.htm##
01295000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704105100085002001301136#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#33#29#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em geral pouco mais de um t
er&ccedil;o dos participantes eram homens (n = 372; <a href="#tab1">Tabela 1</a>
) e a idade m&eacute;dia era de 42,5 anos (intervalo de confian&ccedil;a de 95% 
- IC95%: 41,7 43,3). As press&otilde;es arteriais m&eacute;dias sist&oacute;lica
 e diast&oacute;lica medidas com o m&eacute;todo auscultat&oacute;rio foram 117,
4 (IC95%: 116,2, 118,5) e 75.2 (IC95%: 74,6, 75,8) mmHg respectivamente. Um tota
l de 199 indiv&iacute;duos (18,4%; IC95%: 16,0, 20,7) eram hipertensos (sist&oac
ute;lica <u>&gt;</u> 140 e/ou diast&oacute;lica <u>&gt;</u> 90 mmHg ou tomando m
edicamentos anti-hipertensivos); 114 (10,5%) estavam recebendo medicamento anti-
hipertensivos; e 149 (13,7%) apresentaram valores de press&atilde;o arterial den
tro do intervalo hipertensivo. As m&eacute;dias do &iacute;ndice de massa corpor
al, da circunfer&ecirc;ncia da cintura e da circunfer&ecirc;ncia do quadril fora
m 24,8 kg/m<sup>2</sup>, 77,0 cm e 95,5 cm, respectivamente. </font></p>     ^cY
#aop03111.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#34#30#article#101#<p><a name
="tab1"></a></p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#35#31#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#36#32#article#101#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03111tab01.jpg"></p>     ^cY#a
op03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#37#33#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
02468000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704222400085002001302309#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#38#34#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A diferen&ccedil;a entre os
 valores de press&atilde;o arterial oscilom&eacute;trica e auscultat&oacute;ria 
foi <u>&lt;</u> 15 mmHg em 97,5% das vezes para sist&oacute;lica e 99,5% das vez
es para a press&atilde;o arterial diast&oacute;lica; <u>&lt;</u> 10 mmHg em 90,6
% das vezes para sist&oacute;lica e em 93,5% das vezes para press&atilde;o arter
ial diast&oacute;lica; e <u>&lt;</u> 5 mmHg em 64,0% das vezes para sist&oacute;
lica e 63,7% das vezes para press&atilde;o arterial diast&oacute;lica. A m&eacut
e;dia para as medidas oscilom&eacute;tricas de press&atilde;o arterial sist&oacu
te;lica (119,2 mmHg) foi 1,8 mmHg mais alta que a m&eacute;dia das medidas auscu
ltat&oacute;rias (117,4 mmHg; p &lt; 0,001; <a href="#tab2">Tabela 2</a>). Ao co
ntr&aacute;rio, a m&eacute;dia das medidas oscilom&eacute;tricas da press&atilde
;o arterial diast&oacute;lica (73,7 mmHg) foi 1,6 mmHg mais baixa que a m&eacute
;dia das medidas auscultat&oacute;rias (75,2 mmHg; p &lt; 0,001). A diferen&cced
il;a entre as medidas de press&atilde;o arterial sist&oacute;lica pelos dois m&e
acute;todos para cada indiv&iacute;duo foi plotada versus sua m&eacute;dia na <a
 href="/img/revistas/abc/2011nahead/aop03111fig01m.jpg">Figura 1A</a><sup>9</sup
>. Esta figura mostra que tanto a variabilidade quanto o tamanho do vi&eacute;s 
n&atilde;o tinham rela&ccedil;&atilde;o com a m&eacute;dia da press&atilde;o art
erial sist&oacute;lica. Al&eacute;m disso, de acordo com os limites de concord&a
circ;ncia estimados, em 95% das vezes as diferen&ccedil;as entre as medidas futu
ras com os dois m&eacute;todos em um novo indiv&iacute;duo ficar&aacute; entre -
10,1 e 13,7 mmHg. De forma similar, a <a href="/img/revistas/abc/2011nahead/aop0
3111fig01b.jpg">Figura 1B</a> n&atilde;o mostra um padr&atilde;o no tamanho e va
riabilidade do vi&eacute;s nos valores da press&atilde;o arterial diast&oacute;l
ica como relacionado &agrave;s m&eacute;dias dos dois m&eacute;todos. Al&eacute;
m disso, 95% das diferen&ccedil;as entre os futuros pares de medidas de press&at
ilde;o arterial diast&oacute;lica utilizando os dois m&eacute;todos devem ficar 
no intervalo de -12,3 a 9,6 mmHg. </font></p>     ^cY#aop03111.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#39#35#article#101#<p><a name
="tab2"></a></p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#40#36#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#41#37#article#101#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03111tab02.jpg"></p>     ^cY#a
op03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#42#38#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
01247000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704100300085002001301088#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#43#39#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O vi&eacute;s nas medidas o
scilom&eacute;tricas foi aproximadamente 1 mmHg maior nos homens que nas mulhere
s, tanto para a press&atilde;o arterial diast&oacute;lica quanto para sist&oacut
e;lica (<a href="/img/revistas/abc/2011nahead/aop03111tab03m.jpg">Tabela 3</a>).
 O vi&eacute;s na press&atilde;o arterial sist&oacute;lica tamb&eacute;m pareceu
 aumentar com a idade, mas n&atilde;o houve um padr&atilde;o claro relacionado &
agrave; idade para o vi&eacute;s na press&atilde;o arterial diast&oacute;lica. D
a mesma forma, o vi&eacute;s aumentou significativamente com o &iacute;ndice de 
massa corporal para a sist&oacute;lica, mas n&atilde;o para a press&atilde;o art
erial diast&oacute;lica. Finalmente, o vi&eacute;s na press&atilde;o arterial si
st&oacute;lica diminuiu, enquanto o vi&eacute;s na press&atilde;o arterial diast
&oacute;lica diminuiu com os quintis dos valores de press&atilde;o arterial corr
espondentes. </font></p>     ^cY#aop03111.htm##
01313000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106900085002001301154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#44#40#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Quando comparado com o m&ea
cute;todo auscultat&oacute;rio, o aparelho Omron HEM-705 CP apresentou uma sensi
bilidade de 81,9% (IC95%: 74,7, 87,8) e uma especificidade de 97,6% (IC95%: 96,4
, 98,4) para detectar indiv&iacute;duos com valores de press&atilde;o arterial d
entro do intervalo hipertensivo (press&atilde;o arterial sist&oacute;lica <u>&gt
;</u> 140 mmHg e/ou press&atilde;o arterial diast&oacute;lica <u>&gt;</u> 90 mmH
g). A sensibilidade e especificidade para detectar indiv&iacute;duos com hiperte
ns&atilde;o (valores de press&atilde;o arterial dentro do intervalo hipertensivo
 e/ou recebendo tratamento farmacol&oacute;gico) foram 88,2% (IC95%: 82,8, 92,4)
 e 98,6% (IC95%: 97,6, 99,30), respectivamente. Al&eacute;m disso, a propor&cced
il;&atilde;o de indiv&iacute;duos corretamente classificados de acordo com o seu
 estado hipertensivo, com base somente nos valores de press&atilde;o arterial, f
oi de 95,2%, e a &aacute;rea sob a curva ROC foi de 0,89 (IC95%: 0,86 a 0,92). <
/font></p>     ^cY#aop03111.htm##
01329000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704108500085002001301170#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#45#41#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ao utilizar medidas obtidas
 com o aparelho Omron HEM 705 CP, quando comparado com o m&eacute;todo auscultat
&oacute;rio, os resultados apresentaram leve vi&eacute;s, mas foram similarmente
 precisos na estimativa dos efeitos da idade, sexo e &iacute;ndice de massa corp
oral na press&atilde;o arterial (<a href="#tab4">Tabela 4</a>). Quando as press&
otilde;es arteriais diast&oacute;lica e sist&oacute;lica foram usadas como vari&
aacute;veis cont&iacute;nuas em um modelo de regress&atilde;o linear, o vi&eacut
e;s no efeito nas vari&aacute;veis citadas acima foi sempre menor que 2 mmHg. Da
 mesma forma, um modelo de regress&atilde;o log&iacute;stica com hipertens&atild
e;o como desfecho, mostrou que o vi&eacute;s nas estimativas dos <i>odds ratios<
/i> para estas vari&aacute;veis era <u>&lt;</u> 6%. Al&eacute;m disso, os interv
alos de confian&ccedil;a para as estimativas dos efeitos destas vari&aacute;veis
 apresentaram amplitude similar para as medidas auscultat&oacute;rias e oscilom&
eacute;tricas. </font></p>     ^cY#aop03111.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#46#42#article#101#<p><a name
="tab4"></a></p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#47#43#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#48#44#article#101#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03111tab04.jpg"></p>     ^cY#a
op03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#49#45#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#50#46#article#101#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o </b></f
ont></p>     ^cY#aop03111.htm##
01333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704108900085002001301174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#51#47#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Nossos resultados mostram q
ue o aparelho Omron HEM 705 CP superestimou a press&atilde;o arterial sist&oacut
e;lica em 1,8 mmHg e subestimou a press&atilde;o diast&oacute;lica em 1,6 mmHg q
uando comparadas com o m&eacute;todo auscultat&oacute;rio usando um esfigmoman&o
circ;metro de merc&uacute;rio. Embora sejam estatisticamente significantes, essa
s diferen&ccedil;as s&atilde;o muito pequenas e devem ter pequeno impacto no amb
iente cl&iacute;nico ou nos estudos epidemiol&oacute;gicos. Nossos resultados s&
atilde;o consistentes com os outros estudos<sup>10,11</sup>, mas n&atilde;o todo
s os estudos de outros aparelhos Omron<sup>12-15</sup>. Tamb&eacute;m observamos
 que o HEM-705 CP se qualifica como dispositivo grau A para medidas de press&ati
lde;o arterial, de acordo com o crit&eacute;rio de protocolo BHS<sup>1,2</sup>. 
Este achado &eacute; consistente com aqueles de estudos pr&eacute;vios deste apa
relho, conduzidos em ambiente cl&iacute;nico com grupos selecionados de paciente
s<sup>16-18</sup>. </font></p>     ^cY#aop03111.htm##
01556000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704131200085002001301397#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#52#48#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Estudos pr&eacute;vios do a
parelho Omron HEM-705 CP n&atilde;o reportaram como o vi&eacute;s nas medidas de
 press&atilde;o arterial estava relacionado &agrave;s caracter&iacute;sticas dos
 pacientes. Neste estudo observamos que o vi&eacute;s nas medidas de press&atild
e;o arterial sist&oacute;lica foi maior nos homens que nas mulheres, aumentou co
m a idade e com o &iacute;ndice de massa corporal, mas diminuiu com n&iacute;vei
s maiores de press&atilde;o arterial sist&oacute;lica. Em contraste, o vi&eacute
;s nas medidas de press&atilde;o arterial diast&oacute;lica foi maior nos homens
, mas n&atilde;o estava associado &agrave; idade ou &iacute;ndice de massa corpo
ral, e diminuiu com n&iacute;veis maiores de press&atilde;o arterial diast&oacut
e;lica. Apesar do padr&atilde;o sistem&aacute;tico nos erros do Omron HEM-705 CP
, a magnitude do vi&eacute;s foi pequena, menor que 3 mmHg para quase todos os g
rupos de pacientes. Embora outros aparelhos tenham mostrado um incremento no tam
anho do vi&eacute;s em indiv&iacute;duos obesos, tanto para a press&atilde;o art
erial sist&oacute;lica quanto diast&oacute;lica<sup>10</sup>, nossos resultados 
somente suportam este incremento para a press&atilde;o arterial sist&oacute;lica
. </font></p>     ^cY#aop03111.htm##
01380000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704113600085002001301221#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#53#49#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">De acordo com nossos result
ados, ao utilizar o Omron HEM-705 CP, pode-se identificar corretamente 88% de to
dos os indiv&iacute;duos com hipertens&atilde;o e 99% daqueles sem hipertens&ati
lde;o. Na maior parte das popula&ccedil;&otilde;es ocidentais, a preval&ecirc;nc
ia da hipertens&atilde;o varia de 20% a 30%. A utiliza&ccedil;&atilde;o do Omron
 HEM-705 CP neste contexto resultar&aacute; em uma ligeira subestima&ccedil;&ati
lde;o da preval&ecirc;ncia de hipertens&atilde;o (18,4% se a preval&ecirc;ncia r
eal for 20% e 27,1% se a preval&ecirc;ncia real for 30%). Mais importante, a uti
liza&ccedil;&atilde;o do Omron HEM-705 CP resultar&aacute; em um vi&eacute;s peq
ueno nas estimativas dos efeitos dos fatores de risco relacionados &agrave; pres
s&atilde;o arterial e hipertens&atilde;o. Particularmente, o grau de vi&eacute;s
 nas estimativas dos o<i>dd ratios</i> para fatores de risco conhecidos provavel
mente seria menor que a varia&ccedil;&atilde;o tradicional de 10% nas estimativa
s usadas para identificar importantes confundidores<sup>19</sup>. </font></p>   
  ^cY#aop03111.htm##
00589000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034500085002001300430#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#54#50#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em conclus&atilde;o, nossos
 resultados mostram que o aparelho Omron HEM-705 CP pode ser usado para medir a 
press&atilde;o arterial e detectar a hipertens&atilde;o em grandes estudos epide
miol&oacute;gicos sem comprometer a validade ou precis&atilde;o do estudo. </fon
t></p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#55#51#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#56#52#article#101#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Agradecimentos</b></font
></p>     ^cY#aop03111.htm##
00439000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704019500085002001300280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#57#53#article#101#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">&Agrave; COLCIENCIAS e Univ
ersidad Industrial de Santander pelo apoio financeiro para conduzir o estudo INE
FAC. </font></p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#58#54#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#59#55#article#101#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop03111.htm##
00450000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704019200087002001300279#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#60#56#article#10
1#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Gillman MW
, Cook NR. Blood pressure measurement in childhood epidemiological studies. Circ
ulation. 1995;92(4):1049-57.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#61#57#article#101# </font></
p>     ^cY#aop03111.htm##
00583000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704032500087002001300412#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#62#58#article#10
1#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. O'Brien E,
 Atkins N. A comparison of the British Hypertension Society and Association for 
the Advancement of Medical Instrumentation protocols for validating blood pressu
re measuring devices: can the two be reconciled? J Hypertens. 1994;12(9):1089-94
.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#63#59#article#101# </font></
p>     ^cY#aop03111.htm##
00434000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704017600087002001300263#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#64#60#article#10
1#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Beevers DG
, Beevers M. Blood pressure measurement: worsening chaos. J Hum Hypertens. 2000;
14(7):415-6.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#65#61#article#101# </font></
p>     ^cY#aop03111.htm##
00502000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704024400087002001300331#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#66#62#article#10
1#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. O'Brien E,
 Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: rec
ommendations of the European Society of Hypertension. BMJ. 2001;322(7285):531-6.
    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#67#63#article#101# </font></
p>     ^cY#aop03111.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028000087002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#68#64#article#10
1#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Ni H, Wu C
, Prineas R, Shea S, Liu K, Kronmal R, et al. Comparison of Dinamap PRO-100 and 
mercury sphygmomanometer blood pressure measurements in a population-based study
. Am J Hypertens. 2006;19(4):353-60.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#69#65#article#101# </font></
p>     ^cY#aop03111.htm##
00729000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704047100087002001300558#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#70#66#article#10
1#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Pickering 
TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for
 blood pressure measurement in humans and experimental animals: part 1: blood pr
essure measurement in humans: a statement for professionals from the subcommitte
e of professional and public education of the American Heart Association Council
 on High Blood Pressure Research. Circulation. 2005;111(5):697-716.    ^cY#aop03
111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#71#67#article#101# </font></
p>     ^cY#aop03111.htm##
00549000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704029100087002001300378#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#72#68#article#10
1#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. White WB, 
Berson AS, Robbins C, Jamieson MJ, Prisant LM, Roccella E, et al. National stand
ard for measurement of resting and ambulatory blood pressures with automated sph
ygmomanometers. Hypertension. 1993;21(4):504-9.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#73#69#article#101# </font></
p>     ^cY#aop03111.htm##
00470000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704021200087002001300299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#74#70#article#10
1#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Bland JM, 
Altman DG. Statistical methods for assessing agreement between two methods of cl
inical measurement. Lancet. 1986;1(8476):307-10.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#75#71#article#101# </font></
p>     ^cY#aop03111.htm##
00442000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704018400087002001300271#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#76#72#article#10
1#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Bland JM, 
Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Re
s. 1999;8(2):135-60.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#77#73#article#101# </font></
p>     ^cY#aop03111.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704030700088002001300395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#78#74#article#10
1#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Altunkan
 S, Ilman N, Kayaturk N, Altunkan E. Validation of the Omron M6 (HEM-7001-E) upp
er-arm blood pressure measuring device according to the International Protocol i
n adults and obese adults. Blood Press Monit. 2007;12(4):219-25.    ^cY#aop03111
.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#79#75#article#101# </font></
p>     ^cY#aop03111.htm##
00513000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704025400088002001300342#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#80#76#article#10
1#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Grim CE,
 Grim CM. Omron HEM-711 DLX home Blood pressure monitor passes the European Soci
ety of Hypertension International Validation Protocol. Blood Press Monit. 2008;1
3(4):225-6.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#81#77#article#101# </font></
p>     ^cY#aop03111.htm##
00505000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704024600088002001300334#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#82#78#article#10
1#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Rotch AL
, Dean JO, Kendrach MG, Wright SG, Woolley TW. Blood pressure monitoring with ho
me monitors versus mercury sphygmomanometer. Ann Pharmacother. 2001;35(7-8):817-
22.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#83#79#article#101# </font></
p>     ^cY#aop03111.htm##
00618000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704035900088002001300447#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#84#80#article#10
1#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Omboni S
, Riva I, Giglio A, Caldara G, Groppelli A, Parati G. Validation of the Omron M5
-I, R5-I and HEM-907 automated blood pressure monitors in elderly individuals ac
cording to the International Protocol of the European Society of Hypertension. B
lood Press Monit. 2007;12(4):233-42.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#85#81#article#101# </font></
p>     ^cY#aop03111.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704030800088002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#86#82#article#10
1#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Coleman 
A, Steel S, Freeman P, de Greeff A, Shennan A. Validation of the Omron M7 (HEM-7
80-E) oscillometric blood pressure monitoring device according to the British Hy
pertension Society protocol. Blood Press Monit. 2008;13(1):49-54.    ^cY#aop0311
1.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#87#83#article#101# </font></
p>     ^cY#aop03111.htm##
00477000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704021800088002001300306#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#88#84#article#10
1#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Lewis JE
, Boyle E, Magharious L, Myers MG. Evaluation of a community-based automated blo
od pressure measuring device. CMAJ. 2002;166(9):1145-8.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#89#85#article#101# </font></
p>     ^cY#aop03111.htm##
00616000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704035700088002001300445#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#90#86#article#10
1#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Iglesias
 Bonilla P, Mayoral S&aacute;nchez E, Lapetra Peralta J, Iborra Oquendo M, Villa
lba Alcal&aacute; F, Cayuela Dominguez A. Validation of two systems of self-meas
urement of blood pressure, the OMRON HEM-705 CP and OMRON M1 (HEM 422C2-E) model
s. Aten Primaria. 2002;30(1):22-8.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#91#87#article#101# </font></
p>     ^cY#aop03111.htm##
00594000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704033500088002001300423#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#92#88#article#10
1#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. O'Brien 
E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement o
f blood pressure according to the revised British Hypertension Society Protocol:
 the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit. 1996
;1(1):55-61.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#93#89#article#101# </font></
p>     ^cY#aop03111.htm##
00515000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704025600088002001300344#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#94#90#article#10
1#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Furusawa
 EA, Ruiz MF, Saito MI, Koch VH. Evaluation of the Omron 705-CP blood pressure m
easuring device for use in adolescents and young adults. Arq Bras Cardiol. 2005;
84(5):367-70.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#95#91#article#101# </font></
p>     ^cY#aop03111.htm##
00443000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704018400088002001300272#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#96#92#article#10
1#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Greenlan
d S. Modeling and variable selection in epidemiologic analysis. Am J Public Heal
th. 1989;79(3):340-9.    ^cY#aop03111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#97#93#article#101# </font></
p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#98#94#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#99#95#article#101#<p>&nbsp;<
/p>     ^cY#aop03111.htm##
00445000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704020000086002001300286#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#100#96#article#101#<p><a nam
e="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href
="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a> <b>Cor
respond&ecirc;ncia:</b>    ^cY#aop03111.htm##
00274000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002900086002001300115#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#101#97#article#101#<br>   Li
na Vera-Cala    ^cY#aop03111.htm##
00304000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704005900086002001300145#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#102#98#article#101#<br>   61
0 Walnut Street, 636 WARF - Walnut Street     ^cY#aop03111.htm##
00285000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704004000086002001300126#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#103#99#article#101#<br>   US
A - Madison - Wisconsin    ^cY#aop03111.htm##
00338000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704009200087002001300179#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#104#100#article#101#<br>   E
-mail: <a href="mailto:veracala@wisc.edu">veracala@wisc.edu</a> </font></p>     
^cY#aop03111.htm##
00409000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016300087002001300250#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03111.htm#S#p#105#101#article#101#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 17/02/
10; revisado recebido em 07/10/10; aceito em 30/11/10. </font></p>     ^cY#aop03
111.htm##
00560000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100015001040120
06800119030001200187065000900199064000500208031000300213032000200216014000800218
865000900226002001300235035001000248801001200258#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03111.htm#S#c#106#1#article#19#1#^rND^sGillman^nMW#^rND^sC
ook^nNR#Blood pressure measurement in childhood epidemiological studies^len#Circ
ulation#19950000#1995#92#4#1049-57#20110000#aop03111.htm#0009-7322#Circulation##
00694000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030120
20200119030001200321065000900333064000500342031000300347032000200350014000800352
865000900360002001300369035001000382801001200392#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03111.htm#S#c#107#2#article#19#2#^rND^sO'Brien^nE#^rND^sAt
kins^nN#A comparison of the British Hypertension Society and Association for the
 Advancement of Medical Instrumentation protocols for validating blood pressure 
measuring devices: can the two be reconciled?^len#J Hypertens#19940000#1994#12#9
#1089-94#20110000#aop03111.htm#0263-6352#J Hypertens##
00548000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100017001040120
04800121030001600169065000900185064000500194031000300199032000200202014000600204
865000900210002001300219035001000232801001600242#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03111.htm#S#c#108#3#article#19#3#^rND^sBeevers^nDG#^rND^sB
eevers^nM#Blood pressure measurement: worsening chaos^len#J Hum Hypertens#200000
00#2000#14#7#415-6#20110000#aop03111.htm#0950-9240#J Hum Hypertens##
00658000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030100
01600119010001800135010001600153012009400169030000400263065000900267064000500276
03100040028103200050028501400060029086500090029600200130030503500100031880100040
0328#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#c#109#4#ar
ticle#19#4#^rND^sO'Brien^nE#^rND^sWaeber^nB#^rND^sParati^nG#^rND^sStaessen^nJ#^r
ND^sMyers^nMG#Blood pressure measuring devices: recommendations of the European 
Society of Hypertension^len#BMJ#20010000#2001#322#7285#531-6#20110000#aop03111.h
tm#0959-8138#BMJ##
00734000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100012000860100012000980100
01700110010001400127010001300141010001700154810000600171012011900177030001500296
06500090031106400050032003100030032503200020032801400070033086500090033700200130
0346035001000359801001500369#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03111.htm#S#c#110#5#article#19#5#^rND^sNi^nH#^rND^sWu^nC#^rND^sPrineas^nR#^rND
^sShea^nS#^rND^sLiu^nK#^rND^sKronmal^nR#et al#Comparison of Dinamap PRO-100 and 
mercury sphygmomanometer blood pressure measurements in a population-based study
^len#Am J Hypertens#20060000#2006#19#4#353-60#20110000#aop03111.htm#0895-7061#Am
 J Hypertens##
00922000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100015001060100
01600121010001800137010001600155010001500171810000600186012029600192030001200488
06500090050006400050050903100040051403200020051801400080052086500090052800200130
0537035001000550801001200560#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03111.htm#S#c#111#6#article#19#6#^rND^sPickering^nTG#^rND^sHall^nJE#^rND^sAppe
l^nLJ#^rND^sFalkner^nBE#^rND^sGraves^nJ#^rND^sHill^nMN#et al#Recommendations for
 blood pressure measurement in humans and experimental animals: part 1: blood pr
essure measurement in humans: a statement for professionals from the subcommitte
e of professional and public education of the American Heart Association Council
 on High Blood Pressure Research^len#Circulation#20050000#2005#111#5#697-716#201
10000#aop03111.htm#0009-7322#Circulation##
00743000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100017001020100
01700119010001900136010001800155010001800173810000600191012011300197030001300310
06500090032306400050033203100030033703200020034001400060034286500090034800200130
0357035001000370801001300380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03111.htm#S#c#112#7#article#19#7#^rND^sWhite^nWB#^rND^sBerson^nAS#^rND^sRobbin
s^nC#^rND^sJamieson^nMJ#^rND^sPrisant^nLM#^rND^sRoccella^nE#et al#National stand
ard for measurement of resting and ambulatory blood pressures with automated sph
ygmomanometers^len#Hypertension#19930000#1993#21#4#504-9#20110000#aop03111.htm#0
194-911X#Hypertension##
00575000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100017001020120
09200119030000700211065000900218064000500227031000200232032000500234014000700239
865000900246002001300255035001000268801000700278#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03111.htm#S#c#113#8#article#19#8#^rND^sBland^nJM#^rND^sAlt
man^nDG#Statistical methods for assessing agreement between two methods of clini
cal measurement^len#Lancet#19860000#1986#1#8476#307-10#20110000#aop03111.htm#009
9-5355#Lancet##
00561000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100017001020120
05300119030002100172065000900193064000500202031000200207032000200209014000700211
865000900218002001300227035001000240801002100250#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03111.htm#S#c#114#9#article#19#9#^rND^sBland^nJM#^rND^sAlt
man^nDG#Measuring agreement in method comparison studies^len#Stat Methods Med Re
s#19990000#1999#8#2#135-60#20110000#aop03111.htm#0962-2802#Stat Methods Med Res#
#
00718000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01800121010001800139012015300157030001800310065000900328064000500337031000300342
032000200345014000700347865000900354002001300363035001000376801001800386#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#c#115#10#article#19#10
#^rND^sAltunkan^nS#^rND^sIlman^nN#^rND^sKayaturk^nN#^rND^sAltunkan^nE#Validation
 of the Omron M6 (HEM-7001-E) upper-arm blood pressure measuring device accordin
g to the International Protocol in adults and obese adults^len#Blood Press Monit
#20070000#2007#12#4#219-25#20110000#aop03111.htm#1359-5237#Blood Press Monit##
00629000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100015001030120
12800118030001800246065000900264064000500273031000300278032000200281014000600283
865000900289002001300298035001000311801001800321#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03111.htm#S#c#116#11#article#19#11#^rND^sGrim^nCE#^rND^sGr
im^nCM#Omron HEM-711 DLX home Blood pressure monitor passes the European Society
 of Hypertension International Validation Protocol^len#Blood Press Monit#2008000
0#2008#13#4#225-6#20110000#aop03111.htm#1359-5237#Blood Press Monit##
00674000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01900119010001700138010001800155012008100173030001700254065000900271064000500280
03100030028503200040028801400070029286500090029900200130030803500100032180100170
0331#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#c#117#12#a
rticle#19#12#^rND^sRotch^nAL#^rND^sDean^nJO#^rND^sKendrach^nMG#^rND^sWright^nSG#
^rND^sWoolley^nTW#Blood pressure monitoring with home monitors versus mercury sp
hygmomanometer^len#Ann Pharmacother#20010000#2001#35#7-8#817-22#20110000#aop0311
1.htm#1060-0280#Ann Pharmacother##
00806000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100014001040100
01600118010001700134010001900151010001600170012018800186030001800374065000900392
06400050040103100030040603200020040901400070041186500090041800200130042703500100
0440801001800450#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#
S#c#118#13#article#19#13#^rND^sOmboni^nS#^rND^sRiva^nI#^rND^sGiglio^nA#^rND^sCal
dara^nG#^rND^sGroppelli^nA#^rND^sParati^nG#Validation of the Omron M5-I, R5-I an
d HEM-907 automated blood pressure monitors in elderly individuals according to 
the International Protocol of the European Society of Hypertension^len#Blood Pre
ss Monit#20070000#2007#12#4#233-42#20110000#aop03111.htm#1359-5237#Blood Press M
onit##
00737000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01700120010001900137010001700156012014500173030001800318065000900336064000500345
03100030035003200020035301400060035586500090036100200130037003500100038380100180
0393#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#c#119#14#a
rticle#19#14#^rND^sColeman^nA#^rND^sSteel^nS#^rND^sFreeman^nP#^rND^sde Greeff^nA
#^rND^sShennan^nA#Validation of the Omron M7 (HEM-780-E) oscillometric blood pre
ssure monitoring device according to the British Hypertension Society protocol^l
en#Blood Press Monit#20080000#2008#13#1#49-54#20110000#aop03111.htm#1359-5237#Bl
ood Press Monit##
00616000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
02000119010001600139012007800155030000500233065000900238064000500247031000400252
032000200256014000700258865000900265002001300274035001000287801000500297#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#c#120#15#article#19#15
#^rND^sLewis^nJE#^rND^sBoyle^nE#^rND^sMagharious^nL#^rND^sMyers^nMG#Evaluation o
f a community-based automated blood pressure measuring device^len#CMAJ#20020000#
2002#166#9#1145-8#20110000#aop03111.htm#0820-3946#CMAJ##
00786000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100026000880100025001140100
02500139010002400164010002500188010002700213012012400240030001400364065000900378
06400050038703100030039203200020039501400050039786500090040200200130041103500100
0424801001400434#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#
S#c#121#16#article#19#16#^rND^sIglesias Bonilla^nP#^rND^sMayoral Sánchez^nE#^rND
^sLapetra Peralta^nJ#^rND^sIborra Oquendo^nM#^rND^sVillalba Alcalá^nF#^rND^sCayu
ela Dominguez^nA#Validation of two systems of self-measurement of blood pressure
, the OMRON HEM-705 CP and OMRON M1 (HEM 422C2-E) models^len#Aten Primaria#20020
000#2002#30#1#22-8#20110000#aop03111.htm#0212-6567#Aten Primaria##
00746000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100013001050100
01600118010001600134012019000150030001800340065000900358064000500367031000200372
032000200374014000600376865000900382002001300391035001000404801001800414#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#c#122#17#article#19#17
#^rND^sO'Brien^nE#^rND^sMee^nF#^rND^sAtkins^nN#^rND^sThomas^nM#Evaluation of thr
ee devices for self-measurement of blood pressure according to the revised Briti
sh Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nisse
i DS-175^len#Blood Press Monit#19960000#1996#1#1#55-61#20110000#aop03111.htm#135
9-5237#Blood Press Monit##
00666000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100015001070100
01600122010001500138012010700153030001700260065000900277064000500286031000300291
032000200294014000700296865000900303002001300312035001000325801001700335#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03111.htm#S#c#123#18#article#19#18
#^rND^sFurusawa^nEA#^rND^sRuiz^nMF#^rND^sSaito^nMI#^rND^sKoch^nVH#Evaluation of 
the Omron 705-CP blood pressure measuring device for use in adolescents and youn
g adults^len#Arq Bras Cardiol#20050000#2005#84#5#367-70#20110000#aop03111.htm#00
66-782X#Arq Bras Cardiol##
00542000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880120062001070300
01900169065000900188064000500197031000300202032000200205014000600207865000900213
002001300222035001000235801001900245#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop03111.htm#S#c#124#19#article#19#19#^rND^sGreenland^nS#Modeling and var
iable selection in epidemiologic analysis^len#Am J Public Health#19890000#1989#7
9#3#340-9#20110000#aop03111.htm#0090-0036#Am J Public Health##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#o#1#1#
article#1#20110331#081839#aop03211.htm#197##
04799000000000613000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401200960017301200880
02690100046003570100037004030100030004400700081004700831672005510850008022230850
03902231085003702270085002202307085002902329083163502358085000803993085003604001
08500360403708500340407311700080410707200030411511200090411811100090412711600090
4136115000904145114000904154113000904163002001304172#2011nahead#V:\SciELO\serial
\abc\2011nahead\markup\aop03211.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#40#n
d#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#Circunferência
 abdominal como preditor de evolução em 30 dias na síndrome coronariana aguda^lp
t#abdominal circumference as a predictor of 30-day outcome in acute coronary syn
drome^len#^rND^1A01^nPriscilla Azambuja Lopes de^sSouza#^rND^1A01^nAna Paula Tru
ssardi^sFayh#^rND^1A01^nVera Lúcia^sPortal#Instituto de Cardiologia do Rio Grand
e do Sul/FUC^iA01^cPorto Alegre^sRS^pBrasil#^lpt^aFUNDAMENTO: A circunferência a
bdominal (CA) é a medida que mais se correlaciona com os fatores de risco e mort
e por doença cardiovascular. Entretanto, o impacto da obesidade no prognóstico d
e pacientes com doenças cardiovasculares permanece controverso e requer maiores 
esclarecimentos. OBJETIVO: Avaliar a CA como preditor de evolução em 30 dias em 
pacientes que internaram com síndrome coronariana aguda (SCA), em hospital de re
ferência no tratamento de doenças cardiovasculares. MÉTODOS: Coorte contemporâne
a com 267 pacientes que internaram por SCA e que foram seguidos por 30 dias após
 a alta levando em consideração os eventos cardiovasculares maiores - MACE - (ób
ito, reinfarto, reinternação para procedimentos de revascularização). Nas primei
ras 24 horas da admissão, os pacientes responderam a um questionário e posterior
mente tiveram a CA mensurada. A análise estatística foi realizada com SPSS 17.0,
 utilizando o teste do Qui-quadrado para variáveis categóricas e o teste t de St
udent para as variáveis numéricas, com o nível de significância de p < 0,05. As 
variáveis que apresentaram valores de p < 0,10, na análise bivariada, foram incl
uídas em um modelo de regressão logística para avaliar o papel da CA como predit
or independente de MACE. RESULTADOS: Após análise multivariável, apenas o gênero
 feminino (RC = 8,86; 95% IC:4,55-17,10; p < 0,00), hipertensão arterial sistêmi
ca (RC = 2,06; 95% IC:1,10-3,87; p = 0,02) e história familiar de cardiopatia is
quêmica (RC = 2,10; 95% IC:1,17-3,74; p = 0,01) permaneceram associados com os M
ACE. CONCLUSÃO: Em nosso estudo, a CA alterada não se associou à maior incidênci
a de MACE em 30 dias de seguimento.#^dnd^i1#^tm^lpt^kSíndrome coronariana aguda^
i1#^tm^lpt^kcircunferência abdominal^i1#^tm^lpt^kobesidade^i1#^tm^lpt^kfatores d
e risco^i1#^len^aBACKGROUND: Abdominal circumference (WC) is the measure that co
rrelates most closely with the risk factors and death from cardiovascular diseas
e. However, the impact of obesity on the prognosis of patients with cardiovascul
ar disease remains controversial and requires further clarification. OBJECTIVE: 
To evaluate WA as a predictor of 30-day outcome in patients who were hospitalize
d with acute coronary syndrome (ACS), in a referral hospital for the treatment o
f cardiovascular diseases. METHODS: Contemporary cohort 267 patients who were ho
spitalized for ACS and who were followed for 30 days after discharge, taking int
o account the major cardiovascular events - MACE - (death, reinfarction, rehospi
talization for coronary artery bypass grafting procedures). In the first 24 hour
s of admission, patients answered a questionnaire and were subsequently measured
 for WC. The statistical analysis was performed with SPSS 17.0, using the chi-sq
uare test for categorical variables and Student t test for numerical variables, 
with significance level of p < 0.05. The variables that had p < 0.10 in the biva
riate analysis were included in a logistic regression model to evaluate the WC r
ole as an independent predictor of MACE. RESULTS: After multivariate analysis, o
nly the female gender (OR = 8.86; 95% CI: 4.55-17. 10, p < 0.00), hypertension (
OR = 2.06; 95% CI: 1.10-3.87; p = 0.02) and family history of ischemic heart dis
ease (OR = 2.10; 95% CI: 1.17-3.74; p = 0.01) remained associated with the MACE.
 CONCLUSION: In our study, the modified AC was not associated with increased inc
idence of MACE over the 30 days of follow-up.#^dnd^i2#^tm^len^kAcute coronary sy
ndrome^i2#^tm^len^kabdominal circumference^i2#^tm^len^kobesity, risk factors^i2#
vancouv#37#20100315#15/03/10#20101022#22/10/10#20101202#02/12/10#aop03211.htm##
04929000000000613000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201030017301200950
02760100046003710100037004170100030004540700081004840831737005650850008023020850
03902310085003702349085002202386085002902408083168602437085000804123085003604131
08500360416708500340420311700080423707200030424511200090424811100090425711600090
4266115000904275114000904284113000904293002001304302#2011nahead#V:\SciELO\serial
\abc\2011nahead\markup\aop03211.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#40#n
d#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#<b>Circunferên
cia abdominal como preditor de evolução em 30 dias na síndrome coronariana aguda
</b>^lpt#<b>abdominal circumference as a predictor of 30-day outcome in acute co
ronary syndrome</b>^len#^rND^1A01^nPriscilla Azambuja Lopes de^sSouza#^rND^1A01^
nAna Paula Trussardi^sFayh#^rND^1A01^nVera Lúcia^sPortal#Instituto de Cardiologi
a do Rio Grande do Sul/FUC^iA01^cPorto Alegre^sRS^pBrasil#^lpt^a<b>FUNDAMENTO:</
b> A circunferência abdominal (CA) é a medida que mais se correlaciona com os fa
tores de risco e morte por doença cardiovascular. Entretanto, o impacto da obesi
dade no prognóstico de pacientes com doenças cardiovasculares permanece controve
rso e requer maiores esclarecimentos. <b>OBJETIVO:</b> Avaliar a CA como predito
r de evolução em 30 dias em pacientes que internaram com síndrome coronariana ag
uda (SCA), em hospital de referência no tratamento de doenças cardiovasculares. 
<b>MÉTODOS:</b> Coorte contemporânea com 267 pacientes que internaram por SCA e 
que foram seguidos por 30 dias após a alta levando em consideração os eventos ca
rdiovasculares maiores - MACE - (óbito, reinfarto, reinternação para procediment
os de revascularização). Nas primeiras 24 horas da admissão, os pacientes respon
deram a um questionário e posteriormente tiveram a CA mensurada. A análise estat
ística foi realizada com SPSS 17.0, utilizando o teste do Qui-quadrado para vari
áveis categóricas e o teste <i>t</i> de <i>Student</i> para as variáveis numéric
as, com o nível de significância de p <u>&lt;</u> 0,05. As variáveis que apresen
taram valores de p &lt; 0,10, na análise bivariada, foram incluídas em um modelo
 de regressão logística para avaliar o papel da CA como preditor independente de
 MACE. <b>RESULTADOS:</b> Após análise multivariável, apenas o gênero feminino (
RC = 8,86; 95% IC:4,55-17,10; p &lt; 0,00), hipertensão arterial sistêmica (RC =
 2,06; 95% IC:1,10-3,87; p = 0,02) e história familiar de cardiopatia isquêmica 
(RC = 2,10; 95% IC:1,17-3,74; p = 0,01) permaneceram associados com os MACE. <b>
CONCLUSÃO:</b> Em nosso estudo, a CA alterada não se associou à maior incidência
 de MACE em 30 dias de seguimento.#^dnd^i1#^tm^lpt^kSíndrome coronariana aguda^i
1#^tm^lpt^kcircunferência abdominal^i1#^tm^lpt^kobesidade^i1#^tm^lpt^kfatores de
 risco^i1#^len^a<b>BACKGROUND:</b> Abdominal circumference (WC) is the measure t
hat correlates most closely with the risk factors and death from cardiovascular 
disease. However, the impact of obesity on the prognosis of patients with cardio
vascular disease remains controversial and requires further clarification. <b>OB
JECTIVE:</b> To evaluate WA as a predictor of 30-day outcome in patients who wer
e hospitalized with acute coronary syndrome (ACS), in a referral hospital for th
e treatment of cardiovascular diseases. <b>METHODS:</b> Contemporary cohort 267 
patients who were hospitalized for ACS and who were followed for 30 days after d
ischarge, taking into account the major cardiovascular events - MACE - (death, r
einfarction, rehospitalization for coronary artery bypass grafting procedures). 
In the first 24 hours of admission, patients answered a questionnaire and were s
ubsequently measured for WC. The statistical analysis was performed with SPSS 17
.0, using the chi-square test for categorical variables and Student t test for n
umerical variables, with significance level of p <u>&lt;</u> 0.05. The variables
 that had p &lt; 0.10 in the bivariate analysis were included in a logistic regr
ession model to evaluate the WC role as an independent predictor of MACE. <b>RES
ULTS:</b> After multivariate analysis, only the female gender (OR = 8.86; 95% CI
: 4.55-17. 10, p &lt; 0.00), hypertension (OR = 2.06; 95% CI: 1.10-3.87; p = 0.0
2) and family history of ischemic heart disease (OR = 2.10; 95% CI: 1.17-3.74; p
 = 0.01) remained associated with the MACE. <b>CONCLUSION:</b> In our study, the
 modified AC was not associated with increased incidence of MACE over the 30 day
s of follow-up.#^dnd^i2#^tm^len^kAcute coronary syndrome^i2#^tm^len^kabdominal c
ircumference^i2#^tm^len^kobesity, risk factors^i2#vancouv#37#20100315#15/03/10#2
0101022#22/10/10#20101202#02/12/10#aop03211.htm##
04968000000000637000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001200960
01790120088002750100046003630100037004090100030004460700083004760831699005590850
00802258085003902266085003702305085002202342085002902364083165602393085000804049
08500360405708500360409308500340412911700080416307200030417111200090417411100090
4183116000904192115000904201114000904210113000904219002001304228008008904241#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#l#4#1#article#1#^a
2011#oa#pt#br1.1#1#4.0#tab#40#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#006
6-782X#20110401#Circunferência abdominal como preditor de evolução em 30 dias na
 síndrome coronariana aguda^lpt#abdominal circumference as a predictor of 30-day
 outcome in acute coronary syndrome^len#^rND^1A01^nPriscilla Azambuja Lopes de^s
Souza#^rND^1A01^nAna Paula Trussardi^sFayh#^rND^1A01^nVera Lúcia^sPortal#^iA01^1
Instituto de Cardiologia do Rio Grande do Sul/FUC^cPorto Alegre^sRS^pBrasil#^lpt
^aFUNDAMENTO: A circunferência abdominal (CA) é a medida que mais se correlacion
a com os fatores de risco e morte por doença cardiovascular. Entretanto, o impac
to da obesidade no prognóstico de pacientes com doenças cardiovasculares permane
ce controverso e requer maiores esclarecimentos. OBJETIVO: Avaliar a CA como pre
ditor de evolução em 30 dias em pacientes que internaram com síndrome coronarian
a aguda (SCA), em hospital de referência no tratamento de doenças cardiovascular
es. MÉTODOS: Coorte contemporânea com 267 pacientes que internaram por SCA e que
 foram seguidos por 30 dias após a alta levando em consideração os eventos cardi
ovasculares maiores - MACE - (óbito, reinfarto, reinternação para procedimentos 
de revascularização). Nas primeiras 24 horas da admissão, os pacientes responder
am a um questionário e posteriormente tiveram a CA mensurada. A análise estatíst
ica foi realizada com SPSS 17.0, utilizando o teste do Qui-quadrado para variáve
is categóricas e o teste t de Student para as variáveis numéricas, com o nível d
e significância de p < 0,05. As variáveis que apresentaram valores de p < 0,10, 
na análise bivariada, foram incluídas em um modelo de regressão logística para a
valiar o papel da CA como preditor independente de MACE. RESULTADOS: Após anális
e multivariável, apenas o gênero feminino (RC = 8,86; 95 por cento IC:4,55-17,10
; p < 0,00), hipertensão arterial sistêmica (RC = 2,06; 95 por cento IC:1,10-3,8
7; p = 0,02) e história familiar de cardiopatia isquêmica (RC = 2,10; 95 por cen
to IC:1,17-3,74; p = 0,01) permaneceram associados com os MACE. CONCLUSÃO: Em no
sso estudo, a CA alterada não se associou à maior incidência de MACE em 30 dias 
de seguimento.#^dnd^i1#^tm^lpt^kSíndrome coronariana aguda^i1#^tm^lpt^kcircunfer
ência abdominal^i1#^tm^lpt^kobesidade^i1#^tm^lpt^kfatores de risco^i1#^len^aBACK
GROUND: Abdominal circumference (WC) is the measure that correlates most closely
 with the risk factors and death from cardiovascular disease. However, the impac
t of obesity on the prognosis of patients with cardiovascular disease remains co
ntroversial and requires further clarification. OBJECTIVE: To evaluate WA as a p
redictor of 30-day outcome in patients who were hospitalized with acute coronary
 syndrome (ACS), in a referral hospital for the treatment of cardiovascular dise
ases. METHODS: Contemporary cohort 267 patients who were hospitalized for ACS an
d who were followed for 30 days after discharge, taking into account the major c
ardiovascular events - MACE - (death, reinfarction, rehospitalization for corona
ry artery bypass grafting procedures). In the first 24 hours of admission, patie
nts answered a questionnaire and were subsequently measured for WC. The statisti
cal analysis was performed with SPSS 17.0, using the chi-square test for categor
ical variables and Student t test for numerical variables, with significance lev
el of p < 0.05. The variables that had p < 0.10 in the bivariate analysis were i
ncluded in a logistic regression model to evaluate the WC role as an independent
 predictor of MACE. RESULTS: After multivariate analysis, only the female gender
 (OR = 8.86; 95 percent CI: 4.55-17. 10, p < 0.00), hypertension (OR = 2.06; 95 
percent CI: 1.10-3.87; p = 0.02) and family history of ischemic heart disease (O
R = 2.10; 95 percent CI: 1.17-3.74; p = 0.01) remained associated with the MACE.
 CONCLUSION: In our study, the modified AC was not associated with increased inc
idence of MACE over the 30 days of follow-up.#^dnd^i2#^tm^len^kAcute coronary sy
ndrome^i2#^tm^len^kabdominal circumference^i2#^tm^len^kobesity, risk factors^i2#
vancouv#37#20100315#15/03/10#20101022#22/10/10#20101202#02/12/10#aop03211.htm#In
ternet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005
000040##
00469000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704022700083002001300310#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#5#1#article#156#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Circunf
er&ecirc;ncia abdominal como preditor de evolu&ccedil;&atilde;o em 30 dias na s&
iacute;ndrome coronariana aguda</b></font></p>     ^cY#aop03211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#6#2#article#156#<p>&nbsp;</p
>     ^cY#aop03211.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#7#3#article#156#<p>&nbsp;</p
>     ^cY#aop03211.htm##
00418000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704017600083002001300259#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#8#4#article#156#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Priscilla Azambuja Lopes d
e Souza; Ana Paula Trussardi Fayh; Vera L&uacute;cia Portal </b></font></p>     
^cY#aop03211.htm##
00410000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704016800083002001300251#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#9#5#article#156#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif">Instituto de Cardiologia do R
io Grande do Sul/FUC (IC/FUC), Porto Alegre, RS - Brasil</font></p>     ^cY#aop0
3211.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#10#6#article#156#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#11#7#article#156#<p>&nbsp;</
p>     ^cY#aop03211.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#12#8#article#156#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop03211.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#13#9#article#156#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>    
 ^cY#aop03211.htm##
00643000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039900085002001300484#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#14#10#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO:</b> A circun
fer&ecirc;ncia abdominal (CA) &eacute; a medida que mais se correlaciona com os 
fatores de risco e morte por doen&ccedil;a cardiovascular. Entretanto, o impacto
 da obesidade no progn&oacute;stico de pacientes com doen&ccedil;as cardiovascul
ares permanece controverso e requer maiores esclarecimentos.     ^cY#aop03211.ht
m##
00495000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025100085002001300336#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#15#11#article#156#<br>   <b>
OBJETIVO:</b> Avaliar a CA como preditor de evolu&ccedil;&atilde;o em 30 dias em
 pacientes que internaram com s&iacute;ndrome coronariana aguda (SCA), em hospit
al de refer&ecirc;ncia no tratamento de doen&ccedil;as cardiovasculares.     ^cY
#aop03211.htm##
01238000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704099400085002001301079#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#16#12#article#156#<br>   <b>
M&Eacute;TODOS:</b> Coorte contempor&acirc;nea com 267 pacientes que internaram 
por SCA e que foram seguidos por 30 dias ap&oacute;s a alta levando em considera
&ccedil;&atilde;o os eventos cardiovasculares maiores - MACE - (&oacute;bito, re
infarto, reinterna&ccedil;&atilde;o para procedimentos de revasculariza&ccedil;&
atilde;o). Nas primeiras 24 horas da admiss&atilde;o, os pacientes responderam a
 um question&aacute;rio e posteriormente tiveram a CA mensurada. A an&aacute;lis
e estat&iacute;stica foi realizada com SPSS 17.0, utilizando o teste do Qui-quad
rado para vari&aacute;veis categ&oacute;ricas e o teste <i>t</i> de <i>Student</
i> para as vari&aacute;veis num&eacute;ricas, com o n&iacute;vel de signific&aci
rc;ncia de p <u>&lt;</u> 0,05. As vari&aacute;veis que apresentaram valores de p
 &lt; 0,10, na an&aacute;lise bivariada, foram inclu&iacute;das em um modelo de 
regress&atilde;o log&iacute;stica para avaliar o papel da CA como preditor indep
endente de MACE.    ^cY#aop03211.htm##
00622000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037800085002001300463#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#17#13#article#156#<br>   <b>
RESULTADOS:</b> Ap&oacute;s an&aacute;lise multivari&aacute;vel, apenas o g&ecir
c;nero feminino (RC = 8,86; 95% IC:4,55-17,10; p &lt; 0,00), hipertens&atilde;o 
arterial sist&ecirc;mica (RC = 2,06; 95% IC:1,10-3,87; p = 0,02) e hist&oacute;r
ia familiar de cardiopatia isqu&ecirc;mica (RC = 2,10; 95% IC:1,17-3,74; p = 0,0
1) permaneceram associados com os MACE.     ^cY#aop03211.htm##
00416000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704017200085002001300257#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#18#14#article#156#<br>   <b>
CONCLUS&Atilde;O:</b> Em nosso estudo, a CA alterada n&atilde;o se associou &agr
ave; maior incid&ecirc;ncia de MACE em 30 dias de seguimento. </font></p>     ^c
Y#aop03211.htm##
00468000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704022400085002001300309#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#19#15#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> S&ia
cute;ndrome coronariana aguda, circunfer&ecirc;ncia abdominal, obesidade, fatore
s de risco. </font></p> <hr size="1" noshade>     ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#20#16#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#21#17#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#22#18#article#156#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop03211.htm##
00673000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042900085002001300514#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#23#19#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As doen&ccedil;as cardiovas
culares (DCV) s&atilde;o respons&aacute;veis por 17 milh&otilde;es de mortes, ce
rca de um ter&ccedil;o das mortes anuais mundiais<sup>1</sup>. No Rio Grande do 
Sul (RS) essa tend&ecirc;ncia tamb&eacute;m &eacute; observada<sup>2</sup>, prin
cipalmente no que se refere &agrave; doen&ccedil;a arterial coronariana (DAC). <
/font></p>     ^cY#aop03211.htm##
00678000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043400085002001300519#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#24#20#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A s&iacute;ndrome coronaria
na aguda (SCA) &eacute; caracterizada por um espectro de manifesta&ccedil;&otild
e;es cl&iacute;nicas e laboratoriais de isquemia mioc&aacute;rdica aguda, sendo 
classificada em tr&ecirc;s formas: angina inst&aacute;vel (AI) e infarto agudo d
o mioc&aacute;rdio (IAM) com e sem supradesn&iacute;vel do segmento ST<sup>3</su
p>. </font></p>     ^cY#aop03211.htm##
00734000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049000085002001300575#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#25#21#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Diversos estudos demonstram
 a rela&ccedil;&atilde;o entre obesidade, principalmente abdominal, e o desenvol
vimento de doen&ccedil;as cardiovasculares<sup>4-7</sup>. Os pacientes com exces
so de peso possuem maior risco para o desenvolvimento DAC, principalmente como c
onsequ&ecirc;ncia de condi&ccedil;&otilde;es relacionadas com a obesidade tais c
omo diabete, hipertens&atilde;o e dislipidemia<sup>4</sup>. </font></p>     ^cY#
aop03211.htm##
00976000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073200085002001300817#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#26#22#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os riscos associados &agrav
e; obesidade abdominal s&atilde;o melhores identificados por vari&aacute;veis an
tropom&eacute;tricas que possam refletir a distribui&ccedil;&atilde;o da gordura
 corporal, como a circunfer&ecirc;ncia abdominal (CA) e a rela&ccedil;&atilde;o 
cintura-quadril (RCQ)<sup>8</sup><sub>. </sub>Esses t&ecirc;m demonstrado maior 
correla&ccedil;&atilde;o com o risco cardiovascular do que indicadores de obesid
ade generalizada como o &iacute;ndice de massa corporal (IMC)<sup>9,10</sup>. En
tretanto, a CA &eacute; a medida que mais se correlaciona com os fatores de risc
o e morte por doen&ccedil;a cardiovascular<sup>9,11,12</sup>. </font></p>     ^c
Y#aop03211.htm##
01136000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704089200085002001300977#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#27#23#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No que diz respeito ao prog
n&oacute;stico de pacientes ap&oacute;s eventos cardiovasculares, os dados ainda
 s&atilde;o controversos: a grande maioria demonstra uma associa&ccedil;&atilde;
o inversa entre obesidade geral (paradoxo da obesidade), mortalidade ap&oacute;s
 IAM e interven&ccedil;&atilde;o coron&aacute;ria percut&acirc;nea<sup>13,14</su
p>. Por outro lado, existem estudos demonstrando a rela&ccedil;&atilde;o direta 
entre obesidade e eventos cardiovasculares maiores - MACE - (&oacute;bito, reinf
arto, reinterna&ccedil;&atilde;o para procedimentos de revasculariza&ccedil;&ati
lde;o)<sup>15,16 </sup>e que sugerem que a obesidade abdominal atue como fator p
rogn&oacute;stico em curto e longo prazo na DCV. Pacientes com baixo IMC e com C
A alterada fariam parte do grupo de maior risco<sup>17</sup>. </font></p>     ^c
Y#aop03211.htm##
00894000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704065000085002001300735#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#28#24#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Embora a associa&ccedil;&at
ilde;o entre excesso de adiposidade e risco cardiovascular na popula&ccedil;&ati
lde;o geral esteja bem estabelecida, o impacto da obesidade no progn&oacute;stic
o de pacientes com DCV permanece controverso e requer maiores esclarecimentos. P
or isso, esse estudo tem como objetivo avaliar a circunfer&ecirc;ncia abdominal 
como preditor de evolu&ccedil;&atilde;o em 30 dias em pacientes que internaram c
om s&iacute;ndrome coronariana aguda, em hospital de refer&ecirc;ncia no tratame
nto de doen&ccedil;as cardiovasculares, em Porto Alegre/RS. </font></p>     ^cY#
aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#29#25#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#30#26#article#156#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos</b></font
></p>     ^cY#aop03211.htm##
00343000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009900085002001300184#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#31#27#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Pacientes</b></font></p>
     ^cY#aop03211.htm##
00821000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704057700085002001300662#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#32#28#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Estudo de coorte contempor&
acirc;nea com pacientes que internaram por SCA no per&iacute;odo de novembro de 
2006 a janeiro de 2008. A pesquisa foi realizada a partir de um banco de dados p
r&eacute;-existente, contendo 412 indiv&iacute;duos. Desses, foram exclu&iacute;
dos todos com idade superior a 65 anos, sendo a amostra final constitu&iacute;da
 ent&atilde;o por 267 pacientes. Esse estudo foi aprovado pelo Comit&ecirc; de &
Eacute;tica em Pesquisa da Institui&ccedil;&atilde;o (UP 4173/08). </font></p>  
   ^cY#aop03211.htm##
00701000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704045700085002001300542#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#33#29#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Foram inclu&iacute;dos na p
esquisa pacientes com diagn&oacute;stico de SCA: infarto agudo do mioc&aacute;rd
io (IAM) com e sem supradesnivelamento do segmento ST, angina inst&aacute;vel (A
I) com altera&ccedil;&atilde;o eletrocardiogr&aacute;fica (infradesnivelamento d
o segmento ST superior a 1 mm, em pelo menos duas deriva&ccedil;&otilde;es, ou i
nvers&atilde;o de onda T). </font></p>     ^cY#aop03211.htm##
00915000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704067100085002001300756#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#34#30#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Por tratar-se de uma coorte
 que avalia tamb&eacute;m resposta inflamat&oacute;ria, os crit&eacute;rios de e
xclus&atilde;o foram: presen&ccedil;a de doen&ccedil;a inflamat&oacute;ria sist&
ecirc;mica, neoplasia maligna diagnosticada com ou sem tratamento, HIV+, uso rec
ente (menos de um m&ecirc;s) ou atual de anti-inflamat&oacute;rios ou corticoide
, tempo de evolu&ccedil;&atilde;o da SCA maior do que 12h, aus&ecirc;ncia de jej
um de 12 h, idade superior a 65 anos e paciente impossibilitado ou com alguma pa
tologia que dificulte aferi&ccedil;&atilde;o das medidas antropom&eacute;tricas.
 </font></p>     ^cY#aop03211.htm##
00365000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012100085002001300206#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#35#31#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Procedimento de coleta d
e dados</b></font></p>     ^cY#aop03211.htm##
01042000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079800085002001300883#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#36#32#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s assinarem o Ter
mo de Consentimento Livre e Esclarecido, previamente aprovado pelo Comit&ecirc; 
de &Eacute;tica em Pesquisa, os pacientes permaneceram em jejum para a coleta do
s exames bioqu&iacute;micos (colesterol total, HDL-c, LDL-c triglicer&iacute;deo
s e glicemia de jejum). Ainda, responderam a um question&aacute;rio onde informa
ram idade, sexo, fatores de risco cardiovasculares - sedentarismo, tabagismo, hi
st&oacute;ria familiar de cardiopatia isqu&ecirc;mica, hipertens&atilde;o arteri
al sist&ecirc;mica, obesidade, diabete, dislipidemia e uso de &aacute;lcool - e 
doen&ccedil;as pr&eacute;vias. A coleta das medidas antropom&eacute;tricas (peso
, altura e CA) foi realizada nas primeiras 72h. </font></p>     ^cY#aop03211.htm
##
01000000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075600085002001300841#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#37#33#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Foram considerados sedent&a
acute;rios os pacientes que n&atilde;o praticavam atividade f&iacute;sica regula
r (&lt; 3 vezes/semana por no m&iacute;nimo 30 minutos)<sup>18</sup>. Foram defi
nidos como tabagistas os que eram fumantes regulares, e como ex-tabagistas os qu
e haviam suspendido o cigarro h&aacute; pelo menos um ano. Hist&oacute;ria famil
iar para cardiopatia isqu&ecirc;mica incluiu aqueles que apresentaram familiar d
e primeiro grau com idade inferior a 55 anos, quando do sexo masculino e inferio
r a 65 anos, quando do sexo feminino com diagn&oacute;stico de doen&ccedil;a art
erial coronariana ou outro tipo de doen&ccedil;a ateroscler&oacute;tica<sup>18</
sup>. </font></p>     ^cY#aop03211.htm##
01306000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704106200085002001301147#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#38#34#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Hipertens&atilde;o arterial
 sist&ecirc;mica foi considerada naqueles que possu&iacute;am esse diagn&oacute;
stico previamente &agrave; interna&ccedil;&atilde;o e/ou faziam o uso de drogas 
anti-hipertensivas<sup>19</sup>. Dislipidemia incluiu aqueles que possu&iacute;a
m valores de colesterol total, triglicer&iacute;deos, LDL e HDL colesterol alter
ados conforme a IV Diretriz Brasileira Sobre Dislipidemias e Preven&ccedil;&atil
de;o da Aterosclerose<sup>18</sup>. Foram classificados como diab&eacute;ticos o
s indiv&iacute;duos que apresentavam o diagn&oacute;stico pr&eacute;vio da doen&
ccedil;a e/ou estavam em uso de drogas antidiab&eacute;ticas<sup>20</sup>. Quant
o ao uso de &aacute;lcool, foram utilizadas as recomenda&ccedil;&otilde;es da V 
Diretriz Brasileira de Hipertens&atilde;o Arterial<sup>19</sup>. Uso regular de 
&aacute;lcool foi considerado para aquele indiv&iacute;duo que consumisse at&eac
ute; 30 g etanol/dia para os homens e 15 g etanol/dia para as mulheres. </font><
/p>     ^cY#aop03211.htm##
00728000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048400085002001300569#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#39#35#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As medidas de peso e altura
 foram feitas em balan&ccedil;a antropom&eacute;trica Filizola (capacidade m&aac
ute;xima de 150 kg e varia&ccedil;&atilde;o de 100 g) com estadi&ocirc;metro aco
plado, estando o paciente sem sapatos e com roupas leves. O IMC foi calculado pe
la raz&atilde;o peso (kg)/altura<sup>2</sup> (m), sendo considerado obeso o paci
ente com IMC igual ou superior a 30 kg/m<sup>2</sup>. </font></p>     ^cY#aop032
11.htm##
00645000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040100085002001300486#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#40#36#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A CA foi mensurada atrav&ea
cute;s de fita antropom&eacute;trica flex&iacute;vel com precis&atilde;o de 0,1 
cm, no ponto m&eacute;dio entre a crista il&iacute;aca e o rebordo costal inferi
or<sup>21</sup>. Foram utilizados os pontos de corte segundo NCEP-ATP III (homen
s &gt; 102 cm e mulheres &gt; 88 cm)<sup>22</sup>. </font></p>     ^cY#aop03211.
htm##
00627000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038300085002001300468#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#41#37#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Todos os exames laboratoria
is foram coletados em uma &uacute;nica amostra, com 12 horas de jejum, dentro da
s primeiras 24 horas do in&iacute;cio do quadro isqu&ecirc;mico coronariano. A a
n&aacute;lise foi realizada no laborat&oacute;rio de an&aacute;lises cl&iacute;n
icas do pr&oacute;prio hospital. </font></p>     ^cY#aop03211.htm##
00712000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046800085002001300553#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#42#38#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s a alta hospital
ar, foram feitos contatos telef&ocirc;nicos e revis&atilde;o de prontu&aacute;ri
o em busca de MACE (&oacute;bito, reinfarto, reinterna&ccedil;&atilde;o para pro
cedimentos de revasculariza&ccedil;&atilde;o), al&eacute;m de outras complica&cc
edil;&otilde;es tais como insufici&ecirc;ncia card&iacute;aca (IC), arritmia e a
ngina, ocorridas no prazo de 30 dias. </font></p>     ^cY#aop03211.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012300085002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#43#39#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lise estat&iac
ute;stica</b></font></p>     ^cY#aop03211.htm##
00904000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704066000085002001300745#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#44#40#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os dados foram analisados n
o programa <i>Statistical  Package for Social Sciences</i> vers&atilde;o 17.0 (S
PSS Inc., Chicago, IL, USA, 2008) para Windows. As vari&aacute;veis coletadas fo
ram apresentadas em forma descritiva, com utiliza&ccedil;&atilde;o de m&eacute;d
ia e desvio padr&atilde;o para vari&aacute;veis num&eacute;ricas e frequ&ecirc;n
cia (absoluta e relativa) para vari&aacute;veis categ&oacute;ricas. Foram utiliz
ados o teste do Qui-quadrado para vari&aacute;veis categ&oacute;ricas e o teste 
<i>t</i> de <i>Student</i> para as vari&aacute;veis num&eacute;ricas. </font></p
>     ^cY#aop03211.htm##
00654000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041000085002001300495#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#45#41#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As vari&aacute;veis que apr
esentaram valores de p &lt; 0,10 na an&aacute;lise bivariada foram inclu&iacute;
das em um modelo de regress&atilde;o log&iacute;stica para avaliar o papel da CA
 como preditor independente de desfechos cl&iacute;nicos. Foram considerados est
atisticamente significativos valores de p <u>&lt;</u> 0,05. </font></p>     ^cY#
aop03211.htm##
00683000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043900085002001300524#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#46#42#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os modelos de regress&atild
e;o log&iacute;stica bivariada e multivariada foram utilizados para o c&aacute;l
culo da raz&atilde;o de chances (RC) e foram realizados os ajustes para as segui
ntes vari&aacute;veis: g&ecirc;nero, hipertens&atilde;o arterial sist&ecirc;mica
 (HAS), tabagismo, hist&oacute;ria familiar de cardiopatia isqu&ecirc;mica, angi
na e IC. </font></p>     ^cY#aop03211.htm##
00408000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704016400085002001300249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#47#43#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A Curva ROC foi realizada c
onsiderando a CA uma vari&aacute;vel cont&iacute;nua. </font></p>     ^cY#aop032
11.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#48#44#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#49#45#article#156#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop03211.htm##
00641000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039700085002001300482#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#50#46#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">De um total de 267 paciente
s avaliados, 75,3% (201) eram do g&ecirc;nero masculino, desses, 24,3% (49) tinh
am CA alterada, enquanto o percentual observado no g&ecirc;nero feminino foi de 
74,2% (49). A m&eacute;dia de CA encontrada no g&ecirc;nero masculino foi de 96,
6 cm ± 12,96 cm e no feminino 94,8 ± 15,11 cm. </font></p>     ^cY#aop03211.htm#
#
00588000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034400085002001300429#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#51#47#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A idade m&eacute;dia dos ho
mens com CA alterada foi de 55,0 ± 8,2 anos e das mulheres de 54,1 ± 6,91 anos, 
n&atilde;o apresentando diferen&ccedil;a estatisticamente significativa entre os
 indiv&iacute;duos com CA normal e alterada nos diferentes g&ecirc;neros. </font
></p>     ^cY#aop03211.htm##
00632000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704038800085002001300473#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#52#48#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As caracter&iacute;sticas g
erais, conforme as categorias de circunfer&ecirc;ncia abdominal, nos diferentes 
g&ecirc;neros est&atilde;o dispostas na <a href="/img/revistas/abc/2011nahead/ao
p03211tab01m.jpg">Tabela 1</a>. Os valores apresentados em percentual s&atilde;o
 de acordo com o fator de risco (CA). </font></p>     ^cY#aop03211.htm##
00673000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704042900085002001300514#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#53#49#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o ao
 tipo de SCA, 38,8% (19) dos pacientes do g&ecirc;nero masculino e 44,9% (22) do
 g&ecirc;nero feminino com CA alterada internaram por IAM sem supradesnivelament
o do segmento ST ou AI e 61,2% (30) dos homens e 55,1% (27) das mulheres por IAM
 com supradesnivelamento do segmento ST (p = 0,45; p = 0,68, respectivamente). <
/font></p>     ^cY#aop03211.htm##
00515000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704027100085002001300356#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#54#50#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o se observou dife
ren&ccedil;a estatisticamente significativa entre as doen&ccedil;as pr&eacute;vi
as apresentadas pelos pacientes e as categorias de CA em ambos os g&ecirc;neros.
 </font></p>     ^cY#aop03211.htm##
00682000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704043800085002001300523#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#55#51#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Quanto aos fatores de risco
, observou-se diferen&ccedil;a estatisticamente significativa para homens com CA
 alterada em rela&ccedil;&atilde;o &agrave; HAS (p = 0,03), obesidade (p = 0,00)
 e hist&oacute;ria familiar de cardiopatia isqu&ecirc;mica (p = 0,01), enquanto 
que nas mulheres essa diferen&ccedil;a foi observada somente para obesidade (p =
 0,00). </font></p>     ^cY#aop03211.htm##
00998000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704075400085002001300839#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#56#52#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Durante os 30 dias de segui
mento, 7,9% (21) dos indiv&iacute;duos apresentaram um dos MACE, sendo que 16,4%
 (8) dos homens e 2% (1) das mulheres tinham CA alterada. O &uacute;nico desfech
o que se correlacionou com as categorias de CA foi IC (p = 0,01), onde 11,1% (5)
 dos homens com CA alterada apresentaram essa complica&ccedil;&atilde;o durante 
os primeiros 30 dias, incluindo a interna&ccedil;&atilde;o. No g&ecirc;nero femi
nino, o mesmo n&atilde;o foi observado. As incid&ecirc;ncias de desfechos cardio
vasculares em rela&ccedil;&atilde;o &agrave;s categorias de CA est&atilde;o apre
sentadas na <a href="/img/revistas/abc/2011nahead/aop03211tab02m.jpg">Tabela 2</
a>. </font></p>     ^cY#aop03211.htm##
00836000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704059200085002001300677#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#57#53#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Ap&oacute;s o ajuste para a
s vari&aacute;veis que apresentaram valor de p &lt; 0,10 na an&aacute;lise bivar
iada (g&ecirc;nero, HAS, tabagismo, hist&oacute;ria familiar de cardiopatia isqu
&ecirc;mica, angina e IC), apenas o g&ecirc;nero feminino (RC = 8,86; 95% IC:4,5
5-17,10; p &lt; 0,00), HAS (RC = 2,06; 95% IC:1,10-3,87; p = 0,02) e hist&oacute
;ria familiar (RC = 2,10; 95% IC:1,17-3,74; p = 0,01) permaneceram associados co
m os MACE. Esses dados est&atilde;o apresentados na <a href="#tab3">Tabela 3</a>
. </font></p>     ^cY#aop03211.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#58#54#article#156#<p><a name
="tab3"></a></p>     ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#59#55#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#60#56#article#156#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop03211tab03.jpg"></p>     ^cY#a
op03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#61#57#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00551000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704030700085002001300392#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#62#58#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Quando a CA foi avaliada co
mo vari&aacute;vel cont&iacute;nua, para ambos os sexos, atrav&eacute;s da curva
 ROC, observamos uma &aacute;rea sob a curva pequena (0,60), o que demonstra a b
aixa sensibilidade e especificidade. </font></p>     ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#63#59#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#64#60#article#156#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o </b></f
ont></p>     ^cY#aop03211.htm##
00592000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704034800085002001300433#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#65#61#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">No presente estudo, a grand
e maioria dos pacientes que internaram por SCA era do g&ecirc;nero masculino (75
,3%), percentuais parecidos (73,4%<sup>23</sup>; 60,8%<sup>24</sup>) tamb&eacute
;m s&atilde;o observados em outros estudos abordando esse grupo de pacientes. </
font></p>     ^cY#aop03211.htm##
01514000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704127000085002001301355#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#66#62#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A m&eacute;dia da CA encont
rada no nosso estudo, no g&ecirc;nero masculino (96,62 cm ± 12,96) &eacute; seme
lhante &agrave; de outras pesquisas que correlacionam a CA com risco cardiovascu
lar (92,7 cm ± 12,96<sup>25</sup>; 93,3 cm ± 11,3<sup>26</sup>; 95,9 cm ± 9,8<su
p>27</sup>), entretanto a m&eacute;dia de CA feminina (94,88 cm ± 15,11) ficou b
em acima do observado na literatura (84,1 cm ± 12,50<sup>25</sup>; 85,9 cm ± 12,
00<sup>26</sup>; 82,4 ± 10,80<sup>27</sup>). Essa diferen&ccedil;a deve-se prova
velmente ao fato de a maioria dos estudos ser realizada com a popula&ccedil;&ati
lde;o geral para predizer risco cardiovascular e n&atilde;o por pacientes, ap&oa
cute;s um evento cardiovascular. Assim, os valores de CA alterada foram maiores 
no g&ecirc;nero feminino (74,2%) em rela&ccedil;&atilde;o ao masculino (24,4%). 
Essa predomin&acirc;ncia tamb&eacute;m foi observada por Hauner e cols. <sup>12 
</sup>(41,5%/36,4%) e por Ingelsson e cols. <sup>5 </sup>(67,0%/49,5%). J&aacute
; Koutsovasilis e cols. <sup>28</sup>, comparando um grupo controle com paciente
s que tiveram o primeiro evento de SCA, encontraram associa&ccedil;&atilde;o ent
re CA alterada e SCA em ambos os sexos. </font></p>     ^cY#aop03211.htm##
01215000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097100085002001301056#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#67#63#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Quando a vari&aacute;vel g&
ecirc;nero foi inclu&iacute;da na an&aacute;lise bivariada, verificou-se que as 
mulheres com CA alterada possuem maior risco de MACE em 30 dias (RC = 8,86; 95% 
IC:4,55-17,10; p &lt; 0,00). Na literatura, n&atilde;o h&aacute; estudos que cor
relacionam CA com desfechos em 30 dias em pacientes com SCA. Bonarjee e cols. <s
up>29</sup>, avaliando a sobrevida em curto e longo prazo de pacientes com IAM, 
constataram que as mulheres possuem maior risco de morte por qualquer causa e po
r doen&ccedil;a cardiovascular, re-IAM e nova interna&ccedil;&atilde;o para reva
sculariza&ccedil;&atilde;o (p &lt; 0,00). Entretanto, Tarastchuk e cols. <sup>30
 </sup>encontraram associa&ccedil;&atilde;o entre CA alterada (masculino 90 cm e
 feminino 80 cm) e desfechos card&iacute;acos, ap&oacute;s interven&ccedil;&atil
de;o coronariana percut&acirc;nea, apenas no sexo masculino. </font></p>     ^cY
#aop03211.htm##
01224000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098000085002001301065#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#68#64#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Quanto aos fatores de risco
, h&aacute; evid&ecirc;ncias na literatura que os homens com CA alterada t&ecirc
;m maiores &iacute;ndices de hipertens&atilde;o do que as mulheres<sup>27,12,31<
/sup>. Ap&oacute;s a an&aacute;lise bivariada (RC = 2,06; 95% IC:1,10-3,87; p = 
0,02), observou-se o papel da HAS como preditor de MACE em 30 dias. Pesquisas t&
ecirc;m demonstrado que excesso de tecido adiposo &eacute; um dos principais fat
ores de risco associados &agrave; hipertens&atilde;o<sup>4,32</sup>. No Brasil, 
estudo mostra que para os homens, o impacto da obesidade abdominal sobre a hiper
tens&atilde;o arterial foi maior do que o impacto da obesidade total, e que a CA
 &eacute; a &uacute;nica medida antropom&eacute;trica que se relaciona com essa 
patologia<sup>32</sup>. Ainda, h&aacute; evidencias de que pacientes hipertensos
 possuem maiores chances de ter SCA<sup>28</sup> e MACE<sup>33</sup>. </font></p
>     ^cY#aop03211.htm##
01120000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704087600085002001300961#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#69#65#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Outro fator de risco que mo
strou associa&ccedil;&atilde;o significativa com CA alterada nos homens foi hist
&oacute;ria familiar precoce de cardiopatia isqu&ecirc;mica (RC = 2,10; 95% IC:1
,17-3,74; p = 0,01). Canoy e cols. <sup>27 </sup>ao realizarem um estudo avalian
do a rela&ccedil;&atilde;o entre a distribui&ccedil;&atilde;o da gordura corpora
l e risco para DAC em homens e mulheres, n&atilde;o encontraram associa&ccedil;&
atilde;o entre CA alterada e hist&oacute;ria familiar, neste caso, a &uacute;nic
a medida antropom&eacute;trica que foi significativa foi a RCQ. Tarastchuk e col
s. <sup>30</sup> verificaram que 43,8% dos pacientes que tiveram desfechos ap&oa
cute;s interven&ccedil;&atilde;o coronariana percut&acirc;nea tinham hist&oacute
;ria familiar de cardiopatia isqu&ecirc;mica. </font></p>     ^cY#aop03211.htm##
00786000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704054200085002001300627#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#70#66#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O percentual de pacientes c
om CA alterada que apresentaram um dos MACE durante os 30 dias de seguimento (16
,4% g&ecirc;nero masculino e 2,0% g&ecirc;nero feminino), fica pr&oacute;ximo do
 observado em uma coorte realizada com 6.364 indiv&iacute;duos e em estudo rando
mizado com 456 pacientes ap&oacute;s interven&ccedil;&atilde;o coronariana percu
t&acirc;nea, onde 5,7% apresentaram algum MACE nos primeiros 30 dias de evolu&cc
edil;&atilde;o<sup>34,35</sup>. </font></p>     ^cY#aop03211.htm##
00960000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704071600085002001300801#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#71#67#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A IC foi o &uacute;nico des
fecho cardiovascular que se associou com CA alterada nos homens (11,1%) durante 
os primeiros 30 dias. Na literatura n&atilde;o h&aacute; artigos que descrevam e
sta rela&ccedil;&atilde;o. No entanto, Pinheiro e cols. <sup>36</sup> observaram
 que 70% das mulheres brasileiras com IC tinham CA alterada, enquanto nos homens
 a incid&ecirc;ncia foi bem menor (24,2%). J&aacute; O'Meara e cols. <sup>37</su
p> comparando as caracter&iacute;sticas de homens e mulheres com IC, constataram
 que a maioria tem sobrepeso e os homens s&atilde;o mais prop&iacute;cios a ter 
IAM e morte por doen&ccedil;a cardiovascular. </font></p>     ^cY#aop03211.htm##
00368000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012400085002001300209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#72#68#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Limita&ccedil;&otilde;es
 do estudo</b></font></p>     ^cY#aop03211.htm##
01318000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704107400085002001301159#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#73#69#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Trata-se de um estudo obser
vacional e com tempo de seguimento reduzido, fato que poderia reduzir a chance d
e identifica&ccedil;&atilde;o de eventos cardiovasculares adversos e o poder est
at&iacute;stico das associa&ccedil;&otilde;es. Outro aspecto a considerar &eacut
e; que aqueles pacientes que n&atilde;o compareciam &agrave; consulta de revis&a
tilde;o em 30 dias tinham o seguimento realizado por telefone, aumentando a chan
ce de interpreta&ccedil;&atilde;o equivocada da informa&ccedil;&atilde;o e impos
sibilidade de confirma&ccedil;&atilde;o dos dados. Embora a coorte completa foss
e constitu&iacute;da por 412 pacientes, foram inclu&iacute;dos nesta an&aacute;l
ise somente 267. Isso ocorreu porque tivemos a preocupa&ccedil;&atilde;o de excl
uir aqueles indiv&iacute;duos com mais de 65 anos de idade j&aacute; que estudos
 mostram que h&aacute; mudan&ccedil;as na distribui&ccedil;&atilde;o corporal de
 acordo com a idade, com maior ac&uacute;mulo na regi&atilde;o abdominal de idos
os. </font></p>     ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#74#70#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#75#71#article#156#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop03211.htm##
00618000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704037400085002001300459#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#76#72#article#156#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em conclus&atilde;o, na amo
stra estudada, a CA alterada n&atilde;o foi associada a MACE, em 30 dias de segu
imento, em pacientes com SCA. Os MACE foram associados ao g&ecirc;nero feminino,
 hipertens&atilde;o arterial sist&ecirc;mica e hist&oacute;ria familiar de cardi
opatia isqu&ecirc;mica. </font></p>     ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#77#73#article#156#<p>&nbsp;<
/p>     ^cY#aop03211.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#78#74#article#156#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop03211.htm##
00521000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704026300087002001300350#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#79#75#article#15
6#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. World Heal
th Organization. Integrated. Management of cardiovascular risk. In: Report of a 
WHO meeting, Geneva, 9-12 July; 2002. Geneva: Noncommunicable Diseases and Menta
l Health/WHO; 2002.    ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#80#76#article#156# </font></
p>     ^cY#aop03211.htm##
00646000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704038800087002001300475#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#81#77#article#15
6#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Rio Grande
 do Sul. Secretaria Estadual da Sa&uacute;de. Centro Estadual de Vigil&acirc;nci
a em Sa&uacute;de. Rede Estadual de An&aacute;lise e Divulga&ccedil;&atilde;o de
 Indicadores para a Sa&uacute;de. A Sa&uacute;de da popula&ccedil;&atilde;o do e
stado do Rio Grande do Sul. Porto Alegre: CEVS, 2006. p. 119-20.    ^cY#aop03211
.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#82#78#article#156# </font></
p>     ^cY#aop03211.htm##
00452000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704019400087002001300281#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#83#79#article#15
6#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Bassan, F,
 Bassan, R. Abordagem da s&iacute;ndrome coronariana aguda. Rev Soc Cardiol Rio 
Grande do Sul. 2006;15(7):1-6.    ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#84#80#article#156# </font></
p>     ^cY#aop03211.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027500087002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#85#81#article#15
6#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Field AE, 
Coakley EH, Must A, Spadano JL, Laird N, Dietz HW, et al. Impact of overweight o
n the risk of developing common chronic diseases during a 10-year period. Arch I
ntern Med. 2001;161(13):1581-6.    ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#86#82#article#156# </font></
p>     ^cY#aop03211.htm##
00549000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704029100087002001300378#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#87#83#article#15
6#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Ingelsson 
E, Sullivan LM, Fox CS, Murabito JM, Benjamin EJ, Polak JF, et al. Burden and pr
ognostic importance of subclinical cardiovascular disease in overweight and obes
e individuals. Circulation. 2007;116(4):375-84.    ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#88#84#article#156# </font></
p>     ^cY#aop03211.htm##
00493000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023500087002001300322#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#89#85#article#15
6#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Wilson PWF
, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as dete
rminants of cardiovascular risk. Arch Intern Med. 2002;162(16):1867-72.    ^cY#a
op03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#90#86#article#156# </font></
p>     ^cY#aop03211.htm##
00564000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704030600087002001300393#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#91#87#article#15
6#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Janssen I,
 Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumf
erence independently contribute to the prediction of nonabdominal, abdominal sub
cutaneous, and visceral fat. Am J Clin Nutr. 2002;75(4):683-8.    ^cY#aop03211.h
tm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#92#88#article#156# </font></
p>     ^cY#aop03211.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028000087002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#93#89#article#15
6#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Pitanga FJ
G, Lessa I. Indicadores antropom&eacute;tricos de obesidade como instrumento de 
triagem para risco coronariano elevado em adultos na cidade de Salvador - Bahia.
 Arq Bras Cardiol. 2005;85(1):26-31.    ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#94#90#article#156# </font></
p>     ^cY#aop03211.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704028000087002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#95#91#article#15
6#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Schneider 
HJ, Glaesmer H, Klotsche J, B&ouml;hler S, Lehnert H, Zeiher AM, et al. Accuracy
 of anthropometric indicators of obesity to predict cardiovascular risk. J Clin 
Endocrinol Metab. 2007;92(2):589-94.    ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#96#92#article#156# </font></
p>     ^cY#aop03211.htm##
00538000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704027900088002001300367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#97#93#article#15
6#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Koning L
, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as 
predictors of cardiovascular events: meta-regression analysis of prospective stu
dies. Eur Heart J. 2007;28(7):850-6.    ^cY#aop03211.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#98#94#article#156# </font></
p>     ^cY#aop03211.htm##
00580000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704032100088002001300409#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#99#95#article#15
6#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Rezende 
FAC, Rosado LEFPL, Ribeiro RL, Vidigal FC, Vasques AJ, Bonard IS, et al. &Iacute
;ndice de massa corporal e circunfer&ecirc;ncia abdominal: associa&ccedil;&atild
e;o com fatores de risco cardiovascular. Arq Bras Cardiol. 2006; 87(6):728-34.  
  ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#100#96#article#156# </font><
/p>     ^cY#aop03211.htm##
00606000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704034600089002001300435#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#101#97#article#1
56#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Hauner 
H, Bramlage P, L&ouml;sch C, Steinhagen-Thiessen E, Schunkert H, Wasem J, et al.
 Prevalence of obesity in primary care using different anthropometric measures: 
results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). BMC Pu
blic Health. 2008;8:282.    ^cY#aop03211.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#102#98#article#156# </font><
/p>     ^cY#aop03211.htm##
00544000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704028400089002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#103#99#article#1
56#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Hastie 
CE, Padmanabhan S, Slack R, Pell ACH, Oldroyd KG, Flapan AD, et al. Obesity para
dox in a cohort of 4880 consecutive patients undergoing percutaneous coronary in
tervention. Eur Heart J. 2010;31(2):222-6.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#104#100#article#156# </font>
</p>     ^cY#aop03211.htm##
00576000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031500090002001300405#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#105#101#article#
156#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Kosuge
 M, Kimura K, Kojima S, Sakamoto T, Ishihara M, Asada Y, et al. Impact of body m
ass index on in-hospital outcomes after percutaneous coronary intervention for S
T segment elevation acute myocardial infarction. Circ J. 2008;72(4):521-5.    ^c
Y#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#106#102#article#156# </font>
</p>     ^cY#aop03211.htm##
00529000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026800090002001300358#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#107#103#article#
156#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Buettn
er HJ, Mueller C, Gick M, Ferenc M, Allgeier J, Comberg T, et al.The impact of o
besity on mortality in UA/non-STsegment elevation myocardial infarction. Eur Hea
rt J. 2007;28(14):1694-701.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#108#104#article#156# </font>
</p>     ^cY#aop03211.htm##
00510000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024900090002001300339#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#109#105#article#
156#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Domans
ki MJ, Jablonski KA, Rice MM, Fowler SE, Braunwald E. Obesity and cardiovascular
 events in patients with established coronary disease. Eur Heart J. 2006;27(12):
1416-22.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#110#106#article#156# </font>
</p>     ^cY#aop03211.htm##
00522000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026100090002001300351#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#111#107#article#
156#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Dagena
is GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weigh
t and abdominal obesity in women and men with cardiovascular disease. Am Heart J
. 2005;149(1):54-60.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#112#108#article#156# </font>
</p>     ^cY#aop03211.htm##
00653000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704039200090002001300482#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#113#109#article#
156#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Sposit
o AC, Caramelli B, Fonseca FAH, Bertolami MC, Afiune NA, Souza AD, et al. / Soci
edade Brasileira de Cardiologia IV Diretriz brasileira sobre dislipidemias e pre
ven&ccedil;&atilde;o da aterosclerose. Departamento de Aterosclerose da Sociedad
e Brasileira de Cardiologia. Arq Bras Cardiol. 2007; 88 (supl 1):S2-19.    ^cY#a
op03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#114#110#article#156# </font>
</p>     ^cY#aop03211.htm##
00542000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028100090002001300371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#115#111#article#
156#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Gomes 
MAM, Nobre F, Amodeo C, Kohlmann O, Praxedes JN, Machado CA, et al. / Sociedade 
Brasileira de Cardiologia. V Diretrizes brasileiras de hipertens&atilde;o arteri
al. Arq Bras Cardiol. 2007;89(3):e24-79.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#116#112#article#156# </font>
</p>     ^cY#aop03211.htm##
00450000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704018900090002001300279#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#117#113#article#
156#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Socied
ade Brasileira de Diabetes. Diretrizes do tratamento do diabetes mellitus. Rio d
e Janeiro: Diagraphic; 2006.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#118#114#article#156# </font>
</p>     ^cY#aop03211.htm##
00607000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704034600090002001300436#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#119#115#article#
156#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Brand&
atilde;o AP, Brand&atilde;o AA, Nogueira AR, Suplicy H, Guimar&atilde;es JI, Oli
veira JEP/ Sociedade Brasileira de Cardiologia. I Diretriz brasileira de diagn&o
acute;stico e tratamento da s&iacute;ndrome metab&oacute;lica. Arq Bras Cardiol.
 2005; 84 (supl 1):S3-28.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#120#116#article#156# </font>
</p>     ^cY#aop03211.htm##
00553000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029200090002001300382#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#121#117#article#
156#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. The Th
ird Report of the National Cholesterol Education Program (NECP). Expert Panel on
 Detection. Evaluation, and treatment of high blood cholesterol in adults (Adult
 Treatment Panel III). JAMA. 2001; 285(19):2486-97.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#122#118#article#156# </font>
</p>     ^cY#aop03211.htm##
00528000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026700090002001300357#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#123#119#article#
156#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Zeller
 M, Steg PG, Ravisy J, Lorgis L, Laurent Y, Sicard P. Relation between body mass
 index, waist circumference, and death after acute myocardial infarction. Circul
ation. 2008;118(5):482-90.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#124#120#article#156# </font>
</p>     ^cY#aop03211.htm##
00529000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026800090002001300358#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#125#121#article#
156#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Jneid 
H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, et al. Sex differ
ences in medical care and early death after acute myocardial infarction. Circula
tion. 2008;118(25):2803-10.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#126#122#article#156# </font>
</p>     ^cY#aop03211.htm##
00492000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023100090002001300321#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#127#123#article#
156#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Menke 
A, Muntner P, Wildman RP, Reynolds K, He J. Measures of adiposity and cardiovasc
ular disease risk factors. Obesity (Silver Spring). 2007;15(3):785-95.    ^cY#ao
p03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#128#124#article#156# </font>
</p>     ^cY#aop03211.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704022500090002001300315#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#129#125#article#
156#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Jansse
n I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains
 obesity related health risk. Am J Clin Nutr. 2004;79(3):379-84.    ^cY#aop03211
.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#130#126#article#156# </font>
</p>     ^cY#aop03211.htm##
00639000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037800090002001300468#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#131#127#article#
156#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Canoy 
D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, et al. Body fat distrib
ution and risk of coronary heart disease in men and women in the European Prospe
ctive Investigation Into Cancer and Nutrition in Norfolk Cohort. A Population-Ba
sed Prospective Study. Circulation. 2007;116(25):2933-43.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#132#128#article#156# </font>
</p>     ^cY#aop03211.htm##
00586000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032500090002001300415#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#133#129#article#
156#28#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Tarast
chuk JCE, Gu&eacute;rios EE, Bueno RRL, Andrade PMP, Nercolini DC, Ferraz JGG, e
t al. Obesidade e interven&ccedil;&atilde;o coronariana: devemos continuar valor
izando o &iacute;ndice de massa corp&oacute;rea? Arq Bras Cardiol. 2008;90(5):31
1-6.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#134#130#article#156# </font>
</p>     ^cY#aop03211.htm##
00528000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704026700090002001300357#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#135#131#article#
156#29#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Bonarj
ee VVS, Rosengren A, Snapinn SM, James MK, Dickstein K. Sex-based short- and lon
g-term survival in patients following complicated myocardial infarction. Eur Hea
rt J. 2006;27(18):2177-83.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#136#132#article#156# </font>
</p>     ^cY#aop03211.htm##
00569000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030800090002001300398#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#137#133#article#
156#30#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Koutso
vasilis A, Protopsaltis J, Triposkiadis F, Kokkoris S, Milionis HJ, Zairis MN, e
t al. Comparative performance of three metabolic syndrome. definitions in the pr
ediction of acute coronary syndrome. Intern Med. 2009;48(4):179-87.    ^cY#aop03
211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#138#134#article#156# </font>
</p>     ^cY#aop03211.htm##
00543000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028200090002001300372#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#139#135#article#
156#31#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Wildma
n RP, Gu D, Reynolds K, Duan X, Wu X, He J. Are waist circumference and body mas
s index independently associated with cardiovascular disease risk in Chinese adu
lts? Am J Clin Nutr. 2005;82(6):1195-202.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#140#136#article#156# </font>
</p>     ^cY#aop03211.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028500090002001300375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#141#137#article#
156#32#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Peixot
o MRG, Ben&iacute;cio MHD, Latorre MRDO, Jardim PCBV. Circunfer&ecirc;ncia da ci
ntura e &iacute;ndice de massa corporal como preditores da hipertens&atilde;o ar
terial. Arq Bras Cardiol. 2006;87(4):462-70.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#142#138#article#156# </font>
</p>     ^cY#aop03211.htm##
00565000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030400090002001300394#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#143#139#article#
156#33#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Chirin
os JA, Zambrano JP, Chakko S, Veerani A, Schob S, Willens HJ, et al. Aortic Pres
sure Augmentation Predicts Adverse Cardiovascular Events in Patients With Establ
ished Coronary Artery Disease. Hypertension. 2005; 45(5):980-5.    ^cY#aop03211.
htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#144#140#article#156# </font>
</p>     ^cY#aop03211.htm##
00573000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031200090002001300402#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#145#141#article#
156#34#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Ajani 
AE, Reid CM, Duffy SJ, Andrianopoulos N, Lefkovits J, Black A, et al. Outcomes a
fter percutaneous coronary intervention in contemporary Australian practice: ins
ights from a large multicentre registry. Med J Aust. 2008;189(8):423-8.    ^cY#a
op03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#146#142#article#156# </font>
</p>     ^cY#aop03211.htm##
00598000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033700090002001300427#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#147#143#article#
156#35#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Sorajj
a P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, et al. Combined
 prognostic utility of ST-segment recovery and myocardial blush after primary pe
rcutaneous coronary intervention in acute myocardial infarction. Eur Heart J. 20
05;26(7):667-74.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#148#144#article#156# </font>
</p>     ^cY#aop03211.htm##
00500000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704023900090002001300329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#149#145#article#
156#36#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Pinhei
ro AS, Nakasato M, Isosaki M, Bocchi EA. Obesidade: fator protetor nos pacientes
 com insufici&ecirc;ncia card&iacute;aca? Rev Bras Nutr Clin. 2007;22(1):20-7.  
  ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#150#146#article#156# </font>
</p>     ^cY#aop03211.htm##
00679000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704041800090002001300508#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#151#147#article#
156#37#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. O'Mear
a E, Clayton T, McEntegart MB, McMurray JJV, Pi&ntilde;a IL, Granger CB, et al. 
Sex differences in clinical characteristics and prognosis in a broad spectrum of
 patients with heart failure: results of the Candesartan in Heart failure: Asses
sment of Reduction in Mortality and morbidity (CHARM) Program. Circulation. 2007
;115(24):3111-20.    ^cY#aop03211.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#152#148#article#156# </font>
</p>     ^cY#aop03211.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#153#149#article#156#<p>&nbsp
;</p>     ^cY#aop03211.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#154#150#article#156#<p>&nbsp
;</p>     ^cY#aop03211.htm##
00447000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020100087002001300288#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#155#151#article#156#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a> <b>Co
rrespond&ecirc;ncia:</b>     ^cY#aop03211.htm##
00278000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704003200087002001300119#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#156#152#article#156#<br>   V
era Lucia Portal    ^cY#aop03211.htm##
00315000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704006900087002001300156#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#157#153#article#156#<br>   R
ua Luciana de Abreu 471, sala 603 - Moinhos de Vento     ^cY#aop03211.htm##
00299000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005300087002001300140#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#158#154#article#156#<br>   9
0570-080 - Porto Alegre, RS - Brasil     ^cY#aop03211.htm##
00506000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704026000087002001300347#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#159#155#article#156#<br>   E
-mail: <a href="mailto:veraportal@cardiol.br">veraportal@cardiol.br</a>, <a href
="mailto:verap.pesquisa@cardiologia.org.br">verap.pesquisa@cardiologia.org.br</a
>, <a href="mailto:vera.portal@hotmail.com">vera.portal@hotmail.com</a> </font><
/p>     ^cY#aop03211.htm##
00409000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016300087002001300250#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03211.htm#S#p#160#156#article#156#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 15/03/
10; revisado recebido em 22/10/10; aceito em 02/12/10. </font></p>     ^cY#aop03
211.htm##
00547000000000241000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840110026000860120050001120180
05300162066000700215062004700222065000900269064000500278865000900283002001300292
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#161#1#articl
e#37#1#World Health Organization#Integrated. Management of cardiovascular risk^l
en#Report of a WHO meeting, Geneva, 9-12 July; 2002^len#Geneva#Noncommunicable D
iseases and Mental Health/WHO#20020000#2002#20110000#aop03211.htm##
00592000000000241000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840170018000860170069001040180
12300173066001300296062000500309065000900314064000500323865000900328002001300337
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#162#2#articl
e#37#2#Rio Grande do Sul#Secretaria Estadual da Saúde^dCentro Estadual de Vigilâ
ncia em Saúde#Rede Estadual de Análise e Divulgação de Indicadores para a Saúde:
 A Saúde da população do estado do Rio Grande do Sul^lpt#Porto Alegre#CEVS#20060
000#2006#20110000#aop03211.htm##
00521000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020120
04400118030003400162710000200196065000900198064000500207031000300212032000200215
014000400217865000900221002001300230#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop03211.htm#S#c#163#3#article#37#3#^rND^sBassan^nF#^rND^sBassan^nR#Abord
agem da síndrome coronariana aguda^lpt#Rev Soc Cardiol Rio Grande do Sul#2#20060
000#2006#15#7#1-6#20110000#aop03211.htm##
00730000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01400120010001800134010001500152010001600167810000600183012009900189030001600288
06500090030406400050031303100040031803200030032201400070032586500090033200200130
0341035001000354801001600364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#164#4#article#37#4#^rND^sField^nAE#^rND^sCoakley^nEH#^rND^sMust^
nA#^rND^sSpadano^nJL#^rND^sLaird^nN#^rND^sDietz^nHW#et al#Impact of overweight o
n the risk of developing common chronic diseases during a 10-year period^len#Arc
h Intern Med#20010000#2001#161#13#1581-6#20110000#aop03211.htm#0003-9926#Arch In
tern Med##
00742000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100019001050100
01400124010001900138010001900157010001600176810000600192012011100198030001200309
06500090032106400050033003100040033503200020033901400070034186500090034800200130
0357035001000370801001200380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#165#5#article#37#5#^rND^sIngelsson^nE#^rND^sSullivan^nLM#^rND^sF
ox^nCS#^rND^sMurabito^nJM#^rND^sBenjamin^nEJ#^rND^sPolak^nJF#et al#Burden and pr
ognostic importance of subclinical cardiovascular disease in overweight and obes
e individuals^len#Circulation#20070000#2007#116#4#375-84#20110000#aop03211.htm#0
009-7322#Circulation##
00661000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100021001040100
01800125010001600143010001700159012006600176030001600242065000900258064000500267
03100040027203200030027601400080027986500090028700200130029603500100030980100160
0319#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#166#6#ar
ticle#37#6#^rND^sWilson^nPWF#^rND^sD'Agostino^nRB#^rND^sSullivan^nL#^rND^sParise
^nH#^rND^sKannel^nWB#Overweight and obesity as determinants of cardiovascular ri
sk^len#Arch Intern Med#20020000#2002#162#16#1867-72#20110000#aop03211.htm#0003-9
926#Arch Intern Med##
00731000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100021001030100
01800124010001700142010001400159012014500173030001500318065000900333064000500342
03100030034703200020035001400060035286500090035800200130036703500100038080100150
0390#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#167#7#ar
ticle#37#7#^rND^sJanssen^nI#^rND^sHeymsfield^nSB#^rND^sAllison^nDB#^rND^sKotler^
nDP#^rND^sRoss^nR#Body mass index and waist circumference independently contribu
te to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat^l
en#Am J Clin Nutr#20020000#2002#75#4#683-8#20110000#aop03211.htm#0002-9165#Am J 
Clin Nutr##
00646000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100015001050120
14500120030001700265065000900282064000500291031000300296032000200299014000600301
865000900307002001300316035001000329801001700339#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03211.htm#S#c#168#8#article#37#8#^rND^sPitanga^nFJG#^rND^s
Lessa^nI#Indicadores antropométricos de obesidade como instrumento de triagem pa
ra risco coronariano elevado em adultos na cidade de Salvador - Bahia^lpt#Arq Br
as Cardiol#20050000#2005#85#1#26-31#20110000#aop03211.htm#0066-782X#Arq Bras Car
diol##
00738000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100018001060100
01800124010001600142010001700158010001700175810000600192012008400198030002400282
06500090030606400050031503100030032003200020032301400070032586500090033200200130
0341035001000354801002400364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#169#9#article#37#9#^rND^sSchneider^nHJ#^rND^sGlaesmer^nH#^rND^sK
lotsche^nJ#^rND^sBöhler^nS#^rND^sLehnert^nH#^rND^sZeiher^nAM#et al#Accuracy of a
nthropometric indicators of obesity to predict cardiovascular risk^len#J Clin En
docrinol Metab#20070000#2007#92#2#589-94#20110000#aop03211.htm#0021-972X#J Clin 
Endocrinol Metab##
00684000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
01500123010001600138012013500154030001200289065000900301064000500310031000300315
032000200318014000600320865000900326002001300335035001000348801001200358#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#170#10#article#37#10
#^rND^sKoning^nL#^rND^sMerchant^nAT#^rND^sPogue^nJ#^rND^sAnand^nSS#Waist circumf
erence and waist-to-hip ratio as predictors of cardiovascular events: meta-regre
ssion analysis of prospective studies^len#Eur Heart J#20070000#2007#28#7#850-6#2
0110000#aop03211.htm#0195-668X#Eur Heart J##
00750000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100020001070100
01800127010001800145010001800163010001700181810000600198012010400204030001700308
06500090032506400050033403100030033903200020034201400070034486500090035100200130
0360035001000373801001700383#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#171#11#article#37#11#^rND^sRezende^nFAC#^rND^sRosado^nLEFPL#^rND
^sRibeiro^nRL#^rND^sVidigal^nFC#^rND^sVasques^nAJ#^rND^sBonard^nIS#et al#Índice 
de massa corporal e circunferência abdominal: associação com fatores de risco ca
rdiovascular^lpt#Arq Bras Cardiol#20060000#2006#87#6#728-34#20110000#aop03211.ht
m#0066-782X#Arq Bras Cardiol##
00750000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100018001040100
01500122010002900137010001900166010001500185810000600200012015600206030001800362
71000020038006500090038206400050039103100020039601400040039886500090040200200130
0411#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#172#12#a
rticle#37#12#^rND^sHauner^nH#^rND^sBramlage^nP#^rND^sLösch^nC#^rND^sSteinhagen-T
hiessen^nE#^rND^sSchunkert^nH#^rND^sWasem^nJ#et al#Prevalence of obesity in prim
ary care using different anthropometric measures: results of the German Metaboli
c and Cardiovascular Risk Project (GEMCAS)^len#BMC Public Health#2#20080000#2008
#8#282#20110000#aop03211.htm##
00736000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01500126010001600141010001800157010001700175810000600192012010700198030001200305
06500090031706400050032603100030033103200020033401400060033686500090034200200130
0351035001000364801001200374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#173#13#article#37#13#^rND^sHastie^nCE#^rND^sPadmanabhan^nS#^rND^
sSlack^nR#^rND^sPell^nACH#^rND^sOldroyd^nKG#^rND^sFlapan^nAD#et al#Obesity parad
ox in a cohort of 4880 consecutive patients undergoing percutaneous coronary int
ervention^len#Eur Heart J#20100000#2010#31#2#222-6#20110000#aop03211.htm#0195-66
8X#Eur Heart J##
00735000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01600120010001800136010001800154010001500172810000600187012014800193030000700341
71000020034806500090035006400050035903100030036403200020036701400060036986500090
0375002001300384#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#
S#c#174#14#article#37#14#^rND^sKosuge^nM#^rND^sKimura^nK#^rND^sKojima^nS#^rND^sS
akamoto^nT#^rND^sIshihara^nM#^rND^sAsada^nY#et al#Impact of body mass index on i
n-hospital outcomes after percutaneous coronary intervention for ST segment elev
ation acute myocardial infarction^len#Circ J#2#20080000#2008#72#4#521-5#20110000
#aop03211.htm##
00721000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070100
01400124010001600138010001800154010001700172810000600189012009100195030001200286
06500090029806400050030703100030031203200030031501400090031886500090032700200130
0336035001000349801001200359#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#175#15#article#37#15#^rND^sBuettner^nHJ#^rND^sMueller^nC#^rND^sG
ick^nM#^rND^sFerenc^nM#^rND^sAllgeier^nJ#^rND^sComberg^nT#et al#The impact of ob
esity on mortality in UA/non-STsegment elevation myocardial infarction^len#Eur H
eart J#20070000#2007#28#14#1694-701#20110000#aop03211.htm#0195-668X#Eur Heart J#
#
00672000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100020001070100
01500127010001700142010001900159012008400178030001200262065000900274064000500283
03100030028803200030029101400080029486500090030200200130031103500100032480100120
0334#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#176#16#a
rticle#37#16#^rND^sDomanski^nMJ#^rND^sJablonski^nKA#^rND^sRice^nMM#^rND^sFowler^
nSE#^rND^sBraunwald^nE#Obesity and cardiovascular events in patients with establ
ished coronary disease^len#Eur Heart J#20060000#2006#27#12#1416-22#20110000#aop0
3211.htm#0195-668X#Eur Heart J##
00701000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100012001070100
01500119010001500134010001500149010001500164012010400179030001100283065000900294
06400050030303100040030803200020031201400060031486500090032000200130032903500100
0342801001100352#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#
S#c#177#17#article#37#17#^rND^sDagenais^nGR#^rND^sYi^nQ#^rND^sMann^nJF#^rND^sBos
ch^nJ#^rND^sPogue^nJ#^rND^sYusuf^nS#Prognostic impact of body weight and abdomin
al obesity in women and men with cardiovascular disease^len#Am Heart J#20050000#
2005#149#1#54-60#20110000#aop03211.htm#0002-8703#Am Heart J##
00792000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100019001060100
01900125010002000144010001700164010001600181810000600197012014600203030001700349
06500090036606400050037503100030038003200040038301400060038786500090039300200130
0402035001000415801001700425#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#178#18#article#37#18#^rND^sSposito^nAC#^rND^sCaramelli^nB#^rND^s
Fonseca^nFAH#^rND^sBertolami^nMC#^rND^sAfiune^nNA#^rND^sSouza^nAD#et al#IV Diret
riz brasileira sobre dislipidemias e prevenção da aterosclerose: Departamento de
 Aterosclerose da Sociedade Brasileira de Cardiologia^lpt#Arq Bras Cardiol#20070
000#2007#88#^s1#S2-19#20110000#aop03211.htm#0066-782X#Arq Bras Cardiol##
00692000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01600120010001800136010001900154010001800173810000600191012005300197030001700250
06500090026706400050027603100030028103200020028401400070028686500090029300200130
0302035001000315801001700325#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#179#19#article#37#19#^rND^sGomes^nMAM#^rND^sNobre^nF#^rND^sAmode
o^nC#^rND^sKohlmann^nO#^rND^sPraxedes^nJN#^rND^sMachado^nCA#et al#V Diretrizes b
rasileiras de hipertensão arterial^lpt#Arq Bras Cardiol#20070000#2007#89#3#e24-7
9#20110000#aop03211.htm#0066-782X#Arq Bras Cardiol##
00463000000000229000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170033000880180050001210660
01500171062001100186065000900197064000500206865000900211002001300220#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#180#20#article#37#20#Soc
iedade Brasileira de Diabetes#Diretrizes do tratamento do diabetes mellitus^lpt#
Rio de Janeiro#Diagraphic#20060000#2006#20110000#aop03211.htm##
00756000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01900124010001700143010002000160010002000180011003600200012007700236030001700313
06500090033006400050033903100030034403200040034701400060035186500090035700200130
0366035001000379801001700389#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#181#21#article#37#21#^rND^sBrandão^nAP#^rND^sBrandão^nAA#^rND^sN
ogueira^nAR#^rND^sSuplicy^nH#^rND^sGuimarães^nJI#^rND^sOliveira^nJEP#Sociedade B
rasileira de Cardiologia#I Diretriz brasileira de diagnóstico e tratamento da sí
ndrome metabólica^lpt#Arq Bras Cardiol#20050000#2005#84#^s1#S3-28#20110000#aop03
211.htm#0066-782X#Arq Bras Cardiol##
00621000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850110063000880120121001510300
00500272065000900277064000500286031000400291032000300295014000800298865000900306
002001300315035001000328801000500338#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop03211.htm#S#c#182#22#article#37#22#The Third Report of the National Ch
olesterol Education Program#Expert Panel on Detection: Evaluation, and treatment
 of high blood cholesterol in adults (Adult Treatment Panel III)^len#JAMA#200100
00#2001#285#19#2486-97#20110000#aop03211.htm#0098-7484#JAMA##
00708000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01600119010001600135010001700151010001600168012010300184030001200287065000900299
06400050030803100040031303200020031701400070031986500090032600200130033503500100
0348801001200358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#
S#c#183#23#article#37#23#^rND^sZeller^nM#^rND^sSteg^nPG#^rND^sRavisy^nJ#^rND^sLo
rgis^nL#^rND^sLaurent^nY#^rND^sSicard^nP#Relation between body mass index, waist
 circumference, and death after acute myocardial infarction^len#Circulation#2008
0000#2008#118#5#482-90#20110000#aop03211.htm#0009-7322#Circulation##
00720000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100018001030100
01700121010002000138010001900158010001600177810000600193012008600199030001200285
06500090029706400050030603100040031103200030031501400080031886500090032600200130
0335035001000348801001200358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#184#24#article#37#24#^rND^sJneid^nH#^rND^sFonarow^nGC#^rND^sCann
on^nCP#^rND^sHernandez^nAF#^rND^sPalacios^nIF#^rND^sMaree^nAO#et al#Sex differen
ces in medical care and early death after acute myocardial infarction^len#Circul
ation#20080000#2008#118#25#2803-10#20110000#aop03211.htm#0009-7322#Circulation##
00622000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01800120010001800138010001200156012006600168030002400234710000200258065000900260
064000500269031000300274032000200277014000700279865000900286002001300295#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#185#25#article#37#25
#^rND^sMenke^nA#^rND^sMuntner^nP#^rND^sWildman^nRP#^rND^sReynolds^nK#^rND^sHe^nJ
#Measures of adiposity and cardiovascular disease risk factors^len#Obesity (Silv
er Spring)#2#20070000#2007#15#3#785-95#20110000#aop03211.htm##
00615000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100021001050100
01400126012008500140030001500225065000900240064000500249031000300254032000200257
014000700259865000900266002001300275035001000288801001500298#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop03211.htm#S#c#186#26#article#37#26#^rND^sJanss
en^nI#^rND^sKatzmarzyk^nPT#^rND^sRoss^nR#Waist circumference and not body mass i
ndex explains obesity related health risk^len#Am J Clin Nutr#20040000#2004#79#3#
379-84#20110000#aop03211.htm#0002-9165#Am J Clin Nutr##
00830000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100020001030100
01700123010001500140010001500155010001700170810000600187012020200193030001200395
06500090040706400050041603100040042103200030042501400080042886500090043600200130
0445035001000458801001200468#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#187#27#article#37#27#^rND^sCanoy^nD#^rND^sBoekholdt^nSM#^rND^sWa
reham^nN#^rND^sLuben^nR#^rND^sWelch^nA#^rND^sBingham^nS#et al#Body fat distribut
ion and risk of coronary heart disease in men and women in the European Prospect
ive Investigation Into Cancer and Nutrition in Norfolk Cohort: A Population-Base
d Prospective Study^len#Circulation#20070000#2007#116#25#2933-43#20110000#aop032
11.htm#0009-7322#Circulation##
00748000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100022000880100018001100100
01700128010001900145010002000164010001800184810000600202012009900208030001700307
06500090032406400050033303100030033803200020034101400060034386500090034900200130
0358035001000371801001700381#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#188#28#article#37#28#^rND^sTarastchuk^nJCE#^rND^sGuérios^nEE#^rN
D^sBueno^nRRL#^rND^sAndrade^nPMP#^rND^sNercolini^nDC#^rND^sFerraz^nJGG#et al#Obe
sidade e intervenção coronariana: devemos continuar valorizando o índice de mass
a corpórea?^lpt#Arq Bras Cardiol#20080000#2008#90#5#311-6#20110000#aop03211.htm#
0066-782X#Arq Bras Cardiol##
00690000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100019001080100
01800127010001600145010001900161012010000180030001200280065000900292064000500301
03100030030603200030030901400080031286500090032000200130032903500100034280100120
0352#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#189#29#a
rticle#37#29#^rND^sBonarjee^nVVS#^rND^sRosengren^nA#^rND^sSnapinn^nSM#^rND^sJame
s^nMK#^rND^sDickstein^nK#Sex-based short- and long-term survival in patients fol
lowing complicated myocardial infarction^len#Eur Heart J#20060000#2006#27#18#217
7-83#20110000#aop03211.htm#0195-668X#Eur Heart J##
00759000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100023000880100022001110100
02200133010001800155010001900173010001700192810000600209012011400215030001100329
06500090034006400050034903100030035403200020035701400070035986500090036600200130
0375035001000388801001100398#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#190#30#article#37#30#^rND^sKoutsovasilis^nA#^rND^sProtopsaltis^n
J#^rND^sTriposkiadis^nF#^rND^sKokkoris^nS#^rND^sMilionis^nHJ#^rND^sZairis^nMN#et
 al#Comparative performance of three metabolic syndrome: definitions in the pred
iction of acute coronary syndrome^len#Intern Med#20090000#2009#48#4#179-87#20110
000#aop03211.htm#0918-2918#Intern Med##
00726000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100012001060100
01800118010001400136010001200150010001200162012012400174030001500298065000900313
06400050032203100030032703200020033001400090033286500090034100200130035003500100
0363801001500373#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#
S#c#191#31#article#37#31#^rND^sWildman^nRP#^rND^sGu^nD#^rND^sReynolds^nK#^rND^sD
uan^nX#^rND^sWu^nX#^rND^sHe^nJ#Are waist circumference and body mass index indep
endently associated with cardiovascular disease risk in Chinese adults^len#Am J 
Clin Nutr#20050000#2005#82#6#1195-202#20110000#aop03211.htm#0002-9165#Am J Clin 
Nutr##
00668000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
02000126010001900146012009700165030001700262065000900279064000500288031000300293
032000200296014000700298865000900305002001300314035001000327801001700337#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03211.htm#S#c#192#32#article#37#32
#^rND^sPeixoto^nMRG#^rND^sBenício^nMHD#^rND^sLatorre^nMRDO#^rND^sJardim^nPCBV#Ci
rcunferência da cintura e índice de massa corporal como preditores da hipertensã
o arterial^lpt#Arq Bras Cardiol#20060000#2006#87#4#462-70#20110000#aop03211.htm#
0066-782X#Arq Bras Cardiol##
00756000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100019001070100
01600126010001700142010001500159010001800174810000600192012012500198030001300323
06500090033606400050034503100030035003200020035301400060035586500090036100200130
0370035001000383801001300393#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#193#33#article#37#33#^rND^sChirinos^nJA#^rND^sZambrano^nJP#^rND^
sChakko^nS#^rND^sVeerani^nA#^rND^sSchob^nS#^rND^sWillens^nHJ#et al#Aortic Pressu
re Augmentation Predicts Adverse Cardiovascular Events in Patients With Establis
hed Coronary Artery Disease^len#Hypertension#20050000#2005#45#5#980-5#20110000#a
op03211.htm#0194-911X#Hypertension##
00763000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01600119010002400135010001900159010001500178810000600193012013400199030001100333
06500090034406400050035303100040035803200020036201400060036486500090037000200130
0379035001000392801001100402#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#194#34#article#37#34#^rND^sAjani^nAE#^rND^sReid^nCM#^rND^sDuffy^
nSJ#^rND^sAndrianopoulos^nN#^rND^sLefkovits^nJ#^rND^sBlack^nA#et al#Outcomes aft
er percutaneous coronary intervention in contemporary Australian practice: insig
hts from a large multicentre registry^len#Med J Aust#20080000#2008#189#8#423-8#2
0110000#aop03211.htm#0025-729X#Med J Aust##
00789000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
02000121010002100141010001900162010001400181810000600195012015600201030001200357
06500090036906400050037803100030038303200020038601400070038886500090039500200130
0404035001000417801001200427#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#195#35#article#37#35#^rND^sSorajja^nP#^rND^sGersh^nBJ#^rND^sCost
antini^nC#^rND^sMcLaughlin^nMG#^rND^sZimetbaum^nP#^rND^sCox^nDA#et al#Combined p
rognostic utility of ST-segment recovery and myocardial blush after primary perc
utaneous coronary intervention in acute myocardial infarction^len#Eur Heart J#20
050000#2005#26#7#667-74#20110000#aop03211.htm#0195-668X#Eur Heart J##
00600000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01700125010001700142012007200159030001900231710000200250065000900252064000500261
031000300266032000200269014000500271865000900276002001300285#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop03211.htm#S#c#196#36#article#37#36#^rND^sPinhe
iro^nAS#^rND^sNakasato^nM#^rND^sIsosaki^nM#^rND^sBocchi^nEA#Obesidade: fator pro
tetor nos pacientes com insuficiência cardíaca?^lpt#Rev Bras Nutr Clin#2#2007000
0#2007#22#1#20-7#20110000#aop03211.htm##
00863000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
02100122010002000143010001500163010001800178810000600196012022600202030001200428
06500090044006400050044903100040045403200030045801400080046186500090046900200130
0478035001000491801001200501#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03211.htm#S#c#197#37#article#37#37#^rND^sO'Meara^nE#^rND^sClayton^nT#^rND^sMcE
ntegart^nMB#^rND^sMcMurray^nJJV#^rND^sPiña^nIL#^rND^sGranger^nCB#et al#Sex diffe
rences in clinical characteristics and prognosis in a broad spectrum of patients
 with heart failure: results of the Candesartan in Heart failure: Assessment of 
Reduction in Mortality and morbidity (CHARM) Program^len#Circulation#20070000#20
07#115#24#3111-20#20110000#aop03211.htm#0009-7322#Circulation##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#o#1#1#
article#1#20110331#081813#aop02911.htm#122##
05101000000000673000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200690
01780120073002470100032003200100041003520100032003930100038004250100045004630100
02500508070006600533083173100599085000802330085002302338085005602361085003502417
08500320245208317230248408500080420708500240421508500510423908500260429008500330
43161170008043490720003043571120009043601110009043691160009043781150009043871140
00904396113000904405002001304414#2011nahead#V:\SciELO\serial\abc\2011nahead\mark
up\aop02911.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#41#nd#nd#Arq. Bras.
 Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#Avaliação eletrofisiológica c
ardíaca em pacientes com sarcoidose^lpt#Cardiac electrophysiological assessment 
in patients with sarcoidosis^len#^rND^1A01^nJefferson^sCurimbaba#^rND^1A01^nSilv
ia Carla Souza^sRodrigues#^rND^1A01^nJosé Marcos^sMoreira#^rND^1A01^nLenine Ânge
lo Alves^sSilva#^rND^1A01^nCarlos Alberto de Castro^sPereira#^rND^1A01^nJoão^sPi
menta#Hospital do Servidor Público Estadual^iA01^cSão Paulo^sSP^pBrasil#^lpt^aFU
NDAMENTO: Sarcoidose é uma doença granulomatosa multissistêmica de origem descon
hecida que pode causar morte súbita. OBJETIVO: Avaliação eletrofisiológica de pa
cientes com sarcoidose com suspeita de comprometimento cardíaco. MÉTODOS: Foram 
estudados 22 pacientes com média de idade de 55,32 ±13,13 anos, com diagnóstico 
de sarcoidose e suspeita de comprometimento cardíaco. Foram submetidos à avaliaç
ão clínica, exames laboratoriais, eletrocardiograma, ecocardiograma, Holter de 2
4h, cintilografia com gálio ou tecnécio e estudo eletrofisiológico. Em casos sel
ecionados foi realizada tomografia por emissão de pósitrons ou ressonância magné
tica. Os pacientes foram seguidos ambulatoriamente com consultas trimestrais. RE
SULTADOS: Comprometimento cardíaco foi comprovado em quatro (18,2%) pacientes. E
xtrassístoles ventriculares com densidade > 100/24h foram documentadas no Holter
 de 24h em 12 (54,5 %) pacientes. O estudo eletrofisiológico revelou aumento do 
intervalo HV em sete (31,8%) e ponto de Wenckebach aumentado em quatro (18,2%) p
acientes. Houve indução de fibrilação atrial em sete (31,8%) e de taquicardia ve
ntricular sustentada em um (4,5%). Nos quatro pacientes com sarcoidose cardíaca 
confirmada, extrassístoles ventriculares, com densidade > 100/24h foram document
adas em todos, dois apresentavam intervalo HV prolongado e fibrilação atrial foi
 induzida em dois. Taquicardia ventricular sustentada não foi induzida em nenhum
 desses pacientes. Após período médio de acompanhamento de 20,9 ± 15,7 meses, um
 paciente com sarcoidose cardíaca apresentou morte súbita. CONCLUSÃO: Pacientes 
com sarcoidose e suspeita de envolvimento cardíaco apresentam alta prevalência d
e EVs e distúrbios do sistema de condução.#^dnd^i1#^tm^lpt^kSarcoidose^i1#^tm^lp
t^ksistema de condução cardíaca^i1^sanormalidades#^tm^lpt^kinsuficiência cardíac
a^i1#^tm^lpt^karritmias cardíacas^i1#^len^aBACKGROUND: Sarcoidosis is a multisys
tem granulomatous disease of unknown origin that can cause sudden death. OBJECTI
VE: Electrophysiological evaluation of patients with suspected sarcoidosis with 
cardiac involvement. METHODS: We studied 22 patients with mean age of 55.32 ± 13
.13 years, diagnosed with sarcoidosis and suspected cardiac involvement. These p
atients underwent clinical evaluation, laboratory tests, electrocardiogram, echo
cardiogram, 24-hour Holter, technetium or gallium scintigraphy and electrophysio
logical study. In selected cases, we performed positron emission tomography or m
agnetic resonance imaging. Patients were followed up in the outpatient care serv
ice with quarterly visits. RESULTS: Cardiac involvement was confirmed in four (1
8.2%) patients. Ventricular extrasystoles with density > 100/24h were documented
 in 24-Holter monitoring in 12 (54.5%) patients. Electrophysiological studies re
vealed an increased HV interval in seven patients (31.8%) and increased Wenckeba
ch point in four (18.2%) patients. There was induction of atrial fibrillation in
 seven patients (31.8%) and sustained ventricular tachycardia in one patient (4.
5%). Four patients with confirmed cardiac sarcoidosis had documented ventricular
 extrasystoles with density > 100/24h. Out of these, two had prolonged HV interv
al and atrial fibrillation was induced in two of them. Sustained ventricular tac
hycardia was not induced in any of these patients. After mean follow-up period o
f 20.9 ± 15.7 months, one patient with cardiac sarcoidosis had sudden death. CON
CLUSION: Patients with sarcoidosis and suspected cardiac involvement have a high
 prevalence of ventricular extrasystoles (VEs) and conduction system disorders.#
^dnd^i2#^tm^len^kSarcoidosis^i2#^tm^len^kheart conduction system^i2^sabnormaliti
es#^tm^len^kheart failure^i2#^tm^len^karrhythmias, cardiac^i2#vancouv#19#2010081
9#19/08/10#20101127#27/11/10#20101208#08/12/10#aop02911.htm##
05197000000000673000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901200760
01780120080002540100032003340100041003660100032004070100038004390100045004770100
02500522070006600547083177200613085000802385085002302393085005602416085003502472
08500320250708317640253908500080430308500240431108500510433508500260438608500330
44121170008044450720003044531120009044561110009044651160009044741150009044831140
00904492113000904501002001304510#2011nahead#V:\SciELO\serial\abc\2011nahead\mark
up\aop02911.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#41#nd#nd#Arq. Bras.
 Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110401#<b>Avaliação eletrofisiológic
a cardíaca em pacientes com sarcoidose</b>^lpt#<b>Cardiac electrophysiological a
ssessment in patients with sarcoidosis</b>^len#^rND^1A01^nJefferson^sCurimbaba#^
rND^1A01^nSilvia Carla Souza^sRodrigues#^rND^1A01^nJosé Marcos^sMoreira#^rND^1A0
1^nLenine Ângelo Alves^sSilva#^rND^1A01^nCarlos Alberto de Castro^sPereira#^rND^
1A01^nJoão^sPimenta#Hospital do Servidor Público Estadual^iA01^cSão Paulo^sSP^pB
rasil#^lpt^a<b>FUNDAMENTO:</b> Sarcoidose é uma doença granulomatosa multissistê
mica de origem desconhecida que pode causar morte súbita. <b>OBJETIVO:</b> Avali
ação eletrofisiológica de pacientes com sarcoidose com suspeita de comprometimen
to cardíaco. <b>MÉTODOS:</b> Foram estudados 22 pacientes com média de idade de 
55,32 ±13,13 anos, com diagnóstico de sarcoidose e suspeita de comprometimento c
ardíaco. Foram submetidos à avaliação clínica, exames laboratoriais, eletrocardi
ograma, ecocardiograma, Holter de 24h, cintilografia com gálio ou tecnécio e est
udo eletrofisiológico. Em casos selecionados foi realizada tomografia por emissã
o de pósitrons ou ressonância magnética. Os pacientes foram seguidos ambulatoria
mente com consultas trimestrais. <b>RESULTADOS:</b> Comprometimento cardíaco foi
 comprovado em quatro (18,2%) pacientes. Extrassístoles ventriculares com densid
ade &gt; 100/24h foram documentadas no Holter de 24h em 12 (54,5 %) pacientes. O
 estudo eletrofisiológico revelou aumento do intervalo HV em sete (31,8%) e pont
o de Wenckebach aumentado em quatro (18,2%) pacientes. Houve indução de fibrilaç
ão atrial em sete (31,8%) e de taquicardia ventricular sustentada em um (4,5%). 
Nos quatro pacientes com sarcoidose cardíaca confirmada, extrassístoles ventricu
lares, com densidade &gt; 100/24h foram documentadas em todos, dois apresentavam
 intervalo HV prolongado e fibrilação atrial foi induzida em dois. Taquicardia v
entricular sustentada não foi induzida em nenhum desses pacientes. Após período 
médio de acompanhamento de 20,9 ± 15,7 meses, um paciente com sarcoidose cardíac
a apresentou morte súbita. <b>CONCLUSÃO:</b> Pacientes com sarcoidose e suspeita
 de envolvimento cardíaco apresentam alta prevalência de EVs e distúrbios do sis
tema de condução.#^dnd^i1#^tm^lpt^kSarcoidose^i1#^tm^lpt^ksistema de condução ca
rdíaca^i1^sanormalidades#^tm^lpt^kinsuficiência cardíaca^i1#^tm^lpt^karritmias c
ardíacas^i1#^len^a<b>BACKGROUND:</b> Sarcoidosis is a multisystem granulomatous 
disease of unknown origin that can cause sudden death. <b>OBJECTIVE:</b> Electro
physiological evaluation of patients with suspected sarcoidosis with cardiac inv
olvement. <b>METHODS:</b> We studied 22 patients with mean age of 55.32 ± 13.13 
years, diagnosed with sarcoidosis and suspected cardiac involvement. These patie
nts underwent clinical evaluation, laboratory tests, electrocardiogram, echocard
iogram, 24-hour Holter, technetium or gallium scintigraphy and electrophysiologi
cal study. In selected cases, we performed positron emission tomography or magne
tic resonance imaging. Patients were followed up in the outpatient care service 
with quarterly visits. <b>RESULTS:</b> Cardiac involvement was confirmed in four
 (18.2%) patients. Ventricular extrasystoles with density &gt; 100/24h were docu
mented in 24-Holter monitoring in 12 (54.5%) patients. Electrophysiological stud
ies revealed an increased HV interval in seven patients (31.8%) and increased We
nckebach point in four (18.2%) patients. There was induction of atrial fibrillat
ion in seven patients (31.8%) and sustained ventricular tachycardia in one patie
nt (4.5%). Four patients with confirmed cardiac sarcoidosis had documented ventr
icular extrasystoles with density &gt; 100/24h. Out of these, two had prolonged 
HV interval and atrial fibrillation was induced in two of them. Sustained ventri
cular tachycardia was not induced in any of these patients. After mean follow-up
 period of 20.9 ± 15.7 months, one patient with cardiac sarcoidosis had sudden d
eath. <b>CONCLUSION:</b> Patients with sarcoidosis and suspected cardiac involve
ment have a high prevalence of ventricular extrasystoles (VEs) and conduction sy
stem disorders.#^dnd^i2#^tm^len^kSarcoidosis^i2#^tm^len^kheart conduction system
^i2^sabnormalities#^tm^len^kheart failure^i2#^tm^len^karrhythmias, cardiac^i2#va
ncouv#19#20100819#19/08/10#20101127#27/11/10#20101208#08/12/10#aop02911.htm##
05318000000000697000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120069001840120073002530100032003260100041003580100032003990100038004310100
04500469010002500514070006800539083178500607085000802392085002302400085005602423
08500350247908500320251408317650254608500080431108500240431908500510434308500260
43940850033044201170008044530720003044611120009044641110009044731160009044821150
00904491114000904500113000904509002001304518008008904531#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop02911.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4
.0#ilus#tab#41#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110401
#Avaliação eletrofisiológica cardíaca em pacientes com sarcoidose^lpt#Cardiac el
ectrophysiological assessment in patients with sarcoidosis^len#^rND^1A01^nJeffer
son^sCurimbaba#^rND^1A01^nSilvia Carla Souza^sRodrigues#^rND^1A01^nJosé Marcos^s
Moreira#^rND^1A01^nLenine Ângelo Alves^sSilva#^rND^1A01^nCarlos Alberto de Castr
o^sPereira#^rND^1A01^nJoão^sPimenta#^iA01^1Hospital do Servidor Público Estadual
^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: Sarcoidose é uma doença granulomatosa 
multissistêmica de origem desconhecida que pode causar morte súbita. OBJETIVO: A
valiação eletrofisiológica de pacientes com sarcoidose com suspeita de compromet
imento cardíaco. MÉTODOS: Foram estudados 22 pacientes com média de idade de 55,
32 ±13,13 anos, com diagnóstico de sarcoidose e suspeita de comprometimento card
íaco. Foram submetidos à avaliação clínica, exames laboratoriais, eletrocardiogr
ama, ecocardiograma, Holter de 24h, cintilografia com gálio ou tecnécio e estudo
 eletrofisiológico. Em casos selecionados foi realizada tomografia por emissão d
e pósitrons ou ressonância magnética. Os pacientes foram seguidos ambulatoriamen
te com consultas trimestrais. RESULTADOS: Comprometimento cardíaco foi comprovad
o em quatro (18,2 por cento) pacientes. Extrassístoles ventriculares com densida
de > 100/24h foram documentadas no Holter de 24h em 12 (54,5  por cento) pacient
es. O estudo eletrofisiológico revelou aumento do intervalo HV em sete (31,8 por
 cento) e ponto de Wenckebach aumentado em quatro (18,2 por cento) pacientes. Ho
uve indução de fibrilação atrial em sete (31,8 por cento) e de taquicardia ventr
icular sustentada em um (4,5 por cento). Nos quatro pacientes com sarcoidose car
díaca confirmada, extrassístoles ventriculares, com densidade > 100/24h foram do
cumentadas em todos, dois apresentavam intervalo HV prolongado e fibrilação atri
al foi induzida em dois. Taquicardia ventricular sustentada não foi induzida em 
nenhum desses pacientes. Após período médio de acompanhamento de 20,9 ± 15,7 mes
es, um paciente com sarcoidose cardíaca apresentou morte súbita. CONCLUSÃO: Paci
entes com sarcoidose e suspeita de envolvimento cardíaco apresentam alta prevalê
ncia de EVs e distúrbios do sistema de condução.#^dnd^i1#^tm^lpt^kSarcoidose^i1#
^tm^lpt^ksistema de condução cardíaca^i1^sanormalidades#^tm^lpt^kinsuficiência c
ardíaca^i1#^tm^lpt^karritmias cardíacas^i1#^len^aBACKGROUND: Sarcoidosis is a mu
ltisystem granulomatous disease of unknown origin that can cause sudden death. O
BJECTIVE: Electrophysiological evaluation of patients with suspected sarcoidosis
 with cardiac involvement. METHODS: We studied 22 patients with mean age of 55.3
2 ± 13.13 years, diagnosed with sarcoidosis and suspected cardiac involvement. T
hese patients underwent clinical evaluation, laboratory tests, electrocardiogram
, echocardiogram, 24-hour Holter, technetium or gallium scintigraphy and electro
physiological study. In selected cases, we performed positron emission tomograph
y or magnetic resonance imaging. Patients were followed up in the outpatient car
e service with quarterly visits. RESULTS: Cardiac involvement was confirmed in f
our (18.2 percent) patients. Ventricular extrasystoles with density > 100/24h we
re documented in 24-Holter monitoring in 12 (54.5 percent) patients. Electrophys
iological studies revealed an increased HV interval in seven patients (31.8 perc
ent) and increased Wenckebach point in four (18.2 percent) patients. There was i
nduction of atrial fibrillation in seven patients (31.8 percent) and sustained v
entricular tachycardia in one patient (4.5 percent). Four patients with confirme
d cardiac sarcoidosis had documented ventricular extrasystoles with density > 10
0/24h. Out of these, two had prolonged HV interval and atrial fibrillation was i
nduced in two of them. Sustained ventricular tachycardia was not induced in any 
of these patients. After mean follow-up period of 20.9 ± 15.7 months, one patien
t with cardiac sarcoidosis had sudden death. CONCLUSION: Patients with sarcoidos
is and suspected cardiac involvement have a high prevalence of ventricular extra
systoles (VEs) and conduction system disorders.#^dnd^i2#^tm^len^kSarcoidosis^i2#
^tm^len^kheart conduction system^i2^sabnormalities#^tm^len^kheart failure^i2#^tm
^len^karrhythmias, cardiac^i2#vancouv#19#20100819#19/08/10#20101127#27/11/10#201
01208#08/12/10#aop02911.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci
_arttext&pid=S0066-782X2011005000041##
00442000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000300079704020100082002001300283#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#5#1#article#99#<p><a name="e
nda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Avalia&c
cedil;&atilde;o eletrofisiol&oacute;gica card&iacute;aca em pacientes com sarcoi
dose</b></font></p>     ^cY#aop02911.htm##
00263000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000300079704002200082002001300104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#6#2#article#99#<p>&nbsp;</p>
     ^cY#aop02911.htm##
00263000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000300079704002200082002001300104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#7#3#article#99#<p>&nbsp;</p>
     ^cY#aop02911.htm##
00497000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000300079704025600082002001300338#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#8#4#article#99#<p><font size
="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Jefferson Curimbaba; Silvia
 Carla Souza Rodrigues; Jos&eacute; Marcos Moreira; Lenine &Acirc;ngelo Alves Si
lva; Carlos Alberto  de Castro Pereira; Jo&atilde;o Pimenta</b></font></p>     ^
cY#aop02911.htm##
00400000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000300079704015900082002001300241#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#9#5#article#99#<p><font size
="2" face="Verdana, Arial, Helvetica, sans-serif"> Hospital do Servidor P&uacute
;blico Estadual, S&atilde;o Paulo, SP - Brasil</font></p>     ^cY#aop02911.htm##
00366000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000300080704012400083002001300207#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#10#6#article#99#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ec
irc;ncia</a></font></p>     ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000300080704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#11#7#article#99#<p>&nbsp;</p
>     ^cY#aop02911.htm##
00286000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000300080704004400083002001300127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#12#8#article#99#<p>&nbsp;</p
> <hr size="1" noshade>     ^cY#aop02911.htm##
00338000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000300080704009600083002001300179#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#13#9#article#99#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     
^cY#aop02911.htm##
00467000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704022400084002001300308#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#14#10#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO:</b> Sarcoidos
e &eacute; uma doen&ccedil;a granulomatosa multissist&ecirc;mica de origem desco
nhecida que pode causar morte s&uacute;bita.     ^cY#aop02911.htm##
00401000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704015800084002001300242#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#15#11#article#99#<br>   <b>O
BJETIVO:</b> Avalia&ccedil;&atilde;o eletrofisiol&oacute;gica de pacientes com s
arcoidose com suspeita de comprometimento card&iacute;aco.     ^cY#aop02911.htm#
#
00862000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704061900084002001300703#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#16#12#article#99#<br>   <b>M
&Eacute;TODOS:</b> Foram estudados 22 pacientes com m&eacute;dia de idade de 55,
32 ±13,13 anos, com diagn&oacute;stico de sarcoidose e suspeita de comprometimen
to card&iacute;aco. Foram submetidos &agrave; avalia&ccedil;&atilde;o cl&iacute;
nica, exames laboratoriais, eletrocardiograma, ecocardiograma, Holter de 24h, ci
ntilografia com g&aacute;lio ou tecn&eacute;cio e estudo eletrofisiol&oacute;gic
o. Em casos selecionados foi realizada tomografia por emiss&atilde;o de p&oacute
;sitrons ou resson&acirc;ncia magn&eacute;tica. Os pacientes foram seguidos ambu
latoriamente com consultas trimestrais.     ^cY#aop02911.htm##
01251000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704100800084002001301092#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#17#13#article#99#<br>   <b>R
ESULTADOS:</b> Comprometimento card&iacute;aco foi comprovado em quatro (18,2%) 
pacientes. Extrass&iacute;stoles ventriculares com densidade &gt; 100/24h foram 
documentadas no Holter de 24h em 12 (54,5 %) pacientes. O estudo eletrofisiol&oa
cute;gico revelou aumento do intervalo HV em sete (31,8%) e ponto de Wenckebach 
aumentado em quatro (18,2%) pacientes. Houve indu&ccedil;&atilde;o de fibrila&cc
edil;&atilde;o atrial em sete (31,8%) e de taquicardia ventricular sustentada em
 um (4,5%). Nos quatro pacientes com sarcoidose card&iacute;aca confirmada, extr
ass&iacute;stoles ventriculares, com densidade &gt; 100/24h foram documentadas e
m todos, dois apresentavam intervalo HV prolongado e fibrila&ccedil;&atilde;o at
rial foi induzida em dois. Taquicardia ventricular sustentada n&atilde;o foi ind
uzida em nenhum desses pacientes. Ap&oacute;s per&iacute;odo m&eacute;dio de aco
mpanhamento de 20,9 ± 15,7 meses, um paciente com sarcoidose card&iacute;aca apr
esentou morte s&uacute;bita.     ^cY#aop02911.htm##
00462000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704021900084002001300303#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#18#14#article#99#<br>   <b>C
ONCLUS&Atilde;O:</b> Pacientes com sarcoidose e suspeita de envolvimento card&ia
cute;aco apresentam alta preval&ecirc;ncia de EVs e dist&uacute;rbios do sistema
 de condu&ccedil;&atilde;o. </font></p>     ^cY#aop02911.htm##
00514000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704027100084002001300355#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#19#15#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b> Sarco
idose, sistema de condu&ccedil;&atilde;o card&iacute;aca/anormalidades , insufic
i&ecirc;ncia card&iacute;aca, arritmias card&iacute;acas. </font></p> <hr size="
1" noshade>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#20#16#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#21#17#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00357000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704011400084002001300198#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#22#18#article#99#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o<
/b></font></p>     ^cY#aop02911.htm##
00969000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704072600084002001300810#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#23#19#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Sarcoidose &eacute; uma doen
&ccedil;a granulomatosa multissist&ecirc;mica de origem desconhecida<sup>1</sup>
, frequentemente observada em indiv&iacute;duos entre a 2ª e 5ª d&eacute;cadas d
e vida. A sua etiologia continua n&atilde;o totalmente esclarecida; causas infec
ciosas, ambientais, ocupacionais e gen&eacute;ticas podem estar implicadas, mas 
n&atilde;o totalmente comprovadas<sup>2</sup>. Quase todos os sistemas do organi
smo humano podem ser afetados, sendo os mais comuns o respirat&oacute;rio (pulm&
atilde;o 90%) e linf&aacute;tico, manifestando-se com a cl&aacute;ssica presen&c
cedil;a de granulomas n&atilde;o caseosos<sup>3</sup>. </font></p>     ^cY#aop02
911.htm##
01041000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704079800084002001300882#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#24#20#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">O envolvimento card&iacute;a
co ocorre em 20 a 50% dos pacientes que podem apresentar progn&oacute;stico e ev
olu&ccedil;&atilde;o adversa<sup>4-7</sup>. Todas as estruturas card&iacute;acas
 podem ser envolvidas, por&eacute;m o mioc&aacute;rdio &eacute; o local mais com
um<sup>8</sup>. As tr&ecirc;s principais sequelas card&iacute;acas s&atilde;o an
ormalidades do sistema de condu&ccedil;&atilde;o, arritmias e insufici&ecirc;nci
a card&iacute;aca (IC). A manifesta&ccedil;&atilde;o card&iacute;aca &eacute; pl
eom&oacute;rfica variando desde o paciente totalmente assintom&aacute;tico at&ea
cute; com palpita&ccedil;&otilde;es, dor precordial, sintomas de IC, s&iacute;nc
ope e morte s&uacute;bita (MS)<sup>9,10</sup>. </font></p>     ^cY#aop02911.htm#
#
01312000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704106900084002001301153#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#25#21#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">A MS &eacute; a mais temida 
manifesta&ccedil;&atilde;o card&iacute;aca da sarcoidose, sendo geralmente impre
vis&iacute;vel, podendo ocorrer como primeira manifesta&ccedil;&atilde;o da doen
&ccedil;a ou em qualquer momento, sendo mais comum nas fases mais avan&ccedil;ad
as quando h&aacute; maior dano card&iacute;aco. Apresenta incid&ecirc;ncia muito
 vari&aacute;vel, chegando a at&eacute; 67% dos casos<sup>8</sup>, podendo ser o
casionada por bloqueio AV total e arritmias ventriculares<sup>11,12</sup>. Dessa
 forma, a estratifica&ccedil;&atilde;o de risco torna-se importante quando se es
tabelece o diagn&oacute;stico de comprometimento card&iacute;aco. Assim, esse es
tudo foi desenvolvido para avaliar o sistema de condu&ccedil;&atilde;o atriovent
ricular (AV) e intraventricular (IV) e a indu&ccedil;&atilde;o de arritmias atri
ais e ventriculares de pacientes com diagn&oacute;stico cl&iacute;nico e laborat
orial recente de sarcoidose  com suspeita de comprometimento card&iacute;aco. </
font></p>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#26#22#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00364000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704012100084002001300205#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#27#23#article#99#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Casu&iacute;stica e metod
ologia</b></font></p>     ^cY#aop02911.htm##
00356000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704011300084002001300197#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#28#24#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Delineamento do estudo </
b></font></p>     ^cY#aop02911.htm##
00491000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704024800084002001300332#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#29#25#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Prospectivo, aberto, iniciad
o em abril de 2005 e encerrado em abril de 2009, aprovado pela Comiss&atilde;o d
e &Eacute;tica em Pesquisa da Institui&ccedil;&atilde;o. </font></p>     ^cY#aop
02911.htm##
00356000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704011300084002001300197#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#30#26#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Popula&ccedil;&atilde;o</
b></font></p>     ^cY#aop02911.htm##
01132000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704088900084002001300973#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#31#27#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Foram estudados, de forma n&
atilde;o consecutiva, 22 pacientes (7 homens) de qualquer ra&ccedil;a, de ambos 
os sexos, com idade entre 31 e 84 (55,32 ± 13,13) anos com diagn&oacute;stico re
cente de sarcoidose definido por exame histopatol&oacute;gico. Foram avaliados p
acientes com suspeita de envolvimento card&iacute;aco, selecionados por sintomas
 e altera&ccedil;&otilde;es de exames cardiol&oacute;gicos iniciais, ainda sem t
ratamento espec&iacute;fico padr&atilde;o, n&atilde;o estando em uso de qualquer
 f&aacute;rmaco que pudesse alterar as condi&ccedil;&otilde;es eletrofisiol&oacu
te;gicas do sistema de condu&ccedil;&atilde;o do cora&ccedil;&atilde;o. Ap&oacut
e;s elegibilidade para admiss&atilde;o no estudo, os pacientes foram informados 
e assinaram o Termo de Consentimento Livre e Esclarecido. </font></p>     ^cY#ao
p02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#32#28#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704010500084002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#33#29#article#99#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos </b></font
></p>     ^cY#aop02911.htm##
01073000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704083000084002001300914#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#34#30#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Todos os pacientes foram sub
metidos a avalia&ccedil;&atilde;o cl&iacute;nica, avalia&ccedil;&atilde;o labora
torial de rotina, eletrocardiograma (ECG) e Holter de 24h com. O envolvimento ca
rd&iacute;aco foi documentado pela radiografia de t&oacute;rax, ecocardiograma b
idimensional (ECO) e um dos seguintes m&eacute;todos de imagem: cintilografia co
m g&aacute;lio ou tecn&eacute;cio, tomografia por emiss&atilde;o de p&oacute;sit
rons e resson&acirc;ncia magn&eacute;tica. Ap&oacute;s concord&acirc;ncia em par
ticipar do estudo, foram submetidos ao estudo eletrofisiol&oacute;gico (EEF) por
 t&eacute;cnicas j&aacute; descritas<sup>13</sup>. O seguimento cl&iacute;nico f
oi realizado com consultas ambulatoriais trimestrais, ou conforme necessidade. <
/font></p>     ^cY#aop02911.htm##
01570000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704132700084002001301411#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#35#31#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Foram analisados dados demog
r&aacute;ficos, cl&iacute;nicos e est&aacute;gio pulmonar da sarcoidose (classif
ica&ccedil;&atilde;o radiol&oacute;gica de<i> Scadding)</i><sup>14</sup>. No ECG
 obtido pelo pol&iacute;grafo TEB de 12 deriva&ccedil;&otilde;es simult&acirc;ne
as e cont&iacute;nuas foram avaliados o ritmo fundamental, o &Acirc;QRS, presen&
ccedil;a de ondas Q anormais, altera&ccedil;&otilde;es de segmento ST, presen&cc
edil;a de bloqueios AV e IV, bloqueios divisionais, intervalo QT corrigido (QT<s
ub>C</sub>) pela f&oacute;rmula de Bazett e dispers&atilde;o de intervalo QT. O 
intervalo QT foi medido pelo m&eacute;todo manual na velocidade de 100 mm/s. O r
itmo basal, presen&ccedil;a de bloqueios AV, IV, pausas, arritmias atriais, como
 extrass&iacute;stoles supraventriculares e taquicardias, arritmias ventriculare
s tipo extrass&iacute;stoles ventriculares (EV) com densidades de &lt;100/dia e 
&gt;100/dia<sup>15 </sup>e taquicardia ventricular n&atilde;o sustentada (TVNS),
 variabilidade da frequ&ecirc;ncia card&iacute;aca (VFC) no dom&iacute;nio do te
mpo e frequ&ecirc;ncia foram analisados pelo Holter de 24h. O aparelho utilizado
 foi da marca DMI Cardios Systemas. Todos os exames foram analisados por um mesm
o profissional. </font></p>     ^cY#aop02911.htm##
01266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704102300084002001301107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#36#32#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">Os intervalos AH, H, HV e V 
foram avaliados em condi&ccedil;&otilde;es basais durante o EEF. O tempo de recu
pera&ccedil;&atilde;o do n&oacute; sinusal (TRNS), o TRNS corrigido sob tr&ecirc
;s ciclos de frequ&ecirc;ncias de estimula&ccedil;&atilde;o (600, 500 e 400 ms),
 o ponto de Wenckebach (PW) e o per&iacute;odo refrat&aacute;rio efetivo do n&oa
cute; AV (PRNAV) foram avaliados sob estimula&ccedil;&atilde;o atrial programada
. A condu&ccedil;&atilde;o ventr&iacute;culo-atrial, o per&iacute;odo refrat&aac
ute;rio efetivo e a indu&ccedil;&atilde;o de taquiarritmias foram analisados pel
a estimula&ccedil;&atilde;o ventricular programada do &aacute;pice e da via de s
a&iacute;da do VD com at&eacute; tr&ecirc;s extraest&iacute;mulos acoplados a ca
da ciclo de frequ&ecirc;ncia de 600, 500 e 400 ms. As medidas dos par&acirc;metr
os eletrofisiol&oacute;gicos foram realizadas na velocidade de registro de 200 m
m/s para maior precis&atilde;o. </font></p>     ^cY#aop02911.htm##
00585000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704034200084002001300426#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#37#33#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise estat&iacut
e;stica foi realizada pelo software SPSS for Windows vers&atilde;o 13.0. Para a 
an&aacute;lise dos dados qualitativos foram feitas as distribui&ccedil;&otilde;e
s de frequ&ecirc;ncia na forma de m&eacute;dia ± desvio-padr&atilde;o. </font></
p>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#38#34#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00343000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704010000084002001300184#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#39#35#article#99#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p>
     ^cY#aop02911.htm##
01517000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704127400084002001301358#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#40#36#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">As caracter&iacute;sticas da
 popula&ccedil;&atilde;o e as altera&ccedil;&otilde;es nos principais exames (EC
G, ECO e Holter) est&atilde;o apresentadas na <a href="/img/revistas/abc/2011nah
ead/aop02911tab01m.jpg">Tabela 1</a>. Nenhum paciente apresentava qualquer manif
esta&ccedil;&atilde;o de taquicardia parox&iacute;stica, pr&eacute;-s&iacute;nco
pe ou s&iacute;ncope antes do estudo. Todos apresentavam sarcoidose pulmonar nos
 est&aacute;gios da classifica&ccedil;&atilde;o radiol&oacute;gica de <i>Scaddin
g</i> 0, 1, 2, 3 e 4 (4,5%, 18,2%, 31,8%, 36,4% e 9,1%, respectivamente). O diag
n&oacute;stico de sarcoidose card&iacute;aca foi confirmado em 4 (18,2%) por cin
tilografia com g&aacute;lio (Ga-67), tomografia por emiss&atilde;o de p&oacute;s
itron (PET) ou resson&acirc;ncia nuclear magn&eacute;tica (RNM). A presen&ccedil
;a de granuloma n&atilde;o caseoso t&iacute;pico da sarcoidose em bi&oacute;psia
 de g&acirc;nglio linf&aacute;tico e capta&ccedil;&atilde;o an&ocirc;mala no PET
 em cora&ccedil;&atilde;o e outros &oacute;rg&atilde;os num paciente com diagn&o
acute;stico confirmado SC s&atilde;o ilustrados na <a href="/img/revistas/abc/20
11nahead/aop02911fig01m.jpg">Figura 1</a>. </font></p>     ^cY#aop02911.htm##
00630000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704038700084002001300471#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#41#37#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">No Holter as principais alte
ra&ccedil;&otilde;es foram a presen&ccedil;a de EV e predom&iacute;nio do tono s
imp&aacute;tico na VFC. Todos os quatro pacientes com sarcoidose card&iacute;aca
 apresentaram EV com densidade &gt; 100/24h. Houve predom&iacute;nio do tono sim
p&aacute;tico em 3 (75%) pacientes. </font></p>     ^cY#aop02911.htm##
00695000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704045200084002001300536#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#42#38#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">As altera&ccedil;&otilde;es 
mais relevantes observadas no EEF foram anormalidades fun&ccedil;&atilde;o do n&
oacute; AV e no intervalo HV, PW, PRNAV e indu&ccedil;&atilde;o de fibrila&ccedi
l;&atilde;o atrial em n&uacute;mero consider&aacute;vel de pacientes. As princip
ais altera&ccedil;&otilde;es encontradas est&atilde;o representadas na <a href="
#tab2">Tabela 2</a>. </font></p>     ^cY#aop02911.htm##
00278000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704003500084002001300119#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#43#39#article#99#<p><a name=
"tab2"></a></p>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#44#40#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00332000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704008900084002001300173#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#45#41#article#99#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop02911tab02.jpg"></p>     ^cY#ao
p02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#46#42#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
02308000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704206500084002001302149#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#47#43#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"> Taquicardia ventricular sus
tentada monom&oacute;rfica (TVSM), inst&aacute;vel, foi induzida em um &uacute;n
ico paciente sem diagn&oacute;stico confirmado de envolvimento card&iacute;aco. 
Dentre os quatro pacientes com diagn&oacute;stico de sarcoidose card&iacute;aca,
 a de  n&uacute;mero #, com 60 anos de idade portadora de HAS e DM, tinha cansa&
ccedil;o e palpita&ccedil;&otilde;es. Seu ECG mostrava bloqueio completo do ramo
 esquerdo, Holter com 1.707 EV em 24h e fra&ccedil;&atilde;o de eje&ccedil;&atil
de;o de 65%, com disfun&ccedil;&atilde;o dist&oacute;lica de VE. Outro paciente 
(n&uacute;mero #), com 46 anos de idade, masculino, tamb&eacute;m apresentava ca
nsa&ccedil;o e palpita&ccedil;&otilde;es, tinha ECG com &Acirc;QRS para esquerda
, ecocardiograma com FE 69% e Holter com 17.781 EV/24h. O terceiro paciente (num
ero #), tamb&eacute;m masculino, de 54 anos, apresentava sintomas de cansa&ccedi
l;o f&iacute;sico, ECG normal e ecocardiograma com FE 62%, com hipertrofia ventr
icular esquerda e disfun&ccedil;&atilde;o diast&oacute;lica e Holter com 27.572 
EV/24h e per&iacute;odos de TVNS. E por fim, o quarto paciente (numero #), 80 an
os, portadora de HAS, apresentava sintomas de cansa&ccedil;o, ECG com bloqueio d
ivisional anterossuperior, ecocardiograma com FE de 69% com hipertrofia ventricu
lar esquerda e disfun&ccedil;&atilde;o diast&oacute;lica e Holter com 1010 EV/24
h e TVNS. Durante seguimento m&eacute;dio de 20,9 ± 15,7 meses um paciente    (n
&uacute;mero #) (4,5%) portador de SC apresentou MS. Esse paciente havia apresen
tado manifesta&ccedil;&atilde;o de insufici&ecirc;ncia card&iacute;aca, controla
da com medica&ccedil;&atilde;o habitual. Quatro pacientes (tr&ecirc;s com SC) fo
ram submetidos a novo EEF por apresentarem piora dos sintomas de palpita&ccedil;
&atilde;o e aumento da densidade de EV ao Holter. Os EEFs n&atilde;o apresentara
m  altera&ccedil;&otilde;es significativas quando comparados aos anteriores e o 
tratamento n&atilde;o modificado. </font></p>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#48#44#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704010700084002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#49#45#article#99#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o </b></fo
nt></p>     ^cY#aop02911.htm##
01580000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704133700084002001301421#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#50#46#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo tem a orig
inalidade em dar &ecirc;nfase &agrave; investiga&ccedil;&atilde;o eletrofisiol&o
acute;gica de pacientes com diagn&oacute;stico de sarcoidose e suspeita de compr
ometimento card&iacute;aco, ainda n&atilde;o recebendo tratamento padr&atilde;o.
 Observou-se uma elevada incid&ecirc;ncia de altera&ccedil;&otilde;es nas propri
edades eletrofisiol&oacute;gicas (68,2% dos pacientes), como comprometimento da 
fun&ccedil;&atilde;o do n&oacute; AV, aumento do intervalo HV e instabilidade el
&eacute;trica atrial &agrave; estimula&ccedil;&atilde;o card&iacute;aca, indepen
dente da confirma&ccedil;&atilde;o do envolvimento card&iacute;aco pela sarcoido
se. Considerando-se que o diagn&oacute;stico de envolvimento card&iacute;aco &ea
cute; muito dif&iacute;cil pela limitada sensibilidade e especificidade dos exam
es diagn&oacute;sticos, habitualmente reveste-se de um diagn&oacute;stico de exc
lus&atilde;o, notadamente pela aus&ecirc;ncia de um marcador biol&oacute;gico es
pec&iacute;fico. A bi&oacute;psia endomioc&aacute;rdica, considerada "padr&atild
e;o-ouro", tamb&eacute;m apresenta baixa sensibilidade por ser uma doen&ccedil;a
 granulomatosa que acomete predominantemente a regi&atilde;o basal e ponta do ve
ntr&iacute;culo esquerdo. </font></p>     ^cY#aop02911.htm##
01345000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704110200084002001301186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#51#47#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">A estratifica&ccedil;&atilde
;o de risco para MS &eacute; uma quest&atilde;o importante em pacientes com sarc
oidose, dado o seu car&aacute;ter catastr&oacute;fico e imprevis&iacute;vel. H&a
acute; uma infinidade de m&eacute;todos como Holter 24h, variabilidade da frequ&
ecirc;ncia card&iacute;aca, ECG de alta resolu&ccedil;&atilde;o, dispers&atilde;
o de QT, microaltern&acirc;ncia de onda T, EEF, que tentam predizer a ocorr&ecir
c;ncia de MS, entretanto, o valor desses m&eacute;todos ainda &eacute; muito que
stionado em pacientes com sarcoidose. A presen&ccedil;a EV no Holter com densida
de &gt; 100/dia (12.017,7 ± 10.540,56) ocorreu nos 4 pacientes com envolvimento 
card&iacute;aco documentado, em concord&acirc;ncia com as observa&ccedil;&otilde
;es de Suzuki e cols. <sup>15</sup>. Esse autor em estudo envolvendo 38 paciente
s sugeriu que a presen&ccedil;a de EV com densidade &gt; 100/dia seria um fator 
preditor de envolvimento card&iacute;aco pela sarcoidose com uma sensibilidade d
e 67% e especificidade de 80%. </font></p>     ^cY#aop02911.htm##
01181000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704093800084002001301022#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#52#48#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">O papel do EEF na avalia&cce
dil;&atilde;o de pacientes com sarcoidose, apesar de ainda n&atilde;o bem defini
da, estaria na avalia&ccedil;&atilde;o do sistema de condu&ccedil;&atilde;o, dad
a a alta preval&ecirc;ncia de infiltra&ccedil;&atilde;o granulomatosa nesse teci
do, com taxas de MS por bloqueio AV total de at&eacute; 40%<sup>8</sup>. Em noss
a casu&iacute;stica altera&ccedil;&otilde;es no sistema de condu&ccedil;&atilde;
o foram encontradas em dois (50%) dos quatro pacientes com envolvimento card&iac
ute;aco. Por outro lado, altera&ccedil;&otilde;es eletrofisiol&oacute;gicas fora
m tamb&eacute;m encontradas em uma porcentagem significativa de pacientes sem en
volvimento card&iacute;aco, que pode corroborar o conceito de que possa haver fi
brose mioc&aacute;rdica latente antes do diagn&oacute;stico de sarcoidose card&i
acute;aca<sup>16-18</sup>. </font></p>     ^cY#aop02911.htm##
01736000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704149300084002001301577#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#53#49#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">A indu&ccedil;&atilde;o de T
V monom&oacute;rfica tem sido valorizada como um preditor de risco de MS em paci
entes com cardiopatia isqu&ecirc;mica, mas seu valor &eacute; discut&iacute;vel 
em pacientes com cardiopatias n&atilde;o isqu&ecirc;micas. Yasaki e cols. <sup>1
9</sup>, observaram que a classe funcional de NYHA, o di&acirc;metro diast&oacut
e;lico do VE e a presen&ccedil;a de TVS foram importantes fatores independentes 
de mortalidade em pacientes com sarcoidose card&iacute;aca. Em nossa popula&cced
il;&atilde;o, apenas um paciente sem o diagn&oacute;stico definitivo de envolvim
ento card&iacute;aco teve TVS induzida. Apresentava boa fun&ccedil;&atilde;o ven
tricular (ECO = 67%) e permanecia com sintomas leves e palpita&ccedil;&otilde;es
 at&eacute; o fechamento desse trabalho, recebendo somente corticoide como terap
&ecirc;utica medicamentosa. A evolu&ccedil;&atilde;o dos pacientes com diagn&oac
ute;stico sarcoidose card&iacute;aca foi boa, n&atilde;o diferindo dos demais, e
xceto pela maior dose de corticode, e/ou uso de outros medicamentos. Por&eacute;
m, um paciente com SC teve MS, embora tenha sido submetida a um segundo EEF sem 
evidenciar indu&ccedil;&atilde;o de taquiarritmias ou altera&ccedil;&otilde;es e
xpressivas no sistema de condu&ccedil;&atilde;o, sugerindo que a avalia&ccedil;&
atilde;o eletrofisiol&oacute;gica n&atilde;o teve papel preponderante como predi
tor de risco para MS. </font></p>     ^cY#aop02911.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#54#50#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Limita&ccedil;&otilde;es 
do estudo</b></font></p>     ^cY#aop02911.htm##
00996000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704075300084002001300837#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#55#51#article#99#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">As principais limita&ccedil;
&otilde;es desse estudo foram a pequena casu&iacute;stica e as dificuldades enco
ntradas na investiga&ccedil;&atilde;o diagn&oacute;stica completa de todos os pa
cientes. A literatura mundial preconiza a utiliza&ccedil;&atilde;o de exames com
o RNM e PET quando h&aacute; d&uacute;vida no diagn&oacute;stico, o que n&atilde
;o foi poss&iacute;vel realizar em todos os pacientes. O curto seguimento n&atil
de;o nos permitiu avaliar adequadamente os fatores de risco para MS e a presen&c
cedil;a de HAS e DM tamb&eacute;m podem ter causado dificuldades na interpreta&c
cedil;&atilde;o das altera&ccedil;&otilde;es encontradas nos pacientes estudados
. </font></p>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#56#52#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704010700084002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#57#53#article#99#<p><font si
ze="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></fo
nt></p>     ^cY#aop02911.htm##
00418000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704016100086002001300247#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#58#54#article#99
#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Iannuzzi MC
, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153-65.    
^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#59#55#article#99# </font></p
>     ^cY#aop02911.htm##
00409000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704015200086002001300238#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#60#56#article#99
#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Baughman RP
, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361(9363):1111-8.    ^cY#aop02
911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#61#57#article#99# </font></p
>     ^cY#aop02911.htm##
00450000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704019300086002001300279#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#62#58#article#99
#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Thomas PD, 
Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Resp
ir Dis. 1987;135 (3):747-60.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#63#59#article#99# </font></p
>     ^cY#aop02911.htm##
00464000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704020700086002001300293#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#64#60#article#99
#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Bernstein M
, Konzelmann FW, Sidlick DM. Boeck's sarcoid: report of a case with visceral inv
olvement. Arch Intern Med. 1929;44:721-34.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#65#61#article#99# </font></p
>     ^cY#aop02911.htm##
00558000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704030100086002001300387#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#66#62#article#99
#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> 5. Longcope W
T, Freiman DG. A study of sarcoidosis: based on a combined investigation of 160 
cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts G
eneral Hospital. Medicine (Baltimore). 1952;31(1):1-132.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#67#63#article#99# </font></p
>     ^cY#aop02911.htm##
00499000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704024200086002001300328#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#68#64#article#99
#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Silverman K
J, Hutchins GM, Bulckley BH. Cardiac sarcoid: a clinicopathologic study of 84 un
selected patients with systemic sarcoidosis. Circulation. 1978;58(6):1204-11.   
 ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#69#65#article#99# </font></p
>     ^cY#aop02911.htm##
00416000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704015900086002001300245#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#70#66#article#99
#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Sharma OP, 
Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993; 103(1):253-8.    ^c
Y#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#71#67#article#99# </font></p
>     ^cY#aop02911.htm##
00555000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704029800086002001300384#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#72#68#article#99
#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Roberts WC,
 McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart: a clinicopathologic stu
dy of 35 necropsy patients (group I) and review of 78 previously described necro
psy patients (group II). Am J Med. 1977;63(1):86-108.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#73#69#article#99# </font></p
>     ^cY#aop02911.htm##
00529000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000200084704027200086002001300358#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#74#70#article#99
#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Corrado D, 
Thiene G. Cardiac sarcoidosis mimicking arrhythmogenic right ventricular cardiom
yophaty/dysplasia: the renaissance of endomyocardial biopsy? J Cardiovasc Electr
ophysiol. 2009;20(5):477-9.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#75#71#article#99# </font></p
>     ^cY#aop02911.htm##
00485000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704022700087002001300314#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#76#72#article#99
#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Baughman 
RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis
 patients. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14(2):154-8.    ^cY#aop02911.
htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#77#73#article#99# </font></p
>     ^cY#aop02911.htm##
00418000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704016000087002001300247#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#78#74#article#99
#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Abeler V.
 Sarcoidosis of the cardiac conducting system. Am Heart J. 1979;97(6):701-7.    
^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#79#75#article#99# </font></p
>     ^cY#aop02911.htm##
00526000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704026800087002001300355#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#80#76#article#99
#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Furushima
 H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrh
ythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Car
diol. 2004;27(4):217-22.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#81#77#article#99# </font></p
>     ^cY#aop02911.htm##
00474000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704021600087002001300303#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#82#78#article#99
#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Pimenta J
, Miranda M, Pereira CB. Electrophysiologic findings in long-term asymptomatic c
hagasic individuals. Am Heart J. 1983;106(2):374-80.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#83#79#article#99# </font></p
>     ^cY#aop02911.htm##
00428000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704017000087002001300257#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#84#80#article#99
#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Scadding 
JG. Prognosis of intrathoracic sarcoidosis in England. Br Med J. 1961;2(5261):11
65-72.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#85#81#article#99# </font></p
>     ^cY#aop02911.htm##
00490000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704023200087002001300319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#86#82#article#99
#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Suzuki T,
 Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicat
or of cardiac involvement of sarcoidosis. Chest. 1994;106(4):1021-4.    ^cY#aop0
2911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#87#83#article#99# </font></p
>     ^cY#aop02911.htm##
00473000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704021500087002001300302#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#88#84#article#99
#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Gibbons W
J, Levy RD, Nava S, Malcolm I, Marin JM, Tardif C, et al. Subclinical cardiac dy
sfunction in sarcoidosis. Chest. 1991;100(1):44-50.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#89#85#article#99# </font></p
>     ^cY#aop02911.htm##
00503000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704024500087002001300332#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#90#86#article#99
#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Uslu N, A
kyol A, Gorgulu S, Eren M, Ocakli B, Celik S, et al. Heart rate variability in p
atients with systemic sarcoidosis. Ann Noninvas Electrocardiol. 2006;11(1):38-42
.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#91#87#article#99# </font></p
>     ^cY#aop02911.htm##
00537000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704027900087002001300366#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#92#88#article#99
#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Yodogawa 
K, Seino Y, Ohara T, Takayama H, Kobayashi Y, Katoh T, et al. Non-invasive detec
tion of latent cardiac conduction abnormalities in patients with pulmonary sarco
idosis. Circ Jap. 2007;71(4):540-5.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#93#89#article#99# </font></p
>     ^cY#aop02911.htm##
00553000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081888000300084704029500087002001300382#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#94#90#article#99
#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Yazaki Y,
 Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T, et al. Prognostic determin
ants of long-term survival in japanese patients with cardiac sarcoidosis treated
 with prednisone. Am J Cardiol. 2001;88(9):1006-10.    ^cY#aop02911.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002100084002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#95#91#article#99# </font></p
>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#96#92#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#97#93#article#99#<p>&nbsp;</
p>     ^cY#aop02911.htm##
00444000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704020100084002001300285#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#98#94#article#99#<p><a name=
"endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="
#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a> <b>Corre
spond&ecirc;ncia:</b>     ^cY#aop02911.htm##
00277000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000300081704003400084002001300118#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#99#95#article#99#<br>   Jeff
erson Curimbaba    ^cY#aop02911.htm##
00306000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000300082704006200085002001300147#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#100#96#article#99#<br>   Rua
 Jacaracanga, 157 - Apto 112 - Vila Formosa     ^cY#aop02911.htm##
00300000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000300082704005600085002001300141#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#101#97#article#99#<br>   033
58-140 - S&atilde;o Paulo, SP - Brasil    ^cY#aop02911.htm##
00403000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000300082704015900085002001300244#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#102#98#article#99#<br>   E-m
ail: <a href="mailto:jcurimbaba@cardiol.br">jcurimbaba@cardiol.br</a>, <a href="
mailto:jeffery@uol.com.br">jeffery@uol.com.br</a></font></p>     ^cY#aop02911.ht
m##
00408000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000300082704016400085002001300249#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop02911.htm#S#p#103#99#article#99#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"> Artigo recebido em 19/08/1
0; revisado recebido em 27/11/10; aceito em 08/12/10. </font></p>     ^cY#aop029
11.htm##
00548000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100018001050100
02000123012001600143030001300159065000900172064000500181031000400186032000300190
014000800193865000900201002001300210035001000223801001300233#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02911.htm#S#c#104#1#article#19#1#^rND^sIannuzz
i^nMC#^rND^sRybicki^nBA#^rND^sTeirstein^nAS#Sarcoidosis^len#N Engl J Med#2007000
0#2007#357#21#2153-65#20110000#aop02911.htm#0028-4793#N Engl J Med##
00533000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100016001050100
01800121012001600139030000700155065000900162064000500171031000400176032000500180
014000700185865000900192002001300201035001000214801000700224#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02911.htm#S#c#105#2#article#19#2#^rND^sBaughma
n^nRP#^rND^sLower^nEE#^rND^sdu Bois^nRM#Sarcoidosis^len#Lancet#20030000#2003#361
#9363#1111-8#20110000#aop02911.htm#0099-5355#Lancet##
00566000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100022001030120
05600125030001800181065000900199064000500208031000400213032000200217014000700219
865000900226002001300235035001000248801001800258#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02911.htm#S#c#106#3#article#19#3#^rND^sThomas^nPD#^rND^sHu
nninghake^nGW#Current concepts of the pathogenesis of sarcoidosis^len#Am Rev Res
pir Dis#19870000#1987#135#3#747-60#20110000#aop02911.htm#0003-0805#Am Rev Respir
 Dis##
00586000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100021001050100
01800126012006400144030001600208065000900224064000500233031000300238014000700241
865000900248002001300257035001000270801001600280#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02911.htm#S#c#107#4#article#19#4#^rND^sBernstein^nM#^rND^s
Konzelmann^nFW#^rND^sSidlick^nDM#Boeck's sarcoid: report of a case with visceral
 involvement^len#Arch Intern Med#19290000#1929#44#721-34#20110000#aop02911.htm#0
003-9926#Arch Intern Med##
00677000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100018001050120
16500123030002100288065000900309064000500318031000300323032000200326014000600328
865000900334002001300343035001000356801002100366#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02911.htm#S#c#108#5#article#19#5#^rND^sLongcope^nWT#^rND^s
Freiman^nDG#A study of sarcoidosis: based on a combined investigation of 160 cas
es including 30 autopsies from The Johns Hopkins Hospital and Massachusetts Gene
ral Hospital^len#Medicine (Baltimore)#19520000#1952#31#1#1-132#20110000#aop02911
.htm#0025-7974#Medicine (Baltimore)##
00628000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100020000860100019001060100
01900125012009900144030001200243065000900255064000500264031000300269032000200272
014000800274865000900282002001300291035001000304801001200314#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02911.htm#S#c#109#6#article#19#6#^rND^sSilverm
an^nKJ#^rND^sHutchins^nGM#^rND^sBulckley^nBH#Cardiac sarcoid: a clinicopathologi
c study of 84 unselected patients with systemic sarcoidosis^len#Circulation#1978
0000#1978#58#6#1204-11#20110000#aop02911.htm#0009-7322#Circulation##
00538000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100020001030100
01600123012002700139030000600166065000900172064000500181031000400186032000200190
014000600192865000900198002001300207035001000220801000600230#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02911.htm#S#c#110#7#article#19#7#^rND^sSharma^
nOP#^rND^sMaheshwari^nA#^rND^sThaker^nK#Myocardial sarcoidosis^len#Chest#1993000
0#1993#103#1#253-8#20110000#aop02911.htm#0012-3692#Chest##
00681000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100024001040100
01800128012015700146030000900303065000900312064000500321031000300326032000200329
014000700331865000900338002001300347035001000360801000900370#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02911.htm#S#c#111#8#article#19#8#^rND^sRoberts
^nWC#^rND^sMcAllister Jr^nHA#^rND^sFerrans^nVJ#Sarcoidosis of the heart: a clini
copathologic study of 35 necropsy patients (group I) and review of 78 previously
 described necropsy patients (group II)^len#Am J Med#19770000#1977#63#1#86-108#2
0110000#aop02911.htm#0002-9343#Am J Med##
00657000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100016001030120
13500119030002800254065000900282064000500291031000300296032000200299014000600301
865000900307002001300316035001000329801002800339#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop02911.htm#S#c#112#9#article#19#9#^rND^sCorrado^nD#^rND^sTh
iene^nG#Cardiac sarcoidosis mimicking arrhythmogenic right ventricular cardiomyo
phaty/dysplasia: the renaissance of endomyocardial biopsy?^len#J Cardiovasc Elec
trophysiol#20090000#2009#20#5#477-9#20110000#aop02911.htm#1045-3873#J Cardiovasc
 Electrophysiol##
00654000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100017001070100
01600124010001600140012005900156030003400215065000900249064000500258031000300263
032000200266014000600268865000900274002001300283035001000296801003400306#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#c#113#10#article#19#10
#^rND^sBaughman^nRP#^rND^sWinget^nDB#^rND^sBowen^nEH#^rND^sLower^nEE#Predicting 
respiratory failure in sarcoidosis patients^len#Sarcoidosis Vasc Diffuse Lung Di
s#19970000#1997#14#2#154-8#20110000#aop02911.htm#1124-0490#Sarcoidosis Vasc Diff
use Lung Dis##
00510000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880120049001040300
01100153065000900164064000500173031000300178032000200181014000600183865000900189
002001300198035001000211801001100221#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02911.htm#S#c#114#11#article#19#11#^rND^sAbeler^nV#Sarcoidosis of the 
cardiac conducting system^len#Am Heart J#19790000#1979#97#6#701-7#20110000#aop02
911.htm#0002-8703#Am Heart J##
00710000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01700125010001500142010001900157010001600176012009600192030001300288065000900301
06400050031003100030031503200020031801400070032086500090032700200130033603500100
0349801001300359#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#
S#c#115#12#article#19#12#^rND^sFurushima^nH#^rND^sChinushi^nM#^rND^sSugiura^nH#^
rND^sKasai^nH#^rND^sWashizuka^nT#^rND^sAizawa^nY#Ventricular tachyarrhythmia ass
ociated with cardiac sarcoidosis: its mechanisms and outcome^len#Clin Cardiol#20
040000#2004#27#4#217-22#20110000#aop02911.htm#0160-9289#Clin Cardiol##
00602000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01800122012007900140030001100219065000900230064000500239031000400244032000200248
014000700250865000900257002001300266035001000279801001100289#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop02911.htm#S#c#116#13#article#19#13#^rND^sPimen
ta^nJ#^rND^sMiranda^nM#^rND^sPereira^nCB#Electrophysiologic findings in long-ter
m asymptomatic chagasic individuals^len#Am Heart J#19830000#1983#106#2#374-80#20
110000#aop02911.htm#0002-8703#Am Heart J##
00518000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880120054001070300
00900161065000900170064000500179031000200184032000500186014000800191865000900199
002001300208035001000221801000900231#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop02911.htm#S#c#117#14#article#19#14#^rND^sScadding^nJG#Prognosis of int
rathoracic sarcoidosis in England^len#Br Med J#19610000#1961#2#5261#1165-72#2011
0000#aop02911.htm#0007-1447#Br Med J##
00649000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01600119010001400135010001600149012008700165030000600252065000900258064000500267
03100040027203200020027601400070027886500090028500200130029403500100030780100060
0317#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#S#c#118#15#a
rticle#19#15#^rND^sSuzuki^nT#^rND^sKanda^nT#^rND^sKubota^nS#^rND^sImai^nS#^rND^s
Murata^nK#Holter monitoring as a noninvasive indicator of cardiac involvement of
 sarcoidosis^len#Chest#19940000#1994#106#4#1021-4#20110000#aop02911.htm#0012-369
2#Chest##
00661000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01400121010001700135010001600152010001600168810000600184012005100190030000600241
06500090024706400050025603100040026103200020026501400060026786500090027300200130
0282035001000295801000600305#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02911.htm#S#c#119#16#article#19#16#^rND^sGibbons^nWJ#^rND^sLevy^nRD#^rND^sNava
^nS#^rND^sMalcolm^nI#^rND^sMarin^nJM#^rND^sTardif^nC#et al#Subclinical cardiac d
ysfunction in sarcoidosis^len#Chest#19910000#1991#100#1#44-50#20110000#aop02911.
htm#0012-3692#Chest##
00665000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100015001020100
01700117010001400134010001600148010001500164810000600179012006500185030002800250
71000020027806500090028006400050028903100030029403200020029701400060029986500090
0305002001300314#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#
S#c#120#17#article#19#17#^rND^sUslu^nN#^rND^sAkyol^nA#^rND^sGorgulu^nS#^rND^sEre
n^nM#^rND^sOcakli^nB#^rND^sCelik^nS#et al#Heart rate variability in patients wit
h systemic sarcoidosis^len#Ann Noninvas Electrocardiol#2#20060000#2006#11#1#38-4
2#20110000#aop02911.htm##
00699000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100015001060100
01500121010001800136010001900154010001500173810000600188012010900194030000900303
71000020031206500090031406400050032303100030032803200020033101400060033386500090
0339002001300348#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop02911.htm#
S#c#121#18#article#19#18#^rND^sYodogawa^nK#^rND^sSeino^nY#^rND^sOhara^nT#^rND^sT
akayama^nH#^rND^sKobayashi^nY#^rND^sKatoh^nT#et al#Non-invasive detection of lat
ent cardiac conduction abnormalities in patients with pulmonary sarcoidosis^len#
Circ Jap#2#20070000#2007#71#4#540-5#20110000#aop02911.htm##
00748000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100015001040100
01500119010001800134010001900152010001600171810000600187012012000193030001300313
06500090032606400050033503100030034003200020034301400080034586500090035300200130
0362035001000375801001300385#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op02911.htm#S#c#122#19#article#19#19#^rND^sYazaki^nY#^rND^sIsobe^nM#^rND^sHiroe^
nM#^rND^sMorimoto^nS#^rND^sHiramitsu^nS#^rND^sNakano^nT#et al#Prognostic determi
nants of long-term survival in japanese patients with cardiac sarcoidosis treate
d with prednisone^len#Am J Cardiol#20010000#2001#88#9#1006-10#20110000#aop02911.
htm#0002-9149#Am J Cardiol##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#o#1#1#a
rticle#1#20110411#104654#aop3511.htm#157##
04799000000000649000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201200920017101200870
02630100040003500100035003900100033004250700059004580831671005170850008021880850
02202196085004002218085002902258085002602287085002402313083158102337085000803918
08500230392608500390394908500260398808500330401408500250404711700080407207200030
40801120009040831110009040921160009041011150009041101140009041191130009041280020
01204137#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#h#2#1#a
rticle#1#tr#pt#br1.1#1#4.0#ND#42#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0
#0066-782X#20110415#Quantificação da dilatação ventricular esquerda na cintilogr
afia miocárdica perfusional^lpt#Quantification of left ventricular dilatation in
 myocardial perfusion scintigraphy^len#^rND^1A01^nMauren B. Azambuja^sGonzalez#^
rND^1A01^nRoberto Alves^sAzambuja#^rND^1A01^nLuiz Carlos^sBodanese#PUCRS^iA01^1H
ospital São Lucas^cRio de Janeiro^sRJ^pBrasil#^lpt^aFUNDAMENTO: O índice de dila
tação transitória pode ser determinado através de teste ergométrico ou estresse 
farmacológico. Desconhece-se se o tipo de estresse tem impacto sobre os valores 
médios do índice de dilatação transitória. OBJETIVO: Comparar os valores médios 
do índice de dilatação transitória na cintilografia com 99mTc-sestamibi, em paci
entes submetidos a teste ergométrico em esteira, versus estresse com dipiridamol
. O objetivo secundário foi avaliar o impacto sobre o valor médio do índice exer
cido pelas características demográficas, pelos fatores de risco para doença arte
rial coronariana e a gravidade da isquemia. MÉTODOS: O estudo transversal inclui
u 200 pacientes, entre 40 e 70 anos, portadores ou não de fatores de risco para 
cardiopatia isquêmica, com ou sem diagnóstico prévio de cardiopatia isquêmica. A
 separação entre grupos foi sequencial. O software 4D-MSPECT calculou o índice d
e dilatação transitória e forneceu um sistema de escores para análise da perfusã
o. RESULTADOS: O valor do índice de dilatação transitória médio do grupo submeti
do a teste ergométrico foi de 1,06 (±0,23). O do grupo submetido ao estresse com
 dipiridamol foi de 1,10 (±0,22);(p = 0,200). Não houve associação entre o tipo 
de estresse e os valores médios do índice de dilatação transitória. Encontrou-se
 associação entre os valores médios do índice e a faixa etária somente para os p
acientes do grupo do teste ergométrico (p = 0,009). CONCLUSÃO: Os resultados do 
nosso estudo demonstram que o índice de dilatação transitória não difere quando 
os pacientes são submetidos a estresse pelo teste ergométrico em esteira ou estr
esse farmacológico pelo dipiridamol.#^dnd^i1#^tm^lpt^kDilatação^i1#^tm^lpt^kfunç
ão ventricular esquerda^i1#^tm^lpt^kteste de esforço^i1#^tm^lpt^kcintilografia^i
1#^tm^lpt^kdipiridamol^i1#^len^aBACKGROUND: The rate of transient dilatation can
 be determined by exercise testing or pharmacological stress test. It is unknown
 whether the type of stress has an impact on average transient dilatation index 
values. OBJECTIVE: To compare average transient dilation index values in 99mTc-s
estamibi scintigraphy in patients undergoing treadmill stress test, versus dipyr
idamole stress test. The secondary purpose was to evaluate the impact on the ave
rage index value by demographic characteristics, risk factors for coronary arter
y disease and severity of ischemia. METHODS: The cross-sectional study included 
200 patients between 40 and 70 years old, with or without risk factors for ische
mic heart disease, with or without a previous diagnosis of ischemic heart diseas
e. The separation between groups was sequential. The software 4D-MSPECT calculat
ed the transient dilatation index and provided a scoring system for perfusion an
alysis. RESULTS: The average transient dilation index value of the group undergo
ing exercise stress test was 1.06 (±0.23). For the group undergoing the dipyrida
mole stress test, it was 1.10 (±0.22); (p = 0.200). There was no association bet
ween the type of stress and the average transient dilatation index values. An as
sociation was found between the average index values and age only for those pati
ents from the exercise test group (p = 0.009). CONCLUSION: The results of our st
udy demonstrate that the transient dilation index does not differ when patients 
undergo exercise stress test on a treadmill or pharmacological stress by dipyrid
amole.#^dnd^i2#^tm^len^kDilatation^i2#^tm^len^kventricular function, left^i2#^tm
^len^kexercise test^i2#^tm^len^kradionuclide imaging^i2#^tm^len^kdipyridamole^i2
#vancouv#19#20100623#23/06/10#20101024#24/10/10#20110111#11/01/11#aop3511.htm##
04904000000000649000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201200990017101200940
02700100040003640100035004040100033004390700059004720831720005310850008022510850
02202259085004002281085002902321085002602350085002402376083162302400085000804023
08500230403108500390405408500260409308500330411908500250415211700080417707200030
41851120009041881110009041971160009042061150009042151140009042241130009042330020
01204242#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#f#3#1#a
rticle#1#tr#pt#br1.1#1#4.0#ND#42#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0
#0066-782X#20110415#<b>Quantificação da dilatação ventricular esquerda na cintil
ografia miocárdica perfusional</b>^lpt#<b>Quantification of left ventricular dil
atation in myocardial perfusion scintigraphy</b>^len#^rND^1A01^nMauren B. Azambu
ja^sGonzalez#^rND^1A01^nRoberto Alves^sAzambuja#^rND^1A01^nLuiz Carlos^sBodanese
#PUCRS^iA01^1Hospital São Lucas^cRio de Janeiro^sRJ^pBrasil#^lpt^a<b>FUNDAMENTO:
</b> O índice de dilatação transitória pode ser determinado através de teste erg
ométrico ou estresse farmacológico. Desconhece-se se o tipo de estresse tem impa
cto sobre os valores médios do índice de dilatação transitória. <b>OBJETIVO:</b>
 Comparar os valores médios do índice de dilatação transitória na cintilografia 
com 99mTc-sestamibi, em pacientes submetidos a teste ergométrico em esteira, <i>
versus</i> estresse com dipiridamol. O objetivo secundário foi avaliar o impacto
 sobre o valor médio do índice exercido pelas características demográficas, pelo
s fatores de risco para doença arterial coronariana e a gravidade da isquemia. <
b>MÉTODOS:</b> O estudo transversal incluiu 200 pacientes, entre 40 e 70 anos, p
ortadores ou não de fatores de risco para cardiopatia isquêmica, com ou sem diag
nóstico prévio de cardiopatia isquêmica. A separação entre grupos foi sequencial
. O <i>software</i> 4D-MSPECT calculou o índice de dilatação transitória e forne
ceu um sistema de escores para análise da perfusão. <b>RESULTADOS:</b> O valor d
o índice de dilatação transitória médio do grupo submetido a teste ergométrico f
oi de 1,06 (±0,23). O do grupo submetido ao estresse com dipiridamol foi de 1,10
 (±0,22);(p = 0,200). Não houve associação entre o tipo de estresse e os valores
 médios do índice de dilatação transitória. Encontrou-se associação entre os val
ores médios do índice e a faixa etária somente para os pacientes do grupo do tes
te ergométrico (p = 0,009). <b>CONCLUSÃO:</b> Os resultados do nosso estudo demo
nstram que o índice de dilatação transitória não difere quando os pacientes são 
submetidos a estresse pelo teste ergométrico em esteira ou estresse farmacológic
o pelo dipiridamol.#^dnd^i1#^tm^lpt^kDilatação^i1#^tm^lpt^kfunção ventricular es
querda^i1#^tm^lpt^kteste de esforço^i1#^tm^lpt^kcintilografia^i1#^tm^lpt^kdipiri
damol^i1#^len^a<b>BACKGROUND:</b> The rate of transient dilatation can be determ
ined by exercise testing or pharmacological stress test. It is unknown whether t
he type of stress has an impact on average transient dilatation index values. <b
>OBJECTIVE:</b> To compare average transient dilation index values in 99mTc-sest
amibi scintigraphy in patients undergoing treadmill stress test, <i>versus</i> d
ipyridamole stress test. The secondary purpose was to evaluate the impact on the
 average index value by demographic characteristics, risk factors for coronary a
rtery disease and severity of ischemia. <b>METHODS:</b> The cross-sectional stud
y included 200 patients between 40 and 70 years old, with or without risk factor
s for ischemic heart disease, with or without a previous diagnosis of ischemic h
eart disease. The separation between groups was sequential. The software 4D-MSPE
CT calculated the transient dilatation index and provided a scoring system for p
erfusion analysis. <b>RESULTS:</b> The average transient dilation index value of
 the group undergoing exercise stress test was 1.06 (±0.23). For the group under
going the dipyridamole stress test, it was 1.10 (±0.22); (p = 0.200). There was 
no association between the type of stress and the average transient dilatation i
ndex values. An association was found between the average index values and age o
nly for those patients from the exercise test group (p = 0.009). <b>CONCLUSION:<
/b> The results of our study demonstrate that the transient dilation index does 
not differ when patients undergo exercise stress test on a treadmill or pharmaco
logical stress by dipyridamole.#^dnd^i2#^tm^len^kDilatation^i2#^tm^len^kventricu
lar function, left^i2#^tm^len^kexercise test^i2#^tm^len^kradionuclide imaging^i2
#^tm^len^kdipyridamole^i2#vancouv#19#20100623#23/06/10#20101024#24/10/10#2011011
1#11/01/11#aop3511.htm##
04905000000000661000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030001900114
03200060013306500090013901400070014803500100015522300090016501200920017401200870
02660100040003530100035003930100033004280700061004610831671005220850008021930850
02202201085004002223085002902263085002602292085002402318083158102342085000803923
08500230393108500390395408500260399308500330401908500250405211700080407707200030
40851120009040881110009040971160009041061150009041151140009041241130009041330020
01204142008008904154#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.h
tm#S#l#4#1#article#1#^a2011#tr#pt#br1.1#1#4.0#42#nd#nd#Arq. bras. cardiol#ahead#
20110000#^f0^l0#0066-782X#20110415#Quantificação da dilatação ventricular esquer
da na cintilografia miocárdica perfusional^lpt#Quantification of left ventricula
r dilatation in myocardial perfusion scintigraphy^len#^rND^1A01^nMauren B. Azamb
uja^sGonzalez#^rND^1A01^nRoberto Alves^sAzambuja#^rND^1A01^nLuiz Carlos^sBodanes
e#^iA01^1PUCRS^2Hospital São Lucas^cRio de Janeiro^sRJ^pBrasil#^lpt^aFUNDAMENTO:
 O índice de dilatação transitória pode ser determinado através de teste ergomét
rico ou estresse farmacológico. Desconhece-se se o tipo de estresse tem impacto 
sobre os valores médios do índice de dilatação transitória. OBJETIVO: Comparar o
s valores médios do índice de dilatação transitória na cintilografia com 99mTc-s
estamibi, em pacientes submetidos a teste ergométrico em esteira, versus estress
e com dipiridamol. O objetivo secundário foi avaliar o impacto sobre o valor méd
io do índice exercido pelas características demográficas, pelos fatores de risco
 para doença arterial coronariana e a gravidade da isquemia. MÉTODOS: O estudo t
ransversal incluiu 200 pacientes, entre 40 e 70 anos, portadores ou não de fator
es de risco para cardiopatia isquêmica, com ou sem diagnóstico prévio de cardiop
atia isquêmica. A separação entre grupos foi sequencial. O software 4D-MSPECT ca
lculou o índice de dilatação transitória e forneceu um sistema de escores para a
nálise da perfusão. RESULTADOS: O valor do índice de dilatação transitória médio
 do grupo submetido a teste ergométrico foi de 1,06 (±0,23). O do grupo submetid
o ao estresse com dipiridamol foi de 1,10 (±0,22);(p = 0,200). Não houve associa
ção entre o tipo de estresse e os valores médios do índice de dilatação transitó
ria. Encontrou-se associação entre os valores médios do índice e a faixa etária 
somente para os pacientes do grupo do teste ergométrico (p = 0,009). CONCLUSÃO: 
Os resultados do nosso estudo demonstram que o índice de dilatação transitória n
ão difere quando os pacientes são submetidos a estresse pelo teste ergométrico e
m esteira ou estresse farmacológico pelo dipiridamol.#^dnd^i1#^tm^lpt^kDilatação
^i1#^tm^lpt^kfunção ventricular esquerda^i1#^tm^lpt^kteste de esforço^i1#^tm^lpt
^kcintilografia^i1#^tm^lpt^kdipiridamol^i1#^len^aBACKGROUND: The rate of transie
nt dilatation can be determined by exercise testing or pharmacological stress te
st. It is unknown whether the type of stress has an impact on average transient 
dilatation index values. OBJECTIVE: To compare average transient dilation index 
values in 99mTc-sestamibi scintigraphy in patients undergoing treadmill stress t
est, versus dipyridamole stress test. The secondary purpose was to evaluate the 
impact on the average index value by demographic characteristics, risk factors f
or coronary artery disease and severity of ischemia. METHODS: The cross-sectiona
l study included 200 patients between 40 and 70 years old, with or without risk 
factors for ischemic heart disease, with or without a previous diagnosis of isch
emic heart disease. The separation between groups was sequential. The software 4
D-MSPECT calculated the transient dilatation index and provided a scoring system
 for perfusion analysis. RESULTS: The average transient dilation index value of 
the group undergoing exercise stress test was 1.06 (±0.23). For the group underg
oing the dipyridamole stress test, it was 1.10 (±0.22); (p = 0.200). There was n
o association between the type of stress and the average transient dilatation in
dex values. An association was found between the average index values and age on
ly for those patients from the exercise test group (p = 0.009). CONCLUSION: The 
results of our study demonstrate that the transient dilation index does not diff
er when patients undergo exercise stress test on a treadmill or pharmacological 
stress by dipyridamole.#^dnd^i2#^tm^len^kDilatation^i2#^tm^len^kventricular func
tion, left^i2#^tm^len^kexercise test^i2#^tm^len^kradionuclide imaging^i2#^tm^len
^kdipyridamole^i2#vancouv#19#20100623#23/06/10#20101024#24/10/10#20110111#11/01/
11#aop3511.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=
S0066-782X2011005000042##
00454000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704021400082002001200296#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#5#1#article#134#<p><font size
="4" face="verdana"><b><a name="title"></a>Quantifica&ccedil;&atilde;o       da 
dilata&ccedil;&atilde;o ventricular esquerda na cintilografia mioc&aacute;rdica 
      perfusional</b></font></p>     ^cY#aop3511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#6#2#article#134#<p>&nbsp;</p>
     ^cY#aop3511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#7#3#article#134#<p>&nbsp;</p>
     ^cY#aop3511.htm##
00379000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704013900082002001200221#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#8#4#article#134#<p><font size
="2" face="Verdana"><b>Mauren B. Azambuja Gonzalez; Roberto Alves       Azambuja
; Luiz Carlos Bodanese</b></font></p>     ^cY#aop3511.htm##
00669000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704042900082002001200511#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#9#5#article#134#<p><font size
="2" face="Verdana"> Servi&ccedil;o de Cardiologia do Hospital S&atilde;o     Lu
cas da PUCRS; Programa de P&oacute;s&#45;Gradua&ccedil;&atilde;o em Medicina    
 e Ci&ecirc;ncias da Sa&uacute;de &#45; Cl&iacute;nica M&eacute;dica da Pontif&i
acute;cia     Universidade Cat&oacute;lica do Rio Grande do Sul, Porto Alegre, R
S; Hospital     S&atilde;o Vicente de Paulo, Rio de Janeiro, RJ &#45; Brasil</fo
nt></p>     ^cY#aop3511.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704009300083002001200176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#10#6#article#134#<p><font siz
e="2" face="Verdana"><a href="#end">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop3511.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704002200083002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#11#7#article#134#<p>&nbsp;</p
>     ^cY#aop3511.htm##
00285000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704004400083002001200127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#12#8#article#134#<p>&nbsp;</p
> <hr size="1" noshade>     ^cY#aop3511.htm##
00307000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704006600083002001200149#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#13#9#article#134#<p><font siz
e="2" face="VERDANA"><b>RESUMO</b></font></p>     ^cY#aop3511.htm##
00624000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038200084002001200466#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#14#10#article#134#<p><font si
ze="2" face="Verdana"><b>FUNDAMENTO:</b> O &iacute;ndice de dilata&ccedil;&atild
e;o     transit&oacute;ria pode ser determinado atrav&eacute;s de teste ergom&ea
cute;trico     ou estresse farmacol&oacute;gico. Desconhece&#45;se se o tipo de 
estresse tem     impacto sobre os valores m&eacute;dios do &iacute;ndice de dila
ta&ccedil;&atilde;o     transit&oacute;ria.    ^cY#aop3511.htm##
00771000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052900084002001200613#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#15#11#article#134#<br>   <b>O
BJETIVO:</b> Comparar os valores m&eacute;dios do &iacute;ndice de dilata&ccedil
;&atilde;o   transit&oacute;ria na cintilografia com 99mTc&#45;sestamibi, em pac
ientes submetidos   a teste ergom&eacute;trico em esteira, <I>versus</I> estress
e com dipiridamol.   O objetivo secund&aacute;rio foi avaliar o impacto sobre o 
valor m&eacute;dio   do &iacute;ndice exercido pelas caracter&iacute;sticas demo
gr&aacute;ficas,   pelos fatores de risco para doen&ccedil;a arterial coronarian
a e a gravidade   da isquemia.    ^cY#aop3511.htm##
00739000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049700084002001200581#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#16#12#article#134#<br>   <b>M
&Eacute;TODOS:</b> O estudo transversal incluiu 200 pacientes, entre 40   e 70 a
nos, portadores ou n&atilde;o de fatores de risco para cardiopatia isqu&ecirc;mi
ca,   com ou sem diagn&oacute;stico pr&eacute;vio de cardiopatia isqu&ecirc;mica
.   A separa&ccedil;&atilde;o entre grupos foi sequencial. O <I>software</I> 4D&
#45;MSPECT   calculou o &iacute;ndice de dilata&ccedil;&atilde;o transit&oacute;
ria e forneceu   um sistema de escores para an&aacute;lise da perfus&atilde;o.  
  ^cY#aop3511.htm##
00884000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064200084002001200726#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#17#13#article#134#<br>   <b>R
ESULTADOS:</b> O valor do &iacute;ndice de dilata&ccedil;&atilde;o transit&oacut
e;ria   m&eacute;dio do grupo submetido a teste ergom&eacute;trico foi de 1,06 (
&plusmn;0,23).   O do grupo submetido ao estresse com dipiridamol foi de 1,10 (&
plusmn;0,22);(p = 0,200).   N&atilde;o houve associa&ccedil;&atilde;o entre o ti
po de estresse e os valores   m&eacute;dios do &iacute;ndice de dilata&ccedil;&a
tilde;o transit&oacute;ria.   Encontrou&#45;se associa&ccedil;&atilde;o entre os
 valores m&eacute;dios do &iacute;ndice   e a faixa et&aacute;ria somente para o
s pacientes do grupo do teste ergom&eacute;trico   (p = 0,009).    ^cY#aop3511.h
tm##
00569000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704032700084002001200411#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#18#14#article#134#<br>   <b>C
ONCLUS&Atilde;O:</b> Os resultados do nosso estudo demonstram que o &iacute;ndic
e   de dilata&ccedil;&atilde;o transit&oacute;ria n&atilde;o difere quando os pa
cientes   s&atilde;o submetidos a estresse pelo teste ergom&eacute;trico em este
ira ou   estresse farmacol&oacute;gico pelo dipiridamol.</font></p>     ^cY#aop3
511.htm##
00472000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023000084002001200314#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#19#15#article#134#<p><font si
ze="2" face="Verdana"><b>Palavras&#45;chave: </b>Dilata&ccedil;&atilde;o,     fu
n&ccedil;&atilde;o ventricular esquerda, teste de esfor&ccedil;o, cintilografia,
     dipiridamol.</font></p> <hr size="1" noshade>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#20#16#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#21#17#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#22#18#article#134#<p><font si
ze="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop3511
.htm##
00514000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027200084002001200356#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#23#19#article#134#<p><font si
ze="2" face="Verdana">A cintilografia mioc&aacute;rdica perfusional     (CMP) &e
acute; executada associada ao teste ergom&eacute;trico em esteira,     ou ao est
resse farmacol&oacute;gico com dipiridamol, adenosina, ou dobutamina<SUP>1</SUP>
.</font></p>     ^cY#aop3511.htm##
00691000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704044900084002001200533#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#24#20#article#134#<p><font si
ze="2" face="Verdana">A CMP fornece uma avalia&ccedil;&atilde;o relativa     da 
perfus&atilde;o na an&aacute;lise do grau da capta&ccedil;&atilde;o do     radio
f&aacute;rmaco pelas paredes ventriculares. Na estenose triarterial     balancea
da, os defeitos perfusionais induzidos pelo exerc&iacute;cio podem     distribui
r&#45;se homogeneamente pelo mioc&aacute;rdio, podendo causar um falso     negat
ivo<SUP>2,3</SUP>.</font></p>     ^cY#aop3511.htm##
00687000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704044500084002001200529#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#25#21#article#134#<p><font si
ze="2" face="Verdana">A CMP avalia a dilata&ccedil;&atilde;o da cavidade     ven
tricular esquerda, induzida pelo estresse, quantificada pelo &iacute;ndice     d
e dilata&ccedil;&atilde;o transit&oacute;ria (IDT). Considera&#45;se a dilata&cc
edil;&atilde;o     presente quando a cavidade ventricular esquerda &eacute; maio
r ap&oacute;s     o estresse, em rela&ccedil;&atilde;o &agrave; imagem do repous
o<SUP>4</SUP>.</font></p>     ^cY#aop3511.htm##
01235000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704099300084002001201077#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#26#22#article#134#<p><font si
ze="2" face="Verdana">A dilata&ccedil;&atilde;o foi inicialmente descrita     na
 cintilografia de repouso com t&aacute;lio&#45;201 e estresse ergom&eacute;trico
     com 99mTc&#45;sestamibi, quando o IDT maior que 1,22 teve 71,0% de sensibil
idade     e 95,0% de especificidade no diagn&oacute;stico de estenoses coronaria
nas     a partir de 90,0% do l&uacute;men vascular<SUP>5</SUP>. Foi ainda descri
ta     com os protocolos 99mTc&#45;sestamibi stresse/repouso<SUP>6</SUP> e 99mTc
&#45;tetrofosmin     estresse/repouso<SUP>7</SUP>. No exame associado ao estress
e ergom&eacute;trico,     as imagens s&atilde;o realizadas entre 30 a 60 minutos
 ap&oacute;s o estresse,     dando ao mioc&aacute;rdio tempo de recupera&ccedil;
&atilde;o da disfun&ccedil;&atilde;o     mec&acirc;nica causada por ele. Mas, no
 exame associado ao dipiridamol, quando     o mioc&aacute;rdio n&atilde;o &eacut
e; submetido a um estresse real, o IDT     tamb&eacute;m foi descrito<SUP>8</SUP
>.</font></p>     ^cY#aop3511.htm##
00508000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704026600084002001200350#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#27#23#article#134#<p><font si
ze="2" face="Verdana">Embora o IDT venha sido descrito h&aacute; anos,     ainda
 n&atilde;o foi avaliado se o tipo de estresse, ergom&eacute;trico ou     farmac
ol&oacute;gico, afeta o seu valor m&eacute;dio em grupos homog&ecirc;neos. </fon
t></p>     ^cY#aop3511.htm##
00876000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704063400084002001200718#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#28#24#article#134#<p><font si
ze="2" face="Verdana">Na pr&aacute;tica cl&iacute;nica, a compara&ccedil;&atilde
;o     entre os m&eacute;todos pode direcionar os pacientes ao tipo de estresse 
    que mais afeta o valor m&eacute;dio do IDT, podendo minimizar as limita&cced
il;&otilde;es     da CMP, como em casos de pacientes portadores de coronariopati
a triarterial     balanceada e de estenose do tronco da art&eacute;ria coron&aac
ute;ria esquerda. &Agrave; an&aacute;lise     visual da perfus&atilde;o, essas d
uas situa&ccedil;&otilde;es s&atilde;o     causas j&aacute; estabelecidas de fal
so negativo na cintilografia<SUP>2,3</SUP>.</font></p>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#29#25#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007400084002001200158#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#30#26#article#134#<p><font si
ze="3" face="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#aop3511.htm##
00500000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704025800084002001200342#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#31#27#article#134#<p><font si
ze="2" face="Verdana">A pesquisa foi submetida ao Comit&ecirc; de &Eacute;tica  
   da Pontif&iacute;cia Universidade Cat&oacute;lica de Porto Alegre (registro  
   08/04461) e os participantes assinaram o Termo de Consentimento.</font></p>  
   ^cY#aop3511.htm##
00456000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021400084002001200298#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#32#28#article#134#<p><font si
ze="2" face="Verdana">A hip&oacute;tese operacional afirma que mecanismos     de
 esfor&ccedil;os diferentes induzem respostas diferentes do ventr&iacute;culo   
  esquerdo ao estresse.</font></p>     ^cY#aop3511.htm##
00599000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035700084002001200441#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#33#29#article#134#<p><font si
ze="2" face="Verdana">O objetivo principal do estudo foi comparar     os valores
 m&eacute;dios do IDT na CMP em pacientes submetidos a estresse     ergom&eacute
;trico, em esteira com o protocolo <I>Ellestad</I>, e os valores     m&eacute;di
os do IDT em pacientes submetidos a estresse farmacol&oacute;gico     com dipiri
damol.</font></p>     ^cY#aop3511.htm##
00747000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704050500084002001200589#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#34#30#article#134#<p><font si
ze="2" face="Verdana">O objetivo secund&aacute;rio foi avaliar o impacto     sob
re o valor m&eacute;dio do IDT exercido pela cintilografia normal ou n&atilde;o,
     segundo o <I>summed stress score </I>(<I>SSS</I>). A an&aacute;lise incluiu
     o impacto dos fatores: sexo, idade, &iacute;ndice de massa corporal, hipert
ens&atilde;o     arterial sist&ecirc;mica, diabete melito, dislipidemia e fumo s
obre o IDT     m&eacute;dio de cada um destes par&acirc;metros nos grupos.</font
></p>     ^cY#aop3511.htm##
00457000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021500084002001200299#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#35#31#article#134#<p><font si
ze="2" face="Verdana">A amostra foi recrutada a partir dos pacientes     encamin
hados pelos seus m&eacute;dicos assistentes para realizar cintilografia     na r
otina do servi&ccedil;o.</font></p>     ^cY#aop3511.htm##
00953000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704071100084002001200795#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#36#32#article#134#<p><font si
ze="2" face="Verdana">Para comparar o efeito do estresse farmacol&oacute;gico <I
>versus</I> o     estresse ergom&eacute;trico, tomando como base uma diferen&cce
dil;a m&iacute;nima     significativa de 0,5 desvio&#45;padr&atilde;o, foi estim
ada uma amostra de 86     pacientes por grupo, mantendo&#45;se </font><font>&#94
5;</font><font size="2" face="verdana"> =     0,05 e poder estat&iacute;stico de
 90,0% (</font><font>&#946;</font><font size="2" face="verdana"> =     0,10). Pa
ra possibilitar o ajuste estat&iacute;stico e estimar o impacto     de fatores d
e confus&atilde;o, o tamanho da amostra foi aumentado em aproximadamente     15,
0%, totalizando 100 pacientes por grupo.</font></p>     ^cY#aop3511.htm##
01104000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704086200084002001200946#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#37#33#article#134#<p><font si
ze="2" face="Verdana">A cintilografia foi realizada nos pacientes     com diagn&
oacute;stico pr&eacute;vio de cardiopatia isqu&ecirc;mica coronariana,     ou n&
atilde;o. Foram inclu&iacute;dos pacientes de ambos os sexos, com idade     entr
e 40 a 70 anos, portadores ou n&atilde;o de diabete melito, hipertens&atilde;o  
   arterial sist&ecirc;mica e dislipidemia, fumantes ou n&atilde;o. Foram consid
erados     diab&eacute;ticos todos os pacientes que relataram usar hipoglicemian
tes     orais ou insulina. Foram considerados hipertensos todos pacientes que re
lataram     usar medica&ccedil;&otilde;es hipotensoras, e dislip&ecirc;micos tod
os pacientes     em uso de f&aacute;rmacos hipolipemiantes. Foram considerados f
umantes todos     os que afirmaram j&aacute; ter fumado mais de 100 unidades de 
cigarro em     toda a sua vida.</font></p>     ^cY#aop3511.htm##
00807000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056500084002001200649#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#38#34#article#134#<p><font si
ze="2" face="Verdana">Os pacientes foram separados em um grupo submetido &agrave
; cintilografia     associada a estresse ergom&eacute;trico em esteira <I>versus
</I> o segundo     grupo, submetido &agrave; cintilografia associada a estresse 
com dipiridamol.     A separa&ccedil;&atilde;o entre os grupos foi sequencial. A
 randomiza&ccedil;&atilde;o     n&atilde;o foi poss&iacute;vel, pois analisamos 
os pacientes que realizaram     a cintilografia na rotina do servi&ccedil;o. Rea
lizamos 100 cintilografias     seguidas em cada grupo.</font></p>     ^cY#aop351
1.htm##
00435000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019300084002001200277#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#39#35#article#134#<p><font si
ze="2" face="Verdana">A cintilografia foi executada conforme a primeira     dire
triz da Sociedade Brasileira de Cardiologia sobre Cardiologia Nuclear<SUP>1</SUP
>.</font></p>     ^cY#aop3511.htm##
00737000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049500084002001200579#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#40#36#article#134#<p><font si
ze="2" face="Verdana">Os pacientes foram orientados a suspender: aminofilina    
 e medica&ccedil;&otilde;es com xantinas, 36 horas antes da cintilografia;     b
etabloqueadores e antagonistas dos canais do c&aacute;lcio, 72 horas antes;     
nitratos, 24 horas antes; e medica&ccedil;&otilde;es com cafe&iacute;na,     24 
horas antes. Os pacientes foram orientados a n&atilde;o consumir cafe&iacute;na 
    e seguir dieta pobre em xantinas 24 horas antes<SUP>1</SUP>.</font></p>     
^cY#aop3511.htm##
00582000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704034000084002001200424#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#41#37#article#134#<p><font si
ze="2" face="Verdana">Nos dois grupos, a cintilografia foi feita utilizando     
o protocolo de um dia com 99mTc&#45;sestamibi, administrado por via endovenosa, 
    em atividade de 296 a 370 MBq em repouso e em atividade de 925 a 1110 MBq   
  na fase do estresse, para os pacientes dos dois grupos<SUP>1</SUP>.</font></p>
     ^cY#aop3511.htm##
00698000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045600084002001200540#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#42#38#article#134#<p><font si
ze="2" face="Verdana">Aproximadamente duas horas ap&oacute;s o estudo     de rep
ouso, os pacientes do primeiro grupo foram submetidos a estresse ergom&eacute;tr
ico     em esteira pelo protocolo de <I>Ellestad</I>. Administramos o radiof&aac
ute;rmaco     quando o paciente atingiu pelo menos 85,0% da frequ&ecirc;ncia car
d&iacute;aca     m&aacute;xima para a idade, determinada pela f&oacute;rmula (22
0&#45;idade)<SUP>1</SUP>.</font></p>     ^cY#aop3511.htm##
00619000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037700084002001200461#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#43#39#article#134#<p><font si
ze="2" face="Verdana">Aproximadamente duas horas ap&oacute;s o estudo     de rep
ouso, os pacientes do segundo grupo receberam por via endovenosa 0,14     mg/kg/
minuto de dipiridamol, durante 04 minutos. Administramos o radiof&aacute;rmaco  
   entre o 7º e o 9º minutos ap&oacute;s o in&iacute;cio da infus&atilde;o do   
  dipiridamol<SUP>1</SUP>.</font></p>     ^cY#aop3511.htm##
00576000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033400084002001200418#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#44#40#article#134#<p><font si
ze="2" face="Verdana">A aquisi&ccedil;&atilde;o da imagem ocorreu     entre 15 a
 30 minutos ap&oacute;s estresse ergom&eacute;trico, 45 a 60 minutos     ap&oacu
te;s o estresse farmacol&oacute;gico e entre 45 a 60 minutos ap&oacute;s     a i
nje&ccedil;&atilde;o do tra&ccedil;ador em repouso<SUP>1</SUP>.</font></p>     ^
cY#aop3511.htm##
01651000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704140900084002001201493#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#45#41#article#134#<p><font si
ze="2" face="Verdana">A cintilografia foi realizada na gama&#45;c&acirc;mara    
 E&#45;Cam SIEMENS<SUP>&reg;</SUP>, com colimador LEHR e janela de energia centr
ada     em 140 keV (&plusmn;15%), matriz de 64 por 64 pixels e rota&ccedil;&atil
de;o pelo     m&eacute;todo passo a passo. Os pacientes foram posicionados em de
c&uacute;bito     dorsal horizontal, com os bra&ccedil;os elevados. Foi feita um
a imagem tomogr&aacute;fica     com arco de rota&ccedil;&atilde;o de 180°, em &o
acute;rbita el&iacute;ptica     e em sentido anti&#45;hor&aacute;rio, com aquisi
&ccedil;&atilde;o de 64 proje&ccedil;&otilde;es     de 20 segundos de dura&ccedi
l;&atilde;o cada, em repouso, e de 64 proje&ccedil;&otilde;es     de 25 segundos
 de dura&ccedil;&atilde;o cada, ap&oacute;s cada estresse.     As imagens das du
as fases foram sincronizadas ao eletrocardiograma (ECG).     Cada ciclo card&iac
ute;aco foi dividido em 16 por&ccedil;&otilde;es. O ECG     determinou o interva
lo R&#45;R de cada paciente no momento do exame. A partir     da m&eacute;dia do
 intervalo R&#45;R, criou&#45;se uma janela de aceita&ccedil;&atilde;o     de 15
,0%, excluindo os batimentos fora desta janela. O processamento das     imagens 
usou o filtro <I>Butterworth</I>, seguido da reconstru&ccedil;&atilde;o     das 
imagens atrav&eacute;s da t&eacute;cnica da retroproje&ccedil;&atilde;o     filt
rada<SUP>1</SUP>. </font></p>     ^cY#aop3511.htm##
01209000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704096700084002001201051#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#46#42#article#134#<p><font si
ze="2" face="Verdana">Usamos o <I>software</I> 4D&#45;MSPECT<SUP>&reg;</SUP> no 
    processamento da cintilografia por um operador cego para o c&aacute;lculo   
  autom&aacute;tico do IDT, atrav&eacute;s da divis&atilde;o do volume da superf
&iacute;cie     endoc&aacute;rdica da cavidade ventricular esquerda ap&oacute;s 
o estresse,     sobre o volume da superf&iacute;cie endoc&aacute;rdica da cavida
de em repouso.     O <I>software</I> estimou o volume do ventr&iacute;culo esque
rdo a partir     das imagens tridimensionais fornecidas pela cintilografia. O al
goritmo segmenta     o ventr&iacute;culo esquerdo e determina os limites da supe
rf&iacute;cies     endoc&aacute;rdica e epic&aacute;rdica e do plano valvar para
 as imagens     do estresse e do repouso. Ent&atilde;o, calcula&#45;se o IDT pel
a raz&atilde;o     (volume da cavidade ventricular p&oacute;s&#45;estresse/volum
e da cavidade ventricular     em repouso)<SUP>5,9</SUP>.</font></p>     ^cY#aop3
511.htm##
01306000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704106400084002001201148#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#47#43#article#134#<p><font si
ze="2" face="Verdana">A an&aacute;lise da perfus&atilde;o usou sistema     de es
cores que divide o mioc&aacute;rdio em 17 segmentos e considera uma     escala n
um&eacute;rica com os seguintes valores: zero = normal; um = t&ecirc;nue     hip
ocapta&ccedil;&atilde;o do radiof&aacute;rmaco; dois = moderada hipocapta&ccedil
;&atilde;o;     tr&ecirc;s = acentuada hipocapta&ccedil;&atilde;o; 04 = aus&ecir
c;ncia de     capta&ccedil;&atilde;o do radiof&aacute;rmaco. Os escores tr&ecirc
;s e 04     associam&#45;se a estenoses coronarianas superiores a 90,0%. Cada um
 dos 17 segmentos     recebe um valor entre zero e 04. Calcula&#45;se o somat&oa
cute;rio dos valores     atribu&iacute;dos a cada segmento, representativo da fa
se de estresse e denominada <I>SSS</I> (<I>summed     stress score</I>). Valores
 num&eacute;ricos de <I>SSS</I> menores ou iguais     a tr&ecirc;s s&atilde;o co
nsiderados normais, entre 04 e 08 discretamente     anormais, entre 09 e 13 mode
radamente anormais e a partir de 14 francamente     anormais<SUP>1</SUP>.</font>
</p>     ^cY#aop3511.htm##
00621000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037900084002001200463#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#48#44#article#134#<p><font si
ze="2" face="Verdana">Foram exclu&iacute;dos indiv&iacute;duos com:     ritmo ca
rd&iacute;aco n&atilde;o sinusal; diagn&oacute;stico pr&eacute;vio     de quaisq
uer outras doen&ccedil;as card&iacute;acas (miocardiopatias ou valvulopatias);  
   volume sist&oacute;lico final menor que 15 mililitros e com amputa&ccedil;&at
ilde;o     de extremidades. </font></p>     ^cY#aop3511.htm##
00504000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704026200084002001200346#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#49#45#article#134#<p><font si
ze="2" face="Verdana">A cintilografia n&atilde;o foi realizada quando     o card
iologista julgou o paciente inapto a realizar esfor&ccedil;os. A &uacute;nica   
  contraindica&ccedil;&atilde;o absoluta foi a gesta&ccedil;&atilde;o. </font></
p>     ^cY#aop3511.htm##
00535000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704029300084002001200377#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#50#46#article#134#<p><font si
ze="2" face="Verdana">Os pacientes n&atilde;o foram expostos &agrave; radia&cced
il;&atilde;o     para fins acad&ecirc;micos. Analisamos pacientes que realizaram
 a cintilografia     por solicita&ccedil;&atilde;o do seu m&eacute;dico assisten
te, sem financiamento.</font></p>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#51#47#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00312000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007000084002001200154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#52#48#article#134#<p><font si
ze="3" face="Verdana"><b>Resultados</b></font></p>     ^cY#aop3511.htm##
00928000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704068600084002001200770#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#53#49#article#134#<p><font si
ze="2" face="Verdana">O grau de obesidade dos pacientes foi avaliado     pelo c&
aacute;lculo do &iacute;ndice de massa corporal (IMC), obtido pela     raz&atild
e;o entre o peso do paciente, em quilogramas, sobre a altura em     metros ao qu
adrado. Os pacientes com IMC entre 18,5 e 24,9 foram considerados     normopesos
; entre 25,0 e 29,9 foram considerados sobrepesos; indiv&iacute;duos     com IMC
 maior ou igual a 30,0 foram considerados obesos. Dos pacientes, 64,0%     apres
entaram perfus&atilde;o normal &agrave; cintilografia, segundo o <I>SSS</I>.    
 A <a href="#tab01">Tabela 1</a> mostra que os grupos foram homog&ecirc;neos    
 (p &gt; 0,05).</font></p>     ^cY#aop3511.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#54#50#article#134#<p><a name=
"tab01"></a></p>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#55#51#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#56#52#article#134#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop35tb1.jpg"></p>     ^cY#aop3511
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#57#53#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00885000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064300084002001200727#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#58#54#article#134#<p><font si
ze="2" face="Verdana">Para descrever dados quantitativos, usamos a     m&eacute;
dia &plusmn; desvio&#45;padr&atilde;o. Dados categ&oacute;ricos foram expressos 
    por contagens e percentuais. A compara&ccedil;&atilde;o do IDT entre grupos 
    foi por regress&atilde;o linear m&uacute;ltipla. Dados categ&oacute;ricos   
  foram comparados pelo procedimento do qui&#45;quadrado. O n&iacute;vel de sign
ific&acirc;ncia     adotado foi de </font><font>&#945;</font><font size="2" face
="verdana"> =     0,05. Os dados foram analisados e processados com o aux&iacute
;lio do programa <I>SPSS,</I> vers&atilde;o     17. </font></p>     ^cY#aop3511.
htm##
00856000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061400084002001200698#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#59#55#article#134#<p><font si
ze="2" face="Verdana">A <a href="#tab02">Tabela 2</a> mostra que o     estudo n&
atilde;o encontrou associa&ccedil;&atilde;o entre o tipo de estresse     e os va
lores m&eacute;dios do IDT. Encontrou&#45;se associa&ccedil;&atilde;o     entre 
os valores m&eacute;dios do IDT e as faixas et&aacute;rias dos pacientes     do 
grupo do teste ergom&eacute;trico (p = 0,009). Houve ainda associa&ccedil;&atild
e;o     significativa entre os valores m&eacute;dios do IDT para os pacientes do
     tercil mais jovem, cujo IDT do grupo do dipiridamol teve valor m&eacute;dio
     maior (p = 0,010).</font></p>     ^cY#aop3511.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#60#56#article#134#<p><a name=
"tab02"></a></p>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#61#57#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#62#58#article#134#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop35tb2.jpg"></p>     ^cY#aop3511
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#63#59#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#64#60#article#134#<p><font si
ze="3" face="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#aop3511.htm##
00786000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054400084002001200628#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#65#61#article#134#<p><font si
ze="2" face="Verdana">A CMP &eacute; associada ao teste ergom&eacute;trico     e
m esteira, ou ao estresse com dipiridamol, adenosina, ou dobutamina<SUP>1</SUP>.
     A presen&ccedil;a de defeitos perfusionais extensos e severos, a redu&ccedi
l;&atilde;o     da fra&ccedil;&atilde;o de eje&ccedil;&atilde;o ventricular esqu
erda ap&oacute;s     o estresse e a dilata&ccedil;&atilde;o ventricular esquerda
 induzida pelo     estresse s&atilde;o indicadores de mau progn&oacute;stico &ag
rave; cintilografia<SUP>10</SUP>.</font></p>     ^cY#aop3511.htm##
01151000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704090900084002001200993#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#66#62#article#134#<p><font si
ze="2" face="Verdana">O exerc&iacute;cio f&iacute;sico tem efeitos     inotr&oac
ute;picos e cronotr&oacute;picos positivos sobre o cora&ccedil;&atilde;o     e a
umenta a press&atilde;o sangu&iacute;nea arterial. Em art&eacute;rias     coron&
aacute;rias saud&aacute;veis, o aumento da necessidade de oxig&ecirc;nio &eacute
; compensado     pela vasodilata&ccedil;&atilde;o fisiol&oacute;gica arterial, q
ue aumenta     o fluxo sangu&iacute;neo arterial duas a tr&ecirc;s vezes acima d
o basal.     Assim, o estresse card&iacute;aco causa isquemia em art&eacute;rias
 coron&aacute;rias     estenosadas ou incapazes de dilatar&#45;se (com compromet
imento da reserva coronariana),     resultando em dist&uacute;rbios da cinesia e
 da perfus&atilde;o das paredes     ventriculares e do tra&ccedil;ado do eletroc
ardiograma, bem como em sintomas     como a dor tor&aacute;cica<SUP>11</SUP>. </
font></p>     ^cY#aop3511.htm##
02086000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704184400084002001201928#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#67#63#article#134#<p><font si
ze="2" face="Verdana">O dipiridamol possui efeito vasodilatador indireto     por
 bloquear a recapta&ccedil;&atilde;o da adenosina para o meio intracelular.     
Nas coron&aacute;rias com obstru&ccedil;&atilde;o a partir de 50,0% do l&uacute;
men     vascular, para manuten&ccedil;&atilde;o do fluxo, h&aacute; intensa dila
ta&ccedil;&atilde;o     arteriolar distal &agrave; obstru&ccedil;&atilde;o em re
pouso. Nas coron&aacute;rias     obstru&iacute;das, o dipiridamol causar&aacute;
 pouca dilata&ccedil;&atilde;o.     As arter&iacute;olas das coron&aacute;rias n
ormais ter&atilde;o dilata&ccedil;&atilde;o     m&aacute;xima. A reserva coronar
iana come&ccedil;a a diminuir devido a estenoses     de 45,0% a 50,0% do l&uacut
e;men vascular. O fluxo coronariano basal mant&eacute;m&#45;se     normal at&eac
ute; o di&acirc;metro do vaso alcan&ccedil;ar estreitamentos     maiores que 70,
0%. Portanto, a causa dos defeitos de perfus&atilde;o ap&oacute;s     a administ
ra&ccedil;&atilde;o de dipiridamol &eacute; a heterogeneidade do     fluxo mioc&
aacute;rdico regional, com importante aumento do fluxo nas art&eacute;rias     n
ormais e pequeno ou inexistente aumento nas art&eacute;rias com estenose.     O 
fen&ocirc;meno do "roubo" coronariano ap&oacute;s inje&ccedil;&atilde;o     de d
ipiridamol ocorre somente quando o fluxo distal &agrave; estenose &eacute; reduz
ido,     por desvio de parte do fluxo sangu&iacute;neo para outro territ&oacute;
rio     coronariano (competi&ccedil;&atilde;o induzida pela vasodilata&ccedil;&a
tilde;o     m&aacute;xima), habitualmente do subendoc&aacute;rdio para o subepic
&aacute;rdio:     as arter&iacute;olas subepic&aacute;rdicas mant&ecirc;m ainda 
reserva residual     de vasodilata&ccedil;&atilde;o, enquanto a reserva subendoc
&aacute;rdica     j&aacute; foi esgotada<SUP>1</SUP>.</font></p>     ^cY#aop3511
.htm##
00894000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704065200084002001200736#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#68#64#article#134#<p><font si
ze="2" face="Verdana">A dilata&ccedil;&atilde;o ventricular induzida     pelo es
tresse foi descrita em protocolos cintilogr&aacute;ficos, como repouso/estresse 
    com 99mTc&#45;sestamibi, repouso/estresse com 99mTc&#45;tetrofosmin, ou repo
uso com     t&aacute;lio&#45;201 e estresse com 99mTc&#45;sestamibi. A dilata&cc
edil;&atilde;o     tamb&eacute;m j&aacute; foi descrita em situa&ccedil;&otilde;
es de est&iacute;mulo     com o dipiridamol<SUP>4</SUP>. Como nenhum estudo aind
a havia avaliado o     impacto do tipo de estresse sobre os valores m&eacute;dio
s do IDT, este foi     o objetivo principal de nosso estudo. </font></p>     ^cY
#aop3511.htm##
00606000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036400084002001200448#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#69#65#article#134#<p><font si
ze="2" face="Verdana">A CMP avalia a dilata&ccedil;&atilde;o da cavidade     ven
tricular esquerda induzida pelo estresse, quantificada pelo IDT. Considera&#45;s
e     a dilata&ccedil;&atilde;o presente quando a cavidade ventricular &eacute; 
maior     ap&oacute;s o estresse, em rela&ccedil;&atilde;o &agrave; imagem basal
<SUP>4</SUP>.</font></p>     ^cY#aop3511.htm##
01182000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704094000084002001201024#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#70#66#article#134#<p><font si
ze="2" face="Verdana">V&aacute;rios mecanismos fisiopatol&oacute;gicos     podem
 estar associados ao aumento do IDT. O IDT pode estar associado &agrave; hipoper
fus&atilde;o     subendoc&aacute;rdica e &agrave; disfun&ccedil;&atilde;o ventri
cular sist&oacute;lica.     A coronariopatia multivascular associa&#45;se &agrav
e; isquemia subendoc&aacute;rdica     difusa, que compromete a perfus&atilde;o d
o endoc&aacute;rdio, resultando     na menor concentra&ccedil;&atilde;o endoc&aa
cute;rdica do tra&ccedil;ador.     Outra explica&ccedil;&atilde;o seria a isquem
ia causar uma disfun&ccedil;&atilde;o     sist&oacute;lica que resultaria no aum
ento da cavidade ventricular, devido     ao aumento do volume sist&oacute;lico f
inal do ventr&iacute;culo esquerdo.     A disfun&ccedil;&atilde;o sist&oacute;li
ca tamb&eacute;m causa a impress&atilde;o     de dilata&ccedil;&atilde;o da cavi
dade ventricular<SUP>4</SUP>.</font></p>     ^cY#aop3511.htm##
01117000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704087500084002001200959#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#71#67#article#134#<p><font si
ze="2" face="Verdana">Outros estudos sugerem que a doen&ccedil;a card&iacute;aca
     hipertensiva severa seja outra causa de isquemia subendoc&aacute;rdica difu
sa     na aus&ecirc;ncia de estenoses coronarianas, pois se associa ao retardo n
o     relaxamento diast&oacute;lico, &agrave; disfun&ccedil;&atilde;o endotelial
     das art&eacute;rias coron&aacute;rias, &agrave; redu&ccedil;&atilde;o da   
  densidade capilar no mioc&aacute;rdio hipertrofiado e ao aumento da press&atil
de;o     diast&oacute;lica final ventricular esquerda. Embora em casos de hipert
rofia     ventricular severa possa haver dilata&ccedil;&atilde;o compensat&oacut
e;ria     das art&eacute;rias coron&aacute;rias epic&aacute;rdicas, o mioc&aacut
e;rdio     parece sofrer isquemia transmural, sem rela&ccedil;&atilde;o com qual
quer     estenose coronariana<SUP>12</SUP>. </font></p>     ^cY#aop3511.htm##
01359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704111700084002001201201#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#72#68#article#134#<p><font si
ze="2" face="Verdana">Robinson e cols.<SUP>13</SUP> avaliaram 237     cintilogra
fias consecutivas e constataram dilata&ccedil;&atilde;o transit&oacute;ria     v
entricular em 23 delas. Nove entre 23 pacientes apresentaram dilata&ccedil;&atil
de;o     na aus&ecirc;ncia de defeitos segmentares perfusionais &agrave; imagem 
e     na aus&ecirc;ncia de estenoses coronarianas. Em 07 desses 09 pacientes, at
ribui&#45;se     a dilata&ccedil;&atilde;o exclusivamente &agrave; hipertrofia v
entricular     esquerda. Assim, a dilata&ccedil;&atilde;o transit&oacute;ria n&a
tilde;o &eacute; um     marcador espec&iacute;fico para DAC em popula&ccedil;&ot
ilde;es com alta     preval&ecirc;ncia de cardiopatia hipertensiva, associada &a
grave; hipertrofia     ventricular<SUP>13</SUP>. Nossa pesquisa n&atilde;o avali
ou a preval&ecirc;ncia     de hipertrofia ventricular no subgrupo portador de hi
pertens&atilde;o desta     amostra. Por&eacute;m, como a preval&ecirc;ncia de hi
pertens&atilde;o foi     similar nos dois grupos, acreditamos que esse fator n&a
tilde;o tenha comprometido     os resultados. </font></p>     ^cY#aop3511.htm##
00981000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704073900084002001200823#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#73#69#article#134#<p><font si
ze="2" face="Verdana">Emmet e cols.<SUP>10</SUP> avaliaram o impacto     da hipe
rtrofia ventricular esquerda e do diabete melito na preval&ecirc;ncia     do IDT
. A amostra (n = 103) foi submetida &agrave; cintilografia, ao ecocardiograma   
  transtor&aacute;cico e ao cateterismo. Foram considerados anormais IDT <u>&gt;
</u> 1,22     e parede ventricular com espessura <u>&gt;</u> 11 mm. Os fatores <
I>SSS</I> <u>&gt;</u> 14,     hipertrofia e diabete foram preditores independent
es do IDT anormal. Em pacientes     com estenoses <u>&gt;</u> 90,0% do l&uacute;
men vascular, a presen&ccedil;a     da hipertrofia ou do diabete aumentou signif
icativamente a preval&ecirc;ncia     do IDT anormal (p &lt; 0,005). </font></p> 
    ^cY#aop3511.htm##
00914000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704067200084002001200756#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#74#70#article#134#<p><font si
ze="2" face="Verdana">Assim, o aumento do IDT associa&#45;se &agrave; DAC     se
vera e a associa&ccedil;&atilde;o &eacute; magnificada na presen&ccedil;a     de
 hipertrofia ventricular esquerda ou de diabete. A hipertrofia estaria     assoc
iada &agrave; isquemia subendoc&aacute;rdica difusa. O diabete estaria     assoc
iado ao comprometimento da reserva coronariana secund&aacute;rio &agrave; doen&c
cedil;a     microvascular<SUP>10</SUP>. Nosso estudo n&atilde;o encontrou essa a
ssocia&ccedil;&atilde;o     no subgrupo dos diab&eacute;ticos, talvez devido ao 
pequeno n&uacute;mero     de pacientes diab&eacute;ticos dessa amostra (n = 36).
 </font></p>     ^cY#aop3511.htm##
00706000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046400084002001200548#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#75#71#article#134#<p><font si
ze="2" face="Verdana">Na aus&ecirc;ncia de estenoses coronarianas     epic&aacut
e;rdicas, a dilata&ccedil;&atilde;o transit&oacute;ria foi descrita     em pacie
ntes com miocardiopatia dilatada. Sugere&#45;se que a limita&ccedil;&atilde;o   
  da reserva coronariana desses pacientes seja a explica&ccedil;&atilde;o<SUP>14
</SUP>.     Nossa pesquisa excluiu pacientes com diagn&oacute;stico pr&eacute;vi
o de     qualquer miocardiopatia.</font></p>     ^cY#aop3511.htm##
01109000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704086700084002001200951#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#76#72#article#134#<p><font si
ze="2" face="Verdana">A dilata&ccedil;&atilde;o da cavidade ventricular     indu
zida pelo estresse foi inicialmente descrita na cintilografia de repouso     com
 t&aacute;lio&#45;201 e estresse ergom&eacute;trico (protocolo de Bruce) com    
 99mTc&#45;sestamibi. Este estudo analisou a associa&ccedil;&atilde;o entre o   
  aumento do IDT e a presen&ccedil;a de estenoses coronarianas ao cateterismo.  
   O valor da positividade do IDT correspondeu a 1,22 (&plusmn;2). No diagn&oacu
te;stico     de estenoses coronarianas a partir de 70,0% do l&uacute;men vascula
r, o IDT     maior ou igual a 1,22 teve 40,0% de sensibilidade e especificidade 
superior     a 90,0%. O IDT maior que 1,22 teve 71,0% de sensibilidade e 95,0% d
e especificidade     no diagn&oacute;stico de estenoses coronarianas maiores ou 
iguais a 90,0%     do l&uacute;men. </font></p>     ^cY#aop3511.htm##
00901000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704065900084002001200743#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#77#73#article#134#<p><font si
ze="2" face="Verdana">Trinta e tr&ecirc;s por cento dos pacientes     com <I>SSS
</I> entre 04 e 08 apresentaram IDT elevado, 38% com <I>SSS</I> entre     09 e 1
3 e 48% dos pacientes estavam com SSS maior ou igual a 14. Entre os     paciente
s portadores de estenoses maiores ou iguais a 90,0% em duas art&eacute;rias     
coron&aacute;rias, 34,0% apresentaram <I>SSS</I> acima de 8,0 e 76,0% apresentar
am     aumento do IDT. Portanto, o IDT permitiu a identifica&ccedil;&atilde;o de
     pacientes com estenoses coronarianas extensas e severas, que teriam sido   
  subestimadas na an&aacute;lise isolada do <I>SSS<sup>5</sup></I>. </font></p> 
    ^cY#aop3511.htm##
01273000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704103100084002001201115#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#78#74#article#134#<p><font si
ze="2" face="Verdana">Nosso estudo encontrou valores m&eacute;dios     do IDT me
nores que os relatados por este estudo com duplo is&oacute;topo,     mesmo nos p
acientes com perfus&atilde;o anormal segundo o <I>SSS</I>, o que     pode ser at
ribu&iacute;do ao fato dos dois estudos terem sido realizados     com radiof&aac
ute;rmacos diferentes<SUP>3</SUP>. Por&eacute;m, como nossa     pesquisa n&atild
e;o realizou cateterismo card&iacute;aco para comprovar a     presen&ccedil;a de
 estenose coronariana nos pacientes desta amostra, a presen&ccedil;a     e o gra
u das eventuais estenoses n&atilde;o puderam ser avaliados. Nossa     pesquisa n
&atilde;o encontrou diferen&ccedil;a significativa entre os valores     m&eacute
;dios do IDT nos pacientes com <I>SSS</I> anormal, nos diferentes     m&eacute;t
odos de esfor&ccedil;o. Talvez isso se deva ao n&uacute;mero pequeno     de paci
entes nesses subgrupos, uma vez que 64,0% da amostra apresentou perfus&atilde;o 
    normal (<I>SSS</I> <u>&lt;</u> 3,0).</font></p>     ^cY#aop3511.htm##
01609000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704136700084002001201451#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#79#75#article#134#<p><font si
ze="2" face="Verdana">Um estudo avaliou o valor m&eacute;dio do IDT     em 356 p
acientes submetidos &agrave; CMP com adenosina, no protocolo de estresse     com
 99mTc&#45;sestamibi e repouso com t&aacute;lio&#45;201. O IDT de 1,36 (&plusmn;
 2) teve     71,0% de sensibilidade e 86,0% de especificidade no diagn&oacute;st
ico de     estenoses coronarianas maiores ou iguais a 70,0% do l&uacute;men vasc
ular.     J&aacute; a an&aacute;lise visual da perfus&atilde;o teve sensibilidad
e e     especificidade de 87,0% e 49,0%, respectivamente. A an&aacute;lise da pe
rfus&atilde;o     foi atrav&eacute;s da associa&ccedil;&atilde;o do <I>SSS</I> e
 da extens&atilde;o     percentual do mioc&aacute;rdio hipoperfundido. O IDT foi
 anormal em: 12,2%     dos pacientes com perfus&atilde;o normal; em 28,2% dos pa
cientes com hipoperfus&atilde;o     discreta; em 29,4% dos pacientes com hipoper
fus&atilde;o moderada; e em 40,3%     dos pacientes com hipoperfus&atilde;o acen
tuada<SUP>15</SUP>. Assim, o IDT     associado &agrave; presen&ccedil;a de DAC t
eve valor num&eacute;rico superior     ao descrito no protocolo com teste ergom&
eacute;trico em esteira (1,22)<SUP>5</SUP>.     Na nossa pesquisa, os valores gl
obais m&eacute;dios do IDT foram numericamente     superiores no grupo do dipiri
damol, confirmando os achados de estudos pr&eacute;vios.</font></p>     ^cY#aop3
511.htm##
01079000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704083700084002001200921#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#80#76#article#134#<p><font si
ze="2" face="Verdana">Nossa pesquisa encontrou associa&ccedil;&atilde;o     entr
e os valores m&eacute;dios do IDT e as faixas et&aacute;rias dos pacientes     d
o grupo do teste ergom&eacute;trico (p = 0,009). Houve ainda associa&ccedil;&ati
lde;o     significativa entre os valores m&eacute;dios do IDT para os pacientes 
do     tercil mais jovem, cujo IDT do grupo do dipiridamol teve valor m&eacute;d
io     maior (p = 0,010). Esses achados ainda n&atilde;o haviam sido referidos n
a     literatura e n&atilde;o encontramos teorias que pudessem explic&aacute;&#4
5;los.     Talvez estudos com resson&acirc;ncia magn&eacute;tica card&iacute;aca
 possam     elucidar a preval&ecirc;ncia e a import&acirc;ncia relativa dos meca
nismos     associados ao aumento do IDT no estresse farmacol&oacute;gico<SUP>16<
/SUP>.</font></p>     ^cY#aop3511.htm##
01317000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704107500084002001201159#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#81#77#article#134#<p><font si
ze="2" face="Verdana">A perfus&atilde;o ventricular pode ser avaliada     pela t
omografia por emiss&atilde;o de p&oacute;sitrons com rub&iacute;dio&#45;82,     
associada ao dipiridamol. Nesse protocolo, a administra&ccedil;&atilde;o     do 
estressor farmacol&oacute;gico antecede a administra&ccedil;&atilde;o     do rub
&iacute;dio&#45;82 e as imagens podem ser adquiridas durante o pico do     estre
sse<SUP>17</SUP>. Um estudo aferiu o IDT em pacientes submetidos a estresse     
farmacol&oacute;gico no exame com rub&iacute;dio&#45;82 e, posteriormente, subme
tidos &agrave; cineangiocoronariografia     em at&eacute; 15 dias. O limite supe
rior da normalidade do IDT foi de 1,15(&plusmn;2),     com alta especificidade n
o diagn&oacute;stico da estenose de vaso &uacute;nico     e multivascular (100,0
% e 93,0%, respectivamente). Assim, mostrou&#45;se que     a dilata&ccedil;&atil
de;o associada ao estresse farmacol&oacute;gico &eacute; evidente     antes do t
empo habitual da aquisi&ccedil;&atilde;o da imagem da CPM convencional<SUP>18</S
UP>.</font></p>     ^cY#aop3511.htm##
00833000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704059100084002001200675#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#82#78#article#134#<p><font si
ze="2" face="Verdana">Deve haver cautela na an&aacute;lise da cintilografia     
associada &agrave; dilata&ccedil;&atilde;o transit&oacute;ria do ventr&iacute;cu
lo     esquerdo, pois o IDT pode estar associado a doen&ccedil;as n&atilde;o cor
onarianas,     como miocardiopatia hipertr&oacute;fica ou dilatada. O IDT pode s
er potencializado     pelo diabete melito. Al&eacute;m disso, o IDT pode estar f
alsamente aumentado     em cora&ccedil;&otilde;es pequenos, devido a limita&cced
il;&otilde;es t&eacute;cnicas     inerentes &agrave; cintilografia<SUP>19</SUP>.
</font></p>     ^cY#aop3511.htm##
00866000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704062400084002001200708#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#83#79#article#134#<p><font si
ze="2" face="Verdana">O nosso estudo apresentou algumas limita&ccedil;&otilde;es
,     como a n&atilde;o randomiza&ccedil;&atilde;o, pois alguns pacientes n&atil
de;o     conseguiriam desenvolver o esfor&ccedil;o por limita&ccedil;&atilde;o f
&iacute;sica.     Os pacientes n&atilde;o foram submetidos &agrave; cineangiocor
onariografia     de rotina, pois estavam fazendo exames avaliativos de isquemia 
mioc&aacute;rdica     e devido tamb&eacute;m &agrave; aus&ecirc;ncia de recursos
. Deste modo, n&atilde;o     relacionamos os achados com a presen&ccedil;a e gra
u de comprometimento coronariano.</font></p>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#84#80#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#85#81#article#134#<p><font si
ze="3" face="Verdana"><b>Conclus&atilde;o</b></font></p>     ^cY#aop3511.htm##
00592000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035000084002001200434#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#86#82#article#134#<p><font si
ze="2" face="Verdana">O &iacute;ndice de dilata&ccedil;&atilde;o transit&oacute;
ria     n&atilde;o difere quando os pacientes s&atilde;o submetidos a estresse p
elo     teste ergom&eacute;trico em esteira quando comparado ao estresse farmaco
l&oacute;gico     pelo dipiridamol, demonstrando a mesma capacidade avaliativa.<
/font></p>     ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#87#83#article#134#<p>&nbsp;</
p>     ^cY#aop3511.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#88#84#article#134#<p><font si
ze="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop3511.htm##
00499000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704024300086002001200329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#89#85#article#134
#1#<p><font size="2" face="Verdana">1. Chalela WA, Camargo EE, Marin&#45;Neto JA
,     Nicolau JC, Meneghetti JC/ / Sociedade Brasileira de Cardiologia. I Diretr
iz     sobre cardiologia nuclear. Arq Bras Cardiol. 2002;78(supl. 3):5&#45;42.  
  ^cY#aop3511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#90#86#article#134#</font></p>
     ^cY#aop3511.htm##
00550000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704029400086002001200380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#91#87#article#134
#2#<p><font size="2" face="Verdana">2. Duarte PS, Smanio PE, Oliveira CA, Martin
s     LR, Mastrocolla LE, Pereira JC. Clinical significance of transient left ve
ntricular     dilation assessed during myocardial Tc&#45;99m sestamibi scintigra
phy. Arq Bras     Cardiol. 2003;81(5):474&#45;82.    ^cY#aop3511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#92#88#article#134#</font></p>
     ^cY#aop3511.htm##
00592000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704033600086002001200422#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#93#89#article#134
#3#<p><font size="2" face="Verdana">3. Berman DS, Shaw LJ, Hachamovitch R, Fried
man     JD, Polk DM, Hayes SW, et al. Comparative use of radionuclide stress tes
ting,     coronary artery calcium scanning, and noninvasive coronary angiography
 for     diagnostic and prognostic cardiac assessment. Semin Nucl Med. 2007;37(1
):2&#45;16.    ^cY#aop3511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#94#90#article#134#</font></p>
     ^cY#aop3511.htm##
00484000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022800086002001200314#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#95#91#article#134
#4#<p><font size="2" face="Verdana">4. McLaughlin MG, Danias PG. Transient ische
mic     dilation: a powerful diagnostic and prognostic finding of stress myocard
ial     perfusion imaging. J Nucl Cardiol. 2002;9(6):663&#45;7.    ^cY#aop3511.h
tm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#96#92#article#134#</font></p>
     ^cY#aop3511.htm##
00627000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704037100086002001200457#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#97#93#article#134
#5#<p><font size="2" face="Verdana">5. Mazzanti M, Germano G, Kiat H, Kavanagh  
   PB, Alexanderson E, Friedman JD, et al. Identification of severe and extensiv
e     coronary artery disease by automatic measurement of transient ischemic dil
ation     of the left ventricle in dual&#45;isotope myocardial perfusion SPECT. 
J Am Coll     Cardiol. 1996;27(7):1612&#45;20.    ^cY#aop3511.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#98#94#article#134#</font></p>
     ^cY#aop3511.htm##
00558000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704030200086002001200388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#99#95#article#134
#6#<p><font size="2" face="Verdana">6. Marcassa C, Galli M, Baroffio C, Campini 
    R, Giannuzzi P. Transient left ventricular dilation at quantitative stress&#
45;rest     sestamibi tomography: clinical, electrocardiographic, and angiograph
ic correlates.     J Nucl Cardiol. 1999;6(4):397&#45;405.    ^cY#aop3511.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#100#96#article#134#</font></p
>     ^cY#aop3511.htm##
00537000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704028000087002001200367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#101#97#article#13
4#7#<p><font size="2" face="Verdana">7. Kinoshita N, Sugihara H, Adachi Y, Nakam
ura     T, Azuma A, Kohno Y, et al. Assessment of transient left ventricular dil
atation     on rest and exercise on Tc&#45;99m tetrofosmin myocardial SPECT. Cli
n Nucl Med.     2002;27(1):34&#45;9.    ^cY#aop3511.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#102#98#article#134#</font></p
>     ^cY#aop3511.htm##
00555000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704029800087002001200385#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#103#99#article#13
4#8#<p><font size="2" face="Verdana">8. Chouraqui P, Rodrigues EA, Berman DS,   
  Maddahi J. Significance of dipyridamole&#45;induced transient dilation of the 
    left ventricle during thallium&#45;201 scintigraphy in suspected coronary ar
tery     disease. Am J Cardiol. 1990;66(7):689&#45;94.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#104#100#article#134#</font></
p>     ^cY#aop3511.htm##
00462000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020400088002001200292#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#105#101#article#1
34#9#<p><font size="2" face="Verdana">9. Ficaro EP, Lee BC, Kritzman JN, Corbett
     JR. Corridor4DM: the Michigan method for quantitative nuclear cardiology.  
   J Nucl Cardiol. 2007;14(4):455&#45;65.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#106#102#article#134#</font></
p>     ^cY#aop3511.htm##
00586000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032700089002001200416#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#107#103#article#1
34#10#<p><font size="2" face="Verdana">10. Emmett L, Magee M, Freedman SB, Van d
er     Wall H, Bush V, Trieu J, et al. The role of left ventricular hypertrophy 
    and diabetes in the presence of transient ischemic dilation of the left vent
ricle     on myocardial perfusion SPECT images. J Nucl Med. 2005;46(10):1596&#45
;601.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#108#104#article#134#</font></
p>     ^cY#aop3511.htm##
00432000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704017300089002001200262#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#109#105#article#1
34#11#<p><font size="2" face="Verdana">11. Vesely MR, Dilsizian V. Nuclear cardi
ac     stress testing in the era of molecular medicine. J Nucl Med. 2008;49(3):3
99&#45;413.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#110#106#article#134#</font></
p>     ^cY#aop3511.htm##
00521000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026200089002001200351#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#111#107#article#1
34#12#<p><font size="2" face="Verdana">12. Robinson VJ, Corley JH, Marks DS, Ebe
rhardt     LW, Eubig C, Burke GJ, et al. Causes of transient dilatation of the l
eft     ventricle during myocardial perfusion imaging. AJR Am J Roentgenol. 2000
;174(5):1349&#45;52.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#112#108#article#134#</font></
p>     ^cY#aop3511.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021300089002001200302#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#113#109#article#1
34#13#<p><font size="2" face="Verdana">13. Robinson VJB, Corley JH, Gunter LE. T
ransient     ischemic dilation occurs in patients without severe multivessel epi
cardial     stenoses. J Investig Med. 1997;45:226A.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#114#110#article#134#</font></
p>     ^cY#aop3511.htm##
00481000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022200089002001200311#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#115#111#article#1
34#14#<p><font size="2" face="Verdana">14. Inoue T, Sakai Y, Morooka S, Hayashi 
    T, Takayanagi K, Yamanaka T, et al. Coronary flow reserve in patients with  
   dilated cardiomyopathy. Am Heart J. 1993;125(1):93&#45;8.    ^cY#aop3511.htm#
#
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#116#112#article#134#</font></
p>     ^cY#aop3511.htm##
00599000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034000089002001200429#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#117#113#article#1
34#15#<p><font size="2" face="Verdana">15. Abidov A, Bax JJ, Hayes SW, Cohen I, 
    Nishina H, Yoda S, et al. Integration of automatically measured transient   
  ischemic dilation ratio into interpretation of adenosine stress myocardial    
 perfusion SPECT for detection of severe and extensive CAD. J Nucl Med. 2004;45(
12):1999&#45;2007.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#118#114#article#134#</font></
p>     ^cY#aop3511.htm##
00542000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028300089002001200372#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#119#115#article#1
34#16#<p><font size="2" face="Verdana">16. Panting JR, Gatehouse PD, Yang GZ, Gr
othues     F, Firmin DN, Collins P, et al. Abnormal subendocardial perfusion in 
cardiac     syndrome X detected by cardiovascular magnetic resonance imaging. N 
Engl     J Med. 2002;346(25):1948&#45;53.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#120#116#article#134#</font></
p>     ^cY#aop3511.htm##
00493000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023400089002001200323#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#121#117#article#1
34#17#<p><font size="2" face="Verdana">17. Strauss HW, Miller DD, Wittry MD, Cer
queira     MD, Garcia EV, Iskandrian AS, et al. Procedure guideline for myocardi
al perfusion     imaging 3.3. J Nucl Med Technol. 2008;36(3):155&#45;61.    ^cY#
aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#122#118#article#134#</font></
p>     ^cY#aop3511.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028600089002001200375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#123#119#article#1
34#18#<p><font size="2" face="Verdana">18. Shi H, Santana CA, Rivero A, Sanyal R
,     Esteves FP, Verdes L, et al. Normal values and prospective validation of  
   transient ischaemic dilation index in 82Rb PET myocardial perfusion imaging. 
    Nucl Med Commun. 2007;28(11):859&#45;63.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#124#120#article#134#</font></
p>     ^cY#aop3511.htm##
00526000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026700089002001200356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#125#121#article#1
34#19#<p><font size="2" face="Verdana">19. Kakhki VR, Sadeghi R, Zakavi SR. Asse
ssment     of transient left ventricular dilation ratio via 2&#45;day dipyridamo
le Tc&#45;99m     sestamibi nongated myocardial perfusion imaging. J Nucl Cardio
l. 2007;14(4):529&#45;36.    ^cY#aop3511.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#126#122#article#134#</font></
p>     ^cY#aop3511.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#127#123#article#134#<p>&nbsp;
</p>     ^cY#aop3511.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#128#124#article#134#<p>&nbsp;
</p>     ^cY#aop3511.htm##
00414000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704017000086002001200256#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#129#125#article#134#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:</b>    ^cY
#aop3511.htm##
00286000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004200086002001200128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#130#126#article#134#<br>   Ma
uren B. Azambuja Gonzalez    ^cY#aop3511.htm##
00331000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704008700086002001200173#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#131#127#article#134#<BR>   De
partamento de Medicina Nuclear do Hospital S&atilde;o Vicente de Paulo    ^cY#ao
p3511.htm##
00282000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704003800086002001200124#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#132#128#article#134#<br>   Ru
a Teixeira Soares 808    ^cY#aop3511.htm##
00307000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006300086002001200149#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#133#129#article#134#<br>   99
010&#45;080 &#45; Passo Fundo, RS &#45; Brasil    ^cY#aop3511.htm##
00426000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704018200086002001200268#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#134#130#article#134#<BR>   E&
#45;mail:<a href="mailto:medicinanuclear@hsvp.br">medicinanuclear@hsvp.br</a> ou
 <a href="mailto:mauren.gonzalez@gmail.com">mauren.gonzalez@gmail.com</a></font>
</p>     ^cY#aop3511.htm##
00380000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704013600086002001200222#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#135#131#article#134#<p><font 
size="2" face="Verdana"> Artigo recebido em 23/06/10; revisado recebido     em 2
4/10/10; aceito em 11/01/11</font></p>     ^cY#aop3511.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#136#132#article#134#<p>&nbsp;
</p>     ^cY#aop3511.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#137#133#article#134#<p>&nbsp;
</p>     ^cY#aop3511.htm##
00420000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704017600086002001200262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3511.htm#S#p#138#134#article#134#<p><font 
size="2" face="Verdana">Full texts in English &#45; <A href="http://www.arquivos
online.com.br" target="_blank">http://www.arquivosonline.com.br</A></font></p>  
   ^cY#aop3511.htm##
00664000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100018001030100
02100121010001800142012009500160030001700255065000900272064000500281031000300286
032000800289014000500297865000900302002001200311035001000323801001700333#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#c#139#1#article#19#1#^r
ND^sChalela^nWA#^rND^sCamargo^nEE#^rND^sMarin-Neto^nJA#^rND^sNicolau^nJC#Meneghe
tti JC/ / Sociedade Brasileira de Cardiologia: I Diretriz sobre cardiologia nucl
ear^lpt#Arq Bras Cardiol#20020000#2002#78#supl. 3#5-42#20110000#aop3511.htm#0066
-782X#Arq Bras Cardiol##
00747000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100017001020100
01900119010001800138010002200156010001800178012012200196030001700318065000900335
06400050034403100030034903200020035201400070035486500090036100200120037003500100
0382801001700392#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S
#c#140#2#article#19#2#^rND^sDuarte^nPS#^rND^sSmanio^nPE#^rND^sOliveira^nCA#^rND^
sMartins^nLR#^rND^sMastrocolla^nLE#^rND^sPereira^nJC#Clinical significance of tr
ansient left ventricular dilation assessed during myocardial Tc-99m sestamibi sc
intigraphy^len#Arq Bras Cardiol#20030000#2003#81#5#474-82#20110000#aop3511.htm#0
066-782X#Arq Bras Cardiol##
00802000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100015001020100
02200117010001900139010001500158010001600173810000600189012017200195030001500367
06500090038206400050039103100030039603200020039901400050040186500090040600200120
0415035001000427801001500437#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#141#3#article#19#3#^rND^sBerman^nDS#^rND^sShaw^nLJ#^rND^sHachamov
itch^nR#^rND^sFriedman^nJD#^rND^sPolk^nDM#^rND^sHayes^nSW#et al#Comparative use 
of radionuclide stress testing, coronary artery calcium scanning, and noninvasiv
e coronary angiography for diagnostic and prognostic cardiac assessment^len#Semi
n Nucl Med#20070000#2007#37#1#2-16#20110000#aop3511.htm#0001-2998#Semin Nucl Med
##
00615000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100021000850100017001060120
11700123030001500240065000900255064000500264031000200269032000200271014000600273
865000900279002001200288035001000300801001500310#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3511.htm#S#c#142#4#article#19#4#^rND^sMcLaughlin^nMG#^rND^
sDanias^nPG#Transient ischemic dilation: a powerful diagnostic and prognostic fi
nding of stress myocardial perfusion imaging^len#J Nucl Cardiol#20020000#2002#9#
6#663-7#20110000#aop3511.htm#1071-3581#J Nucl Cardiol##
00832000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100017001030100
01400120010001900134010002200153010001900175810000600194012018800200030001800388
06500090040606400050041503100030042003200020042301400080042586500090043300200120
0442035001000454801001800464#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#143#5#article#19#5#^rND^sMazzanti^nM#^rND^sGermano^nG#^rND^sKiat^
nH#^rND^sKavanagh^nPB#^rND^sAlexanderson^nE#^rND^sFriedman^nJD#et al#Identificat
ion of severe and extensive coronary artery disease by automatic measurement of 
transient ischemic dilation of the left ventricle in dual-isotope myocardial per
fusion SPECT^len#J Am Coll Cardiol#19960000#1996#27#7#1612-20#20110000#aop3511.h
tm#0735-1097#J Am Coll Cardiol##
00735000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100015001030100
01800118010001700136010001900153012015000172030001500322065000900337064000500346
03100020035103200020035301400080035586500090036300200120037203500100038480100150
0394#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#c#144#6#art
icle#19#6#^rND^sMarcassa^nC#^rND^sGalli^nM#^rND^sBaroffio^nC#^rND^sCampini^nR#^r
ND^sGiannuzzi^nP#Transient left ventricular dilation at quantitative stress-rest
 sestamibi tomography: clinical, electrocardiographic, and angiographic correlat
es^len#J Nucl Cardiol#19990000#1999#6#4#397-405#20110000#aop3511.htm#1071-3581#J
 Nucl Cardiol##
00741000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100018001040100
01600122010001800138010001500156010001500171810000600186012011600192030001400308
06500090032206400050033103100030033603200020033901400050034186500090034600200120
0355035001000367801001400377#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#145#7#article#19#7#^rND^sKinoshita^nN#^rND^sSugihara^nH#^rND^sAda
chi^nY#^rND^sNakamura^nT#^rND^sAzuma^nA#^rND^sKohno^nY#et al#Assessment of trans
ient left ventricular dilatation on rest and exercise on Tc-99m tetrofosmin myoc
ardial SPECT^len#Clin Nucl Med#20020000#2002#27#1#34-9#20110000#aop3511.htm#0363
-9762#Clin Nucl Med##
00707000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100020001040100
01700124010001700141012015200158030001300310065000900323064000500332031000300337
032000200340014000700342865000900349002001200358035001000370801001300380#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#c#146#8#article#19#8#^r
ND^sChouraqui^nP#^rND^sRodrigues^nEA#^rND^sBerman^nDS#^rND^sMaddahi^nJ#Significa
nce of dipyridamole-induced transient dilation of the left ventricle during thal
lium-201 scintigraphy in suspected coronary artery disease^len#Am J Cardiol#1990
0000#1990#66#7#689-94#20110000#aop3511.htm#0002-9149#Am J Cardiol##
00627000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100014001020100
01900116010001800135012007300153030001500226065000900241064000500250031000300255
032000200258014000700260865000900267002001200276035001000288801001500298#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3511.htm#S#c#147#9#article#19#9#^r
ND^sFicaro^nEP#^rND^sLee^nBC#^rND^sKritzman^nJN#^rND^sCorbett^nJR#Corridor4DM: t
he Michigan method for quantitative nuclear cardiology^len#J Nucl Cardiol#200700
00#2007#14#4#455-65#20110000#aop3511.htm#1071-3581#J Nucl Cardiol##
00790000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01900118010002200137010001400159010001500173810000600188012016400194030001100358
06500090036906400050037803100030038303200030038601400090038986500090039800200120
0407035001000419801001100429#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#148#10#article#19#10#^rND^sEmmett^nL#^rND^sMagee^nM#^rND^sFreedma
n^nSB#^rND^sVan der Wall^nH#^rND^sBush^nV#^rND^sTrieu^nJ#et al#The role of left 
ventricular hypertrophy and diabetes in the presence of transient ischemic dilat
ion of the left ventricle on myocardial perfusion SPECT images^len#J Nucl Med#20
050000#2005#46#10#1596-601#20110000#aop3511.htm#0161-5505#J Nucl Med##
00561000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040120
06800123030001100191065000900202064000500211031000300216032000200219014000800221
865000900229002001200238035001000250801001100260#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3511.htm#S#c#149#11#article#19#11#^rND^sVesely^nMR#^rND^sD
ilsizian^nV#Nuclear cardiac stress testing in the era of molecular medicine^len#
J Nucl Med#20080000#2008#49#3#399-413#20110000#aop3511.htm#0161-5505#J Nucl Med#
#
00738000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060100
01600123010002000139010001500159010001600174810000600190012009300196030002000289
06500090030906400050031803100040032303200020032701400080032986500090033700200120
0346035001000358801002000368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#150#12#article#19#12#^rND^sRobinson^nVJ#^rND^sCorley^nJH#^rND^sMa
rks^nDS#^rND^sEberhardt^nLW#^rND^sEubig^nC#^rND^sBurke^nGJ#et al#Causes of trans
ient dilatation of the left ventricle during myocardial perfusion imaging^len#AJ
R Am J Roentgenol#20000000#2000#174#5#1349-52#20110000#aop3511.htm#0361-803X#AJR
 Am J Roentgenol##
00612000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100017001070100
01700124012009800141030001500239065000900254064000500263031000300268014000500271
865000900276002001200285035001000297801001500307#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3511.htm#S#c#151#13#article#19#13#^rND^sRobinson^nVJB#^rND
^sCorley^nJH#^rND^sGunter^nLE#Transient ischemic dilation occurs in patients wit
hout severe multivessel epicardial stenoses^len#J Investig Med#19970000#1997#45#
226A#20110000#aop3511.htm#1081-5589#J Investig Med##
00689000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100015001020100
01700117010001700134010002000151010001800171810000600189012006600195030001100261
06500090027206400050028103100040028603200020029001400050029286500090029700200120
0306035001000318801001100328#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#152#14#article#19#14#^rND^sInoue^nT#^rND^sSakai^nY#^rND^sMorooka^
nS#^rND^sHayashi^nT#^rND^sTakayanagi^nK#^rND^sYamanaka^nT#et al#Coronary flow re
serve in patients with dilated cardiomyopathy^len#Am Heart J#19930000#1993#125#1
#93-8#20110000#aop3511.htm#0002-8703#Am Heart J##
00803000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100014001030100
01600117010001500133010001700148010001400165810000600179012018500185030001100370
06500090038106400050039003100030039503200030039801400100040186500090041100200120
0420035001000432801001100442#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#153#15#article#19#15#^rND^sAbidov^nA#^rND^sBax^nJJ#^rND^sHayes^nS
W#^rND^sCohen^nI#^rND^sNishina^nH#^rND^sYoda^nS#et al#Integration of automatical
ly measured transient ischemic dilation ratio into interpretation of adenosine s
tress myocardial perfusion SPECT for detection of severe and extensive CAD^len#J
 Nucl Med#20040000#2004#45#12#1999-2007#20110000#aop3511.htm#0161-5505#J Nucl Me
d##
00748000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100020001050100
01500125010001800140010001700158010001700175810000600192012011400198030001300312
06500090032506400050033403100040033903200030034301400080034686500090035400200120
0363035001000375801001300385#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#154#16#article#19#16#^rND^sPanting^nJR#^rND^sGatehouse^nPD#^rND^s
Yang^nGZ#^rND^sGrothues^nF#^rND^sFirmin^nDN#^rND^sCollins^nP#et al#Abnormal sube
ndocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic r
esonance imaging^len#N Engl J Med#20020000#2002#346#25#1948-53#20110000#aop3511.
htm#0028-4793#N Engl J Med##
00710000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050100
01700122010002000139010001700159010002100176810000600197012006200203030001900265
06500090028406400050029303100030029803200020030101400070030386500090031000200120
0319035001000331801001900341#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#155#17#article#19#17#^rND^sStrauss^nHW#^rND^sMiller^nDD#^rND^sWit
try^nMD#^rND^sCerqueira^nMD#^rND^sGarcia^nEV#^rND^sIskandrian^nAS#et al#Procedur
e guideline for myocardial perfusion imaging 3: 3^len#J Nucl Med Technol#2008000
0#2008#36#3#155-61#20110000#aop3511.htm#0091-4916#J Nucl Med Technol##
00754000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100013000870100018001000100
01600118010001600134010001800150010001600168810000600184012012400190030001600314
06500090033006400050033903100030034403200030034701400070035086500090035700200120
0366035001000378801001600388#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3511.htm#S#c#156#18#article#19#18#^rND^sShi^nH#^rND^sSantana^nCA#^rND^sRivero^
nA#^rND^sSanyal^nR#^rND^sEsteves^nFP#^rND^sVerdes^nL#et al#Normal values and pro
spective validation of transient ischaemic dilation index in 82Rb PET myocardial
 perfusion imaging^len#Nucl Med Commun#20070000#2007#28#11#859-63#20110000#aop35
11.htm#0143-3636#Nucl Med Commun##
00665000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
01700121012013800138030001500276065000900291064000500300031000300305032000200308
014000700310865000900317002001200326035001000338801001500348#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3511.htm#S#c#157#19#article#19#19#^rND^sKakhki
^nVR#^rND^sSadeghi^nR#^rND^sZakavi^nSR#Assessment of transient left ventricular 
dilation ratio via 2-day dipyridamole Tc-99m sestamibi nongated myocardial perfu
sion imaging^len#J Nucl Cardiol#20070000#2007#14#4#529-36#20110000#aop3511.htm#1
071-3581#J Nucl Cardiol##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#o#1#1#a
rticle#1#20110408#165219#aop3611.htm#197##
05258000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201201170017101201030
02880100031003910100031004220100030004530100028004830100030005110100023005410100
02900564010003100593070005700624070003700681083178400718085000802502085004002510
08500340255008500210258408500240260508316990262908500080432808500320433608500200
43680850032043880850021044200850030044411170008044710720003044791120009044821110
00904491116000904500115000904509114000904518113000904527002001204536#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#h#2#1#article#1#tr#pt#br1.1
#1#4.0#ND#45#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#
Impacto da insuficiência renal crônica na eficácia de stents farmacológicos: est
udo de seguimento de longo prazo^lpt#Impact of chronic kidney disease on the eff
icacy of drug-eluting stents: long-term follow-up study^len#^rND^1A01^nVitor Osó
rio^sGomes#^rND^1A01 A02^nPatrícia^sBlaya#^rND^1A01^nRicardo^sLasevitch#^rND^1A0
1^nDenise^sOliveira#^rND^1A01^nPatrícia^sHickmann#^rND^1A01^nLuís^sSmidt#^rND^1A
02^nCarisi^sPolanczyk#^rND^1A01 A02^nPaulo^sCaramori#PUCRS^iA01^1Hospital São Lu
cas^cPorto Alegre^sRS^pBrasil#UFRGS^iA02^cPorto Alegre^sRS^pBrasil#^lpt^aFUNDAME
NTO: Pacientes com Insuficiência Renal Crônica (IRC) submetidos à angioplastia c
oronária apresentam maiores taxas de revascularização da lesão alvo (RLA) e mort
alidade. Os stents farmacológicos (SF) estão associados com taxas menores de ree
stenose, quando comparados aos stents não farmacológicos (SNF), embora em pacien
tes com IRC os dados da eficácia e segurança do SF sejam limitados. OBJETIVO: Bu
scamos avaliar a segurança e eficácia dos SF em pacientes com IRC significante, 
quando comparados a pacientes com função renal normal em um registro da "vida re
al". MÉTODOS: 504 pacientes submetidos à intervenção coronariana percutânea com 
SF em dois centros foram incluídos. Os desfechos foram estratificados baseados n
a presença de IRC, definida como taxa de filtração glomerular basal < 60 ml/min/
1,73 m². RESULTADOS: O acompanhamento médio foi de 22,7 meses. A IRC estava pres
ente em 165 pacientes (32,7%). Pacientes com IRC eram mais velhos, tinham mais h
ipertensão e diabete. Pacientes com IRC apresentaram maior incidência de morte (
12,3% vs 2,4%, p < 0,001) e infarto do miocárdio (IM) (7,4% vs 3,3%, p = 0,04), 
quando comparados aos pacientes sem IRC. Taxas de RLA foram similares entre os g
rupos (4.8% vs 5.6%, p = 0,7, pacientes com e sem IRC, respectivamente). Predito
res independentes de morte foram a IRC (HR 6,93; 2,4 - 19,5, p < 0,001), tabagis
mo atual (HR 3,66; 1,20 - 11,10, p = 0,02) e diabete (HR 2,66; 1,3 - 6,60, p = 0
,045). CONCLUSÃO: Neste registro, a intervenção coronariana com SF em pacientes 
com IRC foi associada com RLA similar comparada aos pacientes sem IRC, demonstra
ndo a eficácia dos FS na prevenção da reestenose intra-stent nessa população de 
pacientes. A IRC foi relacionada a um aumento significativo das taxas de IM e mo
rtalidade.#^dnd^i1#^tm^lpt^kInsuficiência renal crônica^i1#^tm^lpt^kstents farma
cológicos^i1#^tm^lpt^keficácia^i1#^tm^lpt^kseguimentos^i1#^len^aBACKGROUND: Pati
ents with chronic kidney disease (CKD) submitted to coronary angioplasty have hi
gher rates of target lesion revascularization (TLR) and mortality. Drug-eluting 
stents (DES) are associated with a lower rate of restenosis, compared to bare me
tal stents (BMS), although data on DES efficacy and safety is limited in patient
s with CKD. OBJECTIVE: We sought to evaluate the safety and efficacy of DES in p
atients with significant CKD as compared to patients without normal renal functi
on in a real world registry. METHODS: 504 patients who underwent percutaneous co
ronary intervention with DES in two centers were included. Outcomes were stratif
ied based on the presence of CKD, defined as a baseline glomerular filtration ra
te (GFR) < 60 ml/min/1.73 m². RESULTS: The mean follow-up was 22.7 months. CKD w
as present in 165 patients (32.7%). Patients with CKD were older, had a higher i
ncidence of hypertension and diabetes. CKD patients presented an increased incid
ence of death (12.3% vs 2.4%, p < 0.001) and myocardial infarction (MI) (7.4% vs
 3.3%, p = 0.04) compared to patients without CKD. TLR rates were similar betwee
n groups (4.8% vs 5.6%, p = 0.7, CKD and no CKD patients, respectively). Indepen
dent predictors of death were CKD (HR 6.93; 2.4 - 19.5, p < 0.001), current smok
ing (HR 3.66; 1.20 - 11.10, p = 0.02) and diabetes (HR 2.66; 1.03 - 6.60, p = 0.
045). CONCLUSION: In this registry, coronary intervention with DES in patients w
ith CKD was associated with similar TLR compared to patients without CKD, demons
trating the efficacy of DES in preventing in-stent restenosis in this patient po
pulation. CKD was related to significantly increased MI and mortality rates.#^dn
d^i2#^tm^len^kRenal insufficiency^i2#^tm^len^kchronic^i2#^tm^len^kdrug-eluting s
tents^i2#^tm^len^kefficacy^i2#^tm^len^kfollow-up studies^i2#vancouv#32#20100823#
23/08/10#20101117#17/11/10#20101129#29/11/10#aop3611.htm##
05451000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201201380017101201170
03090100031004260100031004570100030004880100028005180100030005460100023005760100
02900599010003100628070005700659070003700716083187000753085000802623085004002631
08500410267108500210271208500240273308317640275708500080452108500320452908500200
45610850032045810850021046130850030046341170008046640720003046721120009046751110
00904684116000904693115000904702114000904711113000904720002001204729#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#f#3#1#article#1#tr#pt#br1.1
#1#4.0#ND#45#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#
<b>Impacto da insuficiência renal crônica na eficácia de <i>stents</i> farmacoló
gicos</b>: <b>estudo de seguimento de longo prazo</b>^lpt#<b>Impact of chronic k
idney disease on the efficacy of drug-eluting stents</b>: <b>long-term follow-up
 study</b>^len#^rND^1A01^nVitor Osório^sGomes#^rND^1A01 A02^nPatrícia^sBlaya#^rN
D^1A01^nRicardo^sLasevitch#^rND^1A01^nDenise^sOliveira#^rND^1A01^nPatrícia^sHick
mann#^rND^1A01^nLuís^sSmidt#^rND^1A02^nCarisi^sPolanczyk#^rND^1A01 A02^nPaulo^sC
aramori#PUCRS^iA01^1Hospital São Lucas^cPorto Alegre^sRS^pBrasil#UFRGS^iA02^cPor
to Alegre^sRS^pBrasil#^lpt^a<b>FUNDAMENTO:</b> Pacientes com Insuficiência Renal
 Crônica (IRC) submetidos à angioplastia coronária apresentam maiores taxas de r
evascularização da lesão alvo (RLA) e mortalidade. Os <i>stents</i> farmacológic
os (SF) estão associados com taxas menores de reestenose, quando comparados aos 
<i>stents</i> não farmacológicos (SNF), embora em pacientes com IRC os dados da 
eficácia e segurança do SF sejam limitados. <b>OBJETIVO:</b> Buscamos avaliar a 
segurança e eficácia dos SF em pacientes com IRC significante, quando comparados
 a pacientes com função renal normal em um registro da "vida real". <b>MÉTODOS:<
/b> 504 pacientes submetidos à intervenção coronariana percutânea com SF em dois
 centros foram incluídos. Os desfechos foram estratificados baseados na presença
 de IRC, definida como taxa de filtração glomerular basal &lt; 60 ml/min/1,73 m²
. <b>RESULTADOS:</b> O acompanhamento médio foi de 22,7 meses. A IRC estava pres
ente em 165 pacientes (32,7%). Pacientes com IRC eram mais velhos, tinham mais h
ipertensão e diabete. Pacientes com IRC apresentaram maior incidência de morte (
12,3% <i>vs</i> 2,4%, p &lt; 0,001) e infarto do miocárdio (IM) (7,4% <i>vs</i> 
3,3%, p = 0,04), quando comparados aos pacientes sem IRC. Taxas de RLA foram sim
ilares entre os grupos (4.8% <i>vs</i> 5.6%, p = 0,7, pacientes com e sem IRC, r
espectivamente). Preditores independentes de morte foram a IRC (HR 6,93; 2,4 - 1
9,5, p &lt; 0,001), tabagismo atual (HR 3,66; 1,20 - 11,10, p = 0,02) e diabete 
(HR 2,66; 1,3 - 6,60, p = 0,045). <b>CONCLUSÃO:</b> Neste registro, a intervençã
o coronariana com SF em pacientes com IRC foi associada com RLA similar comparad
a aos pacientes sem IRC, demonstrando a eficácia dos FS na prevenção da reesteno
se intra-<i>stent</i> nessa população de pacientes. A IRC foi relacionada a um a
umento significativo das taxas de IM e mortalidade.#^dnd^i1#^tm^lpt^kInsuficiênc
ia renal crônica^i1#^tm^lpt^k<i>stents</i> farmacológicos^i1#^tm^lpt^keficácia^i
1#^tm^lpt^kseguimentos^i1#^len^a<b>BACKGROUND:</b> Patients with chronic kidney 
disease (CKD) submitted to coronary angioplasty have higher rates of target lesi
on revascularization (TLR) and mortality. Drug-eluting stents (DES) are associat
ed with a lower rate of restenosis, compared to bare metal stents (BMS), althoug
h data on DES efficacy and safety is limited in patients with CKD. <b>OBJECTIVE:
</b> We sought to evaluate the safety and efficacy of DES in patients with signi
ficant CKD as compared to patients without normal renal function in a real world
 registry. <b>METHODS:</b> 504 patients who underwent percutaneous coronary inte
rvention with DES in two centers were included. Outcomes were stratified based o
n the presence of CKD, defined as a baseline glomerular filtration rate (GFR) &l
t; 60 ml/min/1.73 m². <b>RESULTS:</b> The mean follow-up was 22.7 months. CKD wa
s present in 165 patients (32.7%). Patients with CKD were older, had a higher in
cidence of hypertension and diabetes. CKD patients presented an increased incide
nce of death (12.3% <i>vs</i> 2.4%, p &lt; 0.001) and myocardial infarction (MI)
 (7.4% <i>vs</i> 3.3%, p = 0.04) compared to patients without CKD. TLR rates wer
e similar between groups (4.8% <i>vs</i> 5.6%, p = 0.7, CKD and no CKD patients,
 respectively). Independent predictors of death were CKD (HR 6.93; 2.4 - 19.5, p
 &lt; 0.001), current smoking (HR 3.66; 1.20 - 11.10, p = 0.02) and diabetes (HR
 2.66; 1.03 - 6.60, p = 0.045). <b>CONCLUSION:</b> In this registry, coronary in
tervention with DES in patients with CKD was associated with similar TLR compare
d to patients without CKD, demonstrating the efficacy of DES in preventing in-st
ent restenosis in this patient population. CKD was related to significantly incr
eased MI and mortality rates.#^dnd^i2#^tm^len^kRenal insufficiency^i2#^tm^len^kc
hronic^i2#^tm^len^kdrug-eluting stents^i2#^tm^len^kefficacy^i2#^tm^len^kfollow-u
p studies^i2#vancouv#32#20100823#23/08/10#20101117#17/11/10#20101129#29/11/10#ao
p3611.htm##
05478000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030001900114
03200060013306500090013901400070014803500100015522300090016501201170017401201030
02910100031003940100031004250100030004560100028004860100030005140100023005440100
02900567010003100596070005900627070003900686083184700725085000802572085004002580
08500340262008500210265408500240267508317480269908500080444708500320445508500200
44870850032045070850021045390850030045601170008045900720003045981120009046011110
00904610116000904619115000904628114000904637113000904646002001204655008008904667
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#l#4#1#article#1
#^a2011#tr#pt#br1.1#1#4.0#45#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066
-782X#20110415#Impacto da insuficiência renal crônica na eficácia de stents farm
acológicos: estudo de seguimento de longo prazo^lpt#Impact of chronic kidney dis
ease on the efficacy of drug-eluting stents: long-term follow-up study^len#^rND^
1A01^nVitor Osório^sGomes#^rND^1A01 A02^nPatrícia^sBlaya#^rND^1A01^nRicardo^sLas
evitch#^rND^1A01^nDenise^sOliveira#^rND^1A01^nPatrícia^sHickmann#^rND^1A01^nLuís
^sSmidt#^rND^1A02^nCarisi^sPolanczyk#^rND^1A01 A02^nPaulo^sCaramori#^iA01^1PUCRS
^2Hospital São Lucas^cPorto Alegre^sRS^pBrasil#^iA02^1UFRGS^cPorto Alegre^sRS^pB
rasil#^lpt^aFUNDAMENTO: Pacientes com Insuficiência Renal Crônica (IRC) submetid
os à angioplastia coronária apresentam maiores taxas de revascularização da lesã
o alvo (RLA) e mortalidade. Os stents farmacológicos (SF) estão associados com t
axas menores de reestenose, quando comparados aos stents não farmacológicos (SNF
), embora em pacientes com IRC os dados da eficácia e segurança do SF sejam limi
tados. OBJETIVO: Buscamos avaliar a segurança e eficácia dos SF em pacientes com
 IRC significante, quando comparados a pacientes com função renal normal em um r
egistro da "vida real". MÉTODOS: 504 pacientes submetidos à intervenção coronari
ana percutânea com SF em dois centros foram incluídos. Os desfechos foram estrat
ificados baseados na presença de IRC, definida como taxa de filtração glomerular
 basal < 60 ml/min/1,73 m². RESULTADOS: O acompanhamento médio foi de 22,7 meses
. A IRC estava presente em 165 pacientes (32,7 por cento). Pacientes com IRC era
m mais velhos, tinham mais hipertensão e diabete. Pacientes com IRC apresentaram
 maior incidência de morte (12,3 por cento vs 2,4 por cento, p < 0,001) e infart
o do miocárdio (IM) (7,4 por cento vs 3,3 por cento, p = 0,04), quando comparado
s aos pacientes sem IRC. Taxas de RLA foram similares entre os grupos (4.8 por c
ento vs 5.6 por cento, p = 0,7, pacientes com e sem IRC, respectivamente). Predi
tores independentes de morte foram a IRC (HR 6,93; 2,4 - 19,5, p < 0,001), tabag
ismo atual (HR 3,66; 1,20 - 11,10, p = 0,02) e diabete (HR 2,66; 1,3 - 6,60, p =
 0,045). CONCLUSÃO: Neste registro, a intervenção coronariana com SF em paciente
s com IRC foi associada com RLA similar comparada aos pacientes sem IRC, demonst
rando a eficácia dos FS na prevenção da reestenose intra-stent nessa população d
e pacientes. A IRC foi relacionada a um aumento significativo das taxas de IM e 
mortalidade.#^dnd^i1#^tm^lpt^kInsuficiência renal crônica^i1#^tm^lpt^kstents far
macológicos^i1#^tm^lpt^keficácia^i1#^tm^lpt^kseguimentos^i1#^len^aBACKGROUND: Pa
tients with chronic kidney disease (CKD) submitted to coronary angioplasty have 
higher rates of target lesion revascularization (TLR) and mortality. Drug-elutin
g stents (DES) are associated with a lower rate of restenosis, compared to bare 
metal stents (BMS), although data on DES efficacy and safety is limited in patie
nts with CKD. OBJECTIVE: We sought to evaluate the safety and efficacy of DES in
 patients with significant CKD as compared to patients without normal renal func
tion in a real world registry. METHODS: 504 patients who underwent percutaneous 
coronary intervention with DES in two centers were included. Outcomes were strat
ified based on the presence of CKD, defined as a baseline glomerular filtration 
rate (GFR) < 60 ml/min/1.73 m². RESULTS: The mean follow-up was 22.7 months. CKD
 was present in 165 patients (32.7 percent). Patients with CKD were older, had a
 higher incidence of hypertension and diabetes. CKD patients presented an increa
sed incidence of death (12.3 percent vs 2.4 percent, p < 0.001) and myocardial i
nfarction (MI) (7.4 percent vs 3.3 percent, p = 0.04) compared to patients witho
ut CKD. TLR rates were similar between groups (4.8 percent vs 5.6 percent, p = 0
.7, CKD and no CKD patients, respectively). Independent predictors of death were
 CKD (HR 6.93; 2.4 - 19.5, p < 0.001), current smoking (HR 3.66; 1.20 - 11.10, p
 = 0.02) and diabetes (HR 2.66; 1.03 - 6.60, p = 0.045). CONCLUSION: In this reg
istry, coronary intervention with DES in patients with CKD was associated with s
imilar TLR compared to patients without CKD, demonstrating the efficacy of DES i
n preventing in-stent restenosis in this patient population. CKD was related to 
significantly increased MI and mortality rates.#^dnd^i2#^tm^len^kRenal insuffici
ency^i2#^tm^len^kchronic^i2#^tm^len^kdrug-eluting stents^i2#^tm^len^kefficacy^i2
#^tm^len^kfollow-up studies^i2#vancouv#32#20100823#23/08/10#20101117#17/11/10#20
101129#29/11/10#aop3611.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci
_arttext&pid=S0066-782X2011005000045##
00477000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704023700082002001200319#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#5#1#article#161#<p><font size
="4" face="verdana"><b><a name="title"></a>Impacto da insufici&ecirc;ncia       
renal cr&ocirc;nica na efic&aacute;cia de <I>stents</I> farmacol&oacute;gicos:  
     estudo de seguimento de longo prazo</b></font></p>     ^cY#aop3611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#6#2#article#161#<p>&nbsp;</p>
     ^cY#aop3611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#7#3#article#161#<p>&nbsp;</p>
     ^cY#aop3611.htm##
00584000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704034400082002001200426#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#8#4#article#161#<p><font size
="2" face="Verdana"><b>Vitor Os&oacute;rio Gomes<SUP>I</SUP>; Patr&iacute;cia   
    Blaya<SUP>I,II</SUP>; Ricardo Lasevitch<SUP>I</SUP>; Denise Oliveira<SUP>I</
SUP>; Patr&iacute;cia       Hickmann<SUP>I</SUP>; Lu&iacute;s Smidt<SUP>I</SUP>;
 Carisi Polanczyk<SUP>II</SUP>; Paulo       Caramori<SUP>I,II</SUP></b></font></
p>     ^cY#aop3611.htm##
00366000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704012600082002001200208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#9#5#article#161#<p><font size
="2" face="Verdana"> <sup>I</sup>Hospital S&atilde;o Lucas &#45; PUCRS,     Port
o Alegre, RS &#45; Brasil    ^cY#aop3611.htm##
00391000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704015000083002001200233#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#10#6#article#161#<br>   <sup>
II</sup>Programa de P&oacute;s&#45;gradua&ccedil;&atilde;o em Cardiologia   &#45
; UFRGS, Porto Alegre, RS &#45; Brasil</font></p>     ^cY#aop3611.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704009300083002001200176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#11#7#article#161#<p><font siz
e="2" face="Verdana"><a href="#end">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop3611.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704002200083002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#12#8#article#161#<p>&nbsp;</p
>     ^cY#aop3611.htm##
00285000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704004400083002001200127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#13#9#article#161#<p>&nbsp;</p
> <hr size="1" noshade>     ^cY#aop3611.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006600084002001200150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#14#10#article#161#<p><font si
ze="2" face="VERDANA"><b>RESUMO</b></font></p>     ^cY#aop3611.htm##
00811000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056900084002001200653#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#15#11#article#161#<p><font si
ze="2" face="Verdana"><b>FUNDAMENTO:</b> Pacientes com Insufici&ecirc;ncia     R
enal Cr&ocirc;nica (IRC) submetidos &agrave; angioplastia coron&aacute;ria     a
presentam maiores taxas de revasculariza&ccedil;&atilde;o da les&atilde;o     al
vo (RLA) e mortalidade. Os <I>stents</I> farmacol&oacute;gicos (SF) est&atilde;o
     associados com taxas menores de reestenose, quando comparados aos <I>stents
</I> n&atilde;o     farmacol&oacute;gicos (SNF), embora em pacientes com IRC os 
dados da efic&aacute;cia     e seguran&ccedil;a do SF sejam limitados.    ^cY#ao
p3611.htm##
00472000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023000084002001200314#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#16#12#article#161#<br>   <b>O
BJETIVO:</b> Buscamos avaliar a seguran&ccedil;a e efic&aacute;cia dos   SF em p
acientes com IRC significante, quando comparados a pacientes com fun&ccedil;&ati
lde;o   renal normal em um registro da "vida real".    ^cY#aop3611.htm##
00578000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033600084002001200420#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#17#13#article#161#<br>   <b>M
&Eacute;TODOS:</b> 504 pacientes submetidos &agrave; interven&ccedil;&atilde;o  
 coronariana percut&acirc;nea com SF em dois centros foram inclu&iacute;dos.   O
s desfechos foram estratificados baseados na presen&ccedil;a de IRC, definida   
como taxa de filtra&ccedil;&atilde;o glomerular basal &lt; 60 ml/min/1,73 m².   
 ^cY#aop3611.htm##
00983000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704074100084002001200825#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#18#14#article#161#<br>   <b>R
ESULTADOS:</b> O acompanhamento m&eacute;dio foi de 22,7 meses. A IRC estava   p
resente em 165 pacientes (32,7%). Pacientes com IRC eram mais velhos, tinham   m
ais hipertens&atilde;o e diabete. Pacientes com IRC apresentaram maior incid&eci
rc;ncia   de morte (12,3% <I>vs</I> 2,4%, p &lt; 0,001) e infarto do mioc&aacute
;rdio   (IM) (7,4% <I>vs</I> 3,3%, p = 0,04), quando comparados aos pacientes se
m IRC.   Taxas de RLA foram similares entre os grupos (4.8% <I>vs</I> 5.6%, p = 
0,7,   pacientes com e sem IRC, respectivamente). Preditores independentes de mo
rte   foram a IRC (HR 6,93; 2,4 &#45; 19,5, p &lt; 0,001), tabagismo atual (HR 3
,66;   1,20 &#45; 11,10, p = 0,02) e diabete (HR 2,66; 1,3 &#45; 6,60, p = 0,045
).    ^cY#aop3611.htm##
00674000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704043200084002001200516#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#19#15#article#161#<br>   <b>C
ONCLUS&Atilde;O:</b> Neste registro, a interven&ccedil;&atilde;o coronariana   c
om SF em pacientes com IRC foi associada com RLA similar comparada aos pacientes
   sem IRC, demonstrando a efic&aacute;cia dos FS na preven&ccedil;&atilde;o da 
  reestenose intra&#45;<I>stent</I> nessa popula&ccedil;&atilde;o de pacientes. 
A   IRC foi relacionada a um aumento significativo das taxas de IM e mortalidade
.</font></p>     ^cY#aop3611.htm##
00455000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021300084002001200297#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#20#16#article#161#<p><font si
ze="2" face="Verdana"><b>Palavras&#45;chave:</b> Insufici&ecirc;ncia renal     c
r&ocirc;nica, <I>stents</I> farmacol&oacute;gicos, efic&aacute;cia, seguimentos.
</font></p> <hr size="1" noshade>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#21#17#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#22#18#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#23#19#article#161#<p><font si
ze="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop3611
.htm##
01081000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704083900084002001200923#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#24#20#article#161#<p><font si
ze="2" face="Verdana">A insufici&ecirc;ncia renal cr&ocirc;nica (IRC) &eacute; u
m     importante problema de sa&uacute;de p&uacute;blica no mundo todo. Existe  
   uma forte associa&ccedil;&atilde;o entre a IRC e a preval&ecirc;ncia de doen&
ccedil;a     arterial coronariana (DAC) e mortalidade<SUP>1</SUP>. Entre pacient
es com     insufici&ecirc;ncia renal cr&ocirc;nica terminal (IRCT), a mortalidad
e card&iacute;aca &eacute; de     10 a 30 vezes maior que na popula&ccedil;&atil
de;o em geral. O mecanismo     desta associa&ccedil;&atilde;o n&atilde;o &eacute
; inteiramente conhecido,     mas uma maior preval&ecirc;ncia de fatores de risc
o tradicionais na popula&ccedil;&atilde;o,     como idade avan&ccedil;ada, hiper
tens&atilde;o e diabete, contribui para     a aterosclerose acelerada<SUP>2&#45;
4</SUP>.</font></p>     ^cY#aop3611.htm##
00934000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704069200084002001200776#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#25#21#article#161#<p><font si
ze="2" face="Verdana">Ap&oacute;s a interven&ccedil;&atilde;o coronariana     pe
rcut&acirc;nea (ICP) com <I>stents</I> n&atilde;o&#45;farmacol&oacute;gicos     
(SNF), pacientes com IRC tiveram um aumento na incid&ecirc;ncia de reestenose   
  e eventos card&iacute;acos quando comparados &agrave; pacientes sem disfun&cce
dil;&atilde;o     renal<SUP>5&#45;7</SUP>. Contudo, mesmo considerando os result
ados limitados,     a ICP &eacute; uma alternativa muito importante no tratament
o de pacientes     com IRC que possam apresentar um risco cir&uacute;rgico aumen
tado e que apresentem     angina limitante, apesar do tratamento m&eacute;dico o
timizado<SUP>7</SUP>.</font></p>     ^cY#aop3611.htm##
00718000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047600084002001200560#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#26#22#article#161#<p><font si
ze="2" face="Verdana"><i>Stents</i> farmacol&oacute;gicos (SF) reduziram     a i
ncid&ecirc;ncia de reestenose e a necessidade de revasculariza&ccedil;&atilde;o 
    futura quando comparados aos SNF. H&aacute; escassez de dados sobre a segura
n&ccedil;a     e efic&aacute;cia do SF em pacientes com IRC, considerando que es
sa popula&ccedil;&atilde;o &eacute; frequentemente     exclu&iacute;da de grande
s estudos cl&iacute;nicos<SUP>8&#45;10</SUP>.</font></p>     ^cY#aop3611.htm##
00524000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028200084002001200366#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#27#23#article#161#<p><font si
ze="2" face="Verdana">O objetivo deste estudo foi avaliar a efic&aacute;cia     
e seguran&ccedil;a dos FS em pacientes com IRC significante, quando comparados &
agrave; pacientes     com fun&ccedil;&atilde;o renal normal em um registro da "v
ida real". </font></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#28#24#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007400084002001200158#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#29#25#article#161#<p><font si
ze="3" face="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#aop3611.htm##
00335000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009300084002001200177#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#30#26#article#161#<p><font si
ze="2" face="Verdana"><b>Popula&ccedil;&atilde;o do estudo</b></font></p>     ^c
Y#aop3611.htm##
00735000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049300084002001200577#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#31#27#article#161#<p><font si
ze="2" face="Verdana">A popula&ccedil;&atilde;o do estudo consistiu     em 611 p
acientes consecutivos submetidos &agrave; ICP com SF entre junho     de 2002 e j
unho de 2006 em dois hospitais terci&aacute;rios em Porto Alegre,     Brasil. Um
 total de 504 pacientes foi inclu&iacute;do nesta an&aacute;lise,     pois os me
smos tinham medidas de creatinina s&eacute;ricas dispon&iacute;veis     de at&ea
cute; 30 dias antes da interven&ccedil;&atilde;o coronariana. </font></p>     ^c
Y#aop3611.htm##
00795000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704055300084002001200637#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#32#28#article#161#<p><font si
ze="2" face="Verdana">A IRC foi definida como a taxa de filtra&ccedil;&atilde;o 
    glomerular (TFG) &lt; 60 ml/min/1,73 m², um valor de corte previamente propo
sto     pela <I>National Foundation's Kidney Disease Outcome Quality Initiative 
Advisory     Board </I>(K/DOQI), para identificar pacientes com insufici&ecirc;n
cia renal     moderada<SUP>11</SUP>. Em conformidade, os pacientes foram dividid
os em 2     grupos: 1) pacientes com a TFG <U>&gt;</u> 60 ml/min/1,73 m² e 2) pa
cientes     com GFR &lt; 60 ml/min/1,73 m²</font></p>     ^cY#aop3611.htm##
00711000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046900084002001200553#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#33#29#article#161#<p><font si
ze="2" face="Verdana">A TFG foi calculada pela equa&ccedil;&atilde;o     da modi
fica&ccedil;&atilde;o da dieta na doen&ccedil;a renal (MDRD): TFG <I>Estimada</I
> =     186 x (creatinina s&eacute;rica)<SUP>&#45;1.154</SUP> x (idade)<SUP>&#45
; 0.203 </SUP>x     (0.742 se for do sexo feminino) x (1.210 se negro/a), onde a
 creatinina &eacute; medida     em mg/dl, idade em anos e a TFG &eacute; express
a em ml/min/1,73 m² <SUP>12,13</SUP>. </font></p>     ^cY#aop3611.htm##
00412000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704017000084002001200254#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#34#30#article#161#<p><font si
ze="2" face="Verdana">Este estudo foi aprovado pelo Comit&ecirc; de &Eacute;tica
     e Pesquisa Institucional local de ambos os hospitais. </font></p>     ^cY#a
op3611.htm##
00577000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704033500084002001200419#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#35#31#article#161#<p><font si
ze="2" face="Verdana">Este estudo foi financiado por um fundo para     educa&cce
dil;&atilde;o irrestrito do Boston Scientific, Cordis Corporation     e Medtroni
c. Estas empresas n&atilde;o tiveram acesso aos dados e n&atilde;o     tem o dir
eito de revisar o artigo antes de sua publica&ccedil;&atilde;o. </font></p>     
^cY#aop3611.htm##
00384000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704014200084002001200226#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#36#32#article#161#<p><font si
ze="2" face="Verdana"><b>Defini&ccedil;&otilde;es de <I>endpoints</I> e       ac
ompanhamento cl&iacute;nico</b></font></p>     ^cY#aop3611.htm##
01279000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704103700084002001201121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#37#33#article#161#<p><font si
ze="2" face="Verdana">O infarto do mioc&aacute;rdio (IM) foi definido     como u
ma eleva&ccedil;&atilde;o da fra&ccedil;&atilde;o creatina quinase&#45;MB     de
 tr&ecirc;s vezes acima do limite da varia&ccedil;&atilde;o normal<SUP>14</SUP>.
     A taxa de revasculariza&ccedil;&atilde;o do vaso&#45;alvo (RVA) foi definid
a     como uma revasculariza&ccedil;&atilde;o percut&acirc;nea repetida ou cir&u
acute;rgica     do vaso tratado. A revasculariza&ccedil;&atilde;o da les&atilde;
o alvo (RLA)     foi definida como uma revasculariza&ccedil;&atilde;o percut&aci
rc;nea ou     cir&uacute;rgica da les&atilde;o&#45;&iacute;ndice durante o acomp
anhamento.     Um evento adverso card&iacute;aco maior (MACE) foi definido como 
um <I>endpoint</I> composto     de morte card&iacute;aca, IM n&atilde;o fatal ou
 RVA durante o acompanhamento.     A defini&ccedil;&atilde;o de trombose de <I>s
tent</I> (TS) foi baseada nos     crit&eacute;rios estabelecidos pelo <I>Academi
c Research Consortium </I>(ARC)<SUP>15</SUP>. </font></p>     ^cY#aop3611.htm##
00617000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037500084002001200459#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#38#34#article#161#<p><font si
ze="2" face="Verdana">O sucesso angiogr&aacute;fico foi definido como     esteno
se &lt; 20% e fluxo TIMI 3 ao fim do procedimento. O sucesso cl&iacute;nico     
foi definido como sucesso angiogr&aacute;fico e a aus&ecirc;ncia de complica&cce
dil;&otilde;es     cl&iacute;nicas como morte, IM, revasculariza&ccedil;&atilde;
o urgente e     derrame.</font></p>     ^cY#aop3611.htm##
00517000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704027500084002001200359#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#39#35#article#161#<p><font si
ze="2" face="Verdana">Para pacientes com mais de uma interven&ccedil;&atilde;o  
   durante o per&iacute;odo de acompanhamento do estudo, somente a primeira     
interven&ccedil;&atilde;o foi considerada para an&aacute;lise dos <I>endpoints</
I>. </font></p>     ^cY#aop3611.htm##
00423000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704018100084002001200265#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#40#36#article#161#<p><font si
ze="2" face="Verdana">O tipo de ST usado durante o procedimento coron&aacute;rio
     foi deixado a crit&eacute;rio do cardiologista intervencionista. </font></p
>     ^cY#aop3611.htm##
00696000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045400084002001200538#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#41#37#article#161#<p><font si
ze="2" face="Verdana">O acompanhamento clinico foi feito atrav&eacute;s     de e
ntrevistas telef&ocirc;nicas com o paciente, revis&atilde;o dos hist&oacute;rico
s     dos pacientes ambulatoriais e contato com o m&eacute;dico assistente. Todo
s     os eventos cl&iacute;nicos foram adjudicados pela an&aacute;lise das fonte
s     de documenta&ccedil;&atilde;o por um cardiologista cego para os outros dad
os     cl&iacute;nicos.</font></p>     ^cY#aop3611.htm##
00367000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012500084002001200209#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#42#38#article#161#<p><font si
ze="2" face="Verdana"><b>An&aacute;lise angiogr&aacute;fica coronariana       qu
antitativa</b></font></p>     ^cY#aop3611.htm##
00963000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704072100084002001200805#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#43#39#article#161#<p><font si
ze="2" face="Verdana">Os angiogramas coronarianos basais e p&oacute;s&#45;proced
imento     obtidos foram analisados por um cardiologista experiente. A angiograf
ia coronariana     quantitativa off&#45;line da interven&ccedil;&atilde;o &iacut
e;ndice foi executada     usando o cateter&#45;guia para calibra&ccedil;&atilde;
o da magnifica&ccedil;&atilde;o     da imagem (<I>CardioNow Websend DICOM Study 
Sharing Software</I>, HeartLab,     Inc., Westerly, Rhode Island). Foram medidos
 o di&acirc;metro luminal m&iacute;nimo     e di&acirc;metro do vaso de refer&ec
irc;ncia antes e depois da interven&ccedil;&atilde;o     a partir de corte &uacu
te;nico mostrando o menor di&acirc;metro luminal. </font></p>     ^cY#aop3611.ht
m##
00335000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009300084002001200177#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#44#40#article#161#<p><font si
ze="2" face="Verdana"><b>An&aacute;lise estat&iacute;stica</b></font></p>     ^c
Y#aop3611.htm##
01371000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704112900084002001201213#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#45#41#article#161#<p><font si
ze="2" face="Verdana">A an&aacute;lise estat&iacute;stica foi realizada     com 
o <I>software</I> SPSS 13.0 (SPSS Inc, Chicago, Illinois). Dados absolutos     f
oram apresentados como frequ&ecirc;ncias (%) e comparados pelo teste Qui&#45;qua
drado.Vari&aacute;veis     cont&iacute;nuas foram apresentadas como m&eacute;dia
 &plusmn; desvio padr&atilde;o     (DP) e comparadas usando o teste <I>t</I> de 
<I>student</I> ou o teste U     de Mann&#45;Whitney quando apropriado. Resultado
s cl&iacute;nicos foram calculados     por qui&#45;quadrado. Os tempos para ocor
r&ecirc;ncia de morte, IM, trombose     e revasculariza&ccedil;&atilde;o nos 2 g
rupos s&atilde;o apresentados como     curvas de Kaplan&#45;Meier e comparados u
sando&#45;se o teste log&#45;rank. Caracter&iacute;sticas     basais significant
es, preditivas de morte e RLA foram identificadas usando     an&aacute;lises mul
tivariadas de Cox, selecionando vari&aacute;veis pelo     m&eacute;todo Backward
 Wald. Para todas as an&aacute;lises, um valor de p     bilateral &lt; 0,05 foi 
considerado para indicar diferen&ccedil;as significantes. </font></p>     ^cY#ao
p3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#46#42#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00312000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007000084002001200154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#47#43#article#161#<p><font si
ze="3" face="Verdana"><b>Resultados</b></font></p>     ^cY#aop3611.htm##
00758000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704051600084002001200600#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#48#44#article#161#<p><font si
ze="2" face="Verdana">A m&eacute;dia do acompanhamento cl&iacute;nico     foi de
 22,6 &plusmn; 13,0 meses, com uma varia&ccedil;&atilde;o de 6,0 a 63,5 meses   
  e estava dispon&iacute;vel em 98,2% dos pacientes. Havia 181 mulheres e 323   
  homens. A m&eacute;dia da idade na popula&ccedil;&atilde;o de estudo era     d
e 63,7 &plusmn; 11,0, variando de 30 a 90 anos de idade. A creatinina s&eacute;r
ica     m&eacute;dia e a TFG eram 1,22 mg/dl e 69,8 ml/min/1,73 m², respectivame
nte. </font></p>     ^cY#aop3611.htm##
00709000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046700084002001200551#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#49#45#article#161#<p><font si
ze="2" face="Verdana">Dos 504 pacientes inclu&iacute;dos nessa an&aacute;lise,  
   339 (67,3%) apresentaram TFG <U>&gt;</u> 60 ml/min/1,73 m², e 165 (32,7%)    
 apresentaram TFG &lt; 60 ml/min/1,73 m². Dez pacientes apresentavam insufici&ec
irc;ncia     renal em est&aacute;gio terminal na di&aacute;lise. A creatinina s&
eacute;rica     m&eacute;dia dos grupos foi de 0,95 &plusmn; 0,17 mg/dl e 1,76 &
plusmn; 1,38 mg/dl, respectivamente.</font></p>     ^cY#aop3611.htm##
00922000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704068000084002001200764#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#50#46#article#161#<p><font si
ze="2" face="Verdana">As caracter&iacute;sticas cl&iacute;nicas de     ambos os 
grupos s&atilde;o mostradas na <a href="#tab01">Tabela 1</a>. Pacientes     com 
IRC, comparados aos pacientes sem IRC, eram significativamente mais velhos     (
68,6 &plusmn; 10 anos <I>vs</I> 61,2 &plusmn; 9 anos, p &lt; 0,001), com maior p
robabilidade     de serem mulheres (50,3% <I>vs</I> 28,9%, p &lt; 0,001), tinham
 hipertens&atilde;o     (88,8% <I>vs</I> 72,8%, p &lt; 0,001), diabete (47.5% <I
>vs</I> 31.5%, p     = 0,001), e eram menos propensos a usar aspirina (74,5% <I>
vs</I> 87,4%,     p &lt; 0,001), ou serem fumantes atuais (5,7% <I>vs</I> 10%, p
 = 0,02).</font></p>     ^cY#aop3611.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#51#47#article#161#<p><a name=
"tab01"></a></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#52#48#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#53#49#article#161#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop36tb1.jpg"></p>     ^cY#aop3611
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#54#50#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
01129000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704088700084002001200971#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#55#51#article#161#<p><font si
ze="2" face="Verdana">Caracter&iacute;sticas angiogr&aacute;ficas     e procedur
ais dos dois grupos s&atilde;o apresentadas na <a href="#tab02">Tabela     2</a>
. A taxa de sucesso angiogr&aacute;fico foi alta e similar nos dois     grupos. 
Comparados aos pacientes sem IRC, aqueles com IRC tiveram maior probabilidade   
  de serem submetidos ao uso de <I>stent</I> direto (26,6% <I>vs</I> 35,7%,     
p = 0,05). Pela angiografia coronariana quantitativa, o di&acirc;metro luminal  
   m&iacute;nimo tendeu a ser maior na condi&ccedil;&atilde;o basal (0,9 &plusmn
; 0,72     mm <I>vs</I> 1,0 &plusmn; 0,42 mm, p = 0,06) e ap&oacute;s o <I>stent
</I> (2,7 &plusmn; 0,48     mm <I>vs</I> 2,8 &plusmn; 0.49 mm, p = 0,05) nos pac
ientes com IRC, mas o ganho     agudo foi similar. Outras caracter&iacute;sticas
 das les&otilde;es foram     similares entre os grupos. </font></p>     ^cY#aop3
611.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#56#52#article#161#<p><a name=
"tab02"></a></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#57#53#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#58#54#article#161#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop36tb2.jpg"></p>     ^cY#aop3611
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#59#55#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00713000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704047100084002001200555#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#60#56#article#161#<p><font si
ze="2" face="Verdana">A incid&ecirc;ncia de eventos cardiovasculares     adverso
s durante a hospitaliza&ccedil;&atilde;o foi alta em pacientes com     IRC. Paci
entes com IRC apresentaram sucesso cl&iacute;nico reduzido (92,1% <I>vs</I> 98,2
%,     p = 0,001), com aumento nas taxas de IM (3,7% <I>vs</I> 0,6%, p = 0,01) e
     morte (3,7% <I>vs</I> 0,3%, p = 0,003). Nenhum paciente sofreu derrame dura
nte     a hospitaliza&ccedil;&atilde;o. </font></p>     ^cY#aop3611.htm##
01343000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704110100084002001201185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#61#57#article#161#<p><font si
ze="2" face="Verdana">Os resultados cl&iacute;nicos de longo prazo     s&atilde;
o apresentados na <a href="#tab03">Tabela 3</a>. As an&aacute;lises     de sobre
viv&ecirc;ncia de Kaplan&#45;Meier para morte, infarto do mioc&aacute;rdio,     
revasculariza&ccedil;&atilde;o da les&atilde;o alvo, e trombose de <I>stent</I> 
definitiva     s&atilde;o apresentadas na <a href="#fig01">Figura 1</a>. Pacient
es com IRC apresentaram maior     incid&ecirc;ncia de morte e morte card&iacute;
aca (12,3% <I>vs</I> 2,4%,     p &lt; 0,001, e 6,1% <I>vs</I> 1,2%, p = 0,002, r
espectivamente) quando comparados     com pacientes sem IRC. A incid&ecirc;ncia 
de IM tamb&eacute;m foi alta em     pacientes com IRC (7,4% <I>vs</I> 3,3%, p = 
0,04). Contudo, as taxas de RVA     e RLA foram similares entre os grupos (12,5%
, <I>vs</I> 11,3%, p = 0,7, e     4,8% <I>vs</I> 5,6%, p = 0,7, respectivamente 
pacientes com IRC e sem IRC).     A taxa de trombose de <I>stent</I> definitiva 
foi similar nos dois grupos     (1,9% <I>vs</I> 1,2%, p = 0,21, pacientes com IR
C e sem IRC, respectivamente).</font></p>     ^cY#aop3611.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#62#58#article#161#<p><a name=
"tab03"></a></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#63#59#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#64#60#article#161#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop36tb3.jpg"></p>     ^cY#aop3611
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#65#61#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#66#62#article#161#<p><a name=
"fig01"></a></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#67#63#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#68#64#article#161#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop36fg1.jpg"></p>     ^cY#aop3611
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#69#65#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
01197000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704095500084002001201039#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#70#66#article#161#<p><font si
ze="2" face="Verdana">Para determinar se a IRC era um preditor independente     
de RLA e morte ap&oacute;s SF, n&oacute;s executamos an&aacute;lise multivariada
 <I>backward</I> usando     o modelo de riscos proporcionais de Cox. Vari&aacute
;veis consideradas para     o modelo incluem IRC, idade, sexo, diabete melito, t
abagismo atual, hipertens&atilde;o,     hipercolesterolemia, comprimento da les&
atilde;o, di&acirc;metro luminal     m&iacute;nimo, n&uacute;mero de vasos com d
oen&ccedil;a arterial coronariana.     O comprimento de les&atilde;o (HR 1,06; I
C95% 1,007 &#45; 1,070, p = 0,02) foi     o &uacute;nico preditor independente d
a revasculariza&ccedil;&atilde;o da     les&atilde;o alvo subsequente. Preditore
s independentes de morte foram IRC     (HR 6,93; IC95% 2,4 &#45; 19.5, p &lt; 0,
001), tabagismo atual (HR 3,66; IC95%     1,20 &#45; 11,10, p = 0,02) e diabete 
(HR 2,66; IC95% 1,03 &#45; 6,60, p = 0,045).</font></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#71#67#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#72#68#article#161#<p><font si
ze="3" face="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#aop3611.htm##
00687000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704044500084002001200529#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#73#69#article#161#<p><font si
ze="2" face="Verdana">Esse &eacute; um registro de pacientes consecutivos     de
 dois centros que foram submetidos &agrave; ICP com SF, sem crit&eacute;rios    
 de exclus&atilde;o e que, portanto, representa a pr&aacute;tica do "mundo     r
eal". At&eacute; onde sabemos, o presente estudo tem o mais longo per&iacute;odo
     de acompanhamento de pacientes com IRC ap&oacute;s a implanta&ccedil;&atild
e;o     do SF.</font></p>     ^cY#aop3611.htm##
00829000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704058700084002001200671#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#74#70#article#161#<p><font si
ze="2" face="Verdana">O principal achado deste estudo &eacute; que,     embora o
s pacientes com IRC tenham apresentado maior incid&ecirc;ncia de     morte, IM e
 MACE comparados com pacientes com fun&ccedil;&otilde;es renais     preservadas,
 n&atilde;o h&aacute; associa&ccedil;&atilde;o entre a presen&ccedil;a     de IR
C e o risco de revasculariza&ccedil;&atilde;o ap&oacute;s a implanta&ccedil;&ati
lde;o     do SF. Isto demonstra que o uso do SF permanece t&atilde;o efetivo em 
pacientes     com IRC quanto em pacientes sem IRC por at&eacute; cinco anos.</fo
nt></p>     ^cY#aop3611.htm##
01271000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704102900084002001201113#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#75#71#article#161#<p><font si
ze="2" face="Verdana">Pacientes com IRC apresentam aterosclerose acelerada,     
maior incid&ecirc;ncia de fatores de risco de DAC e DAC mais grave<SUP>16</SUP>.
     Diversos estudos anteriores observaram que uma IRC m&eacute;dia a moderada 
    est&aacute; associada com taxas maiores de morte por qualquer causa e morte 
    cardiovascular<SUP>17&#45;19</SUP>. Ap&oacute;s a ICP, foi observado que a m
ortalidade     est&aacute; diretamente relacionada &agrave; gravidade da IRC. Al
&eacute;m     disso, uma IRC moderada aumenta o risco de nefropatia induzida por
 contraste,     IM recorrente, insufici&ecirc;ncia card&iacute;aca e arritmias<S
UP>18&#45;21</SUP>.     Nosso estudo encontrou um aumento na preval&ecirc;ncia d
e diabete, hipertens&atilde;o,     e idade avan&ccedil;ada associados com um aum
ento da mortalidade entre os     pacientes com IRC. A an&aacute;lise multivariad
a confirmou a IRC, tabagismo     atual e diabete como preditores independentes d
e mortalidade por todas as     causas.</font></p>     ^cY#aop3611.htm##
00763000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052100084002001200605#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#76#72#article#161#<p><font si
ze="2" face="Verdana">Estudos anteriores comparando pacientes com     IRC e paci
entes sem IRC submetidos a ICP com SF, observaram que a mortalidade &eacute; uni
formemente     maior em pacientes com IRC<SUP>22&#45;24</SUP>. Al&eacute;m disso
, pacientes     com IRC apresentaram um aumento da mortalidade apesar do uso de 
SF ou SNF<SUP>22,23,25</SUP>.     Somente um estudo relatou uma taxa de mortalid
ade menor em pacientes com     IRC submetidos a ICP com SF ap&oacute;s 1 ano<SUP
>25</SUP>.</font></p>     ^cY#aop3611.htm##
00890000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064800084002001200732#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#77#73#article#161#<p><font si
ze="2" face="Verdana">Encontramos uma maior incid&ecirc;ncia de MACE     em paci
entes com IRC, primariamente devido &agrave;s altas taxas de mortalidade     e I
M. Esse achado difere do estudo Nakazawa, onde a maior incid&ecirc;ncia     de M
ACE ap&oacute;s a implanta&ccedil;&atilde;o do SF em pacientes com IRC     ocorr
ia principalmente devido &agrave; maior incid&ecirc;ncia de RVA<SUP>24</SUP>.   
  Naquele estudo, o acompanhamento angiogr&aacute;fico de rotina foi executado  
   oito meses ap&oacute;s o <I>stenting</I> e pode ter contribu&iacute;do para  
   um aumento na taxa de revasculariza&ccedil;&atilde;o. </font></p>     ^cY#aop
3611.htm##
00905000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704066300084002001200747#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#78#74#article#161#<p><font si
ze="2" face="Verdana">Poucos estudos avaliaram as taxas de reestenose     e reva
sculariza&ccedil;&atilde;o ap&oacute;s a interven&ccedil;&atilde;o     coronaria
na percut&acirc;nea com SF em pacientes com IRC. Meta&#45;an&aacute;lises     de
 grandes estudos cl&iacute;nicos randomizados n&atilde;o foram capazes     de av
aliar essa quest&atilde;o, considerando que a maior parte dos estudos     exclui
u os pacientes com insufici&ecirc;ncia renal<SUP>26</SUP>. Da mesma     forma, m
eta&#45;an&aacute;lises de redes maiores impedem an&aacute;lises de subgrupos   
  devido &agrave; falta de dados individuais dos pacientes<SUP>27</SUP>.</font><
/p>     ^cY#aop3611.htm##
01226000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704098400084002001201068#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#79#75#article#161#<p><font si
ze="2" face="Verdana">Em nosso estudo, a taxa de RLA foi baixa, independentement
e     da fun&ccedil;&atilde;o renal. Esse achado &eacute; similar &agrave; de ou
tros     estudos em pacientes com IRC moderada, que relataram uma diminui&ccedil
;&atilde;o     na incid&ecirc;ncia de revasculariza&ccedil;&atilde;o ap&oacute;s
 a implanta&ccedil;&atilde;o     do SF quando comparado ao SNF<SUP>22,23,25</SUP
>. Uma sub&#45;an&aacute;lise     do estudo TAXUS&#45;IV<SUP>25</SUP>, de pacien
tes com insufici&ecirc;ncia renal     moderada basal (TFG &lt; 60 ml/min), rando
mizados para o <I>stent</I> eluidor     de paclitaxel (n = 123) ou SNF (n = 100)
, demonstrou taxas significativamente     menores de RLA (3,3% <I>vs</I> 12,2%, 
p = 0,01) e RVA (6,6% <I>vs</I> 15,2%,     p = 0,04). Por outro lado, um pequeno
 estudo de caso&#45;controle incluindo pacientes     com IRC apresentou taxas si
milares de revasculariza&ccedil;&atilde;o com     SF ou SNF<SUP>28</SUP>.</font>
</p>     ^cY#aop3611.htm##
01219000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704097700084002001201061#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#80#76#article#161#<p><font si
ze="2" face="Verdana">Kuchulakanti e cols.<SUP>29</SUP>, em um estudo     envolv
endo 76 pacientes com IRC e 1466 controles, relataram baixas taxas     de revasc
ulariza&ccedil;&atilde;o ap&oacute;s a implanta&ccedil;&atilde;o     do SF nos d
ois grupos. A taxa de RVA em seis meses foi significativamente     maior nos pac
ientes com IRC do que nos pacientes sem IRC (7% <I>vs</I> 4%,     p &lt; 0,001) 
(23). Outro estudo avaliando a revasculariza&ccedil;&atilde;o     envolveu pacie
ntes que foram divididos em tr&ecirc;s grupos: TFG <U>&gt;</u> 60     ml/min; TF
G &lt; 60 ml/min e pacientes em hemodi&aacute;lise. O acompanhamento     angiogr
&aacute;fico foi realizado aos oito meses. Ap&oacute;s a implanta&ccedil;&atilde
;o     do SF, a taxa de RVA aumentou significativamente em pacientes em hemodi&a
acute;lise,     quando comparado a pacientes com IRC moderada e pacientes sem IR
C (32,3%,     13% e 9,8%, p = 0,002 respectivamente)<SUP>24</SUP>.</font></p>   
  ^cY#aop3611.htm##
00885000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064300084002001200727#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#81#77#article#161#<p><font si
ze="2" face="Verdana">Tem sido demonstrado que a IRC &eacute; um fator     de ri
sco independente para a trombose de <I>stent</I> ap&oacute;s a implanta&ccedil;&
atilde;o     de SF em alguns<SUP>29,30</SUP>, mas n&atilde;o em todos os estudos
<SUP>31</SUP>.     Em nosso estudo, observamos que a incid&ecirc;ncia de trombos
e de <I>stent</I> n&atilde;o     estava significativamente aumentada em paciente
s com IRC. &Eacute; poss&iacute;vel     que a falta de signific&acirc;ncia obser
vada em nosso estudo esteja relacionada     ao reduzido poder estat&iacute;stico
 para avaliar esse evento de baixa incid&ecirc;ncia.</font></p>     ^cY#aop3611.
htm##
00724000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048200084002001200566#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#82#78#article#161#<p><font si
ze="2" face="Verdana">Um artigo recentemente publicado, embora limitado     a pa
cientes dos EUA e n&atilde;o exclusivamente &agrave; procedimentos de     SF, co
m 1 ano de acompanhamento cl&iacute;nico, apresentou resultados similares     ao
s do nosso estudo. Pacientes com IRC apresentaram maior incid&ecirc;ncia     de 
morte e IM, e taxas de RLA e trombose de <I>stent</I> n&atilde;o foram     influ
enciados pela presen&ccedil;a da IRC<SUP>32</SUP>. </font></p>     ^cY#aop3611.h
tm##
00336000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009400084002001200178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#83#79#article#161#<p><font si
ze="2" face="Verdana"><b>Limita&ccedil;&otilde;es do estudo</b></font></p>     ^
cY#aop3611.htm##
00811000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704056900084002001200653#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#84#80#article#161#<p><font si
ze="2" face="Verdana">Os achados desse estudo devem ser interpretados     sob a 
luz de algumas limita&ccedil;&otilde;es. O n&uacute;mero de pacientes     com do
en&ccedil;a renal terminal em hemodi&aacute;lise era muito pequeno,     e portan
to nenhuma conclus&atilde;o pode ser tirada, apesar da seguran&ccedil;a     e ef
ic&aacute;cia do SF nessa popula&ccedil;&atilde;o. Al&eacute;m disso,     a falt
a de um grupo de controle de <I>stent</I> n&atilde;o farmacol&oacute;gico     n&
atilde;o nos permitiu comparar resultados entre SF e SNF. </font></p>     ^cY#ao
p3611.htm##
00531000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028900084002001200373#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#85#81#article#161#<p><font si
ze="2" face="Verdana">Finalmente, como os pacientes n&atilde;o foram     submeti
dos &agrave; seguimento mandat&oacute;rio com teste de esfor&ccedil;o     ou ang
iografia coronariana, isquemia silenciosa e reestenose podem ter sido     sub&#4
5;diagnosticadas. </font></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#86#82#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#87#83#article#161#<p><font si
ze="3" face="Verdana"><b>Conclus&atilde;o</b></font></p>     ^cY#aop3611.htm##
00917000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704067500084002001200759#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#88#84#article#161#<p><font si
ze="2" face="Verdana">Nesse registro de "mundo real", a     ICP com SF em pacien
tes com IRC esteve associada com revasculariza&ccedil;&atilde;o     de les&atild
e;o&#45;alvo, quando comparados com pacientes sem IRC, indicando     que o SF pr
eserva o efeito ben&eacute;fico na preven&ccedil;&atilde;o de     reestenose int
ra&#45;<I>stent</I> nessa popula&ccedil;&atilde;o de alto risco.     De qualquer
 forma, a IRC estava associada com taxas mais altas de IM e mortalidade,     dem
onstrando que desfechos cl&iacute;nicos em pacientes com IRC, mesmo ap&oacute;s 
    ICP bem sucedida, dependem da interrela&ccedil;&atilde;o de outras comorbida
des.</font></p>     ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#89#85#article#161#<p>&nbsp;</
p>     ^cY#aop3611.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#90#86#article#161#<p><font si
ze="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop3611.htm##
00844000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704058800086002001200674#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#91#87#article#161
#1#<p><font size="2" face="Verdana">1. Sarnak MJ, Levey AS, Schoolwerth AC, Core
sh     J, Culleton B, Hamm LL, et al. American Heart Association Councils on Kid
ney     in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardio
logy,     and Epidemiology and Prevention. Kidney disease a risk factor for deve
lopment     of cardiovascular disease: a statement from the American Heart Assoc
iation     Councils on Kidney in cardiovascular disease, high blood pressure res
earch,     clinical cardiology, and epidemiology and prevention. Circulation. 20
03;108(17):2154&#45;69.    ^cY#aop3611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#92#88#article#161#</font></p>
     ^cY#aop3611.htm##
00476000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704022000086002001200306#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#93#89#article#161
#2#<p><font size="2" face="Verdana">2. US Renal Data System: USRDS 2000 Annual  
   Data Report. Bethesda, MD: National Institutes of Health, National Institute 
    of Diabetes and Digestive and Kidney Disease; 2000.    ^cY#aop3611.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#94#90#article#161# </font></p
>     ^cY#aop3611.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704023900086002001200325#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#95#91#article#161
#3#<p><font size="2" face="Verdana">3. Herzog CA, Ma JZ, Collins AJ. Long&#45;te
rm     outcome of renal transplant recipients in the United States after coronar
y     revascularization procedures. Circulation. 2004;109(23):2866&#45;71.    ^c
Y#aop3611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#96#92#article#161#</font></p>
     ^cY#aop3611.htm##
00511000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704025500086002001200341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#97#93#article#161
#4#<p><font size="2" face="Verdana">4. Joki N, Hase H, Nakamura R, Yamaguchi    
 T. Onset of coronary artery disease prior to initiation of hemodialysis in     
patients with end&#45;stage renal disease. Nephrol Dial Transplant. 1997;12(4):7
18&#45;23.    ^cY#aop3611.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#98#94#article#161#</font></p>
     ^cY#aop3611.htm##
00529000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027300086002001200359#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#99#95#article#161
#5#<p><font size="2" face="Verdana">5. Gradaus F, Schoebel FC, Ivens K, Jax TW, 
    Heering P, Strauer BE, et al. Rate of restenosis after PTCA in patients with
     terminal renal failure: a quantitative coronary angiography study. Z Kardio
l.     1997;86(5):373&#45;9.    ^cY#aop3611.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#100#96#article#161#</font></p
>     ^cY#aop3611.htm##
00534000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704027700087002001200364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#101#97#article#16
1#6#<p><font size="2" face="Verdana">6. Gruberg L, Dangas G, Mehran R, Mintz GS,
     Kent KM, Pichard AD, et al. Clinical outcome following percutaneous coronar
y     interventions in patients with chronic renal failure. Catheter Cardiovasc 
    Interv. 2002;55(1):66&#45;72.    ^cY#aop3611.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#102#98#article#161#</font></p
>     ^cY#aop3611.htm##
00508000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704025100087002001200338#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#103#99#article#16
1#7#<p><font size="2" face="Verdana">7. Charytan D, Forman JP, Cutlip DE. Risk  
   of target lesion revascularization after coronary stenting in patients with  
   and without chronic kidney disease. Nephrol Dial Transplant. 2007;22(9):2578&
#45;85.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#104#100#article#161#</font></
p>     ^cY#aop3611.htm##
00518000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704026000088002001200348#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#105#101#article#1
61#8#<p><font size="2" face="Verdana">8. Chieffo A, Stankovic G, Bonizzoni E, Ts
agalou     E, Iakovou I, Montorfano M, et al. Early and mid&#45;term results of 
drug eluting     stent implantation in unprotected left main. Circulation. 2005;
111(6):791&#45;5.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#106#102#article#161#</font></
p>     ^cY#aop3611.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704028700088002001200375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#107#103#article#1
61#9#<p><font size="2" face="Verdana">9. Degertekin M, Regar E, Tanabe K, Smits 
    PC, van der Giessen WJ, Carlier SG, et al. Sirolimus&#45;eluting stent for t
reatment     of complex in&#45;stent restenosis: the first clinical experience. 
J Am Coll     Cardiol. 2003;41(2):184&#45;9.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#108#104#article#161#</font></
p>     ^cY#aop3611.htm##
00530000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027100089002001200360#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#109#105#article#1
61#10#<p><font size="2" face="Verdana">10. Dibra A, Kastrati A, Mehilli J, Pache
     J, Sch&uuml;hlen H, von Beckerath N, et al. Paclitaxel&#45;eluting or sirol
imus&#45;eluting     stents to prevent restenosis in diabetic patients. N Engl J
 Med. 2005;353(7):663&#45;70.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#110#106#article#161#</font></
p>     ^cY#aop3611.htm##
00499000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024000089002001200329#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#111#107#article#1
61#11#<p><font size="2" face="Verdana">11. National Kidney Foundation. K/DOQI cl
inical     practice guidelines for chronic kidney disease: evaluation, classific
ation,     and stratification. Am J Kidney Dis. 2002:39(2 Suppl 1):S1&#45;266.  
  ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#112#108#article#161#</font></
p>     ^cY#aop3611.htm##
00576000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031700089002001200406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#113#109#article#1
61#12#<p><font size="2" face="Verdana">12. Levey AS, Bosch JP, Lewis JB, Greene 
    T, Rogers N, Roth D. A more accurate method to estimate glomerular filtratio
n     rate from serum creatinine: a new prediction equation. Modification of Die
t     in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461&#45;70.    ^
cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#114#110#article#161#</font></
p>     ^cY#aop3611.htm##
00497000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023800089002001200327#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#115#111#article#1
61#13#<p><font size="2" face="Verdana">13. N&oacute;brega AM, Gomes CP, Lemos CC
,     Bregman R. Is it possible to use modification of diet in renal disease (MD
RD)     equation in a Brazilian population? J Nephrol. 2006;19(2):196&#45;9.    
^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#116#112#article#161#</font></
p>     ^cY#aop3611.htm##
00752000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704049300089002001200582#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#117#113#article#1
61#14#<p><font size="2" face="Verdana">14.  Smith SC Jr, Feldman TE, Hirshfeld J
W     Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 guideline up
date     for percutaneous coronary intervention &#150; summary article: a report
 of American     College Cardiology / American Heart Association Task Force on P
ractice Guidelines     (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidel
ines for Percutaneous     Coronary Intervention). J Am Coll Cardiol. 2006;47(1):
216&#45;35.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#118#114#article#161#</font></
p>     ^cY#aop3611.htm##
00537000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027800089002001200367#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#119#115#article#1
61#15#<p><font size="2" face="Verdana">15. Cutlip DE, Windecker S, Mehran R, Boa
m     A, Cohen DJ, van Es GA, et al. Academic Research Consortium. Clinical end 
    points in coronary stent trials: a case for standardized definitions. Circul
ation.     2007;115(17):2344&#45;51.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#120#116#article#161#</font></
p>     ^cY#aop3611.htm##
00684000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704042500089002001200514#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#121#117#article#1
61#16#<p><font size="2" face="Verdana">16. Sarnak MJ, Levey AS, Schoolwerth AC, 
    Coresh J, Culleton B, Hamm LL, et al. Kidney diseases a risk factor for deve
lopment     of cardiovascular disease: a statement from the American Heart Assoc
iation     Councils on Kidney in cardiovascular disease, high blood pressure res
earch,     clinical cardiology, and epidemiology and prevention. Circulation. 20
03;108(17):2154&#45;69.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#122#118#article#161#</font></
p>     ^cY#aop3611.htm##
00539000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028000089002001200369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#123#119#article#1
61#17#<p><font size="2" face="Verdana">17. Manjunath G, Tighiouart H, Ibrahim H,
     MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk
     factor for atherosclerotic cardiovascular outcomes in the community. J Am  
   Coll Cardiol. 2003;41(1):47&#45;55.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#124#120#article#161#</font></
p>     ^cY#aop3611.htm##
00556000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029700089002001200386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#125#121#article#1
61#18#<p><font size="2" face="Verdana">18. Reddan DN, Szczech LA, Tuttle RH, Sha
w     LK, Jones RH, Schwab SJ, et al. Chronic kidney disease, mortality, and tre
atment     strategies among patients with clinically significant coronary artery
 disease.     J Am Soc Nephrol. 2003;14(9):2373&#45;80.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#126#122#article#161#</font></
p>     ^cY#aop3611.htm##
00500000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024100089002001200330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#127#123#article#1
61#19#<p><font size="2" face="Verdana">19. McCullough PA, Soman SS, Shah SS, Smi
th     ST, Marks KR, Yee J, et al. Risks associated with renal dysfunction in pa
tients     in the coronary care unit. J Am Coll Cardiol. 2000;36(3):679&#45;84. 
   ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#128#124#article#161#</font></
p>     ^cY#aop3611.htm##
00544000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028500089002001200374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#129#125#article#1
61#20#<p><font size="2" face="Verdana">20. Marenzi G, Lauri G, Assanelli E, Camp
odonico     J, De Metrio M, Marana I, et al. Contrast&#45;induced nephropathy in
 patients     undergoing primary angioplasty for acute myocardial infarction. J 
Am Coll     Cardiol. 2004;44(9):1780&#45;5.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#130#126#article#161#</font></
p>     ^cY#aop3611.htm##
00673000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704041400089002001200503#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#131#127#article#1
61#21#<p><font size="2" face="Verdana">21. Yamaguchi J, Kasanuki H, Ishii Y, Yag
i     M, Nagashima M, Fujii S, et al. HIJC Investigators. Serum creatinine on ad
mission     predicts long&#45;term mortality in acute myocardial infarction pati
ents undergoing     successful primary angioplasty: data from the Heart Institut
e of Japan Acute     Myocardial Infarction (HIJAMI) registry. Circ J. 2007;71(9)
:1354&#45;9.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#132#128#article#161#</font></
p>     ^cY#aop3611.htm##
00562000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030300089002001200392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#133#129#article#1
61#22#<p><font size="2" face="Verdana">22. Lemos PA, Arampatzis CA, Hoye A, Daem
en     J, Ong AT, Saia F, et al. Impact of baseline renal function on mortality 
    after percutaneous coronary intervention with sirolimus&#45;eluting stents o
r     bare metal stents. Am J Cardiol. 2005;95(2):167&#45;72.    ^cY#aop3611.htm
##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#134#130#article#161#</font></
p>     ^cY#aop3611.htm##
00601000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034200089002001200431#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#135#131#article#1
61#23#<p><font size="2" face="Verdana">23. Kuchulakanti PK, Torguson R, Chu WW, 
    Canos DA, Rha SW, Clavijo L, et al. Impact of chronic renal insufficiency   
  on clinical outcomes in patients undergoing percutaneous coronary intervention
     with sirolimus&#45;eluting stents versus bare metal stents. Am J Cardiol. 2
006;97(6):792&#45;7.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#136#132#article#161#</font></
p>     ^cY#aop3611.htm##
00587000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032800089002001200417#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#137#133#article#1
61#24#<p><font size="2" face="Verdana">24. Nakazawa G, Tanabe K, Aoki J, Yamamot
o     H, Higashikuni Y, Onuma Y, et al. Impact of renal insufficiency on clinica
l     and angiographic outcomes following percutaneous coronary intervention wit
h     sirolimus&#45;eluting stents. Catheter Cardiovasc Interv. 2007;69(6):808&#
45;14.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#138#134#article#161#</font></
p>     ^cY#aop3611.htm##
00604000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034500089002001200434#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#139#135#article#1
61#25#<p><font size="2" face="Verdana">25. Halkin A, Mehran R, Casey CW, Gordon 
    P, Matthews R, Wilson BH, et al. Impact of moderate renal insufficiency on  
   restenosis and adverse clinical events after paclitaxel&#45;eluting and bare 
    metal stent implantation: results from the TAXUS&#45;IV Trial. Am Heart J. 2
005;150(6):1163&#45;70.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#140#136#article#161#</font></
p>     ^cY#aop3611.htm##
00506000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024700089002001200336#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#141#137#article#1
61#26#<p><font size="2" face="Verdana">26. Stone GW, Moses JW, Ellis SG, Schofer
     J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus&#45; and 
paclitaxel&#45;eluting     coronary stents. N Engl J Med. 2007; 356(10):998&#45;
1008.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#142#138#article#161#</font></
p>     ^cY#aop3611.htm##
00538000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027900089002001200368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#143#139#article#1
61#27#<p><font size="2" face="Verdana">27. Stettler C, Wandel S, Allemann S, Kas
trati     A, Morice MC, Sch&ouml;mig A, et al. Outcomes associated with drug&#45
;eluting     and bare&#45;metal stents: a collaborative network meta&#45;analysi
s. Lancet. 2007;370(9591):937&#45;48.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#144#140#article#161#</font></
p>     ^cY#aop3611.htm##
00559000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030000089002001200389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#145#141#article#1
61#28#<p><font size="2" face="Verdana">28. Jeong YH, Hong MK, Lee CW, Park DW, K
im     YH, Kim JJ, et al. Impact of significant chronic kidney disease on long&#
45;term     clinical outcomes after drug&#45;eluting stent versus bare metal ste
nt implantation.     Int J Cardiol. 2008;125(1):36&#45;40.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#146#142#article#161#</font></
p>     ^cY#aop3611.htm##
00560000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030100089002001200390#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#147#143#article#1
61#29#<p><font size="2" face="Verdana">29. Kuchulakanti PK, Chu WW, Torguson R, 
    Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long&#45;term outcomes 
of     angiographycally proven stent thrombosis with sirolimus and paclitaxel&#4
5;eluting     stents. Circulation. 2006;113(8):1108&#45;13.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#148#144#article#161#</font></
p>     ^cY#aop3611.htm##
00629000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704037000089002001200459#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#149#145#article#1
61#30#<p><font size="2" face="Verdana">30. Machecourt J, Danchin N, Lablanche JM
,     Fauvel JM, Bonnet JL, Marliere S, et al. EVASTENT Investigators. Risk fact
ors     for stent thrombosis after implantation of sirolimus&#45;eluting stents 
in diabetic     and nondiabetic patients: the EVASTENT matched&#45;cohort regist
ry. J Am Coll     Cardiol. 2007;50(6):501&#45;8.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#150#146#article#161#</font></
p>     ^cY#aop3611.htm##
00596000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033700089002001200426#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#151#147#article#1
61#31#<p><font size="2" face="Verdana">31.  Wenaweser P, Daemen J, Zwahlen M, va
n     Domburg R, J&uuml;ni P, Vaina S, et al. Incidence and correlates of drug&#
45;eluting     stent thrombosis in routine clinical practice. 4&#45;year results
 from a large     2&#45;institutional cohort study. J Am Coll Cardiol. 2008;52(1
4):1134&#45;40.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#152#148#article#161#</font></
p>     ^cY#aop3611.htm##
00683000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704042400089002001200513#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#153#149#article#1
61#32#<p><font size="2" face="Verdana">32. Latif F, Kleiman NS, Cohen DJ, Pencin
a     MJ, Yen CH, Cutlip DE, et al. In&#45;Hospital and 1&#45;year outcomes amon
g percutaneous     coronary intervention in patients with chronic kidney disease
 in the era     of drug&#45;eluting stents: a report from the EVENT (Evaluation 
of Drug Eluting     Stents and Ischemic Events) registry. JACC Cardiovasc Interv
. 2009;2(1):37&#45;45.    ^cY#aop3611.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#154#150#article#161#</font></
p>     ^cY#aop3611.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#155#151#article#161#<p>&nbsp;
</p>     ^cY#aop3611.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#156#152#article#161#<p>&nbsp;
</p>     ^cY#aop3611.htm##
00410000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016600086002001200252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#157#153#article#161#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:    ^cY#aop
3611.htm##
00288000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004400086002001200130#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#158#154#article#161#<br>   </
b>Vitor Os&oacute;rio Gomes    ^cY#aop3611.htm##
00303000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005900086002001200145#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#159#155#article#161#<BR>   Av
. Lageado, 969/401 &#45; Petr&oacute;polis    ^cY#aop3611.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006400086002001200150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#160#156#article#161#<br>   90
460&#45;110 &#45; Porto Alegre, RS &#45; Brasil    ^cY#aop3611.htm##
00405000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016100086002001200247#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#161#157#article#161#<BR>   E&
#45;mail: <a href="mailto:vigomes@cardiol.br">vigomes@cardiol.br</a>, <a href="m
ailto:vigomes@terra.com.br">vigomes@terra.com.br</a></font></p>     ^cY#aop3611.
htm##
00380000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704013600086002001200222#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#162#158#article#161#<p><font 
size="2" face="Verdana"> Artigo recebido em 23/08/10; revisado recebido     em 1
7/11/10; aceito em 29/11/10</font></p>     ^cY#aop3611.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#163#159#article#161#<p>&nbsp;
</p>     ^cY#aop3611.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#164#160#article#161#<p>&nbsp;
</p>     ^cY#aop3611.htm##
00420000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704017600086002001200262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3611.htm#S#p#165#161#article#161#<p><font 
size="2" face="Verdana">Full texts in English &#45; <A href="http://www.arquivos
online.com.br" target="_blank">http://www.arquivosonline.com.br</A></font></p>  
   ^cY#aop3611.htm##
01039000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100016001020100
02200118010001600140010001800156010001500174810000600189012041000195030001200605
06500090061706400050062603100040063103200030063501400080063886500090064600200120
0655035001000667801001200677#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#166#1#article#32#1#^rND^sSarnak^nMJ#^rND^sLevey^nAS#^rND^sSchoolw
erth^nAC#^rND^sCoresh^nJ#^rND^sCulleton^nB#^rND^sHamm^nLL#et al#American Heart A
ssociation Councils on Kidney in Cardiovascular Disease, High Blood Pressure Res
earch, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease a ri
sk factor for development of cardiovascular disease: a statement from the Americ
an Heart Association Councils on Kidney in cardiovascular disease, high blood pr
essure research, clinical cardiology, and epidemiology and prevention^len#Circul
ation#20030000#2003#108#17#2154-69#20110000#aop3611.htm#0009-7322#Circulation##
00502000000000217000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830180056000850660013001410620
09500154065000900249064000500258865000900263002001200272#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop3611.htm#S#c#167#2#article#32#2#US Renal Data Syst
em: USRDS 2000 Annual Data Report^len#Bethesda^eMD#National Institutes of Health
, National Institute of Diabetes and Digestive and Kidney Disease#20000000#2000#
20110000#aop3611.htm##
00637000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100013001020100
01800115012011800133030001200251065000900263064000500272031000400277032000300281
014000800284865000900292002001200301035001000313801001200323#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3611.htm#S#c#168#3#article#32#3#^rND^sHerzog^n
CA#^rND^sMa^nJZ#^rND^sCollins^nAJ#Long-term outcome of renal transplant recipien
ts in the United States after coronary revascularization procedures^len#Circulat
ion#20040000#2004#109#23#2866-71#20110000#aop3611.htm#0009-7322#Circulation##
00683000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100014000850100014000990100
01800113010001900131012011400150030002400264065000900288064000500297031000300302
032000200305014000700307865000900314002001200323035001000335801002400345#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#c#169#4#article#32#4#^r
ND^sJoki^nN#^rND^sHase^nH#^rND^sNakamura^nR#^rND^sYamaguchi^nT#Onset of coronary
 artery disease prior to initiation of hemodialysis in patients with end-stage r
enal disease^len#Nephrol Dial Transplant#19970000#1997#12#4#718-23#20110000#aop3
611.htm#0931-0509#Nephrol Dial Transplant##
00734000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100019001020100
01500121010001400136010001700150010001800167810000600185012011700191030001000308
06500090031806400050032703100030033203200020033501400060033786500090034300200120
0352035001000364801001000374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#170#5#article#32#5#^rND^sGradaus^nF#^rND^sSchoebel^nFC#^rND^sIven
s^nK#^rND^sJax^nTW#^rND^sHeering^nP#^rND^sStrauer^nBE#et al#Rate of restenosis a
fter PTCA in patients with terminal renal failure: a quantitative coronary angio
graphy study^len#Z Kardiol#19970000#1997#86#5#373-9#20110000#aop3611.htm#0300-58
60#Z Kardiol##
00708000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100016001020100
01600118010001600134010001500150010001800165810000600183012010600189030002700295
71000020032206500090032406400050033303100030033803200020034101400060034386500090
0349002001200358#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S
#c#171#6#article#32#6#^rND^sGruberg^nL#^rND^sDangas^nG#^rND^sMehran^nR#^rND^sMin
tz^nGS#^rND^sKent^nKM#^rND^sPichard^nAD#et al#Clinical outcome following percuta
neous coronary interventions in patients with chronic renal failure^len#Catheter
 Cardiovasc Interv#2#20020000#2002#55#1#66-72#20110000#aop3611.htm##
00665000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100017001030100
01700120012012000137030002400257065000900281064000500290031000300295032000200298
014000800300865000900308002001200317035001000329801002400339#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3611.htm#S#c#172#7#article#32#7#^rND^sCharytan
^nD#^rND^sForman^nJP#^rND^sCutlip^nDE#Risk of target lesion revascularization af
ter coronary stenting in patients with and without chronic kidney disease^len#Ne
phrol Dial Transplant#20070000#2007#22#9#2578-85#20110000#aop3611.htm#0931-0509#
Nephrol Dial Transplant##
00723000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100019001020100
01900121010001800140010001700158010002000175810000600195012009100201030001200292
06500090030406400050031303100040031803200020032201400060032486500090033000200120
0339035001000351801001200361#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#173#8#article#32#8#^rND^sChieffo^nA#^rND^sStankovic^nG#^rND^sBoni
zzoni^nE#^rND^sTsagalou^nE#^rND^sIakovou^nI#^rND^sMontorfano^nM#et al#Early and 
mid-term results of drug eluting stent implantation in unprotected left main^len
#Circulation#20050000#2005#111#6#791-5#20110000#aop3611.htm#0009-7322#Circulatio
n##
00748000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100015001050100
01600120010001600136010002600152010001800178810000600196012010400202030001800306
06500090032406400050033303100030033803200020034101400060034386500090034900200120
0358035001000370801001800380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#174#9#article#32#9#^rND^sDegertekin^nM#^rND^sRegar^nE#^rND^sTanab
e^nK#^rND^sSmits^nPC#^rND^svan der Giessen^nWJ#^rND^sCarlier^nSG#et al#Sirolimus
-eluting stent for treatment of complex in-stent restenosis: the first clinical 
experience^len#J Am Coll Cardiol#20030000#2003#41#2#184-9#20110000#aop3611.htm#0
735-1097#J Am Coll Cardiol##
00727000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100018001020100
01700120010001500137010001800152010002300170810000600193012009400199030001300293
06500090030606400050031503100040032003200020032401400070032686500090033300200120
0342035001000354801001300364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#175#10#article#32#10#^rND^sDibra^nA#^rND^sKastrati^nA#^rND^sMehil
li^nJ#^rND^sPache^nJ#^rND^sSchühlen^nH#^rND^svon Beckerath^nN#et al#Paclitaxel-e
luting or sirolimus-eluting stents to prevent restenosis in diabetic patients^le
n#N Engl J Med#20050000#2005#353#7#663-70#20110000#aop3611.htm#0028-4793#N Engl 
J Med##
00570000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840110027000870120115001140300
01700229710000200246065000900248064000500257031000300262032001100265014000700276
865000900283002001200292#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop36
11.htm#S#c#176#11#article#32#11#National Kidney Foundation#K/DOQI clinical pract
ice guidelines for chronic kidney disease: evaluation, classification, and strat
ification^lpt#Am J Kidney Dis.#2#20020000#2002#39#2^sSuppl 1#S1-266#20110000#aop
3611.htm##
00773000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119010001600135010001600151010001400167012016600181030001500347065000900362
06400050037103100040037603200020038001400070038286500090038900200120039803500100
0410801001500420#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S
#c#177#12#article#32#12#^rND^sLevey^nAS#^rND^sBosch^nJP#^rND^sLewis^nJB#^rND^sGr
eene^nT#^rND^sRogers^nN#^rND^sRoth^nD#A more accurate method to estimate glomeru
lar filtration rate from serum creatinine: a new prediction equation. Modificati
on of Diet in Renal Disease Study Group^len#Ann Intern Med#19990000#1999#130#6#4
61-70#20110000#aop3611.htm#0003-4819#Ann Intern Med##
00650000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01600121010001700137012010600154030001000260065000900270064000500279031000300284
032000200287014000600289865000900295002001200304035001000316801001000326#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S#c#178#13#article#32#13#
^rND^sNóbrega^nAM#^rND^sGomes^nCP#^rND^sLemos^nCC#^rND^sBregman^nR#Is it possibl
e to use modification of diet in renal disease (MDRD) equation in a Brazilian po
pulation^len#J Nephrol#20060000#2006#19#2#196-9#20110000#aop3611.htm#1120-3625#J
 Nephrol##
00949000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100018001060100
02300124010001700147010001500164010001900179810000600198012030200204030001800506
06500090052406400050053303100030053803200020054101400070054386500090055000200120
0559035001000571801001800581#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#179#14#article#32#14#^rND^sSmith Jr^nSC#^rND^sFeldman^nTE#^rND^sH
irshfeld Jr^nJW#^rND^sJacobs^nAK#^rND^sKern^nMJ#^rND^sKing 3rd^nSB#et al#ACC/AHA
/SCAI 2005 guideline update for percutaneous coronary intervention - summary art
icle: a report of American College Cardiology / American Heart Association Task 
Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 
Guidelines for Percutaneous Coronary Intervention)^len#J Am Coll Cardiol#2006000
0#2006#47#1#216-35#20110000#aop3611.htm#0735-1097#J Am Coll Cardiol##
00742000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100019001040100
01600123010001400139010001600153010001700169810000600186012011600192030001200308
06500090032006400050032903100040033403200030033801400080034186500090034900200120
0358035001000370801001200380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#180#15#article#32#15#^rND^sCutlip^nDE#^rND^sWindecker^nS#^rND^sMe
hran^nR#^rND^sBoam^nA#^rND^sCohen^nDJ#^rND^svan Es^nGA#et al#Academic Research C
onsortium: Clinical end points in coronary stent trials: a case for standardized
 definitions^len#Circulation#20070000#2007#115#17#2344-51#20110000#aop3611.htm#0
009-7322#Circulation##
00885000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
02200120010001600142010001800158010001500176810000600191012025400197030001200451
06500090046306400050047203100040047703200030048101400080048486500090049200200120
0501035001000513801001200523#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#181#16#article#32#16#^rND^sSarnak^nMJ#^rND^sLevey^nAS#^rND^sSchoo
lwerth^nAC#^rND^sCoresh^nJ#^rND^sCulleton^nB#^rND^sHamm^nLL#et al#Kidney disease
s a risk factor for development of cardiovascular disease: a statement from the 
American Heart Association Councils on Kidney in cardiovascular disease, high bl
ood pressure research, clinical cardiology, and epidemiology and prevention^len#
Circulation#20030000#2003#108#17#2154-69#20110000#aop3611.htm#0009-7322#Circulat
ion##
00750000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100020001060100
01700126010001700143010001600160010001900176810000600195012010700201030001800308
06500090032606400050033503100030034003200020034301400060034586500090035100200120
0360035001000372801001800382#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#182#17#article#32#17#^rND^sManjunath^nG#^rND^sTighiouart^nH#^rND^
sIbrahim^nH#^rND^sMacLeod^nB#^rND^sSalem^nDN#^rND^sGriffith^nJL#et al#Level of k
idney function as a risk factor for atherosclerotic cardiovascular outcomes in t
he community^len#J Am Coll Cardiol#20030000#2003#41#1#47-55#20110000#aop3611.htm
#0735-1097#J Am Coll Cardiol##
00766000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100018001040100
01700122010001500139010001600154010001700170810000600187012013100193030001700324
06500090034106400050035003100030035503200020035801400080036086500090036800200120
0377035001000389801001700399#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#183#18#article#32#18#^rND^sReddan^nDN#^rND^sSzczech^nLA#^rND^sTut
tle^nRH#^rND^sShaw^nLK#^rND^sJones^nRH#^rND^sSchwab^nSJ#et al#Chronic kidney dis
ease, mortality, and treatment strategies among patients with clinically signifi
cant coronary artery disease^len#J Am Soc Nephrol#20030000#2003#14#9#2373-80#201
10000#aop3611.htm#1046-6673#J Am Soc Nephrol##
00715000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100016001080100
01500124010001600139010001600155010001300171810000600184012008200190030001800272
06500090029006400050029903100030030403200020030701400070030986500090031600200120
0325035001000337801001800347#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#184#19#article#32#19#^rND^sMcCullough^nPA#^rND^sSoman^nSS#^rND^sS
hah^nSS#^rND^sSmith^nST#^rND^sMarks^nKR#^rND^sYee^nJ#et al#Risks associated with
 renal dysfunction in patients in the coronary care unit^len#J Am Coll Cardiol#2
0000000#2000#36#3#679-84#20110000#aop3611.htm#0735-1097#J Am Coll Cardiol##
00751000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
01900119010002100138010001900159010001600178810000600194012010800200030001800308
06500090032606400050033503100030034003200020034301400070034586500090035200200120
0361035001000373801001800383#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#185#20#article#32#20#^rND^sMarenzi^nG#^rND^sLauri^nG#^rND^sAssane
lli^nE#^rND^sCampodonico^nJ#^rND^sDe Metrio^nM#^rND^sMarana^nI#et al#Contrast-in
duced nephropathy in patients undergoing primary angioplasty for acute myocardia
l infarction^len#J Am Coll Cardiol#20040000#2004#44#9#1780-5#20110000#aop3611.ht
m#0735-1097#J Am Coll Cardiol##
00838000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100018001060100
01500124010001400139010001900153010001500172810000600187012025100193030000700444
71000020045106500090045306400050046203100030046703200020047001400070047286500090
0479002001200488#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S
#c#186#21#article#32#21#^rND^sYamaguchi^nJ#^rND^sKasanuki^nH#^rND^sIshii^nY#^rND
^sYagi^nM#^rND^sNagashima^nM#^rND^sFujii^nS#et al#HIJC Investigators: Serum crea
tinine on admission predicts long-term mortality in acute myocardial infarction 
patients undergoing successful primary angioplasty: data from the Heart Institut
e of Japan Acute Myocardial Infarction (HIJAMI) registry^len#Circ J#2#20070000#2
007#71#9#1354-9#20110000#aop3611.htm##
00764000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100021001030100
01400124010001600138010001400154010001400168810000600182012014300188030001300331
06500090034406400050035303100030035803200020036101400070036386500090037000200120
0379035001000391801001300401#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#187#22#article#32#22#^rND^sLemos^nPA#^rND^sArampatzis^nCA#^rND^sH
oye^nA#^rND^sDaemen^nJ#^rND^sOng^nAT#^rND^sSaia^nF#et al#Impact of baseline rena
l function on mortality after percutaneous coronary intervention with sirolimus-
eluting stents or bare metal stents^len#Am J Cardiol#20050000#2005#95#2#167-72#2
0110000#aop3611.htm#0002-9149#Am J Cardiol##
00803000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100023000870100018001100100
01400128010001600142010001400158010001700172810000600189012017600195030001300371
06500090038406400050039303100030039803200020040101400060040386500090040900200120
0418035001000430801001300440#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#188#23#article#32#23#^rND^sKuchulakanti^nPK#^rND^sTorguson^nR#^rN
D^sChu^nWW#^rND^sCanos^nDA#^rND^sRha^nSW#^rND^sClavijo^nL#et al#Impact of chroni
c renal insufficiency on clinical outcomes in patients undergoing percutaneous c
oronary intervention with sirolimus-eluting stents versus bare metal stents^len#
Am J Cardiol#20060000#2006#97#6#792-7#20110000#aop3611.htm#0002-9149#Am J Cardio
l##
00756000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01400121010001800135010002100153010001500174810000600189012014700195030002700342
71000020036906500090037106400050038003100030038503200020038801400070039086500090
0397002001200406#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S
#c#189#24#article#32#24#^rND^sNakazawa^nG#^rND^sTanabe^nK#^rND^sAoki^nJ#^rND^sYa
mamoto^nH#^rND^sHigashikuni^nY#^rND^sOnuma^nY#et al#Impact of renal insufficienc
y on clinical and angiographic outcomes following percutaneous coronary interven
tion with sirolimus-eluting stents^len#Catheter Cardiovasc Interv#2#20070000#200
7#69#6#808-14#20110000#aop3611.htm##
00800000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119010001600135010001800151010001700169810000600186012017700192030001100369
06500090038006400050038903100040039403200020039801400080040086500090040800200120
0417035001000429801001100439#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#190#25#article#32#25#^rND^sHalkin^nA#^rND^sMehran^nR#^rND^sCasey^
nCW#^rND^sGordon^nP#^rND^sMatthews^nR#^rND^sWilson^nBH#et al#Impact of moderate 
renal insufficiency on restenosis and adverse clinical events after paclitaxel-e
luting and bare metal stent implantation: results from the TAXUS-IV Trial^len#Am
 Heart J#20050000#2005#150#6#1163-70#20110000#aop3611.htm#0002-8703#Am Heart J##
00707000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119010001700135010001800152010001700170810000600187012007700193030001300270
06500090028306400050029203100040029703200030030101400090030486500090031300200120
0322035001000334801001300344#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#191#26#article#32#26#^rND^sStone^nGW#^rND^sMoses^nJW#^rND^sEllis^
nSG#^rND^sSchofer^nJ#^rND^sDawkins^nKD#^rND^sMorice^nMC#et al#Safety and efficac
y of sirolimus- and paclitaxel-eluting coronary stents^len#N Engl J Med#20070000
#2007#356#10#998-1008#20110000#aop3611.htm#0028-4793#N Engl J Med##
00725000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01800121010001800139010001700157010001700174810000600191012010300197030000700300
06500090030706400050031603100040032103200050032501400070033086500090033700200120
0346035001000358801000700368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#192#27#article#32#27#^rND^sStettler^nC#^rND^sWandel^nS#^rND^sAlle
mann^nS#^rND^sKastrati^nA#^rND^sMorice^nMC#^rND^sSchömig^nA#et al#Outcomes assoc
iated with drug-eluting and bare-metal stents: a collaborative network meta-anal
ysis^len#Lancet#20070000#2007#370#9591#937-48#20110000#aop3611.htm#0099-5355#Lan
cet##
00758000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01400118010001500132010001400147010001400161810000600175012014200181030001400323
06500090033706400050034603100040035103200020035501400060035786500090036300200120
0372035001000384801001400394#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#193#28#article#32#28#^rND^sJeong^nYH#^rND^sHong^nMK#^rND^sLee^nCW
#^rND^sPark^nDW#^rND^sKim^nYH#^rND^sKim^nJJ#et al#Impact of significant chronic 
kidney disease on long-term clinical outcomes after drug-eluting stent versus ba
re metal stent implantation^len#Int J Cardiol#20080000#2008#125#1#36-40#20110000
#aop3611.htm#0167-5273#Int J Cardiol##
00757000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100023000870100014001100100
01800124010001700142010001400159010001800173810000600191012012700197030001200324
06500090033606400050034503100040035003200020035401400080035686500090036400200120
0373035001000385801001200395#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#194#29#article#32#29#^rND^sKuchulakanti^nPK#^rND^sChu^nWW#^rND^sT
orguson^nR#^rND^sOhlmann^nP#^rND^sRha^nSW#^rND^sClavijo^nLC#et al#Correlates and
 long-term outcomes of angiographycally proven stent thrombosis with sirolimus a
nd paclitaxel-eluting stents^len#Circulation#20060000#2006#113#8#1108-13#2011000
0#aop3611.htm#0009-7322#Circulation##
00828000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100017001070100
02000124010001700144010001700161010001800178810000600196012018400202030001800386
06500090040406400050041303100030041803200020042101400060042386500090042900200120
0438035001000450801001800460#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#195#30#article#32#30#^rND^sMachecourt^nJ#^rND^sDanchin^nN#^rND^sL
ablanche^nJM#^rND^sFauvel^nJM#^rND^sBonnet^nJL#^rND^sMarliere^nS#et al#EVASTENT 
Investigators: Risk factors for stent thrombosis after implantation of sirolimus
-eluting stents in diabetic and nondiabetic patients: the EVASTENT matched-cohor
t registry^len#J Am Coll Cardiol#20070000#2007#50#6#501-8#20110000#aop3611.htm#0
735-1097#J Am Coll Cardiol##
00789000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060100
01700122010002100139010001400160010001500174810000600189012014900195030001800344
06500090036206400050037103100030037603200030037901400080038286500090039000200120
0399035001000411801001800421#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3611.htm#S#c#196#31#article#32#31#^rND^sWenaweser^nP#^rND^sDaemen^nJ#^rND^sZwa
hlen^nM#^rND^svan Domburg^nR#^rND^sJüni^nP#^rND^sVaina^nS#et al#Incidence and co
rrelates of drug-eluting stent thrombosis in routine clinical practice: 4-year r
esults from a large 2-institutional cohort study^len#J Am Coll Cardiol#20080000#
2008#52#14#1134-40#20110000#aop3611.htm#0735-1097#J Am Coll Cardiol##
00840000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100018001020100
01600120010001800136010001400154010001700168810000600185012024100191030002300432
71000020045506500090045706400050046603100020047103200020047301400060047586500090
0481002001200490#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3611.htm#S
#c#197#32#article#32#32#^rND^sLatif^nF#^rND^sKleiman^nNS#^rND^sCohen^nDJ#^rND^sP
encina^nMJ#^rND^sYen^nCH#^rND^sCutlip^nDE#et al#In-Hospital and 1-year outcomes 
among percutaneous coronary intervention in patients with chronic kidney disease
 in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug 
Eluting Stents and Ischemic Events) registry^len#JACC Cardiovasc Interv#2#200900
00#2009#2#1#37-45#20110000#aop3611.htm##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#o#1#1#a
rticle#1#20110408#165054#aop3711.htm#208##
05082000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201200920017101200880
02630100034003510100048003850100045004330100039004780100034005170100037005510100
03200588010004900620010004000669070005000709070005400759083169400813085000802507
08500170251508500290253208500350256108316100259608500080420608500170421408500260
42310850026042570580007042830580005042901170008042950720003043031120009043061110
00904315116000904324115000904333114000904342113000904351002001204360#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#h#2#1#article#1#tr#pt#br1.1
#1#4.0#ND#44#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#
Relação entre imagem adrenérgica cardíaca e teste ergométrico na insuficiência c
ardíaca^lpt#Relationship between cardiac adrenergic image and exercise testing i
n heart failure^len#^rND^1A01^nLeandro Rocha^sMessias#^rND^1A01^nMaria Ângela M.
 de Queiroz^sCarreira#^rND^1A01^nSandra Marina Ribeiro de^sMiranda#^rND^1A01 A02
^nJader Cunha de^sAzevedo#^rND^1A01^nIsabela Ambrósio^sGava#^rND^1A01^nRonaldo C
ampos^sRodrigues#^rND^1A01^nElizabeth^sMaróstica#^rND^1A01 A02^nAntônio Claudio 
Lucas da^sNóbrega#^rND^1A01 A02^nClaudio Tinoco^sMesquita#Universidade Federal F
luminense^iA01^cNiterói^sRJ#Hospital Procardíaco^iA02^cRio de Janeiro^sRJ^pBrasi
l#^lpt^aFUNDAMENTO: Na insuficiência cardíaca, o teste ergométrico (TE) avalia c
apacidade funcional, um determinante de prognóstico. A cintilografia com I¹²³ MI
BG mostra a ativação simpática cardíaca. OBJETIVO: Avaliar a associação entre as
 variáveis do TE e as alterações da cintilografia com I¹²³ MIBG. MÉTODOS: Foram 
submetidos 23 pacientes (FEVE < 45%) à cintilografia com I¹²³ MIBG e separados e
m: G1) taxa de Washout < 27%; G2) &gt; 27%. Esses pacientes realizaram TE, onde 
foram analisadas: pressão arterial sistólica no pico do esforço (PASP), frequênc
ia cardíaca no pico do esforço (FCP), variação da pressão arterial sistólica int
raesforço (&#916; PAS), reserva cronotrópica e capacidade funcional em METs. Uti
lizaram-se para a análise estatística, o teste t de Student ou o teste U de Mann
-Whitney, o coeficiente de Spearman e o coeficiente de regressão linear. RESULTA
DOS: A PASP (G1: 181,00 ± 28,01; G2: 153,27 ± 27,71, p = 0,027), a &#916; PAS [G
1: 64 (47,5-80,5); G2: 36 (25-47) mmHg, p = 0,015], a FCP (G1: 136,91 ± 19,66; G
2: 118,45 ± 13,98 bpm, p = 0,018), a reserva cronotrópica (G1: 70,42 ± 17,94; G2
: 49,47 ± 14,89%, p = 0,006) e a capacidade funcional [G1: 8,37 (6,47-10,27); G2
: 4,42 (2,46-6,38) METs, p = 0,003] foram menores no G2. Houve correlação negati
va entre taxa de Washout com PASP (r = -0,505, p = 0,014), &#916; PAS (r = -0,49
3, p = 0,017) e capacidade funcional (r = -0,646, p = 0,001). Após regressão lin
ear, PASP (r = -0,422, p = 0,016) e capacidade funcional (r = -0,804, p = 0,004)
 foram associadas com taxa de Washout. CONCLUSÃO: Em pacientes com insuficiência
 cardíaca, PASP e capacidade funcional foram as varáveis mais associadas com a t
axa de Washout.#^dnd^i1#^tm^lpt^kMIBG^i1#^tm^lpt^kteste de esforço^i1#^tm^lpt^ki
nsuficiência cardíaca^i1#^len^aBACKGROUND: The exercise treadmill test can be us
ed in ventricular dysfunction patients for functional capacity or predicting pro
gnosis. The cardiac image with 123I MIBG shows cardiac sympathetic activation. O
BJECTIVE: To evaluate the relationship between exercise treadmill test variables
 and cardiac image changes in 123I MIBG. METHODS: 23 patients with LVEF < 45% pe
rformed scintigraphy cardiac with 123I MIBG and divided into two groups. G1: Was
hout rate < 27%; G2: &gt; 27%. Systolic blood pressure (SBP), heart rate (HR) an
d functional capacity were evaluated. It was performed Student t test or Mann-Wh
itney U test, Spearman coefficient and linear regression. RESULTS: SBP at exerci
se peak (G1: 181.00 ± 28.01; G2: 153.27 ± 27.71 mmHg, p = 0.027), SBP variation 
[G1: 64(47.5-80.5); G2: 36(25-47) mmHg, p = 0.015], the HR at exercise peak (G1:
 136.91 ± 19.66; G2: 118.45 ± 13.98 bpm, p = 0.018) and chronotropic response (G
1: 70.42 ± 17.94; G2: 49.47 ± 14.89%, p = 0.006), and functional capacity [G1: 8
.37(6.47-10.27); G2: 4.42(2.46-6.38) METs, p = 0.003] were smaller in G2 group. 
There was negative correlation between Washout rate and SBP at exercise peak (r 
= -0.505, p = 0.014), variation in SBP (r = -0.493, p = 0.017) and functional ca
pacity (r = -0.646, p = 0.001). Nevertheless, SBP at exercise peak (r = -0.422, 
p = 0.016) and functional capacity (r = -0.804, p = 0.004) were the only variabl
es associated with Washout rate, after linear regression. CONCLUSION: In heart f
ailure patients, the SBP at exercise peak and functional capacity were the varia
bles associated with Washout rate.#^dnd^i2#^tm^len^kMIBG^i2#^tm^len^kexercise te
st^i2#^tm^len^kheart failure^i2#FAPERJ#CNPq#vancouv#35#20100822#22/08/10#2010110
9#09/11/10#20101220#20/12/10#aop3711.htm##
05262000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201200990017101200950
02700100034003650100048003990100045004470100039004920100034005310100037005650100
03200602010004900634010004000683070005000723070005400773083180500827085000802632
08500170264008500290265708500350268608316650272108500080438608500170439408500260
44110850026044370580007044630580005044701170008044750720003044831120009044861110
00904495116000904504115000904513114000904522113000904531002001204540#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#f#3#1#article#1#tr#pt#br1.1
#1#4.0#ND#44#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#
<b>Relação entre imagem adrenérgica cardíaca e teste ergométrico na insuficiênci
a cardíaca</b>^lpt#<b>Relationship between cardiac adrenergic image and exercise
 testing in heart failure</b>^len#^rND^1A01^nLeandro Rocha^sMessias#^rND^1A01^nM
aria Ângela M. de Queiroz^sCarreira#^rND^1A01^nSandra Marina Ribeiro de^sMiranda
#^rND^1A01 A02^nJader Cunha de^sAzevedo#^rND^1A01^nIsabela Ambrósio^sGava#^rND^1
A01^nRonaldo Campos^sRodrigues#^rND^1A01^nElizabeth^sMaróstica#^rND^1A01 A02^nAn
tônio Claudio Lucas da^sNóbrega#^rND^1A01 A02^nClaudio Tinoco^sMesquita#Universi
dade Federal Fluminense^iA01^cNiterói^sRJ#Hospital Procardíaco^iA02^cRio de Jane
iro^sRJ^pBrasil#^lpt^a<b>FUNDAMENTO:</b> Na insuficiência cardíaca, o teste ergo
métrico (TE) avalia capacidade funcional, um determinante de prognóstico. A cint
ilografia com I¹²³ MIBG mostra a ativação simpática cardíaca. <b>OBJETIVO:</b> A
valiar a associação entre as variáveis do TE e as alterações da cintilografia co
m I¹²³ MIBG. <b>MÉTODOS:</b> Foram submetidos 23 pacientes (FEVE <u>&lt;</u> 45%
) à cintilografia com I¹²³ MIBG e separados em: G1) taxa de <i>Washout</i> &lt; 
27%; G2) <u>&gt;</u> 27%. Esses pacientes realizaram TE, onde foram analisadas: 
pressão arterial sistólica no pico do esforço (PASP), frequência cardíaca no pic
o do esforço (FCP), variação da pressão arterial sistólica intraesforço (&#916; 
PAS), reserva cronotrópica e capacidade funcional em METs. Utilizaram-se para a 
análise estatística, o teste <i>t</i> de <i>Student</i> ou o teste U de <i>Mann-
Whitney</i>, o coeficiente de <i>Spearman </i>e o coeficiente de regressão linea
r. <b>RESULTADOS:</b> A PASP (G1: 181,00 ± 28,01; G2: 153,27 ± 27,71, p = 0,027)
, a &#916; PAS [G1: 64 (47,5-80,5); G2: 36 (25-47) mmHg, p = 0,015], a FCP (G1: 
136,91 ± 19,66; G2: 118,45 ± 13,98 bpm, p = 0,018), a reserva cronotrópica (G1: 
70,42 ± 17,94; G2: 49,47 ± 14,89%, p = 0,006) e a capacidade funcional [G1: 8,37
 (6,47-10,27); G2: 4,42 (2,46-6,38) METs, p = 0,003] foram menores no G2. Houve 
correlação negativa entre taxa de <i>Washout</i> com PASP (r = -0,505, p = 0,014
), &#916; PAS (r = -0,493, p = 0,017) e capacidade funcional (r = -0,646, p = 0,
001). Após regressão linear, PASP (r = -0,422, p = 0,016) e capacidade funcional
 (r = -0,804, p = 0,004) foram associadas com taxa de <i>Washout</i>. <b>CONCLUS
ÃO:</b> Em pacientes com insuficiência cardíaca, PASP e capacidade funcional for
am as varáveis mais associadas com a taxa de <i>Washout</i>.#^dnd^i1#^tm^lpt^kMI
BG^i1#^tm^lpt^kteste de esforço^i1#^tm^lpt^kinsuficiência cardíaca^i1#^len^a<b>B
ACKGROUND:</b> The exercise treadmill test can be used in ventricular dysfunctio
n patients for functional capacity or predicting prognosis. The cardiac image wi
th 123I MIBG shows cardiac sympathetic activation. <b>OBJECTIVE:</b> To evaluate
 the relationship between exercise treadmill test variables and cardiac image ch
anges in 123I MIBG. <b>METHODS:</b> 23 patients with LVEF <u>&lt;</u> 45% perfor
med scintigraphy cardiac with 123I MIBG and divided into two groups. G1: Washout
 rate &lt; 27%; G2: <u>&gt;</u> 27%. Systolic blood pressure (SBP), heart rate (
HR) and functional capacity were evaluated. It was performed Student t test or M
ann-Whitney U test, Spearman coefficient and linear regression. <b>RESULTS:</b> 
SBP at exercise peak (G1: 181.00 ± 28.01; G2: 153.27 ± 27.71 mmHg, p = 0.027), S
BP variation [G1: 64(47.5-80.5); G2: 36(25-47) mmHg, p = 0.015], the HR at exerc
ise peak (G1: 136.91 ± 19.66; G2: 118.45 ± 13.98 bpm, p = 0.018) and chronotropi
c response (G1: 70.42 ± 17.94; G2: 49.47 ± 14.89%, p = 0.006), and functional ca
pacity [G1: 8.37(6.47-10.27); G2: 4.42(2.46-6.38) METs, p = 0.003] were smaller 
in G2 group. There was negative correlation between Washout rate and SBP at exer
cise peak (r = -0.505, p = 0.014), variation in SBP (r = -0.493, p = 0.017) and 
functional capacity (r = -0.646, p = 0.001). Nevertheless, SBP at exercise peak 
(r = -0.422, p = 0.016) and functional capacity (r = -0.804, p = 0.004) were the
 only variables associated with Washout rate, after linear regression. <b>CONCLU
SION:</b> In heart failure patients, the SBP at exercise peak and functional cap
acity were the variables associated with Washout rate.#^dnd^i2#^tm^len^kMIBG^i2#
^tm^len^kexercise test^i2#^tm^len^kheart failure^i2#FAPERJ#CNPq#vancouv#35#20100
822#22/08/10#20101109#09/11/10#20101220#20/12/10#aop3711.htm##
05254000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030001900114
03200060013306500090013901400070014803500100015522300090016501200920017401200880
02660100034003540100048003880100045004360100039004810100034005200100037005540100
03200591010004900623010004000672070005200712070005600764083173000820085000802550
08500170255808500290257508500350260408316380263908500080427708500170428508500260
43020850026043280580007043540580005043611170008043660720003043741120009043771110
00904386116000904395115000904404114000904413113000904422002001204431008008904443
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#l#4#1#article#1
#^a2011#tr#pt#br1.1#1#4.0#44#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066
-782X#20110415#Relação entre imagem adrenérgica cardíaca e teste ergométrico na 
insuficiência cardíaca^lpt#Relationship between cardiac adrenergic image and exe
rcise testing in heart failure^len#^rND^1A01^nLeandro Rocha^sMessias#^rND^1A01^n
Maria Ângela M. de Queiroz^sCarreira#^rND^1A01^nSandra Marina Ribeiro de^sMirand
a#^rND^1A01 A02^nJader Cunha de^sAzevedo#^rND^1A01^nIsabela Ambrósio^sGava#^rND^
1A01^nRonaldo Campos^sRodrigues#^rND^1A01^nElizabeth^sMaróstica#^rND^1A01 A02^nA
ntônio Claudio Lucas da^sNóbrega#^rND^1A01 A02^nClaudio Tinoco^sMesquita#^iA01^1
Universidade Federal Fluminense^cNiterói^sRJ#^iA02^1Hospital Procardíaco^cRio de
 Janeiro^sRJ^pBrasil#^lpt^aFUNDAMENTO: Na insuficiência cardíaca, o teste ergomé
trico (TE) avalia capacidade funcional, um determinante de prognóstico. A cintil
ografia com I¹²³ MIBG mostra a ativação simpática cardíaca. OBJETIVO: Avaliar a 
associação entre as variáveis do TE e as alterações da cintilografia com I¹²³ MI
BG. MÉTODOS: Foram submetidos 23 pacientes (FEVE < 45 por cento) à cintilografia
 com I¹²³ MIBG e separados em: G1) taxa de Washout < 27 por cento; G2) &gt; 27 p
or cento. Esses pacientes realizaram TE, onde foram analisadas: pressão arterial
 sistólica no pico do esforço (PASP), frequência cardíaca no pico do esforço (FC
P), variação da pressão arterial sistólica intraesforço (&#916; PAS), reserva cr
onotrópica e capacidade funcional em METs. Utilizaram-se para a análise estatíst
ica, o teste t de Student ou o teste U de Mann-Whitney, o coeficiente de Spearma
n e o coeficiente de regressão linear. RESULTADOS: A PASP (G1: 181,00 ± 28,01; G
2: 153,27 ± 27,71, p = 0,027), a &#916; PAS [G1: 64 (47,5-80,5); G2: 36 (25-47) 
mmHg, p = 0,015], a FCP (G1: 136,91 ± 19,66; G2: 118,45 ± 13,98 bpm, p = 0,018),
 a reserva cronotrópica (G1: 70,42 ± 17,94; G2: 49,47 ± 14,89 por cento, p = 0,0
06) e a capacidade funcional [G1: 8,37 (6,47-10,27); G2: 4,42 (2,46-6,38) METs, 
p = 0,003] foram menores no G2. Houve correlação negativa entre taxa de Washout 
com PASP (r = -0,505, p = 0,014), &#916; PAS (r = -0,493, p = 0,017) e capacidad
e funcional (r = -0,646, p = 0,001). Após regressão linear, PASP (r = -0,422, p 
= 0,016) e capacidade funcional (r = -0,804, p = 0,004) foram associadas com tax
a de Washout. CONCLUSÃO: Em pacientes com insuficiência cardíaca, PASP e capacid
ade funcional foram as varáveis mais associadas com a taxa de Washout.#^dnd^i1#^
tm^lpt^kMIBG^i1#^tm^lpt^kteste de esforço^i1#^tm^lpt^kinsuficiência cardíaca^i1#
^len^aBACKGROUND: The exercise treadmill test can be used in ventricular dysfunc
tion patients for functional capacity or predicting prognosis. The cardiac image
 with 123I MIBG shows cardiac sympathetic activation. OBJECTIVE: To evaluate the
 relationship between exercise treadmill test variables and cardiac image change
s in 123I MIBG. METHODS: 23 patients with LVEF < 45 percent performed scintigrap
hy cardiac with 123I MIBG and divided into two groups. G1: Washout rate < 27 per
cent; G2: &gt; 27 percent. Systolic blood pressure (SBP), heart rate (HR) and fu
nctional capacity were evaluated. It was performed Student t test or Mann-Whitne
y U test, Spearman coefficient and linear regression. RESULTS: SBP at exercise p
eak (G1: 181.00 ± 28.01; G2: 153.27 ± 27.71 mmHg, p = 0.027), SBP variation [G1:
 64(47.5-80.5); G2: 36(25-47) mmHg, p = 0.015], the HR at exercise peak (G1: 136
.91 ± 19.66; G2: 118.45 ± 13.98 bpm, p = 0.018) and chronotropic response (G1: 7
0.42 ± 17.94; G2: 49.47 ± 14.89 percent, p = 0.006), and functional capacity [G1
: 8.37(6.47-10.27); G2: 4.42(2.46-6.38) METs, p = 0.003] were smaller in G2 grou
p. There was negative correlation between Washout rate and SBP at exercise peak 
(r = -0.505, p = 0.014), variation in SBP (r = -0.493, p = 0.017) and functional
 capacity (r = -0.646, p = 0.001). Nevertheless, SBP at exercise peak (r = -0.42
2, p = 0.016) and functional capacity (r = -0.804, p = 0.004) were the only vari
ables associated with Washout rate, after linear regression. CONCLUSION: In hear
t failure patients, the SBP at exercise peak and functional capacity were the va
riables associated with Washout rate.#^dnd^i2#^tm^len^kMIBG^i2#^tm^len^kexercise
 test^i2#^tm^len^kheart failure^i2#FAPERJ#CNPq#vancouv#35#20100822#22/08/10#2010
1109#09/11/10#20101220#20/12/10#aop3711.htm#Internet^ihttp://www.scielo.br/sciel
o.php?script=sci_arttext&pid=S0066-782X2011005000044##
00467000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704022700082002001200309#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#5#1#article#169#<p><font size
="4" face="verdana"><b><a name="title"></a>Rela&ccedil;&atilde;o       entre ima
gem adren&eacute;rgica card&iacute;aca e teste ergom&eacute;trico       na insuf
ici&ecirc;ncia card&iacute;aca</b></font></p>     ^cY#aop3711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#6#2#article#169#<p>&nbsp;</p>
     ^cY#aop3711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#7#3#article#169#<p>&nbsp;</p>
     ^cY#aop3711.htm##
00726000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704048600082002001200568#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#8#4#article#169#<p><font size
="2" face="Verdana"><b>Leandro Rocha Messias<SUP>I</SUP>; Maria &Acirc;ngela    
   M. de Queiroz Carreira<SUP>I</SUP>; Sandra Marina Ribeiro de Miranda<SUP>I</S
UP>;       Jader Cunha de Azevedo<SUP>I,II</SUP>; Isabela Ambr&oacute;sio Gava<S
UP>I</SUP>;       Ronaldo Campos Rodrigues<SUP>I</SUP>; Elizabeth Mar&oacute;sti
ca<SUP>I</SUP>;       Ant&ocirc;nio Claudio Lucas da N&oacute;brega<SUP>I,II</SU
P>; Claudio Tinoco       Mesquita<SUP>I,II</SUP> </b></font></p>     ^cY#aop3711
.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704010900082002001200191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#9#5#article#169#<p><font size
="2" face="Verdana"> <sup>I</sup>Universidade Federal Fluminense,     Niter&oacu
te;i, RJ    ^cY#aop3711.htm##
00341000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704010000083002001200183#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#10#6#article#169#<br>   <sup>
II</sup>Hospital Procard&iacute;aco, Rio de Janeiro, RJ &#45; Brasil</font></p> 
    ^cY#aop3711.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704009300083002001200176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#11#7#article#169#<p><font siz
e="2" face="Verdana"><a href="#end">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop3711.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704002200083002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#12#8#article#169#<p>&nbsp;</p
>     ^cY#aop3711.htm##
00285000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704004400083002001200127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#13#9#article#169#<p>&nbsp;</p
> <hr size="1" noshade>     ^cY#aop3711.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006600084002001200150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#14#10#article#169#<p><font si
ze="2" face="VERDANA"><b>RESUMO</b></font></p>     ^cY#aop3711.htm##
00549000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704030700084002001200391#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#15#11#article#169#<p><font si
ze="2" face="Verdana"><b>FUNDAMENTO:</b> Na insufici&ecirc;ncia card&iacute;aca,
     o teste ergom&eacute;trico (TE) avalia capacidade funcional, um determinant
e     de progn&oacute;stico. A cintilografia com I¹²³ MIBG mostra a ativa&ccedil
;&atilde;o     simp&aacute;tica card&iacute;aca.    ^cY#aop3711.htm##
00404000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704016200084002001200246#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#16#12#article#169#<br>   <b>O
BJETIVO:</b> Avaliar a associa&ccedil;&atilde;o entre as vari&aacute;veis   do T
E e as altera&ccedil;&otilde;es da cintilografia com I¹²³ MIBG.    ^cY#aop3711.h
tm##
01080000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704083800084002001200922#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#17#13#article#169#<br>   <b>M
&Eacute;TODOS:</b> Foram submetidos 23 pacientes (FEVE <u>&lt;</u> 45%) &agrave;
 cintilografia   com I¹²³ MIBG e separados em: G1) taxa de <I>Washout</I> &lt; 2
7%; G2) <u>&gt;</u> 27%.   Esses pacientes realizaram TE, onde foram analisadas:
 press&atilde;o arterial   sist&oacute;lica no pico do esfor&ccedil;o (PASP), fr
equ&ecirc;ncia card&iacute;aca   no pico do esfor&ccedil;o (FCP), varia&ccedil;&
atilde;o da press&atilde;o arterial   sist&oacute;lica intraesfor&ccedil;o (</fo
nt><font>&#916;</font><font size="2" face="verdana"> PAS),   reserva cronotr&oac
ute;pica e capacidade funcional em METs. Utilizaram&#45;se para   a an&aacute;li
se estat&iacute;stica, o teste <I>t</I> de <I>Student</I> ou   o teste U de <I>M
ann&#45;Whitney</I>, o coeficiente de <I>Spearman </I>e o coeficiente   de regre
ss&atilde;o linear.    ^cY#aop3711.htm##
01210000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704096800084002001201052#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#18#14#article#169#<br>   <b>R
ESULTADOS:</b> A PASP (G1: 181,00 &plusmn; 28,01; G2: 153,27 &plusmn; 27,71, p =
 0,027),   a </font><font>&#916;</font><font size="2" face="verdana"> PAS &#91;G
1: 64 (47,5&#45;80,5);   G2: 36 (25&#45;47) mmHg, p = 0,015&#93;, a FCP (G1: 136
,91 &plusmn; 19,66; G2: 118,45 &plusmn; 13,98   bpm, p = 0,018), a reserva crono
tr&oacute;pica (G1: 70,42 &plusmn; 17,94; G2: 49,47 &plusmn; 14,89%,   p = 0,006
) e a capacidade funcional &#91;G1: 8,37 (6,47&#45;10,27); G2: 4,42 (2,46&#45;6,
38)   METs, p = 0,003&#93; foram menores no G2. Houve correla&ccedil;&atilde;o n
egativa   entre taxa de <I>Washout</I> com PASP (r = &#45;0,505, p = 0,014), </f
ont><font>&#916;</font><font size="2" face="verdana"> PAS   (r = &#45;0,493, p =
 0,017) e capacidade funcional (r = &#45;0,646, p = 0,001). Ap&oacute;s   regres
s&atilde;o linear, PASP (r = &#45;0,422, p = 0,016) e capacidade funcional   (r 
= &#45;0,804, p = 0,004) foram associadas com taxa de <I>Washout</I>.    ^cY#aop
3711.htm##
00450000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704020800084002001200292#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#19#15#article#169#<br>   <b>C
ONCLUS&Atilde;O:</b> Em pacientes com insufici&ecirc;ncia card&iacute;aca,   PAS
P e capacidade funcional foram as var&aacute;veis mais associadas com a   taxa d
e <I>Washout</I>.</font></p>     ^cY#aop3711.htm##
00415000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704017300084002001200257#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#20#16#article#169#<p><font si
ze="2" face="Verdana"><b>Palavras&#45;chave:</b> MIBG, teste de esfor&ccedil;o, 
    insufici&ecirc;ncia card&iacute;aca.</font></p> <hr size="1" noshade>     ^c
Y#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#21#17#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#22#18#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#23#19#article#169#<p><font si
ze="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop3711
.htm##
01684000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704144200084002001201526#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#24#20#article#169#<p><font si
ze="2" face="Verdana">Na insufici&ecirc;ncia card&iacute;aca (IC),     o teste e
rgom&eacute;trico (TE) &eacute; indicado para avaliar capacidade     funcional, 
presen&ccedil;a de sintomas e a terap&ecirc;utica<SUP>1</SUP>.     Alguns dos pa
r&acirc;metros empregados no TE s&atilde;o o comportamento da     press&atilde;o
 arterial sist&oacute;lica (PAS) intraesfor&ccedil;o e a reserva     cronotr&oac
ute;pica, que s&atilde;o reconhecidos preditores de progn&oacute;stico<SUP>2&#45
;4</SUP>.     A hiperatividade adren&eacute;rgica, caracter&iacute;stica da IC, 
pode levar &agrave; incompet&ecirc;ncia     cronotr&oacute;pica, &agrave; queda 
da resposta contr&aacute;til card&iacute;aca &agrave;s     catecolaminas e &agra
ve; diminui&ccedil;&atilde;o da reserva simp&aacute;tica     durante o exerc&iac
ute;cio. Uma inadequada resposta da PAS e da frequ&ecirc;ncia     card&iacute;ac
a (FC) tem sido associada a um risco duas vezes maior de mortalidade     e event
os cardiovasculares adversos<SUP>2,5&#45;7</SUP>. Tanto para a popula&ccedil;&at
ilde;o     geral<SUP>8</SUP>, quanto na popula&ccedil;&atilde;o com IC<SUP>2,9</
SUP>,     a capacidade funcional &eacute; um importante preditor de progn&oacute
;stico     e n&atilde;o est&aacute; relacionada com medidas da fun&ccedil;&atild
e;o     ventricular em repouso e tampouco com a fra&ccedil;&atilde;o de eje&cced
il;&atilde;o     ventricular esquerda<SUP>10</SUP>.</font></p>     ^cY#aop3711.h
tm##
01624000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704138200084002001201466#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#25#21#article#169#<p><font si
ze="2" face="Verdana">A atividade e a inerva&ccedil;&atilde;o simp&aacute;tica  
   card&iacute;aca podem ser avaliadas pela cintilografia com metaiodobenzilguan
idina     marcada com iodo 123 (I<SUP>123</SUP> MIBG)<SUP>11&#45;13</SUP>. Estud
os demonstraram<SUP>13&#45;16</SUP> que     a imagem precoce representa a integr
idade dos terminais nervosos pr&eacute;&#45;sin&aacute;pticos     e a densidade 
dos betarreceptores. A capta&ccedil;&atilde;o neuronal pr&eacute;&#45;sin&aacute
;ptica     contribui para a imagem tardia, combinando informa&ccedil;&otilde;es 
da fun&ccedil;&atilde;o     neural, incluindo capta&ccedil;&atilde;o, libera&cce
dil;&atilde;o e estocagem     da noradrenalina nas ves&iacute;culas pr&eacute;&#
45;sin&aacute;pticas. A taxa     de <I>Washout</I> &eacute; um par&acirc;metro q
ue avalia o grau de atividade     simp&aacute;tica. Pacientes com IC podem apres
entar: (1) reduzida capta&ccedil;&atilde;o     do tra&ccedil;ador devido &agrave
; perda de neur&ocirc;nios simp&aacute;ticos     e/ou dist&uacute;rbios na capta
&ccedil;&atilde;o prim&aacute;ria de noradrenalina;     e (2) aumento da taxa de
 <I>Washout</I>, refletindo o transbordamento de     noradrenalina para a corren
te sangu&iacute;nea<SUP>11,14,17&#45;19</SUP>. Taxa     de <I>Washout</I> menor 
que 27% &eacute; descritor de forte preditor de sobrevida<SUP>20</SUP>.</font></
p>     ^cY#aop3711.htm##
01086000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704084400084002001200928#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#26#22#article#169#<p><font si
ze="2" face="Verdana">At&eacute; o momento, n&atilde;o h&aacute; evid&ecirc;ncia
s     se a hiperativa&ccedil;&atilde;o adren&eacute;rgica em repouso se associa 
    com altera&ccedil;&otilde;es hemodin&acirc;micas no exerc&iacute;cio, ou    
 se as vari&aacute;veis do TE se associam com as vari&aacute;veis da cintilograf
ia.     Portanto, o objetivo deste estudo &eacute; avaliar se as vari&aacute;vei
s     do TE convencional na IC podem detectar pacientes que apresentam disfun&cc
edil;&atilde;o     simp&aacute;tica na cintilografia com I<SUP>123 </SUP>MIBG. E
sses achados     poderiam permitir a avalia&ccedil;&atilde;o do risco com uma t&
eacute;cnica     mais dispon&iacute;vel no nosso meio, selecionando os pacientes
 com maior     probabilidade de apresentarem altera&ccedil;&otilde;es &agrave; c
intilografia.</font></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#27#23#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007400084002001200158#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#28#24#article#169#<p><font si
ze="3" face="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#aop3711.htm##
01566000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704132400084002001201408#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#29#25#article#169#<p><font si
ze="2" face="Verdana">Foram selecionados 23 pacientes consecutivos     atendidos
 no ambulat&oacute;rio especializado em IC do Hospital Universit&aacute;rio     
Ant&ocirc;nio Pedro, da Universidade Federal Fluminense. Os pacientes selecionad
os     apresentavam IC e fra&ccedil;&atilde;o de eje&ccedil;&atilde;o ventricula
r     esquerda menor ou igual a 45%, mensurada atrav&eacute;s da ecocardiografia
,     pela t&eacute;cnica de Simpson. Foram exclu&iacute;dos do estudo os pacien
tes     que apresentavam: fibrila&ccedil;&atilde;o atrial, diab&eacute;ticos, po
rtadores     de dispositivo de estimula&ccedil;&atilde;o ventricular, endocrinop
atias,     doen&ccedil;a de Parkinson, mulheres gr&aacute;vidas ou em per&iacute
;odo     de amamenta&ccedil;&atilde;o. N&atilde;o foi suspensa nenhuma medica&cc
edil;&atilde;o     para realiza&ccedil;&atilde;o do estudo e todos se encontrava
m em tratamento     com doses otimizadas dos medicamentos padr&atilde;o para IC,
 incluindo o     uso de betabloqueador (carvedilol). Os volunt&aacute;rios assin
aram um termo     de consentimento livre e esclarecido concordando em fazer part
e do projeto.     O projeto foi aprovado pelo comit&ecirc; de &eacute;tica em pe
squisa do Hospital     Universit&aacute;rio Ant&ocirc;nio Pedro, sob o n&uacute;
mero 011/09. </font></p>     ^cY#aop3711.htm##
01741000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704149900084002001201583#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#30#26#article#169#<p><font si
ze="2" face="Verdana">Os pacientes realizaram TE sintoma&#45;limitado     (<I>so
ftware </I>ErgoPC 13 vers&atilde;o 2.2) em esteira, marca Imbramed,     devidame
nte calibrada conforme orienta&ccedil;&otilde;es do fabricante, em     protocolo
 de Rampa. Foram avaliados o comportamento da press&atilde;o arterial     sist&o
acute;lica (PAS), da frequ&ecirc;ncia card&iacute;aca (FC) intraesfor&ccedil;o  
   e a capacidade funcional. A medida da press&atilde;o arterial foi realizada  
   por m&eacute;todo indireto com utiliza&ccedil;&atilde;o de esfigmoman&ocirc;m
etro     com coluna de merc&uacute;rio, devidamente calibrado, aferida no bra&cc
edil;o     esquerdo do pacientes em posi&ccedil;&atilde;o ortost&aacute;tica. A 
medida     da frequ&ecirc;ncia card&iacute;aca foi feita atrav&eacute;s do inter
valo     RR do tra&ccedil;ado do eletrocardiograma (ECG) atrav&eacute;s do pr&oa
cute;prio <I>software</I>.     Avaliaram&#45;se a PAS e a FC no pico do esfor&cc
edil;o, a varia&ccedil;&atilde;o     da PAS no pico do esfor&ccedil;o em rela&cc
edil;&atilde;o ao repouso (</font><font>&#916;</font><font size="2" face="verdan
a"> PAS),     o &iacute;ndice de reserva cronotr&oacute;pica, atrav&eacute;s da 
f&oacute;rmula:     (<I>"{&#91;FC no pico do esfor&ccedil;o &#45; FC de repouso 
/ (220 &#45; Idade)     &#45; FC de repouso&#93; x 100}")</I><SUP>4</SUP>. A cap
acidade funcional foi     estimada pelo <I>software </I>de acordo com a carga de
 trabalho alcan&ccedil;ada. </font></p>     ^cY#aop3711.htm##
01257000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704101500084002001201099#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#31#27#article#169#<p><font si
ze="2" face="Verdana">Os pacientes realizaram a cintilografia mioc&aacute;rdica 
    com I¹²³ MIBG, para avaliar a inerva&ccedil;&atilde;o adren&eacute;rgica    
 card&iacute;aca, atrav&eacute;s da capta&ccedil;&atilde;o do radiotra&ccedil;ad
or,     com estudo da rela&ccedil;&atilde;o cora&ccedil;&atilde;o/mediastino (C/
M)     para as imagens precoces (30 minutos) e tardias (4 horas), al&eacute;m do
     c&aacute;lculo da taxa de <I>Washout </I>{<I>&#91;(C/M precoce &#45; C/M ta
rdia)     / (C/M precoce)&#93; x 100}</I><SUP>11</SUP>. Todos os exames cintilog
r&aacute;ficos     foram realizados no Servi&ccedil;o de Medicina Nuclear do Hos
pital Pr&oacute;&#45;Card&iacute;aco     do Rio de Janeiro, em c&acirc;mara de c
intila&ccedil;&atilde;o tipo <I>Anger</I> tomogr&aacute;fica     digital (<I>Sin
gle Photon Emission Computed Tomography</I>) da marca <I>Siemens</I>,     modelo
 <I>E&#45;Cam</I> de detector duplo, com colimador de baixa energia e alta     r
esolu&ccedil;&atilde;o. </font></p>     ^cY#aop3711.htm##
01394000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704115200084002001201236#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#32#28#article#169#<p><font si
ze="2" face="Verdana">Os pacientes foram divididos em dois grupos     de acordo 
com a taxa de <I>Washout</I> (WO): Grupo 1 (G1), taxa de <I>Washout</I> &lt; 27%
     (normal); Grupo 2 (G2), taxa de <I>Washout</I> <U>&gt;</u> 27% (alterado)<S
UP>21</SUP>.     Para a an&aacute;lise estat&iacute;stica, foi utilizado o <I>so
ftware</I> SPSS     vers&atilde;o 15. Para avalia&ccedil;&atilde;o das vari&aacu
te;veis qualitativas,     foi utilizado o teste qui&#45;quadrado. Para avalia&cc
edil;&atilde;o das vari&aacute;veis     quantitativas foi utilizado o teste <I>t
</I> de <I>Student</I> ou teste <I>U</I> de <I>Mann&#45;Withney</I>,     conform
e a distribui&ccedil;&atilde;o dos dados. Foi utilizado o coeficiente     de cor
rela&ccedil;&atilde;o de <I>Spearman</I> para avaliar a correla&ccedil;&atilde;o
     das vari&aacute;veis do exerc&iacute;cio com a WO. Empregamos a regress&ati
lde;o     linear <I>stepwise </I>para identificar as vari&aacute;veis associadas
 com     hipertonia simp&aacute;tica avaliada pela taxa de <I>Washout</I>. Foi c
onsiderado     com signific&acirc;ncia estat&iacute;stica o valor de p &lt; 0,05
.</font></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#33#29#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007100084002001200155#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#34#30#article#169#<p><font si
ze="3" face="Verdana"><b>Resultados</b> </font></p>     ^cY#aop3711.htm##
00659000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704041700084002001200501#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#35#31#article#169#<p><font si
ze="2" face="Verdana">As caracter&iacute;sticas dos pacientes s&atilde;o     mos
tradas na <a href="#tab01">Tabela 1</a>. N&atilde;o houve diferen&ccedil;as     
significativas na idade, sexo, &iacute;ndice de massa corporal, etiologia     da
 IC, fra&ccedil;&atilde;o de eje&ccedil;&atilde;o ventricular esquerda,     uso 
de medica&ccedil;&otilde;es e dose do carvedilol, entre os grupos.</font></p>   
  ^cY#aop3711.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#36#32#article#169#<p><a name=
"tab01"></a></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#37#33#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#38#34#article#169#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop37tb1.jpg"></p>     ^cY#aop3711
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#39#35#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00886000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064400084002001200728#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#40#36#article#169#<p><font si
ze="2" face="Verdana">Os grupos se mostraram semelhantes em repouso.     No pico
 de esfor&ccedil;o, houve diferen&ccedil;a significativa entre o G1     e o G2, 
sendo que este &uacute;ltimo apresentou menores valores absolutos     de PAS e d
a FC, menor varia&ccedil;&atilde;o da PAS intraesfor&ccedil;o,     menor &iacute
;ndice de reserva cronotr&oacute;pica e uma menor capacidade     funcional. Os p
ar&acirc;metros do exerc&iacute;cio s&atilde;o mostrados na <a href="#tab02">Tab
ela     2</a>, e a <a href="#fig01">Figura 1</a> apresenta as diferen&ccedil;as 
no     comportamento da PAS durante o esfor&ccedil;o.</font></p>     ^cY#aop3711
.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#41#37#article#169#<p><a name=
"tab02"></a></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#42#38#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#43#39#article#169#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop37tb2.jpg"></p>     ^cY#aop3711
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#44#40#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#45#41#article#169#<p><a name=
"fig01"></a></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#46#42#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#47#43#article#169#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop37fg1.jpg"></p>     ^cY#aop3711
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#48#44#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
01072000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704083000084002001200914#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#49#45#article#169#<p><font si
ze="2" face="Verdana">Apesar de divididos pela taxa de <I>Washout</I>,     n&ati
lde;o houve diferen&ccedil;a significativa na rela&ccedil;&atilde;o     C/M prec
oce de I<SUP>123</SUP> MIBG (G1: 1,78 &plusmn; 0,25 <I>vs</I> G2: 1,74 &plusmn; 
0,22;     p = 0,710) e na rela&ccedil;&atilde;o C/M tardia (G1: 1,74 &plusmn; 0,
20 <I>vs</I> G2:     1,60 &plusmn; 0,22; p = 0,129). A <a href="#fig02">Figura 2
</a> ilustra a imagem     card&iacute;aca com I<SUP>123 </SUP>MIBG de um pacient
e com IC que apresenta     par&acirc;metros de exerc&iacute;cio normais (capacid
ade funcional de 8,23     METs, varia&ccedil;&atilde;o da PAS intraesfor&ccedil;
o de 65 mmHg e &iacute;ndice     de reserva cronotr&oacute;pica de 68%). A capta
&ccedil;&atilde;o do MIBG     foi normal e a taxa de <I>Washout</I> foi de 21%.<
/font></p>     ^cY#aop3711.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#50#46#article#169#<p><a name=
"fig02"></a></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#51#47#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#52#48#article#169#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop37fg2.jpg"></p>     ^cY#aop3711
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#53#49#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00928000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704068600084002001200770#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#54#50#article#169#<p><font si
ze="2" face="Verdana">Quando analisamos a correla&ccedil;&atilde;o     entre as 
vari&aacute;veis do exerc&iacute;cio e a taxa de <I>Washout</I>,     observamos 
uma significativa correla&ccedil;&atilde;o negativa entre a taxa     de <I>Washo
ut</I> e as seguintes vari&aacute;veis: PAS no pico do esfor&ccedil;o,     varia
&ccedil;&atilde;o da PAS intraesfor&ccedil;o e a capacidade funcional     (<a hr
ef="#tab03">Tabela 3</a>). N&atilde;o foi observada signific&acirc;ncia     esta
t&iacute;stica na correla&ccedil;&atilde;o com a FC no pico do esfor&ccedil;o   
  e do &iacute;ndice de reserva cronotr&oacute;pica com WO (<a href="#tab03">Tab
ela     3</a>).</font></p>     ^cY#aop3711.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#55#51#article#169#<p><a name=
"tab03"></a></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#56#52#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#57#53#article#169#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop37tb3.jpg"></p>     ^cY#aop3711
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#58#54#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00557000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704031500084002001200399#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#59#55#article#169#<p><font si
ze="2" face="Verdana">Ap&oacute;s regress&atilde;o linear stepwise,     as vari&
aacute;veis associadas com disautonomia pela taxa de <I>Washout</I> foram:     a
 PAS no pico do esfor&ccedil;o (r = &#45;0,422; p = 0,016) e a capacidade funcio
nal     em METs (r = &#45;0,804; p = 0,004).</font></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#60#56#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#61#57#article#169#<p><font si
ze="3" face="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#aop3711.htm##
01327000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704108500084002001201169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#62#58#article#169#<p><font si
ze="2" face="Verdana">Em nosso estudo, observamos que em pacientes     com IC a 
PAS no pico do esfor&ccedil;o e a capacidade funcional, medida atrav&eacute;s   
  do n&uacute;mero de METs atingido, est&atilde;o associadas a altera&ccedil;&ot
ilde;es     na inerva&ccedil;&atilde;o adren&eacute;rgica card&iacute;aca, confo
rme evidenciado     pela taxa de <I>Washout</I> obtida atrav&eacute;s da cintilo
grafia mioc&aacute;rdica     com I<SUP>123</SUP> MIBG. Durante o TE, nos pacient
es com taxa de <I>Washout</I> alterada     (estado de hipertonia adren&eacute;rg
ica em repouso), verificamos que a PAS     no pico do esfor&ccedil;o e o n&uacut
e;mero de METs apresentaram menores     valores quando comparados com os dos pac
ientes com taxa de <I>Washout</I> normal.     N&atilde;o h&aacute;, at&eacute; o
 presente momento, descri&ccedil;&atilde;o     na literatura dessa associa&ccedi
l;&atilde;o entre tal comportamento anormal     da PAS e altera&ccedil;&otilde;e
s na inerva&ccedil;&atilde;o adren&eacute;rgica     card&iacute;aca pelo I<SUP>1
23</SUP> MIBG.</font></p>     ^cY#aop3711.htm##
01041000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704079900084002001200883#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#63#59#article#169#<p><font si
ze="2" face="Verdana">A varia&ccedil;&atilde;o da PAS durante o exerc&iacute;cio
     associa&#45;se diretamente com o d&eacute;bito card&iacute;aco durante o es
for&ccedil;o:     uma menor eleva&ccedil;&atilde;o da PAS intraesfor&ccedil;o po
de ser resultado     de d&eacute;ficit inotr&oacute;pico durante o exerc&iacute;
cio, que &eacute; um     fen&ocirc;meno comum em pacientes com disfun&ccedil;&at
ilde;o ventricular,     sendo este achado associado com pior progn&oacute;stico<
SUP>2</SUP>. Fargard     e cols.<SUP>22</SUP>, em uma amostra de pacientes candi
datos a transplante     card&iacute;aco, demonstraram que uma varia&ccedil;&atil
de;o inadequada da     PAS em resposta ao exerc&iacute;cio subm&aacute;ximo &eac
ute; preditora de     eventos card&iacute;acos. </font></p>     ^cY#aop3711.htm#
#
00764000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052200084002001200606#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#64#60#article#169#<p><font si
ze="2" face="Verdana">Willians e cols.<SUP>23</SUP> avaliaram pacientes     com 
IC de diferentes classes funcionais, demonstrando que simples par&acirc;metros  
   obtidos no teste, como a dura&ccedil;&atilde;o e a PAS no pico do esfor&ccedi
l;o,     s&atilde;o fortes preditores de progn&oacute;stico atrav&eacute;s de an
&aacute;lise     multivariada, superando a fra&ccedil;&atilde;o de eje&ccedil;&a
tilde;o ventricular     esquerda e fra&ccedil;&atilde;o N terminal proBNP (NT&#4
5;proBNP). </font></p>     ^cY#aop3711.htm##
01176000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704093400084002001201018#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#65#61#article#169#<p><font si
ze="2" face="Verdana">Nishiyama e cols.<SUP>2</SUP> avaliaram a resposta     da 
PAS durante o exerc&iacute;cio como preditor de progn&oacute;stico em     pacien
tes com IC. Por an&aacute;lise univariada, PAS e FC no pico do esfor&ccedil;o,  
   al&eacute;m de suas varia&ccedil;&otilde;es durante o exerc&iacute;cio (</fon
t><font>&#916;</font><font size="2" face="verdana"> PAS/</font><font>&#916;</fon
t><font size="2" face="verdana"> FC     = pico do esfor&ccedil;o &#45; repouso) 
foram preditores de mortalidade. Nesse     estudo, o grupo n&atilde;o sobreviven
te apresentou menores valores de tais     vari&aacute;veis. Ap&oacute;s an&aacut
e;lise multivariada, o </font><font>&#916;</font><font size="2" face="verdana"> 
PAS     e a capacidade funcional, obtida atrav&eacute;s do n&uacute;mero de METs
     atingido, foram os melhores preditores de mortalidade, independente do uso 
    de betabloqueador. </font></p>     ^cY#aop3711.htm##
01232000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704099000084002001201074#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#66#62#article#169#<p><font si
ze="2" face="Verdana">O consumo de oxig&ecirc;nio (VO<SUB>2</SUB>)     m&aacute;
ximo &eacute; um par&acirc;metro utilizado para avaliar, em pacientes     com IC
, candidatos ao transplante card&iacute;aco<SUP>24</SUP>, sendo tamb&eacute;m   
  um poderoso preditor de progn&oacute;stico<SUP>24&#45;26</SUP>. Willens e cols
.<SUP>27</SUP>,     estudando 40 pacientes com IC, classe funcional II e III da 
<I>New York Heart     Association </I>(NYHA), demonstraram que o VO<SUB>2</SUB> 
m&aacute;ximo,     tanto por medida indireta (de acordo com o tempo do exerc&iac
ute;cio), quanto     por medida direta, atrav&eacute;s do Teste Cardiopulmonar d
o Exerc&iacute;cio, &eacute; um     importante preditor de sobrevida, promovendo
 informa&ccedil;&otilde;es &uacute;teis     para o acompanhamento dos pacientes.
 Outra forma de avaliar o VO<SUB>2</SUB> m&aacute;ximo     por medida indireta &
eacute; atrav&eacute;s do n&uacute;mero de METs atingido     no TE<SUP>2</SUP>.<
/font></p>     ^cY#aop3711.htm##
00844000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060200084002001200686#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#67#63#article#169#<p><font si
ze="2" face="Verdana">Em um estudo envolvendo indiv&iacute;duos saud&aacute;veis
,     Snader e cols.<SUP>8</SUP> demonstraram que a capacidade funcional foi um 
    poderoso preditor de mortalidade cardiovascular. Nesse trabalho, a taxa de  
   mortalidade cardiovascular foi maior no grupo que n&atilde;o conseguiu alcan&
ccedil;ar     06 METs no TE, e sua associa&ccedil;&atilde;o com defeitos diagnos
ticados     na perfus&atilde;o pela cintilografia mioc&aacute;rdica com t&aacute
;lio,     colocou esses pacientes em um patamar de risco ainda maior para evento
s adversos.</font></p>     ^cY#aop3711.htm##
00921000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704067900084002001200763#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#68#64#article#169#<p><font si
ze="2" face="Verdana">Jeng e cols.<SUP>28</SUP> avaliaram a influ&ecirc;ncia    
 da toler&acirc;ncia ao exerc&iacute;cio sobre a qualidade de vida em pacientes 
    com IC. Os pacientes que obtiveram uma capacidade funcional maior ou igual  
   a 05 METs, ou um tempo de TE maior ou igual 180 segundos, apresentavam uma   
  melhor qualidade de vida, mostrando que o TE &eacute; seguro, dispon&iacute;ve
l     e efetivo para avaliar a toler&acirc;ncia ao exerc&iacute;cio nesta popula
&ccedil;&atilde;o.     Rubim e cols.<SUP>29</SUP> demonstraram que o n&uacute;me
ro de METs atingido     no TE correlaciona&#45;se significativamente com a morta
lidade. </font></p>     ^cY#aop3711.htm##
01104000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704086200084002001200946#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#69#65#article#169#<p><font si
ze="2" face="Verdana">Myers e cols.<SUP>30</SUP>, avaliando escores     de quali
dade de vida, teste da caminhada dos 06 minutos e n&uacute;meros     de METs ati
ngido no TE em pacientes com IC, e correlacionando essas vari&aacute;veis     co
m VO<SUB>2</SUB> m&aacute;ximo obtido atrav&eacute;s do Teste Cardiopulmonar    
 do Exerc&iacute;cio, conclu&iacute;ram que ambos refletem, &agrave; sua maneira
,     o estado cl&iacute;nico do paciente e t&ecirc;m sua import&acirc;ncia ness
e     contexto cl&iacute;nico, sem, no entanto, um substituir o outro. Quando co
mparado     com a dist&acirc;ncia percorrida no teste da caminhada dos 06 minuto
s, a     capacidade funcional determinada pelo n&uacute;mero de METs no TE corre
lacionou&#45;se     significativamente melhor com o VO<SUB>2</SUB> m&aacute;ximo
 obtido por medida     direta. </font></p>     ^cY#aop3711.htm##
00902000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704066000084002001200744#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#70#66#article#169#<p><font si
ze="2" face="Verdana">Chandrashekhar e cols.<SUP>31</SUP> analisaram     a capac
idade das vari&aacute;veis comumente empregadas no TE em predizer     o VO<SUB>2
</SUB> m&aacute;ximo. Ap&oacute;s an&aacute;lise de regress&atilde;o <I>stepwise
,</I> o     melhor preditor do VO<SUB>2</SUB> m&aacute;ximo foi o n&uacute;mero 
de METs     alcan&ccedil;ado. Apesar dos autores afirmarem que o n&uacute;mero d
e METs     n&atilde;o tenha uma precis&atilde;o elevada, mesmo assim ainda &eacu
te; melhor     preditor cl&iacute;nico que as outras vari&aacute;veis obtidas, c
omo por     exemplo, o comportamento da FC durante o esfor&ccedil;o. </font></p>
     ^cY#aop3711.htm##
00849000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704060700084002001200691#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#71#67#article#169#<p><font si
ze="2" face="Verdana">Uma das mais significativas modifica&ccedil;&otilde;es    
 no tratamento da insufici&ecirc;ncia card&iacute;aca foi &agrave; introdu&ccedi
l;&atilde;o     dos betabloqueadores. Parikh e cols.<SUP>32</SUP>, em pacientes 
com IC, classe     funcional do NYHA III e IV, avaliaram o efeito do betabloquea
dor metoprolol     sobre o n&uacute;mero de METs atingido no TE, concluindo que 
a otimiza&ccedil;&atilde;o     do betabloqueador melhora o desempenho no exerc&i
acute;cio, avaliado tanto     pelo tempo de exerc&iacute;cio, quanto pelo n&uacu
te;mero de METs.</font></p>     ^cY#aop3711.htm##
00582000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704034000084002001200424#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#72#68#article#169#<p><font si
ze="2" face="Verdana">Alguns estudos sugerem que a melhora, que n&atilde;o &eacu
te; universalmente     observada, pode ser, em parte, decorrente da melhora da f
un&ccedil;&atilde;o     endotelial, devido ao uso dos betabloqueadores associado
 com inibidor da     enzima conversora de angiotensina<SUP>33</SUP>. </font></p>
     ^cY#aop3711.htm##
01655000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704141300084002001201497#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#73#69#article#169#<p><font si
ze="2" face="Verdana">Outra vertente de marcadores de risco na IC &eacute; atrav
&eacute;s     da imagem neuronal. A cintilografia com I<SUP>123 </SUP>MIBG tem s
ido validada     como uma marcadora de progn&oacute;stico, conforme metan&aacute
;lise com     1.755 pacientes, publicada por Verbene e cols.<SUP>19</SUP>, que d
emonstrou     que uma redu&ccedil;&atilde;o da rela&ccedil;&atilde;o C/M na imag
em tardia     ou aumento da taxa de <I>Washout</I> na cintilografia mioc&aacute;
rdica com     I<SUP>123</SUP> MIBG associa&#45;se a pior progn&oacute;stico quan
do comparado     com pacientes que apresentam normalidade destes par&acirc;metro
s. Em recente     publica&ccedil;&atilde;o, Jacobson e cols.<SUP>34</SUP>, em um
 estudo multic&ecirc;ntrico     com pacientes com classe funcional II e III do N
YHA e fra&ccedil;&atilde;o     de eje&ccedil;&atilde;o ventricular esquerda meno
r que 35%, demonstraram     que a avalia&ccedil;&atilde;o adren&eacute;rgica dir
eta do cora&ccedil;&atilde;o,     atrav&eacute;s da cintilografia mioc&aacute;rd
ica com I<SUP>123</SUP> MIBG,     foi preditora de maior mortalidade card&iacute
;aca e de eventos arr&iacute;tmicos,     de modo independente de fatores progn&o
acute;sticos conhecidos como a fra&ccedil;&atilde;o     de eje&ccedil;&atilde;o 
ventricular esquerda, pept&iacute;deo natriur&eacute;tico     cerebral e da clas
se funcional do NYHA. </font></p>     ^cY#aop3711.htm##
01634000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704139200084002001201476#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#74#70#article#169#<p><font si
ze="2" face="Verdana">Analisando as informa&ccedil;&otilde;es funcionais     obt
idas pela imagem neuronal com as do Teste Cardiopulmonar do Exerc&iacute;cio,   
  Cohen&#45;Solal e cols.<SUP>14</SUP> correlacionaram o VO<SUB>2</SUB> m&aacute
;ximo     com a capta&ccedil;&atilde;o de I<SUP>123</SUP> MIBG e diversas outras
 vari&aacute;veis     (fra&ccedil;&atilde;o de eje&ccedil;&atilde;o ventricular 
esquerda, par&acirc;metros     hemodin&acirc;micos, como &iacute;ndice card&iacu
te;aco e press&atilde;o     capilar pulmonar). Observaram uma significativa corr
ela&ccedil;&atilde;o     entre os achados cintilogr&aacute;ficos adren&eacute;rg
icos no I<SUP>123 </SUP>MIBG     e o VO<SUB>2</SUB> m&aacute;ximo no exerc&iacut
e;cio. Analisando seus desfechos     (morte cardiovascular e transplante card&ia
cute;aco), o maior determinante     do progn&oacute;stico foi o VO<SUB>2 </SUB>m
&aacute;ximo. O VO<SUB>2 </SUB>m&aacute;ximo     se correlacionou melhor com a r
ela&ccedil;&atilde;o C/M para imagem tardia     do que com a rela&ccedil;&atilde
;o C/M para imagem precoce e com a taxa de <I>Washout</I>.     Em contrapartida,
 o nosso estudo encontrou uma maior correla&ccedil;&atilde;o     da taxa de <I>W
ashout</I> com o n&uacute;mero de METs atingido, e n&atilde;o     com a rela&cce
dil;&atilde;o C/M tardia, como no estudo de Cohen&#45;Solal e cols.<SUP>14</SUP>
.</font></p>     ^cY#aop3711.htm##
01066000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704082400084002001200908#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#75#71#article#169#<p><font si
ze="2" face="Verdana">Entretanto, existem significativas diferen&ccedil;as     e
ntre os estudos: na nossa casu&iacute;stica, avaliamos o VO<SUB>2</SUB> m&aacute
;ximo     por medida indireta atrav&eacute;s do n&uacute;mero de METs atingidos,
 enquanto     Cohen&#45;Solal e cols<SUP>14</SUP> utilizaram medida direta do VO
<SUB>2</SUB>.     No estudo de Cohen&#45;Solal e cols<SUP>14</SUP>, apenas 13% d
os pacientes estavam     em uso de betabloqueadores, enquanto no nosso todos os 
pacientes estavam     em uso desta medica&ccedil;&atilde;o. Os betabloqueadores 
t&ecirc;m como     uma das suas a&ccedil;&otilde;es a ressensibiliza&ccedil;&ati
lde;o dos betarreceptores,     o que pode influir na rela&ccedil;&atilde;o C/M, 
fato que explicaria as diverg&ecirc;ncias     dos achados<SUP>5,35</SUP>.</font>
</p>     ^cY#aop3711.htm##
00336000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009400084002001200178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#76#72#article#169#<p><font si
ze="2" face="Verdana"><b>Limita&ccedil;&otilde;es do estudo</b></font></p>     ^
cY#aop3711.htm##
00769000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052700084002001200611#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#77#73#article#169#<p><font si
ze="2" face="Verdana">A principal limita&ccedil;&atilde;o do estudo     foi o n&
uacute;mero reduzido de pacientes. Por&eacute;m, atrav&eacute;s de     um estudo
&#45;piloto com 16 pacientes, foi realizado um c&aacute;lculo amostral     e o n
&uacute;mero de 23 pacientes tem um poder estat&iacute;stico de 90%     para ide
ntificar 50% de diferen&ccedil;a na capacidade funcional e um poder     estat&ia
cute;stico de 80% para identificar 50% de diferen&ccedil;a na PAS     no pico do
 esfor&ccedil;o.</font></p>     ^cY#aop3711.htm##
01369000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704112700084002001201211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#78#74#article#169#<p><font si
ze="2" face="Verdana">Outra significativa limita&ccedil;&atilde;o     foi termos
 empregado da capacidade funcional pelo n&uacute;mero de METs atingido,     e n&
atilde;o o VO<SUB>2</SUB> m&aacute;ximo calculado diretamente atrav&eacute;s    
 do Teste Cardiopulmonar do Exerc&iacute;cio, pois n&atilde;o disp&uacute;nhamos
     do equipamento necess&aacute;rio em nossa institui&ccedil;&atilde;o, &agrav
e; &eacute;poca     da realiza&ccedil;&atilde;o deste estudo. Entretanto, como o
 TE &eacute; uma     ferramenta simples e amplamente presente no nosso meio, acr
editamos que as     informa&ccedil;&otilde;es derivadas deste exame possam ser &
uacute;teis para     os cardiologistas envolvidos com a pr&aacute;tica cl&iacute
;nica de pacientes     com IC, uma vez que se correlacionaram com a sofisticada 
an&aacute;lise da     inerva&ccedil;&atilde;o card&iacute;aca. Outra importante 
vari&aacute;vel     observada como significativa no nosso estudo, que foi a PAS 
no pico do esfor&ccedil;o,     tamb&eacute;m &eacute; derivada do TE e n&atilde;
o requer complexas metodologias     para an&aacute;lise.</font></p>     ^cY#aop3
711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#79#75#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#80#76#article#169#<p><font si
ze="3" face="Verdana"><b>Conclus&atilde;o</b></font></p>     ^cY#aop3711.htm##
00959000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704071700084002001200801#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#81#77#article#169#<p><font si
ze="2" face="Verdana">Os pacientes com IC e taxa de <I>Washout</I> alterada     
na cintilografia mioc&aacute;rdica com I<SUP>123</SUP> MIBG apresentaram     men
or resposta inotr&oacute;pica, cronotr&oacute;pica e uma menor capacidade     fu
ncional. A PAS no pico do esfor&ccedil;o e o n&uacute;mero de METs atingidos    
 foram as vari&aacute;veis do TE que mais se associaram com esta hipertonia     
adren&eacute;rgica avaliada pela cintilografia. O TE convencional, atrav&eacute;
s     da avalia&ccedil;&atilde;o dessas duas vari&aacute;veis, pode ser utilizad
o     como uma forma de prever a presen&ccedil;a de hiperatividade adren&eacute;
rgica     card&iacute;aca em pacientes com IC.</font></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#82#78#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007300084002001200157#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#83#79#article#169#<p><font si
ze="3" face="Verdana"><b>Agradecimento</b></font></p>     ^cY#aop3711.htm##
00415000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704017300084002001200257#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#84#80#article#169#<p><font si
ze="2" face="Verdana">Agradecimento &agrave; FAPERJ e ao CNPq pelo     apoio dad
o aos projetos de pesquisa da Universidade Federal Fluminense.</font></p>     ^c
Y#aop3711.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009200084002001200176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#85#81#article#169#<p><font si
ze="2" face="Verdana"><b>Potencial Conflito de Interesses</b></font></p>     ^cY
#aop3711.htm##
00359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011700084002001200201#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#86#82#article#169#<p><font si
ze="2" face="Verdana">Declaro n&atilde;o haver conflito de interesses     pertin
entes.</font></p>     ^cY#aop3711.htm##
00325000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008300084002001200167#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#87#83#article#169#<p><font si
ze="2" face="Verdana"><b>Fontes de Financiamento</b></font></p>     ^cY#aop3711.
htm##
00366000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012400084002001200208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#88#84#article#169#<p><font si
ze="2" face="Verdana">O presente estudo n&atilde;o teve fontes de     financiame
nto externas.</font></p>     ^cY#aop3711.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#89#85#article#169#<p><font si
ze="2" face="Verdana"><b>Vincula&ccedil;&atilde;o Acad&ecirc;mica</b></font></p>
     ^cY#aop3711.htm##
00429000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704018700084002001200271#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#90#86#article#169#<p><font si
ze="2" face="Verdana">Este artigo &eacute; parte de disserta&ccedil;&atilde;o   
  de Mestrado de Leandro Rocha Messias pela Universidade Federal Fluminense.</fo
nt></p>     ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#91#87#article#169#<p>&nbsp;</
p>     ^cY#aop3711.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#92#88#article#169#<p><font si
ze="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop3711.htm##
00534000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027800086002001200364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#93#89#article#169
#1#<p><font size="2" face="Verdana">1. Meneghelo RS, Ara&uacute;jo CGS, Stein   
  R, Mastrocolla LE, Albuquerque PF, Serra SM, et al. / Sociedade Brasileira    
 de Cardiologia. III Diretrizes sobre teste ergom&eacute;trico. Arq Bras Cardiol
.     2010;95(5 supl 1):1&#45;26.    ^cY#aop3711.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#94#90#article#169# </font></p
>     ^cY#aop3711.htm##
00526000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704027000086002001200356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#95#91#article#169
#2#<p><font size="2" face="Verdana">2. Nishiyama Y, Morita H, Harada H, Katoh   
  A, Adachi H, Koga Y, et al. Systolic blood pressure response to exercise     a
s a predictor of mortality in patients with chronic heart failure. Int Heart    
 J. 2010;51(2):111&#45;5.    ^cY#aop3711.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#96#92#article#169#</font></p>
     ^cY#aop3711.htm##
00561000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704030500086002001200391#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#97#93#article#169
#3#<p><font size="2" face="Verdana">3.  Arena R, Myers J, Abella J, Peberdy MA, 
    Bensimhon D, Chase P, et al. The prognostic value of the heart rate response
     during exercise and recovery in patients with heart failure: influence of  
   beta&#45;blockade. Int J Cardiol. 2010;138(2):166&#45;73.    ^cY#aop3711.htm#
#
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002100084002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#98#94#article#169# </font></p
>     ^cY#aop3711.htm##
00541000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704028500086002001200371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#99#95#article#169
#4#<p><font size="2" face="Verdana">4. Kallistratos MS, Dritsas A, Laoutaris    
 ID, Cokkinos DV. Chronotropic and neurohumoral markers for the evaluation     o
f functional capacity in patients with impaired left ventricular function.     H
ellenic J Cardiol. 2008;49(1):26&#45;32.    ^cY#aop3711.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#100#96#article#169#</font></p
>     ^cY#aop3711.htm##
00567000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704031000087002001200397#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#101#97#article#16
9#5#<p><font size="2" face="Verdana">5.  Colucci WS, Ribeiro JP, Rocco MB, Quigg
     RJ, Creager MA, Marsh JD, et al. Impaired chronotropic response to exercise
     in patients with congestive heart failure: role of postysynaptic beta&#45;a
drenergic     desensitization. Circulation. 1989;80(2):314&#45;23.    ^cY#aop371
1.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#102#98#article#169#</font></p
>     ^cY#aop3711.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704023800087002001200325#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#103#99#article#16
9#6#<p><font size="2" face="Verdana">6.  Freeman JV, Dewey FE, Hadley DM, Myers 
    J, Froelicher VF. Autonomic nervous system interaction with the cardiovascul
ar     system during exercise. Prog Cardiovasc Dis. 2006;48(5):342&#45;62.    ^c
Y#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#104#100#article#169#</font></
p>     ^cY#aop3711.htm##
00541000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704028300088002001200371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#105#101#article#1
69#7#<p><font size="2" face="Verdana">7. Maddox TM, Ross C, Ho PM, Masoudi FA,  
   Magid D, Daugherty SL, et al. The prognostic importance of abnormal heart    
 rate recovery and chronotropic response among exercise treadmill test patients.
     Am Heart J. 2008;156(4):736&#45;44.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#106#102#article#169#</font></
p>     ^cY#aop3711.htm##
00652000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704039400088002001200482#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#107#103#article#1
69#8#<p><font size="2" face="Verdana">8. Snader CE, Marwick TH, Pashkow FJ, Harv
ey     SA, Thomas JD, Lauer MS. Importance of estimated functional capacity as a
     predictor of all&#45;cause mortality among patients referred for exercise t
hallium     single&#45;photon emission computed tomography: report of 3,400 pati
ents from     a single center. J Am Coll Cardiol. 1997;30(3):641&#45;8.    ^cY#a
op3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#108#104#article#169#</font></
p>     ^cY#aop3711.htm##
00576000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704031800088002001200406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#109#105#article#1
69#9#<p><font size="2" face="Verdana">9.  Guimar&atilde;es GV, Silva MS, d'Avila
     VM, Ferreira SM, Silva CP, Bocchi EA. VO2 pico e inclina&ccedil;&atilde;o  
   VE/VCO2 na era dos betabloqueadores na insufici&ecirc;ncia card&iacute;aca:  
   uma experi&ecirc;ncia brasileira. Arq Bras Cardiol. 2008;91(1):42&#45;8.    ^
cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#110#106#article#169#</font></
p>     ^cY#aop3711.htm##
00432000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704017300089002001200262#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#111#107#article#1
69#10#<p><font size="2" face="Verdana">10. Hanson P. Exercise testing and traini
ng     in patients with chronic heart failure. Med Sci Sports Exerc. 1994;26(5):
527&#45;37.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#112#108#article#169#</font></
p>     ^cY#aop3711.htm##
00583000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032400089002001200413#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#113#109#article#1
69#11#<p><font size="2" face="Verdana">11. Turpeinen AK, Vanninen E, Magga J, Tu
omainen     P, Kuusisto J, Sipola P, et al. Cardiac sympathetic activity is asso
ciated     with inflammation and neurohumoral activation in patients with idiopa
thic     dilated cardiomyopathy. Clin Physiol Funct Imaging. 2009;29(6):414&#45;
9.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#114#110#article#169#</font></
p>     ^cY#aop3711.htm##
00488000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022900089002001200318#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#115#111#article#1
69#12#<p><font size="2" face="Verdana">12.  Giubbini R, Milan E, Bertagna F, Mut
     F, Metra M, Rodella C, et al. Nuclear cardiology and heart failure. Eur J  
   Nucl Med Mol Imaging. 2009 Aug 12. &#91;Epub ahead of print&#93;    ^cY#aop37
11.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#116#112#article#169#. </font>
</p>     ^cY#aop3711.htm##
00471000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021200089002001200301#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#117#113#article#1
69#13#<p><font size="2" face="Verdana">13. Agostini D, Carrio I, Verberne HJ. Ho
w     to use myocardial 123I&#45;MIBG scintigraphy in chronic heart failure. Eur
 J     Nucl Med Mol Imaging. 2009;36(4):555&#45;9.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#118#114#article#169#</font></
p>     ^cY#aop3711.htm##
00576000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031700089002001200406#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#119#115#article#1
69#14#<p><font size="2" face="Verdana">14. Cohen&#45;Solal A, Esanu Y, Logeart D
, Pessione     F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine up
take in     patients with moderate chronic heart failure: relationship with peak
 oxygen     uptake and prognosis. J Am Coll Cardiol. 1999;33(3):759&#45;66.    ^
cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#120#116#article#169#</font></
p>     ^cY#aop3711.htm##
00574000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031500089002001200404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#121#117#article#1
69#15#<p><font size="2" face="Verdana">15. Diakakis GF, Parthenakis FI, Patriana
kos     AP, Koukouraki SI, Stathaki MI, Karkavitsas NS, et al. Myocardial sympat
hetic     innervation in patients with impaired glucose tolerance: relationship 
to     subclinical inflammation. Cardiovasc Pathol. 2008;17(3):172&#45;7.    ^cY
#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#122#118#article#169#</font></
p>     ^cY#aop3711.htm##
00556000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029700089002001200386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#123#119#article#1
69#16#<p><font size="2" face="Verdana">16. Dae MW, De Marco T, Botvinick EH, O'C
onnell     JW, Hattner RS, Huberty JP, et al. Scintigraphic assessment of MIBG u
ptake     in globally denervated human and canine hearts&#45;implications for cl
inical     studies. J Nucl Med. 1992;33(8):1444&#45;50.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#124#120#article#169#</font></
p>     ^cY#aop3711.htm##
00419000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704016000089002001200249#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#125#121#article#1
69#17#<p><font size="2" face="Verdana">17. Ji SY, Travin MI. Radionuclide imagin
g     of cardiac autonomic innervation. J Nucl Cardiol. 2010;17(4):655&#45;66.  
  ^cY#aop3711.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#126#122#article#169# </font><
/p>     ^cY#aop3711.htm##
00516000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025700089002001200346#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#127#123#article#1
69#18#<p><font size="2" face="Verdana">18. Ando M, Yamamoto T, Hino A, Sato T, N
akamura     Y, Matsuzaki M. Norepinephrine spillover during exercise as a novel 
parameter     to evaluate the severity of heart failure. J Nucl Cardiol. 2010;17
(5):868&#45;73.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#128#124#article#169#</font></
p>     ^cY#aop3711.htm##
00545000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028600089002001200375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#129#125#article#1
69#19#<p><font size="2" face="Verdana">19. Verberne HJ, Brewster LM, Somsen GA, 
    van Eck&#45;Smit BL. Prognostic value of myocardial 123I&#45;metaiodobenzylg
uanidine     (MIBG) parameters in patients with heart failure: a systematic revi
ew. Eur     Heart J. 2008;29(9):1147&#45;59.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#130#126#article#169#</font></
p>     ^cY#aop3711.htm##
00476000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021700089002001200306#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#131#127#article#1
69#20#<p><font size="2" face="Verdana">20.  Carri&oacute; I, Cowie MR, Yamazaki 
    J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart fail
ure.     JACC Cardiovasc Imaging. 2010;3(1):92&#45;100.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#132#128#article#169#</font></
p>     ^cY#aop3711.htm##
00581000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032200089002001200411#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#133#129#article#1
69#21#<p><font size="2" face="Verdana">21. Ogita H, Shimonagata T, Fukunami M, K
umagai     K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)
I metaiodobenzylguanidine     imaging for mortality and morbidity in patients wi
th chronic heart failure:     a prospective study. Heart. 2001;86(6):656&#45;60.
    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#134#130#article#169#</font></
p>     ^cY#aop3711.htm##
00495000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023600089002001200325#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#135#131#article#1
69#22#<p><font size="2" face="Verdana">22. Fagard R, Pardaens K, Vanhaecke J. Pr
ognostic     significance of exercise versus resting blood pressure in patients 
with chronic     heart failure. J Hypertens. 1999;17(12 Pt 2):1977&#45;81.    ^c
Y#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#136#132#article#169#</font></
p>     ^cY#aop3711.htm##
00558000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029900089002001200388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#137#133#article#1
69#23#<p><font size="2" face="Verdana">23. Williams SG, Jackson M, Ng LL, Barker
     D, Patwala A, Tan LB. Exercise duration and peak systolic blood pressure   
  are predictive of mortality in ambulatory patients with mild&#45;moderate chro
nic     heart failure. Cardiology. 2005;104(4):221&#45;6.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#138#134#article#169#</font></
p>     ^cY#aop3711.htm##
00671000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704041200089002001200501#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#139#135#article#1
69#24#<p><font size="2" face="Verdana">24. Costanzo MR, Augustine S, Bourge R, B
ristow     M, O'Connell JB, Driscoll D, et al. Selection and treatment of candid
ates     for heart transplantation: a statement for health professionals from th
e     Committee on Heart Failure and Cardiac Transplantation of the Council on  
   Clinical Cardiology, American Heart Association. Circulation. 1995;92(12):359
3&#45;612.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#140#136#article#169#</font></
p>     ^cY#aop3711.htm##
00526000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026700089002001200356#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#141#137#article#1
69#25#<p><font size="2" face="Verdana">25. Shakar SF, Lowes BD, Lindenfeld J, Zo
lty     R, Simon M, Robertson AD, et al. Peak oxygen consumption and outcome in 
heart     failure patients chronically treated with beta&#45;blockers. J Card Fa
il. 2004;10(1):15&#45;20.    ^cY#aop3711.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#142#138#article#169# </font><
/p>     ^cY#aop3711.htm##
00500000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024100089002001200330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#143#139#article#1
69#26#<p><font size="2" face="Verdana">26. O'Neil JO, Young JB, Pothier CE, Laue
r     MS. Peak oxygen consumption as a predictor of death in patients with heart
     failure receiving beta&#45;blockers. Circulation. 2005;111(18):2313&#45;8. 
   ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#144#140#article#169#</font></
p>     ^cY#aop3711.htm##
00515000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025600089002001200345#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#145#141#article#1
69#27#<p><font size="2" face="Verdana">27. Willens HJ, Blevins RD, Wrisley D, An
tonishen     D, Reinstein D, Rubenfire M. The prognostic value of functional cap
acity     in patients with mild to moderate heart failure. Am Heart J. 1987;114(
2):377&#45;82.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#146#142#article#169#</font></
p>     ^cY#aop3711.htm##
00472000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021300089002001200302#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#147#143#article#1
69#28#<p><font size="2" face="Verdana">28. Jeng C, Yang MH, Chen PL, Ho CH. The 
    influence of exercise tolerance on quality of life among patients with heart
     failure. Qual Life Res. 2004;13(5):925&#45;32.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#148#144#article#169#</font></
p>     ^cY#aop3711.htm##
00502000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024300089002001200332#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#149#145#article#1
69#29#<p><font size="2" face="Verdana">29. Rubim VS, Drumond Neto C, Romeo JL, M
ontera     MW. Valor progn&oacute;stico do teste de caminhada de seis minutos na
 insufici&ecirc;ncia     card&iacute;aca. Arq Bras Cardiol. 2006;86(2):120&#45;5
.    ^cY#aop3711.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#150#146#article#169# </font><
/p>     ^cY#aop3711.htm##
00492000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023300089002001200322#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#151#147#article#1
69#30#<p><font size="2" face="Verdana">30. Myers J, Zaheer N, Quaglietti S, Madh
avan     R, Froelicher V, Heidenreich P. Association of functional and health st
atus     measures in heart failure. J Card Fail. 2006;12(6):439&#45;45.    ^cY#a
op3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#152#148#article#169#</font></
p>     ^cY#aop3711.htm##
00549000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029000089002001200379#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#153#149#article#1
69#31#<p><font size="2" face="Verdana">31. Chandrashekhar Y, Anand IS. Can commo
n     exercise indices determine peak exercise oxygen consumption and anaerobic 
    threshold during stress testing in patients with chronic congestive heart   
  failure? Indian Heart J. 1993;45(6):493&#45;5.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#154#150#article#169#</font></
p>     ^cY#aop3711.htm##
00628000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704036900089002001200458#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#155#151#article#1
69#32#<p><font size="2" face="Verdana">32.  Parikh KH, Hetal A, Milan C, Urmil G
,     Hemang A, Anish C, Ajay M, et al. Effect of Metoprolol CR/XL on pulmonary 
    artery pressure in chronic heart failure patients assessed by an implanted  
   ultrasonic device with special emphasis on diurnal variation and exercise    
 capacity. Indian Heart J. 2009;61(1):34&#45;9.    ^cY#aop3711.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#156#152#article#169# </font><
/p>     ^cY#aop3711.htm##
00633000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704037400089002001200463#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#157#153#article#1
69#33#<p><font size="2" face="Verdana">33. Poelzl G, Frick M, Lackner B, Huegel 
    H, Alber HF, Mair J, et al. Short&#45;term improvement in submaximal exercis
e     capacity by optimized therapy with ACE inhibitors and beta blockers in hea
rt     failure patients is associated with restoration of peripheral endothelial
     function. Int J Cardiol. 2006;108(1):48&#45;54.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#158#154#article#169#</font></
p>     ^cY#aop3711.htm##
00652000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704039300089002001200482#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#159#155#article#1
69#34#<p><font size="2" face="Verdana">34. Jacobson AF, Senior R, Cerqueira MD, 
    Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine&#45;123 meta&#45;iodo
benzylguanidine     imaging and cardiac events in heart failure: results of the 
prospective ADMIRE&#45;HF     (AdreView Myocardial Imaging for Risk Evaluation i
n Heart Failure) study.     J Am Coll Cardiol. 2010;55(20):2212&#45;21.    ^cY#a
op3711.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#160#156#article#169# </font><
/p>     ^cY#aop3711.htm##
00584000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704032500089002001200414#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#161#157#article#1
69#35#<p><font size="2" face="Verdana">35. Kasama S, Toyama T, Hatori T, Sumino 
    H, Kumakura H, Takayama Y, et al. Evaluation of cardiac sympathetic nerve   
  activity and left ventricular remodelling in patients with dilated cardiomyopa
thy     on the treatment containing carvedilol. Eur Heart J. 2007;28(8):989&#45;
95.    ^cY#aop3711.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#162#158#article#169#</font></
p>     ^cY#aop3711.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#163#159#article#169#<p>&nbsp;
</p>     ^cY#aop3711.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#164#160#article#169#<p>&nbsp;
</p>     ^cY#aop3711.htm##
00410000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016600086002001200252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#165#161#article#169#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:    ^cY#aop
3711.htm##
00284000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004000086002001200126#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#166#162#article#169#<br>   </
b>Leandro Rocha Messias    ^cY#aop3711.htm##
00313000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006900086002001200155#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#167#163#article#169#<BR>   Ru
a Noronha Torrez&atilde;o, 46 / 805 &#45; Santa Rosa    ^cY#aop3711.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006600086002001200152#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#168#164#article#169#<br>   24
240&#45;182 &#45; Niter&oacute;i, RJ &#45; Brasil    ^cY#aop3711.htm##
00410000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016600086002001200252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#169#165#article#169#<BR>   E&
#45;mail: <a href="mailto:lmessias@cardiol.br">lmessias@cardiol.br</a>, <a href=
"mailto:leandromess@gmail.com">leandromess@gmail.com</a> </font></p>     ^cY#aop
3711.htm##
00380000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704013600086002001200222#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#170#166#article#169#<p><font 
size="2" face="Verdana"> Artigo recebido em 22/08/10; revisado recebido     em 0
9/11/10; aceito em 20/12/10</font></p>     ^cY#aop3711.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#171#167#article#169#<p>&nbsp;
</p>     ^cY#aop3711.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#172#168#article#169#<p>&nbsp;
</p>     ^cY#aop3711.htm##
00420000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704017600086002001200262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3711.htm#S#p#173#169#article#169#<p><font 
size="2" face="Verdana">Full texts in English &#45; <A href="http://www.arquivos
online.com.br" target="_blank">http://www.arquivosonline.com.br</A></font></p>  
   ^cY#aop3711.htm##
00736000000000361000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100018001050100
01500123010002200138010002200160010001600182011003600198810000600234012004300240
03000170028306500090030006400050030903100030031403200040031701400050032186500090
0326002001200335035001000347801001700357#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop3711.htm#S#c#174#1#article#35#1#^rND^sMeneghelo^nRS#^rND^sAraújo^n
CGS#^rND^sStein^nR#^rND^sMastrocolla^nLE#^rND^sAlbuquerque^nPF#^rND^sSerra^nSM#S
ociedade Brasileira de Cardiologia#et al#III Diretrizes sobre teste ergométrico^
lpt#Arq Bras Cardiol#20100000#2010#95#^s1#1-26#20110000#aop3711.htm#0066-782X#Ar
q Bras Cardiol##
00701000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100016001040100
01600120010001500136010001600151010001400167810000600181012011600187030001200303
71000020031506500090031706400050032603100030033103200020033401400060033686500090
0342002001200351#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#175#2#article#35#2#^rND^sNishiyama^nY#^rND^sMorita^nH#^rND^sHarada^nH#^rND^sK
atoh^nA#^rND^sAdachi^nH#^rND^sKoga^nY#et al#Systolic blood pressure response to 
exercise as a predictor of mortality in patients with chronic heart failure^len#
Int Heart J#2#20100000#2010#51#2#111-5#20110000#aop3711.htm##
00765000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100015001000100
01600115010001800131010001900149010001500168810000600183012014000189030001400329
06500090034306400050035203100040035703200020036101400070036386500090037000200120
0379035001000391801001400401#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#176#3#article#35#3#^rND^sArena^nR#^rND^sMyers^nJ#^rND^sAbella^nJ#
^rND^sPeberdy^nMA#^rND^sBensimhon^nD#^rND^sChase^nP#et al#The prognostic value o
f the heart rate response during exercise and recovery in patients with heart fa
ilure: influence of beta-blockade^len#Int J Cardiol#20100000#2010#138#2#166-73#2
0110000#aop3711.htm#0167-5273#Int J Cardiol##
00669000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100023000850100017001080100
02000125010001900145012013600164030001900300710000200319065000900321064000500330
031000300335032000200338014000600340865000900346002001200355#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3711.htm#S#c#177#4#article#35#4#^rND^sKallistr
atos^nMS#^rND^sDritsas^nA#^rND^sLaoutaris^nID#^rND^sCokkinos^nDV#Chronotropic an
d neurohumoral markers for the evaluation of functional capacity in patients wit
h impaired left ventricular function^len#Hellenic J Cardiol#2#20080000#2008#49#1
#26-32#20110000#aop3711.htm##
00768000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100018001030100
01600121010001600137010001800153010001600171810000600187012014400193030001200337
06500090034906400050035803100030036303200020036601400070036886500090037500200120
0384035001000396801001200406#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#178#5#article#35#5#^rND^sColucci^nWS#^rND^sRibeiro^nJP#^rND^sRocc
o^nMB#^rND^sQuigg^nRJ#^rND^sCreager^nMA#^rND^sMarsh^nJD#et al#Impaired chronotro
pic response to exercise in patients with congestive heart failure: role of post
ysynaptic beta-adrenergic desensitization^len#Circulation#19890000#1989#80#2#314
-23#20110000#aop3711.htm#0009-7322#Circulation##
00683000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100016001030100
01700119010001500136010002100151012008800172030002000260065000900280064000500289
03100030029403200020029701400070029986500090030600200120031503500100032780100200
0337#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#c#179#6#art
icle#35#6#^rND^sFreeman^nJV#^rND^sDewey^nFE#^rND^sHadley^nDM#^rND^sMyers^nJ#^rND
^sFroelicher^nVF#Autonomic nervous system interaction with the cardiovascular sy
stem during exercise^len#Prog Cardiovasc Dis#20060000#2006#48#5#342-62#20110000#
aop3711.htm#0033-0620#Prog Cardiovasc Dis##
00745000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100014001020100
01300116010001800129010001500147010002000162810000600182012012700188030001100315
06500090032606400050033503100040034003200020034401400070034686500090035300200120
0362035001000374801001100384#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#180#7#article#35#7#^rND^sMaddox^nTM#^rND^sRoss^nC#^rND^sHo^nPM#^r
ND^sMasoudi^nFA#^rND^sMagid^nD#^rND^sDaugherty^nSL#et al#The prognostic importan
ce of abnormal heart rate recovery and chronotropic response among exercise trea
dmill test patients^len#Am Heart J#20080000#2008#156#4#736-44#20110000#aop3711.h
tm#0002-8703#Am Heart J##
00840000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100018001020100
01800120010001700138010001700155010001600172012022200188030001800410065000900428
06400050043703100030044203200020044501400060044786500090045300200120046203500100
0474801001800484#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#181#8#article#35#8#^rND^sSnader^nCE#^rND^sMarwick^nTH#^rND^sPashkow^nFJ#^rND^
sHarvey^nSA#^rND^sThomas^nJD#^rND^sLauer^nMS#Importance of estimated functional 
capacity as a predictor of all-cause mortality among patients referred for exerc
ise thallium single-photon emission computed tomography: report of 3,400 patient
s from a single center^len#J Am Coll Cardiol#19970000#1997#30#3#641-8#20110000#a
op3711.htm#0735-1097#J Am Coll Cardiol##
00733000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100016001050100
01700121010001900138010001600157010001700173012011600190030001700306065000900323
06400050033203100030033703200020034001400050034286500090034700200120035603500100
0368801001700378#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#182#9#article#35#9#^rND^sGuimarães^nGV#^rND^sSilva^nMS#^rND^sd'Avila VM#^rND^
sFerreira^nSM#^rND^sSilva^nCP#^rND^sBocchi^nEA#VO2 pico e inclinação VE/VCO2 na 
era dos betabloqueadores na insuficiência cardíaca: uma experiência brasileira^l
pt#Arq Bras Cardiol#20080000#2008#91#1#42-8#20110000#aop3711.htm#0066-782X#Arq B
ras Cardiol##
00553000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870120073001030300
02100176065000900197064000500206031000300211032000200214014000700216865000900223
002001200232035001000244801002100254#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3711.htm#S#c#183#10#article#35#10#^rND^sHanson^nP#Exercise testing and
 training in patients with chronic heart failure^len#Med Sci Sports Exerc#199400
00#1994#26#5#527-37#20110000#aop3711.htm#0195-9131#Med Sci Sports Exerc##
00756000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100018001070100
01500125010001900140010001800159010001600177810000600193012014400199030002700343
71000020037006500090037206400050038103100030038603200020038901400060039186500090
0397002001200406#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#184#11#article#35#11#^rND^sTurpeinen^nAK#^rND^sVanninen^nE#^rND^sMagga^nJ#^rN
D^sTuomainen^nP#^rND^sKuusisto^nJ#^rND^sSipola^nP#et al#Cardiac sympathetic acti
vity is associated with inflammation and neurohumoral activation in patients wit
h idiopathic dilated cardiomyopathy^len#Clin Physiol Funct Imaging#2#20090000#20
09#29#6#414-9#20110000#aop3711.htm##
00604000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100015001050100
01800120010001300138010001500151010001700166810000700183012004100190030002700231
710000200258065000900260064001200269865000900281002001200290#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3711.htm#S#c#185#12#article#35#12#^rND^sGiubbi
ni^nR#^rND^sMilan^nE#^rND^sBertagna^nF#^rND^sMut^nF#^rND^sMetra^nM#^rND^sRodella
^nC#et al.#Nuclear cardiology and heart failure^len#Eur J Nucl Med Mol Imaging#2
#20090812#2009 Aug 12#20110000#aop3711.htm##
00579000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100016001050100
01900121012007400140030002700214710000200241065000900243064000500252031000300257
032000200260014000600262865000900268002001200277#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3711.htm#S#c#186#13#article#35#13#^rND^sAgostini^nD#^rND^s
Carrio^nI#^rND^sVerberne^nHJ#How to use myocardial 123I-MIBG scintigraphy in chr
onic heart failure^len#Eur J Nucl Med Mol Imaging#2#20090000#2009#36#4#555-9#201
10000#aop3711.htm##
00783000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100015001080100
01700123010001800140010001600158010001700174810000600191012014300197030001800340
06500090035806400050036703100030037203200020037501400070037786500090038400200120
0393035001000405801001800415#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#187#14#article#35#14#^rND^sCohen-Solal^nA#^rND^sEsanu^nY#^rND^sLo
geart^nD#^rND^sPessione^nF#^rND^sDubois^nC#^rND^sDreyfus^nG#et al#Cardiac metaio
dobenzylguanidine uptake in patients with moderate chronic heart failure: relati
onship with peak oxygen uptake and prognosis^len#J Am Coll Cardiol#19990000#1999
#33#3#759-66#20110000#aop3711.htm#0735-1097#J Am Coll Cardiol##
00747000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100022001060100
02200128010002100150010001900171010002200190810000600212012012500218030001800343
71000020036106500090036306400050037203100030037703200020038001400060038286500090
0388002001200397#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#188#15#article#35#15#^rND^sDiakakis^nGF#^rND^sParthenakis^nFI#^rND^sPatrianak
os^nAP#^rND^sKoukouraki^nSI#^rND^sStathaki^nMI#^rND^sKarkavitsas^nNS#et al#Myoca
rdial sympathetic innervation in patients with impaired glucose tolerance: relat
ionship to subclinical inflammation^len#Cardiovasc Pathol#2#20080000#2008#17#3#1
72-7#20110000#aop3711.htm##
00755000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100018001010100
02000119010001900139010001800158010001800176810000600194012012500200030001100325
06500090033606400050034503100030035003200020035301400080035586500090036300200120
0372035001000384801001100394#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#189#16#article#35#16#^rND^sDae^nMW#^rND^sDe Marco^nT#^rND^sBotvin
ick^nEH#^rND^sO'Connell JW#^rND^sHattner^nRS#^rND^sHuberty^nJP#et al#Scintigraph
ic assessment of MIBG uptake in globally denervated human and canine hearts-impl
ications for clinical studies^len#J Nucl Med#19920000#1992#33#8#1444-50#20110000
#aop3711.htm#0161-5505#J Nucl Med##
00552000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100013000870100017001000120
05800117030001500175065000900190064000500199031000300204032000200207014000700209
865000900216002001200225035001000237801001500247#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3711.htm#S#c#190#17#article#35#17#^rND^sJi^nSY#^rND^sTravi
n^nMI#Radionuclide imaging of cardiac autonomic innervation^len#J Nucl Cardiol#2
0100000#2010#17#4#655-66#20110000#aop3711.htm#1071-3581#J Nucl Cardiol##
00717000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100018001010100
01400119010001400133010001800147010001900165012010800184030001500292065000900307
06400050031603100030032103200020032401400070032686500090033300200120034203500100
0354801001500364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#191#18#article#35#18#^rND^sAndo^nM#^rND^sYamamoto^nT#^rND^sHino^nA#^rND^sSato
^nT#^rND^sNakamura^nY#^rND^sMatsuzaki^nM#Norepinephrine spillover during exercis
e as a novel parameter to evaluate the severity of heart failure^len#J Nucl Card
iol#20100000#2010#17#5#868-73#20110000#aop3711.htm#1071-3581#J Nucl Cardiol##
00695000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060100
01700125010002300142012013400165030001200299065000900311064000500320031000300325
032000200328014000800330865000900338002001200347035001000359801001200369#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#c#192#19#article#35#19#
^rND^sVerberne^nHJ#^rND^sBrewster^nLM#^rND^sSomsen^nGA#^rND^svan Eck-Smit^nBL#Pr
ognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in p
atients with heart failure: a systematic review^len#Eur Heart J#20080000#2008#29
#9#1147-59#20110000#aop3711.htm#0195-668X#Eur Heart J##
00616000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01800119010001700137010001700154012005900171030002400230710000200254065000900256
064000500265031000200270032000200272014000700274865000900281002001200290#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#c#193#20#article#35#20#
^rND^sCarrió^nI#^rND^sCowie^nMR#^rND^sYamazaki^nJ#^rND^sUdelson^nJ#^rND^sCamici^
nPG#Cardiac sympathetic imaging with mIBG in heart failure^len#JACC Cardiovasc I
maging#2#20100000#2010#3#1#92-100#20110000#aop3711.htm##
00780000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100021001020100
01800123010001700141010001600158010001500174810000600189012016600195030000600361
06500090036706400050037603100030038103200020038401400070038686500090039300200120
0402035001000414801000600424#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#194#21#article#35#21#^rND^sOgita^nH#^rND^sShimonagata^nT#^rND^sFu
kunami^nM#^rND^sKumagai^nK#^rND^sYamada^nT#^rND^sAsano^nY#et al#Prognostic signi
ficance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morb
idity in patients with chronic heart failure: a prospective study^len#Heart#2001
0000#2001#86#6#656-60#20110000#aop3711.htm#1355-6037#Heart##
00639000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100018001030100
01900121012010900140030001200249065000900261064000500270031000300275032000800278
014000800286865000900294002001200303035001000315801001200325#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3711.htm#S#c#195#22#article#35#22#^rND^sFagard
^nR#^rND^sPardaens^nK#^rND^sVanhaecke^nJ#Prognostic significance of exercise ver
sus resting blood pressure in patients with chronic heart failure^len#J Hyperten
s#19990000#1999#17#12 Pt 2#1977-81#20110000#aop3711.htm#0263-6352#J Hypertens##
00747000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060100
01300123010001600136010001700152010001400169012014700183030001100330065000900341
06400050035003100040035503200020035901400060036186500090036700200120037603500100
0388801001100398#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#196#23#article#35#23#^rND^sWilliams^nSG#^rND^sJackson^nM#^rND^sNg^nLL#^rND^sB
arker^nD#^rND^sPatwala^nA#^rND^sTan^nLB#Exercise duration and peak systolic bloo
d pressure are predictive of mortality in ambulatory patients with mild-moderate
 chronic heart failure^len#Cardiology#20050000#2005#104#4#221-6#20110000#aop3711
.htm#0008-6312#Cardiology##
00871000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100019001060100
01600125010001700141010001900158010001800177810000600195012023600201030001200437
06500090044906400050045803100030046303200030046601400090046986500090047800200120
0487035001000499801001200509#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#197#24#article#35#24#^rND^sCostanzo^nMR#^rND^sAugustine^nS#^rND^s
Bourge^nR#^rND^sBristow^nM#^rND^sO'Connell JB#^rND^sDriscoll^nD#et al#Selection 
and treatment of candidates for heart transplantation: a statement for health pr
ofessionals from the Committee on Heart Failure and Cardiac Transplantation of t
he Council on Clinical Cardiology, American Heart Association^len#Circulation#19
950000#1995#92#12#3593-612#20110000#aop3711.htm#0009-7322#Circulation##
00731000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
02000120010001500140010001500155010002000170810000600190012010500196030001200301
06500090031306400050032203100030032703200020033001400060033286500090033800200120
0347035001000359801001200369#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#198#25#article#35#25#^rND^sShakar^nSF#^rND^sLowes^nBD#^rND^sLinde
nfeld^nJ#^rND^sZolty^nR#^rND^sSimon^nM#^rND^sRobertson^nAD#et al#Peak oxygen con
sumption and outcome in heart failure patients chronically treated with beta-blo
ckers^len#J Card Fail#20040000#2004#10#1#15-20#20110000#aop3711.htm#1071-9164#J 
Card Fail##
00657000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01800119010001600137012010700153030001200260065000900272064000500281031000400286
032000300290014000700293865000900300002001200309035001000321801001200331#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#c#199#26#article#35#26#
^rND^sO'Neil JO#^rND^sYoung^nJB#^rND^sPothier^nCE#^rND^sLauer^nMS#Peak oxygen co
nsumption as a predictor of death in patients with heart failure receiving beta-
blockers^len#Circulation#20050000#2005#111#18#2313-8#20110000#aop3711.htm#0009-7
322#Circulation##
00712000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
01700123010002000140010001900160010001900179012009600198030001100294065000900305
06400050031403100040031903200020032301400070032586500090033200200120034103500100
0353801001100363#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#200#27#article#35#27#^rND^sWillens^nHJ#^rND^sBlevins^nRD#^rND^sWrisley^nD#^rN
D^sAntonishen^nD#^rND^sReinstein^nD#^rND^sRubenfire^nM#The prognostic value of f
unctional capacity in patients with mild to moderate heart failure^len#Am Heart 
J#19870000#1987#114#2#377-82#20110000#aop3711.htm#0002-8703#Am Heart J##
00636000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100015001010100
01500116010001300131012009300144030001400237065000900251064000500260031000300265
032000200268014000700270865000900277002001200286035001000298801001400308#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#c#201#28#article#35#28#
^rND^sJeng^nC#^rND^sYang^nMH#^rND^sChen^nPL#^rND^sHo^nCH#The influence of exerci
se tolerance on quality of life among patients with heart failure^len#Qual Life 
Res#20040000#2004#13#5#925-32#20110000#aop3711.htm#0962-9343#Qual Life Res##
00649000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100022001030100
01600125010001800141012008600159030001700245065000900262064000500271031000300276
032000200279014000600281865000900287002001200296035001000308801001700318#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S#c#202#29#article#35#29#
^rND^sRubim^nVS#^rND^sDrumond Neto^nC#^rND^sRomeo^nJL#^rND^sMontera^nMW#Valor pr
ognóstico do teste de caminhada de seis minutos na insuficiência cardíaca^lpt#Ar
q Bras Cardiol#20060000#2006#86#2#120-5#20110000#aop3711.htm#0066-782X#Arq Bras 
Cardiol##
00690000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020100
02000118010001800138010002000156010002100176012007400197030001200271065000900283
06400050029203100030029703200020030001400070030286500090030900200120031803500100
0330801001200340#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3711.htm#S
#c#203#30#article#35#30#^rND^sMyers^nJ#^rND^sZaheer^nN#^rND^sQuaglietti^nS#^rND^
sMadhavan^nR#^rND^sFroelicher^nV#^rND^sHeidenreich^nP#Association of functional 
and health status measures in heart failure^len#J Card Fail#20060000#2006#12#6#4
39-45#20110000#aop3711.htm#1071-9164#J Card Fail##
00674000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100024000870100016001110120
17100127030001500298065000900313064000500322031000300327032000200330014000600332
865000900338002001200347035001000359801001500369#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3711.htm#S#c#204#31#article#35#31#^rND^sChandrashekhar^nY#
^rND^sAnand^nIS#Can common exercise indices determine peak exercise oxygen consu
mption and anaerobic threshold during stress testing in patients with chronic co
ngestive heart failure^len#Indian Heart J#19930000#1993#45#6#493-5#20110000#aop3
711.htm#0019-4832#Indian heart j##
00849000000000361000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
01500119010001500134010001600149010001500165010001400180810000600194012020200200
03000150040206500090041706400050042603100030043103200020043401400050043686500090
0441002001200450035001000462801001500472#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop3711.htm#S#c#205#32#article#35#32#^rND^sParikh^nKH#^rND^sHetal^nA#
^rND^sMilan^nC#^rND^sUrmil^nG#^rND^sHemang^nA#^rND^sAnish^nC#^rND^sAjay^nM#et al
#Effect of Metoprolol CR/XL on pulmonary artery pressure in chronic heart failur
e patients assessed by an implanted ultrasonic device with special emphasis on d
iurnal variation and exercise capacity^len#Indian Heart J#20090000#2009#61#1#34-
9#20110000#aop3711.htm#0019-4832#Indian heart j##
00832000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100015001030100
01700118010001600135010001600151010001400167810000600181012021000187030001400397
06500090041106400050042003100040042503200020042901400060043186500090043700200120
0446035001000458801001400468#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#206#33#article#35#33#^rND^sPoelzl^nG#^rND^sFrick^nM#^rND^sLackner
^nB#^rND^sHuegel^nH#^rND^sAlber^nHF#^rND^sMair^nJ#et al#Short-term improvement i
n submaximal exercise capacity by optimized therapy with ACE inhibitors and beta
 blockers in heart failure patients is associated with restoration of peripheral
 endothelial function^len#Int J Cardiol#20060000#2006#108#1#48-54#20110000#aop37
11.htm#0167-5273#Int J Cardiol##
00847000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100016001060100
02000122010001500142010001700157010001600174810000600190012020600196030001800402
06500090042006400050042903100030043403200030043701400080044086500090044800200120
0457035001000469801001800479#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#207#34#article#35#34#^rND^sJacobson^nAF#^rND^sSenior^nR#^rND^sCer
queira^nMD#^rND^sWong^nND#^rND^sThomas^nGS#^rND^sLopez^nVA#et al#Myocardial iodi
ne-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: res
ults of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluati
on in Heart Failure) study^len#J Am Coll Cardiol#20100000#2010#55#20#2212-21#201
10000#aop3711.htm#0735-1097#J Am Coll Cardiol##
00789000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119010001600135010001800151010001800169810000600187012016500193030001200358
06500090037006400050037903100030038403200020038701400070038986500090039600200120
0405035001000417801001200427#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3711.htm#S#c#208#35#article#35#35#^rND^sKasama^nS#^rND^sToyama^nT#^rND^sHatori
^nT#^rND^sSumino^nH#^rND^sKumakura^nH#^rND^sTakayama^nY#et al#Evaluation of card
iac sympathetic nerve activity and left ventricular remodelling in patients with
 dilated cardiomyopathy on the treatment containing carvedilol^len#Eur Heart J#2
0070000#2007#28#8#989-95#20110000#aop3711.htm#0195-668X#Eur Heart J##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#o#1#1#a
rticle#1#20110408#165105#aop3811.htm#172##
05379000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201201010017101200970
02720100055003690100043004240100044004670100034005110100047005450100038005920700
08000630070009200710083172400802085000802526085002202534085002702556085003702583
08500380262008316440265808500080430208500210431008500300433108500370436108500390
43980580066044370580027045030580062045301170008045920720003046001120009046031110
00904612116000904621115000904630114000904639113000904648002001204657#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#h#2#1#article#1#tr#pt#br1.1
#1#4.0#ND#43#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#
Efeito agudo da intensidade do exercício de força na modulação autonômica cardía
ca pós-exercício^lpt#Acute effect of resistance exercise intensity in cardiac au
tonomic modulation after exercise^len#^rND^1A01^nAluísio Henrique Rodrigues de A
ndrade^sLima#^rND^1A02^nCláudia Lúcia de Moraes^sForjaz#^rND^1A01^nGleyson Queir
oz de Moraes^sSilva#^rND^1A01^nAnnelise Lins^sMenêses#^rND^1A01^nAnderson José M
elo Rodrigues^sSilva#^rND^1A01^nRaphael Mendes^sRitti-Dias#Universidade de Perna
mbuco^iA01^1Escola Superior de Educação Física^cRecife^sPE#Universidade de São P
aulo^iA02^1Escola de Educação Física e Esportes^cSão Paulo^sSP^pBrasil#^lpt^aFUN
DAMENTO: O balanço simpatovagal cardíaco se altera após o exercício de força. Co
ntudo, o impacto das características do treinamento de força nessa resposta aind
a não está claro. OBJETIVO: Analisar o efeito agudo da intensidade do exercício 
de força para tronco e membros superiores na modulação autonômica cardíaca pós-e
xercício. MÉTODOS: Quinze homens jovens realizaram três sessões experimentais em
 ordem aleatória: controle (C), exercício de força com 50% de 1-RM (E50%) e exer
cício de força com 70% de 1-RM (E70%). As sessões incluíram 05 exercícios para t
ronco e membro superior, realizados em três séries de 12, 9 e 6 repetições, resp
ectivamente. Antes e aos 20 e 50 minutos após as intervenções, a frequência card
íaca foi medida para posterior análise espectral da sua variabilidade. RESULTADO
S: Em comparação aos valores anteriores à intervenção, o intervalo RR e a banda 
de alta frequência (AF) aumentaram (maiores alterações: + 112 ± 83 ms; +10 ± 11 
un, respectivamente, p < 0,01), enquanto que a banda de baixa frequência (BF) e 
a razão BF/AF diminuíram (maiores alterações: -10 ± 11 un; -2 ± 2, respectivamen
te, p < 0,01) após a sessão C. Nenhuma dessas variáveis se alterou significantem
ente após a sessão E50% (p &gt; 0,05). Em comparação aos valores pré-exercício, 
o intervalo RR e a banda AF diminuíram (maiores alterações: -69 ± 105 ms; -13 ± 
14 un, respectivamente, p < 0,01), enquanto que a banda BF e a razão BF/AF aumen
taram (maiores alterações: -13 ± 14 un, +13 ± 14 un e +3 ± 3 un, respectivamente
, p < 0,01) após a E70%. CONCLUSÃO: A maior intensidade de exercício de força pa
ra tronco e membros superiores promoveu, agudamente, maior aumento do balanço si
mpatovagal cardíaco pós-exercício.#^dnd^i1#^tm^lpt^kExercício^i1#^tm^lpt^kesforç
o físico^i1#^tm^lpt^ksistema nervoso autônomo^i1#^tm^lpt^ksistema nervoso simpát
ico^i1#^len^aBACKGROUND: Cardiac sympathovagal balance is altered after resistan
ce exercise. However, the impact of the characteristics of resistance training i
n this response remains unclear. OBJECTIVE: Analyze the acute effect of resistan
ce exercise intensity for trunk and upper limbs in cardiac autonomic modulation 
after exercise. METHODS: Fifteen young men performed three experimental sessions
 in random order: control (C), resistance exercise with 50% of 1-RM (E50%) and r
esistance exercise with 70% of 1-RM (E70%). The sessions included 05 exercises f
or the trunk and upper limbs performed in three sets of 12, 9 and 6 repetitions,
 respectively. Before and at 20 and 50 minutes after the interventions, the hear
t rate was measured for spectral analysis of variability. RESULTS: In comparison
 to the values before the intervention, the RR interval and the band of high fre
quency (HF) increased (major changes: + 112 ± 83 ms; +10 ± 11 un, respectively, 
p < 0.01), while the low frequency band (LF) and LF/HF ratio decreased (major ch
anges: -10 ± 11 pc; -2 ± 2, respectively, p < 0.01) after the session C. None of
 these variables changed significantly after the E50% session (p &gt; 0.05). Com
pared to pre-exercise values, the RR interval and the HF band decreased (major c
hanges: -69 ± 105 ms; -13 ± 14 un, respectively, p <0.01), while the LF band and
 the LF/HF ratio increased (major changes: -13 ± 14 un, 13 ± 3 14 ± 3 and un, re
spectively, p <0.01) after E70%. CONCLUSION: The higher intensity of resistance 
exercise for trunk and upper limbs promoted, in an acute manner, greater increas
e in cardiac sympathovagal balance after exercise.#^dnd^i2#^tm^len^kExercise^i2#
^tm^len^kphysical exertion^i2#^tm^len^kautonomic nervous system^i2#^tm^len^ksymp
athetic nervous system^i2#Fundação de Amparo a Ciência e Tecnologia do Estado de
 Pernambuco#Universidade de Pernambuco#Conselho Nacional de Desenvolvimento Cien
tífico e Tecnológico#vancouv#23#20100904#04/09/10#20101103#03/11/10#20101125#25/
11/10#aop3811.htm##
05487000000000709000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201201080017101201040
02790100055003830100043004380100044004810100034005250100047005590100038006060700
08000644070009200724083177100816085000802587085002202595085002702617085003702644
08500380268108316910271908500080441008500210441808500300443908500370446908500390
45060580066045450580027046110580062046381170008047000720003047081120009047111110
00904720116000904729115000904738114000904747113000904756002001204765#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#f#3#1#article#1#tr#pt#br1.1
#1#4.0#ND#43#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#
<b>Efeito agudo da intensidade do exercício de força na modulação autonômica car
díaca pós-exercício</b>^lpt#<b>Acute effect of resistance exercise intensity in 
cardiac autonomic modulation after exercise</b>^len#^rND^1A01^nAluísio Henrique 
Rodrigues de Andrade^sLima#^rND^1A02^nCláudia Lúcia de Moraes^sForjaz#^rND^1A01^
nGleyson Queiroz de Moraes^sSilva#^rND^1A01^nAnnelise Lins^sMenêses#^rND^1A01^nA
nderson José Melo Rodrigues^sSilva#^rND^1A01^nRaphael Mendes^sRitti-Dias#Univers
idade de Pernambuco^iA01^1Escola Superior de Educação Física^cRecife^sPE#Univers
idade de São Paulo^iA02^1Escola de Educação Física e Esportes^cSão Paulo^sSP^pBr
asil#^lpt^a<b>FUNDAMENTO:</b> O balanço simpatovagal cardíaco se altera após o e
xercício de força. Contudo, o impacto das características do treinamento de forç
a nessa resposta ainda não está claro. <b>OBJETIVO:</b> Analisar o efeito agudo 
da intensidade do exercício de força para tronco e membros superiores na modulaç
ão autonômica cardíaca pós-exercício. <b>MÉTODOS:</b> Quinze homens jovens reali
zaram três sessões experimentais em ordem aleatória: controle (C), exercício de 
força com 50% de 1-RM (E50%) e exercício de força com 70% de 1-RM (E70%). As ses
sões incluíram 05 exercícios para tronco e membro superior, realizados em três s
éries de 12, 9 e 6 repetições, respectivamente. Antes e aos 20 e 50 minutos após
 as intervenções, a frequência cardíaca foi medida para posterior análise espect
ral da sua variabilidade. <b>RESULTADOS:</b> Em comparação aos valores anteriore
s à intervenção, o intervalo RR e a banda de alta frequência (AF) aumentaram (ma
iores alterações: + 112 ± 83 ms; +10 ± 11 un, respectivamente, p &lt; 0,01), enq
uanto que a banda de baixa frequência (BF) e a razão BF/AF diminuíram (maiores a
lterações: -10 ± 11 un; -2 ± 2, respectivamente, p &lt; 0,01) após a sessão C. N
enhuma dessas variáveis se alterou significantemente após a sessão E50% (p &gt; 
0,05). Em comparação aos valores pré-exercício, o intervalo RR e a banda AF dimi
nuíram (maiores alterações: -69 ± 105 ms; -13 ± 14 un, respectivamente, p &lt; 0
,01), enquanto que a banda BF e a razão BF/AF aumentaram (maiores alterações: -1
3 ± 14 un, +13 ± 14 un e +3 ± 3 un, respectivamente, p &lt; 0,01) após a E70%. <
b>CONCLUSÃO:</b> A maior intensidade de exercício de força para tronco e membros
 superiores promoveu, agudamente, maior aumento do balanço simpatovagal cardíaco
 pós-exercício.#^dnd^i1#^tm^lpt^kExercício^i1#^tm^lpt^kesforço físico^i1#^tm^lpt
^ksistema nervoso autônomo^i1#^tm^lpt^ksistema nervoso simpático^i1#^len^a<b>BAC
KGROUND:</b> Cardiac sympathovagal balance is altered after resistance exercise.
 However, the impact of the characteristics of resistance training in this respo
nse remains unclear. <b>OBJECTIVE:</b> Analyze the acute effect of resistance ex
ercise intensity for trunk and upper limbs in cardiac autonomic modulation after
 exercise. <b>METHODS:</b> Fifteen young men performed three experimental sessio
ns in random order: control (C), resistance exercise with 50% of 1-RM (E50%) and
 resistance exercise with 70% of 1-RM (E70%). The sessions included 05 exercises
 for the trunk and upper limbs performed in three sets of 12, 9 and 6 repetition
s, respectively. Before and at 20 and 50 minutes after the interventions, the he
art rate was measured for spectral analysis of variability. <b>RESULTS:</b> In c
omparison to the values before the intervention, the RR interval and the band of
 high frequency (HF) increased (major changes: + 112 ± 83 ms; +10 ± 11 un, respe
ctively, p &lt; 0.01), while the low frequency band (LF) and LF/HF ratio decreas
ed (major changes: -10 ± 11 pc; -2 ± 2, respectively, p &lt; 0.01) after the ses
sion C. None of these variables changed significantly after the E50% session (p 
&gt; 0.05). Compared to pre-exercise values, the RR interval and the HF band dec
reased (major changes: -69 ± 105 ms; -13 ± 14 un, respectively, p &lt;0.01), whi
le the LF band and the LF/HF ratio increased (major changes: -13 ± 14 un, 13 ± 3
 14 ± 3 and un, respectively, p &lt;0.01) after E70%. <b>CONCLUSION:</b> The hig
her intensity of resistance exercise for trunk and upper limbs promoted, in an a
cute manner, greater increase in cardiac sympathovagal balance after exercise.#^
dnd^i2#^tm^len^kExercise^i2#^tm^len^kphysical exertion^i2#^tm^len^kautonomic ner
vous system^i2#^tm^len^ksympathetic nervous system^i2#Fundação de Amparo a Ciênc
ia e Tecnologia do Estado de Pernambuco#Universidade de Pernambuco#Conselho Naci
onal de Desenvolvimento Científico e Tecnológico#vancouv#23#20100904#04/09/10#20
101103#03/11/10#20101125#25/11/10#aop3811.htm##
05583000000000721000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030001900114
03200060013306500090013901400070014803500100015522300090016501201010017401200970
02750100055003720100043004270100044004700100034005140100047005480100038005950700
08200633070009400715083177800809085000802587085002202595085002702617085003702644
08500380268108316860271908500080440508500210441308500300443408500370446408500390
45010580066045400580027046060580062046331170008046950720003047031120009047061110
00904715116000904724115000904733114000904742113000904751002001204760008008904772
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#l#4#1#article#1
#^a2011#tr#pt#br1.1#1#4.0#43#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066
-782X#20110415#Efeito agudo da intensidade do exercício de força na modulação au
tonômica cardíaca pós-exercício^lpt#Acute effect of resistance exercise intensit
y in cardiac autonomic modulation after exercise^len#^rND^1A01^nAluísio Henrique
 Rodrigues de Andrade^sLima#^rND^1A02^nCláudia Lúcia de Moraes^sForjaz#^rND^1A01
^nGleyson Queiroz de Moraes^sSilva#^rND^1A01^nAnnelise Lins^sMenêses#^rND^1A01^n
Anderson José Melo Rodrigues^sSilva#^rND^1A01^nRaphael Mendes^sRitti-Dias#^iA01^
1Universidade de Pernambuco^2Escola Superior de Educação Física^cRecife^sPE#^iA0
2^1Universidade de São Paulo^2Escola de Educação Física e Esportes^cSão Paulo^sS
P^pBrasil#^lpt^aFUNDAMENTO: O balanço simpatovagal cardíaco se altera após o exe
rcício de força. Contudo, o impacto das características do treinamento de força 
nessa resposta ainda não está claro. OBJETIVO: Analisar o efeito agudo da intens
idade do exercício de força para tronco e membros superiores na modulação autonô
mica cardíaca pós-exercício. MÉTODOS: Quinze homens jovens realizaram três sessõ
es experimentais em ordem aleatória: controle (C), exercício de força com 50 por
 cento de 1-RM (E50 por cento) e exercício de força com 70 por cento de 1-RM (E7
0 por cento). As sessões incluíram 05 exercícios para tronco e membro superior, 
realizados em três séries de 12, 9 e 6 repetições, respectivamente. Antes e aos 
20 e 50 minutos após as intervenções, a frequência cardíaca foi medida para post
erior análise espectral da sua variabilidade. RESULTADOS: Em comparação aos valo
res anteriores à intervenção, o intervalo RR e a banda de alta frequência (AF) a
umentaram (maiores alterações: + 112 ± 83 ms; +10 ± 11 un, respectivamente, p < 
0,01), enquanto que a banda de baixa frequência (BF) e a razão BF/AF diminuíram 
(maiores alterações: -10 ± 11 un; -2 ± 2, respectivamente, p < 0,01) após a sess
ão C. Nenhuma dessas variáveis se alterou significantemente após a sessão E50 po
r cento (p &gt; 0,05). Em comparação aos valores pré-exercício, o intervalo RR e
 a banda AF diminuíram (maiores alterações: -69 ± 105 ms; -13 ± 14 un, respectiv
amente, p < 0,01), enquanto que a banda BF e a razão BF/AF aumentaram (maiores a
lterações: -13 ± 14 un, +13 ± 14 un e +3 ± 3 un, respectivamente, p < 0,01) após
 a E70 por cento. CONCLUSÃO: A maior intensidade de exercício de força para tron
co e membros superiores promoveu, agudamente, maior aumento do balanço simpatova
gal cardíaco pós-exercício.#^dnd^i1#^tm^lpt^kExercício^i1#^tm^lpt^kesforço físic
o^i1#^tm^lpt^ksistema nervoso autônomo^i1#^tm^lpt^ksistema nervoso simpático^i1#
^len^aBACKGROUND: Cardiac sympathovagal balance is altered after resistance exer
cise. However, the impact of the characteristics of resistance training in this 
response remains unclear. OBJECTIVE: Analyze the acute effect of resistance exer
cise intensity for trunk and upper limbs in cardiac autonomic modulation after e
xercise. METHODS: Fifteen young men performed three experimental sessions in ran
dom order: control (C), resistance exercise with 50 percent of 1-RM (E50 percent
) and resistance exercise with 70 percent of 1-RM (E70 percent). The sessions in
cluded 05 exercises for the trunk and upper limbs performed in three sets of 12,
 9 and 6 repetitions, respectively. Before and at 20 and 50 minutes after the in
terventions, the heart rate was measured for spectral analysis of variability. R
ESULTS: In comparison to the values before the intervention, the RR interval and
 the band of high frequency (HF) increased (major changes: + 112 ± 83 ms; +10 ± 
11 un, respectively, p < 0.01), while the low frequency band (LF) and LF/HF rati
o decreased (major changes: -10 ± 11 pc; -2 ± 2, respectively, p < 0.01) after t
he session C. None of these variables changed significantly after the E50 percen
t session (p &gt; 0.05). Compared to pre-exercise values, the RR interval and th
e HF band decreased (major changes: -69 ± 105 ms; -13 ± 14 un, respectively, p <
0.01), while the LF band and the LF/HF ratio increased (major changes: -13 ± 14 
un, 13 ± 3 14 ± 3 and un, respectively, p <0.01) after E70 percent. CONCLUSION: 
The higher intensity of resistance exercise for trunk and upper limbs promoted, 
in an acute manner, greater increase in cardiac sympathovagal balance after exer
cise.#^dnd^i2#^tm^len^kExercise^i2#^tm^len^kphysical exertion^i2#^tm^len^kautono
mic nervous system^i2#^tm^len^ksympathetic nervous system^i2#Fundação de Amparo 
a Ciência e Tecnologia do Estado de Pernambuco#Universidade de Pernambuco#Consel
ho Nacional de Desenvolvimento Científico e Tecnológico#vancouv#23#20100904#04/0
9/10#20101103#03/11/10#20101125#25/11/10#aop3811.htm#Internet^ihttp://www.scielo
.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000043##
00487000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704024700082002001200329#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#5#1#article#145#<p><font size
="4" face="verdana"><b><a name="title"></a>Efeito agudo da intensidade       do 
exerc&iacute;cio de for&ccedil;a na modula&ccedil;&atilde;o auton&ocirc;mica    
   card&iacute;aca p&oacute;s&#45;exerc&iacute;cio</b></font></p>     ^cY#aop381
1.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#6#2#article#145#<p>&nbsp;</p>
     ^cY#aop3811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#7#3#article#145#<p>&nbsp;</p>
     ^cY#aop3811.htm##
00623000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704038300082002001200465#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#8#4#article#145#<p><font size
="2" face="Verdana"><b>Alu&iacute;sio Henrique Rodrigues de Andrade       Lima<S
UP>I</SUP>; Cl&aacute;udia L&uacute;cia de Moraes Forjaz<SUP>II</SUP>; Gleyson  
     Queiroz de Moraes Silva<SUP>I</SUP>; Annelise Lins Men&ecirc;ses<SUP>I</SUP
>; Anderson       Jos&eacute; Melo Rodrigues Silva<SUP>I</SUP>; Raphael Mendes R
itti&#45;Dias<SUP>I</SUP> </b></font></p>     ^cY#aop3811.htm##
00397000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704015700082002001200239#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#9#5#article#145#<p><font size
="2" face="Verdana"><sup>I</sup>Escola Superior de Educa&ccedil;&atilde;o     F&
iacute;sica &#45; Universidade de Pernambuco, Recife, PE    ^cY#aop3811.htm##
00414000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704017300083002001200256#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#10#6#article#145#<br>   <sup>
II</sup>Escola de Educa&ccedil;&atilde;o F&iacute;sica e Esportes &#45; Universi
dade   de S&atilde;o Paulo, S&atilde;o Paulo, SP &#45; Brasil</font></p>     ^cY
#aop3811.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704009300083002001200176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#11#7#article#145#<p><font siz
e="2" face="Verdana"><a href="#end">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop3811.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704002200083002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#12#8#article#145#<p>&nbsp;</p
>     ^cY#aop3811.htm##
00285000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704004400083002001200127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#13#9#article#145#<p>&nbsp;</p
> <hr size="1" noshade>     ^cY#aop3811.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006600084002001200150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#14#10#article#145#<p><font si
ze="2" face="VERDANA"><b>RESUMO</b></font></p>     ^cY#aop3811.htm##
00545000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704030300084002001200387#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#15#11#article#145#<p><font si
ze="2" face="Verdana"><b>FUNDAMENTO:</b> O balan&ccedil;o simpatovagal     card&
iacute;aco se altera ap&oacute;s o exerc&iacute;cio de for&ccedil;a.     Contudo
, o impacto das caracter&iacute;sticas do treinamento de for&ccedil;a     nessa 
resposta ainda n&atilde;o est&aacute; claro.    ^cY#aop3811.htm##
00478000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023600084002001200320#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#16#12#article#145#<br>   <b>O
BJETIVO:</b> Analisar o efeito agudo da intensidade do exerc&iacute;cio   de for
&ccedil;a para tronco e membros superiores na modula&ccedil;&atilde;o   auton&oc
irc;mica card&iacute;aca p&oacute;s&#45;exerc&iacute;cio.    ^cY#aop3811.htm##
00890000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704064800084002001200732#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#17#13#article#145#<br>   <b>M
&Eacute;TODOS:</b> Quinze homens jovens realizaram tr&ecirc;s sess&otilde;es   e
xperimentais em ordem aleat&oacute;ria: controle (C), exerc&iacute;cio de   for&
ccedil;a com 50% de 1&#45;RM (E50%) e exerc&iacute;cio de for&ccedil;a com   70%
 de 1&#45;RM (E70%). As sess&otilde;es inclu&iacute;ram 05 exerc&iacute;cios   p
ara tronco e membro superior, realizados em tr&ecirc;s s&eacute;ries de 12,   9 
e 6 repeti&ccedil;&otilde;es, respectivamente. Antes e aos 20 e 50 minutos   ap&
oacute;s as interven&ccedil;&otilde;es, a frequ&ecirc;ncia card&iacute;aca   foi
 medida para posterior an&aacute;lise espectral da sua variabilidade.    ^cY#aop
3811.htm##
01339000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704109700084002001201181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#18#14#article#145#<br>   <b>R
ESULTADOS:</b> Em compara&ccedil;&atilde;o aos valores anteriores &agrave; inter
ven&ccedil;&atilde;o,   o intervalo RR e a banda de alta frequ&ecirc;ncia (AF) a
umentaram (maiores   altera&ccedil;&otilde;es: + 112 &plusmn; 83 ms; +10 &plusmn
; 11 un, respectivamente, p &lt; 0,01),   enquanto que a banda de baixa frequ&ec
irc;ncia (BF) e a raz&atilde;o BF/AF   diminu&iacute;ram (maiores altera&ccedil;
&otilde;es: &#45;10 &plusmn; 11 un; &#45;2 &plusmn; 2, respectivamente,   p &lt;
 0,01) ap&oacute;s a sess&atilde;o C. Nenhuma dessas vari&aacute;veis   se alter
ou significantemente ap&oacute;s a sess&atilde;o E50% (p &gt; 0,05).   Em compar
a&ccedil;&atilde;o aos valores pr&eacute;&#45;exerc&iacute;cio, o intervalo   RR
 e a banda AF diminu&iacute;ram (maiores altera&ccedil;&otilde;es: &#45;69 &plus
mn; 105   ms; &#45;13 &plusmn; 14 un, respectivamente, p &lt; 0,01), enquanto qu
e a banda BF e a   raz&atilde;o BF/AF aumentaram (maiores altera&ccedil;&otilde;
es: &#45;13 &plusmn; 14 un,   +13 &plusmn; 14 un e +3 &plusmn; 3 un, respectivam
ente, p &lt; 0,01) ap&oacute;s a E70%.    ^cY#aop3811.htm##
00502000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704026000084002001200344#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#19#15#article#145#<br>   <b>C
ONCLUS&Atilde;O:</b> A maior intensidade de exerc&iacute;cio de for&ccedil;a   p
ara tronco e membros superiores promoveu, agudamente, maior aumento do balan&cce
dil;o   simpatovagal card&iacute;aco p&oacute;s&#45;exerc&iacute;cio.</font></p>
     ^cY#aop3811.htm##
00461000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021900084002001200303#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#20#16#article#145#<p><font si
ze="2" face="Verdana"><b>Palavras&#45;chave:</b> Exerc&iacute;cio, esfor&ccedil;
o     f&iacute;sico, sistema nervoso aut&ocirc;nomo, sistema nervoso simp&aacute
;tico.</font></p> <hr size="1" noshade>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#21#17#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#22#18#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#23#19#article#145#<p><font si
ze="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop3811
.htm##
00976000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704073400084002001200818#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#24#20#article#145#<p><font si
ze="2" face="Verdana">O exerc&iacute;cio de for&ccedil;a &eacute; recomendado   
  para indiv&iacute;duos saud&aacute;veis<SUP>1,2 </SUP>e com cardiopatias<SUP>3
</SUP> devido     a seus benef&iacute;cios sobre a aptid&atilde;o f&iacute;sica<
SUP>4</SUP>,     sa&uacute;de<SUP>4</SUP> e qualidade vida<SUP>5</SUP>. Entretan
to, ap&oacute;s     a realiza&ccedil;&atilde;o do exerc&iacute;cio de for&ccedil
;a, a modula&ccedil;&atilde;o     simp&aacute;tica card&iacute;aca permanece ele
vada, enquanto que a modula&ccedil;&atilde;o     parassimp&aacute;tica mant&eacu
te;m&#45;se reduzida<SUP>6&#45;8</SUP>, o que pode     aumentar o risco de ocorr
&ecirc;ncia de eventos cardiovasculares agudos<SUP>9,10</SUP>. </font></p>     ^
cY#aop3811.htm##
01320000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704107800084002001201162#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#25#21#article#145#<p><font si
ze="2" face="Verdana">Institui&ccedil;&otilde;es de sa&uacute;de,     como o <I>
American College of Sports Medicine,</I> recomendam que o programa     de treina
mento de for&ccedil;a seja dividido em duas sess&otilde;es: uma     com exerc&ia
cute;cios para os membros inferiores e outra com exerc&iacute;cios     para os m
embros superiores<SUP>11</SUP>. Um estudo recente<SUP>12</SUP> mostrou     que r
ealizar exerc&iacute;cios apenas para os membros inferiores promove     aumento 
do balan&ccedil;o simpatovagal card&iacute;aco p&oacute;s&#45;exerc&iacute;cio. 
    Todavia, o impacto da realiza&ccedil;&atilde;o de exerc&iacute;cios para    
 tronco e membros superiores nessas respostas ainda n&atilde;o foram estudadas. 
    Como a resposta cardiovascular ao exerc&iacute;cio de for&ccedil;a &eacute; 
dependente     da quantidade de massa muscular envolvida<SUP>13</SUP>, &eacute; 
poss&iacute;vel     que as respostas auton&ocirc;micas ap&oacute;s o exerc&iacut
e;cio de tronco     e membros superiores sejam diferentes, o que precisa ser ana
lisado.</font></p>     ^cY#aop3811.htm##
01491000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704124900084002001201333#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#26#22#article#145#<p><font si
ze="2" face="Verdana">Outro aspecto importante diz respeito &agrave; sobrecarga 
    durante o exerc&iacute;cio de for&ccedil;a. Em estudo anterior<SUP>6</SUP>, 
    foi evidenciado que dois protocolos de exerc&iacute;cio de for&ccedil;a (10 
    repeti&ccedil;&otilde;es em 80% de 1RM e 20 repeti&ccedil;&otilde;es em 40% 
    de 1RM) promovem altera&ccedil;&otilde;es similares na modula&ccedil;&atilde
;o     auton&ocirc;mica card&iacute;aca. Todavia, como os protocolos diferiam ta
nto     no volume (n&uacute;mero de repeti&ccedil;&otilde;es) como na intensidad
e     (sobrecarga), n&atilde;o foi poss&iacute;vel estabelecer claramente o impa
cto     isolado da intensidade do exerc&iacute;cio na modula&ccedil;&atilde;o au
ton&ocirc;mica     card&iacute;aca p&oacute;s&#45;exerc&iacute;cio. Como a inten
sidade do exerc&iacute;cio     de for&ccedil;a afeta as respostas metab&oacute;l
icas e mec&acirc;nicas na     vasculatura, e consequentemente, nos mecanismos re
flexos de controle cardiovascular, &eacute; poss&iacute;vel     que diferentes i
ntensidades do exerc&iacute;cio de for&ccedil;a promovam     diferentes resposta
s na modula&ccedil;&atilde;o auton&ocirc;mica card&iacute;aca     p&oacute;s&#45
;exerc&iacute;cio.</font></p>     ^cY#aop3811.htm##
00916000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704067400084002001200758#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#27#23#article#145#<p><font si
ze="2" face="Verdana">Dessa forma, o objetivo deste estudo foi analisar     o ef
eito agudo da intensidade do exerc&iacute;cio de for&ccedil;a para tronco     e 
membro superiores na modula&ccedil;&atilde;o auton&ocirc;mica card&iacute;aca   
  p&oacute;s&#45;exerc&iacute;cio. Nossa hip&oacute;tese &eacute; de que o balan
&ccedil;o     simpatovagal aumentar&aacute; ap&oacute;s o exerc&iacute;cio de fo
r&ccedil;a     independentemente da intensidade utilizada, por&eacute;m uma maio
r magnitude     e uma maior dura&ccedil;&atilde;o dessa resposta ser&atilde;o ob
servadas     ap&oacute;s a sess&atilde;o de exerc&iacute;cio com maior intensida
de.</font></p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#28#24#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007400084002001200158#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#29#25#article#145#<p><font si
ze="3" face="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#aop3811.htm##
00309000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006700084002001200151#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#30#26#article#145#<p><font si
ze="2" face="Verdana"><b>Amostra</b></font></p>     ^cY#aop3811.htm##
01117000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704087500084002001200959#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#31#27#article#145#<p><font si
ze="2" face="Verdana">Fizeram parte da amostra 15 homens, com idade     entre 18
 e 25 anos, recrutados na universidade e comunidades locais. Antes     de entrar
em no estudo, os sujeitos foram esclarecidos sobre todos os procedimentos     a 
que seriam submetidos e, aqueles que concordaram em participar, assinaram     o 
termo de consentimento livre e esclarecido. Este estudo foi aprovado pelo     Co
mit&ecirc; de &Eacute;tica em Pesquisa da institui&ccedil;&atilde;o dos     auto
res (223/08). Como crit&eacute;rios de inclus&atilde;o ao estudo, os     indiv&i
acute;duos deveriam ser eutr&oacute;ficos, n&atilde;o apresentarem     qualquer 
doen&ccedil;a cardiovascular, n&atilde;o estarem em uso de medica&ccedil;&atilde
;o     e, nos 06 meses antes do estudo, n&atilde;o serem praticantes de qualquer
     tipo de exerc&iacute;cio f&iacute;sico.</font></p>     ^cY#aop3811.htm##
00323000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008100084002001200165#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#32#28#article#145#<p><font si
ze="2" face="Verdana"><b>Dados cl&iacute;nicos</b></font></p>     ^cY#aop3811.ht
m##
00635000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039300084002001200477#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#33#29#article#145#<p><font si
ze="2" face="Verdana">Para a obten&ccedil;&atilde;o dos dados cl&iacute;nicos   
  dos indiv&iacute;duos, foi feita anamnese que englobava quest&otilde;es sobre 
    os fatores de risco cardiovasculares. Em posse dos dados, os indiv&iacute;du
os     foram estratificados com rela&ccedil;&atilde;o ao risco cardiovascular em
     alto, moderado ou baixo<SUP>1</SUP>. </font></p>     ^cY#aop3811.htm##
01315000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704107300084002001201157#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#34#30#article#145#<p><font si
ze="2" face="Verdana">Al&eacute;m da anamnese, medidas antropom&eacute;tricas   
  e da press&atilde;o arterial foram realizadas. A massa corporal e a estatura  
   foram medidas utilizando uma balan&ccedil;a digital com precis&atilde;o de   
  0,1 kg (Filizola, Brasil) e um estadi&ocirc;metro de madeira com precis&atilde
;o     de 0,1 cm, respectivamente. A press&atilde;o arterial foi medida pelo m&e
acute;todo     auscultat&oacute;rio com os volunt&aacute;rios sentados e em repo
uso, tr&ecirc;s     vezes consecutivas, ap&oacute;s 05 minutos de repouso, em du
as visitas distintas<SUP>14</SUP>.     Para permanecerem no estudo, os indiv&iac
ute;duos deveriam ser normotensos     e apresentar press&atilde;o arterial sist&
oacute;lica igual ou inferior a     120 mmHg e diast&oacute;lica igual ou inferi
or a 80 mmHg<SUP>14</SUP>. Esse     n&iacute;vel de press&atilde;o arterial foi 
escolhido porque sujeitos com     valores acima desses j&aacute; possuem altera&
ccedil;&otilde;es no balan&ccedil;o     simpatovagal card&iacute;aco<SUP>15</SUP
>.</font></p>     ^cY#aop3811.htm##
00410000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704016800084002001200252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#35#31#article#145#<p><font si
ze="2" face="Verdana">As caracter&iacute;sticas cl&iacute;nicas dos     sujeitos
 est&atilde;o presentes na <a href="#tab01">Tabela 1</a>.</font></p>     ^cY#aop
3811.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#36#32#article#145#<p><a name=
"tab01"></a></p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#37#33#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#38#34#article#145#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop38tb1.jpg"></p>     ^cY#aop3811
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#39#35#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00413000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704017100084002001200255#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#40#36#article#145#<p><font si
ze="2" face="Verdana"><b>Sess&otilde;es de adapta&ccedil;&atilde;o       e teste
 de uma repeti&ccedil;&atilde;o m&aacute;xima (1&#45;RM)</b></font></p>     ^cY#
aop3811.htm##
00932000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704069000084002001200774#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#41#37#article#145#<p><font si
ze="2" face="Verdana">Antes das sess&otilde;es experimentais, cada     indiv&iac
ute;duo participou de duas sess&otilde;es de adapta&ccedil;&atilde;o     aos exe
rc&iacute;cios de for&ccedil;a, realizadas em dias distintos. Em cada     sess&a
tilde;o de adapta&ccedil;&atilde;o, os indiv&iacute;duos realizaram     tr&ecirc
;s s&eacute;ries de 12 repeti&ccedil;&otilde;es com a carga m&iacute;nima     pe
rmitida nos seguintes exerc&iacute;cios: i) supino reto, ii) remada curvada,    
 iii) eleva&ccedil;&atilde;o frontal, iv) rosca direta e v) tr&iacute;ceps     t
esta. Todos os exerc&iacute;cios inclu&iacute;dos no estudo foram realizados    
 com pesos livres. </font></p>     ^cY#aop3811.htm##
01368000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704112600084002001201210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#42#38#article#145#<p><font si
ze="2" face="Verdana">Dois dias ap&oacute;s a &uacute;ltima sess&atilde;o     de
 adapta&ccedil;&atilde;o, os indiv&iacute;duos realizaram o teste de uma     rep
eti&ccedil;&atilde;o m&aacute;xima (1&#45;RM)<SUP>16</SUP><SUB>.</SUB> O teste  
   teve in&iacute;cio com um aquecimento (10 repeti&ccedil;&otilde;es), com     
aproximadamente 50% da carga estimada para a primeira tentativa, baseado     na 
experi&ecirc;ncia pr&eacute;via dos participantes. Em seguida, foram realizadas 
    tr&ecirc;s tentativas com carga progressiva at&eacute; se identificar a carg
a     de 1&#45;RM. Entre as tentativas, e entre os exerc&iacute;cios, foi mantid
o um     intervalo de recupera&ccedil;&atilde;o de dois minutos. Com o objetivo 
de     familiarizar os indiv&iacute;duos ao teste<SUP>17</SUP>, foram realizadas
     04 sess&otilde;es de testes de 1&#45;RM, com intervalo m&iacute;nimo de 48 
horas     entre as sess&otilde;es, onde a maior carga encontrada durante a reali
za&ccedil;&atilde;o     dos testes foi utilizada para calcular a intensidade do 
exerc&iacute;cio     nas sess&otilde;es experimentais. </font></p>     ^cY#aop38
11.htm##
00324000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008200084002001200166#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#43#39#article#145#<p><font si
ze="2" face="Verdana"><b>Protocolo experimental</b></font></p>     ^cY#aop3811.h
tm##
00819000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704057700084002001200661#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#44#40#article#145#<p><font si
ze="2" face="Verdana">Ap&oacute;s a determina&ccedil;&atilde;o das     cargas de
 1&#45;RM, os indiv&iacute;duos foram submetidos a tr&ecirc;s sess&otilde;es    
 experimentais: sess&atilde;o controle (C), sess&atilde;o de exerc&iacute;cio   
  de for&ccedil;a com 50% de 1&#45;RM (E50%) e sess&atilde;o de exerc&iacute;cio
     de for&ccedil;a com 70% de 1&#45;RM (E70%). A determina&ccedil;&atilde;o da
 ordem     das sess&otilde;es foi feita de forma aleat&oacute;ria. Entre as sess
&otilde;es,     houve um intervalo de pelo menos tr&ecirc;s dias. </font></p>   
  ^cY#aop3811.htm##
00906000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704066400084002001200748#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#45#41#article#145#<p><font si
ze="2" face="Verdana">As sess&otilde;es foram iniciadas no mesmo hor&aacute;rio 
    do dia. Os sujeitos foram instru&iacute;dos a fazer uma refei&ccedil;&atilde
;o     leve 2 horas antes dos experimentos, evitar exerc&iacute;cios f&iacute;si
cos     e ingest&atilde;o de &aacute;lcool por pelo menos 48 horas de anteced&ec
irc;ncia,     e de cafe&iacute;na nas &uacute;ltimas 12 horas, manter os hor&aac
ute;rios     de sono e atividades di&aacute;rias semelhantes nas tr&ecirc;s sess
&otilde;es.     Al&eacute;m disso, as sess&otilde;es experimentais foram agendad
as em dias     que os indiv&iacute;duos apresentavam rotinas semelhantes.</font>
</p>     ^cY#aop3811.htm##
00817000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704057500084002001200659#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#46#42#article#145#<p><font si
ze="2" face="Verdana">Em cada sess&atilde;o experimental, chegando     ao labora
t&oacute;rio, o indiv&iacute;duo permaneceu em repouso sentado por     10 minuto
s. Em seguida, a frequ&ecirc;ncia card&iacute;aca foi medida por     10 minutos 
cont&iacute;nuos, por meio de um frequenc&iacute;metro (Polar,     RS 800 CX, Es
tados Unidos). Ap&oacute;s as medidas de repouso, o indiv&iacute;duo     se desl
ocava at&eacute; a sala de muscula&ccedil;&atilde;o onde eram realizadas     as 
sess&otilde;es de exerc&iacute;cio de for&ccedil;a ou controle. </font></p>     
^cY#aop3811.htm##
01335000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704109300084002001201177#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#47#43#article#145#<p><font si
ze="2" face="Verdana">As tr&ecirc;s sess&otilde;es foram compostas     pelos 05 
exerc&iacute;cios descritos anteriormente, realizados em tr&ecirc;s     s&eacute
;ries consecutivas de 12, 09 e 06 repeti&ccedil;&otilde;es. Em todas     as sess
&otilde;es (C, E50% e E70%), antes de cada exerc&iacute;cio, uma s&eacute;rie   
  de aquecimento de 10 repeti&ccedil;&otilde;es foi realizada utilizando 25%    
 de 1&#45;RM. Na sess&atilde;o C, os sujeitos realizaram os exerc&iacute;cios   
  com uma barra de pl&aacute;stico (0,1 kg) para assegurar que as diferen&ccedil
;as     encontradas em compara&ccedil;&atilde;o com as sess&otilde;es de exerc&i
acute;cio     (E50% e E70%) se deviam &agrave; intensidade empregada e n&atilde;
o ao movimento     articular ou &agrave;s altera&ccedil;&otilde;es de postura. N
as sess&otilde;es     E50% e E70%, a carga dos exerc&iacute;cios foi de 50% e 70
% de 1&#45;RM, respectivamente.     O intervalo de recupera&ccedil;&atilde;o ent
re as s&eacute;ries, e entre     os exerc&iacute;cios em todas as sess&otilde;es
, foi de dois minutos.</font></p>     ^cY#aop3811.htm##
00688000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704044600084002001200530#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#48#44#article#145#<p><font si
ze="2" face="Verdana">Ap&oacute;s a finaliza&ccedil;&atilde;o das     interven&c
cedil;&otilde;es, o indiv&iacute;duo retornava ao laborat&oacute;rio,     onde p
ermanecia em repouso sentado por mais 60 minutos (per&iacute;odo p&oacute;s&#45;
interven&ccedil;&atilde;o).     A frequ&ecirc;ncia card&iacute;aca foi obtida em
 intervalos de 10 minutos,     entre os minutos 20 e 30 e 50 e 60 da recupera&cc
edil;&atilde;o.</font></p>     ^cY#aop3811.htm##
00375000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704013300084002001200217#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#49#45#article#145#<p><font si
ze="2" face="Verdana"><b>An&aacute;lise da variabilidade da frequ&ecirc;ncia    
   card&iacute;aca</b></font></p>     ^cY#aop3811.htm##
02004000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704176200084002001201846#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#50#46#article#145#<p><font si
ze="2" face="Verdana">A modula&ccedil;&atilde;o auton&ocirc;mica do     sistema 
cardiovascular foi obtida por meio da t&eacute;cnica de an&aacute;lise     espec
tral da variabilidade da frequ&ecirc;ncia card&iacute;aca. Para tanto,     foram
 utilizados os intervalos R&#45;R obtidos com o frequenc&iacute;metro (Polar,   
  RS 800 CX, Estados Unidos). Dessa forma, per&iacute;odos estacion&aacute;rios 
    do tacograma, com pelo menos 500 batimentos, foram decompostos nas bandas   
  de baixa (BF) e alta (AF) frequ&ecirc;ncias pelo m&eacute;todo autorregressivo
,     utilizando&#45;se o <I>software</I> Kubios HRV (Finl&acirc;ndia), seguindo
 as     recomenda&ccedil;&otilde;es do <I>Task Force </I>de An&aacute;lise Espec
tral<SUP>18</SUP>.     Foram consideradas como fisiologicamente significativas a
s frequ&ecirc;ncias     entre 0,04 e 0,4 Hz, sendo que o componente de BF foi re
presentado pelas     oscila&ccedil;&otilde;es entre 0,04 e 0,15 Hz e o de AF pel
as oscila&ccedil;&otilde;es     entre 0,15 e 0,4 Hz. O poder de cada componente 
espectral foi normalizado     dividindo&#45;se o poder de cada banda do espectro
 pela vari&acirc;ncia total,     da qual foi subtra&iacute;do o valor de banda d
e muito baixa frequ&ecirc;ncia     (&lt; 0,04 Hz), sendo o resultado multiplicad
o por 100. Para a interpreta&ccedil;&atilde;o     dos resultados, os componentes
 BF e AF normalizados da variabilidade da frequ&ecirc;ncia     card&iacute;aca f
oram considerados, respectivamente, como representativos     da modula&ccedil;&a
tilde;o predominantemente simp&aacute;tica e parassimp&aacute;tica     do cora&c
cedil;&atilde;o, e a raz&atilde;o entre estas bandas (BF/AF), como     o balan&c
cedil;o simpatovagal card&iacute;aco<SUP>18</SUP>. </font></p>     ^cY#aop3811.h
tm##
00328000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008600084002001200170#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#51#47#article#145#<p><font si
ze="2" face="Verdana">An&aacute;lise estat&iacute;stica</font></p>     ^cY#aop38
11.htm##
01554000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704131200084002001201396#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#52#48#article#145#<p><font si
ze="2" face="Verdana">A normalidade e a homogeinedade de vari&acirc;ncia     dos
 dados foram confirmados pelos testes de Shapiro Wilks e de Levene, respectivame
nte.     Os dados do per&iacute;odo de pr&eacute;&#45;interven&ccedil;&atilde;o 
nas tr&ecirc;s     sess&otilde;es experimentais foram comparados pela an&aacute;
lise de vari&acirc;ncia     (ANOVA) de um fator para medidas repetidas. As respo
stas auton&ocirc;micas     em cada sess&atilde;o experimental foram calculadas p
ela diferen&ccedil;a     entre os valores medidos p&oacute;s e pr&eacute;&#45;in
terven&ccedil;&atilde;o     (</font><font>&#916;</font><font size="2" face="verd
ana">= p&oacute;s &#45; pr&eacute;).     As respostas da variabilidade da frequ&
ecirc;ncia card&iacute;aca ap&oacute;s     as tr&ecirc;s sess&otilde;es experime
ntais foram comparadas pela ANOVA de     dois fatores para medidas repetidas, se
ndo considerados como fatores principais     a sess&atilde;o (C, E50% e E70%) e 
o tempo (pr&eacute;, 20 a 30 e 50 a 60     minutos). Quando observado valor de F
 significante, foi realizado o teste     de <I>post hoc</I> de <I>Newman&#45;Keu
ls</I>. O valor alfa de p &lt; 0,05 foi     considerado como significante e os d
ados s&atilde;o apresentados como m&eacute;dia &plusmn; desvio&#45;padr&atilde;o
.</font></p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#53#49#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00312000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007000084002001200154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#54#50#article#145#<p><font si
ze="3" face="Verdana"><b>Resultados</b></font></p>     ^cY#aop3811.htm##
00686000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704044400084002001200528#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#55#51#article#145#<p><font si
ze="2" face="Verdana">Todos os indiv&iacute;duos inclu&iacute;dos     no estudo 
apresentaram risco cardiovascular baixo. Dos 15 sujeitos, tr&ecirc;s     deles i
niciaram o protocolo com a sess&atilde;o C, 07 com a E50% e 05 com     a E70%. O
s testes de 1&#45;RM e as cargas utilizadas durante as sess&otilde;es     de exe
rc&iacute;cio de for&ccedil;a est&atilde;o apresentados na <a href="#tab02">Tabe
la     2</a>.</font></p>     ^cY#aop3811.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#56#52#article#145#<p><a name=
"tab02"></a></p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#57#53#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#58#54#article#145#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop38tb2.jpg"></p>     ^cY#aop3811
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#59#55#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00643000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704040100084002001200485#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#60#56#article#145#<p><font si
ze="2" face="Verdana">Os dados da variabilidade da frequ&ecirc;ncia     card&iac
ute;aca antes das interven&ccedil;&otilde;es nas tr&ecirc;s sess&otilde;es     e
xperimentais (C, E50% e E70%) s&atilde;o apresentados na <a href="#tab03">Tabela
     3</a>. Os valores pr&eacute;&#45;exerc&iacute;cio foram semelhantes entre a
s     sess&otilde;es C, E50% e E70% (p &gt; 0,05).</font></p>     ^cY#aop3811.ht
m##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#61#57#article#145#<p><a name=
"tab03"></a></p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#62#58#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#63#59#article#145#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop38tb3.jpg"></p>     ^cY#aop3811
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#64#60#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00506000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704026400084002001200348#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#65#61#article#145#<p><font si
ze="2" face="Verdana">As altera&ccedil;&otilde;es na modula&ccedil;&atilde;o    
 auton&ocirc;mica card&iacute;aca ap&oacute;s as tr&ecirc;s sess&otilde;es     e
xperimentais est&atilde;o apresentados na <a href="#fig01">Figura 1</a>. </font>
</p>     ^cY#aop3811.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#66#62#article#145#<p><a name=
"fig01"></a></p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#67#63#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#68#64#article#145#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop38fg1.jpg"></p>     ^cY#aop3811
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#69#65#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
01045000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704080300084002001200887#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#70#66#article#145#<p><font si
ze="2" face="Verdana">Em compara&ccedil;&atilde;o com os valores pr&eacute;&#45;
interven&ccedil;&atilde;o,     o intervalo R&#45;R aumentou ap&oacute;s a sess&a
tilde;o C, durante todo o per&iacute;odo     de recupera&ccedil;&atilde;o (maior
 aumento: +112 &plusmn; 83 ms, p &lt; 0,01),     manteve&#45;se ap&oacute;s a se
ss&atilde;o E50%, durante todo o per&iacute;odo     de recupera&ccedil;&atilde;o
 (p &gt; 0,05) e diminuiu durante os 30 minutos     iniciais de recupera&ccedil;
&atilde;o na sess&atilde;o E70% (maior queda:     &#45;69 &plusmn; 105 ms, p &lt
; 0,01). Assim, o comportamento do intervalo R&#45;R, durante     todo o per&iac
ute;odo de recupera&ccedil;&atilde;o, diferiu significantemente     entre as tr&
ecirc;s sess&otilde;es experimentais (p &lt; 0,05). </font></p>     ^cY#aop3811.
htm##
00933000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704069100084002001200775#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#71#67#article#145#<p><font si
ze="2" face="Verdana">Em compara&ccedil;&atilde;o aos valores pr&eacute;&#45;int
erven&ccedil;&atilde;o,     a banda BF e a raz&atilde;o BF/AF diminu&iacute;ram 
na sess&atilde;o C (maior     queda: &#45;10 &plusmn; 11 un.; &#45;2 &plusmn; 2 
respectivamente, p &lt; 0,01), mantiveram&#45;se     na sess&atilde;o E50% (p &g
t; 0,05) e aumentaram na sess&atilde;o E70% (maior     aumento: +13 &plusmn; 14 
un.; +3 &plusmn; 3, respectivamente, p &lt; 0,01). Assim, o comportamento     de
ssas vari&aacute;veis, durante todo o per&iacute;odo de recupera&ccedil;&atilde;
o,     diferiu significantemente entre as tr&ecirc;s sess&otilde;es experimentai
s     (p &lt; 0,05).</font></p>     ^cY#aop3811.htm##
00859000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704061700084002001200701#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#72#68#article#145#<p><font si
ze="2" face="Verdana">Comparando os valores da pr&eacute;&#45;interven&ccedil;&a
tilde;o,     a banda de AF aumentou na sess&atilde;o C (maior aumento: +10 &plus
mn; 11 un., p &lt; 0,01),     manteve&#45;se na sess&atilde;o E50% (p &gt; 0,05)
 e diminuiu na sess&atilde;o     E70%, em todo per&iacute;odo de recupera&ccedil
;&atilde;o (maior queda: &#45;13 &plusmn; 14     un., p &lt; 0,01). Dessa forma,
 durante todo o per&iacute;odo de recupera&ccedil;&atilde;o,     o comportamento
 da banda AF diferiu significantemente entre as tr&ecirc;s     sess&otilde;es ex
perimentais (p &lt; 0,05).</font></p>     ^cY#aop3811.htm##
00789000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054700084002001200631#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#73#69#article#145#<p><font si
ze="2" face="Verdana">Em compara&ccedil;&atilde;o aos valores pr&eacute;&#45;int
erven&ccedil;&atilde;o,     o poder total aumentou apenas na sess&atilde;o C (ma
ior aumento: +4.227 &plusmn; 4.328     ms<SUP>2</SUP>, p &lt; 0,01) e se manteve
 nas sess&otilde;es E50% e E70%,     durante todo o per&iacute;odo de recupera&c
cedil;&atilde;o. Assim, o comportamento     dessa vari&aacute;vel, em todo o per
&iacute;odo de recupera&ccedil;&atilde;o,     foi diferente entre a sess&atilde;
o C e as sess&otilde;es E50% e E70%.</font></p>     ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#74#70#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#75#71#article#145#<p><font si
ze="3" face="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#aop3811.htm##
00776000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704053400084002001200618#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#76#72#article#145#<p><font si
ze="2" face="Verdana">Os resultados deste estudo demonstraram que     o exerc&ia
cute;cio de for&ccedil;a para tronco e membros superiores promoveu     aumento d
a modula&ccedil;&atilde;o simp&aacute;tica card&iacute;aca e redu&ccedil;&atilde
;o     da modula&ccedil;&atilde;o parassimp&aacute;tica card&iacute;aca. Al&eacu
te;m     disso, essa altera&ccedil;&atilde;o da modula&ccedil;&atilde;o auton&oc
irc;mica     card&iacute;aca foi maior ap&oacute;s o exerc&iacute;cio de for&cce
dil;a     mais intenso.</font></p>     ^cY#aop3811.htm##
01205000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704096300084002001201047#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#77#73#article#145#<p><font si
ze="2" face="Verdana">Durante 60 minutos ap&oacute;s a sess&atilde;o     E70%, f
oram evidenciados aumento da modula&ccedil;&atilde;o simp&aacute;tica     e redu
&ccedil;&atilde;o da modula&ccedil;&atilde;o parassimp&aacute;tica     card&iacu
te;aca. Esses resultados s&atilde;o semelhantes aos observados em     estudos an
teriores que empregaram o exerc&iacute;cio de for&ccedil;a para     os principai
s grupamentos musculares<SUP>6,8</SUP> ou para os membros inferiores<SUP>12</SUP
>.     Esses resultados sugerem que independentemente dos exerc&iacute;cios empr
egados     (principais grupamentos musculares, membros inferiores ou tronco e me
mbros     superiores), a realiza&ccedil;&atilde;o do exerc&iacute;cio de for&cce
dil;a     promove altera&ccedil;&otilde;es na modula&ccedil;&atilde;o auton&ocir
c;mica     card&iacute;aca, que permanecem por um longo per&iacute;odo ap&oacute
;s a     finaliza&ccedil;&atilde;o da sess&atilde;o.</font></p>     ^cY#aop3811.
htm##
01588000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704134600084002001201430#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#78#74#article#145#<p><font si
ze="2" face="Verdana">Os mecanismos envolvidos nessa resposta n&atilde;o     for
am estudados no presente estudo. Todavia, &eacute; poss&iacute;vel que     na se
ss&atilde;o controle o estresse ortost&aacute;tico, ocasionado pelo     per&iacu
te;odo prolongado na posi&ccedil;&atilde;o sentada, promova diminui&ccedil;&atil
de;o     do retorno venoso e aumento da atividade nervosa simp&aacute;tica perif
&eacute;rica,     estimulando o barorreflexo<SUP>19,20</SUP>. Esse est&iacute;mu
lo, por sua     vez, promove a diminui&ccedil;&atilde;o da atividade nervosa sim
p&aacute;tica     e aumento da atividade parassimp&aacute;tica card&iacute;acas<
SUP>21</SUP>.     Por outro lado, na sess&atilde;o de exerc&iacute;cio de for&cc
edil;a, possivelmente     ocorre maior redu&ccedil;&atilde;o do retorno venoso, 
desativando os receptores     cardiopulmonares<SUP>6</SUP>, uma vez que, ap&oacu
te;s essas sess&otilde;es,     n&atilde;o foi observada hipotens&atilde;o p&oacu
te;s&#45;exerc&iacute;cio<SUP>21</SUP>.     Al&eacute;m disso, o estresse ortost
&aacute;tico parece potencializar tal     resposta, uma vez que a recupera&ccedi
l;&atilde;o da frequ&ecirc;ncia card&iacute;aca     na posi&ccedil;&atilde;o sen
tada parece ser mais prolongada em compara&ccedil;&atilde;o &agrave; posi&ccedil
;&atilde;o     supina<SUP>22</SUP>.</font></p>     ^cY#aop3811.htm##
01465000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704122300084002001201307#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#79#75#article#145#<p><font si
ze="2" face="Verdana">No presente estudo, comparado ao exerc&iacute;cio     de f
or&ccedil;a realizado a 50% de 1&#45;RM, o exerc&iacute;cio de for&ccedil;a     
realizado com 70% de 1&#45;RM promoveu maior aumento da modula&ccedil;&atilde;o 
    auton&ocirc;mica simp&aacute;tica card&iacute;aca. Esses resultados s&atilde
;o     diferentes dos observados por Rezk e cols.<SUP>6</SUP>, que verificaram a
ltera&ccedil;&atilde;o     semelhante na modula&ccedil;&atilde;o auton&ocirc;mic
a card&iacute;aca ap&oacute;s     a realiza&ccedil;&atilde;o do exerc&iacute;cio
 de for&ccedil;a com 80% de     1&#45;RM e com 40% de 1&#45;RM at&eacute; a fadi
ga. Essa controv&eacute;rsia foi     possivelmente ocasionada pela varia&ccedil;
&atilde;o do n&uacute;mero de     repeti&ccedil;&otilde;es entre as intensidades
 no estudo de Rezk <I>e </I>cols.<SUP>6</SUP>,     o que n&atilde;o aconteceu no
 presente estudo. Esses resultados indicam que     o aumento da modula&ccedil;&a
tilde;o simp&aacute;tica card&iacute;aca p&oacute;s&#45;exerc&iacute;cio     de 
for&ccedil;a &eacute; dependente da intensidade do exerc&iacute;cio, desde     q
ue o n&uacute;mero de repeti&ccedil;&otilde;es realizadas seja o mesmo. </font><
/p>     ^cY#aop3811.htm##
02463000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704222100084002001202305#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#80#76#article#145#<p><font si
ze="2" face="Verdana">Com rela&ccedil;&atilde;o &agrave; dura&ccedil;&atilde;o  
   das altera&ccedil;&otilde;es auton&ocirc;micas card&iacute;acas ap&oacute;s  
   o exerc&iacute;cio de for&ccedil;a, Rezk e cols.<SUP>6</SUP> evidenciaram    
 que, 75 minutos ap&oacute;s o exerc&iacute;cio de for&ccedil;a, a modula&ccedil
;&atilde;o     auton&ocirc;mica simp&aacute;tica card&iacute;aca continuava elev
ada. Esses     resultados s&atilde;o semelhantes aos observados na sess&atilde;o
 E70% do     presente estudo, em que as altera&ccedil;&otilde;es na modula&ccedi
l;&atilde;o     auton&ocirc;mica ocorreram at&eacute; os 60 minutos de recupera&
ccedil;&atilde;o.     Por outro lado, na sess&atilde;o E50%, os valores da modul
a&ccedil;&atilde;o     auton&ocirc;mica card&iacute;aca nos 60 minutos p&oacute;
s&#45;exerc&iacute;cio     foram similares aos de repouso. Considerando que na E
70% os indiv&iacute;duos     chegavam muito pr&oacute;ximo &agrave; fadiga em ca
da s&eacute;rie, o que     n&atilde;o acontecia na E50%, &eacute; poss&iacute;ve
l sugerir que a realiza&ccedil;&atilde;o     dos exerc&iacute;cios de for&ccedil
;a at&eacute; pr&oacute;ximo &agrave; fadiga     resulte numa maior e mais durad
oura ativa&ccedil;&atilde;o simp&aacute;tica     card&iacute;aca<SUP>9,10</SUP>.
 Essa resposta possivelmente est&aacute; relacionada     a maior sobrecarga mec&
acirc;nica do sistema vascular no exerc&iacute;cio     de maior intensidade, que
 promove maior ativa&ccedil;&atilde;o dos mecanorreceptores<SUP>23</SUP> e     a
 maior ativa&ccedil;&atilde;o do metaborreflexo decorrente da redu&ccedil;&atild
e;o     do fluxo sangu&iacute;neo<SUP>12</SUP>. Outro poss&iacute;vel mecanismo 
&eacute; a     maior diminui&ccedil;&atilde;o do volume plasm&aacute;tico, ap&oa
cute;s o     exerc&iacute;cio de for&ccedil;a com maior intensidade, devido ao e
xtravasamento     de sangue para o espa&ccedil;o intersticial, promovendo assim 
diminui&ccedil;&atilde;o     do retorno venoso. Isso, por sua vez, resultaria na
 desativa&ccedil;&atilde;o     dos receptores cardiopulmonares, e no consequente
 aumento da frequ&ecirc;ncia     card&iacute;aca. Todavia, essas hip&oacute;tese
s ainda precisam ser testadas.</font></p>     ^cY#aop3811.htm##
01322000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704108000084002001201164#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#81#77#article#145#<p><font si
ze="2" face="Verdana">Os resultados deste estudo apresentam aplica&ccedil;&otild
e;es     pr&aacute;ticas importantes. O aumento da modula&ccedil;&atilde;o simp&
aacute;tica     e a diminui&ccedil;&atilde;o da modula&ccedil;&atilde;o parassim
p&aacute;tica     card&iacute;acas est&atilde;o relacionados ao aumento do risco
 cardiovascular<SUP>9,10</SUP>.     Assim, &eacute; poss&iacute;vel sugerir que 
o exerc&iacute;cio de for&ccedil;a     para tronco e membros superiores com 70% 
de 1&#45;RM promove uma transiente altera&ccedil;&atilde;o     na modula&ccedil;
&atilde;o auton&ocirc;mica card&iacute;aca, que pode representar     um aumento 
no risco cardiovascular, o que n&atilde;o acontece quando utilizado     50% de 1
&#45;RM. Dessa forma, a prescri&ccedil;&atilde;o do exerc&iacute;cio     de for&
ccedil;a com 50% de 1&#45;RM pode ser uma importante estrat&eacute;gia     para 
minimizar o risco naqueles indiv&iacute;duos que apresentam maior risco     card
iovascular. Todavia, essa hip&oacute;tese precisa ser confirmada em estudos     
futuros. </font></p>     ^cY#aop3811.htm##
01140000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704089800084002001200982#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#82#78#article#145#<p><font si
ze="2" face="Verdana">Este estudo apresenta limita&ccedil;&otilde;es     que dev
em ser consideradas. N&atilde;o houve controle sobre a frequ&ecirc;ncia     resp
irat&oacute;ria dos indiv&iacute;duos em nenhum dos momentos das sess&otilde;es 
    experimentais. Dessa forma, &eacute; poss&iacute;vel que os movimentos respi
rat&oacute;rios     possam ter influenciado no poder da banda de alta frequ&ecir
c;ncia. Os indiv&iacute;duos     no presente estudo eram jovens e saud&aacute;ve
is e a extrapola&ccedil;&atilde;o     dos resultados para indiv&iacute;duos com 
outras caracter&iacute;sticas &eacute; limitada.     Todavia, considerando a esc
assez de dados sobre esse tema na literatura,     os resultados deste estudo for
necem indicativos iniciais sobre o impacto     do exerc&iacute;cio de for&ccedil
;a na modula&ccedil;&atilde;o auton&ocirc;mica     card&iacute;aca.</font></p>  
   ^cY#aop3811.htm##
00658000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704041600084002001200500#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#83#79#article#145#<p><font si
ze="2" face="Verdana">Finalmente, embora a ordem de realiza&ccedil;&atilde;o    
 das sess&otilde;es tenha sido aleatorizada, a aleatoriza&ccedil;&atilde;o     r
esultou em uma distribui&ccedil;&atilde;o n&atilde;o balanceada entre as     ses
s&otilde;es. Por&eacute;m, acreditamos que a probabilidade desse fator     ter i
mpactado consideravelmente os resultados &eacute; m&iacute;nima. </font></p>    
 ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#84#80#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00318000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007600084002001200160#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#85#81#article#145#<p><font si
ze="3" face="Verdana"><b>Conclus&atilde;o</b></font></p>     ^cY#aop3811.htm##
00648000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704040600084002001200490#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#86#82#article#145#<p><font si
ze="2" face="Verdana">Ap&oacute;s uma sess&atilde;o aguda de exerc&iacute;cio   
  de for&ccedil;a para tronco e membros superiores, ocorre aumento na modula&cce
dil;&atilde;o     simp&aacute;tica e redu&ccedil;&atilde;o da modula&ccedil;&ati
lde;o parassimp&aacute;tica     card&iacute;aca. Essas respostas s&atilde;o mais
 acentuadas na sess&atilde;o     com maior intensidade.</font></p>     ^cY#aop38
11.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009200084002001200176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#87#83#article#145#<p><font si
ze="2" face="Verdana"><b>Potencial Conflito de Interesses</b></font></p>     ^cY
#aop3811.htm##
00359000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704011700084002001200201#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#88#84#article#145#<p><font si
ze="2" face="Verdana">Declaro n&atilde;o haver conflito de interesses     pertin
entes.</font></p>     ^cY#aop3811.htm##
00325000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008300084002001200167#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#89#85#article#145#<p><font si
ze="2" face="Verdana"><b>Fontes de Financiamento</b></font></p>     ^cY#aop3811.
htm##
00617000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037500084002001200459#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#90#86#article#145#<p><font si
ze="2" face="Verdana">O presente estudo foi financiado pela Funda&ccedil;&atilde
;o     de Amparo a Ci&ecirc;ncia e Tecnologia do Estado de Pernambuco (FACEPE); 
    Programa de Fortalecimento Acad&ecirc;mico da Universidade de Pernambuco    
 (PFA&#45;UPE); Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&
oacute;gico     (CNPq) .</font></p>     ^cY#aop3811.htm##
00342000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010000084002001200184#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#91#87#article#145#<p><font si
ze="2" face="Verdana"><b>Vincula&ccedil;&atilde;o Acad&ecirc;mica</b></font></p>
     ^cY#aop3811.htm##
00412000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704017000084002001200254#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#92#88#article#145#<p><font si
ze="2" face="Verdana">N&atilde;o h&aacute; vincula&ccedil;&atilde;o     deste es
tudo a programas de p&oacute;s&#45;gradua&ccedil;&atilde;o.</font></p>     ^cY#a
op3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#93#89#article#145#<p>&nbsp;</
p>     ^cY#aop3811.htm##
00319000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007700084002001200161#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#94#90#article#145#<p><font si
ze="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop3811.htm##
00455000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704019900086002001200285#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#95#91#article#145
#1#<p><font size="2" face="Verdana">1. American College of Sports Medicine Posit
ion     Stand. Exercise and physical activity for older adults. Med Sci Sports E
xerc.     1998;30(6):992&#45;1008.    ^cY#aop3811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#96#92#article#145#</font></p>
     ^cY#aop3811.htm##
00546000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704029000086002001200376#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#97#93#article#145
#2#<p><font size="2" face="Verdana">2. Kraemer WJ, Adams K, Cafarelli E, Dudley 
    GA, Dooly C, Feigenbaum MS, et al. American College of Sports Medicine Posit
ion     Stand. Progression models in resistance training for healthy adults. Med
     Sci Sports Exerc. 2002;34(2):364&#45;80.    ^cY#aop3811.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002000084002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#98#94#article#145#</font></p>
     ^cY#aop3811.htm##
00671000000000157000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080888000200084704041500086002001200501#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#99#95#article#145
#3#<p><font size="2" face="Verdana">3. Williams MA, Haskell WL, Ades PA, Amsterd
am     EA, Bittner V, Franklin BA, et al. Resistance exercise in individuals wit
h     and without cardiovascular disease: 2007 update: a scientific statement fr
om     the American Heart Association Council on Clinical Cardiology and Council
     on Nutrition, Physical Activity, and Metabolism. Circulation. 2007;116(5):5
72&#45;84.    ^cY#aop3811.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#100#96#article#145#</font></p
>     ^cY#aop3811.htm##
00473000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704021600087002001200303#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#101#97#article#14
5#4#<p><font size="2" face="Verdana">4. Dias RMR, Gurj&atilde;o ALD, Marucci MFN
.     Benef&iacute;cios do treinamento com pesos para aptid&atilde;o f&iacute;si
ca     de idosos. Acta Fisiatr. 2006;13(2):90&#45;5.    ^cY#aop3811.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002000085002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#102#98#article#145#</font></p
>     ^cY#aop3811.htm##
00514000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081888000200085704025700087002001200344#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#103#99#article#14
5#5#<p><font size="2" face="Verdana">5. Dalgas U, Stenager E, Jakobsen J, Peters
en     T, Hansen HJ, Knudsen C, et al. Fatigue, mood and quality of life improve
     in MS patients after progressive resistance training. Mult Scler. 2010;16(4
):480&#45;90.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#104#100#article#145#</font></
p>     ^cY#aop3811.htm##
00539000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704028100088002001200369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#105#101#article#1
45#6#<p><font size="2" face="Verdana">6. Rezk CC, Marrache RC, Tinucci T, Mion  
   D Jr, Forjaz CL. Post&#45;resistance exercise hypotension, hemodynamics, and 
    heart rate variability: influence of exercise intensity. Eur J Appl Physiol.
     2006;98(1):105&#45;12</font></p>     ^cY#aop3811.htm##
00500000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704024200088002001200330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#106#102#article#1
45#7#<p><font size="2" face="Verdana">7. Kingsley JD, Panton LB, McMillan V, Fig
ueroa     A. Cardiovascular autonomic modulation after acute resistance exercise
 in     women with fibromyalgia. Arch Phys Med Rehabil. 2009;90(9):1628&#45;34. 
   ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#107#103#article#145#</font></
p>     ^cY#aop3811.htm##
00503000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704024500088002001200333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#108#104#article#1
45#8#<p><font size="2" face="Verdana">8. Heffernan KS, Kelly EE, Collier SR, Fer
nhall     B. Cardiac autonomic modulation during recovery from acute endurance v
ersus     resistance exercise. Eur J Cardiovasc Prev Rehabil. 2006;13(1):80&#45;
6.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#109#105#article#145#</font></
p>     ^cY#aop3811.htm##
00565000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704030700088002001200395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#110#106#article#1
45#9#<p><font size="2" face="Verdana">9. Mourot L, Bouhaddi M, Tordi N, Rouillon
     JD, Regnard J. Short&#45; and long&#45;term effects of a single bout of exe
rcise     on heart rate variability: comparison between constant and interval tr
aining     exercises. Eur J Appl Physiol. 2004;92(4):508&#45;17.    ^cY#aop3811.
htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#111#107#article#145#</font></
p>     ^cY#aop3811.htm##
00474000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021500089002001200304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#112#108#article#1
45#10#<p><font size="2" face="Verdana">10. Seiler S, Haugen O, Kuffel E. Autonom
ic     recovery after exercise in trained athletes: intensity and duration effec
ts.     Med Sci Sports Exerc. 2007;39(8):1366&#45;73.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#113#109#article#145#</font></
p>     ^cY#aop3811.htm##
00471000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021200089002001200301#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#114#110#article#1
45#11#<p><font size="2" face="Verdana">11. American College of Sports Medicine p
osition     stand. Progression models in resistance training for healthy adults.
 Med     Sci Sports Exerc. 2009;41(3):687&#45;708.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#115#111#article#145#</font></
p>     ^cY#aop3811.htm##
00571000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031200089002001200401#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#116#112#article#1
45#12#<p><font size="2" face="Verdana">12. Simoes RP, Mendes RG, Castello V, Mac
hado     HG, Almeida LB, Baldissera V, et al. Heart&#45;rate variability and blo
od&#45;lactate     threshold interaction during progressive resistance exercise 
in healthy older     men. J Strength Cond Res. 2010;24(5):1313&#45;20.    ^cY#ao
p3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#117#113#article#145#</font></
p>     ^cY#aop3811.htm##
00482000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704022300089002001200312#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#118#114#article#1
45#13#<p><font size="2" face="Verdana">13. Polito MD, Farinatti PT. The effects 
    of muscle mass and number of sets during resistance exercise on postexercise
     hypotension. J Strength Cond Res. 2009;23(8):2351&#45;7.    ^cY#aop3811.htm
##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#119#115#article#145#</font></
p>     ^cY#aop3811.htm##
00535000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027600089002001200365#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#120#116#article#1
45#14#<p><font size="2" face="Verdana">14&#45; Sociedade Brasileira de Cardiolog
ia. Sociedade     Brasileira de Hipertens&atilde;o.Sociedade Brasileira de Nefro
logia. VI diretrizes     brasileira de hipertens&atilde;o. Arq Bras Cardiol.2010
;95(1 supl.1):1&#45;51</font></p>     ^cY#aop3811.htm##
00540000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028100089002001200370#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#121#117#article#1
45#15#<p><font size="2" face="Verdana">15. Wu JS, Lu FH, Yang YC, Lin TS, Chen J
J,     Wu CH, et al. Epidemiological study on the effect of pre&#45;hypertension
 and     family history of hypertension on cardiac autonomic function. J Am Coll
 Cardiol.     2008;51(19):1896&#45;901.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#122#118#article#145#</font></
p>     ^cY#aop3811.htm##
00430000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704017100089002001200260#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#123#119#article#1
45#16#<p><font size="2" face="Verdana">16. Clarke DH. Adaptations in strength an
d     muscular endurance resulting from exercise. Exerc Sport Sci Rev. 1973;1:73
&#45;102.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#124#120#article#145#</font></
p>     ^cY#aop3811.htm##
00574000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704031500089002001200404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#125#121#article#1
45#17#<p><font size="2" face="Verdana">17. Dias RMR, Cyrino ES, Salvador EP, Cal
deira     LFS, Nakamura FY, Papst RR, et al. Influ&ecirc;ncia do processo de fam
iliariza&ccedil;&atilde;o     para avalia&ccedil;&atilde;o da for&ccedil;a muscu
lar em testes de 1&#45;RM.     Rev Bras Med Esporte. 2005;11(1):34&#45;8.    ^cY
#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#126#122#article#145#</font></
p>     ^cY#aop3811.htm##
00562000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030300089002001200392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#127#123#article#1
45#18#<p><font size="2" face="Verdana">18. Heart rate variability: standards of 
    measurement, physiological interpretation and clinical use. Task Force of   
  the European Society of Cardiology and the North American Society of Pacing   
  and Electrophysiology. Circulation. 1996;93(5):1043&#45;65.    ^cY#aop3811.htm
##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#128#124#article#145#</font></
p>     ^cY#aop3811.htm##
00469000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021000089002001200299#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#129#125#article#1
45#19#<p><font size="2" face="Verdana">19. Gotshall RW, Aten LA, Yumikura S. Dif
ference     in the cardiovascular response to prolonged sitting in men and women
. Can     J Appl Physiol. 1994;19(2):215&#45;25.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#130#126#article#145#</font></
p>     ^cY#aop3811.htm##
00474000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021500089002001200304#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#131#127#article#1
45#20#<p><font size="2" face="Verdana">20. Queiroz AC, Gagliardi JF, Forjaz CL, 
    Rezk CC. Clinic and ambulatory blood pressure responses after resistance    
 exercise. J Strength Cond Res. 2009;23(2):571&#45;8.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#132#128#article#145#</font></
p>     ^cY#aop3811.htm##
00667000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704040800089002001200497#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#133#129#article#1
45#21#<p><font size="2" face="Verdana">21. Meneses AL, Silva GQM, Lima AHRA, Far
ah     BQ, Forjaz CLM, Dias RMR. Efeito da intensidade do exerc&iacute;cio de fo
r&ccedil;a     para membros superiores nas respostas cardiovasculares p&oacute;s
&#45;exerc&iacute;cio.In:     30 Congresso Brasileiro de Metabolismo, Nutri&cced
il;&atilde;o e Exerc&iacute;cio;     20 de maio,2010 Londrina(PR). Londrina (PR)
;2010;    ^cY#aop3811.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#134#130#article#145# </font><
/p>     ^cY#aop3811.htm##
00511000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025200089002001200341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#135#131#article#1
45#22#<p><font size="2" face="Verdana">22. Farinatti PTV, Nakamura FY, Polito MD
.     Influence of recovery posture on blood pressure and heart rate after resis
tance     exercises in normotensive subjects. J Strength Cond Res. 2009;23(9):24
87&#45;92.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#136#132#article#145#</font></
p>     ^cY#aop3811.htm##
00450000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019100089002001200280#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#137#133#article#1
45#23#<p><font size="2" face="Verdana">23. Mitchell JH. J.B. Wolffe memorial lec
ture.     Neural control of the circulation during exercise. Med Sci Sports Exer
c.     1990;22(2):141&#45;54.    ^cY#aop3811.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#138#134#article#145#</font></
p>     ^cY#aop3811.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#139#135#article#145#<p>&nbsp;
</p>     ^cY#aop3811.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#140#136#article#145#<p>&nbsp;
</p>     ^cY#aop3811.htm##
00410000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016600086002001200252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#141#137#article#145#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:    ^cY#aop
3811.htm##
00288000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004400086002001200130#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#142#138#article#145#<br>   </
b>Raphael Mendes Ritti Dias    ^cY#aop3811.htm##
00308000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006400086002001200150#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#143#139#article#145#<BR>   Ru
a Arn&iacute;bio Marques, 310 &#45; Santo Amaro    ^cY#aop3811.htm##
00302000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704005800086002001200144#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#144#140#article#145#<br>   50
100&#45;130 &#45; Recife, PE &#45; Brasil    ^cY#aop3811.htm##
00349000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010500086002001200191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#145#141#article#145#<BR>   E&
#45;mail: <a href="mailto:raphaelritti@gmail.com">raphaelritti@gmail.com</a></fo
nt></p>     ^cY#aop3811.htm##
00380000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704013600086002001200222#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#146#142#article#145#<p><font 
size="2" face="Verdana"> Artigo recebido em 04/09/10; revisado recebido     em 0
3/11/10; aceito em 25/11/10</font></p>     ^cY#aop3811.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#147#143#article#145#<p>&nbsp;
</p>     ^cY#aop3811.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#148#144#article#145#<p>&nbsp;
</p>     ^cY#aop3811.htm##
00420000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704017600086002001200262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3811.htm#S#p#149#145#article#145#<p><font 
size="2" face="Verdana">Full texts in English &#45; <A href="http://www.arquivos
online.com.br" target="_blank">http://www.arquivosonline.com.br</A></font></p>  
   ^cY#aop3811.htm##
00567000000000277000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830110051000850120052001360300
02100188065000900209064000500218031000300223032000200226014000900228865000900237
002001200246035001000258801002100268#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3811.htm#S#c#150#1#article#23#1#American College of Sports Medicine Po
sition Stand#Exercise and physical activity for older adults^len#Med Sci Sports 
Exerc#19980000#1998#30#6#992-1008#20110000#aop3811.htm#0195-9131#Med Sci Sports 
Exerc##
00762000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100015001030100
01900118010001700137010001500154010002100169810000600190012011700196030002100313
06500090033406400050034303100030034803200020035101400070035386500090036000200120
0369035001000381801002100391#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3811.htm#S#c#151#2#article#23#2#^rND^sKraemer^nWJ#^rND^sAdams^nK#^rND^sCafarel
li^nE#^rND^sDudley^nGA#^rND^sDooly^nC#^rND^sFeigenbaum^nMS#et al#American Colleg
e of Sports Medicine Position Stand: Progression models in resistance training f
or healthy adults^len#Med Sci Sports Exerc#20020000#2002#34#2#364-80#20110000#ao
p3811.htm#0195-9131#Med Sci Sports Exerc##
00874000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100018001040100
01500122010002000137010001700157010001900174810000600193012024300199030001200442
06500090045406400050046303100040046803200020047201400070047486500090048100200120
0490035001000502801001200512#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3811.htm#S#c#152#3#article#23#3#^rND^sWilliams^nMA#^rND^sHaskell^nWL#^rND^sAde
s^nPA#^rND^sAmsterdam^nEA#^rND^sBittner^nV#^rND^sFranklin^nBA#et al#Resistance e
xercise in individuals with and without cardiovascular disease: 2007 update: a s
cientific statement from the American Heart Association Council on Clinical Card
iology and Council on Nutrition, Physical Activity, and Metabolism^len#Circulati
on#20070000#2007#116#5#572-84#20110000#aop3811.htm#0009-7322#Circulation##
00558000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100018001010100
01900119012007000138030001300208710000200221065000900223064000500232031000300237
032000200240014000500242865000900247002001200256#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3811.htm#S#c#153#4#article#23#4#^rND^sDias^nRMR#^rND^sGurj
ão^nALD#^rND^sMarucci^nMFN#Benefícios do treinamento com pesos para aptidão físi
ca de idosos^lpt#Acta Fisiatr#2#20060000#2006#13#2#90-5#20110000#aop3811.htm##
00723000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100018001010100
01800119010001800137010001700155010001700172810000600189012009900195030001100294
06500090030506400050031403100030031903200020032201400070032486500090033100200120
0340035001000352801001100362#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3811.htm#S#c#154#5#article#23#5#^rND^sDalgas^nU#^rND^sStenager^nE#^rND^sJakobs
en^nJ#^rND^sPetersen^nT#^rND^sHansen^nHJ#^rND^sKnudsen^nC#et al#Fatigue, mood an
d quality of life improve in MS patients after progressive resistance training^l
en#Mult Scler#20100000#2010#16#4#480-90#20110000#aop3811.htm#1352-4585#Mult Scle
r##
00707000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100019001000100
01700119010001700136010001700153012011600170030001900286065000900305064000500314
03100030031903200020032201400070032486500090033100200120034003500100035280100190
0362#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#c#155#6#art
icle#23#6#^rND^sRezk^nCC#^rND^sMarrache^nRC#^rND^sTinucci^nT#^rND^sMion Jr^nD#^r
ND^sForjaz^nCL#Post-resistance exercise hypotension, hemodynamics, and heart rat
e variability: influence of exercise intensity^len#Eur J Appl Physiol#20060000#2
006#98#1#105-12#20110000#aop3811.htm#0301-5548#Eur J Appl Physiol##
00672000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100019000850100017001040100
01800121010001800139012009900157030002200256065000900278064000500287031000300292
032000200295014000800297865000900305002001200314035001000326801002200336#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#c#156#7#article#23#7#^r
ND^sKingsley^nJD#^rND^sPanton^nLB#^rND^sMcMillan^nV#^rND^sFigueroa^nA#Cardiovasc
ular autonomic modulation after acute resistance exercise in women with fibromya
lgia^len#Arch Phys Med Rehabil#20090000#2009#90#9#1628-34#20110000#aop3811.htm#0
003-9993#Arch Phys Med Rehabil##
00633000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100016001050100
01800121010001800139012009700157030003000254710000200284065000900286064000500295
031000300300032000200303014000500305865000900310002001200319#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3811.htm#S#c#157#8#article#23#8#^rND^sHefferna
n^nKS#^rND^sKelly^nEE#^rND^sCollier^nSR#^rND^sFernhall^nB#Cardiac autonomic modu
lation during recovery from acute endurance versus resistance exercise^len#Eur J
 Cardiovasc Prev Rehabil#2#20060000#2006#13#1#80-6#20110000#aop3811.htm##
00740000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100018001010100
01500119010001900134010001700153012014900170030001900319065000900338064000500347
03100030035203200020035501400070035786500090036400200120037303500100038580100190
0395#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#c#158#9#art
icle#23#9#^rND^sMourot^nL#^rND^sBouhaddi^nM#^rND^sTordi^nN#^rND^sRouillon^nJD#^r
ND^sRegnard^nJ#Short- and long-term effects of a single bout of exercise on hear
t rate variability: comparison between constant and interval training exercises^
len#Eur J Appl Physiol#20040000#2004#92#4#508-17#20110000#aop3811.htm#0301-5548#
Eur J Appl Physiol##
00627000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100016001030100
01600119012009000135030002100225065000900246064000500255031000300260032000200263
014000800265865000900273002001200282035001000294801002100304#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3811.htm#S#c#159#10#article#23#10#^rND^sSeiler
^nS#^rND^sHaugen^nO#^rND^sKuffel^nE#Autonomic recovery after exercise in trained
 athletes: intensity and duration effects^len#Med Sci Sports Exerc#20070000#2007
#39#8#1366-73#20110000#aop3811.htm#0195-9131#Med Sci Sports Exerc##
00581000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840110051000870120065001380300
02100203065000900224064000500233031000300238032000200241014000800243865000900251
002001200260035001000272801002100282#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3811.htm#S#c#160#11#article#23#11#American College of Sports Medicine 
position stand#Progression models in resistance training for healthy adults^len#
Med Sci Sports Exerc#20090000#2009#41#3#687-708#20110000#aop3811.htm#0195-9131#M
ed Sci Sports Exerc##
00736000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100017001040100
01800121010001800139010001800157010002000175810000600195012012700201030002000328
71000020034806500090035006400050035903100030036403200020036701400080036986500090
0377002001200386#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S
#c#161#12#article#23#12#^rND^sSimoes^nRP#^rND^sMendes^nRG#^rND^sCastello^nV#^rND
^sMachado^nHG#^rND^sAlmeida^nLB#^rND^sBaldissera^nV#et al#Heart-rate variability
 and blood-lactate threshold interaction during progressive resistance exercise 
in healthy older men^len#J Strength Cond Res#2#20100000#2010#24#5#1313-20#201100
00#aop3811.htm##
00576000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100020001040120
10500124030002000229710000200249065000900251064000500260031000300265032000200268
014000700270865000900277002001200286#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3811.htm#S#c#162#13#article#23#13#^rND^sPolito^nMD#^rND^sFarinatti^nPT
#The effects of muscle mass and number of sets during resistance exercise on pos
texercise hypotension^len#J Strength Cond Res#2#20090000#2009#23#8#2351-7#201100
00#aop3811.htm##
00614000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840110036000870120116001230300
01700239065000900256064000500265031000300270032001000273014000500283865000900288
002001200297035001000309801001700319#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3811.htm#S#c#163#14#article#23#14#Sociedade Brasileira de Cardiologia#
Sociedade Brasileira de Hipertensão.Sociedade Brasileira de Nefrologia: VI diret
rizes brasileira de hipertensão^lpt#Arq Bras Cardiol#20100000#2010#95#1^ssupl.1#
1-51#20110000#aop3811.htm#0066-782X#Arq Bras Cardiol##
00747000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100013000870100013001000100
01500113010001400128010001500142010001300157810000600170012012500176030001800301
06500090031906400050032803100030033303200030033601400090033986500090034800200120
0357035001000369801001800379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3811.htm#S#c#164#15#article#23#15#^rND^sWu^nJS#^rND^sLu^nFH#^rND^sYang^nYC#^rN
D^sLin^nTS#^rND^sChen^nJJ#^rND^sWu^nCH#et al#Epidemiological study on the effect
 of pre-hypertension and family history of hypertension on cardiac autonomic fun
ction^len#J Am Coll Cardiol#20080000#2008#51#19#1896-901#20110000#aop3811.htm#07
35-1097#J Am Coll Cardiol##
00539000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870120075001040300
02000179065000900199064000500208031000200213014000700215865000900222002001200231
035001000243801002000253#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop38
11.htm#S#c#165#16#article#23#16#^rND^sClarke^nDH#Adaptations in strength and mus
cular endurance resulting from exercise^len#Exerc Sport Sci Rev#19730000#1973#1#
73-102#20110000#aop3811.htm#0091-6331#Exerc Sport Sci Rev##
00764000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
01900120010002000139010001900159010001600178810000600194012009600200030002100296
06500090031706400050032603100030033103200020033401400050033686500090034100200120
0350035001000362801004200372#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3811.htm#S#c#166#17#article#23#17#^rND^sDias^nRMR#^rND^sCyrino^nES#^rND^sSalva
dor^nEP#^rND^sCaldeira^nLFS#^rND^sNakamura^nFY#^rND^sPapst^nRR#et al#Influência 
do processo de familiarização para avaliação da força muscular em testes de 1-RM
^lpt#Rev Bras Med Esporte#20050000#2005#11#1#34-8#20110000#aop3811.htm#1517-8692
#Revista Brasileira de Medicina do Esporte##
00648000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840120213000870300012003000650
00900312064000500321031000300326032000200329014000800331865000900339002001200348
035001000360801001200370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop38
11.htm#S#c#167#18#article#23#18#Heart rate variability: standards of measurement
, physiological interpretation and clinical use. Task Force of the European Soci
ety of Cardiology and the North American Society of Pacing and Electrophysiology
^len#Circulation#19960000#1996#93#5#1043-65#20110000#aop3811.htm#0009-7322#Circu
lation##
00620000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100015001060100
01800121012008400139030001900223065000900242064000500251031000300256032000200259
014000700261865000900268002001200277035001000289801001900299#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3811.htm#S#c#168#19#article#23#19#^rND^sGotsha
ll^nRW#^rND^sAten^nLA#^rND^sYumikura^nS#Difference in the cardiovascular respons
e to prolonged sitting in men and women^len#Can J Appl Physiol#19940000#1994#19#
2#215-25#20110000#aop3811.htm#1066-7814#Can J Appl Physiol##
00604000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100020001050100
01700125010001500142012007700157030002000234710000200254065000900256064000500265
031000300270032000200273014000600275865000900281002001200290#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3811.htm#S#c#169#20#article#23#20#^rND^sQueiro
z^nAC#^rND^sGagliardi^nJF#^rND^sForjaz^nCL#^rND^sRezk^nCC#Clinic and ambulatory 
blood pressure responses after resistance exercise^len#J Strength Cond Res#2#200
90000#2009#23#2#571-8#20110000#aop3811.htm##
00798000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100017001050100
01700122010001600139010001800155010001600173012011700189053006800306055001200374
05400190038605600190040506600130042406500090043706400050044686500090045100200120
0460#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3811.htm#S#c#170#21#ar
ticle#23#21#^rND^sMeneses^nAL#^rND^sSilva^nGQM#^rND^sLima^nAHRA#^rND^sFarah^nBQ#
^rND^sForjaz^nCLM#^rND^sDias^nRMR#Efeito da intensidade do exercício de força pa
ra membros superiores nas respostas cardiovasculares pós-exercício^lpt#Congresso
 Brasileiro de Metabolismo, Nutrição e Exercício^n30^i1^i1#20100520^i1#20 de mai
o,2010^i1#Londrina^i1^ePR^i1#Londrina^ePR#20100000#2010#20110000#aop3811.htm##
00623000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100021000870100019001080100
01700127012011900144030002000263710000200283065000900285064000500294031000300299
032000200302014000800304865000900312002001200321#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3811.htm#S#c#171#22#article#23#22#^rND^sFarinatti^nPTV#^rN
D^sNakamura^nFY#^rND^sPolito^nMD#Influence of recovery posture on blood pressure
 and heart rate after resistance exercises in normotensive subjects^len#J Streng
th Cond Res#2#20090000#2009#23#9#2487-92#20110000#aop3811.htm##
00569000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100024000870120081001110300
02100192065000900213064000500222031000300227032000200230014000700232865000900239
002001200248035001000260801002100270#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3811.htm#S#c#172#23#article#23#23#^rND^sMitchell^nJH J B.#Wolffe memor
ial lecture: . Neural control of the circulation during exercise^len#Med Sci Spo
rts Exerc#19900000#1990#22#2#141-54#20110000#aop3811.htm#0195-9131#Med Sci Sport
s Exerc##
00282000000000169000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780910009000800920007000890020012000967030
00400108#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#o#1#1#a
rticle#1#20110408#165304#aop3411.htm#259##
05030000000000685000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201200800017101200640
02510100037003150100030003520100030003820100031004120100039004430100042004820100
04000524010003300564070005800597083170800655085000802363085002902371085003402400
08500280243408500240246208316680248608500080415408500260416208500290418808500280
42170850022042451170008042670720003042751120009042781110009042871160009042961150
00904305114000904314113000904323002001204332#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop3411.htm#S#h#2#1#article#1#tr#pt#br1.1#1#4.0#ND#46#nd#nd#Arq. 
Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#Avaliação prognóstica da
 doença coronária estável através de um novo escore^lpt#New prognostic score for
 stable coronary disease evaluation^len#^rND^1A01^nFernanda Coutinho^sStorti#^rN
D^1A01^nPaulo Jorge^sMoffa#^rND^1A01^nAugusto H.^sUchida#^rND^1A01^nWhady Armind
o^sHueb#^rND^1A01^nLuiz Antônio Machado^sCésar#^rND^1A01^nBeatriz Moreira Ayub^s
Ferreira#^rND^1A01^nPaulo Augusto de^sCamargo Jr#^rND^1A01^nWilliam Azem^sChalel
a#HCFMUSP^iA01^1Instituto do Coração^cSão Paulo^sSP^pBrasil#^lpt^aFUNDAMENTO: A 
necessidade de melhorar a acurácia do teste de esforço, determinou o desenvolvim
ento de escores, cuja aplicabilidade já foi amplamente reconhecida. OBJETIVO: Av
aliação prognóstica do coronariopata estável através de um novo escore simplific
ado. MÉTODOS: Um novo escore foi aplicado em 372 coronariopatas multiarteriais e
 função ventricular preservada, 71,8% homens, idade média 59,5 (± 9,07) anos, ra
ndomizados para angioplastia, revascularização cirúrgica e tratamento clínico, a
companhados por 5 anos. Óbito cardiovascular foi o desfecho primário. Infarto do
 miocárdio não-fatal, óbito e re-intervenção formaram o desfecho combinado secun
dário. O escore baseou-se numa equação previamente validada resultante da soma d
e 1 ponto para: sexo masculino, história de infarto, angina, diabete, uso de ins
ulina e ainda 1 ponto para cada década de vida a partir dos 40 anos. Teste posit
ivo adicionou 1 ponto. RESULTADOS: Ocorreram 36 óbitos (10 no grupo angioplastia
, 15 no grupo revascularização e 11 no grupo clínico), p = 0,61. Observou-se 93 
eventos combinados: 37 no grupo angioplastia, 23 no grupo revascularização e 33 
no grupo clínico (p = 0,058). 247 pacientes apresentaram escore clínico &gt; 5 p
ontos e 216 &gt; 6 pontos. O valor de corte &gt; 5 ou &gt; 6 pontos identificou 
maior risco, com p = 0,015 e p = 0,012, respectivamente. A curva de sobrevida mo
strou uma incidência de óbito após a randomização diferente naqueles com escore 
&gt; 6 pontos (p = 0,07), e uma incidência de eventos combinados diferente entre
 pacientes com escore < 6 e &gt; 6 pontos (p = 0,02). CONCLUSÃO: O novo escore d
emonstrou consistência na avaliação prognóstica do coronariopata estável multiar
terial.#^dnd^i1#^tm^lpt^kTeste de esforço^i1#^tm^lpt^kdoença das coronárias^i1#^
tm^lpt^kangina pectoris^i1#^tm^lpt^kprognóstico^i1#^len^aBACKGROUND: The need to
 improve the exercise testing accuracy, pushed the development of scores, whose 
applicability was already broadly recognized. OBJECTIVE: Prognostic evaluation o
f stable coronary disease through a new simplified score. METHODS: A new score w
as applied in 372 multivessel coronary patients with preserved ventricular funct
ion, 71.8% male, age: 59.5 (± 9.07) years old, randomized to medical treatment, 
surgery (CABG) or angioplasty (PTCA), with 5 years of follow-up. Cardiovascular 
death was considered the primary endpoint. Non-fatal myocardial infarction, deat
h and re-intervention were considered for a combined secondary endpoint. The sco
re was based on an equation previously validated, resulting from a sum of one po
int for: male gender, infarction history, angina, diabetes, insulin use and one 
point for each decade of life after 40 years old. Positive exercise testing summ
ed one additional point. RESULTS: Thirty six deaths was observed (10 in group PT
CA, 15 in CABG and 11 in the clinical group), p = 0.61. We observed 93 combined 
events: 37 in PTCA group, 23 in CABG and 33 in the clinical group (p = 0.058). 2
47 patients presented clinical score &gt; 5 points and 216 &gt; 6 points. The cu
toff point &gt; 5 or &gt; 6 points identified higher risk, p = 0.015 and p = 0.0
12, respectively. The survival curve showed a different death incidence after th
e randomization when score reached 06 points or more (p = 0.07), and a distinct 
incidence of combined events between the patients with score < 6 and &gt; 6 poin
ts (p = 0.02). CONCLUSION: The new score was consistent for multiarterial stable
 coronary disease risk stratification.#^dnd^i2#^tm^len^kExercise test^i2#^tm^len
^kcoronary disease^i2#^tm^len^kangina pectoris^i2#^tm^len^kprognosis^i2#vancouv#
37#20100530#30/05/10#20100922#22/09/10#20110111#11/01/11#aop3411.htm##
05169000000000685000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780710003000800400003000830010006000860420
00200092120000400094038000300098121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016201200870017101200710
02580100037003290100030003660100030003960100031004260100039004570100042004960100
04000538010003300578070005800611083174600669085000802415085002902423085003402452
08500350248608500240252108317410254508500080428608500260429408500290432008500350
43490850022043841170008044060720003044141120009044171110009044261160009044351150
00904444114000904453113000904462002001204471#2011nahead#V:\SciELO\serial\abc\201
1nahead\markup\aop3411.htm#S#f#3#1#article#1#tr#pt#br1.1#1#4.0#ND#46#nd#nd#Arq. 
Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#<b>Avaliação prognóstica
 da doença coronária estável através de um novo escore</b>^lpt#<b>New prognostic
 score for stable coronary disease evaluation</b>^len#^rND^1A01^nFernanda Coutin
ho^sStorti#^rND^1A01^nPaulo Jorge^sMoffa#^rND^1A01^nAugusto H.^sUchida#^rND^1A01
^nWhady Armindo^sHueb#^rND^1A01^nLuiz Antônio Machado^sCésar#^rND^1A01^nBeatriz 
Moreira Ayub^sFerreira#^rND^1A01^nPaulo Augusto de^sCamargo Jr#^rND^1A01^nWillia
m Azem^sChalela#HCFMUSP^iA01^1Instituto do Coração^cSão Paulo^sSP^pBrasil#^lpt^a
<b>FUNDAMENTO:</b> A necessidade de melhorar a acurácia do teste de esforço, det
erminou o desenvolvimento de escores, cuja aplicabilidade já foi amplamente reco
nhecida. <b>OBJETIVO:</b> Avaliação prognóstica do coronariopata estável através
 de um novo escore simplificado. <b>MÉTODOS:</b> Um novo escore foi aplicado em 
372 coronariopatas multiarteriais e função ventricular preservada, 71,8% homens,
 idade média 59,5 (± 9,07) anos, randomizados para angioplastia, revascularizaçã
o cirúrgica e tratamento clínico, acompanhados por 5 anos. Óbito cardiovascular 
foi o desfecho primário. Infarto do miocárdio não-fatal, óbito e re-intervenção 
formaram o desfecho combinado secundário. O escore baseou-se numa equação previa
mente validada resultante da soma de 1 ponto para: sexo masculino, história de i
nfarto, angina, diabete, uso de insulina e ainda 1 ponto para cada década de vid
a a partir dos 40 anos. Teste positivo adicionou 1 ponto. <b>RESULTADOS:</b> Oco
rreram 36 óbitos (10 no grupo angioplastia, 15 no grupo revascularização e 11 no
 grupo clínico), p = 0,61. Observou-se 93 eventos combinados: 37 no grupo angiop
lastia, 23 no grupo revascularização e 33 no grupo clínico (p = 0,058). 247 paci
entes apresentaram escore clínico &gt; 5 pontos e 216 &gt; 6 pontos. O valor de 
corte &gt; 5 ou &gt; 6 pontos identificou maior risco, com p = 0,015 e p = 0,012
, respectivamente. A curva de sobrevida mostrou uma incidência de óbito após a r
andomização diferente naqueles com escore &gt; 6 pontos (p = 0,07), e uma incidê
ncia de eventos combinados diferente entre pacientes com escore &lt; 6 e &gt; 6 
pontos (p = 0,02). <b>CONCLUSÃO:</b> O novo escore demonstrou consistência na av
aliação prognóstica do coronariopata estável multiarterial.#^dnd^i1#^tm^lpt^kTes
te de esforço^i1#^tm^lpt^kdoença das coronárias^i1#^tm^lpt^kangina <i>pectoris</
i>^i1#^tm^lpt^kprognóstico^i1#^len^a<b>BACKGROUND:</b> The need to improve the e
xercise testing accuracy, pushed the development of scores, whose applicability 
was already broadly recognized. <b>OBJECTIVE:</b> Prognostic evaluation of stabl
e coronary disease through a new simplified score. <b>METHODS:</b> A new score w
as applied in 372 multivessel coronary patients with preserved ventricular funct
ion, 71.8% male, age: 59.5 (± 9.07) years old, randomized to medical treatment, 
surgery (CABG) or angioplasty (PTCA), with 5 years of follow-up. Cardiovascular 
death was considered the primary endpoint. Non-fatal myocardial infarction, deat
h and re-intervention were considered for a combined secondary endpoint. The sco
re was based on an equation previously validated, resulting from a sum of one po
int for: male gender, infarction history, angina, diabetes, insulin use and one 
point for each decade of life after 40 years old. Positive exercise testing summ
ed one additional point. <b>RESULTS:</b> Thirty six deaths was observed (10 in g
roup PTCA, 15 in CABG and 11 in the clinical group), p = 0.61. We observed 93 co
mbined events: 37 in PTCA group, 23 in CABG and 33 in the clinical group (p = 0.
058). 247 patients presented clinical score <u>&gt;</u> 5 points and 216 <u>&gt;
</u> 6 points. The cutoff point <u>&gt;</u> 5 or <u>&gt;</u> 6 points identified
 higher risk, p = 0.015 and p = 0.012, respectively. The survival curve showed a
 different death incidence after the randomization when score reached 06 points 
or more (p = 0.07), and a distinct incidence of combined events between the pati
ents with score &lt; 6 and <u>&gt;</u> 6 points (p = 0.02). <b>CONCLUSION:</b> T
he new score was consistent for multiarterial stable coronary disease risk strat
ification.#^dnd^i2#^tm^len^kExercise test^i2#^tm^len^kcoronary disease^i2#^tm^le
n^kangina <i>pectoris</i>^i2#^tm^len^kprognosis^i2#vancouv#37#20100530#30/05/10#
20100922#22/09/10#20110111#11/01/11#aop3411.htm##
05155000000000697000450000400110000070200510001170500020006270600020006470000020
00667010002000687090008000707080002000780640007000800710003000870400003000900010
00600093042000200099120000400101121000300105049000300108158000300111030001900114
03200060013306500090013901400070014803500100015522300090016501200800017401200640
02540100037003180100030003550100029003850100031004140100039004450100042004840100
04400526010003300570070006000603083171700663085000802380085002902388085003402417
08500280245108500240247908316750250308500080417808500260418608500290421208500280
42410850022042691170008042910720003042991120009043021110009043111160009043201150
00904329114000904338113000904347002001204356008008904368#2011nahead#V:\SciELO\se
rial\abc\2011nahead\markup\aop3411.htm#S#l#4#1#article#1#^a2011#tr#pt#br1.1#1#4.
0#46#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#0066-782X#20110415#Avaliação
 prognóstica da doença coronária estável através de um novo escore^lpt#New progn
ostic score for stable coronary disease evaluation^len#^rND^1A01^nFernanda Couti
nho^sStorti#^rND^1A01^nPaulo Jorge^sMoffa#^rND^1A01^nAugusto H^sUchida#^rND^1A01
^nWhady Armindo^sHueb#^rND^1A01^nLuiz Antônio Machado^sCésar#^rND^1A01^nBeatriz 
Moreira Ayub^sFerreira#^rND^1A01^nPaulo Augusto de^sCamargo Júnior#^rND^1A01^nWi
lliam Azem^sChalela#^iA01^1HCFMUSP^2Instituto do Coração^cSão Paulo^sSP^pBrasil#
^lpt^aFUNDAMENTO: A necessidade de melhorar a acurácia do teste de esforço, dete
rminou o desenvolvimento de escores, cuja aplicabilidade já foi amplamente recon
hecida. OBJETIVO: Avaliação prognóstica do coronariopata estável através de um n
ovo escore simplificado. MÉTODOS: Um novo escore foi aplicado em 372 coronariopa
tas multiarteriais e função ventricular preservada, 71,8 por cento homens, idade
 média 59,5 (± 9,07) anos, randomizados para angioplastia, revascularização cirú
rgica e tratamento clínico, acompanhados por 5 anos. Óbito cardiovascular foi o 
desfecho primário. Infarto do miocárdio não-fatal, óbito e re-intervenção formar
am o desfecho combinado secundário. O escore baseou-se numa equação previamente 
validada resultante da soma de 1 ponto para: sexo masculino, história de infarto
, angina, diabete, uso de insulina e ainda 1 ponto para cada década de vida a pa
rtir dos 40 anos. Teste positivo adicionou 1 ponto. RESULTADOS: Ocorreram 36 óbi
tos (10 no grupo angioplastia, 15 no grupo revascularização e 11 no grupo clínic
o), p = 0,61. Observou-se 93 eventos combinados: 37 no grupo angioplastia, 23 no
 grupo revascularização e 33 no grupo clínico (p = 0,058). 247 pacientes apresen
taram escore clínico &gt; 5 pontos e 216 &gt; 6 pontos. O valor de corte &gt; 5 
ou &gt; 6 pontos identificou maior risco, com p = 0,015 e p = 0,012, respectivam
ente. A curva de sobrevida mostrou uma incidência de óbito após a randomização d
iferente naqueles com escore &gt; 6 pontos (p = 0,07), e uma incidência de event
os combinados diferente entre pacientes com escore < 6 e &gt; 6 pontos (p = 0,02
). CONCLUSÃO: O novo escore demonstrou consistência na avaliação prognóstica do 
coronariopata estável multiarterial.#^dnd^i1#^tm^lpt^kTeste de esforço^i1#^tm^lp
t^kdoença das coronárias^i1#^tm^lpt^kangina pectoris^i1#^tm^lpt^kprognóstico^i1#
^len^aBACKGROUND: The need to improve the exercise testing accuracy, pushed the 
development of scores, whose applicability was already broadly recognized. OBJEC
TIVE: Prognostic evaluation of stable coronary disease through a new simplified 
score. METHODS: A new score was applied in 372 multivessel coronary patients wit
h preserved ventricular function, 71.8 percent male, age: 59.5 (± 9.07) years ol
d, randomized to medical treatment, surgery (CABG) or angioplasty (PTCA), with 5
 years of follow-up. Cardiovascular death was considered the primary endpoint. N
on-fatal myocardial infarction, death and re-intervention were considered for a 
combined secondary endpoint. The score was based on an equation previously valid
ated, resulting from a sum of one point for: male gender, infarction history, an
gina, diabetes, insulin use and one point for each decade of life after 40 years
 old. Positive exercise testing summed one additional point. RESULTS: Thirty six
 deaths was observed (10 in group PTCA, 15 in CABG and 11 in the clinical group)
, p = 0.61. We observed 93 combined events: 37 in PTCA group, 23 in CABG and 33 
in the clinical group (p = 0.058). 247 patients presented clinical score &gt; 5 
points and 216 &gt; 6 points. The cutoff point &gt; 5 or &gt; 6 points identifie
d higher risk, p = 0.015 and p = 0.012, respectively. The survival curve showed 
a different death incidence after the randomization when score reached 06 points
 or more (p = 0.07), and a distinct incidence of combined events between the pat
ients with score < 6 and &gt; 6 points (p = 0.02). CONCLUSION: The new score was
 consistent for multiarterial stable coronary disease risk stratification.#^dnd^
i2#^tm^len^kExercise test^i2#^tm^len^kcoronary disease^i2#^tm^len^kangina pector
is^i2#^tm^len^kprognosis^i2#vancouv#37#20100530#30/05/10#20100922#22/09/10#20110
111#11/01/11#aop3411.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_ar
ttext&pid=S0066-782X2011005000046##
00456000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704021600082002001200298#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#5#1#article#218#<p><font size
="4" face="verdana"><b><a name="title"></a>Avalia&ccedil;&atilde;o       progn&o
acute;stica da doen&ccedil;a coron&aacute;ria est&aacute;vel atrav&eacute;s     
  de um novo escore</b></font></p>     ^cY#aop3411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#6#2#article#218#<p>&nbsp;</p>
     ^cY#aop3411.htm##
00262000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704002200082002001200104#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#7#3#article#218#<p>&nbsp;</p>
     ^cY#aop3411.htm##
00523000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704028300082002001200365#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#8#4#article#218#<p><font size
="2" face="Verdana"><b>Fernanda Coutinho Storti; Paulo Jorge Moffa;       August
o H. Uchida; Whady Armindo Hueb; Luiz Ant&ocirc;nio Machado C&eacute;sar;       
Beatriz Moreira Ayub Ferreira; Paulo Augusto de Camargo Jr; William Azem       C
halela</b></font></p>     ^cY#aop3411.htm##
00386000000000145000450000400110000070200510001170500020006270600020006470000020
0066701000200068709000800070708000400078704014600082002001200228#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#9#5#article#218#<p><font size
="2" face="Verdana"> Instituto do Cora&ccedil;&atilde;o &#45; HCFMUSP     &#45; 
S&atilde;o Paulo, SP &#45; Brasil</font></p>     ^cY#aop3411.htm##
00334000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704009300083002001200176#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#10#6#article#218#<p><font siz
e="2" face="Verdana"><a href="#end">Correspond&ecirc;ncia</a></font></p>     ^cY
#aop3411.htm##
00263000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704002200083002001200105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#11#7#article#218#<p>&nbsp;</p
>     ^cY#aop3411.htm##
00285000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704004400083002001200127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#12#8#article#218#<p>&nbsp;</p
> <hr size="1" noshade>     ^cY#aop3411.htm##
00307000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000200069709000800071708000400079704006600083002001200149#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#13#9#article#218#<p><font siz
e="2" face="VERDANA"><b>RESUMO</b></font></p>     ^cY#aop3411.htm##
00480000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023800084002001200322#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#14#10#article#218#<p><font si
ze="2" face="Verdana"><b>FUNDAMENTO:</b> A necessidade de melhorar     a acur&aa
cute;cia do teste de esfor&ccedil;o, determinou o desenvolvimento     de escores
, cuja aplicabilidade j&aacute; foi amplamente reconhecida.    ^cY#aop3411.htm##
00397000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704015500084002001200239#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#15#11#article#218#<br>   <b>O
BJETIVO:</b> Avalia&ccedil;&atilde;o progn&oacute;stica do coronariopata   est&a
acute;vel atrav&eacute;s de um novo escore simplificado.    ^cY#aop3411.htm##
01098000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704085600084002001200940#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#16#12#article#218#<br>   <b>M
&Eacute;TODOS:</b> Um novo escore foi aplicado em 372 coronariopatas multiarteri
ais   e fun&ccedil;&atilde;o ventricular preservada, 71,8% homens, idade m&eacut
e;dia   59,5 (&plusmn; 9,07) anos, randomizados para angioplastia, revasculariza
&ccedil;&atilde;o   cir&uacute;rgica e tratamento cl&iacute;nico, acompanhados p
or 5 anos. &Oacute;bito   cardiovascular foi o desfecho prim&aacute;rio. Infarto
 do mioc&aacute;rdio   n&atilde;o&#45;fatal, &oacute;bito e re&#45;interven&cced
il;&atilde;o formaram o desfecho   combinado secund&aacute;rio. O escore baseou&
#45;se numa equa&ccedil;&atilde;o   previamente validada resultante da soma de 1
 ponto para: sexo masculino, hist&oacute;ria   de infarto, angina, diabete, uso 
de insulina e ainda 1 ponto para cada d&eacute;cada   de vida a partir dos 40 an
os. Teste positivo adicionou 1 ponto.    ^cY#aop3411.htm##
01055000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704081300084002001200897#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#17#13#article#218#<br>   <b>R
ESULTADOS:</b> Ocorreram 36 &oacute;bitos (10 no grupo angioplastia, 15   no gru
po revasculariza&ccedil;&atilde;o e 11 no grupo cl&iacute;nico), p =   0,61. Obs
ervou&#45;se 93 eventos combinados: 37 no grupo angioplastia, 23 no grupo   reva
sculariza&ccedil;&atilde;o e 33 no grupo cl&iacute;nico (p = 0,058). 247   pacie
ntes apresentaram escore cl&iacute;nico &gt; 5 pontos e 216 &gt; 6 pontos.   O v
alor de corte &gt; 5 ou &gt; 6 pontos identificou maior risco, com p = 0,015   e
 p = 0,012, respectivamente. A curva de sobrevida mostrou uma incid&ecirc;ncia  
 de &oacute;bito ap&oacute;s a randomiza&ccedil;&atilde;o diferente naqueles   c
om escore &gt; 6 pontos (p = 0,07), e uma incid&ecirc;ncia de eventos combinados
   diferente entre pacientes com escore &lt; 6 e &gt; 6 pontos (p = 0,02).    ^c
Y#aop3411.htm##
00432000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704019000084002001200274#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#18#14#article#218#<br>   <b>C
ONCLUS&Atilde;O:</b> O novo escore demonstrou consist&ecirc;ncia na avalia&ccedi
l;&atilde;o   progn&oacute;stica do coronariopata est&aacute;vel multiarterial.<
/font></p>     ^cY#aop3411.htm##
00453000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704021100084002001200295#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#19#15#article#218#<p><font si
ze="2" face="Verdana"><b>Palavras&#45;chave:</b> Teste de esfor&ccedil;o,     do
en&ccedil;a das coron&aacute;rias, angina <I>pectoris</I>, progn&oacute;stico.</
font></p> <hr size="1" noshade>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#20#16#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#21#17#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#22#18#article#218#<p><font si
ze="3" face="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#aop3411
.htm##
00916000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704067400084002001200758#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#23#19#article#218#<p><font si
ze="2" face="Verdana">Mesmo com os avan&ccedil;os da medicina, o teste     de es
for&ccedil;o (TE) com seu baixo custo, seguran&ccedil;a e f&aacute;cil     aplic
abilidade &eacute; recomendado pela diretriz americana<SUP>1</SUP> como     o pr
imeiro procedimento a ser realizado em pacientes com doen&ccedil;a arterial     
coron&aacute;ria (DAC). Assim, a maximiza&ccedil;&atilde;o das informa&ccedil;&o
tilde;es     obtidas no TE &eacute; de primordial import&acirc;ncia e a necessid
ade de     melhorar sua acur&aacute;cia, determinou o desenvolvimento de escores
, amplamente     reconhecidos pela literatura cient&iacute;fica<SUP>2&#45;9</SUP
>. </font></p>     ^cY#aop3411.htm##
00705000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704046300084002001200547#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#24#20#article#218#<p><font si
ze="2" face="Verdana">Para uma abordagem mais did&aacute;tica da DAC,     tais e
scores foram classificados em: pr&eacute;&#45;teste, p&oacute;s&#45;teste,     s
implificados, multivariados, diagn&oacute;sticos ou progn&oacute;sticos.     Num
 escore pr&eacute;&#45;teste, apenas vari&aacute;veis cl&iacute;nicas s&atilde;o
     analisadas, ao incorporar par&acirc;metros do TE define&#45;se um escore p&
oacute;s&#45;teste<SUP>6</SUP>. </font></p>     ^cY#aop3411.htm##
00614000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037200084002001200456#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#25#21#article#218#<p><font si
ze="2" face="Verdana">Dentre os escores pr&eacute;&#45;teste temos: Diamond&#45;
Forrester<SUP>2</SUP>,     Morise e Jalisi<SUP>3</SUP>, Froelicher e cols.<SUP>4
</SUP> e Hubbard e cols.<SUP>10</SUP>,     entre outros. Essa an&aacute;lise pro
babil&iacute;stica preliminar &eacute; recomendada     pela diretriz americana<S
UP>1</SUP> sobre TE. </font></p>     ^cY#aop3411.htm##
00722000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048000084002001200564#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#26#22#article#218#<p><font si
ze="2" face="Verdana">Entre os principais escores p&oacute;s&#45;teste     temos
: Mark e cols.<SUP>7</SUP>, Raxwal e cols.<SUP>8</SUP>, Morrow e cols.<SUP>11</S
UP>,     Froelicher e cols.<SUP>4</SUP>, Morise e cols.<SUP>3</SUP>, Do e cols.<
SUP>9</SUP>,     Morise e cols.<SUP>6</SUP>, Detrano e cols.<SUP>12</SUP>, Lu e 
cols.<SUP>13</SUP>,     Villella e cols. (GISSI 2)<SUP>14</SUP>, Koide e cols.<S
UP>15</SUP>, Hollenberg     e cols.<SUP>16</SUP>.</font></p>     ^cY#aop3411.htm
##
00504000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704026200084002001200346#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#27#23#article#218#<p><font si
ze="2" face="Verdana">Escores baseados em equa&ccedil;&otilde;es multivariadas  
   possuem f&oacute;rmulas complexas, das quais derivam escores simplificados   
  cujos c&aacute;lculos envolvem a simples somat&oacute;ria de pontos. </font></
p>     ^cY#aop3411.htm##
00738000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049600084002001200580#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#28#24#article#218#<p><font si
ze="2" face="Verdana">Escores diagn&oacute;sticos visam a estimativa     de prob
abilidade de DAC, podendo ter car&aacute;ter progn&oacute;stico quando     reali
zam a estimativa de doen&ccedil;a grave (padr&atilde;o triarterial ou     les&at
ilde;o de tronco de coron&aacute;ria esquerda). Escores progn&oacute;sticos     
s&atilde;o idealizados para avalia&ccedil;&atilde;o de risco, principalmente,   
  de &oacute;bito cardiovascular ou infarto n&atilde;o&#45;fatal.</font></p>    
 ^cY#aop3411.htm##
00872000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704063000084002001200714#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#29#25#article#218#<p><font si
ze="2" face="Verdana">O escore progn&oacute;stico mais utilizado &eacute; o     
de Mark e cols. (Duke)<SUP>17</SUP>, e embora seja amplamente validado, n&atilde
;o     classifica adequadamente assintom&aacute;ticos, idosos, pacientes no p&oa
cute;s&#45;revasculariza&ccedil;&atilde;o     do mioc&aacute;rdio (recente) e no
 p&oacute;s&#45;infarto do mioc&aacute;rdio     recente. Al&eacute;m disso, ele 
&eacute; composto exclusivamente por dados     do TE, seus resultados e sua clas
sifica&ccedil;&atilde;o em categorias de     risco s&atilde;o complexos e de dif
&iacute;cil memoriza&ccedil;&atilde;o. </font></p>     ^cY#aop3411.htm##
00692000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704045000084002001200534#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#30#26#article#218#<p><font si
ze="2" face="Verdana">Um escore cl&iacute;nico simplificado foi idealizado     p
or Hubbard e cols.<SUP>10</SUP> com intuito diagn&oacute;stico, sendo posteriorm
ente     validado<SUP>18</SUP> para an&aacute;lise progn&oacute;stica de DAC. Co
ntudo,     tal escore n&atilde;o inclui uma prova documental de isquemia em sua 
composi&ccedil;&atilde;o,     dado que impacta no progn&oacute;stico do portador
 de coronariopatia.</font></p>     ^cY#aop3411.htm##
00601000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704035900084002001200443#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#31#27#article#218#<p><font si
ze="2" face="Verdana">Visando propiciar uma orienta&ccedil;&atilde;o     mais co
mpleta e objetiva &agrave; estratifica&ccedil;&atilde;o de risco do     coronari
opata est&aacute;vel, propomos um novo escore p&oacute;s&#45;teste, que     incl
ui o resultado do TE com os par&acirc;metros do escore de Hubbard e cols.<SUP>10
</SUP>. </font></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#32#28#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00316000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007400084002001200158#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#33#29#article#218#<p><font si
ze="3" face="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#aop3411.htm##
01195000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704095300084002001201037#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#34#30#article#218#<p><font si
ze="2" face="Verdana">O estudo baseou&#45;se numa an&aacute;lise retrospectiva  
   de dados coletados prospectivamente do estudo (MASS&#45;II) Hueb e cols.<SUP>
19</SUP>,     com 05 anos de seguimento. MASS refere&#45;se a sigla de <I>Medici
ne, Angioplasty     or Surgery Study</I>, cujo objetivo era avaliar, randomicame
nte, o tratamento     de portadores de coronariopatia est&aacute;vel multiarteri
al e fun&ccedil;&atilde;o     ventricular preservada. O modelo do estudo, crit&e
acute;rios de sele&ccedil;&atilde;o     e procedimentos de randomiza&ccedil;&ati
lde;o foram previamente publicados<SUP>20</SUP>.     O estudo foi aprovado pelo 
comit&ecirc; cient&iacute;fico e de &eacute;tica     e todos assinaram um consen
timento livre e esclarecido. Todos os TE foram     realizados em esteira rolante
 Fukuda Denshi STAR ML&#45; 8000, com 15 deriva&ccedil;&otilde;es     simult&aci
rc;neas e protocolo de Bruce<SUP>21</SUP>.</font></p>     ^cY#aop3411.htm##
00724000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048200084002001200566#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#35#31#article#218#<p><font si
ze="2" face="Verdana">Inicialmente, foram selecionados 611 pacientes,     sendo 
que 18 pacientes n&atilde;o realizaram o TE por motivos sociais, 58     tiveram 
o TE considerado como inconclusivo (presen&ccedil;a de bloqueio de     ramo esqu
erdo, fibrila&ccedil;&atilde;o atrial e sobrecarga ventricular esquerda)     e e
m 163 pacientes, o exame foi considerado ineficaz, por n&atilde;o atingir     a 
frequ&ecirc;ncia card&iacute;aca subm&aacute;xima. </font></p>     ^cY#aop3411.h
tm##
00821000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704057900084002001200663#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#36#32#article#218#<p><font si
ze="2" face="Verdana">Assim, a amostra final deste estudo incluiu     372 pacien
tes, todos com confirma&ccedil;&atilde;o cinecoronariogr&aacute;fica     de doen
&ccedil;a bi ou triarterial e fun&ccedil;&atilde;o ventricular esquerda     pres
ervada, sendo 267 homens (71,8%), com idade m&eacute;dia de 59,5 (&plusmn; 9,07)
     anos, distribu&iacute;dos em tr&ecirc;s grupos: angioplastia transluminal  
   coron&aacute;ria (ATC) 34,4%, cirurgia de revasculariza&ccedil;&atilde;o     
mioc&aacute;rdica (RM) 34,9% e tratamento cl&iacute;nico (TC) 30,6%.</font></p> 
    ^cY#aop3411.htm##
00602000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704036000084002001200444#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#37#33#article#218#<p><font si
ze="2" face="Verdana">O delineamento do estudo permitiu aos pacientes     uma tr
ansloca&ccedil;&atilde;o entre os diversos grupos de tratamento, baseados     na
 ocorr&ecirc;ncia de sintomas, em qualquer &eacute;poca do estudo. N&atilde;o   
  houve distin&ccedil;&atilde;o nos tipos de medicamentos entre os tr&ecirc;s   
  grupos.</font></p>     ^cY#aop3411.htm##
00340000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009800084002001200182#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#38#34#article#218#<p><font si
ze="2" face="Verdana">Os crit&eacute;rios de inclus&atilde;o foram:</font></p>  
   ^cY#aop3411.htm##
00320000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007800084002001200162#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#39#35#article#218#<p><font si
ze="2" face="Verdana">1. Angina est&aacute;vel.</font></p>     ^cY#aop3411.htm##
00500000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704025800084002001200342#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#40#36#article#218#<p><font si
ze="2" face="Verdana">2. Fra&ccedil;&atilde;o de eje&ccedil;&atilde;o     do ven
tr&iacute;culo esquerdo (FEVE) considerada normal, avaliada pelo ecodopplercardi
ograma     atrav&eacute;s do m&eacute;todo &aacute;rea comprimento.</font></p>  
   ^cY#aop3411.htm##
00530000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704028800084002001200372#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#41#37#article#218#<p><font si
ze="2" face="Verdana">3. Confirma&ccedil;&atilde;o angiogr&aacute;fica     de DA
C bi ou triarterial, com documenta&ccedil;&atilde;o de obstru&ccedil;&atilde;o  
   luminal de pelo menos 70%, considerando&#45;se somente ramos coron&aacute;rio
s     principais.</font></p>     ^cY#aop3411.htm##
00346000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010400084002001200188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#42#38#article#218#<p><font si
ze="2" face="Verdana">Crit&eacute;rios de n&atilde;o&#45;inclus&atilde;o:</font>
</p>     ^cY#aop3411.htm##
00310000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704006800084002001200152#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#43#39#article#218#<p><font si
ze="2" face="Verdana">1. Valvopatias.</font></p>     ^cY#aop3411.htm##
00338000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009600084002001200180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#44#40#article#218#<p><font si
ze="2" face="Verdana">2. Aneurisma do ventr&iacute;culo esquerdo.</font></p>    
 ^cY#aop3411.htm##
00343000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010100084002001200185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#45#41#article#218#<p><font si
ze="2" face="Verdana">3. Disfun&ccedil;&atilde;o ventricular esquerda.</font></p
>     ^cY#aop3411.htm##
00348000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010600084002001200190#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#46#42#article#218#<p><font si
ze="2" face="Verdana">4. Acidente vascular encef&aacute;lico pr&eacute;vio.</fon
t></p>     ^cY#aop3411.htm##
00732000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704049000084002001200574#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#47#43#article#218#<p><font si
ze="2" face="Verdana">5. Limita&ccedil;&atilde;o de an&aacute;lise     morfol&oa
cute;gica para defini&ccedil;&atilde;o de isquemia mioc&aacute;rdica     no elet
rocardiograma: s&iacute;ndrome de pr&eacute;&#45;excita&ccedil;&atilde;o     ven
tricular, bloqueio de ramo esquerdo al&eacute;m de outros dist&uacute;rbios     
da condu&ccedil;&atilde;o intraventricular, sobrecarga ventricular esquerda,    
 estimula&ccedil;&atilde;o card&iacute;aca artificial, etc.</font></p>     ^cY#a
op3411.htm##
00346000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704010400084002001200188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#48#44#article#218#<p><font si
ze="2" face="Verdana">6. Incapacidade f&iacute;sica de qualquer natureza.</font>
</p>     ^cY#aop3411.htm##
00363000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704012100084002001200205#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#49#45#article#218#<p><font si
ze="2" face="Verdana"><b>Escore cl&iacute;nico simplificado ou escore       de H
ubbard</b></font></p>     ^cY#aop3411.htm##
00919000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704067700084002001200761#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#50#46#article#218#<p><font si
ze="2" face="Verdana">O escore de Hubbard e cols.<SUP>10</SUP> foi     validado 
retrospectivamente em uma popula&ccedil;&atilde;o consecutiva e     sintom&aacut
e;tica, submetida &agrave; investiga&ccedil;&atilde;o de coronariopatia,     atr
av&eacute;s de cintilografia mioc&aacute;rdica e cinecoronariografia em     at&e
acute; 6 meses. Atrav&eacute;s da an&aacute;lise de regress&atilde;o     log&iac
ute;stica, selecionaram&#45;se 5 vari&aacute;veis, compondo um escore     de 5 p
ontos que fornecia estimativas de coronariopatia severa, demonstrando     que a 
gravidade da doen&ccedil;a aumenta em fun&ccedil;&atilde;o da pontua&ccedil;&ati
lde;o.</font></p>     ^cY#aop3411.htm##
00767000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052500084002001200609#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#51#47#article#218#<p><font si
ze="2" face="Verdana">Tal escore resulta da soma de 1 ponto para cada     par&ac
irc;metro: sexo masculino, hist&oacute;ria de infarto do mioc&aacute;rdio     e/
ou ondas Q no eletrocardiograma, angina t&iacute;pica, diabete, uso de     insul
ina e ainda pontua conforme a faixa et&aacute;ria. At&eacute; 39 anos     n&atil
de;o se adiciona pontos, de 40 a 49 anos soma&#45;se 1 ponto, 50 a 59 anos,     
2 pontos, 60 a 69 anos, 3 pontos, 70 a 79 anos, 4 pontos e <u>&gt;</u> 80     an
os, 5 pontos. </font></p>     ^cY#aop3411.htm##
00482000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024000084002001200324#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#52#48#article#218#<p><font si
ze="2" face="Verdana">O escore varia de zero a 10 pontos, estimando     a probab
ilidade de coronariopatia em 3 grupos: alta (&gt; 5 pontos), intermedi&aacute;ri
a     (igual a 5 pontos) e baixa (&lt; 5 pontos).</font></p>     ^cY#aop3411.htm
##
00332000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009000084002001200174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#53#49#article#218#<p><font si
ze="2" face="Verdana"><b>Desenvolvimento do novo escore</b></font></p>     ^cY#a
op3411.htm##
00892000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704065000084002001200734#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#54#50#article#218#<p><font si
ze="2" face="Verdana">O novo escore foi estruturado a partir da somat&oacute;ria
     simples das vari&aacute;veis do escore de Hubbard e cols.<SUP>10</SUP>, inc
orporando     tamb&eacute;m o resultado do TE. Quando o TE resultava positivo, a
dicionou&#45;se     1 ponto. TE negativo n&atilde;o determinou pontua&ccedil;&at
ilde;o adicional.     Assim, a pontua&ccedil;&atilde;o total do novo escore vari
ou de 0 a 11 pontos     conforme ilustra a <a href="#tab01">tabela 1</a>. O valo
r de corte considerado     para alto risco de eventos e &oacute;bito foi de 6 po
ntos, ap&oacute;s an&aacute;lise     da curva de sobrevida.</font></p>     ^cY#a
op3411.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#55#51#article#218#<p><a name=
"tab01"></a></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#56#52#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#57#53#article#218#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop34tb1.jpg"></p>     ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#58#54#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00788000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704054600084002001200630#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#59#55#article#218#<p><font si
ze="2" face="Verdana">Foi considerado teste positivo a presen&ccedil;a     de de
press&atilde;o do segmento ST <u>&gt;</u> 1 mm, de morfologia horizontal     ou 
descendente, durante ou ap&oacute;s o exerc&iacute;cio, sendo a magnitude     do
 desn&iacute;vel aferida a 80 ms do ponto J; ou presen&ccedil;a de eleva&ccedil;
&atilde;o     do segmento ST <u>&gt;</u> 1,0 mm em deriva&ccedil;&otilde;es sem 
ondas Q     patol&oacute;gicas, seguindo as recomenda&ccedil;&otilde;es das dire
trizes     sobre TE<SUP>1,22</SUP>.</font></p>     ^cY#aop3411.htm##
00627000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038500084002001200469#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#60#56#article#218#<p><font si
ze="2" face="Verdana">O resultado positivo foi considerado como a     prova docu
mental da isquemia mioc&aacute;rdica, adicionando um ponto no novo     escore pr
ogn&oacute;stico. O resultado negativo foi considerado como aus&ecirc;ncia     d
e documenta&ccedil;&atilde;o de isquemia mioc&aacute;rdica e sem valor progn&oac
ute;stico     adicional no escore.</font></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#61#57#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00335000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704009300084002001200177#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#62#58#article#218#<p><font si
ze="3" face="Verdana"><b>An&aacute;lise estat&iacute;stica</b></font></p>     ^c
Y#aop3411.htm##
00768000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704052600084002001200610#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#63#59#article#218#<p><font si
ze="2" face="Verdana">A associa&ccedil;&atilde;o entre o novo escore     e cada 
um dos desfechos foi analisada pela regress&atilde;o de Cox<SUP>23</SUP>,     in
clusive para identificar subgrupos de alto risco. A curva de sobrevida     cardi
ovascular foi gerada de acordo com m&eacute;todo de Kaplan&#45;Meier<SUP>24</SUP
> e     o teste Log&#45;Rank aplicado para comparar essas curvas de sobrevida. P
ara todas     as an&aacute;lises uma p &lt; 0,05 foi considerada estatisticament
e significante.</font></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#64#60#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00312000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704007000084002001200154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#65#61#article#218#<p><font si
ze="3" face="Verdana"><b>Resultados</b></font></p>     ^cY#aop3411.htm##
00553000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704031100084002001200395#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#66#62#article#218#<p><font si
ze="2" face="Verdana">Dos 372 pacientes estudados, 156 pacientes tinham     hist
&oacute;ria de infarto do mioc&aacute;rdio, 334 apresentavam angina pelo     men
os classe funcional II, 137 (36,8%) eram diab&eacute;ticos, sendo 16 (0,11%)    
 usu&aacute;rios regulares de insulina. </font></p>     ^cY#aop3411.htm##
00591000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704034900084002001200433#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#67#63#article#218#<p><font si
ze="2" face="Verdana">Durante o per&iacute;odo total de seguimento,     observar
am&#45;se 29 epis&oacute;dios de infarto do mioc&aacute;rdio n&atilde;o&#45;fata
l,     sendo 11 no grupo ATC, 6 no grupo RM e 12 no grupo TC, sendo essa diferen
&ccedil;a     entre os grupos considerada n&atilde;o significativa (p = 0,21).</
font></p>     ^cY#aop3411.htm##
00568000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704032600084002001200410#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#68#64#article#218#<p><font si
ze="2" face="Verdana">Com rela&ccedil;&atilde;o &agrave; necessidade     de RM a
p&oacute;s a randomiza&ccedil;&atilde;o, observaram&#45;se 06 casos no     grupo
 ATC, 2 casos no grupo RM e 16 casos no grupo TC, sendo essa diferen&ccedil;a   
  entre os grupos considerada significante (p = 0,001).</font></p>     ^cY#aop34
11.htm##
00538000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704029600084002001200380#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#69#65#article#218#<p><font si
ze="2" face="Verdana">A necessidade de ATC ap&oacute;s a randomiza&ccedil;&atild
e;o     foi observada em 18 casos no grupo ATC, 03 casos no grupo RM e em 04 cas
os     no grupo TC, sendo essa diferen&ccedil;a entre os grupos considerada sign
ificante     (p = 0,001).</font></p>     ^cY#aop3411.htm##
00636000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704039400084002001200478#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#70#66#article#218#<p><font si
ze="2" face="Verdana">Foram observados 36 &oacute;bitos durante o     seguimento
, sendo 10 no grupo ATC, 15 no grupo RM e em 11 casos no grupo     TC, (p = 0,61
). A incid&ecirc;ncia de &oacute;bito ap&oacute;s a randomiza&ccedil;&atilde;o  
   foi observada em 10 pacientes com escore &lt; 6 pontos e em 26 pacientes     
com escore <u>&gt;</u> 6 pontos (p = 0,07).</font></p>     ^cY#aop3411.htm##
00724000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704048200084002001200566#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#71#67#article#218#<p><font si
ze="2" face="Verdana">O total de eventos combinados foi de 93, com     a seguint
e distribui&ccedil;&atilde;o entre os grupos: 37 no grupo ATC, 23     no grupo R
M e 33 no grupo TC, com diferen&ccedil;a marginalmente significante     (p = 0,0
58). A incid&ecirc;ncia de eventos combinados ap&oacute;s a randomiza&ccedil;&at
ilde;o     foi observada em 34 pacientes com escore &lt; 6 pontos e em 59 pacien
tes     com escore <u>&gt;</u> 6 pontos (p = 0,22).</font></p>     ^cY#aop3411.h
tm##
00628000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704038600084002001200470#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#72#68#article#218#<p><font si
ze="2" face="Verdana">Quando se avaliou a idade, para os diferentes     grupos, 
n&atilde;o se observou diferen&ccedil;a significativa (p = 0,73),     com idade 
m&eacute;dia de 59,75 &plusmn; 9,5 anos para o grupo ATC (127 pacientes),     59
,97 &plusmn; 8,4 anos para o grupo RM (130 pacientes), 59,08 &plusmn; 9,3 anos p
ara o     grupo TC (115 pacientes).</font></p>     ^cY#aop3411.htm##
00489000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704024700084002001200331#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#73#69#article#218#<p><font si
ze="2" face="Verdana">Com rela&ccedil;&atilde;o ao sexo, um escore     inferior 
a 06 pontos foi observado em 97 homens e em 59 mulheres. Escore <u>&gt;</u> 06  
   pontos foi observado em 169 homens e em 47 mulheres. </font></p>     ^cY#aop3
411.htm##
00479000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023700084002001200321#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#74#70#article#218#<p><font si
ze="2" face="Verdana">A necessidade de RM ap&oacute;s a randomiza&ccedil;&atilde
;o     foi observada em 8 pacientes com escore &lt; 6 pontos e em 16 pacientes c
om     escore <u>&gt;</u> 6 pontos (p = 0,37).</font></p>     ^cY#aop3411.htm##
00481000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704023900084002001200323#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#75#71#article#218#<p><font si
ze="2" face="Verdana">A necessidade de ATC ap&oacute;s a randomiza&ccedil;&atild
e;o     foi observada em 12 pacientes com escore &lt; 6 pontos e em 13 pacientes
     com escore <u>&gt;</u> 6 pontos (p = 0,52).</font></p>     ^cY#aop3411.htm#
#
00571000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704032900084002001200413#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#76#72#article#218#<p><font si
ze="2" face="Verdana">A an&aacute;lise pela curva de sobrevida demonstrou     qu
e houve diferen&ccedil;a marginalmente significante na incid&ecirc;ncia     de e
ventos combinados para os pacientes com escore de Hubbard &lt; 5 ou <u>&gt;</u> 
5     pontos (p = 0,062), (<a href="#fig01">Figura 1</a>).</font></p>     ^cY#ao
p3411.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#77#73#article#218#<p><a name=
"fig01"></a></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#78#74#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#79#75#article#218#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop34fg1.jpg"></p>     ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#80#76#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00615000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704037300084002001200457#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#81#77#article#218#<p><font si
ze="2" face="Verdana">Quando se avaliou a incid&ecirc;ncia de eventos     combin
ados para o novo escore, houve diferen&ccedil;a estatisticamente significante   
  (p = 0,02) entre os pacientes com escore &lt; 6 e <u>&gt;</u> 6 pontos, confor
me     ilustram as respectivas curvas comparativas de sobrevida da <a href="#fig
02">figura     2</a>. </font></p>     ^cY#aop3411.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#82#78#article#218#<p><a name=
"fig02"></a></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#83#79#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#84#80#article#218#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop34fg2.jpg"></p>     ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#85#81#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00667000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704042500084002001200509#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#86#82#article#218#<p><font si
ze="2" face="Verdana">A incid&ecirc;ncia de &oacute;bito cardiovascular     foi 
maior nos pacientes com escore <u>&gt;</u> 5 pontos pelo escore de Hubbard     (
p = 0,015), <a href="#fig03">figura 3</a>. A diferen&ccedil;a na incid&ecirc;nci
a     de &oacute;bito foi mais significante entre os pacientes com escore &lt; 6
     e <u>&gt;</u> 6 pontos, com p = 0,004, <a href="#fig04">figura 4</a>.</font
></p>     ^cY#aop3411.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#87#83#article#218#<p><a name=
"fig03"></a></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#88#84#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#89#85#article#218#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop34fg3.jpg"></p>     ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#90#86#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#91#87#article#218#<p><a name=
"fig04"></a></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#92#88#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#93#89#article#218#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop34fg4.jpg"></p>     ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#94#90#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
01147000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704090500084002001200989#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#95#91#article#218#<p><font si
ze="2" face="Verdana">Comparando os dois escores, observou&#45;se que     31 pac
ientes foram classificados com alto risco pelo escore de Hubbard, mas,     consi
derados como baixo risco pelo novo escore. Nenhum indiv&iacute;duo de     baixo 
risco pelo escore de Hubbard foi classificado como de alto risco no     novo esc
ore, conforme ilustra a <a href="#tab02">tabela 2</a>. A diferen&ccedil;a     da
 classifica&ccedil;&atilde;o de risco entre os escores foi considerada     estat
isticamente significante (p = 0,001). Do total de pacientes analisados,     247 
(66,4%) apresentaram escore de Hubbard <u>&gt;</u> 5 pontos e 216 (58%) <u>&gt;<
/u> 6     pontos, como demonstra a <a href="#tab02">tabela 2</a>. O valor de cor
te <u>&gt;</u> 5     ou <u>&gt;</u> 6 pontos identificou indiv&iacute;duos de ma
ior risco de &oacute;bito,     com p = 0,015 e p = 0,004, respectivamente.</font
></p>     ^cY#aop3411.htm##
00278000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704003600084002001200120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#96#92#article#218#<p><a name=
"tab02"></a></p>     ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#97#93#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00326000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704008400084002001200168#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#98#94#article#218#<p align="c
enter"><img src="/img/revistas/abc/2011nahead/aop34tb2.jpg"></p>     ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000030
0066701000300069709000800072708000400080704002200084002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#99#95#article#218#<p>&nbsp;</
p>     ^cY#aop3411.htm##
00508000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704026500085002001200350#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#100#96#article#218#<p><font s
ize="2" face="Verdana">Em rela&ccedil;&atilde;o ao desfecho prim&aacute;rio,    
 a an&aacute;lise da curva de sobrevida n&atilde;o demonstrou diferen&ccedil;a  
   entre os tr&ecirc;s grupos de tratamento, <a href="#fig05">figura 5</a>.</fon
t></p>     ^cY#aop3411.htm##
00279000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704003600085002001200121#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#101#97#article#218#<p><a name
="fig05"></a></p>     ^cY#aop3411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704002200085002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#102#98#article#218#<p>&nbsp;<
/p>     ^cY#aop3411.htm##
00327000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000300070709000800073708000400081704008400085002001200169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#103#99#article#218#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop34fg5.jpg"></p>     ^cY#aop341
1.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#104#100#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00631000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704038700086002001200473#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#105#101#article#218#<p><font 
size="2" face="Verdana">Em rela&ccedil;&atilde;o &agrave; incid&ecirc;ncia     d
e &oacute;bito e escore de Hubbard <u>&gt;</u> 5, observaram&#45;se 15 &oacute;b
itos     no grupo ATC, 12 no grupo RM e 10 no grupo TC, (p = 0,59), enquanto que
 com     escore &lt; 5 pontos, observamos 1 &oacute;bito no grupo ATC, 5 no grup
o     RM e 3 no grupo TC (p = 0,176). </font></p>     ^cY#aop3411.htm##
00640000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704039600086002001200482#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#106#102#article#218#<p><font 
size="2" face="Verdana">Em rela&ccedil;&atilde;o &agrave; incid&ecirc;ncia     d
e &oacute;bito e novo escore <u>&gt;</u> 6, observaram&#45;se 11 &oacute;bitos  
   no grupo ATC, 7 no grupo RM e 6 no grupo TC, (p = 0,4). Na presen&ccedil;a   
  de novo escore &lt; 6 pontos evidenciaram&#45;se 1 &oacute;bito no grupo ATC, 
    6 no grupo RM e 3 no grupo TC (p = 0,163). </font></p>     ^cY#aop3411.htm##
00791000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704054700086002001200633#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#107#103#article#218#<p><font 
size="2" face="Verdana">Quanto &agrave; ocorr&ecirc;ncia de eventos     combinad
os nos pacientes com escore de Hubbard <u>&gt;</u> 5 pontos, observaram&#45;se  
   33 eventos no grupo ATC, 13 no grupo RM e 23 no grupo TC, com uma incid&ecirc
;ncia     de eventos significantemente reduzida no grupo RM (p &lt; 0,001). A an
&aacute;lise     da incid&ecirc;ncia de eventos combinados nos pacientes com esc
ore de Hubbard &lt; 5     pontos, mostrou 1 evento no grupo ATC, 5 eventos no gr
upo RM e 3 no grupo     TC (p = 0,24).</font></p>     ^cY#aop3411.htm##
00621000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704037700086002001200463#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#108#104#article#218#<p><font 
size="2" face="Verdana">Ao analisar a incid&ecirc;ncia de eventos combinados    
 nos pacientes com novo escore <u>&gt;</u> 6 pontos, observaram&#45;se 24 evento
s     no grupo ATC, 8 no grupo RM e 12 no grupo TC (p = 0,001). Nos pacientes co
m     escore &lt; 6 pontos observamos 9 eventos no grupo ATC, 5 no grupo RM e 9 
    no grupo TC (p = 0,334).</font></p>     ^cY#aop3411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#109#105#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00320000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007600086002001200162#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#110#106#article#218#<p><font 
size="3" face="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#aop3411.htm##
00713000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704046900086002001200555#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#111#107#article#218#<p><font 
size="2" face="Verdana">A avalia&ccedil;&atilde;o progn&oacute;stica &eacute; um
     componente crucial da avalia&ccedil;&atilde;o cl&iacute;nica da DAC. Embora
     os pacientes com angina est&aacute;vel apresentem baixa mortalidade<SUP>25&
#45;27</SUP>,     o risco de infarto do mioc&aacute;rdio, a necessidade de inter
ven&ccedil;&otilde;es     e os sintomas impactam a evolu&ccedil;&atilde;o cl&iac
ute;nica de maneira     representativa. </font></p>     ^cY#aop3411.htm##
00587000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704034300086002001200429#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#112#108#article#218#<p><font 
size="2" face="Verdana">V&aacute;rios escores foram desenvolvidos para     estra
tifica&ccedil;&atilde;o de DAC adotando&#45;se par&acirc;metros cl&iacute;nicos 
    e do TE ou combinados<SUP>28,29</SUP>, contudo, escores progn&oacute;sticos 
    no portador de angina est&aacute;vel s&atilde;o escassos<SUP>30</SUP>.</font
></p>     ^cY#aop3411.htm##
00600000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704035600086002001200442#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#113#109#article#218#<p><font 
size="2" face="Verdana">A proposta desse estudo foi desenvolver um &iacute;ndice
     para estratifica&ccedil;&atilde;o de risco do coronariopata est&aacute;vel 
    multiarterial, atrav&eacute;s de um m&eacute;todo simples e acess&iacute;vel
,     contrastando com a ampla gama de procedimentos de alto custo dispon&iacute
;veis. </font></p>     ^cY#aop3411.htm##
00750000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704050600086002001200592#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#114#110#article#218#<p><font 
size="2" face="Verdana">Em nossa casu&iacute;stica, a idade m&eacute;dia     de 
59,5 anos, determinou um maior valor inicial do escore. Assim, nossa amostra    
 foi representada por indiv&iacute;duos com uma faixa et&aacute;ria maior,     p
ortanto, com um perfil de maior risco. O predom&iacute;nio masculino na     amos
tra estudada n&atilde;o impactou a interpreta&ccedil;&atilde;o dos resultados   
  devido a documenta&ccedil;&atilde;o de DAC multiarterial em ambos os sexos.</f
ont></p>     ^cY#aop3411.htm##
01062000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704081800086002001200904#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#115#111#article#218#<p><font 
size="2" face="Verdana">A maioria dos homens (63,29%) apresentou escore     <u>&
gt;</u> 6 pontos, enquanto na maioria das mulheres foi observado um escore &lt; 
6 pontos.     A pontua&ccedil;&atilde;o maior para os homens pode estar relacion
ada ao     fato de que o sexo masculino j&aacute; define uma pontua&ccedil;&atil
de;o     adicional. Al&eacute;m disso, infarto do mioc&aacute;rdio &eacute; mais
 comum     em homens, por&eacute;m as mulheres apresentam um progn&oacute;stico 
pior,     devido a maior taxa de &oacute;bito e re&#45;infarto<SUP>31</SUP>. Qua
nto a dor     precordial, embora ela seja mais frequente nas mulheres, a preval&
ecirc;ncia     de DAC significante &eacute; menor, determinando um valor prediti
vo menor     para os testes n&atilde;o&#45;invasivos<SUP>32,33</SUP>.</font></p>
     ^cY#aop3411.htm##
00526000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704028200086002001200368#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#116#112#article#218#<p><font 
size="2" face="Verdana">A an&aacute;lise progn&oacute;stica n&atilde;o     consi
derou a diferen&ccedil;a entre os padr&otilde;es angiogr&aacute;ficos     bi ou 
triarterial devido a um baixo n&uacute;mero de desfechos no per&iacute;odo     d
e seguimento.</font></p>     ^cY#aop3411.htm##
00816000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704057200086002001200658#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#117#113#article#218#<p><font 
size="2" face="Verdana">A taxa de &oacute;bitos (10,33%) em nossa casu&iacute;st
ica     foi superior &agrave; mortalidade geral de pacientes com angina est&aacu
te;vel,     que est&aacute; ao redor de 1% ao ano segundo dados da diretriz sobr
e angina     est&aacute;vel<SUP>33</SUP>. Isto pode ser explicado pela presen&cc
edil;a     de um maior n&uacute;mero de pacientes de alto risco em nosso estudo,
 com     maior preval&ecirc;ncia de multiarteriais e de diab&eacute;ticos, apesa
r     da fun&ccedil;&atilde;o ventricular esquerda preservada. </font></p>     ^
cY#aop3411.htm##
00737000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704049300086002001200579#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#118#114#article#218#<p><font 
size="2" face="Verdana">A incid&ecirc;ncia de eventos combinados e a     necessi
dade de re&#45;interven&ccedil;&atilde;o com angioplastia ap&oacute;s     a rand
omiza&ccedil;&atilde;o foi maior no grupo ATC. Provavelmente, isto     est&aacut
e; relacionado a uma maior taxa de reestenose, j&aacute; que uma     parte repre
sentativa de nossa amostra possui diabete. Taxas maiores de reestenose     s&ati
lde;o comumente encontradas nos diab&eacute;ticos<SUP>34</SUP>. </font></p>     
^cY#aop3411.htm##
00850000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704060600086002001200692#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#119#115#article#218#<p><font 
size="2" face="Verdana">A alta taxa de diab&eacute;ticos (36,8%) determinou     
tamb&eacute;m uma maior pontua&ccedil;&atilde;o inicial no escore. Compat&iacute
;vel     com o fato de que os portadores de diabete possuem maior incid&ecirc;nc
ia     de coronariopatia grave. Est&aacute; bem definido que o diabete &eacute; 
um     fator de risco maior para eventos coron&aacute;rios<SUP>35</SUP>. O diabe
te     tipo 2 &eacute; de particular import&acirc;ncia, pois, &eacute; mais comu
m     e ocorre frequentemente em idosos, quando m&uacute;ltiplos fatores de risc
o     coexistem. </font></p>     ^cY#aop3411.htm##
01050000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704080600086002001200892#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#120#116#article#218#<p><font 
size="2" face="Verdana">Em rela&ccedil;&atilde;o ao TE, os diab&eacute;ticos    
 representam um grupo particularizado: h&aacute; uma maior incid&ecirc;ncia     
de hipertens&atilde;o arterial, vasculopatia perif&eacute;rica, neuropatia     p
erif&eacute;rica, obesidade e menor capacidade funcional. Al&eacute;m disso,    
 est&atilde;o mais expostos ao uso de medicamentos que limitam a frequ&ecirc;nci
a     card&iacute;aca. Assim, quando m&uacute;ltiplos fatores de risco coexistem
,     h&aacute; limita&ccedil;&atilde;o para que se atinja um baixo risco no esc
ore     de Duke. Adicionalmente, o n&iacute;vel de trabalho alcan&ccedil;ado pod
e     n&atilde;o ser suficiente para a documenta&ccedil;&atilde;o de isquemia mi
oc&aacute;rdica,     mesmo com eventual DAC significante.</font></p>     ^cY#aop
3411.htm##
01158000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704091400086002001201000#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#121#117#article#218#<p><font 
size="2" face="Verdana">O escore de Hubbard foi selecionado inicialmente     par
a compor o novo escore, pois, cont&ecirc;m vari&aacute;veis de f&aacute;cil     
avalia&ccedil;&atilde;o. O n&uacute;mero de vari&aacute;veis &eacute; pequeno,  
   a somat&oacute;ria dos pontos &eacute; simplificada e de f&aacute;cil interpr
eta&ccedil;&atilde;o,     possuindo correla&ccedil;&atilde;o linear entre o resu
ltado e o progn&oacute;stico.     Al&eacute;m disso, pode identificar indiv&iacu
te;duos de alto risco, mesmo     quando classificados em baixo risco pelo escore
 de Duke<SUP>36</SUP>. Contudo,     ele possui limita&ccedil;&otilde;es, como a 
an&aacute;lise exclusiva de vari&aacute;veis     cl&iacute;nicas, n&atilde;o con
siderando uma prova documental de isquemia     mioc&aacute;rdica que comprovadam
ente fornece informa&ccedil;&atilde;o progn&oacute;stica     adicional<SUP>37</S
UP>. </font></p>     ^cY#aop3411.htm##
00599000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704035500086002001200441#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#122#118#article#218#<p><font 
size="2" face="Verdana">Ao acrescentar essa vari&aacute;vel na an&aacute;lise,  
   31 pacientes foram classificados como baixo risco pelo novo escore, pois     
apresentavam teste ergom&eacute;trico negativo. Assim, o escore de Hubbard     p
ode ter superestimado o grupo de maior risco na popula&ccedil;&atilde;o     estu
dada. </font></p>     ^cY#aop3411.htm##
01231000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704098700086002001201073#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#123#119#article#218#<p><font 
size="2" face="Verdana">No TE, embora outras vari&aacute;veis como capacidade   
  funcional, arritmias, respostas cronotr&oacute;pica e inotr&oacute;pica,     s
ejam consideradas de maior valor preditivo do que a depress&atilde;o do     segm
ento ST, existe um v&iacute;cio de interpreta&ccedil;&atilde;o dos v&aacute;rios
     estudos. N&atilde;o se considerou que na pr&aacute;tica cl&iacute;nica um  
   TE positivo acaba implicando na indica&ccedil;&atilde;o de estudo cineangioco
ronariogr&aacute;fico     e, consequentemente, de tratamento farmacol&oacute;gic
o ou procedimentos     de revasculariza&ccedil;&atilde;o mioc&aacute;rdica (cir&
uacute;rgica ou     percut&acirc;nea). Tais interven&ccedil;&otilde;es terap&eci
rc;uticas determinam     uma altera&ccedil;&atilde;o na evolu&ccedil;&atilde;o n
atural da doen&ccedil;a     coron&aacute;ria que impacta no valor progn&oacute;s
tico do marcador eletrocardiogr&aacute;fico     de isquemia mioc&aacute;rdica.</
font></p>     ^cY#aop3411.htm##
00802000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704055800086002001200644#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#124#120#article#218#<p><font 
size="2" face="Verdana">A an&aacute;lise progn&oacute;stica do novo     escore n
&atilde;o incorporou essas in&uacute;meras vari&aacute;veis espec&iacute;ficas  
   do TE, adotando somente a presen&ccedil;a de documenta&ccedil;&atilde;o eletr
ocardiogr&aacute;fica     de isquemia mioc&aacute;rdica, pois o objetivo foi apl
icar um sistema pr&aacute;tico,     de f&aacute;cil memoriza&ccedil;&atilde;o e 
interpreta&ccedil;&atilde;o,     para que ele seja mais amplamente aceito tanto 
pelo cl&iacute;nico quanto     pelo especialista.</font></p>     ^cY#aop3411.htm
##
00567000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704032300086002001200409#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#125#121#article#218#<p><font 
size="2" face="Verdana">Com o uso de escores progn&oacute;sticos simplificados  
   aplicados em associa&ccedil;&atilde;o ao TE podemos estratificar de forma    
 mais acurada o coronariopata est&aacute;vel, reduzindo a taxa de solicita&ccedi
l;&atilde;o     de procedimentos de alta complexidade.</font></p>     ^cY#aop341
1.htm##
00791000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704054700086002001200633#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#126#122#article#218#<p><font 
size="2" face="Verdana">Escores melhoram a acur&aacute;cia progn&oacute;stica   
  do TE, diminuem v&iacute;cios de interpreta&ccedil;&atilde;o e organizam     a
s diversas informa&ccedil;&otilde;es cl&iacute;nicas, determinando uma redu&cced
il;&atilde;o     na subjetividade e na variabilidade da estratifica&ccedil;&atil
de;o de risco.     Particularmente, o escore proposto por este estudo demonstrou
 seu valor progn&oacute;stico     de forma abrangente, atrav&eacute;s de uma sis
tem&aacute;tica simples e organizada. </font></p>     ^cY#aop3411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#127#123#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00321000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007700086002001200163#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#128#124#article#218#<p><font 
size="3" face="Verdana"><b>Conclus&otilde;es</b></font></p>     ^cY#aop3411.htm#
#
00438000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704019400086002001200280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#129#125#article#218#<p><font 
size="2" face="Verdana">Este novo escore &eacute; um m&eacute;todo objetivo     
e simples para estratifica&ccedil;&atilde;o de risco do coronariopata est&aacute
;vel.</font></p>     ^cY#aop3411.htm##
00336000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704009200086002001200178#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#130#126#article#218#<p><font 
size="2" face="Verdana"><b>Potencial Conflito de Interesses</b></font></p>     ^
cY#aop3411.htm##
00361000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704011700086002001200203#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#131#127#article#218#<p><font 
size="2" face="Verdana">Declaro n&atilde;o haver conflito de interesses     pert
inentes.</font></p>     ^cY#aop3411.htm##
00327000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704008300086002001200169#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#132#128#article#218#<p><font 
size="2" face="Verdana"><b>Fontes de Financiamento</b></font></p>     ^cY#aop341
1.htm##
00368000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704012400086002001200210#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#133#129#article#218#<p><font 
size="2" face="Verdana">O presente estudo n&atilde;o teve fontes de     financia
mento externas.</font></p>     ^cY#aop3411.htm##
00344000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704010000086002001200186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#134#130#article#218#<p><font 
size="2" face="Verdana"><b>Vincula&ccedil;&atilde;o Acad&ecirc;mica</b></font></
p>     ^cY#aop3411.htm##
00402000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704015800086002001200244#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#135#131#article#218#<p><font 
size="2" face="Verdana">Este artigo &eacute; parte de tese de doutorado     de F
ernanda Coutinho Storti pelo InCor &#45; HCFMUSP.</font></p>     ^cY#aop3411.htm
##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#136#132#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00321000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704007700086002001200163#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#137#133#article#218#<p><font 
size="3" face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#aop3411.htm#
#
00845000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704058700088002001200675#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#138#134#article#2
18#1#<p><font size="2" face="Verdana">1. Gibbons RJ, Balady GJ, Bricker JT, Chai
tman     BR, Fletcher GF, Froelicher VF, Mark DB, et al. American College of Car
diology/American     Heart Association Task Force on Practice Guidelines (Commit
tee to Update     the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline 
update for     exercise testing: summary article: a report of the American Colle
ge of Cardiology/American     Heart Association Task Force on Practice Guideline
s (Committee to Update     the 1997 Exercise Testing Guidelines). Circulation. 2
002;106(14):1883&#45;92.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#139#135#article#218#</font></
p>     ^cY#aop3411.htm##
00466000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020800088002001200296#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#140#136#article#2
18#2#<p><font size="2" face="Verdana">2. Diamond GA, Forrester JS. Analysis of  
   probability as an aid in the clinical diagnosis of coronary&#45;artery diseas
e.     N Engl J Med. 1979;300(24):1350&#45;8.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#141#137#article#218#</font></
p>     ^cY#aop3411.htm##
00564000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704030600088002001200394#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#142#138#article#2
18#3#<p><font size="2" face="Verdana">3. Morise AP, Jalisi F. Evaluation of pret
est     and exercise test scores to assess all&#45;cause mortality in unselected
 patients     presenting for exercise testing with symptoms of suspected coronar
y artery     disease. J Am Coll Cardiol. 2003;42(5):842&#45;50.    ^cY#aop3411.h
tm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#143#139#article#218#</font></
p>     ^cY#aop3411.htm##
00413000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704015500088002001200243#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#144#140#article#2
18#4#<p><font size="2" face="Verdana">4. Ashley EA, Myers J, Froelicher V. Exerc
ise     testing in clinical medicine. Lancet. 2000;356(9241):1592&#45;7.    ^cY#
aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#145#141#article#218#</font></
p>     ^cY#aop3411.htm##
00448000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704019000088002001200278#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#146#142#article#2
18#5#<p><font size="2" face="Verdana">5. Froelicher V, Shetler K, Ashley E. Bett
er     decisions through science: exercise testing scores. Prog Cardiovasc Dis. 
    2002;44(5):395&#45;414.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#147#143#article#218#</font></
p>     ^cY#aop3411.htm##
00579000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704032100088002001200409#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#148#144#article#2
18#6#<p><font size="2" face="Verdana">6. Morise AP, Detrano R, Bobbio M, Diamond
     GA. Development and validation of a logistic regression&#45;derived algorit
hm     for estimating the incremental probability of coronary artery disease bef
ore     and after exercise testing. J Am Coll Cardiol. 1992;20(5):1187&#45;96.  
  ^cY#aop3411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#149#145#article#218# </font><
/p>     ^cY#aop3411.htm##
00487000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704022900088002001200317#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#150#146#article#2
18#7#<p><font size="2" face="Verdana">7. Mark DB, Mark AH, Harrell FE, Lee KL,  
   Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in    
 coronary artery disease. Ann Intern Med. 1987;106(6):793&#45;800.    ^cY#aop341
1.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#151#147#article#218#</font></
p>     ^cY#aop3411.htm##
00458000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704020000088002001200288#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#152#148#article#2
18#8#<p><font size="2" face="Verdana">8. Raxwal V, Shetler K, Morise A, Do D, My
ers     J, Atwood JE, et al. Simple treadmill score to diagnose coronary disease
.     Chest. 2001;119(6):1933&#45;40.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#153#149#article#218#</font></
p>     ^cY#aop3411.htm##
00490000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000200086704023200088002001200320#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#154#150#article#2
18#9#<p><font size="2" face="Verdana">9. Do D, West JA, Morise A, Atwood E, Froe
licher     V. A consensus approach to diagnosing coronary artery disease based o
n clinical     and exercise test data. Chest. 1997;111(6):1742&#45;9.    ^cY#aop
3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#155#151#article#218#</font></
p>     ^cY#aop3411.htm##
00504000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024500089002001200334#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#156#152#article#2
18#10#<p><font size="2" face="Verdana">10. Hubbard BL, Gibbons RJ, Lapeyre AC 3r
d,     Zinsmeister AR, Clements IP. Identification of severe coronary artery dis
ease     using simple clinical parameters. Arch Intern Med. 1992;152(2):309&#45;
12.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#157#153#article#218#</font></
p>     ^cY#aop3411.htm##
00533000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704027400089002001200363#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#158#154#article#2
18#11#<p><font size="2" face="Verdana">11. Morrow K, Morris CK, Froelicher VF, H
ideg     A, Hunter D, Johnson E, et al. Prediction of cardiovascular death in me
n     undergoing noninvasive evaluation for coronary artery disease. Ann Intern 
    Med. 1993;118(9):689&#45;95.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#159#155#article#218#</font></
p>     ^cY#aop3411.htm##
00566000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030700089002001200396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#160#156#article#2
18#12#<p><font size="2" face="Verdana">12. Detrano R, Bobbio M, Olson H, Shandli
ng     A, Ellestad MH, Alegria E, et al. Computer probability estimates of angio
graphic     coronary artery disease: transportability and comparison with cardio
logist's     estimates. Comput Biomed Res. 1992;25(5):468&#45;85.    ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#161#157#article#218#</font></
p>     ^cY#aop3411.htm##
00466000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704020700089002001200296#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#162#158#article#2
18#13#<p><font size="2" face="Verdana">13. Lu ZY, Haus S. Evaluation of exercise
&#45;induced     QRS amplitude changes (Athens score) and their clinical value. 
J Tongji Med     Univ. 1993;13(3):177&#45;82.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#163#159#article#218#</font></
p>     ^cY#aop3411.htm##
00695000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704043600089002001200525#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#164#160#article#2
18#14#<p><font size="2" face="Verdana">14. Villella M, Villella A, Santoro L, Sa
ntoro     E, Franzosi MG, Maggioni AP, et al. Ergometric score systems after myo
cardial     infarction: prognostic performance of the Duke Treadmill Score, Vete
rans     Administration Medical Center Score, and of a novel score system, GISSI
&#45;2     Index, in a cohort of survivors of acute myocardial infarction. Am He
art     J. 2003;145(3):475&#45;83.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#165#161#article#218#</font></
p>     ^cY#aop3411.htm##
00516000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025700089002001200346#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#166#162#article#2
18#15#<p><font size="2" face="Verdana">15. Koide Y, Yotsukura M, Yoshino H, Ishi
kawa     K. A new coronary artery disease index of treadmill exercise electrocar
diograms     based on the step&#45;up diagnostic method. Am J Cardiol. 2001;15;8
7(2):142&#45;7.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#167#163#article#218#</font></
p>     ^cY#aop3411.htm##
00511000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025200089002001200341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#168#164#article#2
18#16#<p><font size="2" face="Verdana">16. Hollenberg M, Budge WR, Wisneski JA, 
    Gertz EW. Treadmill score quantifies electrocardiographic response to exerci
se     and improves test accuracy and reproducibility. Circulation. 1980;61(2):2
76&#45;85.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#169#165#article#218#</font></
p>     ^cY#aop3411.htm##
00527000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026800089002001200357#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#170#166#article#2
18#17#<p><font size="2" face="Verdana">17. Mark DB, Shaw L, Harrell FE Jr, Hlatk
y     MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise  
   score in outpatients with suspected coronary artery disease. N Engl J Med.   
  1991;325(12):849&#45;53.    ^cY#aop3411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#171#167#article#218# </font><
/p>     ^cY#aop3411.htm##
00589000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704033000089002001200419#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#172#168#article#2
18#18#<p><font size="2" face="Verdana">18. Ho KT, Miller TD, Hodge DO, Bailey KR
,     Gibbons RJ. Use of a simple clinical score to predict prognosis of patient
s     with normal or mildly abnormal resting electrocardiographic findings under
going     evaluation for coronary artery disease. Mayo Clin Proc. 2002;77(6):515
&#45;21.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#173#169#article#218#</font></
p>     ^cY#aop3411.htm##
00677000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704041800089002001200507#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#174#170#article#2
18#19#<p><font size="2" face="Verdana">19. Soares PR, Hueb WA, Lemos PA, Lopes N
,     Martinez EE, Cesar LA, et al. Coronary revascularization (surgical or perc
utaneous)     decreases mortality after the first year in diabetic subjects but 
not in     nondiabetic subjects with multivessel disease: an analysis from the M
edicine,     Angioplasty, or Surgery Study (MASS II). Circulation. 2006;114(1 Su
ppl):I420&#45;4.    ^cY#aop3411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#175#171#article#218# </font><
/p>     ^cY#aop3411.htm##
00640000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704038100089002001200470#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#176#172#article#2
18#20#<p><font size="2" face="Verdana">20. Hueb WA, Bellotti G, Oliveira SA, Ari
e     S, Albuquerque CP, Jatene AD, et al. The Medicine, Angioplasty or Surgery 
    Study (MASS): a prospective, randomized trial of medical therapy, balloon   
  angioplasty or bypass surgery for single proximal left anterior descending    
 artery stenoses. J Am Coll Cardiol. 1995;26(7):1600&#45;5.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#177#173#article#218#</font></
p>     ^cY#aop3411.htm##
00450000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019100089002001200280#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#178#174#article#2
18#21#<p><font size="2" face="Verdana">21. Bruce RA. Evaluation of functional ca
pacity     and exercise tolerance of cardiac patients. Mod Concepts Cardiovasc D
is.     1956;25(4):321&#45;6.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#179#175#article#218#</font></
p>     ^cY#aop3411.htm##
00528000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026900089002001200358#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#180#176#article#2
18#22#<p><font size="2" face="Verdana">22. Brito FS, Vilas&#45;Boas F, Castro I,
 Oliveira     J&Aacute;, Guimar&atilde;es JI, Stein R/ Sociedade Brasileira de C
ardiologia.     II Diretriz sobre teste ergom&eacute;trico. Arq Bras Cardiol. 20
02;78(supl     2):1&#45;18.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#181#177#article#218#</font></
p>     ^cY#aop3411.htm##
00406000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704014700089002001200236#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#182#178#article#2
18#23#<p><font size="2" face="Verdana">23. Cox DR. Regression models and life&#4
5;tables.     J R Stat Soc Ser B Metodol. 1972;34(2):187&#45;220.    ^cY#aop3411
.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#183#179#article#218#</font></
p>     ^cY#aop3411.htm##
00415000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704015600089002001200245#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#184#180#article#2
18#24#<p><font size="2" face="Verdana">24. Kaplan EL, Meier P. Nonparametric est
imation     from incomplete observations. Am Stat Soc. 1958;53:457&#45;81.    ^c
Y#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#185#181#article#218#</font></
p>     ^cY#aop3411.htm##
00600000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704034100089002001200430#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#186#182#article#2
18#25#<p><font size="2" face="Verdana">25. Yusuf S, Sleight P, Pogue J, Bosch J,
     Davies R, Dagenais G. Effects of an angiotensin&#45;converting&#45;enzyme i
nhibitor,     ramipril, on cardiovascular events in high&#45;risk patients: the 
heart outcomes     prevention evaluation study investigators. N Engl J Med. 2000
;342(3):145&#45;53.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#187#183#article#218#</font></
p>     ^cY#aop3411.htm##
00563000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704030400089002001200393#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#188#184#article#2
18#26#<p><font size="2" face="Verdana">26. Fox KM. Efficacy of perindopril in re
duction     of cardiovascular events among patients with stable coronary artery 
disease:     randomised, double&#45;blind, placebo&#45;controlled, multicentre t
rial (the EUROPA     study). Lancet. 2003;362(9386):782&#45;8.    ^cY#aop3411.ht
m##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#189#185#article#218#</font></
p>     ^cY#aop3411.htm##
00614000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704035500089002001200444#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#190#186#article#2
18#27#<p><font size="2" face="Verdana">27. Poole&#45;Wilson PA, Lubsen J, Kirwan
 BA,     van Dalen FJ, Wagener G, Danchin N, et al. Effect of long&#45;acting ni
fedipine     on mortality and cardiovascular morbidity in patients with stable a
ngina     requiring treatment (ACTION trial): randomised controlled trial. Lance
t.     2004;364(9437):849&#45;57.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#191#187#article#218#</font></
p>     ^cY#aop3411.htm##
00473000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704021400089002001200303#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#192#188#article#2
18#28#<p><font size="2" face="Verdana">28. Pryor DB, Shaw L, Harrell FE Jr, Lee 
    KL, Hlatky MA, Mark DB, et al. Estimating the likelihood of severe coronary 
    artery disease. Am J Med. 1991;90(5):553&#45;62.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#193#189#article#218#</font></
p>     ^cY#aop3411.htm##
00541000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028200089002001200371#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#194#190#article#2
18#29#<p><font size="2" face="Verdana">29. Yamada H, Do D, Morise A, Atwood JE, 
    Froelicher V. Review of studies using multivariable analysis of clinical    
 and exercise test data to predict angiographic coronary artery disease. Prog   
  Cardiovasc Dis. 1997;39(5):457&#45;81.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#195#191#article#218#</font></
p>     ^cY#aop3411.htm##
00544000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704028500089002001200374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#196#192#article#2
18#30#<p><font size="2" face="Verdana">30. Prakash M, Myers J, Froelicher VF, Ma
rcus     R, Do D, Kalisetti D, et al. Clinical and exercise test predictors of a
ll&#45;cause     mortality: results from &gt; 6,000 consecutive referred male pa
tients. Chest.     2001;120(3):1003&#45;13.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#197#193#article#218#</font></
p>     ^cY#aop3411.htm##
00449000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704019000089002001200279#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#198#194#article#2
18#31#<p><font size="2" face="Verdana">31. Kannel WB, Sorlie P, McNamara PM. Pro
gnosis     after initial myocardial infarction: the Framingham study. Am J Cardi
ol.     1979;44(1):53&#45;9.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#199#195#article#218#</font></
p>     ^cY#aop3411.htm##
00524000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704026500089002001200354#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#200#196#article#2
18#32#<p><font size="2" face="Verdana">32. Gibbons RJ. Exercise ECG testing with
     and without radionuclide studies. In Wenger NK, Speroff L, Packard B, eds. 
    Cardiovascular health and disease in women. London: Le Jacq Communications; 
    1993. p. 73&#45;80.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#201#197#article#218#</font></
p>     ^cY#aop3411.htm##
00552000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704029300089002001200382#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#202#198#article#2
18#33#<p><font size="2" face="Verdana">33. Mansur AP, Armaganijan D, Amino JG, S
ousa     AC, Sim&atilde;o AF, Brito AX, et al./Sociedade Brasileira de Cardiolog
ia.     Diretriz de doen&ccedil;a coronariana cr&ocirc;nica angina est&aacute;ve
l.     Arq Bras Cardiol. 2004; 83(supl.2):7&#45;40.    ^cY#aop3411.htm##
00265000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002100086002001200107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#203#199#article#218# </font><
/p>     ^cY#aop3411.htm##
00614000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704035500089002001200444#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#204#200#article#2
18#34#<p><font size="2" face="Verdana">34. Singh M, Gersh BJ, McClelland RL, Ho 
    KK, Willerson JT, Penny WF, et al. Clinical and angiographic predictors of  
   restenosis after percutaneous coronary intervention: insights from the Preven
tion     of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulati
on.     2004;109(22):2727&#45;31.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#205#201#article#218#</font></
p>     ^cY#aop3411.htm##
00489000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704023000089002001200319#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#206#202#article#2
18#35#<p><font size="2" face="Verdana">35. Wilson PW, D'Agostino RB, Levy D, Bel
anger     AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease usi
ng     risk factor categories. Circulation. 1998;97(18):1837&#45;47.    ^cY#aop3
411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#207#203#article#218#</font></
p>     ^cY#aop3411.htm##
00511000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704025200089002001200341#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#208#204#article#2
18#36#<p><font size="2" face="Verdana">36. Poornima IG, Miller TD, Christian TF,
     Hodge DO, Bailey KR, Gibbons RJ. Utility of myocardial perfusion imaging   
  in patients with low&#45;risk treadmill scores. J Am Coll Cardiol. 2004;43(2):
194&#45;9.    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#209#205#article#218#</font></
p>     ^cY#aop3411.htm##
00501000000000157000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082888000300086704024200089002001200331#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#210#206#article#2
18#37#<p><font size="2" face="Verdana">37. Mora S, Redberg RF, Sharrett AR, Blum
enthal     RS. Enhanced risk assessment in asymptomatic individuals with exercis
e testing     and Framingham risk scores. Circulation. 2005;112(11):1566&#45;72.
    ^cY#aop3411.htm##
00264000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002000086002001200106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#211#207#article#218#</font></
p>     ^cY#aop3411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#212#208#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#213#209#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00410000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704016600086002001200252#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#214#210#article#218#<p><font 
size="2" face="Verdana"><b><a name="end"></a><a href="#title"><img src="/img/rev
istas/abc/2011nahead/seta.jpg" border="0"></a> Correspond&ecirc;ncia:    ^cY#aop
3411.htm##
00287000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704004300086002001200129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#215#211#article#218#<br>   </
b>Fernanda Coutinho Storti    ^cY#aop3411.htm##
00306000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006200086002001200148#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#216#212#article#218#<BR>   Ru
a Doutor Alberto Torres, 16/61 &#45; Perdizes    ^cY#aop3411.htm##
00312000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704006800086002001200154#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#217#213#article#218#<br>   05
006&#45;030 &#45; S&atilde;o Paulo, SP &#45; Brasil    ^cY#aop3411.htm##
00403000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704015900086002001200245#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#218#214#article#218#<BR>   E&
#45;mail: <a href="mailto:storti@cardiol.br">storti@cardiol.br</a>, <a href="mai
lto:fcstorti@hotmail.com">fcstorti@hotmail.com</a></font></p>     ^cY#aop3411.ht
m##
00381000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704013700086002001200223#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#219#215#article#218#<p><font 
size="2" face="Verdana"> Artigo recebido em 30/05/10; revisado recebido     em 2
2/09/10; aceito em 11/01/11.</font></p>     ^cY#aop3411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#220#216#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00266000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704002200086002001200108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#221#217#article#218#<p>&nbsp;
</p>     ^cY#aop3411.htm##
00420000000000145000450000400110000070200510001170500020006270600020006470000040
0066701000400070709000800074708000400082704017600086002001200262#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop3411.htm#S#p#222#218#article#218#<p><font 
size="2" face="Verdana">Full texts in English &#45; <A href="http://www.arquivos
online.com.br" target="_blank">http://www.arquivosonline.com.br</A></font></p>  
   ^cY#aop3411.htm##
01056000000000361000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100017001030100
01800120010001900138010001900157010002100176010001500197810000600212012039200218
03000120061006500090062206400050063103100040063603200030064001400080064386500090
0651002001200660035001000672801001200682#2011nahead#V:\SciELO\serial\abc\2011nah
ead\markup\aop3411.htm#S#c#223#1#article#37#1#^rND^sGibbons^nRJ#^rND^sBalady^nGJ
#^rND^sBricker^nJT#^rND^sChaitman^nBR#^rND^sFletcher^nGF#^rND^sFroelicher^nVF#^r
ND^sMark^nDB#et al#American College of Cardiology/American Heart Association Tas
k Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Gu
idelines): ACC/AHA 2002 guideline update for exercise testing: summary article: 
a report of the American College of Cardiology/American Heart Association Task F
orce on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guide
lines)^len#Circulation#20020000#2002#106#14#1883-92#20110000#aop3411.htm#0009-73
22#Circulation##
00589000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100018000850100020001030120
09100123030001300214065000900227064000500236031000400241032000300245014000700248
865000900255002001200264035001000276801001300286#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3411.htm#S#c#224#2#article#37#2#^rND^sDiamond^nGA#^rND^sFo
rrester^nJS#Analysis of probability as an aid in the clinical diagnosis of coron
ary-artery disease^len#N Engl J Med#19790000#1979#300#24#1350-8#20110000#aop3411
.htm#0028-4793#N Engl J Med##
00688000000000289000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100016001020120
18700118030001800305065000900323064000500332031000300337032000200340014000700342
865000900349002001200358035001000370801001800380#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3411.htm#S#c#225#3#article#37#3#^rND^sMorise^nAP#^rND^sJal
isi^nF#Evaluation of pretest and exercise test scores to assess all-cause mortal
ity in unselected patients presenting for exercise testing with symptoms of susp
ected coronary artery disease^len#J Am Coll Cardiol#20030000#2003#42#5#842-50#20
110000#aop3411.htm#0735-1097#J Am Coll Cardiol##
00556000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100015001020100
02000117012004200137030000700179065000900186064000500195031000400200032000500204
014000700209865000900216002001200225035001000237801000700247#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3411.htm#S#c#226#4#article#37#4#^rND^sAshley^n
EA#^rND^sMyers^nJ#^rND^sFroelicher^nV#Exercise testing in clinical medicine^len#
Lancet#20000000#2000#356#9241#1592-7#20110000#aop3411.htm#0099-5355#Lancet##
00600000000000301000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100020000850100017001050100
01600122012006200138030002000200065000900220064000500229031000300234032000200237
014000800239865000900247002001200256035001000268801002000278#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3411.htm#S#c#227#5#article#37#5#^rND^sFroelich
er^nV#^rND^sShetler^nK#^rND^sAshley^nE#Better decisions through science: exercis
e testing scores^len#Prog Cardiovasc Dis#20020000#2002#44#5#395-414#20110000#aop
3411.htm#0033-0620#Prog Cardiovasc Dis##
00739000000000313000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100017000850100017001020100
01600119010001800135012017800153030001800331065000900349064000500358031000300363
032000200366014000800368865000900376002001200385035001000397801001800407#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#228#6#article#37#6#^r
ND^sMorise^nAP#^rND^sDetrano^nR#^rND^sBobbio^nM#^rND^sDiamond^nGA#Development an
d validation of a logistic regression-derived algorithm for estimating the incre
mental probability of coronary artery disease before and after exercise testing^
len#J Am Coll Cardiol#19920000#1992#20#5#1187-96#20110000#aop3411.htm#0735-1097#
J Am Coll Cardiol##
00688000000000337000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100015000850100015001000100
01800115010001400133010001700147010001600164012008100180030001500261065000900276
06400050028503100040029003200020029401400080029686500090030400200120031303500100
0325801001500335#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S
#c#229#7#article#37#7#^rND^sMark^nDB#^rND^sMark^nAH#^rND^sHarrell^nFE#^rND^sLee^
nKL#^rND^sCaliff^nRM#^rND^sPryor^nDB#Exercise treadmill score for predicting pro
gnosis in coronary artery disease^len#Ann Intern Med#19870000#1987#106#6#793-800
#20110000#aop3411.htm#0003-4819#Ann Intern Med##
00661000000000349000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100016000850100017001010100
01600118010001200134010001500146010001700161810000600178012005600184030000600240
06500090024606400050025503100040026003200020026401400080026686500090027400200120
0283035001000295801000600305#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#230#8#article#37#8#^rND^sRaxwal^nV#^rND^sShetler^nK#^rND^sMorise^
nA#^rND^sDo^nD#^rND^sMyers^nJ#^rND^sAtwood^nJE#et al#Simple treadmill score to d
iagnose coronary disease^len#Chest#20010000#2001#119#6#1933-40#20110000#aop3411.
htm#0012-3692#Chest##
00664000000000325000450000400110000070200510001170500020006270600020006470000040
00667010002000707090008000727080003000801180002000830100012000850100015000970100
01600112010001600128010002000144012010400164030000600268065000900274064000500283
03100040028803200020029201400070029486500090030100200120031003500100032280100060
0332#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#231#9#art
icle#37#9#^rND^sDo^nD#^rND^sWest^nJA#^rND^sMorise^nA#^rND^sAtwood^nE#^rND^sFroel
icher^nV#A consensus approach to diagnosing coronary artery disease based on cli
nical and exercise test data^len#Chest#19970000#1997#111#6#1742-9#20110000#aop34
11.htm#0012-3692#Chest##
00688000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
02200123010002200145010001900167012008600186030001600272065000900288064000500297
03100040030203200020030601400070030886500090031500200120032403500100033680100160
0346#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#232#10#ar
ticle#37#10#^rND^sHubbard^nBL#^rND^sGibbons^nRJ#^rND^sLapeyre 3rd^nAC#^rND^sZins
meister^nAR#^rND^sClements^nIP#Identification of severe coronary artery disease 
using simple clinical parameters^len#Arch Intern Med#19920000#1992#152#2#309-12#
20110000#aop3411.htm#0003-9926#Arch Intern Med##
00741000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100017001030100
02100120010001500141010001600156010001700172810000600189012010800195030001500303
06500090031806400050032703100040033203200020033601400070033886500090034500200120
0354035001000366801001500376#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#233#11#article#37#11#^rND^sMorrow^nK#^rND^sMorris^nCK#^rND^sFroel
icher^nVF#^rND^sHideg^nA#^rND^sHunter^nD#^rND^sJohnson^nE#et al#Prediction of ca
rdiovascular death in men undergoing noninvasive evaluation for coronary artery 
disease^len#Ann Intern Med#19930000#1993#118#9#689-95#20110000#aop3411.htm#0003-
4819#Ann Intern Med##
00777000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01500120010001900135010001900154010001700173810000600190012013800196030001800334
06500090035206400050036103100030036603200020036901400070037186500090037800200120
0387035001000399801001800409#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#234#12#article#37#12#^rND^sDetrano^nR#^rND^sBobbio^nM#^rND^sOlson
^nH#^rND^sShandling^nA#^rND^sEllestad^nMH#^rND^sAlegria^nE#et al#Computer probab
ility estimates of angiographic coronary artery disease: transportability and co
mparison with cardiologist's estimates^len#Comput Biomed Res#19920000#1992#25#5#
468-85#20110000#aop3411.htm#0010-4809#Comput Biomed Res##
00594000000000289000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100013000870100014001000120
09700114030001800211065000900229064000500238031000300243032000200246014000700248
865000900255002001200264035001000276801001800286#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop3411.htm#S#c#235#13#article#37#13#^rND^sLu^nZY#^rND^sHaus^
nS#Evaluation of exercise-induced QRS amplitude changes (Athens score) and their
 clinical value^len#J Tongji Med Univ#19930000#1993#13#3#177-82#20110000#aop3411
.htm#0257-716X#J Tongji Med Univ##
00887000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100018000870100018001050100
01700123010001700140010001900157010001900176810000600195012025600201030001100457
06500090046806400050047703100040048203200020048601400070048886500090049500200120
0504035001000516801001100526#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#236#14#article#37#14#^rND^sVillella^nM#^rND^sVillella^nA#^rND^sSa
ntoro^nL#^rND^sSantoro^nE#^rND^sFranzosi^nMG#^rND^sMaggioni^nAP#et al#Ergometric
 score systems after myocardial infarction: prognostic performance of the Duke T
readmill Score, Veterans Administration Medical Center Score, and of a novel sco
re system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarctio
n^len#Am Heart J#20030000#2003#145#3#475-83#20110000#aop3411.htm#0002-8703#Am He
art J##
00655000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100019001020100
01700121010001800138012012000156030001400276710000200290065000900292064000500301
031000300306031000300309032000200312014000600314865000900320002001200329#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#237#15#article#37#15#
^rND^sKoide^nY#^rND^sYotsukura^nM#^rND^sYoshino^nH#^rND^sIshikawa^nK#A new coron
ary artery disease index of treadmill exercise electrocardiograms based on the s
tep-up diagnostic method^len#Am J Cardiol.#2#20010000#2001#15#87#2#142-7#2011000
0#aop3411.htm##
00673000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100020000870100016001070100
01900123010001600142012012000158030001200278065000900290064000500299031000300304
032000200307014000700309865000900316002001200325035001000337801001200347#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#238#16#article#37#16#
^rND^sHollenberg^nM#^rND^sBudge^nWR#^rND^sWisneski^nJA#^rND^sGertz^nEW#Treadmill
 score quantifies electrocardiographic response to exercise and improves test ac
curacy and reproducibility^len#Circulation#19800000#1980#61#2#276-85#20110000#ao
p3411.htm#0009-7322#Circulation##
00733000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100014001020100
02100116010001700137010001400154010001900168810000600187012010500193030001300298
06500090031106400050032003100040032503200030032901400070033286500090033900200120
0348035001000360801001300370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#239#17#article#37#17#^rND^sMark^nDB#^rND^sShaw^nL#^rND^sHarrell J
r^nFE#^rND^sHlatky^nMA#^rND^sLee^nKL#^rND^sBengtson^nJR#et al#Prognostic value o
f a treadmill exercise score in outpatients with suspected coronary artery disea
se^len#N Engl J Med#19910000#1991#325#12#849-53#20110000#aop3411.htm#0028-4793#N
 Engl J Med##
00768000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100013000870100017001000100
01600117010001700133010001800150012018700168030001500355065000900370064000500379
03100030038403200020038701400070038986500090039600200120040503500100041780100150
0427#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#240#18#ar
ticle#37#18#^rND^sHo^nKT#^rND^sMiller^nTD#^rND^sHodge^nDO#^rND^sBailey^nKR#^rND^
sGibbons^nRJ#Use of a simple clinical score to predict prognosis of patients wit
h normal or mildly abnormal resting electrocardiographic findings undergoing eva
luation for coronary artery disease^len#Mayo Clin Proc#20020000#2002#77#6#515-21
#20110000#aop3411.htm#0025-6196#Mayo Clin Proc##
00858000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
01600119010001500135010001900150010001600169810000600185012024900191030001200440
06500090045206400050046103100040046601400070047086500090047700200120048603500100
0498801001200508#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S
#c#241#19#article#37#19#^rND^sSoares^nPR#^rND^sHueb^nWA#^rND^sLemos^nPA#^rND^sLo
pes^nN#^rND^sMartinez^nEE#^rND^sCesar^nLA#et al#Coronary revascularization (surg
ical or percutaneous) decreases mortality after the first year in diabetic subje
cts but not in nondiabetic subjects with multivessel disease: an analysis from t
he Medicine, Angioplasty, or Surgery Study (MASS II)^len#Circulation#20060000#20
06#114#I420-4#20110000#aop3411.htm#0009-7322#Circulation##
00847000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100018001020100
01900120010001400139010002200153010001700175810000600192012020600198030001800404
06500090042206400050043103100030043603200020043901400070044186500090044800200120
0457035001000469801001800479#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#242#20#article#37#20#^rND^sHueb^nWA#^rND^sBellotti^nG#^rND^sOlive
ira^nSA#^rND^sArie^nS#^rND^sAlbuquerque^nCP#^rND^sJatene^nAD#et al#The Medicine,
 Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical
 therapy, balloon angioplasty or bypass surgery for single proximal left anterio
r descending artery stenoses^len#J Am Coll Cardiol#19950000#1995#26#7#1600-5#201
10000#aop3411.htm#0735-1097#J Am Coll Cardiol##
00574000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870120081001030300
02800184065000900212064000500221031000300226032000200229014000600231865000900237
002001200246035001000258801002800268#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3411.htm#S#c#243#21#article#37#21#^rND^sBruce^nRA#Evaluation of functi
onal capacity and exercise tolerance of cardiac patients^len#Mod Concepts Cardio
vasc Dis#19560000#1956#25#4#321-6#20110000#aop3411.htm#0026-7600#Mod Concepts Ca
rdiovasc Dis##
00692000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100020001030100
01600123010001900139010002000158011004500178012004000223030001700263065000900280
06400050028903100030029403200040029701400050030186500090030600200120031503500100
0327801001700337#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S
#c#244#22#article#37#22#^rND^sBrito^nFS#^rND^sVilas-Boas^nF#^rND^sCastro^nI#^rND
^sOliveira^nJÁ#^rND^sGuimarães^nJI#Stein R/ Sociedade Brasileira de Cardiologia#
II Diretriz sobre teste ergométrico^lpt#Arq Bras Cardiol#20020000#2002#78#^s2#1-
18#20110000#aop3411.htm#0066-782X#Arq Bras Cardiol##
00482000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870120038001010300
02700139710000200166065000900168064000500177031000300182032000200185014000800187
865000900195002001200204#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop34
11.htm#S#c#245#23#article#37#23#^rND^sCox^nDR#Regression models and life-tables^
len#J R Stat Soc Ser B Metodol#2#19720000#1972#34#2#187-220#20110000#aop3411.htm
##
00502000000000265000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040120
05800119030001200177710000200189065000900191064000500200031000300205014000700208
865000900215002001200224#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop34
11.htm#S#c#246#24#article#37#24#^rND^sKaplan^nEL#^rND^sMeier^nP#Nonparametric es
timation from incomplete observations^len#Am Stat Soc#2#19580000#1958#53#457-81#
20110000#aop3411.htm##
00783000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100017001020100
01500119010001500134010001600149010001800165012017800183030001300361065000900374
06400050038303100040038803200020039201400070039486500090040100200120041003500100
0422801001300432#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S
#c#247#25#article#37#25#^rND^sYusuf^nS#^rND^sSleight^nP#^rND^sPogue^nJ#^rND^sBos
ch^nJ#^rND^sDavies^nR#^rND^sDagenais^nG#Effects of an angiotensin-converting-enz
yme inhibitor, ramipril, on cardiovascular events in high-risk patients: the hea
rt outcomes prevention evaluation study investigators^len#N Engl J Med#20000000#
2000#342#3#145-53#20110000#aop3411.htm#0028-4793#N Engl J Med##
00654000000000277000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870120201001010300
00700302065000900309064000500318031000400323032000500327014000600332865000900338
002001200347035001000359801000700369#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop3411.htm#S#c#248#26#article#37#26#^rND^sFox^nKM#Efficacy of perindopri
l in reduction of cardiovascular events among patients with stable coronary arte
ry disease: randomised, double-blind, placebo-controlled, multicentre trial (the
 EUROPA study)^len#Lancet#20030000#2003#362#9386#782-8#20110000#aop3411.htm#0099
-5355#Lancet##
00802000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100023000870100016001100100
01700126010002000143010001700163010001700180810000600197012017400203030000700377
06500090038406400050039303100040039803200050040201400070040786500090041400200120
0423035001000435801000700445#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#249#27#article#37#27#^rND^sPoole-Wilson^nPA#^rND^sLubsen^nJ#^rND^
sKirwan^nBA#^rND^svan Dalen^nFJ#^rND^sWagener^nG#^rND^sDanchin^nN#et al#Effect o
f long-acting nifedipine on mortality and cardiovascular morbidity in patients w
ith stable angina requiring treatment (ACTION trial): randomised controlled tria
l^len#Lancet#20040000#2004#364#9437#849-57#20110000#aop3411.htm#0099-5355#Lancet
##
00679000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100014001030100
02100117010001400138010001700152010001500169810000600184012006400190030000900254
06500090026306400050027203100030027703200020028001400070028286500090028900200120
0298035001000310801000900320#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#250#28#article#37#28#^rND^sPryor^nDB#^rND^sShaw^nL#^rND^sHarrell 
Jr^nFE#^rND^sLee^nKL#^rND^sHlatky^nMA#^rND^sMark^nDB#et al#Estimating the likeli
hood of severe coronary artery disease^len#Am J Med#19910000#1991#90#5#553-62#20
110000#aop3411.htm#0002-9343#Am J Med##
00725000000000325000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100016000870100012001030100
01600115010001700131010002000148012013400168030002000302065000900322064000500331
03100030033603200020033901400070034186500090034800200120035703500100036980100200
0379#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#251#29#ar
ticle#37#29#^rND^sYamada^nH#^rND^sDo^nD#^rND^sMorise^nA#^rND^sAtwood^nJE#^rND^sF
roelicher^nV#Review of studies using multivariable analysis of clinical and exer
cise test data to predict angiographic coronary artery disease^len#Prog Cardiova
sc Dis#19970000#1997#39#5#457-81#20110000#aop3411.htm#0033-0620#Prog Cardiovasc 
Dis##
00736000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100015001040100
02100119010001600140010001200156010001900168810000600187012012200193030000600315
06500090032106400050033003100040033503200020033901400080034186500090034900200120
0358035001000370801000600380#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#252#30#article#37#30#^rND^sPrakash^nM#^rND^sMyers^nJ#^rND^sFroeli
cher^nVF#^rND^sMarcus^nR#^rND^sDo^nD#^rND^sKalisetti^nD#et al#Clinical and exerc
ise test predictors of all-cause mortality: results from > 6,000 consecutive ref
erred male patients^len#Chest#20010000#2001#120#3#1003-13#20110000#aop3411.htm#0
012-3692#Chest##
00594000000000301000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100016001040100
01900120012007200139030001300211065000900224064000500233031000300238032000200241
014000500243865000900248002001200257035001000269801001300279#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop3411.htm#S#c#253#31#article#37#31#^rND^sKannel
^nWB#^rND^sSorlie^nP#^rND^sMcNamara^nPM#Prognosis after initial myocardial infar
ction: the Framingham study^len#Am J Cardiol#19790000#1979#44#1#53-9#20110000#ao
p3411.htm#0002-9149#Am J Cardiol##
00547000000000229000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840160018000870180147001050660
00700252062002300259065000900282064000500291865000900296002001200305#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#254#32#article#37#32#^rND
^sGibbons^nRJ#Exercise ECG testing with and without radionuclide studies.In Weng
er NK, Speroff L, Packard B, eds. Cardiovascular health and disease in women^len
#London#Le Jacq Communications#19930000#1993#20110000#aop3411.htm##
00737000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100021001040100
01600125010001600141010001600157010001600173810000700189012009500196030001700291
06500090030806400050031703100030032203200090032501400050033486500090033900200120
0348035001000360801001700370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#255#33#article#37#33#^rND^sMansur^nAP#^rND^sArmaganijan^nD#^rND^s
Amino^nJG#^rND^sSousa^nAC#^rND^sSimão^nAF#^rND^sBrito^nAX#et al.#Sociedade Brasi
leira de Cardiologia: Diretriz de doença coronariana crônica angina estável^lpt#
Arq Bras Cardiol#20040000#2004#83#^ssupl.2#7-40#20110000#aop3411.htm#0066-782X#A
rq Bras Cardiol##
00815000000000349000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100015000870100016001020100
02100118010001300139010002000152010001600172810000600188012018700194030001200381
06500090039306400050040203100040040703200030041101400080041486500090042200200120
0431035001000443801001200453#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op3411.htm#S#c#256#34#article#37#34#^rND^sSingh^nM#^rND^sGersh^nBJ#^rND^sMcClell
and^nRL#^rND^sHo^nKK#^rND^sWillerson^nJT#^rND^sPenny^nWF#et al#Clinical and angi
ographic predictors of restenosis after percutaneous coronary intervention: insi
ghts from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) 
trial^len#Circulation#20040000#2004#109#22#2727-31#20110000#aop3411.htm#0009-732
2#Circulation##
00687000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100017000870100021001040100
01400125010001900139010002100158010001700179012007000196030001200266065000900278
06400050028703100030029203200030029501400080029886500090030600200120031503500100
0327801001200337#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S
#c#257#35#article#37#35#^rND^sWilson^nPW#^rND^sD'Agostino^nRB#^rND^sLevy^nD#^rND
^sBelanger^nAM#^rND^sSilbershatz^nH#^rND^sKannel^nWB#Prediction of coronary hear
t disease using risk factor categories^len#Circulation#19980000#1998#97#18#1837-
47#20110000#aop3411.htm#0009-7322#Circulation##
00711000000000337000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100019000870100017001060100
02000123010001600143010001700159010001800176012008700194030001800281065000900299
06400050030803100030031303200020031601400060031886500090032400200120033303500100
0345801001800355#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S
#c#258#36#article#37#36#^rND^sPoornima^nIG#^rND^sMiller^nTD#^rND^sChristian^nTF#
^rND^sHodge^nDO#^rND^sBailey^nKR#^rND^sGibbons^nRJ#Utility of myocardial perfusi
on imaging in patients with low-risk treadmill scores^len#J Am Coll Cardiol#2004
0000#2004#43#2#194-9#20110000#aop3411.htm#0735-1097#J Am Coll Cardiol##
00663000000000313000450000400110000070200510001170500020006270600020006470000040
00667010003000707090008000737080003000811180003000840100014000870100018001010100
01900119010002100138012010600159030001200265065000900277064000500286031000400291
032000300295014000800298865000900306002001200315035001000327801001200337#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop3411.htm#S#c#259#37#article#37#37#
^rND^sMora^nS#^rND^sRedberg^nRF#^rND^sSharrett^nAR#^rND^sBlumenthal^nRS#Enhanced
 risk assessment in asymptomatic individuals with exercise testing and Framingha
m risk scores^len#Circulation#20050000#2005#112#11#1566-72#20110000#aop3411.htm#
0009-7322#Circulation##
00281000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090005000717080002000760910009000780920007000870020013000947030
00400107#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#o#1#1#
text#1#20110411#104640#aop03911.htm#122##
00873000000000397000450000400110000070200520001170500020006370600020006570000020
00677010002000697090005000717080002000760710003000780400003000810010006000840420
00200090120000400092038000500096121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016212300020017101201060
0173012010100279010002900380070004200409117000800451072000300459002001300462#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#h#2#1#text#1#oa#pt
#br1.1#1#4.0#ILUS#49#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#2
0110415#1#Características fisiopatológicas do modelo de insuficiência cardíaca p
ós-infarto do miocárdio no rato^lpt#Pathophysiological characteristics of the po
st-myocardial infarction heart failure model in rats^len#^rND^1A01^nPaulo J. F^s
Tucci#Unifesp^iA01^1Escola Paulista de Medicina#vancouv#25#aop03911.htm##
00887000000000397000450000400110000070200520001170500020006370600020006570000020
00677010002000697090005000717080002000760710003000780400003000810010006000840420
00200090120000400092038000500096121000300101049000300104158000300107030002000110
03200060013006500090013601400070014503500100015222300090016212300020017101201130
0173012010800286010002900394070004200423117000800465072000300473002001300476#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#f#3#1#text#1#oa#pt
#br1.1#1#4.0#ILUS#49#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#2
0110415#1#<b>Características fisiopatológicas do modelo de insuficiência cardíac
a pós-infarto do miocárdio no rato</b>^lpt#<b>Pathophysiological characteristics
 of the post-myocardial infarction heart failure model in rats</b>^len#^rND^1A01
^nPaulo J. F^sTucci#Unifesp^iA01^1Escola Paulista de Medicina#vancouv#25#aop0391
1.htm##
00994000000000421000450000400110000070200520001170500020006370600020006570000020
00677010002000697090005000717080002000760640007000780710003000850400003000880010
00600091042000200097120000400099038000500103121000300108049000300111158000300114
03000190011703200060013606500090014201400070015103500100015822300090016812300020
01770120106001790120101002850100029003860700044004151170008004590720003004670020
01300470008008900483#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.
htm#S#l#4#1#text#1#^a2011#oa#pt#br1.1#1#4.0#ilus#49#nd#nd#Arq. bras. cardiol#ahe
ad#20110000#^f0^l0#0066-782X#20110415#1#Características fisiopatológicas do mode
lo de insuficiência cardíaca pós-infarto do miocárdio no rato^lpt#Pathophysiolog
ical characteristics of the post-myocardial infarction heart failure model in ra
ts^len#^rND^1A01^nPaulo J. F^sTucci#^iA01^1Unifesp^2Escola Paulista de Medicina#
vancouv#25#aop03911.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_art
text&pid=S0066-782X2011005000049##
00489000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000500071708000300076704025100079002001300330#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#5#1#text#93#<p><a name="enda
"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Caracter&ia
cute;sticas fisiopatol&oacute;gicas do modelo de insufici&ecirc;ncia card&iacute
;aca p&oacute;s-infarto do mioc&aacute;rdio no rato</b></font></p>     ^cY#aop03
911.htm##
00260000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000500071708000300076704002200079002001300101#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#6#2#text#93#<p>&nbsp;</p>   
  ^cY#aop03911.htm##
00260000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000500071708000300076704002200079002001300101#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#7#3#text#93#<p>&nbsp;</p>   
  ^cY#aop03911.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000500071708000300076704010700079002001300186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#8#4#text#93#<p><font size="2
" face="Verdana, Arial, Helvetica, sans-serif"><b>Paulo J. F. Tucci</b></font></
p>     ^cY#aop03911.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000500071708000300076704012000079002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#9#5#text#93#<p><font size="2
" face="Verdana, Arial, Helvetica, sans-serif">Escola Paulista de Medicina - Uni
fesp</font></p>     ^cY#aop03911.htm##
00363000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000500072708000300077704012400080002001300204#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#10#6#text#93#<p><font size="
2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&ecirc
;ncia</a></font></p>     ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000500072708000300077704002200080002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#11#7#text#93#<p>&nbsp;</p>  
   ^cY#aop03911.htm##
00283000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000500072708000300077704004400080002001300124#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#12#8#text#93#<p>&nbsp;</p> <
hr size="1" noshade>     ^cY#aop03911.htm##
00456000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000500072708000300077704021700080002001300297#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#13#9#text#93#<p><font size="
2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b>  Insufici
&ecirc;ncia card&iacute;aca/fisiopatologia, infarto do mioc&aacute;rdio, ratos. 
</font></p> <hr size="1" noshade>     ^cY#aop03911.htm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#14#10#text#93#<p>&nbsp;</p> 
    ^cY#aop03911.htm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#15#11#text#93#<p>&nbsp;</p> 
    ^cY#aop03911.htm##
00336000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704009600081002001300177#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#16#12#text#93#<p><font size=
"3" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>     ^c
Y#aop03911.htm##
01499000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704125900081002001301340#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#17#13#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">A insufici&ecirc;ncia card&iacu
te;aca congestiva (ICC), desencadeada no rato como consequ&ecirc;ncia de Infarto
 do Mioc&aacute;rdio, &eacute; o modelo mais comumente utilizado em pesquisa exp
erimental para desenvolver a s&iacute;ndrome congestiva. Seguindo-se &agrave; ne
crose mioc&aacute;rdica, as manifesta&ccedil;&otilde;es que ocorrem no roedor re
produzem muito satisfatoriamente os achados encontrados em humanos com descompen
sa&ccedil;&atilde;o card&iacute;aca, e fundamentam an&aacute;lises da patogenia,
 da fisiopatologia e do tratamento da ICC com reconhecido proveito cl&iacute;nic
o. Duas caracter&iacute;sticas s&atilde;o inadequadas no modelo: a mortalidade e
levada nas primeiras 24 h que se seguem &agrave; oclus&atilde;o coron&aacute;ria
 e a expressiva diversidade dos tamanhos dos infartos obtidos. Neste texto s&ati
lde;o descritas particularidades metodol&oacute;gicas e fisiopatol&oacute;gicas 
do modelo, terminando por fazer refer&ecirc;ncia a uma t&eacute;cnica alternativ
a de produ&ccedil;&atilde;o de necrose mioc&aacute;rdica por corrente el&eacute;
trica com radiofrequ&ecirc;ncia, que evolui com baixa mortalidade e tamanho homo
g&ecirc;neo dos infartos.</font></p>     ^cY#aop03911.htm##
01305000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704106500081002001301146#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#18#14#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif"> H&aacute; anos a insufici&ecir
c;ncia card&iacute;aca congestiva (ICC) situa-se entre os temas mais investigado
s em Cardiologia. Ao lado das informa&ccedil;&otilde;es colhidas em humanos, &ea
cute; destacada a contribui&ccedil;&atilde;o de investiga&ccedil;&otilde;es cond
uzidas em animais de laborat&oacute;rio. Entre v&aacute;rios modelos experimenta
is dispon&iacute;veis, aquele que promove a s&iacute;ndrome congestiva a partir 
da indu&ccedil;&atilde;o de necrose mioc&aacute;rdica no rato &eacute; o mais ut
ilizado. A popularidade do modelo nos dias atuais e a previs&atilde;o poss&iacut
e;vel de amplia&ccedil;&atilde;o do interesse por este modelo tornam importante 
a descri&ccedil;&atilde;o de caracter&iacute;sticas fisiopatol&oacute;gicas que 
se seguem ao infarto do mioc&aacute;rdio (IM) no rato. Recentemente, uma valiosa
 revis&atilde;o da literatura sobre o modelo de infarto do mioc&aacute;rdio no r
ato foi publicado nos Arquivos Brasileiros de Cardiologia<sup>1</sup>. </font></
p>     ^cY#aop03911.htm##
00983000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704074300081002001300824#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#19#15#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">&Eacute; necess&aacute;rio ante
cipar que embora o processo fisiopatol&oacute;gico que se estabelece nos roedore
s ap&oacute;s ligadura da coron&aacute;ria seja &uacute;til para analisar o remo
delamento mioc&aacute;rdico que ocorre no m&uacute;sculo card&iacute;aco remanes
cente e a s&iacute;ndrome congestiva ele n&atilde;o guarda analogia com as s&iac
ute;ndromes coron&aacute;rias humanas. Faltam ao modelo as les&otilde;es arteria
is que conferem perfil pr&oacute;prio &agrave; coronariopatia de humanos: arritm
ias, isquemias transit&oacute;rias e reincid&ecirc;ncias de oclus&atilde;o coron
&aacute;ria, inexistentes no animal de experimenta&ccedil;&atilde;o. </font></p>
     ^cY#aop03911.htm##
00496000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704025600081002001300337#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#20#16#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">A oclus&atilde;o da art&eacute;
ria coron&aacute;ria interventricular anterior &eacute; a estrat&eacute;gia mais
 frequentemente aplicada para a produ&ccedil;&atilde;o de IM. </font></p>     ^c
Y#aop03911.htm##
01920000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704168000081002001301761#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#21#17#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">O eletrocardiograma<sup>2</sup>
 e o ecocardiograma<sup>3-15</sup> s&atilde;o m&eacute;todos n&atilde;o invasivo
s capazes de identificar a &aacute;rea de necrose ou cicatriz. Embora identifiqu
e a presen&ccedil;a da zona inativa dependente do IM, o eletrocardiograma n&atil
de;o &eacute; um m&eacute;todo apto a quantific&aacute;-la<sup>2</sup>. O ecocar
diograma possibilita caracterizar a presen&ccedil;a e o tamanho do IM com muito 
boa sensibilidade<sup>3-15</sup>, mesmo em per&iacute;odos precoces como dois di
as ap&oacute;s promover a necrose, al&eacute;m de informar sobre os desvios das 
fun&ccedil;&otilde;es atrial e ventricular. O melhor m&eacute;todo para diagn&oa
cute;stico post-mortem do IM depende da fase em que ocorre a necropsia. Nos prim
eiros dias de necrose mioc&aacute;rdica o exame histopatol&oacute;gico pode susc
itar d&uacute;vidas quanto aos limites do territ&oacute;rio necrosado. Para esta
 fase, o uso de trifenil-tetraz&oacute;lio (TTZ) &eacute; mais preciso. Em conta
cto com c&eacute;lulas vivas, este corante &eacute; reduzido por desidrogenases 
e assume a cor vermelha escura. C&eacute;lulas mortas, que n&atilde;o mais disp&
otilde;em das formas reduzidas de desidrogenases, n&atilde;o s&atilde;o coradas.
 A coloca&ccedil;&atilde;o do mioc&aacute;rdio em &aacute;gua oxigenada, posteri
ormente, elimina a cor vermelha da hemoglobina presente no hematoma da regi&atil
de;o necrosada, clareando-a (<a href="/img/revistas/abc/2011nahead/aop03911fig01
m.jpg">Figura 1A</a>). O TTZ possibilita a caracteriza&ccedil;&atilde;o da necro
se imediatamente ap&oacute;s a morte celular. </font></p>     ^cY#aop03911.htm##
01945000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704170500081002001301786#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#22#18#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Duas particularidades chamam a 
aten&ccedil;&atilde;o no modelo: grande variabilidade no que se refere tanto &ag
rave; mortalidade nas primeiras 24 horas ap&oacute;s a oclus&atilde;o da coron&a
acute;ria, quanto ao tamanho do infarto resultante. Os limites de mortalidade de
scritos na literatura na fase imediata &agrave; oclus&atilde;o coron&aacute;ria 
variam do valor mais baixo de 13%<sup>16</sup> at&eacute; o m&aacute;ximo de 65%
<sup>17</sup>. Em nosso laborat&oacute;rio, considerando v&aacute;rias s&eacute;
ries que foram acompanhadas, a mortalidade imediata situou-se em torno de 44% pa
ra os ratos machos e de 17% para as ratas. A raz&atilde;o desta discrep&acirc;nc
ia entre as mortalidades dos dois g&ecirc;neros n&atilde;o &eacute; original, ma
s sua causa n&atilde;o est&aacute; definida. H&aacute; documenta&ccedil;&atilde;
o convincente para afirmar que as arritmias constituem a causa de morte durante 
as 48 h que se seguem &agrave; oclus&atilde;o coron&aacute;ria<sup>17</sup>. Uma
 particularidade marcante do modelo &eacute; a grande dispers&atilde;o do tamanh
o do IM, ap&oacute;s ligadura padronizada da art&eacute;ria coron&aacute;ria int
erventricular anterior. Em nossa &uacute;ltima s&eacute;rie, conduzida para dete
rminar os tamanhos dos infartos resultantes das oclus&otilde;es coron&aacute;ria
s, verificamos tamanho m&eacute;dio de 40 ± 19% (x ± SD). A grande variabilidade
 fica patente pelo valor elevado do desvio padr&atilde;o: 48% do valor da m&eacu
te;dia. Os grandes infartos (<u>&gt;</u> 40% do VE) - que mais interessam para o
 acompanhamento da fisiopatologia da ICC - ocorreram em 60% dos casos. </font></
p>     ^cY#aop03911.htm##
03126000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704288600081002001302967#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#23#19#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Tal como descrito para humanos,
 o tamanho do IM &eacute; determinante cr&iacute;tico da repercuss&atilde;o func
ional no cora&ccedil;&atilde;o. A <a href="/img/revistas/abc/2011nahead/aop03911
fig01m.jpg">figura 1B</a> ilustra a correla&ccedil;&atilde;o que se estabeleceu 
no quinto dia ap&oacute;s oclus&atilde;o coron&aacute;ria<sup>6</sup> entre o vo
lume diast&oacute;lico do ventr&iacute;culo esquerdo (VE) e o tamanho do IM, enq
uanto a <a href="/img/revistas/abc/2011nahead/aop03911fig01m.jpg">figura 1C</a> 
indica a rela&ccedil;&atilde;o que se verificou entre tamanho do IM e press&atil
de;o diast&oacute;lica final do ventr&iacute;culo esquerdo (PDFVE), seis semanas
 ap&oacute;s indu&ccedil;&atilde;o da necrose mioc&aacute;rdica. &Eacute; percep
t&iacute;vel a associa&ccedil;&atilde;o linear tanto do volume quanto da PDFVE c
om a magnitude do VE ocupada pelo IM. Curiosamente, a press&atilde;o diast&oacut
e;lica ventricular n&atilde;o guardou rela&ccedil;&atilde;o com o tempo decorrid
o ap&oacute;s promo&ccedil;&atilde;o do IM. A fra&ccedil;&atilde;o de encurtamen
to da &aacute;rea transversa<a name="1b"></a><a href="#1a"><sup>*</sup></a> do v
entr&iacute;culo esquerdo, analisada seis semanas ap&oacute;s indu&ccedil;&atild
e;o do infarto, assumiu rela&ccedil;&atilde;o linear inversa com o tamanho da ci
catriz (F<a href="/img/revistas/abc/2011nahead/html/aop03911fig02.html">igura 2A
</a>), configurando decremento crescente da capacidade de eje&ccedil;&atilde;o c
onforme aumenta o tamanho do IM. Neste mesmo per&iacute;odo p&oacute;s-oclus&ati
lde;o coron&aacute;ria, correla&ccedil;&otilde;es mais chamativas entre tamanho 
do IM e repercuss&otilde;es funcionais foram verificadas (<a href="/img/revistas
/abc/2011nahead/html/aop03911fig02.html">Figura 2</a>), quando se analisaram as 
rela&ccedil;&otilde;es entre o tamanho do IM e indicadores de esvaziamento atria
l (raz&atilde;o E/A) e de congest&atilde;o pulmonar (raz&atilde;o peso do pulm&a
tilde;o direito/peso corp&oacute;reo). Estas raz&otilde;es aumentaram em fun&cce
dil;&atilde;o exponencial com rela&ccedil;&atilde;o ao tamanho do IM (<a href="/
img/revistas/abc/2011nahead/html/aop03911fig02.html">Figuras 2B</a> e <a href="/
img/revistas/abc/2011nahead/html/aop03911fig02.html">2C</a>), destacando-se a pa
rticularidade de repercuss&atilde;o ausente ou pouco expressiva, para ambas as v
ari&aacute;veis, em infartos que ocupam menos de 25% do per&iacute;metro ventric
ular. &Eacute; evidente que n&atilde;o h&aacute; altera&ccedil;&otilde;es consid
er&aacute;veis desses indicadores enquanto o IM &eacute; inferior a 25% da circu
nfer&ecirc;ncia do VE, o que indica que, no per&iacute;odo em que foram analisad
os, infartos menores que 25% afetam pouco o esvaziamento atrial e, portanto, n&a
tilde;o induzem &agrave; congest&atilde;o pulmonar. </font></p>     ^cY#aop03911
.htm##
06003000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704576300081002001305844#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#24#20#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Uma quest&atilde;o crucial no a
companhamento de ratos infartados &eacute; determinar a presen&ccedil;a de ICC p
orque, nos roedores, os sintomas e sinais cl&iacute;nicos do estado congestivo s
&atilde;o sutis e pouco frequentes<sup>18</sup>. Em s&eacute;ries acompanhadas n
o laborat&oacute;rio, todos os animais infartados, que faleceram durante acompan
hamento mais prolongado do que uma semana, sofriam de ICC, com congest&atilde;o 
pulmonar e hep&aacute;tica; as manifesta&ccedil;&otilde;es cl&iacute;nicas pr&oa
cute;prias da ICC passaram despercebidas<sup>18</sup>. A fal&ecirc;ncia ventricu
lar esquerda dos ratos infartados pode ser caracterizada indiretamente por m&eac
ute;todo n&atilde;o invasivo (Doppler ecocardiograma; DE), invasivo (press&atild
e;o diast&oacute;lica ventricular esquerda - Pd<sub>2</sub>VE) ou post-mortem (t
eor de &aacute;gua do pulm&atilde;o ou raz&atilde;o peso do pulm&atilde;o/peso c
orp&oacute;reo). A an&aacute;lise pelo DE oferece informa&ccedil;&atilde;o valio
sa para o acompanhamento seriado dos animais, por indicar a dificuldade de esvaz
iamento atrial consequente &agrave; Pd<sub>2</sub>VE elevada. Tanto a raz&atilde
;o E/A quanto a an&aacute;lise pelo Doppler tecidual (raz&atilde;o E/Em) podem d
enunciar a Pd<sub>2</sub>VE elevada<sup>15</sup>. Curiosamente, nos ratos, o pad
r&atilde;o inicial de dificuldade de esvaziamento atrial analisado a partir do f
luxo pela valva mitral (redu&ccedil;&atilde;o da raz&atilde;o E/A) n&atilde;o se
 manifesta, ao passo que se identifica o padr&atilde;o restritivo de DE (aumento
 da raz&atilde;o E/A). Em v&aacute;rias s&eacute;ries por n&oacute;s acompanhada
s, em ratos normais, os valores m&eacute;dios ± SD da raz&atilde;o E/A oscilam p
ouco acima de 2,0. Em um conjunto de ratos infartados analisados, valores da raz
&atilde;o E/A superiores a 2,7 identificaram Pd<sub>2</sub>VE superior a 12 mmHg
 com 90% de sensibilidade e 80% de especificidade<sup>15</sup>. Em uma s&eacute;
rie mais recente, ainda em an&aacute;lise, o estudo indicou valores de raz&atild
e;o E/A de 2,15 ± 0,44 em 44 ratos normais. Em animais portadores de IM <u>&gt;<
/u> 40% VE, o comum &eacute; verificar m&eacute;dias superiores a 4,0. Essa pare
ce ser a informa&ccedil;&atilde;o n&atilde;o invasiva mais confi&aacute;vel de q
ue a Pd<sub>2</sub>VE est&aacute; em n&iacute;vel elevado<sup>15</sup> e, portan
to, estamos diante de um portador de ICC. Cabe, portanto, assinalar o m&eacute;r
ito do DE em tornar patentes disfun&ccedil;&otilde;es ventriculares clinicamente
 ocultas, atrav&eacute;s da determina&ccedil;&atilde;o das raz&otilde;es entre d
imens&otilde;es ventriculares (di&acirc;metro, &aacute;rea, volume) sist&oacute;
licas e diast&oacute;licas<sup>11</sup>. Considera-se, tamb&eacute;m, que o &iac
ute;ndice de TEI &eacute; capaz de indicar a fun&ccedil;&atilde;o sist&oacute;li
ca ventricular<sup>3,19</sup>. Adicione-se a capacidade do DE em oferecer indica
&ccedil;&otilde;es capazes de detectar hipertens&atilde;o pulmonar<sup>7</sup> e
 de prognosticar sobrevida<sup>14</sup> em ratos. A detec&ccedil;&atilde;o hemod
in&acirc;mica da disfun&ccedil;&atilde;o ventricular se caracteriza por uma t&ec
irc;nue redu&ccedil;&atilde;o da press&atilde;o sist&oacute;lica e aumento perce
pt&iacute;vel da Pd<sub>2</sub>VE (<a href="/img/revistas/abc/2011nahead/html/ao
p03911fig02.html#fig2b">Figura 2D</a>). Em animais anestesiados, respirando espo
ntaneamente, sem ventila&ccedil;&atilde;o mec&acirc;nica, identificamos valores 
limites de 12 mmHg para o n&iacute;vel superior admiss&iacute;vel como normal pa
ra a Pd<sub>2</sub>VE<sup>15</sup>. N&atilde;o raro, a curva da press&atilde;o d
iast&oacute;lica assume morfologia muito sugestiva da restri&ccedil;&atilde;o ao
 enchimento ventricular (<a href="/img/revistas/abc/2011nahead/html/aop03911fig0
2.html#fig2b">Figura 2D</a>). O teor de &aacute;gua dos &oacute;rg&atilde;os<a n
ame="2b"></a><a href="#2a"><sup>**</sup></a> &eacute; uma vari&aacute;vel rigoro
samente controlada dentro de limites bastante estreitos. No caso do pulm&atilde;
o, o valor m&eacute;dio normal &eacute; de 79% e a variabilidade extremamente ba
ixa (desvio padr&atilde;o de 1%). Essas caracter&iacute;sticas tornam o teor de 
&aacute;gua do pulm&atilde;o indicador muito sens&iacute;vel para se caracteriza
r a presen&ccedil;a de congest&atilde;o pulmonar quando consideramos um grupo de
 animais infartados, pois a variabilidade baixa facilita a signific&acirc;ncia e
stat&iacute;stica da diferen&ccedil;a entre m&eacute;dias. Contudo, quando se an
alisam valores individuais de animais infartados, o rigor fisiol&oacute;gico no 
controle do teor de &aacute;gua dificulta a identifica&ccedil;&atilde;o de valor
es anormais isolados, uma vez que as diferen&ccedil;as individuais entre os norm
ais e os patol&oacute;gicos, habitualmente, n&atilde;o assumem n&iacute;veis exp
ressivos. Para a an&aacute;lise individual, a rela&ccedil;&atilde;o peso do pulm
&atilde;o direito/peso corp&oacute;reo &eacute; um indicador de maior sensibilid
ade, dada a faixa mais ampla (3,83 ± 0,63 mg/g) dos valores normais desta raz&at
ilde;o. Em ratos normais, &eacute; muito raro que esta raz&atilde;o supere o val
or de 5 mg/g, algo que, usualmente, ocorre em animais com a s&iacute;ndrome cong
estiva. Dados do laborat&oacute;rio indicam que, comumente, ao final da primeira
 semana ap&oacute;s a instala&ccedil;&atilde;o da necrose mioc&aacute;rdica, os 
ratos com IM &gt; 40% t&ecirc;m congest&atilde;o pulmonar<sup>20</sup>. Notifica
&ccedil;&otilde;es da literatura d&atilde;o conta de que, j&aacute; na primeira 
semana p&oacute;s-IM, vari&aacute;veis neuro-humorais desviam-se do normal<sup>2
1</sup> em ratos portadores de grandes infartos. </font></p>     ^cY#aop03911.ht
m##
02522000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704228200081002001302363#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#25#21#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Na fase aguda do IM, o fator de
terminante da disfun&ccedil;&atilde;o ventricular &eacute; a perda de cardiomi&o
acute;citos. O preju&iacute;zo inevit&aacute;vel para a fun&ccedil;&atilde;o eje
tante acarreta aumento do volume residual do VE e, portanto, dilata&ccedil;&atil
de;o ventricular. Evidenciamos que dois dias ap&oacute;s indu&ccedil;&atilde;o d
e oclus&atilde;o coron&aacute;ria as dimens&otilde;es ventriculares est&atilde;o
 ampliadas<sup>22</sup>. O aumento do volume da cavidade ventricular &eacute; o 
promotor do remodelamento mioc&aacute;rdico da fase cr&ocirc;nica. Recorrendo &a
grave; lei de Laplace<a name="3b"></a><a href="#3a"><sup>***</sup></a> &eacute; 
poss&iacute;vel compreender que uma cavidade dotada de grande raio aumenta a for
&ccedil;a exigida para gerar determinada press&atilde;o, isto &eacute;, aumenta 
a p&oacute;s-carga. A dilata&ccedil;&atilde;o da cavidade ventricular &eacute; r
econhecida, h&aacute; anos, como fator cr&iacute;tico na determina&ccedil;&atild
e;o do remodelamento e da disfun&ccedil;&atilde;o ventricular<sup>23</sup>. Trab
alhos de nosso laborat&oacute;rio documentaram a import&acirc;ncia do volume ven
tricular expandido na capacidade de gerar press&atilde;o<sup>8</sup> e de ejetar
<sup>7</sup>. A redu&ccedil;&atilde;o da eje&ccedil;&atilde;o se manifesta imedi
atamente ap&oacute;s a promo&ccedil;&atilde;o da necrose mioc&aacute;rdica. Rato
s estudados imediatamente ap&oacute;s oclus&atilde;o das coron&aacute;rias t&eci
rc;m redu&ccedil;&atilde;o da fra&ccedil;&atilde;o de encurtamento da &aacute;re
a transversa (FEAT) do VE (dados n&atilde;o publicados). Dois dias depois, a FEA
T assume valores que permanecer&atilde;o est&aacute;veis at&eacute; as fases mai
s avan&ccedil;adas do remodelamento e ICC<sup>20,22</sup>. Nas fases iniciais, o
 comprometimento da contratilidade do mioc&aacute;rdio remanescente n&atilde;o c
ontribui para a disfun&ccedil;&atilde;o ventricular. Ratos analisados tr&ecirc;s
 semanas ap&oacute;s oclus&atilde;o arterial denotaram sinais claros de disfun&c
cedil;&atilde;o ventricular, embora n&atilde;o tenha sido identificado acometime
nto do inotropismo do mioc&aacute;rdio n&atilde;o envolvido na necrose<sup>11,24
</sup>. </font></p>     ^cY#aop03911.htm##
02983000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704274300081002001302824#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#26#22#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Nas &uacute;ltimas d&eacute;cad
as o modelo experimental de ICC secund&aacute;ria ao IM, nos ratos, vem contribu
indo marcadamente para se analisar a fisiopatologia e a terap&ecirc;utica da s&i
acute;ndrome congestiva, n&atilde;o obstante seus dois grandes impasses: mortali
dade imediata elevada e heterogeneidade do tamanho do IM. Visando superar estes 
inconvenientes, h&aacute; alguns anos foi descrito um modelo de IM promovido por
 crioinj&uacute;ria<sup>25</sup>. Nossa experi&ecirc;ncia com esta t&eacute;cnic
a n&atilde;o foi satisfat&oacute;ria (dados n&atilde;o publicados). &Eacute; gra
nde o n&uacute;mero de congelamentos do mioc&aacute;rdio necess&aacute;rios para
 se conseguir necrose, nem sempre a les&atilde;o &eacute; transmural e, n&atilde
;o raro, as manobras para obter a hipotermia mioc&aacute;rdica acarretam assisto
lia definitiva. Mais recentemente, descrevemos<sup>20</sup> modelo original de p
romo&ccedil;&atilde;o de necrose mioc&aacute;rdica no VE de ratos em consequ&eci
rc;ncia da abla&ccedil;&atilde;o por corrente el&eacute;trica com r&aacute;dio-f
requ&ecirc;ncia (CRF), tal como rotineiramente &eacute; aplicada na cl&iacute;ni
ca para corre&ccedil;&atilde;o de arritmias. O prop&oacute;sito foi buscar uma t
&eacute;cnica que possibilitasse a obten&ccedil;&atilde;o de IM com menor variab
ilidade de tamanho, e menor ocorr&ecirc;ncia de mortalidade imediata. Verificamo
s infartos com tamanho de 45 ± 8% da circunfer&ecirc;ncia ventricular. A menor d
ispers&atilde;o do tamanho do IM obtido por CRF est&aacute; caracteriza por desv
io padr&atilde;o expressivamente menor do que aquele verificado para o tamanho d
o IM obtido por oclus&atilde;o da descendente anterior. A mortalidade imediata c
onstatada para a t&eacute;cnica de CRF foi de 7%. Paralelamente, documentamos qu
e, quando infartos de tamanhos semelhantes s&atilde;o comparados, a evolu&ccedil
;&atilde;o das disfun&ccedil;&otilde;es mioc&aacute;rdica e ventricular, assim c
omo a de congest&atilde;o pulmonar, encontradas no IM obtido por CRF foram equiv
alentes &agrave;quelas despertadas pela oclus&atilde;o coron&aacute;ria. Acres&c
cedil;a-se a isso a possibilidade de se controlar o tamanho do infarto variando-
se o tamanho do eletrodo positivo utilizado ou as caracter&iacute;sticas de ener
gia e de dura&ccedil;&atilde;o da CRF liberada no mioc&aacute;rdio. Mais recente
mente, testamos, com igual sucesso, esta nova t&eacute;cnica em camundongos. O i
nteresse pela utiliza&ccedil;&atilde;o deste modelo deve se ampliar j&aacute; em
 curto prazo, dada a expans&atilde;o contempor&acirc;nea dos estudos de tratamen
to p&oacute;s-infarto do mioc&aacute;rdio com c&eacute;lulas tronco. </font></p>
     ^cY#aop03911.htm##
00362000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704012200081002001300203#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#27#23#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif"><b>Potencial Conflito de Intere
sses</b></font></p>     ^cY#aop03911.htm##
00384000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704014400081002001300225#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#28#24#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Declaro n&atilde;o haver confli
to de interesses pertinentes. </font></p>     ^cY#aop03911.htm##
00353000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704011300081002001300194#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#29#25#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fontes de Financiamento</b><
/font></p>     ^cY#aop03911.htm##
00385000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704014500081002001300226#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#30#26#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">O presente estudo foi financiad
o pela FAPESP, CNPq e UNIFESP. </font></p>     ^cY#aop03911.htm##
00370000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704013000081002001300211#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#31#27#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif"><b>Vincula&ccedil;&atilde;o Aca
d&ecirc;mica</b></font></p>     ^cY#aop03911.htm##
00433000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704019300081002001300274#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#32#28#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">N&atilde;o h&aacute; vincula&cc
edil;&atilde;o deste estudo a programas de p&oacute;s-gradua&ccedil;&atilde;o. <
/font></p>     ^cY#aop03911.htm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#33#29#text#93#<p>&nbsp;</p> 
    ^cY#aop03911.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704010700081002001300188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#34#30#text#93#<p><font size=
"3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></font>
</p>     ^cY#aop03911.htm##
00495000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704024100083002001300324#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#35#31#text#93#1#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Zornof LAM, Pa
iva SAR, Minicucci MF, Spadaro J. Infarto do mioc&aacute;rdio experimental em ra
tos: an&aacute;lise do m&eacute;todo. Arq Bras Cardiol. 2009; 93: 434-40.    ^cY
#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#36#32#text#93# </font></p>  
   ^cY#aop03911.htm##
00544000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704029000083002001300373#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#37#33#text#93#2#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Bonilha AMM, S
araiva RM, Kanashiro RM, Portes LA, Antonio EL, Tucci PJF. A routine electrocard
iogram should not be used to determine the size of myocardial infarction in the 
rat. Braz J Med Biol Res. 2005; 38: 615-9.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#38#34#text#93# </font></p>  
   ^cY#aop03911.htm##
00604000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704035000083002001300433#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#39#35#text#93#3#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Cury AF, Bonil
ha AMM, Saraiva RM, Campos Fo O, Carvalho AC, de Paola AAV, et al. Myocardial pe
rformance index in female rats with myocardial infarction: relationship with ven
tricular function parameters by Doppler echocardiography. J Am Soc Echocardiogr.
 2005; 18 (5): 454-60.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#40#36#text#93# </font></p>  
   ^cY#aop03911.htm##
00560000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704030600083002001300389#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#41#37#text#93#4#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. dos Santos L, 
Mello AF, Antonio EL, Tucci PJF. Determination of myocardial infarction size in 
rats by echocardiogrphy and tetrazolium staining: correlating, agreements, and s
implification. Braz J Med Biol Res. 2008; 41 (3): 199-201.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#42#38#text#93# </font></p>  
   ^cY#aop03911.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704030500083002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#43#39#text#93#5#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. dos Santos L, 
Serra AJ, Antonio EL, Hull HF, Tucci PJF. Hiperbaric oxygenation applied immedia
tely after coronary occlusion reduces myocardial necrosis and acute mortality in
 rats. Clin Exp Pharmacol Physiol. 2009; 36 (5-6): 594-8.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#44#40#text#93# </font></p>  
   ^cY#aop03911.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704028500083002001300368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#45#41#text#93#6#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Helber I, Sant
os AA, Antonio EL, Flumignan RLC, Bocalini D, Piccolo C, et al. Digitoxin prolon
gs survival of female rats with heart failure due to large myocardial infarction
. J Card Fail. 2009; 15 (9): 798-804.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#46#42#text#93# </font></p>  
   ^cY#aop03911.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704029100083002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#47#43#text#93#7#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Kanashiro RM, 
Saraiva RM, Alberta A, Antonio EL, Mois&eacute;s VA, Tucci PJF. Immediate functi
onal effects of left ventricular reduction: a Doppler echocardiographic study in
 the rat. J Card Fail. 2006; 12 (2): 163-9.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#48#44#text#93# </font></p>  
   ^cY#aop03911.htm##
00551000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704029700083002001300380#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#49#45#text#93#8#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Kanashiro RM, 
Nozawa E, Murad N, Gerola LR, Mois&eacute;s VA, Tucci PJF. Myocardial infarction
 scar plication in the rat: cardiac mechanics in an animal model for surgical pr
ocedures. Ann Thorac Surg. 2002; 73 (5): 1507-13.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#50#46#text#93# </font></p>  
   ^cY#aop03911.htm##
00573000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000200081704031900083002001300402#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#51#47#text#93#9#
<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Nozawa E, Kana
shiro R, Murad N, Carvalho ACC, Cravo SL, Campos O, et al. Performance of two-di
mensional Doppler echocardiography for the assessment of infarct size and left v
entricular function in rats. Braz J Med Biol Res. 2006; 39 (5): 687-95.    ^cY#a
op03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#52#48#text#93# </font></p>  
   ^cY#aop03911.htm##
00603000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704034800084002001300432#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#53#49#text#93#10
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Mois&eacute;
s VA, Ferreira RL, Nozawa E, Kanashiro RM, Campos Fo O, Andrade JL, et al. Struc
tural and functional characteristics of rat hearts with and and without myocardi
al infarct: initial experience with Doppler echocardiography. Arq Bras Cardiol. 
2000; 75 (2): 125-36.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#54#50#text#93# </font></p>  
   ^cY#aop03911.htm##
00534000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704027900084002001300363#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#55#51#text#93#11
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Peron APON, 
Saraiva RM, Antonio EL, Andriolo A, Tucci PJF. Food restriction does not impair 
myocardial mechanics during the healing period of myocardial infarction in the r
at. Nutr Res. 2005; 25: 1075-84.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#56#52#text#93# </font></p>  
   ^cY#aop03911.htm##
00613000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704035800084002001300442#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#57#53#text#93#12
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Portes LA, T
ucci PJF. O treinamento f&iacute;sico por nata&ccedil;&atilde;o atenua o remodel
amento mioc&aacute;rdico e congest&atilde;o pulmonar em ratas Wistar com insufic
i&ecirc;ncia card&iacute;aca secund&aacute;ria a infarto do mioc&aacute;rdio. Ar
q Bras Cardiol. 2006; 87: 54-9.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#58#54#text#93# </font></p>  
   ^cY#aop03911.htm##
00567000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704031200084002001300396#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#59#55#text#93#13
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Portes LA, S
araiva RM, Santos AA, Tucci PJF. Swimming training attenuates remodeling, contra
tile dysfunction and congestive heart failure in rats with moderate and large my
ocardial infarction. Clin Exp Pharmacol Physiol. 2009; 36: 394-9.    ^cY#aop0391
1.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#60#56#text#93# </font></p>  
   ^cY#aop03911.htm##
00536000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704028100084002001300365#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#61#57#text#93#14
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Santos AA, H
elber I, Flumignan RLC, Antonio EL, Carvalho AC, Paola AAV, et al. Doppler echoc
ardiographic predictors of mortality in female rats after myocardial infarction.
 J Card Fail. 2009; 15 (2): 163-8.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#62#58#text#93# </font></p>  
   ^cY#aop03911.htm##
00593000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704033800084002001300422#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#63#59#text#93#15
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Saraiva RM, 
Kanashiro RM, Antonio EL, Campos Fo O, Tucci PJF, Mois&eacute;s VA. Rats with hi
gh left ventricular end-diastolic pressure can be identified by Doppler echocard
iography one week after myocardial infarction. Braz J Med Biol Res. 2007; 40 (11
): 1557-65.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#64#60#text#93# </font></p>  
   ^cY#aop03911.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704030400084002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#65#61#text#93#16
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Jain M, Liao
 R, Ngoy S, Whittaker P, Apstein CS, Eberli FR. Angiotensin II receptor blockade
 attenuates the deleterious effects of exercise training on post-MI ventricular 
remodelling in rats. Cardiovasc Res. 2000; 46 (1): 66-72.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#66#62#text#93# </font></p>  
   ^cY#aop03911.htm##
00545000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704029000084002001300374#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#67#63#text#93#17
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Opitz CF, Mi
tchell GF, Pfeffer MA, Pfeffer JM. Arrhythmias and death after coronary artery o
cclusion in the rat: continuous telemetric ECG monitoring in conscious, untether
ed rats. Circulation. 1995; 92 (2): 253-61.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#68#64#text#93# </font></p>  
   ^cY#aop03911.htm##
00521000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704026600084002001300350#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#69#65#text#93#18
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Flumignan RL
, Kanashiro RM, Saraiva RM, Portes LA, Antonio EL, Ishiga MMS, et al. Incidence 
of heart failure in infarcted rats that die spontaneously. Braz J Med Biol Res. 
2006; 39 (10): 1-6.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#70#66#text#93# </font></p>  
   ^cY#aop03911.htm##
00640000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704038500084002001300469#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#71#67#text#93#19
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Barberato SH
, Pecoits Filho R. Influ&ecirc;ncia da redu&ccedil;&atilde;o da pr&eacute;-carga
 sobre o &iacute;ndice de desempenho mioc&aacute;rdico (&Iacute;ndice de Tei) e 
outros par&acirc;metros Doppler ecocardiogr&aacute;ficos da fun&ccedil;&atilde;o
 ventricular esquerda. Arq Bras Cardiol. 2006; 86: 425-31.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#72#68#text#93# </font></p>  
   ^cY#aop03911.htm##
00594000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704033900084002001300423#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#73#69#text#93#20
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Antonio EL, 
Santos AA, Araujo SRR, Bocalini D, dos Santos L, Fenelon G, et al. Left ventricl
e radio-frequency ablation in the rat: a new model of heart failure due to myoca
rdial infarction homogeneous in size and low in mortality. J Card Fail. 2009; 15
 (6): 540-8.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#74#70#text#93# </font></p>  
   ^cY#aop03911.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704026500084002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#75#71#text#93#21
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Francis J, W
eiss RM, Wei SG, Johnson AK, Felder RB. Progression of heart failure after myoca
rdial infarction in the rat. Am J Physiol Regul Integrat Comp Physiol. 2001; 281
 (4): R1734-R1745.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#76#72#text#93# </font></p>  
   ^cY#aop03911.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704030400084002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#77#73#text#93#22
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Santos L, Sa
ntos AA, Gon&ccedil;alves GA, Krieger JE, Tucci PJF. Bone marrow cell therapy pr
events infarct expansion and improves border zone remodeling after coronary occl
usion in rats. J Card Fail. 2009 &#91;ahead of print&#93;    ^cY#aop03911.htm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#78#74#text#93#. </font></p> 
    ^cY#aop03911.htm##
00546000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704029100084002001300375#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#79#75#text#93#23
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. White HD, No
rris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systo
lic volume as the major determinant of survival after recovery from myocardial i
nfarction. Circulation. 1987; 76 (1): 44-51.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#80#76#text#93# </font></p>  
   ^cY#aop03911.htm##
00639000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704038400084002001300468#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#81#77#text#93#24
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Peron APON, 
Saraiva RM, Antonio EL, Tucci PJF. A fun&ccedil;&atilde;o mec&acirc;nica do mioc
&aacute;rdio remanescente a um infarto do mioc&aacute;rdio &eacute; normal duran
te o per&iacute;odo de cicatriza&ccedil;&atilde;o, embora exista insufici&ecirc;
ncia card&iacute;aca. Arq Bras Cardiol. 2006; 86: 105-12.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#82#78#text#93# </font></p>  
   ^cY#aop03911.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078888000300081704027800084002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#83#79#text#93#25
#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Huwer H, Win
ning J, Vollmar B, Welter C, Menger MD, Schafers HJ. Model of chronic systolic a
nd diastolic dysfunction after cryothermia-induced myocardial necrosis in rats. 
Comp Med. 2000; 50 (4): 385-90.    ^cY#aop03911.htm##
00261000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002100081002001300102#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#84#80#text#93# </font></p>  
   ^cY#aop03911.htm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#85#81#text#93#<p>&nbsp;</p> 
    ^cY#aop03911.htm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#86#82#text#93#<p>&nbsp;</p> 
    ^cY#aop03911.htm##
00442000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704020200081002001300283#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#87#83#text#93#<p><a name="en
db"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#en
da"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a> <b>Correspo
nd&ecirc;ncia:</b>      ^cY#aop03911.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704004800081002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#88#84#text#93#<br>   Paulo J
os&eacute; Ferreira Tucci     ^cY#aop03911.htm##
00302000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704006200081002001300143#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#89#85#text#93#<br>   Rua Est
ado de Israel, 181/94 - Vila Clementino     ^cY#aop03911.htm##
00295000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704005500081002001300136#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#90#86#text#93#<br>   04022-0
00 S&atilde;o Paulo, SP - Brasil     ^cY#aop03911.htm##
00401000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704016100081002001300242#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#91#87#text#93#<br>   E-mail:
 <a href="mailto:ptucci@cardiol.br">ptucci@cardiol.br</a>, <a href="mailto:paulo
tucci@terra.com.br">paulotucci@terra.com.br</a></font></p>     ^cY#aop03911.htm#
#
00404000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704016400081002001300245#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#92#88#text#93#<p><font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 29/10/09; re
visado recebido em 05/01/10;   aceito em 23/02/10.</font></p>     ^cY#aop03911.h
tm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#93#89#text#93#<p>&nbsp;</p> 
    ^cY#aop03911.htm##
00262000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704002200081002001300103#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#94#90#text#93#<p>&nbsp;</p> 
    ^cY#aop03911.htm##
00673000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704043300081002001300514#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#95#91#text#93#<p><a name="1a
"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#1b">
*</a> N&atilde;o nos valemos mais dos volumes ventriculares para analisar fun&cc
edil;&atilde;o ventricular de ratos por considerar que: a incid&ecirc;ncia do ec
ocardiograma, as implica&ccedil;&otilde;es da geometria e o tamanho reduzido da 
c&acirc;mara - especialmente o volume sist&oacute;lico final - comprometem a fid
elidade dos    ^cY#aop03911.htm##
00378000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704013800081002001300219#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#96#92#text#93#<br>   <a name
="2a"></a><a href="#2b">**</a> Teor de &aacute;gua (%) = (peso &uacute;mido - pe
so seco / peso &uacute;mido) x 100.     ^cY#aop03911.htm##
00565000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000500073708000300078704032500081002001300406#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop03911.htm#S#p#97#93#text#93#<br>   <a name
="3a"></a><a href="#3b">***</a> A for&ccedil;a (F) desenvolvida pelo mioc&aacute
;rdio para gerar determinada press&atilde;o (P) no interior da cavidade &eacute;
 diretamente proporcional ao raio da cavidade (R) e inversamente proporcional &a
grave; espessura da parede (h): F = P &#215; R/2h. </font></p>     ^cY#aop03911.
htm##
00612000000000301000450000400110000070200520001170500020006370600020006570000030
00677010002000707090005000727080003000771180002000800100018000820100017001000100
02000117010001700137012006600154030001700220065000900237064000500246031000300251
014000700254865000900261002001300270035001000283801001700293#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop03911.htm#S#c#98#1#text#25#1#^rND^sZornof^nLAM
#^rND^sPaiva^nSAR#^rND^sMinicucci^nMF#^rND^sSpadaro^nJ#Infarto do miocárdio expe
rimental em ratos: análise do método^lpt#Arq Bras Cardiol#20090000#2009#93#434-4
0#20110000#aop03911.htm#0066-782X#Arq Bras Cardiol##
00721000000000325000450000400110000070200520001170500020006370600020006570000030
00677010002000707090005000727080003000771180002000800100019000820100018001010100
02000119010001700139010001800156010001700174012010900191030002000300065000900320
06400050032903100030033401400060033786500090034300200130035203500100036580100200
0375#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#c#99#2#tex
t#25#2#^rND^sBonilha^nAMM#^rND^sSaraiva^nRM#^rND^sKanashiro^nRM#^rND^sPortes^nLA
#^rND^sAntonio^nEL#^rND^sTucci^nPJF#A routine electrocardiogram should not be us
ed to determine the size of myocardial infarction in the rat^len#Braz J Med Biol
 Res#20050000#2005#38#615-9#20110000#aop03911.htm#0100-879X#Braz J Med Biol Res#
#
00805000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090005000737080003000781180002000810100015000830100019000980100
01800117010001900135010001900154010002000173810000600193012015400199030002200353
06500090037506400050038403100030038903200020039201400070039486500090040100200130
0410035001000423801002200433#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03911.htm#S#c#100#3#text#25#3#^rND^sCury^nAF#^rND^sBonilha^nAMM#^rND^sSaraiva^
nRM#^rND^sCampos Fo^nO#^rND^sCarvalho^nAC#^rND^sde Paola^nAAV#et al#Myocardial p
erformance index in female rats with myocardial infarction: relationship with ve
ntricular function parameters by Doppler echocardiography^len#J Am Soc Echocardi
ogr#20050000#2005#18#5#454-60#20110000#aop03911.htm#0894-7317#J Am Soc Echocardi
ogr##
00712000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090005000737080003000781180002000810100020000830100016001030100
01800119010001700137012014500154030002000299065000900319064000500328031000300333
032000200336014000800338865000900346002001300355035001000368801002000378#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#c#101#4#text#25#4#^rND
^sdos Santos^nL#^rND^sMello^nAF#^rND^sAntonio^nEL#^rND^sTucci^nPJF#Determination
 of myocardial infarction size in rats by echocardiogrphy and tetrazolium staini
ng: correlating, agreements, and simplification^len#Braz J Med Biol Res#20080000
#2008#41#3#199-201#20110000#aop03911.htm#0100-879X#Braz J Med Biol Res##
00736000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090005000737080003000781180002000810100020000830100016001030100
01800119010001500137010001700152012012800169030002700297065000900324064000500333
03100030033803200040034101400060034586500090035100200130036003500100037380100270
0383#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#c#102#5#te
xt#25#5#^rND^sdos Santos^nL#^rND^sSerra^nAJ#^rND^sAntonio^nEL#^rND^sHull^nHF#^rN
D^sTucci^nPJF#Hiperbaric oxygenation applied immediately after coronary occlusio
n reduces myocardial necrosis and acute mortality in rats^len#Clin Exp Pharmacol
 Physiol#20090000#2009#36#5-6#594-8#20110000#aop03911.htm#0305-1870#Clin Exp Pha
rmacol Physiol##
00730000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090005000737080003000781180002000810100016000830100017000990100
01800116010002100134010001800155010001700173810000600190012010100196030001200297
06500090030906400050031803100030032303200020032601400080032886500090033600200130
0345035001000358801001200368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03911.htm#S#c#103#6#text#25#6#^rND^sHelber^nI#^rND^sSantos^nAA#^rND^sAntonio^n
EL#^rND^sFlumignan^nRLC#^rND^sBocalini^nD#^rND^sPiccolo^nC#et al#Digitoxin prolo
ngs survival of female rats with heart failure due to large myocardial infarctio
n^len#J Card Fail#20090000#2009#15#9#798-804#20110000#aop03911.htm#1071-9164#J C
ard Fail##
00718000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090005000737080003000781180002000810100020000830100018001030100
01700121010001800138010001700156010001700173012010900190030001200299065000900311
06400050032003100030032503200020032801400060033086500090033600200130034503500100
0358801001200368#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#
S#c#104#7#text#25#7#^rND^sKanashiro^nRM#^rND^sSaraiva^nRM#^rND^sAlberta^nA#^rND^
sAntonio^nEL#^rND^sMoisés^nVA#^rND^sTucci^nPJF#Immediate functional effects of l
eft ventricular reduction: a Doppler echocardiographic study in the rat^len#J Ca
rd Fail#20060000#2006#12#2#163-9#20110000#aop03911.htm#1071-9164#J Card Fail##
00728000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090005000737080003000781180002000810100020000830100016001030100
01500119010001700134010001700151010001700168012011400185030001600299065000900315
06400050032403100030032903200020033201400080033486500090034200200130035103500100
0364801001600374#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#
S#c#105#8#text#25#8#^rND^sKanashiro^nRM#^rND^sNozawa^nE#^rND^sMurad^nN#^rND^sGer
ola^nLR#^rND^sMoisés^nVA#^rND^sTucci^nPJF#Myocardial infarction scar plication i
n the rat: cardiac mechanics in an animal model for surgical procedures^len#Ann 
Thorac Surg#20020000#2002#73#5#1507-13#20110000#aop03911.htm#0003-4975#Ann Thora
c Surg##
00772000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090005000737080003000781180002000810100016000830100019000990100
01500118010002000133010001600153010001600169810000600185012013300191030002000324
06500090034406400050035303100030035803200020036101400070036386500090037000200130
0379035001000392801002000402#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03911.htm#S#c#106#9#text#25#9#^rND^sNozawa^nE#^rND^sKanashiro^nR#^rND^sMurad^n
N#^rND^sCarvalho^nACC#^rND^sCravo^nSL#^rND^sCampos^nO#et al#Performance of two-d
imensional Doppler echocardiography for the assessment of infarct size and left 
ventricular function in rats^len#Braz J Med Biol Res#20060000#2006#39#5#687-95#2
0110000#aop03911.htm#0100-879X#Braz J Med Biol Res##
00792000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100017000850100019001020100
01600121010002000137010001900157010001800176810000600194012015000200030001700350
06500090036706400050037603100030038103200020038401400070038686500090039300200130
0402035001000415801001700425#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03911.htm#S#c#107#10#text#25#10#^rND^sMoisés^nVA#^rND^sFerreira^nRL#^rND^sNoza
wa^nE#^rND^sKanashiro^nRM#^rND^sCampos Fo^nO#^rND^sAndrade^nJL#et al#Structural 
and functional characteristics of rat hearts with and and without myocardial inf
arct: initial experience with Doppler echocardiography^len#Arq Bras Cardiol#2000
0000#2000#75#2#125-36#20110000#aop03911.htm#0066-782X#Arq Bras Cardiol##
00654000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100018000850100018001030100
01800121010001800139010001700157012012000174030000900294710000200303065000900305
064000500314031000300319014000800322865000900330002001300339#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop03911.htm#S#c#108#11#text#25#11#^rND^sPeron^nA
PON#^rND^sSaraiva^nRM#^rND^sAntonio^nEL#^rND^sAndriolo^nA#^rND^sTucci^nPJF#Food 
restriction does not impair myocardial mechanics during the healing period of my
ocardial infarction in the rat^len#Nutr Res#2#20050000#2005#25#1075-84#20110000#
aop03911.htm##
00654000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100017000850100017001020120
16900119030001700288065000900305064000500314031000300319014000500322865000900327
002001300336035001000349801001700359#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop03911.htm#S#c#109#12#text#25#12#^rND^sPortes^nLA#^rND^sTucci^nPJF#O tr
einamento físico por natação atenua o remodelamento miocárdico e congestão pulmo
nar em ratas Wistar com insuficiência cardíaca secundária a infarto do miocárdio
^lpt#Arq Bras Cardiol#20060000#2006#87#54-9#20110000#aop03911.htm#0066-782X#Arq 
Bras Cardiol##
00716000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100017000850100018001020100
01700120010001700137012015100154030002700305065000900332064000500341031000300346
014000600349865000900355002001300364035001000377801002700387#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop03911.htm#S#c#110#13#text#25#13#^rND^sPortes^n
LA#^rND^sSaraiva^nRM#^rND^sSantos^nAA#^rND^sTucci^nPJF#Swimming training attenua
tes remodeling, contratile dysfunction and congestive heart failure in rats with
 moderate and large myocardial infarction^len#Clin Exp Pharmacol Physiol#2009000
0#2009#36#394-9#20110000#aop03911.htm#0305-1870#Clin Exp Pharmacol Physiol##
00727000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100017000850100016001020100
02100118010001800139010001900157010001700176810000600193012009700199030001200296
06500090030806400050031703100030032203200020032501400060032786500090033300200130
0342035001000355801001200365#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03911.htm#S#c#111#14#text#25#14#^rND^sSantos^nAA#^rND^sHelber^nI#^rND^sFlumign
an^nRLC#^rND^sAntonio^nEL#^rND^sCarvalho^nAC#^rND^sPaola^nAAV#et al#Doppler echo
cardiographic predictors of mortality in female rats after myocardial infarction
^len#J Card Fail#20090000#2009#15#2#163-8#20110000#aop03911.htm#1071-9164#J Card
 Fail##
00774000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100018000850100020001030100
01800123010001900141010001700160010001700177012014200194030002000336065000900356
06400050036503100030037003200030037301400080037686500090038400200130039303500100
0406801002000416#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#
S#c#112#15#text#25#15#^rND^sSaraiva^nRM#^rND^sKanashiro^nRM#^rND^sAntonio^nEL#^r
ND^sCampos Fo^nO#^rND^sTucci^nPJF#^rND^sMoisés^nVA#Rats with high left ventricul
ar end-diastolic pressure can be identified by Doppler echocardiography one week
 after myocardial infarction^len#Braz J Med Biol Res#20070000#2007#40#11#1557-65
#20110000#aop03911.htm#0100-879X#Braz J Med Biol Res##
00742000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100014000850100014000990100
01400113010001900127010001800146010001700164012013600181030001500317065000900332
06400050034103100030034603200020034901400060035186500090035700200130036603500100
0379801001500389#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#
S#c#113#16#text#25#16#^rND^sJain^nM#^rND^sLiao^nR#^rND^sNgoy^nS#^rND^sWhittaker^
nP#^rND^sApstein^nCS#^rND^sEberli^nFR#Angiotensin II receptor blockade attenuate
s the deleterious effects of exercise training on post-MI ventricular remodellin
g in rats^len#Cardiovasc Res#20000000#2000#46#1#66-72#20110000#aop03911.htm#0008
-6363#Cardiovasc Res##
00689000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100016000850100019001010100
01800120010001800138012013700156030001200293065000900305064000500314031000300319
032000200322014000700324865000900331002001300340035001000353801001200363#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#c#114#17#text#25#17#^r
ND^sOpitz^nCF#^rND^sMitchell^nGF#^rND^sPfeffer^nMA#^rND^sPfeffer^nJM#Arrhythmias
 and death after coronary artery occlusion in the rat: continuous telemetric ECG
 monitoring in conscious, untethered rats^len#Circulation#19950000#1995#92#2#253
-61#20110000#aop03911.htm#0009-7322#Circulation##
00720000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100020000850100020001050100
01800125010001700143010001800160010001800178810000600196012007200202030002000274
06500090029406400050030303100030030803200030031101400040031486500090031800200130
0327035001000340801002000350#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03911.htm#S#c#115#18#text#25#18#^rND^sFlumignan^nRL#^rND^sKanashiro^nRM#^rND^s
Saraiva^nRM#^rND^sPortes^nLA#^rND^sAntonio^nEL#^rND^sIshiga^nMMS#et al#Incidence
 of heart failure in infarcted rats that die spontaneously^len#Braz J Med Biol R
es#20060000#2006#39#10#1-6#20110000#aop03911.htm#0100-879X#Braz J Med Biol Res##
00668000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100020000850100023001050120
17200128030001700300065000900317064000500326031000300331014000700334865000900341
002001300350035001000363801001700373#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop03911.htm#S#c#116#19#text#25#19#^rND^sBarberato^nSH#^rND^sPecoits Filh
o^nR#Influência da redução da pré-carga sobre o índice de desempenho miocárdico 
(Índice de Tei) e outros parâmetros Doppler ecocardiográficos da função ventricu
lar esquerda^lpt#Arq Bras Cardiol#20060000#2006#86#425-31#20110000#aop03911.htm#
0066-782X#Arq Bras Cardiol##
00785000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100018000850100017001030100
01800120010001800138010002000156010001700176810000600193012015500199030001200354
06500090036606400050037503100030038003200020038301400060038586500090039100200130
0400035001000413801001200423#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op03911.htm#S#c#117#20#text#25#20#^rND^sAntonio^nEL#^rND^sSantos^nAA#^rND^sArauj
o^nSRR#^rND^sBocalini^nD#^rND^sdos Santos^nL#^rND^sFenelon^nG#et al#Left ventric
le radio-frequency ablation in the rat: a new model of heart failure due to myoc
ardial infarction homogeneous in size and low in mortality^len#J Card Fail#20090
000#2009#15#6#540-8#20110000#aop03911.htm#1071-9164#J Card Fail##
00650000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100017000850100016001020100
01400118010001800132010001700150012007200167030004100239710000200280065000900282
064000500291031000400296032000200300014001200302865000900314002001300323#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#c#118#21#text#25#21#^r
ND^sFrancis^nJ#^rND^sWeiss^nRM#^rND^sWei^nSG#^rND^sJohnson^nAK#^rND^sFelder^nRB#
Progression of heart failure after myocardial infarction in the rat^len#Am J Phy
siol Regul Integrat Comp Physiol#2#20010000#2001#281#4#R1734-R1745#20110000#aop0
3911.htm##
00658000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100016000850100017001010100
02000118010001800138010001700156012012500173030001200298065000900310064000500319
865000900324002001300333035001000346801001200356#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop03911.htm#S#c#119#22#text#25#22#^rND^sSantos^nL#^rND^sSant
os^nAA#^rND^sGonçalves^nGA#^rND^sKrieger^nJE#^rND^sTucci^nPJF#Bone marrow cell t
herapy prevents infarct expansion and improves border zone remodeling after coro
nary occlusion in rats^len#J Card Fail#20090000#2009#20110000#aop03911.htm#1071-
9164#J Card Fail##
00726000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100016000850100017001010100
01600118010001800134010002000152010001500172012012000187030001200307065000900319
06400050032803100030033303200020033601400060033886500090034400200130035303500100
0366801001200376#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#
S#c#120#23#text#25#23#^rND^sWhite^nHD#^rND^sNorris^nRM#^rND^sBrown^nMA#^rND^sBra
ndt^nPWT#^rND^sWhitlock^nRML#^rND^sWild^nCJ#Left ventricular end-systolic volume
 as the major determinant of survival after recovery from myocardial infarction^
len#Circulation#19870000#1987#76#1#44-51#20110000#aop03911.htm#0009-7322#Circula
tion##
00703000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100018000850100018001030100
01800121010001700139012015500156030001700311065000900328064000500337031000300342
014000700345865000900352002001300361035001000374801001700384#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop03911.htm#S#c#121#24#text#25#24#^rND^sPeron^nA
PON#^rND^sSaraiva^nRM#^rND^sAntonio^nEL#^rND^sTucci^nPJF#A função mecânica do mi
ocárdio remanescente a um infarto do miocárdio é normal durante o período de cic
atrização, embora exista insuficiência cardíaca^lpt#Arq Bras Cardiol#20060000#20
06#86#105-12#20110000#aop03911.htm#0066-782X#Arq Bras Cardiol##
00681000000000325000450000400110000070200520001170500020006370600020006570000040
00677010003000717090005000747080003000791180003000820100015000850100017001000100
01700117010001600134010001700150010001900167012011000186030000900296710000200305
06500090030706400050031603100030032103200020032401400070032686500090033300200130
0342#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop03911.htm#S#c#122#25#t
ext#25#25#^rND^sHuwer^nH#^rND^sWinning^nJ#^rND^sVollmar^nB#^rND^sWelter^nC#^rND^
sMenger^nMD#^rND^sSchafers^nHJ#Model of chronic systolic and diastolic dysfuncti
on after cryothermia-induced myocardial necrosis in rats^len#Comp Med#2#20000000
#2000#50#4#385-90#20110000#aop03911.htm##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#o#1#1#
article#1#20110411#104644#aop04011.htm#144##
04753000000000613000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201040017301201080
02770100026003850100021004110100027004320831688004590850008021470850051021550850
03502206085003502241085002902276083160102305085000803906085005303914085003403967
08500340400108500260403511700080406107200030406911200090407211100090408111600090
4090115000904099114000904108113000904117002001304126#2011nahead#V:\SciELO\serial
\abc\2011nahead\markup\aop04011.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#47#n
d#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#Complicações m
icrovasculares e disfunção autonômica cardíaca em pacientes com diabete melito t
ipo 1^lpt#Microvascular complications and cardiac autonomic dysfunction in patie
nts with diabetes mellitus type 1^len#^rND^nFernando K^sAlmeida#^rND^nJorge L^sG
ross#^rND^nTiciana C^sRodrigues#^lpt^aFUNDAMENTO: A presença de neuropatia auton
ômica cardíaca (NAC) em pacientes com diabete melito (DM) está associada a aumen
to da mortalidade e a complicações crônicas microvasculares do diabete. OBJETIVO
: Investigar uma possível associação entre achados sugestivos de NAC durante a r
ealização do teste ergométrico (TE) e nefropatia e retinopatia em pacientes com 
DM tipo 1. MÉTODOS: Realizamos um estudo transversal com 84 pacientes com DM tip
o 1. Todos os pacientes foram submetidos à avaliação clínica e laboratorial e re
alizaram TE, sendo que aqueles que apresentaram achados sugestivos de isquemia m
iocárdica foram excluídos da análise dos dados (n = 3). A avaliação de complicaç
ões microvasculares (retinopatia e nefropatia) foi realizada na amostra. RESULTA
DOS: Os pacientes com nefropatia e aqueles com retinopatia atingiram uma frequên
cia cardíaca (FC) durante o pico de exercício (FC máxima) menor e apresentaram a
umento menor da FC em relação ao repouso (&#916;FC pico) quando comparados com a
queles sem estas complicações. Esses pacientes também apresentaram menor redução
 da FC no segundo e 4º minutos após o final do teste (&#916;FC recuperação dois 
e 4 minutos). Após realização de análise multivariada com controle para os possí
veis fatores de confusão, os &#916;FC recuperação em dois e 4 minutos, FC máxima
 e o &#916;FC pico permaneceram significativamente associados à retinopatia; e o
s &#916;FC recuperação no segundo e 4º minutos permaneceram associados à presenç
a de nefropatia. CONCLUSÃO: O TE pode ser considerado um instrumento adicional p
ara a detecção precoce de NAC e para identificar pacientes em maior risco para c
omplicações microvasculares do diabete.#^dnd^i1#^tm^lpt^kDiabetes mellitus tipo 
1^i1^scomplicações#^tm^lpt^kneuropatias diabéticas^i1#^tm^lpt^kangiopatias diabé
ticas^i1#^tm^lpt^kteste de esforço^i1#^len^aBACKGROUND: The presence of cardiac 
autonomic neuropathy (CAN) in patients with diabetes mellitus (DM) is associated
 with increased mortality and chronic microvascular complications of diabetes. O
BJECTIVE: To investigate a possible association between specific findings of CAN
 during exercise testing (ET) and nephropathy and retinopathy in patients with t
ype 1 DM. METHODS: We conducted a cross-sectional study of 84 patients with type
 1 DM. All patients underwent clinical laboratory evaluation and performed ET, a
nd those who presented findings suggesting myocardial ischemia were excluded fro
m data analysis (n = 3). The assessment of microvascular complications (retinopa
thy and nephropathy) was performed in the sample. RESULTS: Patients with nephrop
athy and those with retinopathy achieved a lower heart rate (HR) at peak exercis
e (HR max) and smaller increase in HR in relation to rest (Peak &#916;HR) compar
ed with those without these complications. These patients also had a smaller red
uction in HR in the second and 4th minutes after the end of the test (&#916;HR r
ecovery 2 and 4 minutes). After performing a multivariate analysis with control 
for possible confounding factors, the &#916;HR recovery in two and four minutes,
 maximum HR and Peak &#916;HR remained significantly associated with retinopathy
; and &#916;HR recovery in the second and 4th minutes remained associated with t
he presence of nephropathy. CONCLUSION: The ET can be considered an additional t
ool for early detection of CAN and to identify patients at increased risk for mi
crovascular complications of diabetes.#^dnd^i2#^tm^len^kDiabetes mellitus, type 
1^i2^scomplications#^tm^len^kdiabetic neuropathies^i2#^tm^len^kdiabetic angiopat
hies^i2#^tm^len^kexercise test^i2#vancouv#21#20101017#17/10/10#20101223#23/12/10
#20110111#11/01/11#aop04011.htm##
04859000000000613000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000400099121000300103049000300106158000300109030002000112
03200060013206500090013801400070014703500100015422300090016401201110017301201150
02840100026003990100021004250100027004460831723004730850008021960850051022040850
03502255085003502290085002902325083165802354085000804012085005304020085003404073
08500340410708500260414111700080416707200030417511200090417811100090418711600090
4196115000904205114000904214113000904223002001304232#2011nahead#V:\SciELO\serial
\abc\2011nahead\markup\aop04011.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#47#n
d#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#0066-782X#20110415#<b>Complicaçõe
s microvasculares e disfunção autonômica cardíaca em pacientes com diabete melit
o tipo 1</b>^lpt#<b>Microvascular complications and cardiac autonomic dysfunctio
n in patients with diabetes mellitus type 1</b>^len#^rND^nFernando K^sAlmeida#^r
ND^nJorge L^sGross#^rND^nTiciana C^sRodrigues#^lpt^a<b>FUNDAMENTO:</b> A presenç
a de neuropatia autonômica cardíaca (NAC) em pacientes com diabete melito (DM) e
stá associada a aumento da mortalidade e a complicações crônicas microvasculares
 do diabete. <b>OBJETIVO:</b> Investigar uma possível associação entre achados s
ugestivos de NAC durante a realização do teste ergométrico (TE) e nefropatia e r
etinopatia em pacientes com DM tipo 1. <b>MÉTODOS:</b> Realizamos um estudo tran
sversal com 84 pacientes com DM tipo 1. Todos os pacientes foram submetidos à av
aliação clínica e laboratorial e realizaram TE, sendo que aqueles que apresentar
am achados sugestivos de isquemia miocárdica foram excluídos da análise dos dado
s (n = 3). A avaliação de complicações microvasculares (retinopatia e nefropatia
) foi realizada na amostra. <b>RESULTADOS:</b> Os pacientes com nefropatia e aqu
eles com retinopatia atingiram uma frequência cardíaca (FC) durante o pico de ex
ercício (FC máxima) menor e apresentaram aumento menor da FC em relação ao repou
so (&#916;FC pico) quando comparados com aqueles sem estas complicações. Esses p
acientes também apresentaram menor redução da FC no segundo e 4º minutos após o 
final do teste (&#916;FC recuperação dois e 4 minutos). Após realização de análi
se multivariada com controle para os possíveis fatores de confusão, os &#916;FC 
recuperação em dois e 4 minutos, FC máxima e o &#916;FC pico permaneceram signif
icativamente associados à retinopatia; e os &#916;FC recuperação no segundo e 4º
 minutos permaneceram associados à presença de nefropatia. <b>CONCLUSÃO:</b> O T
E pode ser considerado um instrumento adicional para a detecção precoce de NAC e
 para identificar pacientes em maior risco para complicações microvasculares do 
diabete.#^dnd^i1#^tm^lpt^kDiabetes mellitus tipo 1^i1^scomplicações#^tm^lpt^kneu
ropatias diabéticas^i1#^tm^lpt^kangiopatias diabéticas^i1#^tm^lpt^kteste de esfo
rço^i1#^len^a<b>BACKGROUND:</b> The presence of cardiac autonomic neuropathy (CA
N) in patients with diabetes mellitus (DM) is associated with increased mortalit
y and chronic microvascular complications of diabetes. <b>OBJECTIVE:</b> To inve
stigate a possible association between specific findings of CAN during exercise 
testing (ET) and nephropathy and retinopathy in patients with type 1 DM. <b>METH
ODS:</b> We conducted a cross-sectional study of 84 patients with type 1 DM. All
 patients underwent clinical laboratory evaluation and performed ET, and those w
ho presented findings suggesting myocardial ischemia were excluded from data ana
lysis (n = 3). The assessment of microvascular complications (retinopathy and ne
phropathy) was performed in the sample. <b>RESULTS:</b> Patients with nephropath
y and those with retinopathy achieved a lower heart rate (HR) at peak exercise (
HR max) and smaller increase in HR in relation to rest (Peak &#916;HR) compared 
with those without these complications. These patients also had a smaller reduct
ion in HR in the second and 4<sup>th</sup> minutes after the end of the test (&#
916;HR recovery 2 and 4 minutes). After performing a multivariate analysis with 
control for possible confounding factors, the &#916;HR recovery in two and four 
minutes, maximum HR and Peak &#916;HR remained significantly associated with ret
inopathy; and &#916;HR recovery in the second and 4<sup>th</sup> minutes remaine
d associated with the presence of nephropathy. <b>CONCLUSION:</b> The ET can be 
considered an additional tool for early detection of CAN and to identify patient
s at increased risk for microvascular complications of diabetes.#^dnd^i2#^tm^len
^kDiabetes mellitus, type 1^i2^scomplications#^tm^len^kdiabetic neuropathies^i2#
^tm^len^kdiabetic angiopathies^i2#^tm^len^kexercise test^i2#vancouv#21#20101017#
17/10/10#20101223#23/12/10#20110111#11/01/11#aop04011.htm##
04872000000000637000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000400106121000300110049000300113158000300116
03000190011903200060013806500090014401400070015303500100016022300090017001201040
01790120108002830100026003910100021004170100027004380831688004650850008021530850
05102161085003502212085003502247085002902282083160102311085000803912085005303920
08500340397308500340400708500260404111700080406707200030407511200090407811100090
4087116000904096115000904105114000904114113000904123002001304132008008904145#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#l#4#1#article#1#^a
2011#oa#pt#br1.1#1#4.0#tab#47#nd#nd#Arq. bras. cardiol#ahead#20110000#^f0^l0#006
6-782X#20110415#Complicações microvasculares e disfunção autonômica cardíaca em 
pacientes com diabete melito tipo 1^lpt#Microvascular complications and cardiac 
autonomic dysfunction in patients with diabetes mellitus type 1^len#^rND^nFernan
do K^sAlmeida#^rND^nJorge L^sGross#^rND^nTiciana C^sRodrigues#^lpt^aFUNDAMENTO: 
A presença de neuropatia autonômica cardíaca (NAC) em pacientes com diabete meli
to (DM) está associada a aumento da mortalidade e a complicações crônicas microv
asculares do diabete. OBJETIVO: Investigar uma possível associação entre achados
 sugestivos de NAC durante a realização do teste ergométrico (TE) e nefropatia e
 retinopatia em pacientes com DM tipo 1. MÉTODOS: Realizamos um estudo transvers
al com 84 pacientes com DM tipo 1. Todos os pacientes foram submetidos à avaliaç
ão clínica e laboratorial e realizaram TE, sendo que aqueles que apresentaram ac
hados sugestivos de isquemia miocárdica foram excluídos da análise dos dados (n 
= 3). A avaliação de complicações microvasculares (retinopatia e nefropatia) foi
 realizada na amostra. RESULTADOS: Os pacientes com nefropatia e aqueles com ret
inopatia atingiram uma frequência cardíaca (FC) durante o pico de exercício (FC 
máxima) menor e apresentaram aumento menor da FC em relação ao repouso (&#916;FC
 pico) quando comparados com aqueles sem estas complicações. Esses pacientes tam
bém apresentaram menor redução da FC no segundo e 4º minutos após o final do tes
te (&#916;FC recuperação dois e 4 minutos). Após realização de análise multivari
ada com controle para os possíveis fatores de confusão, os &#916;FC recuperação 
em dois e 4 minutos, FC máxima e o &#916;FC pico permaneceram significativamente
 associados à retinopatia; e os &#916;FC recuperação no segundo e 4º minutos per
maneceram associados à presença de nefropatia. CONCLUSÃO: O TE pode ser consider
ado um instrumento adicional para a detecção precoce de NAC e para identificar p
acientes em maior risco para complicações microvasculares do diabete.#^dnd^i1#^t
m^lpt^kDiabetes mellitus tipo 1^i1^scomplicações#^tm^lpt^kneuropatias diabéticas
^i1#^tm^lpt^kangiopatias diabéticas^i1#^tm^lpt^kteste de esforço^i1#^len^aBACKGR
OUND: The presence of cardiac autonomic neuropathy (CAN) in patients with diabet
es mellitus (DM) is associated with increased mortality and chronic microvascula
r complications of diabetes. OBJECTIVE: To investigate a possible association be
tween specific findings of CAN during exercise testing (ET) and nephropathy and 
retinopathy in patients with type 1 DM. METHODS: We conducted a cross-sectional 
study of 84 patients with type 1 DM. All patients underwent clinical laboratory 
evaluation and performed ET, and those who presented findings suggesting myocard
ial ischemia were excluded from data analysis (n = 3). The assessment of microva
scular complications (retinopathy and nephropathy) was performed in the sample. 
RESULTS: Patients with nephropathy and those with retinopathy achieved a lower h
eart rate (HR) at peak exercise (HR max) and smaller increase in HR in relation 
to rest (Peak &#916;HR) compared with those without these complications. These p
atients also had a smaller reduction in HR in the second and 4th minutes after t
he end of the test (&#916;HR recovery 2 and 4 minutes). After performing a multi
variate analysis with control for possible confounding factors, the &#916;HR rec
overy in two and four minutes, maximum HR and Peak &#916;HR remained significant
ly associated with retinopathy; and &#916;HR recovery in the second and 4th minu
tes remained associated with the presence of nephropathy. CONCLUSION: The ET can
 be considered an additional tool for early detection of CAN and to identify pat
ients at increased risk for microvascular complications of diabetes.#^dnd^i2#^tm
^len^kDiabetes mellitus, type 1^i2^scomplications#^tm^len^kdiabetic neuropathies
^i2#^tm^len^kdiabetic angiopathies^i2#^tm^len^kexercise test^i2#vancouv#21#20101
017#17/10/10#20101223#23/12/10#20110111#11/01/11#aop04011.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000047##
00491000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704024900083002001300332#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#5#1#article#119#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Complic
a&ccedil;&otilde;es microvasculares e disfun&ccedil;&atilde;o auton&ocirc;mica c
ard&iacute;aca em pacientes com diabete melito tipo 1</b></font></p>     ^cY#aop
04011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#6#2#article#119#<p>&nbsp;</p
>     ^cY#aop04011.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#7#3#article#119#<p>&nbsp;</p
>     ^cY#aop04011.htm##
00389000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704014700083002001300230#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#8#4#article#119#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Fernando K. Almeida; Jorge
 L. Gross; Ticiana C. Rodrigues</b></font></p>     ^cY#aop04011.htm##
00404000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704016200083002001300245#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#9#5#article#119#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><sup>I</sup>Servi&ccedil;o de
 Endocrinologia do Hospital de Cl&iacute;nicas de Porto Alegre    ^cY#aop04011.h
tm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704010800084002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#10#6#article#119#<br>   <sup
>II</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brasil</f
ont></p>     ^cY#aop04011.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#11#7#article#119#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#12#8#article#119#<p>&nbsp;</
p>     ^cY#aop04011.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#13#9#article#119#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop04011.htm##
00340000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009600085002001300181#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#14#10#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>   
  ^cY#aop04011.htm##
00564000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704032000085002001300405#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#15#11#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO:</b>  A prese
n&ccedil;a de neuropatia auton&ocirc;mica card&iacute;aca (NAC) em pacientes com
 diabete melito (DM) est&aacute; associada a aumento da mortalidade e a complica
&ccedil;&otilde;es cr&ocirc;nicas microvasculares do diabete.     ^cY#aop04011.h
tm##
00488000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704024400085002001300329#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#16#12#article#119#<br>   <b>
OBJETIVO:</b>  Investigar uma poss&iacute;vel associa&ccedil;&atilde;o entre ach
ados sugestivos de NAC durante a realiza&ccedil;&atilde;o do teste ergom&eacute;
trico (TE) e nefropatia e retinopatia em pacientes com DM tipo 1.     ^cY#aop040
11.htm##
00733000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704048900085002001300574#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#17#13#article#119#<br>   <b>
M&Eacute;TODOS:</b>  Realizamos um estudo transversal com 84 pacientes com DM ti
po 1. Todos os pacientes foram submetidos &agrave; avalia&ccedil;&atilde;o cl&ia
cute;nica e laboratorial e realizaram TE, sendo que aqueles que apresentaram ach
ados sugestivos de isquemia mioc&aacute;rdica foram exclu&iacute;dos da an&aacut
e;lise dos dados (n = 3). A avalia&ccedil;&atilde;o de complica&ccedil;&otilde;e
s microvasculares (retinopatia e nefropatia) foi realizada na amostra.     ^cY#a
op04011.htm##
01541000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704129700085002001301382#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#18#14#article#119#<br>   <b>
RESULTADOS:</b>  Os pacientes com nefropatia e aqueles com retinopatia atingiram
 uma frequ&ecirc;ncia card&iacute;aca (FC) durante o pico de exerc&iacute;cio (F
C m&aacute;xima) menor e apresentaram aumento menor da FC em rela&ccedil;&atilde
;o ao repouso (</font>&#916;<font size="2" face="Verdana, Arial, Helvetica, sans
-serif">FC pico) quando comparados com aqueles sem estas complica&ccedil;&otilde
;es. Esses pacientes tamb&eacute;m apresentaram menor redu&ccedil;&atilde;o da F
C no segundo e 4º minutos ap&oacute;s o final do teste (</font>&#916;<font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">FC recupera&ccedil;&atilde;o do
is e 4 minutos). Ap&oacute;s realiza&ccedil;&atilde;o de an&aacute;lise multivar
iada com controle para os poss&iacute;veis fatores de confus&atilde;o, os </font
>&#916;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">FC recupera&c
cedil;&atilde;o em dois e 4 minutos, FC m&aacute;xima e o </font>&#916;<font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif">FC pico permaneceram signific
ativamente associados &agrave; retinopatia; e os </font>&#916;<font size="2" fac
e="Verdana, Arial, Helvetica, sans-serif">FC recupera&ccedil;&atilde;o no segund
o e 4º minutos permaneceram associados &agrave; presen&ccedil;a de nefropatia.  
   ^cY#aop04011.htm##
00497000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025300085002001300338#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#19#15#article#119#<br>   <b>
CONCLUS&Atilde;O:</b>  O TE pode ser considerado um instrumento adicional para a
 detec&ccedil;&atilde;o precoce de NAC e para identificar pacientes em maior ris
co para complica&ccedil;&otilde;es microvasculares do diabete. </font></p>     ^
cY#aop04011.htm##
00513000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704026900085002001300354#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#20#16#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b>  Dia
betes mellitus tipo 1/complica&ccedil;&otilde;es, neuropatias diab&eacute;ticas,
 angiopatias diab&eacute;ticas, teste de esfor&ccedil;o. </font></p> <hr size="1
" noshade>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#21#17#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#22#18#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#23#19#article#119#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop04011.htm##
01909000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704166500085002001301750#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#24#20#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A neuropatia auton&ocirc;mi
ca &eacute; uma complica&ccedil;&atilde;o cr&ocirc;nica decorrente da presen&cce
dil;a do diabete melito (DM) e est&aacute; associada a um controle glic&ecirc;mi
co inadequado<sup>1-3</sup>. Entretanto, apesar de sua elevada preval&ecirc;ncia
 e do significativo impacto que seus sintomas acarretam sobre a qualidade de vid
a dos indiv&iacute;duos afetados, ela continua sendo subdiagnosticada. A grande 
variedade de manifesta&ccedil;&otilde;es cl&iacute;nicas e a complexidade dos m&
eacute;todos de avalia&ccedil;&atilde;o contribuem para a pouca identifica&ccedi
l;&atilde;o da neuropatia auton&ocirc;mica. Adicionalmente, j&aacute; foi demons
trado que a sua presen&ccedil;a eleva o risco de eventos cardiovasculares e a mo
rtalidade nos pacientes com DM<sup>3,4</sup>. A neuropatia auton&ocirc;mica card
&iacute;aca (NAC) possui uma estreita associa&ccedil;&atilde;o com mortalidade d
e origem cardiovascular<sup>4,5</sup> e, mais recentemente, as evid&ecirc;ncias 
t&ecirc;m indicado uma associa&ccedil;&atilde;o entre NAC e complica&ccedil;&oti
lde;es microvasculares, possivelmente relacionadas a uma altera&ccedil;&atilde;o
 do controle vasomotor dos pequenos vasos<sup>6</sup>. Em rela&ccedil;&atilde;o 
a NAC, h&aacute; diversos m&eacute;todos de avalia&ccedil;&atilde;o bem validado
s, muitos deles dispon&iacute;veis no consult&oacute;rio, como a resposta auton&
ocirc;mica ao ortostatismo postural, a manobra de Valsalva e a varia&ccedil;&ati
lde;o da frequ&ecirc;ncia card&iacute;aca (FC) durante os ciclos de inspira&cced
il;&atilde;o profunda<sup>4</sup>. </font></p>     ^cY#aop04011.htm##
02202000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704195800085002001302043#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#25#21#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Entre as manifesta&ccedil;&
otilde;es t&iacute;picas de neuropatia auton&ocirc;mica, destacam-se: perda da p
ercep&ccedil;&atilde;o de hipoglicemias, altera&ccedil;&otilde;es gastrointestin
ais (diarreia, constipa&ccedil;&atilde;o, incontin&ecirc;ncia fecal e gastropare
sia), altera&ccedil;&otilde;es urin&aacute;rias (bexiga neurog&ecirc;nica, manif
estada tanto por incontin&ecirc;ncia quanto por reten&ccedil;&atilde;o urin&aacu
te;ria), disfun&ccedil;&otilde;es sexuais, altera&ccedil;&otilde;es das gl&acirc
;ndulas sudor&iacute;paras (pele seca) e cardiovasculares. As altera&ccedil;&oti
lde;es auton&ocirc;micas cardiovasculares refletem-se mais precocemente em uma r
edu&ccedil;&atilde;o da variabilidade da FC, fen&ocirc;meno que predisp&otilde;e
 a hipotens&atilde;o postural, intoler&acirc;ncia ao exerc&iacute;cio e instabil
idade cardiovascular transoperat&oacute;ria, al&eacute;m de taquicardia em repou
so<sup>4</sup>. H&aacute; concomitantemente uma menor redu&ccedil;&atilde;o nos 
n&iacute;veis da press&atilde;o arterial diast&oacute;lica noturna, fen&ocirc;me
no que tamb&eacute;m poderia estar implicado no desenvolvimento de les&otilde;es
 de &oacute;rg&atilde;os-alvo<sup>7,8</sup>. A frequ&ecirc;ncia de NAC aumenta c
om a idade e com o tempo de dura&ccedil;&atilde;o do diabete, e sua presen&ccedi
l;a associa-se a retinopatia, nefropatia e neuropatia perif&eacute;rica<sup>3,4,
9,10</sup>. H&aacute; concomitantemente uma menor redu&ccedil;&atilde;o nos n&ia
cute;veis da press&atilde;o arterial diast&oacute;lica noturna, fen&ocirc;meno q
ue tamb&eacute;m poderia estar implicado no desenvolvimento de les&otilde;es de 
&oacute;rg&atilde;os-alvo<sup>7,8</sup>. A frequ&ecirc;ncia de NAC aumenta com a
 idade e com o tempo de dura&ccedil;&atilde;o do diabete, e sua presen&ccedil;a 
associa-se a retinopatia, nefropatia e neuropatia perif&eacute;rica<sup>3,4,9,10
</sup>. </font></p>     ^cY#aop04011.htm##
01172000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704092800085002001301013#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#26#22#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em pacientes com DM tipo 1 
(DM1), as altera&ccedil;&otilde;es auton&ocirc;micas card&iacute;acas, avaliadas
 pelo &iacute;ndice da FC na inspira&ccedil;&atilde;o/expira&ccedil;&atilde;o e 
pela resposta card&iacute;aca durante a indu&ccedil;&atilde;o de ortostatismo, r
elacionaram-se ao desenvolvimento de nefropatia diab&eacute;tica (ND) ao longo d
os anos<sup>11</sup>. Tamb&eacute;m j&aacute; foi demonstrado que dist&uacute;rb
ios auton&ocirc;micos detectados por pupilometria aumentam o risco de doen&ccedi
l;a renal futura<sup>12</sup>. Pacientes com nefropatia e varia&ccedil;&atilde;o
 anormal da FC durante o ciclo de inspira&ccedil;&atilde;o/expira&ccedil;&atilde
;o apresentam um risco de eventos cardiovasculares fatal e n&atilde;o fatal maio
r do que aqueles com apenas nefropatia e sem os dist&uacute;rbios auton&ocirc;mi
cos<sup>13</sup>. </font></p>     ^cY#aop04011.htm##
00953000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704070900085002001300794#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#27#23#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A varia&ccedil;&atilde;o da
 FC em rela&ccedil;&atilde;o ao pico do exerc&iacute;cio e aos primeiros minutos
 de recupera&ccedil;&atilde;o ap&oacute;s teste ergom&eacute;trico (TE) j&aacute
; foi validada como fator progn&oacute;stico cardiovascular<sup>14,15</sup>. Ent
retanto, a associa&ccedil;&atilde;o desse marcador de disfun&ccedil;&atilde;o au
ton&ocirc;mica card&iacute;aca com complica&ccedil;&otilde;es renais do DM ainda
 n&atilde;o foi demonstrada. O objetivo do presente trabalho foi descrever a ass
ocia&ccedil;&atilde;o da varia&ccedil;&atilde;o do cronotropismo com doen&ccedil
;a microvascular em pacientes com DM1. </font></p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#28#24#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00345000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010100085002001300186#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#29#25#article#119#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Metodologia</b></font></
p>     ^cY#aop04011.htm##
01699000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704145500085002001301540#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#30#26#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Realizamos um estudo transv
ersal com pacientes com DM1, os quais foram selecionados de uma coorte com mais 
de 300 pacientes acompanhados ambulatorialmente no Hospital de Cl&iacute;nicas d
e Porto Alegre<sup>16</sup>. O Comit&ecirc; de &Eacute;tica em pesquisa do hospi
tal (projeto 08-470) aprovou previamente a pesquisa e todos os pacientes, antes 
de participarem neste estudo, assinaram termo de consentimento livre e esclareci
do. Todos os pacientes selecionados haviam realizado TE como estabelecido no pro
tocolo de pesquisa, e, como crit&eacute;rio de inclus&atilde;o, foi exigido que 
os pacientes n&atilde;o demonstrassem presen&ccedil;a de isquemia mioc&aacute;rd
ica ou arritmias card&iacute;acas durante o exame. Esse crit&eacute;rio foi util
izado porque os pacientes com isquemia mioc&aacute;rdica estavam em uso de medic
a&ccedil;&otilde;es com interfer&ecirc;ncia na frequ&ecirc;ncia card&iacute;aca 
e por terem limita&ccedil;&atilde;o no esfor&ccedil;o f&iacute;sico m&aacute;xim
o. Para o indiv&iacute;duo ser considerado eleg&iacute;vel, ele deveria tamb&eac
ute;m ter teste de sensibilidade perif&eacute;rica (monofilamento) normal e n&at
ilde;o ter sintomas de neuropatia auton&ocirc;mica ou hipotens&atilde;o postural
 durante a avalia&ccedil;&atilde;o cl&iacute;nica. Atrav&eacute;s de tais crit&e
acute;rios, foi obtida-se uma amostra composta por 84 pacientes. </font></p>    
 ^cY#aop04011.htm##
01282000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704103800085002001301123#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#31#27#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As vari&aacute;veis demogr&
aacute;ficas e antropom&eacute;tricas desse grupo foram obtidas atrav&eacute;s d
e entrevista e exame cl&iacute;nico. Os pacientes foram tamb&eacute;m avaliados 
quanto &agrave; presen&ccedil;a de nefropatia diab&eacute;tica (ND) e retinopati
a diab&eacute;tica (RD). A presen&ccedil;a de RD foi avaliada por oftalmoscopia 
ap&oacute;s midr&iacute;ase realizada por um mesmo oftalmologista. Os pacientes 
com qualquer grau de retinopatia durante o exame foram classificados como positi
vos para a presen&ccedil;a desta vari&aacute;vel. Os pacientes foram categorizad
os como presen&ccedil;a de nefropatia atrav&eacute;s da an&aacute;lise de urina 
de amostra ou de urina em 24 horas, sendo considerados com nefropatia aqueles co
m excre&ccedil;&atilde;o urin&aacute;ria de albumina superior a 17 mg/dl em amos
tra ou superior a 20 &#181;g/min em urina de 24 horas<sup>15</sup>, confirmada e
m pelo duas amostras com intervalo de 06 meses. </font></p>     ^cY#aop04011.htm
##
01921000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704167700085002001301762#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#32#28#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O TE foi realizado de acord
o com protocolo de Bruce<sup>16</sup>. Informa&ccedil;&otilde;es sobre sintomas,
 ritmo, FC e press&atilde;o arterial foram coletados no basal e durante os est&a
acute;gios do protocolo: exerc&iacute;cio m&aacute;ximo, 1, 2 e 4 minutos ap&oac
ute;s o t&eacute;rmino do exame. A carga de trabalho foi avaliada pelo n&uacute;
mero de equivalentes metab&oacute;licos obtidos (METs), definidos em tabelas pad
ronizadas e correspondentes a 3,5 ml de obten&ccedil;&atilde;o de oxig&ecirc;nio
 por quilo de peso por minuto<sup>17</sup>. O aumento da FC foi definido como a 
diferen&ccedil;a entre a FC do exerc&iacute;cio m&aacute;ximo e do repouso basal
 (</font>&#916;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">FC pi
co). A FC de recupera&ccedil;&atilde;o foi definida como a diferen&ccedil;a entr
e o pico do exerc&iacute;cio m&aacute;ximo e a FC das fases de recupera&ccedil;&
atilde;o com 1, 2 e 4 minutos ap&oacute;s o t&eacute;rmino do exame (</font>&#91
6;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">FC recupera&ccedil
;&atilde;o 1, 2 e 4 minutos). Da mesma maneira, pode-se calcular o aumento da pr
ess&atilde;o arterial sist&oacute;lica e diast&oacute;lica at&eacute; o pico de 
exerc&iacute;cio e a recupera&ccedil;&atilde;o da PA em 1, 2 e 4 minutos ap&oacu
te;s o final do esfor&ccedil;o (</font>&#916;<font size="2" face="Verdana, Arial
, Helvetica, sans-serif">PAS pico, recupera&ccedil;&atilde;o 1, 2 e 4 minutos; <
/font>&#916;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">PAD pico
, recupera&ccedil;&atilde;o 1, 2 e 4 minutos). </font></p>     ^cY#aop04011.htm#
#
01447000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704120300085002001301288#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#33#29#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A excre&ccedil;&atilde;o ur
in&aacute;ria de albumina (EUA) foi medida em amostras casuais ou em coletas de 
24 horas por imunoturbidimetria (MicroAlb Sera-Pak<sup>&reg;</sup> imuno microal
buminuria, Roche<sup>&reg;</sup>, USA) em pelo duas medidas com intervalo de 06 
meses<sup>18</sup>. A hemoglobina glicosilada (HbA1c) foi medida por cromatograf
ia l&iacute;quida de alta performance (valores de refer&ecirc;ncia entre 4,7 e 6
,0%; Merck-Hitachi 9100, Alemanha). A glicemia de jejum foi medida pelo m&eacute
;todo da colorim&eacute;trico enzim&aacute;tico da glicose-peroxidase (Biodiagn&
oacute;stica, Brasil). A creatinina s&eacute;rica foi medida pelo m&eacute;todo 
de Jaff&eacute; e o colesterol total e triglicer&iacute;deos s&eacute;ricos fora
m medidos por m&eacute;todos colorim&eacute;tricos enzim&aacute;ticos (Merck Dia
gn&oacute;stica, Boeringher Manheim, Alemanha). Para medida do colesterol HDL, f
oi utilizado m&eacute;todo homog&ecirc;neo direto (<i>autoanalyzer</i>, ADVIA 16
50, Siemens <i>Healthcare  Diagnostics</i>, Alemanha). O colesterol LDL foi calc
ulado pela f&oacute;rmula de Friedwald<sup>19</sup>. </font></p>     ^cY#aop0401
1.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704012300085002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#34#30#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>An&aacute;lise estat&iac
ute;stica</b></font></p>     ^cY#aop04011.htm##
01225000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704098100085002001301066#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#35#31#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Para an&aacute;lise das var
i&aacute;veis cl&iacute;nicas e laboratoriais, foram utilizados os testes <i>t</
i> de <i>student</i> para as vari&aacute;veis quantitativas (apresentadas em m&e
acute;dia ± desvio-padr&atilde;o) e o qui-quadrado para as qualitativas (apresen
tadas em percentual do total da amostra). Vari&aacute;veis quantitativas sem dis
tribui&ccedil;&atilde;o normal foram log transformadas e s&atilde;o apresentadas
 em mediana e valor m&iacute;nimo-m&aacute;ximo. An&aacute;lises multivariadas f
oram realizadas com as vari&aacute;veis de varia&ccedil;&atilde;o da FC como var
i&aacute;veis independentes e a presen&ccedil;a de retinopatia ou nefropatia com
o vari&aacute;veis dependentes. As compara&ccedil;&otilde;es foram ajustadas par
a m&uacute;ltiplos poss&iacute;veis fatores de confus&atilde;o. Valores <i>p </i
>inferiores a 0,05 foram considerados estatisticamente significativos. </font></
p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#36#32#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00343000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704009900085002001300184#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#37#33#article#119#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultado</b></font></p>
     ^cY#aop04011.htm##
01588000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704134400085002001301429#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#38#34#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A amostra foi composta por 
84 pacientes com DM1, tr&ecirc;s pacientes foram exclu&iacute;dos ap&oacute;s o 
teste por apresentarem sinais sugestivos de cardiopatia isqu&ecirc;mica durante 
o exame. Da amostra, restaram 81 pacientes: 54,3% (n = 44) masculinos, 17,2% (n 
= 14) eram tabagistas ativos no momento deste estudo e 46,9% (n = 38) tinham o d
iagn&oacute;stico pr&eacute;vio de hipertens&atilde;o arterial (HAS). Os pacient
es tinham em m&eacute;dia 17,6 ± 11,2 anos de dura&ccedil;&atilde;o da doen&cced
il;a e idade m&eacute;dia de 40,5 ± 10,8 anos. Ap&oacute;s a investiga&ccedil;&a
tilde;o para as complica&ccedil;&otilde;es microvasculares do diabete, 54,3% (n 
= 44) dos pacientes demonstraram ter algum grau de retinopatia e 33,3% (n = 27) 
deles foram considerados como tendo nefropatia pelo resultado da microalbumin&ua
cute;ria. Dos pacientes com nefropatia, 37,0% (n = 10) tinham excre&ccedil;&atil
de;o de albumina na urina em n&iacute;veis de macroalbumin&uacute;ria. Por outro
 lado, entre os pacientes com retinopatia, 20 (45,5%) tinham retinopatia n&atild
e;o proliferativa leve, dois (4,5%) tinham a forma n&atilde;o proliferativa mode
rada, 06 (13,6%) tinham retinopatia n&atilde;o proliferativa grave e 16 (36,4%) 
tinham retinopatia proliferativa. </font></p>     ^cY#aop04011.htm##
01851000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704160700085002001301692#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#39#35#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os dados cl&iacute;nicos e 
laboratoriais dos pacientes estratificados pela presen&ccedil;a de RD est&atilde
;o exibidos na <a href="#tab1">Tabela 1</a>. Pacientes com presen&ccedil;a de re
tinopatia diab&eacute;tica apresentavam maior dura&ccedil;&atilde;o do diabete d
o que aqueles sem RD (11,4 ± 7,8 <i>vs</i> 23,4 ± 11,3 anos; p &lt; 0,01). A pre
val&ecirc;ncia do diagn&oacute;stico pr&eacute;vio de HAS tamb&eacute;m foi maio
r entre os pacientes com RD (28,1% <i>vs</i> 59,1%, p = 0,014), al&eacute;m de m
aiores n&iacute;veis s&eacute;ricos de creatinina e maior EUA. O controle glic&e
circ;mico, avaliado pela hemoglobina glicosilada, n&atilde;o apresentou associa&
ccedil;&atilde;o com esta complica&ccedil;&atilde;o (8,15% ± 1,9 <i>vs</i> 8,7% 
± 1,7; p = 0,24). N&atilde;o houve diferen&ccedil;a em rela&ccedil;&atilde;o &ag
rave; idade, sexo ou tabagismo. Durante o TE, observou-se que aqueles pacientes 
que n&atilde;o tinham altera&ccedil;&otilde;es na retina atingiram maiores valor
es de FC (FC m&aacute;xima) durante o exerc&iacute;cio, al&eacute;m de terem tam
b&eacute;m um aumento maior da FC em resposta ao exerc&iacute;cio em rela&ccedil
;&atilde;o &agrave; FC basal de repouso (</font>&#916;<font size="2" face="Verda
na, Arial, Helvetica, sans-serif">FC pico), quando comparados com aqueles que ap
resentaram RD. Da mesma maneira, o </font>&#916;<font size="2" face="Verdana, Ar
ial, Helvetica, sans-serif">FC recupera&ccedil;&atilde;o em dois e 04 minutos ta
mb&eacute;m foi maior naqueles que n&atilde;o tinham RD. </font></p>     ^cY#aop
04011.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#40#36#article#119#<p><a name
="tab1"></a></p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#41#37#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#42#38#article#119#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop04011tab01.jpg"></p>     ^cY#a
op04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#43#39#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00947000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704070300085002001300788#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#44#40#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Considerando as medidas da 
press&atilde;o arterial durante o exerc&iacute;cio, os pacientes com RD apresent
aram valores mais elevados da press&atilde;o arterial sist&oacute;lica e diast&o
acute;lica no repouso, e houve tamb&eacute;m um incremento maior da press&atilde
;o sist&oacute;lica at&eacute; o pico do exerc&iacute;cio (</font>&#916;<font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif">PAS pico). N&atilde;o houve 
diferen&ccedil;a no n&uacute;mero de METs atingidos pelos dois grupos. Os valore
s referentes ao teste ergom&eacute;trico em pacientes com e sem RD encontram-se 
na <a href="#tab1">Tabela 1</a>. </font></p>     ^cY#aop04011.htm##
01040000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079600085002001300881#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#45#41#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Quando estratificamos os pa
cientes pelos diferentes graus de RD, observamos que pacientes com a forma RD n&
atilde;o proliferativa (RDNP) leve apresentaram maior </font>&#916;<font size="2
" face="Verdana, Arial, Helvetica, sans-serif">FC pico que aqueles com RDNP mode
rada; pacientes sem RD apresentaram maior </font>&#916;<font size="2" face="Verd
ana, Arial, Helvetica, sans-serif">FC pico que aqueles com RDNP moderada e RD pr
oliferativa. Ainda, pacientes sem RD apresentaram maior FC m&aacute;xima, maior 
</font>&#916;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">FC 2 mi
n e maior </font>&#916;<font size="2" face="Verdana, Arial, Helvetica, sans-seri
f">FC 4 min que aqueles com RD proliferativa. </font></p>     ^cY#aop04011.htm##
01709000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704146500085002001301550#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#46#42#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os pacientes com nefropatia
 diab&eacute;tica apresentaram maior dura&ccedil;&atilde;o do DM por ocasi&atild
e;o do TE que aqueles sem nefropatia (11,4 ± 7,8 <i>vs</i> 23,4 ± 11,3 anos; p &
lt; 0,01). Valores mais elevados de triglicer&iacute;deos e creatinina tamb&eacu
te;m apresentaram associa&ccedil;&atilde;o com essa complica&ccedil;&atilde;o. A
 preval&ecirc;ncia de HAS foi maior naqueles pacientes com nefropatia (34% <i>vs
</i> 73,1%; p = 0,04), sem que houvesse diferen&ccedil;a em rela&ccedil;&atilde;
o a sexo e tabagismo. Nesta compara&ccedil;&atilde;o, n&atilde;o encontramos dif
eren&ccedil;a no controle glic&ecirc;mico nos pacientes com nefropatia (8,15% ± 
1,9 <i>vs</i> 8,7% ± 1,7; p = 0,38). Indiv&iacute;duos sem ND tamb&eacute;m apre
sentaram maior </font>&#916;<font size="2" face="Verdana, Arial, Helvetica, sans
-serif">FC pico, maior FC m&aacute;xima e maior </font>&#916;<font size="2" face
="Verdana, Arial, Helvetica, sans-serif">FC repouso em dois e 04 minutos. Neste 
caso, encontramos um </font>&#916;<font size="2" face="Verdana, Arial, Helvetica
, sans-serif">PAD repouso em dois e 04 minutos significativamente maior entre os
 pacientes sem nefropatia, achado este que n&atilde;o havia sido observado em re
la&ccedil;&atilde;o &agrave; retinopatia. Novamente, o n&uacute;mero de METs ati
ngido foi muito semelhante entre os grupos (<a href="#tab2">Tabela 2</a>). </fon
t></p>     ^cY#aop04011.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#47#43#article#119#<p><a name
="tab2"></a></p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#48#44#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#49#45#article#119#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop04011tab02.jpg"></p>     ^cY#a
op04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#50#46#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
01125000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704088100085002001300966#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#51#47#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Realizamos uma regress&atil
de;o log&iacute;stica com controle para os poss&iacute;veis fatores de confus&at
ilde;o a fim de verificar se os achados da varia&ccedil;&atilde;o do cronotropis
mo anteriormente associados com RD permaneceriam estatisticamente significativos
. Ap&oacute;s o controle para presen&ccedil;a de HAS e tempo de DM, os </font>&#
916;<font size="2" face="Verdana, Arial, Helvetica, sans-serif">FC recupera&cced
il;&atilde;o em dois e 04 minutos, FC m&aacute;xima e o </font>&#916;<font size=
"2" face="Verdana, Arial, Helvetica, sans-serif">FC pico permaneceram significat
ivamente associados &agrave; retinopatia; a </font>&#916;<font size="2" face="Ve
rdana, Arial, Helvetica, sans-serif">PAS pico perdeu a signific&acirc;ncia ap&oa
cute;s esse ajuste (<a href="#tab3">Tabela 3</a>). </font></p>     ^cY#aop04011.
htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#52#48#article#119#<p><a name
="tab3"></a></p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#53#49#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#54#50#article#119#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop04011tab03.jpg"></p>     ^cY#a
op04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#55#51#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00713000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704046900085002001300554#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#56#52#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o &a
grave; ND, a an&aacute;lise foi feita tamb&eacute;m com controle para presen&cce
dil;a de HAS e dura&ccedil;&atilde;o do DM. Apenas o </font>&#916;<font size="2"
 face="Verdana, Arial, Helvetica, sans-serif">FC recupera&ccedil;&atilde;o em do
is e 04 minutos apresentou signific&acirc;ncia estat&iacute;stica nessa an&aacut
e;lise (<a href="#tab4">Tabela 4</a>). </font></p>     ^cY#aop04011.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#57#53#article#119#<p><a name
="tab4"></a></p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#58#54#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#59#55#article#119#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop04011tab04.jpg"></p>     ^cY#a
op04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#60#56#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
01014000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704077000085002001300855#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#61#57#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A diferen&ccedil;a entre os
 valores da FC do pico de exerc&iacute;cio para o repouso basal mostrou correla&
ccedil;&atilde;o negativa com a press&atilde;o arterial sist&oacute;lica (PAS) d
iurna e noturna nos 67 pacientes da amostra que realizaram monitoriza&ccedil;&at
ilde;o ambulatorial da press&atilde;o arterial (MAPA) (r = -0,367, p = 0,003; r 
= -0,412, p = 0,001, respectivamente). Da mesma maneira, a diferen&ccedil;a entr
e a FC no pico de exerc&iacute;cio e ap&oacute;s 04 minutos de recupera&ccedil;&
atilde;o tamb&eacute;m apresentou correla&ccedil;&atilde;o negativa com a PAS di
urna e noturna em tais pacientes (r = - 0, 329, p = 0,009; r = -0,359, p = 0,004
, respectivamente). </font></p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#62#58#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#63#59#article#119#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop04011.htm##
01710000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704146600085002001301551#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#64#60#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Uma resposta cronotr&oacute
;pica card&iacute;aca inadequada &agrave; atividade f&iacute;sica sugere forteme
nte disfun&ccedil;&atilde;o vagal<sup>20</sup>. Pacientes com diabete e disauton
omia card&iacute;aca reconhecidamente t&ecirc;m uma toler&acirc;ncia reduzida ao
 exerc&iacute;cio e menor variabilidade da FC em diversas situa&ccedil;&otilde;e
s<sup>4</sup>. Kramer e cols. <sup>6</sup> observaram a associa&ccedil;&atilde;o
 entre baixa resposta da FC ao exerc&iacute;cio f&iacute;sico com a presen&ccedi
l;a de RD em um grupo de pacientes com DM1 e DM2. Nesse mesmo estudo, a variabil
idade no TE apresentou correla&ccedil;&atilde;o significativa com a variabilidad
e da FC em testes padr&otilde;es para NAC<sup>6</sup>. Nossos dados confirmaram 
os achados de Kramer; a presen&ccedil;a de RD foi associada &agrave; menor varia
&ccedil;&atilde;o da FC no TE, e adicionalmente encontramos  o mesmo achado para
 a nefropatia. A menor recupera&ccedil;&atilde;o da FC, no segundo e 4º minutos 
de repouso ap&oacute;s o t&eacute;rmino do TE, apresentou significativa associa&
ccedil;&atilde;o com a presen&ccedil;a de nefropatia. O fato de o aumento da FC 
do basal at&eacute; o pico de exerc&iacute;cio ter demonstrado associa&ccedil;&a
tilde;o apenas com a retinopatia, e n&atilde;o com nefropatia, pode dever-se &ag
rave; maior preval&ecirc;ncia de retinopatia em nossa amostra de pacientes. </fo
nt></p>     ^cY#aop04011.htm##
01522000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704127800085002001301363#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#65#61#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A associa&ccedil;&atilde;o 
entre NAC e nefropatia j&aacute; foi demonstrada previamente em pacientes com di
abete<sup>9-12,20,21</sup>, entretanto, foram utilizados m&eacute;todos mais com
plexos para a detec&ccedil;&atilde;o de neuropatia auton&ocirc;mica. A presen&cc
edil;a de NAC tamb&eacute;m est&aacute; relacionada &agrave; menor redu&ccedil;&
atilde;o da press&atilde;o arterial noturna em pacientes com DM1<sup>20,21</sup>
. Tal fato nos permite considerar a menor variabilidade press&oacute;rica durant
e o ciclo sono-vig&iacute;lia em pacientes com neuropatia auton&ocirc;mica como 
um dos poss&iacute;veis mecanismos fisiopatog&ecirc;nicos para a maior preval&ec
irc;ncia de nefropatia nestes indiv&iacute;duos. Em nossa amostra, observamos qu
e um menor aumento da FC durante o exerc&iacute;cio e uma menor redu&ccedil;&ati
lde;o da FC ap&oacute;s 04 minutos do t&eacute;rmino do exerc&iacute;cio correla
cionaram-se com medidas maiores de PAS durante o dia e a noite naqueles paciente
s que realizaram MAPA. Uma an&aacute;lise mais detalhada destes achados pode fut
uramente contribuir para o melhor entendimento da rela&ccedil;&atilde;o entre NA
C e complica&ccedil;&otilde;es microvasculares. </font></p>     ^cY#aop04011.htm
##
00938000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704069400085002001300779#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#66#62#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Dentre as limita&ccedil;&ot
ilde;es do nosso estudo, podemos citar o pequeno tamanho da amostra e o delineam
ento transversal. Essa &uacute;ltima impede-nos de estabelecer rela&ccedil;&otil
de;es de causa e efeito entre as vari&aacute;veis e de conhecer melhor a interfe
r&ecirc;ncia de fatores de risco pr&eacute;vios sobre os desfechos (p.ex. , cont
role glic&ecirc;mico inadequado e complica&ccedil;&atilde;o microvascular). Espe
ramos corrigir tais limita&ccedil;&otilde;es atrav&eacute;s de uma amplia&ccedil
;&atilde;o da amostra e da realiza&ccedil;&atilde;o de uma an&aacute;lise prospe
ctiva desses pacientes. </font></p>     ^cY#aop04011.htm##
01465000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122100085002001301306#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#67#63#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A vantagem da utiliza&ccedi
l;&atilde;o do TE para avalia&ccedil;&atilde;o de NAC &eacute; que se trata de u
m m&eacute;todo diagn&oacute;stico frequentemente utilizado para outras finalida
des na aten&ccedil;&atilde;o m&eacute;dica a pacientes com DM. A observa&ccedil;
&atilde;o cuidadosa dos dados fornecidos pelo exame, especialmente a varia&ccedi
l;&atilde;o da FC, enriquece a avalia&ccedil;&atilde;o do paciente, permitindo s
uspeitar da presen&ccedil;a de neuropatia auton&ocirc;mica e reconhecer paciente
s com maior risco para complica&ccedil;&otilde;es microvasculares. Isso pode amp
liar as informa&ccedil;&otilde;es clinicamente relevantes obtidas quando o pacie
nte j&aacute; realizou o exame, mesmo que este n&atilde;o seja realizado especif
icamente com esta indica&ccedil;&atilde;o. Desta forma, se utilizado corretament
e, seria poss&iacute;vel reconhecer precocemente as altera&ccedil;&otilde;es aut
on&ocirc;micas card&iacute;acas, j&aacute; que os testes espec&iacute;ficos para
 NAC n&atilde;o s&atilde;o rotineiramente realizados pela maioria dos m&eacute;d
icos cl&iacute;nicos por sua complexidade de realiza&ccedil;&atilde;o. </font></
p>     ^cY#aop04011.htm##
00924000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704068000085002001300765#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#68#64#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A relev&acirc;ncia deste ac
hado evidencia-se n&atilde;o apenas pela sintomatologia envolvida com tal condi&
ccedil;&atilde;o, mas tamb&eacute;m pelo maior risco vascular j&aacute; reconhec
ido nesses pacientes. Assim, aqueles pacientes, nos quais fossem identificadas a
s altera&ccedil;&otilde;es sugestivas de disfun&ccedil;&atilde;o auton&ocirc;mic
a, mesmo que iniciais, deveriam ser mais atentamente investigados para complica&
ccedil;&otilde;es microvasculares e ter seus fatores de risco modific&aacute;vei
s, como press&atilde;o arterial e controle glic&ecirc;mico, mais rigidamente con
trolados. </font></p>     ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#69#65#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#70#66#article#119#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Conclus&atilde;o</b></fo
nt></p>     ^cY#aop04011.htm##
00802000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704055800085002001300643#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#71#67#article#119#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Altera&ccedil;&atilde;o do 
cronotropismo card&iacute;aco avaliado por TE representa manifesta&ccedil;&atild
e;o de NAC e est&aacute; associada &agrave; presen&ccedil;a de complica&ccedil;&
otilde;es microvasculares, mais especificamente RD e ND. Estudos adicionais s&at
ilde;o necess&aacute;rios para saber quais s&atilde;o os valores de varia&ccedil
;&atilde;o da FC que podem indicar risco aumentado para a presen&ccedil;a ou des
envolvimento dessas complica&ccedil;&otilde;es. </font></p>     ^cY#aop04011.htm
##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#72#68#article#119#<p>&nbsp;<
/p>     ^cY#aop04011.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#73#69#article#119#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop04011.htm##
00534000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027600087002001300363#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#74#70#article#11
9#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Ko SH, Par
k SA, Cho JH, Song KH, Yoon KH, Cha BY, et al. Progression of cardiovascular aut
onomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study. D
iabetes Care. 2008;31(9):1832-6.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#75#71#article#119# </font></
p>     ^cY#aop04011.htm##
00494000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704023600087002001300323#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#76#72#article#11
9#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Tesfaye S,
 Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular
 risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341-50.    ^cY#
aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#77#73#article#119# </font></
p>     ^cY#aop04011.htm##
00508000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704025000087002001300337#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#78#74#article#11
9#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Rolim LC, 
S&aacute; JR, Chacra AR, Dib SA. Diabetic cardiovascular autonomic neuropathy: r
isk factors, clinical impact and early diagnosis. Arq Bras Cardiol. 2008;90(4):e
24-31.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#79#75#article#119# </font></
p>     ^cY#aop04011.htm##
00441000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704018300087002001300270#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#80#76#article#11
9#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Vinik AI, 
Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 
2003;26(5):1553-79.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#81#77#article#119# </font></
p>     ^cY#aop04011.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027400087002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#82#78#article#11
9#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Maser RE, 
Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonom
ic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabe
tes Care. 2003;26(6):1895-901.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#83#79#article#119# </font></
p>     ^cY#aop04011.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704031700087002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#84#80#article#11
9#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Kramer CK,
 Leit&atilde;o CB, Azevedo MJ, Valiatti FB, Rodrigues TC, Canani LH, et al. Diab
etic retinopathy is associated with early autonomic dysfunction assessed by exer
cise-related heart rate changes. Braz J Med Biol Res. 2008;41(12):1110-5.    ^cY
#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#85#81#article#119# </font></
p>     ^cY#aop04011.htm##
00589000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704033100087002001300418#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#86#82#article#11
9#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Pecis M, A
zevedo MJ, Moraes RS, Ferlin EL, Gross JL. Autonomic dysfunction and urinary alb
umin excretion rate are associated with an abnormal blood pressure pattern in no
rmotensive normoalbuminuric type 1 diabetic patients. Diabetes Care. 2000;23(7):
989-93.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#87#83#article#119# </font></
p>     ^cY#aop04011.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704031400087002001300401#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#88#84#article#11
9#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Garcia C, 
Mayaudon H, Bordier L, Le Berre JP, Dupuy O, Bauduceau B. Modifications of 24-h 
blood pressure profile associated with reduction of the heart rate variability i
n type 1 diabetic patients. Arch Mal Coeur Vaiss. 2007;100(8):699-703.    ^cY#ao
p04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#89#85#article#119# </font></
p>     ^cY#aop04011.htm##
00624000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704036600087002001300453#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#90#86#article#11
9#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Bilal N, E
rdogan M, Ozbek M, Cetinkalp S, Karadeniz M, Ozgen AG, et al. Increasing severit
y of cardiac autonomic neuropathy is associated with increasing prevalence of ne
phropathy, retinopathy, and peripheral neuropathy in Turkish type 2 diabetics. J
 Diabetes Complications. 2008;22(3):181-5.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#91#87#article#119# </font></
p>     ^cY#aop04011.htm##
00539000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704028000088002001300368#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#92#88#article#11
9#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Chen HT,
 Lin HD, Won JG, Lee CH, Wu SC, Lin JD, et al. Cardiovascular autonomic neuropat
hy, autonomic symptoms and diabetic complications in 674 type 2 diabetes. Diabet
es Res Clin Pract. 2008;82(2):282-90.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#93#89#article#119# </font></
p>     ^cY#aop04011.htm##
00558000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704029900088002001300387#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#94#90#article#11
9#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. Fors&eac
ute;n A, Kangro M, Sterner G, Norrgren K, Thorsson O, Wollmer P, et al. A 14-yea
r prospective study of autonomic nerve function in Type 1 diabetic patients: ass
ociation with nephropathy. Diabet Med. 2004;21(8):852-8.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#95#91#article#119# </font></
p>     ^cY#aop04011.htm##
00533000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704027400088002001300362#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#96#92#article#11
9#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Maguire 
AM, Craig ME, Craighead A, Chan AK, Cusumano JM, Hing SJ, et al. Autonomic nerve
 testing predicts the development of complications: a 12-year follow-up study. D
iabetes Care. 2007;30(1):77-82.    ^cY#aop04011.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#97#93#article#119# </font></
p>     ^cY#aop04011.htm##
00564000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704030500088002001300393#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#98#94#article#11
9#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Astrup A
S, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neur
opathy predicts cardiovascular morbidity and mortality in type 1 diabetic patien
ts with diabetic nephropathy. Diabetes Care. 2006;29(2):334-9.    ^cY#aop04011.h
tm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#99#95#article#119# </font></
p>     ^cY#aop04011.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704024400089002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#100#96#article#1
19#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. Leeper 
NJ, Dewey FE, Ashley EA, Sandri M, Tan SY, Hadley D, et al. Prognostic value of 
heart rate increase at onset of exercise testing. Circulation. 2007;115(4):468-7
4.    ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#101#97#article#119# </font><
/p>     ^cY#aop04011.htm##
00504000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704024400089002001300333#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#102#98#article#1
19#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Shetler
 K, Marcus R, Froelicher VF, Vora S, Kalisetti D, Prakash M, et al. Heart rate r
ecovery: validation and methodologic issues. J Am Coll Cardiol. 2001;38(7):1980-
7.    ^cY#aop04011.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#103#99#article#119# </font><
/p>     ^cY#aop04011.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#104#100#article#
119#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. Rodrig
ues TC, Pecis M, Canani LH, Schreiner L, Kramer CK, Biavatti K, et al. Character
ization of patients with type 1 diabetes mellitus in southern Brazil: chronic co
mplications and associated factors. Rev Assoc Med Bras. 2010;56(1):67-73.    ^cY
#aop04011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#105#101#article#119# </font>
</p>     ^cY#aop04011.htm##
00557000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029600090002001300386#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#106#102#article#
119#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Fletch
er GF, Balady G, Froelicher VF, Haartley LH, Haskell WL, Pollock ML. Exercise st
andards: a statement for health acre professionals from the American Heart Assoc
iation. Writing Group. Circulation. 1995;91(2):580-615.    ^cY#aop04011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#107#103#article#119# </font>
</p>     ^cY#aop04011.htm##
00507000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024600090002001300336#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#108#104#article#
119#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Gross 
JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic 
nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28(1):16
4-76.    ^cY#aop04011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#109#105#article#119# </font>
</p>     ^cY#aop04011.htm##
00535000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027400090002001300364#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#110#106#article#
119#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Friede
wald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density
 lipoprotein cholesterol in plasma without use of the preparative ultracentrifug
e. Clin Chem. 1972;18(6):499-502.    ^cY#aop04011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#111#107#article#119# </font>
</p>     ^cY#aop04011.htm##
00575000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704031400090002001300404#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#112#108#article#
119#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Montea
gudo PT, N&oacute;brega JC, Cezarini PR, Ferreira SR, Kohlmann O Jr, Ribeiro AB,
 et al. Altered blood pressure profile, autonomic neuropathy and nephropathy in 
insulin-dependent diabetic patients. Eur J Endocrinol. 1996;135(6):683-8.    ^cY
#aop04011.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#113#109#article#119# </font>
</p>     ^cY#aop04011.htm##
00562000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030100090002001300391#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#114#110#article#
119#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Spallo
ne V, Gambardella S, Maiello MR, Barini A, Frontoni S, Menzinger G. Relationship
 between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in n
ormotensive IDDM patients. Diabetes Care. 1994;17(6):578-84.    ^cY#aop04011.htm
##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#115#111#article#119# </font>
</p>     ^cY#aop04011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#116#112#article#119#<p>&nbsp
;</p>     ^cY#aop04011.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#117#113#article#119#<p>&nbsp
;</p>     ^cY#aop04011.htm##
00448000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020200087002001300289#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#118#114#article#119#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a> <b>Co
rrespond&ecirc;ncia:</b>      ^cY#aop04011.htm##
00288000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004200087002001300129#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#119#115#article#119#<br>   T
iciana da Costa Rodrigues     ^cY#aop04011.htm##
00297000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005100087002001300138#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#120#116#article#119#<br>   R
ua Ramiro Barcelos, 2350 - Bom Fim     ^cY#aop04011.htm##
00299000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005300087002001300140#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#121#117#article#119#<br>   9
0520-100 - Porto Alegre, RS - Brasil     ^cY#aop04011.htm##
00347000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704010100087002001300188#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#122#118#article#119#<br>   E
-mail: <a href="mailto:ticianacr@yahoo.com.br">ticianacr@yahoo.com.br</a></font>
</p>     ^cY#aop04011.htm##
00409000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016300087002001300250#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04011.htm#S#p#123#119#article#119#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif">Artigo recebido em 17/10/
10; revisado recebido em 23/12/10; aceito em 11/01/11. </font></p>     ^cY#aop04
011.htm##
00729000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100013000860100015000990100
01400114010001500128010001500143010001400158810000600172012011500178030001400293
06500090030706400050031603100030032103200020032401400070032686500090033300200130
0342035001000355801001400365#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#124#1#article#21#1#^rND^sKo^nSH#^rND^sPark^nSA#^rND^sCho^nJH#^rN
D^sSong^nKH#^rND^sYoon^nKH#^rND^sCha^nBY#et al#Progression of cardiovascular aut
onomic dysfunction in patients with type 2 diabetes: a 7-year follow-up study^le
n#Diabetes Care#20080000#2008#31#9#1832-6#20110000#aop04011.htm#0149-5992#Diabet
es Care##
00688000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100020001030100
01600123010001500139010001500154010002800169810000600197012005000203030001300253
06500090026606400050027503100040028003200020028401400070028686500090029300200130
0302035001000315801001300325#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#125#2#article#21#2#^rND^sTesfaye^nS#^rND^sChaturvedi^nN#^rND^sEa
ton^nSE#^rND^sWard^nJD#^rND^sManes^nC#^rND^sIonescu-Tirgoviste^nC#et al#Vascular
 risk factors and diabetic neuropathy^len#N Engl J Med#20050000#2005#352#4#341-5
0#20110000#aop04011.htm#0028-4793#N Engl J Med##
00652000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100013001020100
01700115010001400132012010000146030001700246065000900263064000500272031000300277
032000200280014000700282865000900289002001300298035001000311801001700321#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#c#126#3#article#21#3#^
rND^sRolim^nLC#^rND^sSá^nJR#^rND^sChacra^nAR#^rND^sDib^nSA#Diabetic cardiovascul
ar autonomic neuropathy: risk factors, clinical impact and early diagnosis^len#A
rq Bras Cardiol#20080000#2008#90#4#e24-31#20110000#aop04011.htm#0066-782X#Arq Br
as Cardiol##
00589000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100016001020100
01900118010001700137012003400154030001400188065000900202064000500211031000300216
032000200219014000800221865000900229002001300238035001000251801001400261#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#c#127#4#article#21#4#^
rND^sVinik^nAI#^rND^sMaser^nRE#^rND^sMitchell^nBD#^rND^sFreeman^nR#Diabetic auto
nomic neuropathy^len#Diabetes Care#20030000#2003#26#5#1553-79#20110000#aop04011.
htm#0149-5992#Diabetes Care##
00680000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100019001020100
01600121010001700137012012400154030001400278065000900292064000500301031000300306
032000200309014000900311865000900320002001300329035001000342801001400352#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#c#128#5#article#21#5#^
rND^sMaser^nRE#^rND^sMitchell^nBD#^rND^sVinik^nAI#^rND^sFreeman^nR#The associati
on between cardiovascular autonomic neuropathy and mortality in individuals with
 diabetes: a meta-analysis^len#Diabetes Care#20030000#2003#26#6#1895-901#2011000
0#aop04011.htm#0149-5992#Diabetes Care##
00769000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100017001030100
01800120010001900138010002000157010001700177810000600194012012000200030002000320
06500090034006400050034903100030035403200030035701400070036086500090036700200130
0376035001000389801002000399#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#129#6#article#21#6#^rND^sKramer^nCK#^rND^sLeitão^nCB#^rND^sAzeve
do^nMJ#^rND^sValiatti^nFB#^rND^sRodrigues^nTC#^rND^sCanani^nLH#et al#Diabetic re
tinopathy is associated with early autonomic dysfunction assessed by exercise-re
lated heart rate changes^len#Braz J Med Biol Res#20080000#2008#41#12#1110-5#2011
0000#aop04011.htm#0100-879X#Braz J Med Biol Res##
00755000000000325000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100018001010100
01700119010001700136010001600153012017400169030001400343065000900357064000500366
03100030037103200020037401400070037686500090038300200130039203500100040580100140
0415#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#S#c#130#7#ar
ticle#21#7#^rND^sPecis^nM#^rND^sAzevedo^nMJ#^rND^sMoraes^nRS#^rND^sFerlin^nEL#^r
ND^sGross^nJL#Autonomic dysfunction and urinary albumin excretion rate are assoc
iated with an abnormal blood pressure pattern in normotensive normoalbuminuric t
ype 1 diabetic patients^len#Diabetes Care#20000000#2000#23#7#989-93#20110000#aop
04011.htm#0149-5992#Diabetes Care##
00763000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100018001020100
01700120010001900137010001500156010001900171012013300190030002100323065000900344
06400050035303100040035803200020036201400080036486500090037200200130038103500100
0394801002100404#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#
S#c#131#8#article#21#8#^rND^sGarcia^nC#^rND^sMayaudon^nH#^rND^sBordier^nL#^rND^s
Le Berre^nJP#^rND^sDupuy^nO#^rND^sBauduceau^nB#Modifications of 24-h blood press
ure profile associated with reduction of the heart rate variability in type 1 di
abetic patients^len#Arch Mal Coeur Vaiss#20070000#2007#100#8#699-703#20110000#ao
p04011.htm#0003-9683#Arch Mal Coeur Vaiss##
00830000000000349000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100017001010100
01500118010001900133010001900152010001600171810000600187012018000193030002500373
06500090039806400050040703100030041203200020041501400060041786500090042300200130
0432035001000445801002500455#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#132#9#article#21#9#^rND^sBilal^nN#^rND^sErdogan^nM#^rND^sOzbek^n
M#^rND^sCetinkalp^nS#^rND^sKaradeniz^nM#^rND^sOzgen^nAG#et al#Increasing severit
y of cardiac autonomic neuropathy is associated with increasing prevalence of ne
phropathy, retinopathy, and peripheral neuropathy in Turkish type 2 diabetics^le
n#J Diabetes Complications#20080000#2008#22#3#181-5#20110000#aop04011.htm#1056-8
727#J Diabetes Complications##
00744000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100014001030100
01400117010001400131010001300145010001400158810000600172012011000178030002400288
06500090031206400050032103100030032603200020032901400070033186500090033800200130
0347035001000360801002400370#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#133#10#article#21#10#^rND^sChen^nHT#^rND^sLin^nHD#^rND^sWon^nJG#
^rND^sLee^nCH#^rND^sWu^nSC#^rND^sLin^nJD#et al#Cardiovascular autonomic neuropat
hy, autonomic symptoms and diabetic complications in 674 type 2 diabetes^len#Dia
betes Res Clin Pract#20080000#2008#82#2#282-90#20110000#aop04011.htm#0168-8227#D
iabetes Res Clin Pract##
00743000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01700120010001800137010001800155010001700173810000600190012011800196030001100314
06500090032506400050033403100030033903200020034201400060034486500090035000200130
0359035001000372801001100382#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#134#11#article#21#11#^rND^sForsén^nA#^rND^sKangro^nM#^rND^sStern
er^nG#^rND^sNorrgren^nK#^rND^sThorsson^nO#^rND^sWollmer^nP#et al#A 14-year prosp
ective study of autonomic nerve function in Type 1 diabetic patients: associatio
n with nephropathy^len#Diabet Med#20040000#2004#21#8#852-8#20110000#aop04011.htm
#0742-3071#Diabet Med##
00728000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01900122010001500141010001900156010001500175810000600190012009700196030001400293
06500090030706400050031603100030032103200020032401400060032686500090033200200130
0341035001000354801001400364#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#135#12#article#21#12#^rND^sMaguire^nAM#^rND^sCraig^nME#^rND^sCra
ighead^nA#^rND^sChan^nAK#^rND^sCusumano^nJM#^rND^sHing^nSJ#et al#Autonomic nerve
 testing predicts the development of complications: a 12-year follow-up study^le
n#Diabetes Care#20070000#2007#30#1#77-82#20110000#aop04011.htm#0149-5992#Diabete
s Care##
00748000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01700121010001700138010001700155010001800172012013500190030001400325065000900339
06400050034803100030035303200020035601400060035886500090036400200130037303500100
0386801001400396#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#
S#c#136#13#article#21#13#^rND^sAstrup^nAS#^rND^sTarnow^nL#^rND^sRossing^nP#^rND^
sHansen^nBV#^rND^sHilsted^nJ#^rND^sParving^nHH#Cardiac autonomic neuropathy pred
icts cardiovascular morbidity and mortality in type 1 diabetic patients with dia
betic nephropathy^len#Diabetes Care#20060000#2006#29#2#334-9#20110000#aop04011.h
tm#0149-5992#Diabetes Care##
00696000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
01700121010001600138010001400154010001600168810000600184012007300190030001200263
06500090027506400050028403100040028903200020029301400070029586500090030200200130
0311035001000324801001200334#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#137#14#article#21#14#^rND^sLeeper^nNJ#^rND^sDewey^nFE#^rND^sAshl
ey^nEA#^rND^sSandri^nM#^rND^sTan^nSY#^rND^sHadley^nD#et al#Prognostic value of h
eart rate increase at onset of exercise testing^len#Circulation#20070000#2007#11
5#4#468-74#20110000#aop04011.htm#0009-7322#Circulation##
00702000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100016001050100
02100121010001400142010001900156010001700175810000600192012006000198030001800258
06500090027606400050028503100030029003200020029301400070029586500090030200200130
0311035001000324801001800334#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#138#15#article#21#15#^rND^sShetler^nK#^rND^sMarcus^nR#^rND^sFroe
licher^nVF#^rND^sVora^nS#^rND^sKalisetti^nD#^rND^sPrakash^nM#et al#Heart rate re
covery: validation and methodologic issues^len#J Am Coll Cardiol#20010000#2001#3
8#7#1980-7#20110000#aop04011.htm#0735-1097#J Am Coll Cardiol##
00773000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100015001080100
01700123010001900140010001700159010001800176810000600194012012800200030001900328
06500090034706400050035603100030036103200020036401400060036686500090037200200130
0381035001000394801001900404#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#139#16#article#21#16#^rND^sRodrigues^nTC#^rND^sPecis^nM#^rND^sCa
nani^nLH#^rND^sSchreiner^nL#^rND^sKramer^nCK#^rND^sBiavatti^nK#et al#Characteriz
ation of patients with type 1 diabetes mellitus in southern Brazil: chronic comp
lications and associated factors^len#Rev Assoc Med Bras#20100000#2010#56#1#67-73
#20110000#aop04011.htm#0004-5241#Rev Assoc Med Bras##
00737000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
02100123010001900144010001800163010001800181012011700199030001200316065000900328
06400050033703100030034203200020034501400080034786500090035500200130036403500100
0377801001200387#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#
S#c#140#17#article#21#17#^rND^sFletcher^nGF#^rND^sBalady^nG#^rND^sFroelicher^nVF
#^rND^sHaartley^nLH#^rND^sHaskell^nWL#^rND^sPollock^nML#Exercise standards: a st
atement for health acre professionals from the American Heart Association. Writi
ng Group^len#Circulation#19950000#1995#91#2#580-615#20110000#aop04011.htm#0009-7
322#Circulation##
00688000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100021001040100
01900125010001700144010001900161010002100180012006300201030001400264065000900278
06400050028703100030029203200020029501400070029786500090030400200130031303500100
0326801001400336#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#
S#c#141#18#article#21#18#^rND^sGross^nJL#^rND^sde Azevedo^nMJ#^rND^sSilveiro^nSP
#^rND^sCanani^nLH#^rND^sCaramori^nML#^rND^sZelmanovitz^nT#Diabetic nephropathy: 
diagnosis, prevention, and treatment^len#Diabetes Care#20050000#2005#28#1#164-76
#20110000#aop04011.htm#0149-5992#Diabetes Care##
00659000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100015001090100
02200124012013200146030001000278065000900288064000500297031000300302032000200305
014000800307865000900315002001300324035001000337801001000347#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop04011.htm#S#c#142#19#article#21#19#^rND^sFried
ewald^nWT#^rND^sLevy^nRI#^rND^sFredrickson^nDS#Estimation of the concentration o
f low-density lipoprotein cholesterol in plasma without use of the preparative u
ltracentrifuge^len#Clin Chem#19720000#1972#18#6#499-502#20110000#aop04011.htm#00
09-9147#Clin Chem##
00764000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100021000880100018001090100
01900127010001900146010002100165010001800186810000600204012011200210030001700322
06500090033906400050034803100040035303200020035701400060035986500090036500200130
0374035001000387801001700397#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04011.htm#S#c#143#20#article#21#20#^rND^sMonteagudo^nPT#^rND^sNóbrega^nJC#^rND
^sCezarini^nPR#^rND^sFerreira^nSR#^rND^sKohlmann Jr^nO#^rND^sRibeiro^nAB#et al#A
ltered blood pressure profile, autonomic neuropathy and nephropathy in insulin-d
ependent diabetic patients^len#Eur J Endocrinol#19960000#1996#135#6#683-8#201100
00#aop04011.htm#0804-4643#Eur J Endocrinol##
00744000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100021001060100
01800127010001600145010001800161010001900179012012200198030001400320065000900334
06400050034303100030034803200020035101400070035386500090036000200130036903500100
0382801001400392#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04011.htm#
S#c#144#21#article#21#21#^rND^sSpallone^nV#^rND^sGambardella^nS#^rND^sMaiello^nM
R#^rND^sBarini^nA#^rND^sFrontoni^nS#^rND^sMenzinger^nG#Relationship between auto
nomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive I
DDM patients^len#Diabetes Care#19940000#1994#17#6#578-84#20110000#aop04011.htm#0
149-5992#Diabetes Care##
00284000000000169000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790910009000810920007000900020013000977030
00400110#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#o#1#1#
article#1#20110411#104651#aop04111.htm#195##
05471000000000721000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201030
01780120096002810100049003770100048004260100047004740700038005210700061005590700
05300620070006500673083183900738085000802577085002502585085002202610085003102632
08500270266308500220269008317420271208500080445408500240446208500200448608500310
45060850029045370850031045660580062045970600012046591170008046710720003046791120
00904682111000904691116000904700115000904709114000904718113000904727002001304736
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#h#2#1#article#
1#oa#pt#br1.1#1#4.0#ILUS#TAB#48#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#
0066-782X#20110415#Influência do estado nutricional e do VO2max nos níveis de ad
iponectina em homens acima de 35 anos^lpt#Influence of nutritional status and VO
2max on adiponectin levels in men older than 35 years^len#^rND^1A01 A02 A03 A04^
nEduardo Camillo^sMartinez#^rND^1A01 A02 A03 A04^nMacos de Sá Rego^sFortes#^rND^
1A01 A02 A03 A04^nLuiz Antônio dos^sAnjos#Escola Nacional de Saúde Pública^iA01#
Instituto de Pesquisa da Capacitação Física do Exército^iA02#Instituto Estadual 
de Diabetes e Endocrinologia^iA03#Universidade Federal Fluminense^iA04^cRio de J
aneiro^sRJ^pBrasil#^lpt^aFUNDAMENTO: A adiponectina é considerada importante fat
or na patogênese das doenças cardiovasculares e metabólicas, por suas propriedad
es antiaterogênicas e antiinflamatórias. Poucos estudos, entretanto, sugerem a e
xistência de relação direta entre os níveis de adiponectina e os níveis de condi
cionamento cardiorrespiratório e atividade física. OBJETIVO: Verificar a influên
cia do estado nutricional e do condicionamento cardiorrespiratório nos níveis pl
asmáticos de adiponectina em homens adultos. MÉTODOS: Foram avaliados 250 sujeit
os, homens, todos militares da ativa do Exército Brasileiro (42,6 ± 4,8 anos). F
oram mensurados os níveis plasmáticos de adiponectina, massa corporal, estatura,
 circunferência da cintura (CC), percentual de gordura por pesagem hidrostática 
e VO2max por ergoespirometria. Um questionário foi utilizado para obter as carac
terísticas do treinamento físico realizado pelos sujeitos. RESULTADOS: Na amostr
a, 121 (48%) sujeitos apresentaram sobrepeso e 36 (14%) eram obesos. Ainda, 66 s
ujeitos (27%) apresentaram percentual de gordura maior que 25% e 26.7% apresenta
ram CC > 94 cm. Sujeitos com sobrepeso e obesidade apresentaram valores signific
ativamente menores de adiponectina em relação aqueles com estado nutricional nor
mal. Sujeitos no mais alto tercil de VO2max apresentaram níveis de adiponectina 
mais altos que os demais. Os níveis de adiponectina estiveram positivamente corr
elacionados com o tempo total de treinamento físico semanal e com o VO2max e inv
ersamente correlacionados com os valores de massa corporal, IMC e CC. A correlaç
ão dos níveis de adiponectina e do VO2max não permaneceu significante após contr
olada pelo IMC e CC. CONCLUSÃO: Sujeitos com melhor condicionamento cardiorrespi
ratório e com estado nutricional normal parecem apresentar níveis mais saudáveis
 de adiponectina.#^dnd^i1#^tm^lpt^kAdiponectina^i1#^tm^lpt^kobesidade^i1#^tm^lpt
^kestado nutricional^i1#^tm^lpt^kaptidão física^i1#^tm^lpt^kmilitares^i1#^len^aB
ACKGROUND: Adiponectin is considered an important factor in the pathogenesis of 
cardiovascular and metabolic diseases, due to its anti- atherogenic and anti-inf
lammatory properties. Few studies, however, have suggested the existence of a di
rect association between adiponectin levels and cardiorespiratory fitness and ph
ysical activity levels. OBJECTIVE: To verify the influence of the nutritional st
atus and cardiorespiratory fitness on plasma adiponectin levels in adult men. ME
THODS: A total of 250 subjects, all in active duty in the Brazilian Army (BA), w
ith a mean age of 42,6 ± 4,8 years volunteered to participate in the study. Plas
ma levels of adiponectin were measured, as well as body mass, height, waist circ
umference (WC), fat percentage by hydrostatic weighing and VO2max by ergospirome
try. A questionnaire was used to obtain the characteristics of the physical trai
ning performed by the individuals. RESULTS: The sample showed that 121 (48%) ind
ividuals were overweight and 36 (14%) were obese. Moreover, 66 individuals (27%)
 had a body fat percentage > 25% and 26,7% had a WC > 94 cm. Overweight and obes
e individuals had significantly lower adiponectin levels than those with an adeq
uate nutritional status. Individuals at the highest tertile of VO2max had higher
 adiponectin levels than the others. The adiponectin levels were positively corr
elated with the total weekly physical training time and VO2max and inversely cor
related with body mass, BMI and WC. The correlation between adiponectin levels a
nd VO2max did not remain significant after being adjusted for BMI and WC. CONCLU
SION: Individuals with better cardiorespiratory fitness and normal nutritional s
tatus seem to present healthier levels of adiponectin.#^dnd^i2#^tm^len^kAdiponec
tin^i2#^tm^len^kobesity^i2#^tm^len^knutritional states^i2#^tm^len^kphysical fitn
ess^i2#^tm^len^kmilitary personnel^i2#Conselho Nacional de Desenvolvimento Cient
ífico e Tecnológico#311801/06-4#vancouv#40#20100812#12/08/10#20101022#22/10/10#2
0101210#10/12/10#aop04111.htm##
05792000000000721000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790710003000810400003000840010006000870420
00200093120000400095038000500099038000400104121000300108049000300111158000300114
03000200011703200060013706500090014301400070015203500100015922300090016901201210
01780120114002990100049004130100048004620100047005100700038005570700061005950700
05300656070006500709083192800774085000802702085002502710085002202735085003102757
08500270278808500220281508318340283708500080467108500310467908500270471008500380
47370850036047750850038048110580062048490600081049111170008049920720003050001120
00905003111000905012116000905021115000905030114000905039113000905048002001305057
#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#f#3#1#article#
1#oa#pt#br1.1#1#4.0#ILUS#TAB#48#nd#nd#Arq. Bras. Cardiol.#ahead#20110000#^f0^l0#
0066-782X#20110415#<b>Influência do estado nutricional e do VO<sub>2max</sub> no
s níveis de adiponectina em homens acima de 35 anos</b>^lpt#<b>Influence of nutr
itional status and VO<sub>2max</sub> on adiponectin levels in men older than 35 
years</b>^len#^rND^1A01 A02 A03 A04^nEduardo Camillo^sMartinez#^rND^1A01 A02 A03
 A04^nMacos de Sá Rego^sFortes#^rND^1A01 A02 A03 A04^nLuiz Antônio dos^sAnjos#Es
cola Nacional de Saúde Pública^iA01#Instituto de Pesquisa da Capacitação Física 
do Exército^iA02#Instituto Estadual de Diabetes e Endocrinologia^iA03#Universida
de Federal Fluminense^iA04^cRio de Janeiro^sRJ^pBrasil#^lpt^a<b>FUNDAMENTO:</b> 
A adiponectina é considerada importante fator na patogênese das doenças cardiova
sculares e metabólicas, por suas propriedades antiaterogênicas e antiinflamatóri
as. Poucos estudos, entretanto, sugerem a existência de relação direta entre os 
níveis de adiponectina e os níveis de condicionamento cardiorrespiratório e ativ
idade física. <b>OBJETIVO:</b> Verificar a influência do estado nutricional e do
 condicionamento cardiorrespiratório nos níveis plasmáticos de adiponectina em h
omens adultos. <b>MÉTODOS:</b> Foram avaliados 250 sujeitos, homens, todos milit
ares da ativa do Exército Brasileiro (42,6 ± 4,8 anos). Foram mensurados os níve
is plasmáticos de adiponectina, massa corporal, estatura, circunferência da cint
ura (CC), percentual de gordura por pesagem hidrostática e VO<sub>2max</sub> por
 ergoespirometria. Um questionário foi utilizado para obter as características d
o treinamento físico realizado pelos sujeitos. <b>RESULTADOS:</b> Na amostra, 12
1 (48%) sujeitos apresentaram sobrepeso e 36 (14%) eram obesos. Ainda, 66 sujeit
os (27%) apresentaram percentual de gordura maior que 25% e 26.7% apresentaram C
C <u>&gt;</u> 94 cm. Sujeitos com sobrepeso e obesidade apresentaram valores sig
nificativamente menores de adiponectina em relação aqueles com estado nutriciona
l normal. Sujeitos no mais alto tercil de VO<sub>2max</sub> apresentaram níveis 
de adiponectina mais altos que os demais. Os níveis de adiponectina estiveram po
sitivamente correlacionados com o tempo total de treinamento físico semanal e co
m o VO<sub>2max</sub> e inversamente correlacionados com os valores de massa cor
poral, IMC e CC. A correlação dos níveis de adiponectina e do VO<sub>2max</sub> 
não permaneceu significante após controlada pelo IMC e CC. <b>CONCLUSÃO:</b> Suj
eitos com melhor condicionamento cardiorrespiratório e com estado nutricional no
rmal parecem apresentar níveis mais saudáveis de adiponectina.#^dnd^i1#^tm^lpt^k
Adiponectina^i1#^tm^lpt^kobesidade^i1#^tm^lpt^kestado nutricional^i1#^tm^lpt^kap
tidão física^i1#^tm^lpt^kmilitares^i1#^len^a<b>BACKGROUND:</b> Adiponectin is co
nsidered an important factor in the pathogenesis of cardiovascular and metabolic
 diseases, due to its anti- atherogenic and anti-inflammatory properties. Few st
udies, however, have suggested the existence of a direct association between adi
ponectin levels and cardiorespiratory fitness and physical activity levels. <b>O
BJECTIVE:</b> To verify the influence of the nutritional status and cardiorespir
atory fitness on plasma adiponectin levels in adult men. <b>METHODS:</b> A total
 of 250 subjects, all in active duty in the Brazilian Army (BA), with a mean age
 of 42,6 ± 4,8 years volunteered to participate in the study. Plasma levels of a
diponectin were measured, as well as body mass, height, waist circumference (WC)
, fat percentage by hydrostatic weighing and VO<sub>2max</sub> by ergospirometry
. A questionnaire was used to obtain the characteristics of the physical trainin
g performed by the individuals. <b>RESULTS:</b> The sample showed that 121 (48%)
 individuals were overweight and 36 (14%) were obese. Moreover, 66 individuals (
27%) had a body fat percentage &gt; 25% and 26,7% had a WC <u>&gt;</u> 94 cm. Ov
erweight and obese individuals had significantly lower adiponectin levels than t
hose with an adequate nutritional status. Individuals at the highest tertile of 
VO<sub>2max</sub> had higher adiponectin levels than the others. The adiponectin
 levels were positively correlated with the total weekly physical training time 
and VO<sub>2max</sub> and inversely correlated with body mass, BMI and WC. The c
orrelation between adiponectin levels and VO<sub>2max</sub> did not remain signi
ficant after being adjusted for BMI and WC. <b>CONCLUSION:</b> Individuals with 
better cardiorespiratory fitness and normal nutritional status seem to present h
ealthier levels of adiponectin.#^dnd^i2#^tm^len^k<i>Adiponectin</i>^i2#^tm^len^k
<i>obesity</i>^i2#^tm^len^k<i>nutritional states</i>^i2#^tm^len^k<i>physical fit
ness</i>^i2#^tm^len^k<i>military personnel</i>^i2#Conselho Nacional de Desenvolv
imento Científico e Tecnológico#<span lang=EN-US style='font-size:10.0pt;font-fa
mily:Verdana'>311801/06-4</span>#vancouv#40#20100812#12/08/10#20101022#22/10/10#
20101210#10/12/10#aop04111.htm##
05678000000000745000450000400110000070200520001170500020006370600020006570000020
00677010002000697090008000717080002000790640007000810710003000880400003000910010
00600094042000200100120000400102038000500106038000400111121000300115049000300118
15800030012103000190012403200060014306500090014901400070015803500100016522300090
01750120103001840120096002870100049003830100048004320100047004800700040005270700
06300567070005500630070006700685083188400752085000802636085002502644085002202669
08500310269108500270272208500220274908317770277108500080454808500240455608500200
45800850031046000850029046310850031046600580062046910600012047531170008047650720
00304773112000904776111000904785116000904794115000904803114000904812113000904821
002001304830008008904843#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04
111.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#ilus#tab#48#nd#nd#Arq. bras. 
cardiol#ahead#20110000#^f0^l0#0066-782X#20110415#Influência do estado nutriciona
l e do VO2max nos níveis de adiponectina em homens acima de 35 anos^lpt#Influenc
e of nutritional status and VO2max on adiponectin levels in men older than 35 ye
ars^len#^rND^1A01 A02 A03 A04^nEduardo Camillo^sMartinez#^rND^1A01 A02 A03 A04^n
Macos de Sá Rego^sFortes#^rND^1A01 A02 A03 A04^nLuiz Antônio dos^sAnjos#^iA01^1E
scola Nacional de Saúde Pública#^iA02^1Instituto de Pesquisa da Capacitação Físi
ca do Exército#^iA03^1Instituto Estadual de Diabetes e Endocrinologia#^iA04^1Uni
versidade Federal Fluminense^cRio de Janeiro^sRJ^pBrasil#^lpt^aFUNDAMENTO: A adi
ponectina é considerada importante fator na patogênese das doenças cardiovascula
res e metabólicas, por suas propriedades antiaterogênicas e antiinflamatórias. P
oucos estudos, entretanto, sugerem a existência de relação direta entre os nívei
s de adiponectina e os níveis de condicionamento cardiorrespiratório e atividade
 física. OBJETIVO: Verificar a influência do estado nutricional e do condicionam
ento cardiorrespiratório nos níveis plasmáticos de adiponectina em homens adulto
s. MÉTODOS: Foram avaliados 250 sujeitos, homens, todos militares da ativa do Ex
ército Brasileiro (42,6 ± 4,8 anos). Foram mensurados os níveis plasmáticos de a
diponectina, massa corporal, estatura, circunferência da cintura (CC), percentua
l de gordura por pesagem hidrostática e VO2max por ergoespirometria. Um question
ário foi utilizado para obter as características do treinamento físico realizado
 pelos sujeitos. RESULTADOS: Na amostra, 121 (48 por cento) sujeitos apresentara
m sobrepeso e 36 (14 por cento) eram obesos. Ainda, 66 sujeitos (27 por cento) a
presentaram percentual de gordura maior que 25 por cento e 26.7 por cento aprese
ntaram CC > 94 cm. Sujeitos com sobrepeso e obesidade apresentaram valores signi
ficativamente menores de adiponectina em relação aqueles com estado nutricional 
normal. Sujeitos no mais alto tercil de VO2max apresentaram níveis de adiponecti
na mais altos que os demais. Os níveis de adiponectina estiveram positivamente c
orrelacionados com o tempo total de treinamento físico semanal e com o VO2max e 
inversamente correlacionados com os valores de massa corporal, IMC e CC. A corre
lação dos níveis de adiponectina e do VO2max não permaneceu significante após co
ntrolada pelo IMC e CC. CONCLUSÃO: Sujeitos com melhor condicionamento cardiorre
spiratório e com estado nutricional normal parecem apresentar níveis mais saudáv
eis de adiponectina.#^dnd^i1#^tm^lpt^kAdiponectina^i1#^tm^lpt^kobesidade^i1#^tm^
lpt^kestado nutricional^i1#^tm^lpt^kaptidão física^i1#^tm^lpt^kmilitares^i1#^len
^aBACKGROUND: Adiponectin is considered an important factor in the pathogenesis 
of cardiovascular and metabolic diseases, due to its anti- atherogenic and anti-
inflammatory properties. Few studies, however, have suggested the existence of a
 direct association between adiponectin levels and cardiorespiratory fitness and
 physical activity levels. OBJECTIVE: To verify the influence of the nutritional
 status and cardiorespiratory fitness on plasma adiponectin levels in adult men.
 METHODS: A total of 250 subjects, all in active duty in the Brazilian Army (BA)
, with a mean age of 42,6 ± 4,8 years volunteered to participate in the study. P
lasma levels of adiponectin were measured, as well as body mass, height, waist c
ircumference (WC), fat percentage by hydrostatic weighing and VO2max by ergospir
ometry. A questionnaire was used to obtain the characteristics of the physical t
raining performed by the individuals. RESULTS: The sample showed that 121 (48 pe
rcent) individuals were overweight and 36 (14 percent) were obese. Moreover, 66 
individuals (27 percent) had a body fat percentage > 25 percent and 26,7 percent
 had a WC > 94 cm. Overweight and obese individuals had significantly lower adip
onectin levels than those with an adequate nutritional status. Individuals at th
e highest tertile of VO2max had higher adiponectin levels than the others. The a
diponectin levels were positively correlated with the total weekly physical trai
ning time and VO2max and inversely correlated with body mass, BMI and WC. The co
rrelation between adiponectin levels and VO2max did not remain significant after
 being adjusted for BMI and WC. CONCLUSION: Individuals with better cardiorespir
atory fitness and normal nutritional status seem to present healthier levels of 
adiponectin.#^dnd^i2#^tm^len^kAdiponectin^i2#^tm^len^kobesity^i2#^tm^len^knutrit
ional states^i2#^tm^len^kphysical fitness^i2#^tm^len^kmilitary personnel^i2#Cons
elho Nacional de Desenvolvimento Científico e Tecnológico#311801/06-4#vancouv#40
#20100812#12/08/10#20101022#22/10/10#20101210#10/12/10#aop04111.htm#Internet^iht
tp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2011005000048##
00473000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704023100083002001300314#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#5#1#article#151#<p><a name="
enda"></a><font size="4" face="Verdana, Arial, Helvetica, sans-serif"><b>Influ&e
circ;ncia do estado nutricional e do VO<sub>2max</sub> nos n&iacute;veis de adip
onectina em homens acima de 35 anos</b></font></p>     ^cY#aop04111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#6#2#article#151#<p>&nbsp;</p
>     ^cY#aop04111.htm##
00264000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704002200083002001300105#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#7#3#article#151#<p>&nbsp;</p
>     ^cY#aop04111.htm##
00418000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704017600083002001300259#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#8#4#article#151#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Eduardo Camillo Martinez; 
Macos de S&aacute; Rego Fortes; Luiz Ant&ocirc;nio dos Anjos</b></font></p>     
^cY#aop04111.htm##
00569000000000145000450000400110000070200520001170500020006370600020006570000020
0067701000200069709000800071708000400079704032700083002001300410#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#9#5#article#151#<p><font siz
e="2" face="Verdana, Arial, Helvetica, sans-serif"> Escola Nacional de Sa&uacute
;de P&uacute;blica; Instituto de Pesquisa da Capacita&ccedil;&atilde;o F&iacute;
sica do Ex&eacute;rcito; Instituto Estadual de Diabetes e Endocrinologia;  Unive
rsidade Federal Fluminense, Rio de Janeiro, RJ - Brasil</font></p>     ^cY#aop04
111.htm##
00367000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704012400084002001300208#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#10#6#article#151#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><a href="#endb">Correspond&e
circ;ncia</a></font></p>     ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704002200084002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#11#7#article#151#<p>&nbsp;</
p>     ^cY#aop04111.htm##
00287000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704004400084002001300128#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#12#8#article#151#<p>&nbsp;</
p> <hr size="1" noshade>     ^cY#aop04111.htm##
00339000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000200070709000800072708000400080704009600084002001300180#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#13#9#article#151#<p><font si
ze="2" face="Verdana, Arial, Helvetica, sans-serif"><b>RESUMO</b></font></p>    
 ^cY#aop04111.htm##
00757000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051300085002001300598#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#14#10#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>FUNDAMENTO:</b>  A adipo
nectina &eacute; considerada importante fator na patog&ecirc;nese das doen&ccedi
l;as cardiovasculares e metab&oacute;licas, por suas propriedades antiaterog&eci
rc;nicas e antiinflamat&oacute;rias. Poucos estudos, entretanto, sugerem a exist
&ecirc;ncia de rela&ccedil;&atilde;o direta entre os n&iacute;veis de adiponecti
na e os n&iacute;veis de condicionamento cardiorrespirat&oacute;rio e atividade 
f&iacute;sica.     ^cY#aop04111.htm##
00448000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704020400085002001300289#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#15#11#article#151#<br>   <b>
OBJETIVO:</b>  Verificar a influ&ecirc;ncia do estado nutricional e do condicion
amento cardiorrespirat&oacute;rio nos n&iacute;veis plasm&aacute;ticos de adipon
ectina em homens adultos.     ^cY#aop04111.htm##
00754000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704051000085002001300595#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#16#12#article#151#<br>   <b>
M&Eacute;TODOS:</b>  Foram avaliados 250 sujeitos, homens, todos militares da at
iva do Ex&eacute;rcito Brasileiro (42,6 ± 4,8 anos). Foram mensurados os n&iacut
e;veis plasm&aacute;ticos de adiponectina, massa corporal, estatura, circunfer&e
circ;ncia da cintura (CC), percentual de gordura por pesagem hidrost&aacute;tica
 e VO<sub>2max</sub> por ergoespirometria. Um question&aacute;rio foi utilizado 
para obter as caracter&iacute;sticas do treinamento f&iacute;sico realizado pelo
s sujeitos.     ^cY#aop04111.htm##
01142000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704089800085002001300983#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#17#13#article#151#<br>   <b>
RESULTADOS:</b>  Na amostra, 121 (48%) sujeitos apresentaram sobrepeso e 36 (14%
) eram obesos. Ainda, 66 sujeitos (27%) apresentaram percentual de gordura maior
 que 25% e 26.7% apresentaram CC <u>&gt;</u> 94 cm. Sujeitos com sobrepeso e obe
sidade apresentaram valores significativamente menores de adiponectina em rela&c
cedil;&atilde;o aqueles com estado nutricional normal. Sujeitos no mais alto ter
cil de VO<sub>2max</sub> apresentaram n&iacute;veis de adiponectina mais altos q
ue os demais. Os n&iacute;veis de adiponectina estiveram positivamente correlaci
onados com o tempo total de treinamento f&iacute;sico semanal e com o VO<sub>2ma
x</sub> e inversamente correlacionados com os valores de massa corporal, IMC e C
C. A correla&ccedil;&atilde;o dos n&iacute;veis de adiponectina e do VO<sub>2max
</sub> n&atilde;o permaneceu significante ap&oacute;s controlada pelo IMC e CC. 
    ^cY#aop04111.htm##
00463000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704021900085002001300304#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#18#14#article#151#<br>   <b>
CONCLUS&Atilde;O:</b>  Sujeitos com melhor condicionamento cardiorrespirat&oacut
e;rio e com estado nutricional normal parecem apresentar n&iacute;veis mais saud
&aacute;veis de adiponectina.</font></p>     ^cY#aop04111.htm##
00459000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704021500085002001300300#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#19#15#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Palavras-chave:</b>  Adi
ponectina, obesidade, estado nutricional, aptid&atilde;o f&iacute;sica, militare
s. </font></p> <hr size="1" noshade>     ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#20#16#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#21#17#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00358000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011400085002001300199#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#22#18#article#151#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Introdu&ccedil;&atilde;o
</b></font></p>     ^cY#aop04111.htm##
01285000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704104100085002001301126#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#23#19#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Recentes avan&ccedil;os nas
 ci&ecirc;ncias biom&eacute;dicas est&atilde;o continuamente modificando conceit
os em rela&ccedil;&atilde;o ao papel de diferentes tecidos e &oacute;rg&atilde;o
s na fisiologia do corpo humano. Al&eacute;m de sua fun&ccedil;&atilde;o cl&aacu
te;ssica de armazenamento de energia, o tecido adiposo (TA) &eacute; agora recon
hecido como uma gl&acirc;ndula end&oacute;crina importante e bastante ativa<sup>
1</sup>. De acordo com Hauner<sup>2</sup>, o TA produz e secreta uma variedade d
e pept&iacute;deos e prote&iacute;nas bioativas, chamadas adipocitocinas, especi
almente a adiponectina, que &eacute; um potente modulador do metabolismo da glic
ose e lip&iacute;deos, bem como um indicador de dist&uacute;rbios metab&oacute;l
icos<sup>3</sup>. Esse horm&ocirc;nio &eacute; produzido exclusivamente pelos ad
ip&oacute;citos e difere dos outros por sua reduzida concentra&ccedil;&atilde;o 
no plasma em indiv&iacute;duos obesos<sup>4</sup>. </font></p>     ^cY#aop04111.
htm##
00738000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704049400085002001300579#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#24#20#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A adiponectina &eacute; con
siderada um fator importante na patog&ecirc;nese das doen&ccedil;as metab&oacute
;licas<sup>5</sup>, devido aos seus efeitos anti-aterog&ecirc;nicos, anti-diab&e
acute;ticos e antiinflamat&oacute;rios<sup>6</sup>. Indiv&iacute;duos com concen
tra&ccedil;&otilde;es mais altas de adiponectina apresentam menor de risco de do
en&ccedil;as cardiovasculares e metab&oacute;licas<sup>7</sup>. </font></p>     
^cY#aop04111.htm##
01472000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704122800085002001301313#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#25#21#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Tem sido sugerido que o exe
rc&iacute;cio f&iacute;sico, aumento da aptid&atilde;o f&iacute;sica e redu&cced
il;&atilde;o da obesidade est&atilde;o associados com a melhora no estado metab&
oacute;lico, embora concentra&ccedil;&otilde;es de adiponectina n&atilde;o tenha
m se alterado ap&oacute;s alguns estudos experimentais<sup>8,9</sup>. Embora con
troversos, alguns estudos<sup>10-12</sup> sugeriram uma rela&ccedil;&atilde;o di
reta entre os n&iacute;veis de adiponectina e atividade f&iacute;sica e, como re
ssaltado por Bl&uuml;her e cols. <sup>13</sup>, o treinamento f&iacute;sico pare
ce aumentar o n&uacute;mero de receptores de adiponectina na gordura subcut&acir
c;nea. Entretanto, somente alguns estudos associaram os n&iacute;veis plasm&aacu
te;ticos da adiponectina com mensura&ccedil;&otilde;es objetivas da aptid&atilde
;o cardiorrespirat&oacute;ria. Assim, o objetivo do presente estudo foi verifica
r a associa&ccedil;&atilde;o entre medidas antropom&eacute;tricas, estimativa do
 estado nutricional e aptid&atilde;o f&iacute;sica com os n&iacute;veis plasm&aa
cute;ticos da adiponectina em indiv&iacute;duos com mais de 35 anos de idade. </
font></p>     ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#26#22#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#27#23#article#151#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&eacute;todos</b></font
></p>     ^cY#aop04111.htm##
00637000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704039300085002001300478#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#28#24#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os indiv&iacute;duos do est
udo foram recrutados atrav&eacute;s de folhetos impressos em Organiza&ccedil;&ot
ilde;es Militares do Ex&eacute;rcito Brasileiro (EB) na cidade do Rio de Janeiro
, Brasil. Um total de 250 indiv&iacute;duos, todos militares na ativa, foram vol
unt&aacute;rios para participar do estudo. </font></p>     ^cY#aop04111.htm##
00883000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704063900085002001300724#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#29#25#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif"> Em um dia pr&eacute;-marca
do, todos os indiv&iacute;duos vieram ao laborat&oacute;rio na parte da manh&ati
lde; (entre 7 e 8 da manh&atilde;) ap&oacute;s 12 horas de jejum. Todos os proce
dimentos foram explicados em detalhes aos indiv&iacute;duos, os quais assinaram 
o Termo de Consentimento Livre e Informado (TCLI) antes da coleta de dados. Um t
ubo de ensaio de 4,5 ml de sangue foi obtido de cada participante e mantido cong
elado at&eacute; o momento da mensura&ccedil;&atilde;o dos n&iacute;veis de adip
onectina (ADIP - imunoensaio enzim&aacute;tico). </font></p>     ^cY#aop04111.ht
m##
02209000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704196500085002001302050#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#30#26#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em seguida, o &iacute;ndice
 de massa corporal (IMC) e altura foram medidos utilizando-se uma balan&ccedil;a
 digital Filizola com divis&otilde;es de 50 g e um estadi&ocirc;metro de parede 
Sanny com precis&atilde;o de 1 mm, respectivamente. O IMC foi calculado como mas
sa corporal (MC) em quilogramas (kg) dividida pela altura ao quadrado (m<sup>2</
sup>) e usado para estabelecer o estado nutricional como adequado (18,5 <u>&lt;<
/u> IMC &lt; 25 kg.m<sup>-2</sup>), sobrepeso (25 <u>&lt;</u> IMC &lt; 30 kg.m<s
up>-2</sup>), e obesidade (IMC <u>&gt;</u> 30 kg.m<sup>-2</sup>) de acordo com a
 OMS<sup>14</sup>. A circunfer&ecirc;ncia da cintura (CC) foi medida na menor cu
rvatura localizada entre a &uacute;ltima costela e a crista il&iacute;aca. O pon
to de corte da CC de 94 cm foi utilizado para avaliar o aumento de risco de comp
lica&ccedil;&otilde;es metab&oacute;licas associadas com a obesidade<sup>14</sup
>. Essas medidas foram seguidas por pesagem hidrost&aacute;tica, para obter-se a
 densidade corporal e a porcentagem de gordura corporal (%GC) foi calculada. A g
ordura corporal total (GCT) foi computada (MC x %GC) e utilizada na an&aacute;li
se. Ap&oacute;s a pesagem dentro da &aacute;gua, os indiv&iacute;duos tomaram o 
caf&eacute; da manh&atilde; e responderam um question&aacute;rio sobre suas roti
nas de treinamento f&iacute;sico, seguido por um eletrocardiograma (ECG) de repo
uso e um Teste de Exerc&iacute;cio Cardiopulmonar M&aacute;ximo (TECM) na esteir
a. O tempo total gasto no treinamento f&iacute;sico (TF), em minutos por semana,
 foi calculado multiplicando-se a frequ&ecirc;ncia semanal da atividade f&iacute
;sica pela dura&ccedil;&atilde;o m&eacute;dia das sess&otilde;es. O valor de cor
te de 150 min.sem<sup>-1</sup> de atividade f&iacute;sica com intensidade modera
da a alta foi considerado o m&iacute;nimo recomendado de atividade f&iacute;sica
<sup>15</sup>. </font></p>     ^cY#aop04111.htm##
01576000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704133200085002001301417#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#31#27#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Um protocolo de rampa foi u
tilizado no TECM, que consistiu em um per&iacute;odo de aquecimento de 3 minutos
 em ritmo de caminhada r&aacute;pida, seguido por corrida sem inclina&ccedil;&at
ilde;o na esteira (Inbrasport Super ATL - Porto Alegre - Brasil) com aumentos co
nstantes na velocidade por 8 minutos ap&oacute;s os quais a velocidade foi manti
da constante e a inclina&ccedil;&atilde;o foi aumentada at&eacute; a exaust&atil
de;o volitiva. Todos os testes duraram de 8 a 12 minutos. O consumo de oxig&ecir
c;nio e a produ&ccedil;&atilde;o de di&oacute;xido de carbono foram medidos util
izando-se o sistema CPX-D (Medical Graphics - St Paul Minnesota) durante o TECM.
 Antes do primeiro teste de cada dia, o equipamento era calibrado manualmente, s
eguido por autocalibra&ccedil;&atilde;o antes de cada teste. O VO<sub>2max</sub>
 foi medido ao esfor&ccedil;o m&aacute;ximo, definido como a incapacidade de con
tinuar o exerc&iacute;cio a despeito de vigoroso encorajamento e confirmado pela
 raz&atilde;o de troca respirat&oacute;ria (R) <u>&gt;</u>1.1, VE/VO<sub>2</sub>
 <u>&gt;</u>35, frequ&ecirc;ncia card&iacute;aca (FC) <u>&gt;</u> 95% do m&aacut
e;ximo previsto para a idade e frequ&ecirc;ncia respirat&oacute;ria (FR) <u>&gt;
</u> 30<sup>16</sup>. </font></p>     ^cY#aop04111.htm##
01332000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704108800085002001301173#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#32#28#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A an&aacute;lise estat&iacu
te;stica incluiu as caracter&iacute;sticas descritivas dos indiv&iacute;duos (m&
eacute;dia, desvio-padr&atilde;o, valores m&aacute;ximo e m&iacute;nimo). Os coe
ficientes de correla&ccedil;&atilde;o de Pearson foram calculados para verificar
 a associa&ccedil;&atilde;o entre as vari&aacute;veis. O teste de an&aacute;lise
 de vari&acirc;ncia (ANOVA) foi utilizado para testar a signific&acirc;ncia do p
rincipal efeito da aptid&atilde;o cardiorrespirat&oacute;ria (tercis de VO<sub>2
max</sub>: &lt; 36,43; 36,43-42,45 e <u>&gt;</u> 42,45 ml O<sub>2</sub>.kg<sup>-
1</sup>.min<sup>-1</sup>) e do estado nutricional nos n&iacute;veis plasm&aacute
;ticos de adiponectina. As mesmas an&aacute;lises foram realizadas controlando p
ara CC, VO<sub>2max</sub> ou ambos (An&aacute;lise de covari&acirc;ncia - ANCOVA
). Os testes <i>post hoc</i> de Tukey foram utilizados para testar a signific&ac
irc;ncia entre as m&eacute;dias. A signific&acirc;ncia estat&iacute;stica foi es
tabelecida em 5%. </font></p>     ^cY#aop04111.htm##
00496000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704025200085002001300337#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#33#29#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As an&aacute;lises bioqu&ia
cute;micas foram realizadas por NKB Medicina Diagn&oacute;stica (Rio de Janeiro,
 Brasil) e Roche Diagn&oacute;stica (Rio de Janeiro, Brasil). </font></p>     ^c
Y#aop04111.htm##
00558000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704031400085002001300399#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#34#30#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Todos os procedimentos de p
esquisa foram aprovados pelo Comit&ecirc; de &Eacute;tica da Escola de Sa&uacute
;de P&uacute;blica S&eacute;rgio Arouca, Funda&ccedil;&atilde;o Oswaldo Cruz e t
odos os indiv&iacute;duos assinaram o TCLI. </font></p>     ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#35#31#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00344000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010000085002001300185#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#36#32#article#151#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Resultados</b></font></p
>     ^cY#aop04111.htm##
00746000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704050200085002001300587#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#37#33#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A m&eacute;dia (± DP) da id
ade dos indiv&iacute;duos era 42,6 ± 4,8 anos, com IMC de 26,5 ± 3,8 kg.m<sup>-2
</sup> e n&iacute;veis s&eacute;ricos de adiponectina de 15,1 ± 9,9 <i>&#181;</i
>g.ml<sup>-1</sup> (<a href="#tab1">Tabela 1</a>). A amostra incluiu 121 indiv&i
acute;duos com sobrepeso (48%) e 36 obesos (14%). Um total de 66 indiv&iacute;du
os (27%) apresentavam %GC &gt; 25% e 26,7% tinham CC <u>&gt;</u> 94 cm. </font><
/p>     ^cY#aop04111.htm##
00279000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704003500085002001300120#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#38#34#article#151#<p><a name
="tab1"></a></p>     ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#39#35#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00333000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704008900085002001300174#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#40#36#article#151#<p align="
center"><img src="/img/revistas/abc/2011nahead/aop04111tab01.jpg"></p>     ^cY#a
op04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#41#37#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
01205000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704096100085002001301046#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#42#38#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Indiv&iacute;duos com sobre
peso (13,9 ± 8,88 <i>&#181;</i>g.ml<sup>-1</sup>) e obesos (12,0 ± 7,5 <i>&#181;
</i>g.ml<sup>-1</sup>) tinham valores significantemente mais baixos de adiponect
ina, em compara&ccedil;&atilde;o com indiv&iacute;duos com IMC adequado (18,1 ± 
11,3 <i>&#181;</i>g.ml<sup>-1</sup>). Essas diferen&ccedil;as foram mantidas mes
mo quando a an&aacute;lise foi controlada pela CC, VO<sub>2max</sub> ou ambos. O
s indiv&iacute;duos no tercil mais baixo de VO<sub>2max</sub> tinham n&iacute;ve
is de adiponectina significantemente mais baixos (<a href="/img/revistas/abc/201
1nahead/aop04111fig01m.jpg">Figura 1</a>). Indiv&iacute;duos com alta %GC (<u>&g
t;</u> 25%) tinham n&iacute;veis significantemente mais baixos de adiponectina (
12,7 ± 7,4 <i>&#181;</i>g.ml<sup>-1</sup>) do que indiv&iacute;duos com %GC &lt;
 15% (18,7 ± 11,4 <i>&#181;</i>g.ml<sup>-1</sup>). </font></p>     ^cY#aop04111.
htm##
01216000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097200085002001301057#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#43#39#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Os n&iacute;veis s&eacute;r
icos de adiponectina apresentaram uma fraca correla&ccedil;&atilde;o positiva co
m TF e eram inversamente correlacionados com MC, IMC, %GC, gordura corporal tota
l (GCT) e CC (<a href="/img/revistas/abc/2011nahead/aop04111tab02m.jpg">Tabela 2
</a>). A correla&ccedil;&atilde;o entre a adiponectina e VO<sub>2max</sub> (r = 
0,07) n&atilde;o foi significante (p = 0,29) ap&oacute;s controle para IMC e CC.
 A correla&ccedil;&atilde;o com o TF permaneceu significante ap&oacute;s o contr
ole para idade, IMC e CC (r = 0,14). Indiv&iacute;duos que realizavam pelo menos
 150 min.sem<sup>-1</sup> de treinamento com intensidade moderada a alta apresen
tavam os n&iacute;veis mais altos de adiponectina (16,9 ± 10,4 <i>&#181;</i>g.ml
<sup>-1</sup>), quando comparados com aqueles que n&atilde;o atingiam tal volume
 de treinamento (14,3 ± 10,1 <i>&#181;</i>g.ml<sup>-1</sup>). </font></p>     ^c
Y#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#44#40#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00350000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010600085002001300191#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#45#41#article#151#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Discuss&atilde;o</b></fo
nt></p>     ^cY#aop04111.htm##
01218000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097400085002001301059#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#46#42#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em geral, os resultados do 
presente estudo est&atilde;o de acordo com a literatura, que mostra que os n&iac
ute;veis circulantes de adiponectina s&atilde;o mais altos em indiv&iacute;duos 
n&atilde;o-obesos, em compara&ccedil;&atilde;o a obesos e que os n&iacute;veis d
e adiponectina mostram uma correla&ccedil;&atilde;o negativa com medidas antropo
m&eacute;tricas (IMC e CC), mesmo ap&oacute;s ajuste para idade e gordura corpor
al total<sup>7,17</sup>. Kantartzis e cols. <sup>18</sup> n&atilde;o encontraram
 diferen&ccedil;a nos n&iacute;veis de adiponectina entre indiv&iacute;duos com 
sobrepeso e obesos, mesmo ap&oacute;s o controle para gordura abdominal. No pres
ente estudo, a adiponectina tamb&eacute;m n&atilde;o foi diferente entre indiv&i
acute;duos com sobrepeso e obesos, mas indiv&iacute;duos com estado nutricional 
adequado apresentavam n&iacute;veis mais altos de adiponectina. </font></p>     
^cY#aop04111.htm##
01551000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704130700085002001301392#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#47#43#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A rela&ccedil;&atilde;o inv
ersa entre a adiponectina e o IMC ou a %GC encontrada no presente estudo est&aac
ute; de acordo com v&aacute;rios outros estudos<sup>7,12,18</sup>. Gavrila e col
s. <sup>19</sup> sugeriram que a obesidade e a distribui&ccedil;&atilde;o de gor
dura central eram preditores negativos independentes da adiponectina s&eacute;ri
ca e que a adiponectina poderia representar uma liga&ccedil;&atilde;o entre a ob
esidade central e doen&ccedil;as metab&oacute;licas, provavelmente devido ao aum
ento na express&atilde;o de TNF-</font>&#945;<font size="2" face="Verdana, Arial
, Helvetica, sans-serif">, que reduz a express&atilde;o da adiponectina e a secr
e&ccedil;&atilde;o <i>in vitro</i> dos adip&oacute;citos<sup>20,21</sup>. Esposi
to e cols. <sup>22</sup> encontraram um aumento de 48% nos n&iacute;veis de adip
onectina ap&oacute;s 2 anos de dieta do Mediterr&acirc;neo de baixa energia e au
mento da atividade f&iacute;sica por 8 semanas em mulheres. Ap&oacute;s a interv
en&ccedil;&atilde;o, os indiv&iacute;duos apresentaram IMC, %GC e MC mais baixos
 e menor CC e n&iacute;veis mais altos de adiponectina s&eacute;rica, em compara
&ccedil;&atilde;o com o per&iacute;odo pr&eacute;-interven&ccedil;&atilde;o. </f
ont></p>     ^cY#aop04111.htm##
01669000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704142500085002001301510#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#48#44#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">De acordo com Tsukinoki e c
ols. <sup>12</sup>, os indiv&iacute;duos com n&iacute;veis de adiponectina &lt; 
4 <i>&#181;</i>g.dl<sup>-1</sup> apresentavam IMC mais alto do que os indiv&iacu
te;duos com n&iacute;veis &gt; 4 <i>&#181;</i>g.dl<sup>-1</sup>. Homens com IMC 
&gt; 30 kg.m<sup>-2</sup> e mais do que 25% de gordura corporal apresentavam val
ores mais baixos de adiponectina do que aqueles com menor IMC e %GC<sup>23</sup>
. A altera&ccedil;&atilde;o na MC e massa gordurosa corporal ap&oacute;s o trein
amento correlacionavam-se significantemente e negativamente com altera&ccedil;&o
tilde;es nos n&iacute;veis de adiponectina. Hulver e cols. <sup>8</sup> conclu&i
acute;ram que a perda da massa corporal um ano ap&oacute;s a cirurgia bari&aacut
e;trica causou significantes redu&ccedil;&otilde;es no IMC, n&iacute;veis de ins
ulina e glicose de jejum e aumentos significantes nos n&iacute;veis de adiponect
ina. Al&eacute;m disso, uma redu&ccedil;&atilde;o na massa do tecido adiposo (TA
) subcut&acirc;neo, isoladamente, ap&oacute;s lipoaspira&ccedil;&atilde;o abdomi
nal, n&atilde;o leva a uma redu&ccedil;&atilde;o similar na inflama&ccedil;&atil
de;o de baixo grau<sup>24</sup>, indicando que o TA visceral est&aacute; mais in
timamente associado com o estado inflamat&oacute;rio na obesidade do que o dep&o
acute;sito de TA subcut&acirc;neo. </font></p>     ^cY#aop04111.htm##
02474000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704223000085002001302315#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#49#45#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Embora indiv&iacute;duos ob
esos tenham mais gordura corporal, eles tamb&eacute;m apresentam n&iacute;veis m
ais altos de citocinas pr&oacute;-inflamat&oacute;rias IL-6 e TNF-</font>&#945;<
font size="2" face="Verdana, Arial, Helvetica, sans-serif">. Isso pode causar um
a redu&ccedil;&atilde;o na express&atilde;o do mRNA da adiponectina e na libera&
ccedil;&atilde;o da adiponectina dos adip&oacute;citos. A adiponectina e TNF-</f
ont>&#945;<font size="2" face="Verdana, Arial, Helvetica, sans-serif"> inibem um
 ao outro. A express&atilde;o da adiponectina &eacute; suprimida pela IL-6<sup>2
5</sup>. Isso pode explicar porque indiv&iacute;duos obesos tem n&iacute;veis de
 adiponectina circulantes mais baixos. Em indiv&iacute;duos obesos, os n&iacute;
veis plasm&aacute;ticos de adiponectina eram mais baixos, apesar do tecido adipo
so ser o &uacute;nico tecido de sua s&iacute;ntese, sugerindo uma retroalimenta&
ccedil;&atilde;o negativa na sua produ&ccedil;&atilde;o imposta pelo desenvolvim
ento da obesidade. Portanto, a redu&ccedil;&atilde;o do peso corporal resultaria
 em uma desinibi&ccedil;&atilde;o pelo menos transit&oacute;ria, e, portanto, em
 um aumento da adiponectina no plasma. Nadler e cols. <sup>26</sup> mostraram at
rav&eacute;s de microarranjo, que a express&atilde;o dos genes adipog&ecirc;nico
s estava suprimida no desenvolvimento de obesidade em camundongos, sugerindo a e
xist&ecirc;ncia de uma via inibit&oacute;ria de retroalimenta&ccedil;&atilde;o. 
Em camundongos obesos ob/ob, a express&atilde;o do gene adipoQ estava "down-regu
lada". O fato de que o mRNA est&aacute;vel do gene adipoQ diminuiu em camundongo
s ob/ob quando comparados com os do tipo selvagem indica que o n&iacute;vel da r
egula&ccedil;&atilde;o est&aacute; relacionado, em parte, com o transcrito ou a 
estabilidade do mRNA. Al&eacute;m disso, o estado est&aacute;vel do mRNA da adip
onectina no tecido adiposo parece estar reduzido em indiv&iacute;duos obesos<sup
>27</sup>. Entretanto, os mecanismos biol&oacute;gicos que modulam a express&ati
lde;o da adiponectina durante a redu&ccedil;&atilde;o do peso precisam ser mais 
estudados para serem melhor entendidos. </font></p>     ^cY#aop04111.htm##
01043000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704079900085002001300884#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#50#46#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Embora a literatura ainda s
eja inconsistente em rela&ccedil;&atilde;o aos efeitos agudos e cr&ocirc;nicos d
o treinamento aer&oacute;bico e o papel da intensidade do exerc&iacute;cio nos n
&iacute;veis de adiponectina<sup>28</sup>, St-Pierre e cols. <sup>11</sup> suger
iram uma correla&ccedil;&atilde;o positiva entre a adiponectina e a atividade f&
iacute;sica. Kraemer e cols. <sup>29</sup> sugeriram que o efeito era mais frequ
entemente observado com atividade f&iacute;sica vigorosa. Entretanto, Bl&uuml;he
r e cols. <sup>10</sup> e Oberbach e cols. <sup>30</sup> mostraram aumentos sign
ificantes nos n&iacute;veis de adiponectina em indiv&iacute;duos obesos e insuli
no-resistentes que se exercitavam moderadamente. </font></p>     ^cY#aop04111.ht
m##
00650000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704040600085002001300491#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#51#47#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Tem sido estimado<sup>31</s
up> que exerc&iacute;cio aer&oacute;bico vigoroso (80 a 90% da FC m&aacute;xima)
 pode representar um aumento nos n&iacute;veis de adiponectina de 0,9 <i>&#181;<
/i>g.ml<sup>-1</sup>, enquanto exerc&iacute;cios moderadamente intensos podem le
var a um aumento de 0,7 <i>&#181;</i>g.ml<sup>-1</sup>. </font></p>     ^cY#aop0
4111.htm##
01348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704110400085002001301189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#52#48#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">O exerc&iacute;cio produz u
m aumento na libera&ccedil;&atilde;o de interleucina-6 de m&uacute;sculos ativos
, os quais, por sua vez, suprimem outros marcadores pr&oacute;-inflamat&oacute;r
ios, tais como TNF-</font>&#945;<font size="2" face="Verdana, Arial, Helvetica, 
sans-serif"> e podem estar associados com o aumento nos n&iacute;veis de adipone
ctina<sup>32</sup>. Os efeitos do treinamento de resist&ecirc;ncia incluem uma "
up-regula&ccedil;&atilde;o" da express&atilde;o de GLUT4, ativa&ccedil;&atilde;o
 cr&ocirc;nica de AMPK, facilita&ccedil;&atilde;o da transdu&ccedil;&atilde;o do
 sinal da insulina, bem como aumentos na express&atilde;o de v&aacute;rias prote
&iacute;nas envolvidas na utiliza&ccedil;&atilde;o da glicose e dos l&iacute;pid
es e seu turnover pode estar associado com a adiponectina. Al&eacute;m disso, o 
treinamento poderia modular a produ&ccedil;&atilde;o de citocinas ao n&iacute;ve
l de express&atilde;o g&ecirc;nica, ligante de prote&iacute;na e liga&ccedil;&at
ilde;o a receptores<sup>33</sup>. </font></p>     ^cY#aop04111.htm##
01439000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704119500085002001301280#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#53#49#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Esposito e cols. <sup>22</s
up> e Hulver e cols. <sup>8</sup> sugerem que o exerc&iacute;cio f&iacute;sico a
penas n&atilde;o &eacute; suficiente para aumentar os n&iacute;veis de adiponect
ina. Eles conclu&iacute;ram que alguma perda de massa corporal &eacute; necess&a
acute;ria para aumentar os n&iacute;veis de adiponectina em indiv&iacute;duos se
dent&aacute;rios ou aqueles com padr&otilde;es de atividade f&iacute;sica. Ap&oa
cute;s seis semanas de treinamento aer&oacute;bico cinco vezes por semana, Yatag
ai e cols. <sup>34</sup> n&atilde;o observaram mudan&ccedil;as nos n&iacute;veis
 de adiponectina. As mudan&ccedil;as no VO<sub>2max</sub>, %GC e GCT ap&oacute;s
 o treinamento n&atilde;o estavam associadas com mudan&ccedil;as nos n&iacute;ve
is de adiponectina, em contraste com os achados de Bruun e cols. <sup>35</sup> q
ue demonstraram um aumento de cerca de 29% nos n&iacute;veis circulantes de adip
onectina ap&oacute;s 15 semanas de dieta hipocal&oacute;rica mais exerc&iacute;c
io em homens com obesidade grave, que estava associado com redu&ccedil;&atilde;o
 no IMC e CC e aumento no VO<sub>2max</sub>. </font></p>     ^cY#aop04111.htm##
02051000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704180700085002001301892#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#54#50#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Kim e cols. <sup>36</sup> m
ostraram um aumento de 10% nos n&iacute;veis de adiponectina ap&oacute;s treinam
ento (exerc&iacute;cio de pular cordas com supervis&atilde;o), cinco vezes por s
emana, 40 minutos por dia por seis semanas em jovens coreanos obesos. Os n&iacut
e;veis de adiponectina aumentaram 81% ap&oacute;s exerc&iacute;cios vigorosos po
r 2 semanas (expedi&ccedil;&atilde;o de esqui nas montanhas suecas), mas retorna
ram aos valores basais ap&oacute;s 6 semanas em 20 homens<sup>37</sup>. Ap&oacut
e;s 24 meses de treinamento f&iacute;sico (andar de bicicleta <u>&gt;</u> tr&eci
rc;s vezes por semana, <u>&gt;</u> 45 minutos por sess&atilde;o a 50-65% do VO<s
ub>2pico</sub>) em adultos com predisposi&ccedil;&atilde;o &agrave; s&iacute;ndr
ome metab&oacute;lica, Ring-Dimitriou e cols. <sup>28</sup> observou que uma mel
hora de 4,7 ml O<sub>2</sub>.kg<sup>-1</sup>.min<sup>-1</sup> no VO<sub>2pico</s
ub> estava associada com um aumento de 1,6 <i>&#181;</i>g.ml<sup>-1</sup> nos n&
iacute;veis de adiponectina em homens. Ap&oacute;s um ano de treinamento, os n&i
acute;veis de adiponectina aumentaram de forma significante em homens (1,7 <i>&#
181;</i>g.ml<sup>-1</sup>), mas nenhuma altera&ccedil;&atilde;o foi observada no
 VO<sub>2pico</sub>, IMC e %GC em homens obesos. No presente estudo, VO<sub>2max
</sub> estava diretamente (mas fracamente) associado com os n&iacute;veis s&eacu
te;ricos de adiponectina. Indiv&iacute;duos com os maiores valores de VO<sub>2ma
x</sub> apresentavam valores significantemente mais altos de adiponectina, de ac
ordo com os dados de Kumagai e cols. <sup>38</sup>, que tamb&eacute;m observaram
 uma associa&ccedil;&atilde;o direta entre os n&iacute;veis de adiponectina e VO
<sub>2max</sub>. </font></p>     ^cY#aop04111.htm##
00982000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704073800085002001300823#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#55#51#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em rela&ccedil;&atilde;o ao
 efeito agudo do exerc&iacute;cio, o estudo de J&uuml;rim&auml;e e cols. <sup>39
</sup> n&atilde;o observou mudan&ccedil;as nos n&iacute;veis de adiponectina ime
diatamente ap&oacute;s exerc&iacute;cios aer&oacute;bicos com dura&ccedil;&atild
e;o aproximada de 1 hora em indiv&iacute;duos saud&aacute;veis. Entretanto, os n
&iacute;veis de adiponectina estavam alterados nos atletas altamente treinados a
p&oacute;s exerc&iacute;cios de alta intensidade envolvendo v&aacute;rios grupos
 musculares e aumentaram significantemente acima do valor de repouso ap&oacute;s
 os primeiros 30 minutos de recupera&ccedil;&atilde;o<sup>39</sup>. </font></p> 
    ^cY#aop04111.htm##
01217000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704097300085002001301058#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#56#52#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Recentes avan&ccedil;os na 
an&aacute;lise bioqu&iacute;mica da adiponectina tem mostrado que a express&atil
de;o do receptor da adiponectina tamb&eacute;m aumenta ap&oacute;s o treinamento
 f&iacute;sico. A express&atilde;o do AdipoR2 mRNA na gordura visceral e subcut&
acirc;nea est&aacute; positivamente associada com os n&iacute;veis circulantes d
e adiponectina, mas negativamente associada com obesidade, mesmo ap&oacute;s o a
juste para massa gorda<sup>10</sup>. Quatro semanas de treinamento f&iacute;sico
 intenso resultou em aumentos na express&atilde;o do gene AdipoR1/R2 mRNA do m&u
acute;sculo esquel&eacute;tico. A mesma interven&ccedil;&atilde;o levou a aument
os na express&atilde;o do mRNA dos genes AdipoR1 e AdipoR2 na gordura subcut&aci
rc;nea e estava significantemente e positivamente correlacionada com os aumentos
 de AdipoR2 no m&uacute;sculo esquel&eacute;tico<sup>13</sup>. </font></p>     ^
cY#aop04111.htm##
00767000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704052300085002001300608#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#57#53#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A despeito do aumento no VO
<sub>2max</sub> e redu&ccedil;&atilde;o na MC, IMC, massa gorda e CC, Polak e co
ls. <sup>40</sup> n&atilde;o demonstraram diferen&ccedil;as significantes nos n&
iacute;veis de adiponectina ap&oacute;s 12 semanas de treinamento aer&oacute;bic
o. Os autores especularam que a manuten&ccedil;&atilde;o dos n&iacute;veis de mR
NA para adiponectina no tecido adiposo subcut&acirc;neo seria a raz&atilde;o des
ses achados. </font></p>     ^cY#aop04111.htm##
00775000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704053100085002001300616#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#58#54#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">A adiponectina pode ativar 
a prote&iacute;na-quinase AMP-ativada e aumentar a oxida&ccedil;&atilde;o dos &a
acute;cidos graxos no m&uacute;sculo esquel&eacute;tico. Enquanto a atividade to
tal da prote&iacute;na-quinase AMP-ativada est&aacute; relacionada &agrave; mass
a muscular, pode ser postulado que atletas que utilizam maior massa muscular dur
ante o exerc&iacute;cio precisam de mais adiponectina a fim de regular os fluxos
 metab&oacute;licos. </font></p>     ^cY#aop04111.htm##
01139000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704089500085002001300980#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#59#55#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">Em conclus&atilde;o, embora
 a associa&ccedil;&atilde;o entre os n&iacute;veis de adiponectina e %GC e IMC s
eja fraca, ela est&aacute; de acordo com alguns estudos. Parece que o aumento no
s n&iacute;veis de adiponectina n&atilde;o &eacute; causado pelo exerc&iacute;ci
o em si, mas &eacute; modulado por altera&ccedil;&otilde;es na composi&ccedil;&a
tilde;o corporal. Entretanto, ainda &eacute; preciso esclarecer quanta gordura c
orporal &eacute; necess&aacute;rio reduzir para que os n&iacute;veis de adiponec
tina aumentem. De forma inversa, embora os resultados sugiram que uma massa corp
oral adequada represente o maior benef&iacute;cio, &eacute; importante promover 
a atividade f&iacute;sica para obter o benef&iacute;cio duplo de manter um IMC m
ais saud&aacute;vel e aptid&atilde;o cardiorrespirat&oacute;ria. </font></p>    
 ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#60#56#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00361000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704011700085002001300202#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#61#57#article#151#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Contribui&ccedil;&otilde
;es</b></font></p>     ^cY#aop04111.htm##
00596000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704035200085002001300437#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#62#58#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">EC Martinez e LA Anjos plan
ejaram a pesquisa e conduziram a an&aacute;lise dos dados. EC Martinez e MSR For
tes supervisionaram a coleta de dados em campo. EC Martinez escreveu a primeira 
vers&atilde;o do manuscrito, o qual foi revisado e aprovado pelos outros autores
. </font></p>     ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#63#59#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00348000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010400085002001300189#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#64#60#article#151#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Agradecimentos</b></font
></p>     ^cY#aop04111.htm##
00661000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704041700085002001300502#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#65#61#article#151#<p><font s
ize="2" face="Verdana, Arial, Helvetica, sans-serif">As an&aacute;lises bioqu&ia
cute;micas foram conduzidas por NKB Medicina Diagn&oacute;stica (Rio de Janeiro,
 Brasil) e Roche Diagn&oacute;stica (Rio de Janeiro, Brasil). L. A. Anjos recebe
u uma bolsa de produtividade em pesquisa do Conselho Nacional de Desenvolvimento
 Cient&iacute;fico e Tecnol&oacute;gico (CNPq, Proc. 311801/06-4). </font></p>  
   ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002200085002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#66#62#article#151#<p>&nbsp;<
/p>     ^cY#aop04111.htm##
00351000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704010700085002001300192#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#67#63#article#151#<p><font s
ize="3" face="Verdana, Arial, Helvetica, sans-serif"><b>Refer&ecirc;ncias</b></f
ont></p>     ^cY#aop04111.htm##
00505000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704024700087002001300334#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#68#64#article#15
1#1#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1. Havel PJ. 
Control of energy homeostasis and insulin action by adipocyte hormones: leptin, 
acylation stimulating protein, and adiponectin. Curr Opin Lipidol. 2002;13(1):51
-9.    ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#69#65#article#151# </font></
p>     ^cY#aop04111.htm##
00418000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704016000087002001300247#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#70#66#article#15
1#2#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2. Hauner H. 
The new concept of adipose tissue function. Physiol Behav. 2004;83(4):653-8.    
^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#71#67#article#151# </font></
p>     ^cY#aop04111.htm##
00486000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704022800087002001300315#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#72#68#article#15
1#3#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3. Trujillo M
E, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomar
ker of the metabolic syndrome. J Intern Med. 2005;257(2):167-75.    ^cY#aop04111
.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#73#69#article#151# </font></
p>     ^cY#aop04111.htm##
00520000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704026200087002001300349#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#74#70#article#15
1#4#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4. Haluz&iacu
te;k M, Par&iacute;zkov&aacute; J, Haluz&iacute;k MM. Adiponectin and its role i
n the obesity-induced insulin resistance and related complications. Physiol Res.
 2004;53(2):123-9.    ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#75#71#article#151# </font></
p>     ^cY#aop04111.htm##
00462000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704020400087002001300291#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#76#72#article#15
1#5#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5. Ukkola O, 
Santaniemi M. Adiponectin: a link between excess adiposity and associated comorb
idities? J Mol Med. 2002;80(11):696-702.    ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#77#73#article#151# </font></
p>     ^cY#aop04111.htm##
00436000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704017800087002001300265#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#78#74#article#15
1#6#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6. Kershaw EE
, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;
89(6):2548-56.    ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#79#75#article#151# </font></
p>     ^cY#aop04111.htm##
00509000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704025100087002001300338#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#80#76#article#15
1#7#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7. Rothenbach
er D, Brenner H, M&auml;rz W, Koenig W. Adiponectin, risk of coronary heart dise
ase and correlations with cardiovascular risk markers. Eur Heart J. 2005;26(16):
1640-6.    ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#81#77#article#151# </font></
p>     ^cY#aop04111.htm##
00536000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704027800087002001300365#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#82#78#article#15
1#8#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8. Hulver MW,
 Zheng D, Tanner CJ, Houmard JA, Kraus WE, Slentz CA, et al. Adiponectin is not 
altered with exercise training despite enhanced insulin action. Am J Physiol End
ocrinol Metab. 2002;283(4):E861-5.    ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#83#79#article#151# </font></
p>     ^cY#aop04111.htm##
00438000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000200085704018000087002001300267#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#84#80#article#15
1#9#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9. Yang WS, C
huang LM. Human genetics of adiponectin in the metabolic syndrome. J Mol Med. 20
06;84(2):112-21.    ^cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#85#81#article#151# </font></
p>     ^cY#aop04111.htm##
00652000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704039300088002001300481#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#86#82#article#15
1#10#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10. Bl&uuml;
her M, Bullen JW Jr, Lee JH, Kralisch S, Fasshauer M, Kl&ouml;ting N, et al. Cir
culating adiponectin and expression of adiponectina receptors in human skeletal 
muscle: associations with metabolic parameters and insulin resistance and regula
tion by physical training. J Clin Endocrinol Metab. 2006;91(6):2310-6.    ^cY#ao
p04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#87#83#article#151# </font></
p>     ^cY#aop04111.htm##
00572000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704031300088002001300401#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#88#84#article#15
1#11#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11. St-Pierr
e DH, Faraj M, Karelis AD, Conus F, Henry JF, St-Onge M, et al. Lifestyle behavi
ours and components of energy balance as independent predictors of ghrelin and a
diponectin in young non-obese women. Diabetes Metab. 2006;32(2):131-9.    ^cY#ao
p04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#89#85#article#151# </font></
p>     ^cY#aop04111.htm##
00485000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704022600088002001300314#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#90#86#article#15
1#12#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12. Tsukinok
i R, Morimoto K, Nakayama K. Association between lifestyle factors and plasma ad
iponectin levels in Japanese men. Lipids Health Dis. 2005;4:27.    ^cY#aop04111.
htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#91#87#article#151# </font></
p>     ^cY#aop04111.htm##
00647000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704038800088002001300476#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#92#88#article#15
1#13#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13. Bl&uuml;
her M, Williams CJ, Kl&ouml;ting N, Hsi A, Ruschke K, Oberbach A, et al. Gene ex
pression of adiponectin receptors in human visceral and subcutaneous adipose tis
sue is related to insulin resistance and metabolic parameters and is altered in 
response to physical training. Diabetes Care. 2007;30(12):3110-5.    ^cY#aop0411
1.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#93#89#article#151# </font></
p>     ^cY#aop04111.htm##
00497000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704023800088002001300326#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#94#90#article#15
1#14#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14. WHO. Obe
sity: preventing and managing the global epidemic, report of a WHO consultation.
 Geneva: World Health Organization 2000. (WHO Technical Report Series 894).    ^
cY#aop04111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#95#91#article#151# </font></
p>     ^cY#aop04111.htm##
00644000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704038500088002001300473#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#96#92#article#15
1#15#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15. Donnelly
 JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK. American College of S
ports Medicine. American College of Sports Medicine Position Stand. Appropriate 
physical activity intervention strategies for weight loss and prevention of weig
ht regain for adults. Med Sci Sports Exerc. 2009;41(2):459-71.    ^cY#aop04111.h
tm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#97#93#article#151# </font></
p>     ^cY#aop04111.htm##
00570000000000157000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081888000300085704031100088002001300399#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#98#94#article#15
1#16#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16. McGuire 
DK, Levine BD, Williamson JW, Snell PG, Blomqvist CG, Saltin B, et al. A 30-year
 follow-up of the Dallas Bed Rest and Training Study: I. Effect of age on the ca
rdiovascular response to exercise. Circulation. 2001;104(12):1350-7.    ^cY#aop0
4111.htm##
00265000000000145000450000400110000070200520001170500020006370600020006570000030
0067701000300070709000800073708000400081704002100085002001300106#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#99#95#article#151# </font></
p>     ^cY#aop04111.htm##
00596000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704033600089002001300425#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#100#96#article#1
51#17#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17. Baratta
 R, Amato S, Degano C, Farina MG, Patan&egrave; G, Vigneri R, et al. Adiponectin
 relationship with lipid metabolism is independent of body fat mass: evidence fr
om both cross-sectional and intervention studies. J Clin Endocrinol Metab. 2004;
89(6):2665-71.    ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#101#97#article#151# </font><
/p>     ^cY#aop04111.htm##
00597000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082888000300086704033700089002001300426#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#102#98#article#1
51#18#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18. Kantart
zis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K, et al. The rel
ationships of plasma adiponectin with a favorable lipid profile, decreased infla
mmation, and less ectopic fat accumulation depend on adiposity. Clin Chem. 2006;
52(10):1934-42.    ^cY#aop04111.htm##
00266000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000300071709000800074708000400082704002100086002001300107#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#103#99#article#151# </font><
/p>     ^cY#aop04111.htm##
00681000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704042000090002001300510#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#104#100#article#
151#19#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19. Gavril
a A, Chan JL, Yiannakouris N, Kontogianni M, Miller LC, Orlova C, et al. Serum a
diponectin levels are inversely associated with overall and central fat distribu
tion but are not directly regulated by acute fasting or leptin administration in
 humans: cross-sectional and interventional studies. J Clin Endocrinol Metab. 20
03; 88(10):4823-31.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#105#101#article#151# </font>
</p>     ^cY#aop04111.htm##
00566000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030500090002001300395#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#106#102#article#
151#20#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20. Kappes
 A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis f
actor-alpha on intracellular amount and secretion of apM1 in differentiating pri
mary human preadipocytes. Horm Metab Res. 2000;32(11-12):548-54.    ^cY#aop04111
.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#107#103#article#151# </font>
</p>     ^cY#aop04111.htm##
00548000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704028700090002001300377#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#108#104#article#
151#21#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21. Maeda 
N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma 
ligands increase expression and plasma concentrations of adiponectin, an adipose
-derived protein. Diabetes. 2001;50(9):2094-9.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#109#105#article#151# </font>
</p>     ^cY#aop04111.htm##
00555000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029400090002001300384#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#110#106#article#
151#22#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22. Esposi
to K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect o
f weight loss and lifestyle changes on vascular inflammatory markers in obese wo
men: a randomized trial. JAMA. 2003;289(14):1799-804.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#111#107#article#151# </font>
</p>     ^cY#aop04111.htm##
00559000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029800090002001300388#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#112#108#article#
151#23#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23. Vilarr
asa N, Vendrell J, Maravall J, Broch M, Estepa A, Megia A, et al. Distribution a
nd determinants of adiponectin, resistin and ghrelin in a randomly selected heal
thy population. Clin Endocrinol (Oxf). 2005;63(3):329-35.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#113#109#article#151# </font>
</p>     ^cY#aop04111.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#114#110#article#
151#24#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24. Klein 
S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an ef
fect of liposuction on insulin action and risk factors for coronary heart diseas
e. N Engl J Med. 2004;350(25):2549-57.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#115#111#article#151# </font>
</p>     ^cY#aop04111.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030200090002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#116#112#article#
151#25#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25. Ouchi 
N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adi
pocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through 
a cAMP-dependent pathway. Circulation. 2000;102(11):1296-301.    ^cY#aop04111.ht
m##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#117#113#article#151# </font>
</p>     ^cY#aop04111.htm##
00531000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027000090002001300360#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#118#114#article#
151#26#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26. Nadler
 ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of
 adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad 
Sci USA. 2000;97(21):11371-6.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#119#115#article#151# </font>
</p>     ^cY#aop04111.htm##
00469000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704020800090002001300298#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#120#116#article#
151#27#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27. Hu E, 
Liang P, Spiegelman BM. AdipoQ is a novel adipocyte-specific gene dysregulated i
n obesity. J Biol Chem. 1996;271(18):10697-703.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#121#117#article#151# </font>
</p>     ^cY#aop04111.htm##
00590000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032900090002001300419#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#122#118#article#
151#28#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28. Ring-D
imitriou S, Paulweber B, von Duvillard SP, Stadlmann M, LeMura LM, Lang J, et al
. The effect of physical activity and physical fitness on plasma adiponectin in 
adults with predisposition to metabolic syndrome. Eur J Appl Physiol. 2006;98(5)
:472-81.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#123#119#article#151# </font>
</p>     ^cY#aop04111.htm##
00540000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027900090002001300369#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#124#120#article#
151#29#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29. Kraeme
r RR, Aboudehen KS, Carruth AK, Durand RT, Acevedo EO, Hebert EP, et al. Adipone
ctin responses to continuous and progressively intense intermittent exercise. Me
d Sci Sports Exerc. 2003;35(8):1320-5.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#125#121#article#151# </font>
</p>     ^cY#aop04111.htm##
00597000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704033600090002001300426#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#126#122#article#
151#30#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30. Oberba
ch A, T&ouml;njes A, Kl&ouml;ting N, Fasshauer M, Kratzsch J, Busse MW, et al. E
ffect of a 4 week physical training program on plasma concentrations of inflamma
tory markers in patients with abnormal glucose tolerance. Eur J Endocrinol. 2006
;154(4):577-85.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#127#123#article#151# </font>
</p>     ^cY#aop04111.htm##
00513000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025200090002001300342#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#128#124#article#
151#31#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31. Marcel
l TJ, McAuley KA, Traustadottir T, Reaven PD. Exercise training is not associate
d with improved levels of C-reactive protein or adiponectin. Metabolism. 2005;54
(4):533-41.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#129#125#article#151# </font>
</p>     ^cY#aop04111.htm##
00532000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704027100090002001300361#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#130#126#article#
151#32#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32. Leving
er I, Goodman C, Peake J, Garnham A, Hare DL, Jerums G, et al. Inflammation, hep
atic enzymes and resistance training in individuals with metabolic risk factors.
 Diabet Med. 2009;26(3):220-7.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#131#127#article#151# </font>
</p>     ^cY#aop04111.htm##
00455000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704019400090002001300284#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#132#128#article#
151#33#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33. Hawley
 JA , Lessard SJ . Exercise training-induced improvements in insulin action. Act
a Physiol (Oxf). 2008;192:127-35.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#133#129#article#151# </font>
</p>     ^cY#aop04111.htm##
00553000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704029200090002001300382#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#134#130#article#
151#34#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34. Yataga
i T, Nishida Y, Nagasaka S, Nakamura T, Tokuyama K, Shindo M, et al. Relationshi
p between exercise training-induced increase in insulin sensitivity and adiponec
tinemia in healthy men. Endocr J. 2003;50(2):233-8.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#135#131#article#151# </font>
</p>     ^cY#aop04111.htm##
00583000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704032200090002001300412#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#136#132#article#
151#35#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35. Bruun 
JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inf
lammation and macrophage infiltration in adipose tissue but not in skeletal musc
le in severely obese subjects. Am J Physiol Endocrinol Metab. 2006;290(5):E961-7
.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#137#133#article#151# </font>
</p>     ^cY#aop04111.htm##
00519000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704025800090002001300348#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#138#134#article#
151#36#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36. Kim ES
, Im JA, Kim KC, Park JH, Suh SH, Kang ES, et al. Improved insulin sensitivity a
nd adiponectin level after exercise training in obese Korean youth. Obesity. 200
7;15(12):3023-30.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#139#135#article#151# </font>
</p>     ^cY#aop04111.htm##
00563000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704030200090002001300392#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#140#136#article#
151#37#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37. Erikss
on M, Johnson O, Boman K, Hallmans G, Hellsten G, Nilsson TK, et al. Improved fi
brinolytic activity during exercise may be an effect of the adipocyte-derived ho
rmones leptin and adiponectin. Thromb Res. 2008;122(5):701-8.    ^cY#aop04111.ht
m##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#141#137#article#151# </font>
</p>     ^cY#aop04111.htm##
00633000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704037200090002001300462#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#142#138#article#
151#38#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">38. Kumaga
i S, Kishimoto H, Masatakasuwa, Zou B, Harukasasaki The leptin to adiponectin ra
tio is a good biomarker for the prevalence of metabolic syndrome, dependent on v
isceral fat accumulation and endurance fitness in obese patients with diabetes m
ellitus. Metab Syndr Relat Disord. 2005;3(2):85-94.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#143#139#article#151# </font>
</p>     ^cY#aop04111.htm##
00501000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704024000090002001300330#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#144#140#article#
151#39#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">39. J&uuml
;rim&auml;e J, Purge P, J&uuml;rim&auml;e T. Adiponectin is altered after maxima
l exercise in highly trained male rowers. Eur J Appl Physiol. 2005;93(4):502-5. 
   ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#145#141#article#151# </font>
</p>     ^cY#aop04111.htm##
00628000000000157000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083888000300087704036700090002001300457#201
1nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#146#142#article#
151#40#<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">40. Polak 
J, Klimcakova E, Moro C, Viguerie N, Berlan M, Hejnova J, et al. Effect of aerob
ic training on plasma levels and subcutaneous abdominal adipose tissue gene expr
ession of adiponectin, leptin, interleukin 6, and tumor necrosis factor alpha in
 obese women. Metabolism. 2006;55(10):1375-81.    ^cY#aop04111.htm##
00267000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002100087002001300108#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#147#143#article#151# </font>
</p>     ^cY#aop04111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#148#144#article#151#<p>&nbsp
;</p>     ^cY#aop04111.htm##
00268000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704002200087002001300109#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#149#145#article#151#<p>&nbsp
;</p>     ^cY#aop04111.htm##
00448000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704020200087002001300289#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#150#146#article#151#<p><a na
me="endb"></a><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><a hre
f="#enda"><img src="/img/revistas/abc/2011nahead/seta.jpg" border="0"></a> <b>Co
rrespond&ecirc;ncia:</b>      ^cY#aop04111.htm##
00286000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704004000087002001300127#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#151#147#article#151#<br>   E
duardo Camillo Martinez     ^cY#aop04111.htm##
00305000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005900087002001300146#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#152#148#article#151#<br>   R
ua Pontes Correa, 101/404 - Andara&iacute;     ^cY#aop04111.htm##
00301000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704005500087002001300142#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#153#149#article#151#<br>   2
0510-050 - Rio de Janeiro, RJ - Brasil     ^cY#aop04111.htm##
00435000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704018900087002001300276#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#154#150#article#151#<br>   E
-mail: <a href="mailto:eduardocmartinez@gmail.com">eduardocmartinez@gmail.com</a
>, <a href="mailto:eduardocmartinez@hotmail.com">eduardocmartinez@hotmail.com</a
></font></p>     ^cY#aop04111.htm##
00410000000000145000450000400110000070200520001170500020006370600020006570000040
0067701000400071709000800075708000400083704016400087002001300251#2011nahead#V:\S
ciELO\serial\abc\2011nahead\markup\aop04111.htm#S#p#155#151#article#151#<p><font
 size="2" face="Verdana, Arial, Helvetica, sans-serif"> Artigo recebido em 12/08
/10; revisado recebido em 22/10/10; aceito em 10/12/10. </font></p>     ^cY#aop0
4111.htm##
00603000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860120131001020300
01800233065000900251064000500260031000300265032000200268014000500270865000900275
002001300284035001000297801001800307#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop04111.htm#S#c#156#1#article#40#1#^rND^sHavel^nPJ#Control of energy hom
eostasis and insulin action by adipocyte hormones: leptin, acylation stimulating
 protein, and adiponectin^len#Curr Opin Lipidol#20020000#2002#13#1#51-9#20110000
#aop04111.htm#0957-9672#Curr Opin Lipidol##
00512000000000277000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860120047001020300
01400149065000900163064000500172031000300177032000200180014000600182865000900188
002001300197035001000210801001400220#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop04111.htm#S#c#157#2#article#40#2#^rND^sHauner^nH#The new concept of ad
ipose tissue function^len#Physiol Behav#20040000#2004#83#4#653-8#20110000#aop041
11.htm#0031-9384#Physiol Behav##
00597000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100019000860100018001050120
09900123030001300222065000900235064000500244031000400249032000200253014000700255
865000900262002001300271035001000284801001300294#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop04111.htm#S#c#158#3#article#40#3#^rND^sTrujillo^nME#^rND^s
Scherer^nPE#Adiponectin-journey from an adipocyte secretory protein to biomarker
 of the metabolic syndrome^len#J Intern Med#20050000#2005#257#2#167-75#20110000#
aop04111.htm#0954-6820#J Intern Med##
00620000000000301000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100019001030100
01800122012009700140030001200237065000900249064000500258031000300263032000200266
014000600268865000900274002001300283035001000296801001200306#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop04111.htm#S#c#159#4#article#40#4#^rND^sHaluzík
^nM#^rND^sParízková^nJ#^rND^sHaluzík^nMM#Adiponectin and its role in the obesity
-induced insulin resistance and related complications^len#Physiol Res#20040000#2
004#53#2#123-9#20110000#aop04111.htm#0862-8408#Physiol Res##
00571000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100016000860100020001020120
07900122030001000201065000900211064000500220031000300225032000300228014000800231
865000900239002001300248035001000261801001000271#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop04111.htm#S#c#160#5#article#40#5#^rND^sUkkola^nO#^rND^sSan
taniemi^nM#Adiponectin: a link between excess adiposity and associated comorbidi
ties?^len#J Mol Med#20020000#2002#80#11#696-702#20110000#aop04111.htm#0377-046X#
J Mol Med##
00558000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100018000860100016001040120
04100120030002400161065000900185064000500194031000300199032000200202014000800204
865000900212002001300221035001000234801002400244#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop04111.htm#S#c#161#6#article#40#6#^rND^sKershaw^nEE#^rND^sF
lier^nJS#Adipose tissue as an endocrine organ^len#J Clin Endocrinol Metab#200400
00#2004#89#6#2548-56#20110000#aop04111.htm#0021-972X#J Clin Endocrinol Metab##
00650000000000313000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100022000860100017001080100
01400125010001600139012009800155030001200253065000900265064000500274031000300279
032000300282014000700285865000900292002001300301035001000314801001200324#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#c#162#7#article#40#7#^
rND^sRothenbacher^nD#^rND^sBrenner^nH#^rND^sMärz^nW#^rND^sKoenig^nW#Adiponectin,
 risk of coronary heart disease and correlations with cardiovascular risk marker
s^len#Eur Heart J#20050000#2005#26#16#1640-6#20110000#aop04111.htm#0195-668X#Eur
 Heart J##
00697000000000337000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100017000860100015001030100
01700118010001800135010001600153010001700169810000600186012008600192030003000278
71000020030806500090031006400050031903100040032403200020032801400070033086500090
0337002001300346#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#
S#c#163#8#article#40#8#^rND^sHulver^nMW#^rND^sZheng^nD#^rND^sTanner^nCJ#^rND^sHo
umard^nJA#^rND^sKraus^nWE#^rND^sSlentz^nCA#et al#Adiponectin is not altered with
 exercise training despite enhanced insulin action^len#Am J Physiol Endocrinol M
etab#2#20020000#2002#283#4#E861-5#20110000#aop04111.htm##
00546000000000289000450000400110000070200520001170500020006370600020006570000040
00677010002000717090008000737080003000811180002000840100015000860100017001010120
06000118030001000178065000900188064000500197031000300202032000200205014000700207
865000900214002001300223035001000236801001000246#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop04111.htm#S#c#164#9#article#40#9#^rND^sYang^nWS#^rND^sChua
ng^nLM#Human genetics of adiponectin in the metabolic syndrome^len#J Mol Med#200
60000#2006#84#2#112-21#20110000#aop04111.htm#0377-046X#J Mol Med##
00847000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100020001040100
01400124010001800138010001900156010001700175810000600192012019300198030002400391
06500090041506400050042403100030042903200020043201400070043486500090044100200130
0450035001000463801002400473#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#165#10#article#40#10#^rND^sBlüher^nM#^rND^sBullen Jr^nJW#^rND^sL
ee^nJH#^rND^sKralisch^nS#^rND^sFasshauer^nM#^rND^sKlöting^nN#et al#Circulating a
diponectin and expression of adiponectina receptors in human skeletal muscle: as
sociations with metabolic parameters and insulin resistance and regulation by ph
ysical training^len#J Clin Endocrinol Metab#20060000#2006#91#6#2310-6#20110000#a
op04111.htm#0021-972X#J Clin Endocrinol Metab##
00768000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100015001080100
01800123010001500141010001600156010001700172810000600189012013600195030001500331
06500090034606400050035503100030036003200020036301400060036586500090037100200130
0380035001000393801001500403#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#166#11#article#40#11#^rND^sSt-Pierre^nDH#^rND^sFaraj^nM#^rND^sKa
relis^nAD#^rND^sConus^nF#^rND^sHenry^nJF#^rND^sSt-Onge^nM#et al#Lifestyle behavi
ours and components of energy balance as independent predictors of ghrelin and a
diponectin in young non-obese women^len#Diabetes Metab#20060000#2006#32#2#131-9#
20110000#aop04111.htm#0338-1684#Diabetes metab##
00570000000000277000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01800125012008800143030001800231710000200249065000900251064000500260031000200265
014000300267865000900270002001300279#2011nahead#V:\SciELO\serial\abc\2011nahead\
markup\aop04111.htm#S#c#167#12#article#40#12#^rND^sTsukinoki^nR#^rND^sMorimoto^n
K#^rND^sNakayama^nK#Association between lifestyle factors and plasma adiponectin
 levels in Japanese men^len#Lipids Health Dis#2#20050000#2005#4#27#20110000#aop0
4111.htm##
00832000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100019001040100
01700123010001300140010001700153010001800170810000600188012020100194030001400395
06500090040906400050041803100030042303200030042601400070042986500090043600200130
0445035001000458801001400468#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#168#13#article#40#13#^rND^sBlüher^nM#^rND^sWilliams^nCJ#^rND^sKl
öting^nN#^rND^sHsi^nA#^rND^sRuschke^nK#^rND^sOberbach^nA#et al#Gene expression o
f adiponectin receptors in human visceral and subcutaneous adipose tissue is rel
ated to insulin resistance and metabolic parameters and is altered in response t
o physical training^len#Diabetes Care#20070000#2007#30#12#3110-5#20110000#aop041
11.htm#0149-5992#Diabetes Care##
00478000000000229000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850170004000880180087000920660
00700179062002600186065000900212064000500221865000900226002001300235#2011nahead#
V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#c#169#14#article#40#14#WHO
#Obesity: preventing and managing the global epidemic, report of a WHO consultat
ion^len#Geneva#World Health Organization#20000000#2000#20110000#aop04111.htm##
00835000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100016001070100
01800123010001700141010001700158010001600175012020600191030002100397065000900418
06400050042703100030043203200020043501400070043786500090044400200130045303500100
0466801002100476#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#
S#c#170#15#article#40#15#^rND^sDonnelly^nJE#^rND^sBlair^nSN#^rND^sJakicic^nJM#^r
ND^sManore^nMM#^rND^sRankin^nJW#^rND^sSmith^nBK#American College of Sports Medic
ine: American College of Sports Medicine Position Stand. Appropriate physical ac
tivity intervention strategies for weight loss and prevention of weight regain f
or adults^len#Med Sci Sports Exerc#20090000#2009#41#2#459-71#20110000#aop04111.h
tm#0195-9131#Med Sci Sports Exerc##
00763000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
02100123010001600144010002000160010001600180810000600196012012700202030001200329
06500090034106400050035003100040035503200030035901400070036286500090036900200130
0378035001000391801001200401#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#171#16#article#40#16#^rND^sMcGuire^nDK#^rND^sLevine^nBD#^rND^sWi
lliamson^nJW#^rND^sSnell^nPG#^rND^sBlomqvist^nCG#^rND^sSaltin^nB#et al#A 30-year
 follow-up of the Dallas Bed Rest and Training Study: I. Effect of age on the ca
rdiovascular response to exercise^len#Circulation#20010000#2001#104#12#1350-7#20
110000#aop04111.htm#0009-7322#Circulation##
00793000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01600120010001700136010001600153010001700169810000600186012014400192030002400336
06500090036006400050036903100030037403200020037701400080037986500090038700200130
0396035001000409801002400419#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#172#17#article#40#17#^rND^sBaratta^nR#^rND^sAmato^nS#^rND^sDegan
o^nC#^rND^sFarina^nMG#^rND^sPatanè^nG#^rND^sVigneri^nR#et al#Adiponectin relatio
nship with lipid metabolism is independent of body fat mass: evidence from both 
cross-sectional and intervention studies^len#J Clin Endocrinol Metab#20040000#20
04#89#6#2665-71#20110000#aop04111.htm#0021-972X#J Clin Endocrinol Metab##
00787000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100020000880100016001080100
02200124010001700146010001600163010001800179810000600197012015400203030001000357
06500090036706400050037603100030038103200030038401400080038786500090039500200130
0404035001000417801001000427#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#173#18#article#40#18#^rND^sKantartzis^nK#^rND^sRittig^nK#^rND^sB
alletshofer^nB#^rND^sMachann^nJ#^rND^sSchick^nF#^rND^sPorubska^nK#et al#The rela
tionships of plasma adiponectin with a favorable lipid profile, decreased inflam
mation, and less ectopic fat accumulation depend on adiposity^len#Clin Chem#2006
0000#2006#52#10#1934-42#20110000#aop04111.htm#0009-9147#Clin Chem##
00883000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
02200120010002100142010001700163010001600180810000600196012022300202030002400425
06500090044906400050045803100030046303200030046601400080046986500090047700200130
0486035001000499801002400509#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#174#19#article#40#19#^rND^sGavrila^nA#^rND^sChan^nJL#^rND^sYiann
akouris^nN#^rND^sKontogianni^nM#^rND^sMiller^nLC#^rND^sOrlova^nC#et al#Serum adi
ponectin levels are inversely associated with overall and central fat distributi
on but are not directly regulated by acute fasting or leptin administration in h
umans: cross-sectional and interventional studies^len#J Clin Endocrinol Metab#20
030000#2003#88#10#4823-31#20110000#aop04111.htm#0021-972X#J Clin Endocrinol Meta
b##
00677000000000289000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100017001040120
17400121030001500295065000900310064000500319031000300324032000600327014000700333
865000900340002001300349035001000362801001500372#2011nahead#V:\SciELO\serial\abc
\2011nahead\markup\aop04111.htm#S#c#175#20#article#40#20#^rND^sKappes^nA#^rND^sL
offler^nG#Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor
-alpha on intracellular amount and secretion of apM1 in differentiating primary 
human preadipocytes^len#Horm Metab Res#20000000#2000#32#11-12#548-54#20110000#ao
p04111.htm#0018-5043#Horm Metab Res##
00736000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100019001030100
01900122010001600141010001900157010001700176810000600193012011100199030000900310
06500090031906400050032803100030033303200020033601400070033886500090034500200130
0354035001000367801000900377#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#176#21#article#40#21#^rND^sMaeda^nN#^rND^sTakahashi^nM#^rND^sFun
ahashi^nT#^rND^sKihara^nS#^rND^sNishizawa^nH#^rND^sKishida^nK#et al#PPARgamma li
gands increase expression and plasma concentrations of adiponectin, an adipose-d
erived protein^len#Diabetes#20010000#2001#50#9#2094-9#20110000#aop04111.htm#0012
-1797#Diabetes##
00739000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
01700124010001900141010001700160010001800177810000600195012011600201030000500317
06500090032206400050033103100040033603200030034001400090034386500090035200200130
0361035001000374801000500384#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#177#22#article#40#22#^rND^sEsposito^nK#^rND^sPontillo^nA#^rND^sD
i Palo^nC#^rND^sGiugliano^nG#^rND^sMasella^nM#^rND^sMarfella^nR#et al#Effect of 
weight loss and lifestyle changes on vascular inflammatory markers in obese wome
n: a randomized trial^len#JAMA#20030000#2003#289#14#1799-804#20110000#aop04111.h
tm#0098-7484#JAMA##
00760000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100019000880100018001070100
01800125010001500143010001600158010001500174810000600189012011300195030002200308
06500090033006400050033903100030034403200020034701400070034986500090035600200130
0365035001000378801002200388#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#178#23#article#40#23#^rND^sVilarrasa^nN#^rND^sVendrell^nJ#^rND^s
Maravall^nJ#^rND^sBroch^nM#^rND^sEstepa^nA#^rND^sMegia^nA#et al#Distribution and
 determinants of adiponectin, resistin and ghrelin in a randomly selected health
y population^len#Clin Endocrinol (Oxf)#20050000#2005#63#3#329-35#20110000#aop041
11.htm#0300-0664#Clin Endocrinol (Oxf)##
00732000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100017001030100
01600120010001700136010001400153010002000167810000600187012010200193030001300295
06500090030806400050031703100040032203200030032601400080032986500090033700200130
0346035001000359801001300369#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#179#24#article#40#24#^rND^sKlein^nS#^rND^sFontana^nL#^rND^sYoung
^nVL#^rND^sCoggan^nAR#^rND^sKilo^nC#^rND^sPatterson^nBW#et al#Absence of an effe
ct of liposuction on insulin action and risk factors for coronary heart disease^
len#N Engl J Med#20040000#2004#350#25#2549-57#20110000#aop04111.htm#0028-4793#N 
Engl J Med##
00754000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100016001030100
01500119010001700134010001500151010001800166810000600184012012800190030001200318
06500090033006400050033903100040034403200030034801400090035186500090036000200130
0369035001000382801001200392#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#180#25#article#40#25#^rND^sOuchi^nN#^rND^sKihara^nS#^rND^sArita^
nY#^rND^sOkamoto^nY#^rND^sMaeda^nK#^rND^sKuriyama^nH#et al#Adiponectin, an adipo
cyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a 
cAMP-dependent pathway^len#Circulation#20000000#2000#102#11#1296-301#20110000#ao
p04111.htm#0009-7322#Circulation##
00722000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01900122010001800141010001800159010001600177012008500193030002300278065000900301
06400050031003100030031503200030031801400080032186500090032900200130033803500100
0351801002300361#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#
S#c#181#26#article#40#26#^rND^sNadler^nST#^rND^sStoehr^nJP#^rND^sSchueler^nKL#^r
ND^sTanimoto^nG#^rND^sYandell^nBS#^rND^sAttie^nAD#The expression of adipogenic g
enes is decreased in obesity and diabetes mellitus^len#Proc Natl Acad Sci USA#20
000000#2000#97#21#11371-6#20110000#aop04111.htm#0027-8424#Proc Natl Acad Sci USA
##
00595000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100012000880100015001000100
02100115012007000136030001200206065000900218064000500227031000400232032000300236
014001000239865000900249002001300258035001000271801001200281#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop04111.htm#S#c#182#27#article#40#27#^rND^sHu^nE
#^rND^sLiang^nP#^rND^sSpiegelman^nBM#AdipoQ is a novel adipocyte-specific gene d
ysregulated in obesity^len#J Biol Chem#19960000#1996#271#18#10697-703#20110000#a
op04111.htm#0021-9258#J Biol Chem##
00788000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100024000880100019001120100
02400131010001900155010001700174010001400191810000600205012013100211030001900342
06500090036106400050037003100030037503200020037801400070038086500090038700200130
0396035001000409801001900419#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#183#28#article#40#28#^rND^sRing-Dimitriou^nS#^rND^sPaulweber^nB#
^rND^svon Duvillard^nSP#^rND^sStadlmann^nM#^rND^sLeMura^nLM#^rND^sLang^nJ#et al#
The effect of physical activity and physical fitness on plasma adiponectin in ad
ults with predisposition to metabolic syndrome^len#Eur J Appl Physiol#20060000#2
006#98#5#472-81#20110000#aop04111.htm#0301-5548#Eur J Appl Physiol##
00740000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100020001060100
01800126010001700144010001800161010001700179810000600196012008800202030002100290
06500090031106400050032003100030032503200020032801400070033086500090033700200130
0346035001000359801002100369#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#184#29#article#40#29#^rND^sKraemer^nRR#^rND^sAboudehen^nKS#^rND^
sCarruth^nAK#^rND^sDurand^nRT#^rND^sAcevedo^nEO#^rND^sHebert^nEP#et al#Adiponect
in responses to continuous and progressively intense intermittent exercise^len#M
ed Sci Sports Exerc#20030000#2003#35#8#1320-5#20110000#aop04111.htm#0195-9131#Me
d Sci Sports Exerc##
00783000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100016001060100
01700122010001900139010001800158010001600176810000600192012014200198030001700340
06500090035706400050036603100040037103200020037501400070037786500090038400200130
0393035001000406801001700416#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#185#30#article#40#30#^rND^sOberbach^nA#^rND^sTönjes^nA#^rND^sKlö
ting^nN#^rND^sFasshauer^nM#^rND^sKratzsch^nJ#^rND^sBusse^nMW#et al#Effect of a 4
 week physical training program on plasma concentrations of inflammatory markers
 in patients with abnormal glucose tolerance^len#Eur J Endocrinol#20060000#2006#
154#4#577-85#20110000#aop04111.htm#0804-4643#Eur J Endocrinol##
00656000000000313000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100018001060100
02300124010001700147012009800164030001100262065000900273064000500282031000300287
032000200290014000700292865000900299002001300308035001000321801001100331#2011nah
ead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#S#c#186#31#article#40#31
#^rND^sMarcell^nTJ#^rND^sMcAuley^nKA#^rND^sTraustadottir^nT#^rND^sReaven^nPD#Exe
rcise training is not associated with improved levels of C-reactive protein or a
diponectin^len#Metabolism#20050000#2005#54#4#533-41#20110000#aop04111.htm#0026-0
495#Metabolism##
00722000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01500123010001700138010001500155010001600170810000600186012010100192030001100293
06500090030406400050031303100030031803200020032101400060032386500090032900200130
0338035001000351801001100361#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#187#32#article#40#32#^rND^sLevinger^nI#^rND^sGoodman^nC#^rND^sPe
ake^nJ#^rND^sGarnham^nA#^rND^sHare^nDL#^rND^sJerums^nG#et al#Inflammation, hepat
ic enzymes and resistance training in individuals with metabolic risk factors^le
n#Diabet Med#20090000#2009#26#3#220-7#20110000#aop04111.htm#0742-3071#Diabet Med
##
00518000000000265000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100018001050120
06100123030001900184710000200203065000900205064000500214031000400219014000700223
865000900230002001300239#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04
111.htm#S#c#188#33#article#40#33#^rND^sHawley^nJA#^rND^sLessard^nSJ#Exercise tra
ining-induced improvements in insulin action^len#Acta Physiol (Oxf)#2#20080000#2
008#192#127-35#20110000#aop04111.htm##
00741000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100017001050100
01800122010001800140010001800158010001600176810000600192012011800198030000900316
06500090032506400050033403100030033903200020034201400060034486500090035000200130
0359035001000372801000900382#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#189#34#article#40#34#^rND^sYatagai^nT#^rND^sNishida^nY#^rND^sNag
asaka^nS#^rND^sNakamura^nT#^rND^sTokuyama^nK#^rND^sShindo^nM#et al#Relationship 
between exercise training-induced increase in insulin sensitivity and adiponecti
nemia in healthy men^len#Endocr J#20030000#2003#50#2#233-8#20110000#aop04111.htm
#0918-8959#Endocr J##
00695000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100016000880100016001040100
01900120010002100139012015200160030003000312710000200342065000900344064000500353
031000400358032000200362014000700364865000900371002001300380#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop04111.htm#S#c#190#35#article#40#35#^rND^sBruun
^nJM#^rND^sHelge^nJW#^rND^sRichelsen^nB#^rND^sStallknecht^nB#Diet and exercise r
educe low-grade inflammation and macrophage infiltration in adipose tissue but n
ot in skeletal muscle in severely obese subjects^len#Am J Physiol Endocrinol Met
ab#2#20060000#2006#290#5#E961-7#20110000#aop04111.htm##
00678000000000337000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100014000880100013001020100
01400115010001500129010001400144010001500158810000600173012010100179030000800280
71000020028806500090029006400050029903100030030403200030030701400080031086500090
0318002001300327#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\aop04111.htm#
S#c#191#36#article#40#36#^rND^sKim^nES#^rND^sIm^nJA#^rND^sKim^nKC#^rND^sPark^nJH
#^rND^sSuh^nSH#^rND^sKang^nES#et al#Improved insulin sensitivity and adiponectin
 level after exercise training in obese Korean youth^len#Obesity#2#20070000#2007
#15#12#3023-30#20110000#aop04111.htm##
00753000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100018000880100017001060100
01500123010001800138010001800156010001800174810000600192012012500198030001100323
06500090033406400050034303100040034803200020035201400060035486500090036000200130
0369035001000382801001100392#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#192#37#article#40#37#^rND^sEriksson^nM#^rND^sJohnson^nO#^rND^sBo
man^nK#^rND^sHallmans^nG#^rND^sHellsten^nG#^rND^sNilsson^nTK#et al#Improved fibr
inolytic activity during exercise may be an effect of the adipocyte-derived horm
ones leptin and adiponectin^len#Thromb Res#20080000#2008#122#5#701-8#20110000#ao
p04111.htm#0049-3848#Thromb Res##
00744000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100019001050100
01900124010001300143012021300156030002500369710000200394065000900396064000500405
031000200410032000200412014000600414865000900420002001300429#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop04111.htm#S#c#193#38#article#40#38#^rND^sKumag
ai^nS#^rND^sKishimoto^nH#^rND^sMasatakasuwa#^rND^sZou^nB#Harukasasaki The leptin
 to adiponectin ratio is a good biomarker for the prevalence of metabolic syndro
me, dependent on visceral fat accumulation and endurance fitness in obese patien
ts with diabetes mellitus^len#Metab Syndr Relat Disord#2#20050000#2005#3#2#85-94
#20110000#aop04111.htm##
00614000000000301000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100017000880100015001050100
01700120012008000137030001900217065000900236064000500245031000300250032000200253
014000600255865000900261002001300270035001000283801001900293#2011nahead#V:\SciEL
O\serial\abc\2011nahead\markup\aop04111.htm#S#c#194#39#article#40#39#^rND^sJürim
äe^nJ#^rND^sPurge^nP#^rND^sJürimäe^nT#Adiponectin is altered after maximal exerc
ise in highly trained male rowers^len#Eur J Appl Physiol#20050000#2005#93#4#502-
5#20110000#aop04111.htm#0301-5548#Eur J Appl Physiol##
00818000000000349000450000400110000070200520001170500020006370600020006570000040
00677010003000717090008000747080003000821180003000850100015000880100020001030100
01400123010001800137010001600155010001700171810000600188012019200194030001100386
06500090039706400050040603100030041103200030041401400080041786500090042500200130
0434035001000447801001100457#2011nahead#V:\SciELO\serial\abc\2011nahead\markup\a
op04111.htm#S#c#195#40#article#40#40#^rND^sPolak^nJ#^rND^sKlimcakova^nE#^rND^sMo
ro^nC#^rND^sViguerie^nN#^rND^sBerlan^nM#^rND^sHejnova^nJ#et al#Effect of aerobic
 training on plasma levels and subcutaneous abdominal adipose tissue gene expres
sion of adiponectin, leptin, interleukin 6, and tumor necrosis factor alpha in o
bese women^len#Metabolism#20060000#2006#55#10#1375-81#20110000#aop04111.htm#0026
-0495#Metabolism##
